<SEC-DOCUMENT>0001193125-26-081986.txt : 20260410
<SEC-HEADER>0001193125-26-081986.hdr.sgml : 20260410
<ACCEPTANCE-DATETIME>20260227141421
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-26-081986
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20260227
<PUBLIC-REL-DATE>20260410
DATE AS OF CHANGE:		20260227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hemab Therapeutics Holdings, Inc.
		CENTRAL INDEX KEY:			0002114044
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				414241952
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-09105
		FILM NUMBER:		26697551

	BUSINESS ADDRESS:	
		STREET 1:		101 MAIN STREET
		STREET 2:		SUITE 1220
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		45 2138 7627

	MAIL ADDRESS:	
		STREET 1:		101 MAIN STREET
		STREET 2:		SUITE 1220
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on February&nbsp;27, 2026.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains
confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8195;&#8195;&#8195;</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933 </I></B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>HEMAB THERAPEUTICS HOLDINGS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name
of registrant as specified in its charter) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">41-4241952</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>101 Main Street Suite 1220 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA 02142
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) 553-3952 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Address, including
zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Benny S&oslash;rensen, M.D., Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>President
and Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Hemab Therapeutics Holdings, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>101 Main Street Suite 1220 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA 02142
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) 553-3952 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Name, address,
including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cynthia T. Mazareas, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Scott N. Lunin, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Wilmer Cutler Pickering
Hale and Dorr LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>60 State Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Boston, Massachusetts 02109</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">526-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Benjamin K. Marsh, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Kristopher D. Brown, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Justin S. Platt,
Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>The New York
Times Building</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>620 Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New
York, NY 10018</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">813-8800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this registration statement is declared effective.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a
further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e">The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities in any state or
other jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT
 COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED&#8195;&#8195;&#8195;&#8195;, 2026 </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;Shares </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g62g77.jpg" ALT="LOGO" STYLE="width:1.76267in;height:0.348971in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This is the initial public offering of shares of common stock of Hemab Therapeutics Holdings, Inc. We are offering&#8195;&#8195;&#8195;&#8195; shares of
our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public
offering price per share will be between $&#8195;&#8195;&#8195;&#8195;and $&#8195;&#8195;&#8195;&#8195;. We intend to apply to list our common stock on the Nasdaq Global Market under the symbol &#8220;COAG.&#8221; We believe that upon the completion
of this offering, we will meet the standards for listing on Nasdaq, and the completion of this offering is contingent upon such listing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an
&#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under the U.S. federal securities laws, and, as such, have elected to comply with certain reduced reporting requirements in this prospectus. See the
section titled &#8220;<I>Prospectus Summary&#8212;Implications of Being an Emerging Growth Company and a Smaller Reporting Company</I>.&#8221; </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>See the section titled &#8220;<A HREF="#tx50309_3">Risk Factors</A>&#8221; beginning on page 13 to read about factors that you should consider before
deciding to invest in shares of our common stock. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See the section titled &#8220;<I>Underwriting</I>&#8221; for additional information regarding compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have granted the underwriters the option to purchase up to an additional&#8195;&#8195;&#8195;&#8195;shares of
common stock from us, at the initial public offering price, less the underwriting discounts and commissions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the
shares of common stock on or about&#8195;&#8195;&#8195;&#8195; , 2026. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Manager </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Wedbush PacGrow </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;, 2026 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i<FONT STYLE="font-size:5pt">&#8201;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_4">Cautionary Note Regarding Forward-Looking Statements and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_7">Corporate Reorganization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_10">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_14">Transactions with Related Persons</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_18">Material U.S. Federal Income Tax Considerations for <FONT STYLE="white-space:nowrap">Non-U.S.
</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx50309_23">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other
than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of,
any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this
prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have
changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit
this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the
trademarks and trade names in this prospectus may be referred to without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;symbols, but such references
should not be construed as any indicator that their respective owners will not assert their rights thereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently operate as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark. For purposes of this offering, we
formed Hemab Therapeutics Holdings, Inc., a Delaware corporation, which is the registrant whose name appears on the cover of the registration statement of which this prospectus is a part. Prior to the completion of this offering, we will complete a
corporate reorganization pursuant to which our existing shareholders will exchange their shares in Hemab ApS for the same number, classes and series of newly issued shares in the newly incorporated Delaware company, Hemab Therapeutics Holdings, Inc.
and, as a result, Hemab ApS will become a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Additionally, it is expected that, in connection with the corporate reorganization, Hemab ApS will transfer its shares of Hemab Therapeutics Inc.,
a Delaware corporation and wholly-owned subsidiary of Hemab ApS, to Hemab Therapeutics Holdings, Inc. and, as a result, Hemab Therapeutics Inc. will become a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Hemab Therapeutics Holdings,
Inc. will have nominal assets and liabilities and will not have conducted any operations prior to this offering other than such acquisition, its incorporation and the corporate reorganization. We refer to this reorganization transaction throughout
this prospectus as the &#8220;corporate reorganization.&#8221; See the section of the prospectus titled &#8220;<I>Corporate Reorganization</I>&#8221; for further details. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated or the context otherwise requires, all references in this prospectus to the terms &#8220;Hemab ApS,&#8221; &#8220;Hemab
Therapeutics Holdings, Inc.,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to (1)&nbsp;Hemab ApS and its wholly owned U.S. subsidiary, Hemab Therapeutics Inc., prior to the completion of our
corporate reorganization and (2)&nbsp;Hemab Therapeutics Holdings, Inc. and its subsidiaries, Hemab ApS and Hemab Therapeutics Inc., after the completion of the corporate reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">References in this prospectus to &#8220;ordinary shares&#8221; and &#8220;preference shares&#8221; refer to the historic share capital of Hemab ApS
prior to the completion of the corporate reorganization. All references to &#8220;common stock&#8221; and &#8220;preferred stock&#8221; refer to the capital structure of Hemab Therapeutics Holdings, Inc. following completion of the corporate
reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all references to &#8220;$&#8221; or &#8220;dollars&#8221; in this prospectus refer to U.S. dollars.
References to &#8220;DKK&#8221; in this prospectus refer to Danish kroner. The rate of exchange on December 31, 2025, as reported by the U.S. Treasury for the conversion of U.S. dollars to DKK was $1.00 equals DKK 6.3550. Numerical figures presented
in this prospectus have been subject to rounding adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, the historical financial and operating information
presented in this prospectus as of and for the years ended December&nbsp;31, 2024 and 2025 is that of Hemab ApS. Upon consummation of the corporate reorganization, the historical consolidated financial statements of Hemab ApS will become the
historical consolidated financial statements of Hemab Therapeutics Holdings, Inc., the entity whose shares are being sold in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares
of common stock of Hemab Therapeutics Holdings, Inc. are being offered by the prospectus included in this registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth in the sections
titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a late clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain
life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.
Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing
treatment approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the
prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the
subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate
that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets,
including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of
these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We aim to establish the industry&#8217;s leading coagulation franchise through the execution of our &#8220;Hemab 2x3 by 2030&#8221; strategic roadmap,
which is designed to build a franchise consisting of <B>2</B> commercial medicines, <B>2</B> new late-stage clinical programs, and <B>2</B> new early-stage clinical programs by 2030. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Franchise </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are building a franchise designed to
address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management. We design our assets to address critical gaps in the treatment of coagulation
disorders, and we anticipate multiple potentially value-driving clinical data events in&nbsp;&#8195;&#8195;&#8195;. The following table summarizes our assets and our target indications, as well as the status of development
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and anticipated clinical data events. We maintain all global economic development and commercialization rights to the assets in our franchise. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g99a30.jpg" ALT="LOGO" STYLE="width:6.30579in;height:2.73814in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig, is a bispecific antibody, which we are currently evaluating in a Phase&nbsp;1/2 clinical
trial for the prophylactic treatment of Glanzmann thrombasthenia and in a Phase 2 clinical trial for the prophylactic treatment of Factor VII deficiency. Glanzmann thrombasthenia and Factor VII deficiency are both congenital, severe, chronic
bleeding disorders for which there are no approved subcutaneous prophylactic therapies. Patients with Glanzmann thrombasthenia and Factor&nbsp;VII deficiency suffer from what can be a devastating combination of life-threatening acute hemorrhages and
relentless chronic bleeding that profoundly impact patients&#8217; physical health, mental health, and quality of life. Both disorders also carry additional risks for female patients, including heavy menstrual bleeding and potentially
life-threatening post-partum hemorrhage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, we have completed
the Part A (single ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing. The data from Part A of the trial established
proof-of-mechanism. In Part B, the reduction in mean annualized treated bleed rate, or ATBR, for patients treated with sutacimig ranged from 19% to 87%, indicating clinical activity at all regimens tested. Sutacimig also achieved a 100% reduction in
mean high-intensity ATBR during the Part B treatment period. In addition, 92% of patients in Part B who had at least one bleed event during the six week prospective run-in period experienced a reduction in ATBR and over 50% of those patients
experienced a 50% or greater reduction in ATBR. Based on the clinical activity and favorable safety and tolerability profile observed as of the data cutoff date of October 14, 2025, we expect to commence a Phase 3 clinical trial of sutacimig in
Glanzmann thrombasthenia in &#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also conducting a Phase 2 clinical trial that aims to establish proof-of-concept by
demonstrating sutacimig&#8217;s ability to increase Factor VII levels for patients with Factor VII deficiency. We anticipate reporting clinical data from our Phase 2 trial in &#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beyond these two initial indications, we believe sutacimig&#8217;s mechanism of action has potential applicability across multiple other inherited and
acquired bleeding conditions characterized by platelet dysfunction, and other causes of impaired hemostasis where platelet activation occurs at bleeding </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sites. We believe this represents a significant opportunity for potential label expansion if sutacimig receives regulatory approval for Glanzmann thrombasthenia or Factor VII deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our second clinical-stage asset, HMB-002, is a monovalent antibody, which we are developing for the subcutaneous prophylactic treatment of Von
Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor, or VWF, and Factor VIII, a blood coagulation protein. Von Willebrand Disease is
the most common inherited bleeding disorder and results from a reduced quantity or function of VWF, a plasma protein essential for normal hemostasis. Von Willebrand Disease is characterized by life-threatening hemorrhagic events and chronic
mucocutaneous bleeding episodes that combine to harm patients&#8217; physical health, mental well-being, and quality of life. Despite the availability of approved treatments, many patients continue to experience recurrent bleeding and substantial
treatment burden, as the approved therapies either require frequent intravenous administration or do not address the underlying biology of the disease. Beyond this initial indication, we believe HMB-002&#8217;s intended mechanism of action has
potential applicability across other bleeding conditions associated with low VWF levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 1/2 clinical trial of
HMB-002 for Von Willebrand Disease, which we refer to as Velora Pioneer. Velora Pioneer employs an adaptive dose-escalation design with two parts (Part A and Part B). In Part A, we are evaluating the safety, tolerability, pharmacokinetics, and
pharmacodynamics of single ascending doses of HMB-002. In Part B, participants transition from Part&nbsp;A into multiple-dose cohorts. As of the data cutoff date of September 2, 2025 for Velora Pioneer, we have completed treatment of two cohorts of
patients in Part A at dose levels of 20 mg and 50 mg and are currently evaluating patients in an ongoing 150 mg cohort. In the 20 mg and 50 mg cohorts, VWF and Factor VIII levels increased over 1.5-fold from baseline in a dose-dependent manner. In
addition, in the 20 mg cohort, HMB-002 corrected prolonged activated partial thromboplastin time and improved thrombin generation assays, resulting in enhanced overall coagulation activity for patients. Furthermore, a sustained VWF multimer
distribution was observed, suggesting that HMB-002 did not impact the protein structure of VWF. We expect to report initial data from Part B of Velora Pioneer in &#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to sutacimig and HMB-002, we are advancing multiple preclinical and discovery-stage assets. The first of our preclinical assets is expected
to enter clinical development in &#8195;&#8195;&#8195;, subject to regulatory submission and clearance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy and Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are guided by our &#8220;All Patients Matter&#8221; philosophy and by the conviction that individuals living with serious bleeding disorders should
not have to live with inadequate treatment options. Our mission is to deliver therapeutics that provide meaningful clinical benefit and enable patients to live full lives that are not defined or limited by their diseases. We aim to establish the
industry&#8217;s leading coagulation franchise through the execution of our &#8220;Hemab 2x3 by 2030&#8221; strategic roadmap, which is designed to build a franchise consisting of <B>2</B> commercial medicines, <B>2</B> new late-stage clinical
programs, and <B>2</B> new early-stage clinical programs by 2030. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following core pillars underpin our strategy and guide our approach to
reimagining the treatment of coagulation disorders. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We deploy a fundamentally patient-centric approach to drug development, beginning with listening, understanding, and
collaboration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We leverage our deep domain expertise to identify optimal therapeutic targets and match them to the most appropriate
validated drug technology platforms. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We apply a flexible approach to clinical trial design, to maximize development outcomes and efficiency by leveraging our
patient-driven insights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are building the foundations of an efficient and scalable commercial franchise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We bring an exceptional depth of experience across the entire value chain of drug discovery, development and
commercialization. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team and History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have assembled a leadership team and board of directors with deep experience in coagulation medicine and building life sciences companies. Members of
our board of directors and leadership and scientific teams have been directly involved in the discovery, development, regulatory approval, or commercialization of an extensive number of drugs approved for hemophilia, Von Willebrand Disease, and
other coagulation disorders, including ADYNOVATE, VONVENDI, QFITLIA, ELOCTATE, ALPROLIX, REFIXIA, NOVOEIGHT, ESPEROCT and ANGIOMAX. This collective expertise positions us to efficiently navigate the scientific, regulatory, and commercial
complexities inherent in developing therapies for coagulation disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since inception, we have raised approximately $346.0 million from
investors, including Access Biotechnology, Avoro Capital Advisors, Capital Group, Deep Track Capital, HealthCap, Invus, Novo Holdings, QIA, RA Capital Management, Rock Springs Capital and Sofinnova. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary of Risks Associated with Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business
is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this prospectus. These risks include, but are not limited to, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have incurred significant losses since our inception and have no products approved for sale. We expect to incur
significant losses for the foreseeable future and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have never generated revenue from product sales and may never achieve or maintain profitability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are heavily dependent on the success of sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> which are our
only clinical-stage product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will need substantial additional funding. If we are unable to raise capital on acceptable terms when needed, or at all,
we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess
our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are early in our clinical development efforts. If we are unable to successfully complete clinical development, obtain
marketing approval for, and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We will be required to incur
substantial costs and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of the success of later-stage
clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If serious adverse events or unacceptable side effects are identified during the development of our product candidates and
any other product candidates we may develop, we may need to abandon or limit our development of those product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we engage in future acquisitions, this may increase our capital requirements, dilute our stockholders, cause us to incur
debt or assume contingent liabilities, and subject us to other risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if any product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical community necessary for commercial success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or
more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not
perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We contract with third parties for the manufacture of our product candidates, plan to contract with third parties for any
other product candidates we may develop for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties entails risks, including that such third parties may not be able to comply with
applicable regulatory requirements. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may enter into collaborations with third parties for the development or commercialization of product candidates. If our
collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we fail to comply with our obligations under our existing license agreements with Novo Nordisk A/S and Genmab A/S, or
under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we are unable to obtain, maintain, enforce, defend and otherwise protect the intellectual property relating to our
technology and product candidates, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize technology and products similar or identical to
ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive,
time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to
commercialize a product candidate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remedy our
material weaknesses, or if we fail to establish and maintain an effective system of internal control over financial reporting, we may be unable to produce timely and accurate financial statements or prevent fraud, which could adversely impact our
business and our stock price. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">An active trading market for our common stock may not develop. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the State of Delaware on February&nbsp;12, 2026 under the name Hemab Therapeutics Holdings, Inc. We currently
operate as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the completion of this offering, we
will complete a corporate reorganization, pursuant to which our existing shareholders will exchange their shares in Hemab ApS for the same number, classes and series of newly issued shares in Hemab Therapeutics Holdings, Inc. and, as a result, Hemab
ApS will become a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Additionally, it is expected, in connection with the corporate reorganization, that Hemab ApS will transfer its shares of Hemab Therapeutics Inc., a Delaware corporation
and wholly-owned subsidiary of Hemab ApS, to Hemab Therapeutics Holdings, Inc. and, as a result, Hemab Therapeutics Inc. will become a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Hemab Therapeutics Holdings, Inc. will have nominal
assets and liabilities and will not have conducted any operations prior to this offering other than such acquisition, its incorporation and the corporate reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our principal executive offices are located at 101 Main Street Suite 1220, Cambridge, MA 02142, and our telephone number is (617) 553-3952. We also
maintain operations in Copenhagen, Denmark. Our website address is www.hemab.com. The information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus and you should not consider any such
information to be a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of
Being an Emerging Growth Company and a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act. As a result, we are able to take advantage of certain reduced reporting requirements that are otherwise applicable to public companies, including delaying auditor attestation of internal control over
financial reporting, providing only two years of audited financial statements and related management&#8217;s discussion and analysis of financial condition and results of operations and reduced executive compensation disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may remain an emerging growth company until the end of the fiscal year in which the fifth anniversary of this offering occurs. However, if certain
events occur prior to the end of such period, including if we become a &#8220;large accelerated filer&#8221; under rules of the Securities and Exchange Commission, or the SEC, our annual gross revenue exceeds $1.235&nbsp;billion, or we issue more
than $1&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and
may elect to take advantage of other reduced reporting requirements in future filings. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that
would be required if we were not an emerging growth company. As a result, the information that we provide to our stockholders may be different than what you might receive from other public reporting companies in which you hold equity interests. In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected not to &#8220;opt out&#8221; of such extended transition
period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at the time private companies
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
adopt the new or revised standard and may do so until such time that we either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify
as an emerging growth company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended,
or the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year
following the determination that (1)&nbsp;our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is $250&nbsp;million or more, measured on the last business day of our second fiscal quarter, or (2)&nbsp;our annual revenues
are $100&nbsp;million or more, during the most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is $700&nbsp;million or more, measured on the last business day of our second fiscal
quarter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"><FONT STYLE="font-size:8pt">&nbsp;</FONT>&#8195;&#8195;&#8195;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares of common stock </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days to purchase up to &#8195;&#8195;&#8195; additional shares of our common stock at the initial public offering price, less the underwriting discounts and commissions.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately following this offering </P></TD>
<TD>&#8195;&#8195;&#8195;shares (or &#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase additional shares of common stock in full). </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $&#8195;&#8195;&#8195; million (or approximately $&#8195;&#8195;&#8195; million if the underwriters exercise their option to purchase additional shares in full),
based on an assumed initial public offering price of $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds to us from this offering, together with our existing cash, cash equivalents, and marketable securities, to fund clinical development of sutacimig for the treatment of Glanzmann
thrombasthenia and Factor VII deficiency and <FONT STYLE="white-space:nowrap">HMB-002</FONT> for the treatment of Von Willebrand Disease; additional discovery, preclinical, and clinical activities for current and future programs; and the remainder
for working capital and other general corporate purposes. See &#8220;Use of Proceeds.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should read the &#8220;Risk Factors&#8221; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#8220;COAG&#8221; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding immediately following this offering is based on
&#8195;&#8195;&#8195;&#8195;&#8195; shares of our common stock outstanding as of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, after giving effect to the corporate reorganization and the automatic conversion of &#8195;&#8195;&#8195;&#8195;&#8195;
shares of our </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195;&#8195; shares of common stock, upon the completion of this offering. See the section of the prospectus titled &#8220;<I>Corporate
Reorganization</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding immediately following this offering excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195; shares of common stock issuable upon exercise of warrants outstanding as
of&#8195;&#8195;&#8195;&#8195;, 2026 with a weighted-average exercise price of $&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195; shares of our common stock that will become available for future issuance under our 2026 Equity
Incentive Plan, or the 2026 Plan, which will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock
reserved for future issuance under the 2026 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 Employee
Stock Purchase Plan, or the 2026 ESPP, which will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock
reserved for future issuance under the 2026 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all information in this prospectus reflects and
assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the consummation of the transactions described under the section titled &#8220;<I>Corporate</I>
<I>Reorganization</I>&#8221; prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no issuance or exercise of outstanding warrants after &#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the automatic conversion of all outstanding shares of our preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195;
shares of our common stock upon the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a &#8195;&#8195;&#8195;&#8195; <FONT STYLE="white-space:nowrap">-for-&#8195;&#8195;&#8195;&#8195;stock</FONT> split of our
common stock, which will become effective prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing and effectiveness of our restated certificate of incorporation and the adoption of our amended and restated
bylaws immediately prior to the completion of this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The following tables set forth our summary consolidated financial data for the years ended December&nbsp;31, 2024 and 2025. We have derived the summary statement of
operations and comprehensive loss data for the years ended December&nbsp;31, 2024 and 2025 and the balance sheet data from our consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements have been
prepared in accordance with U.S. generally accepted accounting principles, or GAAP. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. You should read the following summary
financial data together with the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of this prospectus and our consolidated financial statements and the related notes included elsewhere
in this prospectus. The summary consolidated financial data included in this section are not intended to replace the consolidated financial statements and are qualified in their entirety by our consolidated financial statements and the related notes
included elsewhere in this prospectus. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except<BR>share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,132.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,486.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net unrealized (loss) gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted-average shares outstanding, basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See Note 2 and Note 14 to our consolidated financial statements included elsewhere in this prospectus for an explanation
of the calculations of our net loss per share, basic and diluted, and the weighted-average number of shares used in the computation of <FONT STYLE="white-space:nowrap">per-share</FONT> amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The unaudited pro forma net loss per share, basic and diluted, for the year ended December&nbsp;31, 2025 has been
prepared to give effect to (1)&nbsp;the corporate reorganization, as if the corporate </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
reorganization had occurred on the first day of the period presented, including the exchange by existing shareholders of their shares in Hemab ApS for the same number, classes and series of newly
issued shares in Hemab Therapeutics Holdings, Inc. and the assumption and conversion of each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS into a warrant to purchase the same number of shares of our common stock,
and (2)&nbsp;the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock, which conversion will occur upon the completion of this offering, as if such conversion had occurred on the first day of the
period presented. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except for share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preference shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The pro forma consolidated balance sheet data gives effect to (1)&nbsp;the corporate reorganization, as if the corporate
reorganization had occurred as of December 31, 2025, including the exchange by existing shareholders of their shares in Hemab ApS for the same number, classes and series of newly issued shares in Hemab Therapeutics Holdings, Inc. and the assumption
and conversion of each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS into a warrant to purchase the same number of shares of our common stock, (2)&nbsp;the automatic conversion of all outstanding shares of
convertible preferred stock into shares of common stock, which conversion will occur upon the completion of this offering, and (3)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, which will occur
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted balance sheet data give effect to (i) the pro forma adjustments set forth in footnote (1) above
and (ii) the issuance and sale of &#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover
page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements and the
related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
pro forma as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial
public offering price of $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted amount of each of our cash, cash equivalents, and
marketable securities, working capital, total assets and total stockholders&#8217; (deficit) equity by approximately $&#8195;&#8195;&#8195;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase (decrease) the number of shares </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we are offering. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma
adjusted amount of each of our cash, cash equivalents, and marketable securities, working capital, total assets and total stockholders&#8217; (deficit) equity by approximately $&#8195;&#8195; , assuming the assumed initial public offering price per
share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with
all of the other information contained in this prospectus, including our consolidated financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our common stock. The risks described below are
not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business, prospects, operating
results and financial condition to suffer materially. In such an event, the trading price of our common stock could decline, and you might lose all or part of your investment.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are a late clinical-stage biopharmaceutical company, have no products approved for sale and have incurred significant losses since our inception. We expect to
incur significant losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a late clinical-stage
biopharmaceutical company with a limited operating history. Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including clinical trials and preclinical studies of our product
candidates, sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> and have incurred significant operating losses. Our net losses were $48.7&nbsp;million and $63.9&nbsp;million for the years ended December&nbsp;31, 2024 and 2025,
respectively. As of December&nbsp;31, 2025, we had an accumulated deficit of $181.9&nbsp;million. We have no approved products, and we have not generated any revenue from product sales. We have financed our operations primarily through private
placements of convertible preference shares, including our Series C financing, which we completed in October 2025, for aggregate gross proceeds of $156.9&nbsp;million, and issuances of convertible debt. We are still continuing to research and
develop our product candidates, and we have not yet completed the development of any of our product candidates. We expect to continue to incur significant operating expenses and net losses for the foreseeable future. Our operating expenses and net
losses may fluctuate significantly from quarter to quarter and year to year. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance. Because of the numerous risks
and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we become profitable, we may not be able to sustain or increase our
profitability on a quarterly or annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses will increase substantially, if and as, we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance the clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency, and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with
Von Willebrand Disease, as well as any other product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our clinical-stage product candidates into later-stage clinical trials, including our planned Phase 3 clinical
trial of sutacimig in patients with Glanzmann thrombasthenia, which will be required in order to seek marketing approval of our product candidates, and which we expect will be substantially more expensive than our earlier-stage clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance our research and preclinical activities and seek to discover and develop additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish and <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing processes and capabilities, or arrange for a
third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ultimately establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for
which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop, maintain, expand and protect our intellectual property portfolio (including intellectual property
obtained through license agreements) and provide reimbursement of third-party expenses related to our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish or maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire additional clinical, medical, regulatory, quality control, manufacturing and other scientific and technical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial, clinical, quality and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts of our product candidates and our operations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional audit, legal, regulatory, tax and other expenses with being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any milestone, royalty, or other payments to Novo Nordisk A/S, or Novo Nordisk, under our license agreement with Novo
Nordisk, or the Novo Nordisk Agreement, and to Genmab A/S, or Genmab, under our license agreement with Genmab, or the Genmab Agreement, and under any additional future collaboration or license agreements that we may enter into.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">In addition, our expenses will further increase if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other
regulatory authorities to perform clinical trials or preclinical studies that are in addition to, or different than, those expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any delays in completing our clinical trials or preclinical studies or the development of any of our product
candidates; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual
property-related claim. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we obtain marketing approval for, and are successful in commercializing, one or more of our
product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. We may encounter
unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to
generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have never generated revenue from product sales and may never achieve or maintain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that it will be several years before we have a product candidate ready for commercialization, if ever. To become and remain profitable, we must
succeed in developing, obtaining the necessary marketing approvals and eventually commercializing, a product or products that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing preclinical testing and clinical
trials of our product candidates and any other product candidates we may identify and pursue, obtaining marketing approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain marketing approval.
We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we
are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenue or achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on
a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts,
diversify our product candidates, achieve our strategic objectives or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding
to continue operations. Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain marketing approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether
we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by
competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will need
substantial additional funding. If we are unable to raise capital on acceptable terms when needed, or at all, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operations have consumed substantial amounts of cash since inception. Identifying potential product candidates and conducting preclinical testing and
clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approvals and achieve product sales. We expect to devote
substantial financial resources to our ongoing and planned activities, particularly as we commence our planned Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia and continue our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency and Phase 1/2 trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease, continue
research and development and initiate additional clinical trials of, and seek marketing approval for, these and other product candidates. We expect our expenses to increase substantially in connection with our ongoing and planned activities,
particularly as we advance our preclinical activities and clinical trials of and potentially seek marketing approval for our product candidates and other product candidates we may identify, and if and as we expand our research and development and <FONT
STYLE="white-space:nowrap">scale-up</FONT> and manufacture our product candidates for our current and future indications. We will be required to incur substantial costs and may experience delays in completing, or ultimately be unable to complete,
the development and commercialization of any product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, if we obtain marketing approval for our product candidates and any
other product candidates we may identify and pursue, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, upon the completion of this offering, we expect to incur
additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding to support our continuing operations and pursue our growth strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Identifying potential product candidates and conducting preclinical testing and clinical trials is a
time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, any product candidates, if approved,
may not achieve commercial success. We will not generate commercial revenues, if any, unless and until we, alone or with partners, can achieve sales of products, which we do not anticipate will occur for many years, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had cash, cash equivalents and marketable securities of $185.5&nbsp;million. We believe that our existing cash, cash
equivalents and marketable securities, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195;. However, we have based this
estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to
seek additional funding sooner than planned. We would be required to obtain substantial additional funding in order to initiate and conduct registrational and other clinical trials for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently do not have a credit facility or any committed sources of capital. If we are unable to raise capital or obtain adequate funds when needed
or on acceptable terms, we may be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to
develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, costs and results of our current and future preclinical studies and clinical trials for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether we partner our programs with collaborators for later-stage clinical development or commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and development requirements of any other product candidates we may identify and develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of obtaining clinical and commercial supplies of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully commercialize our product candidates and any other product candidates we may identify and
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the manufacturing, selling and marketing costs associated with our product candidates and any other product candidates we
may identify and develop, including the cost and timing of establishing sales and marketing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, costs and results of any post-marketing studies that could be required by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the amount and timing of sales and other revenues from our product candidates and any other product candidates we may
identify and develop, including the sales price and the availability of coverage and adequate third-party reimbursement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the time and cost necessary to respond to technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">milestone payments and other collaboration-based payments, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of macroeconomic trends including inflation, foreign exchange rate, interest rates and tariffs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining, enforcing and protecting our
intellectual property and proprietary rights and defending any intellectual property-related claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any additional fundraising
efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize any product candidates.
Additionally, volatility in the financial markets and general economic conditions may be a significant obstacle to raising the required funds. We cannot be certain that adequate additional financing will be available to us on acceptable terms, or at
all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If adequate funds are not available to us on a
timely basis or on terms acceptable to us, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more product candidates or discovery stage programs or delay, limit,
reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize any product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of our common stock in this offering, restrict our operations or require
us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Until such time, if ever, as we can generate substantial product
revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, royalty financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any source of
committed capital or external funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or
other preferences that adversely affect your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we raise additional funds through partnerships, collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when
needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to
develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our limited operating history may make it difficult for you to evaluate the success of our business to date and
to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We commenced operations in 2020 and are a late clinical-stage biotechnology company. Our operations to date
have been limited to organizing and staffing our company, business planning, raising capital, securing intellectual property rights, <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology, discovering product candidates, undertaking
preclinical studies and conducting clinical trials. While we are in the process of conducting Phase 1/2 and Phase 2 trials, we have not yet initiated or completed a Phase 3 clinical trial of any product candidate. We have not yet demonstrated our
ability to successfully develop any product candidate, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product
commercialization. Therefore, we cannot be certain that our ongoing preclinical studies and clinical trials will be completed on time or that our planned preclinical studies and clinical trials will begin or be completed on time, if at all. Further,
biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. You should consider our prospects in light of the costs, uncertainties, delays, and difficulties frequently encountered by companies
in clinical development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of
successfully developing and commercializing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as our business grows, we may encounter unforeseen expenses, difficulties,
restrictions, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful
in such a transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our financial condition and operating results to fluctuate significantly from quarter to quarter and year to year
due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income may be subject to certain
limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had $170.9&nbsp;million of net operating losses, or NOLs. Our anticipated activities are also
expected to result in future significant NOLs in Denmark and the United States resulting in additional deferred tax assets. Utilization of most deferred tax assets is dependent on generating sufficient future taxable income in the appropriate
jurisdiction and/or entity. We have recorded a full valuation allowance on our net deferred tax assets as of December&nbsp;31, 2025, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets
will not be realized in a future period. Additionally, most of our deferred tax assets are determined by reference to applicable corporate income tax rates in Denmark. Accordingly, in the event of a reduction of any such corporate income tax rates,
the carrying value of certain of our deferred tax assets would decrease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, our ability to use our NOLs and other deferred tax assets to
offset future taxable income in Denmark and the United States may be limited if we experience an ownership change. For Danish income tax purposes, an ownership change will generally occur when one, or several shareholders together, at once or
successively, acquire shares representing more than 50% of the share capital or voting power. Although such an ownership change entails no reduction of the amount of NOLs to be carried forward, the utilization is restricted to exclude offsetting
against positive net capital income (e.g. income from interest, dividend and royalty) on NOLs incurred in a previous income year, where the ownership differs by 50% (under section 12D of the Danish Corporate Tax Act). In the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
United States, in general, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership
change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its
<FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset future taxable income. We have not conducted a study to assess whether any such ownership changes have occurred. We may have
experienced such ownership changes in the past and may experience such ownership changes in the future as a result of this offering and/or subsequent changes in our stock ownership (which may be outside our control). As a result, if, and to the
extent that, we earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire
or otherwise become unavailable to offset future income tax liabilities. Additionally, in the United States, state NOLs generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain
profitability, we may be unable to use a material portion of our NOLs and other tax attributes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The tax authorities in the jurisdictions in which we operate
may challenge our transfer pricing procedures. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a multinational business that has operations in Denmark and other tax jurisdictions,
and the tax laws of those jurisdictions generally require that royalty and other payments between affiliated companies in different jurisdictions be the same as those between unrelated companies dealing at arm&#8217;s length, and that such prices
are supported by contemporaneous documentation. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities. If
tax authorities in any of these jurisdictions were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income or deductions
to reflect these revised transfer prices, which could result in a higher overall tax liability to us and possibly interest and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, tax authorities in the jurisdictions in which we operate may challenge our treatment of our corporate reorganization. No assets (either
physical or intangible) are being transferred from Denmark to the United States pursuant to our corporate reorganization, nor are any existing business functions or units operating from Denmark being transferred from Hemab ApS to Hemab Therapeutics
Holdings, Inc. as part of our corporate reorganization to form part of our U.S. operations. Accordingly, we do not intend to treat our corporate reorganization as a deemed sale of all or part of our business by Hemab ApS to Hemab Therapeutics
Holdings, Inc. If Danish tax authorities were to disagree with our position and treat our corporate reorganization or any of our activities thereafter as a deemed sale, in whole or in part, of intellectual property rights and/or other assets owned
by Hemab ApS to Hemab Therapeutics Holdings, Inc., we could be subject to a Danish tax, the current rate of which is 22%, on the gain realized calculated as the difference between the fair market value and the tax value of the assets, at the time of
the deemed sale of the assets from Denmark as determined by the Danish tax authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, the nature of our operations can produce
conflicting claims from tax authorities in different countries as to the profits to be taxed in the individual countries. The jurisdictions in which we operate have double tax treaties with other jurisdictions, which provide a framework for
mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untested, can be expected to be very lengthy, and do not always contain a mandatory dispute
resolution clause. In recent years, tax authorities around the world have increased their scrutiny of company tax filings and have become more rigid in exercising any discretion they may have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, tax reform efforts, including with respect to transfer pricing, will require us to
continually assess our organizational structure and could lead to an increased risk of international tax disputes, an increase in our effective tax rate and an adverse effect on our financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Discovery, Development and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are heavily dependent on the success of sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> which are our only clinical-stage product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We expect that a
substantial portion of our efforts and expenditures over the next several years will be devoted to sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> which are currently our only clinical-stage product candidates. Accordingly, our
business currently depends heavily on the successful development, marketing approval and commercialization of these product candidates. We cannot be certain that sutacimig or <FONT STYLE="white-space:nowrap">HMB-002</FONT> will receive marketing
approval, be approved for the indications that we may seek or be successfully commercialized even if we receive marketing approvals. If we were required to discontinue development of sutacimig or <FONT STYLE="white-space:nowrap">HMB-002,</FONT> or
if any of these product candidates do not receive marketing approvals or fail to achieve significant market acceptance, we would be delayed by many years in our ability to achieve profitability, if ever, and may not be able to generate sufficient
revenue to continue our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to successfully complete clinical development, obtain marketing approval for, and ultimately commercialize
our product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To date, we have invested a
majority of our efforts and financial resources in the preclinical and clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of sutacimig in patients Glanzmann thrombasthenia, Phase 2 clinical trial of
sutacimig in patients with Factor VII deficiency and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease. We have not yet initiated a Phase 3 trial of any product candidate.
Our future success is heavily dependent on our ability to successfully develop, obtain marketing approval for and ultimately commercialize our product candidates. We cannot be certain that our product candidates will be successful in clinical trials
or receive marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successfully completing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance by the FDA or other regulatory agencies of regulatory filings for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expanding and maintaining a workforce of experienced scientists and others to continue to develop our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing sales, marketing and distribution capabilities and successfully launching commercial sales, if and when
approved, whether alone or in collaboration with others; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance of the products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">further chemistry, manufacturing and controls, manufacturing or development and optimization of the formulation and
presentation of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">effectively competing or successfully being administered with other approved therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including
government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patients&#8217; willingness to pay out of pocket for our products in the absence of coverage and/or adequate reimbursement
from third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining a continued acceptable safety and tolerability profile following receipt of any marketing approvals.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of these factors are beyond our control, including clinical outcomes, the regulatory review process, potential threats to
our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborators. If we are unable to develop, receive marketing approval for and successfully commercialize our product candidates, or if we experience
delays as a result of any of these factors or otherwise, we may need to spend significant additional time and resources to identify other product candidates, advance them through preclinical and clinical development, and apply for marketing
approvals, which would adversely affect our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical drug development involves a lengthy
and expensive process, with an uncertain outcome. We will be required to incur substantial costs and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The risk of failure for our product candidates and any other product candidates we may develop is high. It is impossible to predict when or
if our product candidates and any other product candidates we may develop will prove effective or safe in humans or will receive marketing approval. The time required to obtain approval from the FDA, EMA or other comparable foreign regulatory
authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. Before obtaining marketing approval from
regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. We have not yet initiated a
pivotal clinical trial for any of our product candidates. Clinical trials may fail to demonstrate that our current or future product candidates are safe for humans and effective for indicated uses. Even if initial clinical trials in any of our
product candidates we may develop are successful, these product candidates may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through preclinical studies and initial clinical
trials. There is a high failure rate for drugs proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials even after achieving
promising results in earlier-stage clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, clinical trials for blood disorders present unique challenges: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The small patient populations in the indications we are pursuing, such as Glanzmann thrombasthenia and Factor VII
deficiency (which we estimate to be approximately 10,000 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
patients in the aggregate in the geographies where we intend to commercialize sutacimig, including the United States, the European Union, Japan, the Gulf Cooperation Council, or GCC, countries
and other select regions), may make it challenging to enroll a sufficient number of patients in our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The variability in bleeding phenotypes and disease severity in these conditions can make it difficult to demonstrate
statistical significance in clinical endpoints. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The lack of validated biomarkers and endpoints in blood disorders requires us to develop novel endpoints, which may not be
accepted by regulatory authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Patients with coagulation disorders may be geographically dispersed, requiring multi-national clinical trials with
associated regulatory complexity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Recruitment of patients for our clinical trials may be slower than anticipated due to the low prevalence of these
conditions, competition for patients from other clinical trials and the burden of our clinical trials on patients, including due to the duration of our clinical trials, the need for a higher degree of oversight by principal investigators, and the
requirement of patient adherence to strict electronic bleed diary protocol requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The potential that rare and severe side effects of our product candidates may be uncovered in the later stages of clinical
development due to accelerated development, which could result in disruptions and delays or a need for increased sample sizes for our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">As with most procoagulant drugs, our product candidates have the potential for adverse effects, including thrombotic
events, which can occur at any active dose level due to sporadic or patient-specific factors that are hard to identify. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The patient populations in coagulation disorders are not as accustomed to participation in clinical trials, as in other
indications, which may impact the ability to recruit and maintain patients in our clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if the clinical trials
are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application
may cause delays in the approval or rejection of an application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before we can commence clinical trials for a product candidate, we must complete
extensive preclinical testing and studies that support investigational new drug applications, or INDs, and other regulatory filings in the United States, marketing applications in the European Union and other applications and filings in other
jurisdictions. We cannot be certain of the timely completion or outcome of preclinical testing and studies and cannot predict if the FDA or other regulatory agencies will accept any proposed clinical programs or if the outcome of any preclinical
testing and studies will ultimately support the further development of any product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for any preclinical programs on the timelines we expect, if at
all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued preclinical safety studies,
which may be conducted concurrently with clinical testing. The outcomes of these safety studies may delay the launch of, or enrollment in, future clinical trials and could impact our ability to continue to conduct our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical testing is expensive and is difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We cannot
guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not
limited to, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product
candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in
any clinical trial could negatively impact the perception of our other product candidates and/or cause the FDA, EMA or other regulatory authorities to require additional testing before approving any of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability
to receive marketing approval or commercialize our product candidates and any other product candidates we may develop, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators or institutional review boards, or IRBs, or independent ethics committees may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial
protocols with prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may decide that longer <FONT STYLE="white-space:nowrap">follow-up</FONT> data are needed before they will
consider our marketing applications, which would delay our ability to obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may decide the design of our clinical trials is flawed, for example, if our trial protocol does not evaluate
treatment effects in trial subjects for a sufficient length of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical trials of our product candidates and any other product candidates we may develop may produce negative or
inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically
meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities would consider likely to predict clinical benefit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional
preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of patients required for clinical trials of our product candidates and any other product candidates we may
develop may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in
a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may decide, or regulators or IRBs may require us, to suspend or terminate clinical trials of our product candidates and
any other product candidates we may develop for various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to
additional post-marketing testing requirements to maintain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may revise the requirements for approving our product candidates and any other product candidates we may
develop, or such requirements may not be as we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of clinical trials of our product candidates and any other product candidates we may develop may be greater than
we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the supply or quality of our product candidates and any other product candidates we may develop or other materials
necessary to conduct clinical trials of such product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our product candidates and any other product candidates we may develop may have undesirable side effects or other
unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a
risk evaluation and mitigation strategy, or REMS. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We could encounter delays if a clinical trial is suspended or terminated by us,
by the IRBs of the institutions in which such trials are conducted or their ethics committees, by the data review committee or data safety monitoring board for such trial or by the FDA, EMA or other foreign regulatory authorities. Such authorities
may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by
the FDA, EMA or other foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidates belong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we
are unable to successfully complete clinical trials or other testing of our product candidates or any other product candidates we may develop, if the results of these trials or tests are not positive or are only modestly positive, or if there are
safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be delayed in obtaining marketing approval for any product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not obtain marketing approval at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals.
We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our
clinical trials, including to add additional patients or arms, which could result in increased costs and expenses and/or delays. Significant preclinical study or clinical trial delays also could shorten any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
periods during which we may have the exclusive right to commercialize any product candidates or allow our competitors to bring products to market before we do and impair our ability to
successfully commercialize any product candidates and may harm our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The outcome of preclinical studies and earlier-stage
clinical trials may not be predictive of the success of later-stage clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The outcome of preclinical testing and earlier-stage
clinical trials may not be predictive of the success of later-stage clinical trials. Our product candidates and any other product candidates we may develop may fail to show the desired safety, potency and purity in clinical development despite
positive results in preclinical studies or having successfully advanced through initial clinical trials. For example, we are currently planning our Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, based off the positive
results of our Phase 1/2 dose-finding study in patients with Glanzmann thrombasthenia. However, we cannot provide assurances that the evidence of activity we observed in our Phase 1/2 trial of sutacimig will translate to our planned Phase 3 clinical
trial. Additionally, any positive results generated in our ongoing and planned clinical trials do not ensure that we will achieve similar results in later-stage clinical trials of these product candidates, and we cannot provide assurances that we
will be able to seek or obtain marketing approval for any of our product candidates even if our clinical trials are successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many companies in
the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving promising results in preclinical testing and earlier-stage clinical trials, and we cannot be certain that we will not
face similar setbacks. In addition, while the animal models used in preclinical studies are designed to be representative of disease states in humans, these preclinical models may not be able to accurately predict the way a product candidate will
affect patients in clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies
and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any product candidate to demonstrate safety, potency and purity in any clinical trial could negatively impact the perception of
any other product candidates we may developing at the time and/or cause the FDA or other regulatory authorities to require additional testing before approving any other product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim, <FONT STYLE="white-space:nowrap">top-line</FONT> and preliminary results from our clinical trials that we announce or publish from time to time may
change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may publish or report interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results from our clinical trials.
For example, we plan to report data for our Phase 2 clinical trial of sutacimig in Factor VII deficiency in&#8195;&#8195;&#8195;&#8195;, and data from our Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with
Von Willebrand Disease in &#8195;&#8195;&#8195;&#8195;. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more
patient data become available. Preliminary, interim or <FONT STYLE="white-space:nowrap">top-line</FONT> results also remain subject to audit and verification procedures that may result in the final data being materially different from the
preliminary or interim data we previously published. As a result, interim, <FONT STYLE="white-space:nowrap">top-line</FONT> and preliminary data should be viewed with caution until the final data are available. Adverse differences between
preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>As an organization, we have never conducted pivotal clinical trials, and we may be unable to do so for our
product candidates or any other product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will need to successfully complete pivotal clinical trials in order to
obtain the approval of the FDA, the EMA, or other regulatory agencies to market our product candidates or any future product candidate. Carrying out later-stage clinical trials is a complicated process. As an organization, we have not previously
conducted any pivotal clinical trials. In order to do so, we will need to significantly expand our clinical development and regulatory capabilities. In addition, we may be unable to recruit and train qualified personnel. Consequently, we may be
unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to approval of our product candidates or future product candidates. We may require more time and incur greater costs than our competitors and
may not succeed in obtaining marketing approvals of product candidates that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to the complexity, expense, scale and size of clinical
trials, we may have to find one or more collaborators to conduct such a trial, and there can be no assurance that we would be able to do so. Even if we are able to find a collaborator, we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. See &#8220;&#8212;Risks Related to Our Dependence on Third Parties&#8212;We may enter into collaborations with third parties
for the development or commercialization of product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.&#8221;
Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If
we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our product candidates may be delayed, and our business and results of operations may be
harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other
product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings or commercialization objectives. From time to
time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval or a commercial launch of a product. The
achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which, if not realized as expected, may cause the timing of achievement of the milestones to vary considerably from
our estimates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including the
extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our receipt of approvals by the FDA, EMA, and other comparable regulatory authorities and the timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing
activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail to achieve announced milestones in the timeframes we expect, the development and commercialization of our
product candidates may be delayed, and our business and results of operations may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we experience delays or difficulties in the enrollment of
patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Identifying and qualifying patients
to participate in clinical trials for our product candidates and any other product candidates we may develop is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients,
as required by the FDA, EMA or similar regulatory authorities in other jurisdictions, who remain in the trial until its conclusion. Additionally, the prevalence of patients in our target indications is estimated to be low, and we estimate that there
are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize, including the United
States, the European Union, Japan, the GCC countries and other select regions. We may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical trials of our product candidates because of the perceived
risks and benefits of our product candidates, the availability of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective subjects and the subject referral practices of physicians, among other
factors. Patient enrollment is affected by a variety of other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the eligibility and the discontinuation criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the perceived risks and benefits of the product candidate under trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the requirements of the trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of existing commercially available treatments for the targeted indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the conduct of clinical trials by competitors for product candidates that treat the targeted indications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to identify specific patient populations for biomarker-defined trial cohort(s); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost to, or lack of adequate compensation for, prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to
abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary marketing approvals, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. Enrollment
delays in our clinical trials may result in increased development costs for our product candidates and any other product candidates we may develop, which would cause the value of our company to decline and limit our ability to obtain additional
financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we are able to enroll a sufficient number of patients for our future clinical trials, we may
have difficulty maintaining patients in our clinical trials, including that patients may drop out of our clinical trials. If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, we may need to
delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in methods
of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As product candidates proceed through preclinical
studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered over the course of development in an
effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical
trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the
conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If serious adverse events or unacceptable side effects are identified during the development of our product candidates and any other product candidates we may
develop, we may need to abandon or limit our development of those product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials by their nature utilize a sample of
the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product
candidate. For example, our Phase 1/2 clinical trial of sutacimig for the treatment of Glanzmann thrombasthenia has included only 34 patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
addition, as we continue to evaluate our product candidates, rare and severe side effects of our product candidates may be uncovered in the later stages of our current and future clinical development. For example, in our Phase 1/2 clinical trial of
sutacimig in Glanzmann thrombasthenia, several patients have experienced events of thrombosis. In particular, one patient experienced a grade&nbsp;2 proximal deep vein thrombotic event at the highest exposure level (0.9 mg/kg) and one patient at the
0.3 mg/kg dose level (whose dose had been reduced from 0.6 mg/kg) experienced grade 2 subsegmental pulmonary embolism. These events were reported to the FDA on an expedited reporting basis as an event of a type referred to as a Suspected Unexpected
Serious Adverse Reaction (SUSAR). While we expect to select a lower dose than 0.6 mg/kg for purposes of our planned Phase 3 clinical trial, thrombotic events have been reported at the 0.3 mg/kg dose level, and there is no guarantee that thrombotic
events or other serious adverse events will not occur even at this lower dose. In addition, sutacimig&#8217;s mechanism of action inherently carries the risk of thrombotic complications if the drug achieves excessive systemic exposure or if patients
have concurrent prothrombotic conditions or other risk factors. <FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of increasing von Willebrand factor, or VWF, and Factor VIII levels could also increase thrombotic risk,
particularly in patients with concurrent conditions that increase VWF levels, such as pregnancy, acute illness, or hormonal contraception use, or result in other adverse events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented
their further development. If our product candidates and any other product candidates we may develop are associated with undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or preclinical
testing, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the side effects or other characteristics are less prevalent, less severe or more
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
acceptable from a risk-benefit perspective. In biopharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects
that delay or prevent further development of the compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, if results of our clinical trials reveal unacceptable side effects, we,
the FDA or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our
product candidates and any other product candidates we may develop for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials.
In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon
any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in harm to patients that are administered our product candidates. Any of these
occurrences may adversely affect our business, financial condition and prospects significantly </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If any product candidate receives marketing approval and we,
or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We conduct, and intend to conduct in the future, clinical trials of product candidates in carefully defined subsets of patients who have agreed to enter
into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side
effects. If any product candidate receives marketing approval, and we, or others, later discover that it is less effective than previously believed, or causes undesirable side effects, a number of potentially significant negative consequences could
result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal or limitation by regulatory authorities of approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seizure of the product by regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recall of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing of the product or the manufacturing process for any component thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirement by regulatory authorities of additional warnings on the label, such as a &#8220;black box&#8221; warning or
contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirement that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution
to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product may become less competitive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiation of regulatory investigations and government enforcement actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiation of legal action against us to hold us liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">harm to our reputation and resulting harm to physician or patient acceptance of our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could
significantly harm our business, financial condition, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Some data for our product candidates comes from clinical trials conducted outside the United States or European
Union. The FDA, EMA, or other comparable regulatory authorities, may not accept data from trials conducted in such locations, which could subject us to additional delays and expense. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may conduct one or more of our clinical trials with one or more trial sites that are located outside the United States or European Union. The
acceptance of data from clinical trials conducted outside the United States or another jurisdiction by the FDA may be subject to certain conditions or may not be accepted at all. Similarly, the EMA, and other equivalent foreign regulatory
authorities may not accept data from trials conducted outside their jurisdiction. For example, we are currently conducting our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency at sites in the United Kingdom, and our
ongoing Phase 1/2 trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease at sites in United Kingdom, Australia, and the United States. We plan to conduct our Phase 3 clinical trial of sutacimig in patients
with Glanzmann thrombasthenia in the United States, Europe and potentially other jurisdictions. In cases where data from clinical trials outside of the United States are intended to serve as the basis for marketing approval in the United States,
acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The FDA must be able to
validate the data from the trial through an onsite inspection, if necessary. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the
FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, whether the FDA accepts the data will depend on its determination that the trials also complied with all applicable U.S. laws and
regulations. Additionally, recent policy proposals in the United States, if enacted in the future, may make acceptance by the FDA or inclusion in a marketing application of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> data more difficult or
costly. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for
additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may
not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of
success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we do not successfully develop and eventually commercialize products, we will not generate product revenue in future periods,
resulting in significant harm to our financial position and adversely affecting our share price. Research programs to identify new product candidates require substantial technical, financial and human resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although our product candidates are currently in clinical development, we may fail to identify other potential product candidates for clinical
development. Our focus on blood coagulation disorders limits our opportunities to a specific therapeutic area. If there are fewer than anticipated viable product targets in this area, or if competitors develop superior products for these
indications, our business may suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain
programs or product candidates or for indications that later prove to have greater commercial potential. For example, we currently intend to focus our capital resources primarily on the development of our product candidates. We have prioritized the
development of sutacimig for Glanzmann thrombasthenia and Factor VII deficiency, which are both blood disorders with small patient populations, instead of potentially expanding into larger platelet disorder indications, which may have larger markets
and potentially greater commercial returns. The development of our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidates may ultimately prove to be unsuccessful or less successful than another potential product candidate in our pipeline that we might have chosen to pursue on a more aggressive basis with
our capital resources. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaborations, licensing or other arrangements in
cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it
would have been more advantageous to enter into a partnering arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we engage in future acquisitions, this may increase our capital requirements,
dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we
evaluate various acquisition opportunities, including licensing or acquiring complementary products, product candidates, intellectual property rights, technologies or businesses. Any potential acquisition may entail numerous risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the assumption of additional indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including
difficulties associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic
merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and
their existing products, product candidates and marketing approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to generate revenue from acquired product candidates or products sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not know if we will be able
to identify acquisitions or strategic relationships we deem suitable, whether we will be able to successfully complete any such transactions on favorable terms, if at all, or whether we will be able to successfully integrate any acquired business,
product or technology into our business or retain any key personnel or suppliers. Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses,
technologies or products and to obtain any necessary financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as consideration, which could dilute
the ownership of our stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration. Additional funds may not be
available on terms that are favorable to us, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if any product candidate receives marketing approval, it may fail to achieve the degree of market
acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any product
candidate receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Sales of medical products depend in part on the willingness of
physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost-effective. In addition, the inclusion or exclusion of products from treatment
guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations,
hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost-effective as compared with competing treatments. Efforts to educate the medical community and
third-party payors on the benefits of our product candidates and any other product candidates we may develop may require significant resources, including management time and financial resources, and may not be successful. If our product candidates
and any other product candidates we may develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates and any
other product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy, safety and potential advantages of our product candidates compared to the advantages and relative risks of
alternative treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of treatment in relation to alternative treatments, including any similar generic or biosimilar treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations or warnings, including distribution or use restrictions contained in the product&#8217;s approved labeling;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the clinical indications for which the product is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of the target patient population to try new therapies and to continue treatment over time and of physicians
to prescribe these therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket
for required <FONT STYLE="white-space:nowrap">co-payments</FONT> or in the absence of third-party coverage or adequate reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any restrictions on the use of our products, if approved, together with other medications; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any failure by one or more of our product candidates that obtains regulatory approval to achieve market acceptance or
commercial success would adversely affect our business prospects. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the market opportunities for any product candidates we develop are smaller than we believe they are, our
revenue may be adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We focus our research and product development on treatments for bleeding
disorders. Given the small number of patients who have certain of the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these diseases. Our projections
of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with any product candidates we may develop, are based on our beliefs and estimates. These
estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and &#8220;360&#8221; natural history studies that we conducted, and may prove to be incorrect or
contain errors. New studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we
cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our
product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product
candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.&nbsp;Additionally, if the actual market for any product candidates we may develop is smaller
than we estimate, our revenues, if any, may be limited and it may be more difficult for us to achieve or maintain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even with high
penetration rates and premium pricing typical of orphan drugs, the revenue potential for sutacimig for the treatment of Glanzmann thrombasthenia and Factor VII deficiency may be limited due to the small patient populations. The pricing and
reimbursement of any product candidates we may develop, if approved, is uncertain, and it may not be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of pricing or reimbursement, our ability to successfully
market and sell product candidates will be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to establish sales, marketing and distribution capabilities or enter into
sales, marketing and distribution agreements with third parties, we may not be successful in commercializing any product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve
commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the future, we expect to build a sales and marketing infrastructure to market our product candidates and any other product candidates we may develop
in the United States, Europe and potentially other jurisdictions, if and when approved by the respective regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are risks
involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate
for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our
investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factors that may inhibit our efforts to commercialize
our products on our own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement,
customer service, medical affairs and other support personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of sales personnel to educate adequate numbers of physicians on the benefits of any future products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other
acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient
population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third
parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering
into arrangements with third parties to sell, market and distribute any product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote
the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be
successful in commercializing any product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing
products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The development and commercialization of new drug products is highly competitive. We face
competition with respect to our product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies
and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the same disease indications we
are pursuing. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic
institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Any product
candidates that we successfully develop and commercialize will compete with existing products and new products that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are currently no subcutaneous prophylactic therapies for Glanzmann thrombasthenia or Factor VII deficiency that are in development or approved.
However, companies could develop new therapies or repurpose existing therapies for Glanzmann thrombasthenia or Factor VII deficiency, such as emicizumab (Hemlibra), which was developed for hemophilia A, but could potentially be studied in other
bleeding disorders, potentially including our target indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For Von Willebrand Disease, the competitive landscape includes currently
available therapies and products in development. The current standard of care includes desmopressin and VWF replacement products, including both plasma-derived products <FONT STYLE="white-space:nowrap">(Humate-P,</FONT> Wilate, Alphanate) and
recombinant VWF (Vonvendi). These products have established positions in the market and physician familiarity. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
addition, Star Therapeutics Inc. is currently developing <FONT STYLE="white-space:nowrap">VGA-039,</FONT> an investigational monoclonal antibody that inhibits protein S, which is currently in
Phase 3 clinical development for Von Willebrand Disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by
insurers or other third-party payors seeking to encourage the use of generic and/or biosimilar products. If any product candidates achieve marketing approval, we expect that they would be priced at a significant premium over competitive generic or
biosimilar products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of the companies against which we are competing or against which we may compete in the future have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. If we successfully obtain approval for any
product candidate, we will face competition based on many different factors, including the safety, tolerability and effectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for
these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective,
tolerable or convenient, safer, less expensive or marketed and sold more effectively than any products we may develop. Competing products may render any product candidates we develop obsolete or noncompetitive before we recover the expense of
developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Mergers and acquisitions in the pharmaceutical, biopharmaceutical and biotechnology industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with
us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or
reimbursement practices or healthcare reform initiatives, which could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The regulations that govern marketing approvals,
pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in
obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets,
prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country but then be subject to price
regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our
ability to recoup our investment in one or more product candidates, even if any product candidates obtain marketing approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to commercialize any product candidates successfully will depend in part on the extent to
which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third- party
payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment.
Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with
predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement
may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. There can be no
assurance that any product candidates, even if they are approved for sale in the United States, Europe or in other jurisdictions, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party
payors. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available, we may not be able to
successfully commercialize any product candidate for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There may be significant delays in obtaining coverage and
reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA, European Commission or similar regulatory authorities in other jurisdictions. Moreover, eligibility for coverage
and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable,
may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost
drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that
presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Further, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and processes apart from Medicare determinations. As a result, obtaining and maintaining coverage and adequate reimbursement is
often time-consuming and costly. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our
operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future growth depends, in part, on
our ability to penetrate markets outside the United States and the European Union, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future profitability will depend, in part, on our ability to commercialize our product candidates and any other product candidates we may develop in
markets outside of the United States and the European Union. We are not permitted to market or promote any product candidate before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive
such regulatory approvals for any product candidates. If we commercialize our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidates and any other product candidates we may develop in foreign markets, we will be subject to additional risks and uncertainties, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">economic weakness, including inflation, or political instability in particular economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which
vary between countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">tariffs and trade barriers, as well as other governmental controls and trade restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other trade protection measures, import or export licensing requirements or other restrictive actions by governments in the
jurisdictions in which we operate or plan to operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">longer accounts receivable collection times; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">longer lead times for shipping; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">language barriers for technical training; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic
alternatives to therapeutics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign currency exchange rate fluctuations and currency controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">differing foreign reimbursement landscapes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">uncertain and potentially inadequate reimbursement of our products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If risks related to any of these uncertainties materialize, it could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit
commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face an inherent risk of clinical trial and product liability exposure related to
the testing of our product candidates and any other product candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have
been approved for commercial sale, the current and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the
product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates and any other product candidates or products we may develop caused
injuries, we will incur substantial liabilities. Even a successful defense would require significant financial and management resources. Regardless of merit or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for our product candidates and any other product candidates or products that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we currently hold clinical trial liability insurance coverage in amounts we believe to be adequate, the coverage limits may be inadequate to
cover all liabilities we may incur, and we may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of any product candidates. Insurance coverage is increasingly expensive. We may not be able
to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in
excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If any product candidate
receives marketing approval, we will be required to report to regulatory authorities if the product causes or contributes to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are successful in commercializing any product candidate, the FDA and foreign regulatory authorities would require that we report
certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the
nature of the event. We may fail to report adverse events within the prescribed timeframe. If we fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the
imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Dependence on Third
Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily,
including failing to meet deadlines for the completion of such trials, which may harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently rely on third-party
clinical research organizations, or CROs, to conduct our planned and ongoing clinical trials. We do not plan to independently conduct clinical trials of our product candidates. We expect to continue to rely on third parties, such as CROs, clinical
data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These third parties are not our
employees, and except for remedies available to us under our agreements with such third parties, we have limited ability to control the amount or timing of resources that any such third party will devote to our preclinical studies or our clinical
trials. The third parties we rely on for these services may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could
affect their performance on our behalf. Some of these third parties may terminate their engagements with us at any time. We also have to negotiate budgets and contracts with CROs and clinical trial sites and we may not be able to do so on favorable
terms, which may result in delays to our development timelines and increased costs. If we need to enter into alternative arrangements with, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
replace or add any such third parties, it would involve substantial cost and require extensive management time and focus, or involve a transition period, and may delay our drug development
activities, as well as materially impact our ability to meet our desired clinical development timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while our reliance on these
third parties for research and development activities will reduce our control over these activities, it will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted
in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our failure or the failure of third parties to comply with the applicable
protocol, legal and regulatory requirements and scientific standards can result in rejection of our clinical trial data or other sanctions. Additionally, if we or our third-party contractors fail to comply with applicable GCPs, the clinical data
generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot be certain that, upon
inspection, the FDA will determine that any of our clinical trials comply with GCPs. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov,
within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also rely on other third
parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting
products, producing additional losses and depriving us of potential product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If these third parties do not successfully carry out their
contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product
candidates and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize any product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Manufacturing
biologics is complex, and we may experience manufacturing problems that result in delays in our development or future commercialization programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The manufacturing of biologics is complex and difficult and we, or our CMOs, may experience production issues or interruptions for sutacimig, <FONT
STYLE="white-space:nowrap">HMB-002</FONT> or any other product candidate we may develop, including raw material or starting material variability in terms of quality, cell line viability, productivity or stability issues, shortages of any kind,
shipping, distribution, storage and supply chain failures, growth media contamination, equipment malfunctions, operator errors, facility contamination, labor problems, natural disasters, disruption in utility services, terrorist activities, or acts
of god that are beyond our control or the control of our third party manufacturers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Given the nature of biologics manufacturing, there is a risk of
contamination during manufacturing. Any contamination could materially harm our or our third party manufacturers&#8217; ability to produce sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> or any other product candidate we may develop on
schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we require in our manufacturing process are derived from biologic sources. Such raw materials may be difficult to procure and may be
subject to contamination or recall. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Problems with the manufacturing process, even minor deviations from the normal process, could result in product
defects or manufacturing failures that result in lot failures, product recalls, product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
liability claims, insufficient inventory or potentially delay progression of our preclinical or clinical development of sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> and any other
product candidate we may develop. If we successfully develop sutacimig, <FONT STYLE="white-space:nowrap">HMB-002</FONT> and any other product candidate, we may encounter problems achieving adequate quantities and quality that meet FDA, EMA or other
comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. The ability to scale our manufacturing through manufacturers of active pharmaceutical ingredient, or API, for our product
candidates and for finished drug product and maintain the manufacturing process at the same levels of quality and efficiency is yet to be tested. If we or our third party manufacturers are unable to scale our manufacturing at the same levels of
quality and efficiency, we may not be able to supply the required number of doses for clinical trials or commercial supply. A material shortage, contamination or manufacturing failure in the manufacture of sutacimig,
<FONT STYLE="white-space:nowrap">HMB-002</FONT> and any other product candidate we may develop or other adverse impact or disruption in the commercial manufacturing or the production of clinical material could materially harm our development
timelines and our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We contract with third parties for the manufacture of our product
candidates, plan to contract with third parties for any other product candidates we may develop for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties entails risks, including that
such third parties may not be able to comply with applicable regulatory requirements. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have any manufacturing facilities. We currently rely on a small number of manufacturers of API for our product candidates and for finished drug
product, and we expect to continue to rely on third parties to manufacture clinical supplies of our product candidates and any other product candidates we may develop and commercial supplies of our products, if and when approved for marketing by
applicable regulatory authorities, as well as for packaging, sterilization, storage, distribution and other production logistics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Reliance on
third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or manufacture any product
candidates in accordance with regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities to support commercialization of any product candidates for which we obtain marketing
approval, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements. These facilities may also be affected by natural disasters, such as floods or fire, or geopolitical developments,
or such facilities could face manufacturing issues, such as contamination or regulatory concerns following a regulatory inspection of such facility. In such instances, we may need to locate an appropriate replacement third-party facility and
establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause additional delay and increased expense, and may have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements
outside of the United States. Our failure, or the failure of our third- party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays,
suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product candidates and any other product candidates or products that we may develop may compete with other product candidates and products for
access to manufacturing facilities. There are a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We or our third-party manufacturers may also encounter shortages in the raw materials or API necessary to produce our product candidates and any other
product candidates we may develop in the quantities needed for our clinical trials or, if our product candidates and any other product candidates we may develop are approved, in sufficient quantities for commercialization or to meet an increase in
demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. Even if raw materials or API are
available, we may be unable to obtain sufficient quantities at an acceptable cost or quality. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product
candidates and any other product candidates we may develop could delay, prevent or impair our development efforts and may have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not have
long-term supply agreements in place for drug product or drug substance for our product candidates. If any of our future contract manufacturers cannot perform as agreed, or decline to continue to supply us, we may be required to replace such
manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates and any other product candidates we may develop, we may incur added costs and delays in identifying and
qualifying any such replacement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our current and anticipated future dependence upon others for the manufacture of our product candidates and any
other product candidates or products we may develop may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may from time to time be dependent on single-source suppliers for some of the components and materials used in the product candidates we may develop.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may from time to time depend on single-source suppliers for some of the components and materials used in any product candidate we may
develop. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested
in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply, price increases or late deliveries. There are, in
general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for
these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service
provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If
we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement
suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further
delay. While we seek to maintain adequate inventory of the single source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may enter into collaborations with third parties for the development or commercialization of product candidates. If our collaborations are not successful, we
may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may
utilize collaboration, distribution and other marketing arrangements with third parties to develop our product candidates or any future product candidates of ours or to commercialize any product for which we obtain marketing approval. Our likely
collaborators for any sales, marketing, distribution, development, licensing or broader collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical
companies and biotechnology companies. We are not currently party to any such arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face significant competition in seeking appropriate
collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over
us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a
definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s
evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by regulatory authorities, the potential market for the subject product candidate, the costs and complexities of
manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard
to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a
collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among
large pharmaceutical and biotechnology companies that have resulted in a reduced number of potential future collaborators. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the
development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our
expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital,
which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to
further develop any product candidates or bring them to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are able to enter into collaborations with any third parties in the future,
we will likely have limited control over the amount and timing of resources that any future collaborators of ours dedicate to the development or commercialization of our product candidates and any future product candidates of ours. Our ability to
generate revenues from these arrangements will depend on any future collaborators of ours abilities and efforts to successfully perform the functions assigned to them in these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
arrangements. We cannot be certain that, following a collaboration, license or strategic transaction, we will achieve an economic benefit that justifies such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators.
Collaborations pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will
apply to these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not pursue development of our product candidates and any future product candidates of ours or may elect
not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or
create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being
developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
any product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product candidates discovered in collaboration with us may be viewed by any future collaborators of ours as competitive
with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of any product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture,
distribution or marketing of a product candidate or product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a collaborator with marketing and distribution rights to one or more of any product candidates that achieves marketing
approval may not commit sufficient resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract
interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates,
or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights
or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third
parties, which may expose us to litigation and potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to invest resources and attention into collaborations, which could distract from other business
objectives; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may be terminated by the collaborator (including for convenience), and, if terminated, we could be required
to raise additional capital to pursue further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any
collaborations that we enter into do not result in the successful development and commercialization of products or if one of our future collaborators terminates its agreement with us, we may not receive any future research funding or milestone or
royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of any product candidates could be delayed and we may need additional resources to develop any product candidates. All of
the risks relating to product development, marketing approval and commercialization described in this prospectus also apply to the activities of any future collaborators of ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might
deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If any future collaborators of ours terminates its agreement with us, we may find it more difficult to attract new collaborators and our
perception in the business and financial communities could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or independent
contractors have wrongfully used or disclosed confidential information or trade secrets of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We employ individuals who were
previously employed at other biotechnology or biopharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information, trade secrets or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information
of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in
substantial cost and be a distraction to our management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply with our obligations under our existing license agreements with Novo Nordisk and Genmab, or under any future intellectual property licenses,
or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are party to existing license agreements with each of Novo Nordisk and Genmab with respect to sutacimig. Termination of either of these agreements or
a reduction or elimination of our licensed rights could lead to the loss of our ability to develop and commercialize sutacimig. Under the Novo Nordisk Agreement, we have been granted an exclusive (even as to Novo Nordisk), worldwide and
sublicensable license under specified patent rights, and a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified <FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have
made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, products containing bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig,
for the treatment of bleeding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
conditions, including hemophilia. Under the Genmab Agreement, we have been granted an exclusive (even as to Genmab and its affiliates), worldwide and sublicensable license under platform
technology patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform to research, develop, make, have made, use, manufacture,
import, export and commercialize products containing bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding conditions, including hemophilia. For further
information regarding our license agreements with Novo Nordisk and Genmab see &#8220;Business&#8212;License Agreements.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may enter into
additional license agreements in the future. Our future license agreements may not provide us with exclusive rights to use the licensed intellectual property and technology or may not provide us with exclusive rights to use such intellectual
property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our product candidates and technology in the future. Additionally, future agreements may impose various development,
diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our license agreements with Novo Nordisk and Genmab impose, and we expect that future licenses may impose, specified diligence, milestone payments,
royalties and other obligations on us. Furthermore, Novo Nordisk and Genmab each has the right to terminate their respective license agreement if we materially breach such agreement and fail to cure such breach within a specified period or in the
event of insolvency. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to
develop and commercialize product candidates and technology covered by these license agreements. As a result, we may be required to cease our development and commercialization of our product candidates and use of our proprietary technologies covered
by the patent rights owned by such licensors. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property fails to provide the intended exclusivity,
competitors may have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to
the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our current or future licensors, and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of
any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the
relevant agreement, either of which could have a material adverse effect on our business, financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements
on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such
agreements, our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently have rights to intellectual property, through licenses from third parties, to
identify and develop certain product candidates, and we may enter into additional licenses in the future as we expand our product candidate pipeline. Although we have succeeded in licensing intellectual property from third-party licensors, including
Genmab and Novo Nordisk, in the past, we cannot assure our stockholders that we will be able to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to any potential product candidates from third parties on acceptable terms or at
all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our license agreements may provide that our fields of use exclude particular fields. If we determine that rights to such fields
are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain additional license rights in order to continue developing, manufacturing or marketing our product candidates. In addition, we may seek
to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable
third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various third parties practice in competitive areas and may have issued patents or patent applications that will issue as patents in the future, which
could impede or preclude our ability to commercialize our product candidates. For any third-party patents that could be relevant to our product candidates, we rely in part on the &#8220;safe harbor&#8221; or research exemption under 35 U.S.C. &#167;
271(e)(1), which exempts activities related to pursuing FDA approval for a drug product from patent infringement. However, while U.S. patent law provides such a &#8220;safe harbor&#8221; to our clinical product candidates under this provision, that
exemption may expire when a Biologics License Application, or BLA, is submitted. Given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we may submit a BLA for one of our future
product candidates at a time when one or more relevant third-party patents is in force. It may therefore be necessary for us to use the patented or proprietary intellectual property of third parties to commercialize our products, in which case we
would be required to obtain a license from these third parties. If we are unable to license such intellectual property, or if we are forced to license such intellectual property on unfavorable terms, our business could be materially harmed. If we
are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an
injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our
competitors access to the same intellectual property licensed to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we may collaborate with academic institutions to accelerate our
preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in intellectual property resulting
from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the
intellectual property rights to others, potentially blocking our ability to pursue our program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the licensing or acquisition of third-party intellectual property rights is a highly
competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive
advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be
unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual
property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the applicable product candidate, which could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing
intellectual property rights we have, we may be required to expend significant time and resources to redesign our product candidates, or the methods for manufacturing them or to develop or license replacement intellectual property, all of which may
not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects
significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate
these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such
agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or
current and future restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less
favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or impede, or delay or prohibit the further development or commercialization of one or more potential product candidates
that rely on such agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain, maintain, enforce, defend and otherwise protect the intellectual property relating to our
technology and product candidates, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize technology and products similar or identical to
ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our success
depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents with respect to any proprietary technology and product
candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States, Europe and other jurisdictions in which we plan to market any products, if approved, related to our product candidates and any
other product candidates we may develop that are important to our business and by <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property related to our technologies and product candidates. If we, or our licensors, are unable to
obtain or maintain patent protection with respect to any proprietary technology or product candidates, our business, financial condition, results of operations and prospects could be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to
file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection. Therefore, these <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with
the best interests of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves
complex legal and factual questions and has in recent years been the subject of much litigation. With respect to both owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we cannot predict whether the patent applications we
and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party
intellectual property rights potentially relating to our product candidates and any other product candidates we may develop. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications are typically not published until 18 months after filing of the priority application, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the
first to make the inventions claimed in the patents and patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, or that either we or our licensors were the first to file for patent protection of such
inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are highly uncertain. Moreover, our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> pending and future patent applications may not result in patents being issued that protect our technology and product candidates, in whole or in part, or that effectively prevent others from
commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States, the European Union and other countries may diminish the value of our patents and our ability to
obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value of, or narrow the scope of, our patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we own, <FONT STYLE="white-space:nowrap">co-own,</FONT> or hold exclusive license rights to approximately 11 issued
patents and 36 pending patent applications related to our product candidates. In order to continue to pursue protection based on provisional patent applications, we will need to file Patent Cooperation Treaty applications, <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> applications and/or U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications prior to applicable deadlines. Even then, as highlighted above, patents may never issue from our patent
applications, or the scope of any patent may not be sufficient to provide a competitive advantage. With respect to sutacimig, our foundational composition of matter patent application was filed in April 2020 (and claims priority to April 2019) with
an expected expiration in April 2040, potentially extending to 2045 with patent term extension. For <FONT STYLE="white-space:nowrap">HMB-002,</FONT> our initial composition of matter patent application was filed in February 2023 (and claims priority
to February 2022) with an expected expiration in February&nbsp;2043. The initial composition of matter patent application encompasses HMB-002 by, e.g., percent amino acid sequence identity and target epitope-binding characteristics. A second
composition of matter patent application covering HMB-002 was filed in August&nbsp;2024 (and claims priority to August 2023), with an expected expiration in August 2044. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or
USPTO, or become involved in opposition, derivation, revocation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> inter partes review, post-grant review, interference or other similar proceedings challenging our patent rights or the patent
rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize technology and product candidates that are identical or
similar to ours and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted
after issuance, including as a result of challenges brought in patent offices or court proceedings. Even if our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications issue as patents, they may not issue in a form that
will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability,
and our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be challenged in the courts or patent offices in the United States, the European Union and other jurisdictions. Such challenges may result in loss of exclusivity or
freedom to operate, or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the
duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Moreover, some of our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may in the future be, and certain of our current patent applications are, <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain
an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#8217;</FONT> interest in such patents or patent applications, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our
patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our competitors may be able to circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents by
developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. As a result, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio may not provide us with
sufficient rights to exclude others from using or commercializing technology and products similar or identical to any of our technology and product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on any product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years
from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting
a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Notwithstanding these and other extensions that
may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering any product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including
generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a
result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Given the expected expiration date of these patents, and the fact that safe
harbor protections in many jurisdictions permit third parties to engage in development, including clinical trials, prior to patent expiry, these patents may not provide us with a meaningful competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms, or fail to comply with
our obligations under such agreements, our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It may be necessary for us to use the patented or proprietary
technology of one or more third parties to develop or commercialize our current and future product candidates, in which case we would be required to obtain a license from these third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially
harmed. If we are unable to obtain a necessary license, or to otherwise acquire the relevant intellectual property rights, we may be unable to develop or commercialize the affected product candidates, or such development and commercialization may be
delayed, which could materially harm our business. In addition, the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of
compensation. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we
may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or
commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could materially harm our business, financial condition, results of operations and prospects
significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, if we fail to comply with our obligations under our current and future license agreements, our counterparties may have
the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other
penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these
agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable
terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely
on such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not have the right to control the prosecution, maintenance, enforcement or defense of patents and patent applications
that we license from third parties. In such cases, we would be reliant on the licensor to take any necessary actions. We cannot be certain that such licensor would act with our best interests in mind, or in compliance with applicable laws and
regulations, or that their actions would result in valid and enforceable patents. For example, it is possible that a licensor&#8217;s actions in enforcing and/or defending a patent licensed by use may be less vigorous than had we conducted them
ourselves. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we do not
obtain patent term extensions in the United States under the Hatch-Waxman Act and in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries under similar legislation, thereby potentially limiting the term of our marketing exclusivity for any
product candidates we may develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the patent term of a patent that covers an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension
of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14
years from the date of product approval, and only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions
are available in the European Union and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when any product candidates receive FDA
approval or equivalent approvals in foreign jurisdictions, if available, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment
of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extensions either in the United States or in any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> country because of,
for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable
requirements. In addition, to the extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of that third party. Moreover, the term
of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less
than we request, our competitors may obtain approval of competing products earlier than if such extension was granted as requested by us, and our business, financial condition, results of operations and prospects could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering any of any product candidates that we
may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we may not have the right to control prosecution,
including filing with the USPTO a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition
to obtain a patent term extension is filed, or obtained, from the USPTO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Also, there are detailed rules and requirements regarding the patents that
may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain patents covering any product candidates that contain one or more claims that satisfy the
requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If a product candidate is approved and a
patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application, or ANDA, filed with the FDA to obtain permission to sell
a generic version of such product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in
general, thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Changes in either the patent laws or interpretation of patent laws in the
United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and the maintenance, enforcement or defense of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents. The Leahy-Smith Act includes a number of
significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of
patents, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings,
including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the
patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-to-file</FONT></FONT> system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention
regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain.
Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the
validity and enforceability of patents once obtained. Depending on future actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect
on our patent rights and our ability to protect, defend and enforce our patent rights in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, a new court system recently became
operational in the European Union. The Unified Patent Court, or UPC, began accepting patent cases on June&nbsp;1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple
European Union member states. The broad geographic reach of the UPC could enable third parties to seek revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual
European Union member states in which the European patent is validated. Under the UPC, a successful revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a
single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on our business and our ability to
commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and we cannot predict
what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely affect our ability to enforce or defend the validity of our European patents. Patent owners have the option to
<FONT STYLE="white-space:nowrap">opt-out</FONT> their European Patents from the jurisdiction of the UPC, defaulting to <FONT STYLE="white-space:nowrap">pre-UPC</FONT> enforcement mechanisms. We have decided to opt out certain European patents and
patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be subject to the jurisdiction of the UPC. We cannot be certain that our European patents and patent
applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We and our licensors, and any future licensors, may
become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful, and which may result in our patents being found invalid or unenforceable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our current and future licensors&#8217; issued patents or
other intellectual property. As a result, we or any current or future licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time- consuming. Any claims we assert against
perceived </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition, in a patent
infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are
commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an
unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, interference proceedings,
derivation proceedings, and equivalent proceedings in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable, and the
outcome of any intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in
intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An adverse
result in any such proceeding could put one or more of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents at risk of being invalidated or interpreted narrowly and could put any of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material
adverse impact on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interference or derivation proceedings provoked by third
parties, or brought by us or by our licensors, or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome in such proceedings could require us to cease
using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the uncertainties associated with litigation could have a material
adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring any product
candidates to market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their
intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends upon our ability and the ability of any future collaborators of ours to develop, manufacture, market and sell any product
candidates we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual
property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to our technology and product candidates, including interference proceedings, post-grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, such as oppositions before the European Patent Office. Numerous U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent applications, which are owned by
third parties, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may
identify may be subject to claims of infringement of the patent rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The legal threshold for initiating litigation or contested
proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our
adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as any product
candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future,
regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that
our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe,
misappropriate or otherwise violate any third party&#8217;s intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Third parties may assert that we are employing their proprietary
technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the
product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates
that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or
that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may
identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable
patents, or until such patents expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively
block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee
resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing
products, be forced to indemnify our customers or collaborators or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights,
we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable
terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court
order, to cease developing, manufacturing and commercializing the infringing technology or product. A finding of infringement could prevent us from commercializing any product candidates or force us to cease some of our business operations, which
could materially harm our business. In addition, we may be forced to redesign any product candidates, seek new marketing approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential
information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our
personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Litigation or other legal proceedings relating to intellectual property claims, with or
without merit, are unpredictable and generally expensive and time-consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such
litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting
from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the
USPTO and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies in several stages or annually over the lifetime of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications. The USPTO and various <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies also require compliance with a number of procedural, documentary and other similar provisions during the patent application process. With respect to our patents, we rely on an annuity
service, outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the
applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or
our current or future licensors fail to maintain the patents and patent applications covering any product candidates, it may have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and
the laws of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries may not protect our rights to the same extent as the laws of the United States. In addition, the laws of some <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries do not
protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or
licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property rights in
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. The legal systems of certain countries do not favor the enforcement of patents, trade secrets, and other intellectual property rights, particularly those relating to biotechnology
products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect
to the same extent or at all inventions that constitute new methods of treatment. Proceedings to enforce our intellectual property and proprietary rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to
assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the
value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial
condition, results of operations and prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims challenging the inventorship or ownership of our
patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We or our licensors may be subject to claims that former employees, collaborators or other third
parties have an interest in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we or our
licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing any product candidates. Litigation may be necessary to defend against these and other claims challenging
inventorship or our or our licensors&#8217; ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to any product candidates. Even if we are successful in defending against such
claims, litigation could result in substantial costs and be a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information
of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own
intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain of our employees, consultants and contractors were previously employed at universities or other
pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while it is our policy
to require that our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that we regard as our own. In addition, even when we obtain agreements assigning intellectual property to us, such intellectual property assignment agreements may not be self-executing or may be
breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may
have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Such claims could have a material
adverse effect on our business, financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we or our licensors may in the future be
subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or licensed patents or patent applications. An adverse determination in any such claim or proceeding may result in loss of
exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and product candidates. Such
challenges may also result in our inability to develop, manufacture or commercialize technology and product candidates infringing third-party patent rights. Any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required
to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> Even
if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our proprietary information, our business and competitive
position may be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to seeking patents for any product candidates, we also rely on confidentiality agreements to protect our
unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. We seek to protect our proprietary technology, in part, by entering into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants,
advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or
has had access to our proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information and we may not be able to obtain adequate remedies for such breaches. We may also rely on
trade secrets to maintain our competitive position. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a
competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently
developed by a competitor or other third party, our competitive position may be materially and adversely harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition in our markets of interest. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future trademark applications in the
United States and in foreign jurisdictions may not be allowed or may subsequently be opposed. Once filed and registered, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on
other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming. We may not be
able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours,
thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that
incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our
business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and
diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may
not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the
patents that we own or license; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we, or our licensors or current or future collaborators, might not have been the first to make the inventions covered by
the issued patent or pending patent applications that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we, or our licensors or current or future collaborators, might not have been the first to file patent applications covering
certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies or duplicate our technologies without infringing our
owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may circumvent our regulatory exclusivities, such as by pursuing approval of a competitive product via the
traditional approval pathway based on their own clinical data, rather than relying on the abbreviated pathway provided for biosimilar or generic applicants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications or those
we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issued patents that we hold rights to now or in the future may be held invalid or unenforceable, including as a result of
legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights, or in
countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be
costly and time consuming regardless of outcome; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on
our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors,
will include claims having a scope sufficient to protect any product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that any patents issued to us or our current or future licensors will provide a basis for an exclusive
market for our commercially viable product candidates or will provide us with any competitive advantages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot ensure that we will be able to successfully commercialize any product candidates on a substantial scale, if
approved, before the relevant patents that we own or license expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may choose not to file a patent in order to maintain certain technology as trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Marketing Approval of Our Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may
prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to
extensive regulation by the FDA, EMA and comparable regulatory authorities in other jurisdictions. We are not permitted to market our product candidates in the United States, the European Union or in other jurisdictions until we receive approval of
a BLA from the FDA or marketing approval from the European Union or other applicable regulatory authorities. Our product candidates are in various stages of development and are subject to the risks of failure inherent in development. We have not
submitted an application for or received marketing approval for any of our product candidates in the United States, the European Union or in any other jurisdiction. Additionally, we have no experience as a company in filing and supporting the
applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process of obtaining
marketing approvals, both in the United States, the European Union and in other jurisdictions, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors,
including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to
regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety, potency and purity. The FDA or other regulatory authorities may determine that our product candidates are not safe, potent or pure, only
moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us and receive compensation in connection
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data
generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory
authority, as applicable, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, under the
Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety, potency and purity of the product for the claimed indications in all relevant pediatric subpopulations and to
support dosing and administration for each pediatric subpopulation for which the product is safe, potent or pure, unless granted a deferral or waiver. A deferral may be granted for several reasons, including a finding that the product or therapeutic
candidate is ready for approval for use in adults before pediatric trials are complete or that additional data needs to be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either
conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Pediatric Committee. For
any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of our product candidates for which we are seeking marketing approval in the United States or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively
complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes,
regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. For example, in December 2022, with the passage of the Food and Drug Omnibus Reform Act,
or FDORA, Congress required sponsors to develop and submit a diversity action plan, or DAP, for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug product. These plans are meant to encourage the enrollment of more
diverse patient populations in late-stage clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most
guidance documents issued by the FDA, the DAP guidance, when finalized, will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On January&nbsp;27, 2025, in response to an Executive Order issued by President Trump on January&nbsp;21, 2025, relating to Diversity, Equity and
Inclusion programs, the FDA removed the draft DAP guidance from its website. That action, along with similar actions by the Trump Administration to remove many other healthcare webpages, is currently the subject of ongoing litigation. In late July
2025, pursuant to a court order, the FDA restored the draft DAP guidance to its website with a statement that &#8220;information on this page may be modified and/or removed in the future subject to the terms of the court&#8217;s order and
implemented consistent with applicable law.&#8221; Accordingly, in light of these ongoing actions, there is considerable uncertainty surrounding the draft DAP guidance and how the FDA will consider diversity action plans in connection with its
review of BLAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, in January 2022, the new Clinical Trials Regulation (EU) No 536/2014, or CTR, became effective in the European Union and
replaced the prior Clinical Trials Directive 2001/20/EC. This regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the coordinated procedure for the approval of
clinical trials, the sponsor of a clinical trial to be conducted in more than one European Union member state is only required to submit a single application for approval by each applicable European Union member state. The submission will be made
through the Clinical Trials Information System, a clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the European Union member states and the public. While the CTR has been in place for
several years, and applied to all clinical studies in the European Union as of January&nbsp;31, 2025, we will need to carefully navigate our compliance with the CTR to ensure that it does not delay our ability to commence and conduct clinical
studies in the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the FDA may determine that we must provide additional evidence and data before approving a BLA for any
of our product candidates. For example, the novel nature of our product candidates may create further challenges in obtaining regulatory approval. That may be because: sutacimig is a bispecific antibody with a novel mechanism targeting Factor VII to
activated platelets via <FONT STYLE="white-space:nowrap">TLT-1,</FONT> which has not been previously exploited therapeutically, and regulatory authorities may have limited experience reviewing similar mechanisms and may require additional data to
support approval; our product candidates target bleeding disorders where traditional clinical trial designs and endpoints used in more common bleeding disorders (such as hemophilia A and B) may not be fully applicable or validated; for Glanzmann
thrombasthenia and Factor VII deficiency, there are no approved prophylactic therapies, so we cannot rely on precedent for endpoint selection, trial design, or benefit-risk assessment; and for Von Willebrand Disease, we will need to demonstrate that
increasing endogenous VWF and Factor VIII levels translates to clinically meaningful bleeding reduction, which may require longer-term trials with bleed rate endpoints. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA reviews an application to determine whether there is &#8220;substantial evidence&#8221; to
support a finding of effectiveness for the proposed product for its intended use(s). The FDA has interpreted this evidentiary standard to generally require two adequate and well-controlled clinical trials to establish effectiveness of a new product.
Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. The FDA issued draft guidance in September 2023 that outlines considerations for
relying on confirmatory evidence in lieu of a second clinical trial to demonstrate efficacy. The FDA has not yet finalized such guidance but, in February 2026, the Commissioner of the FDA and the Director of the FDA&#8217;s Center for Biologics
Evaluation and Research published an editorial in the New England Journal of Medicine in which they declared that, in most cases, the new default requirement for FDA approval of a new product will be one robust pivotal clinical trial plus
confirmatory evidence, rather than two pivotal clinical trials. In determining whether to rely on one trial, the FDA will focus on the single trial&#8217;s quality, including magnitude of effect, appropriateness of control arms, endpoint selection,
statistical power, blinding, handling of missing data, biological plausibility and alignment with intermediate biomarkers. While the FDA has long had authority to approve new products in this manner and, in recent years, has exercised that authority
with respect to certain types of products, the publication declares that this will be the new official default standard for most new products. This approach will reportedly be implemented as the FDA places a greater emphasis on collecting robust
post-marketing data on all pharmaceutical products. At this point, it is unclear how this new policy will be implemented by the FDA and how, if at all, it will affect our clinical development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory authorities have substantial discretion in the approval process and varying interpretations of the data obtained from preclinical and
clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not
commercially viable. Regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the
performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We could also be adversely affected by several
significant administrative law cases decided by the U.S. Supreme Court in 2024. In <I>Loper Bright Enterprises v. Raimondo</I>, for example, the court overruled <I>Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc.</I>, which for 40
years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must
exercise their independent judgment when deciding whether an agency such as the FDA acted within its statutory authority under the Administrative Procedure Act, or APA. Additionally, in <I>Corner Post, Inc. v. Board of Governors of the Federal
Reserve System</I>, the U.S. Supreme Court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears
to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision, <I>Securities and Exchange Commission v. Jarkesy</I>, overturned regulatory agencies&#8217; ability to impose civil
penalties in administrative proceedings. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and the
Center for Medicare&nbsp;&amp; Medicaid Services, or CMS, on which we rely. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts,
any of which could adversely impact our business and operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, our ability to develop and market new drug products may be impacted if litigation challenging
the FDA&#8217;s approval of another company&#8217;s drug product continues. In April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved
in 2000 and whose distribution is governed by various measures adopted under a REMS. The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in
their claim that changes allowing for expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June 2024, the U.S. Supreme Court reversed that decision after unanimously finding that the
plaintiffs did not have standing to bring this legal action against the FDA. On October&nbsp;11, 2024, the Attorneys General of three states filed an amended complaint in the district court in Texas challenging the FDA&#8217;s actions. On
January&nbsp;16, 2025, the district court in Texas agreed to allow these states to file an amended complaint and continue to pursue this challenge. Thereafter, on September&nbsp;30, 2025, the district court in Texas declined to dismiss the case and,
instead, transferred it to the federal district court in the Eastern District of Missouri. Depending on the outcome of this litigation, our ability to develop new product candidates and to maintain approval of any then-existing drug products could
be at risk and could be delayed, undermined or subject to protracted litigation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Failure to obtain marketing approval in the European Union or other
jurisdictions outside the United States would prevent our product candidates from being marketed in those jurisdictions. Any approval we may be granted for our product candidates in the United States would not ensure approval of our product
candidates in the European Union or any other jurisdictions and any of our product candidates that may be approved for marketing in the European Union or another jurisdiction will be subject to risks associated with operation in such jurisdiction.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to market our current product candidates, if approved, in the European Union and other markets outside of the United States either
directly or through collaborations. In order to market and sell our products in the European Union and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, we must obtain separate marketing approvals and comply with numerous and
varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval
process outside the United States generally includes all of the risks associated with obtaining FDA approval. We may not obtain approvals from the European Union and regulatory authorities outside the United States on a timely basis, if at all.
Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or
jurisdictions or by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our product candidates in any market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some
cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining <FONT STYLE="white-space:nowrap">non-U.S.</FONT> marketing approvals and compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we fail to obtain the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> approvals required to market our product candidates outside the United States or if we fail to comply with applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements, our target
markets will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom as a result of the withdrawal of
the United Kingdom from the European Union, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and EU Customs Union. As of January&nbsp;1, 2025, the Medicines and Healthcare products
Regulatory Agency, or MHRA, is responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland). On April&nbsp;28, 2025, the U.K. Parliament adopted amendments to improve and strengthen the
United Kingdom&#8217;s clinical trials regulatory regime, which will take effect on April&nbsp;28, 2026. Since the United Kingdom left the European Union prior to the date on which the EU Clinical Trials Regulation (Regulation EU No 536/2014) took
effect, the U.K. legal framework (which was based upon the <FONT STYLE="white-space:nowrap">now-repealed</FONT> EU Clinical Trials Directive (2001/20/EC)) did not benefit from the same revisions as occurred in the European Union. In anticipation of
these new requirements, on October&nbsp;1, 2025, the MHRA updated its guidance for clinical trials to address, among other things, research transparency requirements for clinical trials, the approvals process, the Research Ethics Committee review of
clinical trials, simplified arrangements for consent in clinical trials and pharmacovigilance. We will need to ensure that we comply with the new U.K. regulatory regime for any clinical trials we conduct in the United Kingdom, which could add time
and expense to our conduct of such trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the same time, the United Kingdom has introduced a new international recognition procedure, or IRP,
which is intended to facilitate approval of pharmaceutical products in the United Kingdom. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or
RRs. The RRs notably include the EMA and regulators in the European Union/European Economic Area, or EEA, member states for approvals in the European Union centralized procedure and mutual recognition procedure as well as the FDA (for product
approvals granted in the United States). However, the IRP does not guarantee that a marketing authorization will be granted in the United Kingdom for all products with an approval from the EMA, and the MHRA retains the authority to reject
applications if the evidence provided is considered insufficiently robust. Any delay in obtaining, or an inability to obtain, any marketing approvals may force us or any of our future collaborators to restrict or delay efforts to seek regulatory
approval in the United Kingdom for our product candidates, which could significantly and materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the EU
pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for
revision of several legislative instruments related to medicinal products, which may reduce the duration of regulatory data protection and exclusivity periods for orphan drugs, and revise the eligibility for expedited pathways in addition to other
changes, was published on April&nbsp;26, 2023. On June&nbsp;4, 2025, after almost two years of negotiations among the European Union member states, the Council of the European Union adopted its position on the proposed overhaul of the EU general
pharmaceutical legislative framework, which is known as the new Pharma Package. On December&nbsp;11, 2025, the European Parliament and European Council reached a provisional political agreement on the legislation. The revisions may have a
significant impact on the pharmaceutical industry and our business. The new Pharma Package would, among other things, set a baseline period of eight years of data exclusivity and one year of market exclusivity with possible extensions for new
indications up to a maximum of 11 years total. The new framework is expected to be adopted by <FONT STYLE="white-space:nowrap">mid-2026</FONT> and there will likely be a transition period of 24 months, with the changes taking effect in <FONT
STYLE="white-space:nowrap">mid-2028.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that we will be subject to additional risks in commercializing any of our product candidates
that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation or political instability in particular foreign economies and markets; compliance with
tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
country; and workforce uncertainty in countries where labor unrest is more common than in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any marketing approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting
the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA, EMA, MHRA and
other government agencies. In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug product. Moreover, with the passage of the <FONT
STYLE="white-space:nowrap">Pre-Approval</FONT> Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite
patient access upon product approval. Physicians may nevertheless prescribe our products <FONT STYLE="white-space:nowrap">off-label</FONT> to their patients in a manner that is inconsistent with the approved label. The use of our product candidates
for indications other than those approved by the FDA may not effectively treat such conditions. Any such <FONT STYLE="white-space:nowrap">off-label</FONT> use of our product candidates could harm our reputation in the marketplace among physicians
and patients. There may also be increased risk of injury to patients if physicians attempt to use our product candidates for these uses for which they are not approved, which could lead to product liability suits that might require significant
financial and management resources and that could harm our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2025, the FDA published final guidance outlining its policies
governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, <FONT STYLE="white-space:nowrap">non-misleading</FONT> and
scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. Notwithstanding these
programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our products for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable
regulations regarding the promotion of products for unapproved uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, companies may also communicate information that is consistent
with the prescribing information and may proactively speak to payors, formulary committees, and similar entities regarding healthcare economic information data for an unapproved drug or unapproved uses of an approved drug. We may engage in these
discussions and communicate with healthcare providers, payors and other constituencies in compliance with all applicable laws, regulatory guidance and industry best practices. We will need to carefully navigate the FDA&#8217;s various regulations,
guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
recent years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection
with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the
Federal Trade Commission, or the FTC, and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the
Federal Food, Drug and Cosmetic Act, or FDCA, the False Claims Act, the Prescription Drug Marketing Act and anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare
and/</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
or Medicaid reimbursement. Many of these investigations originate as &#8220;<I>qui tam</I>&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim
on behalf of the government alleging that a person or entity has presented a false claim or caused a false claim to be submitted to the government for payment. The person bringing a <I>qui tam </I>suit is entitled to a share of any recovery or
settlement. <I>Qui tam </I>suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a <I>qui tam </I>suit, the government must decide whether to intervene and prosecute the case. If
it declines, the individual may pursue the case alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, in September 2025, President Trump issued a Memorandum&nbsp;directing the U.S.
Department of Health and Human Services, or HHS, to &#8220;ensure transparency and accuracy in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> prescription drug advertising, including by increasing
the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements.&#8221; To that end, the FDA announced that it is initiating a rulemaking process
&#8220;to eliminate the &#8216;adequate provision&#8217; loophole that allows pharmaceutical advertisements to hide safety information by placing it in another format or location.&#8221; In this context, the FDA declared that it will no longer
tolerate what it characterized as &#8220;deceptive practices&#8221; in prescription drug advertising and that the FDA would &#8220;aggressively deploy&#8221; its available enforcement tools, with &#8220;heightened scrutiny&#8221; of fair balance and
disclosures in social media promotions. The FDA also issued a generic &#8220;notice letter&#8221; directing companies to &#8220;remove any noncompliant advertising and bring all promotional communications into compliance.&#8221; The FDA has
subsequently increased its enforcement scrutiny over prescription drug advertising, particularly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> product promotion and advertising. If the FDA finds
any of our promotional communications or advertising to be violative, we may receive an untitled or warning letter, requests for corrective advertising, or fines, amongst other enforcement tools available to the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a <I>qui tam </I>suit and it is
determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity
agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue,
business, financial prospects and reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any product for which we obtain marketing approval in the future could be subject to post-marketing
restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any product for which we obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and
promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and
reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and
recordkeeping. Manufacturers of approved products and their facilities are subject to continual review and periodic and unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. Even if
marketing approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a
product. The FDA and other agencies, including the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved
indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we market any product
for an indication that is not approved, we may be subject to warnings or enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the
promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, later discovery of previously unknown adverse events or other problems with any product for which we may obtain marketing approval and its
manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on such product, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the labeling or marketing of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of the product from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recall of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on coverage by third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to permit the import or export of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar restrictions apply to the authorization and post-authorization supervision of our products in the European Union. The holder of a marketing
authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the European Union&#8217;s stringent pharmacovigilance or safety
reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion
of authorized drugs, which are strictly regulated in the European Union and are also subject to European Union member state laws. The failure to comply with these and other EU requirements can also lead to significant penalties and sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accordingly, assuming we, or any future collaborators of ours, receive marketing approval for one or more of our product candidates, we, and any future
collaborators of ours, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we, and any
future collaborators of ours, are not able to comply with post-approval regulatory requirements, our or any future collaborators of ours ability to market any future products could be limited, which could adversely affect our ability to achieve or
sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If approved, our product candidates that are licensed and regulated as biologics may face competition from
biosimilars approved through an abbreviated regulatory pathway. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Biologics Price Competition and Innovation Act of 2009, or the BPCIA,
was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Amendment, or ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable
biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an
approved biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the
product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the licensure of a
biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still
develop and receive licensure of a competing biologic, so long as its BLA does not rely on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that any of the product candidates we develop as a biological product under a BLA should qualify for the
<FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to U.S. congressional action or otherwise, or that the FDA will not consider our product candidates to be
reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Further, the FDA may revise the standards governing the approval of biosimilars so as to bring such products to the
market more quickly. For example, in October 2025, the FDA issued draft guidance which proposes to eliminate the need for sponsors of biosimilar products to conduct comparative human clinical efficacy studies in many circumstances, allowing them to
rely instead on analytical testing to assess product differences from a reference product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, the extent to which a biosimilar, once
approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products will depend on a number of marketplace and
regulatory factors that are still developing. There have been recent government proposals to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period, but none has been enacted to date. At the same time, since
passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products. The approval of a biosimilar to our product candidates would have a material adverse impact on our business due
to increased competition and pricing pressure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have sought and received Fast Track designation and ILAP designation in the United Kingdom and may in the
future seek additional designations for our product candidates, including but not limited to Breakthrough Therapy and Priority Review designations in the United States, and PRIority Medicines, or PRIME, Designation in the European Union, but we
might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have received and may in the future seek certain designations for one or more of our product candidates that could expedite review and approval by the
FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while
minimizing the number of patients placed in ineffective control regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may also designate a product for Fast Track review if it is
intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For
Fast Track products, sponsors may have greater interactions with the FDA, and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA
determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. We have received Fast Track designation for sutacimig and may seek Fast Track designation for sutacimig in other
indications or for other of our product candidates, but such designation may not lead to a faster regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also seek a
Priority Review designation for one or more of our product candidates. If the FDA determines that a product candidate is intended to treat a serious condition and, if approved, offers a significant improvement in safety or effectiveness, the FDA may
designate the product candidate for priority review. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction,
documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A Priority Review designation means that the goal for the FDA to review an application is
six months, rather than the standard review period of ten months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These designations are within the discretion of the FDA. Accordingly, even if we
believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product
candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or
more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2025, the FDA introduced a framework intended to streamline the approval of new therapies for ultrarare diseases. The Rare Disease
Evidence Principles framework is intended to allow sponsors to rely on a <FONT STYLE="white-space:nowrap">single-arm</FONT> trial in support of approval of biologics that treat rare diseases with very small patient populations and where the disease
is linked to a known genetic defect and characterized by progressive functional deterioration leading to disability or death in a short period of time. The targeted diseases should also lack adequate alternative therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, we may seek PRIME designation for our product candidates in the future. PRIME is a voluntary program aimed at enhancing the
EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The
program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or, if such a method exists, the medicine offers a major therapeutic advantage over existing treatments. PRIME is
limited to medicines under development and not authorized in the European Union, where the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate
must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The benefits of a PRIME designation include the appointment of a Committee for Medicinal Products for
Human Use, or CHMP, rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for
accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to
facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further,
obtaining PRIME designation does not assure or increase the likelihood of the European Commission&#8217;s grant of a marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
the United Kingdom, sutacimig has received innovative licensing and access pathway, or ILAP. designation from the MHRA for the treatment of Glanzmann thrombasthenia. The ILAP is open to sponsors of potentially transformative medicines or drug-device
combination products that address unmet medical needs. It supports products with evidence of safe use in humans but before confirmatory trials have started. It is designed to reduce the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> timeline for research and development, regulatory approval and timely adoption of new technologies to benefit patients and the healthcare system in the United
Kingdom. To these ends, the ILAP comprises an Innovation Passport designation, a Target Development profile and a toolkit to support all stages of the design, development and approval process. As with expedited review and approval programs in other
jurisdictions, the designation of sutacimig under the ILAP does not guarantee approval of this candidate product in the United Kingdom by the MHRA. Further, we will need to carefully navigate the requirements of the ILAP to ensure that we benefit
from this accelerated pathway to approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have received orphan drug designation for sutacimig for the treatment of Glanzmann thrombasthenia, but we may
be unable to maintain this designation or realize the benefits associated with orphan drug designation, including exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We sought and
obtained orphan drug designation for sutacimig from the FDA and the EMA for the treatment of Glanzmann thrombasthenia, however, we may not be able to maintain these designations. We also may seek orphan drug designation for sutacimig in other
specific orphan indications, or for <FONT STYLE="white-space:nowrap">HMB-002</FONT> or any future product candidates, but we may never receive such designations.&nbsp;Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it
is a drug intended to treat a rare disease or condition. A similar regulatory scheme governs orphan designation by the European Commission, following a recommendation from the EMA&#8217;s Committee for Orphan Medicinal Products in the European
Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for
which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or EMA from approving another marketing authorization application for the same product (or a similar medicinal product in the
European Union) for the same approved use indication for that time period, subject to limited exceptions. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can
be reduced to six years if a product no longer meets the criteria for orphan drug designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order for the FDA to grant orphan drug exclusivity, the FDA must find that the product is indicated for the treatment of a condition or disease with
a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if orphan drug exclusivity is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
obtained for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same approved use or indication. In addition,
even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major
contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the
needs of the patients with the rare disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and Congress may further reevaluate and revise the Orphan Drug Act and its
regulations and policies. For example, in September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of orphan drug exclusivity, the term &#8220;same disease or condition&#8221; means the designated
&#8220;rare disease or condition&#8221; and not the &#8220;indication or use&#8221; for which the product is approved.&nbsp;Subsequently, in another case, a federal district court in Washington, D.C. followed the reasoning of the 11th Circuit
decision, and that decision was appealed to the U.S. Court of Appeals for the D.C. Circuit.&nbsp;On February&nbsp;3, 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It overruled these court decisions and codified the
FDA&#8217;s longstanding interpretation of the scope of orphan drug exclusivity to apply to &#8220;the same drug for the same approved use or indication within such [designated] rare disease or condition.&#8221; This change, which applies
retroactively, expressly authorizes the FDA to approve multiple versions of the same orphan drug for different <FONT STYLE="white-space:nowrap">sub-indications</FONT> and subpopulations, such as adult and pediatric patients or multiple variations of
the same disease that are caused by different genetic variants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not know if, when, or how the FDA or Congress may change the orphan drug
regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, obtaining orphan drug designation in the European Union requires demonstrating that there exists no satisfactory method of diagnosis,
prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. There is no assurance that we
would be able to meet that standard for sutacimig in indications other than Glanzmann thrombasthenia or for any of our product candidates. Further, orphan drug designation for a product candidate in the European Union cannot be maintained at the
time of a marketing authorization application without a showing, to the satisfaction of the EU regulatory authorities, that the product candidate is of significant benefit to patients over available commercial products for the indication in the
European Union and any additional products that are ahead of our product candidate in clinical development for the indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Disruptions at the FDA and
other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure
approval of our product candidates in a timely manner, which would negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and comparable regulatory
agencies in foreign jurisdictions, such as the EMA and CHMP, play a critical role in the development of our product candidates by providing guidance on our clinical development programs and reviewing and approving our regulatory submissions,
including INDs, requests for special designations and marketing applications. If these oversight and review activities are disrupted or delayed, then correspondingly our ability to develop and secure timely approval of our product candidates could
be impacted in a negative manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, the loss of FDA leadership and personnel could lead to disruptions and delays in FDA
guidance, review and potential approval of our product candidates. In November 2025, a Congressional Continuing Resolution ended the government shutdown, which began on October 1, 2025, providing full-year funding of the FDA for the 2026 federal
fiscal year of approximately $7&nbsp;billion with a slight increase in user fees for drug and device companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While the FDA&#8217;s review of
marketing applications and other activities for new drugs and biologics is largely funded through the user fee program established under the Prescription Drug User Fee Act, or PDUFA, it remains unclear how the FDA&#8217;s 2025 reduction in force and
budget cuts will impact this program and the ability of the FDA to provide guidance and review our product candidates in a timely manner. For example, while the FDA&#8217;s 2025 reduction in force did not reportedly specifically target FDA
reviewers, many operations, administrative and policy staff that help support such reviews were affected and those losses could lead to delays in PDUFA reviews and related activities. There has been at least one report in which the FDA failed to
meet a PDUFA goal date for approval of an NDA or BLA due to heavy workload and limited resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is also substantial uncertainty as to how
regulatory reform measures being implemented by the Trump Administration across the government will impact the FDA and other federal agencies with jurisdiction over our activities. For example, since taking office, the President has issued a number
of executive orders that could have a significant impact on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. These include E.O. 14192, &#8220;Unleashing Prosperity Through Deregulation,&#8221;
January&nbsp;31, 2025; E.O. 14212, &#8220;Establishing the President&#8217;s Make America Healthy Again Commission,&#8221; February&nbsp;13, 2025; and E.O. 14219, &#8220;Ensuring Lawful Governance and Implementing the President&#8217;s
&#8216;Department of Government Efficiency&#8221; Deregulatory Initiative,&#8221; February&nbsp;21, 2025. If these or other orders or executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similarly, actions by the U.S. government have significantly disrupted
the operations of U.S. government agencies such as the National Institutes of Health, National Science Foundation, Centers for Disease Control and Prevention, and the FDA, which have traditionally provided funding for basic research, research and
development, and clinical testing. These U.S. government actions have included, among other things, suspending, terminating and withholding of disbursements of funds owed under ongoing contracts, grants, and other financial assistance agreements;
declining to continue multi-year research projects for additional annual budget periods; canceling or delaying solicitations for new contract, grant and other financial assistance awards; canceling or delaying proposal evaluation processes and
issuance of such new awards; substantially reducing federal agency staff responsible for managing contract and financial assistance programs; eliminating agency information and resources for facilitating research activity; delaying or terminating
federal agency procedures for authorizing international transactions; initiating aggressive enforcement actions that may disrupt the operations of major research universities that are significant contributors to life sciences research in the United
States, and threatening access to federal agency contracts and other funding awards based on companies&#8217; otherwise lawful corporate policies and choice of counsel. These U.S. government actions could, directly or indirectly, significantly
disrupt, delay, prevent, or increase the costs of our research and product commercialization programs, including our ability to develop new product candidates, conduct clinical trials, implement research collaborations with other companies or
institutions, and obtain approvals to market and sell new products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, government funding of the SEC and other government agencies on
which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. government has shut
down several times and certain regulatory agencies, such as the FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the
ability of the FDA to timely review and process our regulatory submissions and could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, the federal government shut down on October&nbsp;1, 2025, and reopened on November&nbsp;13, 2025. At the outset of that shutdown, the FDA
issued a public notice stating that FDA operations would continue to the extent permitted by law, such as activities necessary to address imminent threats to the safety of human life and activities funded by carryover user fee funds. The FDA
declared that, during the shutdown period, it does not have legal authority to accept user fees assessed for fiscal year 2026 until a fiscal year 2026 appropriation or Continuing Resolution for the FDA is enacted. As a result, during the government
shutdown, the FDA did not accept any regulatory submissions for fiscal year 2026 that require a fee payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the same time, disruptions at the
FDA and other government agencies may result from public health events similar to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. For example, during the pandemic, a number of companies announced receipt of complete response letters
due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended.
Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical
development programs or delay the FDA&#8217;s review and processing of our regulatory submissions, including INDs and BLAs, our business would be negatively impacted. Further, any future government shutdown could impact our ability to access the
public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accelerated approval by the FDA, even if granted for
any of our current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the future, we may seek approval of our product candidates using the FDA&#8217;s accelerated approval pathway. A product candidate may be eligible for
accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.
The FDA or other applicable regulatory agency makes the determination regarding whether a surrogate endpoint is reasonably likely to predict long-term clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated
approval. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform an adequate and well-controlled post-marketing confirmatory clinical trial or trials. These confirmatory trials must be
completed with due diligence and we may be required to evaluate different or additional endpoints in these post-marketing confirmatory trials. These confirmatory trials may require enrollment of more patients than we currently anticipate and will
result in additional costs, which may be greater than the estimated costs we currently anticipate. In addition, the FDA currently requires as a condition for accelerated approval preapproval of promotional materials, which could adversely impact the
timing of the commercial launch of the product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There can be no assurance that the FDA will agree with any proposed surrogate endpoints or that we
will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval for any of our current or future product candidates. Similarly, there can be no assurance that, after feedback from FDA,
we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under
another expedited regulatory designation, there can be no assurance that such submission or application will be accepted or that any expedited review or approval will be granted on a timely basis, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the
predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates
that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials
relating to our product candidate. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period for
commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, there can be no assurance that we will satisfy all FDA requirements, including new provisions, that govern accelerated approval. For example,
with the passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of products. Specifically, the legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway
before accelerated approval is awarded and to submit progress reports on its post-approval studies to FDA every six months until the study is completed. Moreover, FDORA established expedited procedures authorizing FDA to withdraw an accelerated
approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of
use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the
Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the Commissioner of the FDA or the designee of the Commissioner of the FDA and a written
appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any product candidate that qualifies for accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2023, the FDA issued draft guidance that outlines its views and approach to accelerated approval. The FDA indicated that the accelerated
approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although <FONT STYLE="white-space:nowrap">single-arm</FONT> trials have been commonly used to support accelerated approval, a
randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and
analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidances relating to accelerated approval. These guidances describe the
FDA&#8217;s views on what it means to conduct a confirmatory trial with due diligence and how the FDA plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and
will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, a conditional marketing authorization may be granted for certain medicines on
less comprehensive clinical data than normally required, where the benefit of immediate availability of the medicine outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization is subject to
conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the
applicable pending studies are provided, a conditional marketing authorization can be converted to a standard marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will
cease to be renewed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our activities, including our interactions with healthcare providers, third party payors, patients and government officials, are, and
will continue to be, subject to extensive regulation involving healthcare, anti-corruption, data privacy and security and consumer protection laws. Failure to comply with applicable laws could result in substantial penalties, contractual damages,
reputational harm, diminished revenues and curtailment or restructuring of our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our activities may now or in the future be
directly or indirectly subject to various federal and state laws related to healthcare, anti-corruption, data privacy and security consumer protection. If we obtain FDA approval for any of our product candidates and begin commercializing those
products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from
knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or
providing any remuneration, directly or indirectly, to induce, either the referral of an individual for, or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act, enacted in 2018, which prohibits
certain payments related to referrals of patients to certain providers (recovery homes, clinical treatment facilities and laboratories) and applies to services reimbursed by private health plans as well as government healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal law known as Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to
privacy protections to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program (which may include private health plans) or making false statements relating to healthcare matters;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products
for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or
provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">so-called</FONT> &#8220;federal sunshine&#8221; law, which requires pharmaceutical and
medical device companies to monitor and report certain financial interactions with teaching hospitals, physicians and certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners to the federal government for <FONT
STYLE="white-space:nowrap">re-disclosure</FONT> to the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the privacy, security and breach provisions of HIPAA, which impose obligations on certain &#8220;covered entities&#8221;
(healthcare providers, health plans and healthcare clearinghouses) and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
certain of their &#8220;business associate&#8221; contractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal and state laws and regulations, including state security breach notification laws, state comprehensive privacy
laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Foreign Corrupt Practices Act, or FCPA, a United States law which regulates certain financial relationships with
foreign government officials (which could include, for example, certain medical professionals); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">state law analogues of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items
or services reimbursed by any third-party payor, including private health plans, state privacy laws, state consumer protection laws, and state laws regulating interactions between pharmaceutical manufacturers and healthcare providers, requiring
disclosure of such financial interactions or mandating adoption of certain compliance standards, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Companies that violate these laws can be subject to civil and criminal fines and penalties for each violation, plus up to three
times the remuneration involved, imprisonment, and exclusion from government healthcare programs. Further, lack of knowledge (anti-kickback laws, HIPAA) or lack of intent (false claims laws) may not be valid defenses to violating such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the marketing approval and commercialization of any of our product candidates in the European Union and other jurisdictions outside the
United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial
costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil, criminal and
administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and
curtailment or restructuring of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and
regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably
sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on
the price that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ACA was enacted in March 2010, and other legislative changes have been proposed and adopted since its enactment. In August 2011, the Budget Control
Act of 2011, among other things, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years
2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per
fiscal year, which went into effect in April 2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products or
product candidates for which we may obtain marketing approval or the frequency with which any such product is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since enactment
of the ACA, there have been and continue to be numerous legal challenges and U.S. congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act, or the Tax Act, in 2017, Congress repealed
the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed a challenge to the ACA
brought by several states without specifically ruling on the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, on December&nbsp;13, 2021, Regulation (EU) 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was
adopted. While the Regulation entered into force in January 2022, it only began to apply from January 2025 onwards and has a phased implementation depending on the concerned products. The Regulation intends to boost cooperation among European Union
member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It permits European
Union member states to use common HTA tools, methodologies, and procedures across the European Union, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact
for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas.
Individual European Union member states will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technology and making decisions on pricing and
reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result
in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement
physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction
in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we
may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to
considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The prices of
prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things,
bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section&nbsp;804 Importation
Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal
district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states have passed laws allowing for the importation of drugs from Canada. On January&nbsp;5, 2024, the FDA approved Florida&#8217;s plan for
Canadian drug importation. That state now has authority to import certain drugs from Canada for a period of two years once certain conditions are met. Florida will first need to submit a <FONT STYLE="white-space:nowrap">pre-import</FONT> request for
each drug selected for importation, which must be approved by the FDA. The state will also need to relabel the drugs and perform quality testing of the products to meet FDA standards. On May&nbsp;21, 2025, the FDA announced that it would offer
individual states the opportunity to submit a draft proposal for <FONT STYLE="white-space:nowrap">pre-review</FONT> and meet with the FDA to obtain initial feedback from FDA prior to formally submitting their SIP proposals. The intent of these
meetings is to assist states in developing their proposals by further clarifying requirements, enhancing the quality of proposals submitted to the FDA and ultimately shortening the review timeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2022, the Inflation Reduction Act, or IRA, was signed into law by President Biden. The legislation has implications for Medicare Part D, which
is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires
manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap, and replaces the Part D coverage gap discount program with a new discounting program (beginning in
2025). In addition, the IRA established inflation rebate programs under Medicare Part B and Part D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B and Part D drugs faster than the rate
of inflation. On December&nbsp;9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules governing the IRA inflation rebate programs. The IRA permits the Secretary of HHS to implement many of these
provisions through guidance, as opposed to regulation, for the initial years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, the IRA subjects drug manufacturers to civil monetary
penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation.
The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The law also capped Medicare
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs at an estimated $4,000 a year in 2024 and at $2,000 a year in 2025 and onwards. In addition, the IRA potentially raises legal risks with respect
to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic
period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things,
the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">co-insurance</FONT> and <FONT STYLE="white-space:nowrap">co-payment</FONT> costs, expanding eligibility for lower income subsidy plans, and price caps on annual <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, each of which could have potential pricing and reporting implications. Accordingly, while it is currently unclear how the IRA will be effectuated, we
cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of
which could adversely affect our business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, with respect to price negotiations,
Congress authorized Medicare to negotiate lower prices for certain costly single-source drug products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost
drugs paid for by Medicare Part D starting in 2026, followed by 15 additional Medicare Part D drugs in 2027, 15 additional Medicare Part B or Part D drugs in 2028, and 20 additional Medicare Part B or Part D drugs per year in 2029 and beyond. This
provision applies to drug products that have been approved for at least nine years. Drugs that have been approved for a single rare disease or condition were originally categorically excluded from price negotiation. With the passage of the One Big
Beautiful Bill Act, or OBBBA, on July&nbsp;3, 2025, which was signed into law on July&nbsp;4, 2025, Congress extended this exemption to drugs with multiple orphan drug designations. Nonetheless, since CMS may establish a maximum price for these
products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the
risk that we would not be able to achieve the expected return on any of our product candidates, if approved, or the full value of our patents protecting any such approved drug products if prices are set after any such approved products have been on
the market for nine years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023 with the
negotiated prices for ten selected drug products becoming effective on January&nbsp;1, 2026. The second cycle of negotiations with participating drug companies occurred during 2025, and the negotiated prices for this second set of 15 drugs will
become effective on January&nbsp;1, 2027. On January&nbsp;27, 2026, CMS published the list of 15 drugs selected for the third cycle of negotiations. These negotiated prices will become effective on January&nbsp;1, 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On June&nbsp;6, 2023, Merck&nbsp;&amp; Co. filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price
Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, a number of other parties also filed lawsuits in various courts with similar constitutional claims. HHS
has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing or on the merits. For example, on May&nbsp;8, 2025, the U.S. Court of Appeals for the Third Circuit rejected AstraZeneca
L.P.&#8217;s challenge to the Medicare price negotiation program, finding that the program did not violate the company&#8217;s due process rights under the U.S. Constitution. Litigation involving these and other provisions of the IRA will continue
with unpredictable and uncertain results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that litigation involving these and other provisions of the IRA will continue, with
unpredictable and uncertain results. Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or
more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, if approved, any of which could adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the Trump Administration has taken a number of actions to reduce the costs of pharmaceutical products. For example, on April&nbsp;15, 2025,
President Trump issued an Executive Order which directs HHS to take steps to reduce the prices of pharmaceutical products.&nbsp;Such measures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
include streamlining the state drug importation program and modifying provisions of the 340B program. Further, on May&nbsp;12, 2025, President Trump issued an additional Executive Order calling
on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The Executive Order provides that if such actions do not lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions,
including proposing a rulemaking that imposes most-favored nation, or MFN, pricing in the United States. Thereafter, on July&nbsp;31, 2025, President Trump issued letters to 17 pharmaceutical companies reiterating the requirements of the
May&nbsp;12, 2025 Executive Order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly-launched drug products, return increased revenues abroad to American patients and provide for direct
purchasing at MFN pricing. Since that time, virtually all of these pharmaceutical companies have entered into agreements with the Trump Administration to provide for lower prices on certain pharmaceuticals. On February&nbsp;5, 2026, President Trump
launched TrumpRx.gov, a website that directs individuals to pharmaceutical manufacturer websites that are offering price discounts based on the administration&#8217;s pricing agreements with pharmaceutical manufacturers.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December&nbsp;23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, proposed two five-year pilot programs to implement a
&#8220;reference pricing&#8221; regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for Efficient Drug Pricing Model for Medicare Part B drugs, referred to as GLOBE, and the
Guarding U.S. Medicare Against Rising Drug Costs for Medicare Part D drugs, referred to as GUARD. Under the proposed pilot programs, a manufacturer would owe rebates to Medicare if prices for their drugs exceeded the prices paid by other
economically comparable reference countries, defined in the proposed regulations as Organisation for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development countries with a gross domestic product of $400&nbsp;billion and a per
capita gross domestic product that is at least 60% of the U.S. per capita gross domestic product (an initial list of 19 reference countries is included in the proposed rule). The pilot programs are proposed to go into effect beginning
October&nbsp;1, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. States, including through their Medicaid programs and regulatory
agencies, as well as other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval products have insufficient or limited evidence despite
meeting the FDA&#8217;s standards for accelerated approval. Certain states are also pursuing cost containment efforts through Prescription Drug Affordability Boards, or PDABs, and similar entities. While many PDABs have been granted authority to
promote drug price transparency and reporting, some states have granted PDABs more expansive authority, including to set Upper Payment Limits, or UPLs, on select, high price drugs. The adoption and implementation of UPLs may put downward pressure on
drug prices and impact our company&#8217;s future revenues. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be
included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal
and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This is increasingly true with respect to products approved pursuant to the
accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product
candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies.
In many countries, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time
after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or any future collaborators of ours may be required to conduct a clinical trial that compares the cost-effectiveness of our
product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels, our business could be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security, and a
failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage, use, disclosure and other
processing of sensitive, confidential and personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of such information, including comprehensive regulatory systems in
the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection
issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by
affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. At the federal level,
regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative,
physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has
been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our
contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity under HIPAA can result in financial liability and
reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that
threaten the privacy or security of the personal information of state residents, including pursuant to the state privacy laws discussed below. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In
addition to the risks associated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require
ongoing modifications to our policies, procedures and systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We make public statements about our use, collection, disclosure and other processing
of personal information through our privacy policies and information provided on our website. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The
publication of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of
our actual practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to potential enforcement by HHS, we are also potentially subject to privacy enforcement from the FTC. The FTC has
been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section&nbsp;5 of the
Federal Trade Commission Act of 1914, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). We will need to account for the FTC&#8217;s evolving rules and
guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that
requires us to adhere to very specific privacy and security practices (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are also increased restrictions at the federal level relating to transferring sensitive data outside of the United States to certain foreign
countries. For example, the Department of Justice&#8217;s January&nbsp;8, 2025, rule on &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; prohibits data brokerage
transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict certain investment agreements, employment agreements
and vendor agreements involving such data and countries of concern, absent specified cybersecurity controls. Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions and may result in exclusion from
participation in federal and state programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Numerous states have also created comprehensive privacy laws which govern the processing of personal
information. For example, the California Consumer Privacy Act, or the CCPA, took effect on January&nbsp;1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s
requirements are similar to those found in the EU General Data Protection Regulation, or the EU GDPR, which is further described below, including requiring businesses to provide notice to data subjects regarding the information collected about them
and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the
right to opt out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. The California Privacy Rights Act, or the CPRA, went into effect on January&nbsp;1, 2023 and
significantly expanded the CCPA to incorporate additional EU GDPR-like provisions including requiring that the use, retention and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of
collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created an enforcement agency&#8212;the
California Privacy Protection Agency&#8212;the sole responsibility of which is to enforce the CPRA and other California privacy laws, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business
activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to California, a number of other states have passed similarly comprehensive privacy laws.
Like the CCPA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of
these laws may apply to our business activities. There are also states that are specifically regulating specific categories of personal information, such as health information that may affect our business. For example, the State of Washington
recently passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Additionally, a small number of states,
such as Illinois and Texas, have enacted laws that specifically target the collection and use of biometric information. These laws may impact our business activities, including our identification of research subjects, relationships with business
partners and ultimately the marketing and distribution of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, laws in all 50 states require businesses to provide notice to
customers whose personal information has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently
amending existing laws, requiring attention to changing regulatory requirements. We also may be contractually required to notify affected individuals or other counterparties of a cybersecurity incident, data breach, or other compromise. Although we
may have contractual protections with our vendors, any actual or perceived security breach, incident, or compromise could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security
and in responding to any such actual or perceived cybersecurity incident, data breach, or other compromise. Any contractual protections we may have from our vendors may not be sufficient to adequately protect us from any such liabilities and losses,
and we may be unable to enforce any such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry
standards may legally or contractually apply to us, or we may elect to comply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Plaintiffs&#8217; lawyers are also increasingly using
privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other
web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk
for our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar to the laws in the United States, there are significant and evolving privacy and data security laws that apply in Europe
and other countries. The collection, use, disclosure, transfer or other processing of personal data, including personal health data, regarding individuals who are located in the EEA and the United Kingdom and the processing of personal data that
takes place in the EEA and the United Kingdom, is regulated by the EU GDPR with respect to the EEA, and the U.K. General Data Protection Regulation, or U.K. GDPR, with respect to the United Kingdom, and collectively with the EU GDPR referred to as
the &#8220;GDPR&#8221; in this report unless specified otherwise. The GDPR applies to all organizations processing or holding personal data of EEA and/or U.K. data subjects (regardless of the organization&#8217;s location) as well as to
organizations outside these jurisdictions that offer goods or services in the EEA and United Kingdom, or that monitor the behavior of EEA and/or U.K. data subjects. The GDPR imposes extensive obligations on companies that process personal data,
including requirements relating to lawful bases for processing, transparency, consent where required, security safeguards, data processing agreements, data subject rights, breach notification, record-keeping, data protection impact assessments and,
in some cases, appointment of a data protection officer. It also restricts transfers of personal data outside the EEA and United Kingdom (including to the United States). Breaches can result in significant penalties (up to <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million / &pound;17.5&nbsp;million or 4% of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
global annual turnover, whichever is higher), and data subjects have rights to lodge complaints and seek compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The GDPR imposes strict rules on the transfer of personal data out of the EEA/United Kingdom to countries not regarded by the European Commission and
the U.K. government as providing adequate protection, or third countries, including the United States. These transfers are prohibited unless an appropriate safeguard specified by data protection laws is implemented, such as the Standard Contractual
Clauses, or SCCs, approved by the European Commission, or a derogation applies. Transfers made pursuant to the SCCs need to be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis to ensure
the law in the recipient country provides &#8220;essentially equivalent&#8221; protections to safeguard the transferred data. If the standard is not met, businesses will be required to adopt supplementary measures. Further, the European Union and
United States have adopted its adequacy decision for the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, or the Framework, which entered into force on July&nbsp;11, 2023. This Framework provides that the protection of
personal data transferred between the European Union and the United States is comparable to that offered in the European Union. This provides a further avenue to ensuring transfers to the United States are carried out in line with the GDPR. The
United Kingdom is not subject to the European Commission&#8217;s SCCs but the U.K. Information Commissioner&#8217;s Office has published the United Kingdom&#8217;s own transfer mechanisms for personal data originating from the United Kingdom (the
International Data Transfer Agreement and International Data Transfer Addendum, or, each, an IDTA), which have been in force since March&nbsp;21, 2022. The IDTA requires the same
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> risk assessment of the transfer. In addition, there has been an extension to the Framework to cover U.K. transfers to the United States. The Framework could
be challenged like its predecessor frameworks. The international transfer obligations under the EEA and U.K. data protection regimes will require significant effort and cost, and may result in us needing to make strategic considerations around where
EEA/U.K. personal data is located and which service providers we can utilize for the processing of EEA/U.K. personal data, particularly as the enforcement around GDPR international transfer compliance obligations is currently unclear. The above
transfer requirements and other future developments regarding the flow of data across borders could increase the cost and complexity of delivering our services in some markets and may lead to governmental enforcement actions, litigation, fines, and
penalties or adverse publicity, which could adversely affect our business and financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although the United Kingdom is regarded as a
third country under the EU GDPR, the European Commission has now issued a decision recognizing the United Kingdom as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the European Union to the
United Kingdom remain unrestricted. In December 2025, the European Commission adopted a decision to extend the validity of the U.K. adequacy decision for six years until December 2031, determining that the United Kingdom continues to offer a level
of data protection that is &#8220;essentially equivalent&#8221; to the EU standards. This follows the United Kingdom&#8217;s adoption of the Data (Use and Access) Act 2025 on June&nbsp;19, 2025. Like the EU GDPR, the U.K. GDPR restricts personal
data transfers outside the United Kingdom to countries not regarded by the United Kingdom as providing adequate protection. The U.K. government has confirmed that personal data transfers from the United Kingdom to the EEA remain free flowing. The
respective provisions and enforcement of the EU GDPR and U.K. GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. This lack of clarity on future U.K. laws and regulations and their interaction with
EU laws and regulations could add legal risk, complexity and cost to our handling of personal data and our privacy and data security compliance programs and could require us to implement different compliance measures for the United Kingdom and the
EEA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a
model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
clinical trials and the sale and distribution of commercial products, if approved, through increased compliance costs, costs associated with contracting and potential enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the
domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with such evolving data protection laws, rules and regulations may be unsuccessful. These laws are not consistent,
and compliance in the event of a widespread data breach is costly and time-consuming. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices, which could adversely affect our business. We
must devote significant resources to understanding and complying with this changing landscape. Failure by us or our third-party vendors to comply with federal, state and international laws regarding privacy and security of personal information could
expose us to the risk of enforcement actions taken by data protection authorities and can carry with it the potential for significant fines and penalties under such laws if we are found to be <FONT STYLE="white-space:nowrap">non-compliant.</FONT>
Even if we are not determined to have violated these laws, rules or regulations, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business,
financial condition, results of operations or prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Laws and regulations governing international operations may preclude us from developing,
manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have operations in Denmark and are required to dedicate additional resources to comply with U.S. laws regarding international operations and the laws
and regulations in Denmark and any additional jurisdiction in which we operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FCPA prohibits any U.S. individual or business from paying,
offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the
individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that
accurately and fairly reflect all transactions of the company, including international subsidiaries and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA
presents particular challenges in the pharmaceutical industry because in many countries, hospitals are operated by the government and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection
with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States or the sharing with certain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Further, the provision of benefits or advantages to physicians
to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national
anti-bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain European Union member states must be publicly
disclosed. Moreover, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory
authorities of the individual European Union member states. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union member states. Failure to comply with these
requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we expand our international
presence beyond Denmark, it will require us to dedicate additional resources to comply with these laws and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside of the United States,
which could limit our growth potential and increase our development costs. The creation, implementation and maintenance of international business practices compliance programs may be necessary and costly, and such programs are difficult to enforce,
particularly where reliance on third parties is required. The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The
SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We and our
third-party contract manufacturers must comply with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant costs or liabilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain
aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or
injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages and any such liability could exceed our assets and resources. We could also incur significant costs associated
with civil or criminal fines and penalties for failure to comply with such laws and regulations. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our
storage or disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Environmental, health and safety laws and regulations are becoming
increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or
production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or business disruption, any of which could have a material adverse effect on our business, financial
condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, with respect to the operations of our third-party contract manufacturers, it is possible
that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm
or experience a disruption in the manufacture and supply of our product candidates or products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees, consultants and business partners may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to the risk of fraud or other
misconduct by our employees, consultants and business partners. Misconduct by these parties could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have
established, to comply with federal and state healthcare fraud and abuse laws and regulations, to comply with state and federal securities laws, to report financial information or data accurately or to disclose unauthorized activities to us. In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict
or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of
clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and serious harm to our reputation. We are also exposed to risks in connection with any insider trading violations by employees
or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other
misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of
civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and
future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating
results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2025, the Trump Administration imposed a series of tariffs against U.S. trading partners pursuant to the International Emergency
Economic Powers Act (IEEPA). On February 20, 2026, the U.S. Supreme Court ruled these tariffs unlawful. The Trump Administration immediately imposed new global tariffs pursuant to Section 122 of the Trade Act of 1974, which allows for tariffs of up
to 15% for a period of up to 150 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Separately, in April 2025, the Department of Commerce announced an investigation under Section&nbsp;232 of
the Trade Expansion Act of 1962 into imports of pharmaceuticals and pharmaceutical ingredients, including finished products, medical countermeasures, critical inputs such as active pharmaceutical ingredients, and key starting materials, and
derivative products of those items. On September&nbsp;25, 2025, via a post on Truth Social, President Trump announced that, beginning October&nbsp;1, 2025, all branded or patented drugs imported in the United States would face a 100% tariff. At the
same time, President Trump indicated that these tariffs could be avoided by building pharmaceutical manufacturing facilities in the United States. Thereafter, President Trump delayed the October&nbsp;1, 2025 effective date of the tariffs on branded
or patented pharmaceutical products announcing that the Trump Administration had now &#8220;begun preparing&#8221; tariffs on manufacturers that do not build in the United States or enter into a most-favored-nation drug pricing agreement with the
Trump Administration. A host of other U.S. tariff actions remain possible, including additional 25% tariffs on products from countries that do certain business with Iran or Cuba. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result of changes in tariffs that have been announced and/or implemented, and the underlying
uncertainty currently surrounding international trade, we could experience a negative impact to our costs of materials and production processes, and supply chain disruptions and delays as a result of any new tariff policies or trade restrictions. If
we are unable to obtain necessary raw materials or product components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical
trials of our product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. We cannot yet predict the effect of the
recently imposed U.S. tariffs on imports, or the extent to which other countries will impose quotas, duties, tariffs, taxes or other similar restrictions upon imports or exports in the future, nor can we predict future trade policy or the terms of
any renegotiated trade agreements and their impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, some of our manufacturers and suppliers are located in China. Trade
tensions and conflicts between the United States and China have been escalated in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules,
regulations and policies of the governments of the United States or China, or due to geopolitical unrest and unstable economic conditions. Certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory
requirements or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting their supply of material to us. For example, in February 2024, U.S. lawmakers
called for investigations into and the imposition of possible economic sanctions against Chinese biotechnology companies WuXi AppTec and WuXi Biologics, or collectively WuXi, over alleged ties to the Chinese military. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subsequently, in December 2025, as part of the Fiscal Year 2026 National Defense Authorization Act, President Trump signed into law the BIOSECURE Act.
Under the BIOSECURE Act, U.S. government agencies cannot (1)&nbsp;buy or obtain biotechnology equipment or services provided by biotechnology companies of concern, or BCCs, (2)&nbsp;enter into, extend, or renew a contract with any entity using
biotechnology equipment or services provided by a BCC to perform a government contract, or (3)&nbsp;expend, loan or grant funds for biotechnology equipment or services provided by a BCC, whether directly or through a loan or grant recipient. The
BIOSECURE Act does not name specific companies as BCCs but treats any company on the Department of Defense 1260H list of &#8220;Chinese military companies&#8221; as a BCC. On December&nbsp;18, 2025, the Chairs of multiple Senate and House
committees, including the House Select Committee on China, sent a letter to the Department of Defense recommending that WuXi be added to the 1260H list, which would make it a BCC. The 1260H list was updated by the Department of Defense in January
2024 and January 2025. On February&nbsp;13, 2026, the Department published an updated list, which included WuXi, but then abruptly withdrew the list. The implications of this action remain unclear. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Employee Matters and Managing Growth </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future
success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are highly dependent on
the research and development, clinical, regulatory, and business development expertise of Benny S&oslash;rensen, M.D., Ph.D., our president and chief executive officer, as well as the other principal members of our management, scientific and
clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or
other employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals. Recruiting and retaining qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and
commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to
hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we rely on consultants and advisors, including scientific and clinical
advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. Our success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and
retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to expand our development and regulatory capabilities and
potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development,
clinical, regulatory affairs, manufacturing and quality control and, if any product candidate receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our
managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company
with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management
and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future
acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may acquire
additional businesses, technologies or assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies,
those markets or technologies may not achieve the outcomes that we expect. Acquiring new product candidates is inherently risky, and there can be no assurance that any acquired product candidates would prove to be successful. In addition, we may not
be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new
products or product candidates resulting from a strategic alliance or acquisition that may delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure our stockholders that, following any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of management time and focus from operating our business to addressing acquisition integration challenges;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coordination of research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retention of key employees from the acquired company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in relationships with collaborators as a result of product acquisitions or strategic positioning resulting from the
acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cultural challenges associated with integrating employees from the acquired company into our organization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have
lacked sufficiently effective controls, procedures and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">liability for activities of the acquired company before the acquisition, including intellectual property infringement
claims, violation of laws, commercial disputes, tax liabilities and other known liabilities unanticipated write-offs or charges; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers,
former stockholders or other third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The internal information technology systems, or those of any future collaborators of ours,
vendors or other contractors or consultants, on which we depend have in the past and may in the future fail or suffer cybersecurity incidents, data breaches, loss of data and other disruptions, which could result in a material disruption of our
product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, trigger contractual and legal obligations, potentially exposing us to liability, reputational harm or otherwise
adversely affect our business and financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are dependent upon information technology systems, infrastructure and data to
operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Despite the implementation of security measures, our internal information technology systems and those of any collaborators, vendors, contractors or
consultants are vulnerable to breakdowns, damage or interruption from computer viruses, computer hackers, malicious code, ransomware, malware, malicious conduct or error by employees or other users, theft or misuse, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, wars or other armed conflict, telecommunication and electrical
failures or other compromise. There could also be an increase in cybersecurity attacks generally as a result of ongoing military conflicts and the resulting sanctions imposed by the United States and European governments, together with any
additional future sanctions or other actions by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Cyberattacks are increasing in their frequency, sophistication and intensity, and have become
increasingly difficult to detect. Cyberattacks could include the deployment of harmful malware, ransomware, business email compromises, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks,
unauthorized access to or deletion of files, social engineering (including phishing attacks) and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyberattacks also could include
phishing attempts or <FONT STYLE="white-space:nowrap">e-mail</FONT> fraud to cause payments or information to be transmitted to an unintended recipient. These attacks and activity are also being facilitated or enhanced by evolving technologies,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
including artificial intelligence. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security
threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates,
terrorist organizations or hostile foreign governments or agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Like other companies in our industry, we, and our third-party vendors, have
experienced threats and cybersecurity incidents relating to our information systems and infrastructure. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any future
system failures, cyberattacks, accidents or cybersecurity incidents or data breaches with respect to our information technology systems, or the information technology systems of our vendors, collaborators or other contractors or consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent we or our vendors, collaborators or other contractors or consultants experience a material system failure, accident, cyberattack or
security breach, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the
loss of clinical trial data from our ongoing or planned clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. If we do not allocate and effectively manage the
resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption (and may suffer such disruption notwithstanding the building and sustaining of such infrastructure),
including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that any disruption, cybersecurity incident or data breach were to result in a loss of, or damage to, our or our vendors&#8217;,
collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, including litigation exposure, penalties and fines, we
could become the subject of regulatory action or investigation, our competitive position and reputation could be harmed and the further development and commercialization of our product candidates could be delayed. As a result of such an event, we
may also be in breach of our contractual obligations. Due to applicable laws, rules, regulations and standards or contractual obligations, we may be held responsible for any system failure or security incident attributed to our third-party vendors
as they relate to the information we share with them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal
information, including personal information regarding our customers or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective
action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damage. Any of the above could
have a material adverse effect on our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial exposure from the events
referenced above could either not be insured against or not be fully covered through any insurance that we maintain and could have a material adverse effect on our business, financial condition, results of operations or prospects. In addition, we
cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. There can be no assurance that the limitations of liability in our contracts
would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>While we do not currently use artificial intelligence, or AI, in a manner that is central to our operations, we
may decide to do so, which may cause us to expend material resources in the future. Our current use of AI is limited, but we are still exposed to the inherent risks of the use of AI. The risks and challenges associated with the use of AI, whether in
the more limited manner that we currently do so or the manner that we may do so in the future, include security and other risks to our confidential information, proprietary information and personal information, any of which may result in
reputational harm and liability, &#8220;hallucinations&#8221; or other errors, and biases, among other potential adverse effects to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may use and integrate AI into our business processes both in our own development and implementation of AI and through the adoption of commercially
available tools. The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain such systems to help ensure that AI is implemented in accordance with applicable law and regulation and in a
socially responsible manner and to minimize any real or perceived unintended harmful impact. Engaging appropriate resources (including computing power) to properly develop such technologies may require substantial expense and it may require
substantial time to develop a properly functioning AI system, including because expertise in the use of AI for drug discovery or other life sciences applications is rare, and we may be unable to successfully integrate AI tools into our business or
to do so efficiently. We may also need to license data from third-party sources or develop data internally, each of which may take substantial time and require substantial expense. If we enable or offer solutions that draw controversy due to
perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm or legal liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Whether with our
current, limited use of AI or a future, more fundamental use of AI, we are exposed to the risk related to the use and integration of AI. Use of this technology could pose cybersecurity, data privacy, IT, intellectual property, regulatory, legal,
operational, competitive, reputational and other risks and challenges that could affect our business. Specifically, risks related to accuracy, bias, AI hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks
(including model poisoning or data poisoning), surveillance, data leakage, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No assurance can be provided that the use of AI will enhance our business or assist our business in becoming more efficient or profitable. The use of AI
can give rise to intellectual property risks, including compromises to our proprietary intellectual property and risks of infringement or misappropriation of third party intellectual property, each of which may result in time-consuming and costly
litigation and could require us to purchase a costly license or cease use of any material created using AI (and any intellectual property derived from such material). In addition, there is currently significant uncertainty around the extent to which
we would be able to claim ownership in, or otherwise protect using intellectual property or similar proprietary rights, any inventions or other materials, which we develop through the use of AI. As a result, we could have no remedy if third parties
reused those same materials, or similar materials also generated by AI. In addition, the use of AI by any of our personnel or our third-party providers could include the input of proprietary or confidential information (including material <FONT
STYLE="white-space:nowrap">non-public</FONT> information) into any AI systems, resulting in such proprietary or confidential information becoming part of a dataset that is accessible by other third-party AI users. Not all providers of AI tools may
offer an option to <FONT STYLE="white-space:nowrap">opt-out</FONT> of usage of such inputs or prompts to further train the tools, and, even where we do <FONT STYLE="white-space:nowrap">opt-out,</FONT> we cannot guarantee that the <FONT
STYLE="white-space:nowrap">opt-out</FONT> will be fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AI is generally highly reliant on the collection and analysis of large amounts
of data. The data we may use to train AI models may be inaccurate, such as if we do not generate the data in an accurate manner, we license third-party data that is inaccurate, or we use a third-party AI system trained on data
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that is inaccurate. As a result of this potential inaccuracy, we may have analyses, recommendations or other outputs that are deficient, inaccurate, incomplete, overbroad, or biased, which may in
turn adversely affect our business, financial condition and results of operations. Another data-related risk of the use of AI, even if the underlying data is accurate, is that AI may be subject to data herding and interconnectedness (i.e., multiple
market participants utilizing the same data to generate the same or similar results), and if those results are important to our business, that may adversely impact our financial or operational condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we may see increasing government and supranational regulation and ethical concerns related to AI use which may also significantly increase
the burden and cost of research, development and compliance in this area. For example, the European Union began implementing the Artificial Intelligence Act, or the AI Act, on August&nbsp;1, 2024, with a significant part of the law scheduled to come
into effect in August 2026. As currently enacted, the AI Act, which may be amended as part of the EU&#8217;s Digital Omnibus, imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages
providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on judicial interpretations and forthcoming legislative amendments, and <FONT
STYLE="white-space:nowrap">non-compliance</FONT> can lead to significant fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the AI regulatory environment is complex and
uncertain. Over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI governance and regulation, including on deployment of AI in healthcare settings. At the federal level, the Trump Administration has endorsed
a federal moratorium on the enforcement of state AI laws, including through a December&nbsp;11, 2025, Executive Order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful
at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. If we develop or use AI systems that are governed by the these laws or regulations, we will need to
meet higher standards of data quality, transparency, and human oversight, and we would need to adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. Because of the interest in AI by many
governmental authorities, there may be additional laws or regulations that limit our ability to use AI or apply novel liability frameworks to the use of AI, and these risks may cause adverse effects to our business, operations or financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may collaborate with third parties, or source work from vendors, that use AI, with or without our knowledge that those third parties
or vendors are using AI. As a result, we may face the risks associated with the use of AI without knowingly using AI. Bad actors around the world also use increasingly sophisticated methods, including the use of AI, to engage in illegal activities
involving the theft and misuse of personal information, confidential information and intellectual property. In addition, the use of generative AI models in our internal or third-party systems may create new attack surfaces or methods for
adversaries, which could impact us and our vendors. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be exposed to significant foreign exchange risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our consolidated financial statements are presented in U.S. dollars. We have operations in Denmark, and we incur portions of our expenses, and may in the
future derive revenues, in a variety of currencies. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Fluctuations in currency
exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign
currencies and the U.S. dollar. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to this Offering, Ownership of Our Common Stock and Operating as a Public Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>An active trading market for our common stock may not develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has not been a public market for our common stock. The initial public offering price for our common stock will be
determined through negotiations with the underwriters. Although we intend to apply to list our common stock on the Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. If an active
market for our common stock does not develop, it may be difficult for you to sell shares you purchase in this offering without depressing the market price for the shares or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#8217;s
listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#8217;s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a
national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders&#8217; ability to buy and sell our common stock and could have an adverse effect on the market
price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The initial public offering price of our common stock will be substantially higher than the pro forma as adjusted net tangible book value per share of
our common stock after this offering. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share as
of&#8195;&#8195;&#8195;&#8195;&#8195;. Based on an assumed initial public offering price of $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of
$&#8195;&#8195;&#8195; per share. To the extent outstanding warrants are exercised, you will incur further dilution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The price of our common stock may be
volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
stock price is likely to be volatile. The stock market in general and the market for smaller biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular
companies. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results of or developments in preclinical studies and clinical trials of our product candidates and any other product
candidates we may develop or those of our competitors or potential collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of our preclinical studies and clinical trials of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our success in commercializing any product candidates, if and when approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments with respect to competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements by us or our competitors of significant acquisitions, <FONT STYLE="white-space:nowrap">in-licensing</FONT>
arrangements, strategic partnerships, joint ventures or collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of expenses related to our development efforts with respect to our product candidates and any future product
candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products,
product candidates, technologies or data referencing rights, and the costs of commercializing any products we are able to successfully develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements or expectations of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of common stock by us, our executive officers, directors or principal stockholders, or others; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the other factors described in this &#8220;Risk Factors&#8221; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been
instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of
substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#8217;s attention and
resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the
ability to control all matters submitted to stockholders for approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, our executive officers and
directors and our stockholders who owned more than 5% of our outstanding common stock before this offering will, in the aggregate, beneficially own shares representing approximately&#8195;% of our capital stock. As a result, if these stockholders
were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of
directors and approval of any merger, consolidation or sale of all or substantially all of our assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This concentration of ownership control may:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay, defer or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">entrench our management and board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders may
desire. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Participation in this offering by our existing stockholders and their affiliated entities may reduce the public
float for our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent certain of our existing stockholders and their affiliated entities participate in this offering,
such purchases would reduce <FONT STYLE="white-space:nowrap">the&nbsp;non-affiliate&nbsp;public</FONT> float of our shares, meaning the number of shares of our common stock that are not held by officers, directors and principal stockholders. A
reduction in the public float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at which you may be able to sell shares of
common stock purchased in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways
that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could cause the price of our common stock to decline and
delay the development of our product candidates and any other product candidates we may develop. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of
gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any,
to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. There is no guarantee that our common stock will appreciate or even
maintain the price at which our stockholders purchase it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares are eligible to be sold into the market in
the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of
a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we
will have &#8195;&#8195;&#8195;&#8195;shares of common stock outstanding based on the number of shares outstanding as of &#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;after giving effect to the corporate reorganization. This includes the
shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. The remaining shares are currently restricted as a result of securities laws or <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements but will become eligible to be sold at various times after the offering as described in the section of this prospectus titled &#8220;Shares Eligible for Future Sale.&#8221; The representatives of
the underwriters may release some or all of the shares of common stock subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and without notice, which would allow for earlier sales of shares in the public market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, certain of our executive officers, directors and stockholders affiliated with our directors may enter into Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plans providing for sales of shares of our common stock from time to time. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the
executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan may be amended or
terminated in some circumstances. Our executive officers, directors and stockholders affiliated with our directors also may buy or sell shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of
material, nonpublic information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, beginning 180 days after the completion of this offering, holders of an aggregate of
&#8195;&#8195;&#8195;&#8195;shares of our common stock will have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for
ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#8220;Underwriting&#8221; section of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an &#8220;emerging growth
company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#8220;emerging growth company,&#8221; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an
EGC until the end of the fiscal year in which the fifth anniversary of this offering occurs, although if the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of
any June&nbsp;30 before that time or if we have annual gross revenues of $1.235&nbsp;billion or more in any fiscal year, we would cease to be an EGC as of December&nbsp;31 of the applicable year. We also would cease to be an EGC if we issue more
than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are
applicable to other public companies that are not EGCs. These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to provide only two years of audited financial statements in this prospectus, in addition to any required
unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have taken advantage of reduced reporting obligations in this
prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if we were not an EGC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock
less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition,
the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to
opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt
the new or revised standard and will do so until such time that we either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify as an EGC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, or the Exchange Act. We may continue to be a
smaller reporting company even after we are no longer an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so
long as our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during
the most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance
initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a public company, and particularly after we are no longer an EGC or smaller reporting
company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing
requirements of the Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate
governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements
that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and
disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time
to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and
financial reporting requirements, and will make some activities more time-consuming and costly compared to when we were a private company. For example, we expect that these rules and regulations may make it more difficult and more expensive for us
to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing
bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, in our second annual report due to be filed with the SEC after becoming a
public company, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial
reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting,
which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work
plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous
reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
our internal control over financial reporting is effective as required by Section&nbsp;404. If we are unable to conclude that our internal control over financial reporting is effective, it could
result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. Moreover, any material weakness or other deficiencies in our internal control over financial reporting may impede our
ability to file timely and accurate reports with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have identified material weaknesses in our internal control over financial reporting. If we are
unable to remedy our material weaknesses, or if we fail to establish and maintain an effective system of internal control over financial reporting, we may be unable to produce timely and accurate financial statements or prevent fraud, which could
adversely impact our business and our stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, we were a private company and have limited accounting and
financial reporting personnel and other resources with which to address our internal controls and related procedures. In connection with the audit of our consolidated financial statements for the years ended December&nbsp;31, 2024 and 2025, we
identified material weaknesses in our internal control over financial reporting. As defined in the standards of the Public Company Accounting Oversight Board (United States), a material weakness is a deficiency, or a combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The material weaknesses were (1)&nbsp;controls around the financial statement close process were not designed or operating effectively, including as a
result of an inappropriate segregation of conflicting duties and insufficient evidence of performance and review of controls, and (2)&nbsp;information system controls around user access, segregation of conflicting duties and change management were
not designed or operating effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To remediate these material weaknesses, we have made and plan to continue to make improvements to the design
and operating effectiveness of our internal controls over financial reporting, including the monitoring, oversight and evaluation of our internal controls. We also plan to allocate more internal resources to our internal controls, including by
hiring additional staff, and intend to engage external advisors to provide training and to reassess and redesign processes and develop new controls as appropriate, including information technology controls covering access and change management as
well as cyber risks, and assisting with the evaluation and documentation of the risk assessment, design and operating effectiveness of our internal controls over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot assure you that the measures we have taken to date, and actions we plan to take in the future, will be sufficient to remediate the control
deficiencies that led to the material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. In addition, neither our management nor an independent registered public
accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation has been required. Had we or our independent registered public
accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. If we are unable to successfully remediate
our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses in the future, or otherwise fail to maintain an effective system of internal controls, the accuracy and
timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements,
investors may lose confidence in our financial reporting, and the market price of our common stock may decline as a result. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures
are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented
by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error
or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which
may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions in our certificate of incorporation and our bylaws that will become effective upon the completion of this offering may discourage, delay or
prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team,
these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our
stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a
&#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to
amend or repeal specified provisions of our certificate of incorporation or bylaws that will become effective upon the completion of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or the
DGCL, which prohibits a person who </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15%
of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our certificate of incorporation designates the Court
of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our
stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
certificate of incorporation that will become effective upon the completion of this offering provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of
Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for any action asserting an internal corporate claim as defined in Section&nbsp;115 of the
DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore,
Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to
litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our certificate of incorporation provides that, unless we consent in writing to the selection of an
alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware
courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to
vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no
assurance that the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These exclusive forum provisions may limit the ability of
our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a
court were to find either exclusive forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other
jurisdictions, all of which could materially adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities analysts do not
publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our
business. We do not currently have, and may never obtain, research coverage by industry or financial analysts. If no, or few, analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst
coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the
price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The global credit and financial markets have in recent years experienced volatility and disruptions (including as a result of actual or perceived changes
in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic
stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, terrorism, or other geopolitical
events. Sanctions imposed by the United States and other countries in response to such conflicts may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others
could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a
variety of risks to our business, including a decrease in the demand for our product candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or
public health crises, could negatively impact the timely execution of our ongoing and future clinical trials. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses,
among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the
current economic climate and financial market conditions generally, could adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in tax laws or in their interpretation could
adversely affect our business and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Income, sales, use or other tax laws, statutes, rules or regulations could be enacted
or amended at any time, which could affect our business or financial condition, including causing potentially adverse impacts to our effective tax rate, tax liabilities and cash tax obligations. For example, the IRA was signed into law in August
2022, and the OBBBA was signed into law in July 2025. The IRA introduced new tax provisions, including a one percent excise tax imposed on certain stock repurchases by publicly traded companies. The one percent excise tax generally applies to any
acquisition of stock by the publicly traded company (or certain of its affiliates) from a stockholder of the company in exchange for money or other property (other than stock of the company itself), subject to a de minimis exception. Thus, the
excise tax could apply to certain transactions that are not traditional stock repurchases. The OBBBA contains numerous tax provisions that we are currently in the process of evaluating, and which may significantly affect our business or financial
condition. The recent changes under the OBBBA include tax rate extensions and changes to the business interest deduction limitation, the expensing of domestic research and development expenditures (in contrast to the continued capitalization and
amortization of foreign research and development expenditures), the bonus depreciation deduction rules and the international tax framework. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory guidance under the IRA, the OBBBA and additional legislation is and continues to be forthcoming, and such guidance could ultimately increase
or lessen the impact of these laws on our business and financial condition. Congress may enact additional legislation, some of which could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform
to such legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may become involved in litigation that could divert management&#8217;s attention and harm our business, and
insurance coverage may not be sufficient to cover all costs and damages. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may be subject to litigation claims through
the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal data, contractual relations with collaborators and licensors and intellectual property
rights. In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, the announcement of negative events, such as
negative results from clinical trials, or periods of volatility in the market price of a company&#8217;s securities. These events may also result in or be concurrent with investigations by the SEC. We may be exposed to such litigation or
investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a
potential strategic transaction or the ultimate value our stockholders receive in any such transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our insurance policies are expensive and only protect
us from some business risks, which will leave us exposed to significant uninsured liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we maintain commercial insurance at a
level we believe is appropriate against certain risks commonly insured in the industry in which we operate, there is no guarantee that our insurer will cover costs or that we will be able to obtain the desired level of coverage on acceptable terms
in the future. Some of the policies we currently maintain include property, general liability, crime insurance, workers&#8217; compensation, and directors&#8217; and officers&#8217;, employment practices and fiduciary liability insurance, clinical
trial insurance, transportation insurance and umbrella insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Changes in the market conditions and our business operations may necessitate the
addition of new insurance policies or change of our existing insurance policies. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also expect that operating as a U.S. public company will make it more difficult and more expensive for us to obtain director and officer liability
insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve
on our board of directors, on our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any significant uninsured liability may require us to pay substantial amounts, which would negatively affect our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond our control, which
could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our main facilities are located in Cambridge, Massachusetts and Copenhagen, Denmark. We have not undertaken a
systematic analysis of the potential consequences to our business and financial results from a major flood, power loss, terrorist activity, pandemics or other regional or global disasters and generally do not have a recovery plan for such events. In
addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions
could seriously harm our operations and financial condition and increase our costs and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of
historical fact, contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements.
The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221;
&#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these words or other similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The forward-looking statements
in this prospectus include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, timing, progress and results of our research and development programs and preclinical studies and clinical
trials, including the timing of our planned Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over
which we believe that the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of and our ability to complete clinical development of, submit applications for and obtain and maintain
regulatory approvals for our current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential advantages of our current and future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our plans to develop and, if approved, subsequently commercialize any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance and clinical utility of our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our estimates regarding the addressable patient population and potential market opportunity for our current and future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection and to remain in compliance
with our existing license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to identify additional products, product candidates or technologies with significant commercial potential that
are consistent with our commercial objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding milestone and/or royalty payments under any of our current or future license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of government laws and regulations, including any new regulatory requirements in the countries in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitive position and expectations regarding developments and projections relating to our competitors and any
competing therapies that are or become available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our reliance on and the performance of third parties that conduct clinical trials of our product candidates and manufacture
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to identify, establish and maintain collaborations or obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry and market conditions, including rising interest rates, inflation and tariffs;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act or a smaller
reporting company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our anticipated use of our existing cash, cash equivalents, and marketable securities and the proceeds from this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should
not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the
cautionary statements included in this prospectus, particularly in the &#8220;<I>Risk Factors</I>&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Moreover,
we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements
contained in this prospectus. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement of which
this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this prospectus are made as of the date of this prospectus,
and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds from our issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering will be
approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise in full their option to purchase additional shares of our common stock, assuming an initial public offering price
of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range
set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming the number of shares offered by us, as set forth on the cover page of
this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as
set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming that the assumed initial public offering price per share remains the
same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the initial price to the public or the number of shares by these amounts would have a
material effect on uses of the proceeds from this offering, although a decrease in the initial offering price without a corresponding increase in the number of shares offered may accelerate the time at which we will need to seek additional capital.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had cash, cash equivalents, and marketable securities of $185.5&nbsp;million. We currently expect to use the net
proceeds from this offering, together with our cash, cash equivalents, and marketable securities, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to fund clinical development of sutacimig for the treatment of Glanzmann
thrombasthenia and Factor VII deficiency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to fund clinical development of
<FONT STYLE="white-space:nowrap">HMB-002</FONT> for the treatment of Von Willebrand Disease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million for additional discovery, preclinical, and clinical activities for
current and future programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our expected use of net proceeds from this offering and our existing cash, cash equivalents, and marketable securities represents our intentions based
upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the
scope, progress, costs and results of our research and development efforts, as well as any collaborations that we may enter into with third parties, and any unforeseen cash needs. We believe opportunities may exist from time to time to expand our
current business through acquisitions of complementary companies, products or technologies. While we have no current agreements, commitments or understandings for any specific acquisitions at this time, we may also use a portion of the net proceeds
for these purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable
securities, will be sufficient to enable us to&#8195;&#8195;&#8195;&#8195; . The expected net proceeds from this offering will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise
substantial additional capital to complete the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
development and commercialization of our product candidates. The specific allocation of the net proceeds from this offering and our existing cash, cash equivalents, and marketable securities to
any product candidate will depend on, among other things, the results of our research and development efforts, the timing and success of our preclinical studies and clinical trials and the timing and outcome of regulatory submissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current plans, we believe that the anticipated net proceeds from this offering, together with our cash, cash equivalents, and marketable
securities, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into&#8195;&#8195;&#8195;&#8195;. We have based our estimates as to how long we expect we will be able to fund our operations on
assumptions that may prove to be wrong. We could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing, which may not be available to us on acceptable terms, or at all.
Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will have broad discretion over how to use the net proceeds to us from this offering. Pending our use of the net proceeds from this offering, we
intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund
the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will
depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities
we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_7"></A>CORPORATE REORGANIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently operate as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark. For purposes of this offering, we
formed Hemab Therapeutics Holdings, Inc., a Delaware corporation, which is the registrant whose name appears on the cover of the registration statement of which this prospectus is a part. Prior to the completion of this offering, we will complete a
corporate reorganization pursuant to which our existing shareholders will exchange their shares in Hemab ApS for the same number, classes and series of newly issued shares in the newly incorporated Delaware company, Hemab Therapeutics Holdings, Inc.
and, as a result, Hemab ApS will become a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Additionally, it is expected that, in connection with the corporate reorganization, Hemab ApS will transfer its shares of Hemab Therapeutics Inc.,
a Delaware corporation and wholly-owned subsidiary of Hemab ApS, to Hemab Therapeutics Holdings, Inc. and, as a result, Hemab Therapeutics Inc. will become a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. Hemab Therapeutics Holdings,
Inc. will have nominal assets and liabilities and will not have conducted any operations prior to this offering other than such acquisition, its incorporation and the corporate reorganization, including, but not limited to, the assumption and
conversion of warrants described below. Upon completion of the corporate reorganization, the historical consolidated financial statements of Hemab ApS will become the historical consolidated financial statements of Hemab Therapeutics Holdings, Inc.
Investors in this offering will only acquire, and this prospectus only describes the offering of, shares of the common stock of Hemab Therapeutics Holdings, Inc. We refer to this reorganization transaction throughout this prospectus as the
&#8220;corporate reorganization.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, Hemab ApS, and the holders of all of the issued and outstanding shares of Hemab ApS expect to enter
into a share contribution and exchange agreement, pursuant to which the corporation reorganization will be effected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Exchange of Hemab ApS Ordinary Shares
for Hemab Therapeutics Holdings, Inc. Common Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the corporate reorganization, the share capital of Hemab ApS was divided into
ordinary shares, Seed Preference Shares, Series A Preference Shares, Series B Preference Shares and Series C Preference Shares. Prior to the effectiveness of the registration statement of which this prospectus forms a part, the existing shareholders
of Hemab ApS will exchange each of these classes of shares of Hemab ApS for the same number, classes and series of common stock and preferred stock of Hemab Therapeutics Holdings, Inc. on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis. The newly issued shares of Hemab Therapeutics Holdings, Inc. will have substantially identical rights to the exchanged shares of Hemab ApS. As a result of the exchange, Hemab Therapeutics
Holdings, Inc. will become the sole shareholder of Hemab ApS, and the shareholders of Hemab ApS will solely hold shares of Hemab Therapeutics Holdings, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Assumption and Conversion of Hemab ApS Warrants for Hemab Therapeutics Holdings, Inc. Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the corporate reorganization, we expect that each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS
will be assumed by Hemab Therapeutics Holdings, Inc. and converted into a warrant to purchase the same number of shares of common stock of Hemab Therapeutics Holdings, Inc. Each new warrant will otherwise have and be subject to the same terms and
conditions as were in effect immediately prior to the assumption and conversion. No warrants of Hemab ApS will be outstanding following the assumption and conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash, cash equivalents, and marketable securities and our capitalization as of December&nbsp;31, 2025: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to (1)&nbsp;the corporate reorganization, (2)&nbsp;the automatic conversion of all
outstanding shares of our preferred stock into an aggregate of&#8195;&#8195;&#8195;&#8195; shares of our common stock, which conversion will occur upon the completion of this offering, and (3)&nbsp;the filing and effectiveness of our restated
certificate of incorporation immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of
our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The pro forma as adjusted information below
is illustrative only and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the information in this
table together with our consolidated financial statements and the related notes appearing elsewhere in this prospectus and the &#8220;<I>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#8221; section
of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preference Shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Seed Preference Shares, DKK 1 par value: 23,343 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Series A Preference Shares, DKK 1 par value; 225,866 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Series B Preference Shares, DKK 1 par value; 442,205 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible Series C Preference Shares, DKK 1 par value; 512,991 shares authorized, issued and outstanding,
actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shareholder&#8217;s (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ordinary shares, DKK 1 par value; 43,000 shares authorized, issued and outstanding, actual; no shares
authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value; no shares authorized, issued and outstanding, actual;
&#8195;&#8195;&#8195;&#8195;shares authorized, shares issued and outstanding, pro forma; &#8195;&#8195;&#8195;&#8195;shares authorized, &#8195;&#8195;&#8195;&#8195;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock, $0.0001 par value; no shares authorized, issued and outstanding, actual;
&#8195;&#8195;&#8195;&#8195;shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The pro forma as adjusted information in the table above is illustrative only, and our capitalization following the
completion of this offering will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of
$&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and marketable
securities, total stockholders&#8217; equity, and total capitalization by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase (decrease) the number of shares we are offering. A 1.0&nbsp;million share increase (decrease) in the number of
shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and marketable securities, total stockholders&#8217; equity, and total
capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming the assumed initial public offering price per share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above does not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195; shares of common stock issuable upon exercise of warrants outstanding as
of&#8195;&#8195;&#8195;&#8195;, 2026 with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 Plan which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 ESPP, which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our historical net tangible book value (deficit) as of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;was $(&#8195;&#8195;&#8195;&#8195;)
million, or $(&#8195;&#8195;&#8195;&#8195;) per share of our common stock. Our historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and the carrying value of our convertible preferred
stock, which is not included within stockholders&#8217; (deficit) equity. Historical net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by the&#8195;&#8195;&#8195;&#8195;shares of our common
stock outstanding as of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our pro forma net tangible book value (deficit) as
of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;was $&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195;per share of our common stock. Pro forma net tangible book value represents the amount of our total tangible assets
less our total liabilities, after giving effect to (1)&nbsp;the corporate reorganization, (2)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock,
which conversion will occur upon the completion of this offering, and (3)&nbsp;the filing and effectiveness of our restated certificate of incorporation immediately prior to the completion of this offering. Pro forma net tangible book value
(deficit) per share represents pro forma net tangible book value (deficit) divided by the total number of shares of common stock outstanding as of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;, after giving effect to the pro forma
adjustments described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After giving further effect to our issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this
offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;would have been $&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195;per
share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to existing stockholders and an immediate dilution of $&#8195;&#8195;&#8195;&#8195;in pro forma as adjusted net
tangible book value per share to new investors purchasing shares of common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the
assumed initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of &#8195;,&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of &#8195;,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to new investors purchasing
shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The dilution information discussed above is illustrative only and will change based on the actual initial public
offering price and other terms of this offering determined at pricing. Each $1.00 increase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
(decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase
(decrease) our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;, dilution per share to new investors purchasing shares of common stock in this offering by $&#8195;&#8195;&#8195;&#8195;,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also increase or decrease the number of shares we are offering. A 1.0&nbsp;million share increase in the number of shares offered by us, as set
forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;and decrease the dilution per share to new investors purchasing shares of
common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming the assumed initial public offering price per share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. A 1.0&nbsp;million share decrease in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per share after this offering by
$&#8195;&#8195;&#8195;&#8195;and increase the dilution per share to new investors purchasing shares of common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming the assumed initial public offering price per share remains the same, and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters exercise in
full their option to purchase additional shares of our common stock, our pro forma as adjusted net tangible book value per share after this offering would be $&#8195;&#8195;&#8195;&#8195;, representing an immediate increase in pro forma as adjusted
net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to new investors purchasing shares of common
stock in this offering, assuming an initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes, as
of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;on the pro forma as adjusted basis described above, the total number of shares of common stock purchased from us on an as converted to common stock basis, the total consideration paid or to
be paid and the weighted average price per share paid or to be paid by existing stockholders and by new investors in this offering at the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the estimated
offering price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing shares of common stock
in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Price</B><br><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#8217; option to purchase additional shares in this offering. If
the underwriters exercise in full their option to purchase additional shares of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
common stock, the number of shares of our common stock held by existing stockholders would be reduced to&#8195;&#8195;&#8195;&#8195; % of the total number of shares of our common stock
outstanding after this offering, and the number of shares of common stock held by new investors purchasing shares of common stock in this offering would be increased to&#8195;&#8195;&#8195;&#8195;% of the total number of shares of our common stock
outstanding after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The tables and discussion above are based on the number of shares of our common stock outstanding as
of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;, and exclude: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195; shares of common stock issuable upon exercise of warrants outstanding as
of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 Plan which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under our 2026 ESPP, which
will become effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2026
ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that outstanding stock options are exercised, new stock options are issued, or we issue additional shares of
common stock in the future, there will be further dilution to our stockholders, including investors purchasing shares of common stock in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic
considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in
further dilution to our stockholders, including investors purchasing shares of common stock in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_10"></A>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>You should
read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and related notes and other financial information included elsewhere in this prospectus. This
discussion and analysis and other parts of this prospectus contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, strategies,
objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under
&#8220;Risk Factors&#8221; and elsewhere in this prospectus. You should carefully read the &#8220;Risk Factors&#8221; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially
from our forward-looking statements. Please also see &#8220;Cautionary Note Regarding Forward-Looking Statements and Industry Data.&#8221; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a late clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and
human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases, including
Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause significant life-long burden to patients. We are building a comprehensive franchise of investigational
therapeutics spanning from late-stage pivotal programs through discovery research. Our assets address critical gaps in the treatment of coagulation disorders, with multiple value-driving clinical data events anticipated in
&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig <FONT STYLE="white-space:nowrap">(HMB-001),</FONT> is a bispecific antibody currently in
Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset,
<FONT STYLE="white-space:nowrap">HMB-002,</FONT> is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception in 2020, we have devoted substantially all of our resources to drug discovery, the development of our lead product candidates,
sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> along with several preclinical programs focusing on coagulation disorders. In addition to our research and development efforts, our operations to date have been limited to organizing and
staffing our company, business planning, raising capital, securing intellectual property rights, <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology, discovering product candidates, undertaking preclinical studies, conducting clinical
trials and providing general and administrative support for these operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have no approved products, and we have not generated any revenue
from product sales. We have financed our operations primarily through private placements of convertible preference shares and issuance of convertible debt. Since our inception through December&nbsp;31, 2025, we have received aggregate gross proceeds
of approximately $346.0&nbsp;million from such transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred significant operating losses since inception. Our net losses were
$48.7&nbsp;million and $63.9&nbsp;million for the years ended December&nbsp;31, 2024 and 2025, respectively. As of December&nbsp;31, 2025, we had an accumulated deficit of $181.9&nbsp;million. We expect to continue to incur significant operating
expenses and net losses for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance the clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency, and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with
Von Willebrand Disease, as well as any other product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our clinical-stage product candidates into later-stage clinical trials, including our planned Phase 3 clinical
trial of sutacimig in patients with Glanzmann thrombasthenia, which will be required in order to seek marketing approval of our product candidates, and which we expect will be substantially more expensive than our earlier-stage clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance our research and preclinical activities and seek to discover and develop additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish and <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing processes and capabilities, or arrange for a
third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ultimately establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for
which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop, maintain, expand and protect our intellectual property portfolio (including intellectual property
obtained through license agreements) and provide reimbursement of third-party expenses related to our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish or maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire additional clinical, medical, regulatory, quality control, manufacturing and other scientific and technical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial, clinical, quality and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts of our product candidates and our operations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional audit, legal, regulatory, tax and other expenses with being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any milestone, royalty, or other payments to Novo Nordisk A/S, or Novo Nordisk, under our license agreement with Novo
Nordisk, or the Novo Nordisk Agreement, and to Genmab A/S, or Genmab, under our license agreement with Genmab, or the Genmab Agreement, and under any additional future collaboration or license agreements that we may enter into.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our expenses will further increase if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are required by the U.S. Food and Drug Administration, the European Medicines Agency, or other regulatory authorities to
perform clinical trials or preclinical studies that are in addition to, or different than, those expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any delays in completing our clinical trials or preclinical studies or the development of any of our product
candidates; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual
property-related claim. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will not generate revenue from product sales unless and until we successfully complete the clinical
development or future clinical development of, and obtain regulatory approval for, one or more of our current or future product candidates, which may not occur for several years, if at all. In addition, if we obtain marketing approval for our
product candidates and any other product candidates we may identify and pursue, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our net losses may fluctuate significantly from period to period, depending on the timing of our current and potential future clinical trials and
expenditures related to our research and developmental activities. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding to support our continuing operations and pursue our growth strategy. Until such a time when we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity
offerings, debt financings, royalty financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed,
on favorable terms, or at all. Our failure to raise capital or enter into such agreements or arrangements as, and when needed, could have a material adverse effect on our business, results of operations and financial condition, including potentially
requiring us to delay, limit, reduce or eliminate product development or future commercialization efforts, or grant rights to develop and market current or future development product candidates that we would otherwise prefer to develop and market
ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As there are numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or
amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a
continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
December&nbsp;31, 2025, we had cash, cash equivalents and marketable securities of $185.5&nbsp;million. We believe that our existing cash, cash equivalents and marketable securities, together with the anticipated net proceeds from this offering,
will enable us to fund our operating expenses and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195;. For more information, see the section titled &#8220;<I>Liquidity and Capital Resources</I>&#8221; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have not generated any revenues from the sale of products to date and do not expect to generate any revenue from the sale of products until we
successfully complete development and obtain regulatory approval for one or more of our product candidates, which may not occur for several years, if at all. If our development efforts for our product candidates are successful and result in
regulatory approval or we successfully enter into collaboration or license agreements with third parties, we may generate revenues in the future from product sales, or payments from such collaboration or license agreements, or a combination thereof.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operating expenses
consist of research and development expenses and general and administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development expenses consist primarily of external and internal costs incurred for our research and development activities, including our
product candidate discovery and development efforts. These expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external costs, including expenses incurred under arrangements with third-parties, such as contract manufacturing
organizations, or CMOs, contract research organizations, or CROs, providers of sponsored research, consultants and our scientific advisors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">laboratory and vendor costs related to the execution of preclinical studies and planned and ongoing clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs related to compliance with regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">direct costs of conducting internal research and development for our internal preclinical programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquisition of intellectual property and related future payments should certain development and regulatory milestones be
achieved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">personnel-related costs, including salaries, bonuses, benefits and equity-based compensation for employees engaged in
research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses incurred for the procurement of materials, laboratory supplies and
<FONT STYLE="white-space:nowrap">non-capital</FONT> equipment used in the research and development process; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">depreciation, amortization and other direct and allocated expenses, including rent, insurance, maintenance of facilities
and other operating costs, incurred as a result of our research and development activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expense research and development
costs as incurred. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid
amounts are expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We record accruals for estimated ongoing research costs and
receive updated estimates of costs and amounts owed on a monthly basis from our third-party service providers. When evaluating the adequacy of the prepaid expenses and accrued liabilities, we analyze progress of the studies, including the phase or
completion of events, invoices received and contracted cost estimates from its third-party service providers. Estimates are made in determining the balances at the end of any reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A significant portion of our research and development costs have been, and will continue to be, external costs. External costs, which are specific to a
product candidate, are tracked on a product <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">candidate-by-product</FONT></FONT> candidate basis upon our designation of a preclinical asset as a product candidate. Because we can use
certain resources across several product candidates, personnel-related expenses and indirect or shared operating costs incurred for our research and development activities are not recorded or allocated on a product <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">candidate-by-product</FONT></FONT> candidate basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have historically met the requirements to receive a tax credit in
Denmark of up to 5.5&nbsp;million Danish Kroner, or DKK, per year for losses resulting from research and development costs of up to DKK 25&nbsp;million per year. The tax credit is presented as a reduction to research and development expense in the
consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our research and development expenses will increase substantially
for the foreseeable future in connection with our ongoing clinical trials and our planned clinical development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
activities. However, we cannot reasonably estimate the costs or timing of the efforts that will be necessary to complete the development of any of our product candidates due to the numerous risks
and uncertainties associated with their development, including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, costs and results of our current and future preclinical studies and clinical trials for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether we partner our programs with collaborators for later-stage clinical development or commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and development requirements of any other product candidates we may identify and develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of obtaining clinical and commercial supplies of our product candidates and any other product candidates we may
identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully commercialize our product candidates and any other product candidates we may identify and
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the time and cost necessary to respond to technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">milestone payments and other collaboration-based payments, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract, hire and retain qualified personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of macroeconomic trends including inflation, foreign exchange rate, interest rates and tariffs.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any changes in the outcome of any of these variables with respect to the development of our programs and product candidates or
any future programs and product candidates that we may develop could result in a significant change in the costs and timing associated with the development of that program or product candidate. We may never succeed in achieving regulatory approval
for any of our product candidates or any future product candidates that we may identify and develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and administrative expenses consist primarily of personnel-related costs, including salaries, bonuses, benefits and equity-based compensation
expenses for employees in executive, accounting and finance, business development, human resources, legal and other administrative functions. Other significant general and administrative expenses include facility related costs including
depreciation, legal fees relating to corporate and intellectual property matters and other corporate matters, professional fees for accounting, audit and tax services, consulting fees and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our general and administrative expenses will increase as we increase our headcount to support our research and development activities
and the potential commercialization of our product candidates, if approved. Additionally, these increases will likely include increased costs related to the hiring of additional personnel, among other expenses. We also expect to incur increased
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expenses associated with being a public company, including increased costs of accounting, audit, legal, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with
maintaining compliance with Nasdaq listing requirements and the requirements of the Securities and Exchange Commission, or the SEC, director and officer insurance costs, and investor and public relations costs. We also expect to incur additional
intellectual property-related expenses as we file patent applications to protect innovations arising from our research and development activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other Income
(Expense), Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other income (expense), net primarily consists of interest income generated from interest on cash, cash equivalents and
marketable securities, realized and unrealized gains and losses on foreign currency transactions and interest expense associated with our finance lease for certain laboratory equipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Income Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to taxation in the United States
and Denmark. As of December&nbsp;31, 2025, we had $170.9&nbsp;million of net operating loss carryforwards that can be carried forward indefinitely according to Danish Tax Authority regulations. These loss carryforwards are available to reduce future
taxable income, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected
to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that includes the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the level of historical operating results and projections for the taxable income for the future, we have
determined that it is more likely than not that our net deferred tax assets will not be realized. Accordingly, we have recorded a full valuation allowance to reduce our net deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recognize tax benefits from uncertain tax positions only if, based on the technical merits of the position, it is more likely than not that the tax
positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate
settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for taxes in our statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We operate in Denmark and may be subject to audits from various tax authorities. Management&#8217;s judgment is required in determining our provision
for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We plan to monitor the extent to which our deferred tax assets may be
realized and adjust the valuation allowance accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2024 and 2025 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the years presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for the years presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development costs by product candidate:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">sutacimig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">HMB-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,699</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other research and development costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Discovery and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Total research and development expenses were $41.4&nbsp;million for the year ended December&nbsp;31, 2024, compared to
$59.6&nbsp;million for the year ended December&nbsp;31, 2025. The $18.2&nbsp;million increase in research and development expenses for the year ended December&nbsp;31, 2025 was primarily due to an increase of $9.4&nbsp;million in spending on the
clinical development of sutacimig and an increase of $6.4&nbsp;million in personnel-related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">External research and development expenses
related to sutacimig for the years ended December&nbsp;31, 2024 and 2025 were $12.7&nbsp;million and $22.1&nbsp;million, respectively. The increase of $9.4&nbsp;million for the year ended December&nbsp;31, 2025 was primarily driven by continued
clinical development of sutacimig, including increased <FONT STYLE="white-space:nowrap">scale-up</FONT> activities and Good Manufacturing Practices batch production to support our planned Phase 3 clinical trial as well as increased CRO costs from
our ongoing Phase 1/2 clinical trials of sutacimig. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">External research and development expenses related to <FONT STYLE="white-space:nowrap">HMB-002</FONT>
for the years ended December&nbsp;31, 2024 and 2025 were $15.3&nbsp;million and $12.6&nbsp;million, respectively. The decrease of $2.7&nbsp;million for the year ended December&nbsp;31, 2025 was primarily driven by Chemistry, Manufacturing, and
Controls, or CMC, costs and preclinical toxicology studies and costs related to submission of an investigational new drug application in 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other external research and development expenses increased by $3.2&nbsp;million for the year ended December&nbsp;31, 2025 compared to the year ended
December&nbsp;31, 2024, primarily driven by the initiation of preclinical toxicology studies and CMC activities to support investigational new drug enabling studies for a product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Personnel-related expenses and equity-based compensation increased by $6.4&nbsp;million and $0.3&nbsp;million in the year ended December&nbsp;31, 2025,
respectively, compared to the year ended December&nbsp;31, 2024, primarily driven by an increase in average headcount across clinical development, CMC, and clinical operations related to the pursuit of identifying and developing product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Discovery and other costs increased by $1.6&nbsp;million for the year ended December&nbsp;31, 2025 compared to the year ended December&nbsp;31,
2024, primarily driven by an increase in discovery activities and consultancy expense related to clinical operations, clinical research, and regulatory research. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
summarizes our general and administrative expenses for the years presented (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Total general and administrative expenses were $9.0&nbsp;million for the year ended December&nbsp;31, 2024, compared to
$10.5&nbsp;million for the year ended December&nbsp;31, 2025. The $1.5&nbsp;million increase was primarily due to an increase in personnel-related costs of $0.6&nbsp;million driven by an increase in average headcount as well as an increase in
professional service fees of $0.7&nbsp;million. These costs were partially offset by a $0.2&nbsp;million decrease in equity-based compensation expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other
Income (Expense), Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other income (expense), net for the years ended December&nbsp;31, 2024 and 2025 were net income of $1.9&nbsp;million and
$6.0&nbsp;million, respectively. The $4.1&nbsp;million increase was primarily related to foreign currency gains recognized due to favorable movements between the currencies which we regularly transact in, including DKK, Euros, British Pounds and our
functional currency, the U.S.&nbsp;dollar. This was offset by a decrease in interest income of $1.8&nbsp;million due to a decrease in our cash, cash equivalents and marketable securities throughout the year prior to the closing of our Series C
financing in October 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception, we have
incurred significant operating losses. To date, we have financed our operations primarily through private placements of convertible preference shares and issuance of convertible debt. Through December&nbsp;31, 2025, we have received aggregate gross
proceeds of approximately $346.0&nbsp;million from such transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table provides information regarding our cash flows for the years presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,883</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effect of&nbsp;foreign exchange&nbsp;rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
cash flows from operating activities are significantly influenced by our use of cash for operating expenses and working capital requirements to support our business. We have historically experienced negative cash flows from operating activities as
we invested in the research and development of our product candidates and programs, including preclinical studies, clinical trials, manufacturing and manufacturing process development. The cash used in operating activities resulted primarily from
our net losses adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges, which are generally due to equity-based compensation, depreciation and amortization and <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense, <FONT
STYLE="white-space:nowrap">non-cash</FONT> interest income, as well as changes in components of operating assets and liabilities, which are generally due to increased expenses and timing of vendor payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2024, net cash used in operating activities was $45.6&nbsp;million, due to a net loss of $48.7&nbsp;million,
which was partially offset by changes in operating assets and liabilities that provided $1.4&nbsp;million in cash and net <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses of $1.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, net cash used in operating activities was $61.5&nbsp;million, due to a net loss of&#8201;
$63.9&nbsp;million, which was partially offset by changes in operating assets and liabilities that provided $1.3&nbsp;million in cash and net <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses of $1.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31,
2024, net cash provided by investing activities was $61.9&nbsp;million, which primarily consisted of maturities of marketable securities, which were partially offset by purchases of marketable securities and property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, net cash used in investing activities was $81.5&nbsp;million, which primarily consisted of purchases of
marketable securities, which were partially offset by maturities of marketable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2024, net cash used in financing activities was $0.1&nbsp;million, related to principal payments on finance lease
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2025, net cash provided by financing activities of $156.3&nbsp;million, which primarily
related to proceeds received from the issuance of Series C preference shares of Hemab ApS, net of issuance costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we commence our planned Phase 3
clinical trial of sutacimig in patients with Glanzmann thrombasthenia and continue our ongoing Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, Phase 2 clinical trial of sutacimig in patients with Factor VII
deficiency and Phase 1/2 trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with Von Willebrand Disease, continue research and development and initiate additional clinical trials of, and seek marketing approval for, these and other
product candidates. In addition, if we obtain marketing approval for our product candidates and any other product candidates we may identify and pursue, we expect to incur significant commercialization expenses related to product manufacturing,
sales, marketing and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant operating expenses and net
losses for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, we had total cash, cash equivalents and marketable securities of
$185.5&nbsp;million. We believe that our existing cash, cash equivalents and marketable securities, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements
into&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with product development, and because the extent to which we may enter into collaborations
with third-parties for the development of our product candidates is unknown, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our
product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors. We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance the clinical development of our product candidates, including our ongoing Phase 1/2 clinical trial of
sutacimig in patients with Glanzmann thrombasthenia, our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency, and our ongoing Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> in patients with
Von Willebrand Disease, as well as any other product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our clinical-stage product candidates into later-stage clinical trials, including our planned Phase 3 clinical
trial of sutacimig in patients with Glanzmann thrombasthenia, which will be required in order to seek marketing approval of our product candidates, and which we expect will be substantially more expensive than our earlier-stage clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to advance our research and preclinical activities and seek to discover and develop additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish and <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing processes and capabilities, or arrange for a
third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ultimately establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for
which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop, maintain, expand and protect our intellectual property portfolio (including intellectual property
obtained through license agreements) and provide reimbursement of third-party expenses related to our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish or maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire additional clinical, medical, regulatory, quality control, manufacturing and other scientific and technical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial, clinical, quality and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts of our product candidates and our operations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional audit, legal, regulatory, tax and other expenses with being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any milestone, royalty, or other payments under the Novo Nordisk Agreement, under the Genmab Agreement, and under any
additional future collaboration or license agreements that we may enter into. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our expenses will further increase if,
among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are required by the U.S. Food and Drug Administration, the European Medicines Agency, or other regulatory authorities to
perform clinical trials or preclinical studies that are in addition to, or different than, those expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any delays in completing our clinical trials or preclinical studies or the development of any of our product
candidates; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual
property-related claim. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time
consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may
not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to
achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our expectation with respect to our ability to fund current planned operations is based on estimates that are
subject to risks and uncertainties. Our operating plan may change as a result of many factors currently unknown to management and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by us, and we
may need to seek additional funds sooner than planned. If we are unable to raise this capital when needed, we may be forced to delay, limit, reduce or eliminate one or more of our research and development programs or other operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not have
any source of committed capital or external funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as stockholder. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring debt, selling or licensing our assets, making capital expenditures or declaring dividends or encumbering our assets to secure future indebtedness. If we raise additional funds through equity offerings, debt
financings, royalty financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or development
product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development
programs or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For additional information on risks associated with our substantial capital requirements, please see &#8220;<I>Risk Factors &#8212; We will need
substantial additional funding. If we are unable to raise capital on acceptable terms when needed, or at all, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts</I>.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Contractual Obligations and Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Purchase and Other
Obligations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We enter into contracts in the normal course of business with CROs, CMOs and other third-parties for preclinical research studies,
clinical trials and testing and manufacturing services. These contracts typically do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation generally consist of payments for services
provided or expenses incurred up to the date of cancellation, including <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations of our service providers and, in some cases, wind-down costs. For further information regarding certain of our
license agreements and amounts that could become payable in the future under those agreements, please see Note 8 in our consolidated financial statements appearing elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Below is a summary of the key terms for
certain of our license agreements. For a more detailed description of these agreements, see the section titled &#8220;<I>Business&#8212;License Agreements.</I>&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with Novo Nordisk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November
2019, we entered into a license agreement with Novo Nordisk A/S, or Novo Nordisk, pursuant to which Novo Nordisk granted us an exclusive (even as to Novo Nordisk), worldwide and sublicensable license under specified patent rights, and a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified <FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise
exploit, or transfer possession of or title in, products, or Novo Licensed Products, containing bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding
conditions, including hemophilia. We refer to this agreement as the Novo Nordisk Agreement. Under the terms of the Novo Nordisk Agreement, we have agreed to use commercially reasonable efforts to develop and commercialize a Novo Licensed Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are obligated to pay to Novo Nordisk a <FONT STYLE="white-space:nowrap">one-time</FONT> DKK 40&nbsp;million milestone payment upon achievement
by a Novo Licensed Product of a specified regulatory milestone event, and we are also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
obligated to pay Novo Nordisk tiered royalties, in the low single-digit percentages, on aggregate annual net sales of all Novo Licensed Products, on a Novo Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Novo</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the later of the
expiration of the last valid claim in the licensed patents under the Novo Nordisk Agreement covering such Novo Licensed Product in such country and ten years following the first commercial sale of such Novo Licensed Product in such country. Under
the Novo Nordisk Agreement, we initially granted to Novo Nordisk a right of first negotiation, following a specified clinical event and during a specified period of time, to obtain a license back from us to exploit Novo Licensed Products if we
determined to engage with a third party with respect to a license of any Novo Licensed Products. However, Novo Nordisk&#8217;s right of first negotiation under the Novo Nordisk Agreement has expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Novo Nordisk Agreement will continue in force until it is terminated. On expiration of each royalty term, our license becomes royalty-free,
perpetual, and irrevocable with respect to the applicable Novo Licensed Product in the applicable country. Either party may terminate the Novo Nordisk Agreement for the other party&#8217;s uncured material breach or insolvency. We may terminate the
Novo Nordisk Agreement for any reason upon 90 days&#8217; written notice to Novo Nordisk. In the event that Novo Nordisk regains control of the exclusive right to exploit the Novo Licensed Product, the Novo Nordisk Agreement will automatically
terminate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with Genmab </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
April 2020, we entered into a license agreement with Genmab A/S, or Genmab, pursuant to which Genmab granted us an exclusive (even as to Genmab and its affiliates), worldwide and sublicensable license under platform technology patent rights and <FONT
STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform to research, develop, make, have made, use, manufacture, import, export and commercialize
products comprising bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor&nbsp;VII, or <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including sutacimig, for the treatment of
bleeding conditions, including hemophilia. Under the terms of the Genmab Agreement, we have agreed to use commercially reasonable efforts to develop, manufacture, obtain regulatory approval for and commercialize
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Genmab Agreement, we are obligated to pay Genmab a
percentage of all net profit (i.e., revenue and other proceeds less specified direct costs we incur to conduct research, development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products) we
or our affiliates receive with respect to any <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including (1)&nbsp;net profit from commercial sales of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody
Products and any revenue from third parties, other than Novo Nordisk, in respect of a sublicense or assignment with respect to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including assignment fees, sublicensing fees,
upfront and milestone fees, royalties and other consideration, whether in kind or cash, and (2)&nbsp;the net profit allocated to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products that we or our affiliates receive if we
undergo a change of control (other than an acquisition by Novo Nordisk). The percentage of net profit we owe with respect to each TLT-1/Factor VII Antibody Product is in the low teens from the effective date of the Genmab Agreement until the first
commercial sale of such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product. From and after the first commercial sale of a TLT-1/Factor&nbsp;VII Antibody Product, the percentage of net profit we owe with respect to such
TLT-1/Factor VII Antibody Product is in the high single digits in all territories in which we commercialize such TLT-1/Factor&nbsp;VII Antibody Product and in the mid-teens in all territories in which a third party, other than Novo Nordisk,
commercializes such TLT-1/Factor VII Antibody Product. We are obligated to pay such percentage of net profit on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-TLT-1/Factor</FONT></FONT></FONT> VII Antibody Product basis until the
later of the expiration of the last-to-expire of the platform technology patent rights licensed under the Genmab Agreement covering such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country and twelve years
following the first commercial sale of such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
country, which we refer to as the net profit share term. Following the expiration of the last-to-expire of the platform technology patent rights licensed under the Genmab Agreement covering a
given <FONT STYLE="white-space:nowrap">TLT-1/Factor&nbsp;VII</FONT> Antibody Product in a given country, the percentage of net profit that we are obligated to pay with respect to sales of such TLT-1/Factor VII Antibody Product in such country will
be reduced by a specified percentage for the remainder of the net profit share term for such TLT-1/Factor VII Antibody Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
the event we seek to sell, license or otherwise dispose of our rights to TLT-1/Factor VII Antibody Products, including through a change of control to any third party other than Novo Nordisk, we are obligated to provide Genmab the right to
participate in any bidding process as a <I>bona fide</I> potential acquirer of such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless earlier terminated, the Genmab Agreement will
expire, on a TLT-1/Factor VII Antibody Product-by-TLT-1/Factor VII Antibody Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon the expiration of the last net profit share term
for such TLT-1/Factor VII Antibody Product in such country. On expiration of each net profit share term, our license becomes perpetual, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
with respect to the applicable TLT-1/Factor VII Antibody Product in the applicable country. Either party may terminate the Genmab Agreement for the other party&#8217;s uncured material breach or insolvency or in certain events of force majeure.
Genmab may terminate the Genmab Agreement if we or our affiliates or sublicensees challenge any of the platform technology patent rights licensed under the Genmab Agreement. We may terminate the Genmab Agreement for any reason upon 120 days written
notice to Genmab. If Novo Nordisk obtains from us the exclusive right to exploit TLT-1/Factor VII Antibody Products, including upon termination of the Novo Nordisk Agreement, then the Genmab Agreement will terminate in all territories in which Novo
Nordisk obtains such exclusive rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements in accordance with GAAP. As defined in the standards of the Public Company Accounting Oversight Board (United States), a material weakness is a deficiency, or a combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the audit of our consolidated financial statements for the years ended December&nbsp;31, 2024 and 2025, we identified material
weaknesses in our internal control over financial reporting. The material weaknesses were (1)&nbsp;controls around the financial statement close process were not designed or operating effectively, including as a result of an inappropriate
segregation of conflicting duties and insufficient evidence of performance and review of controls, and (2)&nbsp;information system controls around user access, segregation of conflicting duties and change management were not designed or operating
effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To remediate these material weaknesses, we have made and plan to continue to make improvements to the design and operating
effectiveness of our internal controls over financial reporting, including the monitoring, oversight and evaluation of our internal controls. We also plan to allocate more internal resources to our internal controls, including by hiring additional
staff, and intend to engage external advisors to provide training and to reassess and redesign processes and develop new controls as appropriate, including information technology controls covering access and change management as well as cyber risks,
and assisting with the evaluation and documentation of the risk assessment, design and operating effectiveness of our internal controls over financial reporting. See the section titled &#8220;<I>Risk</I> <I>Factors</I>&#8212;<I>We have identified
material weaknesses in our internal control over</I> <I>financial reporting. If we are unable to remedy our material weaknesses, or if we fail to establish and </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<I>maintain an effective system of internal control over financial reporting, we may be unable to produce timely and accurate financial statements or prevent fraud, which could adversely impact
our business and our stock price.</I>&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates
are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While our
significant accounting policies are described in more detail in Note 2 to our consolidated financial statements included elsewhere in this prospectus, we believe the following accounting policies used in the preparation of our consolidated financial
statements are the most critical for fully understanding and evaluating our financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Expenses
and Related Accruals and Prepaid Expenses&#8195; </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development costs are expensed as incurred and include internal and external
costs incurred in the development of the Company&#8217;s product candidates. These costs primarily consist of personnel costs, including equity-based compensation, expenses incurred under agreements with third-party laboratories, CROs, CMOs and
other vendors, facility-related costs, supplies, and consulting costs. Research and development costs that are paid in advance of performance (if any) are capitalized as a prepaid expense and amortized over the service period as the services are
provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued and prepaid expenses
as of each balance sheet date. We make estimates of these based on facts and circumstances known to us at that time. This process involves recording accruals and prepaids for estimated ongoing research costs and receiving updated estimates of costs
and amounts owed on a monthly basis from our third-party service providers. When evaluating the adequacy of the accrued liabilities and prepaid expenses, we analyze progress of the studies, including the phase or completion of events, invoices
received and contracted cost estimates from its third-party service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we do not expect our estimates to be materially different
from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting accrued amounts that are overstated or understated in any
particular period. To date, there have been no material differences between our estimates of such expenses and the amounts incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have issued and continue to issue equity-based awards to our employees, managers, executives, and <FONT
STYLE="white-space:nowrap">non-employees</FONT> in the form of warrants. We account for equity-based compensation awards in accordance with the Financial Accounting Standards Board ASC Topic 718, <I>Compensation&#8212;Stock Compensation</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We measure equity-based awards based on the fair value on the date of the grant using the
Black-Scholes option-pricing model, or the Black-Scholes OPM, and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. For equity-based awards with
service-based vesting conditions, we recognize compensation expense using the straight-line method. For equity-based awards with performance-based vesting conditions, we recognize compensation expense using the accelerated attribution method over
the requisite service period, commencing when achievement of the performance condition becomes probable. Forfeitures are recorded as they occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Determination
of the Fair Value of Equity-Based Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes OPM ,
which requires inputs based on the fair value of the ordinary shares of Hemab ApS and certain subjective assumptions, including (i) the expected share price volatility, (ii)&nbsp;the expected term of the award, (iii)&nbsp;the risk-free interest
rate, and (iv)&nbsp;expected dividends. Due to the lack of a public market for the ordinary shares of Hemab ApS to date and lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the
historical volatility of a representative group of publicly traded peer companies. We estimate the expected term of our warrants granted to employees and directors using the simplified method for awards that qualify as &#8220;plain-vanilla&#8221;
warrants, whereby the expected term equals the midpoint between the vesting date and the end of the contractual term of the warrant. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon
which to estimate the expected term. For awards with service-based and performance-based conditions, the expected term is determined based on the expected period to vest and the contractual term. The risk-free interest rate is based on U.S. Treasury
securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on the ordinary shares of
Hemab ApS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, there was approximately $3.1&nbsp;million of unrecognized compensation expense related to unvested
warrants which were subject to service-based vesting or performance-based vesting awards for which the performance condition had been achieved and have a remaining service condition. That cost is expected to be recognized over a weighted-average
period of 2.1 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Determination of the Fair Value of Ordinary Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As there has been no public market for the ordinary shares of Hemab ApS to date, the estimated fair value of the ordinary shares of Hemab ApS has been
determined by the board of directors of Hemab ApS, or the Board, with input from management, considering our most recently available third-party valuations of ordinary shares, as well as additional factors which may have changed since the date of
the most recent valuation through the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Significant changes to the key assumptions underlying the factors used could result in
different fair values of ordinary shares at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with the guidance outlined in the American Institute of Certified
Public Accountants&#8217; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities</I> <I>Issued as Compensation</I>, a third-party valuation firm prepared valuations of ordinary shares of Hemab ApS, using the
option-pricing method, or OPM, which used a market approach to estimate its enterprise value. The OPM treats ordinary shares and preference shares as call options on the total equity value of a company, with exercise prices based on the value
thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to stockholders exceed the value of the preference
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
share liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A&nbsp;discount for lack of marketability of the ordinary shares is then applied to arrive
at an indication of value for the ordinary shares. These third-party valuations were performed at various dates, which resulted in valuation of the ordinary shares of Hemab ApS of $153.28 per share as of December&nbsp;31, 2023, $168.72 per share as
of December&nbsp;31, 2024, and $131.98 as of October&nbsp;23, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to considering the results of these third-party valuations, the
Board, with input from management, considered various objective and subjective factors to determine the fair value of the ordinary shares of Hemab ApS as of each grant date, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our operating results and financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the progress of our research and development efforts, including the status of our programs, and the preclinical studies,
clinical trials, and manufacturing process development for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of an active public market for the ordinary shares or preference shares of Hemab ApS as a private company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the price at which Hemab ApS sold preference shares, and the rights, preferences and privileges of such preference shares
relative to its ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the achievement of enterprise milestones, including entering into strategic alliance and license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any external market conditions affecting the biotechnology industry, and trends within the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the likelihood of achieving a liquidity event, such as an IPO, or a sale of our company, given prevailing market
conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biotechnology industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are significant judgments and estimates inherent in these valuations. These judgments and estimates include assumptions regarding our future
operating performance and the stage of development of our product candidates. If our Board had made different assumptions, our equity-based compensation expense and net loss could have been significantly different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once a public trading market for our common stock has been established in connection with the consummation of this offering, our board of directors, or
a committee thereof, will not have to estimate the fair value of our common stock in connection with our accounting for granted warrants and other awards, as the fair value of our common stock will be determined based on the quoted market price of
our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. As a result, we are able to take
advantage of certain reduced reporting requirements that are otherwise applicable to public companies, including delaying auditor attestation of internal control over financial reporting, providing only two years of audited financial statements and
related management&#8217;s discussion and analysis of financial condition and results of operations and reduced executive compensation disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may remain an emerging growth company until the end of the fiscal year in which the fifth
anniversary of this offering occurs. However, if certain events occurs prior to the end of such period, including if we become a &#8220;large accelerated filer&#8221; under SEC rules, our annual gross revenue exceeds $1.235&nbsp;billion, or we issue
more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and
may elect to take advantage of other reduced reporting requirements in future filings. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that
would be required if we were not an emerging growth company. As a result, the information that we provide to our stockholders may be different than what you might receive from other public reporting companies in which you hold equity interests. In
addition, the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected not to &#8220;opt out&#8221; of such extended
transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at the time private companies adopt the new or revised standard
and may do so until such time that we either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify as an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934. We may continue to be a smaller reporting
company even after we are no longer an &#8220;emerging growth company&#8221;. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so
long as our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the
most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A description of
recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the periods presented, we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as
defined under SEC rules and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a smaller reporting company as defined by Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and are not required to provide the
information otherwise required under this item. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a late clinical-stage biotechnology company
developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for
the millions of patients worldwide suffering from serious bleeding and thrombotic diseases, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause
significant life-long burden to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are executing on an ambitious strategic roadmap, which we call &#8220;Hemab 2x3 by 2030,&#8221; to
establish our company as the leading franchise in blood coagulation disorders. This strategy targets six&nbsp;major milestones by 2030: <B>2</B> commercial medicines, <B>2</B> new late-stage clinical programs, and <B>2</B> new early-stage clinical
programs (2+2+2 = 6 major milestones). We believe that executing this strategy has the potential to enable us to treat the millions of people living with neglected blood coagulation conditions worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead asset, sutacimig <FONT STYLE="white-space:nowrap">(HMB-001),</FONT> is a bispecific antibody, which we are currently evaluating in a Phase 1/2
clinical trial for the prophylactic treatment of Glanzmann thrombasthenia and in a Phase&nbsp;2 clinical trial for the prophylactic treatment of Factor VII deficiency. In our ongoing Phase 1/2 clinical trial in Glanzmann thrombasthenia, 34 patients
were treated with sutacimig and amongst 31&nbsp;efficacy evaluable patients, we observed a significant reduction in annualized treated bleed rate, or ATBR, and we expect to commence a Phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia
in &#8195;&#8195;&#8195;&#8195;. In addition, we are conducting a Phase 2 clinical trial of sutacimig in Factor VII deficiency and expect to report clinical data in&#8195;&#8195;&#8195;&#8195;. Our second clinical-stage asset, <FONT
STYLE="white-space:nowrap">HMB-002,</FONT> is a monovalent antibody, which we are developing for the subcutaneous prophylactic treatment of Von Willebrand Disease. In Part A of our ongoing Phase 1/2 clinical trial of
<FONT STYLE="white-space:nowrap">HMB-002,</FONT> patients with Von Willebrand Disease treated with <FONT STYLE="white-space:nowrap">HMB-002</FONT> demonstrated an over <FONT STYLE="white-space:nowrap">1.5-fold</FONT> increase in von Willebrand
factor and Factor VIII, with correction of coagulation parameters such as activated partial thromboplastin time, or aPTT, and thrombin generation, and we expect to report data from our ongoing Phase 1/2 clinical trial in
&#8195;&#8195;&#8195;&#8195;. We are also advancing multiple preclinical and discovery-stage assets, the first of which is expected to enter the clinic in &#8195;&#8195;&#8195;&#8195;, subject to regulatory submission and clearance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Franchise </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are building a franchise designed to
address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management. We design our assets to address critical gaps in the treatment of coagulation
disorders, and we anticipate multiple potentially value-driving clinical data events in &#8195;&#8195;&#8195;&#8195;. The following table summarizes our assets and our target indications, as well as </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the status of development and anticipated clinical data events. We maintain all global economic development and commercialization rights to the assets in our franchise. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g01a30.jpg" ALT="LOGO" STYLE="width:6.30667in;height:2.74in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Sutacimig for the Prophylactic Treatment of Glanzmann Thrombasthenia, Factor VII Deficiency and Other Platelet
Disorders</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing sutacimig as a subcutaneous prophylactic treatment for patients with Glanzmann thrombasthenia and Factor
VII deficiency, which are both congenital, severe, chronic bleeding disorders with no approved prophylactic therapies. Glanzmann thrombasthenia is characterized by deficient or dysfunctional glycoprotein IIb/IIIa expression on platelets, which
impairs platelet-fibrinogen binding and platelet aggregation during primary hemostasis. Patients with Glanzmann thrombasthenia suffer from what can be a devastating combination of life-threatening acute hemorrhages and relentless chronic bleeding
that profoundly impact patients&#8217; physical health, mental health, and quality of life. Factor VII deficiency is characterized by reduced levels of Factor VII, a naturally circulating blood coagulation protein. Patients with clinically severe
Factor VII deficiency suffer from recurrent, unpredictable, life-threatening or potentially disabling bleeding at critical sites, such as in the central nervous system, gastrointestinal tract and intra-articular locations, as well as recurrent
mucocutaneous bleeds of the nose and gums. Both Glanzmann thrombasthenia and Factor VII deficiency also carry additional risks for female patients, including heavy menstrual bleeding and potentially life-threatening post-partum hemorrhage. We
estimate there are approximately 10,000 patients in the aggregate with Glanzmann thrombasthenia and Factor VII deficiency in the geographies where we intend to commercialize sutacimig, including the United States, the European Union, Japan, the Gulf
Cooperation Council, or GCC, countries and other select regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig is a bispecific antibody engineered with high-affinity binding sites for
both endogenous Factor VII and TREML1, or <FONT STYLE="white-space:nowrap">TLT-1,</FONT> a receptor that is exclusively expressed on the surface of activated platelets. When Factor&nbsp;VII is converted to activated Factor VII, or Factor VIIa, it
plays a critical role in initiating the coagulation cascade and generating thrombin, a key enzyme in blood coagulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently evaluating
sutacimig in two clinical trials, a Phase 1/2 clinical trial in Glanzmann thrombasthenia and a Phase 2 clinical trial in Factor VII deficiency. In our Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, we have completed
the Part A (single ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing. The data from Part A of the trial established
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for sutacimig in Glanzmann thrombasthenia by demonstrating an impact on pharmacodynamic markers,
and in addition demonstrated a favorable safety and tolerability profile and predictable dose-dependent pharmacokinetics, all of which supported advancement to Part B of the trial. In Part B, we evaluated several, multi-dose regimens and observed a
favorable safety and tolerability profile. In addition, mean ATBR reduction for patients treated with sutacimig in Part B of the trial ranged from 19% to 87%, indicating clinical activity at all regimens tested. Sutacimig also achieved a 100%
reduction in mean high-intensity ATBR during the Part B treatment period. In addition, 92% of patients in Part B who had at least one bleed event during the six-week prospective <FONT STYLE="white-space:nowrap">run-in</FONT> period experienced a
reduction in ATBR and over 50% of those patients experienced a 50% or greater reduction in ATBR. Overall, we believe the Part A and Part B data support sutacimig&#8217;s potential to deliver meaningful prophylactic ATBR reduction with a convenient
low dose administered weekly. We expect to commence a Phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia in &#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ongoing Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency follows a dose-escalation design. In the trial, we are evaluating
multiple dose levels, progressing from initial lower doses through higher dose cohorts and utilizing interim analyses to assess safety and pharmacodynamics. Our goal is to establish
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> by demonstrating sutacimig&#8217;s ability to increase Factor VII levels for patients with Factor VII deficiency. We anticipate reporting clinical data
from our Phase 2 trial in &#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beyond these two initial indications, we believe sutacimig&#8217;s mechanism of action has
potential applicability across multiple other inherited and acquired bleeding conditions characterized by platelet dysfunction, and other causes of impaired hemostasis where platelet activation occurs at bleeding sites. We believe this represents a
significant opportunity for potential label expansion if sutacimig receives regulatory approval for Glanzmann thrombasthenia or Factor VII deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig has received Fast Track designation from the U.S. Food and Drug Administration, or the FDA, orphan drug designation from the FDA and European
Medicines Agency, or EMA, for Glanzmann thrombasthenia, and innovative licensing and access pathway, or ILAP, designation from the U.K. Medicines and Healthcare products Regulatory Agency, or MHRA, for Glanzmann thrombasthenia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I><FONT STYLE="white-space:nowrap">HMB-002</FONT> for the Prophylactic Treatment of Von Willebrand Disease</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> as a novel subcutaneous prophylactic treatment for Von Willebrand Disease. HMB-002 is
designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor, or VWF, and Factor VIII, a blood coagulation protein. Von Willebrand Disease is the most common inherited
bleeding disorder and results from a reduced quantity or function of VWF, a plasma protein essential for normal hemostasis through its dual role in platelet adhesion and as a carrier protein protecting coagulation Factor VIII from premature
degradation and clearance. Beyond its role in hemostasis, VWF plays an essential role in maintaining normal vascular structure, and reduced VWF levels have been associated with an increased risk of angiodysplasia &#8212; a potential contributing
factor to bleeding in patients with Von Willebrand Disease. Von Willebrand Disease is characterized by life-threatening hemorrhagic events and chronic mucocutaneous bleeding episodes that combine to harm patients&#8217; physical health, mental
well-being, and quality of life. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Moderate-to-severe</FONT></FONT> levels of Von Willebrand Disease are estimated to affect approximately 1 in 10,000 to 1 in 5,000 individuals
globally. In the United States, there are approximately 140,000 patients who have been diagnosed with Von Willebrand Disease across all severity levels, of whom more than an estimated 50,000 require treatment for bleeding events. The treatment
landscape in Von Willebrand Disease is more established than for Glanzmann thrombasthenia and Factor VII deficiency, with approved therapies available for the management of acute bleeding episodes. However, despite the availability of approved
treatments, many patients continue to experience recurrent bleeding and substantial treatment burden, as the approved therapies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
either require frequent intravenous administration or do not address the underlying biology of the disease. Beyond this initial indication, we believe
<FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of action &#8211; stabilizing and extending the half-life of endogenous VWF and Factor VIII &#8211; has potential applicability across other bleeding conditions associated
with low VWF levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">HMB-002</FONT> is a monovalent antibody that selectively binds the <FONT
STYLE="white-space:nowrap">C-terminal</FONT> cystine knot, or CK, domain of the coagulation protein VWF with high affinity and is designed to target the CK domain. VWF is a large multimeric glycoprotein that serves two essential functions in
hemostasis: mediating platelet adhesion to damaged vessel walls and serving as the carrier protein for Factor VIII, protecting it from premature degradation and clearance. The CK domain plays a critical regulatory role in VWF clearance from
circulation. By selectively binding to the inactive CK domain, <FONT STYLE="white-space:nowrap">HMB-002</FONT> is designed to stabilize VWF structure, endow it with an extended half-life and thereby reduce its clearance rate and increase circulating
levels of VWF. Because VWF functions as the carrier molecule for Factor VIII, increases in VWF levels lead to corresponding increases in Factor VIII levels, as Factor VIII bound to VWF is protected from degradation. This dual effect on both VWF and
Factor VIII levels is particularly important because Von Willebrand Disease is fundamentally characterized by low levels of VWF, which in turn directly limits platelet adhesion and results in low levels of Factor VIII due to accelerated Factor VIII
degradation in the absence of adequate VWF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 1/2 clinical trial of
<FONT STYLE="white-space:nowrap">HMB-002</FONT> for the subcutaneous prophylactic treatment of Von Willebrand Disease, which we refer to as Velora Pioneer. Velora Pioneer employs an adaptive dose-escalation design with two parts (Part A and Part B).
Part A of Velora Pioneer explores sequential dose escalation across multiple cohorts, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of <FONT STYLE="white-space:nowrap">HMB-002,</FONT> and Part B of
Velora Pioneer explores several multi-dose cohorts. In addition, we are conducting a prospective natural history study, which we refer to as Velora Discover, running in parallel with Velora Pioneer and enrolling Von Willebrand Disease patients to
establish baseline disease characteristics, bleeding patterns, and quality of life measures. As of the data cutoff date of September&nbsp;2, 2025, for Velora Pioneer, we have completed treatment of two cohorts of patients in Part A at dose levels of
20 mg and 50 mg and are currently evaluating patients in an ongoing 150 mg cohort. In the 20 mg and 50 mg cohorts, VWF and Factor VIII levels increased over <FONT STYLE="white-space:nowrap">1.5-fold</FONT> from baseline in a dose-dependent manner.
In addition, in the 20 mg cohort, <FONT STYLE="white-space:nowrap">HMB-002</FONT> corrected prolonged aPTT and improved thrombin generation assays, resulting in enhanced overall coagulation activity for patients. Furthermore, a sustained VWF
multimer distribution, a measure of protein integrity structure, was observed, suggesting that <FONT STYLE="white-space:nowrap">HMB-002</FONT> did not impact the protein structure of VWF. We expect to report initial data from Part B of Velora
Pioneer in &#8195;&#8195;&#8195;&#8195; &#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Preclinical and Discovery Stage Assets for Additional Coagulation Disorders</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> we are advancing multiple preclinical and discovery-stage assets. The first
of our preclinical assets is expected to enter clinical development in &#8195;&#8195;&#8195;&#8195;, subject to regulatory submission and clearance. We plan to report initial clinical data for this asset in &#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Strategy and Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are guided by our &#8220;All
Patients Matter&#8221; philosophy and by the conviction that individuals living with serious bleeding disorders should not have to live with inadequate treatment options. Our mission is to deliver therapeutics that provide meaningful clinical
benefit and enable patients to live full lives that are not defined or limited by their diseases. We aim to establish the industry&#8217;s leading coagulation franchise through the execution of our &#8220;Hemab 2x3 by 2030&#8221; strategic roadmap,
which is designed to build a franchise consisting of <B>2</B> commercial medicines, <B>2</B> new late-stage clinical programs, and <B>2</B> new early-stage clinical programs by 2030. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following core pillars underpin our strategy and guide our approach to reimagining the treatment
of coagulation disorders. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We deploy a fundamentally patient-centric approach to drug development, beginning with listening, understanding, and
collaboration. </B>We conduct comprehensive natural history studies, which we refer to as our &#8220;360&#8221; natural history studies. These studies capture detailed insights into patients&#8217; lived experiences, including bleed rates, treatment
patterns, and the impact of bleeding disorders on social life, economic status, psychological wellbeing, and work or education. We engage patients through advisory boards and collaborate extensively with patient advocacy organizations and expert
physicians and nurses. These &#8220;360&#8221; insights inform every aspect of our development strategy, from target selection to clinical trial design and commercial positioning. We believe our comprehensive approach demonstrates authentic
patient-centricity that differentiates us and builds trust and credibility across the bleeding disorder community, benefiting our entire franchise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We leverage our deep domain expertise to identify optimal therapeutic targets and match them to the most appropriate
validated drug technology platforms. </B>Our deep understanding of the underlying biology of blood coagulation enables us to match ideal pharmacological targets with the best suited technologies to deliver prophylactic therapies for our target
indications. We are modality agnostic, adopting multiple validated technologies, including bispecific antibodies, monovalent antibodies, peptides and oligonucleotides, when designing our product candidates and programs. We focus on building
proprietary product candidates that are optimally designed for the therapeutic target and patient experience rather than being constrained by a single platform. We believe that this approach of utilizing validated modalities and applying them to
therapeutic targets with the highest scientific rationale maximizes our probability of success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We apply a flexible approach to clinical trial design, to maximize development outcomes and efficiency by leveraging our
patient-driven insights.</B> Our approach to clinical trial design is grounded in identifying the most efficient path to establishing meaningful clinical data. Where appropriate, and subject to the underlying disease biology and current treatment
paradigm, we conduct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies directly in patient populations rather than exclusively in healthy volunteers. This provides more relevant safety data, early
pharmacodynamic assessment and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism,</FONT></FONT> accelerated timelines, and improved capital efficiency through informed decision-making on dose selection and program
advancement. In addition, we leverage the insights generated by our &#8220;360&#8221; natural history studies and our extensive engagement with physicians and patient advocacy communities to inform endpoint selection, support regulatory interactions
and facilitate trial enrollment. For example, we have leveraged these insights to design a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;fit-for-indication&#8221;</FONT></FONT> electronic bleed diary that patients in our
clinical trials utilize to record bleeding events and help ensure precision in our clinical data generation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We are building the foundations of an efficient and scalable commercial franchise.</B> We maintain all global economic
development and commercialization rights to the assets in our franchise, and our ongoing engagement with bleeding-disorder communities provides insights into patient-care patterns and the organization of treatment networks globally. Across our
indications, patients are predominantly treated within a concentrated network of specialized centers, including federally funded Hemophilia Treatment Centers and comprehensive bleeding disorder centers in the United States. The concentration of care
within these sites allows for operational efficiencies in patient identification, engagement, and education, and may reduce the incremental commercial infrastructure required as potential future product candidates advance through development and, if
approved, commercialization. This structure is expected to support a commercial model that we believe can be scaled efficiently as we aim to expand our franchise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>We bring an exceptional depth of experience across the entire value chain of drug discovery, development and
commercialization.</B> Members of our leadership and scientific teams have been directly involved in the discovery, development, regulatory approval, or commercialization of an extensive number of drugs approved for hemophilia, Von Willebrand
Disease, and other coagulation disorders. This collective expertise positions us to efficiently navigate the scientific, regulatory, and commercial complexities inherent in developing therapies for coagulation disorders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Team and History </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have assembled a leadership team
with deep experience in coagulation medicine, drug discovery and development, regulatory affairs, launching specialty pharmaceuticals and building life sciences companies. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Benny Sorensen, M.D., Ph.D., our Chief Executive Officer, has more than 25 years of leadership and clinical experience in
coagulation medicine. He previously held positions at Codiak Biosciences, Inc., Alnylam Pharmaceuticals, Inc., or Alnylam, and Baxter Healthcare Corporation, where he advanced the development of ADYNOVATE, VONVENDI, QFITLIA and other hematology
drugs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Catherine Madigan, M.D., our Chief Medical Officer, has more than 15 years of hematology experience, most recently at
Syndax Pharmaceuticals, Inc., where she led regulatory approval efforts for REVUFORJ and NIKTIMVO. She previously held positions at Alnylam and Biogen Inc.&#8217;s Rare Disease Innovation Unit, advancing treatments including ELOCTATE, ALPROLIX and
QFITLIA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Erik Bjornson, our Vice President of Regulatory Affairs, has more than 30 years of pharmaceutical industry experience
focused on rare bleeding disorders. Most recently at Galderma S.A., he has advanced multiple treatments including ADVATE, ADYNOVATE, VONVENDI, RIXUBIS and CEPROTIN. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Anant Murthy, Ph.D., our Chief Operating Officer, has more than 25 years of healthcare leadership experience, most recently
as General Manager of Europe, Middle East and Africa for argenx SE, where he led the international commercial launch of VYVGART. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Henrik Ostergaard, Ph.D., MSc, our Scientific Vice President, has 18 years of experience in early-stage drug discovery and
development, most recently as Scientific Director at Novo Nordisk A/S. He has led several drug development projects within the hemophilia space, including REFIXIA, NOVOEIGHT and ESPEROCT. Mr.&nbsp;Ostergaard is also a
<FONT STYLE="white-space:nowrap">co-inventor</FONT> of sutacimig. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our leadership team is supported by our board of directors,
which is chaired by John M. Maraganore, Ph.D., founding Chief Executive Officer of Alnylam, who pioneered RNA interference therapeutics. Akshay Vaishnaw, M.D., Ph.D., also serves on our board of directors and is President of Research and Development
at Scholar Rock Holding Corporation and a Venture Partner at Atlas Ventures. He was previously Chief Innovation Officer and President of Alnylam. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since inception, we have raised approximately $346.0&nbsp;million from investors, including Access Biotechnology, Avoro Capital Advisors, Capital Group,
Deep Track Capital, HealthCap, Invus, Novo Holdings, QIA, RA Capital Management, Rock Springs Capital and Sofinnova. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Our Programs, Disease Background and Market
Opportunity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Coagulation disorders encompass a broad and heterogeneous group of conditions affecting millions of people worldwide. While these
conditions differ substantially in prevalence, many patients continue to experience significant disease burden and limitations associated with existing treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approaches. Our franchise is designed to address select bleeding and thrombotic disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully
improve disease management. Our lead clinical-stage assets, sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> are subcutaneous prophylactic therapeutics that we believe have the potential to significantly improve the lives of patients.
Sutacimig is currently in clinical development for Glanzmann thrombasthenia and Factor VII deficiency, and <FONT STYLE="white-space:nowrap">HMB-002</FONT> is currently in clinical development for Von Willebrand Disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on patient registries, published prevalence estimates, and our market insights we estimate that there are approximately an aggregate of 10,000
patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize, including the United States, the European Union, Japan, the GCC
countries and other select regions. However, the emergence of prophylactic options in other diseases has changed the treatment paradigm for patients with blood coagulation disorders such as hemophilia. With greater disease burden awareness,
potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be
greater than we currently estimate. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sutacimig &#8211; Bispecific Antibody for the Prophylactic Treatment of Glanzmann Thrombasthenia and Factor VII
Deficiency </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Overview of Glanzmann Thrombasthenia</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Glanzmann thrombasthenia is a congenital severe, lifelong bleeding disorder with no approved prophylactic therapies. Most patients are diagnosed before
the age of two, and the disease is characterized by a devastating combination of life-threatening acute hemorrhages and chronic bleeding that profoundly impacts patients&#8217; physical health, mental health, and quality of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The clinical severity of Glanzmann thrombasthenia is significant, with over 75% of patients experiencing at least one major, potentially
life-threatening bleeding episode requiring blood component transfusions during their lifetime. The frequency of bleeding is similarly alarming. In our Glanzmann thrombasthenia &#8220;360&#8221; natural history study of 117 Glanzmann thrombasthenia
patients and caregivers across 20 countries, patients reported an average of three bleeding events per week, with 88% experiencing at least one bleeding event within the preceding seven days and 65% requiring a bleed-related hospital visit in the
prior six months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Glanzmann thrombasthenia&#8217;s bleeding manifestations create particularly challenging circumstances for patients. The two most
common bleeding sites are the nose and mouth, highly visible facial locations that can create social stigma and psychological distress. Bleeding into joints, muscles and the central nervous system can also cause serious complications. For women with
Glanzmann thrombasthenia, the burden is especially severe: heavy menstrual bleeding is extremely common and more than 50% of childbirths of patients with Glanzmann thrombasthenia are complicated by potentially life-threatening postpartum hemorrhage.
As a result, women with Glanzmann thrombasthenia may be counseled to avoid pregnancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to the impact of bleeding manifestation,
Glanzmann thrombasthenia frequently leads to chronic iron deficiency anemia, which triggers a cascade of systemic effects including debilitating fatigue, cognitive impairment, compromised cardiovascular health, adverse obstetric outcomes, and
further deterioration in quality of life. These adverse impacts can compound the direct effects of the bleeding disorder itself. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The psychosocial
impact of Glanzmann thrombasthenia can also be challenging for patients. Patients can face unpredictable, potentially severe bleeding episodes&#8212;often in visible or stigmatized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
locations&#8212;that fundamentally restrict their ability to live normal lives. For example, approximately 30% of Glanzmann thrombasthenia patients meet the criteria for symptomatic depression,
nearly five times the rate in the general population. Based on our &#8220;360&#8221; natural history studies, over 85% of patients reported that Glanzmann thrombasthenia has negatively affected their mood and caused emotional problems or social
isolation. The practical and economic consequences for patients are similarly stark based on data collected from our &#8220;360&#8221; natural history studies: over 80% have missed work or school, over 50% face limitations in attending social
events, and over 50% experience restrictions in travel. Glanzmann thrombasthenia is not merely a bleeding disorder, it is a disease that pervades most aspects of patients&#8217; lives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Overview of Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factor VII deficiency<B> </B>is a congenital severe bleeding disorder characterized by reduced levels of a blood coagulation protein called Factor VII.
There are no subcutaneous prophylactic treatment options for Factor VII deficiency, and while the clinical manifestations of bleeding in the disorder are highly variable, they are potentially devastating. Patients with clinically severe Factor VII
deficiency are usually diagnosed before two years of age and suffer from recurrent unpredictable life-threatening or potentially disabling severe bleeding at critical sites, including central nervous system, gastrointestinal tract, and
intra-articular locations, as well as recurrent mucocutaneous bleeds of the nose and gums with additional risks for female patients, consisting of heavy menstrual bleeding and potentially life-threatening post-partum hemorrhage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unlike patients with hemophilia, who mainly experience bleeding events when their factor levels are under 1%, patients with Factor VII deficiency are 10
times more likely to have bleeding when factor levels are under 26% than those with levels above this threshold. Patients live with the risk of recurrent bleeding that ranges from mucocutaneous bleeding to life-threatening and potentially disabling
events. Further, the mucocutaneous bleeds of the nose and gums are from highly visible sites, creating potential social stigma and psychological distress. As with Glanzmann thrombasthenia, recurrent, suboptimally treated bleeding events contribute
to chronic iron deficiency anemia, which similarly can trigger a cascade of systemic health consequences. Despite this high-risk profile, there are no subcutaneous prophylactic treatment options available to patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Market Opportunity in Glanzmann Thrombasthenia and Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Glanzmann thrombasthenia demonstrates substantial geographic variation in prevalence. Based on the available scientific literature, we estimate the
prevalence of Glanzmann thrombasthenia ranges from approximately 1 in 100,000 individuals in high-prevalence regions, such as the GCC countries, to a range of approximately 1 in 250,000 to 1 in 500,000 in the United States, Europe, and Japan. In the
United States, we estimate the prevalence of Glanzmann thrombasthenia at between 1 in 350,000 and 1 in 600,000, with approximately 500 to 1,000 patients in the United States. For Factor VII Deficiency, we estimate that prevalence of moderate and
severe forms of Factor VII deficiency are approximately 1 in 500,000 globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate there are approximately 10,000 patients in the aggregate
with Glanzmann thrombasthenia and Factor VII deficiency in the geographies where we intend to commercialize sutacimig, including the United States, the European Union, Japan, the GCC countries and other select regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our &#8220;360&#8221; natural history study and market insights, we believe patients most likely to benefit from prophylactic therapy include
those with a history of recurrent bleeding episodes that require medical intervention or that impact quality of life, a history of major bleeding events or severe mucocutaneous bleeding, chronic iron deficiency anemia, or the inability to manage
bleeding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
adequately with available <FONT STYLE="white-space:nowrap">on-demand</FONT> treatments. While the data from our &#8220;360&#8221; natural history study suggests there are already a significant
number of Glanzmann thrombasthenia and Factor VII deficiency patients who would benefit from a prophylactic blood coagulation treatment to prevent severe bleeding events, we believe the total number of Glanzmann thrombasthenia patients who would
seek treatment may be greater than we currently estimate. This is based on the experience in other blood coagulation disorders, such as hemophilia, where the number of patients seeking treatment increased as convenient and effective treatment
options became available and more widely adopted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Current Treatment Landscape and Limitations in Glanzmann Thrombasthenia and Factor VII
Deficiency</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are no subcutaneous prophylactic medicines approved to treat Glanzmann&#8217;s thrombasthenia or Factor VII
deficiency. Patients with these disorders mainly receive reactive treatment in response to bleeding events without the ability to prevent them. This results in significant negative impact to physical health, mental health, and quality of life, along
with marked healthcare system utilization. As a result, some patients with severe disease attempt <FONT STYLE="white-space:nowrap">off-label</FONT> prophylactic regimens using recombinant Factor VIIa, typically administered intravenously several
times per week. This approach requires frequent venous access, is associated with substantial treatment burden, has uncertain effectiveness in preventing bleeding over time, and has not been validated in rigorous clinical trials. In addition, the
cost of such regimens can be significant. Consequently, many patients continue to rely on reactive management strategies rather than preventive treatment approaches. In addition, we are not aware of any other companies with active clinical
development programs specifically targeting Glanzmann thrombasthenia or Factor VII deficiency as primary indications. Current treatment options for patients with Glanzmann thrombasthenia and Factor VII deficiency, and their limitations, are
summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Platelet Transfusions (primarily for Glanzmann thrombasthenia).</B>&nbsp;Platelet transfusions may temporarily provide
functional platelets capable of supporting clot formation. However, repeated exposure to allogeneic platelets carries significant risks including alloimmunization, with many patients developing antibodies against platelet antigens (particularly
human leukocyte antigen antibodies or anti-integrin IIb&szlig;3 antibodies in Glanzmann thrombasthenia), leading to platelet refractoriness and reduced effectiveness of subsequent transfusions. Additional limitations include the need for
hospital-based intravenous administration, the potential for transfusion reactions, and residual risk of infectious disease transmission despite modern screening practices. With recurrent transfusion, 30% to 40% of patients become refractory and
experience no benefit from platelet transfusion over time. Physicians often prioritize use of antifibrinolytics, which is less effective than platelet transfusion, to increase the chance that platelet transfusion will be effective if the patient has
a future major life-threatening bleeding event. The lack of preventive options leaves patients to cope with less effective treatments, which may prolong bleeding events and result in more significant medical consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Recombinant Factor</B><B></B><B>&nbsp;VIIa.</B> Recombinant Factor&nbsp;VIIa, or rFVIIa,&nbsp;is administered intravenously, often every two to three
hours, until bleeding is controlled.&nbsp;While&nbsp;rFVIIa&nbsp;can be effective in certain settings,&nbsp;including as a&nbsp;bypassing agent for patients with Glanzmann thrombasthenia who have developed platelet antibodies&nbsp;and as replacement
therapy for patients with Factor VII deficiency,&nbsp;its short circulating half-life of&nbsp;approximately two&nbsp;to three hours necessitates frequent repeat dosing.&nbsp;This often requires repeated venous access, which can be burdensome for
patients and caregivers.&nbsp;Clinical response may be variable, particularly in Glanzmann thrombasthenia, where effectiveness can depend on residual platelet function and the use of supraphysiologic levels of Factor&nbsp;VIIa&nbsp;is associated
with a potential risk of thrombotic&nbsp;complications.&nbsp;In addition, the cost of treatment is substantial, with management of a single bleeding event potentially requiring significant healthcare resources.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Bone Marrow Transplantation.</B> Allogeneic hematopoietic stem cell transplantation, or HSCT, has been employed in rare cases of Glanzmann
thrombasthenia, primarily for patients with severe, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
refractory bleeding or who have developed antibodies against platelet antigens rendering standard of care treatments ineffective. While HSCT can theoretically cure Glanzmann thrombasthenia by
replacing defective platelet-producing cells, the procedure carries substantial risks including transplant-related mortality of 10% to 20%, graft-versus-host disease, opportunistic infections, organ toxicity from conditioning regimens, and graft
failure. Given that Glanzmann thrombasthenia is not inherently fatal when managed with appropriate hemostatic support, the risk-benefit calculus of HSCT remains unfavorable for most patients. Transplantation is therefore reserved only for the most
severe cases where quality of life is profoundly compromised despite maximal medical intervention, alloimmunization precludes effective treatment, or life-threatening bleeding events occur with unacceptable frequency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Other treatment modalities</B> for Glanzmann thrombasthenia and Factor VII deficiency include blood component transfusion resulting from blood loss,
intravenous iron supplementation, and frequent use of antifibrinolytic therapy to help stabilize clots and reduce bleeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Solution - Sutacimig</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig is a bispecific antibody engineered with high-affinity binding sites for both endogenous Factor VII and
<FONT STYLE="white-space:nowrap">TLT-1,</FONT> a receptor that is exclusively expressed on the surface of activated and adhered platelets at sites of vascular injury. Factor VII is a naturally circulating coagulation protein that, when converted to
Factor VIIa, plays a critical role in initiating the coagulation cascade and generating thrombin, a key enzyme in blood coagulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As described
above, high-dose rFVIIa has been administered intravenously for decades to manage acute bleeding events in patients with Glanzmann thrombasthenia and Factor VII deficiency, establishing a well-validated clinical mechanism for hemostatic control.
This extensive real-world experience across thousands of patients has demonstrated that pharmacologic augmentation of thrombin generation through exogenous Factor VIIa administration effectively controls acute bleeds in these bleeding disorders,
providing strong clinical precedent for Factor VIIa-based therapeutic interventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig captures Factor VII from circulation with high
affinity, effectively carrying it through the bloodstream, and then targets it specifically to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TLT-1-expressing</FONT></FONT> activated platelets that have adhered to sites of vessel
lesions. By concentrating Factor VII/VIIa precisely where hemostasis is needed, sutacimig enhances local thrombin generation at bleeding sites to promote clot formation to stop bleeding events. This targeted approach represents a fundamentally
different strategy from traditional Factor VIIa replacement therapy, which distributes Factor VIIa systemically rather than directing it to specific sites of need. The image below depicts sutacimig&#8217;s mechanism of action. As illustrated,
following subcutaneous administration, one arm of sutacimig captures endogenous Factor VII and carries it through the blood stream. Once vessel damage occurs, platelets adhere to the vessel lesion site and become activated and begin to express <FONT
STYLE="white-space:nowrap">TLT-1</FONT> on the surface. At this stage, sutacimig targets Factor VII to the surface of activated platelets via binding to <FONT STYLE="white-space:nowrap">TLT-1.</FONT> Then, Factor VIIa on the surface of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
an activated platelet activates coagulation Factor X and converts prothrombin to thrombin, leading to the formation of a hemostatic plug that stops bleeding. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Mechanism of Action of Sutacimig </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g03m01.jpg" ALT="LOGO" STYLE="width:6.30667in;height:3.25667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are initially developing sutacimig as a prophylactic treatment for patients with Glanzmann thrombasthenia and
Factor VII deficiency. Beyond these two initial indications, we believe sutacimig&#8217;s mechanism of action&#8212;redirecting endogenous Factor VII coagulation to sites of platelet activation marked by <FONT STYLE="white-space:nowrap">TLT-1</FONT>
expression&#8212;has potential applicability across multiple other inherited and acquired bleeding conditions characterized by platelet dysfunction, and other causes of impaired hemostasis where platelet activation occurs at bleeding sites. We
believe this represents a significant opportunity for potential label expansion if sutacimig receives regulatory approval for Glanzmann thrombasthenia or Factor VII deficiency. If approved, sutacimig could represent an important prophylactic option
for patients with significant coagulation disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Clinical Development of Sutacimig </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently evaluating sutacimig in two clinical trials, a Phase 1/2 clinical trial in Glanzmann thrombasthenia and a Phase 2 clinical trial in
Factor VII deficiency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our Phase 1/2 clinical trial of sutacimig in patients with Glanzmann thrombasthenia, we have completed the Part A (single
ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing. We have dosed a total of 36 patients with Glanzmann thrombasthenia in the
trial, including a total of seven patients in Part A and a total of 34 patients in Part B, five of whom participated in both Part A and Part B. In our Phase 2 clinical trial of sutacimig in patients with Factor VII deficiency, which we initiated in
October 2025, we are evaluating the pharmacokinetics, pharmacodynamics, and preliminary safety and tolerability of single ascending doses of sutacimig in patients with Factor VII deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Phase 1/2 Clinical Trial of Sutacimig for Glanzmann Thrombasthenia</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Trial Design and Demographics. </B>In Part A, we evaluated the safety and tolerability, pharmacokinetics, and pharmacodynamics of sutacimig in
patients with Glanzmann thrombasthenia </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
across three single ascending dose cohorts, with doses of 0.2 mg/kg, 0.5 mg/kg, and 1.25 mg/kg, which were then followed by 56 days of observation. In Part A, we enrolled seven patients with
Glanzmann thrombasthenia, who ranged from age 27 to 49 years, with a mean age of 38.9 years. The cohort was comprised of six female participants and one male participant, six of whom were Asian and one of whom was White. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B, we evaluated the pharmacokinetic and pharmacodynamic profile and the safety and tolerability profile of sutacimig and explored clinical
efficacy over three months at multiple dose levels, with the last visit of the last patient in Part B occurring in July 2025. In Part C, we are evaluating the long-term safety and tolerability profile of sutacimig and the persistence of clinical
activity following up to 24 months of dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B, before receiving the first dose of sutacimig, all patients completed a minimum <FONT
STYLE="white-space:nowrap">six-week</FONT> prospective <FONT STYLE="white-space:nowrap">run-in</FONT> period. During the three-month treatment period, patients received doses of sutacimig according to one of four regimens: 0.3 mg/kg, 0.6 mg/kg, or
0.9 mg/kg every two weeks, or 0.3 mg/kg weekly. Throughout the <FONT STYLE="white-space:nowrap">run-in</FONT> and treatment periods, patients recorded bleeding events and treatments in an electronic diary, and patients were examined at the trial
site and contacted by investigators regularly between visits to monitor for adverse events and ensure adherence to strict electronic diary data entry protocol requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part C &#8211; Trial Design </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g04m02.jpg" ALT="LOGO" STYLE="width:5.43in;height:2.50333in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B, we enrolled 34 patients with Glanzmann thrombasthenia, who ranged from age 18 to 66 years,
with a median age of 40.5 years. The cohort had 16 female participants and 18 male participants. Additional demographic information and baseline characteristics are included in the image below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Demographics and Baseline Characteristics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g05m03.jpg" ALT="LOGO" STYLE="width:4.55in;height:2.23333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Sutacimig Phase 1/2 Clinical Efficacy Data.</B>&nbsp;In our Phase 1/2 clinical trial in patients with Glanzmann
thrombasthenia, sutacimig demonstrated clinical activity at all evaluated dose levels. Of the 34 patients participating in the trial, 31 patients met the protocol criteria to be analyzed for clinical activity. Three participants were excluded either
due to a technical malfunction with the patient&#8217;s electronic bleed diary (one patient) or due to failure to participate in the trial for at least the protocol specified <FONT STYLE="white-space:nowrap">six-week</FONT> minimum <FONT
STYLE="white-space:nowrap">run-in</FONT> period (two patients). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We present data below for both Part B and for the combined Part B and Part C
treatment period, which reflect continuous treatment through both Parts B and C as of October&nbsp;14, 2025, the data cutoff date. In Part B, 34 patients were treated with sutacimig and had a median exposure of 3.3 months (with a range of 1.9 to 3.5
months), while in the combined Part B and Part C portions, 34 patients were treated with sutacimig and had a median exposure of 6.9 months (with a range of 1.9 to 15.9 months). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ATBR was selected as the clinical efficacy endpoint for the Phase 1/2 clinical trial, analogous to the annualized bleeding rate used for regulatory
approval in other bleeding disorders, such as hemophilia, and includes only bleeding events that required treatment with a prescribed medication consisting of antifibrinolytics, rFVIIa, platelet transfusion, or medical procedures. The statistical
methodology used to generate and compare mean ATBR for the <FONT STYLE="white-space:nowrap">run-in</FONT> period and treatment period was negative binomial regression with general estimating equation. This is a methodology commonly found in labels
for approved drugs in bleeding disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Individual patient-level data was also analyzed to determine the proportion of patients experiencing ATBR
reduction, among patients with treated bleeding events in the <FONT STYLE="white-space:nowrap">run-in</FONT> period (N=24). This was performed to understand the generalizability of the mean ATBR reduction results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Key Clinical Efficacy Data Findings.</B> In our Phase 1/2 clinical trial of sutacimig for Glanzmann thrombasthenia, mean ATBR reduction&nbsp;ranged
from 19% to 87% across regimens in the treatment period, indicating clinical activity at all tested doses, with a mean 47% reduction when patients treated at all doses were combined. In three out of four tested regimens and the <FONT
STYLE="white-space:nowrap">all-regimen</FONT> analysis, the 95% confidence intervals around the mean ATBR excluded zero, underscoring the robustness of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
assessment. Clinical activity was also consistent across bleed location and causality, whether spontaneous or traumatic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the clinical efficacy data accrued as of the data cutoff date, we believe the 0.3 mg/kg weekly dose cohort established that a low dose weekly
dosing regimen has the potential to deliver optimal exposure for prophylaxis. As depicted in the image below, the weekly 0.3 mg/kg dose achieved an 87% mean ATBR reduction (95% CI: <FONT STYLE="white-space:nowrap">80-92%)</FONT> in the treatment
period, consistent with attainment of sustained exposure throughout the dosing interval, avoiding high peaks and low troughs in drug exposure seen in the every-other-week regimens. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Mean ATBR Reduction </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g06m01.jpg" ALT="LOGO" STYLE="width:5.07in;height:3.10333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, as depicted in the table below, the clinical activity observed in Part B of the trial persisted with
extended treatment, with a mean ATBR reduction of 47% (95% CI: <FONT STYLE="white-space:nowrap">75-90%).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part B and C Combined
&#8211; Mean ATBR Reduction </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g06m02.jpg" ALT="LOGO" STYLE="width:5.55667in;height:1.47667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A particularly notable finding was the impact that sutacimig had on limiting the types of severe bleeding events that
required high-intensity interventions with rFVIIa infusion, platelet transfusion, or medical procedures, which reflects sutacimig&#8217;s potential to meaningfully impact the most severe bleeds experienced by Glanzmann thrombasthenia patients.
Fourteen patients (41%) required this treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
in the 12 months prior to receiving sutacimig. However, there was a 100% reduction in mean high-intensity ATBR during the treatment period, and a 62.4% reduction in mean high-intensity ATBR was
maintained through the combined treatment and extension period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part B and C Combined &#8211; Mean High Intensity ATBR Reduction
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g07m01.jpg" ALT="LOGO" STYLE="width:5.55667in;height:1.36333in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe these substantial rates of reduction in medically significant, potentially life-threatening bleeding events
during active treatment demonstrate sutacimig&#8217;s potential to prevent even the most severe manifestations of Glanzmann thrombasthenia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
patient-level ATBR reductions observed in the Phase 1/2 clinical trial further support the clinical findings described above. As depicted in the image below, nearly 92% of patients who had at least one bleed event during the <FONT
STYLE="white-space:nowrap">run-in</FONT> period experienced an ATBR reduction, and over 50% of these<B> </B>patients&nbsp;experienced a 50% or higher ATBR reduction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Patient-Level ATBR Reduction </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g07m02.jpg" ALT="LOGO" STYLE="width:5.55667in;height:2.65333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Overall, we believe this data demonstrates sutacimig&#8217;s potential to deliver meaningful prophylactic ATBR
reduction with convenient weekly subcutaneous dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part A Pharmacokinetics and Pharmacodynamics</B>. In Part A of the trial, we observed
dose-dependent plasma exposure to sutacimig across all dose levels evaluated, as depicted in the image on the left below. In addition, as depicted in the image on the right below, we observed dose-dependent increases in Factor VIIa accumulation,
with peak levels occurring three to seven days following dosing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and higher doses achieving a longer duration of Factor VIIa elevation. Sutacimig also remained quantifiable through approximately day 42 in most participants, and in certain patients&#8217;
plasma for the entire 56 day observation period. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part A &#8211; Pharmacokinetics and Pharmacodynamics </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g08m03.jpg" ALT="LOGO" STYLE="width:6.30667in;height:2.07667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The data from Part A of the trial established
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for sutacimig in Glanzmann thrombasthenia by demonstrating an impact on pharmacodynamic markers, and in addition demonstrated a favorable safety and
tolerability profile and predictable dose-dependent pharmacokinetics, all of which supported advancement to Part B of the trial. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part A
Safety and Tolerability Profile</B>. In Part A, no patients experienced dose-limiting toxicities. One serious adverse event of moderate iron deficiency anemia occurred, which was deemed unrelated to study drug and subsequently resolved. In addition,
there were no adverse events of disseminated intravascular coagulation. We did detect anti-drug antibodies, or ADAs, which is an identified potential risk for sutacimig as a protein therapeutic, in four patients and two of these patients entered
Part B with a positive ADA titer. However, there was no measurable impact on pharmacokinetics and pharmacodynamics, and no safety events related to immunogenicity were observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part B Pharmacokinetics and Pharmacodynamics</B>. In Part B of the trial, we observed dose proportional exposure, pharmacodynamic activity, and
higher peak elevation in Factor VIIa in the 0.9 mg/kg dose cohort. The weekly dosing regimen of 0.3 mg/kg notably provided consistent exposure and Factor VIIa activity, while avoiding the high peaks and lower troughs seen in the dose levels
administered every two weeks. The image below depicts the mean sutacimig plasma concentration levels observed on the left, the total Factor VIIa levels observed in the middle and the change in Factor VIIa levels compared to baseline on the right
over 84 days across the four dose levels evaluated. The 0.9 mg/kg regimen administered every two weeks demonstrated higher peak Factor VIIa levels </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
compared to other regimens, while the 0.3 mg/kg weekly regimen provided consistent exposure with minimal peak-trough fluctuation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B &#8211; Pharmacokinetics and Pharmacodynamics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g09m01.jpg" ALT="LOGO" STYLE="width:6.30667in;height:2.24667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Part B and Part C Safety and Tolerability. </B>As of the data cutoff date, 34 patients had completed Part B of the
trial and 27 of those patients continued long-term dosing in Part C of the trial. Safety data is presented for all patients who received at least one dose of sutacimig and includes patients treated in Part B and Part C of the trial. In Part B and
Part C of the trial, sutacimig demonstrated a favorable safety and tolerability profile. Of the 34 patients evaluated, 32 (94.1%) experienced at least one treatment-emergent adverse event, or TEAE, the majority of which were mild to moderate in
severity. The image below summarizes the TEAEs reported in Part B and Part C of the trial. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary of Part B and Part C Treatment-Emergent
Adverse Events </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g01e02.jpg" ALT="LOGO" STYLE="width:4.58334in;height:3.09176in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The most frequently reported TEAEs have been either nonspecific symptoms, low-grade laboratory
abnormalities related to the coagulation system, or complications of the underlying disease, including headache and fibrin <FONT STYLE="white-space:nowrap">D-dimer</FONT> increases (each 23.5%), nasopharyngitis (20.6%), and back pain (17.6%). The
image below summarizes the TEAEs reported in Part B and Part C of the trial that occurred in three or more participants. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Treatment-Emergent
Adverse Events Occurring in Three or More Participants </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g10m01.jpg" ALT="LOGO" STYLE="width:5.23667in;height:5.54333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As with most approved procoagulant drugs, sutacimig carries an inherent risk of thromboembolic events. As a result,
such events were monitored as adverse events of special interest, or AESI, in the trial. As of the data cutoff date, three participants had experienced thromboembolic events deemed related to sutacimig: one proximal deep vein thrombosis, or DVT, of
the lower extremity, one isolated distal DVT, and one subsegmental pulmonary embolism, or SSPE. All three events were Grade 2 in severity, and the proximal DVT and SSPE were reported to the FDA on an expedited basis as Suspected Unexpected Serious
Adverse Reactions (SUSARs). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As depicted in the image below, analysis of these AESI revealed an association with high dose levels
of sutacimig, the presence of multiple concurrent venous thromboembolism risk factors (such as smoking, obesity, hypertension, hospitalization for acute illness, or gastrointestinal bleeding and administration of concurrent hemostatic agents), or
both. We believe the proximal DVT event is the one with the highest potential medical significance due to higher risk of embolism. This is reflected in treatment guidelines that recommend a full course of anticoagulation for a proximal DVT, but
offer the option to monitor patients with isolated distal or SSPE without anticoagulation. The proximal DVT event occurred in a patient with multiple DVT risk factors who was dosed at the highest dose level of 0.9&nbsp;mg/kg, which achieved mean
peak levels notably higher than the other regimens evaluated. The other two AESI were thrombotic events that occurred in patients at lower dose levels with multiple (more than two) venous thromboembolism risk factors. Notably, the other 31 patients
in the trial in whom no treatment-related AESIs occurred, had no more than two identified concurrent venous thromboembolism risk factors. This pattern suggests a potential relationship to elevated drug exposure with potential contribution from other
venous thromboembolism risk factors. We believe this is one key principle to leverage in our planned Phase 3 clinical trial design and dose optimization, along with the finding that high exposures appear unnecessary for clinical efficacy, and weekly
regimens have yielded sustained exposures. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part B and Part C&#8212;Adverse Events of Special Interest </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g11m02.jpg" ALT="LOGO" STYLE="width:5.41667in;height:1.54667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no instances of other protocol-defined <FONT STYLE="white-space:nowrap">non-bleeding</FONT> AESI, such as
cerebrovascular accident, acute cardiac events, peripheral arterial embolism or disseminated intravascular coagulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Among the five patients
experiencing six serious adverse events during treatment, two events (33.3%) were deemed treatment-related &#8211; the DVT and the subsegmental pulmonary embolism described above. The remaining four serious adverse events were judged unrelated to
study drug (one each of intra-abdominal hemorrhage, gastrointestinal bleeding, epistaxis, and invasive ductal carcinoma). In addition, treatment discontinuation due to adverse events occurred in four participants (11.8%), including two cases of DVT,
one case of pulmonary embolism, and one case of invasive ductal breast carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part B and Part C of the trial, ADAs were detected in a total
of six patients, two of whom had been positive for ADAs at their last Part A assessment. In three of these six patients, the ADAs were resolved or resolving at the last assessment prior to the data cutoff date. Notably, although the assessment of
ADA impact on ATBR was inconclusive given the variability of ATBR at baseline and the small sample size, these ADAs did not appear to cause Factor VII levels to drop below the lower limit of normal in patients, and there were no adverse events
associated with immunogenicity reported in association with these ADA events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the safety and tolerability profile observed as of the data cutoff date supports continued
clinical development of sutacimig with appropriate dose selection and patient monitoring protocols. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Phase 3 Development Plans for Glanzmann
Thrombasthenia</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are planning to conduct a multinational, multicenter, Phase 3, <FONT STYLE="white-space:nowrap">single-arm,</FONT>
open-label clinical trial evaluating sutacimig as a prophylactic therapy in adolescents and adults with Glanzmann thrombasthenia. We anticipate initiating enrollment in the clinical trial in &#8195;&#8195;&#8195;and, subject to discussions with
regulators, we intend for the data generated by this trial to form the basis of our regulatory submissions for marketing approval of sutacimig as the first prophylactic treatment for Glanzmann thrombasthenia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Preclinical Study of Sutacimig for Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We evaluated sutacimig for Factor VII deficiency in a cynomolgus monkey model of Factor VII deficiency created through siRNA-mediated reduction of Factor
VII. In the study, sutacimig demonstrated the ability to restore deficient coagulation Factor VII levels to ranges expected to be therapeutically beneficial. The study employed a siRNA to reduce endogenous Factor VII to approximately 10% of normal
levels, mimicking severe Factor VII deficiency. Following subcutaneous administration of sutacimig at 5.0 mg/kg, the bispecific antibody accumulated and elevated both Factor VII and Factor VIIa levels, with treated animals achieving accumulation
levels approaching those observed in normal animals. We believe this preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data supports sutacimig&#8217;s mechanism of accumulating residual
Factor VII and Factor VIIa at sites of vascular injury and the potential to restore hemostatic function even for patients with severe Factor VII deficiency. The image below depicts the study design and results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Sutacimig Demonstrated Restoration of Factor VII Levels in <FONT STYLE="white-space:nowrap">Non-Human</FONT> Primates </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g12m03.jpg" ALT="LOGO" STYLE="width:6.30667in;height:2.14667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Ongoing Phase 2 Clinical Trial of Sutacimig for Severe Factor VII Deficiency</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Building on the mechanistic rationale observed in our preclinical study of sutacimig in the cynomolgus monkey model, we initiated a Phase 2 single
ascending dose clinical trial in patients with severe Factor VII deficiency, which includes those patients with 10% or less of normal Factor VII levels. The ongoing clinical trial follows a dose-escalation design, evaluating multiple dose levels,
and progressing from initial lower doses through higher dose cohorts with planned interim analyses to assess safety and pharmacodynamics. This trial aims to establish
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> by demonstrating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sutacimig&#8217;s ability to increase Factor VII&nbsp;levels in patients with Factor VII deficiency. The image below depicts the clinical trial design of our ongoing Phase 2 clinical trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g13m04.jpg" ALT="LOGO" STYLE="width:3.19333in;height:1.80333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If successful, we expect this trial would support advancement to a Phase 3 clinical trial, potentially expanding
sutacimig&#8217;s utility beyond Glanzmann thrombasthenia to address additional bleeding disorders characterized by factor deficiencies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Regulatory
Status and Designations for Sutacimig</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sutacimig has received multiple regulatory designations, including Fast Track, orphan drug and
ILAP: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>FDA Fast Track Designation:</B>&nbsp;Potentially facilitates development and expedites review, providing more frequent
FDA interactions and eligibility for priority review if criteria are met at the time of BLA submission. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Orphan Drug Designations in Glanzmann Thrombasthenia:</B>&nbsp;FDA designation provides the potential for seven years of
market exclusivity upon approval, user fee exemption, and tax credits. The European Commission orphan medicinal product designation provides the potential for ten years of market exclusivity in the European Union, protocol assistance eligibility,
and reduced regulatory fees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>UK MHRA ILAP Designation in Glanzmann Thrombasthenia:</B>&nbsp;Provides the potential for enhanced regulatory support
through the Innovation Passport and Target Development Profile and coordinated engagement with the National Institute for Health and Care Excellence and the Scottish Medicines Consortium to support timely patient access following marketing
authorization in the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These designations may provide sutacimig with the opportunity for expedited regulatory
pathways, extended market exclusivity, reduced fees, and enhanced regulatory support throughout development and commercialization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">HMB-002</FONT> &#8211; Monovalent Antibody for the Subcutaneous Prophylactic Treatment of Von Willebrand Disease </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Overview of
Von Willebrand Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Von Willebrand Disease is the most common inherited bleeding disorder. It is characterized by both life-threatening
hemorrhagic events and relentless mucocutaneous bleeding episodes that combine to inflict significant harm to physical health, mental well-being, and quality of life. The age of diagnosis varies considerably. Patients with early severe bleeding
manifestations are diagnosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
shortly after birth, while patients with more variable bleeds may be diagnosed later in life. First described by Erik von Willebrand in 1926, Von Willebrand Disease results from reduced quantity
or function of VWF, a plasma protein essential for normal hemostasis through its dual role in platelet adhesion and as a carrier protein protecting coagulation Factor VIII from degradation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The clinical severity of Von Willebrand Disease varies by subtype but is substantial across the disease spectrum. Von Willebrand Disease is classified
into three main types: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 1</B> &#8211; 70% to 80% of cases, characterized by partial quantitative VWF deficiency </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 2</B> &#8211; 20% of cases, with qualitative functional defects </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 3</B> &#8211; Less than 1% of cases, representing near-complete absence of functional VWF </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patients with Von Willebrand Disease can experience potentially life-threatening bleeding events regardless of subtype. While Type 3 patients face the
most severe hemorrhagic complications, even patients with Type 1 disease, which has traditionally been considered &#8220;mild&#8221;, experience a serious clinical burden, with up to 15% reporting gastrointestinal bleeding events and approximately
20% experiencing joint bleeding events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Findings from our &#8220;360&#8221; natural history study in Von Willebrand Disease (N=611) highlight the
substantial burden across all disease subtypes. For example, patients across subtypes experienced frequent weekly bleeding events as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 1</B> &#8211; 1.2 bleeds per week </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 2</B> &#8211; 1.4 bleeds per week </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Type 3</B> &#8211; 1.9 bleeds per week </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">More than half of participants required hospital admission for bleeding management within the prior year, demonstrating both the severity of bleeding
episodes and the failure of existing treatments to prevent clinically significant hemorrhage necessitating acute medical intervention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The most
common bleeding manifestations of Von Willebrand Disease are mucocutaneous events that can cause both physical and psychosocial harm in men and women. Women face a particularly severe burden, with 94% having experienced heavy menstrual bleeding in
our &#8220;360&#8221; natural history study, which can profoundly impact quality of life, reproductive choices, and iron status. Across both genders, over 60% of patients report cutaneous and oral cavity bleeding and over 50% experienced nose
bleeds, which are highly visible and socially disruptive. Patients also suffered gastrointestinal hemorrhage, hemarthrosis, and other critical bleeding events. This relentless frequency can create a constant burden pervading every aspect of
patients&#8217; lives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Market Opportunity in Von Willebrand Disease</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Moderate-to-severe</FONT></FONT> Von Willebrand Disease is estimated to affect
approximately 1 in 5,000 to 1 in 10,000 individuals globally. In the United States, based on published prevalence estimates and our market insights, we estimate there are approximately 140,000 patients with Von Willebrand Disease across all severity
levels and types. Of these patients, between 40,000 and 50,000 patients have sought medical treatment for bleeding events based on healthcare claims analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the geographies where we intend to commercialize HMB-002, including the United States, the European Union, Japan, the GCC countries and other select
regions, we estimate the diagnosed Von Willebrand Disease population includes approximately 120,000 symptomatic patients who have sought medical care across all disease types, which likely represents only a portion of the overall patient population
in these markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Epidemiological data indicate that approximately 30% to 40% of patients with Von Willebrand Disease
have concomitant anemia or iron deficiency, objective markers of ongoing bleeding that can adversely affect health and quality of life. This subset of patients represents those most likely to benefit from a prophylactic therapy that increases VWF
and Factor VIII levels to reduce bleeding frequency. Notably, the joint evidence-based clinical practice guidelines published in 2021 by the American Society of Hematology, the International Society on Thrombosis and Haemostasis, the National
Hemophilia Foundation and the World Federation of Hemophilia conditionally recommended long-term prophylaxis treatment for Von Willebrand Disease patients with a history of severe and frequent bleeds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Current Treatment Landscape and Limitations in Von Willebrand Disease</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The treatment landscape in Von Willebrand Disease is more established than in Glanzmann Thrombasthenia or Factor VII deficiency, with therapies available
for management of acute bleeding episodes. Despite existing treatments, many patients continue to experience recurrent bleeding and substantial treatment burden, particularly in the context of therapies that require frequent intravenous
administration or do not address the underlying biology of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Current management of Von Willebrand Disease focuses primarily on acute bleeding event
management rather than prevention. Patients are typically managed using a combination of the following pharmacologic and replacement therapies depending on disease type, severity, and bleeding risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Desmopressin.</B>&nbsp;Desmopressin, or DDAVP, is a synthetic vasopressin analog that stimulates release of VWF stored in endothelial cells and is
administered intranasally or intravenously. DDAVP is effective in patients with Type 1 and Type 2 Von Willebrand Disease. However, its use is limited by tachyphylaxis, resulting in diminished response with repeated dosing, and it is ineffective in
patients with Type 3 disease. As a result, DDAVP is generally used in anticipation of bleeding risk, such as prior to procedures, rather than as a continuous preventive therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Antifibrinolytic Therapy. </B>Antifibrinolytic agents, such as tranexamic acid, are commonly used as adjunctive therapy, particularly for mucosal
bleeding, including heavy menstrual bleeding. While these agents can help reduce bleeding in certain settings, they do not address the underlying deficiency of VWF and are generally insufficient for controlling more severe bleeding or bleeding at <FONT
STYLE="white-space:nowrap">non-mucosal</FONT> sites. Treatment often requires multiple daily doses during bleeding episodes, which can affect adherence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>VWF Intravenous Replacement Products.</B>&nbsp;Plasma-derived and recombinant VWF replacement products are approved for the treatment and prevention
of bleeding in Von Willebrand Disease. These therapies are administered intravenously and have relatively short circulating half-lives, typically requiring repeated infusions. For patients receiving prophylaxis, this often involves intravenous
administration two to three times per week, which can impose a significant burden related to venous access, time commitment, and interference with daily activities. In some patients, particularly children or those with difficult venous access,
long-term intravenous therapy may require central venous catheters. As a result, adherence to prophylactic regimens can be challenging for many patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Blood Component Transfusions.</B>&nbsp;Patients with severe bleeding episodes may require a transfusion of red blood cells to manage anemia resulting
from blood loss and, in some cases, fresh frozen plasma to provide coagulation factors. While these interventions can be necessary to stabilize patients during acute events, they address the consequences of bleeding rather than preventing future
episodes and usually require hospital-based care.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Intravenous Iron Supplementation.</B>&nbsp;Chronic blood loss&nbsp;frequently&nbsp;leads to
iron deficiency,&nbsp;necessitating&nbsp;repeated intravenous iron supplementation. This treatment addresses a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
downstream consequence of ongoing bleeding but does not reduce bleeding frequency or underlying disease activity.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Pipeline Competition. </B>We are aware of other therapies in clinical development for the prophylactic treatment of Von Willebrand Disease that focus
on other mechanisms of action, such as monoclonal antibody inhibition of the natural anticoagulation called protein S, aiming to act as a bypassing agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our <FONT
STYLE="white-space:nowrap">Solution&#8212;HMB-002</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> as a subcutaneous
prophylactic treatment for Von Willebrand Disease. <FONT STYLE="white-space:nowrap">HMB-002,</FONT> a monovalent antibody, is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of VWF and
Factor VIII. Rather than bypassing the deficiency or providing exogenous replacement protein, <FONT STYLE="white-space:nowrap">HMB-002</FONT> aims to stabilize patients&#8217; own VWF, extend its circulating half-life, and thereby increase VWF and
Factor VIII levels over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We believe this approach offers several potential advantages: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Restoration of Hemostasis by Directly Addressing the Root Cause:</B> By increasing endogenous VWF and Factor VIII
levels, <FONT STYLE="white-space:nowrap">HMB-002</FONT> is designed to support restoration of hemostasis rather than creating an artificial rebalancing of the coagulation system. We believe this approach has the potential to carry lower thrombotic
risk than rebalancing agents that promote hemostasis by inhibiting natural anticoagulants. Preclinical studies in animal models of Von Willebrand Disease have demonstrated that an approximately <FONT STYLE="white-space:nowrap">1.5-fold</FONT>
increases in VWF and Factor VIII levels can meaningfully improve coagulation parameters and reduce bleeding. In addition, clinical observations in patients with Von Willebrand Disease demonstrate that even modest increases in VWF and Factor VIII
levels can meaningfully reduce bleeding symptoms. In our Phase 1 clinical study, <FONT STYLE="white-space:nowrap">HMB-002</FONT> achieved greater than <FONT STYLE="white-space:nowrap">1.5-fold</FONT> increases in both VWF and Factor VIII levels,
along with correction of laboratory coagulation measures, such as aPTT and thrombin generation, supporting continued clinical evaluation of this approach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Convenient Subcutaneous Administration:</B> We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> to be
administered subcutaneously, with potential dosing intervals ranging from weekly to monthly, reflecting both the extended half-life of VWF achieved through stabilization and the inherent pharmacokinetic properties of an antibody therapeutic. We
believe that this dosing profile could reduce the treatment burden associated with frequent intravenous infusions required for current prophylactic options. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Applicability Across Von Willebrand Disease Types:</B> Because <FONT STYLE="white-space:nowrap">HMB-002</FONT> acts by
reducing clearance of endogenous VWF, we believe it may potentially be applicable across multiple Von Willebrand Disease subtypes, including Type 1, Type 2, and potentially Type 3 disease in patients receiving baseline VWF replacement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Potential for Transformative Impact:</B> In other inherited bleeding disorders, such as hemophilia A, the introduction
of subcutaneously administered prophylactic therapies has been associated with reduced treatment burden and improved disease management. We are developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> with the goal of enabling a similar shift
toward preventive care in Von Willebrand Disease by facilitating more consistent bleeding control while minimizing disruption to daily life. If our ongoing and future clinical trials are successful, we believe
<FONT STYLE="white-space:nowrap">HMB-002</FONT> could represent an important subcutaneous prophylactic treatment option for patients with Von Willebrand Disease who require ongoing bleeding prevention. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">HMB-002</FONT> is a monovalent antibody that selectively binds the CK
domain of the coagulation protein VWF with high affinity, specifically targeting this domain in its inactive conformation. VWF is a large multimeric glycoprotein that serves two essential functions in hemostasis: mediating platelet adhesion to
damaged vessel walls and serving as the carrier protein for Factor VIII, protecting it from premature degradation and clearance. By selectively binding to the inactive CK domain, <FONT STYLE="white-space:nowrap">HMB-002</FONT> stabilizes VWF
structure and endows it with an extended half-life, thereby reducing its clearance rate. As a result, circulating levels of VWF increase. Because VWF functions as the carrier molecule for Factor VIII, increases in VWF levels lead to corresponding
increases in Factor VIII levels, as Factor VIII bound to VWF is protected from degradation. This dual effect on both VWF and Factor VIII levels is particularly important because Von Willebrand Disease is fundamentally characterized by low levels of
VWF, which in turn directly limits platelet adhesion and results in low levels of Factor VIII due to accelerated Factor VIII degradation in the absence of adequate VWF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As described above, DDAVP has been used for over 50 years as the standard of care to manage acute bleeding episodes and provide short-term hemostatic
prophylaxis in patients with Type 1 and Type 2 Von Willebrand Disease. DDAVP functions by stimulating the release of endogenous VWF stored in endothelial cells, resulting in greater than <FONT STYLE="white-space:nowrap">1.5-fold</FONT> increases in
both VWF and Factor VIII levels that persist for approximately four to six hours. The decades-long clinical experience with DDAVP demonstrates that acute elevation of VWF levels provides effective hemostatic control in Von Willebrand Disease
patients and serves as important clinical validation for the therapeutic mechanism of <FONT STYLE="white-space:nowrap">HMB-002.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The image
below depicts <FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of action. As illustrated, following subcutaneous administration, <FONT STYLE="white-space:nowrap">HMB-002</FONT> binds to circulating VWF, preventing clearance
via neonatal Fc receptor-mediated rescue from vascular endothelium, leading to increased circulating VWF available for platelet adhesion and Factor VIII carrier function at sites of vascular injury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Mechanism of Action of <FONT STYLE="white-space:nowrap">HMB-002</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g00a01.jpg" ALT="LOGO" STYLE="width:5.55667in;height:3.00667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are initially developing <FONT STYLE="white-space:nowrap">HMB-002</FONT> as a subcutaneous prophylactic treatment
for patients with Von Willebrand Disease. Beyond this initial indication, we believe <FONT STYLE="white-space:nowrap">HMB-002&#8217;s</FONT> intended mechanism of action &#8211; stabilizing and extending the half-life of endogenous VWF and Factor
VIII &#8211; has potential applicability across other bleeding conditions associated with low VWF levels. We believe this represents a significant opportunity for potential label expansion if <FONT STYLE="white-space:nowrap">HMB-002</FONT> receives
regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approval for Von Willebrand Disease. If approved, <FONT STYLE="white-space:nowrap">HMB-002</FONT> could represent an important subcutaneous prophylactic option for patients with significant
coagulation disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Clinical Development of <FONT STYLE="white-space:nowrap">HMB-002</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT> for Von Willebrand Disease, which we refer to
as Velora Pioneer. This trial is supported by a prospective identification and <FONT STYLE="white-space:nowrap">run-in</FONT> natural history study, which we refer to as Velora Discover, that has enrolled more than 80 patients as of December 31,
2025 and is generating prospectively collected data on bleeding and treatment patterns based on an electronic bleed diary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B></B><B><I>Phase 1/2 Clinical Trial of
<FONT STYLE="white-space:nowrap">HMB-002</FONT> for Von Willebrand Disease</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Study Design and Enrolled Patient Demographics</B>.
Velora Pioneer employs an adaptive dose-escalation design with two parts (Part A and Part B). The adaptive design allows real-time dose optimization based on emerging safety and efficacy data. Velora Discovery is a prospective natural history study
running in parallel with Velora Pioneer and enrolling Von Willebrand Disease patients to establish baseline disease characteristics, bleeding patterns, and quality of life measures. The purpose of Velora Discover is to provide contemporary control
data and contextualize treatment effects observed in the interventional components of the trial, and the majority of patients are expected to complete Velora Discovery before progressing to Part A of Velora Pioneer. In Part A of Velora Pioneer, we
are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of <FONT STYLE="white-space:nowrap">HMB-002.</FONT> In Part B, participants transition from Part A into multiple-dose cohorts, with the first
cohort in Part B (Cohort B1) receiving repeated dosing based on Part A data, with potential expansion for additional efficacy and safety assessment, and the second cohort in Part B (Cohort B2) receive a higher dose than the first Part B cohort with
its own expansion cohort to further characterize the therapeutic profile. In each case, the doses administered in Part B will be informed by the safety data from Part A. The image below depicts the design of our Phase 1/2 clinical trial of <FONT
STYLE="white-space:nowrap">HMB-002</FONT> for Von Willebrand Disease. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Phase 1/2 Clinical Trial of <FONT STYLE="white-space:nowrap">HMB-002</FONT>
&#8211; Trial Design </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g15m06.jpg" ALT="LOGO" STYLE="width:6.30667in;height:3.59in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of the data cutoff date of September 2, 2025, we have completed dosing of a total of six patients
in the 20 mg (Cohort A1) and 50 mg (Cohort A2) dose levels in Part A of the trial and are currently enrolling patients into a 150 mg dose cohort (Cohort A3). Demographic information and baseline characteristics of the patients from the first two
dose cohorts of Part A of the trial are included in the image below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Phase 1/2 Clinical Trial of
<FONT STYLE="white-space:nowrap">HMB-002&#8211;</FONT> Demographics and Baseline Characteristics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g16m01.jpg" ALT="LOGO" STYLE="width:4.51333in;height:2.30333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Initial Safety and Tolerability Data:</B>&nbsp;As of the data cutoff date,
<FONT STYLE="white-space:nowrap">HMB-002</FONT> has demonstrated a favorable safety and tolerability profile. None of the patients in the 20 mg cohort reported adverse events and only two Grade 1 adverse events that were deemed unrelated to
treatment were reported in the 50 mg cohort. In addition, no safety signals of concern have been observed, including no thrombotic events, thrombocytopenia, <FONT STYLE="white-space:nowrap">D-dimer</FONT> elevations, injection site reactions, or
hypersensitivity reactions. Additionally, interim immunogenicity assessments showed no ADA formation at any timepoint evaluated, and inflammatory markers (C3a and cytokines) remained unchanged, indicating no complement activation or inflammatory
response to the drug at the dose levels evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Pharmacokinetic Data</B>. Initial data from the first two cohorts in the Phase 1/2 clinical
trial suggest dose dependent plasma exposure of <FONT STYLE="white-space:nowrap">HMB-002</FONT> after subcutaneous administration, as depicted in the image below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Cohorts A1 and A2 &#8211; Pharmacokinetics </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g16m02.jpg" ALT="LOGO" STYLE="width:3in;height:2.49667in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Pharmacodynamic Data.</B>&nbsp;In the first two cohorts from Part A of the trial, following
administration with <FONT STYLE="white-space:nowrap">HMB-002,</FONT> we observed dose-dependent accumulation of plasma VWF antigen, as depicted in the image on the left below, VWF activity, as depicted in the image in the middle below, and Factor
VIII coagulant activity, as depicted in the image on the right below. Notably, VWF and Factor VIII&nbsp;levels increased over <FONT STYLE="white-space:nowrap">1.5-fold</FONT> from baseline in a dose-dependent manner, with sustained increases for at
least eight to ten days, commensurate with the pharmacokinetic data described above. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Cohorts A1 and A2 &#8211; Pharmacodynamics </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g17m01.jpg" ALT="LOGO" STYLE="width:6.32in;height:1.84667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Data from Cohort A1 demonstrated that <FONT STYLE="white-space:nowrap">HMB-002</FONT> corrected aPTT and improved
thrombin generation assays, resulting in enhanced overall coagulation activity. Furthermore, a sustained VWF multimer distribution was observed, suggesting that <FONT STYLE="white-space:nowrap">HMB-002</FONT> did not impact the protein structure of
VWF. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Cohorts A1 and A2 &#8211; Coagulation Parameters and Multimer Distribution </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g17m02.jpg" ALT="LOGO" STYLE="width:6.30667in;height:2.31in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Status and Next Steps </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate reporting initial data from Part B of the trial in &#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical and Discovery Stage Assets for Additional Coagulation Disorders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to sutacimig and <FONT STYLE="white-space:nowrap">HMB-002,</FONT> we are advancing multiple preclinical and discovery-stage assets. The first
of our preclinical assets, which is expected to enter clinical development in &#8195;&#8195;&#8195;&#8195;, subject to regulatory submission and clearance. We plan to report initial clinical data for this asset in &#8195;&#8195;&#8195;&#8195;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our
business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platforms and <FONT
STYLE="white-space:nowrap">on&nbsp;know-how,&nbsp;continuing</FONT> technological innovation <FONT STYLE="white-space:nowrap">and&nbsp;in-licensing&nbsp;opportunities</FONT> to develop, strengthen and maintain our proprietary and intellectual
property position. We additionally may rely on regulatory and other protections afforded through data exclusivity, market exclusivity and patent term extensions, where available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success may depend in part on our ability to: obtain, maintain, enforce and protect our intellectual property and other proprietary
rights for commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business; defend and enforce any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future;
prevent others from infringing any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and
proprietary rights of third parties. Our ability to limit third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade
secrets that cover these activities. In some cases, enforcement of these rights may depend on third party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect
to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in
protecting our commercial products and methods of manufacturing the same. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sutacimig </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our intellectual property portfolio for sutacimig includes a foundational composition of matter patent application filed in April 2020 (and claims
priority to April 2019) covering the bispecific antibody composition, with an expected expiration in April 2040. With patent term extension, or supplementary protection certificate, or SPC, eligibility, this patent could potentially extend to 2045.
This application family has granted patents in the United States, Bahrain, Russia, China, Malaysia, South Africa, Saudi&nbsp;Arabia, South Korea, and Japan; and also has currently pending applications in the United States, Europe, Australia, Brazil,
Israel, India, Kuwait, Mexico, Peru, Qatar, Thailand, United Arab Emirates, Canada, Chile, Algeria, Egypt, Morocco, Oman, Russia and Japan. We filed an additional patent application in February 2025 (which claims priority to February 2024) covering
dosing regimens for sutacimig, with an expected expiration in February 2045 and national phase entry due in August 2026. Based on anticipated approval timelines, if sutacimig receives regulatory approval in 2030, we expect regulatory exclusivity to
extend through 2042, while approval in 2034 would provide regulatory exclusivity through 2046. We are actively pursuing additional patent filings covering formulation improvements, biomarkers for patient selection, manufacturing processes, and
routes of administration to further strengthen and extend our intellectual property protection for sutacimig. These additional filings are designed to create multiple layers of patent protection extending the commercial exclusivity period beyond the
expiration of our composition of matter patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">HMB-002</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our patent portfolio for <FONT STYLE="white-space:nowrap">HMB-002</FONT> includes multiple patent families providing layered protection. Our initial
composition of matter patent application for the <FONT STYLE="white-space:nowrap">VWF-targeting</FONT> antibody was filed in February 2023 (and claims priority to February 2022) with an expected expiration in February 2043. This application family
is currently pending in the United States, Europe, Saudi Arabia, Brazil, Japan, South Korea, Russia, Canada, Australia, China, India, and Hong Kong. We filed a subsequent composition of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
matter patent application in August 2024 (which claims priority to August 2023) as an international Patent Cooperation Treaty (PCT) application as well as direct filings in Argentina and Taiwan.
This application family has an expected expiration in August 2044 and potential patent term extension or supplementary protection certificate extending protection to 2049. We filed an additional patent application covering combination therapy of <FONT
STYLE="white-space:nowrap">HMB-002</FONT> with VWF replacement products and dosing regimens in February 2026 (which claims priority to February&nbsp;2025), with expected expiration in February&nbsp;2046. This application is not yet published. Based
on anticipated regulatory timelines, if <FONT STYLE="white-space:nowrap">HMB-002</FONT> receives approval in 2030, regulatory exclusivity would extend through 2042, while approval in 2034 would provide regulatory exclusivity through 2046. Similar to
sutacimig, we are pursuing additional patent filings covering formulation, biomarkers, manufacturing processes, and routes of administration to maximize the duration of intellectual property protection for
<FONT STYLE="white-space:nowrap">HMB-002.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a party to license agreements under which we license patents, patent applications, and other intellectual property from third parties. The
licensed intellectual property covers, in part, our lead product candidate, sutacimig. These licenses impose various diligence and financial payment obligations on us. We consider the following license agreements to be material to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement with Novo Nordisk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2019, we
entered into a license agreement with Novo Nordisk A/S, or Novo Nordisk, pursuant to which Novo Nordisk granted us an exclusive (even as to Novo Nordisk), worldwide and sublicensable license under specified patent rights, and a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified <FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise
exploit, or transfer possession of or title in, products, or Novo Licensed Products, containing bispecific IgG antibodies targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding
conditions, including hemophilia. We refer to this agreement as the Novo Nordisk Agreement. Under the terms of the Novo Nordisk Agreement, we have agreed to use commercially reasonable efforts to develop and commercialize a Novo Licensed Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are obligated to pay to Novo Nordisk a <FONT STYLE="white-space:nowrap">one-time</FONT> DKK 40&nbsp;million milestone payment upon achievement
by a Novo Licensed Product of a specified regulatory milestone event, and we are also obligated to pay Novo Nordisk tiered royalties, in the low single-digit percentages, on aggregate annual net sales of all Novo Licensed Products, on a Novo
Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Novo</FONT></FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the later
of the expiration of the last valid claim in the licensed patents under the Novo Nordisk Agreement covering such Novo Licensed Product in such country and ten years following the first commercial sale of such Novo Licensed Product in such country.
Under the Novo Nordisk Agreement, we initially granted to Novo Nordisk a right of first negotiation, following a specified clinical event and during a specified period of time, to obtain a license back from us to exploit Novo Licensed Products if we
determined to engage with a third party with respect to a license of any Novo Licensed Products. However, Novo Nordisk&#8217;s right of first negotiation under the Novo Nordisk Agreement has expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Novo Nordisk Agreement will continue in force until it is terminated. On expiration of each royalty term, our license becomes royalty-free,
perpetual, and irrevocable with respect to the applicable Novo Licensed Product in the applicable country. Either party may terminate the Novo Nordisk Agreement for the other party&#8217;s uncured material breach or insolvency. We may terminate the
Novo Nordisk Agreement for any reason upon 90 days&#8217; written notice to Novo Nordisk. In the event that Novo Nordisk regains control of the exclusive right to exploit the Novo Licensed Product, the Novo Nordisk Agreement will automatically
terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement with Genmab </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, we entered into a license agreement with Genmab A/S, or Genmab, pursuant to which Genmab granted us an exclusive (even as to Genmab and
its affiliates), worldwide and sublicensable license under platform technology patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary
DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform to research, develop, make, have made, use, manufacture, import, export and commercialize products comprising bispecific IgG antibodies targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and Factor&nbsp;VII, or <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including sutacimig, for the treatment of bleeding conditions, including hemophilia. We refer to this
agreement as the Genmab Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the Genmab Agreement, we have agreed to use commercially reasonable efforts to develop,
manufacture, obtain regulatory approval for and commercialize TLT-1/Factor VII Antibody Products worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Genmab Agreement, we are
obligated to pay Genmab a percentage of all net profit (i.e., revenue and other proceeds less specified direct costs we incur to conduct research, development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT>
VII Antibody Products) we or our affiliates receive with respect to any <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including (1)&nbsp;net profit from commercial sales of
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products and any revenue from third parties, other than Novo Nordisk, in respect of a sublicense or assignment with respect to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII
Antibody Products, including assignment fees, sublicensing fees, upfront and milestone fees, royalties and other consideration, whether in kind or cash, and (2)&nbsp;the net profit allocated to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT>
VII Antibody Products that we or our affiliates receive if we undergo a change of control (other than an acquisition by Novo Nordisk). The percentage of net profit we owe with respect to each TLT-1/Factor VII Antibody Product is in the low teens
from the effective date of the Genmab Agreement until the first commercial sale of such TLT-1/Factor VII Antibody Product. From and after the first commercial sale of a <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product, the
percentage of net profit we owe with respect to such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product is in the high single digits in all territories in which we commercialize such TLT-1/Factor VII Antibody Product and in
the mid-teens in all territories in which a third party, other than Novo Nordisk, commercializes such TLT-1/Factor VII Antibody Product. We are obligated to pay such percentage of net profit on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-TLT-1/Factor</FONT></FONT></FONT> VII Antibody Product basis until the later of the expiration of the last-to-expire of the platform
technology patent rights licensed under the Genmab Agreement covering such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country and twelve years following the first commercial sale of such <FONT
STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country, which we refer to as the net profit share term. Following the expiration of the last-to-expire of the platform technology patent rights licensed under the Genmab
Agreement covering a given TLT-1/Factor VII Antibody Product in a given country, the percentage of net profit that we are obligated to pay with respect to sales of such TLT-1/Factor VII Antibody Product in such country will be reduced by a specified
percentage for the remainder of the net profit share term for such TLT-1/Factor VII Antibody Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event we seek to sell,
license or otherwise dispose of our rights to TLT-1/Factor VII Antibody Products, including through a change of control to any third party other than Novo Nordisk, we are obligated to provide Genmab the right to participate in any bidding process as
a <I>bona fide</I> potential acquirer of such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless earlier terminated, the Genmab Agreement will expire, on a TLT-1/Factor VII Antibody
Product-by-TLT-1/Factor VII Antibody Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon the expiration of the last net profit share term for such TLT-1/Factor VII Antibody
Product in such country. On expiration of each net profit share term, our license becomes perpetual, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to the applicable
TLT-1/Factor VII Antibody Product in the applicable country. Either party may terminate the Genmab Agreement for the other party&#8217;s uncured material breach or insolvency or in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
certain events of force majeure. Genmab may terminate the Genmab Agreement if we or our affiliates or sublicensees challenge any of the platform technology patent rights licensed under the Genmab
Agreement. We may terminate the Genmab Agreement for any reason upon 120 days written notice to Genmab. If Novo Nordisk obtains from us the exclusive right to exploit TLT-1/Factor VII Antibody Products, including upon termination of the Novo Nordisk
Agreement, then the Genmab Agreement will terminate in all territories in which Novo Nordisk obtains such exclusive rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Manufacturing and Supply Chain
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have leveraged multiple third-party manufacturers to support the manufacturing of our assets for clinical trials and, if we receive
regulatory approval, we intend to rely on third parties for commercial manufacture. We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We expect this strategy will enable us to maintain a more efficient
infrastructure, outsourcing instead of building manufacturing and supply chain capabilities, while simultaneously enabling us to focus our expertise on the clinical development of our assets. We expect to enter into commercial supply agreements with
such manufacturers prior to any potential approval of our assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are characterized by rapidly advancing innovative technologies under intense competition with an emphasis
on proprietary products or product candidates. While we believe we have competitive advantages, we face substantial competition from many different sources, including from major pharmaceutical companies, specialty pharmaceutical companies and
biotechnology companies worldwide. Any product candidates that we successfully develop and commercialize will compete with existing products and new products that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face potential competition from many different sources, including larger and better-funded pharmaceutical and biotechnology companies. Moreover, we
may also compete with academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and
commercialization. Many of our potential competitors, either alone or through strategic partnerships, have significantly greater access to financial, technical, manufacturing, marketing, sales and supply resources. These entities may also compete
with us in hiring and retaining scientific and management personnel, establishing clinical trial sites, enrolling patients in clinical trials and pursuing strategic collaborations. As a result, our competitors may discover, develop or commercialize
products before or more successfully than we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are currently no subcutaneous, prophylactic therapies for Glanzmann thrombasthenia or Factor
VII deficiency that are in development or approved. Patients with these disorders mainly receive reactive treatment in response to bleeding events without the ability to prevent them. However, companies could develop new therapies or repurpose
existing therapies for Glanzmann thrombasthenia or Factor VII deficiency, such as emicizumab (Hemlibra), which was developed for hemophilia A, but could potentially be studied in other bleeding disorders, potentially including our target
indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For Von Willebrand Disease, the competitive landscape includes currently available therapies and products in development. The current
standard of care includes DDAVP and VWF replacement products, including both plasma-derived products <FONT STYLE="white-space:nowrap">(Humate-P,</FONT> Wilate, Alphanate) and recombinant Won Willebrand Factor (Vonvendi). These products have
established positions in the market and physician familiarity. In addition, Star Therapeutics Inc. is currently developing <FONT STYLE="white-space:nowrap">VGA-039,</FONT> an investigational monoclonal antibody that inhibits protein S, which is
currently in Phase 3 clinical development for Von Willebrand Disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we obtain marketing approval for any of our product candidates, there will be several factors that
will be important to the commercial success of such products. These factors include efficacy, safety, tolerability, convenience, price and the availability of reimbursement. Inability to be competitive in any of these categories could potentially
reduce the commercial opportunity of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In light of our stage of development, we have not yet established a commercial organization or distribution capabilities. We maintain all global economic
development and commercialization rights to the assets in our franchise. If our product candidates receive marketing approval, we may choose to commercialize them with our own sales force and will also consider commercial partnerships to maximize
the worldwide opportunity for and value of our product candidates and programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, particularly with respect to sutacimig for the
treatment of Glanzmann thrombasthenia and Factor VII deficiency, if approved, we intend to build a focused, commercial organization targeting the specialized bleeding disorders care network. In the United States, approximately 140 federally-funded
Hemophilia Treatment Centers and comprehensive bleeding disorder centers manage many patients with inherited bleeding disorders across our target indications. We expect that this concentrated care model will enable us to efficiently commercialize
sutacimig with relatively small field teams. In addition to the United States, we intend to commercialize our product candidates in the European Union, Japan, the GCC countries and other select regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Government authorities in the United
States, at the federal, state and local level, and in other countries and jurisdictions, such as the European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacture, pricing, quality control,
approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sales, reimbursement, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining
marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial
resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Approval and Regulation of Biologics in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, our product candidates are regulated and licensed as biological products, or biologics, under the Public Health Service Act, or the
PHSA, and the Food, Drug, and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for
investigational products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable regulatory requirements at any time during the product development process, including
nonclinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval and/or administrative or judicial sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A sponsor seeking approval to market and distribute a new biologic product in the United States generally must satisfactorily complete each of the
following steps before the product candidate will be approved by the FDA: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical testing including laboratory tests, animal studies and formulation studies, which must be performed in
accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">completion of the manufacture, under current good manufacturing practices, or cGMP, conditions, of the drug substance and
product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">design of a clinical protocol and submission to the FDA of an investigational new drug application, or IND, for human
clinical testing, which must become effective before human clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial
may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the
product candidate for each proposed indication, in accordance with good clinical practices, or GCP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparation and submission to the FDA of a biologic license application, or BLA, for a biologic product, which includes not
only the results of the clinical trials, but also, detailed information on the chemistry, manufacture controls, or CMC, for the product candidate and proposed labeling for one or more proposed indication(s); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties,
at which the product candidate or components thereof are manufactured to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and
purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCP and the integrity of
clinical data in support of the BLA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">payment of user fees pursuant to the Prescription Drug User Fee Act, or PDUFA, and securing FDA approval of the BLA to
allow marketing of the new product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and
Mitigation Strategies, or REMS, and the potential requirement to conduct any post-approval studies or other post-marketing commitments required by the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before a sponsor begins testing a
product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to
evaluate, among other things, the toxicity of the product candidate. These studies are generally referred to as <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. The conduct of the preclinical tests and formulation of the compounds for
testing must comply with federal regulations and requirements, including GLP regulations and standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With passage of the FDA&#8217;s
Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and the PHSA that required animal testing in support of a BLA. While animal testing may still be conducted, the FDA was authorized to rely on alternative <FONT
STYLE="white-space:nowrap">non-clinical</FONT> tests, including cell-based assays, microphysiological systems, or bioprinted or computer models. The results of the preclinical tests, together with manufacturing information and analytical data, are
submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The IND and IRB Processes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational
clinical trial and a request for FDA authorization to administer such investigational product to humans. An IND must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved BLA. In
support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must also be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the
FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials or studies and places the trial on a clinical hold. The FDA may also place a hold or partial hold on a clinical trial based on
chemistry, manufacturing, and controls issues involving the investigational product. In either case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial may proceed. As a result, submission of an IND may not
result in the FDA allowing clinical trials to commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following commencement of a clinical trial under an IND, the FDA may also place a clinical
hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only
part of the clinical work requested under the IND. For example, a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts of a protocol or other protocols may do so. No more than 30 days
after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only
resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the
investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An IRB representing each institution participating in the clinical trial must also review and approve the plan for any clinical trial before it
commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB, which must operate in compliance with Health and Human Services, or HHS, and FDA regulations, must review and approve,
among other things, the study protocol and informed consent information to be provided to study subjects before the study can commence at the institution and must monitor the trial until it is completed. An IRB can suspend or terminate approval of a
clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data
monitoring committee, or DMC. This group provides an independent recommendation as to whether or not a trial may move forward at designated checkpoints based on review of available data from the study, to which only the DMC has access. Suspension or
termination of development during any phase of a clinical trial can occur if the DMC recommends stopping a trial due to safety, potency, purity or other issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expanded Access to an Investigational Product </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients
with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational
products for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis for: individual patients (single-patient IND applications for treatment in emergency settings and
<FONT STYLE="white-space:nowrap">non-emergency</FONT> settings); <FONT STYLE="white-space:nowrap">intermediate-size</FONT> patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND
application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a
group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable
or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be
treated; and the expanded use of the investigational product for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise
compromise the potential development of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is no obligation for a sponsor to make its investigational products available for
expanded access. However, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Specifically, sponsors are required to make such policies publicly available upon the earlier of
initiation of a Phase 2 or Phase 3 clinical trial, or 15 days after the investigational product receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. In October 2025, the FDA issued final
guidance further clarifying the statutory and regulatory requirements governing expanded access. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to and separate from expanded access,
the Right to Try Act, which was enacted in 2018, provides a federal framework for certain patients to access certain investigational new products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval.
Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without needing FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its
investigational products available to eligible patients under the Right to Try Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Human Clinical Trials in Support of a BLA </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator
in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before they participate in any clinical trial. Clinical trials are conducted under written
clinical trial protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol, and any subsequent
material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be
required after approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 1 clinical trials are initially conducted in a limited population, which may be healthy volunteers or patients with
the target disease, to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics. During Phase 1 clinical trials, information about the product
candidate&#8217;s pharmacokinetics and pharmacological effects may be obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 2 clinical trials are generally conducted in a patient population to identify possible adverse
effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior
to beginning larger and more costly Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 3 clinical trials proceed if the prior clinical trials demonstrate that the
product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken in the proposed patient population to provide evidence of clinical safety, potency and purity. A well-controlled, statistically
robust Phase 3 clinical trial is designed to deliver the data that regulatory authorities will use to decide whether or not to approve the product candidate, and, if approved, how to appropriately label a new biologic product. Such Phase 3 clinical
trials are referred to as &#8220;pivotal&#8221; trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A clinical trial may combine the elements of more than one phase. The FDA has often
required more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy
the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA
requirements for the evaluation of a product candidate&#8217;s safety, potency and purity such that it can be used, alone or with other pivotal or <FONT STYLE="white-space:nowrap">non-pivotal</FONT> trials, to support regulatory approval. Generally,
pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need or rare patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the
product candidate&#8217;s safety, potency and purity after approval. Such post-approval trials, typically referred to as post-marketing studies or clinical trials, may be conducted after initial marketing approval. These trials are used to either
gain additional experience from the treatment of a larger number of patients in the intended treatment group or to evaluate a specific outcome of interest (safety or efficacy). In certain instances, the FDA may mandate the performance of
post-marketing studies or clinical trials, such as to verify clinical benefit in the case of products approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting mandatory post-marketing studies or
clinical trials could result in withdrawal of FDA approval for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sponsors of clinical trials are required to register and disclose certain
clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health. In particular, information related to the product candidate, patient population, phase of investigation, study sites and
investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The failure of a sponsor to submit clinical trial information to clinicaltrials.gov is a prohibited act under the FDCA, with
violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Violations may also result in injunctions and/or criminal prosecution or disqualification from federal grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Clinical Studies Outside of the United States </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted
under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for a BLA. Specifically, the studies must be conducted in accordance with GCPs, including undergoing
review and receiving approval by an independent ethics committee and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are
intended to help ensure the protection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that <FONT
STYLE="white-space:nowrap">non-IND</FONT> foreign studies are conducted in a manner comparable to that required for IND studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The acceptance by
the FDA of study data from clinical trials conducted outside the United States in support of United States approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to
serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are applicable to the U.S. population and U.S. medical practice;
(ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&nbsp;the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT>
inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for
an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign
regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Interactions with the FDA During the Clinical Development Program </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the clearance of an IND and the commencement of clinical trials, a sponsor is given the opportunity to meet with the FDA at certain points in
the clinical development program. There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important
safety issue. Type B meetings include <FONT STYLE="white-space:nowrap">pre-IND</FONT> and <FONT STYLE="white-space:nowrap">pre-BLA</FONT> meetings as well as end of phase meetings, such as end of Phase 2, or EOP2, meetings. A Type C meeting is any
meeting other than a Type A or Type B meeting regarding the development and review of a product candidate. A Type D meeting is focused on a narrow set of issues and should not require input from more than three disciplines or divisions. Finally,
INTERACT meetings are intended for novel products and development programs that present unique challenges early in the development of an investigational product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the conclusion of these meetings, the FDA will typically provide its responses to questions posed by the sponsor regarding the clinical development
program. The FDA will not indicate whether a BLA will be approved, but it will provide guidance to the sponsor on various questions, including whether an application should be submitted in the first place on the basis of the studies and data
proposed by the sponsor. The FDA may also generally express support for the sponsor&#8217;s approach in the clinical development program but indicate that questions concerning whether the data support approval will be subject to review by the FDA
following its acceptance for filing of the BLA. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by
such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Manufacturing Requirements </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Concurrently
with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently
producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be selected and
tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with
cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls,
holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their
establishments with the FDA and some state agencies and are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign manufacturing establishments are subject to registration and
listing requirements even if a biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside of the United States prior to being imported or offered for import into the United
States. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their
establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are
strictly regulated and often require prior FDA approval before being implemented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety, potency
and purity of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless granted a deferral or
waiver. The sponsor must submit an initial pediatric study plan within 60 days of an EOP2 meeting or as may be agreed between the sponsor and the FDA. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must
contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the
FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults
before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. A waiver may be granted when the disease or condition does not occur in pediatrics. Unless otherwise
required by regulation, the pediatric data requirements generally do not apply to products with orphan designation, although FDA has taken steps to limit what it considers abuse of this statutory exemption in the PREA by announcing that it does not
intend to grant any additional orphan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA maintains a list of diseases that are exempt from PREA requirements due to low prevalence of
disease in the pediatric population. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Expedited Review Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA is authorized to expedite the review of applications in several ways. None of these expedited programs, however, changes the standards for
approval but each may help expedite the development or approval process governing product candidates. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Fast Track Designation</U>. Product candidates are eligible for Fast Track designation if they are intended to treat a
serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being
studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, this designation enables a company to petition the FDA to initiate review of sections of a BLA before the application is complete, a process known
as rolling review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Breakthrough therapy designation</U>. To qualify for the breakthrough therapy program, a product candidate must be
intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence must indicate that such product candidate may demonstrate substantial improvement on one or more clinically significant endpoints over existing
therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, involvement of senior managers and experienced staff on a proactive, collaborative and
cross-disciplinary review and rolling review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Priority review</U>. A product candidate is eligible for priority review if it treats a serious condition and, if
approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. Significant improvement may be illustrated by evidence of increased effectiveness in the
treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new
subpopulation. The FDA aims to complete its review of priority review applications within six months as opposed to ten months for standard review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Regenerative Medicine Advanced Therapy designation</U>. With the passage of the 21st Century Cures Act in December 2016,
Congress authorized the FDA to accelerate review and approval of product candidates designated as regenerative advanced therapies. A product candidate is eligible for this designation if it is a regenerative medicine therapy that is intended to
treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of
a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on
surrogate or intermediate endpoints. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Commissioner&#8217;s National Priority Voucher Program</U>. On June&nbsp;17, 2025, the FDA announced the creation of the
&#8220;Commissioner&#8217;s National Priority Voucher, or CNPV, Program. Vouchers issued under this program can be redeemed by sponsors to shorten the review time of a BLA from approximately ten to twelve months to one to two months. The CNPV
Program convenes experts from the FDA&#8217;s offices for a team-based review rather than using the standard review system. Clinical data will be reviewed by a multidisciplinary team of physicians and scientists who will <FONT
STYLE="white-space:nowrap">pre-review</FONT> the submitted information and convene for a <FONT STYLE="white-space:nowrap">one-day</FONT> meeting. Vouchers under the CNPV Program will be given to companies aligned with U.S. national priorities.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Rare Disease Evidence Principles</U>. In September 2025, the FDA introduced a framework intended to streamline the
approval of new therapies for ultrarare diseases. The Rare Disease Evidence Principles framework is intended to allow sponsors to rely on a <FONT STYLE="white-space:nowrap">single-arm</FONT> trial in support of approval of biologics that treat rare
diseases with very small patient populations and where the disease is linked to a known genetic defect and characterized by progressive functional deterioration leading to disability or death in a short period of time. The targeted diseases should
also lack adequate alternative therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Accelerated Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to programs that allow for expedited review of BLAs, the FDA is authorized to approve new products through an accelerated approval pathway.
Under this pathway, a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack
of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing studies or clinical trials. In addition, the
FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of all promotional materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2022, Congress directed the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and to
submit progress reports on its post-approval studies to the FDA every six months until the trial is completed. Moreover, the FDA was authorized to withdraw an accelerated approval if certain conditions are met, including where a required
confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product candidate is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an
accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The procedures include the provision of due notice,
an explanation for a proposed withdrawal, opportunities to meet with the FDA Commissioner or the FDA Commissioner&#8217;s designee and a written appeal, among other things. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Submission of a BLA to the FDA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA&#8217;s approval is
required before any new biologic product can be marketed in the United States. Assuming successful completion of all required preclinical and human testing in accordance with all applicable regulatory requirements, detailed product information is
submitted to the FDA in the form of a BLA. Under the Prescription Drug User Fee Act, or PDUFA, each BLA must be accompanied by a significant user fee, unless an exception or waiver applies, such as the first application filed by a small business or
BLAs for product candidates designated as orphan drugs for indications that are rare diseases or conditions. For federal fiscal year 2026, the application user fee is $4,682,003 for an application requiring clinical data, and the sponsor of a
licensed BLA is subject to an annual program fee, which for fiscal year 2026 is $442,213. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA conducts a preliminary review of all applications
within 60 days of receipt and must inform the sponsor during that period whether an application is sufficiently complete to permit substantive review. The FDA&#8217;s regulations state that an application &#8220;shall not be considered as filed
until all pertinent information and data have been received&#8221; by the FDA. In the event the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. In this event,
the BLA must be resubmitted. In October 2025, the FDA issued internal guidance clarifying that &#8220;materially incomplete or inadequately organized&#8221; applications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that would not permit timely, efficient and complete review will be the subject of an RTF. The internal guidance also provides that the FDA will issue an RTF for an application that relies on a
single, adequate and well-controlled investigation to support approval if prior communications with the FDA determined the need for more than one clinical trial and any justification for a single investigation is inadequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the BLA submission is accepted for filing, the FDA&#8217;s goal is to review the BLA, within ten months for a standard review, or, if the BLA relates
to an unmet medical need in the treatment of a serious or life-threatening condition, perform a priority review, within six months. The review process may be extended by the FDA for three additional months to consider new information or after a
clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an application to extend beyond the PDUFA target
action date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA seeks to meet these timelines for review of a BLA but its ability to do so may be affected by a variety of factors, including
government budget and funding levels, the ability to hire and retain key personnel and statutory, regulatory and policy changes. Average review times at the FDA have fluctuated in recent years as a result. For example, the U.S. government has shut
down several times during the past decade and certain regulatory agencies, including the FDA, have had to furlough critical employees and stop critical activities, including the review of BLAs, when funding from PDUFA fee payments was exhausted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an
advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the BLA should be approved and under what conditions. The FDA is not bound by the recommendations of an
advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a REMS is necessary to assure the safe use of the biological product. If
the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS, and the FDA will not approve the BLA without a REMS, if required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of
the BLA. Depending on the level of compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial
relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the clinical trial, or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may
exclude data from the clinical trial site in connection with its determination of the approvability of the application for the investigational product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with its review of a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product
candidate unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, the FDA will typically
inspect one or more clinical trial sites to assure that the clinical trials were conducted in compliance with IND requirements and GCP requirements. With passage of FDORA, Congress expressly permitted inspection by the FDA of facilities involved in
the preparation, conduct, or analysis of clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies submitted to the FDA as well as other persons holding clinical trial records or involved in the clinical trial process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The FDA&#8217;s Decision on a BLA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA reviews a BLA to determine, among other things, whether the product is safe, pure, and potent. To reach this determination, the FDA must
determine that the investigational product is effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product
candidate&#8217;s safety, purity and potency in the BLA. This assessment is also informed by other factors, including the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies,
uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product candidate in the post-market setting, and whether risk management tools are necessary to manage specific risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2026, the Commissioner of the FDA and the Director of Center for Biologics Evaluation and Research published an editorial in the New England
Journal of Medicine in which they declared that, in most cases, the new default requirement for FDA approval of a new product will be one adequate and well-controlled pivotal clinical trial plus confirmatory evidence, rather than two pivotal
clinical trials. In determining whether to rely on one trial, the FDA will focus on the single trial&#8217;s quality, including magnitude of effect, appropriateness of control arms, endpoint selection, statistical power, blinding, handling of
missing data, biological plausibility and alignment with intermediate biomarkers. The FDA has long had authority to approve new products on the basis of one trial plus confirmatory evidence and, in recent years, the FDA has exercised that authority
with respect to certain types of products. The FDA now takes the position that this will be the new official default standard for most new products. At this point, it is unclear how this new policy will be implemented by the FDA and how, if at all,
it will affect our clinical development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After evaluating the BLA and all related information, including the advisory committee
recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter. A CRL indicates that the review cycle of the application is
complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the BLA submission and may require substantial additional testing or information in order for the FDA to reconsider the application.
If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional
<FONT STYLE="white-space:nowrap">six-month</FONT> extension to respond. While CRLs were previously treated by the FDA as confidential and were only disclosed in action packages for approved products, the FDA announced in September 2025 that it will
now release CRLs promptly after they are issued to sponsors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An approval letter, on the other hand, authorizes commercial marketing of the product
with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described in the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling.
Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including post-marketing studies or clinical
trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other
risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies, clinical trials,
or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Post-Approval Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Biologic products manufactured or distributed pursuant to regulatory approvals are subject to pervasive and continuing regulation by the regulatory
authorities, including, among other things, requirements relating to formal commitments for post approval clinical trials and studies, manufacturing, recordkeeping, periodic reporting, product sampling and distribution, marketing, labeling,
advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Manufacturers are subject to periodic unannounced inspections by regulatory authorities and country or state agencies for compliance with cGMP and other
requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval. The FDA&#8217;s regulations also require investigation and correction of any deviations from
cGMP and impose reporting and documentation requirements upon a company and any third-party manufacturers that it may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality
control to maintain compliance with cGMP and other aspects of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, although physicians may prescribe legally available
products for unapproved uses or patient populations, which are commonly referred to as <FONT STYLE="white-space:nowrap">&#8220;off-label</FONT> uses,&#8221; manufacturers may not market or promote such uses. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to
significant liability. In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a biologic. If a company is found to have promoted <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, it may become subject to administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS, as well as state authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It may be permissible under very specific and narrow conditions for a manufacturer to engage in nonpromotional,
<FONT STYLE="white-space:nowrap">non-misleading</FONT> communication regarding <FONT STYLE="white-space:nowrap">off-label</FONT> information, such as distributing scientific or medical journal information. Moreover, with passage of the <FONT
STYLE="white-space:nowrap">Pre-Approval</FONT> Information Exchange Act in December 2022, sponsors of product candidates that have not been approved may proactively communicate to payors certain information about product candidates in development to
help expedite patient access upon approval. Previously, such communications were permitted under FDA guidance, but this legislation explicitly provides protection to sponsors who convey certain information about product candidates in development to
payors, including unapproved uses of approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in January 2025, the FDA published final guidance outlining its policies
governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, <FONT STYLE="white-space:nowrap">non-misleading</FONT> and
scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in
such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, the distribution of prescription pharmaceutical products is subject to a variety of federal and state laws. The Prescription Drug Marketing
Act, or PDMA, was the first federal law to set minimum standards for the registration and regulation of distributors by the states and to regulate the distribution of samples. Both the PDMA and state laws limit the distribution of prescription
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
pharmaceutical product samples and impose requirements to ensure accountability in distribution. In November 2013, the federal Drug Supply Chain Security Act became effective in the United
States, mandating an industry-wide, electronic, interoperable system to trace prescription products through the pharmaceutical distribution supply chain with a <FONT STYLE="white-space:nowrap">ten-year</FONT>
<FONT STYLE="white-space:nowrap">phase-in</FONT> process. Manufacturers were required by November 2023 to have such systems and processes in place. So as not to disrupt supply chains, the FDA granted certain exemptions from enhanced distribution
security requirements for eligible trading partners for particular periods of time. The exemptions for manufacturers have expired, and entities that are unable to meet the enhanced drug distribution security requirements must now request a waiver,
exception, or exemption from the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Reference Product Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When a biological product is licensed for marketing by the FDA with approval of a BLA, the product may be entitled to certain types of market and data
exclusivity barring the FDA from approving competing products for certain periods of time. In March 2010, the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, was enacted into law. The BPCIA amended the PHSA to create an
abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. To date, the FDA has approved both biosimilar products and
interchangeable biosimilar products. In December 2022, Congress clarified through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a
product is approved as interchangeable with the reference product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the BPCIA, the approval of a BLA for a biosimilar product may not be made
effective until twelve years after the date of first licensure of the reference product, which under the statute excludes the date of licensure of supplements and certain other applications. Additionally, an application for a biosimilar or
interchangeable biosimilar product cannot be submitted for review until four years after the date on which the reference product was first licensed under the PHSA. Even if a product is considered to be a reference product eligible for exclusivity,
however, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well controlled clinical trials to demonstrate
the safety, purity, and potency of their product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The BPCIA also includes provisions to protect reference products that have patent protection. The
biosimilar product sponsor and reference product sponsor may exchange certain patent and product information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome of negotiations surrounding the
exchanged information, the reference product sponsor may bring a patent infringement suit and injunction proceedings against the biosimilar product sponsor. The biosimilar applicant may also be able to bring an action for declaratory judgment
concerning the patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA maintains a publicly-available online database of licensed biological products, which is commonly referred to as the
&#8220;Purple Book.&#8221; The Purple Book lists product names, dates of licensure, and applicable periods of exclusivity. Further, the reference product sponsor must provide patent information and patent expiry dates to FDA following the exchange
of patent information between biosimilar and reference product sponsors. This information is then published in the Purple Book. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and
Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A biologic product may qualify for orphan drug designation under the Orphan Drug Act, if it is intended to treat a rare disease or
condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
United&nbsp;States and for which there is no reasonable expectation that the cost of developing and making a biological product available in the United States for this type of disease or
condition will be recovered from sales of the product as stipulated in the Orphan Drug Act. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and
its potential orphan use are disclosed publicly by the FDA. Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages and
<FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product that has orphan drug designation receives the first FDA approval for the disease or condition for which it has such designation, the
product is entitled to orphan product exclusivity. That exclusivity bars the FDA from approving any other applications to market the same product for the same indication for seven years, except in limited circumstances, such as not being able to
supply the product for patients or showing clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of a different therapy for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and Congress may further
reevaluate and revise the Orphan Drug Act and its regulations and policies. For example, in September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of orphan drug exclusivity, the term
&#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and not the &#8220;indication or use&#8221; for which the product is approved. Subsequently, in another case, a federal district court in
Washington, D.C. followed the reasoning of the 11th Circuit decision and that decision was appealed to the U.S. Court of Appeals for the D.C. Circuit. On February&nbsp;3, 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It
overruled these court decisions and codified the FDA&#8217;s longstanding interpretation of the scope of orphan drug exclusivity to apply to &#8220;the same drug for the same approved use or indication within such [designated] rare disease or
condition.&#8221; This change, which applies retroactively, expressly authorizes the FDA to approve multiple versions of the same orphan drug for different <FONT STYLE="white-space:nowrap">sub-indications</FONT> and subpopulations, such as adult and
pediatric patients or multiple variations of the same disease that are caused by different genetic variants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pediatric exclusivity is a type of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity in the United States and, if granted,
provides for the attachment of an additional six months of exclusivity. For biologic products, the <FONT STYLE="white-space:nowrap">six-month</FONT> period may be attached to any existing regulatory exclusivities but not to any patent terms. The
conditions for pediatric exclusivity include the FDA determining that information relating to the use of a new product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric
clinical trials, and the sponsor agreeing to perform, and report on, the requested clinical trials within the statutory time period. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted if a sponsor submits pediatric
data that fairly responds to a written request from the FDA for such data within statutory time limits. The data does not need to show the product to be effective in the pediatric population studied, rather if the clinical trial is deemed to fairly
respond to the FDA&#8217;s request, the additional protection is granted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Patent Term Restoration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for
limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a
total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of a BLA plus the time
between the submission date and approval of a BLA, less any time the sponsor failed to act with due diligence. Only one patent applicable to an approved biological product is eligible for extension, and the application for the extension must be
submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of
patent term for one of our owned or licensed patents, depending on the expected length of the applicable clinical trials and other factors involved in the filing of the relevant BLA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Healthcare Reform </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A primary trend in the U.S. healthcare
industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of biologic products, limiting coverage and reimbursement for medical products and other changes to
the healthcare system in the United States. In March 2010, the U.S. Congress enacted the Affordable Care Act, or ACA, which, among other things, changed the coverage and payment for pharmaceutical products under government healthcare programs. The
ACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes
and fees on the health industry and impose additional health policy reforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The American Taxpayer Relief Act of 2012, which was enacted in January
2013, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to
providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval
or the frequency with which any such product candidate is prescribed or used. Under current legislation, the actual reductions in Medicare payments may vary up to 4%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of
the law. For example, with the enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December&nbsp;22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which required most
Americans to carry a minimal level of health insurance, became effective in 2019. Further, on June&nbsp;17, 2021, the U.S. Supreme Court dismissed a challenge to the ACA after finding that the plaintiffs did not have standing to challenge the
constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmaceutical Price
Reform </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been
U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient
programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, on August&nbsp;16, 2022, the Inflation Reduction Act,
or IRA, was signed into law. The legislation has implications for Medicare Part D, which is a program available to individuals who are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
entitled to Medicare Part A or enrolled in Medicare Part B providing the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires
manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first
due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (first due in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for
the initial years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain
single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. The Center for Medicare&nbsp;&amp; Medicaid Services, or CMS, was directed to negotiate prices for ten
high-cost drugs paid for by Medicare Part D, beginning in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved
for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition were originally categorically excluded from price negotiation but, with passage of the One
Big Beautiful Bill Act in July 2025, Congress extended this exemption to drugs and biologics with multiple orphan drug designations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The IRA
subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for
taking price increases that exceed inflation. In addition, the IRA established inflation rebate programs under Medicare Part B and Part D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B
and Part D drugs faster than the rate of inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs at an estimated $2,000 a year beginning in 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The first cycle of negotiations
for the Medicare Drug Price Negotiation Program commenced in the summer of 2023 with the negotiated prices for ten selected drug products becoming effective on January&nbsp;1, 2026. The second cycle of negotiations with participating drug companies
occurred during 2025, and the negotiated prices for this second set of 15 drugs will become effective on January&nbsp;1, 2027. On January&nbsp;27, 2026, CMS published the list of 15 drugs selected for the third cycle of negotiations, and the
negotiated prices will become effective on January&nbsp;1, 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On June&nbsp;6, 2023, Merck&nbsp;&amp; Co. filed a lawsuit against HHS and CMS
asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, a number of other parties also filed
lawsuits in various courts with similar constitutional claims. HHS has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing or on the merits. Litigation involving these and other
provisions of the IRA will likely continue with unpredictable and uncertain results. Since adoption of the IRA, the Trump Administration has taken a number of actions to reduce the costs of pharmaceutical products. For example, on April&nbsp;15,
2025, President Trump issued an Executive Order which directs HHS to take steps to reduce the prices of pharmaceutical products. Further, on May&nbsp;12, 2025, President Trump issued an additional Executive Order calling on pharmaceutical
manufacturers to voluntarily reduce the prices of medicines in the United States. The Executive Order provides that if such actions do not lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a
rulemaking that imposes most-favored nation, or MFN, pricing in the United States. Thereafter, on July&nbsp;31, 2025, the President issued letters to 17 pharmaceutical companies reiterating the requirements of the May&nbsp;12, 2025 Executive Order
and demanding that such companies extend MFN pricing to Medicaid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patients. Virtually all of these pharmaceutical companies have entered into agreements with the Trump Administration to provide for lower prices on certain pharmaceuticals. On February&nbsp;5,
2026, President Trump launched TrumpRx.gov, a website that directs individuals to pharmaceutical manufacturer websites that are offering pricing discounts based on the Trump Administration&#8217;s pricing agreements with pharmaceutical
manufacturers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December&nbsp;23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, proposed two five-year pilot programs to
implement a &#8220;reference pricing&#8221; regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for Efficient Drug Pricing Model for Medicare Part B drugs, referred to as
GLOBE, and the Guarding U.S. Medicare Against Rising Drug Costs for Medicare Part D drugs, referred to as GUARD. Under the proposed pilot programs, a manufacturer would owe rebates to Medicare if prices for their drugs exceeded the prices paid by
other economically comparable reference countries, defined in the proposed regulations as Organisation for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development countries with a gross domestic product of $400&nbsp;billion and
a per capita gross domestic product that is at least 60% of the U.S. per capita gross domestic product (an initial list of 19 reference countries is included in the proposed rule). The pilot programs are proposed to go into effect beginning
October&nbsp;1, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, these
regulations are designed to encourage importation from other countries and bulk purchasing, which may be increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are
developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for
accelerated approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Federal and State Data Privacy Laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are multiple privacy and data security laws that may impact our business activities in the United States and in other countries where we operate,
conduct clinical trials or may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the federal Health Insurance Portability and
Accountability Act of 1996, or HIPAA, the HHS has issued regulations to protect the privacy and security of protected health information used or disclosed by covered entities including certain healthcare providers, health plans and healthcare
clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business
associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our
relationships with them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to
federal privacy regulations, there are a number of state laws governing the confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations,
state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general
(along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and
security laws. New laws and regulations governing privacy and security may be adopted in the future as well. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the state level, California has enacted legislation that has been dubbed the first
&#8220;GDPR-like&#8221; law in the United States, referring to the EU&#8217;s General Data Protection Regulation, which is described in more detail below. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy
rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January&nbsp;1, 2020 and requires
covered companies to provide new disclosures to California consumers, provides such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information, and allows for a new cause of action for data
breaches. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January&nbsp;1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like
provisions, including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive
personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole
responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to California, at least eighteen other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in
effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221;
data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering additional laws that will go into effect that could go into effect in 2026
and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For
example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the
relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation. These laws may impact our business activities, including our identification of research
subjects, relationships with business partners and ultimately the marketing and distribution of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Plaintiffs&#8217; lawyers are also
increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use
of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Approval and Regulation of Biologics in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To market any product outside of the United States, a sponsor must also comply with numerous regulatory requirements of other countries and jurisdictions
regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain
the necessary approvals by the comparable regulatory authorities of foreign countries or economic areas, such as the <FONT STYLE="white-space:nowrap">27-member</FONT> EU, before it can commence clinical trials or marketing of the product in those
countries or jurisdictions. This process in the EU generally follows the same lines as in the United States and requires the satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and
efficacy of the product for each proposed indication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before a product enters clinical testing in the EU, the sponsor must conduct preclinical studies to demonstrate the safety of the investigational product
for such clinical testing. These studies must be conducted in compliance with the principles of GLP, as set forth in EU Directive 2004/10/EC. In particular, preclinical studies, both <I>in vitro</I> and <I>in vivo</I>, must be planned, performed,
monitored, recorded, reported and archived in accordance with GLP principles, which reflect the requirements of the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Human Clinical Trials in Support of a Marketing Authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials in the EU are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which replaced the prior Clinical Trials Directive
2001/20/EC, or CTD. The CTR is designed to simplify and streamline the authorization, conduct and transparency of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to
be conducted in more than one Member State of the EU submits a single application for approval. The submission is made through the Clinical Trials Information System, the new clinical trials portal overseen by the EMA and available to clinical trial
sponsors, competent authorities of the EU Member States and the public. All clinical trials in the EU are now subject to the CTR following completion of the transition from the Clinical Trials Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The CTR streamlines the process and includes a single set of documents to be prepared and submitted for the application, simplified reporting procedures
for clinical trial sponsors, and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for
authorization of a clinical trial has been submitted, and Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications under the CTR. The role of the relevant
ethics committees in the assessment procedure is governed by the national law of the relevant EU Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As in the United States, sponsors
conducting certain clinical studies in the EU must submit clinical and make public trial information through the Clinical Trials Information System (CTIS) which has replaced Edura CT under the CTR. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to obtaining a marketing
authorization in the EU, sponsors must demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the
EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. This requirement also applies when a sponsor wants to add a new indication, pharmaceutical form or route of administration
for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some products, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its
effectiveness and safety in adults. The PDCO may also grant waivers when the development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before a Marketing Authorization
Application, or MAA, can be filed, or an existing marketing authorization can be amended, the EMA determines whether a sponsor has complied with the agreed studies and measures listed in each relevant PIP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>PRIME Designation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2016, the EMA launched an
initiative to facilitate development of product candidates in indications, which are often rare, for which few or no therapies currently exist. The PRIority MEdicines, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
or PRIME, scheme is intended to encourage drug development in areas of unmet medical need, and it provides for the accelerated regulatory review of product candidates that represent substantial
innovation. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with
PRIME designation, including early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once an application has been submitted.
Importantly, a dedicated EMA contact and rapporteur from the CHMP, or Committee for Advanced Therapies, or CAT, are appointed early in PRIME scheme facilitating increased understanding of the product candidate at the EMA committee level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Marketing Authorization </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To obtain a
marketing authorization, or MA, for a product under the EU regulatory system, a sponsor must submit an MAA either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU Member
States, including the decentralized procedure, national procedure, or mutual recognition procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The centralized procedure provides for the
grant of an MA by the European Commission, or EC, that is valid for all EU Member States. Pursuant to Regulation (EC) No.&nbsp;726/2004, the centralized procedure is compulsory for certain types of product candidates, including those produced by
certain biotechnological processes, designated as orphan drugs, that are advanced therapies, and that have a new active substance indicated for the treatment of certain diseases, including cancer. However, the centralized procedure may be optional
for product candidates with a new active substance indicated for the treatment of other diseases and product candidates that are highly innovative or for which a centralized process is in the interest of patients. Sponsors must demonstrate the
quality, safety, and efficacy of their product candidates to the EMA, which provides an opinion regarding the MAA. The EC then decides whether to grant or refuse marketing authorization in light of the opinion delivered by the EMA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The CHMP was established at the EMA and plays a vital role in the authorization of products in the EU. The CHMP provides scientific advice to sponsors
investigating and developing new products, prepares scientific guidelines and regulatory guidance to help sponsors prepare MAAs, and cooperates with international partners on the harmonization of regulatory requirements. With respect to MAAs filed
under the centralized procedure, the CHMP is responsible for conducting an initial assessment of a product candidate and the data supporting the MAA. The maximum timeframe for the evaluation of an MAA is 210 days, excluding interruptions when
additional information or written or oral explanation is to be provided by the sponsor in response to questions from the CHMP. Accelerated assessment with a time limit of 150 days may be granted by the CHMP in exceptional cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On the basis of its review, the CHMP provides a scientific opinion on whether or not an MA should be granted for a product candidate. Within 15 calendar
days of receipt of a final opinion from the CHMP, the EC must prepare a draft decision concerning an MAA. This draft decision must take the CHMP opinion and any relevant provisions of EU law into account. Before arriving at a final decision, the EC
must consult the Standing Committee on Medicinal Products for Human Use. This committee is composed of representatives of the EU Member States and is chaired by a <FONT STYLE="white-space:nowrap">non-voting</FONT> EC representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of
each EU Member State in which the product candidate is applying to be marketed. This application is substantially the same as an MAA submitted to the EMA in the centralized procedure. The reference Member State, or RMS, prepares a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States which,
within 90 days of receipt, must decide whether to approve the assessment report and related materials. If the relevant EU Member State cannot approve the RMS&#8217;s assessment report and related materials due to concerns relating to a potential
serious risk to public health, disputed elements may be referred to the CMDh and, if unresolved, to the CHMP for arbitration, following which the European Commission adopts a binding decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the MA of a product by the
competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another
EU Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Periods of Authorization and Renewals </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An MA is initially valid for five years and may be renewed after five years following a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the
risk-benefit balance by the EMA or by the competent authority of the EU Member State. In connection with seeking a renewal, the MA holder must provide the EMA or the competent authority of the EU Member State with a consolidated version of the file
in respect of quality, safety and efficacy or the medicine, including all variations introduced since the MAwas granted, at least six months before the MA ceases to be valid. The EC or the competent authority of the EU Member State may decide, on
justified grounds relating to pharmacovigilance, to proceed with an additional five-year period of MA. Once definitively renewed, the MA shall be valid for an unlimited period. If a renewed MA is not followed by the actual placing of the medicine on
the EU market (in the case of the centralized procedure) or on the market of the authorizing EU Member State within three years after renewal, and is no longer actually present on the applicable market for three consecutive years, the MA ceases to
be valid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Marketing Authorization Under Exceptional Circumstances </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EC may grant a &#8220;marketing authorization under exceptional circumstances&#8221; under Article 14(8) of Regulation (EC) No 726/2004. This
authorization is intended for products for which the sponsor can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because: the indications for which the product in question is
intended are encountered so rarely that the sponsor cannot reasonably be expected to provide comprehensive evidence; given the present state of scientific knowledge, comprehensive information cannot be provided; or it would be contrary to generally
accepted principles of medical ethics to collect such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A marketing authorization under exceptional circumstances may be granted subject
to certain specific obligations, which may include the following: the sponsor must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the
benefit-risk profile; the medicine in question may be supplied by medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an
authorized person; and the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the product in question are as yet inadequate in certain specified
respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A marketing authorization under exceptional circumstances is subject to an annual process to review and reassess the risk-benefit
balance. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
suspended or revoked. The renewal of a marketing authorization under exceptional circumstances, however, follows the same rules as a standard MA. Thus, it is granted for an initial five year
period, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Conditional Marketing Authorization </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EC
may also grant a &#8220;conditional marketing authorization&#8221; to a product prior to obtaining the comprehensive clinical data required for an application for a full MA under Article <FONT STYLE="white-space:nowrap">14-a</FONT> of Regulation
(EC) No 726/2004. A conditional marketing authorization may be granted for product candidate (including product candidates designated as orphan drugs) if: (i)&nbsp;the risk-benefit balance of the product candidate is positive, (ii)&nbsp;it is likely
that the sponsor will be in a position to provide the required comprehensive clinical trial data, (iii)&nbsp;the product candidate fulfills an unmet medical need and (iv)&nbsp;the benefit to public health of the immediate availability on the market
of the product candidate outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the holder, including obligations with respect to the
completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an
assessment of the need for additional or modified conditions and/or specific obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Post-Approval Regulatory Requirements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the issuance of an MA for a medicine, the sponsor of the MA is required to comply with a range of requirements applicable to the
manufacturing, marketing, promotion and sale of products. These requirements include compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which may include post-authorization studies and additional monitoring
obligations. Further, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive
2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the EC Guidelines for Good Manufacturing Practice. These requirements include compliance with EU Good Manufacturing Practice (GMP) standards when manufacturing products and active
pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At the same time, the marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed
toward the prescribers of drugs and/or the general public, are strictly regulated in the EU under Directive 2001/83/EC, as amended, and are also subject to EU Member State laws.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is prohibited across the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Regulatory Exclusivity </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">New products
approved on the basis of a complete data package currently qualify for eight years of data exclusivity and an additional two years of market exclusivity. Data exclusivity prevents sponsors that seek MA of generic products from referencing the
innovator&#8217;s data in support of an abbreviated application. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic MAA can be submitted and the innovator&#8217;s data may be referenced in
that application, but no generic product can be placed on the EU market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period may be extended to a maximum of 11 years if, during the first
eight years of those ten years, the MA holder for the innovative product obtains an authorization for one or more new therapeutic indications which are determined to bring a significant clinical benefit in comparison with existing therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2020, the EC launched a review of the EU&#8217;s pharmaceutical legislation, including its
provisions governing regulatory exclusivity. The EC&#8217;s proposal for revision of several legislative measures was published in April 2023 and includes, among other things, provisions that would potentially reduce the duration of regulatory
exclusivity protection. On December&nbsp;11, 2025, the European Parliament and Council reached a provisional political agreement&nbsp;on the legislation, which is expected to be adopted by <FONT STYLE="white-space:nowrap">mid-2026.</FONT> Key
changes include updating regulatory exclusivity to a new system with eight years of data exclusivity and a reduced market exclusivity period to one year, which can be extended if specific conditions are fulfilled up to a maximum of 11 years. This
measure, and others, are expected to be adopted by <FONT STYLE="white-space:nowrap">mid-2026</FONT> and, following a transition period of 24 months, will likely take effect in <FONT STYLE="white-space:nowrap">mid-2028.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and Exclusivity </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As
in the United States, a product candidate can be designated as an orphan medicinal product by the EC if its sponsor can establish that the product candidate is intended for the diagnosis, prevention or treatment of (1)&nbsp;a life-threatening or
chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2)&nbsp;a life-threatening, seriously debilitating or serious and chronic condition in the EU that without incentives
is unlikely to generate sufficient return from marketing in the EU to justify the necessary investment. For either of these categories, the sponsor must demonstrate that there is no satisfactory method of diagnosis, prevention or treatment of the
condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by the condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product candidate is designated as an orphan medicinal product, the product will be eligible for a range of benefits during the development and
regulatory review process, including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure, which is mandatory for orphan medicinal products and results in a single marketing authorization
covering all EU Member States and a reduction or elimination of registration and MA fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, if and when the product is authorized for
marketing, the orphan medicinal product will be entitled to ten years of market exclusivity in all EU Member States. However, MA may be granted to a similar product with the same orphan indication during the
<FONT STYLE="white-space:nowrap">10-year</FONT> period with the consent of the MA holder of the original orphan drug or if the manufacturer of the original orphan drug is unable to supply sufficient quantities. MA may also be granted to a similar
product with the same orphan indication if the product is safer, more effective or otherwise clinically superior to the original orphan drug. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the
basis of available evidence that the original orphan drug is sufficiently profitable not to justify maintenance of market exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Pediatric
Exclusivity </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a sponsor obtains a MA in all EU Member States, or a MA granted in the centralized procedure by the EC, and the study results
for the pediatric population are included in the application, even when negative, the product is eligible for an additional <FONT STYLE="white-space:nowrap">six-month</FONT> period of qualifying patent protection through extension of the term of the
SPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Patent Term Extensions </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EU
provides for patent term extension through SPCs. The rules and requirements for obtaining a SPC are set out in Regulation (EC) 469/2009 and are similar to those in the United States. An SPC may extend the term of a patent for up to five years after
its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. Although SPCs are available throughout the EU, sponsors must apply on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Pricing Decisions </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a
reimbursement price has been agreed. Other countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or
<FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health
insurance systems provide reimbursement and to control the prices of products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the
company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals, and these efforts could continue as countries
attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become
intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement
has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>General Data Protection Regulation </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There
are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the
European Economic Area, or EEA, and the processing of personal data that takes place in the EEA, is subject to the EU&#8217;s General Data Protection Regulation, or GDPR, which became effective in 2018. The GDPR is wide-ranging in scope, imposes
numerous requirements on companies that process personal data, and imposes heightened requirements on companies that process health and other sensitive data. These requirements include, in many situations, that a company obtain consent from an
individual before processing their sensitive personal data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Examples of obligations imposed by the GDPR on companies processing personal data
within its scope include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notifications
of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the U.S., and permits data protection authorities to
impose large penalties for violations of the GDPR, including potential fines of up to the greater of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of annual global revenues. The GDPR also confers a private right of
action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and
time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the July 2020 Court of Justice of the EU judgement invalidating the <FONT STYLE="white-space:nowrap">so-called</FONT> <FONT
STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield, the EC adopted an adequacy decision for the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework in July 2023. This adequacy decision permits U.S. companies who self-certify
under the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the United States. However, some privacy advocacy groups have already suggested that they will be
challenging the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, and there is currently one pending litigation against the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework before the Court of Justice of
the EU (CJEU), <FONT STYLE="white-space:nowrap">C-703/25</FONT> P &#8211; <I>Latombe v Commission</I>. If these challenges are successful, they may not only impact the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, but also
further limit the viability of the <FONT STYLE="white-space:nowrap">so-called</FONT> standard contractual clauses and other data transfer mechanisms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Approval and Regulation of Biologics in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of January&nbsp;1, 2025, the Medicines and Healthcare Products Regulatory Agency, or the MHRA, is responsible for approving all products destined for
the United Kingdom market (Great Britain and Northern Ireland). The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating products. The HMR has incorporated into domestic law the
body of EU law instruments governing products that existed prior to the United Kingdom&#8217;s withdrawal from the EU. On April&nbsp;28, 2025, the U.K. Parliament adopted amendments to improve and strengthen the clinical trials regulatory regime in
the United Kingdom. These revisions will take effect on April&nbsp;28, 2026, and were needed to replace the prior requirements in the United Kingdom that were based on the repealed CTD, which has been replaced by the CTR, while the United Kingdom
has established its own standalone clinical trials regime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as of January&nbsp;1, 2024, an international recognition procedure, or IRP,
applies in the United Kingdom and is designed to facilitate approval of pharmaceutical products in the United Kingdom. The IRP is open to sponsors that have previously received an authorization for the same product from one of the MHRA&#8217;s
specified Reference Regulators, or RRs. The RRs include the EMA and regulators in the EEA member states, for approvals in the EU centralized procedure and mutual recognition procedure, and the FDA for approvals granted in the United States. The RR
assessment must have undergone a full and standalone review. RR assessments based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion is an RR authorization for the purposes of IRP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the withdrawal of the United Kingdom from the EU, the U.K. Data Protection Act applies to the processing of personal data that takes place in
the United Kingdom and includes parallel obligations to those set forth by GDPR. The United Kingdom government has determined that it considers all EU Member States and EEA member states to be adequate for the purposes of data protection, ensuring
that data flows from the United Kingdom to the EU/EEA remain unaffected. Further, the EC decided in June 2021 that the level of data protection in the United Kingdom is &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to
the United Kingdom. On December&nbsp;19, 2025, the EC renewed this decision until December&nbsp;27, 2031. The United Kingdom and the U.S. have also agreed to a U.S.- United Kingdom &#8220;Data Bridge,&#8221; which functions similarly to the <FONT
STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework and provides an additional legal mechanism for companies to transfer personal data from the United Kingdom to the United States.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United Kingdom, following Brexit, the MHRA has established and administers the Innovation Licensing and Access Pathway, or ILAP, to
accelerate the development and approval of new pharmaceutical products. The ILAP is open to sponsors of potentially transformative medicines or drug-device combination products that address unmet medical needs. It supports products with evidence of
safe use in humans but before confirmatory trials have started. It is designed to reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> timeline for research and development, regulatory approval and
timely adoption of new technologies to benefit patients and the healthcare system in the United Kingdom. To these ends, the ILAP comprises an Innovation Passport designation, a Target Development profile and a toolkit to support all stages of the
design, development and approval process. In 2025, the MHRA relaunched </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the ILAP with updated eligibility criteria, simplified application steps, and an increased focus on advanced therapy medicinal products, rare diseases and high unmet medical needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
December&nbsp;31, 2025, we had 59 full-time employees, of which 27 employees are based in the United States and 28 employees are based in Denmark. None of our employees are represented by labor unions or covered by collective bargaining agreements.
We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our human capital resources objectives include, as applicable, identifying, recruiting,
retaining, incentivizing and integrating our existing and new employees, advisors and consultants. Our compensation program is designed to retain, motivate and, as needed, attract highly qualified employees. Accordingly, we use a mix of competitive
base salary, cash-based annual incentive compensation, equity awards and other employee benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our principal facilities consist of office space. We occupy approximately 6,200 square feet of office space in Copenhagen, Denmark under a lease that
currently expires in January 2029. We also occupy 4,274 square feet of office space in Cambridge, Massachusetts under a lease that currently expires in October 2026. We believe our facilities are adequate and suitable for our current needs and that
should it be needed, suitable additional or alternative space will be available to accommodate our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any
material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets
forth the name, age as of February&nbsp;15, 2026 and position of each of our executive officers and directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer, Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt, M.Sc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">43</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and General Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan, M.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Board of Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Anderson, Ph.D. .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Becker, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">J&oslash;rgen S&oslash;berg Petersen, M.D., Ph.D., D.M.Sc., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Audit Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Benny S&oslash;rensen, M.D.,
Ph.D.</I></B> has served as our president and chief executive officer since July 2021 and as a member of our board of directors since November 2021. Prior to that, Dr.&nbsp;S&oslash;rensen served as Senior Vice President, Strategic Projects at
Codiak Biosciences, Inc., or Codiak, a biopharmaceutical company, from October 2016 to July 2021. Previously, Dr.&nbsp;S&oslash;rensen served as Senior Director of Clinical Research at Alnylam Pharmaceuticals, Inc., or Alnylam, a biopharmaceutical
company, from October 2013 to October 2016. From May 2012 to October 2013, Dr.&nbsp;S&oslash;rensen served as a Global Medical Director at Baxter Healthcare Corporation, or Baxter, a medical equipment manufacturing company. Prior to Baxter,
Dr.&nbsp;S&oslash;rensen was the Director of the Haemostasias Research Unit and Honorary Lecturer at Guy&#8217;s and St. Thomas&#8217; Hospital and King&#8217;s College London School of Medicine. Dr.&nbsp;S&oslash;rensen previously served on the
Scientific Advisory Board of Codiak from July 2021 to March 2023. He also served as an Associate Professor of Thrombosis and Haemostasias at Aarhus University, Denmark from 2007 until 2016. Dr.&nbsp;S&oslash;rensen holds an M.D. and Ph.D. from
Aarhus University. We believe that Dr.&nbsp;S&oslash;rensen is qualified to serve on our board of directors based on his extensive knowledge of our company and the biopharmaceutical industry, his experience in hematological research and his current
role as our president and chief executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Mads Behrndt-Eriksen, M.Sc. </I></B>has served as our chief financial officer and general
manager since September 2021. Prior to that, Mr.&nbsp;Behrndt served in roles of increasing responsibility, including as a Partner, in PricewaterhouseCoopers&#8217; Corporate Finance practice from 2007 to September 2021. Mr.&nbsp;Behrndt holds an
M.Sc. in Finance&nbsp;&amp; Strategic and a B.Sc. in Economics and Business Administration Management from the Copenhagen Business School. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Catherine Madigan, M.D. </I></B>has served as our chief medical officer since January 2025.
Prior to that, Dr.&nbsp;Madigan served as Chief Medical Officer at Syndax Pharmaceuticals, Inc., a biopharmaceutical company, from March 2022 to December 2024. Previously, Dr.&nbsp;Madigan served as Vice President, Head of Clinical Development at
Syros Pharmaceuticals, Inc., a biopharmaceutical company, from June 2019 to February 2022. Prior to that, she served as Senior Medical Director, Clinical Research at Alnylam from March 2018 to June 2019, and was a Medical Director in the Rare
Disease Innovation Unit of Biogen Inc., a biotechnology company, from February 2016 to May 2016. Dr.&nbsp;Madigan previously held various academic positions of increasing responsibility at the University of California San Diego/Rady Children&#8217;s
Hospital San Diego. Dr.&nbsp;Madigan holds an M.D. from the Keck School of Medicine of the University of Southern California and a B.A. in Asian Studies from Dartmouth College. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>John Maraganore, Ph.D.</I></B> has served as chair of our board of directors since January 2022. Dr.&nbsp;Maraganore has served as the <FONT
STYLE="white-space:nowrap">co-chief</FONT> executive officer at Corsera Health, Inc., a privately-held clinical-stage cardiovascular company, since September 2025. He has also served as a Senior Advisor at Jefferies Financial Services, an investment
banking and capital markets firm, since November 2024, a Venture Advisor at Atlas Venture, an early-stage venture capital firm, since January 2022, a Senior Advisor at Blackstone Life Sciences, a private equity investment strategy firm, since
January 2022, an Executive Partner at RTW Investments, LP, a life sciences investment and innovation firm, since January 2022, a principal and Chief Executive Officer of JMM Innovations, LLC, a biotechnology strategic advisory practice, since
January 2022, and a Venture Partner at ARCH Venture Partners, an early stage venture capital firm, since October 2021. Previously, Dr.&nbsp;Maraganore served as the founding Chief Executive Officer and a member of the board of directors of Alnylam
from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr.&nbsp;Maraganore has been a member of the boards of directors of Rapport Therapeutics, Inc. since March 2024, Takeda Pharmaceutical Company
Limited since June 2022, Kymera Therapeutics, Inc. since February 2022 and Beam Therapeutics Inc. since November 2021, which are all biopharmaceutical companies. He also previously served on the boards of directors of ProKidney Corp. from August
2022 to May 2024 and Agios Pharmaceuticals, Inc. from June 2010 to May 2023. Dr.&nbsp;Maraganore holds an M.S. and a Ph.D. in Biochemistry and Molecular Biology and a B.A. in Biological Sciences from the University of Chicago. We believe that
Dr.&nbsp;Maraganore is qualified to serve on our board of directors based on his scientific background, his experience in the venture capital industry, and his leadership and management experience in building biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Joseph Anderson, Ph.D.</I></B> has served as a member of our board of directors since October 2025. Dr.&nbsp;Anderson has been a Partner at
Sofinnova Partners since October 2020. Previously, he served as the Chief Executive Officer of Arix Bioscience plc, a global life sciences investment company, where he held several leadership positions from February 2016 to April 2020. Prior to
that, Dr.&nbsp;Anderson was a Partner at Abingworth LLP, an international investment group, from January 2004 to December 2015. From October 1999 through December 2003, Dr.&nbsp;Anderson was at First State Investments in London, part of the
Commonwealth Bank of Australia, where he was the head of global healthcare equities and a portfolio manager. Prior to this, he was a pharmaceuticals analyst at the investment bank Dresdner Kleinwort Benson from June 1998 through October 1999. From
1990 to 1998, Dr.&nbsp;Anderson established and was head of the strategy unit at The Wellcome Trust. Dr.&nbsp;Anderson served on the board of directors of Autolus Therapeutics plc, or Autolus, a biopharmaceutical company, from February 2016 to June
2025. Dr.&nbsp;Anderson holds a Ph.D. in Biochemistry from the University of Aston and a B.Sc. in Biological Science from Queen Mary College, University of London. We believe that Dr.&nbsp;Anderson is qualified to serve on our board of directors
based on his financial experience and extensive experience in the biotechnology industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Linda Bain</I></B> has served as a member of our board of directors since January 2022. Since
April 2025, Ms.&nbsp;Bain has served as a Venture Partner at Atlas Venture. Prior to that, Ms.&nbsp;Bain was the Chief Operating Officer and Chief Financial Officer of Mariana Oncology, Inc., a radiopharmaceutical company and a Novartis company as
of May 2024, from May 2023 to April 2025. Ms.&nbsp;Bain also served as the Chief Financial Officer of Codiak from December 2015 to April 2023, and the Chief Financial Officer and Treasurer of Avalanche Biotechnologies, Inc., a clinical stage gene
therapy company, from April 2014 to November 2015. Previously, Ms.&nbsp;Bain served at bluebird bio, Inc., a gene therapy biotechnology company, as Vice President of Finance and Business Operations from October 2011 to March 2014 and as the
Principal Accounting Officer from June 2013 to March 2014. Ms.&nbsp;Bain previously held senior roles at Genzyme Corporation, a biotechnology company, including Vice President of Finance, Global Manufacturing and Operations, and Vice President of
Finance, Genzyme Genetics, and earlier in her career at Fidelity Investments, AstraZeneca plc, and Deloitte&nbsp;&amp; Touche LLP. Ms.&nbsp;Bain has served as a member of the boards of directors of Arvinas, Inc. since June 2020 and Autolus since
June 2018. She also previously served on the board of directors of VBI Vaccines, Inc. from July 2021 to September 2022. Ms.&nbsp;Bain holds a B.S. degree in Accounting and Business Administration and an Honors Degree in Accounting and Business
Administration from the University of the Free State in South Africa. She is a certified public accountant. We believe that Ms.&nbsp;Bain is qualified to serve on our board of directors based on her extensive experience in the biopharmaceutical
industry and her background in accounting and finance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Dan Becker, M.D., Ph.D.</I></B> has served as a member of our board of directors since
February 2023. Dr.&nbsp;Becker has served as a Managing Director at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held U.S.-based industrial group, since August 2019. Prior to that, Dr.&nbsp;Becker
served as a Principal at New Leaf Venture Partners, a venture capital firm, from January 2015 to May 2019, and as a Principal in the Health Care practice at the Boston Consulting Group from August 2009 to January 2015. Dr.&nbsp;Becker previously
trained clinically in internal medicine and nephrology at Brigham and Women&#8217;s Hospital and Massachusetts General Hospital and was a Research Fellow at Harvard Medical School. Dr.&nbsp;Becker has served on the board of directors of Zura Bio
Limited since May 2025. Previously, Dr.&nbsp;Becker served on the boards of directors of Acelyrin, Inc. from September 2022 until its acquisition by Alumis Inc. in May 2025, Day One Biopharmaceuticals, Inc. from December 2019 to May 2024 and Pandion
Therapeutics, Inc. from March 2020 to March 2021. Dr.&nbsp;Becker holds an M.D. and Ph.D. in Cellular and Molecular Biology from the University of Michigan and a B.S. in Physiology from the University of Illinois at Urbana-Champaign. We believe that
Dr.&nbsp;Becker is qualified to serve on our board of directors based on his medical training and extensive experience with early-stage biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Uya Chuluunbaatar, Ph.D. </I></B>has served as a member of our board of directors since February 2023. Dr.&nbsp;Chuluunbaatar has served as a
Partner and Investor at Avoro Ventures, a global venture capital firm investing in life sciences, since March 2022. Prior to that, from November 2015 to December 2021, she was a Principal and Investor at Amzak Health, a healthcare and venture
capital firm. Previously, Dr.&nbsp;Chuluunbaatar served as an Equity Research Associate at Goldman Sachs. Dr.&nbsp;Chuluunbaatar holds a Ph.D. in Microbiology from New York University Grossman School of Medicine and a B.S. in Biochemistry from
Cornell University. We believe that Dr.&nbsp;Chuluunbaatar is qualified to serve on our board of directors based on her scientific background and experience in the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>J&oslash;rgen S&oslash;berg Petersen, M.D., Ph.D., D.M.Sc., M.B.A</I></B> has served as a member of our board of directors since December 2020.
Dr.&nbsp;Petersen joined Novo Holdings A/S, the Novo Nordisk Foundation&#8217;s asset and management company, in September 2017 where he is currently employed as a Senior Partner. Prior to joining Novo Holdings A/S, Dr.&nbsp;Petersen was President
and Founding Chief Executive Officer at ImCheck Therapeutics from August 2015 to December 2016. Previously, Dr.&nbsp;Petersen served as Corporate Vice President at Novo Nordisk A/S from September 2013 to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
January 2015, and as Senior Vice President at Merck Serono, a pharmaceutical company, from June 2008 to June 2013. Prior to that, Dr.&nbsp;Petersen
<FONT STYLE="white-space:nowrap">co-founded</FONT> and served as Executive Vice President and Chief Scientific Officer at Zealand Pharma A/S, a biotechnology research company, from October 1998 to April 2008. Dr.&nbsp;Petersen holds an M.D., Ph.D.
in Pharmacology, a D.M.Sc. from the University of Copenhagen, Denmark and an M.B.A. from the Technical University of Denmark. We believe that Dr.&nbsp;Petersen is qualified to serve on our board of directors based on his extensive experience in rare
disease therapeutic development and the biopharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Laura Tadvalkar, Ph.D.</I></B> has served as a member of our board of
directors since July 2021. Dr.&nbsp;Tadvalkar is currently a Managing Director on the Venture Team at RA Capital Management, a venture capital firm, where she has served in roles of increasing responsibility since April 2020. Prior to that,
Dr.&nbsp;Tadvalkar served at MP Healthcare Venture Management, Inc., the strategic venture capital fund for Mitsubishi Tanabe Pharma Corporation, a pharmaceutical company, from March 2017 through April 2020. Previously, Dr.&nbsp;Tadvalkar was a
consultant at Clarion Healthcare, a life sciences consultancy company, from September 2014 to March 2017. Dr.&nbsp;Tadvalkar previously served on the board of directors of Cidara Therapeutics, Inc. from April 2024 to January 2025. Dr.&nbsp;Tadvalkar
holds a Ph.D. in Chemical Biology from Harvard University and a B.S. in Chemistry from Yale University. We believe that Dr.&nbsp;Tadvalkar is qualified to serve on our board of directors based on her extensive experience in the life sciences and
venture capital industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Akshay Vaishnaw, M.D., Ph.D.</I></B> has served as a member of our board of directors since January 2024.
Dr.&nbsp;Vaishnaw has served as President of Research&nbsp;&amp; Development at Scholar Rock Holding Corporation, or Scholar Rock, a global biopharmaceutical company, since April 2025, and as a member of the board of directors of Scholar Rock since
May 2019. He also has been a Venture Partner at Atlas Venture since August 2024. Previously, at Alnylam, Dr.&nbsp;Vaishnaw served as Chief Innovation Officer and Member of the Scientific Advisory Board from October 2023 to December 2024, as
President from January 2022 to September 2023 and as President of Research&nbsp;&amp; Development from March 2018 to January 2022. Prior to that, Dr.&nbsp;Vaishnaw served in various other roles of increasing responsibility at Alnylam from January
2006 to February 2018. He previously served on the board of directors of Editas Medicine, Inc. from 2016 to July 2024. Dr.&nbsp;Vaishnaw holds an MBBCh from Cardiff University School of Medicine (formerly, the University of Wales College of
Medicine, U.K.), and a Ph.D. in Molecular Immunology from the University of London, U.K. He is a Fellow of the Royal College of Physicians, U.K. We believe that Dr.&nbsp;Vaishnaw is qualified to serve on our board of directors based on his
scientific background and his experience in the life sciences and venture capital industries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition and Election of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Effective upon the completion of this
offering, our board of directors will be authorized to have&#8195;&#8195;&#8195;&#8195;members and will consist of&#8195;&#8195;&#8195;&#8195;members. Our directors hold office until their successors have been elected and qualified or until the
earlier of their death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation and amended and restated bylaws that will become
effective upon the completion of this offering provide that the authorized number of directors may be changed only by resolution of our board of directors. Our restated certificate of incorporation and amended and restated bylaws will also provide
that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with the terms of our restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion
of this offering, our board of directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
will be divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. As a result, only one class of directors will be elected at
each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Upon the completion of this offering, the members of the classes will be divided as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the class I directors will be&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and their term will expire at the
annual meeting of stockholders to be held in&#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the class II directors will be&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, and their term will expire at
the annual meeting of stockholders to be held in&#8195;&#8195;&#8195;&#8195;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the class III directors will be&#8195;&#8195;&#8195;&#8195; ,&#8195;&#8195;&#8195;&#8195; and&#8195;&#8195;&#8195;&#8195; ,
and their term will expire at the annual meeting of stockholders to be held in&#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the expiration
of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The classification of our board of directors may have the effect of delaying or preventing changes in our control or management. See the section titled,
&#8220;<I>Description of Capital Stock&#8212;Delaware Anti-Takeover Law and Certain Charter and Bylaw Provisions</I>&#8221;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to apply to list our common stock on the Nasdaq Global Market. Nasdaq rules require a majority of a listed company&#8217;s board of directors
to be comprised of independent directors within one year of listing. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance
committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and compensation committee members must also satisfy the
independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under applicable Nasdaq rules, a
director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the listed company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in
carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity
as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an
affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board must consider, for each member of a compensation committee of a
listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a
compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of the director, including any consulting, advisory or other compensatory fee paid by such company to the director; and (2)&nbsp;whether the director
is affiliated with the company or any of its subsidiaries or affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In&#8195;&#8195;&#8195;&#8195;, our board of directors undertook a review
of the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment, and affiliations, including
family relationships, our board of directors has determined that each of our directors, with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
exception of Dr.&nbsp;S&oslash;rensen, is an &#8220;independent director&#8221; as defined under applicable Nasdaq rules, including, in the case of all the members of our audit committee, the
independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. In making such determination, our board of directors considered the relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and
all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director.
Dr.&nbsp;S&oslash;rensen is not an independent director under these rules because he is our president and chief executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are no
family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Bankruptcies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Ms.&nbsp;Bain previously served as Chief Financial Officer of Codiak from December 2015 to April 2023. In March 2023, Codiak filed a voluntary petition
for relief under Chapter 11 of the U.S. Bankruptcy Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board leadership structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors is currently chaired by John Maraganore, who has authority, among other things, to call and preside over meetings of the board of
directors, to set meeting agendas and to determine materials to be distributed to the board of directors. Accordingly, the chair has substantial ability to shape the work of the board of directors. We believe that separation of the positions of
chair and chief executive officer reinforces the independence of the board of directors in its oversight of our business and affairs. In addition, we have a separate chair for each committee of our board of directors. The chair of each committee is
expected to report annually to our board of directors on the activities of their committee in fulfilling their responsibilities as detailed in their respective charters or specify any shortcomings should that be the case. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of the Board of Directors in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">One of the
key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee but rather administers this oversight function directly through the board of
directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing
strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to
govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has established an
audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate under a charter to be adopted by our board of directors and which, together with the composition of each committee, will become
effective upon the effectiveness of the registration statement of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The members of our audit committee
are&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;.&#8195;&#8195;&#8195;&#8195;is the chair of the audit committee. Effective upon the effectiveness of the registration statement of which this prospectus
forms a part, our audit committee&#8217;s responsibilities will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appointing, evaluating, and when necessary, terminating and setting the compensation of, and overseeing the independence of
our registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration
of reports from that firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coordinating our board of director&#8217;s oversight of our internal control over financial reporting, disclosure controls
and procedures and code of business conduct and ethics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing our risk assessment and risk management policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing procedures for the receipt, retention and treatment of accounting related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">meeting independently with our internal auditing staff, if any, our independent registered public accounting firm and
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving or ratifying any related person transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the audit committee report required by SEC rules. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than <I>de minimis</I> <FONT STYLE="white-space:nowrap">non-audit</FONT>
services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board
of directors has determined that&#8195;&#8195;&#8195;&#8195;is an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules and that each of the members of our audit committee possesses the financial sophistication required
for audit committee members under Nasdaq rules. We believe that the composition of our audit committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audit committee will operate under a written charter, which will be effective upon the completion of this offering, that satisfies the applicable
Nasdaq Listing Rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
members of our compensation committee are&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;.&#8195;&#8195;&#8195;&#8195; is the chair of the compensation committee. Effective upon the effectiveness of the
registration statement of which this prospectus forms a part, our compensation committee&#8217;s responsibilities will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our chief
executive officer and our other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing an evaluation of our senior executives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to our board of directors with respect to director compensation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis&#8221; disclosure if and
to the extent then required by SEC rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the compensation committee report if and to the extent then required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retaining or obtaining the advice of compensation consultants, legal counsel or other advisors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approving or recommending for approval by our board of directors, the implementation or revision of any compensation
recovery or &#8220;clawback&#8221; policies and overseeing the administration of such policies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the composition
of our compensation committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation
committee will operate under a written charter, which will be effective upon the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
members of our nominating and corporate governance committee are&#8195;&#8195;&#8195;&#8195; ,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;.&#8195;&#8195;&#8195;&#8195;is the chair of the nominating and corporate governance committee.
Effective upon the effectiveness of the registration statement of which this prospectus forms a part, our nominating and corporate governance committee&#8217;s responsibilities will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying individuals and recommending to our board of directors the nominees for election as directors and to each of
our board&#8217;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to our board with respect to our board leadership structure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to our board with respect to management succession planning; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and recommending to our board of directors corporate governance principles; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing a periodic evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the composition of our nominating and corporate governance committee will meet the requirements for independence under current Nasdaq
and SEC rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our nominating and corporate governance committee will operate under a written charter, which will be effective upon
the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">None of our executive officers serves, or in the past year has served, as a member of the board of directors or compensation committee, or other
committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None of the members of our compensation committee is, or has
ever been, an officer or employee of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Ethics and Code of Conduct </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to adopt, upon the effectiveness of the registration statement of which this prospectus is a part, a written code of business conduct and
ethics that applies to our directors, officers, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We intend to post a current
copy of the code on our website, www.hemab.com. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code. Our website
is not incorporated by reference into this prospectus, and you should not consider any information contained in or accessible from our website to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following discussion relates to the compensation of Benny S&oslash;rensen, our president and chief executive officer, Mads Behrndt, our chief
financial officer and general manager, and Catherine Madigan, our chief medical officer. Dr.&nbsp;S&oslash;rensen, Mr.&nbsp;Behrndt, and Dr.&nbsp;Madigan are collectively referred to in this prospectus as our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In preparing to become a public company, we have begun a thorough review of all elements of our executive compensation program, including the function
and design of our equity incentive programs. We have begun, and expect to continue in the coming months, to evaluate the need for revisions to our executive compensation program to ensure that our program is competitive with the companies with which
we compete for executive talent and is appropriate for a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding compensation awarded to, earned by or paid to each of our named executive officers for the year
ended December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,501</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,112</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Financial Officer and General Manager</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,267,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,241</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,907,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amount reported in the &#8220;Option Awards&#8221; column reflects the aggregate grant date fair value of warrants
granted during 2025 and computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 718. See Note 2 to our financial statements appearing elsewhere in this prospectus regarding
assumptions underlying the valuation of equity awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amounts reported in the <FONT STYLE="white-space:nowrap">&#8220;Non-Equity</FONT> Incentive Plan Compensation&#8221;
column represent performance-based cash bonuses earned by our named executive officers in the year ended December&nbsp;31, 2025, which amounts were paid in February 2026. See &#8220;&#8212;<I>Narrative Disclosure to Summary Compensation
Table&#8212;Annual Bonus</I>&#8221; below for a general description of the criteria that our board of directors used to determine the performance-based cash bonuses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;S&oslash;rensen also serves as a member of our board of directors but does not receive any additional
compensation for service as a director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">All other compensation for 2025 to Dr.&nbsp;S&oslash;rensen reflects: (1)&nbsp;matching contributions of $18,535 made by
us under our 401(k) plan and (2)&nbsp;premiums of $966 paid by us during 2025 with respect to life insurance policies. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For Mr.&nbsp;Behrndt, amounts reported in the Salary, <FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan
Compensation, and All Other Compensation columns were paid in Danish kroner and converted to U.S. dollars using a U.S. dollar/Danish kroner exchange rate of 0.1573 (rounded to 0.16) as of December&nbsp;31, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">All other compensation for 2025 to Mr.&nbsp;Behrndt reflects a contribution to our Pension Plan (as defined below) for
Mr.&nbsp;Behrndt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">All other compensation for 2025 to Dr.&nbsp;Madigan reflects: (1)&nbsp;matching contributions of $12,312 made by us under
our 401(k) plan and (2)&nbsp;premiums of $929 paid by us during 2025 with respect to life insurance policies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Base Salary.</I> In 2025, we paid Dr.&nbsp;S&oslash;rensen an annualized base salary of $561,269, Mr.&nbsp;Behrndt an annualized base salary of DKK
3,083,535, and Dr.&nbsp;Madigan an annualized base salary of $457,019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We use base salaries to recognize the experience, skills, knowledge, and
responsibilities required of all our employees, including our named executive officers. None of our named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled
increases in base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Annual Bonus.</I> Our board of directors may, in its discretion, award annual cash bonuses to our named executive
officers from time to time based on the executive&#8217;s achievement of milestones for the applicable year. Our existing employment arrangements with our named executive officers provide that they will be eligible for annual cash bonuses up to a
specified percentage of their salary (50% for Dr.&nbsp;S&oslash;rensen, 40% for Mr.&nbsp;Behrndt, and 40% for Dr. Madigan), subject to approval by our board of directors. Annual cash bonuses, which are calculated as a percentage of base salary, are
designed to motivate our employees to achieve annual goals based on our strategic, financial and operating performance objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With respect to
2025, our board of directors awarded performance-based cash bonuses of $238,900, DKK 1,085,400 and $170,300 to Dr.&nbsp;S&oslash;rensen, Mr.&nbsp;Behrndt and Dr.&nbsp;Madigan, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Equity Incentives.</I> To further align the interests of our executive officers with the interests of our stockholders and to further focus our
executive officers on our long-term performance, we have historically granted equity compensation in the form of warrants. Warrants operate in a manner similar to options in that the recipient is allowed to exercise the warrant and receive shares
upon exercise, with the exercise price determined by the board of directors in connection with each issuance of warrants at the time of grant. Please see the &#8220;<I>Outstanding Equity Awards at December</I><I></I><I>&nbsp;31, 2025</I>&#8221;
table for further information regarding the outstanding warrants held by our named executive officers as of December&nbsp;31, 2025. In connection with the corporate reorganization, we expect that each outstanding warrant to subscribe for the
purchase of ordinary shares of Hemab ApS will be assumed by us and converted into a warrant to purchase the same number of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>All Other Compensation. </I>We provide an employer-matching contribution on the behalf of our U.S.-based employees under our 401(k) plan of up to
3.5% of their respective eligible compensation as well as payment of insurance premiums on our employees&#8217; behalf. We also provide a pension plan, or the Pension Plan, to all of our employees in Denmark. Contributions to the Pension Plan for
each Denmark-based employee are calculated as a percentage of base salary and paid to an external pension fund. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at December&nbsp;31, 2025 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding all outstanding warrants to subscribe for ordinary shares of Hemab ApS held by each of our named
executive officers as of December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Option Awards</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Number of
securities<BR>underlying<BR>unexercised&nbsp;options&nbsp;(#)<BR>exercisable <BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Number
of<BR>securities<BR>underlying<BR>unexercised&nbsp;options&nbsp;(#)</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>unexercisable <BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Option<BR>exercise<BR>price <BR>($) <BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Option<BR>expiration<BR>date <BR></B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,492</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141.84(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/01/2031</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,451</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.22(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/20/2032</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,677</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,762(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/23/2033</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt, M.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,317</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.22(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/20/2032</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,204</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,911(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/28/2033</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,511(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168.72</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/10/2035</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Of the shares underlying the warrant, 25% vested on March&nbsp;1, 2024, and the remaining shares vest in 36 equal monthly
installments thereafter, subject to the officer&#8217;s continued service through each vesting date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Of the shares underlying the warrant, 25% vested on January&nbsp;1, 2026, and the remaining shares vest in 36 equal
monthly installments thereafter, subject to the officer&#8217;s continued service through each vesting date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Converted from Danish kroner to U.S. dollars using a U.S. dollar/Danish kroner exchange rate of 0.1573 (rounded to 0.16)
as of December&nbsp;31, 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the completion of this offering, we expect to enter into written employment agreements with each of our executive officers. These agreements are
expected to set forth the terms of the executive officer&#8217;s compensation, including base salary, annual discretionary bonus eligibility and severance benefits, among other matters. Our named executive officers are eligible to participate in
company-sponsored benefit programs that are generally available to all of our similarly-situated employees. Under these agreements, each named executive officer is also eligible to receive equity awards at such times and on such terms and conditions
as the board of directors may determine. Furthermore, each of our named executive officers has entered into a standard confidential information and inventions assignment agreement with us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Compensation Plans and Other Benefit Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
connection with this offering, our board of directors expects to adopt, and our current stockholders expect to approve, the 2026 Plan and the 2026 ESPP. Prior to this offering, we granted equity compensation in the form of warrants. Following this
offering, we expect to grant awards to eligible participants from time to time only under the 2026 Plan. In this section, we describe the 2026 Plan and the 2026 ESPP. These summaries of the equity incentive plans are qualified in their entirety by
reference to the actual text of the of plans, which are filed as exhibits to the registration statement of which this prospectus is a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2026 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our board of directors to adopt and that our stockholders will approve the 2026 Plan, to become effective immediately prior to the
effectiveness of the registration statement of which this prospectus forms a part. The 2026 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock
units and other stock-based awards. Upon effectiveness of the 2026 Plan, the number of shares of our common stock that will be reserved for issuance under the 2026 Plan will be the sum of (1)&#8195;&#8195;&#8195;&#8195;; (2)&nbsp;the number of
shares of our common stock subject to warrants that are outstanding as of immediately prior to the effectiveness of the registration statement for the offering and which warrants expire, terminate or are otherwise cancelled without the issuance of
shares of common stock (subject to any limitations under the U.S. Internal Revenue Code of 1986, as amended, or the Code); plus (3)&nbsp;an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending
December&nbsp;31, 2027 and continuing until, and including, the fiscal year ending December&nbsp;31, 2036, equal to the lowest of (i)&#8195;&#8195;&#8195;&#8195;% of the sum of (I)&nbsp;the number of shares of our common stock outstanding on such
date, (II)&nbsp;the number of shares of our common stock issuable upon conversion of any outstanding shares of convertible preferred stock of ours (without giving effect to any restrictions or limitations on conversion) on such date, and
(III)&nbsp;the number of shares of our common stock subject to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or other investment warrants issued by us (without giving effect to any restrictions or limitations on conversion) as of such
date, and (ii)&nbsp;an amount determined by our board of directors. A maximum of&#8195;&#8195;&#8195;&#8195; shares of common stock may be issued pursuant to incentive stock options granted under the 2026 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our employees, officers, directors, consultants and advisors are eligible to receive awards under the 2026 Plan; however, incentive stock options may
only be granted to our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the terms of the 2026 Plan, our board of directors (or a committee delegated by our board of
directors) will administer the 2026 Plan and, subject to any limitations set forth in the 2026 Plan, will select the recipients of awards and determine: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares of our common stock covered by options and the dates upon which the options become exercisable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the type of options to be granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exercise price of options, which price must be at least equal to the fair market value of our common stock on the date
of grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the duration of options, which may not be in excess of ten years; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the methods of payment of the exercise price of options; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares of our common stock subject to and the terms and conditions of any stock appreciation rights, awards
of restricted stock, restricted stock units or other stock-based awards, including conditions for repurchase, measurement price, issue price and repurchase price, if any (though the measurement price of stock appreciation rights must be at least
equal to the fair market value of our common stock on the date of grant and the duration of such awards may not be in excess of ten years) and any performance conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If our board of directors delegates authority to one or more delegated persons to grant awards under the 2026 Plan, the delegated person will have the
power to make awards to all of our employees, except officers and executive officers (as such terms are defined in the 2026 Plan). Our board of directors will fix (i)&nbsp;the maximum number of shares that may be issued (which number shall include,
for the avoidance of doubt, the maximum number of shares issuable upon exercise or settlement of awards), (ii) the time period during which such awards, and during which the shares issuable upon exercise thereof, may be issued, and (iii)&nbsp;the
minimum consideration (if any) for which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
such awards may be issued, and the minimum consideration for the shares issuable upon exercise thereof; provided, however that no delegated person may be authorized to grant awards to itself.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2026 Plan contains limits on the compensation that may be paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The
maximum aggregate amount of cash and value (calculated based on grant date fair value for financial reporting purposes) of awards granted under the plan in any calendar year to any individual <FONT STYLE="white-space:nowrap">non-employee</FONT>
director in his or her capacity as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may not exceed $&#8195;&#8195;&#8195;&#8195;, or in the case of a new director during his or her first year of service, $&#8195;&#8195;&#8195;&#8195;;
provided, however, that fees paid by us on behalf of any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in connection with regulatory compliance, any amounts paid or awards made pursuant to a bona fide consulting agreement for
services other than as a director, any amounts paid to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director as reimbursement of an expense and any financial statement expense associated with the modification of an outstanding award
(whether or not granted under the 2026 Plan) shall not count against the foregoing limit. Our board of directors may make additional exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in
extraordinary circumstances, as the board of directors may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to
award such compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Effect of certain changes in capitalization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, we are required by the 2026 Plan to make equitable
adjustments (or make substitute awards, if applicable), in the manner determined by our board of directors, to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and class of shares available under the 2026 Plan, and the number and class of shares available for issuance
under the 2026 Plan that may be issued as incentive stock options under the Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the share counting rules of the 2026 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number, class, exercise, measurement or purchase price and any other per share related provisions of shares subject to
each outstanding award; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any performance goals applicable to an award. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Effect of certain corporate transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the occurrence
of a merger or other reorganization event (as defined in the 2026 Plan), our board of directors may, on such terms as our board of directors determines (except to the extent specifically provided otherwise in an applicable award agreement or other
agreement between the participant and us), take any one or more of the following actions pursuant to the 2026 Plan as to all or any (or any portion of) outstanding awards, other than awards of restricted stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that outstanding awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring
or succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon written notice to a participant, provide that all of the participant&#8217;s unvested awards will be forfeited
immediately prior to the consummation of such reorganization event and/or vested but unexercised awards will terminate immediately prior to the consummation of such transaction unless exercised, to the extent exercisable, by the participant within a
specified period following the date of such notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award
will lapse, in whole or in part, prior to or upon the reorganization event; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make or provide for a payment in such form (which may include, without limitation, cash, cash equivalents and/or securities
of the acquiring or succeeding corporation (or an affiliate thereof)) to participants with respect to an award held by a participant equal to (1)&nbsp;the number of shares of our common stock subject to the vested portion of the award (after giving
effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (2)&nbsp;the excess, if any, of (i)&nbsp;the amount of cash and/or value, as determined by our board of directors in its
discretion, of any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration per share of common stock to be received by holders of common stock as a result of the reorganization event (referred to as the acquisition price) over (ii)&nbsp;the
exercise, measurement or purchase price of such award and any applicable tax withholdings, in exchange for the termination of such award, <I>provided</I> that any escrow, holdback, earn out or similar provisions in the definitive agreement governing
the reorganization event may, as determined by our board of directors, apply to such payment to the same extent and in the same manner as such provisions apply to holders of our common stock, and <I>provided further</I> that if the acquisition price
does not exceed the exercise price of such award, then the award shall be cancelled without any payment of consideration therefor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that, in connection with our liquidation or dissolution, awards shall convert into the right to receive liquidation
proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In taking any of the foregoing actions, our board of directors is not obligated by the 2026 Plan to treat all awards, all awards held by a participant,
or all awards of the same type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the case of certain restricted stock units, no assumption or substitution is permitted, and the
restricted stock units will instead be settled in accordance with the terms of the applicable restricted stock unit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of
directors may impose a limitation on the ability of participants holding options and/or stock appreciation rights to exercise their awards for the minimum number of days prior to the closing of the reorganization event as is reasonably necessary to
facilitate the orderly closing of the reorganization event. We shall provide reasonable notice to participants of any such limitation on exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the occurrence of a reorganization event other than our liquidation or dissolution, our repurchase and other rights with respect to each
outstanding award of restricted stock will continue for the benefit of the acquiring or succeeding company (or any affiliate thereof) and will, unless our board of directors determines otherwise, apply to the cash, securities, or other property
which our common stock is converted into or exchanged for pursuant to the reorganization event in the same manner and to the same extent as they applied to the common stock subject to the restricted stock award; provided, however, that our board of
directors may provide for the termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement or in any other agreement between a participant and us, either initially or by amendment, or to provide
for forfeiture of such restricted stock if issued at no cost. Upon the occurrence of a reorganization event involving our liquidation or dissolution, except to the extent specifically provided to the contrary in the restricted stock award agreement
or any other agreement between the participant and us, all restrictions and conditions on each outstanding restricted stock award will automatically be deemed terminated or satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors may, at any time, provide that any award under the 2026 Plan will become immediately exercisable in whole or in part, free of
some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Except with respect to certain actions requiring stockholder approval under the Code, or Nasdaq Stock
Market rules, our board of directors may amend, modify or terminate any outstanding award under the 2026 Plan, including but not limited to, substituting for the award another award of the same or a different type, changing the date of exercise or
realization, and converting an incentive stock option to a nonstatutory stock option, subject to certain participant consent requirements. In addition, our board of directors may, without the approval of our stockholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">amend any outstanding stock option or stock appreciation right granted under the 2026 Plan to provide an exercise or
measurement price per share that is lower than the then-current exercise or measurement price per share of such outstanding award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cancel any outstanding stock option or stock appreciation right (whether or not granted under the 2026 Plan) and grant a
new award under the 2026 Plan in substitution for the cancelled award covering the same or a different number of shares of our common stock and having an exercise or measurement price per share lower than the then-current exercise or measurement
price per share of the cancelled award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cancel in exchange for a cash payment any outstanding option or stock appreciation right with an exercise or measurement
price per share above the then-current fair market value of our common stock (valued in the manner determined by (or in the manner approved by) our board of directors); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">take any other action that constitutes a &#8220;repricing&#8221; within the meaning of Nasdaq Stock Market rules or rules
of any other exchange or marketplace on which our common stock is listed or traded. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No award may be granted under the 2026 Plan
on or after the date that is ten years from the effectiveness of the 2026 Plan. Our board of directors may amend, suspend or terminate the 2026 Plan at any time, except that stockholder approval may be required to comply with applicable law or stock
market requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2026 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our board of directors to adopt and that our stockholders will approve the 2026 ESPP, to become effective immediately prior to the
effectiveness of the registration statement of which this prospectus forms a part. The 2026 ESPP will be administered by our board of directors or by a committee appointed by our board of directors. The 2026 ESPP initially provides participating
employees with the opportunity to purchase up to an aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our
common stock reserved for issuance under the 2026 ESPP will automatically increase on the first day of each fiscal year, commencing on January&nbsp;1, 2027 and continuing for each fiscal year until, and including the fiscal year commencing on,
January&nbsp;1, 2036, in an amount equal to the least of (i)&#8195;&#8195;&#8195;&#8195;shares of our common stock, (ii)&#8195;&#8195;&#8195;&#8195;% of the sum of (I)&nbsp;the number of shares of our common stock outstanding on such date,
(II)&nbsp;the number of shares of our common stock issuable upon conversion of any outstanding shares of convertible preferred stock of ours (without giving effect to any restrictions or limitations on conversion) on such date, and (III)&nbsp;the
number of shares of our common stock subject to <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or other investment warrants issued by us as of such date, and (iii)&nbsp;an amount determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the terms of the 2026 ESPP, our board of directors (or a committee delegated by our board of directors) will administer the 2026 ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our employees and employees of any designated subsidiary, as defined in the 2026 ESPP, are
eligible to participate in the 2026 ESPP, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such person is customarily employed by us or a designated subsidiary for more than 20 hours a week and for more than five
months in a calendar year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such person has been employed by us or by a designated subsidiary for at least&#8195;&#8195;&#8195;&#8195;months prior to
the first day of the applicable plan period (as defined in the 2026 ESPP); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such person was our employee or an employee of a designated subsidiary on the first day of the applicable plan period under
the 2026 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We retain the discretion to determine which eligible employees may participate in an offering under applicable
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to make one or more offerings to our eligible employees to purchase stock under the 2026 ESPP beginning at such time and on
such dates as our board of directors may determine, or on the first business day thereafter. Each offering will consist of a&#8195;&#8195;&#8195;&#8195;-month plan period during which payroll deductions will be made and held for the purchase of our
common stock at the end of the plan period. Our board of directors or a committee designated by our board of directors may, at its discretion, choose a different period of not more than twelve months for offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On each offering commencement date, each participant will be granted an option to purchase, on the last business day of the plan period, up to a number
of shares of our common stock determined by multiplying $2,083 by the number of full months in the plan period and dividing that product by the closing price of our common stock on the first day of the plan period. No employee may be granted an
option under the 2026 ESPP that permits the employee&#8217;s rights to purchase shares under the 2026 ESPP and any other employee stock purchase plan of ours or of any of our subsidiaries to accrue at a rate that exceeds $25,000 of the fair market
value of our common stock (determined as of the first day of each plan period) for each calendar year in which the option is outstanding. In addition, no employee may purchase shares of our common stock under the 2026 ESPP that would result in the
employee owning 5% or more of the total combined voting power or value of our stock or the stock of any of our subsidiaries. Our board of directors may, in its discretion, set a fixed maximum number of shares of our common stock that each eligible
employee may purchase per plan period which number may not be greater than the number of shares of our common stock determined by applying the formulas and limitations set forth in the 2026 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On the commencement date of each plan period, each eligible employee may authorize up to a maximum of&#8195;&#8195;&#8195;&#8195;% of his or her
compensation to be deducted by us during the plan period. Each employee who continues to be a participant in the 2026 ESPP on the last business day of the plan period will be deemed to have exercised an option to purchase from us the number of whole
shares of our common stock that his or her accumulated payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the 2026 ESPP, the purchase price will be determined by our board of directors for each plan period, including whether such option
price shall be determined based on the lesser of the closing price of our common stock on (i)&nbsp;the first business day of the plan period or (ii)&nbsp;the exercise date, or shall be based solely on the closing price of the common stock on the
exercise date; provided, however, that such option price will be at least 85% of the applicable closing price of our common stock. If our board of directors does not make a determination of the purchase price, the purchase price will be 85% of the
lesser of the closing price of our common stock on (i)&nbsp;the first business day of the plan period or (ii)&nbsp;the last day of the plan period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An employee may at any time prior to the close of business on the fifteenth business day prior to the
end of the plan period (or such other number of days as is determined by us), and for any reason, permanently withdraw from participating in the offering and permanently withdraw the balance accumulated in the employee&#8217;s account. If an
employee elects to discontinue his or her payroll deductions during a plan period but does not elect to withdraw his or her funds, funds previously deducted will be applied to the purchase of common stock at the end of the plan period. If a
participating employee&#8217;s employment ends before the last business day of a plan period, no additional payroll deductions will be taken and the balance in the employee&#8217;s account will be paid to the employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will be required to make equitable adjustments to the extent determined by our board of directors to the number and class of securities available
under the 2026 ESPP, the share limitations under the 2026 ESPP, and the purchase price for a plan period under the 2026 ESPP to reflect stock splits, reverse stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications
of shares, spin-offs and other similar changes in capitalization or events or any dividends or distributions to holders of our common stock other than ordinary cash dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with a merger or other reorganization event, as defined in the 2026 ESPP, our board of directors or a committee of our board of directors
may take any one or more of the following actions as to outstanding options to purchase shares of our common stock under the 2026 ESPP on such terms as our board of directors or committee thereof determines: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that options will be assumed, or substantially equivalent options will be substituted, by the acquiring or
succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon written notice to employees, provide that all outstanding options will be terminated immediately prior to the
consummation of such reorganization event and that all such outstanding options will become exercisable to the extent of accumulated payroll deductions as of a date specified by board of directors in such notice, which date will not be less than ten
days preceding the effective date of the reorganization event; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon written notice to employees, provide that all outstanding options will be cancelled as of a date prior to the
effective date of the reorganization event and that all accumulated payroll deductions will be returned to participating employees on such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in the event of a reorganization event under the terms of which holders of our common stock will receive upon consummation
thereof a cash payment for each share surrendered in the reorganization event, change the last day of the plan period to be the date of the consummation of the reorganization event and make or provide for a cash payment to each employee equal to
(1)&nbsp;the cash payment for each share surrendered in the reorganization event times the number of shares of our common stock that the employee&#8217;s accumulated payroll deductions as of immediately prior to the reorganization event could
purchase at the applicable purchase price, where the cash payment for each share surrendered in the reorganization event is treated as the fair market value of our common stock on the last day of the applicable plan period for purposes of
determining the purchase price and where the number of shares that could be purchased is subject to the applicable limitations under the 2026 ESPP minus (2)&nbsp;the result of multiplying such number of shares by the purchase price;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that, in connection with our liquidation or dissolution, options will convert into the right to receive liquidation
proceeds (net of the purchase price thereof); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors may at any time, and from time to time, amend or suspend the 2026 ESPP or any portion of the 2026 ESPP. We will obtain
stockholder approval for any amendment if such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approval is required by Section&nbsp;423 of the Code. Further, our board of directors may not make any amendment that would cause the 2026 ESPP to fail to comply with Section&nbsp;423 of the
Code. The 2026 ESPP may be terminated at any time by our board of directors. Upon termination, we will refund all amounts in the accounts of participating employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pension Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We provide the Pension Plan to all of our
employees in Denmark. Contributions for each employee are calculated as a percentage of base salary and paid to an external pension fund. For 2025 and 2026, the base salary contribution percentage was 3.5%. All contributions to the Pension Plan
begin at the time of employment and cease upon termination of employment, with contributions distributed by the pension fund to the participant at retirement. In addition to the Pension Plan, we also maintain a 401(k) Plan for our employees in the
United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>401(k) Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain the Hemab
Therapeutics Inc. 401(k) Plan, a defined contribution employee retirement plan for our eligible employees in the United States. Our 401(k) plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> plan under
Section&nbsp;401(a) of the Code so that contributions to our 401(k) plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the plan. Our 401(k) plan provides that each participant may
contribute up to 100% of his or her eligible compensation, subject to annual statutory limits under the Code. Eligible employees may make both <FONT STYLE="white-space:nowrap">pre-tax</FONT> and Roth elective deferral contributions to the plan, as
well as <FONT STYLE="white-space:nowrap">catch-up</FONT> contributions for participants who are at least 50 years old, in each case, subject to applicable statutory limits under the Code. We may make discretionary employer matching contributions
under the plan, determined annually at our discretion. In addition, the Code imposes a limit on the amount of compensation that may be taken into account for plan purposes, including employer contributions. Each employee is always fully vested in
his or her own contributions. Employer matching contributions vest based on years of service, with participants becoming fully vested after completing two years of service with us. Participants direct the investment of their accounts among
investment options offered under the plan. The plan is intended to comply with Section&nbsp;404(c) of ERISA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Health and Welfare Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans, including medical
and dental benefits, short-term and long-term disability insurance, and life insurance. We believe these benefits are necessary and appropriate to provide a competitive compensation package to our named executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dodd-Frank Compensation Recovery Policy or &#8220;Clawback&#8221; Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to adopt a compensation recovery policy in accordance with Nasdaq Listing Rule 5608, which implements Rule <FONT
STYLE="white-space:nowrap">10D-1</FONT> under the Exchange Act. The policy will provide that, in the event that we are required to prepare an accounting restatement due to our material noncompliance with any financial reporting requirement under
U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement
if the error were corrected in the current period or left uncorrected in the current period, we will attempt to recover, reasonably promptly from each covered executive, any erroneously awarded incentive-based compensation received by our covered
executives during the recovery period under the policy. The policy will be administered by our compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For purposes of this policy, covered executives means any person who served as an executive officer
(as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) at any time during the performance period for the applicable incentive-based compensation. Incentive-based compensation means any compensation that is
granted, earned or vested based wholly or in part upon the attainment of (1)&nbsp;measures that are determined and presented in accordance with the accounting principles used in preparing our financial statements, and any measures that are derived
wholly or in part from such measures, (2)&nbsp;stock price and (3)&nbsp;total shareholder return. Erroneously awarded incentive-based compensation means the amount of incentive-based compensation that was received that exceeds the amount of
incentive-based compensation that otherwise would have been received had it been determined based on the restated amounts, computed without regard to any taxes paid by the covered executives (or by us on their behalf). If the incentive-based
compensation is based on our stock price or total shareholder return and the amount of the erroneously awarded incentive-based compensation is not subject to recalculation directly from the information in an accounting restatement, the amount to be
recovered shall be based on a reasonable estimate by the compensation committee of the effect of the accounting restatement on the stock price or total shareholder return upon which the incentive-based compensation was received. The policy will not
apply to incentive-based compensation received prior to our adoption of the policy or to incentive-based compensation that was received by a covered executive before beginning service as an executive officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitation of Liability and Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated
certificate of incorporation, which will become effective immediately prior to the completion of this offering, limits the personal liability of directors and officers for breach of fiduciary duty to the maximum extent permitted by the Delaware
General Corporation Law, or the DGCL, and provides that no director or officer will have personal liability to us or to our stockholders for monetary damages for a breach of their fiduciary duty of care as a director or officer. However, these
provisions do not eliminate or limit the liability of any of our directors or officers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for any breach of the director&#8217;s or officers&#8217; duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">for any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission, or claim
that occurred or arose prior to such amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal liability of our directors and officers will be
further limited to the greatest extent permitted by the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our restated certificate of incorporation, which will become effective
immediately prior to the completion of this offering, provides that we must indemnify our directors and officers and we must advance expenses, including attorneys&#8217; fees, to our directors and officers in connection with legal proceedings,
subject to very limited exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a general liability insurance policy that covers specified liabilities of our directors and
officers arising out of claims based on acts or omissions in their capacities as directors or officers. In addition, we intend to enter into indemnification agreements with all of our executive officers and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
directors prior to the completion of this offering. These indemnification agreements may require us, among other things, to indemnify each such executive officer or director for some expenses,
including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our executive officers or directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Some of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be insured or
indemnified against specified liabilities incurred in their capacities as members of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for
liabilities arising under the Securities Act, may be permitted to directors, executive officers, or persons controlling us, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore
unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they will
contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer when
entering into the plan, without further direction from the director or officer. It also is possible that the director or officer could amend or terminate the plan when not in possession of material, nonpublic information. In addition, our directors
and executive officers may buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material, nonpublic information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below shows all compensation
to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or</B><br><B>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards</B><br><B>($)(1)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Anderson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Becker, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">J&oslash;rgen S&oslash;berg Petersen, M.D., Ph.D., D.M.Sc., M.B.A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">M&aring;rten Steen, M.D., Ph.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amount reported in the &#8220;Option Awards&#8221; column reflects the aggregate grant date fair value of warrants
granted during 2025 and computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 718. See Note 2 to our financial statements appearing elsewhere in this prospectus regarding
assumptions underlying the valuation of equity awards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">As of December&nbsp;31, 2025, the aggregate number of ordinary shares subject to outstanding warrants for each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director was as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Number&nbsp;of<BR>Ordinary Shares<BR>Underlying<BR>Outstanding<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Anderson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Becker, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">J&oslash;rgen S&oslash;berg Petersen, M.D., Ph.D., D.M.Sc., M.B.A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">M&aring;rten Steen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amounts reported in the &#8220;All Other Compensation&#8221; column represent reimbursements we paid related to
travel expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Reflects fees paid to Dr.&nbsp;Maraganore as the chair of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Reflects fees paid to Ms.&nbsp;Bain as a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Reflects fees paid to Dr.&nbsp;Vaishnaw as a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Steen no longer serves on our board of directors as of November 2025. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, we paid cash fees and granted warrants to subscribe for ordinary shares to certain of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their service on our board of directors. We have reimbursed our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, on an as requested basis, for reasonable travel and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending board of director and committee meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dr.&nbsp;S&oslash;rensen, one of our directors who also serves as our president and chief executive officer, does not receive any additional
compensation for his service as a director. Dr.&nbsp;S&oslash;rensen is one of our named executive officers and, accordingly, the compensation that we pay to Dr.&nbsp;S&oslash;rensen is discussed above under &#8220;&#8212;<I>Summary Compensation
Table</I>&#8221; and &#8220;&#8212;<I>Narrative Disclosure to Summary Compensation Table</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In&#8195;&#8195;&#8195;&#8195;, 2026, our
board of directors approved a director compensation program that will become effective on the effective date of the registration statement of which this prospectus is a part. Under this director compensation program, we will pay our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chair of the board of directors and of each committee will
receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the
director is not serving on our board of directors and no fee under the program will be payable in respect of any period prior to the completion of this offering. The fees paid to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for
service on the board of directors and for service on each committee of the board of directors on which the director is a member are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member<BR>Annual<BR>Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chair<BR>Supplemental<BR>Annual Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also will continue to reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
for reasonable travel and other expenses incurred in connection with attending meetings of our board of directors and any committee of our board of directors on which he or she serves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, under our director compensation program to be effective on the effective date of the registration statement of which this prospectus is a
part, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive, upon his or her initial election or appointment to our board of directors, an option to purchase&#8195;&#8195;&#8195;&#8195;shares of our common stock under the
2026 Plan. Each of these options will vest as to&#8195;% of the shares of our common stock underlying such option at the end of each successive&#8195;&#8195;&#8195;&#8195;period following the grant date until
the&#8195;&#8195;&#8195;&#8195;anniversary of the grant date, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#8217;s continued service as a director. Further, on the date of the first board meeting held after each
annual meeting of stockholders commencing with our&#8195;&#8195;&#8195;&#8195; annual meeting of stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an option to purchase&#8195;&#8195;&#8195;&#8195;shares of
our common stock under the 2026 Plan;<B> </B>provided, however, that for a <FONT STYLE="white-space:nowrap">non-employee</FONT> director who was initially elected to our board of directors within the 12 months preceding the annual meeting of
stockholders, the number of shares subject to such option shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> on a monthly basis for time in service. The foregoing share numbers for initial and annual option grants to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors are subject to adjustment in the event of stock splits, reverse stock splits and other events. Each of these options will vest on the twelve-month anniversary of the date of grant of the award
(or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award). All options issued to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors under our director compensation program will be
issued at exercise prices equal to the fair market value of our common stock on the date of grant, will vest based on continued service, and will become exercisable in full upon specified change in control events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_14"></A>TRANSACTIONS WITH RELATED PERSONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since January&nbsp;1, 2023, we have engaged in the following transactions in which the amounts involved exceeded $120,000 and any of our directors,
executive officers or holders of more than 5% of our voting securities, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements and Transactions with Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series B Preference
Shares Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2023, we issued and sold an aggregate of 442,205 shares of our Series B Preference Shares at a purchase price
of $305.85 per share for aggregate gross proceeds of $135,248,399.25. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate number of shares of our Series B
Preference Shares that were issued to our directors, executive officers and holders of more than 5% of our voting securities and their affiliates in the transaction and the aggregate amount of consideration for such shares: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>Preference&nbsp;Shares<BR>Purchased&nbsp;for&nbsp;Cash&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Cash<BR>Purchase&nbsp;Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,999,944.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Deep Track Capital, LP (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,837.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,999,707.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RA Capital Management, L.P. (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,499,948.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Avoro Ventures Fund L.P. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,718.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">HealthCap VIII, L.P. (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,499,747.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,879.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See &#8220;<I>Principal Stockholders</I>&#8221; for additional information about shares held by these entities.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC is a holder of five percent or more of our capital stock. Dan
Becker, M.D., Ph.D., a member of our board of directors, is the managing director of Access Biotechnology, the biopharmaceutical investing arm of Access Industries Management, LLC, which controls Access Industries Holdings LLC, which directly
controls all of the outstanding voting interest in AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Deep Track Capital, LP are holders of five percent or more of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Novo Holdings A/S, or Novo Holdings, is a holder of five percent or more of our capital stock. J&oslash;rgen
S&oslash;berg Petersen, a member of our board of directors, is employed as a senior partner at Novo Holdings. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with RA Capital Management, L.P. are holders of five percent or more of our capital stock. Laura
Tadvalkar, Ph.D., a member of our board of directors, is a managing director at RA Capital Healthcare Fund, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Avoro Ventures are holders of five percent or more of our capital stock. Uya Chuluunbaatar,
Ph.D., a member of our board of directors, is a partner at Avoro Ventures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">HealthCap VIII, L.P., or HealthCap, is a holder of five percent or more of our capital stock. Novo Holdings is also an
investor in HealthCap. M&aring;rten Steen, M.D., who was a member of our board of directors until his resignation in November 2025, is a managing partner of HealthCap. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">John Maraganore is the chair of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series C Preference Shares Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2025,
we issued and sold an aggregate of 512,991 shares of our Series C Preference Shares at a purchase price of $305.85 per share for aggregate gross proceeds of $156,898,297.35. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate number of shares of our Series C Preference Shares that
were issued to our directors, executive officers and holders of more than 5% of our voting securities and their affiliates in the transaction and the aggregate amount of consideration for such shares: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;C<BR>Preference Shares</B><br><B>Purchased&nbsp;for&nbsp;Cash&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Cash</B><br><B>Purchase&nbsp;Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sofinnova Crossover II SLP (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,999,991.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SMALLCAP World Fund, Inc. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,908.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RA Capital Management, L.P. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,499,902.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,499,819.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Avoro Ventures (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,999,848.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Deep Track Capital, LP (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,499,830.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,765.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,879.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See &#8220;<I>Principal Stockholders</I>&#8221; for additional information about shares held by these entities and
person. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Sofinnova Crossover II SLP, or Sofinnova, is a holder of 5% or more of our capital stock. Joseph Anderson, a member of
our board of directors, is a member of the investment committee of Sofinnova. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">SMALLCAP World Fund, Inc. is a holder of 5% or more of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with RA Capital Management, L.P. are holders of five percent or more of our capital stock. Laura
Tadvalkar, Ph.D., a member of our board of directors, is a managing director at RA Capital Healthcare Fund, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC is a holder of five percent or more of our capital stock. Dan
Becker, M.D., PH.D., a member of our board of directors, and is the managing director of Access Biotechnology, the biopharmaceutical investing arm of Access Industries Management, LLC, which controls Access Industries Holdings LLC, which directly
controls all of the outstanding voting interest in AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Avoro Ventures are holders of five percent or more of our capital stock. Uya Chuluunbaatar,
Ph.D., a member of our board of directors, is a partner at Avoro Ventures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Deep Track Capital, LP are holders of five percent or more of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Novo Holdings A/S is a holder of five percent or more of our capital stock. J&oslash;rgen S&oslash;berg Petersen, a
member of our board of directors, is employed as a senior partner at Novo Holdings A/S. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">John Maraganore is the chair of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Management Rights Letters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the
issuance and sale of our preference shares, we have entered into management rights letters with certain holders of more than 5% of our capital stock and entities with which certain of our directors or officers are affiliated, pursuant to which these
entities are entitled to certain management rights, including, among other things, the right to consult with and advise our management on significant business issues, review our operating plans, examine our books and records and inspect our
facilities. These management rights letters will terminate upon completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Transactions with Novo Holdings and Affiliated Entities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>License Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Novo Holdings is wholly owned by the Novo
Nordisk Foundation and serves as the holding company for the Novo group of companies, including Novo Nordisk A/S, or Novo Nordisk. In November 2019, we entered into a license agreement with Novo Nordisk, pursuant to which Novo Nordisk granted us an
exclusive (even to Novo Nordisk) worldwide and sublicensable license under specified patent rights, and a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified
<FONT STYLE="white-space:nowrap">know-how,</FONT> to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, products containing bispecific IgG antibodies targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding conditions, including hemophilia. For additional information about our license agreement with Novo Nordisk, see &#8220;<I>Business &#8211;
License Agreements &#8211; License Agreement with Novo Nordisk.&#8221;</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preference Shares Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to Novo Holdings purchasing shares of our Series B Preference Shares and Series&nbsp;C Preference Shares, Novo Holdings is also an investor
in HealthCap. HealthCap purchased shares of our Series B Preference Shares in our Series B Preference Shares financing in February 2023. For more information, see &#8220;<I> &#8211; Series B Preference Shares Financing</I>&#8221; and <I>&#8211;
Series C Preference Shares Financing</I>&#8221; above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Agreements with Catalent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2024, Novo Holdings completed its acquisition of Catalent, Inc., including its subsidiary, Catalent Pharma Solutions GmbH, or Catalent. In
December 2023, we entered into an agreement with Catalent related to the development and manufacturing of sutacimig for approximately <FONT STYLE="font-family:Times New Roman">&#128;</FONT>1.27&nbsp;million. Additionally, in April 2025, we entered
into an agreement with Catalent to perform an analytical study related to sutacimig for approximately <FONT STYLE="font-family:Times New Roman">&#128;</FONT>1.18&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Shareholders Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2025, we entered
into a shareholders agreement, or the Shareholders Agreement, with certain holders of our capital stock, including with certain beneficial owners of more than 5% of our capital stock and entities affiliated with certain of our directors. The
Shareholders Agreement, which amended and restated all prior shareholder agreements, provides certain holders of our capital stock with certain information rights, voting rights, registration rights, and preemptive rights. The Shareholders Agreement
is expected to be terminated in connection with the corporate reorganization and we expect to enter into new arrangements that provide such shareholders with substantially similar registration rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Director Affiliations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain of our directors are
affiliated with and, prior to the completion of this offering, have served on our board of directors as representatives of entities which beneficially own or owned 5% or more of our voting securities, as indicated in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Affiliated Stockholder</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Anderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sofinnova Crossover II SLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Becker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Avoro Ventures</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RA Capital Management, L.P.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">J&oslash;rgen S&oslash;berg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each of the directors identified above was elected pursuant to the board composition provisions of the
Shareholders Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we
intend to enter into indemnification agreements with all of our directors and executive officers prior to the completion of this offering. These indemnification agreements may require us, among other things, to indemnify each such director or
executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrant Grants to Directors and Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have
granted warrants to subscribe for ordinary shares to our directors and executive officers as more fully described in the section titled &#8220;<I>Executive Compensation</I>.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the completion of this
offering, we expect to enter into written employment agreements with each of our executive officers. For more information regarding these agreements, see the section titled &#8220;<I>Executive Compensation &#8211; Employment Agreements</I>.&#8221;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors intends to adopt written policies and procedures for the review of any transaction, arrangement or relationship in which our
company is a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees, or 5% stockholders, or their immediate family members, each of whom we refer to as a &#8220;related person,&#8221; has a
direct or indirect material interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a related person proposes to enter into such a transaction, arrangement, or relationship, which we refer
to as a &#8220;related person transaction,&#8221; the related person must report the proposed related person transaction to our chief executive officer or chief financial officer. The policy calls for the proposed related person transaction to be
reviewed and, if deemed appropriate, approved by our audit committee. Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the audit committee
will review, and, in its discretion, may ratify the related person transaction. The policy also permits the chair of the audit committee to review and, if deemed appropriate, approve proposed related person transactions that arise between committee
meetings, subject to ratification by the committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the audit committee after full
disclosure of the related person&#8217;s interest in the transaction. As appropriate for the circumstances, the audit committee will review and consider: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the related person&#8217;s interest in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approximate dollar value of the amount involved in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approximate dollar value of the amount of the related person&#8217;s interest in the transaction without regard to the
amount of any profit or loss; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the transaction was undertaken in the ordinary course of our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated
third party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the purpose, and the potential benefits to us, of the transaction; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any other information regarding the related person transaction or the related person in the context of the proposed
transaction that would be material to investors in light of the circumstances of the particular transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audit committee
may approve or ratify the transaction only if it determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. Our audit committee may impose any conditions on the related person transaction
that it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to the transactions that are excluded by the instructions to the SEC&#8217;s related person transaction
disclosure rule, our board of directors has determined that the following transactions do not create a material direct or indirect interest on behalf of related persons and, therefore, are not related person transactions for purposes of this policy:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interests arising solely from the related person&#8217;s position as an executive officer of another entity, whether or not
the person is also a director of the entity, that is a participant in the transaction where the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity, the related person and his or her
immediate family members are not involved in the negotiation of the terms of the transaction and do not receive any special benefits as a result of the transaction and the amount involved in the transaction is less than the greater of $200,000 or 5%
of the annual gross revenues of the company receiving payment under the transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a transaction that is specifically contemplated by provisions of our restated certificate of incorporation or amended and
restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The policy provides that transactions involving compensation of executive officers shall be reviewed and
approved by our compensation committee in the manner specified in the compensation committee&#8217;s charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We did not have a written policy
regarding the review and approval of related person transactions prior to this offering. Nevertheless, with respect to such transactions, it has been the practice of our board of directors to consider the nature of and business reasons for such
transactions, how the terms of such transactions compared to those which might be obtained from unaffiliated third parties and whether such transactions were otherwise fair to and in the best interests of, or not contrary to, our best interests.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our capital stock as of&#8195;&#8195;&#8195;&#8195;, 2026 by:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our capital stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The column entitled &#8220;Number of Shares Beneficially Owned&#8221; gives effect to the corporate reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The column entitled &#8220;Percentage of Shares Beneficially Owned&#8212;Before Offering&#8221; is based on a total of&#8195;&#8195;&#8195;&#8195;
shares of our common stock outstanding as of&#8195;&#8195;&#8195;&#8195; , 2026, after giving effect to (i)&nbsp;the corporate reorganization and (ii)&nbsp;the automatic conversion of&#8195;&#8195;&#8195;&#8195;shares of our preferred stock into an
aggregate of&#8195;&#8195;&#8195;&#8195; shares of our common stock upon the completion of this offering. The column entitled &#8220;Percentage of Shares Beneficially Owned&#8212;After Offering&#8221; are based on shares of our common stock to be
outstanding after this offering, including the shares of our common stock that we are selling in this offering, but not including any additional shares issuable pursuant to the underwriters&#8217; option to purchase additional shares in this
offering or any additional shares issuable upon exercise of outstanding warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beneficial ownership is determined in accordance with the rules
and regulations of the Securities and Exchange Commission and includes voting or investment power with respect to our securities. Shares of our common stock subject to warrants that are currently exercisable or exercisable within 60 days
after&#8195;&#8195;&#8195;&#8195;, 2026 are considered outstanding and beneficially owned by the person holding the warrants for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage
ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investment power with respect to all of the shares of our common stock beneficially owned by them, subject to community property
laws, where applicable. Except as otherwise set forth below, the address of each beneficial owner is c/o Hemab Therapeutics Holdings, Inc., 101 Main Street Suite 1220, Cambridge, Massachusetts 02142. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RA Capital Management, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AI <FONT STYLE="white-space:nowrap">DEN-MAB</FONT> LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sofinnova Crossover II SLP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Deep Track Capital, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SMALLCAP World Fund, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Healthcap VIII, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Avoro Ventures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mads Behrndt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Catherine Madigan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John Maraganore</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Anderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Becker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Tadvalkar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">J&oslash;rgen S&oslash;berg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">All executive officers and directors as a group (12 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Less than one percent </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the completion of this offering and the completion of the corporate reorganization as described in the &#8220;<I>Corporate</I>
<I>Reorganization</I>&#8221; section of this prospectus, our authorized capital stock will consist of&#8195;&#8195;&#8195;&#8195; shares of common stock, par value $0.0001 per share, and&#8195;&#8195;&#8195;&#8195;shares of preferred stock, par
value $0.0001 per share, all of which preferred stock will be undesignated. The following description of our capital stock and provisions of our restated certificate of incorporation and amended and restated bylaws are summaries only and are
qualified by reference to the restated certificate of incorporation and the amended and restated bylaws that will be in effect immediately prior to the completion of this offering. We will file copies of these documents with the SEC as exhibits to
our registration statement of which this prospectus is a part. The description of the capital stock reflects changes to our capital structure that will be in effect immediately prior to the completion of this offering and gives effect to the
corporate reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, prior to giving effect to the corporate reorganization, we had issued and outstanding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">43,000 ordinary shares held by six stockholders of record; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">23,343 shares of our Seed Preference Shares held by one stockholder of record, convertible into 23,343 ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">225,866 shares of our Series A Preference Shares held by four stockholders of record, convertible into 225,866 ordinary
shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">442,205 shares of our Series B Preference Shares held by twelve stockholders of record, convertible into 442,205 ordinary
shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">512,991 shares of our Series C Preference Shares held by seventeen stockholders of record, convertible into 512,991
ordinary shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, after giving effect to (1)&nbsp;the corporate reorganization and (2)&nbsp;the
automatic conversion of&#8195;&#8195;&#8195;&#8195;shares of our preferred stock into an aggregate of&#8195;&#8195;&#8195;&#8195; shares of our common stock upon the completion of this offering, there would have been&#8195;&#8195;&#8195;&#8195;
shares of our common stock issued and outstanding held by&#8195;&#8195;&#8195;&#8195;stockholders of record and no shares of preferred stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Voting Rights. </I>Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of
stockholders, except on matters relating solely to terms of preferred stock, and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to
vote on the election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Dividends</I>. Dividends may be declared and paid on our common stock from funds lawfully available therefor if, as and
when determined by our board of directors, subject to any preferential dividend or other rights or preferences of any then outstanding shares of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Liquidation, Dissolution and Winding Up</I>. Upon our dissolution, liquidation or winding up, whether voluntary or involuntary, the holders of our
common stock, as such, will be entitled to receive all of our assets available for distribution to our stockholders subject to any preferential liquidation or other rights or preferences of any then outstanding shares of preferred stock that we
designate and issue in the future. Holders of our common stock have no preemptive, subscription, redemption or conversion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred
stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Other Rights. </I>Holders of the common stock have no right to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">convert the stock into any other security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">have the stock redeemed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">purchase additional stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain their proportionate ownership interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Holders of shares of the common stock are not required to make additional capital contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of our restated certificate
of incorporation that will become effective immediately prior to the completion of this offering, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has
the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock. The ability of our
board of directors, without action by the stockholders, to issue shares of preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated
with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings, and other corporate purposes, could have the effect of making it more difficult
for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. These provisions may also have the effect of deferring hostile takeovers or delaying changes in control or
management of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to
holders of shares of common stock. Upon the completion of this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Grants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, warrants for the
subscription for an aggregate of 94,452 ordinary shares at a weighted average subscription price of $124.96, were outstanding. See &#8220;<I>Executive Compensation &#8211;Equity Compensation Plans and Other Benefit Plans</I>&#8221; for additional
information regarding the terms of the outstanding warrants. In connection with the corporate reorganization, we expect each outstanding warrant to subscribe for the purchase of ordinary shares of Hemab ApS will be assumed by us and converted into a
warrant to purchase the same number of shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Delaware Anti-Takeover Law and Certain Charter and Bylaw Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will
be subject to Section&nbsp;203 of the DGCL. Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#8220;business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
combination&#8221; with any &#8220;interested stockholder&#8221; for three years following the date that the person became an interested stockholder, unless either the interested stockholder
attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting
stock in the transaction in which it became an interested stockholder. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more than
10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or
person. The restrictions contained in Section 203 are not applicable to any of our existing stockholders that will own 15% or more of our outstanding voting stock upon the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Staggered Board; Removal of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated
certificate of incorporation and our amended and restated bylaws to be effective immediately prior to the completion of this offering divide our board of directors into three classes with staggered three-year terms. In addition, our restated
certificate of incorporation and our amended and restated bylaws to be effective immediately prior to the completion of this offering provide that, subject to the rights of holders of any series of preferred stock, our directors may be removed only
for cause and only by the affirmative vote of the holders of at least&#8195;&#8195;&#8195;&#8195;% of the voting power of the outstanding shares of our capital stock entitled to vote in the election of directors. Under our restated certificate of
incorporation and our amended and restated bylaws to be effective immediately prior to the completion of this offering, subject to the rights of any holders of any series of preferred stock, any vacancies or newly-creased directorships on our board
of directors, however occurring, shall be filled only by vote of a majority of our directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders. Furthermore, our restated
certificate of incorporation to be effective immediately prior to the completion of this offering provides that subject to the rights of any holders of any series of preferred stock, the number of directors shall be established from time to time by
our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third
party to acquire, or discourage a third party from seeking to acquire, control of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Super-Majority Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a
corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our amended and restated bylaws to be effective immediately prior to
the completion of this offering may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least&#8195;&#8195;&#8195;&#8195;% of the votes that all our stockholders would be entitled to cast
in any annual election of directors. In addition, the affirmative vote of the holders of at least&#8195;&#8195;&#8195;&#8195;% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or
repeal or to adopt any provisions inconsistent with any of the provisions of our restated certificate of incorporation described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated
Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ability of our board of directors, without action by the stockholders, to issue up to&#8195;&#8195;&#8195;&nbsp;shares
of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile
takeovers or delaying changes in control or management of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation will provide that all stockholder actions are required to be taken by a vote of the stockholders at an annual
or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our amended and restated
bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stockholder Action; Special Meeting of Stockholders; Advance
Notice Requirements for Stockholder Proposals and Director Nominations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation and our amended and
restated bylaws to be effective immediately prior to the completion of this offering provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders
may only be taken if it is properly brought before such meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">stockholders may not take action by written consent in lieu of a meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">except as otherwise required by law, special meetings of the stockholders can only be called by our board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws to be effective immediately prior to the completion of this offering establish an advance notice
procedure for stockholder proposals to be brought before an annual or special meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual or special meeting may only
consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the
meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The advance notice provisions in our amended and restated bylaws could have the effect of delaying stockholder actions that are favored by the holders
of a majority of our outstanding voting securities. Moreover, the prohibition on stockholder action by written consent except as noted above could discourage a third party from making a tender offer for our common stock because even if the third
party acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate
of incorporation, which will become effective immediately prior to the completion of this offering, provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we intend to enter into
indemnification agreements with all of our directors and executive officers prior to the completion of this offering. These indemnification agreements may require us, among other things, to indemnify each such director or executive officer for some
expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Exclusive Forum Selection </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of
incorporation to be effective immediately prior to the completion of this offering provides that, unless we consent in writing to the selection of an alternative forum, the Court of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) shall, to the fullest
extent permitted by law, be the sole and exclusive forum for any action asserting an internal corporate claim as defined in Section&nbsp;115 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This choice of forum provision does not apply to claims arising under the Securities Act, the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to
entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation that will become
effective immediately prior to the completion of this offering provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted
by law, be the sole and exclusive forum for the resolution of any claims that are brought by stockholders, when acting in their capacity as stockholders or in our right, and that relate to our business, the conduct of its affairs, or our rights or
powers or pir stockholders, directors or officers, including without limitation claims arising under the Securities Act, the Exchange Act and other applicable claims for which the federal courts have exclusive jurisdiction. While the Delaware courts
have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously
assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no
assurance that the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Shareholders Agreement provides certain holders of our capital stock with certain registration rights. In connection with the corporate
reorganization, we intend to enter into new arrangements with such holders that will provide such holders with substantially similar rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and
Registrar</B><I> </I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Global Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to apply to have our common
stock listed on the Nasdaq Global Market under the symbol &#8220;COAG&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not develop or be
sustained after this offering. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Future sales of substantial amounts of our common stock in
the public market, including shares issued upon exercise of outstanding warrants, or the anticipation of these sales, could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through sales of
equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, we will have outstanding&#8195;&#8195;&#8195;&#8195; shares of our common stock, based on
the&#8195;&#8195;&#8195;&#8195;ordinary shares that were outstanding on December&nbsp;31, 2025, and after giving effect to (i)&nbsp;the corporate reorganization, (ii)&nbsp;the issuance of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this
offering, assuming no exercise by the underwriters of their option to purchase additional shares of our common stock and (iii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate
of&#8195;&#8195;&#8195;&#8195; shares of our common stock upon the completion of this offering. Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless
purchased by our &#8220;affiliates,&#8221; as that term is defined in Rule 144 under the Securities Act, or Rule 144. The remaining&#8195;&#8195;&#8195;&#8195; shares of our common stock will be &#8220;restricted securities&#8221; under Rule 144,
and we expect that substantially all of these restricted securities will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below. These restricted securities may be sold in the public market only upon release or waiver of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement,
which release or waiver may be effected with the consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C. in their sole discretion at any time, and only if registered under the Securities Act or pursuant to an exemption
from registration under the Securities Act, such as the exemptions provided by Rule 144 or Rule 701 under the Securities Act, or Rule 701. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 144, beginning 90 days after the date of this prospectus, any person who is not our affiliate and has held their shares for at
least six months, including the holding period of any prior owner other than one of our affiliates, may sell those shares without restriction, subject to the availability of current public information about us. In addition, under Rule 144, any
person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be
entitled to sell an unlimited number of shares immediately upon the completion of this offering without regard to whether current public information about us is available, subject to the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beginning 90 days after the date of this prospectus, a person who is
our affiliate or who was our affiliate at any time during the preceding three months and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is
entitled to sell a number of shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal
approximately&#8195;&#8195;&#8195;&#8195;shares immediately after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume in our common stock on the Nasdaq Global Market during the four calendar weeks preceding
the date of filing of a Notice of Proposed Sale of Securities Pursuant to Rule 144 with respect to the sale. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales under Rule 144 by our affiliates are also subject to manner of sale provisions and notice
requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon waiver or expiration of the
<FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period described below,approximately &#8195;&#8195;&#8195;&#8195;shares of our common stock will be eligible for sale under Rule 144. We cannot estimate
the number of shares of our common stock that our existing stockholders will elect to sell under Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 701, any of our employees, consultants, or advisors, other than our affiliates, who purchased shares from us in connection with a
qualified compensatory stock plan or other written agreement is eligible to resell these shares 90 days after the date of this prospectus in reliance on Rule 144, but without compliance with the various restrictions, including the availability of
public information about us and holding period and volume limitations, contained in Rule 144. Substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and will become eligible for
sale upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, each of our executive officers and directors and the holders of substantially all of our outstanding equity securities and securities convertible
into or exchangeable for our common stock have agreed that, without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C., we and they will not, subject to limited exceptions, during the period
ending 180 days after the date of this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to
sell, lend or otherwise transfer or dispose of any ordinary shares or preference shares of Hemab ApS, any shares of our common stock, or any options or warrants to purchase any shares of our common stock, or any securities convertible into,
exchangeable for or that represent the right to receive shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">enter into any hedging, swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any demand for or exercise any right with respect to the registration of any such equity securities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make any public announcement of an intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These agreements are subject to certain exceptions, as described in the section of this prospectus titled &#8220;<I>Underwriting</I>.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beginning 180 days after the completion
of this offering, the holders of an aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in
registration statements that we may file for ourselves or other stockholders. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. See &#8220;<I>Description of Capital
Stock&#8212;Registration Rights</I>&#8221; for additional information regarding these registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT>
Registration Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following this offering, we intend to file one or more registration statements on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all of the shares of our common stock subject to outstanding warrants and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reserved for future options and other awards under the 2026 Plan and the 2026 ESPP. See &#8220;<I>Executive Compensation&#8212;Equity Compensation Plans and Other Benefit Plans</I>&#8221; for
additional information regarding these plans. The registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> we intend to file will become effective immediately upon filing. Shares covered by these registration statements will then
be eligible for sale in the public markets, subject to vesting restrictions, any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, and Rule 144 limitations applicable to affiliates. Accordingly, shares of our
common stock registered under these registration statements will be available for sale in the open market, subject to Rule 144 volume limitations applicable to affiliates, and subject to any vesting restrictions and
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements applicable to these shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following is a discussion of material U.S. federal income tax considerations relating to ownership and disposition of shares of our common stock
acquired pursuant to this offering by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder. For purposes of this discussion, the term <FONT STYLE="white-space:nowrap">&#8220;non-U.S.</FONT> holder&#8221; means a beneficial owner (other than a
partnership or other entity or arrangement treated as a pass-through entity) of our common stock that is not, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or
under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust, if (i)&nbsp;a U.S. court is able to exercise primary supervision over the administration of the trust and one or
more U.S. persons has authority to control all substantial decisions of the trust, or (ii)&nbsp;the trust has a valid election in effect to be treated as a U.S. person under applicable U.S. Treasury Regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current
administrative rulings, and judicial decisions, as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could
alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. We have not requested a ruling from the Internal Revenue Service, or the IRS, with respect to statements made and the conclusions
reached in the following summary, and there can be no assurance that the IRS will not challenge one or more of the tax consequences described in this prospectus or that any such challenge would not be sustained by a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion addresses only <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that hold shares of our common stock as a capital asset within
the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s individual circumstances nor does it address the alternative minimum tax, the special tax accounting rules under
Section&nbsp;451(b) of the Code, the Medicare tax on net investment income, or any aspects of U.S. state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes. This discussion also does not consider any specific facts or circumstances
that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">controlled foreign corporations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">passive foreign investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&nbsp;897(1)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons that own, or are deemed to own, more than 5% of our capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security, or other
integrated investment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">certain U.S. expatriates and former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, this discussion does not address the tax treatment of partnerships or persons who hold their common stock through partnerships or other
entities or arrangements that are treated as pass-through entities for U.S. federal income tax purposes. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her, or its own tax advisor
regarding the tax consequences of the purchase, ownership, and disposition of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Prospective investors should consult their own tax advisors regarding the U.S. federal, state, local, and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> income and other tax considerations of acquiring, holding, and disposing of our common stock in light of their particular situations as well as any consequences of any U.S. federal <FONT
STYLE="white-space:nowrap">non-income</FONT> tax laws. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we pay distributions on our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent
paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s investment, up to such holder&#8217;s tax basis in the common stock. Any remaining excess will be treated as capital gain,
subject to the tax treatment described below under the heading &#8220;&#8212;Gain on Disposition of Common Stock.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such
holder&#8217;s country of residence. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder who claims the benefit of an applicable income tax treaty between the United States and such holder&#8217;s country of residence generally will be
required to provide a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) and satisfy applicable certification and
other requirements. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an
appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their own tax advisors regarding their entitlement to benefits under a relevant income tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are
generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder delivers a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected and
satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income is taxed on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code).
Any U.S. effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or
such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Disposition of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussions below under the sections entitled &#8220; - <I>Information Reporting and Backup Withholding</I>&#8221; and &#8220; -
<I>FATCA</I>,&#8221; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on gain realized on a disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a
trade or business in the United States and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United
States; in these cases, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be taxed on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code), and if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, an additional branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty, may also apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien present in the United States for 183
days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable
income tax treaty) on the net gain derived from the disposition, which may be offset by U.S.-source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
has timely filed U.S. federal income tax returns with respect to such losses, if any; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are, or have been at any time during the five-year period preceding such disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s holding period, if shorter), a &#8220;U.S. real property holding corporation,&#8221; unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
generally will be taxed on its net gain derived from the disposition at the U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a corporation is a &#8220;U.S. real property holding
corporation&#8221; if the fair market value of its &#8220;U.S. real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or
business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes. No assurance can be provided that our
common stock will be regularly traded on an established securities market for purposes of the rule described above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and
Backup Withholding </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of
the distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to
establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder will comply with such procedures if it provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or <FONT
STYLE="white-space:nowrap">W-8ECI</FONT> (or other applicable Form <FONT STYLE="white-space:nowrap">W-8)</FONT> or otherwise meets documentary evidence requirements for establishing that it is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder, or otherwise establishes an exemption. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal income tax, as described above under the heading &#8220;&#8212;Distributions,&#8221;
will generally be exempt from U.S. backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Information reporting and backup withholding generally will apply to the proceeds of a
disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions
effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder resides or is incorporated under the provisions of a specific treaty or agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Backup withholding is not an additional tax. Rather, any
amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s U.S. federal
income tax liability, if any, provided that an appropriate claim is timely filed with the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sections 1471 to 1474 of the Code, commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a 30% U.S. federal
withholding tax on dividends on, and gross proceeds from the sale or other disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#8220;foreign financial institution,&#8221; the foreign entity
undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#8220;foreign financial institution,&#8221; the foreign entity identifies certain of its U.S. investors, or
(iii)&nbsp;the foreign entity is otherwise excepted under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Withholding under FATCA generally will apply to payments of dividends on our
common stock. While withholding under FATCA may also apply to payments of gross proceeds from a sale or other disposition of our common stock, under proposed U.S. Treasury Regulations, withholding on payments of gross proceeds is not required.
Although such regulations are not final, applicable withholding agents are permitted to rely on such proposed regulations until final regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If withholding under FATCA is required on any payment related to our common stock, investors not otherwise subject to withholding (or that otherwise
would be entitled to a reduced rate of withholding) on such payment may be required to seek a refund or credit from the IRS. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements
described in this section. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors regarding the possible implications of FATCA on their investment in our common stock and the entities through which they hold
our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>The preceding discussion of material U.S. federal income tax considerations is for prospective investors&#8217; information
only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding, and disposing
of our common stock, including the consequences of any proposed changes in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. are the representatives of the underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the
shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an additional
&#8195;&#8195;&#8195;&#8195; shares from the company to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. The underwriters may exercise that option for 30 days from the date of this
prospectus. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by the company. Such amounts are
shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase&#8195;&#8195;&#8195;&#8195;additional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><U>Paid by the Company </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth
on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&#8195;&#8195;per share from the initial public offering price. After the initial offering of the shares, the
representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company and its officers, directors and holders of substantially all of the company&#8217;s equity securities have agreed with the underwriters,
subject to certain exceptions, not to dispose of or hedge any of their ordinary shares or preference shares of Hemab ApS, any shares of common stock, or any options or warrant to purchase any share of common stock, or any securities convertible
into, exchangeable for or that represent the right to receive shares of common stock (the <FONT STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Securities&#8221;) during the period from the date of such
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement continuing through the date 180&nbsp;days after the date of this prospectus, except with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C.
See the section titled &#8220;<I>Shares Eligible for Future Sale</I>&#8221; for a discussion of certain transfer restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The restrictions described in the immediately preceding paragraph do not apply to our officers,
directors and holders of substantially all of our capital stock and securities convertible into or exchangeable for our common stock with respect to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Transfers of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (i)&nbsp;as one or more bona fide gifts or charitable contributions, or for bona
fide estate planning purposes, (ii)&nbsp;upon death by will, testamentary document or intestate succession, (iii)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a natural person, to any member of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s immediate family or to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the immediate family of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or, if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor, trustee (or <FONT STYLE="white-space:nowrap">co-trustee)</FONT> or beneficiary of the trust or the
estate of a beneficiary of such trust, (iv)&nbsp;to a corporation, partnership, limited liability company or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and the immediate family of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party are the legal and beneficial owner of all of the outstanding equity securities or similar interests, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be
permissible under clauses (a)(i) through (iv)&nbsp;above, (vi) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company,
trust or other business entity that is a subsidiary or an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or immediate family of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity which fund or entity is directly or indirectly controlled or managed by or under common control or common investment management with the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or affiliates of the undersigned, or (B)&nbsp;as part of a disposition, transfer or distribution by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party to its stockholders, partners, members or
other equityholders or to the estate of any such stockholders, partners, members or other equityholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (vii)&nbsp;by operation of law, such as pursuant to a merger, acquisition,
reorganization, qualified domestic order, divorce settlement, divorce decree or separation agreement, (viii)&nbsp;to the company from an employee of the company upon death, disability or termination of employment, in each case, of such employee,
(ix)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is not an officer or director of the company, in connection with a sale of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s shares of common stock acquired
(A)&nbsp;from the underwriters in the Public Offering or (B)&nbsp;in open market transactions after the closing date of this offering, (x)&nbsp;to the company in connection with the vesting, settlement or exercise of restricted stock units, options,
warrants or other rights to purchase shares of common stock or other <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise) that are scheduled to expire or
automatically vest during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, including any transfer to the company for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such
restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all cases pursuant to equity awards granted under a stock incentive plan, other equity award plan or otherwise, or pursuant
to the terms of convertible securities, each as described in the prospectus, provided that any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, or (xi)&nbsp;with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. on behalf of the underwriters; provided that (A)&nbsp;in the case of
clauses (a)(i), (ii), (iii), (iv), (v) and (vi)&nbsp;above, such transfer or distribution shall not involve a disposition for value, (B)&nbsp;in the case of clauses (a)(i), (ii), (iii), (iv), (v), (vi) and (vii)&nbsp;above, it shall be a condition
to the transfer or distribution that the donee, devisee, transferee or distributee, as the case may be, shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the form of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (C)&nbsp;in the case of clauses (a)(ii), (iii), (iv), (v) and (vi)&nbsp;above, no filing by any party (including, without limitation, any donor, donee, devisee, transferor, transferee,
distributor or distributee) under the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall be required or shall be voluntarily
made in connection with such transfer or distribution, and (D)&nbsp;in the case of clauses (a)(i), (vii), (viii), (ix) and (x)&nbsp;above, no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and
if any such filing, report or announcement shall be legally required during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, such filing, report or announcement shall clearly indicate in the footnotes thereto (A)&nbsp;the circumstances of
such transfer or distribution and (B)&nbsp;in the case of a transfer or distribution pursuant to clauses (a)(i) or (vii)&nbsp;above, that the donee, devisee, transferee or distributee has agreed to be bound by a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement containing the same restrictions set forth above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party may (a)&nbsp;enter into a
written plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act relating to the transfer, sale or other disposition of the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities, if then permitted by the company, provided that none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period and no
public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period,
and if any such filing, report or announcement shall be legally required during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, such filing, report or announcement shall clearly indicate that that none of the securities subject to such
plan may be transferred, sold or otherwise disposed of pursuant to such plan until after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period; (b)&nbsp;(i) transfer the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the board of directors of the company and made to all
holders of the company&#8217;s capital stock involving a change of control of the company, in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such
person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the company (or the surviving entity) and (ii)&nbsp;enter into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar
agreement pursuant to which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party may agree to transfer, sell, tender or otherwise dispose of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities in connection with a transaction described
in clause (b)(i) above; provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; (c)&nbsp;convert or exchange outstanding preferred stock or preference shares of the
company into ordinary shares or shares of common stock, provided that any such shares received upon such conversion shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; and (d)&nbsp;transfer the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities or take any other action in connection with the corporate reorganization; provided that any securities converted, transferred pursuant to or otherwise affected by the corporate reorganization
shall remain subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the offering, there has been no public
market for the shares. The initial public offering price has been negotiated among the company and the representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing
market conditions, will be the company&#8217;s historical performance, estimates of the business potential and earnings prospects of the company, an assessment of the company&#8217;s management and the consideration of the above factors in relation
to market valuation of companies in related businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company intends to apply to list the common stock on The Nasdaq Global Market under the
symbol &#8220;COAG.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These
transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the
offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#8220;covered short position&#8221; is a short position that is not greater than the amount of additional shares for which the
underwriters&#8217; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of
shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the
option described above. &#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked
short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for
or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose
a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in
stabilizing or short covering transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the
underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the company&#8217;s stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the
market price of the common stock. As a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these
activities at any time. These transactions may be effected on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company estimates that their share of the total expenses of the offering, including registration, filing and listing fees, printing fees and legal
and accounting expenses, but excluding underwriting discounts and commissions, will be approximately $&#8195;&#8195;. The company has agreed to reimburse the underwriters for certain of their expenses in an amount up to $&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The company has agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and
trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and
services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or
will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and their respective
affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own
account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and/or persons
and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in
respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member State of the European Economic Area (each, a &#8220;Relevant Member&#8221;), no shares have been offered or will be offered
pursuant to the offering to the public in that Relevant Member prior to the publication of a prospectus in relation to the shares which has been approved by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the competent authority in that Relevant Member or, where appropriate, approved in another Relevant Member and notified to the competent authority in that Relevant Member, all in accordance with
the Prospectus Regulation, except that the shares may be offered to the public in that Relevant Member at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#8220;offer to
the public&#8221; in relation to the shares in any Relevant Member means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to
purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the case of any
shares being offered to a financial intermediary as that term is used in Article 5 of the Prospectus Regulation, such financial intermediary will also be deemed to have represented, acknowledged and agreed that the shares acquired by it in the
offering have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any
shares to the public other than their offer or resale in a Relevant Member to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. The company
and the underwriters and their affiliates, and others will rely upon the truth and accuracy of the foregoing representation, acknowledgement and agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No shares have been offered or will be
offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public
in the United Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require the Issuer or Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus
pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares in the United Kingdom means the communication in any form and by any means of
sufficient information on the terms of the offer and any shares to be offered so as to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
enable an investor to decide to purchase or subscribe for any shares and the expression. &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by
virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a
legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be
offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of
Hong Kong) (&#8220;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#8221;) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)
(&#8220;Securities and Futures Ordinance&#8221;), or (ii)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the
document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person
for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong
Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made
thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus has not
been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be
circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as
defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#8220;SFA&#8221;)) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to
Section&nbsp;275(1) of the SFA, or any person pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any
other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned
by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under
Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer in that
corporation&#8217;s securities pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the
SFA or (6)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#8220;Regulation 32&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an
accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that trust
shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in
Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each
transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in
Section&nbsp;276(7) of the SFA or (6)&nbsp;as specified in Regulation 32. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Solely for the purposes of its obligations pursuant to Section&nbsp;309B
of the SFA, the company has determined, and hereby notify all relevant persons (as defined in the CMP Regulations 2018), that the shares are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations 2018) and Excluded
Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment
Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities have not been
and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended) (&#8220;the FIEA&#8221;). The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit
of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident
of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Australia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No placement document, prospectus, product
disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission, in relation to the offering. This offering document does not constitute a prospectus, product disclosure statement or other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
disclosure document under the Corporations Act 2001 (the &#8220;Corporations Act&#8221;), and does not purport to include the information required for a prospectus, product disclosure statement
or other disclosure document under the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any offer in Australia of the shares may only be made to persons (&#8220;Exempt
Investors&#8221;) who are &#8220;sophisticated investors&#8221; (within the meaning of Section&nbsp;708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of Section&nbsp;708(11) of the Corporations Act) or
otherwise pursuant to one or more exemptions contained in Section&nbsp;708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment
under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under Section&nbsp;708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document contains general information only and does not take account of the investment objectives, financial situation or particular needs
of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this offering document is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
(&#8220;DFSA&#8221;). This offering document is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility
for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth in this prospectus and has no responsibility for the offering document. The
securities to which this offering document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand
the contents of this offering document you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document is not intended to constitute an offer or solicitation to purchase or invest in the shares of our common stock. The shares of
common stock may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (&#8220;FinSA&#8221;), and no application has or will be made to admit the shares of common stock to trading on
any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this offering document nor any other offering or marketing material relating to the shares of common stock constitutes a prospectus pursuant to the FinSA, and
neither this offering document nor any other offering or marketing material relating to the shares of common stock may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither this offering document nor any other offering or marketing material relating to the offering, us or the securities have been or will be filed
with or approved by any Swiss regulatory authority. In particular, this offering document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of securities
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#8220;CISA&#8221;). The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Brazil </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The offer and sale of the securities have not
been and will not be registered with the Brazilian Securities Commission (Comiss&atilde;o de Valores Mobili&aacute;rios, or &#8220;CVM&#8221;) and, therefore, will not be carried out by any means that would constitute a public offering in Brazil
under CVM Resolution No 160, dated 13&nbsp;July 2022, as amended (&#8220;CVM Resolution 160&#8221;) or unauthorized distribution under Brazilian laws and regulations. The securities may only be offered to Brazilian professional investors (as defined
by applicable CVM regulation), who may only acquire the securities through a <FONT STYLE="white-space:nowrap">non-Brazilian</FONT> account, with settlement outside Brazil in <FONT STYLE="white-space:nowrap">non-Brazilian</FONT> currency. the trading
of these securities on regulated securities markets in Brazil is prohibited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and Dorr LLP, Boston,
Massachusetts. Goodwin Procter LLP, New York, New York, is acting as counsel for the underwriters in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The consolidated financial statements of Hemab ApS at December&nbsp;31, 2024 and 2025, and for each of the two years in the period ended
December&nbsp;31, 2025, appearing in this prospectus and registration statement, have been audited by EY Godkendt Revisionspartnerselskab, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere
herein, and are included in reliance upon such report given the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
shares of common stock we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement or the exhibits, schedules and amendments to the
registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and schedules to the registration statement. Statements contained in this prospectus about the
contents of any contract, agreement or other document are not necessarily complete, and in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement. Each of these
statements is qualified in all respects by this reference to such contract, agreement or document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The SEC maintains a website, which is located at
www.sec.gov, that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is a part at the SEC&#8217;s
website at www.sec.gov. Upon completion of this offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other information with the SEC. We also
maintain a website at www.hemab.com and upon completion of this offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any amendments to those reports, as soon as reasonably practicable after such material is electronically filed with, or furnished
to, the SEC. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx50309_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Consolidated Financial Statements as of and for the Years Ended December&nbsp;31, 2024 and 2025:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_2">Consolidated Balance Sheets </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_4">Consolidated Statements of Changes in Convertible Preference Shares and Stockholders&#8217;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin50309_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>To the Shareholders and the Board of Directors of Hemab ApS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on
the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have audited the accompanying consolidated balance sheets of Hemab ApS (the Company) as of December 31, 2024 and 2025, the related
consolidated statements of operations and comprehensive loss<B>,</B>&nbsp;convertible preference shares and stockholders&#8217; deficit and cash flows for each of the two years in the period ended December 31, 2025, and the related
notes<B>&nbsp;</B>(collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2024 and 2025, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express
no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ EY Godkendt Revisionspartnerselskab </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#8217;s
auditor since 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Copenhagen, Denmark </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">February 27, 2026 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_2"></A>HEMAB APS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands,
except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Liabilities, convertible preference shares and stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Convertible preference shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series Seed convertible preference shares, DKK 1 par value; 23,343 shares authorized, issued, and outstanding
as of December&nbsp;31, 2024 and December&nbsp;31, 2025; liquidation preference of $2,611 and $2,939 as of December&nbsp;31, 2024 and December&nbsp;31, 2025, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series A convertible preference shares, DKK 1 par value; 225,866 shares authorized, issued, and outstanding
as of December&nbsp;31, 2024 and December&nbsp;31, 2025; liquidation preference of $48,496 and $54,528 as of December&nbsp;31, 2024 and December&nbsp;31, 2025, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series B convertible preference shares, DKK 1 par value; 442,205 shares authorized, issued, and outstanding
as of December&nbsp;31, 2024 and December&nbsp;31, 2025; liquidation preference of $135,248 as of December&nbsp;31, 2024 and December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Series C convertible preference shares, DKK 1 par value; no shares authorized, issued, and outstanding as of
December&nbsp;31, 2024 and 512,991 shares authorized, issued, and outstanding as of December&nbsp;31, 2025; liquidation preference of $0 and $156,898 as of December&nbsp;31, 2024 and December&nbsp;31, 2025, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stockholders&#8217; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Ordinary shares, DKK 1 par value; 43,000 shares authorized, issued, and outstanding as of December&nbsp;31,
2024 and December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities, convertible preference shares and stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_3"></A>HEMAB APS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,132.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,486.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average ordinary shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net unrealized gain (loss) on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_4"></A>HEMAB APS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Changes in Convertible Preference Shares and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands, except share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series Seed<BR>Convertible<BR>Preference<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Convertible<BR>Preference Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Convertible<BR>Preference Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>Convertible</B><br><B>Preference Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(69,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(67,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(117,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(115,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Issuance of Series C convertible preference shares, net of issuance costs of $477</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(181,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(176,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_5"></A>HEMAB APS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in
thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2024&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2025&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion of discount on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-cash</FONT> items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Maturities of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series C convertible preference shares, net of issuance costs of $477</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Principal payments on finance lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effect of&nbsp;foreign exchange&nbsp;rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets obtained
in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin50309_6"></A>HEMAB APS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Description
of Business and Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nature of Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Hemab ApS (the &#8220;Company&#8221;) is a late clinical-stage biotechnology company developing therapies that reimagine the treatment of blood
coagulation disorders to sustain life and human resilience. Based in Denmark and the United States, the Company&#8217;s mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the
millions of patients worldwide suffering from serious bleeding and thrombotic diseases, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause significant
life-long burden to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s lead asset, sutacimig <FONT STYLE="white-space:nowrap">(HMB-001),</FONT> is a bispecific antibody
currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. The Company&#8217;s second clinical-stage asset, <FONT
STYLE="white-space:nowrap">HMB-002,</FONT> is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. The Company is also advancing multiple preclinical and discovery-stage
assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is
subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need
to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s product candidates and programs are in preclinical and clinical development. There can be no assurance that
the Company&#8217;s research and development efforts will be successfully completed, that adequate protection for its intellectual property will be obtained, that any product candidates developed will obtain necessary government regulatory approval
or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates
in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidity and Managements Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since inception, the
Company has devoted substantially all its efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. The Company has financed its operations primarily through private placements
of convertible preference shares and issuance of convertible debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#8217;s continued discovery and development of product candidates
will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate
personnel, infrastructure, and compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has incurred losses since inception and had an accumulated deficit of $181.9&nbsp;million
as of December&nbsp;31, 2025. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as it continues development of its product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had cash and cash equivalents, and marketable securities of $185.5&nbsp;million. The Company believes that its
existing cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Until such a time when the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through a
combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. The company may be unable to raise additional funds or enter into such other agreements or arrangements
when needed, on favorable terms, or at all. The Company&#8217;s failure to raise capital or enter into such agreements or arrangements as, and when needed, could have a material adverse effect on its business, results of operations and financial
condition, including potentially requiring it to delay, limit, reduce or eliminate product development or future commercialization efforts, or grant rights to develop and market current or future development product candidates that the Company would
otherwise prefer to develop and market itself. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The consolidated financial
statements comprise the Company and its wholly-owned subsidiary, Hemab Therapeutics, Inc. All intercompany amounts have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying consolidated
financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative
U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Foreign Currency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial statements are
presented in U.S. dollars, the Company&#8217;s reporting currency. The functional currency of Hemab ApS and Hemab Therapeutics, Inc. is the U.S. dollar. Transaction gains and losses resulting from exchange rate changes on transactions denominated in
currencies other than the U.S. dollar are recognized in other (expense) income, net in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Use
of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it
believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include, but are not limited to, accrued research and development expenses, the fair value of the ordinary shares for equity-based
compensation expense, and the valuation of the Company&#8217;s deferred tax assets. Changes in estimates are recorded in the period in which they become known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s cash as of December&nbsp;31, 2024 and 2025 was held in standard checking accounts maintained by major financial institutions. Cash
equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. As of December&nbsp;31, 2024, the Company had no cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Marketable Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company classifies its
investments in debt instruments as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale.</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> debt securities
are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; deficit until realized. Any premium or discount arising at purchase is amortized and/or accreted to
interest income and/or expense over the life of the instrument. Realized gains and losses are recognized in the income statement, using the specific identification method and are included in other income (expense), net. The Company also reviews its
portfolio <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;available-for-sale&nbsp;debt</FONT></FONT> securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have
resulted from a credit-related loss. If the decline in fair value is due to credit-related factors, a loss is recognized in other income (expense), net. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentrations of Credit Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Financial instruments
that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and marketable securities. The Company&#8217;s investment portfolio is primarily comprised of short term debt securities issued by the
U.S., Danish, and German governments. The Company places its cash in financial institutions that management believes to be of high credit quality and, consequently, the Company does not believe it is subject to unusual credit risk beyond the normal
credit risk associated with commercial banking relationships. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation up to $250,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company follows ASC 820,
<I>Fair Value Measurement</I> (&#8220;ASC 820&#8221;), which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair
value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Accordingly, fair
value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. The fair value hierarchy requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ASC 820 establishes a fair value hierarchy based on three levels of inputs, of which the first two
are considered observable and the last unobservable, that may be used to measure fair value, which are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><B>Level&nbsp;1</B>: Quoted
prices in active markets for identical assets and liabilities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><B>Level&nbsp;2</B>: Inputs other than Level&nbsp;1 that are observable, either
directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full
term of the assets or liabilities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><B>Level&nbsp;3</B>: Unobservable inputs that are supported by little or no market activity and that are
significant to determining the fair value of the assets, including pricing models, discounted cash flow methodologies and similar techniques. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The carrying values of the Company&#8217;s prepaid expenses, accounts payable, and certain accruals
approximate their fair value due to their short-term nature. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment is recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the following
estimated useful lives of the assets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Asset</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Estimated Useful Life</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Three years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Three years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Five years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Shorter&nbsp;period&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;remaining&nbsp;lease&nbsp;term</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain
or loss is included in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to ASC Topic 842, <I>Leases</I>, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when
control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease. The Company has elected not to recognize leases with an original term of one year or less on the
balance sheet. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, lease liabilities and, if applicable, <FONT STYLE="white-space:nowrap">non-current</FONT> operating lease liabilities. Lease liabilities and their
corresponding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and
<FONT STYLE="white-space:nowrap">non-lease</FONT> components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the
Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Impairment of Long-lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Long-lived assets
consist of property and equipment and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets. The Company continually evaluates whether events or circumstances have occurred that indicate that the
estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from
the use or disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. No
impairment losses were recorded during the years ended December&nbsp;31, 2024 and 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development costs are expensed as incurred and include internal and external costs incurred in the development of the Company&#8217;s
product candidates and programs. These costs primarily consist of personnel costs, including equity-based compensation, expenses incurred under agreements with third-party laboratories, contract research organizations (&#8220;CROs&#8221;), contract
manufacturing organizations (&#8220;CMOs&#8221;) and other vendors, facility-related costs, supplies, and consulting costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has
historically met the requirements to receive a tax credit in Denmark for losses resulting from research and development costs. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations
and comprehensive loss. For each of the years ended December&nbsp;31, 2024 and 2025, research and development expenses include refundable tax credits of $0.8&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accrued Research and Development Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Substantial
portions of the Company&#8217;s preclinical studies and clinical trials are performed by CROs, CMOs and other vendors. These vendors generally bill monthly or quarterly for services performed. For studies and trials, the Company accrues expenses
based upon estimated percentage of work completed by each vendor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s estimates depend on the timeliness and accuracy of the data
provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the
Company&#8217;s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the vendors, they are recorded
as prepaid expenses and are recognized as expense when the activities are performed by the vendors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Costs to secure, defend and maintain patents are expensed as incurred, and are classified as general and administrative expenses due to the uncertainty
of future benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Preference Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company records all convertible preference shares at their respective fair values on the dates of issuance, net of tranche assets and liabilities and
associated issuance costs, if applicable. The Company has classified its convertible preference shares as temporary equity in the consolidated balance sheets due to terms that allow for redemption of the shares upon certain events that are outside
of the Company&#8217;s control. The carrying value of the convertible preference shares is not adjusted to the redemption value until the contingent redemption events are considered probable of occurring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company issues
equity-based awards to employees, managers, executives, and <FONT STYLE="white-space:nowrap">non-employees</FONT> in the form of warrants. The Company accounts for equity-based compensation awards in accordance with ASC 718,
<I>Compensation&#8212;Stock Compensation</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the Company&#8217;s ordinary shares issued was determined by management, considering
third-party valuations and an assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company estimates the fair value of its warrants using the Black-Scholes option pricing model, which uses as inputs certain management estimates,
including the fair value of the Company&#8217;s ordinary shares, the expected stock price volatility, the expected term of the award, the risk-free rate, and expected dividends. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The fair value of the Company&#8217;s ordinary shares issued was determined by management, considering third-party
valuations and an assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. The independent third-party valuations
were prepared in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies
for which historical information is available. The Company selects companies with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards. The Company computes the historical
volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period that approximates the calculated expected term of the warrants. The Company will continue to apply this method until a sufficient
amount of historical information regarding the volatility of its stock price becomes available. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The risk-free interest rate is based on the U.S. Treasury, or applicable government issues denominated in the currency of
the applicable underlying share, yield curve in effect at the time of grant commensurate with the expected term assumption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The expected term is determined by the simplified method for service-based awards, under which the expected term is
presumed to be the midpoint between the vesting date and the end of the contractual term. For awards with service-based and performance-based conditions, the expected term is determined based on the expected period to vest and the contractual term.
The Company utilizes these methods due to a lack of historical exercise data. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on ordinary
shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company generally issues equity awards that are subject to service-based vesting conditions and in limited instances,
service-based and performance-based vesting conditions. Compensation expense for awards issued to grantees with service-based vesting conditions are recognized on a straight-line basis based on the grant date fair value over the associated requisite
service period of the award, which is generally the vesting term. Compensation expense for awards to grantees with service-based and performance-based vesting conditions are recognized based on the grant-date fair value over the requisite service
period using the accelerated attribution method to the extent achievement of the performance condition is probable. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not
recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company evaluates whether an
equity award should be classified and accounted for as a liability award or equity award for all equity-based compensation awards granted. As of December&nbsp;31, 2024 and 2025, all of the Company&#8217;s equity-based awards were equity classified.
Forfeitures are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
recognized as they occur. The Company classifies equity-based compensation expense in the consolidated statements of operations and comprehensive loss in the same manner in which the award
recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income
Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deferred income tax assets and liabilities arise from temporary differences between the financial statements and tax basis of assets
and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or <FONT STYLE="white-space:nowrap">non-current,</FONT> depending
upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or <FONT STYLE="white-space:nowrap">non-current</FONT> depending on the
periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company follows the provisions of ASC <FONT STYLE="white-space:nowrap">740-10,</FONT> <I>Uncertainty in Income Taxes</I> (&#8220;ASC <FONT
STYLE="white-space:nowrap">740-10&#8221;).</FONT> The Company has not recognized a liability related to ASC <FONT STYLE="white-space:nowrap">740-10.</FONT> A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been
provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties related to ASC <FONT STYLE="white-space:nowrap">740-10.</FONT> If there were an unrecognized tax benefit, the
Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company
has identified Denmark as its major tax jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Basic net loss per share is calculated by dividing basic net loss by the weighted average number of ordinary shares outstanding for the period. Diluted
net loss per share is calculated by dividing diluted net loss by the weighted average number of ordinary shares outstanding for the period, including potentially dilutive ordinary shares. For purpose of this calculation, outstanding warrants to
purchase ordinary shares and convertible preference shares are considered potentially dilutive ordinary shares. The Company has generated a net loss in all periods presented, and therefore basic and diluted net loss per share is the same, as the
inclusion of the potentially dilutive securities would be anti-dilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has one operating segment and one reporting unit. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is a committee that
includes its Chief Executive Officer and Chief Financial Officer. The CODM manages the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Comprehensive loss includes net
loss as well as other changes in stockholders&#8217; deficit that result from transactions and events other than those with stockholders. The Company&#8217;s unrealized gains and losses on <FONT STYLE="white-space:nowrap">available-for</FONT>
sale-debt securities represent the only component of other comprehensive income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an
&#8220;emerging growth company&#8221; can take advantage of an extended transition period for complying with new or revised accounting standards. The Company has elected not to &#8220;opt out&#8221; of such extended transition period, which means
that when a standard is issued or revised and it has different application dates for public or private companies, the Company can adopt the new or revised standard at the time private companies adopt the new or revised standard and may do so until
such time that the Company either (1)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2)&nbsp;no longer qualify as an emerging growth company. As a result, these consolidated financial statements may not be
comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting
Standards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment Reporting (Topic 280):
Improvements to Reportable Segment Disclosures</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2023-07&#8221;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> improved reportable segment disclosure requirements, primarily through
enhanced disclosures about significant segment expenses. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> also enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit
or loss, provided new segment disclosure requirements for entities with a single reportable segment and contained other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the
financial statements. The guidance is effective in the annual periods beginning after December&nbsp;15, 2023, and interim periods in fiscal years beginning after December&nbsp;15, 2024, with early adoption permitted. The Company adopted ASU <FONT
STYLE="white-space:nowrap">2023-07</FONT> effective December&nbsp;31, 2024. For additional information, refer to Note 15. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Issued Accounting
Standards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements
to Income Tax Disclosures</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2023-09&#8221;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> will require disclosure of additional information in specified categories with respect to the
reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> will also require information pertaining to taxes paid (net of
refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT>
will be effective for the Company in the annual periods beginning after December&nbsp;15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently
assessing the impact adoption of ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> will have on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03,</FONT> <I>Income Statement&#8212;Reporting Comprehensive
Income&#8212;Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of Income Statement Expenses</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2024-03&#8221;).</FONT> ASU <FONT
STYLE="white-space:nowrap">2024-03</FONT> will require disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis, including purchases of inventory, employee compensation, depreciation,
intangible asset amortization and depletion for each income statement line item that contains those expenses. ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> also will require certain amounts already disclosed under existing U.S. GAAP to also be
disclosed as a separate category in disaggregated expense table(s), if those amounts are recognized in the relevant expense line item. The amendments in ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> will be effective for the Company in annual
reporting periods beginning after December&nbsp;15, 2026, and interim reporting periods within annual reporting periods beginning after December&nbsp;15, 2027. The Company is currently assessing the impact adoption of ASU <FONT
STYLE="white-space:nowrap">2024-03</FONT> will have on its consolidated financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2025, the FASB issued ASU <FONT STYLE="white-space:nowrap">2025-06,</FONT>
<I>Intangibles&#8212;Goodwill and <FONT STYLE="white-space:nowrap">Other&#8212;Internal-Use</FONT> Software (Subtopic <FONT STYLE="white-space:nowrap">350-40):</FONT> Targeted Improvements to the Accounting for
<FONT STYLE="white-space:nowrap">Internal-Use</FONT> Software</I> (&#8220;ASU <FONT STYLE="white-space:nowrap">2025-06&#8221;).</FONT> ASU <FONT STYLE="white-space:nowrap">2025-06</FONT> eliminates accounting considerations of software project
development stages and clarifies the threshold applied to begin capitalizing costs. ASU <FONT STYLE="white-space:nowrap">2025-06</FONT> will now require entities to capitalize costs associated with
<FONT STYLE="white-space:nowrap">internal-use</FONT> software only when management has authorized and committed funding, and it is probable that the project will be completed and the software will be used to perform its intended function. The
guidance is effective for fiscal years beginning after December&nbsp;15, 2027 and interim periods within those fiscal years. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. The Company is currently
assessing the impact adoption of ASU <FONT STYLE="white-space:nowrap">2025-06</FONT> will have on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables present
information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of December&nbsp;31, 2024 and 2025 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s cash equivalents and marketable securities were valued based on Level&nbsp;2 inputs and in
determining the fair value the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-For-Sale</FONT></FONT> Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale&nbsp;debt</FONT></FONT> securities consisted of the following as of
December&nbsp;31, 2024 and 2025 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Marketable securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of the Company&#8217;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as of December&nbsp;31, 2024 and 2025 had a contractual maturity of less than 12 months. The Company did not realize any gains or
losses recognized on the sale of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities during the years ended December&nbsp;31, 2024 and 2025, and, as a result, the Company did not
reclassify any amounts out of accumulated comprehensive loss. All of the Company&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as of December&nbsp;31, 2024 and 2025 are
classified as current as they mature within one year from the balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024, the Company held two securities in
an unrealized loss position with an aggregate fair value of $9.9&nbsp;million. As of December&nbsp;31, 2025, the Company held three securities in an unrealized loss position with an aggregate fair value of $97.5&nbsp;million. None of the securities
were in an unrealized loss position for greater than 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has the intent and ability to hold its debt securities until recovery
of their amortized cost bases, which may be maturity. As a result, the Company did not recognize any differences between the fair value and amortized cost basis as a loss in its consolidated statements of operations and comprehensive loss for the
years ended December&nbsp;31, 2024 and 2025. The Company did not record any credit-related impairments for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities for the years ended
December&nbsp;31, 2024 and 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment, net, consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment, at cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024 and 2025, property and equipment, net included finance leased assets of
approximately $0.5&nbsp;million, with accumulated depreciation of approximately $0.2&nbsp;million and $0.3&nbsp;million, respectively. Depreciation expense for each of the years ended December&nbsp;31, 2024 and 2025 was approximately
$0.2&nbsp;million and $0.3&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued employee compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued contract research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License and Collaboration Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is
party to certain agreements that may require future payments upon the achievement of specified development, regulatory, and commercial milestones, as well as royalty payments. These potential obligations are not recorded as liabilities until the
underlying milestone event is deemed probable of occurrence and the related amount is reasonably estimable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Agreement with Novo Nordisk
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2019, the Company entered into a license agreement with Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), pursuant to which Novo
Nordisk granted the Company an exclusive (even as to Novo Nordisk), worldwide and sublicensable license under specified patent rights, and a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide and sublicensable license under specified
know-how, to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, products (&#8220;Novo Licensed Products&#8221;), containing bispecific IgG antibodies targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII, including sutacimig, for the treatment of bleeding conditions, including hemophilia (the &#8220;Novo Nordisk Agreement&#8221;). Under the terms of the Novo Nordisk Agreement, the Company has
agreed to use commercially reasonable efforts to develop and commercialize a Novo Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is obligated to pay to Novo Nordisk
a <FONT STYLE="white-space:nowrap">one-time</FONT> DKK 40&nbsp;million milestone payment upon achievement by a Novo Licensed Product of a specified regulatory milestone event, and the Company is also obligated to pay Novo Nordisk tiered royalties,
in the low single-digit percentages, on aggregate annual net sales of all Novo Licensed Products, on a Novo Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Novo</FONT></FONT> Licensed Product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the later of the expiration of the last valid claim in the licensed patents under the Novo Nordisk Agreement covering such Novo Licensed
Product in such country and ten years following the first commercial sale of such Novo Licensed Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Novo Nordisk Agreement
will continue in force until it is terminated. On expiration of each royalty term, the Company&#8217;s license becomes royalty-free, perpetual, and irrevocable with respect to the applicable Novo Licensed Product in the applicable country. Either
party may terminate the Novo Nordisk Agreement for the other party&#8217;s uncured material breach or insolvency. The Company may terminate the Novo Nordisk Agreement for any reason upon 90 days&#8217; written notice to Novo Nordisk. In the event
that Novo Nordisk regains control of the exclusive right to exploit the Novo Licensed Product, the Novo Nordisk Agreement will automatically terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I>Agreement with Genmab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2020, the Company entered into a license agreement with Genmab A/S (&#8220;Genmab&#8221;), pursuant to which Genmab granted the Company an
exclusive (even as to Genmab and its affiliates), worldwide and sublicensable license under platform technology patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to Genmab&#8217;s proprietary DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform to research, develop, make, have made, use, manufacture, import, export and commercialize products comprising bispecific IgG antibodies targeting
<FONT STYLE="white-space:nowrap">TLT-1</FONT> and Factor VII (the &#8220;TLT-1/Factor VII Antibody Products&#8221;), including sutacimig, for the treatment of bleeding conditions, including hemophilia (the &#8220;Genmab Agreement&#8221;). Under the
terms of the Genmab Agreement, the Company has agreed to use commercially reasonable efforts to develop, manufacture, obtain regulatory approval for and commercialize TLT-1/Factor VII Antibody Products worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Genmab Agreement, the Company is obligated to pay Genmab a percentage of all net profit (i.e., revenue and other proceeds less specified
direct costs the Company incurs to conduct research, development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products) the Company or its affiliates receive with respect to any <FONT
STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including (1)&nbsp;net profit from commercial sales of <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products and any revenue from third parties, other than
Novo Nordisk, in respect of a sublicense or assignment with respect to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including assignment fees, sublicensing fees, upfront and milestone fees, royalties and other
consideration, whether in kind or cash, and (2)&nbsp;the net profit allocated to <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products that the Company or its affiliates receive if the Company undergoes a change of control
(other than an acquisition by Novo Nordisk). The percentage of net profit the Company owes with respect to each TLT-1/Factor VII Antibody Product is in the low teens from the effective date of the Genmab Agreement until the first commercial sale of
such TLT-1/Factor VII Antibody Product. From and after the first commercial sale of a TLT-1/Factor VII Antibody Product, the percentage of net profit the Company owes with respect to such TLT-1/Factor VII Antibody Product is in the high single
digits in all territories in which the Company commercializes such TLT-1/Factor VII Antibody Product and in the mid-teens in all territories in which a third party, other than Novo Nordisk, commercializes such
<FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product. The Company is obligated to pay such percentage of net profit on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT
STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-TLT-1/Factor</FONT></FONT></FONT> VII Antibody Product basis until the later of
the expiration of the last-to-expire of the platform technology patent rights licensed under the Genmab Agreement covering such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country and twelve years following the
first commercial sale of such <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Product in such country, which the Company refers to as the net profit share term. Following the expiration of the last-to-expire of the platform
technology patent rights licensed under the Genmab Agreement covering a given TLT-1/Factor VII Antibody Product in a given country, the percentage of net profit that the Company is obligated to pay with respect to sales of such TLT-1/Factor VII
Antibody Product in such country will be reduced by a specified percentage for the remainder of the net profit share term for such TLT-1/Factor VII Antibody Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event the Company seeks to sell, license or otherwise dispose of its rights to TLT-1/Factor VII Antibody Products, including through a change of
control to any third party other than Novo Nordisk, the Company is obligated to provide Genmab the right to participate in any bidding process as a <I>bona fide</I> potential acquirer of such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless earlier terminated, the Genmab Agreement will expire, on a TLT-1/Factor VII Antibody Product-by-TLT-1/Factor VII Antibody Product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon the expiration of the last net profit share term for such TLT-1/Factor VII Antibody Product in such country. On expiration of each net profit
share term, the Company&#8217;s license becomes perpetual, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to the applicable TLT-1/Factor VII Antibody Product in the
applicable country. Either party may terminate the Genmab Agreement for the other party&#8217;s uncured material breach or insolvency or in certain events of force majeure. Genmab may terminate the Genmab Agreement if the Company or its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
affiliates or sublicensees challenge any of the platform technology patent rights licensed under the Genmab Agreement. The Company may terminate the Genmab Agreement for any reason upon 120 days
written notice to Genmab. If Novo Nordisk obtains from us the exclusive right to exploit <FONT STYLE="white-space:nowrap">TLT-1/Factor</FONT> VII Antibody Products, including upon termination of the Novo Nordisk Agreement, then the Genmab Agreement
will terminate in all territories in which Novo Nordisk obtains such exclusive rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other
parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company,
among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification
agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities
related to such obligations as of December&nbsp;31, 2024 and 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal
proceedings during the years ended December&nbsp;31, 2024 and 2025 and, to the best of its knowledge, no material legal proceedings are currently pending or threatened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Finance Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2023, the Company entered into a finance lease for certain laboratory equipment in Copenhagen, Denmark. The laboratory equipment was
classified as a finance lease due to the existence of a bargain purchase option in the lease agreement. In connection with this lease, the Company recorded a finance lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and finance lease liability of approximately $0.5&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2023, the Company
entered into a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease for office space in Cambridge, Massachusetts. The lease requires the Company to pay annual base rent of approximately $0.4&nbsp;million, which is subject to a 2%
annual increase over the term of the lease. The lease expires in October 2026 and contains a <FONT STYLE="white-space:nowrap">two-year</FONT> renewal option exercisable by the Company. The renewal option is not reasonably certain to be exercised by
the Company and as such, the additional term is not included in the measurement of the lease. In connection with the signing of the lease, the Company is required to maintain a cash deposit of $0.2&nbsp;million which is classified in other <FONT
STYLE="white-space:nowrap">non-current</FONT> assets as of December&nbsp;31, 2024 and 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2024, the Company entered into a <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> operating sublease for office and laboratory space in Copenhagen, Denmark. The lease requires the Company to pay annual base rent of approximately $0.3&nbsp;million, which is subject to a 3% annual
increase over the term of the lease. The lease expires in February 2029 and contains a <FONT STYLE="white-space:nowrap">one-year</FONT> renewal option exercisable by the Company. The renewal option is not reasonably certain to be exercised by the
Company and as such, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
additional term is not included in the measurement of the lease. In connection with the signing of the lease, the Company is required to maintain a cash deposit of $0.2&nbsp;million which is
classified in other <FONT STYLE="white-space:nowrap">non-current</FONT> assets as of December&nbsp;31, 2024 and 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities are recorded within the consolidated balance sheets as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheet<BR>Classifications</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets,
operating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets,
finance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, operating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, finance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-current:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, operating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, finance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The components of lease costs for the years ended December&nbsp;31, 2024 and 2025 were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance lease costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization of finance lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense on finance lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Variable lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short-term lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Variable lease costs include payments for the Company&#8217;s proportionate share of facilities operating expenses under
its operating leases. Such amounts are not included in the measurement of lease liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Supplemental disclosure of cash flow information
related to the leases was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating cash flows used in operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating cash flows used in finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing cash flows used in finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The weighted-average remaining lease terms and discount rates were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because the interest rate implicit in the lease was not readily determinable, the Company&#8217;s estimated incremental
borrowing rate was used to calculate the present value of the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the future minimum lease payments due under the <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> leases was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Finance&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: amounts representing interest or imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Convertible Preference Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series Seed Convertible Preference Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November
2020, the Company executed an investment agreement under which it issued and sold 23,343 shares of Series Seed convertible preference shares (&#8220;Series Seed Convertible Preference Shares&#8221;) for gross cash proceeds of <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>2.5&nbsp;million ($3.0 million). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series A Convertible Preference Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2021, the Company executed an investment agreement (&#8220;Series A Investment Agreement&#8221;) to issue and sell up to 225,866 shares of Series
A convertible preference shares (&#8220;Series A Convertible Preference Shares&#8221;) for gross proceeds of up to DKK 346.4&nbsp;million ($50.9 million). In the initial closing in July 2021, the Company issued 61,600 shares of Series A Convertible
Preference Shares. This included DKK 57.2&nbsp;million in gross cash proceeds (37,297 shares) and DKK 37.3&nbsp;million from the conversion of the principal and interest balance of debt (24,303 shares). Pursuant to the Series A Investment Agreement,
the Company was obligated to issue and the investors were obligated to purchase an additional 164,266 shares of Series A Convertible Preference Shares for total cash proceeds of DKK 251.9&nbsp;million in three separate closings upon the satisfaction
of certain conditions related to clinical development. All of the conditions were achieved prior to February 2023. The Company incurred DKK 1.8&nbsp;million of issuance costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series B Convertible Preference Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2023, the Company executed an investment agreement under which it issued and sold 442,205 shares of Series B convertible preference shares
(&#8220;Series B Convertible Preference Shares&#8221;) for gross cash proceeds of $135.2&nbsp;million. The Company incurred $0.3&nbsp;million of issuance costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series C Convertible Preference Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October
2025, the Company executed an investment agreement under which it issued and sold 512,991 shares of Series C convertible preference shares (&#8220;Series C Convertible Preference Shares&#8221;) for gross cash proceeds of $156.9&nbsp;million. The
Company incurred $0.5&nbsp;million of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024 and 2025, the convertible preference shares consisted of the
following (in thousands, except share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>Shares<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">203,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preference<BR>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>Shares<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">349,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The rights, preferences, and privileges of the convertible preference shares were as follows as of December&nbsp;31,
2025: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidity Preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company liquidity
events (&#8220;Liquidity Events&#8221;) under its articles of association include: (i)&nbsp;the sale, or other transfer of shares, involving all or part of the shares in which shares from more than one share class are transferred, and which
represents more than 20% of the share capital, or by payment for an option to subsequently purchase shares from the shareholders as a whole, (ii)&nbsp;listing of the Company&#8217;s shares on an alternative or regulated market, (iii)&nbsp;payment of
dividends, (iv)&nbsp;reduction of the share capital for distribution to shareholders, (v)&nbsp;liquidation or other dissolution of the Company, (vi)&nbsp;a merger whereby the Company is dissolved, (vii)&nbsp;a demerger of the Company, or
(viii)&nbsp;a combination of Liquidity Events as well as any other situations leading to allocation of proceeds and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
any other consideration among the shareholders. In the case of a Liquidity Event, the proceeds, if any, shall be distributed to the shareholders in accordance with the following priority: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">First, the holders of Series C Convertible Preference Shares shall, for every Series C Convertible Preference Share of
DKK 1, receive in advance the part of the proceeds or other consideration equal to the subscription price paid for the Series C Convertible Preference Share (as adjusted for any stock splits, combinations, and, to the extent relevant, capital
reductions or capital increases or any other similar actions); if the available proceeds are insufficient to make payment in full on the Series C Convertible Preference Shares, then the available proceeds shall be allocated pro rata amongst the
holders in proportion to their holdings of Series C Convertible Preference Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Second, the holders of Series A and/or Series B Convertible Preference Shares shall, for every Series A and/or Series B
Convertible Preference Share of DKK 1, receive in advance the part of the proceeds or other consideration equal to the applicable subscription price paid for the Series A and/or Series B Convertible Preference Shares (as adjusted for any stock
splits, combinations, and, to the extent relevant, capital reductions or capital increases or any other similar actions); if the available proceeds are insufficient to make payment in full on the Series A and/or Series B Convertible Preference
Shares, then the available proceeds shall be allocated pro rata amongst the holders in proportion to their holdings of Series A and/or Series B Convertible Preference Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Third, the holders of Series Seed Convertible Preference Shares shall, for every Series Seed Convertible Preference Share
of DKK 1, receive in advance the part of the proceeds or other consideration equal to the subscription price paid for the Series Seed Convertible Preference Share (as adjusted for any stock splits, combinations, and, to the extent relevant, capital
reductions or capital increases or any other similar actions); if the available proceeds are insufficient to make payment in full on the Series Seed Convertible Preference Shares, then the available proceeds shall be allocated pro rata amongst the
holders in proportion to their holdings of Series Seed Convertible Preference Shares (together with clauses (i)&nbsp;and (ii) above, the &#8220;Liquidity Preference&#8221;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The remaining proceeds, if any, following distribution of the Liquidity Preference shall be distributed to the ordinary shares on a pro rata basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a Liquidity Event will result in all holders of convertible preference shares receiving a higher amount of proceeds by allocating such proceeds pro
rata to all shares in the Company compared to applying the Liquidity Preference, the Liquidity Preference shall not apply, and the convertible preference shares shall automatically convert into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (adjusted for any stock splits, combinations, and to the extent relevant, capital reductions or capital increases or any other similar actions), following which the total proceeds shall be
allocated pro rata to all shares in the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The convertible preference shares are convertible at the option of the holder at any time on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (adjusted for any stock splits, combinations, and to the extent relevant, capital reductions or capital increases or any other similar actions). In addition, the convertible preference
shares will be automatically converted into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (adjusted for any stock splits, combinations, and to the extent relevant, capital
reductions or capital increases or any other similar actions)&nbsp;(i) in the event that 50% of all Preference Shares voting as one share class, including 60% of the Series C Convertible Preference Shares (the &#8220;Investor Majority&#8221;),
consents to such conversion, or (ii)&nbsp;in the event of a public offering which generates gross proceeds of not less than $100&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of convertible preference shares are entitled to one vote per share on all matters to be voted upon at all general meetings and written
actions in lieu of meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
convertible preference shares are not subject to mandatory redemption. Upon certain events that are outside of the Company&#8217;s control, the convertible preference shares are contingently redeemable at a price equal to the greater of the
Liquidity Preference or the amount that would be received on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2024 and 2025, the Company had 43,000 ordinary shares authorized, issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of ordinary shares are entitled to an allocation and distribution of proceeds in a Liquidity Event subject to the Liquidity Preference. When
the Liquidity Preference has been paid in full, any remaining proceeds shall be distributed to the ordinary shares on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders
of ordinary shares are entitled to one vote per share on all matters to be voted upon at all general meetings and written actions in lieu of meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12.
Equity-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
December&nbsp;31, 2025, the Company is authorized to award up to 237,601 warrants. Each vested warrant will entitle the warrant holder the right to subscribe for one ordinary share. Holders of stock warrants are entitled to exercise the vested
portion of the warrant. The service-based warrant grants generally vest over a four-year service period, with the first 25% vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting start date and the remaining
vesting in equal monthly installments over the following 36 months. The service-based and performance-based warrant grants vest in the same manner as the service-based only awards to the extent the performance condition is met. The Company&#8217;s
warrants expire ten years after the initial grant date if they remain unexercised. Upon the exercise date, the Company issues new ordinary shares to the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the Company had 142,085 warrants available for future grant. No warrants were exercised during the years ended
December&nbsp;31, 2024 or 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following assumptions were used in determining the fair value of warrants granted during the periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">89.2%&nbsp;-&nbsp;90.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">89.5%&nbsp;-&nbsp;89.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9% - 4.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2% - 4.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7 - 6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes the Company&#8217;s warrants for the years ended December&nbsp;31, 2024
and 2025: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>&#8195;Warrants&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price<BR>per&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>remaining<BR>contractual term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>intrinsic value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested and expected to vest, December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The weighted-average grant date fair value of the warrants granted during the years ended December&nbsp;31, 2024 and
2025 was $117.06 and $129.76, respectively. The total fair value of the warrants that vested during the years ended December&nbsp;31, 2024 and 2025 was $2.4&nbsp;million and $1.8&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Performance-Based Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During 2022, the Company
issued warrants to certain employees that included two components: (i)&nbsp;a performance condition that is achieved upon the separate closings of the Series A Convertible Preferred Shares, and (ii)&nbsp;a service condition where the employee
provides service over a four-year period. Upon the final closing of the Series A Convertible Preferred Shares in January 2023, all performance conditions had been satisfied and the warrants were subject to ongoing service conditions. Equity-based
compensation expense is recognized using an accelerated attribution method over the remaining requisite service period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2025, the total unrecognized compensation expense related to the Company&#8217;s warrants was
$3.1&nbsp;million, which the Company expects to recognize over a weighted-average period of approximately 2.1 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is subject to taxation in the United States and Denmark. The Company had income tax expense of $0.2&nbsp;million and income tax benefit of
$0.2&nbsp;million for the years ended December&nbsp;31, 2024 and 2025, respectively. The Company&#8217;s effective tax rate differs from the statutory rate each year mainly due to a valuation allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s loss before income tax expense for income taxes for the years ended December&nbsp;31, 2024 and 2025 consisted of the following (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Reconciliation of Effective Tax Rate </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#8217;s effective tax rate for the years ended December&nbsp;31, 2024 and 2025 is different from the statutory rate in Denmark primarily due
to the valuation allowance against deferred tax assets as a result of insufficient sources of income. The reconciliation of the statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax benefit at the statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Permanent adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Deferred Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the
tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
deferred tax assets will not be realized. The principal components of the Company&#8217;s deferred tax assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development tax credits&#8212;Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development tax credits&#8212;State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation/fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it
is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is
calculated as the largest amount that is more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When realization of a deferred tax asset is more likely than not to occur, the benefit
related to the deductible temporary differences attributable to operations is recognized as a reduction of income tax expense. Valuation allowances are provided against deferred tax assets when, based on all available evidence, it is considered more
likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. The Company cannot be certain that future income in Denmark will be sufficient to realize the Company&#8217;s deferred tax assets.
Accordingly, a full valuation allowance has been provided only against the net deferred tax assets of Hemab ApS. The valuation allowance increased by $15.0&nbsp;million in 2025. The increase in 2025 is primarily the result of an increase in net
operating loss carryforwards (&#8220;NOLs&#8221;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Available Carryforward Tax Losses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2025, the Company had NOL carryforwards of approximately $170.9&nbsp;million that can be carried forward indefinitely according to
Danish Tax Authority regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Uncertain Tax Positions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company determines its uncertain tax positions based on whether and how much of a tax benefit taken by the Company in its tax filings is more likely
than not to be sustained upon examination by the relevant income tax authorities. The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by the Danish Tax Authority. As of
December&nbsp;31, 2024 and 2025, the Company has not recorded an uncertain tax position liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Tax filings in Denmark remain subject to
examination by the Danish Tax Authority. As of December&nbsp;31, 2025, tax years 2022 and forward were generally open to examination by the Danish Tax Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Tax Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company recognizes accrued interest related to unrecognized tax benefits and penalties as income tax expense. The Company does not have any material
unrecognized tax benefits which would affect the effective tax rate if recognized. The Company does not have any unrecognized tax benefits which would reverse within the next twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is eligible for the Danish enhanced research and development tax allowance, providing for an increase in the deductible value of the amount
of certain R&amp;D expenditures. The deduction for R&amp;D expenditures is set at 108% for 2023 through 2025, 114% for 2026, 116% for 2027 and 120% for 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in 2013 the Folketinget, or Danish Parliament, introduced a tax credit policy that allows companies with losses resulting from research and
development costs to receive payment of the tax base of losses of up to DKK 25&nbsp;million. The Company has historically met the requirements to receive payment. The tax credit is reported as a reduction to research and development expense in the
consolidated statements of operations and comprehensive loss. For the years ended December&nbsp;31, 2024 and 2025, the Company applied for refundable tax credit of DKK 25&nbsp;million for each year and a receivable was recorded for
$0.8&nbsp;million. Starting in 2027, the limit will increase to DKK 35&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the outstanding ordinary share equivalents, presented based on amounts outstanding at each period end, that were excluded
from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preference shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. Segment Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
Company has one operating segment. The Company&#8217;s operating segment is engaged in the research and development of prophylactic therapeutics for bleeding disorders. The Company&#8217;s Chief Executive Officer and Chief Financial Officer/General
Manager are together considered the Company&#8217;s CODM and together manage the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources based on net loss that also is reported on the
consolidated statement of operations as consolidated net loss. This financial metric is used by the CODM to make key operating decisions such as the allocation of capital between program expenses, early-stage discovery expenses, and general and
administrative expense, including headcount and facilities decisions. The measure of segment assets is reported on the balance sheet as total consolidated assets. The following table presents long-lived assets by geographic location as of
December&nbsp;31, 2024 and 2025 (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">United States of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denmark</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table presents selected financial information about the Company&#8217;s single operating
segment for the years ended December&nbsp;31, 2024 and 2025 (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2024&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2025&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating Expenses<SUP STYLE="font-size:75%; vertical-align:top">(a)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development costs&#8212;sutacimig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External research and development <FONT STYLE="white-space:nowrap">costs&#8212;HMB-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External&#8212;discovery related costs and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (excluding equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External&#8212;general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other segment (income) expenses<SUP STYLE="font-size:75%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Consolidated net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The significant expense categories and amounts align with the segment-level information that is regularly provided to the
CODM. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Other segment expenses include foreign currency exchange loss and other income/expense. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has evaluated subsequent
events through February 27, 2026, which is the date the financial statements were available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;&#8195;Shares </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50309g62g77.jpg" ALT="LOGO" STYLE="width:1.76267in;height:0.348971in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Preliminary Prospectus </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:140pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I></I></B><I></I><B><I>J</I></B><I></I><B><I>oint Book-Running Managers</I></B><I></I><B><I> </I></B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Manager </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-size:10pt"><B>Wedbush PacGrow</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Until&#8195;&#8195;&#8195;&#8195;, 2026 (25 days after the date of this prospectus), all dealers that effect
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#8217; obligation to deliver a prospectus when acting as underwriters
and with respect to their unsold allotments or subscriptions. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&#8195;&#8195;&#8195;, 2026 </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;13.
Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the expenses to be incurred in connection with the offering
described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by the registrant. All amounts are estimates except the SEC registration fee, the Financial Industry Regulatory Authority, Inc.
filing fee and the Nasdaq Global Market initial listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$&#8195;&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financial Industry Regulatory Authority, Inc. filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq Global Market initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer agent and registrar&#8217;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">* To be filed by amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;14.
Indemnification of Directors and Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;102(b)(7) of the DGCL provides, generally, that a corporation may include in its
certificate of incorporation a provision eliminating or limiting the personal liability of a director or officer to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such
provision may not eliminate or limit the liability of (i)&nbsp;a director or officer for any breach of the director&#8217;s or officer&#8217;s duty of loyalty to the corporation or its shareholders, (ii)&nbsp;a director or officer for acts or
omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;a director under section 174 of the DGCL, (iv)&nbsp;a director or officer for any transaction from which the director or officer derived an
improper personal benefit or (v)&nbsp;an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such
provision became effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who
was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer,
employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a
manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may
similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and
in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a
court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem
proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation that will be effective immediately prior to the completion
of this offering provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other
than an action by or in the right of us), by reason of the fact that he or she is or was, or has agreed to become, our director or officer or, while our director or officer, is or was serving, or has agreed to serve, at our request as a director,
officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employment benefit plan) (all such persons being referred to as an
&#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted by an Indemnitee in such capacity, against all expenses (including attorneys&#8217; fees), liabilities, losses judgments, fines (including excise taxes and
penalties arising under the Employee Retirement Income Security Act of 1974), and amounts paid in settlement actually and reasonably incurred on or on behalf of the Indemnitee in connection with such action, suit or proceeding and any appeal
therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his
or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our restated certificate of incorporation that will be effective immediately prior to the completion of this offering
also provides that we will indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of us to procure a judgment in our favor by reason of the fact
that the Indemnitee is or was, or has agreed to become, our director or officer or, while our director or officer, is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee, or trustee of, or in a similar
capacity with, another corporation, partnership, joint venture, trust, or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted by he or she in such capacity, against all expenses
(including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of the Indemnitee in connection with such action, suit or proceeding, and any appeal therefrom, if the
Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have
been adjudged to be liable to us, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon applications that, despite the adjudication of such liability but in
view of all the circumstances of the case, he or she is fairly and reasonably entitled to indemnify for expenses (including attorney&#8217;s fees) which the Court of Chancery of Delaware or such other court shall deem proper. Notwithstanding the
foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#8217; fees) actually and reasonably incurred by him or her or on his or her
behalf in connection therewith. If we do not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
addition, we intend to enter into indemnification agreements with all of our executive officers and directors prior to the completion of this offering. In general, these agreements provide that we will indemnify the executive officer or director to
the fullest extent permitted by law for claims arising in his or her capacity as an executive officer or director of our company or in connection with his or her service at our request for another corporation or entity. The indemnification
agreements also provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or
omissions in their capacities as directors or officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for
indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Exchange Act in connection with such offering. Insofar as the foregoing provisions permit indemnification of
directors, executive officers or persons controlling us for liability arising under the Securities Act we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Set forth below is information regarding ordinary shares, preference shares and equity securities granted by us within the past three years that were not
registered under the Securities Act. Also included is the consideration, if any, received by us for such shares and warrants and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration
was claimed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(a) Issuances of Share Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On
February&nbsp;15, 2023, Hemab ApS issued and sold 442,205 shares of its Series B Preference Shares to twelve investors at a price per share of $305.85 in cash, for an aggregate purchase price of $135,248,399.25. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On October&nbsp;23, 2025, Hemab ApS issued and sold 512,991 shares of its Series C Preference Shares to seventeen investors at a price per share of
$305.85 in cash, for an aggregate purchase price of $156,898,297.35. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The
securities described in this section (a)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and, in certain
cases, Regulation D thereunder relative to transactions by an issuer not involving any public offering, or pursuant to Regulation S thereunder in that offers, sales and issuances were not made to persons in the United States and no directed selling
efforts were made in the United States, to the extent an exemption from such registration was required. All purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made
pursuant to a registration statement or an available exemption from such registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(b) Equity Grants and Exercises </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From March&nbsp;28, 2023 to December&nbsp;14, 2023, Hemab ApS granted to certain of its employees, directors, advisors and consultants warrants to
subscribe for an aggregate of 44,056 ordinary shares at an exercise price of $155.50. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From May&nbsp;13, 2024 to October&nbsp;21, 2024, Hemab ApS
granted to certain of its employees, directors, advisors and consultants warrants to subscribe for an aggregate of 7,968 ordinary shares at an exercise price of $153.28. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From February&nbsp;11, 2025 to June&nbsp;19, 2025, Hemab ApS granted to certain of its employees, directors, advisors and consultants warrants to
subscribe for an aggregate of 13,781 ordinary shares at an exercise price of $168.72. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From January&nbsp;4, 2026 to February&nbsp;16, 2026, Hemab
ApS granted to certain of its employees, directors, advisors and consultants warrants to subscribe for an aggregate of 104,309 ordinary shares at an exercise price of $131.98. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities described in this section (b)&nbsp;of Item 15 were issued pursuant to written
compensatory plans or arrangements with our employees, directors, advisors, and consultants, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act,
relative to transactions by an issuer not involving any public offering, or pursuant to Regulation S thereunder in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United
States, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about our company or had access, through employment
or other relationships, to such information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(a) <B><I>Exhibits</I></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;2.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Share Contribution and Exchange Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation of the Registrant, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws of the Registrant, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Certificate of Incorporation of the Registrant (to be effective immediately prior to the completion of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of the Registrant (to be effective immediately prior to the completion of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Stock Certificate evidencing the shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Investors&#8217; Rights Agreement, to be in effect upon the completion of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2026 Equity Incentive Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Agreements under 2026 Equity Incentive Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2026 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex104.htm">License Agreement, dated November 22, 2019, by and between Novo Nordisk A/S and the Registrant (formerly, Ebumab Hemophilia ApS), as amended by Amendment Agreement to License Agreement, dated March&nbsp;
26, 2020, by and between Novo Nordisk A/S and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d50309dex105.htm">DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License Agreement, dated April&nbsp;1, 2020, by and between Genmab A/S and the Registrant (formerly, Ebumab Hemophilia ApS) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between the Registrant and Benny S&oslash;rensen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between the Registrant and Mads Behrndt</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between the Registrant and Catherine Madigan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Wilmer Cutler Pickering Hale and Door (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">107*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Filing Fee Table</P></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B>(b) </B><B><I>Financial Statement Schedules</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the
related notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B>(c) </B><B><I>Filing Fee Table</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The information required to be furnished by paragraph (c)&nbsp;of this Item is incorporated herein by reference to Exhibit 107. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&#8201;17. Undertakings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(a) Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(b) The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:ARIAL">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of
the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:ARIAL">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this&#8195;&#8195;&#8195;&#8195;day of&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Hemab Therapeutics Holdings, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Benny S&oslash;rensen, M.D., Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><I>President and Chief
Executive Officer</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, the undersigned officers and directors of Hemab Therapeutics Holdings, Inc., hereby severally constitute and appoint Benny S&oslash;rensen and Mads
Behrndt, and each of them singly (with full power to each of them to act alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and
resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and any other registration
statement for the same offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in
and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and
agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the
requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Benny
S&oslash;rensen, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">President and Chief Executive Officer, Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Mads Behrndt,
M.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(<I>Principal Financial and Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">John Maraganore,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Chair of the Board </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Joseph Anderson,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Linda Bain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Dan Becker, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Uya Chuluunbaatar,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Laura Tadvalkar,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Akshay Vaishnaw,
M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">J&oslash;rgen
S&oslash;berg Petersen, M.D., Ph.D., D.M.Sc., M.B.A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain portions of this exhibit have been omitted because they are not material and is the type of information that the registrant treats as
private or confidential. Double asterisks denote omissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">for BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novo Nordisk
A/S </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ebumab
Hemophilia ApS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effective Date </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>22 November 2019 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This LICENSE AGREEMENT (this &#8220;<B>Agreement</B>&#8221;)<B> </B>is entered into as of 22&nbsp;November 2019 (the &#8220;Effective Date&#8221;) by and
between Novo Nordisk A/S, a Danish corporation, CVR No.&nbsp;24256790, with address at Novo All&eacute;, <FONT STYLE="white-space:nowrap">DK-2880</FONT> Bagsv&aelig;rd, Denmark (&#8220;<B>Novo Nordisk</B>&#8221;),<B> </B>and Ebumab Hemophilia ApS, a
Danish corporation, CVR No.40837590, with address at Ole Maal&oslash;es Vej 3, <FONT STYLE="white-space:nowrap">DK-2200</FONT> Copenhagen N, Denmark (&#8220;<B>Licensee</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk and Licensee are sometimes referred to herein individually as a &#8220;<B>Party</B>&#8221;<B> </B>and collectively as the
&#8220;<B>Parties</B>&#8221;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>in 2017, Novo Nordisk and Genmab A/S have entered into a License and Option Agreement (the
&#8220;<B>LOA</B>&#8221;),<B> </B>granting Novo Nordisk a license under Genmab&#8217;s proprietary technology relating to bispecific antibodies for targeting proteins involved in various diseases (the &#8220;<B>DuoBody</B><B><SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP></B><B> Platform Technology</B>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>with use of the
DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology, Novo Nordisk has conducted a research project (&#8220;<B>Project</B>&#8221;),<B> </B>resulting in certain patents,
<FONT STYLE="white-space:nowrap">know-how</FONT> and materials (&#8220;<B>Novo Technology</B>&#8221;)<B> </B>with regard to the therapeutic approach and the concept of a bispecific human IgGl antibody targeting
<FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of haemophilia A; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Novo Nordisk
discontinued the Project in June 2018 due to strategical changes of resource prioritisation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Johan Faber was
employed as a research scientist and department manager at Novo Nordisk and was involved in the Project; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>upon
termination of his employment at Novo Nordisk, Johan Faber incorporated Ebumab Hemophilia ApS (Licensee); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Licensee
desires to obtain from Novo Nordisk a commercial license under the Novo Technology for the further validation and engineering of, and to make, use, distribute and sell a bispecific antibody drug targeting
<FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of bleeding conditions, including haemophilia (&#8220;<B>Products</B>&#8221;). To be able to share the Novo Technology with EH, or with any other Third Party, Novo Nordisk
requires the express written authorization from Genmab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Genmab has granted Licensee a preliminary license under
the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology to allow for further research of the Novo Technology (the &#8220;<B>Research Evaluation Agreement</B>&#8220;<B> </B>and Genmab has, in a side letter to the
LOA, authorized Novo Nordisk the right to, simultaneously and under certain restrictions, grant Licensee a commercial license under the Novo Technology; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Novo Nordisk now wishes to grant Licensee such commercial license in accordance with the terms and conditions of this
agreement (this &#8220;<B>Agreement</B>&#8221;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>,<B> </B>in consideration of the premises and the mutual promises and covenants
contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1. DEFINITIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to particular
Exhibits, Articles and Sections shall mean the Exhibits to and Articles and Sections of this Agreement, unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following
meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Affiliate</B>&#8221;<B> </B>means, with respect to any Person, any other Person which controls, is controlled by or is under common
control with such Person, for as long as such control exists. For purposes of this Section, &#8220;control&#8221; shall mean the direct or indirect ownership of more than fifty percent (50%) of the voting or economic interest of a Person, or the
power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of a Person. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease
to have any rights, including license and sublicense rights, under this Agreement by reason of being an Affiliate of such Party. For purposes of this definition Novo A/S and the Novo Foundation and their affiliates (other than Novo Nordisk and its
subsidiaries) are not considered Affiliates of Novo Nordisk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Audited Party</B>&#8221;<B> </B>shall have the meaning set forth in
Section&nbsp;3.7 (Records and Audits). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Auditor</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;3.7 (Records and Audits).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT></B>&#8221;<B> </B>shall mean an IgG antibody with two (2)&nbsp;different binding arms,
targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Confidential Information</B>&#8221;<B> </B>shall have the meaning set forth
in Section&nbsp;8.1.1 (Confidential Information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Control</B>&#8221;<B> </B>or &#8220;<B>Controlled</B>&#8221;<B> </B>means, with respect to
any <FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials, Patent Right, or other intellectual property right, the possession (whether by ownership or license) by a Party or its Affiliate of the ability to grant to the other Party a license or
access as provided herein to such <FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials, Patent Right, or other intellectual property right, without violating the terms of any agreement or other arrangement with any Third Party in existence as
of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license or access. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Cover</B>&#8221;<B>
</B>means a Valid Claim of a Patent Right that would (absent a license thereunder or ownership thereof) be Infringed by the Exploitation of the Product; provided, however, that in determining whether a Valid Claim that is a claim of a pending
application would be Infringed, such claim shall be treated as if issued as then currently being prosecuted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Disclosing Party</B>&#8221;<B>
</B>shall have the meaning set forth in Section&nbsp;8.1.1 (Confidential Information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>EMA</B>&#8221;<B> </B>means the European Medicines
Agency or any successor entity thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Exploit</B>&#8221;<B> </B>means to research, develop, make, have made, use, offer for sale, sell,
import, export or otherwise exploit, or transfer possession of or title in, a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>FDA</B>&#8221;<B> </B>means the United States Food and
Drug Administration or any successor entity thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>First Commercial Sale</B>&#8221;<B> </B>means, with respect to any Product in any country,
the first sale for end use or consumption of such Product in such country after Marketing Approval has been granted in such country. Sales for clinical studies, compassionate use, named patient programs, sales under the treatment IND, any <FONT
STYLE="white-space:nowrap">non-registrational</FONT> studies, or any similar instance where the Product is sold at cost or supplied without charge such as clinical supplies, free samples (promotional or otherwise) or as donations (for example to <FONT
STYLE="white-space:nowrap">non-profit</FONT> institutions or government agencies for a <FONT STYLE="white-space:nowrap">non-commercial</FONT> purpose) shall not constitute a First Commercial Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>FVII</B>&#8221;<B> </B>means the coagulation factor VII protein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>GAAP</B>&#8221;<B> </B>means the enacted Generally Accepted Accounting Principles, consistently applied. Unless otherwise defined or stated herein,
financial terms shall be calculated under GAAP, or under IFRS if in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Genmab</B>&#8221;<B> </B>means Genmab A/S, a Danish company, with
principal offices located at Kalvebod Brygge 43, <FONT STYLE="white-space:nowrap">DK-1560</FONT> Copenhagen V, Denmark, CVR no. 2102 3884. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Gcnmab-Licensee CLA</B>&#8221;<B> </B>means the license agreement for commercial use by Licensee of the DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology for the development and commercialization of bispecific antibody drug directed at <FONT STYLE="white-space:nowrap">TLT-l/FVII.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Governmental Authority</B>&#8221;<B> </B>means any court, agency, department, authority or other instrumentality of any national, state, county,
city or other political subdivision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>IFRS</B>&#8221;<B> </B>means the enacted International Financial Reporting Standards, consistently
applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Infringe</B>&#8221;<B> </B>or &#8220;<B>Infringement</B>&#8221;<B> </B>means any infringement as determined by Law, including, without
limitation, direct infringement, contributory infringement or any inducement to infringe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Initiation</B>&#8221;<B> </B>means, with respect to a
clinical trial, the first dosing in the first human subject in such clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#8221;<B> </B>means techniques, technology, inventions (whether patentable or not), methods, <FONT
STYLE="white-space:nowrap">know-how,</FONT> data and results (including pharmacological, toxicological and clinical data and results), analytical and quality control data and results, and other similar information, in any tangible or intangible form
whatsoever, that is not in the public domain or otherwise publicly known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Law</B>&#8221;<B> </B>means, individually and collectively, any and
all laws, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>License</B>&#8221;<B> </B>means the license granted by Novo Nordisk to Licensee as defined in Section&nbsp;2.1.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Licensed Field</B>&#8221;<B> </B>means the treatment of bleeding conditions, including
haemophilia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Licensee Indemnified Parties</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;7.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Licensee Patents</B>&#8221;<B> </B>means any Patent Right that (a)&nbsp;is Controlled by Licensee during the Term of this Agreement and
(b)&nbsp;claims an invention that is developed by Licensee, its Affiliates or Sublicensees during the Exploitation of the Product(s) and incorporates, is derived from, or relied on, the Novo Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>LOA</B>&#8221;<B> </B>means the License and Option Agreement, with effective date 22&nbsp;December 2017, between Novo Nordisk and Genmab A/S for the
use by Novo Nordisk of Genmab&#8217;s proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Losses</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;7.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Marketing Approval</B>&#8221;<B> </B>means all approvals, licenses, registrations or authorizations of the Regulatory Authority in a country,
necessary for the manufacture, use, storage, import, marketing and sale of a Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Materials</B>&#8221;<B> </B>means those
samples and/or materials that are part of the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> and listed in Exhibit B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Milestone
Event</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;3.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Milestone Payment</B>&#8221;<B> </B>shall have the meaning set
forth in Section&nbsp;3.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Net Sales</B>&#8221;<B> </B>means, [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo Indemnified Parties</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;7.1.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#8221;<B> </B>means the materials and <FONT STYLE="white-space:nowrap">Know-How</FONT>
relating to the therapeutic approach and the format of Bi Ab <FONT STYLE="white-space:nowrap">FVII/TLT-1,</FONT> as existing on the Effective Date, Controlled by Novo Nordisk and either generated as a result of, or applied in, the Project, as listed
in <U>Exhibit B</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo Patents</B>&#8221;<B> </B>means the Patent Rights listed in <U>Exhibit A</U>, and any additions, divisions,
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> substitutions, and reissues claiming priority thereto, as well as any <FONT STYLE="white-space:nowrap">re-examinations,</FONT>
extensions, registrations, patent term extensions, supplemental protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Novo Technology</B>&#8221;<B> </B>means the Novo Patents and Novo <FONT STYLE="white-space:nowrap">Know-How,</FONT> Controlled by Novo Nordisk at
the Effective Date of the Agreement. For clarity, Novo Technology does not include the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology as licensed by Novo Nordisk from Genmab and used by Novo during the Project.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Patent Rights</B>&#8221;<B> </B>means any provisional and <FONT STYLE="white-space:nowrap">non-provisional</FONT> patents and patent
applications, together with all additions, divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> substitutions, and reissues claiming priority thereto, as well as any <FONT
STYLE="white-space:nowrap">re-examinations,</FONT> extensions, registrations, patent term extensions, supplemental protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Person</B>&#8221;<B> </B>means any corporation, limited or general partnership, limited liability
company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Phase 2 Clinical Trial</B>&#8221;<B> </B>means any human clinical trial of a Product that would satisfy the requirements of 21 CFR &#167; 312.21(b)
(as amended or any replacement thereof), or its <FONT STYLE="white-space:nowrap">non-United</FONT> States equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Product</B>&#8221;<B>
</B>means any product, containing BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1,</FONT> which (i)&nbsp;is Covered by a Valid Claim of the Novo Patents, or (ii)&nbsp;incorporates, is derived from, or is developed using, or relied on, the Novo <FONT
STYLE="white-space:nowrap">Know-How</FONT> or (iii)&nbsp;is made by a process Covered by any Valid Claim of the Novo Patents and/or that utilizes the Novo <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Project</B>&#8221;<B> </B>means the BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT> research project conducted by Novo Nordisk, with
internal reference code [**], which was discontinued in [**]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Receiving Party</B>&#8221;<B> </B>shall have the meaning set forth in
Section&nbsp;8.1.1 (Confidential Information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Regulatory Authority</B>&#8221;<B> </B>means any Governmental Authority or other authority
responsible for granting Marketing Approvals for Products, including without limitation, the FDA, EMA and any corresponding national or regional regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Research Evaluation Agreement</B>&#8221;<B> </B>means the preliminary license agreement entered into between Genmab and Licensee, which allows for
Licensee&#8217;s research of the Novo Technology using the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform Technology, with effective date [**]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Royalty Term</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;3.2.3 (Royalty Term). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Selling Party</B>&#8221;<B> </B>shall have the meaning set forth in the definition of Net Sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Sublicensee</B>(<B>s</B>)&#8221;<B> </B>shall mean any Third Party to which Licensee has granted a sublicense under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Term</B>&#8221;<B> </B>shall have the meaning set forth in Section&nbsp;9.1 (Term). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Territory</B>&#8221;<B> </B>means the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Third Party</B>&#8221;<B> </B>means a Person other than (a)&nbsp;Novo Nordisk or any of its Affiliates and (b)&nbsp;Licensee or any of its
Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B><FONT STYLE="white-space:nowrap">TLT-1</FONT></B>&#8221;<B> </B>means the TREM-like transcript 1 protein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Valid Claim</B>&#8221;<B> </B>means, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis,
an issued and unexpired claim within the Novo Patents or a pending claim in a patent application within the Novo Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<B>Work
Plan</B>&#8221;<B> </B>means the research work plan as set out in <U>Exhibit C</U> of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2. INTELLECTUAL PROPERTY AND LICENSE GRANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;2.1 <U>License Grant</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1.1</B> <B><U>License. </U></B>Subject to the terms and conditions of this Agreement, Novo Nordisk hereby grants to Licensee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an exclusive (even with respect to Novo Nordisk), worldwide, royalty-bearing license, including the right to
sublicense, to the Novo Patents; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-bearing license, including the
right to sublicense, to the Novo <FONT STYLE="white-space:nowrap">Know-How;</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, to Exploit Product(s) in the Licensed
Field in the Territory (the &#8220;<B>License</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1.2</B> <B><U>Temporary Limited License</U></B>. The Parties have agreed that, during the
first [**] of the Term, Licensee shall strictly limit its activities under the License to the <FONT STYLE="white-space:nowrap">non-</FONT> clinical activities as specified in the Work Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.2</B> <B><U>Ownership of IP</U></B>. As between the Parties and subject to the License grant, Novo Nordisk will
continue to own the rights in the Novo Technology. For clarity, Licensee will own all data, <FONT STYLE="white-space:nowrap">Know-How,</FONT> and inventions (including Patent Rights claiming such inventions) generated by or on behalf of Licensee,
its Affiliates and Sublicensees during the Exploitation of the Product(s) in the Licensed Field in the Territory after the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.3</B> <B><U>Sublicenses</U></B>. As of [**], and on the condition that the Genmab- Licensee CLA is effective, Licensee
shall be entitled, subject to Section&nbsp;2.6 (Right of First Negotiation) and the payments as set forth in Article 3, to grant sublicenses by a written agreement to its Affiliates or to Third Parties (with the right to sublicense through multiple
tiers) without the prior written consent of Novo Nordisk, provided, however, that as a condition precedent to and requirement of any such sublicense: (a)&nbsp;any such permitted sublicense shall be consistent with and subject to the terms and
conditions of this Agreement; and (b)&nbsp;Licensee will continue to be responsible for full performance of its obligations under this Agreement and will be responsible for all actions of the Sublicensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;2.4 <U>Transfer of Novo <FONT STYLE="white-space:nowrap">Know-How</FONT></U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.1</B> Upon the Effective Date, Novo Nordisk shall transfer to Licensee the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> listed in Exhibit B.
The Parties will agree on a transfer plan to initiate the transfer to Licensee. On Novo Nordisk&#8217;s side, all communications regarding the transfer plan shall go through [**] (employee initials as known to the Parties). Licensee shall not
contact or communicate with any other Novo Nordisk <FONT STYLE="white-space:nowrap">co-worker</FONT> for this purpose, unless instructed otherwise in writing. Novo Nordisk shall compile and provide Licensee with access to the Novo <FONT
STYLE="white-space:nowrap">Know-How</FONT> in accordance with the transfer plan, including in the format specified therein. During the transfer of Novo <FONT STYLE="white-space:nowrap">Know-How,</FONT> Novo Nordisk shall reasonably assist Licensee
with advice and support free of charge. The work includes preparation of data in interpreted format as necessary to complete the transfer. The Parties estimate that the transfer of Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will have been
completed within [**]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.2</B> Licensee acknowledges that, except as expressly set forth in Section&nbsp;6.2 (Additional Novo
Nordisk Representations and Warranties), the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> is provided &#8220;as is&#8221; and without any representation or warranty, express or implied, as to its accuracy or completeness, including, without
limitation, any implied warranty of merchantability or fitness for a particular purpose, or any warranty that use of the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will not infringe or violate any patent or other proprietary rights of any
third party. Acceptance of the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will constitute acceptance by Licensee of liability for any damages or injuries resulting from its possession or use of the Novo
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.3</B> Licensee hereby agrees to use the Materials in compliance with any and all applicable laws
and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4.4</B> Licensee acknowledges that the Materials transferred by Novo Nordisk to Licensee under this Agreement are experimental in
nature and may have unknown characteristics and therefore agrees to use prudence and reasonable care in the use, handling, storage, transportation and disposition and containment of any such Materials. Accordingly, no Materials shall be used in any
human application, including any clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.5</B> <B><U>No Other Rights</U></B>. Licensee acknowledges that
the rights and licenses granted under this Article 2 (Intellectual Property and License Grant) and elsewhere in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no
right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by Novo Nordisk to Licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;2.6</B> <B><U>Right of First Negotiation</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.1</B> Licensee hereby grants to Novo Nordisk a right of first negotiation (&#8220;<B>ROFN</B>&#8221;)<B> </B>to obtain a license back from Licensee to
Exploit the Product in the Licensed Field in the Territory. Novo Nordisk&#8217;s ROFN shall expire [**] after Licensee [**] (the &#8220;<B>ROFN Expiration Date</B>&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.2</B> If, before the ROFN Expiration Date, Licensee decides to discuss with a Third Party the terms under which such Third Party, either alone or
together with Licensee or Licensee&#8217;s Affiliate(s), shall Exploit the Product in the Licensed Field, Licensee shall notify Novo Nordisk in writing, and provide to Novo Nordisk all information in Licensee&#8217; Control as reasonably necessary
or useful for Novo Nordisk to evaluate its interest, and Novo Nordisk shall have [**] to exercise its ROFN by providing Licensee with a written notice to confirm its interest in obtaining an exclusive license from Licensee to Exploit the Product in
the Licensed Field. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.3</B> If Novo Nordisk exercises its ROFN within such [**], Novo Nordisk shall have the exclusive right, during the next [**],
which period may be extended by mutual written agreement of the Parties, to negotiate with Licensee in good faith regarding the terms and conditions of a license agreement under which Licensee would grant such an exclusive license to Novo Nordisk.
During this exclusive negotiation period, Licensee shall neither license or otherwise grant to any Third Party, nor engage in any negotiations or other discussions with any Third Party regarding any agreement to license or otherwise grant to any
Third Party, any rights to Exploit the Product in the Licensed Field in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.4</B> If Novo Nordisk does not exercise its ROFN within such [**], or if Novo Nordisk exercises its
ROFN within such [**] but the negotiation has not resulted in a binding written agreement by the end of such [**], then Licensee shall be free to negotiate with any Third Party with respect to such a license and to grant such a license to any Third
Party, without any further obligations to Novo Nordisk. For clarity, Licensee shall have no obligation to share with or offer to Novo Nordisk the terms negotiated by Licensee with such Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6.5</B> In all instances Licensee shall provide Novo Nordisk and the Third Party or Third Parties with information that is substantially the same. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3. FEES, ROYALTIES&nbsp;&amp; PAYMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;3.1 <U>Milestone Payment and Milestone Event</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1.1 Licensee shall pay to Novo Nordisk the following <FONT STYLE="white-space:nowrap">one-time</FONT> milestone payment (&#8220;Milestone Payment&#8221;)
following the first occurrence of the milestone event set forth below with respect to a Product (the &#8220;Milestone Event&#8221;): </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Milestone Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Figures in Danish kroner (DKK)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">40,000,000</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1.2</B> Licensee shall pay to Novo Nordisk the applicable Milestone Payment within [**] after the first achievement by
Licensee, its Affiliates or its Sublicensees of an applicable Milestone Event. The Milestone Payment shall be <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable.</FONT> For clarity, the
Milestone Payment is a <FONT STYLE="white-space:nowrap">one-time</FONT> payment only, regardless of the number of times the Milestone Event is achieved or the number of Products that achieve the Milestone Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;3.2 <U>Royalties and Other Payments</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2.1</B> <B><U>Royalty Rate</U></B>. Licensee shall pay to Novo Nordisk the tiered royalties set forth in the following table on annual worldwide Net Sales
of the Product(s) sold by a Selling Party calculated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> during the applicable Royalty Term for each country, and then aggregated to determine the
following tiers of annual worldwide Net Sales: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Net Sales in DKK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Royalty Rate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8804; [**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[**]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">between [**] and <BR>&#8804; [**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[**]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&gt; [**]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[**]%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Example: if the aggregate annual Net Sales of the Product(s) is DKK [**], the amount of the royalties
payable for that period (without considering any applicable royalty reductions) is calculated as follows: [**]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2.2</B> <B><U>Royalty Term</U></B>.
Any such royalty payments shall be made within [**] of the end of each calendar quarter. Licensee&#8217; obligation to pay royalties with respect to a Product in a particular country of sale shall commence upon the First Commercial Sale of such
Product in such country and shall expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT>
basis on the later of (a)&nbsp;the expiration of the last to expire Valid Claim within any Novo Patent that Covers such Product in such country, or (b)&nbsp;the tenth (10th) anniversary of the First Commercial Sale of such Product in such country
(the &#8220;<B>Royalty Term</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.3</B> <B><U>Method of Payment</U></B>. Unless otherwise agreed by the
Parties, all payments due from Licensee to Novo Nordisk under this Agreement shall be paid Danish kroner by wire transfer or electronic funds transfer of immediately available funds to the following account: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficiary Name: [**] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficiary Account #: [to be specified
at the time] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank Name: [to be specified at the time] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BIC
Code: [to be specified at the time] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.4</B> <B><U>Royalty Reports</U></B>. After the First Commercial Sale of the
first Product and until expiration of the last Royalty Term, Licensee shall prepare and deliver to Novo Nordisk royalty reports of the sale of Products by the Selling Parties for each calendar quarter within [**] of the end of each such calendar
quarter specifying in the aggregate and on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis: (a)&nbsp;total gross amounts for Products sold or otherwise disposed of by a Selling Party;
(b)&nbsp;amounts deducted by category, in accordance with the definition of Net Sales in Article 1, from gross amounts to calculate Net Sales; (c)&nbsp;Net Sales; and (d)&nbsp;royalties payable. To the extent Licensee generates for its own purposes
such information on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, then it shall provide such information on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.5</B>
<B><U>Currency Conversion</U></B>. In the case of sales outside Denmark, payments received by Licensee will be expressed in the DKK equivalent calculated on a quarterly basis in the currency of the country of sale and converted to their DKK
equivalent using the average rate of exchange over the applicable calendar quarter to which the sales relate, in accordance with the rates of exchange used by Licensee in producing its quarterly and annual reports to its shareholders, as confirmed
by Licensee&#8217;s independent public accountants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.6</B> <B><U>Late Payments</U></B>. In the event that any
undisputed payment due hereunder is not made when due, Novo Nordisk is entitled to charge interest on such late payment beginning on the day following the due date thereof, calculated annually at the sum of (a) [**] percent ([**]%) plus (b)&nbsp;the
LIBOR interest rate on the date said payment is due, the interest being compounded on the last day of each calendar quarter; provided, however, that in no event shall said annual interest rate exceed the maximum rate permitted by Law. If requested
by Novo Nordisk each such undisputed late payment when made shall be accompanied by all interest so accrued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.7</B> <B><U>Records and Audits</U></B>. Licensee will keep complete
and accurate records relating to the calculations of Net Sales generated in the then current calendar year and payments required under this Agreement, and during the preceding [**]. Novo Nordisk will have the right during the Term and for a period
of [**] thereafter, [**] at its own expense, to have an internationally recognized, independent, certified public accounting firm, currently one of the following: [**] (the &#8220;<B>Auditor</B>&#8221;),<B> </B>selected by it, review any such
records of Licensee and its Affiliates and Sublicensees (the &#8220;<B>Audited Party</B>&#8221;)<B> </B>in the location(s) where such records are maintained by the Audited Party subject to the following terms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo Nordisk shall give Licensee at least [**] prior written notice of when its Auditor shall visit the Audited
Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at least [**] prior to inspecting any records, the Auditor must enter into a confidentiality agreement with the
Audited Party that is reasonably satisfactory to the Audited Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee shall make their books and records available for review by the Auditor solely to verify the accuracy
of its Net Sales report and payments under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee shall give access to the Auditor during regular business hours at the place or places where the books
and records are usually kept. While inspecting such accounts and records, the Auditor must abide by all of Licensee&#8217; standard rules and regulations and the Auditor will not be entitled to take copies of any such accounts and records;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Auditor shall prepare and deliver to each Party a report setting out its findings no later than [**] after
the audit has been completed. The Auditor shall share its findings with Licensee prior to delivering the report in order for the parties to in good faith discuss any discrepancies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any report by the Auditor under this Section&nbsp;3.7 shall be deemed Confidential Information of Licensee and
Novo Nordisk shall keep such report and any other information received or learnt in connection with the audit confidential; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no [**] will be subject to audit under this Section&nbsp;3.7 more than [**]; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">should such inspection lead to the discovery of a discrepancy to Novo Nordisk&#8217;s detriment, Licensee will,
within [**] after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy together with interest at the rate set forth in Section&nbsp;3.6 (Late Payments). Novo Nordisk will pay the full cost of the review
unless the underpayment of amounts due to Novo Nordisk is greater than [**] percent ([**]%) of the amount due for the entire period being examined, in which case Licensee will pay the cost charged by such accounting firm for such review. Should the
audit lead to the discovery of a discrepancy to Licensee&#8217; detriment, Licensee may deduct the amount of the discrepancy, without interest, against future payments payable to Novo Nordisk under this Agreement, and if there are no such payments
payable, then Novo Nordisk shall pay to Licensee the amount of the discrepancy, without interest, within [**] of Novo Nordisk&#8217;s receipt of the report. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;3.8</B> <B><U>Taxes</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.8.1</B> <B><U>Sales Tax</U></B>. Licensee is responsible for the payment of any state or local, sales or use, or similar fees or taxes arising as a result
of the transfer of Materials by Novo Nordisk to Licensee pursuant to Section&nbsp;2.4.1 (but excluding any income taxes), and Licensee will remit such fees or taxes to Novo Nordisk, as the collection agent, upon invoice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.8.2</B> <B><U>Withholding</U></B>. If the applicable Law requires that taxes be withheld with respect to any payments by Licensee to Novo Nordisk under
this Agreement, Licensee may: (a)&nbsp;deduct those taxes from the remittable payment, (b)&nbsp;pay the taxes to the proper taxing authority, and (c)&nbsp;send evidence of the obligation together with proof of tax payment to Novo Nordisk on a timely
basis following that tax payment. Each Party agrees to reasonably cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty which is then in effect (e.g., Licensee
shall not withhold withholding tax without first confirming with Novo Nordisk that Novo Nordisk is not able to provide the documentation of its taxable status and Licensee shall delay making any payment to the extent requested by Novo Nordisk for
the purpose of Novo Nordisk receiving and/or providing such documentation). Upon written request by Novo Nordisk, Licensee shall provide Novo Nordisk with official receipts issued by the appropriate governmental agency documenting the amount of any
withholding tax or any other information as is reasonably requested by Novo Nordisk. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.8.3</B> <B><U>VAT</U></B><B>. </B>All payments shall be based on
invoices and applied value added tax according to local regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4. PATENT PROSECUTION, MAINTENANCE, &amp; INFRINGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;4.1 <U>Prosecution, Maintenance and Enforcement</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1.1</B> Until [**] after the Effective Date, Novo Nordisk shall be responsible, at its own risk and cost, for the prosecution, maintenance and enforcement
of the Novo Patents, including the defense and settlement of claims from Third Parties regarding the Novo Patents; provided that Novo Nordisk may not discontinue its prosecution, maintenance or enforcement of the Novo Patents without
Licensee&#8217;s prior written approval. Licensee shall reasonably cooperate with and assist Novo Nordisk in the prosecution, maintenance and enforcement of the Novo Patents and Novo Nordisk shall reimburse Licensee for its reasonable expenses
incurred in connection herewith. Upon expiry of [**] from the Effective Date, the costs of the prosecution, maintenance and enforcement of the Novo Patents will be borne by Licensee, and, at Licensee&#8217;s option, and if so notified by Licensee in
writing, Novo Nordisk shall transfer to Licensee, and Licensee will take over, the prosecution and maintenance of the Novo Patents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1.2</B> Each
Party shall keep the other Party reasonably informed of its prosecution of the Novo Patents and shall promptly provide the other Party with all material correspondence received from any patent authority in connection therewith. In addition, each
Party shall promptly provide the other Party with drafts of all proposed material filings and correspondence to any patent authority with respect to the Novo Patents for review and comment prior to the submission of such proposed filings and
correspondences and shall consider and implement in good faith any reasonable comment received from the other Party (including request to expand the scope of the claims) that are supported by the disclosure in the Novo
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1.3</B> As the exclusive licensee, Licensee shall the first right, but not the obligation, to enforce
the Novo Patents against any infringement in the Licensed Field in the Territory, at its own expense and as it reasonably determines appropriate. Novo Nordisk shall have the right to be represented by counsel of its choice at its own expense. If
Licensee decides not to enforce the Novo Patents against any particular infringement, Licensee shall promptly notify Novo Nordisk, in which case, Novo Nordisk shall have the right to enforce the Novo Patent against such infringement at its own
expense. At the request and expense of the enforcing Party, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the
action if required. Any recoveries resulting from the enforcement of the Novo Patents shall be first applied against payment of each Party&#8217;s costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses
shall be retained by the enforcing Party; provided however that if the enforcing Party is Licensee, then such excess recovery shall be deemed Net Sales and subject to royalty payment under Section&nbsp;3.2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5. OBLIGATIONS OF THE PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;5.1</B> <B><U>Responsibility</U></B>. Following the Effective Date and at all times during the Term, Licensee shall be
responsible for, and shall bear and be responsible for any costs, expenses and payments associated with, any further research, development and/or commercialization of the Product(s), including regulatory, manufacturing, distribution, marketing and
sales activities, such as, but not limited to, any payments to Genmab in connection with the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License. Subject only to the express written terms of this Agreement, all decisions
concerning the research, development, marketing and sales of Product(s), including the clinical and regulatory strategy, design, sale, price and promotion of Product(s) covered under this Agreement, shall be within the sole discretion of Licensee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;5.2</B> <B><U>Diligence</U></B>. Licensee shall (directly and/or through one or more Affiliates and/or Sublicensees)
use commercially reasonable efforts to develop and commercialize a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;5.3</B> <B><U>Reports</U></B>. Within
[**] of each calendar year, Licensee shall submit to Novo Nordisk a report summarizing the status of Licensee&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; activities related to the Exploitation of Products during the preceding
calendar-year period in relation to the development plan including any updates to the clinical plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6. REPRESENTATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.1</B> <B><U>Mutual Warranties</U></B>. Each of Novo Nordisk and Licensee represent and warrant that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is duly organized and validly existing under the Law of the jurisdiction of its incorporation, and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the
individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Agreement is legally binding upon it and enforceable in accordance with its terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the execution, delivery and performance of this Agreement by it does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable Law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as of the Effective Date, there is no announced investigation, suit, action or proceeding pending or, to such
Party&#8217;s knowledge, threatened, against such Party before or by any court, arbitrator, or Governmental Authority that, individually or in the aggregate, is reasonably expected to (i)&nbsp;materially impair the ability of such Party to perform
its obligations under this Agreement, or (ii)&nbsp;prevent or materially delay or alter the consummation of any or all of the transactions contemplated hereby. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.2</B> <B><U>Additional Novo Nordisk Representations and Warranties</U></B><B>. </B>Novo Nordisk represents and warrants
to Licensee that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo Nordisk is the sole and exclusive owner of the Novo Technology, free and clear of all liens, has the right
to grant to Licensee the rights and licenses as purposed to be granted hereunder, and has not granted (and will not grant during the Term) any rights in Novo Technology that are inconsistent with the rights granted to Licensee hereunder. The Novo
Technology is not subject to any pending reexamination, opposition, interference or litigation proceedings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Novo Nordisk&#8217;s knowledge, there have been no inventorship or ownership challenges with respect to the
Novo Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Novo Nordisk&#8217;s knowledge, and without any obligation on Novo Nordisk to conduct an enquiry into
potential infringement of Third Party-rights and without Novo Nordisk having done an FOO analysis, Novo Nordisk&#8217;s performance of the Project did not infringe or misappropriate any intellectual property rights of a Third Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Novo Nordisk&#8217;s knowledge, Novo Nordisk has complied with all applicable laws and regulations in its
performance of the Project. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.3</B> <B><U>Additional Licensee Representation</U></B>. Licensee
represents and warrants to Novo Nordisk that, on the Effective Date, Johan H. Faber is 100% shareholder of Licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;6.4</B> <B><U>Disclaimer</U></B>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 6 (REPRESENTATIONS), NEITHER
PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> OR
VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENT RIGHTS. WITHOUT LIMITING THE RESPECTIVE RIGHTS AND
OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS WILL BE SUCCESSFUL, IN WHOLE OR IN PART. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7. INDEMNIFICATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U>&nbsp;7.1 <U>Indemnity</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1.1</B>
<B>By Novo Nordisk</B>. Novo Nordisk agrees to defend Licensee and its (and its Affiliates&#8217;) directors, officers, employees and agents (the &#8220;<B>Licensee Indemnified Parties</B>&#8221;)<B> </B>at Novo Nordisk&#8217;s cost and expense, and
will indemnify and hold Licensee and the other Licensee Indemnified Parties harmless from and against any claims, losses, costs, damages, fees or expenses (including legal fees and expenses) (collectively, &#8220;<B>Losses</B>&#8221;) resulting from
any Third Party claim (including product liability claims) arising out of or otherwise relating to (a)&nbsp;the material breach of this Agreement or the representations and warranties made hereunder by Novo Nordisk or (b)&nbsp;the negligence or
wilful misconduct of Novo Nordisk or its Affiliates in connection with its activities under this Agreement; except, in each case, to the extent such Losses result from clause (a), (b), (c) or (d)&nbsp;of Section&nbsp;7.1.2 (&#8216;By
Licensee&#8217;). In the event of any such claim against the Licensee Indemnified Parties by a Third Party, Licensee shall promptly notify Novo Nordisk in writing of the claim (provided, however, that any failure or delay to notify shall not excuse
any obligations of Novo Nordisk except to the extent Novo Nordisk is actually prejudiced thereby) and Novo Nordisk shall solely manage and control, at its sole expense, the defense of the claim and its settlement; provided, however, that Novo
Nordisk shall not settle any such claim without the prior written consent of Licensee if such settlement does not include a complete release from liability or if such settlement would involve undertaking an obligation (including the payment of money
by a Licensee Indemnified Party), would bind or impair a Licensee Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of Licensee or this Agreement is invalid, narrowed in scope or
unenforceable. The Licensee Indemnified Parties shall cooperate with Novo Nordisk and may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1.2</B> <B>By Licensee</B>. Licensee agrees to defend Novo Nordisk and its (and its Affiliates&#8217;) directors, officers, employees and agents (the
&#8220;<B>Novo Indemnified Parties</B>&#8221;)<B> </B>at Licensee&#8217; cost and expense, and will indemnify and hold Novo Nordisk and the other Novo Indemnified Parties harmless from and against any Losses resulting from any Third Party claim
(including product liability claims) arising out of or otherwise relating to (a)&nbsp;the negligence or wilful misconduct of Licensee, its Affiliates, or their respective Sublicensees in connection with its activities under this Agreement,
(b)&nbsp;the material breach of this Agreement or the representations, warranties and covenants made hereunder by Licensee, (c)&nbsp;the Exploitation of any Product by or on behalf of Licensee, its Affiliates, or their respective Sublicensees
(including from product liability and intellectual property infringement claims), or (d)&nbsp;the use of any Materials by or on behalf of Licensee, its Affiliates, or their respective Sublicensees; except, in each case, to the extent such Losses
result from clause (a)&nbsp;or (b) of Section&nbsp;7.1.1 (By Novo Nordisk). In the event of any such claim against the Novo Indemnified Parties by a Third Party, Novo Nordisk shall promptly notify Licensee in writing of the claim (provided, however,
that any failure or delay to notify shall not excuse any obligation of Licensee except to the extent Licensee is actually prejudiced thereby) and Licensee shall solely manage and control, at its sole expense, the defense of the claim and its
settlement; provided, however, that Licensee shall not settle any such claim without the prior written consent of Novo Nordisk if such settlement does not include a complete release from liability or if such settlement would involve undertaking an
obligation (including the payment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
money by a Novo Indemnified Party), would bind or impair an Novo Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of Novo Nordisk
or this Agreement is invalid, narrowed in scope or unenforceable. The Novo Indemnified Parties shall cooperate with Licensee and may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2</B> <B>LIMITATION OF DAMAGES</B>. IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE,
INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION
7.2 (LIMITATION OF DAMAGES) SHALL NOT APPLY WITH RESPECT TO (A)&nbsp;ANY BREACH OF ARTICLE 8 (CONFIDENTIALITY) OR (B)&nbsp;THE INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY. NOTHING IN THIS SECTION 7.2 (LIMITATION OF DAMAGES) IS INTENDED TO
LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF A PARTY UNDER THIS ARTICLE 7 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO A THIRD PARTY IN CONNECTION WITH A THIRD-PARTY CLAIM. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8. CONFIDENTIALITY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.1
Confidential Information. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1.1</B> <B><U>Confidential Information</U></B>. Each Party (&#8220;<B>Disclosing Party</B>&#8221;)<B> </B>may disclose
to the other Party (&#8220;<B>Receiving Party</B>&#8221;),<B> </B>and Receiving Party may acquire during the course and conduct of activities under this Agreement, certain proprietary or confidential information of Disclosing Party in connection
with this Agreement. The term &#8220;<B>Confidential Information</B>&#8221;<B> </B>means all information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which
are transferred, disclosed or made available by Disclosing Party to Receiving Party under this Agreement. Without limiting the foregoing, all Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> will be considered Confidential Information of Novo
Nordisk, and all financial and business disclosures from Licensee to Novo Nordisk will be considered Confidential Information of Licensee. In addition to its confidentiality obligations with respect to Licensee&#8217;s Confidential Information,
Licensee agrees to keep the Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> in confidence in accordance with the terms of <FONT STYLE="white-space:nowrap">non-disclosure</FONT> set forth in Section&nbsp;8.1.2 (Restrictions) as if the Novo <FONT
STYLE="white-space:nowrap">Know-How</FONT> were Confidential Information of Licensee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1.2</B> <B><U>Restrictions</U></B>. During the Term and for
[**] thereafter, Receiving Party will keep all Disclosing Party&#8217;s Confidential Information in confidence with a high degree of care. Receiving Party will not use Disclosing Party&#8217;s Confidential Information except in connection with the
performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose Disclosing Party&#8217;s Confidential Information without Disclosing Party&#8217;s prior written consent, to the extent
reasonably necessary, to Receiving Party&#8217;s Affiliates and their employees, directors, subcontractors, consultants or agents who have a need to know such Confidential Information in order to perform the relevant Party&#8217;s obligations and
exercise its rights under this Agreement and who are required to comply with the restrictions on use and disclosure in this Section&nbsp;8.1.2. Receiving Party will ensure that those entities and persons comply with the restrictions on use and
disclosure in this Section&nbsp;8.1.2. Receiving Party assumes responsibility for those entities and persons maintaining Disclosing Party&#8217;s Confidential Information in confidence and using same only for the purposes described herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1.3</B> <B><U>Exceptions</U></B>. Receiving Party&#8217;s obligation of nondisclosure and the
limitations upon the right to use Disclosing Party&#8217;s Confidential Information will not apply to the extent that Receiving Party can demonstrate that Disclosing Party&#8217;s Confidential Information: (a)&nbsp;was known to Receiving Party or
any of its Affiliates prior to the time of disclosure; (b)&nbsp;is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates in breach of the confidentiality obligations set forth herein; (c)&nbsp;is
obtained by Receiving Party or any of its Affiliates from a Third Party under no obligation of confidentiality to Disclosing Party; or (d)&nbsp;has been independently developed by employees, subcontractors, consultants or agents of Receiving Party
or any of its Affiliates without the use of Disclosing Party&#8217;s Confidential Information, as evidenced by contemporaneous written records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.2</B> <B>Publication</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2.1</B> <B><U>Special Limitations</U></B>. Licensee is not at any time during the Term or thereafter entitled to make any publications or other disclosure
to a Third Party with regard to the Novo Technology until the effective date of the Gcnmab-Licensee CLA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2.2</B> <B><U>General Principles</U></B>.
After the effective date of the Genmab-Licensee CLA, Licensee shall have the right to publish information arising from the development of the Product. However, up to and until the start of a [**], Licensee shall provide Novo Nordisk with the
opportunity to review the draft prior to such publication. If Licensee&#8217;s publication contains Confidential Information of Novo Nordisk, then Licensee shall provide Novo Nordisk with the proposed publication at least [**] prior to the intended
date of submission or disclosure. If Novo Nordisk reasonably determines that the publication would entail disclosure of its Confidential Information, Novo Nordisk shall have the right to reasonably require modifications of the proposed publication.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 9. TERM&nbsp;&amp; TERMINATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9</B>.<B>1 </B><B><U>Term</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1.1</B> <B><U>Term of this Agreement</U></B>. The term of this Agreement (the &#8220;<B>Term</B>&#8221;)<B> </B>shall commence on the Effective Date and
shall continue to be effective until it: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">automatically terminates as provided for in Section&nbsp;9.2, or; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is terminated by a Party as provided for in Sections 9.3, 9.4 or 9.5; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whichever date of (i)&nbsp;or (ii) comes first. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1.2</B>
<B><U>Expiry of Royalty Term</U></B>. Effective upon the expiration of the Royalty Term for a Product in a country, this Agreement shall continue in force but the License shall, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, become royalty-free, perpetual and
irrevocable with respect to such Product in such country. For clarity, if this Agreement terminates as set out in Section&nbsp;9.1.1, the License shall terminate with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.2</B> <B><U>Automatic Termination</U></B>. This Agreement will
automatically terminate: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">upon expiry or termination, on or before 1&nbsp;April 2020, of the LOA, unless upon such expiry or termination
the amendment agreement as referred to under Section&nbsp;9.2 (b) has been entered into, or; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on <B>1</B><B></B><B>&nbsp;April 2020</B>,<B> </B>if, on this date, Genmab and Novo Nordisk have not entered
into an amendment agreement to the LOA which amendment authorizes Novo Nordisk (i)&nbsp;to publish its NN Patents in November 2020, and, (ii)&nbsp;to share, or continue to share, the Novo Technology with Licensee without Novo Nordisk first having to
enter into a commercial license agreement with Genmab, or; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on <B>15</B><B></B><B>&nbsp;September 2020</B>,<B> </B>if, on this date, (i)&nbsp;the Genmab-Licensee CLA is
not in effect, or (ii)&nbsp;Genmab has not agreed to Novo Nordisk&#8217;s cancelation of the <FONT STYLE="white-space:nowrap">TLT-1/FVI1</FONT> Target Binding Pair under the LOA or to publication of the NN Patents, or; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">upon expiry or termination, for any reason whatsoever, of the Research Evaluation Agreement, unless it is
replaced by the Genmab-Licensee CLA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whichever date under Section&nbsp;9.2 under (a), (b), (c) or (d)&nbsp;comes first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.3</B> <B><U>Termination for Convenience</U></B>. Licensee shall have the right to terminate this Agreement without
cause upon ninety (90)&nbsp;days&#8217; prior written notice to Novo Nordisk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.4</B> <B><U>Termination upon
Breach</U></B>. Either Party may terminate this Agreement upon delivery of written notice to the other Party in the event of a material breach by the other Party of any terms and conditions of this Agreement, which notice shall include details
specifying the description of such breach; provided, however, that such termination will not be effective if such breach has been cured within [**] after such written notice has been given; provided further, however, that to the extent such material
breach involves the failure to make a payment when due, such breach must be cured within [**] after written notice thereof is given by Novo Nordisk to Licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.5</B> <B><U>Termination upon Bankruptcy</U></B>. Either Party may terminate this Agreement with immediate effect if, at
any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition is not dismissed within [**] after the filing thereof, or if the other Party proposes, or becomes a Party to, any dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section<U></U> 9.6 <U>Effects of Termination</U>. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Novo Nordisk terminates this Agreement, and Licensee has entered into a sublicense under this Agreement,
Novo Nordisk agrees that, provided that the sublicense agreement is consistent with the terms of this Agreement, upon the Sublicensee&#8217;s written notice to Novo Nordisk, within [**] from Novo Nordisk providing notice of termination of this
Agreement, and provided the Sublicensee is not (a)&nbsp;in breach of its Sublicense or (b)&nbsp;an Affiliate of Licensee, Novo Nordisk shall allow such Sublicensee to step into this Agreement and assume all of Licensee&#8217;s obligations under this
Agreement and become a direct licensee of Novo Nordisk. For such direct license to become effective, the Sublicensee shall provide to Novo Nordisk written notice wherein the Sublicensee: (a)&nbsp;agrees to abide by all of the terms and conditions of
this Agreement and fulfil any obligations formerly applicable to Licensee; (b)&nbsp;acknowledges that Novo Nordisk shall have no duties, obligations or liabilities to the Sublicensee other than or in addition to its obligations set forth in this
Agreement with regard to Novo Nordisk; and (c)&nbsp;confirms it will make any payments earned and due after such termination directly to Novo Nordisk in accordance with this Agreement. The failure of Sublicensee to comply with the provisions of this
Section&nbsp;9.6(a) shall result in the termination of the sublicense contemporaneously with the termination of the License hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In case of termination of the License, for any reason whatsoever: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rights and licenses granted by Novo Nordisk to Licensee in Article 2 (Intellectual Property and License
Grant) will terminate, and Licensee and its Affiliates, and Sublicensees (except to the extent set forth in Section&nbsp;9.6(a)) will cease all use of the Novo Technology and shall not use or exploit the Novo Technology or use a Product that relies
on, or has been developed through use of, the Novo Technology, and; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo Nordisk is automatically granted a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, fully
paid, royalty-free, transferable license, including the right to sublicense, under the Licensee Patents to Exploit the Product in the Licensed Field in the Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, this Section&nbsp;9.6 does not apply to continuation of the License upon expiry of
the Royalty Term as per Section&nbsp;9.1.2. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;9.7</B> <B><U>Survival</U></B>. Those provisions that,
by their nature, are intended to survive termination of this Agreement, irrespective the cause, shall remain in effect after termination, including Article 1 (Definitions), Section&nbsp;2.2 (Ownership of IP), Section&nbsp;3.7 (Records and Audits),
Article 7 (Indemnity), Article 8 (Confidentiality), Section&nbsp;9.6 (Effects of Termination), Section&nbsp;9.7 (Survival), Section&nbsp;10.4 (Dispute Resolution; Jurisdiction), Section&nbsp;10.5 (Governing Law), Section&nbsp;10.6 (Notice), and
Section&nbsp;10.8 <FONT STYLE="white-space:nowrap">(Non-Use</FONT> of Names. Termination or expiration of this Agreement will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such
termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party&#8217;s right to obtain performance of any
obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10. MISCELLANEOUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.1</B> <B><U>Entire Agreement</U></B><U>;</U><B><U> Amendment</U></B>. This Agreement and all Exhibits to this Agreement
constitute the entire agreement between the Parties as to the subject matter hereof. All prior and contemporaneous negotiations, representations, warranties, agreements, statements, promises and understandings with respect to the subject matter of
this Agreement are hereby superseded and merged into, extinguished by and completely expressed by this Agreement. None of the Parties shall be bound by or charged with any written or oral agreements, representations, warranties, statements, promises
or understandings not specifically set forth in this Agreement. No amendment, supplement or other modification to any provision of this Agreement shall be binding unless in writing and signed by all Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.2</B> <B><U>Independent Contractors</U></B>. The relationship between Licensee and Novo Nordisk created by this
Agreement is solely that of independent contractors. This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal
representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. Each Party shall use its own discretion and
shall have complete and authoritative control over its employees and the details of performing its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.3</B> <B><U>Force Majeure</U></B>. Except for the obligation to make payment when due, each Party shall be excused
from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#8217;s reasonable control including but not limited to Acts of God, fire, flood, explosion, earthquake, or other
natural forces, epidemic, quarantine, terrorism, war, acts of war, embargo, civil unrest, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labour
disturbance, or any other event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused
such event(s) to occur. Notice of a Party&#8217;s failure or delay in performance due to force majeure must be given to the other Party within [**] after its occurrence. All delivery dates under this Agreement that have been affected by force
majeure shall be tolled for the duration of such force majeure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.4</B> <B><U>Dispute
Resolution</U></B><U>;</U><B><U> Jurisdiction</U></B>. The Parties will use commercially reasonable efforts to settle all matters in dispute amicably. Any dispute or claim arising out of or in connection with this Agreement, or the breach,
termination or invalidity thereof, shall be settled by arbitration in accordance with the Rules of Procedure of the Danish Institute of Arbitration (the &#8220;Institute&#8221;) in force when such proceedings are commenced. The arbitration tribunal
shall be composed of a sole arbitrator appointed by the Institute. The place of arbitration shall be Copenhagen, Denmark. The language of the arbitral proceedings shall be English. The award of the arbitrator shall be final and binding on both
Parties. Notwithstanding, without resorting to prior arbitration and in addition to any other remedies provided by law, either Party shall be entitled to seek temporary and permanent injunctive relief against any threatened or actual breach of this
Agreement or the continuation of any such breach in any court of competent jurisdiction. Any award of the arbitrator and the fact that arbitration proceedings are pending or have been instigated shall be regarded Confidential Information of both
Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.5</B> <B><U>Governing Law</U></B>. The validity, construction and
performance of this Agreement will be governed by and construed in accordance with the laws of Denmark excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the
substantive law of another jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.6</B> <B><U>Notice</U></B>. All notices or communication required or
permitted to be given by either Party hereunder shall be deemed sufficiently given if mailed by registered mail or certified mail, return receipt requested, or sent by courier to the other Party at its respective address set forth below or to such
other address as one Party shall give notice of to the other from time to time hereunder. Mailed notices shall be deemed to be received on the third (3rd) business day following the date of mailing. Notices sent by courier shall be deemed received
the following business day. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Novo Nordisk:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo All&eacute;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2880 Bagsv&aelig;rd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denmark</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Head of Business Development</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Counsel, Legal Department</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Licensee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ebumab Hemophilia ApS</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ole Maal&oslash;es Vej
3</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2200 K&oslash;benhavn N</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denmark</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Johan Faber, CEO</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.7</B> <B><U>Compliance with Law</U></B><U>;</U><B><U> Severability</U></B>. Nothing in
this Agreement shall be construed to require the commission of any act contrary to Law. If any one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the affected provisions of this Agreement shall be curtailed and
limited only to the extent necessary to bring it within the applicable legal requirements and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.8</B> <B><U><FONT STYLE="white-space:nowrap">Non-Use</FONT> of Names</U></B>. Neither Party nor its Affiliates and
Sublicensees shall use the name, trademark, logo, physical likeness or name of the other Party or any of its Affiliates, its and its Affiliates&#8217; officers, directors or employees, in any advertising, promotional or sales literature, without the
other Party&#8217;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><U></U><B>&nbsp;10.9</B> <B><U>Successors and Assigns</U></B>. Neither this Agreement nor any of
the rights or obligations created herein may be assigned by either Party, in whole or in part, without the prior written consent of the other Party, not to be unreasonably withheld or delayed; provided however that Licensee may, upon payment to Novo
Nordisk of any amounts due as per Article 3 (Fees, Royalties&nbsp;&amp; Payments) at the time of assignment, assign this Agreement, without Novo Nordisk&#8217;s consent, to its Affiliate and its successor to all or substantially all of its business
to which this Agreement relates, whether in a merger, acquisition, sale of asset or similar transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.10</B> <B><U>Waivers</U></B>. A Party&#8217;s consent to or waiver,
express or implied, of any other Party&#8217;s breach of its obligations hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations of such breaching Party. A Party&#8217;s
failure to complain of any act, or failure to act, by the other Party, to declare the other Party in default, to insist upon the strict performance of any obligation or condition of this Agreement or to exercise any right or remedy consequent upon a
breach thereof, no matter how long such failure continues, shall not constitute a waiver by such Party of its rights hereunder, of any such breach, or of any other obligation or condition. A Party&#8217;s consent in any one instance shall not limit
or waive the necessity to obtain such Party&#8217;s consent in any future instance and in any event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed by the Party granting such
consent or waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.11</B> <B><U>No Third Party Beneficiaries</U></B>. Nothing in this Agreement shall be
construed as giving any Person, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof, except for the provisions of Article 7 (Indemnity)
(with respect to which the persons to which Article 7 (Indemnity) applies shall be Third Party beneficiaries in accordance with Article 7 (Indemnity)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.12</B> <B><U>Headings</U></B><U>;</U><B><U> Exhibits</U></B>. Article and Section headings used herein are for
convenient reference only and are not a part of this Agreement. All Exhibits are incorporated herein by this reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.13</B> <B><U>Interpretation</U></B>. Except where the context otherwise requires, wherever used, the singular shall
include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word &#8220;or&#8221; is used in the inclusive sense (and/or). The term &#8220;including&#8221; as used herein shall mean including,
without limiting the generality of any description preceding such term. All references to a &#8220;business day&#8221; or &#8220;business days&#8221; in this Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are
authorized or required to be closed in Denmark. The language in all parts of this Agreement shall be deemed to be the language mutually chosen by the Parties. The Parties and their counsel have cooperated in the drafting and preparation of this
Agreement, and this Agreement therefore shall not be construed against any Party by virtue of its role as the drafter thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B><U></U></B><B>&nbsp;10.14</B> <B><U>Counterparts</U></B>. This Agreement may be executed in counterparts by a single Party, each of which
when taken together shall constitute one and the same agreement and may be executed through the use of facsimiles or .pdf documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22/24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Agreement to be executed by their respective duly authorized representatives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lars Fogh Iversen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johan H. Faber</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novo Nordisk A/S</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Lars Fogh Iversen</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Senior Vice President</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: 19&nbsp;November 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ebumab Hemophilia ApS</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Johan H. Faber</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: CEO</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: ___ November 2019</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibit A: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novo Patents </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibit B: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Description of Novo <FONT STYLE="white-space:nowrap">Know-How</FONT> including the Materials
</P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">to the </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>License Agreement for
BiAb <FONT STYLE="white-space:nowrap">FVII/TLT-1</FONT> of 22&nbsp;November 2019 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novo Nordisk A/S </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ebumab Hemophilia ApS </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This AMENDMENT AGREEMENT (this &#8220;<B>Amendment</B>&#8221;) is entered into as of March&nbsp;26, 2020 (the &#8220;<B>Amendment Effective Date</B>&#8221;)
by and between Novo Nordisk A/S, a Danish corporation, CVR No.&nbsp;24256790, with address at Novo All&eacute;, <FONT STYLE="white-space:nowrap">DK-2880</FONT> Bagsv&aelig;rd, Denmark (&#8220;<B>Novo Nordisk</B>&#8221;), and <U>Ebumab Hemophilia
ApS</U>, a Danish corporation, CVR No.&nbsp;40837590, with address at Ole Maal&oslash;es Vej 3, <FONT STYLE="white-space:nowrap">DK-2200</FONT> Copenhagen N, Denmark (&#8220;<B>Licensee</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk and Licensee are sometimes referred to herein individually as a &#8220;<B>Party</B>&#8221;<B> </B>and collectively as the
&#8220;<B>Parties</B>&#8221;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>by License Agreement, effective 22&nbsp;November 2019, (the &#8220;<B>LA</B>&#8221;)<B> </B>Novo Nordisk has granted EH an
exclusive license to the Novo Patents and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to the Novo <FONT STYLE="white-space:nowrap">Know-How,</FONT> in each case relating to the <FONT STYLE="white-space:nowrap">TLT-1/FVII</FONT>
Target Binding Pair, to Exploit Product(s) in the Licensed Field in the Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>under Section&nbsp;2.6 of the LA, Novo
Nordisk has a Right of First Negotiation (&#8220;<B>ROFN</B>&#8221;) to obtain, under certain conditions, a license back from Licensee to Exploit the Product in the Licensed Field in the Territory (&#8220;<B>Grant-Back License</B>&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Parties now wish to amend the LA to reflect certain financial consequences of such Grant-Back License; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of the foregoing and the mutual covenants contained in this Amendment Agreement, Novo Nordisk and
Licensee, intending to be legally bound, hereby agree as follows, effective upon the Amendment Effective Date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that, by any means whatsoever, including but not limited to a Grant-Back License, Novo
Nordisk regains control of the exclusive rights to Exploit the Product (&#8220;<B>Regained Licensed Product Event</B>&#8221;),<B> </B>the LA shall automatically terminate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Promptly upon such Regained Licensed Product Event, Novo Nordisk will notify Genmab and Novo Nordisk
will pay Genmab: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) the [**] fee in accordance with and as set forth in the LOA in the amount of US$[**]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) any and all payments that would have been due and payable by Novo Nordisk to Genmab under the LOA prior to the Regained Licensed Product
Event, if such corresponding milestone events have occurred. For clarity, the payments up to and including a [**] as agreed in the LOA (in addition to the [**] fee mentioned under (i)) are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">US$[**] upon [**]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">US$[**] upon [**]; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2/3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">US$[**] upon [**]. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties hereby agree that any monies payable by Novo Nordisk to Genmab under (i)&nbsp;and (ii) above will be credited against any monies
paid by Novo Nordisk to EH in connection with the Regained Licensed Product Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For clarification, any and all payments by Novo Nordisk
to Genmab that become due under the LOA for milestone events that occur after the Regained Licensed Product Event will not be credited against any monies paid by Novo Nordisk to EH. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except as expressly modified by this Amendment Agreement, all definitions, terms and provisions of the
LA shall remain in full force and effect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>and intending to be legally bound hereby, the Parties have caused
this Agreement to be executed by their respective duly authorized representatives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lars Fogh Iversen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johan H. Faber</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:Lars Fogh Iversen</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title:Senior Vice President</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: 26/3 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ebumab Hemophilia ApS</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johan H. Faber</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: CEO</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: 25/3 2020</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3/3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain
identified information has been excluded from the exhibit because it is both (i)&nbsp;not material and (ii)&nbsp;is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License Agreement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Genmab A/S</B>, CVR no. 2102 3884,
Kalvebod Brygge 43, <FONT STYLE="white-space:nowrap">DK-1560</FONT> Copenhagen V, Denmark </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(&#8220;<U>Genmab</U>&#8221;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ebumab Hemophilia ApS</B>, CVR no. 4083 7590, Ole
Maal&oslash;es Vej 3, <FONT STYLE="white-space:nowrap">DK-2200</FONT> Copenhagen N, Denmark </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(&#8220;<U>Ebumab</U>&#8221;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genmab and Ebumab individually referred to as &#8220;<U>Party</U>&#8221; or together as &#8220;<U>Parties</U>&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 1 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibits</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 1.37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensed Target Binding Pair</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 1.46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Platform Technology Patent Rights</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Examples of Profit-Share Calculation</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preamble </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab has developed a novel approach for the generation of bispecific antibodies to target antigens using its
proprietary DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab and Novo Nordisk A/S (&#8220;<U>Novo</U>&#8221;) in 2017 entered into the Genmab-Novo Agreement,
granting Novo certain licenses under the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo conducted a research project (&#8220;<U>Project</U>&#8221;) with the use of the DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform, resulting in certain patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and materials with regard to the therapeutic approach and the concept of a bispecific human IgG4 antibody
targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of hemophilia A, but later discontinued the Project; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Johan Faber, previously employed as a research scientist in Novo and involved with the Project, incorporated
Ebumab upon termination of his employment with Novo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab has <FONT STYLE="white-space:nowrap">in-licensed</FONT> that certain Novo Technology pursuant to that
certain License Agreement dated November&nbsp;22, 2019 between Novo and Ebumab (&#8220;<U>Ebumab-Novo Agreement</U>&#8221;) and desires to obtain a license from Genmab to develop and commercialize bispecific antibodies targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and FVII for the treatment of hemophilia using the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab and Genmab entered into a Research Evaluation Agreement dated 22&nbsp;November 2019
(&#8220;<U>REA</U>&#8221;) granting a research license to conduct specific research and preclinical development activities while the Parties continued the negotiation of a commercial license agreement for the research, development, manufacture and
commercialization of a bispecific antibody product targeting <FONT STYLE="white-space:nowrap">TLT-1</FONT> and FVII; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab is willing to grant Ebumab such commercial license, on the terms and conditions set forth in this
Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B> in consideration of the foregoing and the mutual covenants contained in this Agreement, Genmab and
Ebumab, intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1 DEFINITIONS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Affiliate</B>&#8221; of an entity means any person or entity which, directly or indirectly,
controls, is controlled by, or is under common control with, such entity. For the purposes of this definition, &#8220;control&#8221; refers to any of the following: (i)&nbsp;direct or indirect ownership of fifty percent (50%) or more of the voting
securities entitled to vote for the election of directors or management, as applicable, in the case of a corporation, or of fifty percent (50%) or more of the equity interest with the power to direct management in the case of any other type of legal
entity; or (ii)&nbsp;any other arrangement where a person or entity possesses, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract or otherwise.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 3 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Agreement&#8221; </B>means this DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
License Agreement, including any and all Exhibits to it and as it may be amended from time to time in accordance with the provisions of this document. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Alliance Manager</B>&#8221; has the meaning as set forth in Section&nbsp;3.1.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Audited Party</B>&#8221; has the meaning as set forth in Section&nbsp;4.9.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>BLA</B>&#8221; means a Biologics License Application or equivalent submission filed with the
FDA in connection with seeking Marketing Approval of a Licensed Product, or an equivalent application filed with any equivalent Regulatory Authority in any jurisdiction other than the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Calendar Quarter</B>&#8221; shall mean the respective periods of three (3)&nbsp;consecutive
calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December 31. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Calendar Year</B>&#8221; shall mean the period of twelve (12)&nbsp;consecutive calendar months
ending on 31 December. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Change of Control</B>&#8221; shall mean, with respect to a Party (i)&nbsp;the sale to a Third Party
of all or substantially all of such Party&#8217;s business or assets to which this Agreement relates; (ii)&nbsp;any merger, consolidation or acquisition of such Party with, by or into a Third Party that result in the voting securities of such Party
outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the resulting or surviving entity immediately after such merger, reorganization or consolidation; or (iii)&nbsp;any Third Party
acquiring the ownership of more than fifty percent (50%) of the voting capital stock of such Party in one or more related transactions; provided however that, notwithstanding the foregoing, Change of Control shall not include any transaction (or
series of transactions) for bona fide financing purposes (including public offering) or tax purposes (including the change of place of incorporation or domicile) . </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Combination Product</B>&#8221; means a Licensed Product sold in combination with one or more
other pharmaceutical products, in any dosage form and/or <FONT STYLE="white-space:nowrap">co-formulation</FONT> and/or <FONT STYLE="white-space:nowrap">co-packaging</FONT> based on combination of Licensed Product and any other pharmaceutical product
in any device. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Commercially Reasonable Efforts</B>&#8221; means the [**]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Confidential Information</B>&#8221; means any <FONT STYLE="white-space:nowrap">Know-how</FONT>
and all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, provided by or on behalf of a Party or any of its Affiliates to the other Party or
any of its Affiliates in connection with this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 4 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Control</B>&#8221; or &#8220;<B>Controlled</B>&#8221; means, with respect to any <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Patent Rights or other intellectual property rights or information, the possession (whether by ownership or license) by a Party or its Affiliate of the right to grant licenses or sublicenses to the other
Party under such <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patent Rights or other intellectual property rights or information without violating the terms of any agreement or other arrangement with a Third Party and without misappropriating
or infringing the proprietary or trade secret information of a Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Cover</B>&#8221;, &#8220;<B>Covering</B>&#8221; or &#8220;<B>Covered</B>&#8221; means, with
respect to a Patent Right and an invention (e.g. the Licensed Product or part thereof), that, in the absence of ownership of, or a license under, such Patent Right, the practice of such invention (for example the manufacture, use, import or export,
sale, distribution, marketing or commercialization of such invention, e.g. the Licensed Product) would infringe a claim of such Patent Right (including in the case of a Patent Right that is a patent application, a claim of such patent application as
if such patent application were an issued patent). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Direct Cost</B>&#8221; means, with respect to the Licensed Product, the actual direct costs
incurred by Ebumab from the Effective Date to conduct research, development, manufacture and commercialization of the Licensed Product. Direct Costs will include [**]. Direct costs include [**], except such [**]. For the avoidance of doubt, Direct
Costs shall only include costs that (i)&nbsp;are directly attributable or reasonably allocable to Licensed Product; (ii)&nbsp;would be deemed reasonable in the normal course of business given the stage of development or commercialization; and
(iii)&nbsp;represent fair market value. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>DuoBody</B><B><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></B><B>
Platform</B>&#8221; means proprietary technology Controlled by Genmab that is generally applicable to the discovery, modification, optimization, generation and manufacturing of IgG Bispecific Antibodies, including, but not limited to, software,
nucleic acids, vectors, cell lines, libraries, screening systems, reagents, methods, databases and instrumentation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Background Intellectual Property</B>&#8221; means any and all intellectual property
rights, including <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patent Rights, Controlled by Ebumab or any of its Affiliates (i)&nbsp;as of the Effective Date, or (ii)&nbsp;thereafter during the Term which are either conceived by Ebumab
outside of this Agreement or the REA, or are licensed or acquired by Ebumab from a Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab-Novo Agreement</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Platform Improvement</B>&#8221; has the meaning set forth in Section&nbsp;5.1(b).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.19</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Technology</B>&#8221; means all proprietary information and <FONT
STYLE="white-space:nowrap">Know-How</FONT> and other intellectual property generated by or on behalf of Ebumab in the performance of activities under this Agreement or the REA relating to or Covering the research, development, manufacture, use,
import or export, sale, distribution, marketing or commercialization of Licensed Products, excluding, however, any Ebumab Platform Improvement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 5 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.20</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Ebumab Technology Patent Right</B>&#8221; means any and all Patent Rights related to Ebumab
Technology. For the avoidance of doubt, the Ebumab Technology Patent Rights shall not include any of the Ebumab Background Intellectual Property. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.21</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Effective Date</B>&#8221; means the last date on which this Agreement has been duly signed by
the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.22</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>EMA</B>&#8221; means the European Medicines Agency or any successor agency thereto.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.23</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>EU</B>&#8221; means the countries of the European Union, as it is constituted as of the
Effective Date and as it may be changed from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.24</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Exhibit</B>&#8221; means an exhibit attached to this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.25</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>FDA</B>&#8221; means the United States Food and Drug Administration or any successor agency
thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.26</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Field</B>&#8221; means the treatment of bleeding conditions, including hemophilia.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.27</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Financial Report</B>&#8221; has the meaning as set forth in Section&nbsp;4.5.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.28</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>First Commercial Sale</B>&#8221; as to a particular country, means the first commercial sale
of a Licensed Product by Ebumab or any of its Affiliates or Sublicensees to a Third Party for end use in such country after approval of the BLA, or if approval of a BLA is not required in such country, then following receipt of such Marketing
Approval as is required to sell such Licensed Product in such country, provided, that &#8220;First Commercial Sale&#8221; shall not include (i)&nbsp;any sale by Ebumab to an Affiliate or Sublicensee, or (ii)&nbsp;sale, disposal or use of a Licensed
Product for marketing, regulatory, development or charitable purposes, such as clinical trials, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials, compassionate use, named patient use, or indigent patient programs, without consideration.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.29</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Genmab-Novo Agreement</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.30</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IFRS</B>&#8221; means, with respect to Ebumab and Genmab, the then-current IFRS (International
Financial Reporting Standards), in each case, as generally and consistently applied throughout the Party&#8217;s organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.31</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IgG Antibody</B>&#8221; means an immunoglobulin G molecule whether in monospecific,
bispecific, or any other form, that contains at least an Fc region and one (1)&nbsp;or more binding arms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.32</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IgG Bispecific Antibody</B>&#8221; means an IgG Antibody with two (2)&nbsp;different binding
arms targeting a Target Binding Pair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.33</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>IND</B>&#8221; means an Investigational New Drug Application filed with an applicable
Regulatory Authority such as a clinical trial application (CTA) or a clinical trial exemption (CTX). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 6 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.34</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Institute</B>&#8221; has the meaning set forth in Section&nbsp;10.2 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.35</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B><FONT STYLE="white-space:nowrap">Know-how</FONT></B>&#8221; means biological materials and
other tangible materials, information embodied in such biological materials and other tangible materials, inventions, practices, methods, protocols, formulas, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, processes,
procedures, specifications, assays, skills, experience, techniques, data and results of experimentation and testing, including but not limited to pharmacological, toxicological, safety, stability and
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical test data and analytical and quality control data, patentable or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.36</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Licensed Product</B>&#8221; means any product comprising an IgG Bispecific Antibody targeting
the Licensed Target Binding Pair, so that one binding arm targets the first antigen of the Licensed Target Binding Pair, and the second binding arm targets the second antigen of the Licensed Target Binding Pair, which IgG Bispecific Antibody has
been generated by the use of, or incorporating Platform Technology, and which IgG Bispecific Antibody shall be identified by [**]. One Licensed Product will be considered different from another Licensed Product if they do not have identical such
portions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.37</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Licensed Target Binding Pair</B>&#8221; means the Target Binding Pair targeting <FONT
STYLE="white-space:nowrap">TLT-1</FONT> and FVII as further specified in <B><U>Exhibit 1.37</U></B> to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.38</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Marketing Approval</B>&#8221; means any approval, including a registration, license or
authorization, from any Regulatory Authority required to market and sell a Licensed Product in a jurisdiction and shall include an approval, registration, license or authorization granted in connection with a BLA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.39</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Genmab-Novo Agreement</B>&#8221; means the DuoBody<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> License and Option Agreement dated 22&nbsp;December 2017 between Novo and Genmab, as amended by Side Letter dated 22&nbsp;November 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Net Sales</B>&#8221; means the [**]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.41</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Novo</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.42</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Novo Technology</B>&#8221; means the Patent Right and
<FONT STYLE="white-space:nowrap">Know-how</FONT> licensed by Novo to Ebumab under the Ebumab-Novo Agreement. For clarity, Novo Technology does not include the Platform Technology as licensed by Novo and used by Novo under the Genmab-Novo Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.43</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Patent Challenge</B>&#8221; has the meaning set forth in Section&nbsp;9.5.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.44</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Patent Right</B>&#8221; means patents and patent applications and all substitutions,
divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, reexaminations, supplementary protection certificates and extensions and the like thereof, and all
counterparts thereof in any country. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 7 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Platform Technology</B>&#8221; means any and all proprietary information, <FONT
STYLE="white-space:nowrap">Know-how</FONT> and other intellectual property rights, including the Platform Technology Patent Rights, Controlled by Genmab as of the Effective Date or generated thereafter by or on behalf of either Party during the Term
relating to the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform, including Ebumab Platform Improvement . </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.46</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Platform Technology Patent Rights</B>&#8221; means any and all Patent Rights Controlled by
Genmab and its Affiliates as of the Effective Date or at any time during the Term which claim or Cover the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform. Platform Technology Patent Rights existing as of the Effective
Date are listed in <B><U>Exhibit 1.46</U></B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.47</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Profit</B>&#8221; means any proceeds with respect to Licensed Product received by Ebumab or
its Affiliates from Third Parties, such as, but not limited to, sales of Licensed Product, receipt of revenues in respect of a sublicense to any Third Party for rights to the Licensed Product, the grant of a
<FONT STYLE="white-space:nowrap">sub-sublicense</FONT> by any such Third Party to any other party, or any other revenue stream such as assignment fees or upfront licensing fees, royalties, milestone payments, advanced royalties, other running
royalties, sublicensing fees, equity and options to equity or any other similar proceeds received whether in kind or cash, (market value of such equity, option to equity or other similar proceeds shall be determined by an internationally recognized,
independent, certified public accounting firm, selected by Ebumab and reasonably acceptable to Genmab) deriving from the Licensed Product; less any and all Direct Costs. Proceeds received in transaction that involve both the Licensed Product and
other products of Ebumab shall be equitably allocated all such products and only those allocated to the Licensed Product shall be included in the calculation of Profit under this Agreement. For clarification and notwithstanding the foregoing, Profit
shall exclude (a)&nbsp;proceeds received from its investors or creditors in bona fide equity or debt financing transactions, and (b)&nbsp;grants received from Third Parties which do not claim ownership of or rights to any intellectual property
rights to the Licensed Product, shall not be consider Profit. For further clarification, any Direct Costs deducted from such proceeds shall only be deducted one time from the first applicable profit calculation. Finally, Profit shall be determined
prior to application of any income or other direct taxes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.48</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Profit-Share</B>&#8221; has the meaning set forth in Section&nbsp;4.1. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.49</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Profit-Share Term</B>&#8221; has the meaning set forth in Section&nbsp;4.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.50</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>REA</B>&#8221; has the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.51</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Regulatory Authority</B>&#8221; means any federal, national, multinational, state, county,
city, provincial, or local regulatory agency, department, bureau or other governmental entity with authority over the marketing, commercialization, manufacture or sale of a pharmaceutical product in the Territory, including the FDA in the United
States and the EMA in the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.52</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>The Research Committee</B>&#8221; has the meaning set forth in Section&nbsp;3.2.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 8 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.53</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Sublicensee</B>&#8221; means a Third Party to whom Ebumab or any of its Affiliates grants an
express or implied sublicense under all or part of the Platform Technology to develop, manufacture, commercialize or use Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.54</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Target Binding Pair</B>&#8221; means a combination of two (2)&nbsp;different antigens or two
(2)&nbsp;different epitopes on a single antigen as defined by their unique UniProt/Swiss-Prot numbers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.55</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Term</B>&#8221; means the term of this Agreement determined in accordance with
Section&nbsp;9.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.56</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Territory</B>&#8221; means worldwide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.57</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Third Party</B>&#8221; means any individual, company, partnership or other legal entity of any
kind other than a Party or any of its Affiliates or their respective employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.58</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>United States</B>&#8221; or &#8220;<B>U.S.</B>&#8221; means the United States of America and
its territories and possessions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.59</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#8220;<B>Valid Claim</B>&#8221; means a claim of an issued and unexpired patent within the Platform
Technology Patent Rights that has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction from which no appeal can be taken or with respect to which an appeal is not taken
within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise or been dedicated to the public. A claim which at the time of the First Commercial Sale is part
of a pending patent application within the Platform Technology Patent Rights that has not been issued (i) [**] after the earliest filing date from which such claim takes priority, or (ii)&nbsp;by the [**] anniversary of the First Commercial Sale,
whichever earlier, shall not constitute a Valid Claim under this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2 LICENSE </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>License Grant</B>. Subject to the terms and conditions of this Agreement, Genmab hereby grants to Ebumab an
exclusive (even with respect to Genmab and its Affiliates) license under the Platform Technology to research, develop, make, have made, use, manufacture, import, export, offer for sale, sell, and otherwise commercialize Licensed Product in the
Territory within the Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Sublicensing</B>. Subject to Sections 2.3 and 2.4, the rights granted to Ebumab under
Section&nbsp;2.1 may be extended or sublicensed (with the right to sublicense through multiple tiers) to an Affiliate or sublicensed, in whole or in part, to a Third Party (such Third Party, a &#8220;<U>Sublicensee</U>&#8221;). Ebumab will, within
[**] after execution of any such sublicense agreement by Ebumab or any of its Affiliates provide Genmab with a true, complete and unredacted, with respect to sections relevant for assessment of any and all revenues payable to Ebumab, copy of such
sublicense agreement. In addition, Ebumab will provide name and address of the Sublicensee and a description of the rights granted, and the territory covered by the sublicense. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 9 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Genmab Right to Participate in any Disposal of Rights to Licensed Product</B>. In the event that
Ebumab contemplates the disposal of rights to the Licensed Product to achieve one of the outcomes listed in the examples provided in Exhibit 4.1, Sections (b)&nbsp;to (e) (inclusive), as permitted under this Agreement, by virtue of sale, license, or
otherwise, to a Third Party other than Novo, Genmab shall have the right to participate in any bidding process as a bona fide potential acquirer of such rights. For purposes of clarity, this right of Genmab shall be subject to any rights of first
negotiation to Licensed Product or similar right granted to Novo by Ebumab under the Ebumab-Novo Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Performance by Sublicensees</B>. Ebumab will be fully responsible for performance by each Sublicensee
of its obligations under this Agreement. Each sublicense granted by Ebumab pursuant to Section&nbsp;2.2 will contain terms and conditions consistent with this Agreement. Without limiting the foregoing, each sublicense agreement will contain
following provisions: (i)&nbsp;a requirement that any Sublicensee selling Licensed Products submit applicable sales or other reports to Ebumab to the extent necessary or relevant to the reports required to be made or records required to be
maintained under this Agreement; (ii)&nbsp;an audit requirement as to those Sublicensees selling Licensed Products consistent with that set forth in Section&nbsp;4.10 (Records and Audit under Financial Provisions); and (iii)&nbsp;a requirement that
such Sublicensee comply with the confidentiality provisions and restrictions on use with respect to Confidential Information of Genmab consistent with ARTICLE 6 (Confidentiality). If Ebumab becomes aware of a material breach by a Sublicensee of the
rights granted to Ebumab, or the obligations of Ebumab or a Sublicensee under this Agreement, Ebumab will promptly notify Genmab in writing of the particulars of the same and will use its Commercially Reasonable Efforts to have the Sublicensee cure
such material breach or to enforce the terms of such sublicense or to terminate such sublicense (which depending on the circumstances may be deemed a cure of the breach of such Sublicensee). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Responsibility</B>. Ebumab will, including through its Affiliates and Sublicensees, have sole responsibility
for research, development, manufacture, marketing, sale and use of the Licensed Products, and will be responsible for all of its costs and expenses associated with such activities. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Diligence </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Commitment</B>. Ebumab will use Commercially Reasonable Efforts during the Term to develop,
manufacture and obtain Marketing Approval for, and commercialize Licensed Products in all countries of the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Status report</B>. Ebumab will provide to Genmab a written report, on a [**] basis during the Term
describing progress on milestones and activities undertaken by Ebumab, its Affiliates and Sublicensees, the progress made on the Licensed Products and status on the use of the Platform Technology since the last report and activities planned for the
subsequent [**] period. Such reports shall include high-level information relating to the progress on <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and regulatory activities as well as any commercialization plans. Ebumab will send
the written status reports to the Alliance Manager appointed by Genmab. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 10 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3 GOVERNANCE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Alliance Managers</B>. No later than [**] after the Effective Date, each Party shall nominate one
(1)&nbsp;individual to act as a central contact for that Party (&#8220;<U>Alliance Manager</U>&#8221;), to whom any relevant queries and comments relating to the research, development, manufacturing and/or commercialization of the Licensed Products,
or other questions arising in respect of the Agreement, and reports and plans related hereto can be addressed by the other Party throughout the Term and who will ensure that such queries and comments are further directed within his/her organization
appropriately and promptly to ensure efficient communication and cooperation between the Parties. Either Party may replace its Alliance Manager at any time upon written notice to the other Party. Alliance Managers would be expected to attend all
meetings of the Research Committee, unless otherwise agreed by the Parties. Each Party shall pay for its own Alliance Manager&#8217;s time and activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Governance and Communication Management</B>. Promptly after the Effective Date, the Parties shall
form a steering committee consisting of [**] representatives from each Party (the &#8220;<U>Research Committee</U>&#8221;). The function of the Research Committee shall be to exchange information on progress made by Ebumab in respect of the Licensed
Product until Ebumab has filed an IND for such Licensed Product. The Research Committee shall have no authority to amend, modify or supplement the Agreement but it may propose modifications for consideration by the Parties. Any such modification to
the Agreement shall become effective only upon mutual written agreement of the Parties. The Research Committee shall meet from time to time upon the written request by either Party, but not less frequently than [**]. Further, a Party shall promptly
inform the other Party if any major improvements to the DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform are developed, and the Parties shall then set up a meeting. Meetings may be conducted by telephone conference or video
conference or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> as agreed between the Parties. Prior to a meeting, the Parties&#8217; Alliance Managers shall agree on an agenda specifying the topics to be
discussed at the meeting. Further, the Parties shall decide on which Party&#8217;s Alliance Manager shall record the minutes of the meeting in writing. Such minutes shall be approved subsequently by both Parties. Either Party may change its Research
Committee representatives upon written notice to the other Party. Each Party shall pay for its own time and participation on the Research Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4 FINANCIAL PROVISIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Profit-Share</B>. Subject to the terms and conditions of this Agreement (including Section&nbsp;4.4
below), in consideration for the licenses granted to Ebumab hereunder: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>With respect to each Licensed Product, for the period commencing upon the Effective Date and ending upon
First Commercial Sale</B> of such Licensed Product, Ebumab shall pay to Genmab [**] Percent ([**]%) of all and any Profit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 11 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>With respect to each Licensed Product, from First Commercial Sale</B> of such Licensed Product, and lasting
for the remainder of the Term of this Agreement, Ebumab will pay to Genmab [**] Percentage ([**] %) of all and any Profit in territories where Ebumab commercializes Licensed Product itself, and [**] Percent ([**]%) of all and any Profit in
territories where a Third Party, other than Novo, commercializes Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Examples</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of Profit-Share calculations are included in <U>Exhibit 4.1</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Profit-Share Term</B>. The Profit-Share shall apply on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis until the later of (i)&nbsp;twelve (12) years from the date of the First
Commercial Sale of the Licensed Product in such country, or (ii)&nbsp;the date of expiration of the last to expire Platform Technology Patent Right Covering the Licensed Product in said country (the &#8220;<U>Profit-Share Term</U>&#8221;). In the
event that during the Profit-Share Term, such Licensed Product in a country is not Covered by a Valid Claim of a Platform Technology Patent Right, and solely with respect to Profit-Share relating to sales of Licensed Product under
Section&nbsp;4.14.1(b) and not other revenue streams relating to Licensed Product, the Profit-Share rate applicable to sales of Licensed Product shall be reduced by [**] percent ([**]%) on a Licensed
<FONT STYLE="white-space:nowrap">Product-by</FONT> Licensed Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis in such country for the remainder of the Profit-Share Term.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Novo reacquires rights to Licensed Product by direct or indirect means</B>. If Novo requires rights to
Licensed Product, Ebumab shall not be involved in any ongoing agreement between Genmab and Novo with respect to such Licensed Product in such territory for which the rights are granted. [**]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sale of </B><B>Ebumab</B><B>&#8217;</B><B>s</B><B> Business or Assets</B>. In the event of a Change of
Control for a lump sum, i.e. no payments of milestones or royalties received after such sale (except in the case of earn-outs or contingent value rights), Genmab is to receive a [**] percent ([**]%) Profit-Share with respect to such lump sum and of
such earn-outs or contingent value rights. For clarity, this Section&nbsp;4.4 shall not apply in case of a sale to Novo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Payments; Reports</B>. For the Term of this Agreement, Ebumab shall furnish to Genmab written reports
(hereinafter the &#8220;<U>Financial Report</U>&#8221;), within [**] following the end of each Calendar Quarter, for which Profit-Share are due, showing: (i)&nbsp;the calculation of aggregated Profit of Licensed Products generated during the
relevant Calendar Quarter segmented on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, in United States Dollars (USD) translated from local currency; and (ii)&nbsp;the calculation of the
Profit-Share which have accrued hereunder in respect to Profit in determining the amount due. Furthermore, as soon as reasonably practicable, but in any event no later than [**] after each Calendar Quarter, Ebumab shall provide Genmab with a
&#8220;flash sales report&#8221; in order to give Genmab an indication of the magnitude of the Profit-Share that are likely to be due to it pursuant to the applicable Financial Report. Such &#8220;flash sales report&#8221; shall be provided as a
courtesy estimate only and shall not be considered binding in any way.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 12 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ebumab will pay Genmab the Profit-Share received in a Calendar Quarter within [**] of the end
of such Calendar Quarter in USD to: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>CASH &#8212; WIRE TRANSFER </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[**] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IBAN: [**] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SWIFT: [**] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For credit to: <B>&#8195;</B>Account Name:<B>
[**]</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">or to such other account as to which Genmab provides written notice to Ebumab in accordance with Section&nbsp;11.3. Genmab shall
invoice Ebumab for the Profit-Share accordingly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Taxes</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab shall make all payments to Genmab under this Agreement without deduction or withholding for taxes except
to the extent that any such deduction or withholding is required by law in effect at the time of payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any tax required to be withheld on amounts payable under this Agreement will promptly be paid by Ebumab on
behalf of Genmab to the appropriate governmental authority, and Ebumab will furnish Genmab with proof and explanation of payment of such tax within [**] from the payment of such tax to the appropriate governmental authority. Any such tax required to
be withheld will be an expense of and borne by Genmab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ebumab and Genmab will cooperate with respect to all documentation required by any taxing authority or
reasonably requested by Ebumab to secure a reduction in the rate of applicable withholding taxes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Ebumab had a duty to withhold taxes in connection with any payment it made to Genmab under this Agreement
but Ebumab failed to withhold, and such taxes were assessed against and paid by Ebumab, then Genmab will indemnify and hold harmless Ebumab from and against such taxes (including interest but excluding penalties), but only to the extent covered by
the payment received from Ebumab. If Ebumab makes a claim under this Section&nbsp;4.6 (d), it will comply with the obligations imposed by Section&nbsp;4.6 (a) as if Ebumab had originally withheld taxes from a payment to Genmab.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 13 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All payments due to the terms of this Agreement are expressed to be exclusive of value added tax (VAT) or
similar indirect taxes. VAT/indirect taxes shall be added to the payments due to the terms if legally applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>United States Dollars</B>. All dollar ($) amounts specified in this Agreement are United States dollar
amounts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency Exchange</B>. All payment to be made hereunder by one Party to the other Party shall be computed
and paid in U.S. dollars. With respect to sales of a Licensed Product invoiced in a currency other than U.S. dollars such amounts and amounts payable will be expressed in such currency and converted to U.S. dollars using the exchange rate mechanism
generally applied by such Party, provided that such mechanism is in compliance with IFRS. Ebumab will disclose sales in its original reporting currency and the U.S. dollar exchange rate used for the Financial Report. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.9</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Late Payments</B>. Any undisputed payments or portions thereof due hereunder which are not paid on
the date such payments are due under this Agreement will bear interest at a rate equal to [**] percent points above the then-applicable base lending rate of the European Central Bank, calculated on the number of days such payment is delinquent,
compounded on the last day of each Calendar Quarter using a three hundred sixty-five (365)&nbsp;day year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.10</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Records and Audits</B>. Ebumab will keep complete and accurate records relating to the calculations
of Profit (including the allocation of any proceeds received in a transaction that involves both the Licensed Product and other products of Ebumab) generated in the then current Calendar Year, and during the preceding [**]. Genmab will have the
right, [**] at its own expense, to have an internationally recognized, independent, certified public accounting firm, selected by it and reasonably acceptable to Ebumab, review any such records of Ebumab and its Affiliates, including sales reports
and any other reports and records received by Ebumab or its Affiliates from Sublicensees in accordance with Section&nbsp;2.4 (the &#8220;<U>Audited Party</U>&#8221;) in the location(s) where such records are maintained by the Audited Party upon
reasonable written notice (which shall be no less than [**] prior written notice) and during regular business hours and under obligations of strict confidence secured through a confidentiality agreement between the auditor an the Audited Party, for
the sole purpose of verifying the basis and accuracy of payments made and deductions taken under this ARTICLE 4 within the [**] period preceding the date of the request for review. At least [**] prior to inspecting any records, the auditor must
enter into a confidentiality agreement with the Audited Party that is reasonably satisfactory to the Audited Party. While inspecting such accounts and records, the auditor must abide by all of Ebumab&#8217;s standard rules and regulations and the
auditor will not be entitled to take copies of any such accounts and records. The auditor shall prepare and deliver to each Party at the same time a report setting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 14 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
out its findings no later than [**] after the audit has been completed. Before delivering the report to each Party, the auditor shall if necessary share its findings with Ebumab in order for any
uncertainties or discrepancies to be clarified. Any report by the auditor under this Section&nbsp;4.10 shall be deemed Confidential Information of Ebumab and Genmab shall keep such report and any other information received or learnt in connection
with the audit confidential. For clarification, no Calendar Year will be subject to audit under this Section&nbsp;4.10 more than [**]. In the event such inspection leads to the discovery of a discrepancy to Genmab&#8217;s detriment, Ebumab will,
within [**] after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy. Genmab will pay the full cost of the review unless the underpayment of amounts due to Genmab is greater than [**] percent ([**]%) of the
amount due for the entire period being examined, in which case Ebumab will pay the reasonable cost charged by such accounting firm for such review. Any undisputed overpayment of Profit-Share by Ebumab revealed by an examination will be paid by
Genmab back to Ebumab or it&#8217;s Affiliate, as applicable, at Ebumab&#8217;s discretion either as a (i)&nbsp;credit against future Profit-Share owed to Genmab or (ii)&nbsp;within [**] of Genmab&#8217;s receipt of notice from Ebumab pursuant to
the applicable report. Any disagreement regarding the results of any audit conducted under this Section&nbsp;4.10 will be subject to the dispute resolution provisions set forth in ARTICLE 10. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5 INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ownership</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab Ownership</B>. Ebumab Technology and Ebumab Technology Patent Rights shall be solely Controlled by
Ebumab. As between the Parties, Ebumab shall remain the sole owner of the Ebumab Background Intellectual Property and Novo Technology and nothing in this Agreement shall constitute a transfer of ownership or grant of a license to Genmab of such
Ebumab Background Intellectual Property or Novo Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Genmab Ownership</B>. Platform Technology and Platform Technology Patent Rights shall be solely Controlled
by Genmab and Ebumab shall, notwithstanding anything to the contrary in ARTICLE 3, promptly notify Genmab of any invention, discovery or other intellectual property specifically related to the Platform Technology generated by Ebumab, or its
Affiliates or Sublicensees in performance of activities under this Agreement and the REA (&#8220;Ebumab Platform Improvement&#8221;), and assign or arrange for the assignment of such Ebumab Platform Improvement and all and any rights therein to
Genmab, at Genmab&#8217;s sole expense and such rights shall be considered Platform Technology. For clarity and notwithstanding anything to the contrary herein, Ebumab Platform Improvement shall not include any invention, discovery and intellectual
property that are inseparable from and specifically related to the Licensed Product. For the avoidance of doubt, Ebumab shall have no obligation to assign, license or grant any rights under any of the Ebumab Technology, Ebumab Technology Patent
Rights, Ebumab Background Intellectual Property or Novo Technology to Genmab. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 15 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Prosecution and Maintenance of Patent Rights</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Platform Technology</B>. Genmab shall have the sole right, at its own discretion and expense, to file,
conduct prosecution and maintain (including the defense of any interference or opposition proceedings) all Platform Technology Patent Rights, in Genmab&#8217;s name. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab</B><B> Technology</B>. Ebumab shall have the sole right, at its discretion and expense, to file,
conduct prosecution, and maintain (including the defense of any interference or opposition proceedings) all Ebumab Technology Patent Rights, in Ebumab&#8217;s name. However, Ebumab is only entitled to publish Patent Rights in respect of Ebumab
Technology in relation to the Licensed Target Binding Pair under the Platform Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Term Extension</B>. The Parties shall cooperate with each other in good faith in gaining patent term
extension (including those extensions available under U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary Certificate of Protection of Member States of the EU and other similar measures in any other country)
wherever applicable to Patent Rights that Cover the Licensed Product in the Territory. Ebumab shall have the authority to decide on which Ebumab Technology Patent Right to seek patent term extension, <I>provided</I>, however, that Ebumab shall not
have the right to seek any such patent term extension of any Platform Technology Patent Right without Genmab&#8217;s prior written consent, which Genmab may withhold in its sole discretion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Infringements</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices</B>. Each Party will promptly report in writing to the other Party any (i)&nbsp;known or suspected
infringement of any Ebumab Technology Patent Rights or Platform Technology Patent Rights or (ii)&nbsp;unauthorized use or misappropriation of any <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Ebumab Technology or <FONT
STYLE="white-space:nowrap">Know-How</FONT> comprised by Platform Technology by a Third Party, of which such Party becomes aware, in each case only to the extent relevant to the development, manufacture, commercialization or use of the Licensed
Product in the Territory, and will provide the other Party with all available information evidencing such infringement, or unauthorized use or misappropriation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Genmab First Right to Enforce Certain Patent Rights</B>. Genmab or its designated Affiliate will have the
first right, but not the obligation, to initiate a lawsuit or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise protect or enforce, Platform Technology Patent
Rights against a Third Party who is researching, making, using, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 16 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
selling, importing or in any other way exploiting a bispecific product in a country within the Territory that is targeting the Licensed Target Binding Pair, provided that Genmab shall not
initiate any lawsuit or take any enforcement action under this Section&nbsp;5.45.4(b) without first consulting Ebumab and giving good faith consideration to any Ebumab recommendation(s), and provided that for any Platform Technology Patent Right
Covering the Licensed Product, Ebumab shall have the right, at its own expense, to join such action as a party by representation in any such action by counsel of its own choice, and to the extent legally permittable, Ebumab will be allowed to make
separate claims towards such Third Party. Further, Ebumab and its Affiliates and Sublicensees will join such suit if the relevant court would lack jurisdiction if Ebumab or such Affiliate or Sublicensee were absent from such suit, and Ebumab or such
Affiliate or Sublicensee will execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by Genmab; provided, that Genmab will promptly reimburse all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable attorneys&#8217; fees and expenses) incurred by Ebumab and such Affiliates or Sublicensees in connection with joining such suit and providing such other requested
cooperation. Genmab and its Affiliates shall not be allowed to enter into any settlement that has a material adverse impact on the rights granted to Ebumab under this Agreement or result in a payment or other liability by Ebumab to a Third Party
without the prior written consent of Ebumab which shall not be unreasonably withheld. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab</B><B>&#8217;</B><B>s</B><B> Rights if Genmab Elects Not to Proceed</B>. If Genmab does not initiate
a lawsuit or take other appropriate action pursuant to Section&nbsp;5.4(b) with respect to a bispecific product which targets the Licensed Target Binding Pair within [**] after knowledge of such infringement or misappropriation or, to the extent
possible, within [**] before any statutory or regulatory deadline for filing such suit (or as soon as practically possible if shorter statutory or regulatory deadlines are applicable), then Ebumab will have the immediate right to initiate a lawsuit
or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise to protect or enforce the relevant Platform Technology Patent Rights. Genmab and its Affiliates will join
such suit if the relevant court would lack jurisdiction if Genmab or such Affiliates were absent from such suit, and Genmab and such Affiliates will execute such legal papers and cooperate in the prosecution of such suit as may be reasonably
requested by Ebumab provided, that Ebumab will promptly reimburse all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable attorneys&#8217; fees and expenses) incurred by Genmab
and such Affiliates in connection with joining such suit and providing such requested cooperation. Ebumab and its Affiliates and Sublicensees shall not be allowed to enter into any settlement to the detriment of Genmab without the prior written
consent of Genmab which shall not be unreasonably withheld. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 17 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ebumab</B><B>&#8217;</B><B>s</B><B> Right to Enforce Certain Patent Rights</B>. Ebumab or its designated
Affiliate or Sublicensee will have the sole right, but not the obligation, to initiate a lawsuit or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise protect or
enforce, Ebumab Technology Patent Rights against a Third Party. Genmab and its Affiliates will join such suit if the relevant court would lack jurisdiction if Genmab or such Affiliate were absent from such suit, and Genmab and such Affiliates will
execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by Ebumab; provided, that Ebumab will promptly reimburse all
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable attorneys&#8217; fees and expenses) incurred by Genmab and such Affiliates in connection with joining such suit and
providing such other requested cooperation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Enforcement Against Other Infringement of Genmab Patent Rights</B>. Except as provided in Sections 5.4(b)
and (c), Genmab will have the sole right, but not the obligation, to initiate a lawsuit or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement, or otherwise to protect or
enforce, Platform Technology Patent Rights during the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Right to Enforce <FONT STYLE="white-space:nowrap">Know-How</FONT></B>. Responsibility for preventing or
abating actual or threatened misappropriation of, or otherwise protecting <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Platform Technology or <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Ebumab Technology will be
determined in the same manner as the right to enforce certain Patent Rights under paragraphs (b), (c), (d) and (e)&nbsp;of this Section&nbsp;5.4. The protecting Party shall keep the other Party informed of the status of all such protecting
activities, and shall consider in good faith all comments of the other Party regarding any aspect of such protecting activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conduct of Certain Actions; Costs</B>. The Party initiating litigation for Third Party Infringements under
this Section&nbsp;5.4 will have the sole and exclusive right to select counsel for any litigation initiated by it pursuant to these Sections. The initiating Party will assume and pay all of its own <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in connection with any litigation or proceedings initiated by it pursuant to this Section, including the fees and expenses of the legal counsel selected by it.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recoveries</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Ebumab initiates litigation with respect to Platform Technology Patent Rights as permitted in accordance
with Sections 5.4(b) or (c)&nbsp;or, with respect to <FONT STYLE="white-space:nowrap">Know-How</FONT> comprised by Platform Technology under Section&nbsp;5.4(f), if Ebumab initiates proceedings claiming misappropriation of such <FONT
STYLE="white-space:nowrap">Know-How</FONT> (to be conducted in the same manner as if they were Patent Rights under this Section&nbsp;5.4), any damages, settlements, accounts of profits, or other financial compensation actually paid to Ebumab by a
Third Party based upon such litigation, after deducting Ebumab&#8217;s actual out of pocket expenses (including attorneys&#8217; fees and expenses) incurred in pursuing such litigation (such net amount, the &#8220;<U>Recovery</U>&#8221;), will be
treated as [**]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 18 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Genmab initiates litigation pursuant to Section&nbsp;5.4(b) and (e)&nbsp;or with respect to <FONT
STYLE="white-space:nowrap">Know-how</FONT> comprised by Platform Technology under Section&nbsp;5.4 (f), Genmab [**]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Invalidity Claims</B>. Each of the Parties will promptly notify the other Party in the event of any
legal or administrative action by any Third Party against an Ebumab Technology Patent Right or Platform Technology Patent Right Covering Licensed Product, of which it becomes aware, including any nullity, revocation, reexamination or compulsory
license proceeding. Responsibility for defending against any such action shall be determined in the same manner as enforcement of the relevant Patent Rights pursuant to Section&nbsp;5.4. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Infringement Claims</B>. If a Party becomes aware of any claim that the development, manufacture
or commercialization of Licensed Product infringes the Patent Rights of any Third Party in the Territory, such Party shall promptly notify the other Party. Ebumab shall have the first right to control the defense against such claims of infringement
at its sole cost, unless the infringement relates to the Platform Technology, in which case Genmab shall have the first right to control the defense at its sole cost, provided that Ebumab shall be entitled to participate in such defense. If Genmab
chooses not to defend against such claims of infringement related to the Platform Techn&#8195;&#8195;&#8195;&#8195;ology, Ebumab shall have the right to control such defense on its own and at its sole costs, provided that Genmab shall be entitled to
participate in such defense. With respect to any claims of infringement related to Platform Technology Patent Rights, no statements regarding the validity of these Patent Rights shall be made by Ebumab without Genmab&#8217;s prior written consent
which shall not be unreasonably withheld. Furthermore, Ebumab shall not admit any infringement of Third Party Patent Rights with respect to any aspects specifically related to the use of Platform Technology without Genmab&#8217;s prior written
consent which shall not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6 CONFIDENTIALITY </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Confidential Information</B>. During the Term and for a period of [**] after any termination or
expiration of this Agreement, each Party (the &#8220;<U>Receiving Party</U>&#8221;) agrees to keep Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information and not to
disclose to any Third Party, or use for any purpose, except, in each case, pursuant to, and in order to carry out, the terms and objectives of this Agreement (which, in the case of Ebumab and its Affiliates and Sublicensees, include activities
contemplated by the licenses granted pursuant to Article 2) or as otherwise specifically permitted under this Agreement, any Confidential Information of the other Party (the &#8220;<U>Disclosing Party</U>&#8221;). The terms of this Agreement will be
considered Confidential Information of both Parties, subject to permitted disclosures as set forth in this </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 19 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Article 6. The restrictions on the disclosure and use by the Receiving Party of Confidential Information of the Disclosing Party set forth in the first sentence of this Section&nbsp;6.1 will not
apply to any Confidential Information of the Disclosing Party that the Receiving Party can demonstrate: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was known by the Receiving Party or any of its Affiliates prior to disclosure by the Disclosing Party under
this Agreement (as evidenced by the receiving Party&#8217;s written records or other competent evidence); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or becomes part of the public domain through no fault or omission of the Receiving Party or any of its
Affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is disclosed to the Receiving Party or any of its Affiliates by a Third Party, to the best of Receiving
Party&#8217;s knowledge, having a legal right to make such disclosure without violating any confidentiality or <FONT STYLE="white-space:nowrap">non-use</FONT> obligation that such Third Party has to the Disclosing Party and provided such Third Party
is not disclosing such information on behalf of the Disclosing Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is independently developed by personnel of the Receiving Party or any of its Affiliates without the use of the
Confidential Information (as evidenced by the Receiving Party&#8217;s written records or other competent evidence) and other than in connection with activities under this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In addition, if either Party is required to disclose Confidential Information of the other Party by regulation, law or legal process, or of any
stock exchange, such Party shall wherever possible provide at least [**] Days prior written notice, along with a copy of such intended disclosure, to such other Party, will consider in good faith the other Party&#8217;s comments, will disclose only
such Confidential Information of such other Party as is required to be disclosed and will cooperate in the Disclosing Party&#8217;s efforts to obtain a protective order or to limit the scope of the required disclosures. Notwithstanding anything in
this Agreement to the contrary, either Party may disclose to bona fide potential or existing investors or lenders, potential acquirors/acquirees, and, in the case of Ebumab, to potential and existing Sublicensees, and, as to either Party, to such
Party&#8217;s consultants and advisors, the existence and terms of this Agreement to the extent necessary in connection with a proposed equity or debt financing of such Party, or a proposed acquisition or business combination or for purposes related
to this Agreement, so long as such recipients are bound in writing to maintain the confidentiality of such information by terms there are not less strict than the terms set forth herein. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted Disclosures</B>. Each Party agrees that it and its Affiliates will provide or permit access to
Confidential Information received from the other Party and such Party&#8217;s Affiliates and representatives only to the Receiving Party&#8217;s employees, consultants, advisors and bona fide potential acquirers and potential investors, and, in the
case of Ebumab as the Receiving </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 20 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Party, to service providers, investigators, Third Party contractors, potential and existing Sublicensees and distributors, in each case who are subject to obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> that would apply to such Confidential Information and are at least as stringent as the obligations applicable to the receiving Party under this Agreement. Genmab and Ebumab shall each remain responsible for
any failure by its Affiliates, and its and its Affiliates&#8217; respective employees, consultants, advisors and permitted contractors, licensors, Sublicensees and distributors, to treat such Confidential Information as required under
Section&nbsp;6.1 (as if such Affiliates, employees, consultants, advisors, contractors, licensors, Sublicensees and distributors were Parties directly bound to the requirements of Section&nbsp;6.1). Ebumab may also disclose Confidential Information
of Genmab to Regulatory Authorities and other governmental authorities, but solely in connection with the activities contemplated by this Agreement. Furthermore, each Party may disclose Confidential Information to the extent necessary in connection
with patent filings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publicity Related to the Agreement</B>. Except as otherwise expressly permitted in this Agreement, neither
Party will issue a press release, statement or public announcement relating to the existence or terms of this Agreement without the prior written approval of the other Party, which approval shall not be unreasonably withheld or delayed, except that
(i)&nbsp;a Party may issue such press release or public announcement if the contents of such press release or public announcement are consistent with a previously approved press release or have otherwise previously been made public other than
through a breach of this Agreement; (ii)&nbsp;either Party may disclose that they have entered into an agreement with the other Party with respect to the Platform Technology without disclosing the therapeutic area or any other information with
respect to the Licensed Product, and; (iii)&nbsp;a Party may issue such a press release or public announcement if required by applicable law or of any stock exchange; provided that to the extent possible, the issuing Party will provide the other
Party with a copy of any such proposed press release, statement or public announcement and give the receiving Party a reasonable period of time within which the receiving Party may provide any comments (but no less than [**]). If the receiving Party
provides any comments, the Parties will consult and work in good faith to prepare a mutually acceptable press release, statement or public announcement, subject to the understanding that the issuing Party shall have the final say in case the Parties
cannot agree. During the Term and except as otherwise provided for in this Agreement, Genmab will not make any public disclosure related to Ebumab&#8217;s or any of its Affiliates&#8217; or Sublicensees&#8217; activities under this Agreement or
related to the results generated by Ebumab or any of its Affiliates or Sublicensees with respect to Licensed Product without the prior written consent of Ebumab (not to be unreasonably withheld or delayed) except to the extent required by applicable
law, rule or regulation (including the disclosure requirements of the United States Securities and Exchange Commission or the securities exchange or other stock market on which such Party&#8217;s securities are traded). During the Term, in the event
Genmab is required by applicable law to publicly disclose any information provided by Ebumab related to Licensed Product or either Party is required by applicable law to disclose the terms of this Agreement, such Party will wherever possible give
the other Party at least [**] prior written notice, will provide to such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 21 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
other Party a copy of the required disclosure, will, if requested by such other Party, to the extent permitted by applicable law, request confidential treatment of any financial and other
material terms of this Agreement not previously disclosed under this Section&nbsp;6.3, and will consider in good faith any other comments of such other Party on such public disclosure. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return of Confidential Information</B>. Upon termination of this Agreement, the Receiving Party shall, at
the request of, and as directed by, the Disclosing Party, return or destroy Confidential Information of the Disclosing Party in the Receiving Party&#8217;s possession, and shall destroy any reports or notes in Receiving Party&#8217;s possession to
the extent containing the Disclosing Party&#8217;s Confidential Information, and any electronic copies of any of the foregoing, provided that (i)&nbsp;the Receiving Party may retain one (1)&nbsp;copy of Confidential Information of the Disclosing
Party for archival purposes, and (ii)&nbsp;neither Party shall be required to return or destroy copies of the other Party&#8217;s Confidential Information stored on automatically created system <FONT STYLE="white-space:nowrap">back-up</FONT> media.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Publication</B>. Subject to this Section&nbsp;6.5, Ebumab may on its own account freely make
publications related to a Licensed Product. However, to the extent such publication partly contains information on the Platform Technology, beyond the mere mentioning of Ebumab&#8217;s use of the
DuoBody<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform to generate bispecific antibodies, Genmab shall have [**] from receipt of a proposed publication to provide comments and/or proposed changes to Ebumab. To the extent such
comments and/or proposed changes pertain to the Platform Technology, Ebumab shall take into account the comments and/or proposed changes made by Genmab on any publication. If Genmab reasonably determines that the publication would entail the public
disclosure of Genmab&#8217;s Confidential Information and/or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned publication to Third Parties shall be delayed for such
period as may be reasonably necessary for deleting any such Confidential Information of Genmab (if Genmab has requested deletion thereof from the proposed publication), and/or the drafting and filing of a patent application covering such invention,
provided such additional period shall not exceed [**] from the date Ebumab first provided the proposed publication to Genmab. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7 REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual Representations</B>. Each Party hereby represents and warrants to the other Party, as of the
Effective Date, as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is duly organized and validly existing under the laws of its jurisdiction of incorporation and has the
corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution, delivery and performance of this Agreement by such Party has been duly and validly authorized
and approved by proper corporate action on the part of such Party. Such Party has taken all other action required by applicable law, its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 22 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> or any agreement to which it is a party or by which it or its assets are bound, to authorize such execution,
delivery and performance. Assuming due authorization, execution and delivery on the part of the other Party, this Agreement constitutes a legal, valid and binding obligation of such Party. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution and delivery of this Agreement, and the performance as contemplated hereunder, by such Party will
not violate any applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither the execution and delivery of this Agreement nor the performance hereof by such Party requires such
Party to obtain any permit, authorization or consent from any governmental authority (except for any approval by Regulatory Authority, pricing or reimbursement approvals, manufacturing-related approvals or similar approvals necessary for
development, manufacture or commercialization of Licensed Products), or from any other person, and such execution, delivery and performance by such Party, including the granting of the licenses granted under this Agreement, will not result in the
breach of, or give rise to any conflict, termination of, rescission, renegotiation or acceleration under any agreement or contract to which such Party may be a party existing as of the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Genmab&#8217;s Representations and Warranties</B>. Genmab hereby makes the following representations and
warranties to Ebumab as of the Effective Date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab has the right to grant to Ebumab the licenses described in ARTICLE 2 of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genmab has full legal or beneficial title and ownership to the Platform Technology Patent Rights and, to
Genmab&#8217;s knowledge, Exhibit A contains a complete and correct list of all Platform Technology Patent Rights existing as of the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Platform Technology Patent Rights are not subject to any restrictions, liens or encumbrances that would
limit the rights to be granted to Ebumab under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Genmab&#8217;s knowledge, no Third Party is infringing any of the Platform Technology Patent Rights
identified on Exhibit A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Genmab&#8217;s knowledge, there are no administrative proceedings or litigation seeking to invalidate or
otherwise challenge the Platform Technology Patent Rights or threat of such proceedings or litigation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the Platform Technology Patent Rights is the subject of any pending
<FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition, interference or litigation proceedings. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 23 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To Genmab&#8217;s knowledge, there have been no inventorship or ownership challenges with respect to any of the
Platform Technology Patent Rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance with Law</B>. Each Party shall comply with all applicable laws in its performance of activities
contemplated under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disclaimer</B>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY HERETO MAKES ANY
REPRESENTATIONS AND NEITHER PARTY EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING ANY LICENSED PRODUCT), INCLUDING ANY WARRANTY OF MERCHANTABILITY,
NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, OR FITNESS FOR A PARTICULAR PURPOSE. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8 INDEMNIFICATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Indemnification by </B><B>Ebumab</B>. Ebumab will indemnify, hold harmless, and defend Genmab, its
Affiliates, and their respective directors, officers, employees and agents (the &#8220;<U>Genmab Indemnitees</U>&#8221;) from and against any and all damages, liabilities, costs, expenses and amounts paid in settlement (collectively,
&#8220;<U>Losses</U>&#8221;) incurred in connection with any Third Party claim arising out of or resulting from, directly or indirectly; (i)&nbsp;any material breach of, or inaccuracy in, any representation or warranty made by Ebumab in this
Agreement, or any material breach or violation of any term of this Agreement by Ebumab; (ii)&nbsp;the negligence or wilful misconduct of Ebumab, its Affiliates and their respective Sublicensees, and their respective directors, officers, employees,
consultants, agents and contractors; and (iii)&nbsp;the research, development, manufacture, commercialization, or use of Licensed Product by Ebumab and its Affiliates and Sublicensees in the Territory under this Agreement. Notwithstanding the
foregoing or anything in this Agreement to the contrary, Ebumab will have no obligation to indemnify the Genmab Indemnitees for any Losses as to which Genmab is obligated to indemnify Ebumab Indemnitees under Section&nbsp;8.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification by Genmab</B>. Genmab will indemnify, hold harmless, and defend Ebumab, its Affiliates and
their respective directors, officers, employees and agents (the &#8220;<U>Ebumab Indemnitees</U>&#8221;) from and against any and all Losses incurred in connection with any Third Party claim arising out of or resulting from, directly or indirectly,
(i)&nbsp;any material breach of, or inaccuracy in, any representation or warranty made by Genmab in this Agreement, or any material breach or violation of any term of this Agreement by Genmab; or (ii)&nbsp;the negligence or wilful misconduct of any
Genmab Indemnitee. Notwithstanding the foregoing, or anything in this Agreement to the contrary, Genmab will have no obligation to indemnify the Ebumab Indemnitees for any Losses as to which Ebumab is obligated to indemnify Genmab Indemnitees under
Section&nbsp;8.8.1. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 24 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification Procedure</B>. In the event of any such claim against any Ebumab Indemnitee or Genmab
Indemnitee (individually, an &#8220;<U>Indemnitee</U>&#8221; or &#8220;<U>indemnified Party</U>&#8221;), the indemnified Party shall promptly notify the other Party (the &#8220;<U>indemnifying Party</U>&#8221;) in writing of the claim and the
indemnifying Party shall manage and control, at its sole expense, the defense of the claim and its settlement. The indemnified Party will, cooperate with the indemnifying Party and may, at the indemnified Party&#8217;s own cost, be represented in
any such action or proceeding by the indemnified Party&#8217;s own counsel. The indemnifying Party will not be liable for any settlements entered into by any Indemnitee without the indemnifying Party&#8217;s prior written authorization.
Notwithstanding the foregoing, if the indemnifying Party believes that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in this ARTICLE 8&nbsp;may apply, the indemnifying Party will promptly notify the
Indemnitees, who shall then have the right to be represented in any such action or proceeding by separate counsel at their expense; provided that the indemnifying Party will be responsible for payment of such expenses if the Indemnitees are
ultimately determined to be entitled to indemnification from the indemnifying Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Limitation of Liability</B>. WITH THE EXCEPTION OF DAMAGES ARISING OUT OF ANY BREACH OF ARTICLE 6
(CONFIDENTIALITY) OR OUT OF THE GROSS NEGLIGENCE OR WILFUL MISCONDUCT OF THE LIABLE PARTY, NEITHER PARTY HERETO WILL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, INDIRECT OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR
THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. FOR AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION 8.4 IS INTENDED TO LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 9 TERM AND TERMINATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Term</B>. This Agreement will become effective as of the Effective Date, and will continue in full
force and effect, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
until expiration of the last to expire Profit-Share Term for such Licensed Product in such country, unless earlier terminated in accordance with this ARTICLE 9 (&#8220;<U>Term</U>&#8221;). Upon expiration of the Term under the preceding sentence
(but not earlier termination of this Agreement) for a Licensed Product in a country, the licenses granted to Ebumab under ARTICLE 2 with respect to such Licensed Product in such country will continue and will convert to perpetual, fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination for Convenience by Ebumab</B>. Ebumab will have the right to terminate this Agreement in its
entirety basis at any time and for any reason upon at least <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-hundred-and-twenty</FONT></FONT></FONT> (120)&nbsp;days&#8217; prior written notice to
Genmab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination for Cause</B>. This Agreement may be terminated at any time during the Term upon written
notice by either Party if the other Party is in material breach of its obligations hereunder and has not cured such material breach within [**] after written notice describing the nature of such material breach is provided to the breaching Party. To
the extent such material breach involves the failure to make payment when due, such breach must be cured within [**] after written notice hereof is given by Genmab to Ebumab. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 25 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Upon Insolvency or Bankruptcy</B>. Subject to any mandatory provisions of applicable law, either
Party may terminate this Agreement if, at any time, the other Party files in any court or agency, pursuant to any applicable law or regulation, a petition in bankruptcy or insolvency or dissolution or liquidation or for reorganization or for an
arrangement or for the appointment of a receiver or trustee of all or substantially all of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary
petition against it, filed in any insolvency, dissolution or liquidation proceeding, and any petition or filing is not be dismissed within [**] after the filing thereof. With respect to any bankruptcy proceeding under U.S. bankruptcy laws, or
applicable foreign equivalent laws, all license rights granted by Genmab to Ebumab under this Agreement are and shall otherwise be deemed licenses of rights to &#8220;intellectual property&#8221; as defined in Section&nbsp;101(35A) of Title 11 of
the United State Code, as amended (such Title 11, the <U>&#8220;Bankruptcy Code&#8221;</U>). In the event of its bankruptcy, Genmab agree not to interfere with Ebumab&#8217;s exercise of rights and licenses to intellectual property licensed
hereunder and embodiments thereof in accordance with this Agreement and agree to use reasonable efforts to assist Ebumab to obtain such intellectual property and embodiments thereof in the possession or control of Third Parties as reasonably
necessary for Ebumab to exercise such rights and licenses in accordance with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination for Challenge of Platform Technology Patent Rights</B>. Genmab may terminate this
Agreement in its entirety upon [**] written notice if Ebumab or any of its Affiliates or Sublicensees (directly or indirectly, individually or in association with any other person or entity)&nbsp;(a) initiate or request an interference or opposition
proceeding with respect to any Platform Technology Patent Right, (b)&nbsp;make, file or maintain any claim, demand, lawsuit or cause of action to challenge the validity or enforceability of any Platform Technology Patent Right ((a) and
(b)&nbsp;jointly referred to as a &#8220;<U>Patent Challenge</U>&#8221;), then Genmab may terminate this Agreement upon [**] prior written notice to Ebumab. Any such termination shall not become effective if Ebumab has withdrawn such Patent
Challenge before the end of such notice period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination if Novo Regains Control of Rights to Licensed Product</B>. In the event that, by any means
whatsoever, Novo regains control from Ebumab of the exclusive rights with respect to a territory to develop, make, have made, use, manufacture, register, import, export, distribute, market, offer for sale, sell, have sold and/or otherwise
commercialize the Licensed Product, this Agreement shall terminate with respect to such territory for which the exclusive rights to Novo are granted and shall otherwise survive. Where such exclusive right to Licensed Product is granted worldwide to
Novo, this Agreement shall terminate in its entirety. For clarity, where the rights regained by Novo with respect to a territory are not exclusive, but <FONT STYLE="white-space:nowrap">co-exclusive</FONT> or
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> this Agreement shall remain in effect with respect to such territory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 26 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effect of Termination</B>. Upon the termination of this Agreement in its entirety, nothing herein shall be
construed to release either Party from any obligation that has accrued prior to the effective date of such termination, and Ebumab shall remain obligated to provide an accounting for and to share Profit earned prior to the date of termination. In
the event of any termination of this Agreement, (i)&nbsp;the licenses granted to Ebumab under ARTICLE 2 shall terminate; and (ii)&nbsp;all rights granted hereunder by Genmab shall revert to Genmab for the benefit of Genmab (iii)&nbsp;all materials,
information and data generated under the license incorporating Platform Technology shall be destroyed by Ebumab immediately and certified in writing to Genmab. With respect to the Licensed Product, Ebumab shall wind-down any clinical trials and
destroy any Licensed Products, in accordance with applicable laws and in a manner designed to preserve the health and welfare of any clinical trial subjects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival</B>. Any expiration or termination of this Agreement will be without prejudice to the rights of
either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including payment obligations arising prior to such expiration or termination. The provisions of ARTICLES 1, 6, 8, 9, 10, 11 and Sections
4.5, 4.6, 4.7, 4.8, 4.9, 4.10, 5.1 and 5.2 will survive any expiration or termination of this Agreement and all other provisions contained in this Agreement that by their explicit terms survive expiration or termination of this Agreement, will
survive. Except as set forth in this ARTICLE 9, upon termination or expiration of this Agreement all other rights and obligations of the Parties under this Agreement terminate. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 10 DISPUTE RESOLUTION AND GOVERNING LAW </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continuance of Rights and Obligations During Pendency of Dispute Resolution</B>. If there are any disputes
in connection with this Agreement, all rights and obligations of the Parties shall continue until such time as any dispute has been resolved in accordance with the provisions of this ARTICLE 10. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Governing Law and Jurisdiction</B>. The validity, construction and performance of this Agreement will
be governed by and construed in accordance with the laws of the Kingdom of Denmark excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of
another jurisdiction. Any dispute or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be settled by arbitration in accordance with the Rules of Procedure of the Danish Institute of
Arbitration (the &#8220;<U>Institute</U>&#8221;) in force when such proceedings are commenced. The arbitration tribunal shall be composed of a sole arbitrator appointed by the Institute. The place of arbitration shall be Copenhagen, Denmark. The
language of the arbitral proceedings shall be English. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 11 MISCELLANEOUS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure</B>. Neither Party will be held liable or responsible to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term, other than an obligation to make payments hereunder, when such failure or delay is caused by or results from fire, floods, embargoes, government
regulations, prohibitions or interventions, war, acts of war (whether war be declared or not), </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 27 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
insurrections, riots, civil commotions, terrorism, acts of God or any other cause beyond the reasonable control of the affected Party to anticipate, prevent, avoid or mitigate (a &#8220;<U>Force
Majeure Event</U>&#8221;); provided that (i)&nbsp;the affected Party provides prompt written notice to the other Party of such failure or delay, (ii)&nbsp;the affected Party uses Commercially Reasonable Efforts to mitigate the effects of the Force
Majeure Event, and (iii)&nbsp;the affected Party immediately resumes performance upon cessation of the Force Majeure Event. Notwithstanding the foregoing, to the extent that a Force Majeure Event continues for a period in excess of [**], the
affected Party shall promptly notify in writing the other Party of such continued Force Majeure Event and within [**] of the other Party&#8217;s receipt of such notice, the Parties shall negotiate in good faith either (a)&nbsp;a resolution of the
Force Majeure Event, if possible, (b)&nbsp;an extension by mutual agreement of the time period to resolve, eliminate, cure or overcome such Force Majeure Event, (c)&nbsp;an amendment of this Agreement to the extent reasonably possible, or
(d)&nbsp;an early termination of this Agreement. If a solution under subsection (a) - (d) has not been reached after [**] of the other Party&#8217;s receipt of such notice, then the Party not affected shall be entitled to give notice to the affected
Party to terminate this Agreement in relevant part, specifying the date (which shall not be less than [**] after the date on which the notice of termination is given) on which termination will take effect. Such a termination notice shall be
irrevocable, except with the consent of both Parties, and upon termination the effects of termination set forth in Section&nbsp;9.3 shall apply. Notwithstanding the foregoing, any failure or delay in fulfilling a term shall not be considered a
result of a Force Majeure Event if it arises from a failure of Ebumab or Genmab to comply with applicable laws. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Further Assurances</B>. Each Party hereto agrees to perform such acts, execute such further instruments,
documents or certificates, and provide such cooperation in proceedings and actions as may be reasonably requested by the other Party in order to carry out the intent and purpose of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Notices</B>. Any notice required or permitted to be given under this Agreement will be in writing and
will be deemed to have been properly given if delivered, in person or by an internationally recognized overnight courier, to the addresses given below or such other addresses as may be designated in writing by the Parties from time to time during
the Term or on the date sent by <FONT STYLE="white-space:nowrap">e-mail</FONT> of a PDF document if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; provided
however, such notice shall also be delivered via hand, overnight courier, or certified or registered mail. Delivery made pursuant to this Section&nbsp;11.3 shall be deemed received on the day following the date of the notice. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 28 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">In the case of Genmab:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head of Legal</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [**]</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy
to:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[**]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the address of Genmab as registered in the Danish Central Business
Register (or any successors hereof)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the address of Genmab as registered at the GENMAB&#8217;s official homepage (currently www.genmab.com)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">In the case of Ebumab:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [**]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the address of Ebumab Hemophilia ApS as registered in the Danish Central Business Register (or any successors hereof)</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment</B>. This Agreement may not be assigned or otherwise transferred by either Party, without the
written consent of the other Party such consent not to be unreasonably withheld, conditioned or delayed; provided, however, that either Party may, without such consent, assign this Agreement, in whole or in part, (i)&nbsp;to any of its Affiliates,
and (ii)&nbsp;to a Third Party successor or purchaser of all or substantially all of its business or assets to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other similar transaction, provided that, the Third
Party successor or purchaser provides written notice to the other Party that such Third Party agrees to be bound by the terms of this Agreement. In case of an assignment to an Affiliate of a Party, such Party shall continue to be responsible for the
satisfaction, meeting and fulfilling of any obligation, in whole or in part, under this Agreement after the assignment. Any purported assignment in violation of this Section&nbsp;11.14 will be void. Any permitted assignee shall assume all
obligations of its assignor under this Agreement. Notwithstanding the above, Ebumab shall not have the right to assign this Agreement, in whole or in part, to Novo or any of Novo&#8217;s Affiliates. For clarity, should Novo regain control by any
means whatsoever of rights relating to the Licensed Product, then Novo&#8217;s license to Platform Technology shall be governed by separate agreements already in place between Novo and Genmab. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Affiliate Performance</B>. Any obligation of Genmab or Ebumab under or pursuant to this Agreement may be
satisfied, met or fulfilled, in whole or in part, at such Party&#8217;s sole and exclusive option, either by such Party directly or by any Affiliate or Sublicensee (only in the case of Ebumab and subject to Section&nbsp;2.2 of such Party that such
Party causes to satisfy, meet or fulfill such obligation, in whole or in part. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment</B>. The Parties hereto may amend, modify or alter any of the provisions of this Agreement, but
only by a written instrument duly executed by both Parties hereto. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 29 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement</B>. This Agreement, along with all Exhibits attached hereto, contains the entire
understanding of the Parties with respect to the subject matter hereof and supersedes all prior agreements, whether written or oral, including the REA. Each Party confirms that it is not relying on any representations, warranties or covenants of the
other Party except as specifically set out in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Benefit to Third Parties</B>. The provisions of this Agreement are for the sole benefit of the Parties
and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other Persons. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver</B>. The failure of a Party to enforce at any time for any period any of the provisions of this
Agreement will not be construed as a waiver of such provisions or of the rights of such Party thereafter to enforce each such provision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Implied Licenses</B>. Except as expressly and specifically provided under this Agreement, the Parties
agree that neither Party is granted any implied rights to or under any of the other Party&#8217;s current or future patents, trade secrets, copyrights, moral rights, trade or service marks, trade dress, or any other intellectual property rights.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relationship of the Parties</B>. The Parties agree that their relationship established by this Agreement is
that of independent contractors. Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish a partnership or joint venture, and nor shall this Agreement create or establish an
employment, agency or any other relationship. Except as may be specifically provided in this Agreement, neither Party shall have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur
any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability</B>. If any provision of this Agreement is held unenforceable by a court or tribunal of
competent jurisdiction in a final unappealable order because it is invalid or conflicts with any law of any relevant jurisdiction, then such provision will be inoperative in such jurisdiction and the remainder of this Agreement shall remain binding
upon the Parties hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation</B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.1 General</B>. Unless the context of this Agreement otherwise requires, (i)&nbsp;words of one gender include the other gender; and
(ii)&nbsp;words using the singular or plural number also include the plural or singular number, respectively. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.2 Other Definitional and Agreement References</B>. References to any agreement, contract, statute, act, or regulation are to that
agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 30 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.3 Capitalization</B>. Any capitalized terms used in any Exhibit but not otherwise
defined therein, shall have the meaning as defined in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.4 Date References</B>. References from or through any date
mean, unless otherwise specified, from and including or through and including, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.5 Exhibits</B>. All Exhibits
annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.6 Person References</B>. References to any Person include the successors and permitted assigns of that Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.7 References to Parts of this Agreement</B>. References to Articles, Sections and Exhibits are to Articles, Sections and Exhibits of
this Agreement unless otherwise specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.8 Other Definitional and Interpretative Provisions</B>. The words
&#8220;hereof&#8221;, &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. Whenever the words
&#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation&#8221;, whether or not they are in fact followed by those words or words
of like import. The word &#8220;or&#8221; is used in the inclusive sense (and/or). &#8220;Writing&#8221;, &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a
visible form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.9 Headings</B>. The Article and Section headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.13.10 Expenses</B>. Except as otherwise expressly
provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this
Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.14</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Counterparts</B>. This Agreement may be executed in any number of counterparts (including a portable
document format (&#8220;PDF&#8221;) version), each of which shall be deemed an original, but all of which together shall constitute one and the same document. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page is intentionally left blank; Signature page follows. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 31 of 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIDENTIAL &#8211; EXECUTION VERSION </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>Genmab and Ebumab have executed this Agreement as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For and on behalf of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Genmab A/S </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1 April 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Birgitte Stephensen</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Birgitte Stephensen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Position:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior&nbsp;Vice&nbsp;President,&nbsp;IPR&nbsp;&amp; Legal</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For and on behalf of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ebumab
Hemophilia ApS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2020-03-31</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Johan Faber</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">Johan H. Faber</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Position:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"><FONT STYLE="white-space:nowrap">Co-Founder&nbsp;&amp;</FONT> CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ebumab ApS</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ole Maal&oslash;esvej 3</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[**]</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 32 of 32 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g50309g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g00a01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1]^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'V$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(002,1-!!2(R46$4<8&1H14C0K'1,U+!X?!B@O$DLO_:  P# 0 "$0,1 #\
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M $V^:>LY?]-OFAZE6W1:CUG+_IM\T]9R_P"FWS0]2K;HM1ZSE_TV^:>LY?\
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M:2T @N#3R'+?&Y!0O'#%^ZT@J9-+V*6$.-/'6/$I!V!<S#,_7E8O2U?+%5]
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M2/6UNKKB9K \39::ILC9"3][X&#=N!\%TZJ!;4R@^]E0RR^%I$1'.(B("(B
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M-KRMCZ5H](_)^I=1OC#O6._""6\6>6.$<N><J>H3&A$((YC"] )Y#*(>(F%
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MZG>'S5+(3U;7R$ DNY8:W)\"D+4C<N:W&Q#3'1UH_4ULJ8#=H*MTLK&3-,C
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MYS._9:IY:?P#%+KKXAL41$6$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0<CUU^<E-\)/Z@IOI;\6"A&NOSDIOA)_4%-]+?BP0]DE1$0:
MR3\O0_NS_=;-:R3\O0_NS_=;- 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 11;I%UQ:=!6+UI>C,6/>(HHX6<3I)#G#>X
M<N97%6?=/M-4)#I6I]7DX#A,.(_!V.$GP0?2:+2Z-U-;M7:>I;S9Y"^EJ&Y
M<,.81S:X=A"W2 AY(AY((]/^'E_:*MJY/^'E_:*MJ''/D1%!>EK45QLUJMUO
MT\X,OMZJFT=)(6@B+WW[[; CS0B-SI.D7,.D.J?9]6='3:FXR"!E6\54\K^$
M2 1G+G]F-LJ0V+I'TG?;HVW6R\125CSB-CV/CZW]@N #D3VSK<)=C?/:G/FH
MYJK6^GM+/CCO=RC@GD&60M:Z20COX6@D#XK.TWJ&TZFH366&NBK:<.X'.CR"
MUW<0=P?BB-3Y;5%K;)?+;?&U;K35LJ12S.IYBT$<$@YMW"PJO6-AHYKM#4W*
M-DEJ:U]:W@<>I#OFDX&^<]F4-2WZ*&7+I0T=;;AZ'5WR%LHQQ.8Q[V,R,@.<
M 0#ORRI7+6TL5 ZNEJ(FT;8^M,Y<.#@QGBSW80U+(1<FUSTE:;O6BM14=@O3
M7W$4<AAPU\9>0-^!Q !/PW4\T$]\NBK$^1SGO=1Q$N<<DGA")FLQ&V]&W)%S
M6]]+%FMFO8K-+7TK+=#!)Z;.YCRZ*<'#8QC[=BI+===::M5FHKK7W:&*BK6A
M],[A<73 \BUH'%]B';*2H%HM+:ML>JH99+#<8JHQ?A(\%CV?%K@#]:W%6XLI
M)WL.'-C<0?$ HC7LNX':B@G0G>[CJ#0<5?>*IU56&JGC,C@ 2UKR -O!6[M?
M+C#TV:>LD54]MKJ;9//-3X&'O;G!SSVPB>WG2?HN(:6U[>H^F6ZVF\5KI['4
M7&:VTD;F#[Q*T!S ".\;;KIG2'J)NE]'W&Y\YV,ZNG;VNF=LP#OW(\D3-9B=
M)&BYIT"7J]WK3MU.IJ]]=74M<ZG,CFAN,-&6X '(Y4>Z/Z?6VL+%475FNJRC
M(JYH&0^C1O:.!VV^,X0[/+MB'<87.>BW4U\KK[J336J)*>JN-E>P>F4\? R5
MKL\QV%2C7FH6Z4TA=;V^,2^AP\;6'DYQ(#1YD(CMF)TWR+CC[=T@TFD?E4_5
MSYKDRG]/DM9@9Z,68XC&-L[-[>]9M]UQ<M16_1]#HR=M%<M11FHDG?'Q&E@:
M/;(![<Y ^":3V.K)C*Y2VKU+H76-BI+S?Y+Y8+Q(:4R54;6RT\^"6D$#YIQR
M6WNFG-;7>\5TDFKA:+:V0BBAMT +BSOE<X;GER\4.W\I^BY5I*Z:GO=NUAIF
MINV-1627J:>YPQAO6D@EG$,8[ #\5*>B[5#M7:/I;E.P1UK'.IJM@& V9AP[
M'@=C]:(FNDL3&^>U$1 B(B!/YHB)$1$!$1$+%?2LK:"JI)2X1U$3X7%O,!S2
M#CQW7%--='/2'HJFFMFE=26@VN24R-Z^G/$T\LD%IWP!G!7<D1:+3#FW1?T;
M5&EKS<[]?KJVZWVX#$DK(^%C-\DC.Y)V'9L%TE$1$S,\R(B(@1$0$1$!$1 1
M$01>N_.9W[+5/+3^ 8H'7?G,[]EJGEI_ ,4NNOB&Q1$181$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!R/77YR4WPD_J"F^EOQ8*$:Z_.
M2F^$G]04WTM^+!#V25$1!K)/R]#^[/\ =;-:R3\O0_NS_=;- 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!KM062W:@M<M
MNO-)%5T<N.**09!QR7%/NH-26&RZ%?I&E@IA<:W@=%!#& *:,/!ZP #V3M@#
MMRISTX=(@Z.M*1UL5.)ZZLE]&I@YV&-?PD\3CW#'+M7R[T=ZPTI1:CFU-T@O
MK[[>C)QQ,X6.B:>QYRX9/<,8 0?3'W.FF*W2_1I207-KHZJKE=6.B=SC#\8:
M?' !^M=-7+]/],UBO>B=1:EH:.N%)9 .MC>&ATA+<@-P2/#=;+HCZ2J/I'MM
M;4TEOJ:"6CE$<D4SFOYC((<$$^0\D0\D$>G_  \O[15M7)_P\O[15M0XY\BY
MEJ8"?IWT=%4;Q14-5-&#R#^_XKIJYITRT=512:>U;;*9U1/8ZOBJ(XQ[;Z9^
MS\?#&<>*0M3RQ>F"@I;GK3H[H[A&R6EEN3@]C]PX<.<'ZP%=Z?J"CBT-%7QP
MPPUMOK()*-[&!KFOXP.%I&X![@MSKC1E+KWU)6LNL])#1EU1!)3#VG.<WV'
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M;:PW*2AKXIHG$$$9\0@[@BIB?UD3'CDX JI 1$0$1$!$1 4?L.K;9?+E44-
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M].R4(HOZ]N/T:#R/^4]>W'Z-!Y'_ "AZ=DH11?U[<?HT'D?\IZ]N/T:#R/\
ME#T[)0BB_KVX_1H/(_Y3U[<?HT'D?\H>G9*$47]>W'Z-!Y'_ "GKVX_1H/(_
MY0].R4(HOZ]N/T:#R/\ E/7MQ^C0>1_RAZ=DH11?U[<?HT'D?\IZ]N/T:#R/
M^4/3LE"UE\NT=LIB00ZI</O<?;\3X+2S7:[S MC$4.>UK<G[5CT=GGJ9S+.7
M/D<=W..Y1:N+[KNF:5\E1UC\N<YW$YQ[2NE4+.")H\%I[):Q T$A2&-O"%+=
M42 "3R4=FD,LKWGM.WP6_G_ O^!4=')0QR^PB(C 1$0$1$!$1 1$0$1$!$1
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M114HI/113P^C8QU/ .#'PY*>_C3'_"O\R;]W';K7YUV[_HYAITC_ ,$:S?\
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M[M[5V72NI[=J2&=]JZW@@(:[C9P\^6-UF>HK5_PRB_Z#?\+)HZ&EH@X4=-#
M';N$; W/QPHM:)\->BZ//TUI[[Q,3YXG<S^^V0B(J/4$1$!$1 1$0$1$!$1
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M-9K;'6U59&Z*5O%$(SDR?!?(\$HJ;G52UCCUKR3GO*O6YSZIQ-;,1#!L&D[
M+IITLV<63K^WP[1/TSU-1,YMLLSG1@X#GNW*YOTHZ]K]6U%-;YZ<T<4+<OC#
MLASN]76:NI+?1MAM%")9.76.Y?4M#=;C2S4U5472@>RY2 "G?$[#>>_$/@MO
M1I7PPKU.6_U,S0U+ RO9UD8?.2&LC[7E?2FA=/FUP/JZKA]-J&CB:!\P#DU?
M(MMFJX)VU$-3)',-VENQ'P4VT[KK5=L+>"X3RQ YX)?::J98MDC7V6PWQ8;3
M:\\OJ]%&NC_4PU18A5F/JYF.X)6]G%X*2KAF)B=2]6MHM&X$18]>Z=M'*ZE
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M PNC;[.>7$ ,CS4@Z#RX:2J"\@,%4['\+<K4:[O-1K*YLTSIQO6Q,DXJB?\
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M.L+C*6R4-+!-%!Q @'V71Q?6#ERKZ']6.T]T5ZYHJIY,UK#W1-',.>',)_C
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MO1M'_P!I!&*_K'?@\8X>SDMTB*COQT[*Q7>]??R(B(N(B("(B B(@(B("(B
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MY>IO>-5ALKLX1RF6!Q!8>(Y/-:NLKJBZTTD=O#>N8!Q<1Q\<!8U?<753#'2
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M0C77YR4WPD_J"F^EOQ8(>R2HB(-9)^7H?W9_NMFM9)^7H?W9_NMF@(B("(B
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MBZ1[M1MB@D,4C&X9QO;[1/BMXZ>\QMS3UV*+=KMJ+!HJTFSQ5=6 P]7QOQN
MN&:PZ3+I6W.6.TROI::(D MYNQVE8Q69G3NQT[^8\._-E8Z0QM>TO R6YW"K
M7R/1:KN]+=C71UDOI).2XG.?J79]*=*M'44U+!>6/BJ2.%\P'L$]A4S72TXY
M]G445NFGBJ8A+3R,EC/)S#D%7%5F(B("(B B(@(B("(B B(@(B("+Q[@QCG'
MD!E:&2[OZ]XCP6AQYC! 0;]%@VZOCJF 9(?W%9R B(@(B("UU^FZNV3]Y:<+
M8K2ZI876]S@?F@DH(3IEKIM3-ZL##&EX\#D+J"YOI(LI[ZYQQ[49&3\0ND!
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M#2<(.:6W[W=(2>7&&_:NG-.0,\^U<RJ_O-8\\N"0%=(HWA]/&6DD8 R4%XG
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M<9*UN@:0TFF:5I^?)F1Q^)6/TES&/33F-.\TK8_/*D5MB$-#3QC]&-H^Q!D
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MSBN-;5Q\+82=P&L!WYXY'DH1J/5'2AT;55JN6K:^S7NP5%4VGJ130=4^+B.
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MF="YU-' <G@:T[YW.Z^CM$P:AIK&V/6%915EU$CBZ6C861EOZ(P0-UQZW?\
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MXWY+(O,3*6TMIZ<9D?L<<R5YHVWR"V35,OL\;N+!/8MCI$BKUK$R5C9(F-)
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MT<[*0/H:9[@YT,>1R(&%D-:&C#0 @]1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$5BKJF4S.)Y'F@OHL:CK8ZD'@(XAS&5DH
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@Y'KK\Y*;X2?U!
M3?2WXL%"-=?G)3?"3^H*;Z6_%@A[)*B(@UDGY>A_=G^ZV:UDGY>A_=G^ZV:
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MR[QWPIRN2Z5K1;JR)Y/L$X< NKPR"6,/:<@C*2*T1% (B("(B B(@(B("(B
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M\-U!7.8 US1PMV '8%$]:=)4-CJ#16ZG%77 9<''#(SXK)U7?(]/VMU:]@>
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MEY*G*]PI1XX075&B9:FIEK;+,V%SMW0D8!/@HS;&LJ6.I:ML8DC)8XGO&R[
MW8[<_L7/]8Z6JFU4MRLH:2[VIH2<9/>%OCR?=P]1TW.ZH5<-/U=%5N=;Y>&
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M@(B("(B L>L. U9"Q:[DQ$QY8WDF53E,J%WN4RO,KQ!4F52F4%645*;=B#U
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MS$>C2'F?T7)2WLSZJD3'="7!W/9>\2S#1 ]_Q"MFA/8XK>L/)]6(EC$X&2O
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MVA_Q"UM1:F/R&ACP?T7C/VK9\^W8H$2B5=IZE<#UM%C]9@6HGTM3/SU$SH_
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M7ZKN]9=(A',^H@:PDAV>+(.YV1-=HC6:[UI6])]^T?IPT3Y@YII9ZF(=71Q
M O>[&[CN  58U/>NDSHX92WJ_P![ME^LCJAL=5#'3<#F!VWL[ CPQVC=9_1X
M ?N@=>N[131C/_,U;;[I+_RFN7[V'^M#7$RZ92U4=91PU-.289XVRLSL>%PR
M,_45I-54@K[7/3O)#'MP<;;K*TL?_LO9Q_\ N4/] 655LXHR'#(5):TB?9\O
MW.V^BUSVO:_C8[!&.Y2+3</&^-[VNX<X 4OUU34<#)75#VMEX26[;GX+G1J#
M3-B=3S/XW'.#MA=,8YS5Y8]3UV/I)U[N]:;<UL)#1[1[#V*2L>-P.1"X]HN^
MS!@;.\DYV<>?P74+=4B:,$';L\5SVQSCG2V/-3J,??2&16T%/5Q.;(T<1&Q!
M44U 982VF9$#/%AP[G!3'GC')8-PI725+)H0UTH'",CGX+;'>9GMF7+U'3S>
MO=$\_A:LEZBKZ&45;!!)3@=8QV,8':%7276V7>9]/ ]LCV#):6ENW@H;=J2>
MIJ7NC86NB.'-!V<>XK::*IJ>2JDKI:AKJ]F8W0MP!&/#O5,E<E;1->8:='?#
MEI-+?5#9WS25LO+&]:',G8<LF8?:QW?!8M/HFCH0WT!PB('M&0<7$I1Q CLQ
MV'"I>\,!)]G&Y=VA7IGM'B2W389K,S#YZU_/$Z_/IJ1T<K8'%A<UA'$_D0 I
MAIG1!AL[65SV-?)[3\#V]^Q2:72=H]?2780GT@DN+7'+2[WL=BV51.R)G&YV
MP&Q[EI;/:T.'%T-:9)EKA#'0P0T- SA8?88!W]ZD%OLU-31M,L8EJG =8YVX
M'P6!8Z5]1/Z;,PMC!^]^/BI!D8VV7/OGEZ-:ZC<L>KME#5-+)8&X VX=E&=0
MZ3B%HKI()S&1"7<)&1]BEXQV#*PK^[-CN6YR87# V[$I,;T9?EQS+YAL['37
M.GC9\YU0UHR-LDKZ IZ2X4(9Z3$"S '$TY"X'IO/KJDX=\53-L_K+ZDK' 0'
MAW8X  #EG"WZCB(T\SX;JU;6M/O/^[03X,7>3\W';X*':FT1<ZB1]7$YDH.'
M!H., ]GBIS3Q-EJ8HG;,!XB!W=RWC7!K@6C &V/!<T7V].M..7SA/#66Z<B1
MKV/'@0I]HS4%93,9QR<;=O9=R*Z%<[317.+JZN(.QR>!NHU5Z-%.QS[=+D Y
MX'!7W!-/LD,&H(9,\4;FN[B=OJPMK!4QRLXF/:]HYEO8>Y<T$L]%(8ZMAC>.
M9/);G3U>Z2N9%&=W [ =GCX*"NTW[-_K0$*UQ<^W/;WH'%(7GB-RO#"]"LAV
M55Q(B.8X7<H'*V"<'DF4-+F05[D85OB7H*&EP.7H*M90%-HF%X.50<%8"]RB
M-+P<%X7=RM@IQ(:70[;=>APPK8<F>Y2:704RK8)[U[D^"(5Y\$+@UN3W95.>
M] 0AOE!;=IN6Z5TM96DQ4[G' _2=_A3:BI8** 14L08P=RN@@<N: XSXJL5T
MUR9;9.)GA4$7F5X#WJS%4F/$+Q>J-ACQ"'XHO%(]"$['*\1-ITT&HBQD? ]P
MXI >%O:[Q48J*YPIHHB<< P,+:ZNHZPU3IJ=KI8CC?W?!:*AM4M2Z;THEC6,
MSP#M6.6*UGNF>6F.;6^6&MD^^<;@-@=CWIQEO:5,J*WPUMJ;$U@:0WV2.P_W
M45JZ5\,CV/;[33@X6M+3:-L[:B=,8S9:<]ZE%MC,=L:UW-VZB,A$1R[EVJ6P
M5D;J"-[7# 5IG4(K6;<0YS=2^GN52UQ]DN)!'8%;L-FDU!7\62VEC.7./;X+
M-K+/5W>_NAA:6TSW<4DOAX*;TD5-:Z1M+3C@C8, ]KCWE4B9EM:M:5\\LQT;
M8H&-A&(F@- [E9#CGFL5UR:]G"78'+ 1DP=R*M$L9^[++\#FK3I/%6^/(V.5
M0240K=(59DEP%2]^.U8DLF!S0CGB%R27.=UBR2\]U:ED\5B23<\9)1.I7Y),
M=JQ)Y\ [Y*L2U .<.R.]8_$3EW--PC3,CER0.>1R[UK9)6XEB_28<$+(LL<D
MM5Q/'(JO5UK?3-]8T@XFO'WT#L\?@L.HK,UF8>G\-R17)VVG6TGO8ZOH\PSV
M1@?S7.H(OO8^"GPJ6W+H\/">(M'9\5"H .$8Y !>5@CSM]!\/GMBU9\[:BIC
MJ:6H,U$_@E_FMII:ZUUTE?3U1 F!YJN>(/!6J89+;7-JJ9HXASRNO%>8GE/6
M]%3+2;:Y3JOTNRYT3F.(,P&6N/85!I*5U,Y\$XX)&'A72=/W^GN,(+'8>W=S
M>T%:77MN-6]E;0MXZ@G#F-[5OFQ1>(FO+Q_AW53@R3AR<0U?1ZV0W&KA'X#@
MR1XYYJ<34C<$@@#L6#I"T"RVQTL^!53;N[@.[XKR]7FGHHB7$9'Z/:5M2.RO
M+@Z[)7J>HF<:U5AL+"2>7<M9;=44=#?(:5\F3-MEIV:?%12]WRNN3GBGCDAI
MCGVN'=1*HIN%HD8</SDN[<K*V;4\.WI_A7?'S\2^H&'KH^>7MY_#O7/>D_2[
MKC&VX4C<SLV> .8[UL>C;4GK:ULBD.*FG]@YYN;WJ:2!I;EN"P[+H^7)#S>^
MW27UX9O1M2MHM&6Z!@P&M<<>)<25)EKM/,$=IA:WEO\ S*V*1&HTQM;NM-I]
MQ$12J(B("(B#D>NOSDIOA)_4%-]+?BP4(UU^<E-\)/Z@IOI;\6"'LDJ(B#62
M?EZ']V?[K9K62?EZ']V?[K9H"(B B(@(B("\+6D@D D=X7J("(B"S6U I*2:
M=P);&TN(';A<]JM?W&9A]76:9[#G@D )!^Q3C4/Y#KOW+OY+2=&F^F(\]DCO
MYH(/)?=35O$:D5L+,_[AA&RKHC2-=UE7:[G7N!S]]!(_DNO\(3A"#GE#J:&A
M8YM'IJ:+/,-8?\+-.N)VM_(M7GNX3_A3;A"<(00@:YG+=[+5_P )/]EI[W<Z
M6\]6ZLL-=&\''60@M<1W9QR73^$=R<([DF(GS":S-?$H!;=5^KJ&*EI;'5MA
MA'"T<)_PLCY<S_\ !:O^$_X4WX1W)PCN3]D(3\N9_P#@M7Y'_"?+F?\ X+5^
M1_PIMPCN3A'<@A/RYG_X+5^1_P )\N9_^"U?D?\ "FW".Y.$=R"$_+F?_@M7
MY'_"?+F?_@M7Y'_"FW".Y.$=R"$?+F?_ (+5_P )_P +WY<S_P#!:OR/^%-N
M$=R<([D$)^7-1V62K/\ RG_"\^7,Q&19:LM[^$_X4WX0G"$$(^7,_P#P6K\C
M_A>_+F?_ (+5^1_PIMPCN3A'<@A/RYG_ ."U?D?\)\N9_P#@M7Y'_"FW".Y.
M$=R"$_+F?_@M7Y'_  GRYG_X+5^1_P *;<([DX1W((3\N9_^"U?D?\)\N9_^
M"U?D?\*;<([DX1W((3\N9_\ @M7Y'_"?+F?_ (+5^1_PIMPCN3A'<@A/RYG_
M ."U?D?\)\N9_P#@M7Y'_"FW".Y.$=R"$_+F?_@M7Y'_  GRYG_X+5^1_P *
M;<([DX1W((1\N9_^"U?D?\(==3C_ /):OR/^%-^$=R<([D(0@:YG/.R5?\)_
MPM3<ND&U&H%+<;5FH.XCD;O_ "4SU9?Z73EFGKZKVN# 9&.;G'D%\Q=(5QKK
MCJ"2[2S1159C:6P1 DM[A\<+;#AG)N9<^;J*XIB/=UFKJ+=7??:>SUE&9-PZ
MF);Q?#9667>_4#N*A-P>QHPV.=CB%#NCNV:BU#7PR3SU;.K (<\%K6M'<OI.
M-G#&UIW( &53)C[)TO@RS>-RYK0:ZO<30*RRS3./:UI;]F%-M+WIM]M@JVPN
MB]HM+7<P0MA6@"DG( SP._D5&.C/\BU/_J7_ ,U1JQ.D2BNU=44D-#&9*1VS
M@#MQ=Y\%M],:8I;33L?,P35I +Y'#.#W#P4B14G'6;=T^6GJ6BO;'AXUH:,
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M[C\UK^Y<%N]2^:ZF9L!CSCB'9GP4CT[4,=;:UC96M+2'-!VW7IYJ6R?].=O
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MIOD[*ZAYV'#ZUHM;V2>D@934[(8@ Q@P%=1%Q/7B-<+-;^)S_L._D5%^C/\
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MX2?U!3?2WXL$/9)41$&LD_+T/[L_W6S6LD_+T/[L_P!ULT!$1 1$0$1$!$1
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M #C;YJ445 R)N0%E?-;+Q'AWX.BQ88W,\M3;[%&S=[05LV6:$?HA;9@##P@
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MYHRM%IK3-NL49]"C:9'<Y,;E;Y4RY.^>%>EP3AKJ9$5$TC8HGR2.#6,!))[
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M4J(JN9O#57&&EB/*&#F1]2\_%U-*<4KS^75;'%O/#+NE49W'UE,TGZ- =O\
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MAIVD;\6ZDFG]-4MG<9Y)!/4X(XL8PN_'AMN$=7\0P4PS2EN7EQBQ%P-& !@
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M6V5A"OUA8(G$!5T5+'#"&Q,!/:>]:2^U,M*]\<C<,=RPK3PRB-SIIZZI)F<
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MD%EQQX')5B-/2M?N6>J'5R?LG^2S>B_\A3_^I?\ S5#VXC?^P5<Z,?R'4?\
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M+= U523Z,TX/:52V:F./FE?TYM[$\%!4G_;889PW_4&<+"JKA V401N'"?9
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MVOD^<?@%8-0R*%XH6F$?I5$GSG?!<&6]+SVXZ[G[^R\02&.ED]*K(VRW%P_
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M_(<__J7_ ,U2_P# O_9*JZ,?R'/_ .I?_-:XG)U*7HB+9R"(B B(@(B("(B
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MIY8_F\8^:LPNJ)?OUON-.V7M?R+OB.2]NL4MQA+(13U):0<XX9/@>]8CJ*B
MX8I?1)#\Z.://VKEGSW4LUB(L5!U!#(*H11328PXQD8D^(54,D)E%3%%/;JP
MCVV<.6.*LTEOK()'%ERBCB_1(?G=9K:E]-$!/=S)(3C BX@56]K9IW/)K2TV
MX0-K".L;3U/;(T'JW_$%6*NON-94F&B#"/>AY?:KU;6U<>/2*".HI#RD,8:L
M9EQMP:2ZGG@![8GG"M3/DI&M_P#E:(G3SU3+EKKM<7;G' QWM'PV6P=#/1P
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M3K3SX@"$OFW&L:^+I;6G_-9(O5;6@O@>S@[,;JU)47,#/6_4 5BS6FIM9=*
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MX'RQO>!(&<\=GVJ7%J\X?@J3&XTO6VIVBFF-.1443)ZN)LE6X X=N(_ *1\
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M]QK<?S4X:=129TSO./VE'KO?9[C6QTK*=]+2D^TYS?;=_A553G.C$$?L0LY
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M/60T<1_1A&ZP*6RP,D,LO%4U!YOD/%_-;[J-\X'DKC*<\R3GN59M,MZ=E?\
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M[@MM3:W;AC4?=IW16N[\N9T]CN%[+'NI'/8T@@R>R MI'HZ6.5GI,=&V,$'
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MT6/N1$#T6/N3T6/N1$#T6/N3T6/N1$#T6/N3T6/N1$ 4L?<KK(& ;!$07 P
+*I$0$1$!$1!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g50309g01a30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g01a30.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1;44&AO=&]S:&]P(#,N,  X0DE-! 0
M    %K<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"C_P  1" ,V!V0# 2(  A$! Q$!_\0 '  !  $% 0$
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MZT&KW^63]:%^ +#5S_+)^M!J]_ED_6A?@"PU>_RR?K0:O?Y9/UH7X L-7/\
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M]3@AZ<'Y7XG_ !#_ )J/^,?O( #J^$
M
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MB^_=NO9KP -.
M                      %]8?IRW?\ J8__ '(6)?6'Z<MW_J8__<AFKA+T
M;'_F,/\ Y4_O#ZF/-_RE/0\W_*4\;^EH@         "( (H "L@  %"I0$!
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M]3@AZ<'Y7XG_ !#_ )J/^,?O( #J^$
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M;S+KC?$IVBB<*C#M>+;OSB>71; )MW ZOD@
M                                            7UA^G+=_ZF/_ -R%
MB7UA^G+=_P"IC_\ <AFKA+T;'_F,/_E3^\/J8\W_ "E/0\W_ "E/&_I:(
M       B "*  K(  !0J4! 0)D JO\)$E_"1+"!5-Q0JFX$!12I10J  (@
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MS^IP0].#\K\3_B'_ #4?\8_>0 '5\(
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MERK)*#O%]0]U)PJS<%Q::[W>G:I8HF]Y8Q/B.!.%DHIGY9CSMUZ>RS !U?%
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M %5:J(BJU41=RJF\H;?.
M                              OK#].6[_U,?_N0L2^L/TY;O_4Q_P#N
M0S5PEZ-C_P QA_\ *G]X?4QYO^4IZ'F_Y2GC?TM$          1 !% #DG=0
M[H-ZPGC:EIJ)D,UJ92LJ:F%8\WJU7JURH[>G$;HHFN;0Y8F)&'&:IUL'/[GC
M&J=C["%!:9X9+-=Z=T[U6/-SDR54R7BXBXNW=0P]:KA54E:VY,[VG[WFG2D<
ML3'\FD73JY)JT;[SP;P4.?XX[I=)AF]6JAC@=5,J4;-.]C'*K85SR5F7RG+R
M&9BQO:9+K9+<B5;:J\0\/2HZ')$;M^7MV+\529*K7LL8E-YB[9R!JM7W0+)2
M.OS9N^\[(YK:O1ASVN7)-';M/"@[I.'+A'<9:*:KFIZ"%)YIF4[E;EL3)O&J
MHJ[?0HR5<EU*.%VY<1$U3#G=!L5^O$5KIUK:>ME9PD4573K%PK<LUT>78BJ6
M/<YO%?<L0XUIZZI?-#17'@J=KLO\-F;]B=2%R3%[IJ4S:V^[>2J;BA5-QEN
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MQC]Y  =7P@
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M.57.<JJJKQJIJB*K[W@VW%V6JB*=GC???N\(W1Y\94 !T?-
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M-7QTW Z3=N351=J\1HYTIF9C>^9MN'AX>--.%.[\[_WS  :>4
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M2SVKQ&<3%]J=/;YH;G<J&6FI8X'\%"CV29?*:YJ[_,I)FMWP\+X?5$3-H_\
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M;,'9<+9IC"F)JO'C$\^''^\FM@ ZOB   %]8?IRW?^IC_P#<A8E]8?IRW?\
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MPVE=Q%>,DNXBO&<H=T7$4XR3B*<941(KN4D17<I4;'8?HYO\RF0,?8?HYO\
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MUNAW9J^KZ>[YQS&9]'> F&^BH>M>T> F&^BH>M>T:W0[LU?5]/=\XYC,^CO
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MK=#NS5]7T]WSCF,SZ.\!,-]%0]:]H\!,-]%0]:]HUNAW9J^KZ>[YQS&9]'>
MF&^BH>M>T> F&^BH>M>T:W0[LU?5]/=\XYC,^CO 3#?14/6O:/ 3#?14/6O:
M-;H=V:OJ^GN^<<QF?1W@)AOHJ'K7M/+P'PYT5!UN[1K=#NU5]7T]WSMF,SZ)
M\!\.=%0=;NT> ^'.BH.MW:-;H=VJOJ^GN^=LQF?1/@/ASHJ#K=VCP'PYT5!U
MN[1K=#NU5]7T]WSMF,SZ)\!\.=%0=;NT> ^'.BH.MW:-;H=VJOJ^GN^=LQF?
M1/@/ASHJ#K=VCP'PYT5!UN[1K=#NU5]7T]WSMF,SZ)\!\.=%0=;NT> ^'.BH
M.MW:-;H=VJOJ^GN^=LQF?1/@/ASHJ#K=VCP'PYT5!UN[1K=#NU5]7T]WSMF,
MSZ)\!\.=%0=;NT> ^'.BH.MW:-;H=VJOJ^GN^=LQF?1/@/ASHJ#K=VCP'PYT
M5!UN[1K=#NU5]7T]WSMF,SZ)\!\.=%0=;NT> ^'.BH.MW:-;H=VJOJ^GN^=L
MQF?1/@/ASHJ#K=VCP'PYT5!UN[1K=#NU5]7T]WSMF,SZ)\!\.=%0=;NT> ^'
M.BH.MW:-;H=VJOJ^GN^=LR^L/TY;O_41_P#N0[WX#X<Z*@ZW=ICL0X3L=!:9
M*JCMT44\<D2L>U5S3_%:G+YR3C7BUG7 _P /3A8E.)J7M,3PY3^;?#S?\I3T
M/-_RE.+].B      9+R#)>0 !DO(,EY (@KDO(HR7D4BJ KDO("LJ%JRW43*
M]]<RDIVUKTR=4)&B2.3=M=O+L 4*$B(6 @3(@/X2)+^$B6$"J;BA5-P("BDB
MBA7F"N0R(B@*Y#("+BA5Q0*!-X";P,!+\ZF_G4NH-R%K+\ZF_G4NH-R%1D*?
M<A=LWJ6E/N0NV;U")A=P&2Y;@JC=P7<5:BY;@J+EN*(!2N2\A147D4(CQA-Y
M7)<]RC)<PS*A12I12B*\9%"7*10L,J<90EEM(KO$""[BG$57<4XC4(BI3C*E
M.,(AQJ4*\:E"HBH0*$#**D%)J04L)**[B*\9)=Q%>,L(BXBG&2<13C*B)%=R
MDB*[E*C8[#]'-_F4R!C[#]'-_F4R!YJN,O;1\L(3_N7^A3C]H^ME?]O_ &0[
M!/\ N7^A3C]H^ME?]O\ V0RU#K5)\W9Z *3YNST #QA^F9_LF_U+\L(?IF?[
M)O\ 4OP
M
M  'C)\M3V/&3Y:@1  0                             >[/DH5*,^2A4
M*                             "[BW+A=Q;@  $
M          ,/B_ZO5'VD/_*PS!A\7_5ZH^TA_P"5@(; >;_E*>AYO^4H5$
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MS9XM^<-G!:VJXTMUH(JVWS-FII4S:]O4OWET1WIJBJ+TS>  !0
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M=(F)B\!A\7_5ZH^TA_Y6&8,/B_ZO5'VD/_*P+#8#S?\ *4]#S?\ *4*B
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MT\M+6-:LC&N7-'M3?MY3G]#C*&^8YKZ"NHG.M-SC;0-A:OQHD1<FN3S\9T7
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MJJ=.FB/GFJ+>?'R=&<FBY4Y%R*%57-55>,H<WJ  $
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M[1];*_[?^R&6H=:I/F[/0!2?-V>@ >,/TS/]DW^I?EA#],S_ &3?ZE^
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M=:#5]3S:=9G@#1I8'5]3XB=:%%M]3S:>LAGP#1I8#5U3S:=:%-75/-IZR&P
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ME^
M                                                          \9
M/EJ>QXR?+4"( "                             #W9\E"I1GR4*A0
M                          7<6Y<+N+<   @
M     !A\7_5ZH^TA_P"5AF##XO\ J]4?:0_\K 0V \W_ "E/0\W_ "E"H@
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M+4.M4GS=GH I/F[/0 /&'Z9G^R;_ %+\L(?IF?[)O]2_
M
M           !Y5%1' W.1?0B;U!,V>H,:ZZIG\6)<O.I36B\S_J#&I2R8,5K
M;_\ #_J&MEYG_4$U*>;*@Q6MEYG_ %#6Z\S_ *@:M/-E08G6Z\S_ *AKA>9_
MU U:>;+ Q.N%YG_44URO,_Z@:M/-EP8?7*\Q_J&NEYC_ % U:>;, PRWM4_Z
M'^HIKQ>8_P!0-6CFS0,)KQ?)_P#44UZOD_\ K_0)K4<V<!@M?KY/_K_0IX0+
MY/\ Z_T!K4<V>!@%Q"J?]W_U_H47$2^3?Z_T":]'-L!XR?+4P7A(ODW^O]"#
ML1JJK_V5/7_0&O1S9X&O+B14_P"ZIZY'PF7R1/7_ $":^'S;&#6_"A?)$]?]
M"*XI7R1/7_0)VC#YMF!JZXK5/^YI[3]"*XM5/^YI[3] =IPN;:@:IX7KY$GM
M/T(KC%?(D]I^@3M6%S;:#4%QFJ?]Q3VGZ$5QLJ?]P3VGZ%LG:\+G^[<0:9X<
M+Y GM?T(KCE4_P##T]K^A+';,'G^[=0:0N.U3_P]/:_H17'RI_X<GM?T+9.V
MX/XO26\@T1>Z O1R>U_0BO="5/\ PU/;?H+2G;L#\7I+?0: O=$<B?1J>V_0
MBO=&<G_AB>V_06E.W[/^+TET$'//A(=T8GMOT(KW2G)_X6GMOT&64^T-G_%Z
M2Z*#G"]TQR?^%)[;]"B]TUR?^%)[;]"Y93[2V;\7I/\ #I .:KW3W)_X2GM_
MT(_"B[HE/;_H,DI]J;+^+TG^'4V?)0J<L^%9[4RU1_\ W_T*?"P_HA/;_P#\
M1DE/M;9?Q>D_PZH#E2]UIZ?^#_\ ]_\ _B1^%Q_0_P#N/_XETZF9^,;''^OT
MG^'5P<G^%U_0_P#N/_XE/A=?T-_N/_XC3J3[9V/\?I/\.L@Y([NPJW?9T]X_
M_B75N[K]'+(C:ZVS0-5<N$CD21$]*9(HTZN13\9V*J;:GI/\.H@P]+?(JNFB
MJ*5&RP2)I,>UVQ4/76B\S_J,/H1BTS%XEDP8S6B\S_J&M%YG_4%U*63!C-:+
MS/\ J&M%YG_4#4I9,&,UHO,_ZAK1>9_U U*63!C-:+S/^H:T7F?]0-2EDP8S
M6B\S_J&M%YG_ % U*63!C-:+S/\ J&M%YG_4#4I9,&,UHO,_ZAK1>9_U U*6
M37<6Y::T7F?]1YZP7FOQ!J4K\%AK!>:_$:P7FOQ":E*_!8:P7FOQ&L%YK\0:
ME*_!8:P7FOQ&L%YK\0:E*_!8:P7FOQ&L%YK\0:E*_!8:P7FOQ&L%YK\0:E*_
M!8:P7FOQ&L%YK\0:E*_!8:P7FOQ&L%YK\0:E*_!8:P7FOQ&L%YK\0:E*_!8:
MP7FOQ&L%YK\0:E*_!8:P7FOQ*MN"9_&C7+S*#/3S7P(0RLF9I1KFG'RH3#88
M?%_U>J/M(?\ E89@P^+_ *O5'VD/_*P$-@/-_P I3T/-_P I0J(
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M?IF?[)O]2_+"'Z9G^R;_ %+\
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M$VK617,W9,3)5ZT.IEQ.-WR/A-XPZ\.]XIJF(_( !S?4
M                             'I3R+%*UR+LW*G*AF=^[<8)$S7)-Z[#
M.,3)J)QHB((=\+A*IA\7_5ZH^TA_Y6&8,/B_ZO5'VD/_ "L*ZPV \W_*4]#S
M?\I0J(          B4>Y&,<]ZY-:F:KYBIXUOS*H^S=_0YXM4T4551X0U"%-
M74]3)H0/5SLL_DJFPE#5P2PR2L?FR-51ZJF6BJ;RULK)TI(G22,=$K$T&HW)
M4^\QEV;)#5U%' BHE>C5;EQ+GD[\#YM.VXU.ST8^)''PM;C&[QGC.[]? FF+
MS$,VZOIVT3:MTBI3NRR=HKMS7)-A*KJX:1L;JA^BDCTC;LSS<NY#'XAC;#8G
M1MV,8L;4^YR$,5JG 6[_ -9$>NK&KIS1-KQ$3^LWO^S$[E]<;G26U&+62+'I
MJJ-R:KLU^XI;KG1W)KUHIVRZ"Y/3)45OI13%8IFBI[I9I:A[8XF5"JYSMR)D
M>=!+#78KDJK8F=,RGT)IFIDQ[U5<O2=-2<\TL9IBJS8T>U7JQ'-5Z)FK<]J)
MZ#%7+$%LME0Z"NJ'1RM:CE3@W*B(N[:B9&OZON:W78U^EII\?@\LGH[][PG&
MW+/9GQY9'KC^IHIHEI);JRDF@1)N]WQZ39_%1>7T'>C[W%SKQ:HHFJ-UN;:(
MZRGDMS:ULJ)2.CX7A')HHC>5<]Q867$-MO4TT=MG?*Z)$<JK$YK515RS153:
M8?$LE77]SKAG0.BDDBC?-$QNYF:9[.3+;D6V":YRWR2AH[HMUMB4B2<+H(W@
M'(J(C,T3+=Q>8[TX<31-3G5M$QBTT>$_WG_+-W7%5FM5?WE7UG!5"(BN30<K
M8T7=I*B9)F9QJHK45JHJ*F:*G&<LOE71T5+C>AN2(E=52-?3QO3XTS5:B-T>
M7;R'1[''+#9+=%49\,RGC:_-,ES1J'3&P:<.B*H\?7=$[O,V?'JQ*ZJ9MN]-
M\QO\EX44J44\KV(  B   HXH5<4"@3> F\# 2_.IOYU+J#<A:R_.IOYU+J#<
MA49"GW(7;-ZEI3[D+MF]0B87< NXJJ-W!=P;N"[@(A0%"(\83>.,)O#,A12I
M12B*\9%"2\9%"PRIQE"O&4$""[BG$57<4XC4(BI3C*J4XPB'&I0KQJ4*B*A
MH0,HJ04FI!2PDHKN(KQDEW$5XRPB+B*<9)Q%.,J(D5W*2(KN4J-CL/T<W^93
M(&/L/T<W^93('FJXR]M'RPA/^Y?Z%./VCZV5_P!O_9#L$_[E_H4X_:/K97_;
M_P!D,M0ZU2?-V>@"D^;L]  \8?IF?[)O]2_+"'Z9G^R;_4OP
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M=0;D+67YU-_.I=0;D*C(4^Y"[9O4M*?<A=LWJ$3"[@%W%51NX+N#=P7<!$*
MH1'C";QQA-X9D**5**417C(H27C(H6&5.,H5XR@@07<4XBJ[BG$:A$5*<952
MG&$0XU*%>-2A414(%"!E%2"DU(*6$E%=Q%>,DNXBO&6$1<13C).(IQE1$BNY
M21%=RE1L=A^CF_S*9 Q]A^CF_P RF0/-5QE[:/EA"?\ <O\ 0IQ^T?6RO^W_
M +(=@G_<O]"G'[1];*_[?^R&6H=:I/F[/0!2?-V>@ >,/TS/]DW^I?EA#],S
M_9-_J7X
M
M  #QD^6I['C)\M0(@ (                             /=GR4*E&?)0J
M%                             !=Q;EPNXMP  "
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M(KQD4)+QD4+#*G&4*\900(+N*<15=Q3B-0B*E.,JI3C"(<:E"O&I0J(J$"A
MRBI!2:D%+"2BNXBO&27<17C+"(N(IQDG$4XRHB17<I(BNY2HV.P_1S?YE,@8
M^P_1S?YE,@>:KC+VT?+"$_[E_H4X_:/K97_;_P!D.P3_ +E_H4X_:/K97_;_
M -D,M0ZU2?-V>@"D^;L]  \8?IF?[)O]2_+"'Z9G^R;_ %+\
M                          Q550W22HD?!>.!B5?BQ][,=HIZ5WGEJZ\=
M._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77
MCIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=
M._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77
MCIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=
M._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77
MCIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=
M._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77
MCIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=
M._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77
MCIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=
M._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77CIW_ &C!JZ\=._[1AF@!A=77
MCIW_ &C!JZ\=._[1AF@!A=77CIW_ &C"#J"[HJHM]7W-G:9T\9/EJ!A^\+OT
MZON;.T=X7?IU?<V=IE@$8GO"[].K[FSM'>%WZ=7W-G:98 8GO"[].K[FSM'>
M%WZ=7W-G:98 8GO"[].K[FSM'>%WZ=7W-G:98 8GO"[].K[FSM'>%WZ=7W-G
M:98 8GO"[].K[FSM'>%WZ=7W-G:98 8GO"[].K[FSM'>%WZ=7W-G:98 8GO"
M[].K[FSM'>%WZ=7W-G:98 8GO"[].K[FSM'>%WZ=7W-G:98 8GO"[].K[FSM
M'>%WZ=7W-G:98 8GO"[].K[FSM'>%WZ=7W-G:98 8GO"[].K[FSM'>%WZ=7W
M-G:98 8QMNO"I]._[-A75UXZ=_VC#,L^2A4*PNKKQT[_ +1@U=>.G?\ :,,T
M ,+JZ\=._P"T8-77CIW_ &C#- #"ZNO'3O\ M&#5UXZ=_P!HPS0 PNKKQT[_
M +1@U=>.G?\ :,,T ,+JZ\=._P"T8-77CIW_ &C#- #"ZNO'3O\ M&#5UXZ=
M_P!HPS0 PNKKQT[_ +1@U=>.G?\ :,,T ,+JZ\=._P"T8-77CIW_ &C#- #"
MZNO'3O\ M&#5UXZ=_P!HPS0 PNKKQT[_ +1@U=>.G?\ :,,T ,+JZ\=._P"T
M8-77CIW_ &C#- #"ZNO'3O\ M&'GWA=^G5]S9VF>7<6X&)[PN_3J^YL[1WA=
M^G5]S9VF6 1B>\+OTZON;.T=X7?IU?<V=IE@!B>\+OTZON;.T=X7?IU?<V=I
ME@!B>\+OTZON;.T=X7?IU?<V=IE@!B>\+OTZON;.T=X7?IU?<V=IE@!B>\+O
MTZON;.T=X7?IU?<V=IE@!B>\+OTZON;.T=X7?IU?<V=IE@!B>\+OTZON;.T=
MX7?IU?<V=IE@!B>\+OTZON;.T=X7?IU?<V=IE@!B>\+OTZON;.T=X7?IU?<V
M=IE@!B>\+OTZON;.T=X7?IU?<V=IE@!B>\+OTZON;.TQ6)Z.Y1V65\]WX>))
M(LX^]F,TO\5O&AM9A\7_ %>J/M(?^5@5L!YO^4IZ'F_Y2@1          $0
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MS_9-_J7Y80_3,_V3?ZE^
M
M                \9/EJ>QXR?+4"( "
M #W9\E"I1GR$*A0                             7<6Y<+N+<   @
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M+4.M4GS=GH I/F[/0 /&'Z9G^R;_ %+\L(?IF?[)O]2_
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MCZV5_P!O_9#+4.M4GS=GH I/F[/0 /&'Z9G^R;_4ORPA^F9_LF_U+\
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MI#_RL,P8?%_U>J/M(?\ E8&X; >;_E*>AYO^4H5$          1 !%  5D
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M_3,_V3?ZE^
M
M      \9/EJ>QXR?+4"( "                             #W9\E"I1G
MR4*A0                             7<6Y<+N+<   @
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MGH I/F[/0 /&'Z9G^R;_ %+\L(?IF?[)O]2_
M
M                                >,GRU/8\9/EJ!$ !
M                 ![L^2A4HSY*%0H
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M$P*N*D=,ZASX/@D:G"\)GEH99Y9Y^?=M.<]PF.)\&.W5&3I%56R*[Q?\3/\
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MFJJG%GD=).5<1%4Q3P>C"FJ:(FOB  PZ
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M:S]Z]95KG-7-KG(OF4:74U>C9 8ZWURO<D4R_&7Y+N7S*9$YS$QNEUIF*HO
M8?%_U>J/M(?^5AF##XO^KU1]I#_RL(L-@/-_RE/0\W_*4*B          (@
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M./VCZV5_V_\ 9#+4.M4GS=GH I/F[/0 /&'Z9G^R;_4ORPA^F9_LF_U+\
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MZ.YTF'W0I)3Q7"9LSXY$5$5$<FW)=O49G"M3>[=./FJRQ#JX .3N
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MM=.U-.=S=SI7?*R\VY/N,V=*IO,RYX<333$2  RT
M              "K5T514WHN9L;%TFHY>-$4U^FB6:=C&\:[5Y$-A39NW'+$
M=\+A(8?%_P!7JC[2'_E89@P^+_J]4?:0_P#*PY.L-@/-_P I3T/-_P I0J(
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MZ *3YNST #QA^F9_LF_U+\L(?IF?[)O]2_
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MX.<KW&<(*M3G35:QS9Y1K4NT8U5=JL3B7K+_ !#W,,/7ZJAJ*M*V.2.!M.O
M5+F(]C=R.3C-W!=2KF:.':V6&L7+ >'KCAFFL-10)JZEVP-:Y4=$NW:CM^>U
M?24P9@6SX1DJ9;6E4^:H1&OEJ)ED=DFY$SW(;0"9ZK6NNG3>]MX #+8
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MAEJ'6J3YNST 4GS=GH 'C#],S_9-_J7Y80_3,_V3?ZE^
M
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MG\Q<S^&:4[4D=6.FD=P6C3MCR;HM;DY57<CG*[-?_+DB)F/O?B+41_HED*3
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MZQN4NC)%\26I<YJ_XK=Z&VF'Q?\ 5ZH^TA_Y6 ; >;_E*>AYO^4H5$
M    1 !%  5D   H5* @($R 57B(DOX2)80*IN*%4W @**5**%0 !$  !1Q0
MJXH% F\!-X& E^=3?SJ74&Y"UE^=3?SJ74&Y"HR%/N0NV;U+2GW(7;-ZA$PN
MX!=Q54;N"[@W<%W 1"@*$1XPF\<83>&9"BE2BE$5XR*$EXR*%AE3C*%>,H($
M%W%.(JNXIQ&H1%2G&54IQA$.-2A7C4H5$5"!0@914@I-2"EA)17<17C)+N(K
MQEA$7$4XR3B*<941(KN4D17<I4;'8?HYO\RF0,?8?HYO\RF0/-5QE[:/EA"?
M]R_T*<?M'ULK_M_[(=@G_<O]"G'[1];*_P"W_LAEJ'6J3YNST 4GS=GH 'C#
M],S_ &3?ZE^6$/TS/]DW^I?@
M
M                   /&3Y:GL>,GRU B  @
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MV_\ 9#+4.M4GS=GH I/F[/0 /&'Z9G^R;_4ORPA^F9_LF_U+\
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M4U9H##XO^KU1]I#_ ,K#,&'Q?]7JC[2'_E89:AL!YO\ E*>AYO\ E*%1
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M=GH 'C#],S_9-_J7Y80_3,_V3?ZE^
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M5PNV&ZF.MBIN]J2=8:6HIH>!CE8GBMR38G+EQG1SSXD6JF'LP9O1$WN  PZ
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M-$T7JJ;VC$IQ;44;][KTG[Q^7*I$ -
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M^ME?]O\ V0RU#K5)\W9Z *3YNST #QA^F9_LF_U+\L(?IF?[)O\ 4OP
M
M     6U9;Z*M5JUE'3U"L^2LL37Y>C-"Y $8XV11M9$QK&-3)&M3)$3T$@
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M(          B "*  K(  !0J4! 0)D JO\)$E_"1+"!5-Q0JFX$!12I10J
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MGH>;_E*!$          1 !%  5D   H5* @($R 57^$B2_A(EA JFXH53<"
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M/F[/0!2?-V>@ >,/TS/]DW^I?EA#],S_ &3?ZE^
M
M                                   \9/EJ>QXR?+4"( "
M                    #W9\E"I1GR4*A0
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M%./VCZV5_P!O_9#+4.M4GS=GH I/F[/0 /&'Z9G^R;_4ORPA^F9_LF_U+\
M     Q^(KFVSV.MN#FZ:4\2O1N>6DO$G6<KPU8K[C>EGN]?B&LI&NE5(8XU<
MK4RY$S1$1-P'9 <MP%B&YVR\W>P7R66N=1122QO3-\CM#)5:W/:N:*BIQGG@
M_NAW"LNE5'64%75Q3U+6PI#&F5*U55,GJB?UY .I,GB?(Z-DC'/;\IJ+M0]#
MB%KQ F'NZ-B>H[SJ*V6:62*."!,W*NFBK]V2'0\(8XH<105KG1/HI:1NG+'*
MY%R9XV?W;0-L!SA_=3@5)*F&QW&6UQR:#JQ$^*G_ ,Y,S8L0XPH[1A^CO#(G
MU=+4N8C."5$7)R*N>WT;@-E!J.&L;T^(;]-04%#4=[1QJ]*MVQCLLDR1/OY3
M;@
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MT<<6%+0V%K6L[UC7)J9)M:BJO6IF"C&-C8UC&HUC4R1$3)$0J
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M0;N<EP=(D_=*DEHT3@'S5#TR\1=+]#K0
M                                 !<44ZQ/1JK\1R[4Y#*F",XS/13/
M?D@%3#XO^KU1]I#_ ,K#,&'Q?]7JC[2'_E8$AL!YO^4IZ'F_Y2A40
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M_P!R_P!"G'[1];*_[?\ LAV"?]R_T*<?M'ULK_M_[(9:AUJD^;L] %)\W9Z
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MEGU$M7\CO_<H&U@
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MGXE8I8YF(^&1DC%W.:J*@$P
M                                          #QD^6I['C)\M0(@ (
M                            /=GR4*E&?)0J%
M          !=Q;EPNXMP  "                           &'Q?\ 5ZH^
MTA_Y6&8,/B_ZO5'VD/\ RL!#8#S?\I3T/-_RE"H@         "( (H "L@
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MTL6K+G#I21?'EA:C4_Q6[UTC;3#XO^KU1]I#_P K -@/-_RE/0\W_*4"(
M       B "*  K(  !0J4! 0)D JO\)$E_"1+"!5-Q0JFX$!12I10J  (@
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MI?@"SMMJH+6Q66ZBIZ5J[^"C1N?IRWEX
M
M  /&3Y:GL>,GRU B  @                             ]V?)0J49\E"H
M4                             %W%N7"[BW   (
M          8?%_U>J/M(?^5AF##XO^KU1]I#_P K 0V \W_*4]#S?\I0J(
M        B "*  K(  !0J4! 0)D JO\ "1)?PD2P@53<4*IN! 44J44*@ "(
M  "CBA5Q0*!-X";P,!+\ZF_G4NH-R%K+\ZF_G4NH-R%1D*?<A=LWJ6E/N0NV
M;U")A=P"[BJHW<%W!NX+N B% 4(CQA-XXPF\,R%%*E%*(KQD4)+QD4+#*G&4
M*\900(+N*<15=Q3B-0B*E.,JI3C"(<:E"O&I0J(J$"A RBI!2:D%+"2BNXBO
M&27<17C+"(N(IQDG$4XRHB17<I(BNY2HV.P_1S?YE,@8^P_1S?YE,@>:KC+V
MT?+"$_[E_H4X_:/K97_;_P!D.P3_ +E_H4X_:/K97_;_ -D,M0ZU2?-V>@"D
M^;L]  \8?IF?[)O]2_+"'Z9G^R;_ %+\
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M[/0!2?-V>@ >,/TS/]DW^I?EA#],S_9-_J7X
M
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M.IF$PA8F8?M'>VFDE1*[A)GIN5V62(GF1/[F;S  9C, !F
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M2?-V>@"D^;L]  \8?IF?[)O]2_+"'Z9G^R;_ %+\
M
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M2'_E89@P^+_J]4?:0_\ *P$-@/-_RE/0\W_*4*B          (@ B@ *R
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M?IF?[)O]2_+"'Z9G^R;_ %+\
M
M                   !XR?+4]CQD^6H$05 2R@*@%E 5 +* J 64!4 LH"H
M!90%0"R@*@%E 5 +* J 64!4 LH"I0%GNSY*%2C/DH5"@
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M_9-_J7X
M
M
M                                         **B*F2HBH5       &2
M  4R&14 4R&14 4R&14 4R&14 4R&14 4R&14 4R&B5 %,AD5 %,AHE0!31&
MB5 %-$:)4 4T1HE0!3+_ .9#+_YD5 %,O_F0R_\ F14 41"N2
M  R&0 #(9  ,AD  R&2  ,DY!DG(  R3D&2<@ #).1!DG(@ #).1!DG(@ #)
M.1!DG(@ #).1"F2<B%0 R3D0       $)_W+_0IQ^T?6RO\ M_[(=@G_ '+_
M $*<?M'ULK_M_P"R AUJD^;L] %)\W9Z !XP_3,_V3?ZE^6$/TS/]DW^I?@
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M8JI<0U5NK8[5+5HK&-A<LF4<:I&YS$3-,W.7+/DX@.B7B^TM!171S)HWU-#
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MMY;R8JMT>(9+0Z3*6.+A'R+\EJ\3?3EFOH0T&GCDDL])84ME8M947-'7&H?
MJ-3*7/2TN/-&IDJ&0O5140U^,T;2U:UU7''!3Z,#G-6+11N:.39O>JY>8#<(
M<0TU+9:6MOE51T[I]K>!D61KTS7+1V9KLR7<4GQAA^!&K+=:9$<UKTR55^*Y
M,T79Q>?B-1Q+1SVS$UND=)<(**"VI30S45-PSD=GDYNY=%51$R7\2TM=K=18
M5Q34T=!4,EJ7=XTL<L:K*D.QJ9HOG<Y5 WBOQ9;*.[45 ^=KGU+%D5[5S:QF
M7Q55?/GL+>X8TM;+=636N=EPJH6_$IXE7.5RNT41%RVIFJ;4S,&B-L^*9(JZ
MCK)J2"T,I8. @<]'HFU^2IN7)$+[N=NG:^KI(DJ9;-3(UM'-50<%(W/?'M1%
M<B;-H&>O5SFMF&*FXS1,2JBI]/@\\V\)EL;YTTER+>TWI[I%CNDU%&JOCIV)
M&]5<LZLTGL<G$J<29[BWQZDM126Z@CBDDCJZV)LV@U51(VNTW*J\2?%_$U>K
MBJX\&4EV2CJ'U3KQK)T"1KIY+(Y$31XOBY ;U<,0VFW/E965\,4D2M1[%7-R
M*Y,T3)-JKEMRY!4XCM%+04];/<(&TU1^Y?I9\)_*B;5_L<VJ;17V6\T5=<)Z
M]DD]/)+-54=,D[DJ'N^,U$R71^)HM1<N)3+N9!A^]4$K+77STT=LT+>QL3GN
M25SE5Z/7^%RYIFJ[-X&U8:O$EYJ+I+&L3J"&?@:>2-<]-$:BN7/<NU3W@Q':
M)[B^A@N$$E6W/.-BY[DS5$7<JIQHFTP^"Z*KI\ HUD? 7&ICFGT531T9'JY4
M]&6:&K82[TME'3U57!>JBJM<+G1TRT?!LCD>NBY$R3X[U55VJJ[,UV ='CO5
MMD[SX.LA>M8BN@1JY\(B;55/,A;T>)K+65C*6EN5-+.]%5K6NSSRWIGNS\V\
MT2VTM3AVDQ'+<Z70JWT3JBE=&JN9 QZN_P !JKL14>J+LWYYEFZAJKAAFV6>
MQV^JI:BV0NJ:F2:%8\YM!4T6JORG.5R[4\VT#I-%B2SUU7+34EQIY9HT5SFM
M=Q)O5%W+EYBUGQ3;IJ*K?::ZBJ)X6M7X[U2-%<J(U%<B+O5<LMYHD,428<K9
MZ2*[55QI:#O6F26CX%D*/5&JQK41,W<:KMW;S8+S:7TE#A6R6ZG5L;)VR2.8
MU5:W@V*[-R^=V7I V6/$-J6YI;5KX._\]%8D7^++-6Y[L_-O/.+%5CFK8Z.*
MYT[ZF1ZQ-8BK\M%RT?,N:?>:'A&!L=/#'=8[K-6V])JOO9U+H11SIFJN5Z)_
MB.7BVKO+FALL]-A_#%LCIGMJJNJ[_JI=%=CD:Y_QERV+FK4V\F0&[+B6S)<7
M4.L8.^FJJ.8BYZ*HF:HJ[D5$1>,C2XIL=5#4RP72F='3-TY7*[)&MXEV[T\Z
M&C,DDF[GU39*.@KH[C'%IUJ+3JFFNFBR*CEV/<J:62)O)MIK-4VBMJ;DR]U2
MSMBHUG[S6-8VM^,U&1M1,FM5$S7+?D!T"T7>@O$3Y+;4MG9&NB[)%16KYT7:
M+W7.H:+3B=3I.^1D<23O5C7.<Y$RS3CY#6L'XAJG-HZ&\Q3R7&K?*Z&3@4C<
MZ!FZ25N?Q<]V[:2Q_P .^NLS8J>6:*G=-6R:#%7;'&JL39QJY4R3C S$6*;'
M+6QTD=SIW5+WK&UB.WN1<M'TYIN/:KQ!:J2XLH*BNB95O5$2/:JIGNSRW9^<
MTFWV.6*SX-MZ4SFR25*7"L?H+L>UNG\9>)<W(FWDR/.VW*6RV:_TD]!7K?9I
M:B9SV4SG-D5<]!4<B9999(B ;;AW$"5M#!/<9(8'UM1)'2,3>]K55$]*Y(JE
M[78AM-"V9:JOACX&1(GHJYJCU3-&Y)M5<MN2&FSPNL=5A#OBDJI8*&C>B)!"
MLBK.YC6Y+ENWKOY3&V5]11WNGO-YMM6]*I:F:"**%7JR=TB-1KDXET&HB*NS
MS@;6S%#ZIEZGH)*%]-3R0P4DLKU:R61R(KD5R9\;D38F\R3<5V3OQE&ZYTW?
M;I%AT$5=DB+DK<^)<^4T>TPU45GL_?%%,Q]3<YKK4,;$OQ$9I.1J[-F:HS+E
M)P6E\%APO324KVR5M:VOKY%9\G+.1=->+B0#>+EB:S6VK6EKKC!#.B(KF*JK
MHY[L\MV?%F>&++ZMIL+*VE="KII8HXW3+HLR<N]=W%FIHT4]/<+S5LJ9ZFEL
M]QN3)8Y%I%5M2K<M%$FW(USFIDF7H4V+'TK5N]CBJZ2>HML,KJJIX.%9$313
M)N:(FWXSMP&8J<3T$F'KE<K950U/><;E5$5=CT3-$5-Z9["E#B:@:E#27.MI
MH;K+'&LD"*J:+W(BZ/F7D15S-/GI:ZMAN%2ZCFABOUQIHF1K&J/9 Q4^.]/X
M<T1=_F(V&W)/>IJ*^:R?4+7OJG0-ILH7/1V;)'2Y?&;EEDF?FR WZ7$%JBNK
M+:^NA2N<J-2+/;FNY%7<BKR+M,=B+%UMM=-7QQ5E/)<H(G*V!79YORV-7+CS
MRV;S4,%V]RW%M'>-9K6,K)*MT"T^C!PJ*JMD=*B?&3+++;YLBWIFRU-IM]DU
M;5I5SW-)+G420*C4=PFDKM)=^:-3:FS(#JEO?-)04[ZIK6U#HVK(C=R.RVY?
M>>X
M
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MJ*]4TFRL5-V>7%EEN+&KOMPOD]F2BK9Z6E5T-"M0QZIIS/9I2.Y%5J)DF?\
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MKT3B7032S3C5 .K=[PI4K4\$SOA6<'PFBFEHYYY9\F9Z[DS.4S55=/A>HO\
M%=:QE<VJ2"AIF3+H9-?H(QS/XW.R555=O49.A2IJYL17VLN=:E)0U,B4],R9
M6Q+P3<E5R)O153=NW\H&[VNY4UTAEEHW.=''*^%7*W+-S5R7+S9EX<Q[EB5-
M:Z**OJ)J;5\22-H456\*LN;N&>O\2+FN2<7'M,C=Y'W6[7Y]3=ZNW4-JB:QC
M()EBS>K-)9'*FU<L\D3=L WT'-\,:PQ36QOK+E74T-%14S)HX)5CX:9R*]5=
MENV*F>6_-#.=T6XUU)0T-);.%;45U2D*OA<UKT;DJN1JNV(Y43)%7<!MACJR
MLHYJ[4TZ.?+4P.>K-%<N#^2N:\6\T5K;Q3TM-:YJVJHWW:NT8]*IX:6EA:S-
MR)(O\3E;]V>PQ<+WIC%U/17*JGA6NAHFS/F5SDC8BRRLT]ZIGDGW@;S18-H:
M62CTZNX5,%&Y'4]///I1QJGR51,DSRXLU7(V8YM=[_6Q56)JZ@JW.A;+3VZF
M579QQO78]Z)NS17?@7-PM\U'=K79:6\W+_[AI/J:B2I<Y^C&F:HS/Y*N54VI
MQ ;](]L<;GR.1K&HJN<JY(B<JENMQI4J*2'AD62K:YT&BBJCT:B*JYILW*AR
MV:2>>P8DC2Y5E3327"*WT;G3J[XNDB.32SVHNFJ>?),RXN]556B\36RTUT\=
M/ RFH&22RJ_@GSO7X^WC:QN2<29@=4!SU];+AR[7F&"OJZN@I;8E1(M3*LG!
MSYJB(CEW*Y-N1:6J*XVVY816IO%=-45D;YJMLTRK&V-(\\E:NS8JIMWY@=-
M
M
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MFH3*5R.=D[=Q9Y)N3<A;WO#-IO$R5%PH(ZB=K.#15>YNDW//17)=J9\2YF9
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MM5S<BU]&R94BX%,W.3)F:+EL7E1#*@ U$:B(B9(FQ$
M
M
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M#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH
MU;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L
M'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!
MXJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH
M  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#
M5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U
M;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'
MBH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!X
MJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH
M U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5
ML'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;
M!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'B
MH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ
M#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH
MU;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L
M'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!
MXJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH
M  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#
M5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U
M;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'
MBH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!X
MJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH
M U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ#5L'BH  U;!XJ%4
:MT"?PH !<1TD3-J-0]VM1NY  *@    /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g50309g01e02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g01e02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2 R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (!4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" .@!5\# 2(
M A$! Q$!_\0 '  !  (" P$               0'!08" P@!_\0 7A   0,#
M 0,%"PD$!@8'!P(' 0 " P0%$082$R$'%#%2D14R05%35&%QD]'A"!87(H&2
MH:+2,U56<B-"=+&R\#4V-W/!PB0X0V)U@K,8)28G-$248Z/Q18.$M.+#_\0
M&@$! 0 # 0$               $" P0%!O_$ #(1 0 ! @,&!0(' 0 #
M   ! A$#!!,545*1H=$%$B$QX6%Q%"(R-$&!P;$S0O#_V@ , P$  A$#$0 _
M /5*(B B(@(N+GM9WQPNEU2/ $$A%%YP[JISAWB02D43?O7W?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O
M02D47?O3?O02D47?O3?O02D47?O3?O02D47?O3?O02D47G#O$G.,=*"4BZF3
MM=T+M!!Z$!$1 1$0$1$!1Y9\DMCX^E*B3)V&_:N<,08,GBY!UQTY/&0_8NYL
M3&]#1]JYH@8'B"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"8
M1$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"8
M1$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"8
M1$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"8
M1$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"8
M1$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"8
M1$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$#"81$'PM:>EH74^G:>
M]X%=R(,;- 6GQ'K!=4588I-W/@'P'QK+. <,'B%C;A1B2,L)QX6N\103XI0]
MO KL6LVZO=%,^";@]AP<_P#\5L,$@>S(/2@[41$!<9';#"?$N2CU9X 90?*5
MF27G[%)7&$;,;1Z%R0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%QD8'L(*Y(@T
M[5,;J9T-8S((=NY,>+P%9.Q5F^A;QSP79J2F%1;JN,^&,N'K''_@M1TC6DL:
M"?![D%D Y"+IIG[3 NY 46I[\*4HE3WZ"6.A$1 1$0:7KK6YTO7T],*(5&]B
MWFT9-G'$C'1Z%K7TO._= ]O\%"Y<?]/6_P#LW_,Y5NNBBBF8O+Y#/^)YK!S-
M>'15:(^D+5^EYW[H'M_@GTO._= ]O\%52++3IW./;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@GTO._= ]O\ !54B:=.XVQG./I'9:OTO._= ]O\ !/I>=^Z![?X*JD33
MIW&V,YQ]([+5^EYW[H'M_@GTO._= ]O\%52)IT[C;&<X^D=EJ_2\[]T#V_P3
MZ7G?N@>W^"JI$TZ=QMC.<?2.RU?I>=^Z![?X)]+SOW0/;_!54B:=.XVQG./I
M'9:OTO._= ]O\$^EYW[H'M_@JJ1-.G<;8SG'TCLM7Z7G?N@>W^"?2\[]T#V_
MP55(FG3N-L9SCZ1V6K]+SOW0/;_!/I>=^Z![?X*JD33IW&V,YQ]([+5^EYW[
MH'M_@MDT-K@ZGKYZ8T(I]U'M[6\VL\<>)4,K'Y$/]/5W^X_YEA713%-X=OA_
MB>:QLS1AUU7B?I"YT1%H?7(=P +3GJE5+H^<Y:/\^!6W7]!_E*IG2#OKM_SX
MD6%QVQVU"U3ECK.?Z%JR*(*)4]^I:B5/?H):(B B(@IGEQ_T];_[-_S.5;JR
M.7'_ $];_P"S?\SE6ZZJ/TP^!\4_=XGW_P $1%F\\1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!6/
MR(?Z>KO]Q_S*N%8_(A_IZN_W'_,L,3],O1\*_=T??_%SHB+E?>HE=WI_E*I?
M2'?C_/B5T5W>G^4JE](=^/\ /B187#9OV+?4LDL;9OV+?4LDB"B5/?J6HE3W
MZ"6B(@(B(*9Y<?\ 3UO_ +-_S.5;JR.7'_3UO_LW_,Y5NNJC],/@?%/W>)]_
M\$1%F\\1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!6/R(?Z>KO]Q_S*N%8_(A_IZN_P!Q_P RPQ/T
MR]'PK]W1]_\ %SHB+E?>HE=WI_E*I?2'?C_/B5T5W>G^4JE](=^/\^)%A<-F
M_8M]2R2QMF_8M]2R2(*)4]^I:B5/?H):(B B(@IGEQ_T];_[-_S.5;JR.7'_
M $];_P"S?\SE6ZZJ/TP^!\4_=XGW_P $1%F\\1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$66L6G;G?1*;73[X18V_KM;C/K*ROT>:E_=W_[K/>L?-$?RZ*,
MICXE/FHHF8^TM419B^Z:NMBBBDNE-N62N+6';:[)'J*PZL3?V:J\.K#J\M<6
MGZB(BK 1$0$1<Q%(8S((WF,<"X#@/M17!$1$$1$!$1 1$0$1<FQ2.8Y[8WN8
MWI< 2 @XHB("(OB#ZB(@(MK^CS4O[N__ '6>]8V^:8NUCIXYKG2[F.1VPT[;
M79.,^ ^A8Q5$_P NBO*8]%,U543$1])89$19.<1<XXI)=K=1O?L].RTG"X("
M(B B(@(B("+:-):,K=2T=344DT$3(7;&)"<N=C..'V+6'M+'N8[@YIP5(F)]
M&VO!KHHIKJBT5>SXB(JU"(B B+*6*P7&^OF9:Z??.A +_K!N,]'2?0I[,Z**
ML2KRT1>6+1;1/H'4L,9>;8]P'2&2-<>P%:S-%)#*Z.:-\<C3AS7@@CU@I$Q/
MLRQ,#$PO_)3,?>'%$15J$19+3MHGOMVBH*5S&229.T_H '25/9E11-=44T^L
MRQJ++ZIL-1IVZ&BJI(Y';(>'LZ""L0D3=<3#JPZIHKBTP(B*L!%L>CM)U.J'
M53:6HAAYN&D[P'CG/1CU+!W"E=15]32O<'.@E=$2.@EI(S^"EXO9MJP:Z:(Q
M)C\L^SH1$5:A$1 5C\B'^GJ[_<?\RKA6/R(?Z>KO]Q_S+#$_3+T?"OW='W_Q
M<Z(BY7WJ)7=Z?Y2J7TAWX_SXE=%=WI_E*I?2'?C_ #XD6%PV;]BWU+)+&V;]
MBWU+)(@HE3WZEJ)4]^@EHB("(B"F>7'_ $];_P"S?\SE6ZLCEQ_T];_[-_S.
M5;KJH_3#X'Q3]WB??_!$19O/$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&6L
M6H;E8Q*+94;D2XV_J@YQZU<K;S7?1DZZ[[_IPI]YO-D=.>G"H174W_8P[^R?
M\5JKB/1[OA&-B>7%I\TVBF;?171O-QU7<[;07BJ=)"ZH:T;+0"W:(!(X+=)^
M2^@I[B^6JN+X;4Q@^L]S0]SSG(R1@#H5>:1_UHM/]JC_ ,05@\NDT@-JA#W"
M)P>XM!X$\$F\3$0F5TZ\MB9G,4^>:9CWG^F%M^AH;OJBMI+;5.[DTV-JHR'E
MQ(Z 1P)68BT+I6OGEH;;>Y'U[ ?JA[7<1Z,<?L63Y$',.G:YHQO!4DN'AQLC
M'_%8FFU5I6TW(R06"HIZV)Q&<G:!\/25C,U7F(=>%@96G!HQ<2*8\]YF]^46
MW-+98!3:L;9KQ4<U;O-ATP&1@]!X^ \.U;M3:-T;4U3:*GOLDM6[@T-E:<GT
M<,?8N-%1T.O];U-5/'/!2T\#-N%W!SSDC!\04ZAJM.4.LH;1:]/EU3%,&<YV
MC]0CI=QR>"LU3+5ELKA47JF*9HFJT3-[S]HAH.J],NT_J".@EJ :>4M+)W#
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MOV+?4LDB"B5/?J6HE3WZ"6B(@(B(*9Y<?]/6_P#LW_,Y5NK(Y<?]/6_^S?\
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MLW32.MV6*.NAJ+:VJ@JIC,07X+2?!Q!!64NO*:'6V6DLUJ91;P$&0N'U<])
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M_P ^)%A<-F_8M]2R2QMF_8M]2R2(*)4]^I:B5/?H):(B B(@IGEQ_P!/6_\
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M#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2;
MS6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT
M<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%
M=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@
MFK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/
MM?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.
M?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#J
MU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<
MV#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2;
M S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@G
MT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1
M%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?
M@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU
M/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^
M.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#
MJU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T
M<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2
M; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@
MGT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI
M1%=?T<V#JU/M?@GT<V#JU/M?@FK2; S6^.?PI1%=?T<V#JU/M?@GT<V#JU/M
M?@FK2; S6^.?PI1%=?T<V#JU/M?@N4?)O8'/:"RIP3Y7X)JTFP,UOCG\*217
MO]&&GNI5>V^"?1AI[J57MO@FK2; S6^.?PHA%>_T8:>ZE5[;X)]&&GNI5>V^
M":M)L#-;XY_"B$5[_1AI[J57MO@GT8:>ZE5[;X)JTFP,UOCG\*(17O\ 1AI[
MJ57MO@GT8:>ZE5[;X)JTFP,UOCG\*(17O]&&GNI5>V^"?1AI[J57MO@FK2;
MS6^.?PHA%>_T8:>ZE5[;X)]&&GNI5>V^":M)L#-;XY_"B$5[_1AI[J57MO@G
MT8:>ZE5[;X)JTFP,UOCG\*(17O\ 1AI[J57MO@GT8:>ZE5[;X)JTFP,UOCG\
M*(17O]&&GNI5>V^"?1AI[J57MO@FK2; S6^.?PHA%>_T8:>ZE5[;X)]&&GNI
M5>V^":M)L#-;XY_"B$5[_1AI[J57MO@GT8:>ZE5[;X)JTFP,UOCG\*(17O\
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ML+ALW[%OJ626-LW[%OJ621!1*GOU+42I[]!+1$0$1$$6K[X>I1U(J^^'J4=
M6L<IE^;IK0EZNFV&RQ4SQ#DXS(00T=I"V=><_E>:C,=':-.0.XS.-9/@^ 9:
MP?:2X_8$%%4M#<[1;[/K)NT6ON#MV\C_ +2,M?G/I)=]U>\K!<X+W9:&YT;M
MJGJX6S,/H(RO&EUY0[56<D5'HR&QS1STVS(VL=,"-YM;3W;.SG!RX=/B5V_)
M2U-W4T54V>>0NJ+7+AH/DG\6_B'(*[Y/?^M56?VZO_P2I=O^M?3_ /B47^$)
MR>_]:JL_MU?_ ()4NW_6OI__ !*+_"$'K%43RC\A-!>KI?M227NJBFF#ZHP-
MA:6@AN<9SZ%>RQNI?]7+M_9)?\#D'C+D3Y.:;E$N-RIJJX340I8FR!T<8?M9
M=C'$JU^6K2D6B^0.CLE/5254<%Q8X2O:&D[6\=T#UK!_(\_T]J#^RL_QJP?E
M6_[+&_\ B$/^%Z"K^3/D1M6KM'T=XJ]034<TY=F%L;"&X./"5?\ 8[?2<FO)
MG)"VK-52VNGEF$SP&E_%SL</2<+SQR<\B%7J_2=)>8=1"C9/M 0[DNV<''3M
M!;?R]5+M%<D5BT<*HU%34?4DF:-G:CC.3P])+>Q!1-5;+I<[%7ZTE<7--S$4
MKP..]>"_:]6<#[0O<7)_J!FJ='6J\1XS4P@O \#P<.':"O(MJY1+91\D-;HM
M]DGDEJG.E=5[X "3:!#MG9\&RT=/@5J?)"U%OK1=]/3R9?3R"J@:3_4=P<!Z
M 0#_ .9!H'+M;V77E_FM\LIBCJGTD+I ,EH=&P95F::^3[9[/J"VW.#4L\\M
M'41U#8C$SZY:X'' ^A5ER\V]UVY?9[>R7<NJG4L(DQG9VHV#.%9NA^06LTWJ
MRV7B74HJ64<PE,.X<W;]&=HH+Y1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!=D/?M]:ZUV0]^WUH)R(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B M0Y1=!T&NZ:AIKM65\-)3RF1\--+L-G'5?PZ
M.'KZ5MZC72E=6VVKI63/IWSPOB$T??1ES2-H>D9R@H_E<Y)M"6+D^N=QH:%M
MKK:.,24]0RH?M%X/!OUB<Y[5M^C*.X:VY$+3376XUM%6UM$&OJX#LRX!(!X^
M, 9\>5H.M.1.]0VYUR@U;4WQ] TU#:&[L,D,FR"3_6(SCT*UN2#53-9: MEW
M;31TKW-,,D$8PQCF$MPWT< 1XLX0:O-R":"CL$M*ZW2F<1'-<^H=O=K'?YSL
MY\.,873\ER[5URY.YH*Z=U3';ZV2DIIG?UH@&D#/AQM'[,#P+HY3=9UNI[S+
MR>Z$)?<9AL7&X _T=''_ %AGPNQP_#IZ+)T+IBCT?I:@LEN&8:9F'/(P9'GB
MYY])*#-S2-AA?)(<,8TN<?$ J3Y&6_/;6>H^4*X#>,CF=;[8TCA'"WI</201
MVE6IKE[H]%:@?'G;;;Z@MQXQ&Y:'\EZ&*/D;M)CP3++.]Y\9WKA_< $&D\E.
MF+;RM7;4FJ]:Q/N#V5AI*6E=(YL4+&@'@ >G! Z<=/A4^CH(^2?EGM%KLDKX
MM,ZC80ZDD>7-AF&<%I/'IV>W"R5-H76V@K_=I^3V:UUMFN<V_?0UQ+'0/\8/
M01_G'#*TN_6G459R\:(9JJXTM1=GGG)IZ,$0TL3=IP:,\226G)]2#T'K;4]!
MI#3=9>+F_$4##L,!PZ5^#LL;Z2O/.D+=>QRZZ0O^J)'"Z7Z"HK'4YZ*:/8<(
MX_L;CA_QRI6I]?:9U1RK8U9<>:::T[)_T>D?&]_/*D'B]S0"-D8Q@_\ $KGJ
MCE0TE6\M.D+Y2W3;M=!2SQU$NY>-AS@[ QC)Z1T(/2RK/E3L>K]3UD=GME;!
M:]+OA<^NJXCFHDQ_V8'@SCI'CX^(V#9[C2W>UTEQM\F]I*J)LT+\$;3'#(.#
MQZ%VUO\ ]'/_ +MW]Q04]\E*$4_)]<(6$EL=TG8">D@!H7'E^IY-+W"Q<HEJ
M!966RH93U@:.$U.\X(=_=_YO0%W_ "7/]1KK_P"+U'_*M@^4%%'-R/:G;,0&
MBG:\9ZS9&D?B @WFVU<5?;Z:L@.8:B)LS#XVN (_ J2M3Y(Y'R\F&DWR'+NY
ME.,^J, ?W+;$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$01
M*[O3_*52^D._'^?$KHKN]/\ *52^D._'^?$BPN&S?L6^I9)8VS?L6^I9)$%$
MJ>_4M1*GOT$M$1 1$01:OOAZE'4BK[X>I1T!>?=4<ENJ-4<LL-^ND=)W!BJH
M]EIG!=N(SG&SCI/'M7H)$&-GL5JF@DB?;J/9D:6G$+<X(QXE2/(QR8ZKT'KZ
MIJYV4C[-4,? ]S)P7;.<L=LX] [5Z 1!0NDN2_4=KY=:C555'2BTOJJJ4.;,
M"_9D:\-^KC_O!?:_DOU'/R\0ZK9'2]R&UC)RXS#;V0T _5PKY1 4.\T[ZNSU
M]-#C>S4\D;,G R6D#^]3$04?\GKDVU!H:ZW:HOT=,R.IA:R/<S!_$.SQ6V<N
M^DKGK/0XM=D;"ZK%7'-B5^P-D!V>/VA6(B#R]9.3WEEL=NCH+3=HJ6CCSL11
MU;<#/3_577>>2+E%U5>[54:IFI:B.G#(9975(+MWMDN/ <3@GL"]2H@Q\=DM
M4;&L9;:(-:  -PW@.Q47HSDIU/H_E<=>K7'2.L3IWL/], [</Z1L^CAV+T(B
M#SGRN<E.L-0<IM5J+3O-618A=#(^<,>US&-&<8\84S3&F>6:GU%;);Q?!+;8
MZF-U2SG33M1APVAC9X\,KT B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("[(>_;ZUUKLA[]OK03D1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!:7R@.UU#54-1H9EIJ8&M>VJI:YQ:7GALEKAT8
MX^'P]"W1$%)7J?E>U7:ZFT,LEEL,52W=2U;ZDO<&'IV1QZ1D=!Z5G*O1NH-*
M\D%-IGD_G@-U9]22IF<&<'EQD>T^ Y/#Q#U*T40>?- Z;Y4=#VAU#9M/:8+I
M';R>HFJGNEF?XW'/X*U- U.M*@U?SWH+528V=QS&1S]KQ[625MZ((URI&5UN
MJJ27]G41/B=ZG @_WJG?DS5!M-NU!HRM=BX66OD.R>&U$XC#AZ,@]H5UK7)M
M&6F36D6J6LFBO#(=PY\4I:V5GB>WH=\!XD&M:HOG*/2WNKI-/Z8ME70EP%-5
MS51;P(&2]N? <_8NGDTT!=;?J.OU;K>M@KM35C=VT4^=S31=1N0./@]7CXE6
M<B""^SVQ[BY]NHW.)R28&DD]BK_46@9:WE9TQ?*2@H!9Z&FFCJF[+6Y<X.V?
MJXX](5G(@KGE'AUU'>M-,T&ZEAM3)<5K'-;C9R.!R.#=G/>\?P5A5+#)32L;
MWSF$#L78B"O.0_2=ST?IBOH;TV)L\UPEJ&B)^V-AV,<?'P6"^4Y<7.T12Z;H
MW;5RO]9#2PQ#I< \.)]60T?:K@6N3Z-M-3K*#4]4R:>Z4\1A@WDA,<(/26MZ
M >GCZ4&1TQ;19M.6JV#!%%214V1_W&!O_!9)$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1!$KN]/\ *52^D._'^?$KHKN]/\I5+Z0[\?Y\
M2+"X;-^Q;ZEDEC;-^Q;ZEDD042I[]2U$J>_02T1$!$1!%J^_'J4=<KDR9TK3
M%,(QCB"S*B;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJK
MSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ
M\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^
MR^*"2BC;JJ\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIO
MLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH
M)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*
M;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJKSIOLOB@DHH
MVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJK
MSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ
M\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^
MR^*"2BC;JJ\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIO
MLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH
M)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*
M;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJKSIOLOB@DHH
MVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ\Z;[+XINJK
MSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^R^*"2BC;JJ
M\Z;[+XINJKSIOLOB@DHHVZJO.F^R^*;JJ\Z;[+XH)**-NJKSIOLOBFZJO.F^
MR^*"2NR'OV^M0MU5>=-]E\5RBAJS(W%4T<>G=#WH,RB@[BN\]9[$>]-Q7>>L
M]B/>@G(H.XKO/6>Q'O3<5WGK/8CWH)R*#N*[SUGL1[TW%=YZSV(]Z"<B@[BN
M\]9[$>]-Q7>>L]B/>@G(H.XKO/6>Q'O3<5WGK/8CWH)R*#N*[SUGL1[TW%=Y
MZSV(]Z"<B@[BN\]9[$>]-Q7>>L]B/>@G(H.XKO/6>Q'O3<5WGK/8CWH)R*#N
M*[SUGL1[TW%=YZSV(]Z"<B@[BN\]9[$>]-Q7>>L]B/>@G(H.XKO/6>Q'O3<5
MWGK/8CWH)R*#N*[SUGL1[TW%=YZSV(]Z"<B@[BN\]9[$>]-Q7>>L]B/>@G(H
M.XKO/6>Q'O3<5WGK/8CWH)R*#N*[SUGL1[TW%=YZSV(]Z"<B@[BN\]9[$>]-
MQ7>>L]B/>@G(H.XKO/6>Q'O3<5WGK/8CWH)R*#N*[SUGL1[TW%=YZSV(]Z"<
MB@[BN\]9[$>]-Q7>>L]B/>@G(H.XKO/6>Q'O3<5WGK/8CWH)R*#N*[SUGL1[
MTW%=YZSV(]Z"<B@[BN\]9[$>]-Q7>>L]B/>@G(H.XKO/6>Q'O3<5WGK/8CWH
M)R*#N*[SUGL1[TW%=YZSV(]Z"<B@[BN\]9[$>]-Q7>>L]B/>@G(H.XKO/6>Q
M'O3<5WGK/8CWH)R*#N*[SUGL1[TW%=YZSV(]Z"<B@[BN\]9[$>]-Q7>>L]B/
M>@G(H.XKO/6>Q'O3<5WGK/8CWH)R*#N*[SUGL1[TW%=YZSV(]Z"<B@[BN\]9
M[$>]-Q7>>L]B/>@G(H.XKO/6>Q'O3<5WGK/8CWH)R*#N*[SUGL1[TW%=YZSV
M(]Z"<B@[BN\]9[$>]-Q7>>L]B/>@G(H.XKO/6>Q'O7=31U+'DSU#96XX 1[.
M/Q02$1$$2N[T_P I5+Z0[\?Y\2NBN[T_RE4OI#OQ_GQ(L+ALW[%OJ626-LW[
M%OJ621!1*GOU+42I[]!+1$0$1$$6K[X>I1U(J^^'J4= 1$0$1$!$1 1=$-73
M32&.&HAD>.EK'@D?8N] 1$0$1$!$1 1=<\T4#-N>5D3,XVGN#1^*^Q2QS1B2
M%[9&'H<TY!^U!S1$P@(B("(B B(@(B("+BQ[7C+'!P\8.5R0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 79#W[?6NM=D/?M]:"<B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B")7=Z?Y2J7TAWX_P ^
M)717=Z?Y2J7TAWX_SXD6%PV;]BWU+)+&V;]BWU+)(@HE3WZEJ)4]^@EHB("(
MB"+5]\/4HZD5??#U*.@+SE\JG4U\L-\L4=DO%PM\<M-(Y[:6H=&'$.X$X(RO
M1J\M_+%_UAT[_99/\808NZMY7-'6"FU--J&MJ+<YL<I<^KWX:'XV=IC\].0.
MA7[R+:VFUUHN.Y5L3(ZV*0T\^P,-<X ': \&01P7F76VN]:773]JTO?J6*TV
MV>.%L9D@=$)HQLAKRYV<M& <A7566=_)/R W6.W5N^N$C ]U3%WN\D+6DM]
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M!H&.U\H]9JJTW TT=?%NZV@W.TR9PZ'AV1LG.#T'P^-!K?\ [/?)]^[:K_\
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M5<*FYT\E.RNJ1) R08)8&@;6/ "?[E9E)HO3-'4;^FL%LCEZPIF9'JX<%GP
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M8X6!C1Z@."#O"\5Q7^72O+Y>K\REFJJ>@N54^I9$W)$3GN8X^COQT^'"]J*
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M_LEHO[3/_C6@_*HT=7B[46K;7"^2%D;8JET3<F)S22UYQX..,^A>D**CIJ&
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M4T=7("'SLB:'O!\;@,GH'8@\=<F&IG\D'*#=*;4M%4;IS#!,V-H+Q@Y:YH)
M(/KZ"OFOM7#6W*YI^\4])4TM 9::&FW[=ETC&S<7<"1WQ/0? O7=WTY9;Q*R
M6ZVJBK)6=Z^:%KB/M(7=)9;7(8#);*)QIP!#M0,.[ X@-X</L04#\K32M?5R
M6K45%3/J*:FB=!4EHSNQM;321XN+N*UZRZSY'NX=,ZZZ/D%R;$!,R*'::YX'
M$@[8X$KU9(ULC',D:US'#!:X9!"P#M%:8=5<Y=IZU&;.=KFK.GU8P@QW)$ZR
MU.A:.OTW:FVJWUKY)A3 YP0XLR?20P+<0 .@87&*..&)L<+&QQM&&M:, #T!
M<T!$1 1$0%V0]^WUKK79#W[?6@G(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B 2 "3P 5$<F^UR@\L]^UE+LSV6T VZV._J[0QES?'P+G9_[
MX]"O9S0YI:X M(P0?"H]!04=NA,-OI:>EA)VBR",,;GQX'AX()*U'E=H)+GR
M8ZGI(&E\KZ&5S6CI):-K'X+;D(!!!X@H*TY![U!-R*V6NFD CHZ:1DQ''9W;
MG Y'J&545?RA:>Y2M8E^K[XRUZ,M\@=3VUX?MUKQT/DV0>'HS_Q*M?DVT;=M
M%ZHO]KC@BJ-%UQYQ2ET@+H'D?6C+#Q(.2,^@>-;P-*Z>_<-J_P#PX_<@P&F>
M4K0]VK:6SZ?O5++4.&Q!3Q1/:, = RT <%75HNU%R6\LVJ:?44AH[+J%S:RD
MK'M.[$F27-)\'%Q'V#QJZJ33UFHYVST=HMT$[>]DBIF-</40,KMNUHMUXIN;
MW6AIJR'IV)XP\#U9Z$%$:[O%%RJ<INC[)I>47*U6JHY_<:F('=- <WZNUZ@1
M_P";T%6G?^46R6/6MITO6\Y[HW'&[<R/+&$\&AQSGB?$#Z5L5FLELLL!AM%O
MI:*(\2V"(,SZ\=*^5=DME9=*6Y55!3RU]*"(9WL!?'GIP4%(Z<N5+R6<KFJJ
M74QYC9K_ "BKH:UX)BVLDEA=X.^/3T8]*Z.4R^T'*7K[1-CT=.RYB@KA65M5
M"W,<# 6GO^CH#NCPX'2KZNMJH+O2FFNE%3UD!_J3QAX_%=5EL=JLD+HK/;J2
MB8[OA!$UFUZ\#CTH*J^596;ODVAM\>347"NBAC8.EV,D_P!P5LV*DYA9:"DR
M3N(&1\>G@T!5[?='W?5?*M;;E?(HHM,V-N]HH@]KS43DC+G#P#@.!ZOI*L]
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M!;GRUT[ZGDHU5'$"7<QD?@>)OUC^ *VZ@HZ>WT<-)0P1T]-"T,CBC;LM:T=
M 7*KIXJNEFIZF-LD$S#'(QPR'-(P0?L0:/R#5<=;R1Z9EBZ!3;L^MKBT_B%#
M^49_L=U%_)'_ .HU8KD0H+QHVZ7K15RHJU]KII34VVX"!Q@?&\Y<S>8QM D<
M/'M*R-5:?H=46&JM%V:]U%4@"0,=LG@01@^L(,3R:[SZ,[#N,;WN>S8ST9V>
M"IS3FDN6'3UXO%SH8-/3U]SE,D]34RE[R,\&@Y&&CQ+T'9K;3V>U4ENH@X4U
M-&(HPXY.R.C)4Q!Y3<_E2^FP.,5B^=7<G@W)W'-]L^GOLY7I$:AM]%5VVUWB
MX4D%ZJX@6T^V 7NQ];9'KSA<3I2V'60U1L2]UA2\SVMOZN[SGO?'D]*Q]\Y/
M;%>]8VO4U=%,;G;OV6S)ACB.+2X>'!XC!'IR@Q'+QJYVD= 5<E*YPN5=_P!#
MI-GI#W _6'J&?MPLCR0:3;H[0-KMC@.=F,353L<3*_ZSNS./L4_4VB[1J6[V
MFX7ADT\ELDWM/%O,1!^<Y+?#T#L6R(*>^594LAY*9878,E35Q11C&23Q/#L5
MGZ9IWTFG;93RXVXJ:-CL>,-"J[E L]RU]RG6.S26VKATQ97\]JZF>%[(JF3H
M#&.(P[ \7C<KC P,! 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1!$KN]/\I5+Z0[\?Y\2NBN[T_RE4OI#OQ_GQ(L+ALW[%OJ626-LW[%
MOJ621!1*GOU+42I[]!+1$0$1$$6K[X>I1USN%1%#(ULLC6$C(R5$YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4$A%'YY3>7C[4YY3>7C[4
M$A%'YY3>7C[4YY3>7C[4$A=D/?M]:A\\IO+Q]JYQ5U*'MS41\#XT&711.Z5'
MYS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+
M11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'Y
MS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]
MY.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z
M5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y
M!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5
M'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS
M%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11
M.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%
M]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.
MZ5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'
MYS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y.Z5'YS%]Y!+
M11.Z5'YS%]Y.Z5'YS%]Y!+11.Z5'YS%]Y=L%73SN+89F/(XD-.4'<B(@B5W>
MG^4JE](=^/\ /B5T5W>G^4JE](=^/\^)%A<-F_8M]2R2QMF_8M]2R2(*)4]^
MI:B5/?H):(B B(@B5C6EXR >'A"C;#.HWL4JK[X>I1T''89U&]B;#.HWL7)$
M''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;
M#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$'
M'89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#
M.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''
M89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.
MHWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''8
M9U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.H
MWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89
MU&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HW
ML7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U
M&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL
M7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&]B;#.HWL7)$''89U&
M]B[(8V;QOU&]/B7%=D/?M]:"9NH^HWL3=1]1O8N2(..ZCZC>Q-U'U&]BY(@X
M[J/J-[$W4?4;V+DB#CNH^HWL3=1]1O8N2(..ZCZC>Q-U'U&]BY(@X[J/J-[$
MW4?4;V+DB#CNH^HWL3=1]1O8N2(..ZCZC>Q-U'U&]BY(@X[J/J-[$W4?4;V+
MDB#CNH^HWL3=1]1O8N2(..ZCZC>Q-U'U&]BY(@X[J/J-[$W4?4;V+DB#CNH^
MHWL3=1]1O8N2(..ZCZC>Q-U'U&]BY(@X[J/J-[$W4?4;V+DB#CNH^HWL3=1]
M1O8N2(..ZCZC>Q-U'U&]BY(@X[J/J-[$W4?4;V+DB#CNH^HWL3=1]1O8N2(.
M.ZCZC>Q-U'U&]BY(@X[J/J-[$W4?4;V+DB#CNH^HWL3=1]1O8N2(..ZCZC>Q
M-U'U&]BY(@X[J/J-[$W4?4;V+DB#CNH^HWL3=1]1O8N2(..ZCZC>Q-U'U&]B
MY(@X[J/J-[$W4?4;V+DB#CNH^HWL3=1]1O8N2(..ZCZC>Q-U'U&]BY(@X[J/
MJ-[$W4?4;V+DB#CNH^HWL3=1]1O8N2(..ZCZC>Q-U'U&]BY(@X[J/J-[$W4?
M4;V+DB#CNH^HWL3=1]1O8N2(..ZCZC>Q?6L:T_5:!Z@OJ("(B")7=Z?Y2J7T
MAWX_SXE=%=WI_E*I?2'?C_/B187#9OV+?4LDL;9OV+?4LDB"B5/?J6HE3WZ"
M6B(@(B((M7WP]2CJ15]\/4HZ M1UORAZ>T74TT%_J9(9*EA?&&1EV0#@]"VY
M>6_EB?ZPZ=_LLG^,(+<MW+9H2MF$?=H4Y/ .GC<QO;X%8%OK:6XTK*J@J8:F
MFD&62PO#VN'H(5/0\AFC;UHR@DIJ*2AN,]%')SF.:1W](6 Y+7.((SX."KSY
M,^H*^PZ_K=)5TTCJ6;>,$)=EL<T9XD#P9 .<>((/5B*A-:\M%YJ-8RZ7Y/+2
MRX5L4CHG3GZ^VYO?;+>  &#EQ..":/Y9+[0ZQBTSRCVAE!4S/#&U#?J[!/ 9
M'$.:3_6![4%]HJSY7]7:NT]56ZCT?IYUS=6-=F=K'2;MP/>EH&!PXY)\?B5:
M/Y:=<:0O=-3Z^L$;*><!^R&[MVQT%S7#(./"/[D'I<!1;?<:*XMD=;ZRGJA&
M[9>89 _9/B.#P*T/EFU;<K%H%]?IRW2U_/(G U,>=FEC+"=\< \/%T+SQR-:
MLUK8;9<F:1T]+=X9I@^:1L#Y-EV.CZJ#T!RJ<KE#R>WBDM]9;*FK?40;\/B>
MT #:+<<?Y59<;MMC7#P@%>4OE>X.N+)M<!W/&3C_ /5>LA>>6K7]-2Q7F#37
M,M/.+6Q23P/<UXZ!F3 Z?_X(/3Z*L[1RL4=;R35>M)*%S>:'=34K7_\ :Y:-
MD.QT'::<XZ"JOM?*YRG:BIZBZ:?T[%46V%Y8\00&3! !+>G).".@(/3B+6>3
MF]W34.DJ.YWVV=S*V;.:?ZV0T' )! (STX6S("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@+LA[]OK76NR'OV^M!.1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1<97;$3W]4$H-*
MUCRI:6TG<6V^YUSY*_&74]+&97L'_> Z%E=%ZSL>LJ%]58*UE0(SLRQGZLD9
M\3FGB%5?R8:""]6O4.K;G%%4W.Y7%[-]*T/<V-H:< GH&7?@/$%]N,#-)_*9
MLO<J-E-2:@HG-J88AL,>]H?]8@<,_5:>WQE!>J(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B((E=WI_E*I?2'?C_ #XE=%=W
MI_E*I?2'?C_/B187#9OV+?4LDL;9OV+?4LDB"B5/?J6HE3WZ"6B(@(B((M7W
MP]2CJ15]\/4HZ O+?RQ?]8=._P!ED_QA>I%5_+!R2MY1KA;JIUY-NYI$Z+9%
M-O=O)SG.TW"#8J#4MHT_H"UUUUKX(((;?"3EXR2(QP \)]"\Y<@%/4ZIY9ZZ
M_-:YK(M_6/<>(#I"0 ?O'L6Z4GR8Z,2L-?JFJJ(@>+&4@82/%DO=CL5TZ,TE
M9M'6L4%AI&P1$[3WDY?([QN<>)0>.>3JU7VY<HU;;['?&62\.=,W?2/<TO(<
M=I@(!.>'X*R[OR(:RN=XHKAJ'5UOJZF)S&1R3R2%^ [(:"6^,_BMZY1^0RUZ
MKO3[Q;+A)9KC(=N5T<6VR1_6QD;)](]:Q^D.0FHM&IK=>+MJRKN+J&9L\<)B
M(!(Z,ESS_<@UGE(Y1-77;E0^96EJYEL:RH92"=O!SW$#+G..< 9/0/ M"Y>[
M%>[!5V6FU)JF2_5CXI'ACR3S=N6CAGP.(/W5=W*9R&TVK=2OOMMO$EJKI=DR
M@1;8<X# <#M M. %AZKY-]%5VD,J=1U<MW,FV^NEA+\MQW@87^/CG*#==6_]
M7^M_\!;_ .B%HGR/I8QIK4+2]H+:F-Q!/0-D\?P5UBQ4\FE&V"L._I>9BCD=
MC9VVAFR3Z%1?_LT&*KDYGJV:&D>>+12_6QXB0\ H-:^5_P =;64CB.YP_P#4
M>KDY=*>*'D4NL#& 114\36-QT .;A0.5+D9CUY<+94F^.H!14C:0-YKO=L D
M[6=MN.GH6\Z[TP-6:/K;"ZK-**EC6;\1[>S@@][D9Z/&@IOY/=FMVH.0V^6J
M\R;JAJKE)&]^T&EIV(=D@GAG.%I6I=#:UY'MY>M/7ATMIVV[<D#BW(SPWD9X
M$>#PJYK)R/16[DNNNC)+U)-'7U/.>=MIPPL/]'@;.T<_L_'X5I9^3C73-;3U
MFMJF6A!SNN;N([#)@%!9_(OK.HUUHB*ZUT,<-6R9]/*(P0USFX.0#XPX+>E@
M=$:6M^CM.T]GM+7;B++G/><ND>>EQ])6>0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 79#W[?6NM=D/?M]:"<B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+A.TN@D:.DM(_!<T04
ME\DR00Z"NELDRVJH;I*R5AZ1EK,?W'L75K=_=#Y3FBJ6 %SZ&CDFEQ_5!$G3
M^':L_J+DKK#JNJU#HC4T^FZVM %7$R 313.ZVR3@'[/'T9*R7)MR;1:3N-?>
M+G=9[WJ"NX35T[=DAO5:W)P.""P41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$01*[O3_*52^D._'^?$KHKN]/\ *52^D._'
M^?$BPN&S?L6^I9)8VS?L6^I9)$%$J>_4M1*GOT$M$1 1$01:OOAZE'4BK[\>
MI=&$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$
M'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]
MPF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'
MQ%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]P
MF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q%]PF$'Q
M%]PF$'Q=D/?M]:X87.']HWUH)R(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B((E=WI_E*I?2'?C_ #XE=%=WI_E*I?2'?C_/
MB187#9OV+?4LDL;9OV+?4LDB"B5/?J6HE3WZ"6B(@(B((-PACED:7MR0/&HG
M-8>I^)4^K[X>I1T'1S6'J?B4YK#U/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGX
ME.:P]3\2N]$'1S6'J?B4YK#U/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P
M]3\2N]$'1S6'J?B4YK#U/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2
MN]$'1S6'J?B4YK#U/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'
M1S6'J?B4YK#U/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'
MJ?B4YK#U/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4
MYK#U/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U
M/Q*[T0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U/Q*[
MT0='-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U/Q*[T0='
M-8>I^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U/Q*[T0='-8>I
M^)3FL/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U/Q*[T0='-8>I^)3F
ML/4_$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U/Q*[T0='-8>I^)3FL/4_
M$KO1!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U/Q*[T0='-8>I^)3FL/4_$KO1
M!T<UAZGXE.:P]3\2N]$'1S6'J?B4YK#U/Q*[T0='-8>I^)7.*C@+VY9TGQE=
MB[(>_;ZT';S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8IS"
MF\G^8J2B"-S"F\G^8IS"F\G^8J2B"-S"F\G^8KLAIHH7$Q,V2>'25VH@(B((
ME=WI_E*I?2'?C_/B5T5W>G^4JE](=^/\^)%A<-F_8M]2R2QMF_8M]2R2(*)4
M]^I:B5/?H):(B B(@BU??#U*.I%7WP]2CH"AUUSH*!S6U]=2TSG#+1-*UA(]
M&2IB\M_+%_UAT[_99/\ &$'I:EO%LJY REN5%.\\ V.=KB?L!4Y>0=><CE/I
MGDZI=5V^\3ODW4$LD,K0WC)L]X1X03^"NCY.^JZR^<FSJN_U6VZAF?":F9W$
MQM:#ESCTD9Z4%K(J+O7RC;+3W"6"RVBNN4,).W.,,:X#^L!TX])PM_Y-.4BR
M:_I)GVHRPU<&#-2S@![ >APQP(]*"5IOE"TQJ2\S6JRW,5-?$USWQ;F1N TX
M/%S0.DK:UY.^37_MGN_]GJ/_ %&J^^5#E%MW)[0TE1<J.LJC5.<R,0-&,MQG
M:<3PZ>'J*#=D5"6OY25IDKXX;O9*ZB@D(&^!#MD'^L1TD>I9'E]Y4Z2Q::%K
ML=7/W8N=,RHIZB#+1'"YW!^UPXD-<!C[4%U(O.G(?RS1RQ6?3%XCN5==JFH,
M7/9I0\?6/#))SP5A<I?+!8=#5HMTT<]?=2T.-/!C^C!Z-IQZ,^(9*"R45-:.
MY?;'>;O%;+Q0U5GJ)7;+))\&/)Z 3TC/JPMKY4.4RS\GU-!W1;+4UM0"8:6'
M&T0.EQ)X 90;#JK4MITI;!<+_5\TI"\1[PL<_P"L<X&&@GP%=^G+Y;]1V:GN
MMFJ.<T%1M;N79<W:V7%IX. /2TA>7.5CEAMFO]!R6UE%/0U\=3',&R$.:]HR
M" 1X>(/'TJZ_DX?[&-/?_P!Q_P#Y$J"REC+I?[1:I!'<KG1TLAZ&RRM:>S*Z
M]85T]LTG>*ZC87U--22RQ@#/U@TD'_BO(?)#HRW<IM[NCM2Z@GAN)_I&,:YI
MEG)/%V7 YQXAQ0>S**LI:Z 3453#41'H?$\.':%WJJ^2SDLI.3.X7JYONKJF
MFDA#6ND&P(HQ]9Y<.C/ <?$%K]Z^4;9:>XS4]GM%=<H87$.G:0UKFC^LT=./
M2<(+T1:7R:<H]DY0*.9]J=)#5P8,U+-@/8">!X<"/2%J3.7_ $RPWIM935E/
M+;G;#8W;)=4NVBW#./HSQ\""W9YHZ>"2:9X9%&TO>X]#0!DE:]I+7.G-7354
M.GKG'62TH!E:&.;L@G /U@,CAX%KV@N4&CY0M(7ZNDMDM/14P?#)$YX)D;N\
MGU<#A:9\FNITA476^_-*W72EGW4;I75LS7C9+CAK=GHX^-!?**G==\ONGM-W
M2:W4-//=:F$[,CX2&Q-<#Q;M'I(]'!9'DVY:M/ZUN+;;NYK;<GC^BBG(+9CC
M)#7#P\.@X06BBK1W*[;&\I?S,[G5G/.<"GW^6[O);M9Z<X68Y4-?T7)]::2O
MN%)454=1/N&MA(!!V2[)SZD&YHL%:M3T-;HZGU+.31V^6F%4XR],;,9XX5/5
MWRE;2VK>VWV*OJ*5AP97.:TD>/'''VH+^1:MR<ZSH]=:>[KV^EJJ:$2NA+:@
M $N&,X()R./2MH<YL;'/D<&L:,EQ. !XT$*KO%LHIC#67&CIY0,[$L[6.QZB
M5,C>R2-LD;FO8X!S7-.00>@@KP_JQE?RDZOUC?J)I=3T,3JC(Z-TPAK1]K03
M]A7H_P"3;J,W_DTI89G U%M>:-P'3LM +#V'\$%IK"ZLU19])VUE?J"L%)2/
MD$0>8W/RX@D##03X"M<Y4>4^S\GT-.VO9+55]0"Z*FAQG9'#:<3T#/!4)RO<
MK]MY0=#,MT5%44-?#61S[,A#FO:&O!P1X?K#@4'J?3UZM^HK/3W2SU'.*&H!
M,<NR6[6'%IX$ ](*R*HG0>N8- \@>EKG6V^IK*6226%Q@+08R99",Y\!P5:^
MA]54.K]+TU\M[7QT\P=EDF-IA:2"#CU(,^BK+0?+!;=:ZJFLEIME8#$Q\CJE
M[F[ 8T@9Z<\21VK#ZQY?;%9KQ-:[10U5XJ87%CWPX$>T.D ])QQ\&$%RHJWY
M,N5VQZ[JY*"&*>@NC&[?-ZC'UP.G9(Z<>+@5'N_+3IZS:RNE@NT513&@87/J
M3@L>0P.#6@<<G.!Z4%H(JATGRZV2^B^U4]%44-MM< G,TI#G/RX-#0T>$D\
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MF!."T?8!]JE:S<.3OEOL5\I/Z.UZH?S.X, PT2C :_ \.7 Y]#D%Y(B("(B
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MV05,#-V'TD187#.1G+CG"^\M(DN7+;9:"]%VY$=!3R!QQAKL%_XN<M\I-/\
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MN)[72:?@@?;:9IED,DX83*21T'Q-_O04=R5<HM%HFRWJBJ;')<'70;N603;
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MR,;(;(#AN?\ B4'H1%K5_P!<Z>T_?*.T7>XLIJ^KV=S&YCB';3MD<<8''QK
M7#EHT+0W)]%->VNE8[8<Z.%[F YP?K 8[$%B(H]OK::XT<-703QU%-,T/CEC
M=M-</&"M/U/RK:.TU7OH;I=V"K9P?'"QTI8?$=D8!]"#>$5<0<MF@IG,8R]C
M;>0 #3R=)_\ *K$?+''$Z61[61-;M%SC@ >,GP(.:+SY>.76.#E9IZ&GN%.W
M2$.8ZF<0[9>X-=ES7#CC:V1P\2N?2VJ[+JBU2W*R5K9Z*)YC?*6E@:0 3G:
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MQO#"\1Y_FQC'I06,BZS/%S8U >UT&QO-MIR"W&<C'3P6MZ2U]IO5M;4TE@N
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MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M8BZY(8I3F2*-Y\;F@H/)E!IJMY2>4J@N5ATH=-V.F,9EDW6Z:X-<3M] !>>
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M2KXYZ=FJ]U;E_#MP^_'^I.ZMR_AVX??C_4MJ1+FE7QST[-5[JW+^';A]^/\
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M :,=).%$I]2SQ7"DI;O;):$5A(@D,@>-K&=EWB*#9(8F0Q-CA8UD;1AK6C
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MTCGN@B+W##G%@R1XB5VAH#=D !N,8QPP@KW76HK7>-,5,%MJA42AT;RUK'#
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M/)#LC@1CP%;%HYN+UJ@D8S7?\H6R"DIQ-OA3PB7K[ VNU=C6,87%K6M+CEQ
MZ3Z4&J: ;BSW7A@FNG_X+3*2E?\ -6S5LC:CFM)<9G5#H,A[&.<1M#U*WF1L
M8"&,:T$Y( QDHR..-FPQC6M\0& @T>U-TU7WJ@?372LK:R%QDA:^1[@WAQSD
M<%/L+?\ X[U2['2VFX__ --;"YM#;FF4MIJ5KB&E^&LR3T#*D-8P/<]K6ASN
M^<!Q/K05OJ6X"U:XJ74ER-NW]*QT[VP<X$CP2&C9_JD!0:^DH)]-4T]GJIJ_
MF=>VJKWL:63').7;..'C^Q;/';+W:+Q=*FV4]#60UTN^VI7ECV''>D^$*=I:
MRU=%7W*Y7-U/SNOV-J*G!#(PT$ <>D\>)082@?IBNN=NW5UKJRI9,)(8WR/<
M&O'A((X+(V9O_P Q-0''_P!O!@_85L\-)3PO+X8(HWGI<Q@!*[!&P/<\-:'N
MX%P'$H*CUQ&_YR7:9K'NCA=2RO(&<-!=D_BK2M=SH[I3F>WSMGB!V2YH/2I)
MAC)>3&PEXPX[(XCQ%(88H&;$,;(V=5C0!^"#4M<7*>CN=HIWUDM!:YS)SBIC
M;Q! &RW.#LY6K2P07*_W&&S25=5'):9HF2SN<[>/S_5)\'$#UJUIHHYF%DT;
M)&'I:\ A&0Q,V=B-C=D;+<- P/$$%?'4UN?H7F#=LW!M(*<T>[=M[;6X/#'1
MPSE?:FF=%HC35XA:=_;&0S.P.)C( >.P_@M^YM!O72[F+>N&"_8&2/6N>[9N
M]WL-W>,;..&/%A!H-EH*F[:5U#<2P\[O#9-TT\"& %K&K&4$^FYK#%376YW*
M&41-BFI'O>"' 8(#<="M)C6L:&L:&M'0 , +J=24[IMZZ"(R]<L&UVH-3TG
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M'7SBIYA2R2-J7T[BU\;7AH#LCC@8XH,K:=13R7<6N\V\T%9(PR0D2B1D@'2
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M1-.W:DTQ+=;=>Y332&K?41O>TD2L?Q!! XG@@[W:]C+*,06RHDJ)Y7T[Z?:
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M<@;0\ '23ZEQM>H;7=I)(K=6-DE8W:+2QS2!X\$!!DY(HY<;QC'XZ-H97-H
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M6ZR4%N96-HX!&VK>9)0#TD_W#T*'+I&SRVZGHG4SA%3N<Z)S7D/82<G#NE!
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M>]!;&\9UAVIO&=8=JJ?Y]W?S&D_-[T^?=W\QI/S>]!:YE8/ZP^Q=,M4&@D<
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.<!CH1  QT(B("(B#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g50309g03m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g03m01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2%.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (3$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 2(  A$! Q$!_\0 '  !  (" P$               4&! <! @,(_\0 7A
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M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(")E,CQ0$3(\4R/%
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M-760QR"-K7QS0N.'-.,D9]AZJD:(U+8-.:9N%92TU7&Q]2(Q')()'ROY<X&
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M3T\;.PG8P RO)[G-.' #KMUPM>Z[X5:GTMJ6LU5PWK),2O=.^EB.)8\DN<T
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ML"FQT4'8/]F'L"G!T4ND1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MD6<3,=*W\7#DO\R](F?SI#:DTS:]111LND!D,9)8]KBUS<]=PHF+ASIR*E9
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MW8<=5]*(B(O,-$Z>X.W&Q<*-56X.AJM2WN%C.5L@#&!KFN#.8X[^8D]^RN_
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MY,44CV[<VZV_QLJ7M900CT27'X;K458]ODY&1C&Q7)Y/3Z[^S^"+XK6UWO\
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MVB/_  C>!%%J)]UU+,R^4S:.*]O%=!Y$"ZJ?C=S7Y\P';;=;LN7ZMK/\E_\
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M"D@8.KGN<W;W J\V"D?06&VT<OZ2GIHH7>UK #_!0SG]K/1$101$0$1$!$1
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M]!J$-BQ?HPB1?HPB".HOUO4_9"DU&47ZWJ?LA2: B(@(B("(B B(@(B("(B
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ME[1VM:7LR6ES7=H_Z6R^CV'.2O)RTBEM0]K#>;UW+E$19M!$1 1$0$1$!$1
M1$0$1$!$1 7#G8[B5RN">J#J'Y[B%UDF;'"^5V>5C2X^H!<DG!P5JCB7Q-9:
MS/;;,P5%66F.1Q;D-R,(I?)7'&[2U'Q'U=6:FOM4U\SVV^)Y;'#G8X[RH_3K
MXWM<TX![AW*O%LM16R]L>64DD@=Y7:DED9,2T\N-DB7QWE6MEM.Y6V[6]LD8
M.,GQ55J;:8WNP/8K!15DLS V0Y 69Y.'-R=TUMSUO,1]/6E E[1CBT$[KJUT
MK6D-=A3MXHPRH/FXPL^T6.2X!D%)3&69ZKQ=F/R)M&JQN6[?R<VS#24_;MYA
MVYY7$=1A;;Y0[<@9\3U5>T%86Z>TU24)]-K2Y_M))_JK$W&/@KOK,5.-=/.2
MFBE;B:-D@Z>>T%?(W&&Q&UZ^N#1&V.&7EDB#1@8.5]?'HM8\;])17FP27.,8
MJZ)O-GQ8.JTQ7XV1EKRJ^>+80UF?9LK';:[L,Y50@D[,@ J0AJ0X^<5[$7W'
M3P;TG?:VO>VK#LC8C&%3:B!M!<@X],Y4];*CE< L;4<39NS=CS@<J+UW]4&*
MTU^F4_8[F)BT$X?W>"DJX-=)VL [*4;APZY5,MSS#,',[ALK VX!T0>>[91.
M../97)//Z6[>%^HIKQ:I8*SF=4TN 7D^D#T_JKL#DCV96M>"]-_J%=6XVF<&
M>[_[5LIHZ9ZKQ\L16TQ#W\4S->W9$14:!Z+C!\5RB#J =]UP6G&<KNN#T0>,
ML E:YL@:YKAN".JUUK7A;;[R'SVXLH:O)=EH/*\^M;*[BNIPX$=?45:F2:3N
M&>7#3+&K0^2-1:=N6GZM\%P@<P X#V \CQXJ(:3GS<M Z8VPOKZ[6FDNE*ZG
MN%.V:(_LN[O8M'Z\X75-L$E99 9Z,><Z)QRYGL7H8_*Y]7>#YGPZV+^\Q=Q^
M&%H7B77V-S*:YN?5T6PP3YS![5OC3M]H[W3-JJ&821N;G',,M]J^1B<%P>,N
M!P2>[U%2FF[]7Z>K6U%KF,;OVHW>@X)E\:+_ %5/"^(6I]-YZ_\ 3Z\Y_4N0
M<A4/06OJ+4L0C<[L;@W9\9&Q^RKVTY&R\Z]+4GM[V/)7)&ZN0<GHN5PW.ZY4
M-!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!1^*7ZHE^PW^98&A
MO0:L_BE^J)?L-_F6!H;T&H0V+%^C")%^C"((ZB_6]3]D*3491?K>I^R%)H"(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B >BXRCO1*Z<V,9[T'C6U<%%"^:JE;'&/VG*F7#7C3(^.TTOE(
M9L9'Y#3[%":[N$]XU ;7$]S:2G'YT [/<LBU6Z..)C6L# !L /XKDRY^]5>G
M@\6L4YY'9VJ=12$NCIZ9C3W9=_=>D&L+Y3C-100S#_"3_=9[:9@_9RNQIV%V
M QN<9Z+*,UVWR\$_Y679M9T5=,R"K'DD[N@=T)\%9BYA'-S@MZ]=@M<7FU4L
ME+),\-C+ 7=KT+#XJJPZIO-?2&W4E2X4[#RF<>D\+:GD:CMA?PHO.\?IM*\Z
MRLUIRV2I$LW='%YQ/WC95NJXF/+L4EK>[_,/QV58H;)&#S.RYYW+CU*EH;6U
MK=QD>!6=_)M_E;T\#'6-VGMD?Z2;H#DVB+'VC_=2-#Q+I''%?22P-.QD;N!]
MW511M3#T:!]RQ:BSM=GF&?N45\BWW7GPL-HZG39UINUON<8DH*J*8$9P#@C[
MNJSW#8Y<?;X+1GDM99ZIM3:Y713-))Y=@X>!\5LO0VJF:@I3%.T1U\6TK,]?
M7A=&/+%^ON\_/X=L<3:.ZK,8PY(X@TDKM&_F:3RXP<+T:<K=Q1$>S*+E$2!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!%QGU("@Y1%TY_4@[HNO/ZDY_4@[(B("
M(B B(@(B("(B B(@(B("(B AZ+C.^%U<_E;DA"'=>;CN?XK#NEVI;72NJ*Z5
ML48Z9.[O4/%:YOVL:VYE[*%[Z"ESL\>F\?T5J4FWI2^2*>UVNNI[7;,MJ:IC
MI?W<7G$^Y:DUK4QZCU RM@@='"V(-S(1OAQ/3JL>1OG%\>1ODR..7.^]8%54
M]@QKN<ES=]CC*[,?C3'<O.R^;OZ:LR6<O(8 &L;L.7886-/5,A:>4[K!^41+
M&7$X)WZJ)KZO$9P<DGQ7974."T3?N7O6W($D!1DU27]%&F<EYRNP>M.4*12(
M97:%><H#QN=UY!SL^U,^=@JLV:5CMM3@13=IJ*IF/^Y@_BY;Y;X+0/!&YT]!
M?JEM5*V-D\(8QSC@$\P*WXQ^<XW[\]R\C-/U/<\?7!W1=>?;/<@?D]%DV=D0
M'*("(B B(@(B("(B B(@(B("\QL]Z]%XN<2]P .W>A]U.XIWQ]GTV\0[S3GL
MF[XQD+0M'3.C:9IO.E>#SYW*VCQSN<+(Z&AY2:@O$OW#9:S-1FGYCL2=U+Y7
MXQFM;-PB?2M71E.^5PES"1Z+AWJO"5S'G+LMS@%7.OHX:D<XY<^O=5>\4S(_
M0;C'@JL/$BF3J7O35I86\KE/6VX=HX-<1U5"9*6#/,I6WU3NT;AW13$I\CPY
MQ]QZ6B\M:]I(W*W/P-DIA1R0M:TRB-O)D#.._P#HM(2SET.2.HZ]58]#Z@K+
M7=[<*5QRYX86@]6D[J3X;FC#F[CI]3(%PS+F-/B N0,=ZA]AMR>BQ:RFBJZ6
M:GG'-'*PL?ZP5E=RZ\OKV0?,^O.%-RLA?4VP&NHRYSN1H\YF_1:TD8^![V2-
M+7L\TM/5I7W!)$US2'$><,'P*^9^)W#R[TVJJZMMU')/05+S(TPL+N7U;+JQ
M9^/4N3-X_+N%(M]2YK<+-=(^88:'$]Z4-DNC7]FZVU?:9Z=D?[+:/#_AG55-
M3'6WL.AIV$.; X8+O:NN_D1%=;<%?&M:_KIJ\0SQ1\Q@D$9Z/+3N5,Z9T]5Z
MDND5'3#D).99 #@!?2[[!:9H>S?;Z9S,<N#&.B[VNQ6ZUN>Z@I(8'/V<6-P2
MN6?*F:Z=E?"BMMNUAML-IMD-'3XY(AC.,9]:D>]=6LY0 #L%VQT7)[GMW:UU
M B(@(B("(B!A<;+E<<OK4:'#ALN"T$_T*[%N1U7'+OU3T-;Z_P"&U'?F25=O
MQ37%I+@X- #CX+0MYM%=9ZV2DN5.Z&4'&_HN]>5]@&/+LD[9Z*!U7I2W:BHG
MPUT3.8[MD#?.:5UX/)FG5O3S/,^&TS[M3J?_ &^4H)I*>=LE/(65#?1<#@-6
M[>&W$V.J$=MO\@CJ1AK*@G9RUKK71=PTM5<DS3+19_-S-;M_XE6@3XX ]%P[
MBNRU*YZ[AX^+-E\+)PGT^S*>1DHYXW!P(R".A7H=EH/AGQ+?;C%;;Z]TD& R
M.=SO1W[UO6GJHJB)LD3FO8X9:6G((7FY,4XYU+Z3!Y%<]=PR$74.SW+EKLY6
M;=RB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"C\4OU1+]AO\RP-#>@
MU9_%+]42_8;_ #+ T-Z#4(;%B_1A$B_1A$$=1?K>I^R%)J,HOUO4_9"DT!$1
M 1$0$1$!$1 1$0$1$!$1 6'>*X6VUU58Z,R"",R<@.,X'19BA=:?]E;K_P .
M_P#@4$#9-=55VEINPT]6^33/#.W#P6MWP3T[E;G7*B8P/?64S6%Q:'&5H!(Z
MCKU6LN&=+7.H;9,S4$<-*)3F@.,N&3MUSO[%#Z7T_076P:IK*UCGS4IE,!YB
M!&0TNR![<(-V\[>3G+F\F,\V=L>.54]0ZM=0WFRTEO\ )JJ"NE,<D@?S<NX&
MQ!QG=4.NK*G_ $,6X"1X:ZJ,3R#^P'/(!]60%DW*SV>UZFT@+0]I$\C'2!LG
M-S;MP_U9W0;9J*VEIGM;4U,$+G>B)) TGV97I+/%#$99I8XXQU>YP ]ZT[:+
M=;KY<=7U&HGYJZ=[^S$DA:8P.;<#U8 489IJC0VGGU3C4007%\0IW/P9F[$
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M[,\Y ;WGN7J=@H2OJ3/(6M/YMIV]?K16UN,$LU.UQ["GC)^DYJZ&LG/[8 \
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MH?1*ZJS%NX>3>LTG4NV4+M@NK3EI7(&0%;TK]G9$1 1$0$1$!$3* =@5Y\X
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M:Z.JN%*9:[E$A#CL,]%7U+H\3X?;/KEUI6.&W#ZIK)F7.],=% TAT4+V[O\
M6?!;JCA;'$(V -8W8 #HD0#=FMY0  ,>'@O1Q(;U3>WTN'!7!757<(B*&HB(
M@QKC)V=*_'4[!0:E[O\ [.W[040H<^7V(B(R$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0%ATU3Y+<WPYPTX</O68J_=I3'?8@.^(?Q*0UQ3VO\ 3OYV@CH5[*.M
M;^>%I4BI= B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"C\4OU1+]AO
M\RP-#>@U9_%+]42_8;_,L#0WH-0AL6+]&$2+]&$01U%^MZG[(4FHRB_6]3]D
M*30$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%)K:JM??M0U='!Y156R"*"EB
MQS8Y_.>['><8]N,+#OEPDKM%W=QN,-P=&Z,!HIS ^-W./->TDD=RGJJSU;+Y
M7344SX8+C"P2S1D<\,D9\UP!&""#C[ET.D8I:6X-JZV>>IK>S$LY:UIPPY:
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M Z^(SE0B:1$;F6QK7=K==F2/M5PI*UD9 >ZFF;(&D] >4G"\C?K0VY"W&ZT
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M>@U"&Q8OT81(OT81!'47ZWJ?LA2:C*+];U/V0I- 1$0$1$!$1 1$0$1$!$1
M1$0$1$$1>=045HE$=6*DGD[1QB@?(&,SZ1(& -E$ZNU')2"T0VR5S3<'@B=L
M!EQ'C.6C&"3MMX=RQ=54UUK+A<(A#<98'0-91MI91'$XEIYNU.<]?';"]G6J
MM\GT8P4[LT)9Y1N/S>(N4YW\?!!'-U+<):VZ!MP$,%OB YI:%W*]P;YSWG&1
MN=FC&RLM=JBWV^=U-4/GDJHXVR/9! ]Y#2,\VPZ*&N=HKY:35S(Z9SG5C@:<
M9'YSS -M_$*9M%%-#J*ZU,T/+%+#3LC><;\H=S#[LA!UJ[[&V>V34]5$ZCJ8
M)9^01.<^5K6@^;CH1GH=UXV+5]%<Z:BDD9/3253^S8'Q.Y2[<@!V,'8*,M5G
MKX9-,=I3.:*6*J;-DCS"['+GVKQIK;4'0!M]93RT=9:QV[)I,<A>QQ<"TYW&
M!U]:"YPU]/-<*FBB<73T[6NE'*<-YMP,^. HV;4E/%J/Y(=#4.D[-K^T;$YP
M!<[ &PZ?XNB\M"T\PL[Z^L;RU=QE-7(WZ(=Z+?8&@)61U%-K!E8*2>:EGHQ3
M=I$ >S>)"<NR1@8/7U(/675=JBKW4LDLHY9!"Z;LG=DV3Z)?C&5+5U5%14DM
M34%PBC',XM:7''L&Y5%DMUSCTQ4:;9;9997S/:RK):(C&YY=VA.<\P!Z8ZA6
MC5#:\61[;5VAGYF!W98[3DR.;ESMS80=*?5%LFI:R=\DT#:0!TS9XG,<T'T3
MRD9.>["PZ_65'36YE6RFK'<U0RGY)('L=EW?@CP]_15UUCN4M74UD%'6O9%Y
M--"RMF#Y)S'(7.:<GS<@[!3FHW5MYM#'4UKJXWTU7#/V4O*U\C6NR[E&4&35
M:EIZ6X"2HJ1%0^2"<Q/IWB4$R!G,=MAN!CKW]%,RW&GBN%-1.>345#'/8T-)
M\UN,DGNZA5VIMDEZU"Z>HI)H:"HM3Z9YD #FN,F<$9.^-USHNW7**:IJKS%R
M5,4+*&#+L\T;/V__ !'?[D$F_4UOCN!I)#4,=SF(2.@>(W/'[(=C!.WW]RQ;
M+J^AN%JGKYF2TD,',7NEC=R@!Q P<;G;H/'"K7R=>JZ:VNKJ>XR5L5>R:I<^
M4"F8QKS@QMS@[8[L]5[,M%RFT7468T,[*RFJ#,PEP:R<=L7@-?G;(/W(+=:+
M]0W3MVP.ECD@ <^.>-T;@T]'8/=MU4'<-80SSVR*TR2_ZQ6LB,DD#@R6/<.Y
M'$8.^.BZ6RSBI;<BVGNT53-1.INUN$O/CFSYK=ST.^5BQP7.HMVG+>ZT3POM
MU1"ZHD<6\@# 6Y:<^=GKZD%OO%VH[/ R:OD,<;WB-I#"[+B"0,#V*&N&J(9]
M/7:IM3Y(ZRB8"Z.>$L<PGH2UW<4UT^2,61\$/;R-N,9;%D#F\UVP)VRHRZ4-
MPO'R]6,MTM.):)E+!%)RA\Q#BXN(SMUP$$_7ZEHK:(VUOE)=V8DD=' ][6-/
M>X@8 7G=M44UNNE!1NBGF%5&Z4/BC<_#0-L #?/P4!?Z.\5,]R@-/<I8G4[8
MZ-E/,(X=V8=VASUSGKU6=44=;1U>F*T4<U0RCIG03QPX+V%T8 VSON$$M7:G
MME%6.III)2Z/E[5[(G.9#S=.=P&&Y7-BN4M2Z\.JY&=E2U;XV.P &L#0=S]Y
MW53J;#-'<;RVLI;O/35TQFC\BGY6/#@ 62-R,$>.^REZ2Q5+K%J&@Y33FID>
M("XYRWLV@9/W80>\^M[6VBJ9HO*'OCB,T;'0O9VS1WL)&X]?<-UD,U70"WTM
M3(RJ:^HVC@%.\R.( )P,9(&>O15=EAFK*,QOH+PVX1TDL;#55(?"QY86X:<[
M@J4K(O+;/:Q56F[QU-,WD;+3$-EA>&@$CSMVGIZ\=$$I/?\ DDM%2QI-MKI#
M3DOC+)&2'/+L>XD$=/!6!4.XBX5-GT_07$$W.6O9(6G'.(F.+N9V-LAO+G'>
M5? @(B("(B B(@ZOSR[+JW<=_P!Z[GHN!GQ01EUL5MNK?_:%+'-ZR-U7JO0=
M)@?)]1)3C/HDY:/8%=.Y<$ JLTK/N&E<MZ^I:ZFT)=,GL[I$6^MJ[TG#]Y<3
M<KC)(SZ,)Y/[K8)"XP#U5?E4:?JLVO:)LEAMUG!%#3AKL8,AW<?:I?N/FYS\
M5RUH&>5<X5XK$>F%K6MW8"Y;U*Y'1 I1 B(@(B("(B B(@(B("(B B(@(B("
MQ+A4MI*.JJ'=(8W2'[@2LM5O7M0VFTO<7']J,L]^W]5$]0FL;M$-+T;W5]RJ
MJV3=]1(7Y]6=O@K=;8\.55L#1V,0QT:KG;VX 7EWGE9]-Q^7BBJ5I6X;T66W
MHO"+H%[M2'%,NP.R[M<>Y=0N[-BKPI/;NT$]0O4,]2[1-R=E(PTX<W=:5IMS
MWOI$/;A>)&RS*J,-]+.YZ!8-3-%3,<^>00Q-_;=W?<J6K+6EM/"H9EGB52=5
MF&GA>V4[G+#&.I^Y9UXU4Z3F9:6 CIY0[H52ZPOFEYY'NDD\2IB-/0\7!GS3
M,1U"Q4>O;O06JGHXC TQ C)9S9&=N_P6+4<0]0Q^=Y7%[!%_S5<='RY.=SXJ
M-K9 ,X4VS3#V<7P/QI_?';;FAN),EPN$=NO;&-GD($<K.F_BMHQG[POC^FJ7
M076G?&<2<[2/4OK2Q3.JK+23OQS/C!*Z<&3G#YKXU\/KX>75/20"[+JW(79;
M/'$/1$/1!P>Y<$[E<GN0^DH^Q#Y]UE'VE=<Y#N34<Q]6PV5 O$YBFA/=RG=;
M2UI&(ZZ\1EO68.^ 6I[ZSF@>TC?.R]+!$\=O)S_OTEK;4AX;N#LIN(-DCPM;
MVVN?2S!LAV&ROMIJA*QI&,%=E+1+S\N.8[>-:.0J,EDZY*G;DP.:XCP54JW%
MCM_%6E2G;K,WM>8$]57FO=2UKF/]'/>IATV/:HNY 2NY_P!H*DZ=%>NDO2U
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MD;B2YK9.; !R>HR,KZB1%:WF(TUMP@X>RZ%T16T50]DMUK\RU'9G+&NY.5K
M>_&^_K57_)RT3J#25TU%+J"@\DCJFL[$]HU_,0YQ/0[=0MXHASGO^1$1%!5F
M_?KZ#_)_J59E6;]^OH/\G^I2&F+]R[6;] U2JBK-^@:I52Z1$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$%'XI?JB7[#?YE@:&]!JS^*7ZHE^PW^98&
MAO0:A#8L7Z,(D7Z,(@CJ+];U/V0I-1E%^MZG[(4F@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("P;K:J2ZQ,BKXW2QL=S<G.YH/M .X]1V6<B#AK0UH:T  #
M  [ERB(&ZXW\%SNN,H&_@F2F_@@]J!DIDIMXIMXH&_@F_@FWB$V\0@;KG(7&
MWB%QD>(0>%91T]8ZG=4,YW4\HFCW(Y7#(!^)63E=<CQ"9'B$T.=_!-_!<9]:
M9]:#G?P3?P7&4R@YW\$W7&4R@Z&&$SMG,;#,UI:'\OG 'J,^"]<A=<CQ"9":
M'.?!,E<#"Y^] R5R"N-O%![4')SW+C*Y7&4#KLF$!R5R@+JY@<%V1!T$8'>5
MVY0N40=>4+GE"Y1  PB(@(B("(B B(@(B("(B B(@(B("(B J;Q0;SZ2KN8D
M<KF8Q]H*Y*K\08FRZ4N@)Z,#O<<J+>I7QSJ\-3V'>%HP.BMU%L J9IU_YE@_
MP@^]7&BW"\O7U/IL\[B)A,Q= O=JQ8'>M9+4AP6AW 78#==5W9CQ5X9LRF)!
M"F(7 -4%%)@]0LSRG#=BMZ6TYLE-HW4UUI;322U50X89G#>\E:;N5_JKS7%\
MDCS'^S'G;"R.+5[=57SR-A\R X<.XE0-J&!S''-XJMY>Y\*\&+_7>-IV%IY-
MSRCZ(Z+QG>UH(& CIA'$2Y0M75$G8JEK:?28L/VCJ'K55  Z[J(G<7DE=Y'%
MR\W#;U^M86EUUQZ^[SAACY7.Y@9<[>*^@^%>I([A9(K?(]K:NG'*&D[N;XKY
MVE'GYZ.;X=ZE;#>:FV5D533O+)FG8^(\%MXUXKT\'XU\/_44^97V^K@YV-\
MKLUQ(4#I+4%/J*U-J*8^>WS96GJ'>*G&^;CORO1?#3$UGC+ME^?1"YYEP.F0
M<KQ[=AD#0YO-X93VC3W!7#COG[D:[(.1A=#DE1HAH[651Y1>KF>]TO+CNP %
MKV_1M8Q^W<KKK0/H[]< _;\[G!\,=53;D]L\;\D9PO7\74TT\/RK3&3J5/(;
M,TC&'CH1WJ8TY<3&>5QV&VZ@W.,%42!ZEVI/S=7R@['=32=63>.6-L)]6)&'
M'@J[<SEQV'59-++YOBL>N',"<+JZTX(^F4+,[E!4>^7<^"S*W(!43(X G)PN
M>\Z=N.O)V+B7;81KC@YR#[UE6:A;<;A#2EQ:^0@!W<MY6?@./S<E=7X#@">3
M=<DYHB7;7!MHZD@EJ'AD4;G./T=UMGA]PIKKHZ.JN@-/3;'E>-R%N#37#?3]
MB =#2]K..KY'9S]RN36AK T  #8#N6&3--O3HQ^/%?:(M^F+/11QMBM]-F,
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M?5BIG$7B#;]#RV>*NIYJF:YS]C&R)S06C8%QSW;A2?#^^2:DT79[Q.P,FJX
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MA2:C*+];U/V0I- 1$0$1$!$1 1=7.#3N0%T=41-ZRL]Z&GJBQC74PZU$0_\
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MZN:1L<;KZ"RB'S.]Z?+][M>O>,.I;.+YIM]CM=$[#WN:YK6M<07N\_=SB
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M(JI<^U23Z7P"Z1T+YIFQ1,+Y'=&CO31RB/;"COUUA.U7([U.\[^*SK/J;DN
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M*)06-! =T!!;G=;E1-GS):BT+I[6]YL]WM'$R2!UJGH12011EA>UW3G):.H
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M16T3#R<F"U.UB1=,G&SAD]/!=AG'56<[E%PFZ#E$1 55XDS]AI:JQ^T6M]Y
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MUI:>RIF[GNROI0,:YKP<$.'*<]X7HX*1PB9?G/QORLGZBV*E_IGW#Y(U*3-
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M3]#X*NEOD_RLW:Q?O8_Q!.UB_>Q_B"K/S9/T/@GS9/T/@FCY/\K-VL7[V/\
M$$[6+]['^(*L_-D_0^"?-D_0^":/D_RLW:Q?O8_Q!.UB_>Q_B"K/S9/T/@GS
M9/T/@FCY/\K-VL7[V/\ $$[6+]['^(*L_-D_0^"?-D_0^":/D_RLW:Q?O8_Q
M!.UB_>Q_B"K/S9/T/@GS9/T/@FCY/\K-VL7[V/\ $$[6+]['^(*L_-D_0^"?
M-D_0^":/D_RLW:Q?O8_Q!.UB_>Q_B"K/S9/T/@GS9/T/@FCY/\K-VL7[V/\
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MUQ#2M,=I].#RZ12=PFM)7^2WS>353SV3NCL]%=7RQUI:\.#)!Z$@6KI:<-!
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M3"QZ*HYV Y7K4$O80%??2O'5E?;5OBE(<2%EBNS'Z65UJJ+M026[K EA=%D
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M4@CK]ZD+Q=H;?$6-/G=,-ZN]0'>B4L)Z>WQ$N<,#O5?N&L'&004,;IY"<!K
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M[E<M QT7; \%YEIFT[E]%2E<=>-75I"Y;T7. BA81$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MHR.@(03Y *V!5U=!6,Y*VGD:2,;M(4'4:7ME4\R4-68GG]ESAA0TBT?97FU
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M$*LS3/U!<9[M<'NF)>>P8\[,;GI_!3%+3M ;RM '<$$2:>ZU[G&MN]5*YWI
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M1+]AO\RP-#>@U"&Q8OT81(OT81!'47ZWJ?LA2:C*+];U/V0I- 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MEOL\WXK69GFN.A:D/IYJ9QW!R%<H:<R,RM36*O-#<H9QNP'E<"MQVZHB,37
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M*RESLUC3S >P95(J+?6TS^6:DJ(C_B86A<ML5Z_9]/@^)^)GKRI>'-!'$Z4
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MNLCK:**HCQRO:#]ZRG$%N-EU/"F)CI4=>U4D%! TN<R"5_)(YO=U6L;G9*F
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MFTRP.!([SE<'FY1@!<QD\H^]=F.PQWJ6WV>1O>T7<+@RERUV.;NRHN.Z"5Q
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M'<KLM'$(B("(B B(@(B("(B#@YYO4N/N79$'3!.<C95;4]G;)%,YD9=#)CM
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M-PW&-L#I[EUH:3D/(<.(W+AT/J4RR)K&#9$/*"GR.G]%D,@(V#1E!,UFR&J
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M&ULKV_M.R4CI,ZM[1FH]'S,#ZNUM?)&1S.8W<M_Y*G<[N7SAAS3AP6]Z @@
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ML#0WH-0AL6+]&$2+]&$01U%^MZG[(4FHRB_6]3]D*30$1$!$1 1$0$1$!$1
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MIN@QXJRVZ@,>"-CZOX+VHZ 0PM;W#O/]%*1NC$8Y1T4H>3.2$ =,=P7HV82
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M.*>2&U%8:"^TQBN$67'9LP.'-/M6F-8Z.K]/R\^.WHSTD9ORCUK?DNQ)(R/
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M[$@[)$Q/IG:EL?5GF& =R[!N%[!F.Y=@SU*5-O -7<-7LV/U+N& =5*-IC2
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MF)FHOS<C=\ ]5):<U VN<:6J\RI9MOWH+(BZ@DC/<NPZ("(B#&JZ:.JB=',
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ME85CQ[VGE^$E!4EE2U\\4T[&O,F?I$YQ[LK%N%EIZ;R>YU@F9!3#+&=>8_\
M-8]?J)L=E?1VB"5]9SYYR,XRL>T"^&B+:FI%2UV_9RM&&K@\B^V^"MIM]/3K
M275]90W>Z54#F,:T,@B([M\?P"R-/^411/ELI,#Y2!(']Q_ZPNVJ-01VJ&AM
M[J&*:>8"25K>A'=_%=[+7W*:J#'4L,-.&\\A [@=MT\>_&>TY,<37G+UNNE:
M^KD[6[W,RDR!TC,^:-]\K84EHME988J%YIA!#& PY&XQW'VJMONMON37RP3O
M+GDM>,#E+EA01UD]:^""81,(Y6M<.OL7H3EK$=N**6]J9=++\FW"9D5&7-R
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M O+>8X]@6T^/29VYI^(9-:U'_/\ 5KVV:-N%UE%1JB0QPL.64L;NI\7=0K]
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MHH6PP$.>[])*>KG=_P#5:XL<V[EEGRUQ1QK[9D,8I:=L+,<C&X'K6%5R.Y2
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MU6:CG\CFJ>TJGC @BZ-'MZ*V:,T]':*"-TC 9GM#CZEEBPZCZFU[6OW$ZC\
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M]F8?*XX;CN*V9P_L9H*4UE1YTTXSZPO/36C8+>]LM5B21NXV5R:X-&&M  &
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M+NV;Q77DZAF"1WD97F6D;]W@0@R1,,=5W;+XE8>.78]5UR>Y!(M>T]4<0XN
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M QNZY:]H!W7C+4-&5$*O29X+>BQ72!HW7B^IV6-)/GJI&0Z9IRO%THPL1\P
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M ,RZ7RW4D/"BRU4<$;:F2H!?*&CF=GGSO]P]RV_#:K?#0OHHJ*G92/&'PMC
M:[VCO7$MHMTM!'12T-,^CB.60NC!8T[[@?>4--=WVAI:#6^C6T4$< <&!W9M
M#>;!'7'4[]5XR5%GIN*-Y??>Q$/9XC,S<M#N4?'&5LR>WT4]13U$U+!)/3_H
M9',!='[#W+QJ;+:JI\[ZFWTLKY\=JY\0)?CIDHEI%S?_ ,S+T^$.%"ZXQ=AG
MI^WGX<JN-[I8:SB-I:"IC;)$:)KBQPR#CF.X5^=9[8^@;0NH*8T;#S-@,8Y
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M "?'9>3W%K'#Z0(*\W2+S,ASNGV36VIB(]J#;ZAU)>)&3.+1VCFD=V,J3O\
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M3NQSNLQ*L:?[:YU<MXKB3++LTGKA6-L0&2-VXQNO*STXAH86@#(8,>'12!:
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M]!J$-BQ?HPB1?HPB".HOUO4_9"DU&47ZWJ?LA2: B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M2SR''.T=V3WK9 Z+7^J=.LN%/RN\U[3EKQU'L*Q]-ZNEMDL=GU'D.&&Q5(]
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M!_UA3U/7!T;2'*EW":XWN#LXK15.+<<KC&6GWD*0MMAU6RE:^2@:YO[/.\9
M7#EPVW]+V/&\BDU^M9JJO8R%SI'\H ZY5&BNE3<+K+);*6:JG=YC&,:3[3[%
M>;'HFOKGB74,C!!U$##U]JV%;*&DMT8@H((X8OHL6F#%,=V8>7Y%9^FC6%JX
M>W>Z.;+?:P4L!W-/%N3ZCGHK]8]+VFR1@4%%$UX&#(1S//WE3R+K><Z,W.?
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M@<F*39V/4!LMW<CFC#>B[,)Q@=4VQ_Z?SG>:TVC\?9$VBTT-GMODMNIA#$P
M^8-W'Q]:F(,=DW P,=%PTG!SC/<O1O3=0[JQ%8U7J!$10L(B("Z]V2-_6NR(
M.FY\/>N>[<'[EV1!U!]2?<?<NR(.OW'W)W="/N79$'3V97;?U+E$'7!]2 ^Q
M=D0=<9[]O8L>IH*2J:154T$S3UYXP?XA92(*3>N'%@N,9[*F\DF/22$8Q]W1
M4>Z<-=06LNDLE>*R%N[62>:[V +=R'H@^=)+E?+1+V=SMM5"6]7\IP5)T>MV
M!K?/D;XX!6]7M#V\KFA[?6L9MNI _F\FC#O%!J*FNUYU"\T]KI*DQO\ --0X
M'E8#WJ^Z>M<=AM;*(8F>UW:/D(W>\]5:2UO+R@#E\ L:> D$]6^"A:LZ14M!
M#*"8W;G?"BJJW5$>3&"['<%-2PN!)A/9^(/>O(5!:<.'*1USWJDPZ:V5:8/:
M<2,(*QW'"N%0Z&1F'L#@5%U%IIYP>Q=R.\%66M9E7'.7DYRD:NTU4(. 'MSU
M"BI@^)V)&%I56U;?EU>\+S+L#9=2_((#EY.< ,=Z-JZ>W:)SK&+ET[3N4+,Y
MK_%=VO"P&2XSD'W+T$P]?N15G-?G&_10=^B+)?*!GE=U4DV5OK]RYD$<T;HW
MM)YN_P %$^EJVXSM#VVY.A\QYRPJ4;60O&Q"KE;1344I+&E\9\ O"*K#=CS#
M[E7MKPKD[VLD]6"PAA6 S,A.5@MJ 2,$N^Y>IJBT8CYF>.1U3M,5K7J&5Y,7
MG.=EZQT\;>@R5&"N<WIGW(;I*T>8#[E'32.7V2-8YT5*\C8@9"K%1Y_.03@8
M)]JR:JNGG]-QP/4N]OHS7U$<<(/99!?D*L1N>F\Y*XL>I]K[IQ[C9:;F)/FC
MW*0+COA8U,T4].R(=&C 79SQ@K>(T\?>Y=W/\5Y.>.Y>3WA>+I /%1*\/9T@
MW6/+)CO70R#U^Y8\T@_Z"AI#T=*/%=#*/I+#?,-^ON7B9AG."HEI$=,Z2H C
MD>0#RA1L%7$P>75[><D_F&> [MEY5]0T0]#C/@H.Y5!DF+&AW*#ML5C>SO\
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MU#:+MK&O@IJVI?32M,L4E0.7!<02T8VQ_!3]VUO34.G+9=(:5]0ZO<&QP->
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M[-0::_*)T_!8:9E#!(^FG,<.S0\D@D#NSA>?%NUPWO\ */M]JJP32UDE+%*
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M.H9+1I&V1W"6-Q87N:YY>1Z7*UI&P\<H-E:@N]+8;/57.X%XIJ=H<_D;D[D
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M\^":L@TM'%1Q9<XOB>< ==^89QCJ I2W<3IJ_0-WO$5' RYV[D#X7$F-W,X
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MDC2G_P".(OP._LN.+G_=W>O\MO\ .U:IX9Z:TK>+'//J*J;#5-G+&@U(CRS
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M>I1?,'Y,+74/$[4MNAD<:9E-(S!_:Y)6AI/KQWKZ?4*WKQG0B(BBOZKZT/\
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MXX!/LSE9VFK%0:<M3+?:XC' TEQYCESG'JXGO*][W:Z6\VJIMU>POIJAG(\
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M!GMSZJ_:(OD;X(^:;LXIN5\8ZD-<#APZ[''WJW\&-85VI:*MIKIB2HI.4BH
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M;5)H^'3U4Z:6&%[I(I\@2,<23D'[R% VS@S9J>.J%;4U%7)(PMB<<,[(G]H
M=3[=O4@R> A T(\DX JY<G[FK8--64U47"FJ(9BWKV;P['N51@L(T9H"Z45L
M-362%DKXP&Y>7N;@8 ]>%%<"].3V73U355].^"KK)?T<C<.:QNPR#TR<GW(+
MUJ+_ +/W/_AI/Y2M+\ V224^IHX#B5U*QK#_ (B'X6\:ZF;64513/):V:-T9
M(Z@$857T%H6DT?)6/I*J><U+6M=VN-N7/3'M0:RX U=)27ZY0UDD<-2^'#.T
M(:3AWG-&>_U>I8U_FCN/'"E=:WMD_P!<@':1^<,MQS';PQO[%L'5?"BSWRND
MK::66@J93S2=G@L<>]W*>A/J*D=$\.[3I6?RJ'M*JNQRB>7'F#OY0-AE!K8_
M]_K_ /BQ_($_* _[8VK_ (0?^HY;'/#^C^>IU)Y74>4&7M>RVY<XQX)K;A_1
MZKNM-755740O@C[(-CQ@CF)[QZT&L=:N;1<::2IN/F4G;TTO,\>;V8P"?9D%
M6+\H&X4$]EM<,-1!-4]N9!R/#B&<IR=NXY"O6LM%6K5=/$VX,>RHA:6Q3Q'#
MFCP/<1ZBJK9.#5FHJMLUPJJBN:T@MB=AC3CZ6-R$%2UW8IO]%6FKC.'"HI6B
M-X(WY),EN?9YOO7AI.!^M]65DLQYF4]J[(<^XYNRY,_B)*WAJ2R4]^L-3:J@
MNC@F:&YCV+<$$8]P4/H30U%I#RTTL\U0^JY0YTN-@,[#'M0?/4UPGJM-VS3S
M0\R0ULAY?$NY6@8]1YO>MN\::%EMX9VZBB #(*F&,8&,X8X94K2\+K73ZI^6
MFU$Y<*DU+8-N0.SD#IG *L&MM,P:KL[+?532PQMF;,'1XSD C&_M0:;U?_W-
M:2_S'?Q>M@Z:BC;P1Y0P<IM<SB"._E><K+NG#JBN&E+98I*NH;!0.+F2#',[
M.>NWK4[0:>AH](BP,ED= *9]-VAQS8<",^W=!JW@920U^E-3TM4_LX)N5CW_
M $06.R57-!5FH**DOU!I9E+74<KC&Z>9[8BW8@/:'.'4;]ZV%5V=O##0U[JK
M1(^KFE,>\[06LWY<D#&VZU]I/1U@O-E-QN>I:>CJ'.<7P-+&&/?I@[G[MD&S
M.#NCY=-6ZJJ:R>*6KK.7F9$[F;&&YVR.IW5WO5NANUJJZ"I&8:B,QNVSC/>M
M'<&S+2<1:NAM%;)5VD1O[23E(:]H]%V#TW6_4'R[07JHTW8M5Z=F#Q/4/;$"
M'8Y"UV'^]JLEQL$MLX'PS-B<)JJICJI]L$1G(:#ZL8/WJ_:DX76N^:@DNDM1
M40OE<UTD;,<KB/N[PKO/0TU10/HIH&/I'1]D8B-BW&,>Y!H?A]I^]WK3>;/J
MUM#3-<YLE'OYASOD9[^N5;-"Z,HK);-10W*]T%;0540AJ#"X-$/7=Q).#NN*
M_@M:Y*DOH+C64L1_W9P_'J!ZX]JLUDX?VNU:8N%DCEJ7P5^>WD<\<Q.,;;8'
M1!JJ^:4O.AH'WG35]$UN!&9(9 ' 9VYFY+7C/_V*RQ>1<3M%T3KS5T]LN\4[
MXH9>8?G"T#FPTD9!#AD#O"]&<$J 3#FNU8:<']&&M!]__)3]\X7V6XV6@MU,
MZ>C91%QB<QP<27>D79&Y.$&L_E#5'#6]TM'4UHJZ%Q#FP]ISQR,S@\H.[#_U
MNL[C\V62[V>K+7MI9:<\A(V#LY/WX(5LL?!VTT5;'4W"LJ:_LW!S8W8:TD?2
M[R/5E7?4^G+=J6W>176$OC#N9CFNY7,=TR"@U7/HJ]WFQ1OJM<TU3:GM:\=I
MDQC'3OP,*N\1[<+1:M(4#:N*L;%%*1/#Z#P9,@CWJYC@E;^V/-=JPTV?T?*W
M/O\ ^2L&H.&MMN]-:*?RFI@AML78Q!I!+AD=21UV07.W?[!3?Y;?X+67Y0W_
M &:M_P#Q0_E<MI01B&&.,$D,:&@GU*O:YTG3:MM\-)5SRP-BD[0.CQDG!'?[
M4&C=?1RC2VB93D0&B<T'N#N8$_#"L[-%WN]Z=A?-K>GGM,D;7!DF>1H V!WV
MPMDS:+M=5I2EL%>Q]134[ V.0G#VD?M CH52CP2M_;'%VK!3$Y[/E&??_P D
M&33Z+MCN'-+8[I?*0\]0Z6EK8R WF))PW)WVSME46X#4_#"NIA%<FU%OF<7,
M8U_-%)CJ"P^B<8W'O6W+[H"V773%'9#+4Q4]&0Z%X<"X'?KD;]2JU;>"]KAJ
MF27"X5=9$TY$6S ?43UQ[,(*5Q>KOE/4.GJX1F,5-#!-R$YY>9V<?%3GY1L,
MQFL\H#NPY)&9[@[8_P  KMJOAS;]0W*CJY*B:F%+$V)D40'*&M.1U"LNH[%0
M:BM<E!=8>TIW$.&#AS7#HX'N*"D:LO%IDX/O$=33.;+11QQ1AXSSX;@ >((^
M"H5FBF;P2ODC\B%]6WL\]-BW.%;H>"=J;6<\MQJWTV<]D T.QX<V/Z*[7;2-
M!6Z2^;T =24(:UK1%U;@Y[^N2@K/ *-HT,\AHRZKDYCCKLT*H<!7-CU;>W.(
M:QM.XDG8 =H%MK16FH-*V;Y.I9I)H^U=+S28SDXVV]BI-=H6/26G]1UMHDK*
MZLK:5U.(>3F/GN&< #UH-G4U73U0<::>*8-ZF-X=CW+V5 X*Z=?8M)]K5P.A
MK:QYDD8\$.:T;-!!Z'J?O5_0$1$!$1 1$0%CW#_99/8LA8]P_P!ED]B(GT@D
M1%#C%\[WWAKKC3O$^MU/H8TE6*MSY Z9S6F/M/38YKNOJ(7T0B+5MQ?/EHX5
M:OI^*E@U5>:ZGN4AE;57"4.#>Q=YP[-H[P!C&,*=TGH"^VWCO=M4U4,(M%2Z
MH,;Q*"X\[0&Y;U[EN9$VM\R6E.*?#V_ZBXK6*_6R&!UNI&0B5SY0UPY9"XX'
M?LIOCQPXJ->VRCGM4T<=TMY>Z)LFPF:[&6<W<=L@K:"(CG/3YKN_#WBGJO2;
M+?J.OINQM_)Y+1E[.:H</-!>]NWFMSN>N5NSAA9ZO3^@K-:KDUK*REB+) UW
M, >9QV/L(5H1";S,::9X\Z OVL;_ *=J['#!)#1-(F,DH81YX.V>NP4YQWTE
M==8:(I+98XXI*N.KCF<)) P<K6N!W/K(6RD0YSU_#4%[X42ZDX2V"P5LL-'>
M[9&#',[+V Y=S,./V2#U'@JY;[=QQHK;%9X*BA%/$P0QU;Y(W/:P;#SCOL/5
ME?02)M,9):7XV: U)JW2FE*&A=#67&@:[RR:24-#WF-K2X$]<D$J>XMZ1NVI
M>%E%8[5%$^X1/IG.:^0-;YC2';^U;*1$<Y:R^9]V_P! 3M*=G'\L&@\GY.<<
MO/SY]+IT7EPMT!4V_A36Z6U5#&UU7),'B-X?AKP,.!'>.OW+:2(<Y?-5#P_X
MKZ,BK[-I*XT\UHJ7%PF;(QA!(P7 .W8['7"O_"CAA5:'TQ>>:NCDU#<X2WMF
M9#8#RGE:#U/G').%M9$3-YE\XWS3O&:^6*2P7AELKJ*0!CJB1T7.0._FZ@^O
M&5>+1PIFH^"]?HM]RB=6UA?,ZI##V;9"X. QUP.4#/M6UD0F\M <*=*<3M,5
M]!::DTM/IEE49:@-DC>YS2/.#3Z6#@;*+MW#?B)H;65UJ]$F@GI:PN8VHF<W
M]&YW, YKMPX'PZX7TFB;/F2T7P\X6ZBTSQ<;?[G61W*EDIY'3UF0USII&><.
M7K@.VSX*(OG#77FGN)-QU%H22EF;6R22A[WM!C$F>9CFNZX\0OHM$V?,EH;B
MMP_UEK'2FD8I?)JJ\T;)37R.E:QO,_&,=QV'=X*5XT<*J[5\%JNEDJF0WJWT
MS*<Q//*V5HWV?W.!Z=RW(B(B\PTEHVU\7JG4EG=JJX0P6:CE#ZAK)6<U0T#H
M[D&79VZ[+=J(B+6V^/;;0WVOXZZB&D:QE)>Z>HJ9X'R>C(!LYA[MP>_9;"T%
MPMU5<>(<>KN(53&V>EE;-'$U[7F9P!Y1YNS6MZX5RTIPJ%AXF7#5WRJ9S5F8
M^3=CR\O:?XL]RV<I:6O^&D]1\/;_ %W'FBU53PPFT124SG/,H#L,: [S>JP^
M*_#35,W$2/66AY8'5A$;NS<YK'Q2,;RY'-YKFD ;+?"*%8O+YHOO"SB)J*[6
MN_:@K*6MN(G8)*=KVM;30L<' -[MSS;!=>+<MQUKQEAMVBHIJVY65A$K*CD-
M,Q[3DGE=L=R <C=?3(6J-5\'(KCJV?4FG;_7V*Z5#B^=T/G-<X]2-P1GO'12
MM6_Y:WK=9\1.&%?0.U);K2RW5+C_ *O2P0L$N.N\8!!"^G(7B6&.1H(:]H<
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M.>\C(! &1G95R3B]=J9K*JLTM-%0/.&O<][<^QQ;A!MF[W*FM%MJ*^OD,=+
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MGKRD$$#U*5T+P]=IR[/N=9=ZBOJG1F/#QL 3XDDGX(*)>B!^4"S) _UB ?\
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M,[^Q2L,C98FO8?-<,A!V1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!>=3
M"VHII87DALC"PXZX(PO1$%3T5H6VZ1J*F:W354CIV!CNV<"  <[8 5L1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%<UII&AU;34\%
MQEJ(V0/+VF%P!)(QOD%2MCML-GM-+;Z9SW0TS!&PO.7$#Q6<B B(@(B("(B
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8@(B("(B B(@+NWT41!RB(@(B("(B#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g50309g04m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g04m02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1;@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %L,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRE_<U2VH>>QJ"Z16W3N[@@G=W!!<HK<3.[@IZ9W<$'NBM^F=W!.F=W!!<(O
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MD)F?%T;7[X][CCG [UJ.WZHCJMF]#4PYZ*:MAD9GG@L>0KW]'S_L^9_?)?\
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M,&W;=<Z:5CKEIH1T[N6'O8X_47#!78-.WBCO]HI[E;9.DIYQD9X%I[6D=X7
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MV.YM(:,@KB&E-+WRGVP-N$]JJXZ'K":3IW,][NDNP<]W$+Z#'-5Y5QY+CO\
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M=HW/FB(N3N*"I4%""(B@I/-0I/-0@D(@1$0Y0I<H0 A0(40/)4JH\E2B)"!
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M52#FB#FJRJ')$')%&@<D0<D592% 4A0%%@I"A2$5*(BJ"-YHC>:"I$111$1
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MK)(@B(@(B(-6N7RZ;[2MPKBY?+IOM*W"D$A$"()')5-YJD<E4WF@J"D* I"
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M36O>_%WW:W9=+27'3];>9:ME+24V1[YA=TA [/OP%?UFEJ.'9[%?FRS&J>6
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M'IO[3X^3AY9<9AGE[R>OS+\;=%M%?I2WZ9;;:&^144DT8Z>>/XUSB./''/\
MHM&U7:M-4=M$UCO,E=5NE#71N.?>G.3R'J\5J>$5F&KO;AXC]I>?QSCRX\>T
MU/7M_3N['IK65JATE2OK:R)MSI8'1MC?G>) P,?7P6L;+K]1V^MNL=ZJ60T]
M8T/)DY%^3G^JT-%/+G>?+5_:_-<^/.R?P?KVUW;7M+O$-YU,Z2BF$U'#$V.-
M[>1[3C[RM41%N34T^?XCFRY^7+ER];1$15Q$1$!$1 1$0$1$'9-A]:9+-7T3
MG9Z"8/:/4[G_ #"Z4N0;"2>L+P..[T4?CDKKZ\G)-95_0?V+G<_!86_C/^+8
M(B+#Z8B(@*E5*E 1$0$*(4 )V($[$]T0B(J"(B H*E04((B*"D\U"D\U""0B
M!$1#E"ERA "% A1 \E2JCR5*(D($"!!*I52I1!0I4* B(K$0B(@(B**@J.Q2
M5'8B(1$0$1$1"(BI!0I4*""H4E0@@HA1!!4*2H1$%0I*A%05"DJ$01$0 H4A
M0C(H4J$!4JI4I$@H4J$1E++\7+]H+(K'67XN7[0615CU<?TB(B-BU;:+^S]1
M_#<MI6K;1?V?J/X;D&K:!^#']RZ?#\6%S#0/P8_N73X?BPD587/Y71_;626-
MN?RNC^VLDB"(B B(@U:Y?+IOM*W"N+E\NF^TK<*02$0(@D<E4WFJ1R53>:"H
M*0H"D("EJA2U!*(B"I$1 1$18*1R4*B>:*FIY)ZB1L4,;=Y[W' :.\I!Z*IJ
MP UCIH\K[0>T65MUQHKBQS[?64U4UO,PR!^/KQR6K+/6,S*7TJ\1$652$0(@
M*0H4A" Y*6\U Y*'R,AC?+*X,C8TN<X\@!Q)**]$6.M5^M-XEDCM-RIJR2-N
M^]L+LEK<XR5D4LL]699>\2.2E0.2E%%*A8NY:DLEKJW4MRNU)2U+0'&*5^'
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M'E-75PU<CA&2&[SP<''+'=V+J6WJGGJ](Q1TD,D[_+VNW8VEQQNOXX"W]KG
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MK)(@B(@(B(-6N7RZ;[2MPKBY?+IOM*W"D$A$"()')5-YJD<E4WF@J"D* I"
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M37U4#MVHEQ3QG/)S\C/W#*XS&VZ=;9)NJK3KJRW?44EEMIJJBJC+@Z1L7]D
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MJB0GX+(:ESW.^H!JMMN>GQ;;=IZHH62=7T\'D8+SO%O[S<GUC/@K+CEECO\
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M/C>!_P#F"%TQDUC\Z[.-MWG]W?=U']7V:$V:WD6(9N;:0R2U31[Y[QP+AW
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MZ?\ >SAU1;*^FB=+44-5%&WF^2)S0/O(5=AM55?+O26V@9O5%0\,;W-[W'U
M<5V#;]>ZJ*U6>T25W_%31"2N@C(+7$ 8)[O?9PM:_1_$1U[_ &N-X4TFY]?#
M/\E9R6X7-+PR<LX]LQ6;/=$6![*34NJI&7!S07,8  W/;@ D#ZUK>T;9X[2]
M%3W2V5O6-GGP!-@983\'..!!["%B=J!E=M#U 9\E_E3AQ\W W?NQA=%I^D?^
MC;5&LXAOQ)=W"9N[C^:QO+'IN][=-89]>,QUK?Z,)9]#Z/I[+05^I=61QOK8
MP^.*GQ[WU'@3PY'("7W9G06G45CC==)9;)=I.BCG:&A['D9;ZB#PXK6-G>C*
MK5UT+6_V-MIR'5=2[@&M[6@]YX_U6?VL:SI:^X6RVV#A;;*\&*4'X;VX'#U
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MK%M)TG),(VW0C>.!(Z!X83]>%96VW3ZQV04%'4U+HJFIIF_VSLG)8\XWN\$
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MWDX'D5;6N\V^ZU%=!;J@3RT,G15 #2 Q_'AD\#R/+N7/=&7M^E-&:FM]P?\
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M":BIG/=)%25$D,+B<^\#VD >KB4F&.7I\I<\\/J^-N@7':/I2W5/05-V:7@
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M]0RWW1%+=KD6B9HD;.YHP"6$Y=CZ@M:T]!?=>4]1>*J^U=IMYF<RBIZ)H!+
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MB;A101W!_2U-%6L)89/.:1RYE9K3M#J,^6C5U=;ZNGJ(NB;2TD9:U@/!Q+B
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MA)'W!;'H^Y5DNT:UULE3*ZIEKV[[RXDD%V"/JP>2OJM\E+M'U#Y)>HK&15S
M3N+@,;Y][[T$J[LNJST8V2SYTU/J^M]!J_8N_)7NG+?0UE=+US7MH*.G89)<
MM)D> <;C&]KBMU%QN&?^TZD_'-_]BYS7$NJZ@NF$[C(XF8<I#D^^^_FDMJ98
MS#OZ_P#'^*V_:=;;1026":PT;J2EK;<RI+'O+G$EQ&7$GG@#EP5A:+OI^W6B
M-LVGNL;J2>DEJIR(FC/#=:WMQCFLKM/^0:+_ /!(OZE:O8KE36V>22KM5+<F
MN: &5#G ,.>8W2%,9O%O.]/)==OR;+J>WVJOT70ZFL] +6\U3J.>D$A>Q[@,
M[[<\0%::OM5 +'8[]9HA!2UT9AJ( XN$50S&]@GL=S"S6KYX=4Z&@OU&U]!'
M;)FT3[<W'0,WAD/9PYGMSQ6.HW&38_<6R_ BNT;HOK+#E3&W4_JUE);9^&VE
M(B+J\PB(@(B("(B B(@(B("(B B(@(BN+;1S7&X4U#2,+ZBID;%&T=I)P@[Y
M^CC;#!INX7%XQY7/T;?J9_N2NN+%:6LT6G]/4%J@.\REC#"[SG<W'[R2LJOF
M<F75E:^YQ8=&$Q$1%AL1$0% ..2E4H)WCWE-X]Y4(@G>/>5@]7$FWQ9/_>?Z
M+-K#ZGB?-2011-+GNE  ^Y(-4IJ>2JG;# W>>[^7K6[VR@CM]/T<?%YXO?YQ
M_)46>W,M\&.#IW?#?_H/4K_L5VB$1$!$1 4%2H*$$1%!2>:A2>:A!(1 B(AR
MA2Y0@!' .:YK@'-<,$$9!0(41X4]'2TI<ZEIH('.X$QQAI/@%K.U:AJKCL^O
M%)0025%3(U@9%&TN<[#VDX ]2VT\E"LNKMG*=4L8NST$(L]I\KI(C4PTL329
M(P7L<&#(R1D$%97.22>)4($WM4JWIZ6GIB\TU/#"7G+C&P-WOKQS5PJ5$>53
M2T]4&BJIX9PWX/21AV/JRO3      &  , !2H000' AP!!Y@C(*H\G@^8A]F
M/R6 UAK&VZ3=0"ZMGW:QY8UT30X,QC)=QY<5L,3V2QL?$]KXW@.:YIR' \B%
M=63:;F]1#&,9D1L8P'GNM _HO.>EIZB1DD]/#*]GP7/C#B/J)6.L5_I;U4W6
M"D9*U]NJ/)I=\  NX\1ZN"RZ66$NPG/-4N:UXP]K7#N<,A1-*R"&2:9P9%&T
MO>X]C0,D^"T5VTV@DC?4T%HO-9;8\[]9%3X8,<R,GB$F-R]$N4Q]:WMS0X$.
M (/,$9"@ !N   .P#@K*R7>BO=KAN-MF$M+*,AQ&"W',$=A"U:3:+1S33BSV
MJZW6GIW%LM330YC!'/!)XI,+>Q<I/=NK&M8W=8UK6]S1@+RJ:6GJMWRFGAFW
M?@](P.Q]658Z;OUOU';&U]IE,E.7%A#F[KF.'-I'8>(644[RK+OO$ !H :
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MF6NV"RW2WT_O:>>JD='(UF> < 1G"Z B>9>^_=/*FIKMIJMXTU6ZDTBR@O\
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M2.2J;S05!2% 4A 4M4*6H)1$05(B("(B+!2.2A2.20%4U4JIJJ*D1%!(1 B
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M2*"0I4!2K 4E0I*BQ"J9R*I53.12%5(.:(.:K*H<D0<D4:!R1!R15E(4!2%
M46"D*%(14HB*H(WFB-YH*D1%%$1$!$1 7,MMEN<^FM]R8"1$3 \]P/$?S!73
M5CM16J.]62KM\N )F8:X_NN'%I\5<;JM8W5V^:T7K64TM'5STM2TLFA>8W@]
MA!7DN[T"(B B(@(B("(B B(@(B("(B B(@+.:*M45VOT<542*2%CJB?[#.)'
MW\E@UMNSL$NU$UGQAM<F[W\QG^2E]$OHQ\-)6:LO%?+0PQ-D#'3-@8 T;@.
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M]2B:U=K*L@CNNBH;FUD;*RW2BEGW&@=)&>+''':.65JZVS3F1H/5A?\ %?V
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M4RM88XG#,()P2X [PQZU-+TUW1$7'-;;3+U+K"32NA[?%4UT3C'+-)Q]^.8
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MUDD01$0$1$&K7+Y=-]I6X5Q<OETWVE;A2"0B!$$CDJF\U2.2J;S05!2% 4A
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M=OLUUMSXYZL77Y=-42ETDQ["3V8YC"Q,&R>U" 4E?<[M76R,$0T4]03%&<$
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M4MC%.*=^<XP.'#^>$%U=KK16FA=67"H9% !P)XEWJ [2O"FO]#4/MK8WO_\
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MT;:*:T5-MCBD\GGFZ<DO]\U_86D<L8X*]M-F%OF?(ZX7&LWF;@;53;[6CU#
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5&C 61#0.04HB&M#1@*41 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g50309g05m03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g05m03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1B(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &&L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6)?66.5^H851F&RZ3MR] @//WG*Q+ZRQROU#SE8E]98Y7ZAA5&8;+I.W+T"
M\_><K$OK+'*_4/.5B7UECE?J&%49ALND[<O0(#S]YRL2^LL<K]0\Y6)?66.5
M^H851F&RZ3MR] @//WG*Q+ZRQROU#SE8E]98Y7ZAA5&8;+I.W+T" \_><K$O
MK+'*_4/.5B7UECE?J&%49ALND[<O0(#S]YRL2^LL<K]0\Y6)?66.5^H851F&
MRZ3MR] @//WG*Q+ZRQROU#SE8E]98Y7ZAA5&8;+I.W+T" \_><K$OK+'*_4/
M.5B7UECE?J&%49ALND[<O0(#S]YRL2^LL<K]0\Y6)?66.5^H851F&RZ3MR]
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MZ:([.@J(VW:7>R#N7HJN6_:>P1:K-BX%H%!;@4N'+D3F==(=DIS9MB3.Q_\
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MRL@ "SD
M
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M4U]]I2&I)DIE1V],B21&9?B-/&E,WQ>\FU=+!ZU?3CXF=OC^P  +,
M                                                      9S O\
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MY3 ? 'W*ONU_*895]VOY3 ? 'W*ONU_*895]VOY3 ? 'W*ONU_*895]VOY3
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MYE\ ?<J^[7\IAE7W:_E,2J^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF
M^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /
MN5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?
M=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^
M4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PR
MK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M?RF ^ /N5?=K^4PRK[M
M?RF ^#.8%_G*B_\ JD?]C"95]VOY3&<P,E18RHMT+(NE(WI/B*U>I;V7\^C[
MQ^[TN  .-],!S'%O\[Q/Z"?\C'3AS'%O\[Q/Z"?\C AT2F_PJ/< 4W^%1[@
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M/P%0 7*=6CL)^ :M'83\!4 %RG5H["?@&K1V$_ 5 !<IU:.PGX!JT=A/P%0
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M5S=<NT@_1,^O@!<W75H["?@&K1V$_ 5 !<IU:.PGX!JT=A/P%0 7*=6CL)^
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M-I5L6=B+:HRV7,3,#X;B81PG3:' ])J(T25.&1$;JSVJ6?O._P"%@&<
M
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M49#<NMU24N7.D-I-*5*,[)2DNI*4D1%^(VL
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M[=R0S'1L;;27'K,^LP&W
M                    #F.+?YWB?T$_Y&.G#F.+?YWB?T$_Y&!#HE-_A4>X
M IO\*CW  KC?7<]XOBQ&^NY[Q? !1(,R86:2S*ML*]KBL4N_NU>X!B<[_JZ>
M:09W_5T\TA> BN LYW_5T\T@SO\ JZ>:0N-N-ND9M.MN$1V/(LE6^ J 6<[_
M *NGFD&=_P!73S2%X %G._ZNGFD&=_U=/-(7@ 6<[_JZ>:09W_5T\TA> !9S
MO^KIYI!G?]73S2%PW&TI4I3K1)3]91K*R?>?4*BL9$9&1I/:1WV6]X"SG?\
M5T\T@SO^KIYI"YG1ESYT9.UF*WQ%7N,C+B6T@%G._P"KIYI!G?\ 5T\TA> !
M9SO^KIYI!G?]73S2%X %G._ZNGFD&=_U=/-(7@ 6<[_JZ>:09W_5T\TA> !9
MSO\ JZ>:09W_ %=/-(7@ 6<[_JZ>:09W_5T\TA> !9SO^KIYI!G?]73S2%X
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MB [.
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MH#-@
M         #BO[0E"F2*8FKS:J^J#%F0RAP&B)M"%J>02UN&6UP[;"(]A;1M.
MG?%$G">CJ9-@/)CRY#K<-M]6YG6*L:_P3<_>0N:;*5/K&"#BTJ*[*D]-BN:M
MLKGE2\E2C_ B,Q?TPX3DXPP6[ IZFRGQWVID=+GU''&U9B0KV*VE^(#2]'S6
MCVBXDH[4.D5:'6I"5E"JE48>0<Y1I/,I*UGM-1&9V,BV'L+<-KTW5>53<%'"
MIRE(FUF2U2FG$[T&\K*9E[<N:WM&OU"=7L?UC#$)>$:I0X]/J#51FS)^1)(-
MHCLVT9&9J-1G:Y%:WY973VR^WA2FUAA!K31*K%J3Q%M/5MK](_P(S/\  !E*
M]4J=HSP+!A4R,MY:$HI]+A)])<A\R/(G\3(S4?"YC3M$=%E4W2#C>GUN6J?.
M>C0WIKIG9*G7$K4LDD6Y)7L5NHB&T8OP.WC6ITNO0,452G''CJ3&7 6@T67O
M668CL9ELN74-8P)H_K5(TJUF=,KU?D06&XYHD2%(RU \BB-+ED[209[+6_$!
MC]*^C[!&&\,9:5A]HZ[4WDP*8@WW57D.'8CMG_XE=7X":N@M:,<4X!?IZW5L
MS&BP_/NJY/'E-;3AW_Y$LE;>!VW#8G*1/Q)I@14*I >8HN&X]H"W2+)*DN_7
M<21]A)$5^.X1]*:O*^.<!4"&I*Y+51.JOI(]K;+*#](^!&I1$7M =/
M
M    ',<6_P [Q/Z"?\C'3AS'%O\ .\3^@G_(P(=$IO\ "H]P!3?X5'N !7&^
MNY[Q?%B-]=SWB^ "EW]VKW"H4N_NU>X!CP   +@  +<EAJ3&=CR6TNL.I-#C
M:RNE:3WD9<#%P $>!#BT^$S#I\9F+$93D:9902$(3P(BW"0   I<0AQM;;J$
MK;6DTJ2HKDHCV&1EP%0 ,9AV@TO#=.Z!083<&%K#=U+1GE)1[S(C/9N&3  %
MF;&9FPI$26C61I#:FG47,LR#*QE<MNTA&H=(I]!I;%-HT1J' 8OJV&BLE-SN
M?Q,Q/
M                           &0:_=I]PQXO)ADI)*Z1(*^VQ*V%^0"8 B
M=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!
M+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B
M=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!
M+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B
M=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!
M+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B
M=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!
M+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B
M=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!
M+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B=!+UF1\Y> =!+UF1\Y> "6 B
M=!+UF1\Y> =!+UF1\Y> "6+4N.S+BO1I3:78[R%-N-J*Y+296,C]AD8L]!+U
MF1\Y> =!+UF1\Y> "FBTJ%1*7&IM+8*/!C)R--),S)">!7.]A-$3H)>LR/G+
MP#H)>LR/G+P 2QC6*%36*]*K341M-5DM)8=D[34IM.Y.W<7L(7^@EZS(^<O
M.@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+
M 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O
M.@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+
M 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O
M.@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+
M 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O
M.@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+
M 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O .@EZS(^<O !+ 1.@EZS(^<O
M?6X>1:5:]]5CO8U;#_(!*   !S'%O\[Q/Z"?\C'3AS'%O\[Q/Z"?\C AT2F_
MPJ/< 4W^%1[@ 5QOKN>\7Q8C?7<]XO@ I=_=J]PJ%+O[M7N 8\
M
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MT+2*XK#TZ-B!FJI3&FN(A/51.60[&.QHSWVF97,KW.]AT
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M)*5$2,ULQ%M&)KTBFG2M$->PLM;<-,]F#&->QPX[K2DJ0KY"O[2 =M
M
M    ',<6_P [Q/Z"?\C'3AS'%O\ .\3^@G_(P(=$IO\ "H]P!3?X5'N !7&^
MNY[Q?%B-]=SWB^ "EW]VKW"H4/J)+*U*.R2+:8"  L])8[Y =)8[Y "\ L])
M8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\
M L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[
MY "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y
M=)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])
M8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\
M L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[
MY "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y =)8[Y "\ L])8[Y
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M $D!&Z=&[Y =.C=\@!) 1NG1N^0'3HW?( 20$;IT;OD!TZ-WR $D!&Z=&[Y
M=.C=\@!) 1NG1N^0'3HW?( 20$;IT;OD!TZ-WR $D!&Z=&[Y =.C=\@!) 1N
MG1N^0'3HW?( 20$;IT;OD!TZ-WR $D!&Z=&[Y =.C=\@!) 1NG1N^0'3HW?(
M 20$;IT;OD!TZ-WR &&QYA=O%U!.EO25QDZ]I_6(22CNVLED5CXV'W'>$X6,
MJ JF5!QYDDNHD,OL*LMEU!W0LNH['U&,QTZ-WR Z=&[Y #26<!U2?6J7-Q9B
ME^KL4QXI,>*B&W&0;I%Z*UY;YC+:9%L(2]+V')&),%R&J:6:J0G&Y\)-[9GF
ME9DI_&QE[S(;7TZ-WR Z=&[Y #6)+%:Q50Z-4J54YN&)V0UNQWHB'3NHK&AQ
M"^!EL,C_ .Q8P]@)<2NRJ]7JU)J]>>C=$;E&TAA,=K>:6T)V$9GM,]IF-NZ=
M&[Y =.C=\@!H$W 6)ZA37:34,?3':2\WJ74II[*'UMGL-.M+=<MF:UQ#F87.
M7C?"-!@4U^-AC"S73.D*(R0X]ER--I/_ )&5S4H_;ON.E].C=\@.G1N^0 D@
M(W3HW?(#IT;OD )("-TZ-WR Z=&[Y "2 C=.C=\@.G1N^0 D@(W3HW?(#IT;
MOD )("-TZ-WR Z=&[Y "2 C=.C=\@.G1N^0 D@(W3HW?(#IT;OD )("-TZ-W
MR Z=&[Y "2 C=.C=\@.G1N^0 D@(W3HW?(#IT;OD )("-TZ-WR Z=&[Y "2
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M1E?X@)5PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN
M %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN  %PN
M %QD&OW:?<,>,@U^[3[@%5@L Y+B_2+4J3I/APHI,GA:$IB+6'5)+,V_)S:J
MQ\"LDS_\P#K5@L,-BG$](PM34SJ[-1%C+63:#-)J4M9[DI21&9F? B&IU'2/
M1JQ@^O2\.UTJ?)I[1*=D2H3GT8U?5-3:DW.]CW$8#HM@L-6K&-*-AFBTN37Z
MD6>8VG5*;86I4A64C,TH21GMWVML%%-TB87J.':A7(M40=.IYY9:U-K2I@^"
MT&68CV\ &V6"PT:-I8P9)K#5-9K*3?><U+3ALK)EQR]LJ7+93/W&-Y +!8
M+!8  +!8  +!8  +!8  +!8  +!8  +!8  +!8  +!8  +!8  +!8  +!8
M+!8  +!8  +!8  +!8  +!8  +!8  +!8  +!8  +!8<XJ^(Z[B#&<[#N#Y<
M2G1Z0ELZG4I#.N-+CA70TTBY$9V*YF?$AN] C5")2VF*Q4$U&:DU9Y*6"9SE
M<[>@1F1;+%^ #(6"PT;$6)JB>DJ@84HF1.L954:D^M&;5QDF:4I3P4M>R_40
MUZOXYQ1&TH8=I2::BG8>F5!R#K)*24],-"#4:TD1V2WNL>\^! .M6"PT'2MB
M:JT1>'*=0G8D676IY0^FRD&M#!935L3<KJ.UB(]@A8:K^((FDB9@VM5&/5R.
MGE/:GL1B96P9JRY'$$9IV[RX@.EV"PT?1?BF;7$URE5S5^7*%-5#E+:3E0\D
M]K;J2ZB4GJXD8W@ L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@
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M
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M<;9)3;)_N(VEPWG\1W 09U(IT^GI@SH,:1"2:32PZV2D%E.Z;)/9LL5A.
M
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M74DBL1%XC:@
M                      <QQ;_.\3^@G_(QTX<QQ;_.\3^@G_(P(=$IO\*C
MW %-_A4>X %<;Z[GO%\6(WUW/>+X *7?W:O<*A2[^[5[@&/
M
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MCF'X"N1,C1G6&I$AIIQ]61I*UDDW%<$D>\_<+X"+GF]RQS#\ SS>Y8YA^ E
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MEW]VKW ,>
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M0K$+"R*7$<DJC8@ARGB1;T&D&K,L[]17(;^
M      Y]C' ."'%5G$>+83<N[1K=>G/*6EA"4[FR,[(W?\=MPT")J*=&%*.J
MJD76;BHR9%]:B.:SU1*OMOEMOZK#2L=OXHK6.UHJV"ZM4<,TEXEP(\1QLFYC
MI'^]>S**Z2_XIW<> ZU@ZL3ZW2E2JK195&D$ZI!1I*DFHTD165Z)F5CN?P :
M5535B/3M3Z8\XHZ9AZ 51-@_JKE.*-+:C_\ *FYE[3'-:/6L-8B76<0X[H-7
MQ*Z4EXL[4-<B-2XR5J)*"M8B/*691E<^L[#I&;R+^T2?22,F,04=*(SEMAO,
M*,U(]^0\PQ-+1BG!6'ZSA.-A635D../E2IL8VR96AU2C+I!FHC0:35MV'<B
M2M+;D2/@*A8VPFZT7D-QF1&>9,[.1%&2'&MF])I,MA]D==:<2ZTAQL[H61*2
M?$C'"\=45_"?[/M&P3G3*JT];%+;)!_6<6YF69>Q)9MOL(=RC,ICQVF4&9I;
M02"OOL16 7
M                        <QQ;_.\3^@G_ ",=.',<6_SO$_H)_P C AT2
MF_PJ/< 4W^%1[@ 5QOKN>\7Q8C?7<]XO@ I=_=J]PJ%+O[M7N 8\
M
M                                   &0:_=I]PQXD(B)4DCUSY7VV)P
M[ )0"-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2 C=#3WTCFF'0T]]
M(YI@)("-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2 C=#3WTCFF'0T
M]](YI@)("-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2 C=#3WTCFF'
M0T]](YI@)("-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2 C=#3WTCF
MF'0T]](YI@)("-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2 C=#3WT
MCFF'0T]](YI@)("-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2 C=#3
MWTCFF'0T]](YI@)("-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2 C=
M#3WTCFF'0T]](YI@)("-T-/?2.:8=#3WTCFF D@(W0T]](YIAT-/?2.:8"2
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MA4>X %<;Z[GO%\6(WUW/>+X *7?W:O<*A2[^[5[@&/
M
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M+0A^$FKGF6PYN6VA68SR'L,B,SZP'6P
M                                        :?CC2-A_!LF)%JK[KDV4
MM*41HR-8X1&HDYU%<B2FYD5S/W7&SU*=&IE/D3I[R&(D=LW775G8D)(KF9_
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M_5]MS%&E:*W2:MHXETW+&7%K+<%M"-G^RZVI*DE[+)+8 ZD
M                                                         .8X
MM_G>)_03_D8Z<.8XM_G>)_03_D8$.B4W^%1[@"F_PJ/< "N-]=SWB^+$;Z[G
MO%\ %+O[M7N%0I=_=J]P#'@
M
M      R#7[M/N&/%Y-0C(225.6-.P_1,!,&ET;1]3J5I%J^+6'#Z14&DMZC)
MZ+9[,RB.^]64KC:?*47O?[3#RE%[W^TP&K-Z/:>C2>YC77.',7%U&HMZ)+V%
MK+\<I9;"93L(-0M(=6Q6F6M3M0B-1%1S18D$@]][[;C.^4HO>_VF'E*+WO\
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M*47O?[3#RE%[W^TP$L!$\I1>]_M,/*47O?[3 2P$3RE%[W^TP\I1>]_M,!+
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MP(=$IO\ "H]P!3?X5'N !7&^NY[Q?%B-]=SWB^ "EW]VKW"H4N_NU>X!CP
M
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M+,7PVB[AO'U!Q)7I=*HLAV4]&0:UO)95J3L9$9)<ME49&9;C ;4
M
M  T+$5)Q_4*M/=I>)J91J:TGZ(TB#TA;IVWNFHRR[=EDWV"3H@Q/-Q;@>+4:
MJVTBH(==C/J9_=N+;6:36CV';_L!N@#0\28DJ+FDS#^%*(M+1&RJI5)\VR7E
MCI,TI;+@:U;+]1%L&NPJYBG'-4J,BA8AA8:H4>4Y"A*7%1(>G+0>53EEF1$F
M^PB+;Q => <\TBXAJV"8V'*N[+*72T240ZLC5)2:R<+*EY)_\<J]IE>QD=AT
M,
M               !S'%O\[Q/Z"?\C'3AS'%O\[Q/Z"?\C AT2F_PJ/< 4W^%
M1[@ 5QOKN>\7Q8C?7<]XO@ I=_=J]PJ%+O[M7N 8\
M
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M1 *@
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ME,<B$BYR'4_N\QGLRI,S.UMNP;6
M                                          YCBW^=XG]!/^1CIPYC
MBW^=XG]!/^1@0Z)3?X5'N *;_"H]P *XWUW/>+XL1OKN>\7P 4N_NU>X5"EW
M]VKW ,>
M                                                  "\CIF4LA,9
M>JYG>WP%D9!K]VGW (WT[A'^8_ /IW"/\Q^ EBS#EQYK.MAOMOM7-.9M1**Y
M;RN0"U].X1_F/P#Z=PC_ #'X"\S)8>>>::>;6ZR9$XA*B,T&97*Y=0N@(GT[
MA'^8_ /IW"/\Q^ E@ B?3N$?YC\ ^G<(_P Q^ M1:W2Y4C41JA%=>W9$.D9_
M"XR ")].X1_F/P#Z=PC_ #'X"6 ")].X1_F/P#Z=PC_,?@)8 (GT[A'^8_ /
MIW"/\Q^ E@ B?3N$?YC\ ^G<(_S'X"6 ")].X1_F/P#Z=PC_ #'X"VFL4]5<
M51REM'4TL%)5&OZ9-&>4E6X7*PG@(GT[A'^8_ /IW"/\Q^ E@ B?3N$?YC\
M^G<(_P Q^ E@ B?3N$?YC\ ^G<(_S'X"6 ")].X1_F/P#Z=PC_,?@)8 (GT[
MA'^8_ /IW"/\Q^ E@ B?3N$?YC\ ^G<(_P Q^ E@ B?3N$?YC\ ^G<(_S'X"
M6 ")].X1_F/P#Z=PC_,?@)8 (GT[A'^8_ /IW"/\Q^ E@ B?3N$?YC\ ^G<(
M_P Q^ E@ B?3N$?YC\ ^G<(_S'X"6 ")].X1_F/P#Z=PC_,?@)8 (GT[A'^8
M_ /IW"/\Q^ E@ B?3N$?YC\ ^G<(_P Q^ E@ B?3N$?YC\ ^G<(_S'X"6 ")
M].X1_F/P#Z=PC_,?@)8 (GT[A'^8_ /IW"/\Q^ ^5&JP*839U&;'BDX=D:YP
MDYC]EQ+0HEI)23(TF5R,NL!%^G<(_P Q^ ?3N$?YC\!>D268R4*D.H:2M9(2
M:U6NH]Q%[3$=VKTYF>B"[.C(F+ME84X1+5?=8MX"KZ=PC_,?@'T[A'^8_ 79
M<IB''6_+>;981M4XXHDI+WF8M0ZE"FQ%2H<MA^,FY&ZVLE)*V_:0!].X1_F/
MP#Z=PC_,?@+\=]J2PAZ.XAUI99DK0=R47$C%P!$^G<(_S'X!].X1_F/P$L $
M3Z=PC_,?@'T[A'^8_ 2P 1/IW"/\Q^ ?3N$?YC\!+ !$^G<(_P Q^ ?3N$?Y
MC\!+ !$^G<(_S'X!].X1_F/P$L $3Z=PC_,?@'T[A'^8_ 2P 1/IW"/\Q^ ?
M3N$?YC\!+ !$^G<(_P Q^ ?3N$?YC\!+ !$^G<(_S'X!].X1_F/P$L $3Z=P
MC_,?@'T[A'^8_ 2P 1/IW"/\Q^ ?3N$?YC\!+ !$^G<(_P Q^ ?3N$?YC\!+
M !$^G<(_S'X!].X1_F/P$L $3Z=PC_,?@'T[A'^8_ 2P 1/IW"/\Q^ ?3N$?
MYC\!+ !$^G<(_P Q^ ?3N$?YC\!+ !$^G<(_S'X!].X1_F/P$L $3Z=PC_,?
M@'T[A'^8_ 2P 1/IW"/\Q^ ?3N$?YC\!+ !$^G<(_P Q^ J1TS.G.3&2^VQG
M>WP$D     ',<6_SO$_H)_R,=.',<6_SO$_H)_R,"'1*;_"H]P!3?X5'N !7
M&^NY[Q?%B-]=SWB^ "EW]VKW"H4N_NU>X!CP
M
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MBL49=+I\BD)BQVG'DK<1E=O9>782CN9VN=B'4P
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M$M1<2S*V'[!U(
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MBO$.A,<%\Q7B D@(W0F."^8KQ#H3'!?,5X@)("-T)C@OF*\0Z$QP7S%>("2
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MI<KZGW7FTD>]2LQF5O9EV'LZ[CJZ4>2?VI$-PG,K52H_^^B][Y$^C?Y2 =H
M
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M$'$!Q:W@B55WZ8]'E-T^2MA$UDD/Q\S:B45MN4S(NH]PQ?[/G_Y,X3_]'_\
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MV)UB4J41>R__ & Z>
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MY2O /*#'WO*5X )8")Y08^]Y2O /*#'WO*5X )8")Y08^]Y2O /*#'WO*5X
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M8M%>CUB9 Q!26R1'J[24J=,LI$LEI5L4E5KF1]8VKR@Q][RE> >4&/O>4KP
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M38S-W6%]?,1'Z);A]P[I.P]7*TQ2F5S8LR42E1$S8CK!2DD5S-LUI*^P@&[
M-.K^DC#U%JDRER'Y#U5C$@SA1H[CKRR45R-*4D=RMO/<0RV$,4TK%E,.=19!
MNMH6;3J%H-#C2RWH6DR(R,@&; :'B[$E0\X.&\)45>I=E)74)TC*2C;C-W+*
M1'L(UJL5^H2L0Z2<.4&=,I\R4ZNI13;(XC#*W'5YR-194I+:5BVGN+K ;D T
MNO:2*)1EQVG6JG(DNLID&Q%@NNK:;45R4O*FR?QVC)/8UH+>#SQ250;<H9))
M9R4$9D1&HD;MY6,['P ;$ T6G:5,,3JS&I[<B2V4MPF8DIV*XB/*6?\ Q;<-
M.51\-MCZA(Q)I'H="JS]-<*=-FQD$[+;@Q')!Q4&5R4X:2,DE;;M ;D T^/I
M'PX]A9S$1RW6J43A--NN,+2;ZCW$TFUUWOLRD?7P,7\*8UI.+#F1:<[)BU!A
M)&[%EL*8?;2KZJ\BR*Y>TKD VD!HVC'$,^>[7:#7W4O5JARS8=?2C(3[2O2:
M<R]5TG;\!O(
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MWVO;\!FIE>J=&TJ0J947FW*#6XZBA&:22;$EHB-2+_\ (E)N>WK*Q -Z
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M9TR,V6:G'<>V7]#:-IQS@RAX[I--FR)4BG*A-:^+/BK)M;3:D%F(S/\ XV^
MV'%%$B8DPY4:+424<2<R;*S2>U-]RB]I'8_P$3!F'EX?PC#H,Z=Y6;BMFPEY
MUK*;C74E:3,R.Q;/:5@'ER=025HRQ+B_#\>5%I,12:92$YCUB8IN?[[Y\369
MV,RXF0Z/^S:N$SC3&$/##SSN%FH\1QO,9J;2^:2S93/K^O\  =U:BQFHO16H
MS"(N4T:A+9$WE/>66UK>P8^;1FRH$^FT(HU'7):4VEZ/'(B:-16->4K7,BW
M.6?LZ*3(JVD.9&290GZM_LG:Q';->WQ(=I&N:/<(PL#X4BT*G.N/MM*4XX^Y
M]9YQ1W4HRZNHK<"&Q@
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M1?\ 8ZH-;P+A5&%X$Q+DI4ZHSY3DR9,4V2#=<6?41;DD1$1%<[#9
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M(4;(241DG8UJO_R4HR_ M@#:
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M4+(R#7[M/N 1[3>,;X*"TWC&^"A*$>#.B3VE.093$EM*C0:F7"61*+>1F76
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M;&T.9;FVC;NS7(MHXA@S0Q)Q%4*_6]);$N+49TLWFFH\HDGE/:9F:;EP(O<
MS&B)FFZ5M#$*BXK;<?.ERBBOMI>-*B4W^[,S+;]55OP'.]&&C/"^(-*F/J%4
MX*UTZD.Y(B4.J0I!:PT[5%M/876.EZ(\$U[ &D>NQ&HKCF#IR26Q*-Y*LJT[
M4YB^L9V,TWL)&BW!U;H6EG2#6ZI#U--JSIJB.ZQ*M86M-6XCN6P[[1(Y;I;A
MX;8T^I8Q1"ERJ$U2V4*9B$:G;DV9(M8R/8>_:,O^S8W%_P!>8O5AMYV)AQ$9
M26J?*>N^9W*RS1?JV[?;8;)C?#>-H>G L984H+%38;@HCH)]]*$J,T&E5RN1
M[!?T<8"Q0YI(JF.<8L0Z9+>CK8:@1%$HE9DD5SMLL1%UG<SVB!Y[I;&"E82Q
M FLIE_ZN.2OR6F,2K'M,DYK;+9N.W=8>O]#T6KP=&.'XV)$O(JK3!I<2^9FX
ME.8\A*OUY;#D^$M#-0EZ-L2TO$4%$"MKFJF4R02D+6E1%=/I$>PC/9OZ[CK.
MBMW$QX1BQ<<0W6*U$+5./+=2YTE)?57=)GMML/VE?K :1BG2'C&?I2?PCHWA
M4M]5.;)V6].(\JE;#4F]RREM(MFTSZQKO[/DR9#DZ6YTB,B/46'#?<85=26W
MDDZHT^U.8O@,M7\,8SPCIAG8LP-2&*S"J[1(?9=>)&K6=KYC,RL5TD9&7&PR
M&B3 ^(Z9-TC_ .JVVV5UY9ZJ2THEH<-9.9E)(CN1%G+?8P'S"NDZN570-5,:
M2F8!5>*IXD(0THF3R&DBNG-?K/K$6NZ6:W2]$&%L6]'@N3:C()$IO5*R9+JN
M2"S7([)+K,:G0<%:2J;@6KZ.V:)!*F/*<<\JK?+TB.QFE!$>TU&DB*Y;+[1E
ML3Z.\43]!6$L/1:9FK$&03DB.;R"R)(UGOO8]Y;C 9>O5W&3FBS&M8QQ0Z0B
M ;##U-I[GID:%+VD]E5FN19#WD=[B-B'234L':&L"5JBTVEM'/-#3L1+:M4A
M&51Y6RS7(SMO,SWCH6E>B5"O:*:Q1J4QKZC(BM-MM9B3=1&FY7/9U&.:8\T>
M8GJNAW 5"@4[6U2EO(7+9UJ"U9$1]9G8]Y;@$J/I%T@4#2#AREXZIM(;IM>6
M1--PR5GCD9V*ZK[5$9E<C([B[5](N,:MC3&%(P@FCPXF%V5O/KG-J6N3E+:1
M6.R=QC-:7,(UO$.D; =3H\/I$&F/9Y;FL2G5EG(]QG<]E]PY3B"-)QII1Q=4
M\.X;;Q-3633%6:)"H*4K3L42C)1&Y>Q[3V&0#LV@S%U<QSA)RNUTJ>AIUXVX
M[<5M2#3EV*SW,[[;6L-;Q?I(QBSI.J^"\)4N!-F$PVY#6]Z)->CF6MPS41&5
MMA%LVVWC/Z!L5Q<185D0(M";H:Z.\<5R(PO.TDSN=TGOOOO>^WK,0Z?A*ML_
MM$U/%#D.U">@ZA$G6)VKR)*V6]]Y& L5;'F*:%CS1WABIM4TWJU'0JIFELS-
M+MS)6K,E6(MG QDH^.JJY^T"]@=3<3R.B"4DEDV>NS9"5]:]K7/@,-ILPIB>
M7CC"6+\)4]NJ/49)I7$4X2#,R5<CV[R.YELVE81<#X5QFYIQ;QKBJF1X;,J"
MMMQ+#R5ICGE)*&SVW,[)O<MFT!@Z+I1TF8KA5_\ TU3:$14=]S7RG4F7H),\
MJ$I-1D:K),[_ /0Z7HCQ^>,-'Q8@K28U/6PZIB2O/D:NFWI>E]4CN6R^\:OH
M7P17\-T''T:LP>CO520MR(G6)5K"-*R+<9VWEOXB?H3P%)I>BV=AO&U,3DE3
M%K<BK<)1.-GE,MJ3XIX]0"UI^Q93&=%LZ73T46O(;EL-N,/*-YM.8SL9Y%$9
M'LV;>(MZ2=(]4P/AS C]'I\)Y%3:;0Y%-)D1%JD&E#9W]':JVVXMZ7-%49S1
MG/HVCRA-,S)4MAYQEMVV<D9MMUJMLN+6EC ^(*_1]';%*@:]VDFT<Q.L0G59
M4-D>\]NU)[N "S2](F/:)I-H>',>P*03%=5]'Z#<U,$=R+TK[;'L._O(9URC
M-P/V@**[3J<F/".CRENK9:RH-U:S,S,R*V8Q9TCX0K=9TRX!KU.A&]2J6?TM
M[6)+5^F9[C.Y[.!#K-SM;J
M   !D&OW:?<,>,@U^[3[@%0\V_LW2EX>K46"HC*GXH:DRF3,C.TJ.\M"TWZK
MMDE7X#TD.#Q\ XEAZ':6B!#0SC.BU!V=";-:%7S/+NG-?+92%WVGU -?Q5,<
MQ'INP[7%*(X,'$2*+!X*)M"EO+]OIF17_P#".B8OQ]5/]:S,-8<E4.FG3F6W
M9<ZL*/*I:RNEMM!*(S.VTSOL&.E:/JG!AZ+(M/C=(.CU$I=3>SH29*4DS<6=
MS+-=9GNN8^8TPC+IF/:KB5O",/&-/JS3*7(:R:)Z(ZVDDDI)N%8TJ+>1&1W
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MVAHR1*-3&M6HS*Z2)LKD5NLS'20
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M[^[5[A4*7?W:O< QX
M1F1W(]HYS/T-82EU.=.9*JT]R:LW)#4":IEI:CWGE+=?A[1T8 &%PCA>CX1H
MZ:9A^&46(2C6JZC4IQ9[U*4>TS&:
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MQ1X;9FHDYC4I2C.YJ4H]JC,]YF,J
M                 #CFG=O$K=/5/16"@T:-+AE'CPR-+LA:GDI7KE]22(]B
M4[[[=PZ/C'#47%5)33YLJH16B=2[G@R#8<N1&5LQ;;;=WN 9P!P)S!D:F:8,
M,T/#]7Q$\IA)U.IJDU)QY"&4[&T&1G:ZU_D0[#C##,7%5+3 FRZA%:2X3F>#
M(-APS(CV9BVVV[@&< <%3@R'!TO4"AX=K>(7'82#JE3.347'D):*Q-MY3.UU
MJ/;["'7,>X@3A7!M9KBTDOH,9;R4F5R4HB]$OQ.Q ,A2:13Z0F2FEQ&8J)#R
MI#J6DY26XKZRC+B8G#1-'Y)POHT:J^)*@M3[S!U2H27W#425K+.HBX)*Y)(B
MX#0\%U6M5G372ZO5G)$6-5:3)>BTTU&26(Z5H)LU)[:BNH^&8BZ@'=P&BZ9*
MC4H>%XD.B2%1I]7J$>F(D)^LT3BO24G@>4CL?4-/F4=.B[&F#?(,VHNP*[,.
MFU!B;*7():C3=#J<U\JKD=[;#+98!VH0ZA2X-1=AN3HK3ZXCI/L&X5]6X1&1
M*+VE<]HF#!8VQ+&PIAR3592%/&BS;,=OZ[[JCLAM)=9F=O\ OJ 9=F,PR\^\
MRRVAUXR-U:4D1K,BL1J/KV"\.(:-:55*Q7M(=)Q94)I3)C4)Z04:2:>BJ<2M
M1MLJ+ZI)*R;EOL,1I'T=Q:1(H-'PS7,3+KU7F$VWKJJZM+3"/2>=-/L38O>8
M#T, H;2EAA*<QY6TD691W.Q=9F/-K%=PIBZ3*JND?%<R.I^0OH%.BR76FH3&
M<T(-PVBMG5:]UGN,ME@'I4:_BW"-,Q0F&J?TEF7"<UL67$>-IYA1E8S2HN);
M#(:5I5DNX5IV&\7422^ZQ3I#,64G6FM$B&Z9(,U;;&9'E,E;QU4!J%&T?4JG
MUUFLRI-3JU4CI-$>14I2GSCDKZVK+82;]9VN-O
M                               <QQ;_ #O$_H)_R,=.',<6_P [Q/Z"
M?\C AT2F_P *CW %-_A4>X %<;Z[GO%\6(WUW/>+X *7?W:O<*A2[^[5[@&/
M +'P"Q\   L? +'P  "Q\ L?   +'P"Q\   L? +'P  "Q\ L?   +'P"Q\
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MVRN0_"9-U4-]HLMUI*ZLJDGO+K'1<0X;I]>=ISTY"TR:?(3)BOM*R.-K+@?
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M&=U94[B,^L]]M@#-I*Q$7
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M0X_(IQ*.,VI=VFUJ*QKR[C5;81]0S(
M                        #F.+?YWB?T$_Y&.G#F.+?YWB?T$_Y&!#HE-_
MA4>X IO\*CW  KC?7<]XOBQ&^NY[Q? !;D));#B3O8RZCL+@I=_=J]P##]$:
MXN\PPZ(UQ=YAB0(U2GQ*7 ?G5*2U%AL)-;KSJLJ4$7$P'WHC7%WF&'1&N+O,
M,<MC:?<(29+:&H]:..XX32)70SU1J,[<;CK75?J 1^B-<7>88=$:XN\PQ( !
M'Z(UQ=YAAT1KB[S#$@+ (_1&N+O,,.B-<7>88D?_   "/T1KB[S##HC7%WF&
M)%MMNO@-*THZ08>C^F0Y$B$_4)<U[4QHK*B2:SZSS'NZO?<!MO1&N+O,,.B-
M<7>88PV!J_-Q)153JE09E"?)TVRBRSNLR(B]+<6P[_D)T>O4J37YE#CSFG*M
M#;2[(BD1YFTJM8SV6VW+KZP$OHC7%WF&'1&N+O,,2 ZK]0"/T1KB[S##HC7%
MWF&)%CX 6W< C]$:XN\PPZ(UQ=YAB)6:]2J*] :JT]F*[/>*/%2N]WG#_P")
M6]Y?$9.V_P!@"/T1KB[S##HC7%WF&)'5[!K^/\3-X.PC4:\]%7+1#2E1L(62
M#41J(MYD=MX#,=$:XN\PPZ(UQ=YAB!A&M)Q'ABEUE$=49,YA+Y,J42C1?J,R
MWC -:0&5Z69&!?)SI/LQ>E=-UI93+*2K9;7Z[;P&W=$:XN\PPZ(UQ=YABFK2
MRIU)G3E(-PHL=Q_(1VSY$FJU_;8:[HNQFUC_  BU7H\%R$VX\XT3*W"699#(
MKW(BX@-DZ(UQ=YAAT1KB[S#$CJOU  C]$:XN\PPZ(UQ=YAB18:3B+2 Q1=)6
M'\'KISCSM8:UJ):72)+6U96--MOU./6 V[HC7%WF&'1&N+O,,2#V;P,K;P$?
MHC7%WF&'1&N+O,,24)S*25[7.PT71;I"9Q^BMFQ37(/DN4451+=)S6'MVE8B
MMN ;CT1KB[S##HC7%WF&)  (_1&N+O,,.B-<7>88P^.\1NX5PX_5&*1-J[C2
MDIZ+$*ZSN=KGL.Q%[AEJ3*5/I<.8N,[%7(90Z;#I66T:BOE5[2 5=$:XN\PP
MZ(UQ=YAB1U>P/^P$?HC7%WF&'1&N+O,,2  1^B-<7>88=$:XN\PQ( !'Z(UQ
M=YAAT1KB[S#$CJOU  C]$:XN\PPZ(UQ=YAC7-(V+G\'4B+.C4&H5Q3\@F#9A
M%=39&1GF/8>S98O:8VI/I)2=C(S(CL9;2]A^T!8Z(UQ=YAAT1KB[S#$@1*K4
M8E)IDJH5%]$>'&;-UUQ9V(DE_P#/L 5]$:XN\PPZ(UQ=YAC0)NF'#T/#]+JK
M\6J?_>BE]#AI8)4AY"=[A((]B?:,R[I#P\C 2,7IE&Y2EI+(E-M:I9GEU1)O
M]>_5[ &S=$:XN\PPZ(UQ=YAB!.KB8>%UUQRGSE-HCE)5$0V1OI3:YEEOO(MI
ME<863CEB5@)O$V%:?)KR7[)8C1RLK,9V/6=DDV](^H!M/1&N+O,,.B-<7>88
MU_1EB61B[!4"M38[,:1(-9*:9,S0G*HT[#/;U#: $?HC7%WF&'1&N+O,,2
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M>W3SZ.@C0^E&Y:DWL1BC"FB:A4+"E:H<IZ34T5E1JG2';(4X?5E).Q-M_7M
M<%I2<1PZ?0ZUA:%CM_$NL2]+E/MF[$E(49FK*5SNFW$MNW</5=<J#D##-1J:
M&RUT:"Y*2VK;Z26S5E/\2'-:-H:FTF/'@1=(%?316'"6F$E*4G8E9LN8CW;.
M'X#K+[;;[+K+R"6TXDT+2HKDI)E8R/\  P'E"DTFKXDT2U729-Q35T8B:>6Z
MT;;YI;03:B++E+=?9:VPK"QI-F2\4X9T;8CJ<V6J74U]&=:)>5ILTK))NMI_
MXK5O,_\ H=/D: (G1Y=-I^+JW"PY)=UKE+01*3>Y'8E?AUEU%O&S8OT4TNOT
MW#%/C2WJ;#H"R7';;;)>>V7ZQF9=G:?7<!N&&:*B@4*/2F)<N2ADE$E^2YK'
M3S&9W-1[S*X\XX#P4S7-.6.:7*J]83Y-<2\F4W(L\^9.)V.JMZ1>RQ#U%UCE
ME6T/D_CFHXFHN*:G1GJBHERF8Z"//NN1*N1V,RO;J :5CQFLXC_:*FX6@5V7
M2H4^F-JD*949GJTHS*2DK[#,R+;PN-6J3LF1CV1A">K%55H.&6.C-QJ.=WW%
M[+O.;2WFK?MZB'?%:/XRM+/^N_*#I2>B]%Z'JRR9<F6^:]_;N&.QIHJBU[%3
M>):-6Y^'ZYJ]6Z_%(E)>*UB-1'UVV>W@ TC1]B"J4#1MBQO'S]<IM)B*)JFR
MY3:D2R0X2B2E!W])1&1;+\=MASN155X:J^$ZQA(L8042)*6W'ZTX1MSD&:2/
M*FY[[G<CZC+:.[R=$\>IX.JE!Q%B*K5=R<^B1TQ\RS,K05DY$[2MQ+KN,*]H
M+;FL4TJQC"KU"13G&SBJ<;3JVFTG?(2+]=D^E?<5@&M?M%T?I>DW C3D^=J:
MF_J-63OHQO22DU-%_P 5'?:>W<(.E1V71,4X;T>Q9>(I="CM')E(AKSS9IJ6
MI5B5<LUMWL'7=*.CB+CTZ0^JIRJ54*6XIR-)822C*]CL9'P,B,C(QB*[H?8K
M5-HO3<358\04I:U,UHB+7+)2C5E4G@5]FVY -"P'6<384/&2X\#$C&&&*8[,
MI_EIFZF)";$2<QW(]Y[+[;;AK'^DJC4=!%8QS-Q+47ZA,)3LEA;QJ:=:UA$:
M%)/<J]C(RW6'?,+8!D4Q52/$.)ZGB,IT8XBVY7H-I0=[Y2(]YWWC36OV?H3=
M+G4K_5E:\C/*-QB$DDDAER^Q2BW+MPV7WF WO0]_^5F%O_0(_P#D<CQ'0_\
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M![S,O: V'15AN9A+ U/HM3<8=EQU.&M3!F:#S+,RL9D748VP
M!D&OW:?<,>,@U^[3[@%N;&;F0WXKY&;+[:FUD1VNE1&1_D8XW3G\4:&L/:FL
MLQJ]@R!L3,BGJY<5HU6+.V>Q9%?>1W'9)K*I$-]A#JV5N-J03J/K(,R,LQ>T
MMXYS5-'%<KU+\CXFQQ,GT1>4GX[4%IAQ]*3OE4Z5SL=BO8KF P2HJL:Z7JQ3
MGZS4T8=51XLOHD:2IE+QJ4>4S,MI%8]I$97V7W"3@JJ3<+8GQ[AE4N34:=1(
M;50@'*<-QQM*VS4;1J/:97+9<]PQ_P#I^3,TZ5IN@5=ZBR8%'BI96VTEULT9
ME)R+;5L45B*VTC(R'1,%X+9P\JJRITQRK5>K.$N=,?;2G6V*R4$@MB4D6PB
M<QI.%YM9T6%C:3B.KHQ<["7/;F-RU$TR=C4ELF?J9+;#*W$43*M5<:5G16UY
M5G4QBM4I]ZH)B.FV;Q$A!J(C+ZMSO8RVD1G8;4WHGEQJ*_AR#BZHL83?4K-
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M?X1C8-HCL"-)?EN/R7)DB0]8E.O.'=2K$1$6[<0V0
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M(C&51YE;C4HTD1%U[0'3HCW2(K3V7+K$$JW"Y"Z!$1%8BL0
M                                                    .8XM_G>)
M_03_ )&.G#F.+?YWB?T$_P"1@0Z)3?X5'N *;_"H]P *XWUW/>+XL1OKN>\7
MP 4N_NU>X5"EW]VKW ,>
M                       ;MPA)I--3+Z4FFP2DYLVN*.@EWXYK7N)H
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MW>-W
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M0[3E1JS"<-/IH]).9)\+I,R,MP#K0"U$?1*BM/M7R.H):;\#*XN@
M                                                        .8XM
M_G>)_03_ )&.G#F.+?YWB?T$_P"1@0Z)3?X5'N *;_"H]P *XWUW/>+XL1OK
MN>\7P 4N_NU>X5"EW]VKW ,>
M
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M,B/>0#5,'NZ1/*K;&+(^'2IK39DN3#<<-U]?_$R09$22WW_(;R
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M#+:&6D-MEE0@B2DN!$*@
M                         !S'%O\ .\3^@G_(QTX<QQ;_ #O$_H)_R,"'
M1*;_  J/< 4W^%1[@ 5QOKN>\7Q8C?7<]XO@ I=_=J]PJ%+O[M7N 8\
M
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M2K&<.AQ&221,(I[KCBS5?::C58B*VXBVC:P
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MR&X=/<L9:V.PDTZPB/J4HU;?8.G
M                                   #F.+?YWB?T$_Y&.G#F.+?YWB?
MT$_Y&!#HE-_A4>X IO\ "H]P *XWUW/>+XL1OKN>\7P 4N_NU>X5"EW]VKW
M,>
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MJ5KEW+X@.D@
MU;$&D'"F'YQPJO78<>6DLRV;FM39<5$DCR_C8;!39\2J069M-DLRHCR<S;S*
MR6A9<2,MXU[%<K#V#J-6:W,B16ERRL^3;9:V:Y;*ENV]:CW$7_P,9H-P_-PW
MHXI\*IM=&DN+=DG%+=&)Q9K)LO<1E^-P&UUBITN"[!8JK["'9;Z6HK;A74X[
MO(DEOOLW]0PE2TD8/IM4=ITW$$)J6TLFW4YC-+2CV66HBRI/WF0UK+Y9_:(5
MTDU&SA^CI5'09["=?49*7;CD+*.8%7)E"PKCO#M.I":QAYV?(;574,J4RPEU
M1ZPW4D1FZ;9&?I(N6PMP#T/B'%-$P[!8F5FHLQH\A65E6U9N':_HDDC,]A7V
M=0KE8EHT6@(K;]2C%25DA2)1*S(42S(DVMON9D6P<NG+@X28T:5M,J55<-4N
M$]%.8PRI]5W&4DVYE3<[*RFG9NS$-$PS-J#$?"5&<IJY;5+FF::6IPFR>J#J
MG'6FUKVY"8:,EJV'91I*P#TE,KE-A5*GT^7,:9F5#-T5I=R-XTE=1)ZC,B.]
MMXR*B)23)1$9'L,CZQQ;2+6F<4Z*I.)&XSD"LX9J!/:I1DI4>0PZ25I)761E
M?;UD9#L4&2F9"8DMD9(>03A$>^QE<!=:;0RVEMI"4-I*R4I*Q$7L(5
M
M    YCBW^=XG]!/^1CIPYCBW^=XG]!/^1@0Z)3?X5'N *;_"H]P *XWUW/>+
MXL1OKN>\7P 4N_NU>X5"EW]VKW ,>
M
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MI>T;3HFPS+PA@6!1:BZT])CJ=S.-&9I5F<4HCVEOL97]HV\
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M.&A)N$64EVVD7"XJ
M                           !S'%O\[Q/Z"?\C'3AS'%O\[Q/Z"?\C AT
M2F_PJ/< 4W^%1[@ 5QOKN>\7Q8C?7<]XO@ &5RL8  IR)[)? ,B>R7P%0 *<
MB>R7P#(GLE\!4 "G(GLE\ R)[)? 5  IR)[)? ,B>R7P%0 *<B>R7P#(GLE\
M!4 "G(GLE\ R)[)? 5  IR)[)? ,B>R7P%0 *<B>R7P#(GLE\!4 "G(GLE\
MR)[)? 5  IR)[)? ,B>R7P%0 *<B>R7P#(GLE\!4 "G(GLE\ R)[)? 5  IR
M)[)? ,B>R7P%0 *<B>R7P#(GLE\!4 "G(GLE\ R)[)? 5  IR)[)? ,B>R7P
M%0 *<B>R7P#(GLE\!4 "G(GLE\ R)[)? 5  IR)[)? ,B>R7P%0 *<B>R7P#
M(GLE\!4 "G(GLE\ R)[)? 5  IR)[)? ,B>R7P%0 *<B>R7P#(GLE\!4 "G(
MGLE\ R)[)? 5  IR)[)? ,B>R7P%0 *<B>R7P#(GLE\!4 "G(GLE\ R)[)?
M5  IR)[)? ,B>R7P%0 *<B>R7P#(GLE\!4 "G(GLE\ R)[)? 5  IR)[)? ,
MB>R7P%0 *<B.R7P%1%8K$
M
M
M          #F.+?YWB?T$_Y&.G#F.+?YWB?T$_Y&!#HE-_A4>X IO\*CW  K
MC?7<]XOB.R=I"RXB0     AU6HL4R,3\K/JS6E'HI-6TSL6[J]HF"'5X":E
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M0R,O]Q63;N,LMK6&LX0865=A=-DML55MUU4E"HSA.ND9*N2UF>4TVL9'NW6
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M)(6@C,UI))'?_F7IW/@>TQN&&(B:?B:OQ(K2F("286TV1&39*-)YC3U=17L
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MS:<IR2X33;"VV&SLWZ)$K>F^TBW7O8?4PJ=&<I'E:(:H+<B9$(W&U*)*<_\
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M^T<ZH="16DUE=0;<5,-EA+#SN:[:SCH,U)]N;>?L&3P.J95)\JKU(E)=::3
M2@]GI(VNJMNVKW>X!N0
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M>*SFU3#:6TYCN=DE8K_ 7@
M                                    $2HT]FH%&)_/_L/HD(RG;TDG
M<K^P2P                                   1ZA%*9#=CF\\R3A9=8R
MK*M/N/J%-*I[%+I[,.(DTL-%9.8[F=SN9F?69F9F)0
M
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M+^R)7-3X!YPE_9$KFI\!M7D*)V?R#R%$[/Y -5\X2_LB5S4^ ><)?V1*YJ?
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MJ? ;5Y"B=G\@\A1.S^0#5?.$O[(E<U/@'G"7]D2N:GP&U>0HG9_(/(43L_D
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&     ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g50309g06m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g06m01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1I>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &D$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             /_A2)%H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# R(#<Y
M+C$V-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z
M+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R
M-BTP,BTR-E0Q,3HR-#HQ-2TP-3HP,#PO>&UP.D-R96%T941A=&4^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(V+3 R+3(W5# Q.C,V.C W*S U.C,P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!
M9&]B92!);&QU<W1R871O<B S,"XR("A-86-I;G1O<V@I/"]X;7 Z0W)E871O
M<E1O;VP^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#(M,C=4
M,#$Z,S8Z,#<K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#ID,31B.61B
M82UF-SEC+38W-&8M.#-B.2TX9CEE8F,Y8F$V9#(\+WAM<$U-.D1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z.3(S.#%A
M9&,M-SAC9BTX9#0T+6(W.#(M.#4V-F8X8S,V,F9C/"]X;7!-33I);G-T86YC
M94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M1D1!1D1!1$8M0D9%1BTT-#%&+3@R1D(M13=&0T5&041!,T1$/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#
M;&%S<SYP<F]O9CIP9&8\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.CDY,F(P
M,F4T+38X-S0M.3@T."UA9CDU+3)B8F%D.#DQ-#0R83PO<W12968Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#IF
M865E-S1D-2UF-&9E+31B9#(M8F4Q-BTU9#4T8S=F,# W-#<\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^=75I9#I&1$%&1$%$1BU"1D5&+30T,48M.#)&0BU%-T9#149!1$$S1$0\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.G)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO<W12968Z<F5N9&ET:6]N0VQA
M<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX
M;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#IC.69D9F)F-"TS9&,U+31C,3 M838V82TT-C%A-6,U-6$Q.&8\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C8M,#(M,C54,3DZ,3,Z-#4M,#4Z,# \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R(#,P+C(@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F9A964W
M-&0U+68T9F4M-&)D,BUB93$V+35D-31C-V8P,#<T-SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-BTP,BTR
M-E0Q,3HR-#HQ-2TP-3HP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@,S N
M,B H36%C:6YT;W-H*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M($I014<@9FEL92!F
M;W)M870@=&\@:6UA9V4O:G!E9SPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,#0W1#<P148T0S$S1C$Q
M,4$W,#9$.45%.4,S-#-&,D(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C8M,#(M,C=4,#$Z,CDZ,3<K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!I;6%G92]J<&5G
M('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A
M<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C U-T0W,$5&-$,Q,T8Q,3%!-S V1#E%13E#,S0S1C)"/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 R
M+3(W5# Q.C(Y.C$W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.3DR8C R930M-C@W-"TY
M.#0X+6%F.34M,F)B860X.3$T-#)A/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 R+3(W5# Q.C,V.C W
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC
M;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z.3(S.#%A9&,M-SAC9BTX9#0T+6(W.#(M.#4V-F8X8S,V,F9C/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(V+3 R+3(W5# Q.C,V.C W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/&1C
M.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT
M:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^4')O:F5C=$-O86=&:6=486)L
M93(U1F5B7VIS;F]W7T9?;W5T;&EN93PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC
M<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y2=71H=FEK($UA;&QA9&D\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QI
M;&QU<W1R871O<CI)<T9I;&53879E9%9I84EN<W1A;G13879E/E1R=64\+VEL
M;'5S=')A=&]R.DES1FEL95-A=F5D5FEA26YS=&%N=%-A=F4^"B @(" @(" @
M(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!25)O8FEN/"]I;&QU<W1R
M871O<CI#<F5A=&]R4W5B5&]O;#X*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!
M9&]B92!01$8@;&EB<F%R>2 Q."XP,#PO<&1F.E!R;V1U8V5R/@H@(" @(" @
M(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z
M>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X
M<&%C:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/
M#! 7%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!
M!P<'"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( Z,%\0,!(@ "$0$#$0'_Q  <  $
M @,! 0$             ! 4#!@<" 0C_Q !A$  ! P,! P8)!PH#! 8'! L
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M (G.R^BHYV7T5)8 B<[+Z*CG9?14E@")SLOHJ.=E]%26 (G.R^BHYV7T5)8
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M (G.R^BHYV7T5)8 B<[+Z*CG9?14E@")SLOHJ.=E]%26 (G.R^BHYV7T5)8
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M,)YR\#(Y4:U57@A&A:LLBO=P0#U!%GRW[U7J4D
M
M
M
M                                         J9X@ 0*VD:^-S7(JL7L
MXH5=)624=4M-4KOXM=Z2=IL:IE,+P*'4%$Z6F<Z+IH<OC]O:@%W#(CVY0]FM
M:=N:5$3=^_!LC7;29 ^@ #!5NPU&IUF2%NQ&B?:8)?+J&IU;B4
M
M
M
M                                                        ##4L
MS'GK0S'QR9:J=J <[5_S9J6IIF^3$JI(Q$ZD=O\ CDWJ@F22-%3K0T37;>8N
MEMJ4XO:Z-?<J+_S-GTY/SE.W>!?@\;2@# GY4A*(K?RI"4          5<#*
M=H #*8R1(KE0RSK#%6TSYDW<VV5JN^S($L$6IN-%2O1E564\+UWHV25K57W*
MID2J@61L:3Q+(]NTUJ/3+D[43L S           !D(J+P4
M
M
M
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M@
M                                                          (]
M36T]+/30SR(R2I>K(D5/.<B*JI]B*2#7-3_GS3/_ 'M__!>!L8
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M^D6K_=L7_$D-E
M          YKRJ]':?KW_!"ST7T+/[ZD*SE5Z.T_7O\ @A9Z+Z%G]]2!6W@
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MGE-]+27\2?\ \AOH T+9Y3?2TE_$G_\ (8JE_*7!3RS/72:MC:KE1))^"?\
MN'0B)=_S56?4N^"@:GR0ZWDU[IB6Z34243XJE],L:2;:*K<9=G"<<\#=SC'R
M4/T=5O[TJ/BAV<      BNG>CE3=N4^>$/\ ]DQ2=([O/(&?PA_^R/"'_P"R
M8 !G\(?_ +(\(?\ [)@ $AM0]7(F[>I**^/SV]Y8      'B5RLC54XD?PA_
M^R9ZCHE]Q!7B!G\(?_LCPA_^R8 !G\(?_LCPA_\ LF  9_"'_P"R>HIG.>B+
MC"D8R4_3- G     !CG>K&HK<<3(8*OHT[P,?A#_ /9'A#_]DP+Q &?PA_\
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M0L_OJ0K.57H[3]>_X(6>B^A9_?4@5MX "/#?RI"61&_E2$L
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MO5C>?8]/\-J;O-7[#9       A9-X(5J%DW@@     !YEZ)_<0%XD^7HG]Q
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MF,R4_3- G     !@J^C3O,Y@J^C3O B+Q 7B      "71^8[O,Y@H_,=WF<
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M[@Z5O>!/     ##5]%[S,8:OHO>!#       !FI.E]Q,(=)TON)@
M        '->57H[3]>_X(6>B^A9_?4A6<JO1VGZ]_P $+/1?0L_OJ0*V\ !'
MAOY4A+(C?RI"6                                         (EW_-5
M9]2[X*2R)=_S56?4N^"@<C^2A^CJM_>E1\4.SG&/DH?HZK?WI4?%#LX
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MU+TB=QA,U+TB=P$P     (U9^J22-6?J@1@       2*+SG]Q*(M%YS^XE
M    $2L\].XP&>L\].XP       GT_0M[B 3Z?H6]P'L     7@I7*6*\%*Y
M0/@     >X.E;WG@]P=*WO G@    !AJ^B]YF,-7T7O A@       S4G2^XF
M$.DZ7W$P                #FO*KT=I^O?\$+/1?0L_OJ0K.57H[3]>_P""
M%GHOH6?WU(%;>  CPW\J0ED1OY4A+
M          $2[_FJL^I=\%)9$N_YJK/J7?!0.1_)0_1U6_O2H^*'9SC'R4/T
M=5O[TJ/BAV<      KY.D=WGD]2=([O/(     !ZC\]O>6!7Q^>WO+
M QU'1+[B"O$G5'1+[B"O$      &2GZ9IC,E/TS0)P     8*OHT[S.8*OHT
M[P(B\0%X@      ET?F.[S.8*/S'=YG      ,53T+B$O$FU/0N(2\0
M 2:/B[N0C$FCXN[D D@    !$J^D3N)9$J^D3N P        F4GF.[S,8:3S
M'=YF      -6H7U:ZHN[9K3!34R(WFZQC</J.&YR]?\ \BW*"UMIDUE?%BNL
MM3.K6\Y1N1=F#AO3*X^SM+\      (63>"%:A9-X(      >9>B?W$!>)/EZ
M)_<0%X@?      S4O2)W&$S4O2)W 3      C5GZI)(U9^J!&       !(HO
M.?W$HBT7G/[B4      1*SST[C 9ZSST[C       "?3]"WN(!/I^A;W >P
M   !>"E<I8KP4KE ^     ![@Z5O>>#W!TK>\">     &&KZ+WF8PU?1>\"&
M       #-2=+[B80Z3I?<3                 .:\JO1VGZ]_P0L]%]"S^^
MI"LY5>CM/U[_ ((6>B^A9_?4@5MX "/#?RI"61&_E2$L
M                         1+O^:JSZEWP4ED2[_FJL^I=\% Y'\E#]'5;
M^]*CXH=G.,?)0_1U6_O2H^*'9P     "ODZ1W>>3U)TCN\\@     'J/SV]Y
M8%?'Y[>\L      #'4=$ON(*\2=4=$ON(*\0      9*?IFF,R4_3- G
M !@J^C3O,Y@J^C3O B+Q 7B      "71^8[O,Y@H_,=WF<      Q5/0N(2\
M2;4]"XA+Q      !)H^+NY",2:/B[N0"2     $2KZ1.XED2KZ1.X#
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MW"HCIZ2!BR2S2.V6L:G%57L/5#5T]?1PU5',R:FF:CXY&+EKFKP5% S@
M /$<L<NUS;VNV5V5PN<+V'L           !$N_YJK/J7?!261+O^:JSZEWP4
M#D?R4/T=5O[TJ/BAV<XQ\E#]'5;^]*CXH=G      *^3I'=YY/4G2.[SR
M   >H_/;WE@5\?GM[RP      ,=1T2^X@KQ)U1T2^X@KQ      !DI^F:8S)
M3],T"<     &"KZ-.\SF"KZ-.\"(O$!>(      )='YCN\SF"C\QW>9P
M #%4]"XA+Q)M3T+B$O$      $FCXN[D(Q)H^+NY )(     1*OI$[B61*OI
M$[@,        )E)YCN\S&&D\QW>9@    #J U.BV_'"[9LR4S.;;BX;*IX1Y
MODYQ_>"Z**A1GCI=U2\.J7+&W-"N<0>;Y79_]2]      "%DW@A6H63>"
M   'F7HG]Q 7B3Y>B?W$!>('P     ,U+TB=QA,U+TB=P$P     (U9^J22-
M6?J@1@       2*+SG]Q*(M%YS^XE      $2L\].XP&>L\].XP       GT
M_0M[B 3Z?H6]P'L     7@I7*6*\%*Y0/@     >X.E;WG@]P=*WO G@
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M%:F57%TGWKU\#M!QCY*'Z.JW]Z5'Q0[.      5\G2.[SR>I.D=WGD
M]1^>WO+ KX_/;WE@      8ZCHE]Q!7B3JCHE]Q!7B      #)3],TQF2GZ9
MH$X     ,%7T:=YG,%7T:=X$1>("\0      2Z/S'=YG,%'YCN\S@     &*
MIZ%Q"7B3:GH7$)>(      )-'Q=W(1B31\7=R 20     B5?2)W$LB5?2)W
M8        3*3S'=YF,-)YCN\S      &H4#HEUK>$9:'4\B1MVJY7*J3^;NQ
MP^SL+TIJ-LJ:ONJOO,=3$K&[- CLNI_-\I4ZO_F7(      0LF\$*U"R;P0
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M,R4_3- G     !@J^C3O,Y@J^C3O B+Q 7B      "71^8[O,Y@H_,=WF<
M    Q5/0N(2\2;4]"XA+Q      !)H^+NY",2:/B[N0"2     $2KZ1.XED2
MKZ1.X#        "92>8[O,QAI/,=WF8      T^BDI$UQ=XX;3+!5<TU9*Y5
M79F3R?)1.'9]A?%/!X5XY7))+K#-2\RU8Z%J^7$OD^4J8X<>OK+@      (6
M3>"%:A9-X(      >9>B?W$!>)/EZ)_<0%X@?      S4O2)W&$S4O2)W 3
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M^2A^CJM_>E1\4.SG&/DH?HZK?WI4?%#LX     !7R=([O/)ZDZ1W>>0
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MH63>"      'F7HG]Q 7B3Y>B?W$!>('P     ,U+TB=QA,U+TB=P$P
M(U9^J22-6?J@1@       2*+SG]Q*(M%YS^XE      $2L\].XP&>L\].XP
M      GT_0M[B 3Z?H6]P'L     7@I7*6*\%*Y0/@     >X.E;WG@]P=*W
MO G@    !AJ^B]YF,-7T7O A@       S4G2^XF$.DZ7W$P
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MS.8*/S'=YG      ,53T+B$O$FU/0N(2\0      2:/B[N0C$FCXN[D D@
M  !$J^D3N)9$J^D3N P        F4GF.[S,8:3S'=YF      -+HEMZZ_O"0
M451'<$@;SM2Y5YM[<-W(G;P^Q38BJA6X>-MP2>X4\EOYI.:I&JG.1N\GRE3C
MCC]J%J      $+)O!"M0LF\$      /,O1/[B O$GR]$_N("\0/@     9J7
MI$[C"9J7I$[@)@     1JS]4DD:L_5 C        D47G/[B41:+SG]Q*
M  (E9YZ=Q@,]9YZ=Q@      !/I^A;W$ GT_0M[@/8     O!2N4L5X*5R@?
M      ]P=*WO/![@Z5O>!/     ##5]%[S,8:OHO>!#       !FI.E]Q,(=
M)TON)@                '->57H[3]>_P""%GHOH6?WU(5G*KT=I^O?\$+/
M1?0L_OJ0*V\ !'AOY4A+(C?RI"6
M        (EW_ #56?4N^"DLB7?\ -59]2[X*!R/Y*'Z.JW]Z5'Q0[.<8^2A^
MCJM_>E1\4.S@     %?)TCN\\GJ3I'=YY      /4?GM[RP*^/SV]Y8
M &.HZ)?<05XDZHZ)?<05X@      R4_3-,9DI^F:!.     #!5]&G>9S!5]&
MG>!$7B O$      $NC\QW>9S!1^8[O,X     !BJ>A<0EXDVIZ%Q"7B
M "31\7=R$8DT?%W<@$D     (E7TB=Q+(E7TB=P&        $RD\QW>9C#2>
M8[O,P     !I=$^V+R@WAM/2U++FD#>>G<O^&]N&;FIV\/L4V(K(G77QJKVU
M-13.M*1IS$+<<XUWDY5=V<<?M0LP      A9-X(5J%DW@@     !YEZ)_<0%
MXD^7HG]Q 7B!\     #-2](G<83-2](G<!,     "-6?JDDC5GZH$8
M $BB\Y_<2B+1><_N)0     !$K//3N,!GK//3N,       )]/T+>X@$^GZ%O
M<![     %X*5REBO!2N4#X     'N#I6]YX/<'2M[P)X     8:OHO>9C#5]
M%[P(8       ,U)TON)A#I.E]Q,                 YKRJ]':?KW_!"ST7
MT+/[ZD*SE5Z.T_7O^"%GHOH6?WU(%;>  CPW\J0ED1OY4A+
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M]4DD:L_5 C        D47G/[B41:+SG]Q*      (E9YZ=Q@,]9YZ=Q@
M  !/I^A;W$ GT_0M[@/8     O!2N4L5X*5R@?      ]P=*WO/![@Z5O>!/
M     ##5]%[S,8:OHO>!#       !FI.E]Q,(=)TON)@
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MB O$GR]$_N("\0/@     9J7I$[C"9J7I$[@)@     1JS]4DD:L_5 C
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M'R4/T=5O[TJ/BAV<      KY.D=WGD]2=([O/(     !ZC\]O>6!7Q^>WO+
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MRFJ5A=L2)#*U^P[L=A=R^Q1'<:*6OEH8ZNG=6Q-1TE.DB<XQJ\%5N<HGM E
M #6+WH'2U\N4EPN]CHJNMD1&OFE9ESD1,)_0@_15H;]F+=_#7\3=0!I7T5:&
M_9BW?PU_$CW'DNT3#;ZF2/3-N1[(W.1>;Z\+[3?2)=_S56?4N^"@<B^2>B)R
M<UJ(F$2Z3HB)[CM!QCY*'Z.JW]Z5'Q0[.      5\G2.[SR>I.D=WGD
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M1WA^:0="K.2:]Q2JE+4T=1'U.558OO3"_$MK!R5^#5#)K_4QSL3?X/#G#O\
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MM36+-$J.SENPQ,^S>B@3ZSST[C 9ZSST[C       "?3]"WN(!/I^A;W >P
M   !>"E<I8KP4KE ^     ![@Z5O>>#W!TK>\">     &&KZ+WF8PU?1>\"&
M       #-2=+[B80Z3I?<3                 .:\JO1VGZ]_P0L]%]"S^^
MI"LY5>CM/U[_ ((6>B^A9_?4@5MX "/#?RI"61&_E2$L
M   !4:OO<.G-,72[U"M1E'3OE3:X*Y$7">]<(6YSSY0;7/Y'M3(Q%5?!T7=V
M;29 U?DDL4E#R,7B]7%727B_0SU]7*_.TNTU=AN_J1-_O.=<BURJ.3)NF:^L
M>KM*ZN8D<KUPO@M6URM15[$5,>[N.\VZ:&?D:@DIG-=$ME;A6\.AWFH<FVEJ
M+67R<;39+@U-BII'I')LHKHG[;ME[<]:* ^40B+=N3C*9_\ 3S/]TW?7'*!:
MM&5-+#=::YS/J6*]BT=*LR(B+C>J<#\[UE]N$JZ,TCJ57-U%IK4$4,FWQJ*=
M45(Y47._J3[/:?HS6GCEX32^*#;*L&RO/_.'.;6UG=L[*\ -5^G33/J_47^6
MN_$V'6M#?-7Z9M\6E;LEGAK7,DJIGQ+SZ4[DRJ,]%^]/Q0I7?2ULKLLTAM8W
M92?\3H]O\)\!I_#^:\+YMO.\UG8V\;]G._&0.,_)RM%+8;YRB6N@23P:EN<<
M3%D=M.5$8N]5ZU7B;YREZ?ONIJ"DMEGN[+7;9WN;<WM3_'?#A/)B=A=E5WHJ
M[N)J?(C_ -=N5#]\-_W5.N.\U>X#AWR9*"GM=5KF@HF*RFIKIS,:.7:79:W"
M97K7VDOENA=I35VEN4&A:C'TU0VW7#9PG/0291$7=OQE=_5N/GR>/SYRA_OE
MWP)?RJ5:O)!71JW:EDJ8&1)U[:OW8_J!UN-Z21M>U<M<B*AZ(%@9)'8K='.J
MK*VFC:_/I(U,D\   !$N_P":JSZEWP4ED2[_ )JK/J7?!0.1_)0_1U6_O2H^
M*'9SC'R4/T=5O[TJ/BAV<      KY.D=WGD]2=([O/(     !ZC\]O>6!7Q^
M>WO+       QU'1+[B"O$G5'1+[B"O$      &2GZ9IC,E/TS0)P     8*O
MHT[S.8*OHT[P(B\0%X@      ET?F.[S.8*/S'=YG      ,53T+B$O$FU/0
MN(2\0      2:/B[N0C$FCXN[D D@    !$J^D3N)9$J^D3N P        F4
MGF.[S,8:3S'=YF      -,A2W-Y1+CS5;4ON;J9O.4SD_P -C,-WHO;N3[5-
MA*E'5OCG5M?:Z5E!S";->UJ<Z]V$\E5SPX]746P      0LF\$*U"R;P0
M   \R]$_N("\2?+T3^X@+Q ^     !FI>D3N,)FI>D3N F     !&K/U221J
MS]4",       "11><_N)1%HO.?W$H      B5GGIW& SUGGIW&       $^G
MZ%O<0"?3]"WN ]@    "\%*Y2Q7@I7*!\     #W!TK>\\'N#I6]X$\
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MA<0EXDVIZ%Q"7B      "31\7=R$8DT?%W<@$D     (E7TB=Q+(E7TB=P&
M       $RD\QW>9C#2>8[O,P   !U  :;'X'](E=L7&=]=X,FU1*U>;8W#?*
M1>&>'VFP%0U:WQTK$?:X&4',ILUZ-_Q'NPGDJO9Q^PMP      A9-X(5J%DW
M@@     !YEZ)_<0%XD^7HG]Q 7B!\     #-2](G<83-2](G<!,     "-6?
MJDDC5GZH$8       $BB\Y_<2B+1><_N)0     !$K//3N,!GK//3N,
M  )]/T+>X@$^GZ%O<![     %X*5REBO!2N4#X     'N#I6]YX/<'2M[P)X
M     8:OHO>9C#5]%[P(8       ,U)TON)A#I.E]Q,
MYKRJ]':?KW_!"ST7T+/[ZD*SE5Z.T_7O^"%GHOH6?WU(%;>  CPW\J0ED1OY
M4A+                                         $2[_ )JK/J7?!261
M+O\ FJL^I=\% Y'\E#]'5;^]*CXH=G.,?)0_1U6_O2H^*'9P     "ODZ1W>
M>3U)TCN\\@     'J/SV]Y8%?'Y[>\L      #'4=$ON(*\2=4=$ON(*\0
M    9*?IFF,R4_3- G     !@J^C3O,Y@J^C3O B+Q 7B      "71^8[O,Y
M@H_,=WF<      Q5/0N(2\2;4]"XA+Q      !)H^+NY",2:/B[N0"2
M$2KZ1.XED2KZ1.X#        "92>8[O,QAI/,=WF8     Z@-/8RE^D"M>V[
MRR5G@Z(MN5J[$;<-\M%X=B^\OBE:DR:YK5=:(XZ=8$Q<4;Y3UPGD9_O@70
M    0LF\$*U"R;P0      \R]$_N("\2?+T3^X@+Q ^     !FI>D3N,)FI>
MD3N F     !&K/U221JS]4",       "11><_N)1%HO.?W$H      B5GGIW
M& SUGGIW&       $^GZ%O<0"?3]"WN ]@    "\%*Y2Q7@I7*!\     #W!
MTK>\\'N#I6]X$\     ,-7T7O,QAJ^B]X$,       &:DZ7W$PATG2^XF
M              <UY5>CM/U[_@A9Z+Z%G]]2%9RJ]':?KW_!"ST7T+/[ZD"M
MO  1X;^5(2R(W\J0E@                                        ")
M=_S56?4N^"DLB7?\U5GU+O@H'(_DH?HZK?WI4?%#LYQCY*'Z.JW]Z5'Q0[.
M     5\G2.[SR>I.D=WGD      ]1^>WO+ KX_/;WE@      8ZCHE]Q!7B3
MJCHE]Q!7B      #)3],TQF2GZ9H$X     ,%7T:=YG,%7T:=X$1>("\0
M   2Z/S'=YG,%'YCN\S@     &*IZ%Q"7B3:GH7$)>(      )-'Q=W(1B31
M\7=R 20     B5?2)W$LB5?2)W 8        3*3S'=YF,-)YCN\S      &H
M,;3^/]:YMWDDJ?!T1;<J+LQIAOE]GM]Y>E,U9/'FM1;*V.+F$Q<\+F1<)Y&>
M'L]Q<@     !"R;P0K4+)O!      #S+T3^X@+Q)\O1/[B O$#X     &:EZ
M1.XPF:EZ1.X"8     $:L_5))&K/U0(P       )%%YS^XE$6B\Y_<2@
M ")6>>G<8#/6>>G<8       3Z?H6]Q )]/T+>X#V     +P4KE+%>"E<H'P
M     /<'2M[SP>X.E;W@3P     PU?1>\S&&KZ+W@0P       9J3I?<3"'2
M=+[B8                !S7E5Z.T_7O^"%GHOH6?WU(5G*KT=I^O?\ !"ST
M7T+/[ZD"MO  1X;^5(2R(W\J0E@
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MI>D3N,)FI>D3N F     !&K/U221JS]4",       "11><_N)1%HO.?W$H
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M\'N#I6]X$\     ,-7T7O,QAJ^B]X$,       &:DZ7W$PATG2^XF
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M_>E1\4.SG%_DGY7DXK<IA?G.?*9SC@=H      *^3I'=YY/4G2.[SR
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MH_9)/\QC_ ?/FJ/V23_,8_P VJ7HG]Q 7B4;[WJ=6*BZ23&/6,?X$9;OJ/\
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M8S)3],T"<     &"KZ-.\SF"KZ-.\"(O$!>(      )='YCN\SF"C\QW>9P
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MLG,>5G2\\\_SW01NE791E1&Q,N3'!Z)V8W*=."+C@=5MQG;R]9TE.KQ3BO\
M_)?EU%1>!*M=!4W2NBI*&)TL\BX1&IE$]J]B>T_0%=IBR5TRRU5LIG2+Q<UN
MSGOP3K=;Z*VQ+%;Z6&G8O%(VXSWKUFLYOP^<Q_\ C=^?WWCC^/*)I:SLL-AI
M;<QR/?&BND>G!SU7*J6N0#&9V^JQTKCK%*^([)%%YS^XE$6B\Y_<2B.P
M!$J_/3N,&3/6>>G<8 &1D "CO'_6G3'_ &ZK_@EXO$@UE!X3=+96<YL^!+*N
MSC.WMLV?=@G "?3]"WN(!/I^A;W >P    !>"E<I8KP4KE ^     ![@Z5O>
M>#W!TK>\">     &&KZ+WF8PU?1>\"&       #-2=+[B80Z3I?<3
M          .:\JO1VGZ]_P $+/1?0L_OJ0K.57H[3]>_X(6>B^A9_?4@5MX
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M4#D?R4/T=5O[TJ/BAV<XQ\E#]'5;^]*CXH=G      *^3I'=YY/4G2.[SR
M    >H_/;WE@5\?GM[RP      ,=1T2^X@KQ)U1T2^X@KQ      !DI^F:8S
M)3],T"<     &"KZ-.\SF"KZ-.\"(O$!>(      )='YCN\SF"C\QW>9P
M  #%4]"XA+Q)M3T+B$O$      $FCXN[D(Q)H^+NY )(     1*OI$[B61*O
MI$[@,        )E)YCN\S&&D\QW>9@     #6'I6^.,RNNE.ZA6'R:!')SB.
MQY^.."U-=D=;_I'>U*"I^<_!<^%[7^'L[/#';@V(      (63>"%:A9-X(
M    >9>B?W$!>)/EZ)_<0%X@?      S4O2)W&$S4O2)W 3      C5GZI)(
MU9^J!&       !(HO.?W$HBT7G/[B4      1*SST[C 9ZSST[C       "?
M3]"WN(!/I^A;W >P    !>"E<I8KP4KE ^     ![@Z5O>>#W!TK>\">
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M[B41:+SG]Q*      (E9YZ=Q@,]9YZ=Q@      !/I^A;W$ GT_0M[@/8
M  O!2N4L5X*5R@?      ]P=*WO/![@Z5O>!/     ##5]%[S,8:OHO>!#
M     !FI.E]Q,(=)TON)@                '->57H[3]>_X(6>B^A9_?4A
M6<JO1VGZ]_P0L]%]"S^^I K;P $>&_E2$LB-_*D)8
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MG/[B41:+SG]Q*      (E9YZ=Q@,]9YZ=Q@      !/I^A;W$ GT_0M[@/8
M    O!2N4L5X*5R@?      ]P=*WO/![@Z5O>!/     ##5]%[S,8:OHO>!#
M       !FI.E]Q,(=)TON)@                '->57H[3]>_X(6>B^A9_?
M4A6<JO1VGZ]_P0L]%]"S^^I K;P $>&_E2$LB-_*D)8
M                        B7?\U5GU+O@I+(EW_-59]2[X*!R/Y*'Z.JW]
MZ5'Q0[.<8^2A^CJM_>E1\4.S@     %?)TCN\\GJ3I'=YY      /4?GM[RP
M*^/SV]Y8      &.HZ)?<05XDZHZ)?<05X@      R4_3-,9DI^F:!.
M#!5]&G>9S!5]&G>!$7B O$      $NC\QW>9S!1^8[O,X     !BJ>A<0EXD
MVIZ%Q"7B      "31\7=R$8DT?%W<@$D     (E7TB=Q+(E7TB=P&
M $RD\QW>9C#2>8[O,P     !K,WSEXX.S)3?-7,^9NYW;QQ[<9+0UR1UI^DF
M1$;6?//@OG;N9V-G[<X-C      "%DW@A6H63>"      'F7HG]Q 7B3Y>B?
MW$!>('P     ,U+TB=QA,U+TB=P$P     (U9^J22-6?J@1@       2*+SG
M]Q*(M%YS^XE      $2L\].XP&>L\].XP       GT_0M[B 3Z?H6]P'L
M  7@I7*6*\%*Y0/@     >X.E;WG@]P=*WO G@    !AJ^B]YF,-7T7O A@
M      S4G2^XF$.DZ7W$P                #FO*KT=I^O?\$+/1?0L_OJ0
MK.57H[3]>_X(6>B^A9_?4@5MX "/#?RI"61&_E2$L
M  145,HN4                    1+O^:JSZEWP4ED2[_FJL^I=\% Y'\E#
M]'5;^]*CXH=G.,?)0_1U6_O2H^*'9P     "ODZ1W>>3U)TCN\\@     'J/
MSV]Y8%?'Y[>\L      #'4=$ON(*\2=4=$ON(*\0      9*?IFF,R4_3- G
M     !@J^C3O,Y@J^C3O B+Q 7B      "71^8[O,Y@H_,=WF<      Q5/0
MN(2\2;4]"XA+Q      !)H^+NY",2:/B[N0"2     $2KZ1.XED2KZ1.X#
M      "92>8[O,QAI/,=WF8      UN9+MXVN58Z;YFYGS]W.[>/MQDLC7*E
M+=]);%66K^=/!5V68_P=C"[^_&38P      A9-X(5J%DW@@     !YEZ)_<0
M%XD^7HG]Q 7B!\     #-2](G<83-2](G<!,     "-6?JDDC5GZH$8
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M3JCHE]Q!7B      #)3],TQF2GZ9H$X     ,%7T:=YG,%7T:=X$1>("\0
M    2Z/S'=YG,%'YCN\S@     &*IZ%Q"7B3:GH7$+K  C4U;#4U593Q*Y9:
M1Z1RHJ81%5J.3';N4D@   )-'Q=W(1B31\7=R 20     B5?2)W$LB5?2)W
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M_<>*>YT]1=*RWQJ[PFE:Q\B*W"8?G&%Z^"@30    $2L\].XP&>L\].XP
M    GT_0M[B 3Z?H6]P'L     7@I7*6*\%*Y0/@     >X.E;WG@]P=*WO
MG@    !AJ^B]YF,-7T7O A@       S4G2^XF$.DZ7W$P
M #FO*KT=I^O?\$+/1?0L_OJ0K.57H[3]>_X(6>B^A9_?4@5MX "/#?RI"61&
M_E2$L   /CD1S51>"[CBE!8M=\G%TNU'HRTT-^TY6U#JNFBFJ$@?2/?YS5SQ
M;E/_ *'; !S;DFT7=;"M\OFI9:>?4MZFYZ5&95D#43R8T=QPGX%AR5RZUDM=
MS77T--'5I5/2D2)4RL75G"XQV=?:;R .2U]ZY5[G%);Z+2ULM4DBK&MQEKDD
M;&U5QMM8W?E$WFW<F.C*?0NEHK3!,ZIF<]T]34N3"S2N\YRFV #G/+EIBZZJ
MT[:J2R0-GF@N<%3(CGHS#&JJJN\N.5JRUNHN3N^6JU1I+6U4"LB8KD:BKGM7
M<;< -?M5MJJ?0=';96(E9';F4[F;2*B/2-&JF>'$X[5QU>@^02#2UYCJHM07
M=\MOHX*!Z.D?)(Y53"HN,85,^Q3]!&H<I6A:37%LI(IJJ>AN%#,E315L"^5!
M*G7CK3V <PTY1\I^EK)2QTFC=([5#3HSG&.V)'M:G6J+Q7'VF>HK;GRWZ3TF
MZDH/!+.^X*Z]-YUJ\VL*[F-SO<BKOX=A=SZ#Y1;G32T%XY1FI;GMV'+26YD<
MSV\%17=64[#H6CM,VS2&GZ:S62#F:*!%PBKESE7>KG+UJJ@9M0T3ZG2]SH:-
MB+)+1RP1,W(F58K6I[.HY;IGDG=<.0JVZ1U1"VDNE-SDD4T3D<ZGFYQRL>CD
M]BIGV*=F 'YLUM7:LNNC[+R?7RDDDUK45#9HT9(U\-53Q*J[<RYW-7"Y3K5,
MEU77_E'T19ZJ\56C-*PVZD8CZKP*16/6-.*IA?Q-]Y0N3YVI+Q;;_9KO/9=2
M6YCHZ>LC8DC58N<L>Q=RHN5^U>)KM7R:ZPU+ E%KG73JNT*Y.>H[?1MITJ&Y
M15:]R;\;@.E:6O,.H=.VV[TK59#6P,G:U>+<IG'NX&@\I&@+K4ZLH-;:(JX*
M;4=%%S,E/.W_  JR+?Y+E3>BX7&>[A@Z5;J*GMU!3T5%$V&EIXVQ11MX-:B8
M1/L) 'YXUWRD\HMKBH;5>[%;-.-NSUI4O"U#I8J=5W;7D^:N-Z9.B:.TE/H/
MDSEH=+NBNMY<Q\Z5$KD:E3.[?M*O9PQOZC;=4Z=M>J;+46J^4C*JBG3#F.W*
MB]3FKQ14[4&E;#2:9LE/:;<^H=1TZ*D23RK(YK?1VEWX3J X3H*R<J.DG5M5
MXIVFYWFND5]3<JRO1TTB=3$5%\EJ=B'7^3^X:NKXZY=:V:AM;V.9X,E+/SJ2
M(N=K.]<8W?:;: .(47)?<F<O]5J*:)CM-*]U?'F1,K5+&C?-SG<N5R;7RZZ1
MK]7:(=!8FM6]4E1'4TJJY&KE%PY$<NY,M53H@ U3DJTY)I30%EM%4C$K(8$6
MH5O7*[RG;^O>N,^PVL  #3-1VC6M5=YIK%J:AH+<Y&I'3RT"2N:N-ZJ[:WY7
M>5OS!RD?MI:_\J3_ ,P'12)=_P U5GU+O@IHOS!RD?MI:_\ *D_\Q@K[%RB,
MH:ATVLK8^-(W*YOS4F],+N\X"D^2A^CJM_>E1\4.SG%_DG9^CBLVEROSG/E4
M]QV@      KY.D=WGD]2=([O/(     !ZC\]O>6!7Q^>WO+       QU'1+[
MB"O$G5'1+[B"O$      &2GZ9IC,E/TS0)P     8*OHT[S.8*OHT[P(B\0%
MX@      ET?F.[S.8*/S'=YG      ,53T+B&GG>\F5/0N(:>=[P*&P_]8-3
M_P#>XO\ @M+TU."&XS7S4:6FM@I'I61[;I8.=1R<RW"(F4P2O -3^OJ#_+_]
M8&Q UWP#4_KZ@_R__6/ -3^OJ#_+_P#6!L1)H^+NY#5/ =3^OJ#_ "__ %F:
MGM^J55VS?Z!/_P!'_P"L#;@:O\VZK_:"@_R__6/FW5?[04'^7_ZP-H!J_P V
MZK_:"@_R_P#UCYMU7^T%!_E_^L#:")5](G<47S;JO]H*#_+_ /68)[?JA'^5
M?J!5QZO_ -8%Z#7? -3^OJ#_ "__ %CP#4_KZ@_R_P#U@;$#7? -3^OJ#_+_
M /6/ -3^OJ#_ "__ %@;$#7? -3^OJ#_ "__ %CP'4_KZ@_R_P#U@;=2>8[O
M,QJ=/;M5*U=F_P! F_U?_K,GS;JO]H*#_+_]8&T U?YMU7^T%!_E_P#K'S;J
MO]H*#_+_ /6!M -7^;=5_M!0?Y?_ *Q\VZK_ &@H/\O_ -8'JI^</&]N*"F^
M;>97-7A.=1V/-SG./<6AH,]'<DUTR-VI(OGKP=<1^ .YI8\+OQMXR7G@.I_7
MU!_E_P#K V(&N^ :G]?4'^7_ .L> :G]?4'^7_ZP-B!KO@&I_7U!_E_^L> :
MG]?4'^7_ .L#8D+)O!#2_ -3^OJ#_+_]9,2VZKPG_P!H*#_+_P#6!M -7^;=
M5_M!0?Y?_K'S;JO]H*#_ "__ %@4W+'?Y+79(Z"DD6.HKE5%>U<*V-/.QW[D
M^TX9U8.@\KMONU/4VV>[5L-8BM?&Q\4'-(W?G"IE<Y.?'JQ1JKX/ZYDO?K+5
MMXC41_38=AY'[Y+6VZHME5(Z26EPZ)SERO-KNV?<OQ./&[\E='<JBY5LMJJH
MJ5T<2-?)+#SJ+E>&,IOW#)&ZN?HF2U.LK%??M/\ 1VL&N^ :G]?4'^7_ .L>
M :G]?4'^7_ZSROOFQ UWP#4_KZ@_R_\ UCP#4_KZ@_R__6!L1FI>D3N-7\ U
M/Z^H/\O_ -9D@M^J5?NOU F[U?\ ZP-P!J_S;JO]H*#_ "__ %CYMU7^T%!_
ME_\ K V@&K_-NJ_V@H/\O_UCYMU7^T%!_E_^L#:"-6?JE!\VZK_:"@_R_P#U
MF&HM^J6XVK_0+_\ H_\ U@7@-=\ U/Z^H/\ +_\ 6/ -3^OJ#_+_ /6!L0-=
M\ U/Z^H/\O\ ]8\ U/Z^H/\ +_\ 6!L0-=\ U/Z^H/\ +_\ 6/ -3^OJ#_+_
M /6!M5%YS^XH;-^D#4G_ '>D^#S#3V_5+E=LW^@3_P#1_P#K,&D(:Z'6NI&7
M.JBJI^8I?\2.'FTQA_5E0-U     1*SST[C 9ZSST[C       "?3]"WN(!/
MI^A;W >P    !>"E<I8KP4KE ^     ![@Z5O>>#W!TK>\">     &&KZ+WF
M8PU?1>\"&       #-2=+[B80Z3I?<3                 .:\JO1VGZ]_P
M0L]%]"S^^I"LY5>CM/U[_@A9Z+Z%G]]2!6W@ (\-_*D)9$;^5(2P
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MIY[Y6^?[/@ ,WZP  !FI>D3N,)FI>D3N F     !&K/U221JS]4",
M"11><_N*"R_I U)_W>D^#R_H^+^XD-C8U[GM8U'NPCG(F]43AE0/0    ")6
M>>G<8#/6>>G<8       3Z?H6]Q )]/T+>X#V     +P4KE+%>"E<H'P
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MYRHC45?;AOVG:D-4T;H>@TQ=+W=(YYZRZ7B?GZFJJ-G:XKAC<(B(U,\#:P
M $2[_FJL^I=\%)9$N_YJK/J7?!0.1_)0_1U6_O2H^*'9SC'R4/T=5O[TJ/BA
MV<      KY.D=WGD]2=([O/(     !ZC\]O>6!7Q^>WO+       QU'1+[B"
MO$G5'1+[B"O$      &2GZ9IC,E/TS0)P     8*OHT[S.8*OHT[P(B\0%X@
M      ET?F.[S.8*/S'=YG      ,53T+B$O$FU/0N(2\0      2:/B[N0C
M$FCXN[D D@    !$J^D3N)9$J^D3N P        F4GF.[S,8:3S'=YF
M -6J6U/CJUR6N!:3F%S7X_Q$7"^1GL+<HJQM(G*# Y;K*VM\&5&V_978>W"^
M6J\.W["]      "%DW@A6H63>"      'F7HG]Q 7B3Y>B?W$!>('P     ,
MU+TB=QA,U+TB=P$P     (U9^J22-6?J@1@       2*+SG]Q*(M%YS^XE
M    $2L\].XP&>L\].XP       GT_0M[B 3Z?H6]P'L     7@I7*6*\%*Y
M0/@     >X.E;WG@]P=*WO G@    !AJ^B]YF,-7T7O A@       S4G2^XF
M$.DZ7W$P                #FO*KT=I^O?\$+/1?0L_OJ0K.57H[3]>_P""
M%GHOH6?WU(%;>  CPW\J0ED1OY4A+
M          $2[_FJL^I=\%)9$N_YJK/J7?!0.1_)0_1U6_O2H^*'9SC'R4/T
M=5O[TJ/BAV<      KY.D=WGD]2=([O/(     !ZC\]O>6!7Q^>WO+
M QU'1+[B"O$G5'1+[B"O$      &2GZ9IC,E/TS0)P     8*OHT[S.8*OHT
M[P(B\0%X@      ET?F.[S.8*/S'=YG      ,53T+B$O$FU/0N(2\0
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M<I8KP4KE ^     ![@Z5O>>#W!TK>\">     &&KZ+WF8PU?1>\"&
M#-2=+[B80Z3I?<3                 .:\JO1VGZ]_P0L]%]"S^^I"LY5>C
MM/U[_@A9Z+Z%G]]2!6W@ (\-_*D)9$;^5(2P
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MKE+%>"E<H'P     /<'2M[SP>X.E;W@3P     PU?1>\S&&KZ+W@0P
M 9J3I?<3"'2=+[B8                !S7E5Z.T_7O^"%GHOH6?WU(5G*KT
M=I^O?\$+/1?0L_OJ0*V\ !'AOY4A+(C?RI"6
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MU_S+/Q'CCIOU]:_YEGX@7IAJ^B]Y4>..F_7UK_F6?B>)=6Z;D9L_/]K3?_\
MB6?B!.!2TVL-+5//<UJ*V.YJ18G_ ..U,.3&4WK[4,WC/IO]H+9_,L_$"T!5
M^,^F_P!H+9_,L_$>,^F_V@MG\RS\0+0%7XSZ;_:"V?S+/Q'C/IO]H+9_,L_$
M"ZI.E]Q,-8\;M,TSF.=?[:NT]L;4;.U55SE1K4PB]:JALZ;TW
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MJO\ =%%_OR@5WT <G_JEW\5P^@#D_P#5+OXKCJP Y3] ')_ZI=_%</H Y/\
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MR)[-Z(I^ACG7*/\ I"Y-/WC4_P#AG@5OT <G_JEW\5Q]^@#D_P#5+OXKCJP
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M4<J6H=/2V"2:VTS:=T4S97(E.KH=IR+V[2_ WGZ .3_U2[^*XMM(?I9Y0?\
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MH<N%X+*[>=5 ' ^37D9T5?\ 1-LN5RM:OJYDDYQZ2.3:Q*]J?T1#9OH Y/\
MU2[^*XV#D4_1G9O_ (W_ !GF[ <I^@#D_P#5+OXKA] ')_ZI=_%<=6 '*?H
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M@N5SMBR5<KYVO<DBIE&SR,;_ $:B'?I>B?\ ]E31N0W]&5J^MJO_ !,H%)]
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M]%]"S^^I"LY5>CM/U[_@A9Z+Z%G]]2!6W@ (\-_*D)9$;^5(2P
M                              !$N_YJK/J7?!268:R'PBDFAVMGG&*S
M.,XR@''ODH?HZK?WI4?%#LYI/))H=V@=-SVI]>E<LE5)4\XD7-XVL;L97L-V
M      -)9^FN7_V>9_XEQNQ'\!I?G!:_F(_#5BYA9MGR^;SM;.>S._!(
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M?WU(5G*KT=I^O?\ !"ST7T+/[ZD"MO  1X;^5(2R(W\J0E@
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M4YB4^UO8C6INPB8-UY M45]_TK5T-[FYZZV2K?;IY<8=(C-S7.[55.*@=-
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M^@'>44'#])4<O)CRNTVDJ.NJJG3E^I75%-%5S+(ZFECXHUR]2]G<=P
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MJ]':?KW_  0L]%]"S^^I K;P $>&_E2$LB-_*D)8
M
M
M
M                                                '->57H[3]>_X
M(6>B^A9_?4A6<JO1VGZ]_P $+/1?0L_OJ0*V\ !'AOY4A+(C?RI"6
M
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MQSESLHOL-M/-:(B9T]U)F:Q-O( #ET
M                                               .:\JO1VGZ]_P0
ML]%]"S^^I"LY5>CM/U[_ ((6>B^A9_?4@5MX "/#?RI"61&_E2$L
M
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MZHM%?IB"OJJ9JI+E&K(J/:[>U5:G!4/TF#OU[<MSX^&7Z6G'4>?EK>M7.KM
M7=U/'(YT]"]S&(U=I<MRB8XY]AH?R;Z*KHK->6UE+/3N=.Q6I+&K%5-GJR=@
M!G%]5FORVG'N\7^' >7ZBKY=:VBIHJ"IJ60T[7*L43G)E)%7"JB;B!K/4VK.
M4"AAL\.E*BG;SJ2KLL>Y55,XRYR(C4WGZ-!I7-J([>&5NGY3,\M;<#Y3],U]
MKY+=*6F.":KJ:5Z\ZD$:OV55JJO#J15P6VK]$27_ )*K'44E,K+S;J2-Z-V,
M/>Q&^4SMSUI[4]IV8$]:>R_IZSO?B8TT+D?U)7WO3W@U[IJF"Y4>(W.FC<WG
MF8\E^]./4OM[S?0#*TQ,[AM2)K6(F=@ (Z
M                                                   '->57H[3]
M>_X(6>B^A9_?4A6<JO1VGZ]_P0L]%]"S^^I K;P $>&_E2$LB-_*D)8
M
M
M
M
M   '->57H[3]>_X(6>B^A9_?4A6<JO1VGZ]_P0L]%]"S^^I K;P $>&_E2$L
MB-_*D)8
M
M
M
M               '->57H[3]>_X(6>B^A9_?4A6<JO1VGZ]_P0L]%]"S^^I
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MMJ+X2FG%I]K]57H]N[/MP1:%UCKZ2CH:^YZA6JVHV.H)%=Y#T5.K9QA%Z\\
M.K( W<U$            <UY5>CM/U[_@A9Z+Z%G]]2%9RJ]':?KW_!"ST7T+
M/[ZD"MO  1X;^5(2R(W\J0E@     'QZ(K51R(K53"HO#!4Z>LM-9FU"4$TS
MJ:=_.-A>]',BSG*,W;DW\"@K-6U-;27":VV:>JM4.W$^K;*U%543>K6+O<B=
MYZTM7UE%H.R/H+=)<)GLV=A)$C1J97>KEZ@-T!I?CPZ";F+C:WTL\=3'!4)S
MR.;$V1%V),HF]%QCJP6M]U+%:;K343X'2[<$M3,]KNAC8BKM8QORJ80"_!K%
MEU#=+E)22+871V^I1'-J$JF/5K53**YN-V>\LKI>&VZZVRDEA_PJY[XTFVL(
MQZ)E$QUY M0:[;M54];JFMLS(E:M.W*3J[=(J8VFHGLRG6>:34E576-;C06B
M6H5\[HHHDE1-MJ*J;:N5-R;O:!L@--?KCP2*Y-NULEI:NB8R3F62MD21KW;+
M51V[K5,EM9;I=JNK6*XV-:*)6;23-J6RMSZ*X1-X%X>8Y&29V'M=C<N%S@UK
ME'K*NCTK6NHH7O5[%8^5LB,6)J[L]J\<;C7:2GI[9%8'.L<M%5RU"M9'%5YY
MQ6QKASU1,+G?N Z2#1=#Z@OERI*R6IMBSL26962^$-3#D7=$B8ZN&T8]-ZMN
M#;+55]YH52D8Z5R3I,U5<[;5&Q-8B9SGR47V ;\#5J#5%4MRI*6\V=]M;692
M"19VR(YR)G9<B)Y*X/57J:K?=:JCLMGDN3*3#:B5)VQHUR[]E,IY2X V9KVO
MSLN1<+A<'TTWDQG6HM%SG1CV\Y7S/1C]SDRN<+[3QIB_7NOOERAJ+6O@S*GF
MG.6H;_T9$:F[&/*[?>!NH-3GU763U-6ECLDMRI:1ZQRSMG;'EZ><UB*GE8+Z
MRW."[VN"NIE5(I6YP[BU>"HOM1=P%716.M??FW2\5K*AU.U[*6&./8;&CN+E
MW[W8W%NVW4[;G)<$C_Z6^-(5>J_J(JKA.S>IK-3K*IV:JJM]EFK+53/5KZIL
MS6J[9\Y6L5,JB=I-NVJ4@GMM-:J1;A55\2S0MYU(F[")G*N7X ;(56H+'2WR
MFCBJG2Q/BD26*:%VS)&Y.M%-4NNIM0LO%E@;8Y*=\LDN:=:IBI4;+>".QN1,
MYSUEO65F-06-]72315CJ:>3FVSY8Q4:BJU41,.]B@;/&BM8UKG*Y41$5R]?M
M/1HD6O:E]JCNZV"H;:-R2U'/MVF[\*J,QER(O7N)T&KJE*^WQU]EFI**X2)'
M35#IFN557>W:8GFY3V@;:#6;WJ&Z6Z6K=#I^6HHJ9-IT_A+6*Y,956MPJK@A
M:KU#7PPV&6S4KI8:Z>)VWSC6;:+O2+"\-I.OJ W,&J3:HKTFBHZ6R.GNG-\[
M44Z5+4;3IG"(K\855XX1"VTW>67JA?-S#Z:>*1T,T#URZ-Z<47MZMX%J?$>U
MSG-1R*YO%.PTNGO][DUE7T;+4Z2FA;$W86H:WFVJJ_XG#?E.KV$*FN-=1:YU
M/';;7)<9I/!W*B3)&V-$8O%5ZUSN1/:!T(&G1ZV=40014EJFEN[Y7Q/H5E:U
M8E9YRN=P1.&_&_);Z<OKKK)5T]51NH:^E<B2P.>C]RIE'(J<44"Z!KM^U'-;
MKS!;*.URUU5/"LL>Q(C$W+A4<J\$]ON*ZFUA<JN:HHZ33DS[G2NQ4PNJ&M9&
MGZJH_&_/4F -S!JC-9P2V&EKJ:DFEJZJ58(J)'(CUD1<*BKP1$QE5)=CU!-6
MW*:W7.W.M]:R-)F,65)&R,SA5:Y,<%Z@-@!J5XU3<;4L\]3I^7YMADV75'A+
M=K9SC;1F,X]Y[J]4U7SU66NU6>6NJ*=K'[?/-C8K7-1<JJIN7?C'6!M1KM58
MZNXWR&HN=9');Z27GJ:FCCV5V\;E>N=^-^"7IB]MOE'-(M.^FJ*>5T$\#U15
MC>G%,IQ[R'KRX34=E2"B54K:Z5M)"K5WHKN+D[DRH&Q@TW3$4EUL-99;I55*
M55!4+ ^5DBLD>U%RQ^>.%3X%39]/LJ]47Z@EN5UYBBYCFL5;\^4U57/V =(!
MRZC6T25%Z2]7^KI*B&NECC1*US%2-,85&Y[^HQMJ;A5Z?T\VZUU5''47%8^?
MYQ8WR08795RIV@=5!H-K7YNUG0T5FNE3<:&>&1U5')/S[8<>:[/ZN5W&VW^[
MT]CM4U=5;2L9A$8WSGN7<C4]JJ!8.<UN-I43*X3/6I].=W^\7&KJ]/T]SLTM
MOV[C#)&_GFR-5$SEKL8PN_@;99;VESN%WI4IUB^;YDAVE?GG,IG.,;@+@&H5
M.MHZ>QNN<E#(L;:]:)6-?EVY53:3=OX</ZF.YW6IJ*.WRWBT5%#FY0,A8VJ3
M:7.<.=A."=;0-S!IS=7U]347&&U:?FJ_ )WPS/6H:Q%V57&SE-ZJB9QU;C/)
MK%DEHM-5;J&2JJ;DYS(:97HQ45N=K:=U(F -J!K%AU'7W"^5-MK+/X&^F:CI
M7K4H_&?-PF$RB]O43-1W[YIDI*:FI'UM?5N5(8&.1N43BYSEX(G:!=@HM/7]
MURK*J@K:-U#<:9$>^%7I(BL7@YKDXH5T^J[A121RW.P2TMO?,D*SK4-<YF5P
MCE8B<,^T#;CYMMV]C:3:QG'7@U>IU15S7"KIK%9I+DVC=S<\O/MB:C^MK<HN
MTJ=93W6X5E+RA4DU-;9:JKEM>RE,V1&[*[>5VG+N1$QQ Z""CTW?I+I/6TM;
M0OH*^D<U)(72(_+7)E'(J<4(EPU-5MO-5;;/:'5\U(UKIU=4-B1NTF41,HN=
MP&S@TG4M_O5/+86TMK?&^ID19(EG8BN=AW^$J_UR7=BO<MQN%=15-"M)44C(
MG/3G4?O>BKC*)U8 NSXY[6XVG(F5PF5XJ:T_5T$-)>IZBG>U+=4K3-:UVTZ=
MV[&$ZE55X&NZCNMRK:W3D5SLTMNVKC%)&Y9FR([CEJXQA=_#O Z0"@M&IH:V
MRUU?50K2.H9)(ZB)S]I6*SV[N*%A8:]]TL])724[J9:AB2)$YVTJ(O#?[4PO
MO G@U%=65]15W"GM5@FK'4,[X97+.UC5QPV55-ZKV=6[?O,SM94LECI*ZBIY
M:FIJY.9AHT5&O61/.:JKPQUJ!M -0=K&:E@N272TOI*RDI_"6P\\CVS,SA5:
MY$ZEX[B%?;_-<-,7*IK+-5P6KFFOBF2I2.27RDQN1,M[=_5W@;X#5ZK4=4RN
M6WV6T2W&:")CIU6=(VQ;291JN5%R[!];K*C^8*BX2PRQU$$G@\E&O2)-G"1^
MW/:!LSGM:J;3D3*X3*\5/IS?4%UN5;<]-PW.SRVY5KV2,=SS9&N3"Y1<8PN_
M@='>JM8Y417*B<$ZP/H-2\:J^GK:*.ZV*6CI:N=*>.;PAKU:YWF[343=GO/B
MZLN%14W"&UZ?FJ_ IWPRO6H:QJ[*_JY3>J]G4!MQ\5[4<C5<FTO!.M35Y=8T
M[K);ZVAI9:JIN#MBGI$<C7.<F=K*\$1,+E2HCN%96\H5G9<;=);YXZ>;R%E2
M1KT7&%1R<> '0#S*Q)(W,=YKDPN%QN*O5-Y2P62>XN@6=L2M16([9SER)Q]Y
M6>-4\%MJ[C<K1/24;$:M/M2-=).KEPB;">:J[MWM P4FG;W04*6N@O$#+:B.
M:QSZ;,K&JJ[LYPJ[^.#8+);:>QV>GH*=SN8IV81SUWKORJK[U4I*75DT5;#!
M?K6^V-J&.DAD69)&NV4VE1V$\E<;RAU/JBMN6D:^H98ZB.U3QN;%5+*U7*B[
MD<K.*(O;D#I**BIE-Z UVU7I&7*V658%57VUE5SVUN3'D[./^9D=J2&*Y7FF
MJ8EBAMD+)GS*[.TBHJX1/=[P)-BM;[;+<WOD1_A=6^H1$3&RBHF[^A:FCUFJ
M[W+9:BMI=.314KH'R15$E2Q'-3954<K,9]N#Y/=*RIY/:VHO=OFB8RE8J.CJ
MDVZA%1,N143R.[V@;R#4O&2:-::WV.URW&HCIHY)FK.C$A:K4V4<Y4WN7_YG
MJ764<6FZZY244C*FAD2*HHWO1'L<KD3CUIA<HO6!M8-3CU76QUM$VY6*>BH:
MR5(HJET[7*BN\W::GFY[]QL=S<UMMJW/1RM2%ZJC7854PO!>H"2#G]DU4M):
M[)0VVTU57)54JRPL=4(KDPY45'.5.&,KGN3!L>GK]+<:RKH;A0.M]?3(USH5
MD21',=P<CD0"](USH:>Y4$]'6,1\$S58Y/P]I6:JO_S!#1R>"252U-0VG1D;
MD1V51<8SQWIC'M*A=87**O2WU.FZAEQE;MT\3*AKFR-ZU5^,-Q[P-MHJ=*6D
MAITDDD2)B,1\BY<J(F,JO6IF-7H]7,2@NTUXHI+?/;5;ST*O23*.3R5:J8SG
M@>*/5=2E=0PW>SRV^&N=L4\JS))ER[T:]$3R54#:P:C<]65]KVZBNL$T5M9*
MD;I_"&*Y$5<([83J]YDJM45JWBNMMLLDM;44BMVG<^V-FRYN4555-R^P"YN%
MGIJ^Y4%;4K(Y]$YSXF;7D;2_K*G6J=786)4Z:O3+Y;W5"0/IY8Y'0S0O7*QO
M:N%3/60->5D\-JAH:![F5MQG;31N:N]B+YS_ '-S]H&R@TW34;[[IR6V7.IJ
M655!4+3RR12JR1VPODNSQPJ*A4Z>L#*W4&H*6>Y718J&:)L2)5OX*W*YW[P-
MMU'99;E+0U5'5>#5U$]SXG.8CV+M)A4<G_/J(M'8:ZHN])<[[7QSS4:.YB&"
M+88U7)A7*JJJJN#4J-]HEDO#[SJ"KHZJ.NF:Q&UKF*UB+NPW/?U$Z:MNB\D=
M755TT[:SFU5DRKLR*S;39<N.M4 Z(@.8UC8[0VSU%DO=947":>)KZ1:I9DE:
MN-I%;OQW]1TX #7;[J*:AO%/:K=;UKJZ6%9]E9DB:UB+C.5SE<]1'J-45T*4
ME-\QRK=ZC:=X)S[<,8U<;;G\$1>K<!M0-=MNIO"J&Z.J*)]-<+<QSIZ1TB.7
MS5<U4<FY45.LJTUO5);HKK)8*EEF<C5?4K,W:8B[E=L8RK<]>?:!NP*2[W:O
M@=!\TVEUQCECYSG?"&Q,:G4F5SE5*A^NHV6VAJG6VH66HJ'TCJ=CD<^.5J+Y
M/MRN/M W(&O_ #O>&VIL[]//2M=+S:4R53%1&X\]7\$3W&O7O65P2QWAD5M?
M1W2B5C94YYKTC:_A(BX\KLQ[0.@A51$RO UM-13T&GY;A?+>^D<Q49'$V5)7
M3*O#&$3>J]1 GU-5R*^WW>T26^6KIY%IW\^V5KE1JJK5PB8=CJ W)CFO:CFJ
MBM7@J'TT?3-[2UZ?TE334[G0U[>9Y_:PD;_U45,;\]_4; M[1=4-LL4"R/2G
M6HFE1V$C3.&HJ=:J!;2/9&W:D<C6]JK@^HJ*B*BY1>LYMJ^2KK]<T-%-9W5M
M-' ]T=,ZI1C9=^%D]W8I;QZIJ4CG2R6"6KM=#_@K,V=K,HQ,*C&JF7(F/>!N
M8-5N.LZ:GHK154E+-617+:2)(UPY'(FYN.W.[V%W9:JMJZ+G;E0> 5&TJ<SS
MJ2[NI<H!2+I^YT%SKZFQW""..OEYZ:.HAV]AV,9:J*GV*6>G;*EHBJ725#JJ
MKJI5FGF<U&[3E[&IN1#7*'45[?JN\TRVMTM+3NB:K?"&MYAJHJ[?#RMI-^.K
M!.T[JVIO4<-5'9Y(+8K'+-5RSM1K%;G*(F,N3=QW?T VP&EMUM.E.RX3V6>*
MR/>C?#'2MVD:JX1ZQXSLJN.LO;U<J^D6G2UVIUPYU%57<^V)K$W8RJYX@6X.
M>7O6-QEM]"^@M\D%3\XMI*F)TS<H]%SS>>QR?K%[<]2U-KMUOGKK1*E55S<Q
MX-%*CW-5<XPN,+G"=G$#9@::NL+C%7);ZG3E0RY2MVZ>%M0US9&]:J_&&X]Y
M)I-81)0W26[TDE!4VY4;/ KTD5=I/)V53&<]0&T@U:@U15K<:.EO%FEMS*Q5
M;!*L[9$VL91KD1/)52!#K>NJ;6ZY4VG*A]!$CEFE6H:BMV57:5J8RY$1..[K
M W@&CW74MT=?;2VSVY:JCJ('SL3GVQ^$(K47K1=G9S[\FVU56^EM4M7)#_B1
M0K*Z+:ZT3*MS_3($L&DQZWK'6V*Z+IZI2T*C7/J.?;M-3K<C,95J+G?NSQ+*
MZ:G6.NAH;-1+<ZN2))U1LJ1L9&O!RN5%X]2 ;(#37ZZ9'10RRVNI2I6J6CFI
MFN1TD<FSE$3TL[L<.)CN%RGJ+AIQ;Q:JBBJ)*US8HV5:*B)LYVG83?W ;L#6
M[GJ2HCN\MLLUK?<JJ!B/G_QDB9$B\$5RHN57L,;-94OB]57*:FGBGII?!Y*-
M=\B2Y1$:G;G.Y0-G<]K5:CG(BN7"97BI].;:@NMQK;SI:.YVB2W*MP9)&[GD
MD1R=:+C&%WIN.DJN$543( &IMU3<(*JD2Z6"6CHZF9(&S+4M>YCG;F[343<B
M]YA;K"X53J]+9IZ:J90S20S/6H:Q,M5?-RGE+A,XZ@-R/*O:CT9M)M*F43K-
M9J-80_,ELKJ&DFJZBXKLT]*U4:Y53.UE>"(F-ZE+2UU96\I=L2X6]]!/'12H
ML:R)(UR*NYR.3C]@'0@:;K*]W6WZ@LE+;:-TT<[WJK4E:SGU1OF;T7&-RY)E
MWU//:_FN*>TS25E<QV*>*1'*QZ(GDYX*F_CU8 V8&K5.IZRF91TTEG<MZJMI
MS:)M0U4:QJ^>Y^,(GN,EOU-/5TMR9\U3-NM"K4?1)*U5=M<%:[@J>WV ;*#6
M[1J.JJ+PMLNEJ?05+H5FBQ.V5LB(N%3*(F%WE'9M57ITU\FJK2LE+2ROVE\)
M:G,(QF=C&/*SCC[0.@ T=VNJJ*AIKE4:?J8[3/LHDZ3-<Y,\%V..,[D7._WE
MA0:FK'7>DHKM99;<VL1RT\CIFR;2M3.RY$3R5P!M --GUK,L=56T%FFJ[13.
M5LE6V9K5=L^<YC%3+D3MR3;YJMEO99W4E')7I=$7F$B<C55=E%;Q[<IOZ@-E
M!SG4^M;K24%=2R6>2WW%L*2L?S[9&I&KD:KD7&]4543'M-TL%975E&K[G;_
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ML5554<B-5%5-^_>550R)*&2JTY;+S20K/$ROD<UZ32P;\I'M.5=W7C"[SJ
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M+[CS+J^Q17):"2XQI4(_FU39=LH[T5=C91?>!? )O
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MZB.=\3'31HJ,>K?*:B\<*90
M
M             %*Y+%:FU*U"6VC2?.=OF6YSV\.)8@        #Q/#'40OAG
M8V2)Z;+F.3**G8J'V*-D43(XVHUC$1K6M3"(B<$0]                  1
MZVBIJZ%8JRGBGBSG9D8CD_J2 !&H;?24$:LH:6"G:O%(HT;GOP20
M       88J:"*>::.*-LLV.<>C<*_"83*]9F
M  \31,GA?%,QKXWHK7-<F4<B\44]@#S#&R&)D<36LC8B-:UJ81$3J0]
M                                ,52[#-GK=N,JJB)E>!IW*!?TM-GD
MYMW_ $NI18H$SO3M=[L_;@#GU^JTN^LJN:)=J%CDAC7M1N$S]N3I>E85C@:J
M]AS/2%O5\C55%.Q6>#FH&I@*FX!D 1\<F4P4]5FDF61$S&[SD[/:7)AJ84DC
M5%X 8Z6H:]C?*RU?-=VDHU:=*BV2N= WG(57*QKN]Z=A96R[052*V"3:<GG1
MNW.0"W!C9.QW7A>Q3(BYX
M
M
M
M                  "JB<5P "KCB8G3M3<WRE]AJVI]8V^T-?')(E16)PIH
MERN?]I>"?$"WOUXIK7;Y:NL>K*>/CCSGKU(B=:G%ZVNJM2WEU74YV,[,4?5&
MS.Y$/EPK+CJ:O2HKE3#=T<;-S&)V(G_,W'3%@V-ESFJ%6FD[5S3&JJ)P-XA8
MC6<"-04J0QHF.!,"     #!44[96JBHAJUWL6VY9(LM<F]'-W*AN!Y<QKN*
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M?U97_?:2/%6/T$'BK'Z" 1_I&I_5E?\ ?:/I&I_5E?\ ?:2/%6/T$'BK'Z"
M1_I&I_5E?]]H^D:G]65_WVDCQ5C]!!XJQ^@@$?Z1J?U97_?:/I&I_5E?]]I(
M\58_00>*L?H(!'^D:G]65_WVCZ1J?U97_?:2/%6/T$'BK'Z" 1_I&I_5E?\
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M!'^D:G]65_WVCZ1J?U97_?:2/%6/T$'BK'Z" 1_I&I_5E?\ ?:/I&I_5E?\
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M?U97_?:2/%6/T$'BK'Z" 1_I&I_5E?\ ?:/I&I_5E?\ ?:2/%6/T$'BK'Z"
M1_I&I_5E?]]H^D:G]65_WVDCQ5C]!!XJQ^@@$?Z1J?U97_?:/I&I_5E?]]I(
M\58_00>*L?H(!'^D:G]65_WVCZ1J?U97_?:2/%6/T$'BK'Z" 1_I&I_5E?\
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MB  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B
M ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,
M)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V
M(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,
M)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V
M(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(
M PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  P
MG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8
M@PG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(  PG8@P
MG8@ #"=B#"=B  ,)V(,)V(  PG8@PG8@ #"=B'UJ)G@ ![PG8@
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g50309g06m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g06m02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[14N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %1$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          #_
MX4B1:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B
M92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O,#<O,3 M,C(Z
M,#8Z-3,@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM
M;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A
M=&]R+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,C8M,#(M,C94,3$Z,C0Z,34M,#4Z,# \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M-BTP,BTR-U0P,3HS-3HU,RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@,S N,B H
M36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUE
M=&%D871A1&%T93XR,#(V+3 R+3(W5# Q.C,U.C4S*S U.C,P/"]X;7 Z365T
M861A=&%$871E/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID
M;V-I9#IP:&]T;W-H;W Z.35D869E96,M96,Y82TT-C1C+3AE.#$M8S4R,S0W
M,&,X-F,W/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS
M=&%N8V5)1#YX;7 N:6ED.C$Q,&8U8S=A+64Q83$M-60T-RUB83,Y+3@W,S(Y
M9F9B,#<X8SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.D9$049$041&+4)&148M-#0Q1BTX,D9"
M+44W1D-%1D%$03-$1#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]X;7!-33I2
M96YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#IF83(W,#4T.2TS,C,W+3)B-#DM8F4V82UF8F5E
M8F5F,&4Y,V0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z9F%E93<T9#4M9C1F92TT8F0R+6)E,38M
M-60U-&,W9C P-S0W/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z1D1!1D1!1$8M0D9%1BTT
M-#%&+3@R1D(M13=&0T5&041!,T1$/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP
M9&8\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E
M<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z8SEF9&9B9C0M,V1C-2TT8S$P+6$V
M-F$M-#8Q835C-35A,3AF/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 R+3(U5#$Y.C$S.C0U+3 U.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B S,"XR("A-86-I;G1O<V@I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#IF865E-S1D-2UF-&9E+31B9#(M8F4Q-BTU9#4T
M8S=F,# W-#<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C8M,#(M,C94,3$Z,C0Z,34M,#4Z,# \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R(#,P+C(@*$UA8VEN=&]S:"D\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^9G)O;2!*4$5'(&9I;&4@9F]R;6%T('1O(&EM86=E+VIP96<\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C X-T0W,$5&-$,Q,T8Q,3%!-S V1#E%13E#,S0S1C)"/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(V+3 R+3(W5# Q.C,Q.C$W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+VIP
M96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N
M=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HP.3=$-S!%1C1#,3-&,3$Q03<P-D0Y
M144Y0S,T,T8R0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R-BTP,BTR-U0P,3HS,3HQ-RLP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.F9A,C<P-30Y+3,R,S<M,F(T.2UB939A+69B965B968P93DS9#PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R-BTP,BTR-U0P,3HS-3HU,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$Q,&8U8S=A+64Q83$M-60T
M-RUB83,Y+3@W,S(Y9F9B,#<X8SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R-BTP,BTR-U0P,3HS-3HU,RLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-
M.DAI<W1O<GD^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z
M9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/E!R;VIE8W1#;V%G1FEG5&%B;&4R-49E8E]J<VYO=U]&7V]U=&QI;F4\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C
M.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^4G5T:'9I:R!-86QL861I
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D
M8SIC<F5A=&]R/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z27-&:6QE4V%V9616
M:6%);G-T86YT4V%V93Y4<G5E/"]I;&QU<W1R871O<CI)<T9I;&53879E9%9I
M84EN<W1A;G13879E/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U
M8E1O;VP^04E2;V)I;CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3@N,# \
M+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^
M-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  8$
M!08%! 8&!08'!P8("A *"@D)"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@
M(R8G*2HI&1\M,"TH,"4H*2C_VP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1
M" &[!H,# 2(  A$! Q$!_\0 '  !  (" P$               0'!08! P@"
M_\0 5A   0,# @(%" 4)!@4"! ,) 0 " P0%$082(3$'$T%14Q06(E1A<9&2
M%3*!H=$(%R,S57.3L>$T-4)2<J,D-F*RP4/P&"5T=3=C@K/Q)I2BPE9DM/_$
M !L! 0$  P$! 0             ! @,$!08'_\0 .1$!  $# 04' P,# P4
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MYMO[AW\U62ZK?[8?GWUC^]N?C^($1%L>:(B("(B B(@(B("(B B(@(B("(B
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M_P#-"%M1?JV^Y$B_5M]R((]J_65G[U3U M7ZRL_>J>@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@ICIT_OFV_N'?S59*S>G3^^;;^X=_-5DNJW^V'
MY]]8_O;GX_B!$1;'FB(B B(@(B("(B B(@(B("(B B(@WSH7.-7N/=3/_F%D
M^F&E9<8+1>J)I)G<ZD<,?XLG:/B'!8KH<>R/5CW2/:QODS^+CCM"W#0]10W:
MGN=MN,D>+?<W5,67@9_2%PY]F0?BM%4XJR^EV&BF_L4;-5/[IG'WC$_+9::&
M&W:=GL\&-U%0CK,=A<'?S()55:+TA0U6GJB_:ADJ&V^/A'%3YWOP<$\!GGP
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MC"R/1/=ZN]WV_P!=<'M=.^"(':,- &[@ OG56A&ZDO#[O8[G1FFJ@US\G(!
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M-4:]=<P^^B&Y5=VUG<JRX2]=4R4>'/V@9PYH' >P+=K"S4U+<KG-J&III;2
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M05L;&MFFH)#)[2US #[\%:UK"@UQ]'7"3Z0IJJVOW[H(6MWB,D\!EO' ]N5
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M,'-Q)P I$1#95=KNQ31,YQI$.M%]2,='(^-XVO82UP/80<$+Y5:Q$'%$!$1
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MI(LO<-/7"BOS;.Z-LE9(X"+JSEL@/)P/=^"RIT5,\S4U%=+?5W6!I=)11/\
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M:VG%/67*KG@ QU;Y"6_!-W7,E.W4T6XMT9C=SCEKGKT_#8==Y\V]&]WD+O\
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M)/2%_6RNQM:7@\ T-X<!E:K:.A^]471UIJE@N5'2ZNT_525-'4@%\&'O)+'
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M+<W4-9?*&.HALUIA,O\ Q#LO<\M( R.TD\EN/YK[!XM;_$78.C6RMA="VJN
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M*AVR!DTH8Z5W^5H/UCQ' =Z\U#I"UKH>[V>IO>J[7JBV5LH954M,6N=#WC(
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M>&)\D,;LXPZ0#:/BK!<T/:6N +2,$'M6@](D^G-$=&MV@-'3T])/"^&&C@C
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M ]V2@MM$1 1$0$1$!$1 754_J7+M754_J7((2(B M6U1K_3.F*MM'=KFT5Y
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M3Z3T9=KU/MS30.=&T_XY#P8W[7$*IWZ2N-'^3C?'S1&745WIWW*O<!E[W/\
M3+<^QO#'O06EI#7VG=6U,]/9*_K:B%O6&)\;HW.CS@2-#@,M/>%E*#4-KN%\
MK[115;)[A0-:ZJB8">IW?5#CRR>[FO/5TU[:(=;Z?U)I][:Z"T:;=%*(LG=+
M(6MB@/\ U;NSNRLOT6:WH]*B2EN=IN,DU?=3!=K[Z)A-P?C+ ,[MC20S/+F@
M]!D@ DG '$E:_0ZST_6V.LO,%UI_HFD>Z.6L>=D0<W@?2.,\>'#M6M_E 7Z;
M3_1;>)J21T=54M%'$0,G,AV_R)6<T]I&TTN@+?IJIH(9K:RF9')3R#>UQ^LX
MG//+LE!B+7TP:*N5SAH8+P&23OZN"2:%\<<SLX :]P .>Q;_ ,AE4]^4$ZCJ
MK!:=&VZCBGO=UJ(V4$3!CR9K'M+I?^EH (S[^Y9'I'O5T>VVZ$TK4-=J*X1!
MM54$9%)2@8DE)/)QSAO;E!M^GM:6'4#[L+3<89V6N3JJJ4'$;'8)^L>!' \>
M2B:4Z0]-:IN,U#9KB):F-I>UCXW1]:P'&^/<!O;[0JATUIV*W63IBT_IRE='
M%3LAIZ:(.RX_\/SSVDG)^U8\ZSL;*KH[NMFD$IT[99W7!L+,%F8&QL@=W.=+
M@ (/0T&H+94:AJ+'!5LDNE-$)YH&@DQL/(D\AGNYK*+SQT>:ZCTH;G5W^RW&
M:NKJ]GTY=HPWJJ:HD.&0[<YQ&'-:2!P.?8O0Z M%O_2OI"R7*:WU-T,U9 =L
MT5+"^<Q'N<6@@%9+I2N\MBZ.]17*FR)Z>BD=&0<%KB, _82"J>Z+=8#1W1U2
MU-JT3>*^VB(35UWC+&FIDP3)*&..]S0=V#V@(+<U'TB:8T[#2NNMS9'-51-F
M@IV-<^:1AY$,:"?_ &5WZ-UWI[6)J66&O;-/38ZZ!['1RL!Y$M< <>U8V[ZJ
MTU1V&AUP+?/<&3,;'!44=)UM0&/SPQS Y@JO>C^[T>O^FR?4U!$+0VVT3J0T
ME4-E75EQ=^D+.QH! YD\$%DW#I*TK;]3?0-7=8XZ\/;$_+'=7'([ZK'/QM:X
M]Q*S]XOMML\M%%<:ID4];,(*:+BY\KSG@UHX]G/D%YNU7<*"#3G2)IFM<UVJ
M:[4/64L'5$23;WM,4C?8!QSV?:LI!KAMQZ3(+_';*^_RTU/+1V6DI]K2YD>&
MU-7EQ XORP#F1GN07S<-16NW7JWVFOJV4]=7Y\E9("!,1S:UW+/LSE994UTM
M5M!K+H69JZT]8R:WF.YT;G !\4C'@.:>XCT@5:FFZ]UUT]:[@\ .JZ6*<@#&
M"Y@=_P"4&11$0$1$!$1 1$08YWUC[UPN7?6/O7" B(@(B("PMUU39K5?K79:
MZL:RZW(XIJ< ESO:>X<.97WJO4-#I:P5=WNDFVG@;P:.+I7GZK&CM)/ *D#8
M;I!KW0.I-5L#=1WJ[]9+&#Z-- V-PBA'N'$^TH+7N'2=HRW7"JH:Z^QQ5=+(
M8IHS#(=CAS&0,*=IK6^FM45TU'I^ZQUM5#'UTD;6.:6LR!NX@=I"S5SK(+;0
M5=;5[64]+$^:5Q;R:T$G^2J[HGM]3?;-JC6U0S%SU.R5M&PG!BIFAS8FCCPS
MP^ 0;=9ND+2UZOIL]LNK)JXEPC&QS63%OUA&XC#L=N%FIKS;H;Y3V62I:+K4
M0FHCIPTDF,9RXGD!P/->=-/:GLD.G>BZC$[67"PUDU3<6;<.I8H^MZS?W9)&
M._(6;T7KMMHN>H-27>SW&OK:[JJFX5$&T,M5$X_H(BUW$NVY>X#O"#T L91:
M@M-;57&GI*^*5]M.*QX.(X#C.'//#..)X\%TZEO<-MT9<[Y3RM=%#0254,FW
M@?T9<PX^"U7H.L4%'T36R&HC;,ZYMDJZP2>D)7RN.<_9@(.W\[^AO+13B]@L
M+]GE0@>:?=^\QCV+<;C=;?;;8^XW&NIJ:WL9UAJ)) (]N,@@]N>S'-:1TO5-
MGT_T85EC910$W"+R"VVZ)F.LE=@-V@?Y<AV?8JWUF\V*?HPT=J:&IN4=OI!4
MRT5,WK'5=2T-;'$>.-H=D9/ #*"WM,=(VFM3W=EMLM54SU+VN>PNI7L8]K>9
M#B,'@ONU](>EKIJ$V2ANC9*\O=''F-S8YGM^LV-Y&UQ''D>Q8BAZ1)*J\1Z7
MNNGKAIVZ5D#OH_KY(WQ2$-^J'L. ?8JHMNH;/!IKHPMO6-%WL->^HN4>TA]*
MV+>Z9S^[('VY0>BIKS;H;U3V>2J9]*5$;IHZ8 EW5MYO/</>IZ\^Z4Z0(+??
M[_JNX6.Z5]?711SU;X T-M=N)S T@D;G%N7D#N"OZFGBJJ:&HIWB2"9C9(WC
M_$TC(/P0=BU/4W2)I?3=?Y!<[F#< -SJ:FB=/(P=[@T';]JSU\K'6^R7&M8,
MOIJ:29H]K6DC^2HCH7U=46[2E1>;=H^[7ROK'OJ;I=(G,CWR%Q<6-WG<\-&.
M7:@M^X:\TU;M/TEZN%SCIJ&K&:<2-(EE/'@V/ZQ/ ]B^=*:^TUJFKDH[/<0Z
MN8"XTL\;H92W_,&N )'N[BN[3EPL.N;7:]1T5/%5M8YSJ:2:(=9 _BUP]A6C
MWIL>J.GW3[[( ?-F*5]UK8^]X(; 3VGO'9DH-PU'TA:7TY=66V\7,0U9#72-
M;&Y[80XX:9' 88#[5F;W>[98[>RNNU8RGI7O;%&_!=UCW?5:T#F2J,U;=;99
M;CTQ6V_2-;<KO%$ZWL>TN=4M=$YK&L[R'$#'9E&ZG=5ZOTW))15-YBL,#*"@
MH*7:TU5Q;$#-+N/ ,B9EO$_607C>;_:K)4V^"[UC*22OEZBFZP$-?)_EW<@?
M>LF1@X*K+5U=0=(_0Y?JNABD@GI6/?U=0W$E+508>6G':,8R.];3T;7J346@
M-/7:HSU]511OE).<O PX_:02@V1$1 1$0%.IOU(4%3J;]2$'8B(@CW'^PS_Z
M"JFT?_>U3^^?_-6S<?[#/_H*J;1_][5/[Y_\T(6U%^K;[D2+]6WW(@CVK]96
M?O5/4"U?K*S]ZIZ AY(AY(*8_*5ME==^CCR6UT=165'ET+NKIXR]VT$Y.!V+
M5M'=)6L+3:[)8W='-R=#3MAHW5+A(WT1AI>1MX<.*O\ S@G!Q]J;C_F^]!1_
MT/<__BT;=OH^K^BA1.9Y9U3NISU!&-_+.>"^.E^S7.NZ=NCFOHK=5U%%2NCZ
M^HBB<Z.+].3Z3AP'#CQ5Y9X8SP]Z X& >'O5'GG\I&Q7>Z=(&E:BU6NNK((6
M-$DE/ Y[6?IVGB0.' 94"\4FJ.BSIAO>IZ.P5-WL=Q+W/?3-):6/.XMR =KF
MN':..5Z5!QR/WIG@1D8/9E043JZLUITC]$5Z?YMU-IF%9&Z"A:7=;54K>+N!
MQN)SRP <*J#8KG=.C>GMECZ/:V"KH7==<+J8")9W-.-C&X!.=W%HSP'L7LW/
M'.?O7(<1R('VH/*M18=4:%U1IC6]IT]5W"E9:X6U,/5G=$_J]DK'@<6GB"#A
M77T7:QO>MG7>6\Z7ELMI8V-M(:@.+JG=NWYW  @ #D.U;]GGQ''GQ6&UE07.
MZZ7KZ&P7(6RZ2M:*>LR?T)#@2>''B 1]J#R1>=#5D?2Q4='M$^1U%+<F5+6#
MTL0EN=[@.Z-SA[%[/ABBB9'#$T1PQM#&-')K0, ?!5;T5=%4VDK_ %NHM17K
MZ:U!5,<SK]IVL#CZ3LNXEQ  ]@X!6G]H^*#S-TO7!U\NUUMU^Z-:]US9+)!;
M;K0M<TS-!PQ[O1.X<N&3PX<%C:OHNUA5]#%E!M]2Z[V^X3S-MKR.L%,\#DTG
M@=S<[.>"O5>>7$<.7%,\<YX^]!Y9L,5KNU;0V^EZ&9H;CUT;*N9_6"*$9&YP
MX \!DC)6R_E!VF[T'2#I/5=KM%5<J"V,8Z00,+@UT<FX-=C) ([<+T%GGQ''
MGQ7&>?$8/M0:[H'4-=JC3XNESLT]EFDF>UE+/G?U8QM><@<\]RJ/2V=+?E2W
MV@JMK67ZG=+ ]WHAQ(#P!WG+7#[%?Q.>9'Q6IZPT':-4W:U76M?4TUSMCMU-
M54DO5R-XYP3VC/\ ,H*\EL]S_P#BII[J+?5_1@HMAJ^J=U0/4D8WXQSX+3.G
MKH[N]!K&IO&F*"LJ[?>XW-JHJ2(OZN3@7!P'^%VT.'M!7J/<<8W?>N <<CC[
M4%1:1Z-K3JCHNTC2:PMU4*F@IW!L+G.B=&7..0X?8%-I^@K0E-415$%MJ&RP
MO;(P^4.X.:<C[PK0)SS(^*?:/B@HJY=,&KZ-M7;KST:U,U;(YT<.&/,,H[,M
M+3D8QR*[_P F?0]ZTS27BZ7^FFM\EP<UL5')Z)#022]S?\/$X /' 5W[N7$<
M/:N"<\R/B@HUUFN?_P 5K;K]'5?T7Y.&^5]4[JL]21C?RY\%D_RJ;I'0=%KJ
M7T75%PK(H8H\^D[;EQ(^ ^*M_/#&>'O6J:ET'9]2ZCMEWO9J*HVXAU/2/D_X
M<.SG<68XG./@%1-T#:76+1-CMLFX2T]'&V0.YAQ&2/L)6>0G)))&?>GVCXJ
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M=WHDG' J+T:ZBM>CK=3V6SZ+UCB:8&:LJ;>=\TCC@R2.S_\ N"N_+?8GH_\
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MO'2]>-;0VFJLFGWVX4X-7'U+ZQ^0>L+#Q  !XE2/R<"ZY6_5FI W;!>;S-+
M!R,;/1#AWY.?@K+U+:(K]8ZNURU512PU+.K?)32;'[3S /9D</M7;8K70V.T
M4MLM<,=/1TT8CCC8,  ?^3S)03T7&X=X3<.\(.47&X=X3<.\(.47&X=X3<.\
M(.47&X=X3<.\(.5U5/ZER[-P[PNNI(,+N(^*"$B?:/BGVCXH"HGI@O%YOVJ'
MZ8J;+J&+2%,6OJJBUTKI);@[ /5AW "/C@\U>WVCXKD.(Y.^]!6-MU_'26"L
MI['H74-,VVT?64]+)1&)DF'-:(VX[?2SRS@$K2M$:@GH+Q4ZFU9I75=SU/5
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M@]O/FM>TKI.W:;J+M54;IIJVZ5'E%54U$F^1Y[&Y[&CL [T&P(GVCXI]H^*
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M]<?:/B@(GVCXI]H^* B?:/BGVCXH-/Z1]!TNNZ:V0UERK: 6^<U$9I<>D_&
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MV.).2.:W_HGM4UDZ--,V^J&*B&ACZQO^5SO2(^S<INJ=+4&IYK6ZZOG?!05
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MT?7)])^4/TE3U4L\E+1T]3,8@\D -=&3M:3C/-6CHCI%L^LM.W*]6F&MCI*
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M?,^V5Q8^6"6=SP'M^J]N?JN'+(432'0QHW2M\AN]MI*J2O@.Z%]14%XC=_F
MP./O4%9:5!/3GTNM'%SK?6@#O^HNG\GB^6NV=$>L&7&OIZ:09?LD>&N<TTX
M+0>?'AP5ZV?1%BM&K;GJ6AII&W>Y!S:F1TI<UP<03AIX#ZH6KOZ#-"/OWTH;
M9-OZSK?)NO/4;O\ 1W9XXSA!2'14R1_0-TKMB:XOV0G ''&S)^Y;-HRITBW\
MFR[LN,E&*_$XE8YS>N=/G]&6C.['%N,=BO#2.AM/Z3I[I!9*(QT]RDZRIBED
M,C7\",8/(8)&%K-#T&Z$H[M-7LM<LCI&N:V&28NBCW?Y6]F.../#*"A*G/\
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M;28M<!I9J^YW2I;2T='"0UTKLC<23P  .25F[#/#/:*1T$T<K6Q-:71O#AD
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MC7%U95%O5LPTD X';C'VKKZ9]+W_ %%YLSZ:CH)IK7<16215DA8QV =IR!G
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MKM7&D;2UE Y@,3J0$;72OR-ASC!_EVAN^E>E.ANIO-/?+97:?N=J@\JJ*.M
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M?1S_ /TH-N1$0$1$!3J;]2%!4ZF_4A!V(B((]Q_L,_\ H*J;1_\ >U3^^?\
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M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!*HN3E(4>BY.4A 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%U5/ZER
M[5U5/ZER"$B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@#FLD.2Q
MHYK)#D@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B(,<[ZQ]ZX7+OK'WKA 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 4ZF_4A05.IOU(0=B(B"/<?[#/\ Z"JFT?\ WM4_OG_S
M5LW'^PS_ .@JIM'_ -[5/[Y_\T(6U%^K;[D2+]6WW(@CVK]96?O5/4"U?K*S
M]ZIZ AY(AY(,#=;7;[O3"FN]#35U.';Q%41A[0[OP>U28(HZ>&.&"-L4,;0Q
MC&##6M'( =@7V>:(,'/I'3=1=FW2>P6N2XMR14.IFE^3VGAQ/M/%=[=.6-L5
M=$VS6\15QW5;! W%0<Y!>,>EQX\5E40019[8+1]%"W4GT6&[?(^J'58SG&WE
MC/%=MNH*.V4C*6VTD%)2L)+88&!C&YYX 4E$$"[66U7ED3+S;:.O;$28Q4Q!
MX83S(SRROFYV.T76"GANEJHJV&G_ %+)X0]L?#'H@\N "R*(,?=K):KQ%%%>
M+91U\<7ZME1$'AG#'#/+@IT,;(8FQQ,:R-C0QC&C : ,  =R^D0>?.@[0%2V
M]:OAUKIAQM]2\/@\O@!9(>L<<MSQ!P5?-LMU%:J-M):Z.GHZ5O**",,;[\#M
M]JE(@UVIT-I.IKFUE1IJT25323UAI6Y)/:1C!^U9"X6&SW*EIZ:XVFAJJ:G_
M %,4T+7,BX8]$8P.'<LDB"+7V^BN-$:*XT=/549QF"9@<SARX'AP7U345)24
M+**EI8(:)C=C:=C (PW_ "[>6/8I"(,#1:-TQ0W!U?1Z=M4%:2'=<RF8' CD
M1PX'W+)7BUV^]43J.\4--74KCDQ5$8>W/?QY'VA3$08:+2NG8H*.&*PVQL5&
M[?3-%,T=2[AZ3>' \!Q]@6:R<Y/'OSVKA$%:]''1S<-"ZLODMNN5++I>YO,O
MD+F.$T,G9@\00,D<^(QW+?+59[99V2LM%NI*%DSM\@IX@P/=WG',J<B#%U6G
M+'5W(7&KLUOFN +7>4O@:9,M^J=V,Y& LH>)XHB#HKJ.EN%)+27"FAJJ648D
MAF:',>,YX@\^*PWF3I/_ /QBS_\ \JS\%L"((]MH:.UTC*6V4D%'2L)+8H&!
MC6D\3@!=%%9+30W">OHK91T]=/GKJB*(-DDR<G<X<3D\5/1!6NF.CJOINE.[
M:WU'<*2KJIV&*BIZ=KL4S",<2<9(:,#WDJRD1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$$JBY.4A1Z+DY2$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 754_J7+M754_J7((2(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B .:R0Y+&CFLD.2 B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@Q
MSOK'WKA<N^L?>N$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!3J;]2%!4ZF_4A!V(B((]Q_L,_^@JIM'_WM4_OG_P U;-Q_L,_^@JIM
M'_WM4_OG_P T(6U%^K;[D2+]6WW(@CVK]96?O5/4"U?K*S]ZIZ AY(AY(,:>
M:(>:("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"51<G*0H]%R<I" B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+JJ?
MU+EVKJJ?U+D$)$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 '-9(
M<EC1S62') 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$08YWUC[UPN7?6/O7" B(@(B("(B B(@(B("(B B(@(B("(B
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M'>@VZIN5)2UE+2SSM9/4[NJ:?\6T9*F$@<R JCH(*"?S(EN@A="]E5"^29V
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M$?BJXJ:9KM2B+S:\M:RWQ8H^M8/)O2=PR3@_8LQ>F"UMTS<*:D\AE;4LI)(
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MB1WX7VM2HW5=-JNBI;A)3U53Y%,]U2V$,<?3;@#B<!86FU#J!FEX=235%--
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M-(^.)D;J=S1@$8'$8X$%:]IFI-JM]SU)=J$&I<]\;965!D=*XR%HCV\@ 0T
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M>G(]ES#F.:3CJF.SEK>X9<2L<S6S_-FIN#Z6#RBGJA2.#)MT.3C#]X'U>/\
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M'2UL;I(96S[BS:W=A_ #B.Y?&I;U3TMUME5!OJ=E/52M,51B,ED>2'  [O\
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MN;3,ZHEDC.R4RMPXX'+: ,=F NRPVF:#4E+%U<OD-GH13132-V]=([&XM]@
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K#L\)OP4JDT4QKAZ PK'VCN"^F <>"# VBP0T@'HC*S\; P8"^D0$1$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g50309g07m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g07m01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[10V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %!D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @,!               %!@0' @,( ?_$ %(0  $$ @ # @D* P<" P<!"0$
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MUOIH>G>N])FS+ P-]375'^V+J&BO_FLRK+?8SY"A#&0.25[C_:./_2!W[_\
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M_P#:/7[?#<_&O);&,NU>&_ERL^/<4L<A!CWHCH/0?7]RZN',Q/?\(W+E\?\
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M3/#H8*\S)^7J6!SB-Z'OVD3/HM.!A[<[W2)BGTV9B-J(F\?;IJPX<;PK?O\
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M&#X:B@F9))!2+)6M.RQVQT/J*4QPA;,8D7KQ+4S^FG9TCXB?OZ\>"9SM3A;
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MT5B3^^):0UK6D]3M5_P?VX*.=GEM3L@8:<K ][N4<Q T-^M5U\DDH;VTDDA
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MW,W)R#LH;!E#VB770//78/0="OLW#T6'Q$MKB/MXK$DQ@K5HB YW*?GO._\
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MT BMD/!%JW#*[&93%WY(7!LT<,NNSW_U;(T6CUK%N\+2P8NU?IY/'Y&&J0+
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M59$16<PB(@(B("(B B(B!  .X:1$#0WW!/N]"(@:&NX)[U8N'J%2/"Y3,Y6
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M\K-V-2RT30S<I=V4S>[H/0>Y1+\C9DQ4&.>X>*PR.E8W74./?U6>SZ?+T_\
M4TT1%<>M&SZ3:8F.,3Z6U3S;L_%^3Q.%A@KXZDQ[A%%""0P:VYQ)ZN=H*Q<
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M#Y8(LZ:;.P?/KD [ \^]@CZ.U!>%F'CR'(\+><*U0L--S_V/Q4-^:>9G/OE
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MAXM$'O$0&H^GHZ$G\5=\OP=PYF<Q%E<OA:5W(1M:ULTS.8@-[AKN.M^D*=:
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MUT6_HM]Z#$/>B'O1 1$0$1$!$1 1$0%!<3<(8#BCL#G\7#<?!OLI"7,>S?>
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MZ)XK_/\ H@QD63XK_/\ HGBO\_Z(,9%D^*_S_HGBO\_Z(,9%D^*_S_HGBO\
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MZ)XK_/\ H@QD63XK_/\ HGBO\_Z(,9%D^*_S_HGBO\_Z(,9%D^*_S_HGBO\
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M%C<!F<55P%J*I'8LT'66RUA,UI+97$@M<>G3H@M#,^R67+Q05+$TN.>UCF,
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M!V3K>_05=>%J<U#AS'5+30V>&!K'M!WH@>M5*_@\R^K?QL5%CX'Y(78K';-
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MA?"UW31B=]5KFQEPYG =Y [U8T!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MH( [R/5]W1!L.+"XR&\ZY%0K,M.WN1L8#NO>L;'4<+7OS5Z-6K':A+9GM9$
M6\P.CO7JVJKQ1E[K,]EJIR=J@ZO78^A#7AY_&7$'>^AW\[YNNGK7W&8[*7.(
M+43LK8J3"C6=8>UC#(Z0AW3>M #KW#J@N\E>G6JVW/BAC@DYI+&V@!VQ\XN]
M?0=5PK14+M*G)79!-58&R5R&@M;H="WU=%#XC(V;? \MNTYK[3()FN?RC3BP
MN;S:[NO+O2BX[>2M8[A&M3NBH^_ 3-(R)O<(@[H-:!]7H072U7@L1<EF-DC
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MZD#>QWC:@\FR2&YGO'<=7QLTN&F;#%7(<R8#JYQ( ^<.FNG<5W8+=_.X.O\
M)C,3/4@%GMMMY[+.7EY6\O>.NSLH)W \-S19>?(Y&''UR^OXL*U)A$;FD[+G
M[ V?1W=RL9I5C#!$8(C% 6F)O*-,+>X@>C2B.)+T^-R6'L]N&8]\YKV6G6CS
M-/*XGT:(_556MQ+EG4+[)Y@RY?=#+C!H;;'+(6 :].@-_B@OQQE$W7VS4@-F
M1G9OD+!S.;ZB?2NJEA<92[7Q2A5B[4$/Y(@.8>H_=]RI_%N4M0V;S\9E,F]U
M./YT=>JU\,;VC9$CR.N_3H]%]M9+(?*HGR>0NXNG)V3Z\L,+7U2TM'S7N()#
MB21UT$%PI8;&T7!U.C6A<"2',C ()[UDVJE>VT-M013-&]"1H<!L:]/W*O<=
MYBSB\?3CH]IVURPV 21,YWL!!)+6^EW3H%%X>_Q$^OF*]>"[)R0B2G/D8>R>
M7GH6'N!]8/3[T%CLT)L;BG0\,UJ%>8N!U*"UG7O)Y>I/<OF"@J8*G1Q+K##;
MD:Y_7HZ5V]O<![RJ)D)K%JC'"[-Y5ED6JXDIW(61RLV_7..G5N^[6PIWBBY<
MQ-BE''9,LC,?<E,TD;"\N:P%IWKI^'1!:+^'QV0E9)>HUK$C/HNDC#C[NOH6
M3/4KV(F1SP1R1L<'-:YH(:1W$>Y4(29QL>!E^7)"_+@-E:86\L6V<VV#7?H$
M==]ZRSD+5"OF\=<RUATD$\,=:T(0^=QD:'<@:!IQZ$=WIWZ$%LR&+H9!T3KU
M2"PZ([89&!W+^:YQ4:C',?%7A:6AP:6L'0..W:]ZHN/R&0L8WBFG/:OCQ>J)
M89+4363,VUVP0!K7S>_6^JPH+V0HX?AZA!<R<HN5FV'NKPMDEC8&-TQ@UW;/
M4G9Z!!?ZF$Q=1_/5Q]6)_/S\S(@"'>O]2L:G3P4V3OMK5:CKL3F^,ZB',UQ^
M<W9UZ>]5+&Y;.W[M/!V9;=$R22O\<E@$<TD+ " &D:!V=$Z]"E>!X9J_$?%,
M5JP;,S)8 9B "X=GTV!TWK6T$S;K83)9.>E:KU9[K&LFD:^/;M=S3O7W:4GX
MK7[2&3L8^> %L1Y1M@(T0/5T5+LTK-[PB9*.KD)J(%&)SGPM:7N^<[0^<" /
M2NK!<09+QS'R9&=CZ9GFQMA_*&M,K"2R3[N8#1'<@M]?"XRO==;@H58[).S*
MV(!V_2=K(OTJU^N8+L$4\).^21H<-^M5_!92X[AW)YNVYTD;S+8K0D:Y86@\
MH_'6]_>NG!?*0Q$>?OY2:P)*KK+J;6-$0!;S!K>F^GKV=H+"W$X]M:6NVE7$
M$K0U\8C'*X#NV/2L"]BY:=$,X9JX^O8([,ND86AK#WD<HZG>CHJNBWE\?A\?
MQ!9RKK0L/B=+3[-HCY)" &L](+=CKL[TNNS;S%B'B:_'EI8(\7/(((61M+7<
MK0XA^QLCT>A!:L5@:=#AV#$SQLLUHF:=VK 0\[)+M>\DKNX>9C!C(Y<)'"RG
M+\YIB9RAWHW_ /[5<H392OD\*ZUDI+4>5BE,L+F-#(B&<XY-==#NZDJ#PDF2
MP_ M#-Q9*1\4):#2Y&]FZ,R<NMZWS==[W]VD%[\5PN5ORR]A3M6ZKNRD<6!S
MF.UW%?<Q2P[<:TY6O5%*J 6]JP<L8[NGJ5-GR>2=D+%:G:;6=-F_%>T;$W8C
M,._5U._25]S&0R.+BXCQTEYUUM>K'8AEL1L+F\Q(+2-:(Z>I!?(J%)L;!%6@
M;&']LT-8  [7TA]^O2NUU>%UAL[HF&9K2P/(ZAI[QOU*J9.7(W>+:F*JY&2E
M5?C_ !B0Q,:7$A^OFD@Z[PH:7/9./'BM9O/CA@RKZ%B^Q@[01@;!UH@$[UO2
M#8'B-3Q/Q7Q:'Q;O[+D'+W[[O?U5&.$M6+^:K4QALASV"Z2>[&YTT/. >3NT
M0!W:(4UP0^[.<A-9NV[=(2]G4DG8&\[!_P!6M GJ2-^G2BJ>/OWN(.)O$<O+
MCPR:/0CC:[F?V8T7;'=]R"R8.*@,8["-F;<\0C97G;(W?_3T!!Z=RS*F*Q]2
MH^K6IUXZ[]\\;8QRNWZQZ5KKA?B&=N%XLS?9M\:_LG<H^CS\@;OW;ZZ78.(,
MUAX9K,C<K;@\6>9'7JHA9'*-<KFD>@DZY?U0;!IXFA2JR5ZE."*"3Z;&, #O
M?ZUQR1Q]+&<U]L,=&OR:YF[:S1 ;H?<=*I<,7\T,[4BF&6LTYXW^,27:HB;&
M\#8+"!W$]-':C,L<GE>"+&;L91_96'AWB0C;V;8^U #0>_?3>]_=I!L"?Y-R
MK[./G%>TZ#E,T+P'<G,-M)![NBZ7\.X=]9D#L93,49VUO9-Z'T^A4_/Y?)5\
M]E:]"Q' \W:4#']DTZ$C3O?I/XK*MWLO@\ADJ$-R3)O^377838:T.:]KN77S
M0-@[WI!.9?A^.]D,,YL5<4:1E$D#F='-<SE  UKO4M3H5*53Q6K6BBK]=QM8
M T[[]CTJD\,6;M_-434S5^]1\7[:V7Q-:ULG33=\HZ'9^:.O3O6=QGF+<66I
MXNF;T;7QNGEDI0B64@$ - /0#KU/N063'XJACVR"C3KP"3Z?9L YO>NSQ&KX
MJRMXO%XO&06Q\HY6Z.QH>]4;A[/9BKE(!Q!V\5"9LL+'V(NR=N/Y[7D>CF;L
M:];5CSYW+R08N-TUYKLEVMQWBD ?+'#L<D;!ZM$$D@H+Y9Q&/M6VVK-*M+8:
M-"1\8+M>]?9,70<S4E2N6B+L.K!KL][Y?=T'14BED,_<L8K'2V;5$RRV&&>:
MN&RRQ-:TM=RGH'=2-]WITL?B*3(?(N;QUC)3S>(W*P;/RM#Y&2<IY7:'H)[Q
MWZ07_)8Z*[5='H1S"-[(9FM'-"7-+>9OJ/54R#@V]+6IT;<.(@@KO8XW*\9\
M8DY""#LCH3KJ=E9W$K<O1@QK(;>1EICG\:LUHF/F!_Z26Z^B.N]#T*4J2^-\
M(.DJY62T70/+;K6!KB1OKK6@1W=WH03%JM7NUGP6HHYX'C3F/ <"N%>A4KF$
MP5XF&%G9QEK0.1OJ'W*BTYK^(\&+;U:]+)8='"8A*UNH]O:"!H=0=^GJNWB"
MWE<*<;C_ )0O6YLC(]\DT,#721M8T$MC9K74GO.]!!<,AB,?D7,=?I5[#F?1
M,D8<0N,V&QDMF.Q+1JNF8WD8\QC8'< %2XLQD?D^2G=GR]:;QC_V605!XS:C
MT2YO)K0Y?2[7J6#!8R>4?C(K&3NQ.ARKZS7.C:V0@1\P<X:(YALCU?<@V+)B
MJ$DU69]. RU0!"[D&XP.X#U!=CJ%1]>2NZM$89'%[V%@TYQ.R2/7M4SB3*7V
MYEF*K390,K56R22TJXDDE>20"[IH#IOH.NRNG"9'.Y^[%C;EBQBI:M;MIGMB
M#99G%Y:TEK@0!H;(]9072G-0R4SK5;LII:SWUS)R_.8X?2;L_@N$>#Q<5I]F
M/'U6V'[YI!$-G??Z/3LJ"\&C9&8K)MGD$DS<E.'O T''8V=>A0V1XAR\4-W&
M5I^;+1WY&L<6C?8-9VH.M>D?-07>VW&58*=>TVO'#VK(Z\;VC7./HAH]?3HN
M-V+%T)9LQ:B@BEBC_M+/)\X-^\CJJ/+Q)<RO$&,FJO:W&=K5C,98UX,DC'/.
MB1L$  =%TYBK9[+C>63(V)&1!H,3@WE?N,$ ]-C6_1K[T%RM8.#)YQU^W'7L
MTI*;(6LD;S'F#R[FZCU%9F1&+JTH*EZ*NRI-(VO%"Z,%A<?HM UKT*MU'93$
MY/AX3Y.2W#D-QS0O8T-81'S LT-C6M==[65X162R4\.RO((IG9. ,D(WRGYW
M77IT@F10Q.(HF05JM6M7=VY=R!H80-<WOUZ5F0MKS/CN1-C>Y\8#90.I8>O?
MZO2J1E;>0Q#LWCI;[[S!BW78I;$;2YC@2TMT!HCT]0HZ]F,C(Z[&W)6JMR"&
M'Q"K6A#A8YF DD<IWL[&NFM(+Q5KX:;.6WUZ]4Y2OR]N\1CG;S#8.]=Y'I65
M;Q./MVH[-JE7FGCZ-D?&"1^*H^(QF1M<2YZ)N7LU)8HZW:/8QCGR2=EWN.M:
M'J &U;.#<E-E^&J-VR&B>1GS^7N)!(W^.MH,C'1XNSV5F@RL_P 7YH&21M'S
M-'JT>KJI$D ;)T%KJC>R=V?%4J][Q1EJ:X)GQ1-YM,>-:Z:!]&_O]*Q.(;%^
M3%7<=/D9Y'4LG!$)]-#I&/((#NFMC?H[](-H(J-Q/DK^/MXS#0V<A,96/FFL
MUX6OL. /1H &AW]3KT!1]/)\0W+N*QDT]J@)I;$?;S5PV66)K6N:[E/0.ZD;
M[ON0;)71>N5Z-<SW)F0P@AO.\Z&R= ?FJ//=S\4.9QE*Q-<EH68=SAC>W,+V
M\S@T=&EP]'K7RQDGLX4LR09.>Y,RW"QS+L#6R0;>W;7-('OWKW(-@ @]QVBU
M]PW4R+ZO%,M3*6?&&W+$<3'!I:7@-(<>GX>I2&*X@GSM_"0U)##_ .SNM7F@
M=VOF!G7N^?S??T07'8WK?5%2W5;$GA-DY<A89&VBR7LVAO*6]H06=W<=;WW]
M5U8^WE+5C.9"?)2"GBK<S8ZL;&CM0P;TYVN[J -(+RBUGA<]FGR8Z^\9.:*R
MX.M-EK!E6*)W7G8_OTT>DD[795RN0=EZ#:^3RD]:]*Z'MIZC8XB"TEKH]CO&
MO3O:#9 (/<=HM<8B6_C/!E)D8<C.^8Q Q-D:TB(]IHZZ;.]^G:SIZ^:ASM''
M.S\Y;>B?)*\1,YHRS1(CZ= =ZZ[UI!>46M9.(<I#C_DXV+,UKY2DJ>-0PA\Q
MC8T.Z-[N;KK?JV5P9F.( ^O1,MZLR;(1P0VKE<-D?&YCN8%NM$M('5!LW?1!
MU[EK?.39*M%Q'AY<I8GCBHBU',YK1( =AS"0-$'7O5TX?@EIX:$3VIK;N0/#
MI T$#E'S1H#H$&9?NU\?4?9N2B*!A <\^C9 'ZD+(6L,J,GDN"G9JSE'F*S(
MQ[J08WLVL[8 -![]CH=[^[2M^,OV)<WQ'#++N&JZ/L@0/F Q@G]4%@6/!=K3
MVK%:&9CYZ_*)6 ]6<PV-^\*@8_)9K+2\/U(\F^MXY2DFGF;&TNVUPZC8T#Z/
MQ7'(9/*5<KD*52X&RMN4JK9G1-YG!["'%VAUZ]4&R45&DN9?#Y/*4&79,F6X
MUUR$SM:'-D!UKYH&QUWK[ET<,VKU[/T!4S-^_CO%S-:=)$UK6R]--WRCH=GY
MHZ].]!L!%5^*+&1=G\/C<?=-..VR;M9 P.< T-(+=^GO'XKEP[:M^4.<QUFT
M^Q%2BK"-SP 27,<7..O22$%F1:WQ.7S&5K\,UQDGP/OBUV\S8VEQ#''6MC0.
MAI3F R=NG+GZE^:?(#&R,[.1L>Y7M>W>M-'4CW(+-+;@ALP5Y96-GGYNR83U
M?RC9U[@NY4W*YR6>YB9JT4U9KX[>VV(.60%D6P1S#8Z^KO6%4LYBMC\%E[.6
MDL&[-#%+6,;1'RO&NFAL$=^]H+^B@^-;MC'\,W+-*3LK#.3D>1O6WM'^Q45+
M/D>'\S5;:R4F2KVX9W.CD8UO9OC9S[9KT'NT=Z07%=-RU!2K26+4K8H(QMSW
M'0 6O.'LQG+-O&6S\JV&VI!V\;Z@969&[TL=W_-Z=2>J[8K&6?P-9S=W)&:2
M2OID!A9V;?G@!Q&OG'IZ>G7N0;#:X.:'-(+2-@CTKZJE=LW<GQ%'AZUV6A##
M3;:DEA:TOD)/*&C8( '4J.BS.5L4XL6;;6779)]!UYK!OD:WGY@WN#B.B"[M
MN0.O.IB0&RV,2EGI#22 ?S!7>JAP_6LU.-LA#;NONEM&/LY'M >&\[NCM="=
M[ZZ6!Q?E;,=O(28S)Y)SJ<>S%5JM?#$\#>I'D==^GKT07Y%2*4F6X@RN1CCR
MTE"O#%7>QL$;20^2(./4CZ.]]/U73C\OD\^S!5&7#1?/5?9LSQ-!>_E=R -W
ML#9ZE!=*MZM:GLPP2A\M9P9*T _-)&]?DOL5VO+=GJ1RAUB!K72,T=M#N[_9
M5G@6.:'*<1QVI_&)FVFATO*&\_S!HD#IO2QI*%R_QSF65,E+0C;! 7NA8TO<
M='74@Z""X^-P>.^*=JSQGL^U[/?SN3>N;W;7<2 -GN6MZN7S=ZN#4<R3('%N
M<"V-H<YS;!87#?I+03KNVEVU)/PCG6-S.2-J.$.?7MQ-CFA&CL'0&PX>D?@4
M&R$5.N27Z./P^,KY&4V,A*&>-R,:71,#.8AH  W\W0WZRHC,Y'-XG.U<%%E7
M3.LR1/CLRQM+F,<7,+7   ]0' ]$&P3<KMNMIF9@M.89!%OYQ:.A.EWJI5'6
M:'%-2C/:?<#:,LKII8V\[CSMUU Z#7307'A'Y2R]:KG+>6E9',YS_$V,;V36
M;(#=ZWOIO>T%O) !)[@L?'WJ^0K">G*)82YS>8 CJ#H]_P!X6OY\W<;EZ=BE
MD<C:I6;K8-R50RLZ-SN73':V2/7Z=*R>#P:X;:/58G__ &KD%D1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M\6J\_9\[G_/.SMSBX_J5F(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MNE<,5Q1C\C>;3:+->T]I>R*U"Z(R-'>6[[UFXO*P9&:_' V1KJ<YKR<X VX
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M^^UK+,UTO=/&\G8,6] ?[=%M*M!%6KQP0,:R&-H:U@[@!Z%$P<+82"8RQ8V
M/YN<$@GE.]_-!Z-_#2"L\.4CA<[59FH)S>G<]D609:=)'9.B=.83\TZ[NFNB
MS.**T>0XWP]"U/,VK-6F+XHY7,$I&B ='\?P4]C>',3C;7C%*E'%, 0UVR>4
M'OY=GI^"P<YP^W+<24K%N&.:C%7DC>''1#B001KJ.[O""F7[MRC6R.(Q\TLM
M%N5BJ,+IBUS6.;MT?:'9;IVF[[QM2V.HY7%X_B$35O$L<ZB]\,'CAG='(&G9
M:[O /?[U<8L)C8L8['1TH!2=]*+EV'?>?6?O[UUT.'\70AL15*;&1V&\DH)+
MN=O4:))/3J4%/L4!C^%\9.VY;;-E)*T-RVZ9W,V-PV='N;Z!L#N73Q)BAC<K
MC,1BH)I:ESM)I*[[SX^V>T !O.23H DZ'?\ @M@S4*DU#Q&:O')4Y!'V3F[;
MRCN&ONTHUG"F$;4?6&.B,+W!Y!))Y@- @D[!UZB@J&3@RN.X'M06W25"+T0K
MAECM'Q1ND;\WG].MG6_0LF_B8,7G_D^G+:;4NX^=T\;IWNYG-(T[9.P>OH5N
MBP.,BQWB#*<?BG.)3&=D%P(())ZD[ 69)3KR7([;X6.L1L+&2$=0T]X_1!7O
M!QCZ]/A>E/7#^TLPL?)S2.<"0#W G0[_ $*.Q>-@SDV6R.2FL/N5[<L3&-G<
MQL+6=&CE! ZCJ=]^U:L5AZ&)[;Y.K-KB9W,\-)T3U[AW#O/<NBWPYB+=_P =
ML4(GV=@E_4<Q'<2!T/XH*%A\:REPE@\Q7GLC(&>%O,9G<O(Y_*6<N^7ET?4O
MO%D_C#LKE:%6R'4IA%X[)=+!'(QP:0R/N(]_?M;%&*HBC%3%:,58B',CUT:0
M=@C\5B3\,86>W+9FQT#YI3MY(.G'UZ[M_?WH*_?I,S7';*EV6?Q3Y+$SH8Y7
M,:]W::&]'[U"-DG.'CJ6);-G'0YJ6DZ!DA[:5@WR,#M@G1]&^X?<MEMHUF7?
M'&PL%KLNQ[377DWOE]VU6>(^&W26*TM&G!9IMEDFL4'O,;9I'?\ S-Z(V/O0
M5*U1OXNNR*.O8BARN2[)D$MHM>8 W;(B_9Y.9V^[KKIM6_@>AD\?8R$5R 5:
M#N1U>N;/;F,]>;YQZZ/0Z]ZX</<+,9\IG)4JL-.[R<M"-QD9'R[^<2=?.._1
MKN"L&)P]#$-D;CJS8>T(+R"7%VN[9))04/.8RO!;XSN1&=MBO6C?&_MW]"YC
MM^GK]WJ]"R+]!N-QN&ACLVFC,6(8[]ETSB]X+2= [^;L].FNBO$^,ISBWVU:
M-_C;0R?8_O !H _@2N5JA4MTC3LUXY:Q:&]FX;&AW?D@HEN)N&O\08O'6)A2
M&'DL]DZ5S^QD&P.4D[&QLZ^Y=1P4+;W#3&V[_P#[RC/CA-E^Y@(^?1Z].HUT
MUT5WI8'&4JD]:M2B9#8!;*.I,@(UIQ/4]_K63XA5YZK^P9S51J Z_NQKEZ?A
MT05S@=IJ9+B#&QR2NJ5++! V1Y>6!S 2 3UUM0^1L9FKQEQ'-@H:L[V58'2,
MGYMD .URZ[SW]ZOE>E6K3V)X(6,EL.#I7#O>0- G\$BI5HKD]N.%C;,S6MDD
M ZN#>X'W(*'P^V"KE>$(,?<?/3EK6I.<_-$CCIQV!TV"3T]"P\I8EFDXF;#;
MF8/E2M$U\<AVSZ(.O4KS-PUAYJGBSZ$/8B0S!K=MY7GO((ZC?W+G!P]B8('0
MPT(&1.>Q[FM;H%S?HD_>/6@JLD$_#?%<$&!K6;K;55[I:\EKH7-</G[>>_K^
MJCN.+MT2Y-Q?-4F^3*[S$V7?9/-C1T0=;^\+9#J==UQEMT3398PL;)Z0T]X_
M0+'O8?'WGRON5(IG2L;&\N&^9H=S ?@>J"LQT(\!Q?A8L?+8Y,A',+(EF=)V
MA8&D.ZGH[9/<LOC%T4.:X:GND"DRT\.<[Z(D+#V9/X[5BEI5YK5>S+"QT]?F
M$3R.K.8:.O?I<KE2O=K/KW(8YX'C3F2-#@4%<XW>QUC P1.;X^[(1/B;_P!7
M*W?.?<!WJNU<32OW.,+%NQ/'+4M.?&8YG,$)[,'GT#K?3T[[E=L7P]BL7,9J
M-&**8C7:=7. ]0)V0/N"X6^&,+;L.GL8Z!\KWE[W:(YS_-KZ7=W'H@H&%$T<
M5#-\30V)V6GQR,R$%IS3$7$!K'1 @<N_2-]ZYW8<OG<GFY8*CY+=6P8:\XOF
M#Q8 #E(C].^\D]_W:5\9PQAF7A;;CX>W#^T!Z\H=ZPW>@?OTN62X<Q&3L^,7
MJ,4LVN4OV6EP]1T>OXH*[;Q\F7XII4\K/,U@Q39;$4$I8R1_/H]WHV2>GW*,
MR%NQC(<GPO6EE;-+88*LCG%SFUY-N>0>_3 UX_);#92K,M-LLA8)VQ=B'@=0
MS>^7W;7&3'5),A'>DKQNMQL+&2D?.#3WA!K6F3#DL%D*%2S5@MW&1LGGO&1\
M\3@1HQ[( UKW=%RNXZO%=XZMQ&9MBL&.B>)G@M+H]D]_7OZ;[O0KS4X7PM2<
M35\= R1KP]KM$\C@=[;OZ/X:7;=X>Q5VXZU:I123N;R.=U',.[1 Z'\4%:L1
M#,\08W$Y*27Y/&.\9:QLCF=M+L [(.SH==?>HLOGFQPQS+UHUH<['4BL-E/:
M!A'5O-Z=$D=5?<EA<=DJ\4-VK'+'%_=]X+/<1U"Y18C'PU:]:*G"R"O()8F-
M;H->.YWO^]! 8.C%A>,K&/HOF%.6BVP8Y)72 /$A;L<Q)&PH\XRKFN,^)(,E
M9L]E79 ^.)EAT;6$Q]7Z![QKW*[^*0>.^-]DWQGL^R[377DWO7NVJUY*5[W$
MF9N9:K%/7G['L#S$.'*S3@=:Z;UT[D%-AOY3-P\/TK$3K\4E>:0Q&R:_C!9(
M6M)<.ITT Z].]K/KX[)2Y3"XK-2S05W&UJ**R7.=" PM8]XZG1V-]^E?;^$Q
MM^I%6M4H7P1:[-H;R\G^4CJ/P2EA,;2-<U:D<9K\W9D;);S:YNI]>@@J7;V,
M5?XO9CW2%M&C!XNQSB\,U&[KU]V_O7R.A!AW<.7\9<LR6KUB*.8OG=(+#'M)
M<XM)UT[P1W*[QT:T=JQ99 P3V ULK]=7AHT ?S*P<?PYB,=;\:I4(8I^H#@#
M\W??R@]&_AI!0;M"#(<&YG-V[=GY2[25KCV[@V/3^41<N]:UKIKTJS\72R0\
M)T'0R/C=V]8;8X@Z+V["E;'#&%L6Y;,^-KOFEV7DCHXGTD=V_OUM9]FA5M5F
M5[$#)(6%KFL<.@+3L'\$%5M8F'-<:9*"_+8=4BK0N$#)G,:7'F^<>4CJ%RQ$
M5C)>#R>L9Y7V R:*.4N/.2QS@S9]?0*ULJP,MRV61-%B5H:]X[W =P_4I4J0
M4X.QK1-BBV3RM'39.S^I0:OK<16Y[E'B"21XQ])D%6R.O+S2-/:.(_E=RKC(
M<F^A@*<L<ECY5DGN3P.LF'M">K&<_>!RD'7ITMD?(F-&/FHBE#XI,XODBY?F
MN<3LDKG>Q5&_2;4MU8I:[-<K"/HZ[M'O'X(*#BX,MCL]@ZM_GKP/N3&" 63+
MRQ]EOD<[T@'NVL:YB[&9MY*.*"Y-DQDC&;C9RV!D(()9](=S3H@#>_2M@5.'
M\93;#XI3CC="]TD;NI+7.'*7;/IUT5+?PE>DK3TYL;2GNR/<XYB2=P>222'\
MH&^8#0UO71!CQ86O8P_%-XRV63U+4_BYCG<T1%C&G8 /4GILGU+O95CMYYN1
MF;++=&$BO-U(X R@GT ]W0=.Y7NMBJD%"6KV3'QS[,^Q_>N( <YWWG75=<^"
MQD\E*22G&7TP&P.&P6 =PZ=XZ#H>B#7W"M;-6CB,O6@U)/(U]JZ^]SB>,D\[
M>RUH:] '=I9%NI%F,;Q3D\E9L,NTYIH(BR9S&PQM:.4<H.CS;Z[[]JZ1<-8>
M+(>.Q4(F60[G#F[ #O7R[UO\%RO<.8B_=-NY0AEG( <YPZ.UW<P[C^*"!R3W
MQ^"B)\3W1O&/@TYAT1T;W+"L<.5HN(,54;:OFO>AE?;:;+_[9S T@D[Z;+CO
M6E=I,?4DQXH20,=3#!'V1'S>4=P_0+FZI7=9AL.B:9H6N;&_TM!UL#WZ"#6#
MY;L>.^2:_;3U#F9*H:^P8RY@8'-B[3O )W]_32F,6R[@,)G3F(9J^.<&"M7C
MM]M(PO\ F%K7]XV2W7JZJW387&S5;%:6E"Z"Q(996%O1S^GSO?T'5=57A[%5
M:-BG#2C%:Q_>L=MW/[R22@UO999QDF8JB";'AV*?.8?'3.>8/: _?H/4]W>K
M'%C8\+Q%P])4GM.DN<\=DRS.>)O[,NV03K8(]"L5?AG#5XI(XL?"&R,,;R=E
MSFG6P2>I'0*0EI5I9JTLD+'25R3$XCJS8UT_!! >$"Y*S#-QU-AENY)_BT3&
MD D'J_J>@^;OK]ZCN#I;..XCO8ZW0..@MQML5H3(UXVT!K]%O3ZI_-7":E7F
MMP6I86/L0!PB>>]G-T.O>OLU.O-9KV)8FNG@),3SWLV-'7O""BU?\'\;;[O&
MK?\ Y L:W'D(:7"<^2M5[-(3U^SKQQ]F_F+0&G>SS:WO73>E?F8RDRO:@;6C
M$-ISGS,UTD+AIQ/O6'1X8PM&PR>KCH&3,^@[6RWW;[D&OY9,DSA^U!8=5BP,
M^1E@GL-:YTL33*07$?1UOIOT;6UHF".-C&_1: ![@L5N,I-I34Q6B\5F+C)'
MKYKB[J[?OVLF&)D$+(HF\L;&AK1Z@.Y!S1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$5Q/_")O=_P5K[P==S/>M@\3_PB;W?\
M%:^\'7<SWH0VI'] >Y$C^@/<B#!K?QBU_D:I!1DSNPS$<AZ,E;R$_?Z%)H"(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B((GB@ZQ$V_4?]BM?^#GN8K1
MX1\FVEA)6 _VCP6 ?S.! _Y*KW@\@+6,.NY"&S8_H#W(OK/HCW(@PLK!VT#@
M.\=05U8O(ME AL$-F;TV3]+^JDG-YAHJOYC&/)=+7/*__=!845#/$.0QHY)X
MGO:.FVZ(_(KK?X0F,.G5K&_^U^Y!L!%KSSC1>SV/@_N7SSCQ>SV/@_N0;$1:
M[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>
MSV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^
MY/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7
ML]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_
MN0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%
MKOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%
M[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/
M[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ
M>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#
M^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$
M6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\
M7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@
M_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./
M%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX
M/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$
M1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSC
MQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^
M#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X
M\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/
M@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L
M1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_.
M/%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]C
MX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3S
MCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8
M^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&
MQ$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\
MX\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV
M/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/
M./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]
MCX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0
M;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KO
MSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/
M8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D
M\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>S
MV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y
M!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N
M_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L
M]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N
M3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[
M/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[
MD&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:
M[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>
MSV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7L]CX/[D&Q$6N_./%[/8^#^
MY/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_N0;$1:[\X\7L]CX/[D\X\7
ML]CX/[D&Q$6N_./%[/8^#^Y/./%[/8^#^Y!L1%KOSCQ>SV/@_N3SCQ>SV/@_
MN0;$6%D\C!CZ[Y)GM'*-]3K0]9]06O[?A#F>TMJ5)R3W$@,'_)59M/R_$$NK
MC]0EV^R9T;^/K_%!SSF3EXES([,DU(GGD/US];W>I;&X1QWB]<$CJH7A;AH0
M\KGM]2OU:$0QAH&D'<.@1$0%\<T.'5?401]O&Q3@\S=J)GX9@>=\JLRXO]""
MI>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/
MJJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]
M5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*
MIY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^
MJK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U
M4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@J
MGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#Z
MJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?5
M3R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J
M>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/J
MJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5
M/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*I
MY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^J
MK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4
M\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JG
MDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJ
MM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53
MR5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>
M2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJ
MUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/
M)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY
M*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK
M6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\
ME8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGD
MK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM
M:(*IY*P?53R5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R
M5@^JK6B"J>2L'U4\E8/JJUH@JGDK!]5/)6#ZJM:(*IY*P?53R5@^JK6B"J>2
JL'U4\E8/JJUH@K$7"T /T5)T\)!!W-4JWO7-!UQ1-C  &EV(B B(@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g50309g07m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g07m02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1EV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &5D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H_\  $0@#' :# P$B  (1 0,1 ?_$ !P  0 " @,!
M           &!P,% 00( O_$ &$0  $# @(% PP." 0$! ,&!P ! @,$!081
M!Q(3(3$445(7(C(V06%Q<W23L=$(%18S-#4W4U5RD92ALD)68H&2L\'2(U2$
MPAA#1&0D8Z3#176#)28X@J+A\/%&5RBTXO_$ !L! 0 " P$!
M   #! $"!08'_\0 .1$!  $# 04$" 8!!0$! 0    $" Q$2!#$R,W$%$R%1
M%")!4F&!L<$&%313H=&1%B-#8O#A<O'_V@ , P$  A$#$0 _ /5(
M
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MMV "%9
M                                     !\N>UO%4.-JSI(!]@Q[9G.-
MNSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-
MNSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-
MNSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-
MNSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-
MNSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-
MNSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-NSG R Q[=G.-
MNSG R Q[=G.-NSG R$5TG8C7"^#JVX1JG*51(8,T_P"8[<B_NX_N)-MV<Y2_
MLF*Y?:RQ4;'];)-),YO/JM1$_,I):IU5Q$HK]<T6YJA0JJJJJN57.5<U5>*K
MS@ Z3B@  )OX&383)QAE3_\ (IEM?QI0^41_G0]+Z7,?UN"9+6E'14U4VJVF
MNDKG(J:NKN3+GS4CKKF)B(C.4UNW353-54XB'EY%1>!R7CIVM-OJL(VG$\%*
MVCK9G1-D:UJ-5S9&J[)W.K<N)HJ+1'%)#3<KQ7:X:BJ8U\,3=ZNUDW99JBK^
MY#$7:9C,E5BN*IICQ56"87S1_=+/BRFL=3-3-6I36AJWOU(G-[JKGPRYN/,6
M?C/13;7VJRTU!76VUS0,5LT\R9.J79)O[^_-?WF9NTQCXE-BNK/AN4?9K+<K
MW-)#:**>LEC;KO;$W-6MYU.E(QT4CXY&JU[%5KFJF2HJ<44LO0Q17MU_O<.'
MKC24TD,>I*Z>)7MD:CU1%3)4RX9_O(U:\,7;%.,ZZVTSFSU;9Y'5-0[<QN3U
M17KWL^X9U>,Q/L:]WZL3&^47!:LVAN>1E3%:<16VON$"9OI6]:[/FSS7+]Y%
M<$8(K<57FOMC)V45511J^1LS%5<T=JJW).[F(N4S&<DVJXF(F-Z* M:TZ%ZZ
MJC;'77FBH[@Y%=R/+7>U,]RKDO[]W.1NAP!<),=.PS7ST])+'D]\SG]:Z->"
MLYU7/<G'GX"+E,[I9FS<C&8WH:"]-*.C2W;:.IM59;+3%34:JZF<F3YG-UEU
MDW[U5,DS[Q1+5UFHN66:9BBN*XS#%RW5;G%3;4^'[M46:2[06^=]LCSUZE$3
M4;EN4U9=V$__ ,.=[\,_YD('@+1_<,6TU36-J(:"VT^Y]5.G6JJ;U1/ G%>!
MB*]^?9+,VI]6*?&9C*&@L'$VC"LM=A?>;1<Z2]4$7OKJ7BQ$XNXJBHG=RWG2
MO&C^HH,$08GI[C3UM#+J*K8HW(YB.7)<\^9VY3,5TS[6)M5QG,;D+!,L%8!J
ML466XW5*Z"AHJ)51\DS%<CLFZSE3+F3+[3NX5T95EYL?MS<+E2VFV.WQ2U/&
M1N>2.RS3)%[XFNF-\D6JZL8C>@!M*C#UWI[/'=9[?.RVR(BLJ%1-1V>Y,B0X
MXT>5^%Z"&XLJH+C:Y51$JH.#57AFG?YTW$[Q5_\ AXLWU8?SF)N1X8]LMJ;,
M^M%7A,1E1YDV$WS,G\*F)W8KX#T]C[&M7@O"5BJ:&EIZAT[61N2951$39Y[L
MO *ZYIF(B,Y8M6XKB9JG$0\P]U4[J<4YCDOK2;2T.*-%5+BM]#'0W%K&2]:U
M$<J.<C5:JY;T[J9E?X,T;5^(;0^[U=;3VJU)GJ5%1_S,MRJB9IN14XJ*;D3&
M9\&:K-45::?'VH*"=8RT<5N'K.R\4E=376U*J(^HI_T,UR15WKNSW9H?=HT7
MW>[X:MMWMLT4Z5LB,V*-5%B365%>Y>&299F==.,Y:]U7G3CQ0(%@W[1?<+??
M+7:+?5Q7*MK6N>[9MU6PM;EFY55>&\W<FA62+6B?B:VMK&MUEB<U4R3GXYY=
M_(QWM'FS%BY.8QN5&"3X)P5<<7W.HIK<Z-M/3K_C5;\]FQ-^7?55RW(2BNT0
MU2T%5/8;W07B>FSVE/!N?N[B;UW\=RF9KIB<3+%-JNJ-41X*P!.\,:,[IB3#
M,=WMM1 NO.L*P/16JW)V2N5R[LDXY&ZKM#-:VT5%9:KS17*:!JJZ&%O9*B;V
MHN:[_")N4Q.)EF+-R8S$*J!:V@S!--?*V2Z7;DL]%"UT;:.3)SG/W)K.;W$3
M?^\T>D3!$>'&35\-WM]5'+5+&VEI^RB1=94SW\$RR'>4ZM)W-6C7[$%/IC'O
MSU&.=EQU4S/DO71C/!@;1?48FJHD=+7SL1K7+EK,UM1N7_ZE%=6F,L6J-<XF
M<0HM&/5^HC':_1RW_8?>PF^9E_@4N+2Q)+@[2=;L4VZGBG950:S4=NC<]&JQ
M=Z<[512=Z-<?5V*[!>J^LHZ:"2A[!L2N5'=8KM^?@-)NS%,51'@EIL1-<T3/
MCT>8'Q2,3-\;VISN:J'UL)OF9?X%)KCG25<<9VNGH:Z@I*>.*=LR.A<Y5541
M4RW^$NW25C"Z83M]J?:+;'7.J,VO1[7KJY)^R9FY5&(QXRQ1:HJS,5>$?!Y8
M[JIW4XH9&PRN:BMBD<B]U&JIZ!TE145]T1I?KO;(K;>-FR2)BHC9$>KT35X9
MJBIOR[YV<*WZ?#.@2@NU)#'--!&[59)GJKG.Y.YX3'>^&8CVX9]'C5B9\,9>
M<G=:[5<BH[F7<H/1E#74NDS1Q=JR]VF&CJ(-=K)VIGDK6ZR.8Y4S[N2H><F[
MT0WHKU9B8\817+>C$Q.8E]LC>_/48YV7'53,XD:Z-421KF9\-9,B]?8S.U:+
M$;D[CX5_!YM='>.WZ0KA66B_6"E=3I"LFT:U7LW*B:KD=W=^Y<S2J[,3/AN2
M46(JBF9JQ,_!YT!/:'1Y5WW&M\MEF<R*W6^I>QU5,N;8VYKDWOKN_ V%RT25
M3;955=@O5#>7TV:RP0*B.W<<MZIGN7<;]Y3&^4<6:YC,0K(V%DLESOD\D-GH
MIJR6-NN]D29JUN>69NM'^![CC2MFCHW-IZ6!/\:ID3-K5[C<N*JI<NBC TV$
ML2UTS+C37&FFIUA<^%<EB>CD7)R9FM=V*8GS;VK%5R8GV/.M9334=7-2U4;H
MJB%ZQR1NXM<FY44Q$_J,,38MTLXAM=-4QTTBU=1+KR-5R=:_AN\)&[GAV6@Q
M<^P/J(WS-G;!MD:J-S=EORX]TWBJ)1S1,>/LSAI 2O'>"*S"-VH;?+41UL]7
M'KQ[%BIOUM5&Y+W<R646A>M2B@FO-ZH;;/-EE ]-947HJN:(J^ Q-RF(SEF+
M-<S-,1XPJ@%UZ.M%T$6,*OVWK+=<J2A16+ SKMH]S4WJU>"-S^W(B.DS!,.'
M7U5?3W2@GAEJW,91T_90M555$5,]V661B+M,U:8;56*Z:=4PB=58KI26F"Z5
M-!416^=42*H<W)C\^&2_N4UQ:6,8<0MT16*:X7*EFM+MBD4+(G)+O:NJCG*N
M2HB)W$-?A#1;<;[94NU=74]IH'>]OJ$WO3I99IDGA$7(QFIB;4ZM-,>Q7H)S
MCK1M<\*T$=Q;40W&VNRUJB!,MGGP5R<R\Z'<M&B>ZW6Q6JZTM=2)35K==ZR(
MK>3LR7KG*O'AW#/>4XSECNJ\Z<>*N@67B71+6VK#TUXMUTIKK3PIK2-A;DNJ
MG%47-47(K--YFFJ*O&&M=%5$XJAR #9J%G: ,0K:L7K;II,J2Y-U,EX)*G8J
MGAWI]A6)VK35/H;M0U<3M5\%1'(B\V3D4UJIU4S#>W5HJBJ'MP&/;LR1<]RI
MF-NSG.6[C(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'
MMV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'
MMV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'
MMV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'
MMV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'
MMV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#'MV<XV[.<#(#XVK.=#EKT7@H'
MT         8IY=5-5N]R@<RS-CW+O7F,2)-*F:KJ(?<,.KUS][S,!@;3-_25
M54^N3Q\R_:90!BY/'S+]HY/'W_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'
MW_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3*
M ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_
M -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'
MW_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3*
M ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_
M -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'
MW_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3*
M ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_
M -HY/'W_ +3* ,7)X^_]HY/'W_M,H Q<GC[_ -HY/'W_ +3* ,7)X^_]I1WL
MF*79^Y^=O8JLT?Y5]9>Q6VGVRONN!G5$#-::WRI4=_4R5'_@N?[B6S.*X0;1
M3JM3$/,0 .BXX  .S:_C2A\HC_.AZ8TM8FLF'9[4^]V!EVD?M%A5R,799:N?
M9<^:?8>8J>58*B&9J(JQ/;(B+W51<_Z$JT@8[K,:NHG5U'3TW)=?5V3E=K:V
M7'/P$5=&JJ/)/:N]W15'MG#<XCQ37Z4L3VJT1L;;J&25&1Q*[:9.R7-[ER3-
M<L\D)!B.RX%P;?K;:ZFVW6Z7639N:]LRIJKK9)EO3NIP0J&UU]1:[C35]"](
MZJFD22-RIFB.3O=TLJX:9[E5T[7-LMLCN36*UE8Y-=T:\[45-W/EF8JHF,13
MN9HN4S$S7Q=,M][)MC5?AU=5,U=*F?\  ?/LDFYV_#*JU5:FT3/+<G6M*ZQO
MCBOQA2VV*YP0L?1-<B2QJN<BJB(JJG!.&>[G)30::+G#:8*2OM%!720(B,ED
M54SR3)%5,EW]]#6**J8I^&6]5VBN:\SB)Q[/)W_8T_'E]\E9^920:#-C[I<<
M+UO*.5)ETM77DX=[/^A5>#<=UF%KO=+A2T=//+7YZ[)'*UK,W*[=EX3HV/%M
MSL>)I[W;'1QU,[WNDC<FLQ[7.S5J][/N\3-=N:M7QPQ;O4T13'EG^5A6'%NC
M_#&(9*Z@M6((;DU7QR))DY555ZY'(K]ZYFST-W&"[Z5<5W&DCDBAJ85D:R1N
MJY,WMXISFA=IGJ%?RAN&;2E?QVZ[USY\\L_Q(KA#'5=AF_W*[T])3U%17H[:
M,>Y6M;K/UERR[YCNYF)\/'JS%VFFJGQ\(G/A&&\H:RHDT^.G=,_:K=71:R.7
M/415;J^#),LC?:36MZNUAW)OY,J_QJ5G3XCGAQA[HD@B6IY4M5L55=365<\L
M^.1V,7XOK<2XCAO4L45)5PL8UB0JKD16JJHN_P )OHG,3\,-(NTZ9CVYRF_L
ME6YXPM2JW<M"B(N7'_$<8((=%7M<S;3U_+-BBNR=)EM-7>G#G%?IFKZ^V.IZ
MNR6^2I6)T:3JJ];FF2JB9;OM*K1,D1#%%%6F(GPP7+E&N:J<3GSC<N_"7_X<
M[WGSS_F0W^&76IF@.!UQIZBHMZ0*M7'1K_B+_B;^ZG>S[Q3]MQU64&!JO"\=
M'3OI*C7UIW.77367-<DX=P^L":0+K@^*>FI(X*NAG=K/IYT7)%X*K53AFGA0
MUJMU3GKEM1>IIQGRPG%BQ_@>QV2YVVQVV]MAJXW(]CVH]J*K53/LMR;]Y]Z%
MYXL18#OV#ZMV;D:Z2%%WY-=S>!^_]Y&[]I3FN-HK+?16"V6]E7&L4LD2=<K5
MXY9(GXD4P;B.JPI?HKK0QLED8QT:Q2*J->UR<%R_<O[C/=S-,^9WT15'CF(\
M-V-ZUL82>X;0S;[&UNI7W--6;+<N_KI%^S)O[R1XYEPY!HVL"XAHZZJM&K#J
M-HER1J[/K5=O3=Q_>4CCW&5=C2XT]7<(8:?D\6R9%$JJW>N:KO[J[OL-OA#2
MA=</6AMIFI*2Y6QB*C(JA-[$SSRS[J>%#'=58B?:VB_3F8]F,1X?9O+[CO"T
MFC>NPSA^BNS(WHFR6H:CFQNUT=O=K+DF:*;?%7_X>+-]6'\Y!\9:0YL269;5
M%9Z"W4:RMF=L$R<KFYY<,D[IU;CCNLK\$4N&)*.G92TZ-1LS7+KKJKGO3@9B
MW/AX>W+2;L>MF<^&-V$0=V*^ ]/8^OUGL.%+#-?;(R[QO;&V.-R-5&.U./7'
MF%4S14)CC/'U;BJT4%OJZ*GIXZ-45CXWJJNR;J[\S:NC5,-;5V+=-7G+O:1]
M)-1BVBAMU'1I;;5%DNQ1Z.5ZIV.>2(B(G,A:-RDL$6A:Q.O%)6U5G2&#791+
MO1VKO5V]-VMGGW\CS@3C!6DN[X7MJVU(*:OMF:JD%0G89\41>9>93%=OPB*?
M8S;O>M,W/;"2U&.\(4^ ;KAS#]NNS(:ACU:D[4<UCG9;U767),T0DUJK:FW>
MQS=544SX:EE,Y&R,7)6YRY*J+W%R52N\4Z2Y[W8JFTTUDMUNI:G5VKH4ZY=5
MR.3@B)Q1#I-T@UR8"=A/D5-R-6;/;ZSM?+7UL\N'$U[N9C=[6\7HB9\?9B,1
MA+?8V2++BN\NFD=)-R--57N5RY:Z9\?W%>8M;<'8TNS:E*AUP=52)DB+KJFL
MN2)EORRRRR[A@PO?Z_#-XBN=JD:VHC16JCVZS7M7BU4YE+&DTWW!R;9EAMJ5
MV623N55R_K^)O,515-41G*.*J*K<453C"1:!>2MT>8AUXY7R)-)MV0;I7-V2
M9(WNY]EEWS3X/QQ@#"M=/-9+5?8ZB=FRD:Y$?GOSX:_',KW!N,[MA*Y3U=K=
M$YM0O^/!*W-DF]5\**F:[T)E+IEJ$5\M)ANTP5KN,^6:YKW=R(OXFE5N<S[8
MGXI*+U.FGQQ,?#*3V6X+'H*Q%76]7PI)/4NB[CF-=)^"Y*=#V,[E2+$D:*NS
MU8G:O<SR?O*^HL<UE+@6JPLVC@=2U"O<Z=7+KHKG:RY)P[@P#CFLP8E?R*C@
MJ>6(U';5RIJZN?#+PF9MSIJB/;+%-ZG715/LA./8[(GNVQ)XA?YJE58B;EB.
M[=;DJ5<N>[]M39X.Q=7X5O\ -=;?'$]\R.9+#)GJN:KL\L^*9*FY3;X[TBS8
MMMR4;K11T3%F;.^6-<WO<B*F]<N&\VB*HKF?9*/53-J*9GQC*(6JBDN5THZ&
M!%66IF;"U$YW+D>D=(%BPY/AVU8:N=_@M,%(UKVQJYC5D1K5:BY*OA7PGGK"
ME[=AR^TUUBI8JJ:GS6-DKE1J.5%3/=S9F3&6(ZK%=^ENM=''%(]C8TCC55:Q
MK4[F?[U%=$U51Y0S;N4T43$QF9^B\=)%KH[YHD22UUL=T=:4:YE3&J.5R,ZU
MR;N[JKO\!I- 7:5BWP_^VI L$Z0:["EHK+9#0TU;1U3U>YDSE;EFF2HF7.B(
M8\&X[J\*VNYT%%0T\T5>JJY9'N16)JJW),N.Y33NZM,TI(OT37%<^7BA\?Z/
MA3TGIW2QC6YX.M]G?:H:>5U3FU^U:KLLFY[LE/,3=V7>7,MKJXW98V,?9+:]
M&(B)K/<IM=HFJ8F(RCL7(HIJB9Q,X2O%>6.-#K[[>J)]'<*6)\T/7.1N:+Q1
MJ\4<G.=G"MX@L6@.@N-5;X[A##&[6II%1&OSG<F_-%3N\Q56-=)M\Q90<@J6
MT])0JJ*^*G1?\3)<TUE7N=Y,CK.Q[7+@!N$N1T_(VMU=OK+K]GK\.'$T[J=.
M)\TOI%,535'EC/G*UL?W*JQ#HFCN>#WMI[:K5Y920L371F>3FYIPR7BB)O1>
M8\\IPW$PP)CZY8.AJX*2""KI*E4<Z"?/51W#-,N=-RH1:MFCJ*V>:&!M-'(]
M7MA:Y7)&BKGJHJ[U0EMT31F/8AO7(N8J]OM7A[&9=6BQ&JIGD^%<OW/)#A+%
M"8OPA>68/I*6Q7R)<FQ(C')GW';D3//>F>6Y2E\!8]K<&05\5#1T]2E8K5<L
MKE35U45-V7A-5@_$E9A6_1W2W(UTC4<Q\3U5&R-7BU?P7]Q'59FJ9G_"6C:(
MHIIIZY75H:V3-'&)5N$51+5)4U'+F1K_ ([EU$S3GUN.7?-#@['6 ,*U4\EA
MM=]CEJ&)&]BHC\T1<^&OQ(Q!I2NE'B6HO-NH:.E?5M1*NF17.CG<F>3]^]KL
MERS0VE1ICJ-G*ZBPY:J:JE:K73HF:[TR5=R(OXF)MU9G,;_BS%ZB(C$[O@EV
MB&19-&^*IK,U[*U]74/B1B=>F;$5B;NZ1KV-:U7NHNB-638+3(L^>>2OUDRS
M_:X]_B0S 6-[G@NKFDH&QST\^6UIY=R.5.#D5."H2EVFF[QW)L]#:K?34W7+
M)3M3WYR_I.<B9[C-5%7K1$;V*+M'J35.)I^#:Z/E_P#\@+[XVK_,1_$E#43Z
M='4S(G[62OB<U%:O8Y-76\&6_,BU/BJX4N,9<24:1PUTE0^=6=DSKES<WGR7
M/(FURTUW:IBUJ.TV^DKU;J\KRVCFIWLT])G35$YCRPUBY153BJ<>.4OTE)&N
MFK R39:F2<>?7=E^.1#O9%\L]VM/RG7Y'R9O)\\]5%S76R[F>>7?X$6QMC:O
MQ9=:"XU$$5)4T;$9&L+E7>CM9';^[F2ZFTV7-U)'%=;-;Z^:--TKNMS7I:N2
MHB^ Q3153B<;F:KE%>JF9QF<[G9]CBV5N+[KRELB2K1(J[5%UE37;DN_>5KC
M-NKB^_)JY*E;-GNR_34WU-I'N]/CBHQ0R&FY541I#+ F>S<Q$1$3GSZU%S,N
M/-(<V+;>E(ZT4=$BRI*^6-<WO<F?%<N^;Q%45ZL;VE55$V].?&,^S>F6D+_\
M/^&O#3_E<;#3CMET:6#D>?M;G#M-7L<MFNIGWOZY%87K'-9=L&6_#<U'3QTM
M&K%9,URJ]VHBHF:<.Z;/!^E&ZX>M"6J>DI;G;FYZC*CLFHJYZN?!4SYT-.[J
MC$^4M^]HF9C/A,1'^$ZPEM?^'N\^VVNL&QGY/M<\M3)-3+/N:V>1@Q)534WL
M<[.V%[F;9D,3U1<LVJY<T_ @N.-)5VQ50-MSH8*"VM5%6"#/K\N".5>XG,AT
M[GCBLN&!Z/#$E' REI=16S-<NNNJJKO3AW3,6ZM\^>2;U,1-,>6%DZ&G.71+
MB6-556-?-JM7@F<:9Y%$,[!/ 3'"N/:W#F'+A9J:BIYH*USG/DD<J.;K-U=V
M7@(>B9)D;T4S$U3/M17*XJIIB/9#D $B(/N!BR5$,:<7R-:GA5<CX)=HGL;K
M]CJVT^2+# ]*J7/AJL5%R_>N2?O,3.(RS33JF*8>LF4S$8U%S54:B<>9#GD\
M??\ M,H.4[S%R>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[
M3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%
MR>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[3* ,7)X^_P#:
M.3Q]_P"TR@#%R>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[
M3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%
MR>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[3* ,7)X^_P#:
M.3Q]_P"TR@#%R>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[
M3* ,7)X^_P#:.3Q]_P"TR@#%R>/O_:.3Q]_[3* ,7)X^_P#:.3Q]_P"TR@#%
MR>/O_:.3Q]_[3* ,7)X^_P#:.3Q\R_:90!A6F9W,T,3Z=[=[5S.V -<M1)#O
M>BN:G%>ZAVX*ADK<VJBGW+$UZ;]R\YHZUDE ]9XD_P --\C>;OH!OP=2@K&U
M$2.145%0[8   </=JM5R]PP4S=9SI'<5X'-4NYK$[JF9J:K41.X@'(
M
M                        'Q-$R:%\4K4?&]JM<U4S147<J*?8 \C:2\'3
MX/Q!)3HU[K=,JR4LRIN5O05>=.'V*1(]HXFP_;L2VJ2WW>!)H'[T5-SF.3@Y
MJ]Q3S1CO1E>L+2231Q/N%LS56U$#%56-_;:G8^'@7[5Z*HQ.]RK^S3;G-.[Z
M(*#@Y)U4
M                                  #N6BUUUXK&4MKI)ZN=WZ,3%=EW
MU7N)X0?!U&-<][6,:KGN7)&HF:JO,AZ?T*X*7#%B6LN$3F7>N:BRM=EG$Q.Q
M9X>ZO?\  :W1=HGAL$K+GB'8U5T:J.AB;O93KS_M.[_!.YSEL%*]>BKU:71V
M79YI]>O>  K+P
M                              &*IB22-<TSW<.=#* (93S+:KR^E7-(
M7=?%GS+W/W$OIY$D8BIW2(X]9L::GJV;E@F1%7]EW_[HAM\.U>WI6[^X!NP
M!UY-]2Q#L'7?\*8=@
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MN3U#E3[$R)Q;;;16NG2"W4L--"GZ,3$:B^'+B=L&M5=56^6]-NFCAC  #5N
M
M                     ",Z06HN&Z]5_1CUOL4UF!:A7P-13::0>UBY>(4C
MVCUW^$T"QDX(#AO8H ,#_A33L'7?\*:=@
M
M
M
M
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MQ]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q])
M,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>
MWCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2
M#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]
M) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@
M,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WC
MZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;
MQ]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q])
M,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>
MWCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2
M#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]
M) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@
M,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WC
MZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;
MQ]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q]) ,@,>WCZ2#;Q])
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M5;!WTQ'_  .]1]0Z4L(331Q1W=CGR.1C4U';U5<D[@[NKR.]H]Z$V !HD
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MS#/BY?YKB?$"T!_(YAGQ4O\ -<3T
M
M
M
M               -!I [1K]Y&\\DL[%/ >MM(':-?O(WGDAG8IX"[LO#+F[;
MQ0^@ 65(.S:OC>W>51?G0ZQV;5\;V[RJ+\Z >W0 <EWP       $:T@]K%R\
M0I'-'WO;21Z0>UBY>(4CFC[WMH%CL[%/  SL4\  P/\ A33L'7?\*:=@
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M9$SA54SRU5WHO,H$O 5,ER7B
M
M
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M>K575TTDD-M<Z:&DRR8LZIDV55[JM3/).^!NY??'9<Y\@
M
M
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MBDQI*B&KI(*JF>DE//&V6-Z<'-<F:+]B@90
M
M
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MK1(N:QIW&HO.AN8(HX((X8&(R*)J,8U.#6HF2)]B ?8
M
M
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MO)4JFOS2&=4S:QR9;T=O1%SXIP WP"[N(
M
M
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M%!-4.J*6AJMG32*JJFHJ+N3O;D7+OEBY.JF<3N^"I9IBBN,QC.[QRMH %5>
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M<WXCD\G-^(&(&7D\G-^(Y/)S?B!&](':-?O(WGDAG8IX#UUI#B>S M^5R?\
M2/[O>/(S>Q3P%W9>&7-VWBAR "RI!V;5\;V[RJ+\Z'6.S:OC>W>51?G0#VZ
M#DN^        C6D'M8N7B%(YH^][:2/2#VL7+Q"D<T?>]M L=G8IX &=BG@
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M!'5:R*UE1EFV-R)PUD1<EYT D@
M
M
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M0$I
M
M
M              !&])7:%?O)'^@\>-[%/ >P])7:%?O)'^@\>-[%/ 7=FX9<
MW;>*'( +*D'9M7QO;O*HOSH=8[-J^-[=Y5%^= /;H .2[X       "-:0>UB
MY>(4CFC[WMI(](/:Q<O$*1S1][VT"QV=BG@ 9V*>  8'_"FG8.N_X4T[
M"/X[Q'[E<-U%UY*ZJV3F-V37:JKK.RXD@-'C3$4&%K!/=:J"2>*)S6JR/+-=
M9<NZ9IC,PUKG%,SG"CZG2C8):GE51@:E69-ZO=J[_#UN2EMZ,L6NQ;:9ZE+4
M^W4\+TCB15S:],OT=R)DG @]7IRL=13OCDL55.U4RV<FHK7=Y<\SO^QU;6K8
M[Q-412PT$U7KTL;\]5J*BJY&9]S@G[BS73ZDS,8^:I:N9N1$59^2V@ 55T
M         U&,>U&^>0S_ ,MQMS48Q[4;YY#/_+<!$O8\?(WAGQ,G\UY8A7?L
M>/D;PSXF3^:\L0
M
M
M
M (WI*[0K]Y(_T'CQO8IX#V'I*[0K]Y(_T'CQO8IX"[LW#+F[;Q0Y !94@[-J
M^-[=Y5%^=#K'9M7QO;O*HOSH![= !R7?        1K2#VL7+Q"D<T?>]M)'I
M![6+EXA2.:/O>V@6.SL4\ #.Q3P # _X4T[!UW_"FG8    O!2B\2Z1,6Q5=
MQII\*Q36^"5Z:\]-(K%8U5R<JKN_>7H0W2[9:^_X%KJ&THKJI58_9H[)9&M7
M-6DEJ8B?6A#>BJ:<TSN5'38YO]50K64V!;?-2(BKMH[>YS,DXKFB9%J:(L2W
M+$]CJ*NXT-/20,D2.F2!,FN:B;]W>7<5M:=,%WLUFAM4^'D=6TL:0,<JN8G6
MIDFLS+//=W%)GH$LMUMEENE9>(74_MC4I410NW*B*F]VKW,\]R<R$URG%,YC
M"O9KF:XB*IGS\%H  JKP  !!,7QX_N%Y6EPM+:K3;(V(Y:ZJ3;R2N7BU&(G6
MY=\G9'L<8LMV#[(^X7)[E<Y=G3P,3-\\J]BQJ<ZJ!%M'>*[ZN+;QA#&"TM1<
M[=3MJVUU*W4CFB<J<6KP5,T(O@FY:4L96%MYMM[L-+2S2R,CCJ*1RNR:Y4SW
M;NX2?1MA2YRSWK%.+6<FQ!?8]DZ"-?@E.B9,CYM;+)5X[T\)JZ+1->[!9FP8
M;QS=8I:5JK30211['6WJB.;EP5>*]\"TK''7Q6BD9>)H9[BV-J5$D#5:QS^Z
MK47@AW2%Z(<55.+L%TU?<6-;<(WOIZE6)DUTC%R5S4YEXFTQQAZIQ):&45%>
MJVS2-F;*M12=FJ(BIJ^!<_P D!J,8]J-\\AG_EN*]ZDUZ_\ [CXC_P#T^LU^
M(-%UWI+#<ZB32#B"=D--+(Z)^KJR(C5757O+P DOL>/D;PSXF3^:\L0KGV.Z
M9:'<.+FJZT<BY<W^*_<6,
M
M
M
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M_P"6X")>QX^1O#/B9/YKRQ"N_8\?(WAGQ,G\UY8@
M
M
M
M                           1O25VA7[R1_H/'C>Q3P'L/25VA7[R1_H/
M'C>Q3P%W9N&7-VWBAR "RI!V;5\;V[RJ+\Z'6.S:OC>W>51?G0#VZ #DN^
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M(
M
M
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M=^QX^1O#/B9/YKRQ
M
M
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MF4M441.]XSMK;;^S4T3:JQG/E]TLZIF(OGX_-H.J9B+Y^/S:$*!)W=/D\_\
MG.V_N?Q'])KU3,1?/Q^;0X729B)$7_'C\VA"PO8KX!W=/D?G.W?N?Q']+[MC
MKU6VVEJG7YS%GB;(K4I&KJYIGEGF<W%;U26ZKJFWYSU@A?*C5I&HCM5JKEQ[
MQGP[VO6SR:/T'U?^U^[>1S?D<0:8R]O;N531$S/L4FW33B5S47*G3-,^Q.>K
M1B7_ +?^$K&/WMO@0^B[W%OR4(VJ[CB^BS.K1B7_ +?^$=6C$O\ V_\ "5F!
MW%OR/2;OO?1<6$M*&([_ (DM]J?-#3MJY=FLK8T<K-RKGEW>!:FPO/ZPO^YL
M]9YST5?*+8/*4_*X]-E>[133.(A;V>[773,U3[4:Q9<;Y8<.5UTCO*U#Z9B/
M2)U*UJ.WHG'/OE5]6C$O_;_PEGZ4_D^O?BD_,AYD-[-JFJ,S#3:+]RBK%,K,
MZM&)?^W_ (1U:,2_]O\ PE9@E[BWY*_I-WWOHLSJT8E_[?\ A))@#2%B'%=_
M]K9:N.D;LGR[1D2/7K>YDI1Y8>@CMZ_TLOH-:[-$4S,0WM[1<FN(F5Y["\_K
M"_[FSUD=Q_?;[A3#WMG#=DJW;=D.S?3M8G79[\T7O$Q*_P!.O: OEL7H<5J*
M8FJ(E=N5U11,Q*#=6C$O_;_PCJT8E_[?^$K,%ON+?DY_I-WWOHLSJT8E_P"W
M_A'5HQ+_ -O_  E9@=Q;\CTF[[WT7[HVQKB#&53<(IJ]E$E+&QZ+'"C];654
MRWDYV%Y_6%_W-GK*D]CO\8W[R>+\ZEU%6Y1335B%ZQ<JJHB9E7VDG%M_P;#;
MI(+BVMY6Y[522!&:FJB+NR5<^)!^K1B7_M_X3>>R)^!X?\9/Z&%+DUNU1-.9
MA6O;1<IKF(E9G5HQ+_V_\(ZM&)?^W_A*S!)W%OR1>DW?>^BS.K1B7_M_X2P=
M'6)+]B^SU5=-=$HUAGV*,CIVO1>M1<\U7OGG(OGV/W:E<O+O]B$=VU133F(3
M6+]RJO$RGNPO/ZPO^YL]9K;E5WRCF:QM[5Z.;GFM*U/ZDA-!B'X7']3^I3N>
M%.8=G8:(NWHIK\8=+VVOWTO_ .G;ZQ[;7[Z7_P#3M]9@!7UR[?H-CW?JS^VU
M^^E__3M]8]MK]]+_ /IV^LP :Y/0;'N_5O:%;U4TK)77YS%=GN2D:O\ 4S["
M\_K _P"YL]9]6;XMB_?Z3NEFF(F'G;WJW*J8W1,JCQOI)Q%AG$E5:HJF*J9"
MUBI*^)&JNLU%X)X31=6C$O\ V_\ ":G3/\HER^I%^1"$EVFS1-,3,.57M%V*
MIB)69U:,2_\ ;_PCJT8E_P"W_A*S!MW%OR:>DW?>^BS.K1B7+A3_ ,);EAJ+
MW=+';[@^^.B=50,F6-M*U4;K)GEGGO/*R\%/5F!^TNP^11>@AO6J:8\(6-GO
M5US.J7;2"\JO;"_[FSUE=772#B&ANE92-JV2-@E=&CUB1%=DN6>1:K>*'G[$
MW;)=O*7^DCHHB=ZCVSME[9K=-5JK$S/P^Z1=4S$7S\?FT'5,Q%\_'YM"% D[
MNGR>=_.=M_<_B/Z37JF8B^?C\V@327B)7(G*(]ZHGO:$*.6]FSZR>D=W3Y'Y
MSMO[G\1_3T'L+S^L+^'^39ZSA\5Y;&]WN@>NJBK\#9ZS8=Q/ GH/B;WB7ZCO
M008A[J:I5*[27B)'.3E$>Y53WM#CJF8B^?C\VA#']F_ZR^D^2;NZ?)X:>V=M
M_<_B/Z37JF8B^?C\V@ZIF(OGX_-H0H&>[I\F/SG;?W/XC^E@V;'^(+C=:2C=
M5LC;/*D:O2)JJW/NY%AK!>47MA?]S9ZRD<(]M%J\H9Z2_EXJ15T1&YZ+L7;+
MVTVZJKM69B?AY?!%<7W6^8?L_+H[PM0[:MCU'4S6IOSWYY]XA75,Q%\_'YM"
M6Z6.U+_4Q_U*=-J**9CQ4>U^TMIV?:-%JO$8CV1\?@FO5,Q%\_'YM!U3,1?/
MQ^;0A0-^[I\G+_.=M_<_B/Z37JF8B^?C\VAM<+8UO]\O4%!)7-@;(CEVC86N
M5,D5>!6I*-&G;C1?5D_*IK-NF(W+.Q]K;9<OT455YB9CV1_2W-A>?UA?]S9Z
MR-XUO]]PW#22177E6W<YJHZG:S5R3/G4F97>F/X':_&/]!'33$R]+VC?N6=F
MKKHG$Q_;2]4S$7S\?FT'5,Q%\_'YM"% F[NGR>1_.=M_<_B/Z37JF8B^?C\V
M@ZIF(OGX_-H0H#NZ?(_.=M_<_B/Z6K@K%5^Q)7U--+<DIDABVB.; U^>]$R[
MA+]A>?UA?]S9ZRM]#WQY</)D_.A:Y%53$3X/5=E;3=O[-%=R<SX_566D;'6(
M,'W6DHX:UE8V>#;*^2%&*WKE3+),^8B?5HQ+_P!O_"9?9!]L]K\A_P#<<5<6
M+=FB:8F8;7=HN4US$2LSJT8E_P"W_A'5HQ+_ -O_  E9@W[BWY(_2;OO?19G
M5HQ+_P!O_"3K1OBN_P",:2X3SW)M$M+(QB)' U^MK(JY[U3+@>>2[?8\_%5]
M\?%^5Q'<M44TYB$MF_<JKB)E9.PO/ZP/^YL]9!\38TO]EO=10,KVS-B1JI(Z
M!&JN:9\"QREM(_;E7^"/\B%:*8=.SZU6)=[JD8A_S4?FD'5(Q#_FH_-(0T&=
M,+.BGR3+JD8A_P U'YI!U2,19+_XF/S2$-.%X*-,&BGR7M;'WJMME)5NOSF+
M/$V16)2-5&YIGEGF=E(+RJ]L+_N;/6<8;[7+5Y+'Z#8MXH8TPI35.567+'^(
M:.XU5*VL8](9'1HY84179+Q.MU2,0_YJ/S2$=Q#\?W+RA_I->9TPN113A,NJ
M1B'_ #4?FD'5(Q#_ )J/S2$- TPSHI\DT9I&Q"Y[6\JCWJB>](64D-YR1?=
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M3BBY]+O%L@=[7YGH]OR;J@;(VCB2>7;2:O72:NKK?N,YCIO@\?U4,A670
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M/& &:<Z#-.= +ZP9VHV?R=/2IN338+[4;/Y.GI4W)6?1]GY-'2/H  )@
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MB+S[R2$548F4U$YIB8  8;   $<OOQB[ZC21D<OOQB[ZC2*[PNCV7S_E+7@
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M^*K[X^+\KB*]P2GV?F0M@I?2/VY5_P!6/\B%T%+Z1^W*O^K'^1"I#L;/Q(T
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M50L/01V]?Z67T%>%AZ".WK_2R^@TKX926>.'H(K_ $Z]H"^6Q>AQ8!7^G7M
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M(Y:Z*LY4Z-R+'&K-751W/]8F(!I,S5.92TTQ3&(  89
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MDG,I- #6:IJWMJ:8IC$  ,-@
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MQ[E;!]#TGV+ZS<@&NKS?$,4<$,<,+$9%&U&L8G!J)P1#[ #4
M
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M7<5+O'+I;/RX_P#>U3WLCO@F'?&3^AA29=GLCO@F'?&3^AA29/:X(4[_ #)
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M2B^K)^136K<M;!^IM]8^J\0 1/H0
M
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MKUV\CF_EN('TFURZ>D/'\?O;? A]'S'[VWP(?1?<J-P  RE6BCY1L/\ E/\
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M/A.?8  U=P
M                                                        &V@]
MY9X#[/B#WEG@/L@3P        C6D'M8N7B%(YH^][:2/2#VL7+Q"D<T?>]M
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MX2JZ%()V.IZR!RRN;DQ^:.W-7N\2K1/K0Z-V/]NKHH( %UR@  6_['+XRO\
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MP .=9=V]=W :R\Z\YP .5<JYYJN_CWQK.YUYC@ <HY4RR5=W#O#-<LLUYS@
M<ZR[]Z[^(UG;]Z[^)P .=9V>>:Y\ CE3+)5W<.\< #G-<N*\<PKE7/-5W\>^
M< #G6=SKS<1K*G!5W<#@ ;:#WEG@/L^(/>6> ^R!/        "-:0>UBY>(4
MCFC[WMI(](/:Q<O$*1S1][VT"QV=BG@ 9V*>  8'_"FG8.N_X4T[
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MO8OBN']_I.^?,;&QL1L;4:U."(F2'T6*8Q&'&NUZZYJ\Y  91@
M
M
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M)?WL>>U&Y^7?[$(KW"L;-S%G@ JN@
M
M
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M W4CC:JJC4YMYVS1N        C6D'M8N7B%(YH^][:2/2#VL7+Q"D<T?>]M
ML=G8IX &=BG@ &!_PIIV#KO^%-.P              ="@LUOH+A75U'21PU=
M<K75,K>,JM3)%7P(=+$V$K#BAL*7^U4U=L<]FZ5O7-SXY*F_(W@ UU@L=LP_
M;F4%DH8**D:JN2*%N29KQ5>=>^IJ<0X!PMB*OY;>['1U=7JHQ97M5'.1."*J
M99_O). ,%!1TUOHX:2A@BIZ:%J,CBB:C6M1.XB(9P
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M^>1R_E4WAH\==IE\RW_^#E_*H&3!?:=8O((/Y;3<&GP7VGV+R"#^6TW
M  (EH\[+%'_SNI]#"6D2T>(NMBC-%3_[;J>/@8!+0     XD][=X#DXD][=X
M (9H;^3NV?7J/Y\A-"%Z&\^IW;,T5.OJ.*9?\^0F@     !"<1_*C@_Q-9^1
MI-B$XCSZJ&#]RY;&LWY?L(38      $2C^5FH_\ DD?\]Y+2)1_*S4;ER]I(
M]_\ ]=X$M       !"IOE?I?_E,O\QA-2%3(O5>I5R7+VIEWY;O?&$U
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M<*7*X34=)>Z9TT;7O5S\V,<C.S5KW(C7(G=R50)6#2X9Q59,3QU#[!<J>N;
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MG8IX !@?\*:=@Z[_ (4T[
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MU4>6YLJ,15;+NR7=DO$VVABGK:; =)'6Q2PPK+*^CBF3*1E.KU6-']_)?LR
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M;K55<N<FI7NA&*6/#=RD;3U--;:BYSSV^.I14>D#LE1<EWHBNUE1.^6$
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M>V@6.SL4\ #.Q3P # _X4T[!UW_"FG8
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MC8]&OW-<F:)K(O!"14V!+/'ANU6=4J'TU!4,JVN63)\LK7:^L]>[F[>H$L
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M&,<C)-R.1%1,T5-R&_I<!6B/"U)8Y%J)*>&=E4Z19,I)ID?KJ]Z]U5<F\"7
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M1S1][VTD>D'M8N7B%(YH^][:!8[.Q3P ,[%/  ,#_A33L'7?\*:=@
M                                       %67:Y8BQE>:J##EGLRVZQ
MW#4;57663-]5$N]6,C[C5[JKO+3*/MK*:]8_Q)1X5Q1=<+7)M;)MZ5\<<T%9
M(F2/EB:_=GN361-_ "6T6*,4V;$-NM^-K?:DH[E)R>FK;:^16MFR548]C]Z9
MHBY+P+#*NH[%'9,<61^,<07*_P!PJ=JEO=4Q1Q4L$C6YKDQN[:*W/+]^1:(
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MUS7=UKD7/G)20_1906:EPLRIL-9-<&5KUGGK:EVM--+P=M%[BIEEEW,B8
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MX+PW%@E=X$PS3UE938EKL5U.*Y&L7D<DB,9# KMSG,C;N1^29+GO3AN+$
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MT?>]M L=G8IX &=BG@ &!_PIIV#KO^%-.P
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M')Y9W5#MO*LBZ[LLUS7P&_-7AS$-JQ+;UKK%70UM(CUC62)=R.3)53P[T-H
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MFL:C43O(5WA#25A+DEKLWMG+!4LCCI8^5TLL"2N:U$W*Y,M^7#/,L8
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M\0I'-'WO;21Z0>UBY>(4CFC[WMH%CL[%/  SL4\  P/^%-.P==_PIIV
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MVL7+Q"D<T?>]M L=G8IX &=BG@ &!_PIIV#KO^%-.P
M                            "!V/%%5/:<;7.[MAGI+17544$#&(BI%
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M$1S')FJKGDY,^^2HTN$,-4&%;2M!;=L]KY73RS3R+))-([B][EXJN2?8;H
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M2*5&TKWJ[65,LLT:J[U:FXF$F'+?)B6COJQN2OI*9])$K5R:D;E153+]P&X
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M?32+%40Y9;VO3GRX<#LX0PK087I:B.B?45%14R;6HJZJ3:3SNYWO7CEW -\
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MC1F62\45$[IH+7HNL=OO%'6LJ+G-!0RK-1T,]6Y]-3/[BL8O#+N<P$\
M""6/%59=<,8JN=33TCO:VKJH::+55$5L*=;KYJN]5SSRR)V5W>M%M+<+I6ST
M=]O-LH;A(LM?;Z29&PU+E3)RJF6;=9$R7+B!KL$XVQ36U^&&WRUV:"V7V%\M
M-)13/5[-6/7R<UR9)Q[Y:IIUPY;4GLLL<&S]IVN91L8Y4:QJLU,LN[UJ(;@
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M#VL7+Q"D<T?>]M L=G8IX &=BG@ &!_PIIV#KO\ A33L
M
M
M
M
M                 1K2#VL7+Q"D<T?>]M)'I![6+EXA2.:/O>V@6.SL4\ #
M.Q3P # _X4T[!UW_  IIV
M
M                                     </<C&.<O!$S Y!53M.F%VN5
MKJ6[)DJI[PS^\G.$,4VO%EL6NL\SGQM=J/9(W5>QW,J&]5NJF,S".F[17.*9
M\6\ .G=[E26BWS5UQF;!2PIF^1W!#1([@-+=L014N%)[Y0027"%L.WCCA3KI
M4[F1@P)B*3%&'HKE-;YJ!SW*W92]W+])%R3-/W&=,XRUU1G2D( ,-@ UF(+]
M;</TD=3=ZIM-#)(D37.15S<N>2;O HB,[F)G'C+9@ ,@
M
M                                           (UI![6+EXA2.:/O>V
MDCT@]K%R\0I'-'WO;0+'9V*> !G8IX !@?\ "FG8.M(N52P[(
M
M
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MN767)>YGE]I+"M5G/BN6\:8T[@ &K<
M
M                           1K2#VL7+Q"D<T?>]M-]I'E2/"]PS_ $HT
M9^]5-'H^;_A- L5G8IX &]B@ ZU7N>B]T[+%UF(J=U#%5,5T2Y<>X8J*9%35
M7_\ DO,!VP
M
M
M
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MIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]%
M95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ
M*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\
MXI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBC
MW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C
M4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/H
MH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,
M?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<
MWG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><
M4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![
MD:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q
M]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^
MQCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'
M3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;
MSBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H
M/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;
M&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+
M?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&
MHZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CI
MS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 9
M5![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*
M#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\X
MI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW
M(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4
M=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH
M#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?
M10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<W
MG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4
M>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D
M:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]
M% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^Q
MCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3
MF\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;S
MBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H/
M<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?V,?10;&
M/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&HZ<WG%+?
MV,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS><4>Y&H
MZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95![D:CIS
M><4>Y&HZ<WG%+?V,?10;&/HH#*H/<C4=.;SBCW(U'3F\XI;^QCZ*#8Q]% 95
M![D:CIS><4>Y&HZ<WG%+?V,?10;&/HH#*H68+>Y>O:YWUES-I0X,U53-A9:1
D,3@U#*D;4X(@$8MF&XJ?)5;O0D5/3,A;DU$0SY       __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g50309g08m03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g08m03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1>H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %XL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M$6>YT=YML%?;*AE123-WF2,/ _4?,N6^.U/+NQ9JY8[.XB(LVHB(@(B("(B
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MKAR(/(KZ54?V>=1ON6FI[35R[]3;WXCSS,3N(]1R/4K77FWKRS,/:QWB]8M
MB(JKB(B B(@(B("(B B(@(B("(B BPYP:,N( [2NLZX4C3@SL]:#M(NI[)4?
MP[/6GLE2?#L0=M%U/9*D^'8GLE2?#L0=M%U/9*D^'8GLE2?#L0=M%U/9*D^'
M8GLE2?#M04U_:2O[F16ZP1.X3?\ %3@'J:2&@_+D_(J)4\VX5PK]HU>6N#F0
M11PMQYAD_O*@:]+#'+2'C<1;FR2($0+1@(B("LK^S]^/KOV.3^(5:J2[/M4>
MU"_FYFD-6#"Z+HP_<YXXY^14O$S68AIBM%;Q,K/OEKJ-=Z"IJ:F8Z:OM=W?2
MO#.)$6\0X_\ :0?D4NH;BRHUK?;92.'@=JM<=. T\-\[Q/[L#Y%3^A]I<NE[
MG>JGP!U3!<9>F$(EW>C=D]>./ KJ:.U_+8+I?:^JHW5LUUSO'I-W<))/9QYK
M"<5IB8_T=D9Z1,3O^_\ &U@[$X::BV>ZDN!JA0ROED;)6[F^86M& ['FR3A?
M1OVEXM"W>S7+6C+ZZ:)[X'3L.^U^[EHSQSY0&.Q5IH#757I"6LC;3,K;=5G,
MU+(< GCQ![<<#U%;#4&MK!5V:MHK+I"EMTM4-U]02TN;QSY.!]2F<<S:=HKF
MK%(B/^4@TI8KG9=GC:^]:MFT[:*F02QQ0Q[SW%PX<<Y&0,[H]*W6V5T%7LHL
M-7'4OK_NL71U<K-U\@+'>41U9P%$K1M0IFZ2I[%J/3\=WAI@T1N<\ '=]SD$
M<QRR%T-9;1I=4:6@L\ULBI>AG$K'PN\@- (#0W'4#^Y.2TVW,?:/DQQCFL3]
M?E/[#>:NP?V>8*^W.#:IH<QCS^3O3$9]/%<=MNU;J+8%?*B]3FKG89&B1XXX
M:YI;GSA5X==9V:-TC['G@<^%=)_]3?\ <X^1+-KKV-V>W#2_@!D\++SX3TF-
MW>(/N<=6$^.>\Z[[(S5[1OMK7\HA0M#ZVF8[BUTK 1YBX*T_[1$KF:IM,);_
M ,/#2AS6YX'RN(QU<@%4[2YA:6G#FG(/G5N;29X-6:%L&J*9S'U5(1!6PY&^
M..#D=F\/4Y:6[6B6.+OCM$?AO=F^J;+<:/43Z+3%'0-IZ/?D:R0'IQQ\D^2%
M4NK;];;V:0VJQ4UH$(=T@A>'=)G&,\!RP?6IG!M,T_3M>*?0U)$'C=>(Y W?
M'8<#B/2HEK;4-LOSZ,VFP4]F$(=T@AQ]USC&< <L'UJM*ZMO2^7)%J:BV_X?
M.@]65NC;N^Y4,+9XW,Z*>-^0US2<\QR/#@5:E99M+[4[)7W:P1.M][IFYE:&
MAH+R"1O@<' X/E<U66S_ %='I.>N-3:X;G35;&L?%(0,;I)!&00>:D]VVL1B
MS5=OTMI^"RBI&))F;H<.T@-&,^<I>MIMNL=_9BO2*:O.X]-Y;N']F^NSPPU_
M_N+I_P!FJFJ/9Z\UVX\4(I1&9",-+]X$#/F *T^D-IU/8M)1V&LL++C "[?Z
M20;KP3GBT@K&H]K-?7VJ2VV.WT]DHWC==T!!>6GF!P &?-Q5>2TQ:NO,KQDQ
MQ-;[\1X16*J:=?BKH7;C#<]^)S3R'2<PI=_:$B9'KJ)[&@.DHV%Q[2"0M%LE
MLK;OK6AZ<QLH:,^$SOD.&@-Y#Y3A<.T^_-U'K6X5D#LTK#T$![6-SQ^4Y*T_
M\XU]0QW_ /%,S]RGW]FG'AFHM_@WH8\^CBONVZMT-H:WW)^D355]UJ,@&9KA
MQR>!<0, 'CPYJ#[-=<>TJ6Y/- :SPQC6<)-S<QGS<>:AKN+WN'Y3B[UDE5^+
MFM,SX7C/RXZQ7SW7-IR1TO\ 9[U/)(<O?+*YQ[27,)70T%8KE0:$J+Q7ZJ?I
MZQU;@\=$S>>X@EH(.1NYX\!SPHS:];BAV=W'2W@!?X8YQ\)Z3 ;G'Y./,MII
MC:12T&CX].:@L++O0Q$]%EX'#.0"".HD\0DUM$3J/M-<E)F)F?$?Y3;:/+37
M'82RH@N$MU8R6/HZRHC+'OQ)C)!^4+NV>_6G76G[1;[7J2HL%ZHV-:VGC>&[
M[PT#&Z<;[>'(%5QJC:2Z_P"C*G3[K1!1QNE:Z%U.[#(HVD$-W<<3PYKOT&TG
M3].^CJY=%4[KK2M:&5+'M;EP&-X\.?#SJGQVY=:[[:?-6;[WVU'MR6:DN]%M
MYI8]13-GN+G[[IVC#9&;F&D#J&.I2R;5]W=MWI[/'4F.UM/0FG'N7?<RXN/G
MRJO]O=3-M$CU774PE>PX;3,=@-9C :#C]ZP=:@[2FZM\ =AK]_P7I./N=WW6
M%:<<SYCZ_P LZYJUCM/_ )?X6C?=87FFVXV^RP5.Y;2^.%T 'DO#VY)/G\ZB
M^O;#77W;G445E<VGJMR&HZ;ET>ZP$OX<SR]*B]RUJ*W:/3ZK\!+.ADCD\&Z3
M).ZW'NL+M5&T6H\8YU91T0B<Z)L+Z5[\AS0T C>QYLI6DU[Q'U_DMEK;<6GM
MS?X6WI26.DV@OH*K7%7=[F8W]+0]#NQ @9/(D-([%1.T2-D6O=1,C:UC!6R8
M:T8 XJ=.VNT-/>A<[3I2FIJJ5P-5,]PZ25O6T$#AU<?,JWU)<Q>M0W&Z"(PB
MLG=-T9.]NYZL]:G%2T6W/I&?)6U8BL_:X-DK7U>R'4M+;\NKCTXW6^Z)+.'K
M"HN,M+6M'$XQCK4HT%K*OT;=)*JA:V:"9N[/32'#7@<CGJ([5,JS:K9G0S/H
MM&4D-=(UP,[MP8)'/(;E3$6I:=1O:LS3)2(F=3#;[)I/879-J:]6YK#<VF0[
MY;DMW6^3\@R3A=S9;>:_6.B-2TFHWFNIXXW;DTH!/%A.,^8\1V*M-GVNJK1[
MJN+P:.NMM7QGII#@$\B1Z1P(6[O^U)L^GI[-IBR16.EGR)71D;Q!]T &C''M
M5+8[3,]O/VUIFK%8[^(\>TLT]>ZFP_V>&UU"_HZL.='$_&=TNEQGU92FO5;J
M#8'>Y[O+X341 L$CQEQ >W!/G\ZKE^M0[9JW27@!&Z\/\)Z3A[O>]SCY%]6O
M7 H=GUPTOX 7^%DGPCI,;N2#[G'F4_'/G7V1FKXWVY=?RL.6XU.E-@5IJ["\
M0U-06=+.UHWF[Y)<<]O #*@VD+O6:QU_IN#4E6:R*"4M;TH!!P"[!ZCD@!<^
MB=I;K%I]UBO%JCNUJX[D;R,M!.=W!&",K4ZLUA%=+C;*JP6N&QMM^70B'=SO
M$@[QP,=2FM)B9C7\JVR5F*S$^-=EU:LNMNM^N*>>MUPZUBD#,VSHST;V\SO<
M>.>W'!1W3=PM=UV_OKK%-%-2343B9(AAKG[N'?+P"CU3M4M-V93RZET?2W"O
M@:&MG#A@^D$9QYN*T-HUXRW:_EU-%:8HXWQF)M%"[=:P;H;P./-V*E<5HB>W
MTUMGI,Q.^V_RL:DUE>9MN?L2:DMM@D=!X,/<X$9=O>G/6NBVKJ+9_:&EI:"5
MT%/72L-3&S@),1D\?E5>TVLNAVBG57@)/W5TO@W2=K-W&]^]9N6MIJG:%'JJ
MFI!#+&]KQ ]^\" ,$$^<95OBGZCZ_P L_GC7>?O_  W&V[4%SEUA>;-)72NM
MK'1EM,3Y(.X#R]/%6+J[4M?IC91I^KM/1-JY8H(!*]N\6-+,G'J5:[0-?VW5
MENECBTW%1W*8L,E:7-<_#>H$#)[.*Z^K=?#4&CK78A;C3^ ]']VZ3>W]QI;R
MQPRG),Q6)CP?+%9O,6\^&VV94.H=1WB]:@BOGL8T-W:VLW=XNR,D!N0!@#.>
MK@K)T=+07'16HJ>#453J*%L<C7RU,1;NY8> )YA4[LXUZ[1\5PI9[>VX6^MP
M9(M[=(."#C/ @@\BM]1[68+?2UM!:]-TU':IX7,C@A>&N:]W N<<<?0HR4M,
MSJ%L.6E:QN?[^6]V3WRXG9)J*5U9)OT#2VF=\$ P$87S_9_N]=>]17VLNE5)
M55(HXV=(\Y.-X\%"-FNOCHZCK:&IMS+C;ZLASXRX @XP>? @CJ*VEEVFT5EU
M)7W*VZ<CIJ:HIFT[:6&1K W=).\<#&3E3;'/[HB/**9:_LF;>$GV%4\++MK.
MXAK7UL$CF1@C)#=YYX=?$@+[V(:LO&J;S>+??9C6T<D!E<)&Y##O8W/,"">'
MF59Z.UK6Z6U'5W2AB9)'5EW34TA\ES2XN''J([5+:K:[!36ZLATQINGM%75\
M9*AI;[KO8 XGTJ+XYF9[>3'FK$1WUK?;VE&R^<V31&N9+?N_\#65/09&1Y+?
M)_@FQ[4%RU5I'4T-_J36-9'Y)D&2 ]CLCT<."K;2NO#8M(7FQOH7U+[CODU!
MEQNES<9(QQ[5C9UKH:-METHS0&L\.:&[PDW-S#2.SCS2<4ZMV[E<]8FO?MIL
M-ANK[7I>Y5D=[/00UC&M;5;I/1EO4<<@>WS*1[2;'=VZ.J*^SZGEOFFI'B>9
MDKP]S!GAAXYMR>(X* :$U-0:=BKJ>[6."\4M7NDMDQEA&>61Y_,MUJC:-%7Z
M7?I[3UECL]LD/W4!X+G#.<#':1Q*M:D\^XA2F2L8N6TM;L@H*:X[0K3#6[AB
M:72AKAD.<T9:,>E6)>-;7^#;93VJ*9S:$3QT_@F/)>QS<EQ';UY5)VRNJ;9<
M*>NH93%54[Q)&\=1']%:XVQT,E5'<JG25*^^1LW6U0>.'#M(W@F2DS.];[&'
M)6*\LSKOLU^YU@VVT$UGE\&DK70^$='@9WGX=GT@+L_VB[S<(+Q36N&KD;;Z
MBEWI8 ?)>=\\3Z@JQK=15=QU:V_W'[M4"I9.6 X #3D,'8,#"V6TG6(UI=Z:
MN%$:/H8>BW#)OYXDYSCSJ8QS$UW]0BV:)K>(GS+4Z4OE9IN^07:W-#YZ<'>8
MX'=<P\"'8Y#SJY:=FDMK]+4EE,ZVZBABWW.8!O9[21P>,]O'T*HM#ZC]JU]]
MD'44==&Z%T+X)#@.#OD/8IV_:]1T5)4MTUI6EME94,+7SC=&#VX:../.F2MI
MG=8[^S!>M:ZO/;TV>BZ:2CV,ZOI9>,L$U1&_=[0,%<6Q-CO%KK&3'W-P<T'M
M(BXJ*[/=H\^E:>NI*ZB%SH:MYDD8YP#MYWNCQX$'K!6X.UR"*UW"UV[35/16
MVHA=''% \-+'.!!<[ P>:I-+=XUY:4R8_P!MM^(TD&Q"[5SMG&I=ZJD(H&/%
M-D_>AT9/#Y>*K.PNU!KO5=NC%P?+<F .CJ)7?>FM.<_(3R7;V:Z[=HQM?!+0
M"OH:W'21%VZ00".&>!!'#"Y'Z\@I-945\T]8Z:VPTT1B-*W $C2223@<#]2O
MRS%K3$>5.>MJ5BUO'E;FEI&46T$T%;KBLNMT,;NEH.@W8@<9ZB0W"Z&SVVT@
MVMZYJ>C89J9X,(+?<E^2XCY0HG)M=HX;R+I:]*TM/62D>%3O>#)*W&-T$#AU
M<?,HW0;0JVW:\K]24%.&,K79FI'OR'-X<,]O#.5E&.TQ/]FTY\<3'?Q/Y=?4
M&OM2W&2Z4E9<)1!4O<R2FQ@, =[D=8[%/KG_ ,ME+^FS_P!Y1[4VTBTW6W7&
M.BTG34=PKF%DU62TNX\R"!DE:JIUV)]FT>D_8\C<+3X3TG/#][W./D6G+,ZU
M&N[*+UK-MVWN%ET=XK+%_9\I*VVOZ*J$6XR3'%F]*02//@KD@UC=H]A8O3Y]
M^Z F!L[AY7WPM#O3A5E4:]Z;9O%I/V.(W !X3TG8_>]SCY%P#6W_ -VWM3\
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M*D@:P#=EDE\F0GJ;CBOBCV0ZKJ*R>"6"FIA$0T2RR^1)GNXXE3\E/:OP9/\
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M B(@(B("X*[WI)Z%SK@KO>LGH05'I+\-5G[0_P#F*MVD^\-51:2_#59^T/\
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M91# "865A 1$0$"(@)A%E!C"865A$F$^1.U$083"(@)A$0,(B(DPB(B#"81
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MB65A$0$1$0(BR@PB(B1$1$"(LH,(B! 1$0 B(@(B("+*P@RL(B B! @RL(B
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M $A;:J""ON\$,T\;9FM<Q^=QWN2[AY.?/A!O47):JFANMO@KK>]LU+,W>CD
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MRZ!N5=826UD;1F1L?2&-A/E.#>L@()FB\_-K39;SI";1VKKE?JZZ2M-313U
MG9+%CRWD ?<P/J"] A 18>]K!E[@T><X7QT\7PK/^X(*IT;_ ,P>N?V&D_JK
M:52:.</_ ,H'7)R,&AI#GUJV.E9W@@^T7QTK.\$Z5G>"#[) &3P"^>D9WV^M
M<-6RFJZ:6GJ-U\,C2Q[<XR#S4%UGI>Q4.G:BHHZ-L<S71@.$C^ +P#U]A06
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M^0N:?D*W^TFPU5GU-5S21.-)62.FAD R.)XM/80HU0TLU?4"GHV[\A!)/Y+
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M(@(LH@+ 65A 646$ ($"R@PB(@(B(D1$1 B+*#"RL(@(B(EE81$0(B("(B)
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MPJ<PO!/5AV,GT94J6HO.F;+>6%MTM=)4Y&-Y\8W@/,[F/D*#;@@@$'(/6$4
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M&AK<YP /..:GBKO9UM#KM67F>BJ]/U%M9' 91+(XD$[P&.+1V_N5B+*_-O\
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MJV*SK+[U;Z$/IL$1$'#6^])OT2OBV?@^G_0"^ZWWI-^B5\6S\'T_Z 0=E$1
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M!?74@! LK':@+*P$0%#MJVE9=6Z7--1EHKZ:05$&]^60""S/5D?O4Q66@NX
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M3J65A!E%A$2(LHB!865A!E81$!$1 65A$!$1 65A$2(%E80$1908196$!$1
M")UHB!$1 1$0$19081$0<]']]/H7;74I/OI]"[: B(@(B("(B N"N]ZR>A<Z
MX*[WK)Z$%1Z2_#59^T/_ )BK=H_O#546DOPU6?M#_P"8JW:/[PU!S(B("(B
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MEB3',>9!(8WT-R#'L--5"%X<UPW7[CNHCL*Y'UE-'4-@?41-F=[F,O <?D5
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M\2.=D.W3Q]Q@\D'H=%J-(7)UXTM:;A)]\J::.1Y[7%HS^_*VZ B(@(B("(B
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MCB:"2&^G"TU!0U>S?:78;9276XUUAOC'POBKIC,Z.=O$.:3QX]:"YD1$!$1
M1$0$1$!$1 1%$-<Z.J-5U5&UVH+C;K;$TB>EHW=&9SU$O!R,()>BH.TWFIT%
MJ#75KH[S5W.TVJW-J(16/,IIYW9PTO//)ZET[CI>]6'9NS7,6J;O-J6)C*N4
M25!,$@<X9CW.0&#SQU>=!Z(1=&PUXNEDH*]H %3 R7 ZLC*[R B(@(B("(B
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MA!4>DOPU6?M#_P"8JW:3[PU5%I+\-5G[0_\ F*MVC^\-0<R(B B(@(B("(B
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MGTVK+['+=;]6>P+7LD-JC8UK'N:.&\[F03Q4]1!AC6L8UC&AK6C  &  LHB
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MBB@I(G'>+8FXR?.M@BG<^$:C>Q$10D1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M()ZO.N[K1IM-?9+ZSB:>84U2_EF*3 R?01^]!)JJY45+*Z.IJX(I&LZ5S7O
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M=4WN>.:IAA\'<(&OD;EK<1L:!Y1]*"<HJH&I+S34MTIHJRI,D$]*(9:R%K9
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M\!/\U]J"?HH!XR*3X"?YO[4\9%)_AY_F_M03]% /&12?X>?YO[4\9%)\!/\
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M? 3_ #?VH)^B@'C(I/\ #S_-_:GC(I/@)_F_M03]% /&12? 3_-_:GC(I/\
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1V* < %WT0 ,# 1$0$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g50309g09m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g09m01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1HV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &AD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=<$D-U=E<I(E0U."5:+2.&-DPO#Q)B=$@X3BH[,8A:3_Q  ; 0$  P$! 0$
M             0(#! 4&!__$ #,1 0 " @$# @4"!@(" P$    ! @,1(002
M,1-!!10B46%Q@3*1H;'!\-'A!O$C,T(5_]H # ,!  (1 Q$ /P#]4HB("(B
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MZ)\O0^<R_A^F/OW:3_YA^S_S3[]VD_\ F'[/_-?F=$^7H?.9?P_3'W[M)_\
M,/V?^:??NTG_ ,P_9_YK\SHGR]#YS+^'Z8^_=I/_ )A^S_S3[]VD_P#F'[/_
M #7YG1/EZ'SF7\/TQ]^[2?\ S#]G_FGW[M)_\P_9_P":_,Z)\O0^<R_A^F/O
MW:3_ .8?L_\ -/OW:3_YA^S_ ,U^9T3Y>A\YE_#],??NTG_S#]G_ )I]^[2?
M_,/V?^:_,Z)\O0^<R_A^F/OW:3_YA^S_ ,T^_=I/_F'[/_-?F=$^7H?.9?P_
M3<?37I%[MG27F>UU?^!4GP>N=.9MP;C\K Z0_D/W8[_YME^/5\VY[CD?$<BH
MGIJ^RU>MO'F(?N<(ORGH?I.SFF)&122NR&/W'%#.\ES1_==W+](:0U3C-58Q
MMS%3AVP'61'D^(^#@N;)BM3SX=F'J*Y?'EW$1%DW$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1<O
M4F>Q^G<7)?RUAL-=G+VN/< .\K\XZYZ5\SJ)\M>@YV-QO,!L3B))!_>=_HM,
M>*U_#'+GKB\^7Z$SFL,!@]QD\G7B>/R >)WT#=1.;IJTC&XALUV3;O97/^I7
MYC=NYQ<\ESCS+G'<GYT75'35CRXK=;>?$1#],??NTG_S#]G_ )I]^[2?_,/V
M?^:_,Z*?EZ*_.9?P_3'W[M)_\P_9_P":??NTG_S#]G_FOS.B?+T/G,OX?IC[
M]VD_^8?L_P#-/OW:3_YA^S_S7YG1/EZ'SF7\/TQ]^[2?_,/V?^:??NTG_P P
M_9_YK\SHGR]#YS+^'Z8^_=I/_F'[/_-/OW:3_P"8?L_\U^9T3Y>A\YE_#],?
M?NTG_P P_9_YI]^[2?\ S#]G_FOS.B?+T/G,OX?IC[]VD_\ F'[/_-/OW:3_
M .8?L_\ -?F=$^7H?.9?P_3'W[M)_P#,/V?^:??NTG_S#]G_ )K\SHGR]#YS
M+^'Z8^_=I/\ YA^S_P T^_=I/_F'[/\ S7YG1/EZ'SF7\/TP.F[2?CD/V?\
MFNCC>EO2%Z3@&1? 3V=="YH_U7Y67PC?M4?+43'69/?3]OT+U7(0":C8BL1'
M\J-P<%L+\3X;+Y#"VFV<5=GJRM._]&\@'S'85?G1MTO09F6/':D$52^XAL<[
M3M'*? ^J5C?IYKS'+IQ=76\ZMQ*W$1%SNL1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$0\AS7B^PP'8;D^Q![(M?KWGLC*==)_Z90;"+6ZZ3U/
MJ3KI/4^I!LHM;KI/4^I.ND]3ZD&RBUNND]3ZDZZ3U/J0;*+6ZZ3U/J3KI/4^
MI!LHM;KI/4^I.ND]3ZD&RBUNND]3ZDZZ3U/J0;*+6ZZ3U/J3KI/4^I!LHM;K
MI/4^I.ND]3ZD&RBUNND]3ZDZZ3U/J0;*+6ZZ3U/J3KI/4^I!LJLNFK7CM,XT
M8W&2<.7MLW:\;?T+-]B[S[@K"EMF"&2:<<,4;2]Q\ !NOQUJS.3ZCU#=R=D[
MF9Y#!ZK!R:/H6^#'W3N?$.7JLLXZZCS+ER/?+(^25[GR/)<Y[CN7$]I)6*(N
M]Y0B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("[6D-2W]*YF+(8Y[N1 EB
MW^#*SO:5Q443&^)3$S$[A^U--YJIJ##5LECW\4$[=]M^;3W@^T+I+\^?<Z:C
M?6R5S 2.WCL--B 'N>!\(?./L5]==)ZGU+SLE.RVGLX<GJ4BS91:W72>I]2=
M=)ZGU+-JV46MUTGJ?4G72>I]2#91:W72>I]2==)ZGU(-E%K==)ZGU)UTGJ?4
M@V46MUTGJ?4G72>I]2#91:W72>I]2==)ZGU(-E%K==)ZGU)UTGJ?4@V46MUT
MGJ?4G72>I]2#91:W72>I]2==)ZGU(-E%K]>\=K"O@LC\H$(-E%A'*Q^^Q&X6
M: B(@(B("+XYP:-W'9>+K(WV:"4'NBU^N?\ ^F5\ZZ3U/J0;*+6ZZ3U/J3KI
M/4^I!LHM;KI/4^I.ND]3ZD&RBUNND]3ZDZZ3U/J0;*+6ZZ3U/J3KI/4^I!LH
MM;KI/4^I.ND]3ZD&RBUNND]3ZDZZ3U/J0;*+6ZZ3U/J3KI/4^I!LHM;KI/4^
MI<O5&=&"T]?R4XV$$1<WVN[A]*F(WPB9U&Y5;T[:_EK/?IS#3.CD+0;<\;N;
M0?R![3WJAUZVK,URU-9LO+YYGF1[CWDKS7I4I%(U#Q<F2<MNZ1$179B(B B(
M@(B("(B B^#GV+Z@(B("(B B(@(B("(B B(@(B("(B B(@(B("[>CM3W]*9F
M/(8YYV! FAW^#*S?F#_%<1%$Q$QJ4Q,Q.X?M;3^7J9[$5LCCY ^O.WB'/FT]
MX/M!Y+H+\_\ W.FHWU[MS3\CMV3 V( >YPVXA\XYJ]^ND]3ZEYV2G9;3V<.3
MU*19LHM;KI/4^I.ND]3ZEFU;*+6ZZ3U/J3KI/4^I!LHM;KI/4^I.ND]3ZD&R
MBUNND]3ZDZZ3U/J0;*+6ZZ3U/J3KI/4^I!LHM;KI/4^I.ND]3ZD&RBUNND[V
M(+/K-(0;*+R9.QQVWV*]1S0$1$!$1 1$0$7B^PQO(;N/L6/7O/8PH-A%K==)
M_P"FG72>I]2#91:W72>I]2==)ZGU(-E%K==)ZGU)UTGJ?4@V46MUTGJ?4G72
M>I]2#91:W72>I]2==)ZGU(-E%K==)ZGU)UTGJ?4@V46MUTGJ?4G72>I]2#91
M:W72>I]2==)ZGU(-E%K==)ZGU)UTGJ?4@V46MUTGJ?4G72>I]2#96MDKU?&T
M9[ER1L=>%A>]Q/8 $ZZ3U/J5-?=%ZC?'CZ6"A?POG/76 /4'8/G)5\=.^VF>
M7)Z=)LJ[I UE=UCF7V9W/CI,.U>MOR8/$^TJ,(B]*(B(U#Q9M-IW/D1$4H$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$! 2"""01S!'<B(/T+T%Z^DRL7O?S$
MI?<@CWKS/=SE8/R3[0KA7XCQ5^?%9*K?J/+)ZTC9&D>P[K]D8?+-RN*J7ZHX
MH;$8D&P[-^T?,=UP]1C[9W'N]3I,LWKVSYAU$6MUTGJ?4G72>I]2YW6V46MU
MTGJ?4G72>I]2#91:W72>I]2==)ZGU(-E%K==)ZGU)UTGJ?4@V46MUTGJ?4G7
M2>I]2#91:W72>I]2==)ZGU(-E%K==)ZGU)UTGJ?4@V46MUTGJ?4G72>I]2#9
M1:W72>I]2>DD'X3=D&RB\66&$[$['VKV!![$!$1 1$0%\>X,:25]6L=YIMOR
M&H #YSNXEK%[LC:P<@%D  -AV(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B"%],>0=C>CW*R,.SY&B$'_J.R_)@&P '8%^H/N@ 3T<VMAV31D_2OS N[
MIH^AY?6S_P#)$?@1$70Y!='3>*?G,_C\7$\1NMS"/C/Y(/:5SEN86:[6RM6S
MBA(;T#Q+%U;>)VXY]G>HGPF//*TLQI;HVPV1FPV2RV2AR,+1UDQ^*'$;^&RK
M)N%OS8VUE*E2:3$P2%CK)')O/EO[>85SX'(X3I8,V,SV$?3SD4/'Z9&W;LY;
M[\B.T<CN%Q\+3DK]!FK*K-Y7077,):.W9S=RL*WFO$^>'5;%%^:ZUJ?'^57P
M87)3XF;*0TI7XZ$\,E@#X+3X?6%*:/1GFKFC1FX*]EUF24-AI"+X3XS^7OOR
M'S*28*&6'[GO-ND8Y@?,7L)&VXW;S"Z=K-96#[G['7JV0M-NB8,ZYCSQAH>X
M;;CNV 4VO;V^^D4Q4_\ UOQM45'3^7R&1FH4<=8GNPDB6%C=RS;D=_!>V<TK
MG<#$R7,8NQ5A<=A(X;MW\-QV*7]&&#OY49G4$N?LXN"L"VS/$"99-QN5.'34
M\CT+:A=6OY+)5X^+@FR#1Q@C;XIW/)3;),3I%,$6KO\ X4O@M+YS/1NDP^+L
MVHFG8R-;LP'PW/+==G2&!DIZUAQ^I<#=LNZISS2:WX;N1V=MWA3S65^_I[H@
MTK[VYI:D4P:9YJ_(\V[\R/$[_0N%T/Y')93I:I6\U---;?5D'',-G%H8=OF3
MOF:S/L1CK6]:^_'Z(3/AK60U!E*N$QM@B"1[O1NU\+ >P^2]':.U&W%>Z3L+
M<%+;?CX.>WCP]NRLSHKY=,VJS_>G_P#[BZG1#J?+9G5VJH\E;?/7C89(X'\V
M1D.V  [ALHMDM&]>VDTPUMK<^9G^BGK6CM1U,7[I6<-<CHAO&9"SL;XD=H"Z
MNDZ6/L:.U!/:PEN[:B;_ $=R+XD'+O\ #Q5@=%>HLKG:^L8<Q<DMPMB>YC).
M89\8;#P'L7%Z,O\ =/KP#ER__%*3>=3$^VBF.NXFOB8GS^$$P^CM1YB@VYCL
M/:L5G#=LH;L'_P#3OVK5S6 RV#ZKW9Q\]/K=^KZT;<6W:KIE+<CI/0]Z/.C3
M]>NUI=#+NWK>#8$MV[=]CV^*KGI?U+6U-K"6QC9I):,,;8F$D\)(WW<!W*:7
MM:VM*Y,-:5WOEAT4:8HZKU'+0R;IFP-A,@,3N$[_ $*8U^CS1NH7Y*AI;+7F
M9>B'<4<_,$@[=FPY;[#=<K[GC;W[S[]GHI^U=RUKO2>D,EFGZ:Q%J3,SO?'+
M-*=FAVYW[2>6_/;95O-NZ8JTQ5Q^G$WU[_K^R)]&NCL?J*GJ!^6,\<N.82T1
MOX1Q '??E[%Z:1T1CSI:]J36,D]7'-&U..-P:Z<\^8W'?V!23[GR9@K:IGML
MZYG ))6^N-B2%L=([(M<='M+-:<+XZV++A-CP>3!V;[#O Y^23>>^:^Q7'7T
MXOK<\_O_ .E)S.C=-(Z%ACB+CP,)W+1W GO6"^ [C<=B^KH<8B(@D/1Y>.-U
MQA+0)V;8:UWM!Y'[5^Q1S&Z_$V#8Z3-X]D?QS88!]*_;#/BCR7'U/F'H]#/T
MVA]1$7*[A$1 1$0$1$!$1 1$0$1$!$1 1$0%B^-KQLX!9(@T+%8M^%&2".PC
MN6%._P#TAAGV;*WN\1XKI$;C8KAY^J\0F:OREB^&-N\=X0=P'<;A%R\'D&W*
MX<#ONNH@+SFE#!L.;O!9O<&M)/<O"LSB)D?S/<@,A+SQ2D[^"]VM#1R "^H@
M(B("(B B(@(B("(B B(@(B("(B JF^Z1NF#1U.HT[>E6@#Y-!/\ J%;*I?[I
ML?\ @V#/=Z2_G_[0M</\<,.IG6*R@41%Z+QQ$1 4YT+2T3?K5:NH'9'W7GGZ
MH"#DS8D!O/909=727XU8;_&1?O!5M&X7QSJT<;6!K_3F@],S7<:TY/W79"'Q
M;NXF<1'+<[*$Z>T;J'4-8V,1BYIX!RZT[,:3X GM^92+I_\ ]XUS_#1?8I9T
MEWLEB-!:/9IB:Q7IOB!>^KN"YW"" =O;NLJVF*Q]Y^[:U:S:W&HK]E5LTOFS
MGF89V,LMR3B/Z$LYAOK?]/M7?U]T<9/2LLLT3);>*BC8Y]QP#0''M&V_BK#U
MY9M15.CW(RR25\W/+'%.]IX9',(;Q!VW<?#VJ+_= 7\E'K.Q4;8MC'.K1DPA
MSNJ)\2.SM2M[6F$WQ4I6WGV1'":$U-FZC;6-Q,LE9PXF2N<&->/9N>:RTU@I
MJ^O,;B,_1?$YT[6RP3#M:?M"L 8.'2>$T^,UJ'./DM%LE:IC^3(R=CWD;]H7
M9Z26,'2[HYX;L]VP<[;F>?>GJ3,Z_5,8(K$6]]Q_56/2]BZ>&UW<I8R!E>JR
M.,MC9V ENY6_T0:2Q6JI\P,UU_54X6RMZI_">_?[%CT[_P"\K(?HH?W%(ON<
MG,98U*Z1G&QM5A<WUASY),S&+:M:Q.?MF.-RB&JVZ%;B9/>P[(G)"0 "Q\7A
MY[]WDO&GT<ZMN4_2H,)/U1'$WC<UKG#N(!.Y6WJ?,:<U!%7QNG=,MQ-Z6TUO
MI!DX@0200?I!^9630QM?3.M=/XJ_G\]?RGP.!C/D&M[.%PW^*IF\UC\_E-,=
M<EI^WXX_NHAN/NNR7N<VI.;_ !]5Z/P'CXO#9=W*Z"U/B<<;^0Q$L55HW<_B
M:2P>T [A71B:M4].F;D=%'Z0RFU\6X_*Y;D>U4UJC-ZHN7\U7OVLBZ$RN,\)
MXN!H!Y<NP!*Y)M.H5OAKCC=MS^CLP=%6;GT=#EH:]AV2EEX6T2P B+N>23]2
MA^-P.5R>4DQV/HS6+L;BV2-@WX"#L=SV!6_J++91O05@[E6]<%PRM:Z:-[N,
MCB>-B1S[@M3HGDGAZ.-97L?Q.S8+B9 -Y?B[[^._:5$7M%9F?NO.&DVBL?;?
M^_E6NHM(Y[3D;9,UC9:T+CL)=PYF_AN.6ZRJZ.U#;=1%;%3R"\TOKN;MPN:.
MTD]WSJS-%6;V8Z(M3^^>2:Q7B8XP2V=R[BX23L3X'9>^JM1Y' ]$&F/<F<UK
M%AK6.G;\=K0"2!X;\D]2V]>^T>C37=,SK6_RI?(4Y\9D9Z=^/@L5I.":,.!V
M(/,;A33I TGC,5IC 9W B;T.^W:7K'\7"_;<#Z0X?,H-9GEM6);%J1TL\KBZ
M21W:XGM)5M:(A=K+HFR.FVCCNX^9LL&YW(:22-OK^E7O,UU/\V>*L7[JQ'Z(
M]-I/&X_HF&H\B)O=6S+P5F<?"T#?D=N_D"5AT@:5QV T]IB[0$O7Y*,/GXW;
MC?A!Y>':NMT^7F5[.)TY5.T&.J-<]H[.,CE]7VK9Z8?Q,T'^A'[K56MIGMF?
M?:]ZUB+Q$>(C^;@=*&E<=IF/!NQ@EWN5^MEZQ_%SV'9]*TNBS3U+4^KX<9D^
ML]&?$]YZMW"=P-QS4KZ>?D=*_P""_P!&KE] /^\FM_AY?W4BT^EOW+4K&?MU
MQN$CJ:$T-G,CE,-AKF0KYBIQ "5VX<1[-N87-T;H; 2Z6S&3U3Z6)<;8?#+Z
M._;DT[=FR[&6U[I?2N?SC\'@)W9M[WQR6)'_  >/?F>9.PW\ %XZ/EFN]#&J
MII Z6Q/-(]W"-RYQ[5GN^M[^S:*XYMJ(C<;_ $<XZ#TUJ; V[V@LA9==JC=]
M.SVN^PCSYJJ2""0X$.!V(/<5<GW/N,N8ZSE,W?CDJXUE;JRZ9O"'G<'O[AMV
MJHLA*R?(VYHAM'),][1["XD+:DSW37>].;)6.RM]:F7@B(M&(B(@D?1O>=CM
M=86PP['KPP^3N1^U?L-?BK33'2:AQC(_CNL, ^E?M5OQ0N/J?,/1Z&?IF!$1
M<KN$1$!$1 1$0$1$!$1 7QS6N&Q *^H@U+%4$;LW_P!0M6&XZO,([!Y.^*_Q
M757/RM-MB!S1R)[#ZKNXH-]C@]N[2OJC^G<BZ8&&8D2,<6N!\0I .?8@(B(/
MCW!C23V+7 ?.=R>%B._IIN'\EO:MD  ;#D$&#(VL'P0%FB("(B B(@(B("(B
M B(@(B("(B B(@(B("(B OR;TS777>D?+\1W; 6P-]G"%^LE^/\ I.!;TA:@
M!&Q]*<5T]-_%+BZV?HC]491$7:\T4FZ-<'4U'K"GB\CQ^C2M>7<#N$\AN.:C
M*G70?_O*QO\ T2?NJMYU69A?%$3>(G[NAJ3']'&-?DJ4#\K[I5N.-G$=V=8.
MS?EV;J,8#0VI<]3;:QF*DEK.&[92X,:[;MV)/-3#I"U+I5]W/4(M)AF5,CXQ
M>ZS_ ,S?X^RWH\'%I;2&"FSFH,YM=(DK4\=R:QSMG=Y&_:%E%IK7\S]V_IUO
M>8]H^W'\U59?%WL-==3RU66I9:-S'(-N7B/$+LX?0>I\Q2%S'X>=]9PXF2/(
M8'CQ;OVJ=_=!,C?J33?6@\+ZX#R_DXCB[UO=.>4S>)R6"K8*Q:J8YM?>+T7<
M-<X'8 [=O+;DIC),Q&O,HG#6LVWO4:_JB6G^BO.9+%92U<K6:D]8;5X',&\[
MQON.9[/:H?/@LI7S(Q,M&;W3) %9@XG$D;]RN/0^1R\G15JF2U:N'(1/DVXG
M'K(SMOR\%Q^@%[[NLLC:R3GSY-M/>)]@DOWW:-QOS[%$7M'=,^R9Q4GLBN^4
M(S&A-3X:AZ;D<//'5#>)SVD/X!_> [/G7/I:=R][',OT:$UBH^40-?&.+=Y[
MMNWYU;O1#D\[E=1ZEK:@ELSTC&_KH[ / QVY&PW[.7<%CI?*S:?Z(M07,46-
MDAN2MA?MOP#?8$>2>I:./?@C!2?JW.N?Z*@S^#R&G[XI9BOZ/:+!)P<0=\$]
MG8I=C-)8S+]%]_.4>N&8Q[MIVE^[7#ESV\C]2A>5R=[+6S:REN6W9+0WK)3N
M=AV!6#T%9&-N:R."LD>CY:NZ,-/9Q@'_ $5[]T5W[PSQ16U^WVEH=%^D<=J"
MCF\GG3*,=0AXVF-_#N_8G[ L\3I/%WNB?*:F<V9MZO,YL0#_ ((;Q- W&W/D
M5)=8U'Z%Z)H<)NUE[(VGB0MY$Q@D\_FV^E>.FO\ [.N=_3N_?8J=TS]43[PU
MBD5GLF.8B9G]4>DTEC6]$;-2@3>Z1>&D\?P-MP.Q<7!Z%U+G*C;>,Q,LM5PW
M9*YP8UWEN>:G<W/[G2(#OF:/_F"S&#ATII? R9O4&;/I9;)7J8[DR,NV=WD;
M]H2+S$3^IZ46F..-0JC+8R]B+KZ>4JRU;3 "8Y!L=CV$>(4FZ*--T-4ZG./R
MG6^C]2Y_]&[A.X4L^Z18WW=PL@!XW52"X]I&Y[5S?N?/Q\._9Z,_["IF\SC[
ME(QQ7-V3S&W;J:"T1J&WEL3I^]D*^9H\8(E.[26DCPYC=1[HHT;B]16<S'GQ
M./0!_P"2_;8@\^Y2;)](&FM*YG.^]W 3#,RRR12V9'?!+]SN>9/+?GL-EJ]
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MI^D'KW<-3 ]5QGA)>_?AWY;\_!!.-TW5;]#^H\GJ;2]R]FI626H\C-7!8WA
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MT_TG7*.I*+Z^'BB'HS6AQ:\G\IW>>]7MK?4T.D\&[)V:TUF,2-CX(OC;GO\
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MFZ>5\]C+X*-F^_)UEI$9(]NW-3G)]'(MZFR&=K:DR].Y< 83$6[1L'8UFXW
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MW<PITG4ZVFZ+YBJ-N&NYN3MMM3<6X>R/JP!X;;E;OHS/;]*A#1=\;YE\6U+
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M+2U7T@:E,U^3'Y%N-N0U*LU+&,JB8W#*P%SN+8[ $GE[%:\^D,9.<^9#8_\
M&PUMK9XY;-+1P<N7(^U5'EM-9JEG,HTX[.R9%\<=?&VL;.QD/4L8&LZPD<G#
M;GV;H.YTGRWLI#IO3EJ0R6'5'Y/)$MX-VLC) .W(;N!&WL7 Z-]9YJ?2TL&#
M;$RKIW'ODDK/:.MN/)<6EH(Y1MV[1VJS].:-$=.>WGYY;.<R-!E._*'_  0
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M_EV+[T)P3QZ$CM6HS&[(6IKK&$;$,>[=NX/8=E.7L:]A:]K7-/:UPW!^99
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MLHA$Z\(;IGH^QF#O"XZ22Y88=XC*-@P^('BIDB(F9F?+X6M)W+03XD)L"=R
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MLQ 1$0%S-3?B[D_T#ETUS-3?B[D_T#D'OA?ZDQO^%B_<"W%IX7^I,;_A8OW
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M!\0BJH(B("(B".](EM]+0^9DB+1+)#U# >\O(;M]!*\L/'GL7B*-"'#U."M
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MBLL8>%QC=OL?!;A^*=U2]NZTS+3'6*5BL*HU%TTT,7F[6/I8FWD!6=P/FC<
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M7QI:YV_(R1$__BAOTJJZ8N[ L5D[L"Q5H5GR(B(@1$0$1$!$1 1$0$1$!$1
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M]YV1#[F,:_(QQM9?MTRP[\59P:7>PKEC2\V_XPYG]:/X*2(.U#:$X3#V[QR
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MC?\ "Q?N!;BB>@]54LU4AH,:^"[6A:PL?V2!HVW:?F[%+%&M$Q,>1$1$"(B
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M=HY7(5ZN^1E(:]WPSS[FCF?H7BW661RKBW2VG+=J,\A<O?T$';W#M/TA#2;
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M.3O4JU5FF)(8ZTD;HR+##L&=C?B]BVQ9IQ\.?-T\9>=ZE!^@#3[ZN2R.0O\
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MN?R(WO+?IW"\!AM:N>3)JNDQI[HZ+3M](0TF0&YV"IOI&U3:O92QC:DSHL?
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MK6LZJNT^V1R^,Q.KLN\'-9F#%5';%U7%MWDV[P9#_INIFT!K Q@#6-&P:T;
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M+%T64JMF7_9ZLQ(DE8.76GN'%W!;FG^CK+0N-ZT:T=FN.LK02;N;)(.P/V[
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MY2QBL0,E!,6MD9UPC=\'G\'?D>U).C*BZWQ17IV5=_D^1(]FZL' Z0H7<;Z
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MK</I#,66/'P99F]0P^W<J':GEU;0SE;5=BM0P@?MCYSQ&7X#M^&1^P((:?\
M1:O&9]-MJ:7/TZKC_010E[6]W$3S*KM6CJ_266LTZ]C,99EZYSX9F0"-C!ZO
M+M'M4*CTMD72\+A$QGKEVX5ZWK$:EW8\-[4B:QN$MZ,M88O!X>S3SF097'7<
M==KFN<2".>P /+=2@=(-6V)&X3$9C)2-^+U=8L8[_P!Q[!\R]-!Z9IX_%-?/
M4AFG+N)LLL0+]O$$CD%,  WL 'DHWOF')ECMO,(.<UKBYPFCIBE29WF]:XC]
M#=B%KW*>5K[3YM]>6Q+S<^NTMC;_ '>:L!8O8V1A;(UKFGM!&ZK:O=&FG39Y
MP7[M*W;\(AK!Q./( <]U*L3IK&QMCM7,;4DR!&[I9(@YWL&Y\%CC((H]8Y..
M-C6QLJQ.:T#D"7.W(4B5:4URVZOK/7B*UC4/C&MC;M&UK!X-&R^HBT<*!=(&
MC,58I7LQ&V2"XQA>[JSLV0^T+TZ+].X^IAZV5;$7WYVG>1YWX1OMLWP4@UG^
M*F4_0E:_1[^)V-_Z7?O%-RMW3K6TA.Q!! (/:#S!4$U)A,;1S(NTJ,->S.PB
M5\3>$/Y]X')3M<_,XUN2KAG%P2,.[7[*MXW'#;I<E<>6+6\(,NAA=38S"R^A
MY>]'4](<.H,NX:3WCB[!\^R\K./GK9&G2FX!);<YL;AS'(;G=2>#3]#W/-6[
M6@N,<=W]=&' GV;]BRI6=[>EUO48[8IK6=S+J02QV(&35Y&2PO&[9&.#FN'B
M"%FH/8Z/HZDQGTIE[V"EW']'$XR0';N+''_58G-:NP(#,UA69FL -[>+/P^?
MC&1N?F"W>*G2^M^,/-1W!:SP6:/5UKT<5KOK6?Z*5I\.$]_DN^^6.'9TTC6-
MW[7'9-D1OAP=&?(9C_,IOL:I H]HLCJ<MS^-D)7M]K3ML?)>^JM1TM-T!/<)
MDL2G@K58^<MA_<U@[_/N403$QQ+9U!F\?I_&29#+V&UZS"&@D;E[CV-:.TD^
M"BN#QV7U1D&9K48FQU)C7-IXIKN9:?\ S)3ZW@.Y?=/::NY?)LU#K(-DL[;U
M,6?A0TAXD=CI/;W*=)Y3$S6=QY1#$8N"QG,M5EXS%2?&&<_C<3=^:RR71WIJ
M_.^>2@Z*9YXG/@D<PD^/);N!_&C4WZ2#]P*0)%8CPODS7R?QSM"#T=PP[#&Z
MAS])H[&-ME[1\Q7L_!:KJL#,?JSKF#L%NHUQ^<]ZF**=,T"OC4S8VLU"[&RU
M&GX$M5KFN<_^\"=MNU::F&H<=D,BQL=&]!6BV(>V6#K.(]Q'@H^_#NKYJABY
M+)D=8A?(Z8-VV+>WE[5C>DS.X>MT75X\>/LOPUJ6-O97KJM#*38V-P'7RPM!
M>6[]C2?BGVKNZ?T1A,),;$-=UJ\[FZW<=UTKCX[GL7C4P&=HB1M/-56,<[?X
M50$GPW*D&+BMP4VLR-EEFP"=Y&1\ ([N2TI&HTX>JRQFR3>OAMH.U$':K.='
M='?'SG^8R_:L-9::.:C@NXZ84L]1/'2N ?%/>Q_BP]A'M6>COCYS_,9?M4B4
M0(UHS5 SK+%.]!Z%G:.S+M-WY)]=GK,/<5T,OI_&Y>9DN0K":1C>%IXB-@N1
MK73=B[+!FL#(*V?HC>)PY"RSM,+_ !![O E;VCM20:DQKI1$ZK?@=U=NE(?Z
M2O(.T.';MX'O0>3M%8 -<10&X!_+*Y6B]'X2YINI8L4PZ:0$O=Q'=QW/:IN[
MXCO(KD='WXI4/^D_:4E,/?$Z8Q6)N>E4*PCFX2WBXB>17:1% +&3Y-WDLEC)
M\F[R059?_'^UY,_=5FX_\%9Y*LK_ ./]KR9^ZK-Q_P""L\D'R?Y=GFME:T_R
M[/-;*"%]*&I,3IO&UILKCV9&>60LKURP.+G=_:#LJV;TH8@OC;[QHP7R")N[
M6CX>_P 7XG;[%8/29IF[F\EIN_CW0!V-N":7KSLW@W!)/T*KM58/5$V1S.'Q
M%%EW$W\AZ7%<BV<(G$[_ !AV$;\UTXHI,<N/-;)$S,>/TV_15<ET$9+.K):#
MP>KR[%Q-<U,/;TS<&I#MC(V]9*>(C;8\NSGVKKT(GPT:\4KN.1D;6N=XD#8E
M0_IEQ-S,:"R$&.#WS,X9>J8-S( =R/\ 7YEA3^*'3>=4F=;4VW)=%C[W5NP^
M1;4)V%DO=].VZ_0^EJN.IX"E!A'!V.:S>$AW$"T\^WYU^?K.NL7:T6W3\6D'
M>Z9B$ VB')W9Q#EQ;J[>C'%6\-H?%4<AN+,<9+FGM;N2=OFW6^:..=_S<W33
M$VG6OVC24*J_ND*EBYH&M'4@EGD&3K.+8VEQ #CN=AW*U$(!&Q (]JYG8KKI
MPP]_(:8J7\-6=9R&*N1761,^,]K2>(#V[%0_.YQW2EJ32E# X^^VE0M-N9*:
MS 8FQ =C1OVG<%7JL6L:WXK0WR&R#)>/HE?BXNHBWWWWX O9$%4_<W?B7E/\
MWM?O!6I+(V*)\DC@UC 7$GL "JO[F[\2\I_F]K]X*4]*F2?C=%7^HYV+0%2(
M=Y=(>'E[=B2@K^G;LQ=&F6O5XS[K:GR#HX&-&Y(>[8; ^#0[ZE;NGL9%AL'1
MQT&W5UH6Q@@;;D#F?G.Y^=5_B<8+72!B<;$S?':9HM+P6[M-EXY<_$#8_2K0
M05KTP:JM8J.OC,;(89K +Y96_&:SP'@2J<BMVH9A-%;LLE!W#Q(=]U:_37@+
M%CT7+U6.E;$#%*QHY@=SE431Q.X6@N=X '<KIQ:[7POQNV:.KGNWKV_Z_=?W
M1?JB7/X&9V0<WTFFX1R2=@<-MPX_6N;D<C:Z0;LV'T_/)7TW$2R]E83L9R.V
M&$^'<YW_ .1@NG]%9K,U!2I9B3$0RATMH,)WF:0 (W-[QXGVJ;XW,Y?1%*#'
M9G3C7XNNP-;=Q#>*, #F71[;CVGS6%M;G3[#H:YJ]/3YB/JU[_T_HG^)QU3$
MXZ"CCJ\=>I T,CCC&P 5&].>@LC)FGY_#UI+4$S/]I9&-W1N'+B [P0KHP6H
ML3GH>LQ-^"QXM:[X3?-O:%NY"Y7H4IK5R1L=>)O$]SNP!3CO-)W#7-CK>DQ9
M^-,7@,OE;;:N/QUJ:<G;;JR /,GL7ZMZ.=-#2FE*N,<_CF!,DSNXO=V[>P=G
MS*&V.EJG#:>*&'<^'B^4+@PN]NRZ.0Z1FY+$05]+1.DU!>?U,,$@WZ@]ID?_
M '0.?M6N6]K1S&H>?T6?I;9)KCONW^^'OK/*6M0Y7WH:>DV+Q_XK<:?P6$_D
MC^^X;C;N'U3/"8NKA<55QV/C$56LP1QM'AXGVGM*YNB]-0::Q1A#S8O3NZVY
M;?S?8E/:XG[ N^N=ZHB(@+@:QTO4U-19'-)+5NP/$E:[!RE@>.]I\/$=Z[Z(
M*KN7K.8QMW16MA'2R]J,QTK;1_17-OBN:>P.W'-JH7-Z7S6#NOJY+'6&2,.P
M>UA<Q_M!':OU+TC4,7<TQ>?F8N.*",R1R-Y21O'Q7,=W'?94;+JK/V(866,O
M:?U;0T'< G;O/B?:NC!:T;UX>-\5ZO!T\U[]]T_;[-SH9T%D;&H:V:RE22MC
MZA+V"5NSI7]VP/=[5^A]_H\%3^@.D.:&SZ%J2TU]5P+FVY3L8R.X^(4Y?K[2
MS0/_ !JL[?U YWV!5RVF;?4Z?AV?%GP]^+]]_=)D4/EZ2-,L<X-NR2;=A9"X
M@^2\#TF8(D".+(RGO#*I.WGS6>W>FZ*%CI"JR,WK8/4$Q=\3AIG9_ES6#]=7
M.75Z/U"[QXH"W_1-B;HH*S6V:D>&Q:'S!W.P+WA@^?<<DN:OU+#$)6:'MEN_
M"1Z2'.W\@.SVIL2'4>=Q6G:C9\D6-XSM'&U@+GGV!0/3?2#AX<GD#=K200VY
MQ(V1S 0SX(&Q^A0G7&6R67S?79>E)0E;& RJ\D\#?'GXJ/K:N.)C<ODNN^-Y
M\746QXM1%9U^K]3UW0RQ,FK&-T<C0YKV ;.'<5Z*J.C?7&*QN#CQV8O".5DI
M;'Q;D-8>S<]P4U?K?3#!N[.4OF?NL9XG3Z?ILOKXJY=:W&W?E:7Q/:.UP("K
MAS3&]['C9S"01X%25VO-+ $^[E0[>!)/V+@ZCU9I.Q0M6*V1B-YL9,>S'CB=
MW;\EG>O=X>IT751@F8M'$L*N.=EIO0V3SU^,?"E@=PO8/$'N4CT_HK X(A].
MBR2R/_VBS_2RD^/$5P,'KO2U.C#_ +0YL[XVF5S87'=VW/GX;K>=TF:=#MF2
MVI!XMKN(4TCMCE3J^HC/?=?$)E)Q]4X1[<>QX=^S?NW]BBN8RN<PU%US)V,)
M# WEOU<I)/@!Q<RM4])F"/*./(RN\&5B2H!TFZGCU#/0;39;BJPAQ++$1CW?
MXCQY+2L=TZ>1\0ZF>DZ>V6(W,?YG3[8UY):RD,TE2G%"PGCV@=PR;C;=PXM^
M7:K*Q-O.WL?#8QDV"DJO'P',CD \MN+D5^?E/^C#5U73U:]7R8M&O)('1.CC
M+VM=MS'L[E>^.*QN'C_#/C?4=5FC!GG<3X_"YJ7I'HL?IO5>D[?#ZH$,W]F_
M->63]/ZAON6:O7<7/T@.+=OF(YJ+LZ2].$'CL6(SX.@<"MMFO]+.('NS"W?O
M<QP'T[+-](]Y8]32L+)1A'L/:#'(?_QESJ.#SU.S/,TX:0R.XFM?&_:+V-^$
MN@S6^F'@EN<I<O%^RV(M5Z?E<&LS>/)/9O. HU"T7M6-1)6]\?7Q^DNQ'4;_
M  ^K9)Q;>S=W:NWN>XG9<Z+-XJ9I,64H/ Y$ML-Y?6O=M^DX@-N523V;3-_B
MI5<?,Z6BRUN2:>[,V-^V\'5L<P;>P@K\OZYQ$F U7DJ$S2P,DXH]P!Q,/,$?
M,OUX+,!8YXGB+&C=Q#P=E^=]>YZ/568-A]6%L$&\<)X07%OB3W^2VP3VS+RO
MBW58^GQQ-_/M"ML=6FOY"K4IM+[,\C61AO:7$\E^EL-IK6<<#8\AJML+2T,<
MV& /+0/5+NPJL.CW(4M/ZF@M24()6RN$1>1\*+?EQ-\%^D -^;?A#M!'>ISV
M[IA'PGJ<?44M>GGWC[(-][>A9'_C.6S.3.^^T]HAH_\ :%W,7I+ 8PL-+$4V
M/9V/=&'.\]SWKN;%<_*9>IC:[I9WA_"=BR,ASOHW6#UG)U^T,P,(8UK1Z7#R
M:-ORE)W?&/FJTUGK;"W,6R".P63-LQ/+7C;DUVY6]:Z6-+PG=D]J?<_^37<Y
M0)XM#-7;=*NR2CCY,A(7<)CC>&EH\>:B\721C;+3Z!C,U<=MR$-0_P 5B-;Y
M:60-JZ)S3]^^7:(?6$'OE-8WL53=:R.G;,%=NP+W3M[^X#;F5&?OF4/?&[(^
MA6>K;5$#6';=QXB=R>X<UR.E#*YJ\VC'F,6<9$'%T<77"3C/B2.S90-;4QQ,
M;E\O\3^,Y^GZB<6+417^ON_16,U+E+SZSFZ>F%:8M_IQ.US0T_E<NU2I07H9
MEFDT9&V7<LCE>V-Q._P=U.EC,:G3Z+ILWKX:Y=:W$2(B*&ZL>D/\9<3^B?\
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M%C+(R*)\DC@UC!N2>P!9*+])][W/T'F9MB7.@,3=O6=\$?:@T>B"*0Z4=?G
MZW)69;CG>/$?Y*87/2/19/0^J](V^!UH);O[=N:T-)41C=,XNFW_ ,FNQOS[
M<UU4$>'OJW&[L-M^CD_^I<[ Y/4^7QK+<8P\8<YS>$LDY;';UE)\EDJ6,@Z[
M(VX*L6^W%*\-'UJ.=&-ZI;TVQM6S#,YCW<08\$CGWA-2;CPD.*]T>I=[K&J9
M=_@^CAP&WMW)6ZB(('J.0XWI1TW:XQ'!?@EI2?WB 7-!^?93-0_I:B,.(Q^7
MC;O)B[L5C?\ N\8!^U3 .#P'-(+7#<$>!4P@1$4@B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B BX<^I(89Y(CCLLXL<6\3*CBT^T'O"\&ZNJ.L20-H
M94SQ@.?&*CN)H/82$V)&BY6-S<=^SU#*61A.Q/'/7+&_25U4!$1 1$0%$>E5
M[V:)N\#PT%S0[=VVXW[%AF]<1,NG&:9J/SF6[',KN_H8#XR/[!Y+QH:+L9&V
MW(:UOG)V!NZ.E&2VK7)]4?E'LYE(E-9U.U(JP^A02G/7BS?J1 .L\-]^2]-3
M=',5&W6?3OO;7M6&PB-[-S&7;\]^\*Q-*:<IZ:H.K4]WO>>*69WQI#_H/8K3
M:--KWB:\)#'\0+)?(_B!?5FQ$1$$'Z5?ZA'^(C^PKH:*_ V>07/Z5?ZA'^(C
M^PKH:*_ V>01*4(B(AY6ODBLH/DF^2QM?)%90?)-\D&:(B"FNGR.R,QI:W7Q
MTN096E?(^)K"YKMBT[';QV4(?J7,'74&IH=*SPRQQ=6Z%D;@'\MMR=E^G#L!
MN>P*+V=?Z4K3R0S9RDV6,\+AQ;['YEO3)QK6W-DP_5W=VM_HU^C35&0U1CK=
MC*8QV/DAE$;6.!'$-M]^:E[OBGR7-P.>Q>>@EFPUV*W%&[@>Z,\@?!=,\@=U
MC;SXTWIX\[?F/&Y71^!U;J.#4]!V48ZRXPV6LW(Y\P6DC;S5G]%F=T7E,O;B
MTGBY*=IL/%(]T0;Q,W'+XQ[]E!=5:OO2Y>];PV$Q3,+7NMJ26I:K7OE>3S[?
M'GV*P])9:.+I'S>!;C:%9L$0DAEKQ\+W-Y<G'YUTY.:[_P N/#Q?43&M_;]?
M=8B(BY7<(B("PFBCGB=',QLD;N1:X;@K-$%/_<\8VE:T7>=9J02N;E+(!>P'
M8<:BVO=*RZ@UMF<=AHHF6:<!M1Q- :'\V[CSVWV4T^YO_$G(?YK:_?6UHQ@G
MZ8-:3@@]1'!".7>1N?L"M6TUG<*WK%ZS6?=^:+%>>M.Z&Q7FBF:=C&]A#M_)
M6=T74X]*7'9;5^*NLI6X VO)U'6,:-^9>!S'=W*?Y;)NR^6S1W8ZI2R=6M"T
MQC<. /'S[>U6F6M='PN:'-(V((W!6U^HFU>W3FQ=)&.W=,[0FUJ#0U;!G+&3
M&OI]@ZN-KGD\^7#V@\N]5_CNDK1HU)=L6,9,RE.V-D9=6:>$@;$D ]BC_P!T
M'2CIZQKBO4BKP/KAX,; T/=N=R=N]5BKXL%9KN66;JKUO-:^S]FXRE@\A3@N
MT*E*:O*T21R,B&Q'<>Q=D<NQ4U]S/-:?@<O%*7&I'8;U._8"1\(#ZE<JY[U[
M+35V8K^I2+!&XV/8J_Z-2<5G]4:=>3P5K/I=9NW(12\]AY'=3:SD*=601V;=
M>%Y&X;)(&G;YU -69.EC=?:;S5:W7?#8+L=:<V5I#0[X3"=CX\2HT;4!9D>F
MFSQ,=_X7C T.[N-Y!_=<5/U771]?J29O5>8L9&N8[EXPPE\@&[(AL-M^[8J;
M.S&.$,THO5G,A89)."0.X6CM)V[D$1B/N[TLRN^'Z/@*H8.>[3-+S/\ \NWT
M+;Z0-3C'1Q8?&5AD<]?W97J#L:.^20_DM'BH3IW4,V(P\LN.JBYJO5%F2W6K
M-[&L)(:]Y_)8!N>:GNAM)-P#)[V0F].U!>V=<N.':?49X,'</8B8G7,-*'2F
M196@$L]>2;@;UA&X'%MSV]FZ[V!P;<<72S/$EAPVW'8T>Q=I%6*Q$[=-^LRW
MKV3/ N5JO'U,KIS(TLBX-JS1%KW$;\/>'?,0#\RZJ. <"' $'M!5G*J_0FML
M7)I5F/SEH"W0<:4O%&2) WXKN0[V[?05Y:CS>GF0U'XFUM+Z7'U@#'G^CY\7
M:.SL6_J")FF>D/'901-.,S6U&WN-VQS#Y)^W8-^SZ5.NHA!/]#%_V!-;7KDM
M3BLS"/G6VG02!D6[#_[M_P#!;^'U!C,Q-)%C;0GDC;Q. 8X;#YPNAU$/_HQ?
M]@63(XV;ED;&D][6@*S-DBU<G/8K4WRU*CK<PVVA:\-+OG*XGNWG/[+V/VEG
M\$V-BA^.N6_PD/[SEW5"J]O/Q9VYD#IJ8LGA9$&^DLW'"2=^SVKH>[><W'_Z
M+V.W\Y9_!1$I25<W*Y5V/EC8W'7K?&W?BKM:0WV'<CFNB.8!(V.W9X+E9G4%
M+#31Q7?2..1O$WJHB\;;[<]E*''SV6FR6%NTXL+E8WS1EH<^-FP\_A+2T1GG
MU]+4(AA\G,&M<..-C"T_"/BY=236V)=%(T>F[EI WK.\%QM%ZMQE+3-."?TS
MC:';\-=Q'QBH2E^*RCL@Z5KL?=J< !WL-: [RV)717&Q.I<?E;?HU3TGK>$N
M_I(7,&WF5V5,(1K4/XU:9_32_NA251K4/XU:9_32_NA25(!$1!Q\_IK#:@;_
M .,8^&RYH^#(1PR-\G#F/I4)@K,IP^B0RV):T+B(A8DXW-;OV;JS@-^P$J%Y
MC#V:UJ5\4+WUW'B:6C?;V%9Y(XX>C\-M2+SW>?9S:\\M2435CPRM[/ ^P^Q;
M^B,'':N2:BS-^OELVYQ8U\3@Z*DW?Y-@_)/B3S7AC<=8R$O#"QPC#N%\FW)O
MB/-33'XVMCHY&TZ[(1([CDX&[<;MNT^U1BB5_B5J3-=>6TB(M7EH_@?QHU-^
MD@_<"D"C^!_&C4WZ2#]P*0) (B("CN0_'S"_X6?_ $4B4=R'X^87_"S_ .B2
M)$B(@(.U<[,YBIAXXY+O7<,AX6]5&7\_;LN4-;X??_\ ;?V5R;'IH[X^<_S&
M7[5(E --ZJQM-V5,[;@ZZ[)(S:NX[@GDI!0U;C+UR&K7]+ZV4\+>.NYHW]I[
ME$#OJ%ZRT_=AOMU-I1K(\]"T,L,=\6[ .V-P];ER/;]2FB!2./IG4%+4F$;D
M<>7"-W$Q\;QL^)X[6N'<0OG1]^*5#_I/VE1&_!6;G<C<I1>CNLD-F$9X6R%O
M+B(\?:O6C<FH3-DKO(V/-F_P7#PV64Y'I4^&WM3NF>?LLM%Y4YFV:L4S>Q[0
MY>JN\^8U.I%C)\F[R62QD^3=Y(A5E_\ '^UY,_=5FX_\%9Y*LK_X_P!KR9^Z
MK-Q_X*SR0?)_EV>:V5K3_+L\ULH*IZ>[<K:^ Q\EV2EB[UOJ[DS >3.7;]95
M86+V/Q6A,UC,=D'NG;F :7 _X<C6[@..W=LI_J[I/TWDS>P>5PUNW&R1T3@T
M \VG;<>!4.PF3T'A\G#<AT]EY9HW L;8/&UIW[=MEV8XF*ZF'GY-6O,UM'V_
M1^C<47NQE,S;]:86%^_CPC=5OTX:QMX#&LHX^.Y!9L /9<C'P&;.YM)\59U>
M43UXI6@@/:' 'M&XW4(Z:\@_':!NR,@CFXW,C(D9Q- +AN2%SX_XXW#KR_\
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M!3*OI_%UZU>O#3B9% P1L:!V ?:JVKOP[>EZJN&.V\;APM%5G/M2V=B(V-X
M?$E3%8Q1LB8&1M#6CD !L%DIK&HTQZC-ZUYNBV=T)A,M9-P0/I9+M%RF_JI
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MZ""G@866<M(!-+Q-XF5X>+8N=S';V!3_ #64-+ 6\C1A-YT43I(XH3Q&4CL
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M4ZY_@U#;81:_7/\ !J=<_P &H;;"+7ZY_@U.N?X-0VYV3U/B,9<=5O7!%.T
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ME1 D:+"&1DT,<L1XHY&AS3V;@]BS4@H[D/Q\PO\ A9_]%(E'<A^/F%_PL_\
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MA;5R5.)[<?8+CO&7?&:3W@C<<]QS46T5HO,U\W@98<4=-P8UO^UR-O/G]-Y
M%@8>0!.YW[MT'4U!7IY+IVQ-/-!LM:+%NEIUYAO&^4N(<=CR+MEY6:&,I=,,
MU''PUHL;;Q#G9B"/81-V+N%S@.33L!\RGFI=,8C4D4+<O4$KX'<4,S7%DD1[
M^%PV(W45TAT<LPS-1X[(21WL7E#\&=SG>E<!_P#+>_O [N::0X^G<90U1KIM
M_"8VO4TQCZ<U*.Q'&&"\YXX7 #O:WQYJLQ5R.?Q<.F6AW7:4CM67[$\GL?O$
M#\P^M7KI[HVT]@+U:UC(K43ZWR3#9>6-_P#;OLN[CM.8K'97)9&I3C9;R.WI
M+^WK-AMV%-"MNBO)/S^0U9K$ N<:D52$CL)8PN?M_P"X!<*A:OT.B[3]S#WG
M5,EGLV1;M ;O/&Z0$?, -O#97-IW3V+T]C'X_$56P4WO=(Z/<G=SOC'FHY@M
M 04J\N/R$C+>+@R/NCCHQNUU=Q)):?$ D[)H1:+*YW3VH-2:=AS&2O-J106H
M+3JOIEAO'L',X=^;>?;W+9D?J+5FGM08>2YDY)K%,M@%K%BFSCX@=N,'O (V
M]JL:#!T(-0V\W%#MDK43899.(\VMVV&W9W!;UR!ENI/6F+NKF88W<+B#L1MR
M(["FA^>,A4EL9G%XRWIJGA9(L/:BLL9(USI&LC'PBT=P(W:3SW\5<715>GR/
M1Y@K-I_',Z#@+O$-<6CZ@%R[/1Q4IZ?R%/3<IK9.]'Z/+D;3W32]4?C-!.^W
M(D;*8X3&5\-B*>.I-#:]:(1MV&V^W:?G.Y^=(&ZB(I!>\7Q O!>\7Q HDADB
M(H2(B(*QZ0_QEQ/Z)_VE3K3_ .!,\E!>D/\ &7$_HG_:5.M/_@3/)!U%Y6?D
MBO5>5GY(H,H/D6^2S6$'R+?)9H"KK4FE=/PY7.7,EEVU)LS5-<Q2/:UH_O@=
MYW 5BK\\ZXQF'L=+-^/6V0FK4)86OK/8_<#NV/;P]_<M<4;F>6.>W;$<;=?H
MST?%4U95M7]45,FZG&64X(9>)P;\_8!X!7>J@Z/,#H*CJB";3N:?:R+6.X(C
M)N"-N?<K?3+.[&"L5K_WM1O3I8QM#7NFKN5B]+KQPGKJFQYLXCL[P//N]B]L
M1K7H[GR=.*IA"RR^5K8W>C <+B>2Z_2_J6;'YG'8K%82EDLG8A=+UEB)KS&P
M$\AOY$J#Z>U/GK&4P<EG"X2K1OV R*T^HQK3L[8@.'85M6-TC?\ =SVMVY)U
M_;_+]&HB+D=PB(@J'1'^^K7OZ&#[59BK/1'^^K7OZ&#[59B#5R=YN,QMN^\
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MS*SW:T =0I"W-Q;&-THCV'CN5%;F%T-DG.=6L8NK:<-FS4+C8'#R#2!]2^C
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MUY^Z]41%R.X1$05#HC_?5KW]#!]JLQ5GHC_?5KW]#!]JLP#<@((7FA[H]*6
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M(T][3]2D<D<<L;XYHVR1/!:]CAN' ]H*CVL--.S0KWL=9]!SU$E]2T!R)_\
M3D\6'EN%GI#48SD$\%R TLU3/5W:3CSC=W.;XL/(@CQ5G/:W=,S/NY&A7R8+
M+9#25Q_]'!O9Q;G?EUG$[L]I:=_K\%V,Q^,^G?\ ]_\ 8U</I7BM5ZE#.T(F
M>D8=YL"=\P8 WL=&1VN#ARY>*@M_IB@LYG%W(\/(V*IQES3+S=Q ;_8M*4M;
MQ#')EI3^*5Y#L1033.N+VIZTEC"8:"6*-W"]K[8:]GF"ITW?A&_([<U$Q,3J
M4Q,3&X?0N+/JW%5;,D$MF9LD;N%P$+SL?,!=I?02.\_2H2@FG-58J&;.=?/(
M6RWG/:# YV[>$>SV+LTKVG\Y8=5BKP6).$O+9:NPV\R%(1RWVY;\SMRW0DGM
M)*&T>GT5IJ=Q,N#I$GO#"W["N9?Z-M./KS.I4)*]@,<8^KG>!Q;<N1/BIH@0
MB7YHD8^*62.9I;+&XM>T]H(*]<?6EN7J]:L"9Y7AK .W?Q6WTJZPH7M03Q86
ME"7PNX);QWWF<.1V;V;>U='H:U;CX\TRCDZ4,5VQNR&\">T_DD'LW\0NCT[=
MO=I;Y[%,]ONL)N-UW 0(]08B<-Y;35-OK:U9OFU]"=O0=/V@.]DKV$_2X*8[
M;;@\B%]#2[L!*YT;0^7+Z@Z@PY7#1T./D+$5EL@/L '-<_8;=BE6H_1?0'^E
M6Z]8L(<'2R!H!\.U02+-XV:1\<-V"5[#L1&[B^SM6.2)V]OX;DQQCF-ZEVZV
MHZN A+LI+(VHXAK2R,OX7>0[ENQ:_P!+R$ 9B%I_OQO;]K5P\)J">&62;':?
MR^0<[X#'MA,<9_\ <5M6??5DY"UVDM/56$?*77LF(^9NZO3<0\_K;4MFF:>$
MIKYW#SL#XLM0<W_$-!^@G=?G/I-U99S>ILA'5G?'C8I3'&QAVX^'EQ$]^ZM>
M3H^O96';+W<14._Q<?C& D?]7(JF-?Z6M:4SD]>=DCJ3W%U:R1RD;_'V+JZ>
M(FW+RNKM:M/IGCW<["9[(8:TV>K8D+ ?AQ/=NUX\"KAPU[I$SS(WZ>L5*>+Y
M%L]^JP M[@T;$N\U2V'QEW-7HZ.*KOLVI.36,'UD]P7Z"TMJ2MI;!5<9J*KF
M:)@' V6U7+V;> <W\D=RMU,5X^ZO1Y,DUFLSNO\ EJYCH_U)FY&/S6K&W(QL
M?1G5^&%A\0T#G\ZZE/3&8Q%(QLR]:2@P?"JPT61<?_N W4FQ.H</EQ_X9DZE
MD[;\+9 ';>1YKJD%O:"%RZV[J7FEHM]E?CF-PGHF0NGJL-;;3NCX3;#F<0C]
MNW>N[J;'P5\1?O0-+)HHR\;'X)._@NIA:\4./KNC8 Z2)CWGO)+0?]5E7',3
MR]?-\1QVQS%8G<N)C=$8V*VS(9B2;-99O_[5==Q!OL:SL:%*>X#N'(#P1%L\
M5Y/L01NX9+$#'#\E\C6GZ"5PJ5JM[\\L[TFOPFM" >M;L?K70O8+%WK#I[E&
M&:9P +WCF=EKMTA@^L=(,37XG  \CV#V;HF'5;9KO<&LLUW./8ULK23\P*]5
MRJVG<14L,GKX^"*:,[M>T'=I751 O.Q^#R_]#OL6;]^!W"0';<B?%<%]74CV
M.:<GC]G @[5.[Z4&>AOQ2QGZ,_:5W%&,7B<_C*$-.ME*)AA&S2^KN>WS79Q<
M>1C;)[J6:\[B1P&&+J]O/Q0;RYV=I/O5AU>QFC.[=^\>"Z*YV3BRCY&'&6ZT
M# /AB:'C)/LY\DF-QI?'DG':+U\PB;FO;)U;F/$GJD<U(].T)*[7SSMX7/&S
M6]X'M4?S!NT,[4N9/4F%JV(HG,:R6,-)#O[NZ[E9F?F;%,S*XV:N_8AT=;<.
M'L.ZI7'V\NWJ/B%LU.R(U]TOK?(,\EZ+SK?(,\EZ*7% B(@@_2K_ %"/\1']
MA70T5^!L\@N?TJ_U"/\ $1_85T-%?@;/((E*$1$0\K7R164'R3?)8VODBLH/
MDF^2#-$1!5G3CBM3Y5F,ATR+;H/ABPR"7@![-N+GS[U7.%TGJO%.+QHJG<F/
M_F7/Z4^>Q.R_3*+:N::QVZ<]^GBUN[:&]&,N?DQ5INI<;!CY62@0QPL#06[=
MNP7ETPZ:LZFT=-7Q_.Y7>+$3/7+=_@^?-3=%3OU;NAK-(FG9*B\9TR9/%8Z.
MAEM+W'Y"!HC+@2P.VY D<)77Z'<7F,AJ3,:MSM5U-UP=7%"]I:=N1W /<-ME
M;+X(GNXGQL<X=Y"]%:<D:F*QK;.N&VXFUMZ$1%DW1G7&$S67KU7:<STF'N0/
MXN+JQ(R4>#FGM4<P71YE)M3TL[K;/^[5G'[^@PQP"**%Q[7[=[O:K)1 7C<K
M1W*TE>;BZMXV=PN+3](YA>RQE.T;SOMR[4'Y"H9K'T-$G'"*>7(G+33N E<&
M-C;(=@1OMN?';==[2FL&0BX^;$232SV'SF=UMVP+N[;L)'B57]X 7K8;V=<_
M;Z2I#A^'W-AX? [^>Z[?1I%>8?._$/BF?IH[\4ZG>H_"?4=9-=.UMRN8HR=C
M(UW%P^TA2F73VI+;X+F'R4-)VV\4T$Y,<K#V<3"""JDY=_8K3Z.=9 8:'%-J
MNLVZO(,,[(G%I/+A#OC?,N?)BK7F&WP?XYUG6S;!U%NZ-;WJ(_GK3K0W=15(
M74<W>IV+#-B;%1A87;]Q_DOE:Y8ISNL0.XI2/A!YW#]NP%<+5^I#0O2-EJ/B
MNR[/,#W F,'Q(7 IZQD;*/3(&]5WN8>8^98>E>WU0^DGXU\,Z68Z;);GWXW$
M3/WG_=+*TGITMM/S^<M-R>8L<XGN;_1U&;_$B![/:>U2Q<[3A#L'4D:X.9(W
MC:0>X]BZ*M#&\5BT]L[ASLA@Z63LMEM-F,@;P#@G>P;>0(7Y\Z0]358]4.;I
M9L]9U,/JR6S8>YU@;]G;\4'?9?I5FV_,[ C9?D36F%MZ?U)>IWXRTF5[XWD?
M!D822' KHZ>M;3.W%U>2]*QVNIH_6/N0^"KE*[[6,#MB(YWQOCW/-PV.Q7Z2
MQ&(Q]-S+>/ZYPEC!:]T[WAS3S!V)*_(=2M+>M0U*K>LGG>(V-'>2=@OU=DKK
M=%Z$;-+_ $TE"LR%C>WK)>36M'_N/T*>HI6NM*]'DO?<6G<.7>X=4:]@I,.^
M,T\18L][9;+OB,Y';X(&_P!*FQYG<K@:(P[L/@(A9/%D;9-J[(>9=,_F?HWV
M7?7,[1$1 46UUA);=:/,XAS*^?Q@,E><G;K&#?BA<>]KAOV]_FI2OA (((!!
M[04$6PFN\%E<3!;DNQ59S\&:O)OQ0R#M:=A]'B%N^^O ;[>ZU;<=VSOX*)Z\
MZK26HJF=QC8-\@XLOT7MW%G8<I!ZKAOV_P 5%\?KF6OG+>0DQE21ED,:^(#;
MA#?#VJ]:VF.'G]3\2Z;IK^GDMS_OE:GOKP'_ ,6K_0[^"ZU>:.S!'/ \20R-
MXF/'8X>*Y^"N8[.8V*]0AC=#)RX71#B:X=H/)99?-8K!P<63O5JC1V,<[X7S
M-'/ZE'ZNNMJWK%J\Q+I(H9#K:;+@MTK@;^0)W L6 *\&X_O'M^I?68?5N3?O
MFL_%CJY()K8IFSMN\&0\_M1;2297,8W$,X\I?K5!MN!+( XCV-[3\P4==K66
M]*8],X#(978[>D/'40>?$>9^@+=Q.B-/XR430X]L]GOGM.,KR?'GR^I20DD
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M6MEM2ZD=BKK!HVU#Q0/;UOI;3P;M/PMN'GLIV!OV E1_I!L3TM'9*6OQ-D+
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M"-MV@C?M.X6S2Z4]-YVEE(\#>E]TH:<MFNRQ 6=;PL<0YN_QAR44S%C6FO\
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M&C=.8<VSB\-3K&VTMG+&DE[3VCF>0._<FE-OS+I^M9P.B]":@Q^7O16KN2=
M8FRD1-C!'P0WL[U(]<W'Y35VMY=0ZCN8>SB8@<76CE,;2.6S@-_A;_Z[J_/>
MI@?0*E+W*J^B5).MKQ<)X8G>(YKYG-)8#/7H;F:Q-6[;AVX)96GB&WCL>?SI
MHVH?%G-:VU;I3&Y'.9*A[HX02W1"\M=+P$D;CN)V'/YUU>A7'8RGTA:E%O+6
M&Y&I<ZBM!+8YV0002]I^,>SFKN;A<:S*19)E&!M^*/J8YVMV<QFVW".X#9:H
MTI@6Z@.=&*K#+GF;6QX]_'MVW]NR:-J>Z<^L^^OI,07J%"7T-W#8O,#X6?"?
M\8'M47T+F,MC] ZKIZ9QUG(9"WDQ!+=H,+FAA!W?&WNY;@>:_1><TQA,]-'+
MFL76NRQMX&.F!):-]]NWVE;N(QM+#516Q-2&G7'/JX6\(W\3XE3HV_+6B8,7
M[I9?#9"UE-,T?3H)1:D/"YLK.R&7G\9^Y*O3I8,4=?3,^1+#AHLK";?6<V[;
M'A<[V?Q7?OZ0T_?,YN8FM,9YVV92X'X<K=]GG8]HW*ZF1HU<E1EI9"O'8J2M
MX7Q2#=K@FC:!:?OXYO2KJ^]5LUX\7%2@;9L!X$/6\7+<CEOLH]TOO?+C9[E3
M-82?3S9XI9,;7+!8G?N-P' ;\1/-675TE@:N$GP];%5H\9.=Y8!OM(?[QWW/
MTK6AT'I:')-OQ8*FVVUP<'[$@$=_"3MO\RC1MP^EJ2:QIW3\=.S9QIMWZ["Z
M)Q:]C'#XI^;DH?+I(,RNM:(S>8]#PM,6ZD?I)^!*6.)<3_[0KHOT:N0$0O0,
MG$4@E9QC?A>.QP]JP.,I&:[*:L1DNLZNR[;G*W8C9WLV)4Z-OS9D<OD\X*[;
M]ZU:LVL1 ZDZ.X(6UY#\%SW[]Y(WW5F7Z3;F;T=HP2F:K1K#*9%X?U@<6M/"
M"3V@O.X]BU,WT679<OE9,9!@+-&XT-KC(,>7TF[$<+ !L1SY>04^T?I>IIS%
MU8&[6+L=<5Y;CQ\.5H).Q/@-^0]@4:-J7TCD;MNM#7R-R7$MI4+$^&8UY$=R
M4<6\KCWN;W-]BVNB.H[.ZFPV0;-;9!5K.ELBQ?#W69]^3VL!W(W]FVRM;56C
M<?F-+R8FI!!4DC8[T.8,_!GGM([QOV'S40TOT:7Z.H,/?O1X2C'C?A%V,:\2
MVG; ?#)_).VY":-M[.RTZG3ABK&9='%6=BGLI2V"!$V8.)< 3R#ME\ HY3IE
MVPYAGJ#$NCRSJY' \N+@T/(Y$\PIUG,)C,]2-3,T8;E??B#)1V'Q!','R7"T
M/HR+1U[+-Q=D'#W9!-'3<SX5=_?L_M<WV'L4FW&Z-<;2IZNZ0,94@CAHLE@A
M$+1\$-+7@A5;2P]_/BUIAW$?>K#;D8>$G^E+]XMOF ^E?H^K0JU;5JU7KLCL
M6B'3R-'.0CL)^E?*N/J5;MFW6KQQ6K.QFE:-C)MR&Z:-JPZ(KUC.QZIU9(QY
ML30LIPO/:3%&>+Y^( _.H^QLHZ)M(BI>GJ6,GG"+<\#^&1Q<^0.:3Y#97?C,
M=3Q=8U\=6BK0%Q>8XQL"X]I^=<'":,HXQUV%Q;9QTEST^K6D9RJ2G?B+3W[D
M_,AM7[ZF3PNI=4:9T_:S5FO#!7MPQP6N&=CG;!W"]W8WF=PNG@\=F[5+-U-1
M2YZC2LTGP^DY2ZV6*(NY<6VPV*LMF/J1Y*;(,KQB],P1R3@?">T=@/T!>ERK
M!=J35;D3)JTS2R2-XW#FGN*:-J>+[&$#=+V<QC-1XJWB+#/Z&!@DJB./</<6
M\BWVD[\E/>BF>:ST<X"6S(^24URTN<=R0'N ^H!:]OH]PT6%NX_3]>+#.NM$
M4]B!I=(Z+\I@).X!')2RE5AHTH*E1@CKP1MCC:.YH&P403+V1$4H%N4/DW>:
MTUN4/DW>:B4U;*(BA81$05CTA_C+B?T3_M*G6G_P)GDH+TA_C+B?T3_M*G6G
M_P "9Y(.HO*S\D5ZKRL_)%!E!\BWR6:P@^1;Y+- 1$0$1$!$1 1$0$1$%2]'
M_P#OOUW^AA^U6TJEZ/\ _??KO]##]JMI 1$0$1$!$1 1$0$1$!$1 1$0$1$
M]A6LMD]A6LIA B(I!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M .:=B.0[0M[[Y&I_^%^=_P"_^2"SD58_?(U/_P +\[_W_P D^^1J?_A?G?\
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M-,W+#*P/8]LFX<TC<$<EZ??'U/\ \,,[_P!_\DV:6:BK+[X^I_\ AAG?^_\
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M^H1_B(_L*Z&BOP-GD$2E"(B(>5KY(K*#Y)ODL;7R164'R3?)!FB(@(B("(B
MB(@(B((UT@:2KZPP7H,L\E6S%(V>M9C^-#(T\G!1S3?1]DQJ6IG=9YWW:N4&
M&.DUD(B9%OVN(':[VJR$0$1$%5?<W_B3D/\ -;7[ZM553]S<0=$9#8[_ /BM
MK]]6L@(B(*MZ6?Q_Z-/\PG_<:K257]*['NU]T;%C'.#;\Y<0-P/@-[5:" B(
M@*H^AK_>!TF_YHW["K<52]#C'MU]TEES'-#LFT@D;;\CV(+:1$0%A8_!Y?\
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M] 7<0$1$%2?=,_B-B_\ .:G[Q5MJIONE6/DT1C!&QSC[L53LT;\MW*V4!$1
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MK6T1UG2W;TL_4&=]SXL>VTUPM?#XR?';L4W^\U2_M)J/]L_DO"C_ /:3R/\
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MR>"QM'"6!QD&<NL,81NW<;[;^*U<OJ/I#FNWG8'3%!F/K.+6NO6"V27A[7-
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MST/](%O7;LX^U1;3BIS-; WGQN8X$@NW[]@%8R L9/DW>2R6,GR;O)!5E_\
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M)G[JLW'_ (*SR597_P ?[7DS]U6;C_P5GD@^3_+L\ULK6G^79YK90$1$!$1
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M[R3FSQ./N9BC7D<VDWN>[EL7GQ[EUM57\78Z6(+FN@^72,E!DN+=8C<ZKUI
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M/XCI8PXM\EZ7,1CKM)E2W1KS56#9D3XP6M[N0[EO(@YV)P6+Q'&<7CZU4O\
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M)J.A;%:U8DLSQTG-DED.[GNX#N2?-4CT9:=I9+I<OF@_TC#XR1]B)X^*3O\
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MC]HY(/1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MQX3MV;CL*Z?N]COSZI^N">[V._/JGZX*8F8\(FL3Q,.FQK6,#&-#6M&P &P
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M<+?!!5?O%C]1J>\6/U&JU.%O@G"WP056-"Q_^FWZ%N5-#QM_(:![%9'"WP0
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M"OZ.,NMS.O)'U)0RU%PP.+>4IZLC8>/<N1=T_DKFFM)TFUIHY6<;)21\CN"
M7>"M=$$&T-E;%:C1T_;PU^*U6C,<LAC'4@#?8\6_/?\ U4?H26,?G8WZ=JY?
M'PB4OOU;C!Z+'%VO<WGR/+N5L[+&6)DL;XY6-<Q[2US2.1![04'(TCF#GL'%
MD?1359*YW PNW):"1O\ /LH5I_1-7*9S45G/4)P?3RZN\N+0YG;N-NT*RJ\$
M5:!D->-D43!LUC!L /8%Z(*TZ2\!D3D*UO 0R/?<A]SK(8/BQD@AQ72DPTU3
M6V)%6O(:-;%/K]:!\$$<@#[2IRB"L6P9['=&=*"C!9AL"4BR(F_TS(2YQ):/
M'L6?1[1LC6=V_P"CY08^6D&13Y%W%(\AS=]_#L/)66B".:ATU-E[S;$68N4F
MA@9U<(;L>9Y\UNX#%2X>A) ^]/=>YQ<U\P (]G+N761!1V=JY[*U;=>Y7S=C
M,>D!\D+3M49&'<BT=AY;*5X^S:TAG,RRQBKUV+(3-GKSUH^/B.WQ'<^6RL;9
M-D$%N36<9KV')38^W+4O4FU@Z%G$8I.,'9P[E&Y\1FL=4ER^.H3/R5;*6."+
MAYOAD&W%MWC<!6]L$05AD\5E-.Z3PM&EZ8VGQE^2DI#><;\_@_/R^8+E5<'E
M)\)JYT5#($675Y:PMNXIIF-<XG<^.W<KDV1!5FHXI\O/AL_%3S#*<#'P3QUQ
MU5F+^^!WA:K<.8:E/-8C'9:5M;(MLSQW.<T[0/CM'L5N[)L@@6G);>5U]/EC
MB[5.BZD(HY)V<)D(=OS'=_)>W2'A'9O,Z;ADJR3TFS2^D%FX#00W;<CL["IN
MB"N]48B;3F(JU=/1W8<4^QUEU],\=@#;EP[^04:BT[E+M;44\%'(%KWUYZS;
MSN*6PUAY@GQV[OF5TH@K/5]^YJO2\\./PN1AEJR13.9-'P\6Q^$UO/F0O:_;
MG9J?':MBQE^;'.JOK2Q]5_30GB.SN#?L*L;9-@@J*WALI=P.JLA[G3Q.REF%
M\%8CX98UWQBWN)W^U6O188Z4#"WA+6-&WAR7LB"M>D[ 9.WF*MK"PO>;L)H6
MRP?%87;AQ^L+=OX6>MJ?'LIUI'TZ^'?6$@'+B&X \SR4]1!!M$6+F%TWIS&V
M,9:=+8=*V4ANP@'&2"[SW7OTJ8ZQE-/5JU6"6<FY$7MC',-^%N5,D016+1>/
MH8;*U\4QT=J] Z)TTCR]QW!V&Y[MU"[,.3RFE<9I-F%M09"K)&)I7- A8UI/
MPP[?GO\ ZE6\B"JM3">OG[,NG:6;JYPO;L(V U;.W+B?W=F_-=G3+[>*UIFJ
M]^A:'NE*R6&>-G%%R:>+<]W-3S9$$(UG#9H:HPV?CIS7:E9LD4T<+>)[ X<G
M =_\E'Y,1D]08W61CQT]-]]T$E:.8<)D#-SS\"?]5:Z(*S=)=U-E--PQ8BU3
M;BI&RVY+# P,+0!P,\=]OL6FV.Y!J(-TO2S%.66R?2ZT[?\ 9!&X[.>.?(]F
MVRMC9-D%)X_ "I7?A,U2U%+(;!+(ZLF]:5G%N'^ ]ODIOTK,$>@[#&-)X3$&
MM/?LX<E-=ESM08>OG<9)1N%XA>6DEAV/(@_Z((3#);U+G\$UF*M4(L8USK$L
M[.$!Q: &-\0HUC< *<+L+G:.H9)>O);'4?O6E;Q;A_@/Y*ZHF".-K&]C0 %E
ML@IC4,&;N29BE;KYN6T9."G#6/#5Z@'D7>L=O%>V4TGE,EF9;->"1DE.E6E@
M9(W^BFD8!NQWM[0KAV1!QZ4\N=TT725Y:5BQ$YCHY1LZ-VVQ5:3^ZGO+ATN,
M#=-^M*.LD#!U? ).+C#N]7&B"&8C'V6=)V8NR5GBL^E$R.8MY$\MP#\RBNKF
M9N[D\U5N0YF221O#CX:9X:[V>+SWGV*W405%F=.Y25^FXJ]6;J;M*"ED-A\D
M&%KCOX=A"Z.F-/WZNNIX)ZSF8;&F6:D\CX),NW('OV'V*S$05;0P^09T5YVF
M^C,+<L\KF0EOPGCB;L0/F7>UEA[F0T+5AJPN?:K-AE,'>_AVW;Y]OT*:(@KB
M"[>SNM,3D*N&MU:]:O,PR68^#^D+" WRWV45N5<YDZT4=VMGI\NRVV2PR3E5
MC:'';A'8>6WUJ\4V05'G,+/[_P!N&A/_ (=E9H\C.T'FW@WXA\Y'V*Q=58NQ
ME\%9H4[7HCYAPF0-WV;WCYPO#3^EZ6%N6KD<MBS;L<C-9?QN:WU0>X+O(*BF
MT9GSJ3$U'9.6*M#6<QMNI"(^J:/R-QMS/BO?4>)]'S\@U%C\EF<<*C8*4D0Z
MPM?MLXNYC9Q//=6LB" :$RMW',Q.GLC!*ZY)'),0]^[Z\(/P _Q/\EN](%2V
M+>$R]6K)<CQUCK)88QN\M/Y0'>1LI6*=8777!!&+3F=69>'X1;X;^"]T%8U9
M<Q>U!G\SC,79K&7&\%,V&!I>\.'=X]O)<W3]/(7,]@+$D&<F,#G>ERWS\!DA
M',,;W#V^2N!>%ZL+=.:N9)(A*TMXXSLYN_>#XH*KTGA)V:\.)D(?C<))):B.
M^_.0 M:?:.WZ5/=:Y2_BL*^7$49;EQYX&-8WBX-_RB/ +VTSIZGIZK+#3,LC
MYG]9+-,[BDD/M*[""LM,Y&7#8W(25<%F+66E89Y9[$'"9Y/#MY ;]G@%Z:$L
MRQYAUC)XK*R9>_RGMS0<,<0'8QO/DWD/-62FR#A4\W/:HY>8XRU"^D][(V/'
M.?A&X+?-0"'H^O9+3-F]=N78<K;+[;Z>X#.MW):"/'^*MS9$%:YN+*9JMIRV
M_'V&SM@G;886\V/ZMS>?AN>SS4ITS1F]XU*C.U\$YIB)P<-BPENRD*(*>?#E
M/>6W1HPMHY)LO!UP:.H+.,NZSC^=2206,-TA5IYJ=NQ4GH1U&SPLX@'AWY7A
MXJ>IL@JZAA\A'T::CIOI3"W-9D<R+A^$\<3>8\>PK1R&$MX[+4\E=ARXI2XZ
M&!SL:_:6)[6CX+AX<E;Z(*LQ&$=!F=)R8_&WX:,4EF23TH;O87;;.=X;[<E/
M=5XMN:T]>HGXTL9X#MV.'-I^D!=9$%8Z3QNH&X[,YNQ6<S.NK"I6CF',!C=N
M(>9&ZY.#I9&YJ33MHP9V?T:4^F37S\!CR.88.X>U7(FR"HF8G)TM/Z=NOQ]E
MYQN0?-/ QN\G5EW:!WKVGH9+5.7U'9BH6:=>WCFQ5G6&<!D((.Q\-]E:Z(*F
MTUCJ\U_',NX[4DEZE&28[+^*",ANVPW[CML![5[Z2]-KZEJPZ?KYB#$DN]-K
M9!O]'!W@1DG?MWY*TMDV"")])$F5CQ%?W)%D1&=HMOJC>9D7>6#Q4#]R<A:@
MU+-6HY9\-FDQE=UX\<TFSF[CZCR5T(@K76N#N24=+6Z]:TZ+',#;$51W!-&T
MM:"6>T;%=7H[HTV39&_5KY=CY^!KILD?A2[;\P/8IJ@Y=B"N-7W78_I-P]MM
M2>VV&E(7L@;Q/:TDCB [UP:N&REW5U/-/QD\-6UE1,(W-YLC:.3WCNWW^I6E
M-A:TNH(,PXR>E0PN@:-_@\)/AXKI[(*_Z1\79?F<5E8XKTM2N'QS^@/X9XPX
M?&'B%XX#2\.3Q\TF/N:AQ(?.7ODFDX99SL.9]BL9$%:@7-,9[/-FQMR]'E&,
M%::!@>7.:TMV?X;[[KG8W$97&Z:TS==C)I9<9:F?8J@?##'.^,!WD;*VT05G
M'7ES.:S6?L8:V[%R4A595D9PRV.8)/#[-OJ"Y5;&9+)XS+8O#,RQP[JV[(\D
M US)6N!$<9W[-AM[%<.R ;=B"K](T:]G-8XST]1BY3;N[TR3>&!VPW />#M[
M.Q=?7T5FMJ'3V9CJ3V:E)[^N;7;Q/'$-@0.]3G9-D$-TC4L#5^H[\U66*&T(
M#"^1NQ<.$[CYN6ZXG67M.9#4]63$7+@RDKY*DL#.)LA>#\%Q[MM_M5FH@J;3
ME3(Z*R<3KN-N7(YZ+8FNK,X^&7BXN \^6V_:N9=KW*6FL)%)5L09QV4?/7A8
MWBD:WM<0.P]W:KLV7%U)INIGO1GSR3U[-9Q=#8KOX)&;]NQ^9!6-V!E[&9VA
M5K9234%B:*U9CM1!KWQAW)P#>0 W^M3;45"R_76F;%>M(^K79,)'M'P6;MV
M*ZNG-,4L'-/8A?/9NS@-DLV7\<CAX;^"[J"I\,;E/4=8::I9FM4ZTNOT[;/Z
M&-O:>KY\CX?,K'T_D9,KC([<U.:F]Q<.IF&SAL=M_G71V1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
A$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g50309g10m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g10m01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2964&AO=&]S:&]P(#,N,  X0DE-! 0
M    )CD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 9_!B,# 2(  A$! Q$!_\0
M'  !  (# 0$!              4' P0&" (!_\0 8!    4" 08)"00( P4&
M!  /  $" P0%$08'$A,5(3$405%24U21DI,((C)587&!T>$6%Z&Q(S,V0F*B
MLO!CH\$D-W)S=!@T.'6SPB4U0X+Q@R8G1%9DA)32185&1U?_Q  : 0$! 0$!
M 0$              0($ P4&_\0 -!$!  $" P<# @8" @,!      $"$0,$
M$Q(6(3%189$%T>%!<084(C.!P3*A%;$C\/%2_]H # ,!  (1 Q$ /P#U2
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M\ &33IY2[0TZ>4NT8^"_Q_@'!?X_P 9-.GE+M#3IY2[1CX+_ !_@'!?X_P
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M\ &33IY2[0TZ>4NT8^"_Q_@'!?X_P 9-.GE+M#3IY2[1CX+_ !_@'!?X_P
M&33IY2[0TZ>4NT8^"_Q_@'!?X_P 9-.GE+M#3IY2[1CX+_'^ <%_C_ !DTZ>
M4NT-.GE+M&/@O\?X!P7^/\ &33IY2[0TZ>4NT8^"_P ?X!P7^/\  !DTZ>4N
MT-.GE+M&/@O\?X!P7^/\ &33IY2[0TZ>4NT8^"_Q_@'!?X_P 9-.GE+M#3IY
M2[1CX+_'^ <%_C_ !DTZ>4NT-.GE+M&/@O\ '^ <%_C_   9-.GE+M#3IY2[
M1CX+_'^ <%_C_ !DTZ>4NT-.GE+M&/@O\?X!P7^/\ &33IY2[0TZ>4NT8^"_
MQ_@'!?X_P 9-.GE+M#3IY2[1CX+_ !_@'!?X_P  &33IY2[0TZ>4NT8^"_Q_
M@'!?X_P 9-.GE+M#3IY2[1CX+_'^ <%_C_ !DTZ>4NT-.GE+M&/@O\?X!P7^
M/\ &33IY2[0TZ>4NT8^"_P ?X!P7^/\  !DTZ>4NT-.GE+M&/@O\?X!P7^/\
M &33IY2[0TZ>4NT8^"_Q_@'!?X_P 9-.GE+M#3IY2[1CX+_'^ <%_C_ !DTZ
M>4NT-.GV=HQ\%_C_  #@I\[\ &73)Y2[1^DXD^,AKJCK+=8_<,*B46RYI,!(
MW+E(!&(F9B\QWS5>\;S3I+*Y'<!E "V@     PR'<PK)WF,Q[C&D7Z5X^0S_
M   ?;#.=YRMW$-HBL5BW 1$1;
M
M
M
M
M                                     !\N-I65E%\1]  BIL;2(-M1
MV/>E1<0BZ?4%(=4RZ>:X@\TROQW'22$9S9GQD.,Q7>)+C2T;"<_1J]Y'<@'8
MQWB6G?<9QS=$G:1!7/\ NXZ)I6<D!]   /AT[-JMR#!#+SE'R$,S_H'[ABA[
MU@-D
M
M
M
M
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M</=(_P"$8?>CA[I'_",4* :-)O#FNE/B?=?7WHX>Z1_PC#[T</=(_P"$8H4
MT:3>'-=*?$^Z^OO1P]TC_A&'WHX>Z1_PC%"@&C2;PYKI3XGW7U]Z.'ND?\(P
M^]'#W2/^$8H4 T:3>'-=*?$^Z^OO1P]TC_A&'WHX>Z1_PC%"@&C2;PYKI3XG
MW7U]Z.'ND?\ ",/O1P]TC_A&*% -&DWAS72GQ/NOK[T</=(_X1A]Z.'ND?\
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M\KW(RV<8]'9-/V%HW_)_]QC&)1%,<'U/2/5,;.XM5&):T1?A_P#73  #R?H
M      !Q^4/]E:C_ /;_ %$.P''Y0_V5J/N3_40#B,*'YR?A^8M6D[6D_P!\
M8JK"GI)^'YBU*1^J3_?&"I,  $8I/H'[ACA[U>XADD^@?N&.'O5[B ;(
M     .8RF?L/5O\ EE^9#SD/1N4S]AZM_P LOS(><AT8/*7XW\1_OT_;^Y
M![/SP
M
M
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ME+\;^(_WZ?M_<@  ]GYX
M
M
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M-3$Q5120T368:\^^TSO>Q<HZBC93&&J(S K5)*:;*"0E5TFE9$5BN1EL,5H
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MC_?I^W]R  #V?G@
M
M
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M[]/V_N0  >S\\
M
M
M                                           N+(/_ /+JO_SD?TF*
MTK%;JDMV0Q*J,IUG2*+,-P[6N8C69#[!&3#[S1'M,D+--^P8S,S,S,[F?&,1
M1:9EWXN?FO+X>!3>-F]^/.ZPLB"HJ<2RB?S=.;%F+^\KV]MAW*85?CXQ74*O
M5FF:(2\UEE*K9YGL2DRMOO[10J%*0HE(4I*BVDI)V,OB,S\V7(-)R)<ATTG=
M.>X9V/V#-6'>;NG*>J4Y? IPIIG],WX3:_WZN^RJ?[Q(/_+9_P#44)G+U_W2
MB_\ ,=_(A4CCSKJR6ZZXXX6Y2U&9]H_7I#[Y$3[[KI%N)Q9JMVBQ1R[,5^I1
M73C4[/[DQ/VL[;(S*;CXQT;JB2;["D(N>\[D=OP$AE'P3.:EUBOF_'.'<G<R
MYY^TR*UK6_$5JDS2HC29DHMI&1V,AL/SIDA&9(F2'4<U;AF78+-,[6U#SP\[
MA_E?RV+1>TS,3>W%K"\L+4MRLY)FZ>TM+:Y#:DDI>XO/,4:,[<N4T@D-2I"$
M%N2EPR(O@%=.TQZ?G*<I55-=.U%46Z+PP1ADL#1:C+J=0:-I:2,\TS)"2+CV
M\8IG$4QJHUZHS(Y69??6X@K6V&9V&F](??(B??==(N):S5^8Q!33:;S+6<SU
M.-A4X&%1LTT][R^V%$A]M1F=DJ(SL?M'5Y2L0PL1U>))IQO$VU')I6D3FG?.
M,^7VCD0&K1>[DIQZZ,*K"CE5:_\  +ER)&986JIE<C*0=C_^TA30RM27V4FE
MF0\VD]IDA9I(^P2JG:BSWR&;C)XT8LQ?A+;FUNJ3V2;FU"2\WS%N'8QWF0M4
M4JQ44N9O##93HK[\V_G6_ 5F/IM:VUI6TM2%IVDI)V,OB%5-XM"97-U8./3C
MU_JMU7W2H6((N+G9M>JK14U:S;CL(41$LS]$K6Y+CAL<?[VHO_,8_,<$_,EO
MK2M^5(=6C:E2W#,T^[D'PMYU;FD6ZXIPOWU*,U=HQ3AVF[NS'JM.+AZ=-,_Y
M;7&;K0R\%_M5)/\ A<_]HCLB$EIK$\EIQ>:X]',D$?[QDHC/\!P#S[SUM.\Z
M[;=GK-5NT?*5*0HE(4I*BVD:3L9#44?IV7A5ZA?._FXI_C^+.]RAX,G4]^J5
MIU]@XCC^>E)&>>><?):PX ]I&-B1-ER4DF3+D/)+<3CAJ(:XM,3$<7+F\7#Q
M<2:\*G9B>LWXKNH;T/'F!"I3T@FYS*4I47&E2?15;C(QS#F2J?&CR)$RH129
M:0I?Z,E&9V*_&1"NVG%M.$MEQ;:RW*0HR,OB,[]0FR$9DB;)=1S5NF9#,43'
M^,N^OU' QZ:9S&%M5Q%KWM?[M4MI"U:,C6>1.;':+.=C*7=)<I+SOR,54.NR
M?XM3AR1(:FM*?ITE/Z1"=IDKB.WX"UQ,QP<_IN-1A8LTXLVIJB:9GI=^Y)MN
M.(-N:O\ I,;6-JF_1\I\J?%.SC*VU6YQ9I7+XD.1F.LMU%]REK>;CFLS:,SS
M5I2?%L&LXXMQ9K=6I:SWJ4=S/XALWFZ1FYP\O&7IYQ5>[U!1GH529;J\(B/A
M+22S^,R(SV'[C,Q0-$Q74L-2:BBF:&S[QFO2(SMI&=K=H@6I4EE!(9DOMH+<
ME#AD78,1G<S,SN9C-.':]W5G/5Z\QL58<;-5-^,=^;N?O3Q'RP_"^H_:5AR=
ME ;J%7X4PW.)Y*%-J29(,LTMNRXX096)#T=>='>=:5RMK-/Y#6S;_'@Y:<]7
MB3$9J9KIZ7_VN[)YA*3@_A\RJS&296V19B%'F)(CN:CN1;1PL7&,:EX\K%9C
MQ^$L2#4ANQYIVN7G?&PXZ1.ER4YLF7(>3R..&9#7$BCG-3WQ?4XBBC#RU.S%
M$WB_&;_^RN_!F.(E?Q$F*U1VX[ZT*6;^PU;"Y;7'*Y7:JU.K14MF$EN0PX5W
MB(KN9Q6(A7K3CC2\]EQ;:^<A5C[2$MAB="BU^//K1OOML*TF:7G&M1;KWXN,
M33BF;P]*O5<3,X/Y?$FUYXSPM9W^5T^!X4P]3E'^E38U)_X46/\ $Q4XGL:X
MA7B6N.3#2I$=)9C+9GZ*>4_:8@1JBG9IM+D]2S%.8S%5='+E'\   VX0
M  !Z.R:?L+1O^3_[C'G$>CLFG["T;_D_^XQXXW)^A_#?[]?V_N'3  #G?L@
M     !Q^4/\ 96H^Y/\ 40[ <?E#_96H^Y/]1 .(PIZ2?A^8M2D?JD_WQBJ\
M*>DGX?F+4I'ZI/\ ?&"I,  $8I/H'[ACA[U>XADD^@?N&.'O5[B ;(
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ME4:>BCIJJXZB@J5FI=/<9[A'CT#5YN'X6!8+\JGNNT<TMZ)@DD:DWW7\[?\
M$5KAZAT_&&.):83;D6C)3IM&5DJ))6+-WG:Y^T*<2]YEZYKTJ,*NC#PJKU56
MX>>/V<1<KVN NDFL*GB J"6'7-&:M%PG1GFDO_BO?XC3H6"J="Q[/ITIA,J"
M<8GV$NF9FDC5:U_8)JPL^BXFU$4UQ-YM//A*HKD7&!G;>+GBL8+IV)#P\=.-
MZ6M9DIUQ.<DE'M)%[[-AD6X8ZY P7@VI$4Z"Z^Y,//2WZ:64;C/:9;+WY3%U
M.R3Z/,4S7.+3:)M/:5. +*RN8<IM,BP*E26283(7F+2D_-.Y7(R(]PK11V29
M^P:IJVHN^?F\K5E,6<*OC,.EPG@ZIXFSUPR0U&0K-4^[?-OR%RF.ED9(ZDAE
M2H]3B/N$5\S,--SY+[1U.('EX9R5,)I:C:<4TT@EEO(UV-1^_>*NP;6Y].Q+
M =:DNJ)U]#;J%+-1+2I1$=[^\><355>8?7Q,MD\I51@8U,U551$S-[6OTA#U
M*#(ILYZ)-:4U(:.RDF-86GEUA-(ETR:DB)UPE-+.V\BVE_J)^K87PI3Z=!JU
M3CICQV4)-:$7LZI1%8C(MI\>P74X1+QJ]'JG&Q<.FJ(BBW&>D^RC2.^X+ERB
MTZ!2,/XNQC)>B1S12XC"%$RE)MZ1=S]+V"4PVK#%?Q%4*0C#[+91+FAPR].Q
MYIWY!9Q.S&'Z3.);_P D6JF8CGQLI@+ERD.XJKU CX])F;2"9ID8U,N-,J,\
M]6VRK$>WBV#L</HPQB*6] 3AEZ,WF70ZXUFW+WD>PPFNW&S.#Z9JUS1&)%XF
MWU]E+ .LDT./3<HR*0I.FB)DH225G>Z%;;'VCO,4PL&83GMR)U-4Z](39##9
M9R4I+>JQF1<8LUV9PO3*ZZ:ZJZHIBB;3=2^_< M+*=AJDMX>BURBL%')9HSD
MHN25H45R.W$>X5:=[;-^XA::HJB\.;.92O*8FG7-_KP=-A/!=4Q*A3T31L1$
MJS3?=O8SY"+C$[4<E53B0W9#51A/DTDU*(R-%B(KGMVCK,?25X9R>Q(=+4IA
M3F8QGIWD5KJ,CY3MO]HIQFISV6WVVILA+;R30XG2&9+(]][C%,U5<8?2S.!D
M\E;!Q:)JJM>9O;Q#L,'X(BUW"\FJNRWFG&M)9"4D9'FE<<$D[I(_8+JR6?[N
M:A[W_P"D51AAVG,UF&NML*?I][.(29WW;#V;3V\0M-4WJ>6;RV'3A9?9M$U1
MQGQQE&W+E(!=%!^R]?GKIZ,,O1VE(/,><:S2/XD=R,<3(PM$:RD:A-U:81N$
M:3-7G9IIOFWY>((Q(EC&]+KPZ::J*HJBJ;?7G_+C;ER@+OQ)&PWAI;34K#+C
MD T>=*;1GDD^0S,[B*P#A[#U;F5FI-0S=B-/YD6.I1V)-KWL9[SY#$U.%[/6
M?1JXQ8P8KB:I^G'AWY<52D9'N,!9&+)^&DTZ9$>PX_3ZJDC)DE(S+G??<CXM
MXK<ANF;P^?FLO&7KV8JBK[?3[W (R/<8Z? LJA1Y,HZ]3W9KF:1QTMD:KGQE
MFW(N3:8L:DT;#N,*7*2BAO4UUL[)6:<Q5SO8R,CV^X9JKV9XNK*^FSFJ+T5Q
M>;\./T_Z4D!F1;S'99,*7%G8Q5"J3")#2&G+H5NSDF17'8OMX)H&(2H[U.6]
M)D.EG+4G/0T:C\U.T]A>XA9KM-C+^FU8V%&+57%,7MQZJ<'XI1)29\8L?*!@
MZ+%Q52XM)1H6ZBK--N]R09&5S*_L/=[!T.)(N"<*1X].J--6\MY%S4A)J62=
MQJ-5RMMY!-2.%FO^)Q(G$C$JBF*.%YY<>3D<58*C4;"D.K-2WG''R;,VU)(B
M+.3?>.&%UY5293D^@E$4:HQ*:T1GO-&;L_"PI4,.9F.)ZO@8>!CQ1AQ:+0[J
MB9-*C5J5'GLSXK;;Z<XDJ2JY#7Q#DZK%%@N3%*8E1VRSEFR9W27+8^(=\B%,
MJ&2!B-34K7+6PG,)"LTS\^^\9\)Q*C0L"U L3/'9*%K)*U9YH1F[C/CVCSU*
MN=WUH]*RU411L3%Z;[5^$2H<+[;"T<EF&*;7<*S^'QTG(TIMI>_>06:6[M&A
MBMW"BZ25'PRP2ZD3R&R?-!^=ML?G&/7;XV?'_P"-JC C'JKB(F+Q'UF>D*],
M[;PO8C/B%RSJ+A[!E+AIDT=ZJ3'_ $U$DUG<B*Y[[$7(0T<4X>PTQ3X&)$PY
M**:XHN$16S-)F1D9%8C,K'??M&8Q(EZU^C8E%,S-<7CC,<>$>/I]6&!DUI[%
M&9FU^L%%4Z23WI0E)JW%<SVF*]KL6/!K$N+"D<(CLK-"'=GG6X]@O;&U1H4&
MA0'JW <E0EK233:4D9I/-,RV&HN*XK3)OA>)B:LSY$M*RIL96<39';.,S,TI
M/V$1"453::JG7ZAD,/4HRN6IC:G[WY?7LX6Y7M<!=$"/A6M5=^C%AYUA!$I+
M<C1FDE&7(=[EQVN-7!F"X#=:Q#3*FPB44<V]"M9;22HE&1[./Y"ZD.6/1L2J
MJF**HF)F8OQX3$7_ *5#<@%E8G5@ZC42?1X#9OU9"='IU(-1DX1[;JW$>_<)
M]&%L,)PE2*I5F41VFF6WGEH,RTIFDMAVVGMXB%U.S-/I-5=4T4XE,S3%YX\(
M[3/92Q'?<%RY18BJ?0\8XTI\2@LJBTY#"E2,U&89V,]WON17'22&\*0:VW0_
MLZZXV9I97)T9FE*CW>=>Y\6T)Q+?1,/TJK$O5&)&S>T3UGLI<?AF1$>ZX[''
MN%$43$\>#3[\&F9N@)2KFDS.QE?WF0[JLT_!^"Z9&8J=/5+>>V7MGN+Y5;3*
MQ"S7'"S&'Z7B558E.)5%,4<YGDXZJ8*C0\!L5Y$IY3SC;:S:-)9I9QD1[?B.
M&%W8X*&62=!4M2C@YK)LFH[GFYY6N*2$PYF8XM>K9>C Q:*<.+?ICEUX\5CI
MR25122,JE#VE?T5#')R45./'=>7489I;0:S(DJVV*XU<DLR4]C:*AZ5(<1HG
M/-6ZI1;N0S'YE7F2FL:3&VI4A#>C1YB75$6[D(QF]>ULW=>GD?ROYG2GG:VU
M+A4G=)'RC](R/<8L+);A*'6$2JE5T&Y#CGFH;(S(E*(KF9VVV(K;/:.CI,3#
M&*W)-.307Z>LDFIIXVS09D1[R.^_=L,:G$B)LY,OZ3B8V'37M1&URB;\?930
M7VV%KX"P? F1\20*FRAQZ-)..A_]Y!9N\OS$+C:3A*/0G*70&35/9<2DY&8?
MG6/SO./>$5WFT,U^F5X>#K8E41PGA/.\?1P0$=]PNZOT/"="IT.L5&GW2A"4
M)8:W.K46\RN5]Q[SL,DO#N$:I0(U?X(J-";0<A6CNDUI+>E17Y2^HFK'1TSZ
M'B1,TZE-XB]NW51MR/<8"[*72L)XQH$M5-IIQ5M722LW,6A5KD>PSN0I0R-)
MJ2KTDF9'\!JFK:<.;R566BFK:BJFKE,/P  ;<0
M
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ME4I>DU?4),<G#SEDA9V4?*?M]HD8<P]<3U7 KIIHG:FTWO>-J/M\KMK6=5<
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M1)0:S4H#;S<*=(80\><X2%F6>>ZY\HC[%:W$-4T[,RXLYG(S&'AT1$WIO?\
MF;KARS?LK1O^:G_TS&PW_N,/_I#_ /4%35"LU*HL-LSYTB0TV=T(<5<DG:VS
MX#]*MU,J;J\I\C@.;FZ#/\RU[VL,QAS:(=M7JN'./B8NS-JJ=E:&0[_Y'5_^
M87](J%[]>[_QJ_,QNTVLU*F-N-T^=(C-N'=:6UV)1^T:!F9F9GM,SN8U33:9
MEPYC-TXN7PL&(XT7_P!OP  ;<(
M
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M%,Q:GHM>:HQ(S&9Y;<13$?5PH  ]7P   %
M    !Z.R:?L+1O\ D_\ N,><1Z.R:?L+1O\ D_\ N,>.-R?H?PW^_7]O[ATP
M  YW[(       <?E#_96H^Y/]1#L!Q^4/]E:C[D_U$ XC"GI)^'YBU*1^J3_
M 'QBJ\*>DGX?F+4I'ZI/]\8*DP  1BD^@?N&.'O5[B&23Z!^X8X>]7N(!L@
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M-6HW?RG?S\*R^[7$/1Q?&^@?=KB'HXOC?07< :M1N_E._GX4C]VN(>CB^-]
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MQBJ\*>DGX?F+4I'ZI/\ ?&"I,  $8I/H'[ACA[U>XADD^@?N&.'O5[B ;(
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M-*G5,E]6?QQ@E+349]AMB.^\X@GLY*O/)6:1D96XN4=/AO'E%PGD*H>(3I?
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M:.B$
M                                                (2#7ZM/N$>0D
M&OU:?< ^@                                 >>,;9,LF=(Q-5)^,:P
M\A^H7E,QW';&TD[YUC.YJ+.O8N(>AQ26+ZEDBQ\ZJ7B"IQSEQ$*C$;CJV7&R
M)1W(BXSO?E <9Y*4":SC#$CM*5+^RFCS&ENI-*'5$L\PR+=G6O>W*.I>\GW#
MZZE6JQBZKS)S3CBG6UK<S391O//6J]^/D(<7Y.-2>CY7*O2,/S94G"J6GU()
MTS41-I46B6=]QGR\8P99,J"L=5W[,46J,4[#!+(I,YTC+3*+?NN>:7(6\R 2
MWDB.26Z]B>'$=<71&R(T$=\S.SS))EQ$9I*]A9WE%XID87R:S%P5FB7.64)M
M96N@ED9*5\"N/C(O/P%3*>UAS!=3;F223IGEFE6D?5;:M1F7X;B'+^6"RM6!
MJ2\1F33<\B5R74E1%^("M,>TU_ N0[#-)@GP95<?.54'$>:ISS34A*C+:96S
M=AAE(R<4+!N3[#6)<.5!3-7<)I:EI<*[JE))6<BVZQB]\8TG"^)\DU+1BJ8F
M%338CK:EY^8;3F9YID?;LXQYIR@X?P=1(3$'#.(I>):S(<2TRG833"3/;:VP
MU&=B+X@/4.%,>,HR,TO%V(G21>"3KQWVK65RL7*:C+\1Y0Q'4JKB3'-(Q'B!
MLTN5-]+D5M9;6V4N$E)%[-^[D,6?E$P%C1>!L%89I5.>FT^GQ4N26T6(C>WV
M5<^*YEVBN\HLK%SF**&6)Z6Q J49E#<&.V@DI-!+\TK7/CV /<Q;AYE\H6G8
MYK,G$"Z@XB+@ZDM%(92V9YLJY;"/=G*WW(]A>VXM' .4VGU&33\.5^8VUC$T
M&F5%0V9)2Z5S-!'NN22OO&;R@?\ =%B3_I_]0'"9 <.0L3Y!)U%G--G'E2GT
M;4W)*O-LHBY2/:/WR4:],.!7<*5)U:W*.]^@)1W-+9F:33["SBW>TQ->2E_N
MJ+_KWO\ VCD_)V6F9EBRBSHUSBNK5F':Q;7U&7X /1Y
M                              ./RA_LK4?<G^HAV X_*'^RM1]R?ZB
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M "/T]2ZDUX_T#3U+J37C_0!( (_3U+J37C_0-/4NI->/] $@ C]/4NI->/\
M0-/4NI->/] $@ C]/4NI->/] T]2ZDUX_P! $@ C]/4NI->/] T]2ZDUX_T
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M  _;A<?@ /VX7'X #]N%Q^  _;A<?@ /VX7'X #]N%Q^  _;A<?@ /VX7'X
M#]N%Q^  _;A<?@ /VX7'X #]N%Q^  _;A<?@ /VX7'X #]N%Q^  _;A<?@ /
MVX7'X #]N%Q^  _;A<?@ /VX7'X #]N%Q^  _;A<?@ /VX7'X #]N%Q^  _;
MA<?@ /VX7'X #]N%Q^  _;A<?@ /VXWVOU:?<(\A(-?JT^X!]
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M1EJ4HJ=(TK1'^X5S0HNU) /0X 0
M            ./RA_LK4?<G^HAV X_*'^RM1]R?ZB <1A3TD_#\Q:E(_5)_O
MC%5X4])/P_,6I2/U2?[XP5)@  C%)] _<,</>KW$,DGT#]PQP]ZO<0#9
M     !CD?J5#1/>-Z1^I4-$]X#S/B/\ \6\+_GQOZ1GPY_XO*A[Y']!#T"NA
MTIRJ%4ETZ*JHI,C*2;9:0C+<=Q^MT6EMU153;I\9-15>\DD?I#OL/: \]Y6+
M?]IG#W_+A_U+&YY8NR)A#_JI/]*!>\JB4N746Y\JGQ7IS=LQ]:"-:;;K'[!]
M56CTVKDT55@1IA-&9MZ9&=F&>^W80HJ;+;1IM8R'4M5.8<?<A(C27&VRN9MD
MW91V+?:]Q3V$V\F4G#+3N(JQ6HM20DTO1VW%*0LRXT%N,C+B'L9I"6FDMMI2
MEM*22E)%L(BXO<.<E8"PG+G<,D8>IRY&\U:*Q'[R+8 \J?\ PO!&4+"^(8#,
MU6&9&9.BK>(C=6V2C2LO^(K7MO'I7!F5C#F+L3)HM!.6\^;*GE.K:S$)(N+:
M=S/:.KG4.E5"G(I\ZFQ'X+960PMHC2CW%Q#7H&%Z'A_/U)2HD)2BLI32/.,N
M0S/: \M9#\9TG &)L2+Q,<B.2S=01):-2B43E[&7%L(34R2W-\J>B2F3/12)
M#+J+E8\U3!F5R]QCT+4\&X;JE2*?4:' DS"+]:MO:?OY?B-PJ!2"J#<\J9$*
M<W;,?T99Z;%8K'["V /-BJFUDT\HFK3\1-R"@2#<6V\A&=G(=21DHN6QE8[;
MA\3*LSE/\H2B2L.MOG!CFV:WUHS3)#9&:EGR<A7WCTQ6Z)2Z[&*/6:?&FLEM
M)+R+V]Q[R'Y0Z%2J#&-BBTZ+!:,[J)E!)SC]I[S >=L#$7_:MK?&:7YIE[#L
M/C*3_P"*2E?_ +C_ *CT:Q0Z4Q4UU)FG16Z@LS-4E+9$X9GOV^T?DBA4J344
MU"138KL].;FR%MD:RS=VWV""G\N$K)U5,2G1<8KE4^M1XR5-5%MNZ";5M)*M
MNTM^PQQWDY5.I1,I<ZA4BI2*GAA*'5&M25:,DI_5N$DS/,ONL/1->PK0<0*)
M=;I,2:X19I..H\XBY+EM&S1J)2Z''-BC4^-":/TDLH).=[SXQ16'E05JKT;
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M>P4?63>;4:C@'#\RN$HJF_$0M_.38S4>XS+E,K'\1T8?@ @
M
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MA,H3RTNU*2O32W4G<E+M8B+V$7YF [\
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M^8EK@ B>!5#K4?PC^8<"J'6H_A'\Q+7"X")X%4.M1_"/YAP*H=:C^$?S$M<
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M^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/
MJAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_
M,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?
MPC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1
M/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X
M1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K
M4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@
M 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ
M/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5
M#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8
ME@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JA
MUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,.
M!5#K4?PC^8E@ 1/ JAUJ/X1_,.!5#K4?PC^8E@ 1/ JAUJ/X1_,9"CU,BL4N
M/X1_,20 (W05/K<?PC^8:"I];C^$?S$D "-T%3ZW'\(_F&@J?6X_A'\Q)  C
M=!4^MQ_"/YAH*GUN/X1_,20 (W05/K<?PC^8:"I];C^$?S$D "-T%3ZW'\(_
MF&@J?6X_A'\Q)  C=!4^MQ_"/YAH*GUN/X1_,20 (W05/K<?PC^8:"I];C^$
M?S$D "-T%3ZW'\(_F&@J?6X_A'\Q)  C=!4^MQ_"/YAH*GUN/X1_,20 (W05
M/K<?PC^8:"I];C^$?S$D "-T%3ZW'\(_F&@J?6X_A'\Q)  C=!4^MQ_"/YAH
M*GUN/X1_,5_7,M%+I%9GTUZ@8B><B/*84XS"-2%FD[72=]I#8P=E@H^*,4,4
M&-3*O$G/-K=24N.39$E)7,SVW_ !W&@J?6X_A'\PT%3ZW'\(_F-]YU##+CKR
MTH;;2:E*4=B(BWF8XFGY4*!+PU4\0K.1'HD)Y3!2W4>;(,C,C-LBVF5R_$!T
M^@J?6X_A'\PT%3ZW'\(_F*S1EYH*5-.SZ+B"!3G5$E,Z3#S6BOQGMN1"S*K7
M*=2Z"_69LIM%-99TZG\XC3F6N1D?'?9;EN :"I];C^$?S#05/K<?PC^8K:!E
MWH#[T14NE5RGTV6X3;%0E1<QA1F=B.]]A>T6TE25))23)23*Y&1[#(!':"I]
M;C^$?S#05/K<?PC^8B,>XZHV"(;#U9<=4[(5F,1HZ-(\\?(E);3$#3LJC<R#
M4I2\*XDC-0HIR_T\4DFZV1V,T;=ID6VP#M=!4^MQ_"/YAH*GUN/X1_,?F&:Y
M!Q)0X=6I3NEARD$M"N,N4CY#(]@DP$;H*GUN/X1_,-!4^MQ_"/YB2 !&Z"I]
M;C^$?S#05/K<?PC^8D@ 1N@J?6X_A'\PT%3ZW'\(_F)( $;H*GUN/X1_,-!4
M^MQ_"/YB2 !&Z"I];C^$?S#05/K<?PC^8D@ 1N@J?6X_A'\PT%3ZW'\(_F)(
M $;H*GUN/X1_,-!4^MQ_"/YB2 !&Z"I];C^$?S#05/K<?PC^8D@ 1N@J?6X_
MA'\PT%3ZW'\(_F)( $;H*GUN/X1_,-!4^MQ_"/YB2 !&Z"I];C^$?S&]'2XE
ME)/J2MPB\Y22L1_ 9            !Q^4/\ 96H^Y/\ 40[ <?E#_96H^Y/]
M1 .(PIZ2?A^8M2D?JD_WQBJ\*>DGX?F+4I'ZI/\ ?&"I,  $8I/H'[ACA[U>
MXADD^@?N&.'O5[B ;(                      #@<O)YF2/$JBM<F$GM_Y
MB166$93F2G%M,<E*T>#L5,M+0=R,HTPT)OR629F?P/V"SLO"%N9(\2H;0I:C
MCILE)7,_TB>(?L[",+&F2>#1*FDTI=@LFVY;SFG"06:HKEO(P',4[_Q0U;_R
M5O\ T'YBJDXC9<GRJEE):@3D:1<*(VRVAO-*YH)=]I\1'O\ B*XR>NXJ7CC$
M3%0B/(Q)3J Y!;>))_IUH.R%$9;#,TVM;D(9<%R< M8%)-9I4BL8Y=2M+L63
M'=<?<D&9D1$9EFD5[;0%E81RA5FJ9"9.*3C(E5R*R\2DH19+CB#/SB27%:QV
M]XA,#Q<08PHL>MT;*=IZLM)..1T16S9;5N-)H,KE;=NWC;R!S_LSD0=F5.))
MM$DR%.L(;-3ELXB.R>,<9E,E8#J=/UEDX7)C8V4M)Q44J.ZRM:S,MBRS238M
MH#M&:IBC*%C:OT2D5PZ-1,/N)BR9++"3?D2+'??N*Y'NL-["->Q%AG*6G!.*
M9Z:K#EQ52*=/-LD.'FGYR%D7QVCF, U9W)=B_$#&.6GXT2NJ:GM3TM*6T3F;
MY[9YI'MNH2E"EKR@Y<(F(:1&?3AVBPEL)G.-J0F2XH]R241'8@&'#\W&F,\:
M8SHC%?.FT:GSS24AME*GB*Q9K:=FPMAF9[]HEL%5W$6',H[^",6SRJD>3%.3
M2YFB)+BDI,\XEV^/+V#E< XV@X2RFY06ZXAYBF2JF9E.2TI:$.)3Z"LTC,KD
M>P3>&9KF4'+7]I:9'>;H%$A+B-2G6U(*6M9G?-N1';;<! 9+J7B3$51Q;3Z9
M6SH=(CU1UQ;S#1+??=4K=<_121$>[:8[C)=6L11,<8AP9B>:BI'3FFY,6;F$
MA:FE[B41<8^L@;2VX>*=(VI!JK4@RSDF5RN(Q:)Z<MF/7*8A?"SH3)1S(M[E
MMEO;<!L8JHV(^&U!^I92&:6[GK73XK;+:$$C>@EWVF=]A[_B.2JN5#$SN1"F
M8@:?;*MM5Q$!];2$DF025'<K&5B)6S<(; DS <?"#BL4TR55\=.+7IXDUAUU
M]Z09[$IV9I%?E]HC6X4MK('3V'X;K,A.+FU*8-)W;\Z]O<6X!9.(L/Y18.%*
MGB5>+5JK;<8WTTQB.@F$'<CS2,]]DW+=M,=2O*$Q]RIXQ2X6EU?I+6+]?FYM
MK?\ 'Q<@L1:4K2I*TDI)E8R,KD9#R@=$J2<=JR6$A6IG*V55)96N47TS3R;^
M*W$0#IJUBO'=#P;DY=1-T^(*S)7IVG&D9JR619B#L6PB(R/9M$KCZ/C?)[1T
M8K1BURKFR\@IL-^,A+1I4=CS;;MON$OEECF6-,F!,,F3356W(3L06:7)N(2?
ME&MK<R15M#2%+49M62DC,S_2)X@$9C_$M<JN-<*83P_4$TAFKPU39,O1DIPD
M%^ZB^PCV"!5'Q92\KE*PBK&DUV!,BJFI=..V;A9AW-"KEN.QD([+M)A-.Y.D
M/$\T\VDG'I-/VSF&R0FQ((MI$9WVF1[C&_DQQ!@.#C'3N2ZZYB">DF&IM=2H
MU*XLQ"C(K7V .GQC6ZZ>6R@X;I=65 AS:4^\HR90YFN)SK*LHMN[=N')Y#*)
M69$*MS6,3RV&8M9D:>/P="BDJ2JZE*4>TL[CMN'1XD:</RF\(.$A9MIH\DC6
M1'8C\[C$#DFQ53L)OXKPYB13U/J;M7?7'0ME:M.3AG;--)&5MVT^4!U.27%5
M8JF2^LUB>X<^HQ9,PFB-)%G$W?-38K?,<CD[=Q#E H;59B92#9KZB-2H#<5L
MFV5%N2I&\RW7.PZ'R?I)TC)759<EAY28]1F/*;2@\]225?87'N'$Y2:GDVKE
M#?JN%U2(6,+)<BZNBNLR%.W+S5$22(]YW]V\!Z1IZ)#4",W->)^4EM*7723F
MDM9%M5;BN8SB"P(=4/!M$.OD954XC?"25O)>:5[^WE]MQ.@
M
M
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MS_'\Q<A"F\A)HJN+,H%>9,U17ZB4=AQ/HK2@MI]MA<@
M                               X_*'^RM1]R?ZB'8#C\H?[*U'W)_J(
M!Q&%/23\/S%J4C]4G^^,57A3TD_#\Q:E(_5)_OC!4F  ",4GT#]PQP]ZO<0R
M2?0/W#'#WJ]Q -D          !CD-FZTI"7%-F?[R=Y#2U<]U^1V)^0"1 1V
MKGNOR.Q/R#5SW7Y'8GY )$!':N>Z_([$_(-7/=?D=B?D D0$=JY[K\CL3\@U
M<]U^1V)^0"1L CM7/=?D?R_(-7/=?D=B?D D;%>_&,*8D9$@WTQV4OGO<)!9
MQ_'>-35SW7Y'8GY!JY[K\CL3\@$B-=F#$8=-UB*PVX=[K0V1'M]HUM7/=?D=
MB?D&KGNOR.Q/R ;K[#4AO1OM(=1S5I)1=ACZ:;0RVE#2$H0G824E8B^ T-7/
M=?D=B?D&KGNOR.Q/R <'DPPW/IV*<?O5>%FPZE4DO1](1*2Z@D[[>\66TTVR
MVEMI"4-IV$E)6(O<0T-7/=?D=B?D&KGNOR.Q/R 2)%;<%BY!':N>Z_([$_(-
M7/=?D=B?D V^"1BD\(*.SI^DS"SNW>,UBY!':N>Z_([$_(-7/=?D=B?D P8L
MJ=0I%'<ETBCNUB4E22X*VZ3:C(]YD9D>X<+DNPM7#Q77<98Q99CU.HI2S$B)
M42SBL%ML9D5LX]E_<+!U<]U^1V)^0:N>Z_([$_(!(VY0L5A':N>Z_([$_(-7
M/=?D=B?D J^NT#$F&LJL[&-'H[6(8<Z,AA;&E)M^,:>8:B/8?L&IB"A8LRG5
MFA:ZH;.'J%3992U&Z^EV0XI/[I$1%8C_ -.,6WJY[K\CL3\@U<]U^1V)^0"0
MMM&)R+'<>0\XPTIY'HK4@C47N,:FKGNOR.Q/R#5SW7Y'8GY )$B(MQ#71!B-
MOF^W%82\9F>D)LB5MW[=XUM7/=?D=B?D&KGNOR.Q/R 2(".U<]U^1V)^0:N>
MZ_([$_(!(@([5SW7Y'8GY!JY[K\CL3\@$B CM7/=?D=B?D&KGNOR.Q/R 2("
M.U<]U^1V)^0:N>Z_([$_(!(@([5SW7Y'8GY!JY[K\CL3\@$B CM7/=?D=B?D
M&KGNOR.Q/R 2(".U<]U^1V)^0:N>Z_([$_(!(@([5SWK"1_+\@U<]ZPD?R_(
M!(@([5SW7Y'8GY!JY[K\CL3\@$B CM7/=?D=B?D&KGNOR.Q/R 2(".U<]U^1
MV)^0:N>Z_([$_(!(@([5SW7Y'8GY!JY[K\CL3\@$B CM7/=?D=B?D&KGNOR.
MQ/R 2(".U<]U^1V)^0:N>Z_([$_(!(@([5SW7Y'8GY!JY[K\CL3\@$B CM7/
M=?D=B?D&KGNOR.Q/R 2(".U<]U^1V)^0:N>Z_([$_(!(@([5SW7Y'8GY!JY[
MK\CL3\@$B CM7/=?D=B?D&KGNOR.Q/R 2(".U<]U^1V)^0:N>Z_([$_(!(@(
M[5SW7Y'8GY!JY[K\CL3\@$B CM7/=?D=B?D&KGNOR.Q/R 2(".U<]U^1V)^0
M:N>Z_([$_(!(@([5SW7Y'8GY!JY[K\CL3\@$B CM7/=?D=B?D&KGNOR.Q/R
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MW7Y'8GY )$!':N>Z_([$_(-7/=?D=B?D D0$=JY[K\CL3\@U<]U^1V)^0"1
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M"]0
M
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M'RA<,5-E))*KQ7(3Y(V&X96S35[KEV +E "
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M9DG=*ZE-THW[S%N7+E(+ERD _0'Y<N4A^W+E(  +ERD%RY2  "Y<I!<N4@
MN7*07+E(  +ERD%RY2  "Y<I!<N4@  N7*07+E(  +ERD%RY2  "Y<I!<N4@
M  N7*07+E(  +ERD%RY2  "Y<I!<N4@  N7*07+E(  +ERD%RY2  "Y<I!<N
M4@  N7*07+E(  +ERD%RY2  "Y<I!<N4@  N7*07+E(  +ERD%RY2  "Y<I!
M<N4@  N7*07+E(  +ERD%RY2  "Y<I!<N4@  N7*07+E(  +ERD%RY2  "Y<
MI!<N4@  N7*07+E(  +ERD%RY2  "Y<I!<N4@  N7*07+E(  +ERD%RY2  "
MY<I!<N4@  N7*07+E(  +ERD%RY2  "Y<I!<N4@  N7*07+E(  +ERD%RY2
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M4@  N7*07+E(  +ERD%RY2  "Y<I!<N4@  N7*07+E(  ?ERY2'Z6T
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M!9YSWB&-K:&T!J\!9YSWB&' 6><]XAC:V@ U> L\Y[Q##@+/.>\0QM!M :O
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M_.>\0PU1'YSWB&)  $?JB/SGO$,-41^<]XAB0 !'ZHC\Y[Q##5$?G/>(8D
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M1Z4$
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MI]YSSLWVGM["]@\SXOI-72[A[%6(UKUCB.<;Y-+WMLI4@T>[>=BY"]HO;&F
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MM2D?JD_WQ@J3  !&*3Z!^X8X>]7N(9)/H'[ACA[U>X@&R
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M;E&<IMHSV*-.Z_L%QTFH1ZK3(L^$O/C26TNMJ_A,KE\0&V
M
M
M
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M.EPC6E/*9<0DAY[R:89C83\H&HTR,^_*4FE$X])D*SG'W%&DU+4?M/BXAZ$
M0V(\3T;#;!/5RIQ82%%=).N$E2O<6\_@-:-C7#LFBNU9BL0W:>T1&Z\ATC)L
MCW9W-^(J/%JZ3AG+D[6LH44G:-+B):IDMYLW66'"OG),MMC._)QD8_,$4>F8
MMRIX@J^&:>EO!DFGK@RGDHS&9CIV(\Q-N+EL OR.\W(8;>86EQIQ)*0M)W)1
M'N,C'V*C\G*3*BT6O87FN:1>'Z@J,VN]_P!$KSDE\-HMP
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M1%\ &0
M
M
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M[_R1_P#,Q<I"*=P[2G<1,UYR$VJL,M&PW*,SSDH/>G?:VT2I *8I7_BBJ_\
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MCN#',$X.;@S7$/5.0XJ5,=3M)3JSN9$?(16(=N
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MJ6@TZ<4)9+0M$VG-2X=MA;+^T6?7<:5BOXO8PID_=:;<BV74ZHXV3K4<B_\
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MR<JO4*G1JZT]4GZO184XV*;4'TV6\V1;?>1; %O
M
M
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M),_--3J"/S2L1VO_ *#1IM5I.'LNF*)&45QMB2\E!T9^4F[6@+>2.0[WN,M
MF4:L>4)'GX T:XJ(3A5=Z.DTL*/<F_$:MVX!.>3L:Z5]KL*J=SF*/4U%&)6P
MR:7YUB+D(_S%Q"FLAQIJ6-\H=9942HZYZ8[2D[EYI;3_ "%RD
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M.J)-[$HR(S(O9>XDP
M
M
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ML9<1D9<1D>P2HIOR?2*D5/'&&4J/@]/J9NQD*WDAPKG^)?B+D(
M                                      <?E#_96H^Y/]1#L!Q^4/\
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M %!2M*DJ*(V1I45C+8.G
M
M
M                   !\K+.2I-[7*URXA]  J"'D:ET^9/D4K'%;A*FOJD/
M:&Q&M1F9W,[W.U^,<[D1PI4FL<8ID.5ZK(:@5)*7&U%9,_S/3<Y=O(/0( *P
M\H^G.S<EE1?8*[D!QJ81;[DAQ)G^%QVN#*DU6,)4>H1UI6U(B-N$I.[T2O\
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MZ+2DJX/'([K5Z3BS.ZE'[3,3H
M             X_*'^RM1]R?ZB'8#C\H?[*U'W)_J(!Q&%/23\/S%J4C]4G^
M^,57A3TD_#\Q:E(_5)_OC!4F  ",4GT#]PQP]ZO<0R2?0/W#'#WJ]Q -D
M      &.0UIF5-YZT9W[R#L9#2U477)GB?02( ([51=<F>)] U477)GB?02(
M ([51=<F>)] U477)GB?02( ([51=<F>)] U477)GB?02( ([51=<F>)] U4
M77)GB?01F4?$3F$\$5>NL,)D.0FB<2TI6:2O.(M_Q$GARH'5:!3:@X@FU2H[
M;QH([DDU)([7^(!JHNN3/$^@:J+KDSQ/H) UI([&HK\EQS6.ZCB"G082\+TQ
MFHON2D-OH=<S,QH]ZB]P"5U477)GB?0-5%UR9XGT$@:B25U&1%[3 E$HKD9&
M7L 1^JBZY,\3Z!JHNN3/$^@WS6DMAJ(CY#,06*,4T[#;])9J!N&[5):8<=#:
M2,\\^,]NQ)<9^T!O:J+KDSQ/H&JBZY,\3Z#7Q=,J<'#50E8?AHG51IO.CQU*
ML3BK[K^X;&'9$Z30H#]8CHBU!QE*I#*59Q-K,MI$8!JHNN3/$^@:J+KDSQ/H
M)!*DJ]%1'[C'[<N4@$=JHNN3/$^@:J+KDSQ/H)!*DJ]%1'[C'Z CM5%UR9XG
MT#51=<F>)]!OYZ;VSDWY+CF,<5/$=/=HY88I+-10_*)N8;CN9H6N<7+Q@)C5
M1=<F>)] U477)GB?0:6*\4T_#"*<=1TJCGRT0V4M))1FM5[&>W<5MIB=(RM<
MC*P"/U477)GB?0-5%UR9XGT$@E25>BHC]QC] 1VJBZY,\3Z!JHNN3/$^@D#4
MDBN:B(N6X9Q9M[E;E 1^JBZY,\3Z!JHNN3/$^@D$J2HKI,C+V&!K21V-22/V
MF C]5%UR9XGT#51=<F>)]!(C\-:2WJ(O>8"/U477)GB?0-5%UR9XGT&DSBFG
M.XQ?PTV;AU%B(4QPR(LQ*358BO?TN.UMPU,95/$4"?06\.4IJ?'DRB;G+6YF
MZ!K9YQ?B F-5%UR9XGT#51=<F>)]!(&HDEYQD1>T?I&1E<C(R 1VJBZY,\3Z
M!JHNN3/$^@D#4DBN:B(B]H)42BNDR,O8 C]5%UR9XGT#51=<F>)]!(@ CM5%
MUR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)
M]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XG
MT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@
MCM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=
M<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%U
MR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]
M!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT
M#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ C
MM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<
MF>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR
M9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!
M(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#
M51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM
M5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F
M>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9
MXGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(
M@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#5
M1=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5
M%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>
M)]!(@ CM5%UR9XGT#51=<F>)]!(@ CM5%UR9XGT#51=<F>)]!(GN%5/XSQ[6
M)TDL+8+2U"CK4WI:K))A3ID=KI38]@"Q-5%UR9XGT#51=<F>)]!RN2S'Y8T:
MJD:73G:96:4\3$R*XHE9JC+>1\F\=/BBN0\-T"=5ZDO,BQ&C<7;>=BW%[3W
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MZY,\3Z!JHNN3/$^@D0 1VJBZY,\3Z#=CM:%E+>>M>;LSEG<S]XR
M   #C\H?[*U'W)_J(=@./RA_LK4?<G^H@'$84])/P_,6I2/U2?[XQ5>%/23\
M/S%J4C]4G^^,%28  (Q2?0/W#'#WJ]Q#))] _<,</>KW$ V0
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M6%07RI3E&;83*S?T9N$LS--^7: M(
M
M
M                      '"8_KN-Z9*-O".%F*JQHL[A#LI*")=S\W,N1GQ
M;AW:KYIVW\0J4LIV+(YO,SLF&(%OMF9$N*I+C:]N\C.UB[0$?Y.SD)ZH8LDS
M'Y'VPDRB<JL9YG1: ]N:E!7.Z=^T9/*?=6_AS#E&3<TU2L,,K(CMG)([F7NL
M-[)#A^ON8LQ)C/%$%-+D58D,QX%R4MMI.TC69?O<0P>4[ ?<P1 JT5I3BJ/4
M69JR3:Y-I/SC 2>7J%0SR8/,5N8[ C,.-'$<91GK)Y/H)2GCOM*PJ;$^(,:5
M2@T6!E.B*H^$I2D%*J$9G/<>21D:2<*_Z.YD1F+.RO46;C+"=#KN%4MSY,!]
MJH,Q#5YDE.\TWY?J(+&6*<6XVPO+PU$R<UF"_4F^#N29QH2PP1F5U7OMMQ;N
M(!=-(3%12H::<9'"2R@F#2=R-O-+-L?'LL**QE-JM,RW27\F:=:UZ3%0FK4]
MY%HZ$$1$A1NW+-58D[!VF(9>(,G6 ,.0<-49>(93*FH;Y%G'FIMM7LVVN5BY
M!S44L39.<;XBF1L*U#$%)KSB)>D@YINL.$FQH,C/<1F97X]X##D5EE5<HM>J
M&,ENQL=:,FTT]QG1ML1]Y:,_W_:?()7&S9T7+W@VJL(MK-EV Z1%8E$6;M/E
M,LXA\X2A8@Q?E4CXPK% ?P[ ID5<1AB5;32#5?SC(MQ%<?-<4G$GE%4: Q=;
M% AKE25)+]6XJV81G[=@"YB "
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M;Z1/>#2M](CM(:FJ(/5T]IAJB#U=/:8#:-QLR,M(DK\><0Y["V$Z-AJ;59L
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M8DO$G,;46VYYVRQ[2N>ZX\TXIJ>.L)P&JM]Z$.JRB<(EP8TK2D1[_1W&1;C
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M8,H
M          !"0:_5I]PCR$@U^K3[@'T
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M3)RQ$V5N0MOL'1>2P^_2<28UPFZHS9A/Z5";[$&2C;,B+X%V$ ]%@
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M1;+<EA1YF3E G8NR33,+X=ILYFHT^FH7)=3^^TA1$LD<>TC(_=<<#A]W#CV
M9-(I^%I4W&CQK5PLTGF-MEYQK([[+)(]EOB/:;$=F.1E'9::(]^C02;]@_66
M&&5*4RPTVI7I&A!$:O?8!YDP8VM/DMXH2:59W#%[+;?20++\F-*DY(X1+29'
MPR3L,K?_ %#%IV*UK%8?I6+816+V""HO*ACU1_)L14TG5142D*F):O?,XC.V
MW-OO%#SW,.U#)Y'A84PK+*M1&B>JM16@S)M)'8S([V,C,RW$5A[5.QD9&5R/
M??C&-AAEA*DL,MM)5M,D())'V"CS)BY"_P#LJX+3FJ-1/-["+;O='6U%"O\
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M
M       (2#7ZM/N$>0D&OU:?< ^@
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M<G1YQH0?I6*Y;3+8-+)?@>'@'"S-(A+TSF<;C\@TV-U9\?NV .N(
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M1Z)COF&AJ/1,=\Q,  A]#4>B8[YAH:CT3'?,3  (?0U'HF.^8:&H]$QWS$P
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M"%-9'/\ >IE+_P"N1_20N4
M
M
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MI4*HJ:96HS_5+\XB*_$6T6^*<R+$4[*#E&J32B-DIR(R;;249%M,C^ N,@
M                                             !Q^4/\ 96H^Y/\
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MIHV6Y)EYZ4'O3[AN28[4J,['D()QEU)H6D]RDF5C(:?!9_7R\,@X+/Z^7AD
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M2?[XP5)@  C%)] _<,</>KW$,DGT#]PQP]ZO<0#9
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ML-*4VE9);V9QV/V'^ LEE*D-(0XX;BR(B-9D1&H^6Q; 'V
M
M
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MXSZ2O&.%C<-3%)J:CC$K?HW/.[+_ )BXB
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M5(.Y+5MVWV;QZ*'%9(<'KP9@]B',4ARJ2%JDSG$[24\H[G8^0MP[4
M
M
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MD[PE$P5A6+1H)FO1W<>>5O==4=U+/WF.D
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MJZ]+[Q?(20 (W5:NO2^\7R#5:NO2^\7R$D "-U6KKTOO%\@U6KKTOO%\A)
MC=5JZ]+[Q?(-5JZ]+[Q?(20 (W5:NO2^\7R#5:NO2^\7R$D "-U6KKTOO%\@
MU6KKTOO%\A)  C=5JZ]+[Q?(-5JZ]+[Q?(20 (W5:NO2^\7R#5:NO2^\7R$D
M "-U6KKTOO%\@U6KKTOO%\A)  C=5JZ]+[Q?(-5JZ]+[Q?(20 (W5:NO2^\7
MR#5:NO2^\7R$D "-U6KKTOO%\@U6KKTOO%\A)  C=5JZ]+[Q?(-5JZ]+[Q?(
M20 (W5:NO2^\7R#5:NO2^\7R$D "-U6KKTOO%\@U6KKTOO%\A)  C=5JZ]+[
MQ?(-5JZ]+[Q?(20 (W5:NO2^\7R#5:NO2^\7R$D "-U6KKTOO%\@U6KKTOO%
M\A)  C=5JZ]+[Q?(-5JZ]+[Q?(20 (W5:NO2^\7R#5:NO2^\7R$D "-U6KKT
MOO%\@U6KKTOO%\A)  C=5JZ]+[Q?(-5JZ]+[Q?(20 (W5:NO2^\7R#5:NO2^
M\7R&W.EL0(;\N6ZEJ.P@W''%'8DI(KF9]@XK)5E&CY0VZP[$I[\-N ^EDC=4
M1FZ2B,R41<5RL?Q =5JM77I?>+Y!JM77I?>+Y#<F268<1Z3)<2VPR@W%K4=B
M2DBN9F.6P!C5O%U'FUA$%R!2&W5(C27W$VD-I,[N$7[J=G& G=5JZ]+[Q?(-
M5JZ]+[Q?(<10\KE&Q!E%:PM1679;2V7'-8I.S2C07G)3<O.MNN6RXL.5)8AQ
M79$IU#,=I)K<<<424I(MYF9[@&GJM77I?>+Y!JM77I?>+Y#B<&Y6:5B_'$R@
M46,\[&89-Y%0,[-O6,B/-(RN9;=XL@!&ZK5UZ7WB^0:K5UZ7WB^0XW&V4O4F
M(D8?H%"G8BK6BTSL>(9))A)WL:U'L*]A'4O*XY+8K,21AB?"Q)3(_"E4F0XE
M*WFBVFI"MQV+;8!8>JU=>E]XOD&JU=>E]XOD-?!N)(&+,.0ZS27"7%DIO:^U
M"BV&D_:1[!- (W5:NO2^\7R#5:NO2^\7R$D "-U6KKTOO%\@U6KKTOO%\A)
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MC]4G^^,%28  (Q2?0/W#'#WJ]Q#))] _<,</>KW$ V0
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M9R +9
M
M
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MRE:K+5'=**JE)23QI\TS\W9<=4[C=Y&5-C!Y4>0;+D0Y1U"_Z,MA^;:WLMO
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M(*9D]JN(*&MJH5*D5J.XE2HS[A&U+61^BE9$5KF7H_#:/62KFH[[P'X
M
M
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M1<>=[^(27DT(52<IF4&@LJ_V1ATUD7*I+JD7[ 'H\ +<
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M"6.F;[Q!PECIF^\0#, P\)8Z9OO$'"6.F;[Q ,P##PECIF^\0<)8Z9OO$ S
M,/"6.F;[Q!PECIF^\0#, P\)8Z9OO$'"6.F;[Q ,P##PECIF^\0<)8Z9OO$
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MF=MNPA?. \)X=P-$EQ: ^XW&DN:533K^>E*OX>0=3PV+UAKO$ J3$M)QK@7
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M :_#HO6&N\0<.B]8:[Q -@!K\.B]8:[Q#,VM+B"4A1*2>XR/88#Z
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MA!P")U9GN$-D &MP")U9GN$' (G5F>X0V0 :W (G5F>X0< B=69[A#9 !K<
MB=69[A!P")U9GN$-D &MP")U9GN$' (G5F>X0V0 :W (G5F>X0< B=69[A#9
M !K< B=69[A!P")U9GN$-D &MP")U9GN$' (G5F>X0V0 :W (G5F>X0< B=6
M9[A#9 !K< B=69[A!P")U9GN$-D &MP")U9GN$' (G5F>X0V0 :W (G5F>X0
M< B=69[A#9 !K< B=69[A!P")U9GN$-D &MP")U9GN$' (G5F>X0V0 :W (G
M5F>X0< B=69[A#9 !K< B=69[A!P")U9GN$-D &MP")U9GN$' (G5F>X0V0
M:W (G5F>X0< B=69[A#9 !K< B=69[A!P")U9GN$-D &MP")U9GN$' (G5F>
MX0V0 :W (G5F>X0< B=69[A#9 !K< B=69[A!P")U9GN$-D &MP")U9GN$'
M(G5F>X0V0 :W (G5F>X0< B=69[A#9 !K< B=69[A!P")U9GN$-D &MP")U9
MGN$' (G5F>X0V0 :W (G5F>X0< B=69[A#9 !K< B=69[A!P")U9GN$-D &M
MP")U9GN$' (G5F>X0V0 :W (G5F>X0< B=69[A#9 !K< B=69[A!P")U9GN$
M-D &MP")U9GN$' (G5F>X0V0 :W (G5F>X0< B=69[A#9 !K< B=69[A!P")
MU9GN$-D &MP")U9GN$' (G5F>X0V0 :W (G5F>X0< B=69[A#9 !K< B=69[
MA!P")U9GN$-D &MP")U9GN$' (G5F>X0V0 :W (G5F>X0< B=69[A#9 !K<
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MS/<(;  -?@$3JS/<(. 1.K,]PAL  UN 1.K,]PAG;0EM!(;224EN(BL1#Z
M          ''Y0_V5J/N3_40[ <?E#_96H^Y/]1 .(PIZ2?A^8M2D?JD_P!\
M8JO"GI)^'YBU*1^J3_?&"I,  $8I/H'[ACA[U>XADD^@?N&.'O5[B ;(
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MW ,@
M
M
M                        _%*)*3,SV$5Q^C\,B,C(R(R,!YXJ.-\-XQRF
MJ>Q)68<;"^'GK0HSN^7*(]KBBL?F)MLOR[AOY#<64,\;8V8UFP;U5JB7(2;G
M=].9O2+:7@O"ZUJ4O#5$4I1W,S@M&9GW1R.3/)TWAS$>)JA4*;3+29Q/TY2&
MDFIAO-L9)V>9[B :OE,2'&LF3T="C2B9*8CN&7-4XFXL>@1D1J#3HR"NVU&;
M;(C+B))$.5RVX?=Q)DUK4.*@US$-E(8(MYK;42RMW1MY),0M8FR?4:>V=G28
M2R^V9W4VZ@LU25<AW+\0'$5@K>5+A[_R1_\ ,Q<ID2B,E$1D?$8KVH80J4C+
M=2L5(-G5D:FN15W5Y^>HSM8N06& IBE?^*&K_P#E"/\ VBYQ74'!]39RV5#%
M*]!JMZ F.BR_/SRMQ6W;.4;[S&,3RJ,/-OQRP840R6WLSS>L?QWV]E@%98U9
MJ&*\L9EDTO!K=';)NJ51URS&\S2VINQZ0_F-K)(F50LJE7@8[BK<QE4VE.LU
M-+N>S(82=\UM)$1-V+B]@FZA@[%F$\<5G$6 ]7U&/63)<N!.6;>8X7[R5%O'
MU1</5Y>+U8]RBOT^ FFQ'$1X491K0T1EYRU*/>=B.U@&#(H90\H&4>G-I_0G
M/1(3;<DS38R%QBH?)SCR9E*Q%BF6TIDZ_452&FU$9?HD72DROQ'M%O$
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M^<YX9AKJ'SG/#,20 (W74/G.>&8:ZA\YSPS$D "-UU#YSGAF&NH?.<\,Q)
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M( $;KJ'SG/#,-=0^<YX9B2 !&ZZA\YSPS&]'>0^REUNYH45RN5AD
M    ''Y0_P!E:C[D_P!1#L!Q^4/]E:C[D_U$ XC"GI)^'YBU*1^J3_?&*KPI
MZ2?A^8M2D?JD_P!\8*DP  1BD^@?N&.'O5[B&23Z!^X8X>]7N(!L@
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M1+(B)/(5N+V>P1N#,;US%$!<S!N#X\A.:AJ94YCJ&.%N$DB7L(KG8[E<S/X
M+8PUB"EXFI:*C0IK,V$LS23C9GL,MY&1[2/V&.&P)7*%AG"M0FSL9/U> JI.
M-G,EMK+0N&9%HBN1G8CX]P@/)C)UIG&<9UIJ/HJLHSCL'=II1EYQ)]FPNP5L
M\V3V0>LM+]%S$[J#]QN$0"\YF63!,2I+B/UE!(09H5*2TM3)*([6SR*Q[>,M
M@L!AUM]E#K*TN-+22DK0=R41[C(^,AP^,\,TJ)DEJ5%3#8.!%@+)MLD$DB-*
M#LHN0[[;^T?60YQ;N2?#"W%*6HX:+FH[F [D
M
M
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MC9:LGTB,LT275.LN&G>;9YNP_8=S 7$0 0
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MON .3Q]@FI53"M'H^$:NJB)@/-'G),_.:05LVY%>^X_:>\1=6R=5RG8EF5[
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M/]\8JO"GI)^'YBU*1^J3_?&"I,  $8I/H'[ACA[U>XADD^@?N&.'O5[B ;(
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M.%PX\@FUMZ5M+F8X5E)N5['[0&<
M
M
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M";CSSM&J["JE3TNN&X;2R.[B2,S,R3OV>P!<0 0
M                           #C\H?[*U'W)_J(=@./RA_LK4?<G^H@'$8
M4])/P_,6I2/U2?[XQ5>%/23\/S%J4C]4G^^,%28  (Q2?0/W#'#WJ]Q#))]
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MDE\+GVBYAR^3O!\;!-$?ID*0[(;=E.RC6X1$9&L[F6SBV#J
M
M
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MEE5-IQNMF@W5F=G%D1EM3OV^T!<!;@ @
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MF]23XI!K";U)/BD,@ ,>L)O4D^*0:PF]23XI#( #'K";U)/BD&L)O4D^*0R
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M;E[,\_/S32HR]+?<CWB\S$
M
M                             "$@U^K3[A'D)!K]6GW /H
M                       'F'R@6L>5I>(53$% PA1FR=(D*/-F$:BMM_>5
MNV;B'IX5YY0G^YG%7_2E_6D!"^2T5LE$<D];>_,A5F7QG'U9UU*KZ2@87I;R
M$LQT+/,DFH[)46PL\[&=S/86X6IY+?\ NI8_ZM[\R&;RG?\ ='4O^<U_4 V?
M)O(BR140BW9JOS'WY0N*Y&$\F\Q^ HT39BRAM+*UT&LC(U? KCY\G#_='1/^
M%7YCDO+!:</ ](=3?1(GD2]G&:%$7X@,6%\D%/F9#8=.G3GJ;(E.E5),M"CV
MGML2]I9Q9A\>XS,5-E4PG@S#FI4Y.JH]-K3B[*)ATG#,^)1&GT3OQ;1Z<E8G
MPS3L&4.+B*HM1(M4A(9;-=R2LM&5RSB*Q;.4>=,KM P+@Z+ J.3VMNIK.FOF
M,2=(24%^]<B\TR.WO 7?C? -<Q[DZPY3I-:=IU0:0TN=<U9KUTEGDLBVFHO;
MLO<45EJR?4?)=+H+V%JA*157;J7YY$XFQ?K$VL9$9D16VB[2RI'AC(SA^NXG
M2IVN3XA:*.2<TWG+;#/D*V:9G[14V3B10*]BM>-<J.(X/#27G1J>:C-*;;C4
M5CL1<2?B8#U/AUV0_0*8]-OPMR*TMZY6//-!&JY>^XJSR@,;R8,:-A##2U+Q
M#5ST2B;VFRR>PS/DO?LN.R@Y2L*U.LE1J566)-6<0:FF$I5YYYIJ(B5:V[;:
MX\\0HN4NCXTKV*%X.<J%0G$XV;THE$EEH[EYA$>SS;%[@'WY..&(>**#C:@3
M4(5'D(2W<[F25I,R)9<>PRN.\\E+$4MZE5G"M3=4X_1GK,9QW,FC,R,O81*+
M=[3%>^2]4J[$Q>_%I5,1*ILIVU0D'>\8MIE;;R[-HZWR=W$2LLV465&_[JXI
M1H,BL6U]1E^ #T>
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M]+$[J@X)4^EB=U0#, P\$J?2Q.ZH."5/I8G=4 S ,/!*GTL3NJ#@E3Z6)W5
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M.ZH."5/I8G=4 S ,/!*GTL3NJ#@E3Z6)W5 ,P##P2I]+$[J@X)4^EB=U0#,
MP\$J?2Q.ZH."5/I8G=4 S ,/!*GTL3NJ#@E3Z6)W5 ,P##P2I]+$[J@X)4^E
MB=U0#, P\$J?2Q.ZH."5/I8G=4 S ,/!*GTL3NJ#@E3Z6)W5 ,P##P2I]+$[
MJ@X)4^EB=U0#, P\$J?2Q.ZH."5/I8G=4 S ,/!*GTL3NJ#@E3Z6)W5 ,P##
MP2I]+$[J@X)4^EB=U0#, P\$J?2Q.ZH."5/I8G=4 S ,/!*GTL3NJ#@E3Z6)
MW5 ,P##P2I]+$[J@X)4^EB=U0#, P\$J?2Q.ZH."5/I8G=4 S ,/!*GTL3NJ
M#@E3Z6)W5 ,Q"0:_5I]PB>"5/I8G=4,J6ZL22(G8>S^%0"3 1N95NEA]U09E
M6Z6'W5 )(!&YE6Z6'W5!F5;I8?=4 D@$;F5;I8?=4&95NEA]U0"2 1N95NEA
M]U09E6Z6'W5 )(!&YE6Z6'W5!F5;I8?=4 D@$;F5;I8?=4&95NEA]U0"2 1N
M95NEA]U09E6Z6'W5 )(!&YE6Z6'W5!F5;I8?=4 D@$;F5;I8?=4&95NEA]U0
M"2 1N95NEA]U09E6Z6'W5 )(1F)J'"Q)09E'JJ%.0I:,QU*59IF5R/?\!^YE
M6Z6'W5!F5;I8?=4 UL'88IN$:*BE45I34-*U.$E2LX[GOVCZQ=AJG8LH;U)K
M+:G8;JDJ4E*LT[D=RVC/F5;I8?=4&95NEA]U0#'A7#T#"]$CTFD-J;AL$9(2
MI6<9?$0^5;"#>-\$SZ.I1(?4G21W#*^8ZFYI/MV?$3F95NEA]U09E6Z2'W5
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M1^J3_?&"I,  $8I/H'[ACA[U>XADD^@?N&.'O5[B ;(
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M,T^PLEM.H)Q"BW*297(P&4
M
M
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MSOHE^<1%?B([]HM\
M    <?E#_96H^Y/]1#L!Q^4/]E:C[D_U$ XC"GI)^'YBU*1^J3_?&*KPIZ2?
MA^8M2D?JD_WQ@J3  !&*3Z!^X8X>]7N(9)/H'[ACA[U>X@&R
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M!#E8V2W!,:>4QG#5.3(2K/)6CN1'RV/8.S(K%L
M
M
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M(KF9'\!<@XW)+@Q.!\',4Q;NGFN+5(EO<]U9W5;V;B'9
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MAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)
MC> 3/6;OAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9Z
MS=\,A)  C> 3/6;OAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF
M[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20
M (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$D "-X!,]9N^&0< F
M>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$D "-X!,]
M9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$
MD "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD'
M)GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3
M/6;OAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,
MA)  C> 3/6;OAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!
MP"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@
M$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$D "-X!,]9N^&0< F>LW?
M#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$D "-X!,]9N^&
M0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-WPR$D "-
MX!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;OAD' )GK-
MWPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)  C> 3/6;O
MAD' )GK-WPR$D "-X!,]9N^&0< F>LW?#(20 (W@$SUF[X9!P"9ZS=\,A)
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MV](L[87L >D0
M
M
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MB5OT;FWLN7XBXA3>0I2*IB_*%7&3SX[M13'8<3Z*R26TR^-A<A
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M*M[;J"4D_@8PTVE4^F$HJ=!BQ"5Z1,-)1?WV(1VKF>ED>*8:N9Z61XI@)X!
MZN9Z61XIAJYGI9'BF G@$#JYGI9'BF&KF>ED>*8"> 0.KF>ED>*8:N9Z61XI
M@)X! ZN9Z61XIAJYGI9'BF G@$#JYGI9'BF&KF>ED>*8"> 0.KF>ED>*8:N9
MZ61XI@)X! ZN9Z61XIAJYGI9'BF G@$#JYGI9'BF&KF>ED>*8"> 0.KF>ED>
M*8:N9Z61XI@)X! ZN9Z61XIAJYGI9'BF G@$#JYGI9'BF&KF>ED>*8"> 0.K
MF>ED>*8:N9Z61XI@)X! ZN9Z61XIAJYGI9'BF G@$#JYGI9'BF&KF>ED>*8"
M> 0.KF>ED>*8:N9Z61XI@)X! ZN9Z61XIAJYGI9'BF G@$#JYGI9'BF&KF>E
MD>*8"> 0.KF>ED>*8:N9Z61XI@)X! ZN9Z61XIAJYGI9'BF G@$#JYGI9'BF
M&KF>ED>*8"> 0.KF>ED>*8:N9Z61XI@)X! ZN9Z61XIAJYGI9'BF G@$#JYG
MI9'BF&KF>ED>*8"> 0.KF>ED>*8:N9Z61XI@)X! ZN9Z61XIAJYGI9'BF G@
M$#JYGI9'BF&KF>ED>*8"> 0.KF>ED>*8:N9Z61XI@)X! ZN9Z61XIAJYGI9'
MBF G@$#JYGI9'BF&KF>ED>*8"> 0.KF>ED>*8:N9Z61XI@)X! ZN9Z61XIAJ
MYGI9'BF G@$#JYGI9'BF&KF>ED>*8"> 0.KF>ED>*8:N9Z61XI@)X! ZN9Z6
M1XIAJYGI9'BF G@$#JYGI9'BF&KF>ED>*8"> 0.KF>ED>*8:N9Z61XI@)X!
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MJMQW5Q$9D=K<@^ZEEHQO4:0NNX=PZU'H,2R9$AY&D)2RMG;>)-^P!Z/ >?\
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M!["V%<S/E(61DSKV/9U<ET[&]#8AL1V<\I;96)Q1G8DE;S3X]Q@+)
M
M                              A(-?JT^X1Y"0:_5I]P#Z
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MT-)Q V6<PFQ)SEEO]EEH,]@]*%N
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MZBO4&MX8JE9QOC>JE7C-1,4]#RKNF1>:9EN,C/DM8=KD1O\ <ME$O:]BW?\
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MC5*B-4>H4UB12FB2E$99&:$DGT;>X?B<-45&'3H"::P5%-)HX'8]'FF=S+M
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M)DM1%N(S+>-_#>&*)AF.XQA^EQH#;AYSFA18UG[3WF EP"P6$  L%@  L%@
M L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@
M L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@  L%@
M L%@  L%@ A(-?JT^X1XD&OU:?< ^@
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M*KCC&S;;,M1&W#C(=)TD),B(C,RY$E;XBZ2
M                       ''Y0_V5J/N3_40[ <?E#_ &5J/N3_ %$ XC"G
MI)^'YBU*1^J3_?&*KPIZ2?A^8M2D?JD_WQ@J3  !&*3Z!^X8X>]7N(9)/H'[
MACA[U>X@&R         ##+-28ZS0V;BK;$D9$9]HC=-)]7O=](F  0^FD^KW
MN^D--)]7O=](F  0^FD^KWN^D--)]7O=](F  0^FD^KWN^D--)]7O=](F  0
M^FD^KWN^D--)]7O=](F  0^FD^KWN^D--)]7O=](F  0^FD^KWN^D--)]7O=
M](F  0^FD^KWN^D--)]7O=](F  0^FD^KWN^D--)]7O=](F  0^FD^KWN^D?
MANR3*QTUTR]JTF)D $.;\HSN=/>/_P#&)#32?5[W?2)<?H"'TTGU>]WTAII/
MJ][OI$P "&-V0?I4UU7O4DP)Z3ZO>[Z1,@ A]-)]7O=](::3ZO>[Z1,  A]-
M)]7O=](::3ZO>[Z1,  A]-)]7O=](::3ZO>[Z1,  A]-)]7O=](::3ZO>[Z1
M,  A]-)]7O=](::3ZO>[Z1,  AC=DGOISIE[5I,?IORCWT][9N_2)$P "'TT
MGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$
MP "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/
MJ][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]
MWTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'
MTTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][O
MI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAI
MI/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU
M>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P
M"'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J]
M[OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WT
MAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TT
MGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$
MP "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/
MJ][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]
MWTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'TTGU>]WTAII/J][OI$P "'
MTTGU>]WTC,F;*2DBU:]L_C2)( $=P^5ZM>[Z0X?*]6O=](D0 1W#Y7JU[OI#
MA\KU:]WTB1 !'</E>K7N^D.'RO5KW?2)$ $=P^5ZM>[Z0X?*]6O=](D0 1W#
MY7JU[OI#A\KU:]WTB1 !'</E>K7N^D.'RO5KW?2)$ $=P^5ZM>[Z0X?*]6O=
M](D0 1W#Y7JU[OI#A\KU:]WTB1 !'</E>K7N^D.'RO5KW?2)$ $=P^5ZM>[Z
M0X?*]6O=](D0 1W#Y7JU[OI#A\KU:]WTB1 !'</E>K7N^D.'RO5KW?2)$ $=
MP^5ZM>[Z0X?*]6O=](D1^7 1_#Y7JU[OI#A\KU:]WTB1 !'</E>K7N^D.'RO
M5KW?2)$ $=P^5ZM>[Z0X?*]6O=](D+C] 1W#Y7JU[OI#A\KU:]WTB1 !'</E
M>K7N^D.'RO5KW?2)$ $=P^5ZM>[Z0X?*]6O=](D0 1W#Y7JU[OI#A\KU:]WT
MB1 !'</E>K7N^D.'RO5KW?2)$ $=P^5ZM>[Z0X?*]6O=](D0 1W#Y7JU[OI#
MA\KU:]WTB1 !'</E>K7N^D.'RO5KW?2)$ $=P^5ZM>[Z0X?*]6O=](D0 1W#
MY7JU[OI#A\KU:]WTB1 !'</E>K7N^D.'RO5KW?2)$ $=P^5ZM>[Z1NQUJ<:2
MMQLVU&6U!G<R&0            <?E#_96H^Y/]1#L!Q^4/\ 96H^Y/\ 40#B
M,*>DGX?F+4I'ZI/]\8JO"GI)^'YBU*1^J3_?&"I,  $8I/H'[ACA[U>XADD^
M@?N&.'O5[B ;(                      #D<K59FX=R=URK4IQ+<V*R2VE
M*3G$1YY%N]QB2I-:8;PK2ZC69D>-IV&C6Z\M+:36I)':Y[+F?$.<R^?[H,3?
M].G_ -1(X/+OG?\ 9\H>8>:LW())5S3ML/X +C9Q/1'ZSJABK0G:GM_V9#Q*
M<V%<]A<EABJF,,.TJ7P6I5NG1I);#:=D))1>\K[/B.1IN"</X(PD_7*/2XVO
M8L!Q_A[B<]Y;AMF:C-1[=I\0YW(ID_PY7,GT:NXAI<:JU6N$N3*D2T:11F:E
M%FD9[B]P"Y69T5^'PQF2RY$S37ID+(T9I;SSMUA$3<:8:@ML+EUZF-(?3GM&
M<E-EIW9Q;=I;#V^P5#DU-5&DY4\(1EK52*4EU4-M9WT25MF9I+V;1]^3UD]P
MU5,E\"?6Z3%J<R82B6[*1GJ2@CL2$W]$B]G* O.%,CSHK<F$^U(CN%=#C2B4
ME1>PR'Q4:A#IL5<JHRF(L9'I.O+)"2^)BJ/)P:.!!Q;2&EJ.%3ZPZS'0K]Q'
M(7LV#3RMPTXKRN8/PE5#SZ&;3D]^.9V2\I-R(CY2]@#9RV8ZC.8#;DX0Q$WP
MI-1C-K7!D%GDA2K&1V.]CN+7FU&'3('"JE+8BQTI(U.O.$A)?$Q1'E%X#P]1
M\+T^KT6FQJ=*;J$=E?!D9A.(4O<HBV'8R(R'QEGJ*)^5;#M(J-'GUNDP89RE
M4R,DCT[IF=E&1^DDB(OQ 7;3,5T"J,//4^LT^0TR6<ZI#Z3S"Y3V["]HI*'4
M9F4/'6(])E"DX>A0I*(=/BP)*$%(*U\_:?GW]GL$4]!34,?8=FX=R=U2ALK>
MX-5$.QDDQ(C*L5E)+9L]HZ7(CA>A/XOQXIVDP7#IU82F&:F4GH")-R)')\ %
MAX!356:EB%JK8D@5F.R^E$9MA1&[%21&1I=MN4=N/D,23V.,+LS#B.XAI:9!
M'FF@Y*+D?)O'G>H5B71*5EM=ISALR)%<;BDZD[&@G%&DS(_<9BX,)Y)<%Q\+
M4UA_#\&4[HVW7)#J,YQQRQ'G&K?O 35575#RCT9,7$%.CTHXJS?I2U%PB0KS
MK+06^Q;-M^(Q*U?%E HLA,>K5F!$?5M)MY]*56]U]@K+&*RC^4IA-TDD9-4.
M4HB+V9XK7)Y4(%1A5.LU_ -5Q74:I)=4Y-)E+J$HOL;3?=8M]@'JR-+CRHJ)
M,5]IZ.LLY+K:R4E1<I&6RPAYF,L-PF&7Y5>IC;+U]&LY*#)=C,CM8]MC(R%:
MY!HU2I]*Q7!?IM1IE$0^;E,BSDV4VVLE&:;^\MPY_P FO >':O@F34ZW2HM1
MEKFOLH5)02R:;(R/-21["VF9G8!?U-J$.IQ$2J=*8E1E^BZRLEI/XD(JIXSP
MW2Y9Q:C7:='DI.RFG)"24D_:5]GQ%(8$FJP?"RTQJ*1LPZ.\XY"8)1F3)YBO
M1ONXNP=+D9R<88J>3FFU2O4F)5:K56C?F2Y2=(MQ2E'QGN+W +>IM2A5.-PB
MFS(\QC.-.D8<)Q-RWE<CM<?C54@.U!V W-C+G-)SEQTND;B"Y33>Y$*=R:.1
M<G.4/%&#'S3'I+R=<4_:9(;;MYZ2(]]K;3_A&WY/D!VIR\58XFH,G:]-5P4U
M$=TQT&9)(CW&1[.P!<*UI0A2UJ)*4E<S,[$1<HY]K&^%W9R8;6(:6N2H\U*$
MR4'<^0MN\;&,ZM2:+AFH3,1.I:I9-*0]>_G)45LTK;;G>VP>:\H+F%Y632HG
MAW)G4:;$0R3L6KN1$M$T9*+SS,SSOSO<!Z@F5>G0GR9F3XC#QMF\3;KR4J-L
MMZK&>XN4:-(Q;A^L2SC4JM0)<@MNB:?2I1E["OM%"UZDMXKR@Y*(E74IZ-(H
M1+E(,S_3I(B,TJMQ&9;1+9;L+T3"#^$*UABF1:746ZJTSI(K9()2#VYJB+>6
MP!>57J]/HT0Y-6FQX4<CMI'W"01GR%?>8PTC$-(K,=UZDU.',::VN*9>2HD?
M\5CV;CWBA<I=01/RZN1*SA^H8EIM'@-N1Z;&(E()QRQFXM)[#MN[!J4YF0G*
M3#J.&<%57#=*E0WXU50XUF,N%FF:5&23ML^0"^IN,\-0F6'I5>IC;3Y&;2SD
MH,ED1V,RL>TKD9#).Q;A^!$9DS*W3FH[Q7:<5(39PN5.W;\!2_DZY/\ #=7R
M?+J%;I,2H2I#[S6=(1GZ-HE;$)OZ.\]PTO)PP10*O$Q%)K5.8J)P:D]"B(E)
MTB&&B4?FI2>S:>\[ +TJ%2;JF%9\O#U7A(4;"S9G9Y+9:58_.4>ZQ;S&/ [D
MLL(4Y=7JT.JRR:,WI\8RT+MC/SDGNL1;/@*4P'%9I5.RXT6 C14R$IPH\<C,
MTM$IIVY)(]Q>:0[+)+4J92/)WH<RNN);IB*>HGS5N-)J41E\;V =L6.<+*EE
M%+$5*-\SL22E(W^^]AT23(RN1W(>5,;N84GY-ZI]F<F-2B0DQU.QZLN*EDFE
M%MTAF9YUO;MN/0^3-]R3D^PZZ^LW'506<Y1[S\T@'2@
M
M
M                              #\4HDI,SW%M,!!XTQ/!PEAZ75JFXE+
M3*3S$7\YU?[J$\IF>P<+D%Q?B#%GVF^TY(;?ARFT-LI02=$E2,[-/E,KD7P'
M(3\9X=QIE*6_B.KPV,+8?>M$B/GMERB/:Z9<U)ELOV#?R&XIHIXVQPQK%@WJ
MI5$N0TYVU].9O3R@+DQ/68^'L/5&KS3(H\-E3RKG:]BV%\3V?$<9DYQ+5Y6
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M3"Q_E'IS*?T)ST2$VV)29IL96_O<+C
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MC\&UM.),+4NLH:-DIL=+VC,[YIF6TK^\3 XO(OMR5X8VD?\ L2-I<>\=H
M
M
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MALL*^49'?9/10L30E(?3:R3?1;-,K;S/E]HC,&KI#N7UU>3RQ4<X2SK!QO\
MNZGKGF6MLONW"6Q[_P#$\O6"*?'MI8;3LQP^1!6^0"Y" "
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MF9HYN[=[!K4;#M&HJUJI-+APUK])3+*4F?Q(A^<,J/01?$/Y!PRH]!%\0_D
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M;IBCJ-OWWY/@ LT!KTZ;'J,"/-@NI>BR$$XTXF]E)/<>T;
M
M
M                        !"0:_5I]PCR$@U^K3[@'T
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MFEG+22D629\9%<[%Q7'MS#%!I-'IS+E)I<*"M]ALW51V4MFYYI;[%MWBG%9
M9#N3J)1'JQ%UQ#FNR6I*6U:)2',VZ#+??S=ACN\DV#<2X6*=]J,1ZX)UMMJ.
MV1J,F$IXB,_AV *8\GQ]V+B[*)(C7)]JE.N-F7.)Q1E^(D/)=PM0L2L8CE8@
M@QZA*0\AM*9!9UDJ3=2K'QWXQ8&2/)7.P1BFNU6H5&'-9J3)LI::0HC3^DSO
M.OOV;!SU6R%UBFUZ5-R?8F.CQ))&2V%FLE((SN:246]/)?:0#B<E#BJ1C_']
M(I2C<I:HDQL['LS4$K-5\/1&WY*^$Z-B"17IE;@L3N#$VPVT^@EI3GW,U6/C
M\VWQ%K9-\DS&#:%66USN&UNJ1UL.RC29(02DGL26\RSCN9GM,?N0S)M.R=1Z
MNW4:A%G'-<:6DXZ%)S<TE$=[^\@%'9/<,G6,<XUPM3Y/!&I,:1';4K:DLQTC
M02O9YMOB,,-RH9-&W*1CO <.I4IUXSTKS1$X?*;3Q;R]AF0L^/D0K"*[B><5
M?BL)JR'4LJ90LG&34Z2R,SV<EM@TYN1C'==;CP,38[1,I+2R5HS2I9D1;+I(
MR+;;E,P%WX8GT^J8<IDZB_\ RU^.A4<K6S46L16]EK? 28C\/TB)0*'!I-.0
M:(<-E++1&=SL7&?OW_$2 @
M
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ME+\I%RN0LY=#H"22A[]TUI*Q$1[CNI2CMR#TH0
M                          X_*'^RM1]R?ZB'8#C\H?[*U'W)_J(!Q&%/
M23\/S%J4C]4G^^,57A3TD_#\Q:E(_5)_OC!4F  ",4GT#]PQP]ZO<0R2?0/W
M#'#WJ]Q -D         &&6M+<=:G%$E)%M,Q&\-B]8:[1++0E:32M)*2>\C*
MY#%P.-U=GN$ CN&1>L-=H<,B]8:[1(\#C=79[A!P.-U=GN$ CN&1>L-=H<-B
M]8:[1(\#C=79[A!P.-U=GN$ CN&1>L-=H<-B]8:[1(\#C=79[A!P.-U=GN$
MCN&Q>L-=H<-C=8:[1(\#C=79[A!P.-U=GN$ CN&QNL-=H<,B]8:[1(\#C=79
M[A!P.-U=GN$ YS$$&B8AI3U-K*8\J$[;.;4?&6XR/B,N45FC(+DX2\2S5/4D
ME9VC5..U^P7?P.-U=GN$' XW5V>X0#GJ'$HM!IC-.HZ(T2&T5DMM[/B?*?M,
M2'#8O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#8O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
MXW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7
M:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=7
M9[A ([AD7K#7:'#(O6&NT2/ XW5V>X0<#C=79[A ([AD7K#7:'#(O6&NT2/
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M+CMR-&9WS<])*M?CM<;P@\!_L/AW_P NC_\ I)$X
M
M
M                        ."QCE1HF&JXFB\&J54J^;GJB4Z/IEMD97(U;
M2M<;V <H5%QL<MJE\*CS8AV?AS&M$\@N(S3<]GM%5XBKR<EV6FJ5-UHJI$Q
MTG/8BJ)<N.:"*YFC?F\@D\BLA..,>U[* MV/'-;2:>W :=SG&TIMYSI<1GQ$
M NYYQ#32W'%$E""-2E&=B(BXQQM/RE8>FX<J5?TST>CP7E,*E/-YJ75),R/,
MVF:BN0C/*"K#M)R758HJU(DS"1#;-.^[BR2?X&8Z# V'85*P!1:*J,VY&9B-
MI4T\DED:K$9W(]^VX#BV<O.&3<95+IU>A0'E$A,Z3"-#-SY3OL(=WBS%U'PM
M02K%5DVA+MHU-)-PW3,KI)-MYGQ#BO*)JL9O ,C#S*#DUBM&B+"AH3=3BLXC
MO;B(B+\AV="IZ*+@BF1:JT4A=.AMZ1.83AYR$%?-+C,C+8 X=C+MAOA,9%1I
MM>ID:2M*&I4R%F-&9\IWV"V4*2M!*0HE)45R,CN1D/-^5W*;3<;4!K"],B/P
MCJ3R&US*PSP=IDKEM(SWJ'H6CQ2@TF%%2YI$L,H:)?.LDBO^ #B\<95J#@ZN
M-TFI,5-^8MG3D42/I2)-S+;MV;AJT;+#0ZO"JLF'3*\:*;'X4\E<+-4:+V/-
M(SVVW^X<SB!W$5!RUU&NP\*56L1%T]N.PN,1$@CNHU7,_@.QP/E&IV+:C-H$
M^GRZ37F&\Y^G3F[&:#XR/<HK&5_> Z[#M9A8@HL2J4MXGH<E!+;47)R'[2$B
M*<\GDM42L:87)9\'I=3-49*M^8X5S^%_S%Q@
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M+.+V@(O A&6",/$9&1E3HY&1_P#*2)P?B4DE))21$1%8B+B'Z
M
M
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M+!>%HE%I]U(9NIQU7I.N*.ZEG[3,=$
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M&?!^H:"I]<9\'ZB1 !':"I]<9\'ZC=CDXEE)/K);A%M416(_@,@
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MI6/<.'RGN8YF8"IE0Q/"H$*@R7$.0V(;24/)-23,MVXC+:?P >DL8X[H.$:
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M-080^RWI'R;65TFM+9&DS+C$ECN,S3O*?IJ(+3<=M2X3AI;224YRKD9V+EL
MO3*'E#HF 8\5VNE,4<HS2RB,SGFHRW[;V(<]@_+AA3$]:CTEE$^#-D*)#)2F
MB)+BN).<1[#$)EHR@SX.-J9A##U#IU2JCN8M+D]LEDAQ=\TD$>S=O,Q4N4=G
M%4;*)AS[;%2$50WHYHU8DDD2-,5L^W[V_P" #J\O)J++IAHLY9>=#V$9E_\
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MT[G%L61<1[+&+2
M                         "$@U^K3[A'D)!K]6GW /H
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MP71Y1^!5QB_VC,:W%<_3<_TN/1H
M               X_*'^RM1]R?ZB'8#C\H?[*U'W)_J(!Q&%/23\/S%J4C]4
MG^^,57A3TD_#\Q:E(_5)_OC!4F  ",4GT#]PQP]ZO<0R2?0/W#'#WJ]Q -D
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MLHW.7W##64;G+[A@-P!IZRC<Y?<,-91N<ON& W &GK*-SE]PPUE&YR^X8#<
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MM@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L
M%@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L
M%@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L
M%@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L  %@L
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MWQBJ\*>DGX?F+4I'ZI/]\8*DP  1BD^@?N&.'O5[B&23Z!^X8X>]7N(!L@
M                    *=\J-*SR?0UIOHFJG'6\=MA((SO?V"VH#K#\-AV&
M:3C+0E31I*Q&DRV6^ U,342'B.@3Z/4T&N',:-IPDG8R(^,O:1V,591\,Y4,
M'0DTC#M5HM6H["31%746U$\VF^PE&1E>P#!E4-+N7G)FS&29RT*==<S3VDUM
MW^RY&(V=AN!B3RF:@S5VBD0XU/9D''7?,=65\W.+C(CVV/8.TR?Y.YM.Q*_B
MS&-335,3O-Z%*FD9C,=OFH(;T#!DZ/E>J6+%/QS@R82(R6B,](2DGO/9:WQ
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MB^::DH))F7L$!D6P;-P-@Y=(J;\=]\YCTC/8,S399W(MI%M =X
M
M
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M0L)98R\H5Z1&3I*7A>*;*W-N:J2OB+VEM[ %SD $
M                             X_*'^RM1]R?ZB'8#C\H?[*U'W)_J(!Q
M&%/23\/S%J4C]4G^^,57A3TD_#\Q:E(_5)_OC!4F  ",4GT#]PQP]ZO<0R2?
M0/W#'#WJ]Q -D         &.2[H&5N9BEYO[J2N9B/UO_P#L4KNB0D?J5#1
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M':S7U"9W UFOJ$SN"1 !':S7U"9W!NQW#=92LT+;-1>BLK&7O&0
M   <?E#_ &5J/N3_ %$.P''Y0_V5J/N3_40#B,*>DGX?F+4I'ZI/]\8JO"GI
M)^'YBU*1^J3_ 'Q@J3  !&*3Z!^X8X>]7N(9)/H'[ACA[U>X@&R
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M2BNQZM5J76X[B5K@RW<YN6LOW4+*UN6V_B >JP ]IG?> @
M
M                $)!K]6GW"/(2#7ZM/N ?0
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MYR#+W6(NP>D"
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MI\@9I\@#\ ?N:?(&:?( _"$@U^K3[AH9I\@WVMC:?< ^@
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M2.Z4B:O/???=-UQ7LSCVD7'8=80
M               X_*'^RM1]R?ZB'8#C\H?[*U'W)_J(!Q&%/23\/S%J4C]4
MG^^,57A3TD_#\Q:E(_5)_OC!4F  ",4GT#]PQP]ZO<0R2?0/W#'#WJ]Q -D
M        &.0RE]E3;E\U6^QV&EJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2(
M([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]
M\QM3ID>!%<DS7VH\=LKK<<424I*]MIGN$3&QAAR2\EJ/7:6XZK824RD&9_B
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M+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\
M%[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2(
M([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]
M\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YA
MJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T
M7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@
M CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_
M (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[
MYAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM3
M1?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?
M,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:
M+_B]\Q(@ CM31?\ %[YAJ:+_ (O?,2( ([4T7_%[YAJ:+_B]\Q(@ CM31?\
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MX@O1O>QF5^([7'4@
M
M
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M\V APW&H;J3.V;S;V+8)+*0?#<MN3^%&;)<F.;LERV_1^;M/W6,!<0 0
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M]7'XR0X7/]7'XR0$B CN%S_5I^,D;L=2ULI4ZWHUF6U%[V^(#(
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M@$H Q1)+$R,W(AOM2([A70XTLE)47L,M@_9,AB*RIZ4^TPRGTG'5DA)>\SV
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MNJPI;A;T,O)4JW+:]P$F
M
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M8"G<F64>M2LH57P3C9J,BK,9SD5V.V;:74%8]QWWI/.OLW"X@
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MK+2HSMQ6L(/%.2_*3C XM6Q'*A/U)M1,IBH4E!-MEYQJN1YMS,!.^4_183F
MJ/75H4=1C<'B-+SO-)M9745N79O&3)E@2A0<E98LCQW$UJ51Y"77#7YID9*(
M]GN20[K*W@J3C+)WJ>(ZAJ<SHGFR5Z*UH+T3/BOMVCA\GN&,ID"E.T&M\$:P
M^U ?8892MM2U+4D\PC41F=KF>\!7>0K)=3,H5)G.UV9,1 @+2TW&C*)%U*3G
M&JYD=NP2^!Z?'C>4_+I[23*.V4F.6WSLPF\TMO+86?Y/F":O@BA5:+74-(>D
MR$.()MPE["1;B]HBJ!D\KL'+W+Q8^TR5(<=?4E1.D:K+3L\W> J^+@6AR?*
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M.MW64:+F^>X:<W<GS2(BO?E,!>X  @
M
M          $)!K]6GW"/(2#7ZM/N ?0
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M0#TU-H#9&X\E.<DC01W2?O6NWP'I,@
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M\629#RZ:<HX%.;-1YA-H/SE$F^_=M]H"X@ @
M
M
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M_3N>\Q*XR;U'E^PC5(Z"+6K#L%[-*V?:UC/EM<NP!<8 0
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MB/@7%>)<9TFKX\J%.53:0XIV-3X;9FEUS]U:S5R<@MP@
M
M
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MJ.Z63*D&2G%;[)(R(K)*^P@'3$
M                ./RA_LK4?<G^HAV X_*'^RM1]R?ZB <1A3TD_#\Q:E(_
M5)_OC%5X4])/P_,6I2/U2?[XP5)@  C%)] _<,</>KW$,DGT#]PQP]ZO<0#9
M
M
M
M
M
M                 <?E#_96H^Y/]1#L!Q^4/]E:C[D_U$ XC"GI)^'YBU*1
M^J3_ 'QBJ\*>DGX?F+4I'ZI/]\8*DP  1BD^@?N&.'O5[B&23Z!^X8X>]7N(
M!L@             #CZ7C9J9C"7078ILJ:6MMMW/OGFGV6V;+CJI<AN)%>D/
M'9II!K4?L(KF S .5P)BW[4HFJX&<8HZDD1&O.SB5?V>P=5<  +B&QC4'Z5A
MFH3HAI)]EO.0:BN5[D6X!,@.3J^*'J3ANCSE12E2)I-)-!*S"SE)O^8P3,5U
MJFH-VIX8D)CIVJ6P^ETTERV(!V8"#7B2([A=^MP/]H8;;->;?-.Y;TGR&("-
MC*M/0&YR<,/+B*1I"4A\C,T\I%:X#NP$7AJMQL04EN?"):6U&:5(65E)46\C
M$1(QC'9QHU0=":B79*I!*V)69&9)L ZL       ''5#&[4#&**&_%/1J-">$
M9^PC46S9;E.P[&]BN>X  <CA7&:*_7Y]/9BFVU'2I2'C7?2$2B3NMLWCK@
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M0  N%P     +A<  :$&K1IM0GPV,\W82DI=,RL5U%<K#?(     "X
M  %P   +@  .89K,M>/GJ29HX&F(3Q%F^=G7MO =. !<   N     #3J\Y%-
MI<N:XDU)8:4X9%QV(SL.:PE)Q/4U1*C/>IZ*8^DUZ!"#TB2VYNWZ@.Q +@
M   !<8Y#R&&''73LA"34H^0B 9 $0=6<F8954Z/'4^XXSI&&G/--1\1&-NCO
M29%,BO3F28E+;)3C9'Z*N,@&X "(P_,J4M4\JI"3%)I\T,6.^>CE 2X!<+@
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M< 6>?G'G7V\8CL,8/:KN&(4ZK5"H+E.,EHS0^9):26Q-BY;6,[B7@P92<E7
MU1W2E\"6C0FGS\[;LMRB7P0P]&PA2V)+2VGD,$2D+*QI/D,@$;DMGRIN&5%.
M>4\[&D+8)Q6\TE:U^T0.,:!%DY0**VZ]+-,[2FY9XRS,U.PD<TA.Y+X4F#0Y
MC<V.ZPXJ:ZLDN)S3-)VL?N&#';,Z-7Z%6H<)V:S"-9/-LE=9$HK7(NT!!5B@
MJ8QG1:13)<EALX[F<\;F<X2#,S591\=AL5NCHP=5*/-H\J79Z2EAYIYXUI61
M_P#X!OQ%RZMCFD575DR+%*.Z@S?;L:=Y%?DN-S*+"E3$4<HD=UXVYJ%KS$WS
M4[=I^P!!XSJT2;BTJ55ZDY3Z5%:);A-FHE/+/BN1;K6_$8<,5*!3L9QH6'ZD
M]-I4Q!DMEQ2E:%9;2,C4)?$4&=1\5:]@T]53BR&B:DL((C6BVY1%Q\0D</5Q
M=3J26D8<EPF229JD/MDC-/B(BL F<1'-*AS3I97G:(]$7\7L]HK7#<##E6;:
M:F5:I1Z_<M*3KZD+TG&1$>PR%HU20_%I[[\6,J4^A-TLI.QK/DN*ZQ--7B:$
MJ*SA*>W4U&1(D.M9FA.Y;<\!(Y2*OP$J52$SUPV)*K29-S-:6TV+?RG<^P<Q
M-G42B2(DG"M9DOK4X34B.MQ:L]"MZBN16,=7B>@U%,*@SX3:9M1I:4DZTK_Z
MY6+.L9\>S\1DA8D=F2F6&<(SFUJ41+6\T2$-E?:=[;; ('"V$H$[$6(67WYV
M;$D()M29!DI5R,_./CW"U2*PKQF34,,8MK3CE(F38M1<0XTY&1G$1ELL?)O'
M1U2LU&+6J7$C4EU^-*/],\5_T.[?Q;-X#H!5>#L/GB-%6559LTX;,UQMIEMX
MTEG;#,S/>?%86H0Y')M#DPJ=54S&'&%+J+KB26FV<DR38R]@#2P(3]-Q/7:$
M<AU^%%)MQC2JSE))7%?^]P[*J':G23X246R#_3&5]'[1S-#AR6LH>(9+K#J(
MSK+)-NFFR5F1;;'QCK'FFWVEM/(2XVLK*2HKD9<AD K@GTV_W@M^&CYCK,(+
M)<)XRK2:OY_ZTDD6;[-@S?9>A>IX'@)^0WX%/ATYM3<"*S&0H[FEI!)(S^ #
MBLIIS#JF'6J=(6Q(=D&A*B/81GLVEN,1^+L,M89I95FESZ@4YAQ!J4Z^:R=N
MHB/.+XB>QI"DR<0X8=CQW76V99*=4A-R07*?(,^4J)(FX3DLPV''WC4@R0VF
MYG99&>P!&8BD..8NP@O.4@G<]2DI49$=R2>X9<KSBV\*H-IQ:%<*;*Z5&1_O
M<@PXNA5!AS#E7A0W)BJ?L>CH+S[&1;2[!$8UGUG%-*;9@4">S%:>2XXIY%EJ
M/:1$E.\RVW,_8 W\:L29V/Z) CRWXS<B,M+IM+L>;YQJM[;%O$?B"A.X;K-)
M9P_49C)5-9QG=([GV([><5^/:8Z2KPI3F4J@RVX[JHK49Q*W23YJ3-*[$9_$
MA^XTA29.(,+NQX[CK;,LU.J0FY(+S=I\@"!Q'0F\'N4VJTB9--PY2674//&L
MG241WOV!6*:[5LJ"XJ9+T=A<,M.IE6:I2+GYI'Q7.PZ#*7#DS:1!1#8=?6F:
MVM26TW,DD2MON$166ZO R@+J\&FORXC<9*721L-9&9W)/*9;#L QU&G_ &'K
ME(DTR3)7 F/E&?8><-9%?<HO;O&GB&K4ZJXPF1*_5'85*A))#;+:E)-U=MIF
M:2W;_P !(255#&=<I:54N73Z7!=*0MR4G--Q16LDB[>T?=2BSL-XJFU*/2G*
MI3)R4FXAI)*6TLME[<9;/Q 05/JD>*_7*51JB]-I3L!UYI2U*-3*R2>PC.QB
M4P1A8JU1*;5*Q/FN.$E)L-MNFE*$I/9?E,[;1*:R?K=(K#+&'9<)/ W"0XZV
M25.*,C(DDFUQ,8 CO1,'TMB4TMEY#5E(65E).Y[R ?>-JLY0\-39\>VF;21-
MYQ7+.,[$.9A8$;E4AN;+J51.KNM$]IB?.R5F5[$7(.KQ;2->X?F4\EDA;J?,
M49;"41W+\ARL7$U:ATM%->PW4'*DTV3*5H*[2S(K$K.Y &BZZ[B+)O,=JC[Y
M3*:3R%Z-9I)Q22V&LN,3V3>@Q8-(B5!ER2I^1'(EI6Z:D%MOL3Q;AK1,/RZ;
MDXJ,1U!O5&2TZZXA!7,UJ(_-+E'18/9=C89IK+[:FW4,D2D**QD?M 0N5=QU
MG"JEL.+;<)YNRDG:WG$(^;@BU&<J)5.H:[0UIS?TQYIK(KVMQ%<;N5V_V17F
M[],W;O$-&5B2MN4=5+1AV<=36UH3=(KL[2MGDKDXP&]"J;.(,GS,JK5%=/)S
MS7GV5DV=TJ,K$?ML..FRJ'2:E2Y.%*O*>D<(2AYM;BUI<29V.]RL):M88ETJ
MA8=0W$54X]/<-<J*V5](:CO>W';:0^,1NU'$+4'5V'Y4.'&DMK6;K6:M9W(M
MB2+<6\S 2^51R6A5 33W5-2')I(0HCV7,K%?E&OB#!,*GX<J<DIM1>DZ$UK6
MN0=G#+;M+DOQ"5Q["DRYV'%16''DLSTK<-";YB=FT^0A/U^$JHT6=#;,B6\T
MI!&?*9 *Z@X?BP\G+E89>EE+7 4=C?5F%<K;$\0^D/S:M!PIAZ/*=CMR(:7Y
M+R%66I!%N(^W\!]PYM1=P5(PZ[0JBW+:B+:TFCNVHR(S*Q^W=L&0Z55J;!PQ
M6H$)Q^5"BI8DQ+9JS09%>WMW@.GH.#H%$J)3(4F<:LPT&VZ]GH._&96WB)R9
M...)Q+I'%KS:@X19RC.Q6XA*T#$TJK5$HZJ#4(;.:9J?D)S229;BMQW&ADZ@
MRH:<1<,CNL:6<XMO2)MG)MO+E(!S^#</GB-%3559TQ4)F6XEIEMXTEG7VF?'
MR6^(S1".DU2L87J%6D,TTV"D,RU.6<:*Y7+./BWD-7!-;G48JLHJ5+G0')CF
M:J,6<I"R/:1ER&1EM]@TJW1:U6YZ\2RJ2Z;:7D(*G*+](MHBVG]+<8#YJTB@
M4E<*7A:LRWJ@V^DEDIQ:TN),]N=<K#K<J[LA%*I*H;JV7U3FR2I)[C,CM[Q#
MXF?J&(:6VS2L-RH<9AQ"W#=:)"E6,B)*$EOM>YGR$.ARAPI4R'14Q([KRFIS
M2UDA-\U)7N9^P!#8LPDU1:#(J\*HU'6<>SAO+?,R6=]MR&#&\!NJ.X3FR79&
MDG.LMN)2X9)22B(S-)<1[=X[+'\9Z7A"IL16EO/+;(DH05S/:6XA 8HIU0/#
MN&I42(X^_3%,O.QTEYYV25RMRW(!&8JI#5!>@1GWZFG#:U*7(<:=-:\^VPE'
MO)/U'1X*I-$9?7/P_4I,EA2-&II3YK0D[[['M(]G&,*\92UMDM>%:LJ(KS5&
M;=U7_P"'D]HT,*P7Y6-%5>%2'J-3"8-#C;B<S3K/CS"_O8 L0
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M-&C5"/ 80F?%2^VI.B<299R4WY2,^PAU^*Z^<_ U-1#.\JLYD=))/:1G;/\
ME\1T="E5F>X^=8IK,.*:;(1I"<4H^.]MEARV&<'U")BA*YV:=)IZW7()9U]J
MSV;/80".Q0;$*L4?#LE$MVD0XQ..,Q4FI3RMI;2+B^9CYA/1F,8T=_#5-J,%
MAQ>AE-*86AM23W*/BV?Z$.KQ71:B=9B5W#YM'4&$&TXRZ=DNM\E^49Z74\1S
M*@PB516H43_ZSBWR6>[]TB 0&)Z>FJ92Z=#><<3&<B&;R$*-.D22C/-.W$>P
M,14:'AW$>'95$;X&I^44=U#:CS5I.V\A.RZ1,<R@PJHAM)PVHJFE+SBN2C,]
MEOB/O&%*EU*?07(B$K1$F$Z[=1%9.S;[0'*RL/TM_*HJ&]$2N,[#-]:#4K:L
MS/SMXLJ'':AQ6H\=!(9:22$)+B(MQ#CL0TVK1,9,5ZE1$3F^#<'<9TA(46T]
MI7^ D:5+Q&]7B*?"88I:HZ5G91*4ERVTKEOVW =,.'J?^]RD?^7K_-8[@ART
MVD3'<H=.JJ&R.$S$4TM><5R49JV6^) )'&'[*5?_ *5S^DQQF#G<7)PQ3BIK
M-*5$T7Z,W<_.,KGOL8[K$<5V;0*C%CD2GGF%H01G:YF1V''4%6+Z11XD!NB1
M'$QT9A*.25S ?F5"JJ9P_!I<QQ+4J<:.$&T1F2$E8UF1;[7$.>(Z3&QC1)='
M<6F.ILH,E*FS069L)"KGOM_[1T]%I-3J&+55NO16V"9CDS':2X2R(S](_P ^
MT2V,*$FLX?EQ&6T%)S<]D]UEEM+;_>\!S.+U5!.4.CG1TQU3.#.9I/WS+;;W
MM[!T-#<Q.JH)*LM4U$/-.YL9V=?BWF.<D4_$I5&AU5N T_,C139?0MXB+.VE
M>_NVCH*-/Q*_46VZI28T>(=\]Q#^<9;-FSW@)JKFV5+EF_(7&:T2L]Y!V4V5
MMJB/E(5KGX>__7JM^,K_ /E%JJ22B,C(C(]AD8Q<%C] WW2 06"#A'3W]75>
M756]+YSLE1J4D[%YI7(M@YO*?2X;U<PVXZR2ER9B&'3,S\Y%RV>S>8L5MM#9
M&3:4I+D(K#EL?T:=4FZ9+I:6W)-/D%()E9VTEN*_P ?F)*5"I&!ZPQ36"89-
ME:C2DS/;;VC0P+A:"Y2:?5*D2IE04E+J'7%&>C(O1217M8B$E-*K5S"=38E4
MXHDMUM3;31NDK.V;S/<0EL,1'8.'X$621)>992A9$=[&1 *NIM1IU4J=5G8C
MI]0J2E/J:80VRIQME!<16V7_ +XQ(X2EQXS&((515,AX=L2F%2B4VI!*N1I2
M9_D0EHM.KN%:E/U1#;J5+ENF\EK2DA;*CWEMXOD0^<1TW$.*,/K1)A18CS4A
M#[#!NYQK))*(R4>[C <KBIR@-4%3] I<^)*:4E;4W0K2G?QJ/E$J_1*=-R@T
MQ$J,EQ$R"<A\C,_/<.]SWC>Q-'Q3B>A/P=5,0&B(E*)3Q*4Z9'<DIML(O>-N
MM4FKPZW1JQ2XJ):HT4H[[!N$D]V\C/9Q@,65"$U3\%18E/3H&VY3:6R29^;Z
M7'[QJ8[PM3:+A%V= ;6W48JD**42STBU&HB,S._'<3.+Z?5,085AMIAI9G<(
M0ZXR;A'F$1GQ\>RPD,?TV55\*384!!.2',W-2:B*]E$>\_< YJJ84IJ,"O3U
MMJ75"BE).8I:C<-RV=>]Q&8@K4B7AO"D.2Y+-N8@ERC8(U..I21;+%M.X[VI
MT^0_@MZGMH(Y2H>A).=LSLVUK^\<[(PK4U88H!PE-,5NED1I)9W2KE29]@#F
MZI(@19$"9A2D52%.8=3G%P=:4N(XR5ON)'#5"C5O&F)SJ1*>C,2;DP:C)"E*
MOM,N.Q%^(Z6'5L4R)##3M"9CISBTKRY!&DD\=B+:/K"-(F4_$&))4MM*69DA
M*V3)1'G$5^S>0"$I=/CTG*3*I,)*FZ;,@&MR.2CS2.]MG)N/M&I@/#5(FU'$
M"9,-#A19F8S=1^86W9O'3*H\P\HR*MHT\!*%H37G%?.N>RPC8,*NX=K]5.#3
MFY\*H/$\3A/$@VSX[D?O 3-0QG2:?.=AR#D:5I6:K-9497]]AR&+*HQ4,:HA
MU-F;)I,5A+W!HZ%*TBU$1D:B+BL?]W%I$DCVF17''XAHU4BXB1B##R6GGU-Z
M&3&<5FDXCB,CY=A=A .;HCK+6.8)X?I]0A4V2A3<IEUE:&R.QF2MNPMQ#[R;
M89@5;#KLFK-G+4;BVVDN+,R:27-*^P[G<=;2JAB"=.)$VD-08.:K/4I\EK,[
M;+$7M'SD\I,NC8<*)/02'](M5B41[#W .4R?8<B5/62:J;DV/"D+C1V7EF:6
MR([F9%RG<?E)G.8:@8S8A+6;4%:51TJ.Y-FJY;/P[!U>!:3,I*:MPUM*.$3%
MNMV41W2>XQHPL+OOS\4HJ""1$J6:3:R41GN/;;V'8!QM/*A.X?/AM,J\FJ/M
MZ14W@ZU*)PRN1I5R$?:.C@R9LG)',UDEY,EMAULS=(R4HBO8SOMW?D-FE.XL
MH4%NFJI+-10PG1LR&WR01I+85R,354BU.IX,E1Y3#2*F^PM)M-K\TC.]BN?L
ML B<#88A.4NG5:H9\RI*2EU+[JS,T6+S4D5]Q$.=PVBAR=?+Q>MC6A2%DHI2
M[*2CBS"/VWW>P6%0&U4C"\1$\R;.+'+2G>Y)L6T5[2(=7J<VI5B%1H-0B39!
MN,.5"Q+2DC.Q$6VQ?(!&QE+HN3MZ;":6Q(G3#C-R2(R=4R=S_P!#(9JLBBHH
MIHHE(K$>K,D2FI7!W"4I1'MN?MVCH7%/XQ@U'#U0C(IU6IZD/(-!YS=_W;>S
M;^(D&JKC%$<H[E"CN2R+-X1P@B;,^6V\!&X_?DR\"49YTULRW76%*/:DTK,M
M_LVC+BG!M*A82E/LM**?':TO"\\S<4LMMS._&)?'5)GUBB0F8S:%R42&G'")
M5B*V^QF)7%,-Z?AR?$C))3[K)H21G:YF0"M<+T.FU/%Q,S(B7&G*8U(4DU'M
M<,DW5>][F9F+;BL-Q8S;#""0TVDD(27$1;B%=QJ/7J%5853A0&YMX"(KS.E)
M*D*27$9[RV$+#AK=<BM+DMDT\I!&M!'?-/C*X" QR[0R@,-X@<5HS=)3;*#5
MG.&7%9.TRVCAT/4^/C3#[E!ITVF)==-IU+C2FT.I/V'OW_D.JQA2:D>(*96Z
M5&:FG%(T+CK423V\9&>P:4JG8BK>(*+4YL1B)%AOD?!]*2ED7&LSW<1; &KA
M&E1L55.N5.NM\+S)2H[#3BC-+22Y"&*AT.-'R@UVDH-1PW*?FH2HS5F)4:=A
M7Y#,["0B4ZNX5JE2U3!;J5-FO&^E!.DA32CWD=QGPO2*VC&DVLUEIE"947,)
M+2\XFSSBLCV["W@-;!-:52<'U1FHF?"*,M;:B4>U2=Z>T]A? 0+ZI5#R>(DY
M[J)E<E$MYQ-\]*57/9\"_F$UB_"%1J.(UJI^8BF5!+:9IYQ$99BKWM\"[!TF
M+L.E6:"F'%6EA^.:7(RC]%*D[K^RVP!7-911T4A":#2:Q%JK!I4W)X,LE*,M
M^<?M$DN$K$./V6)RWFF'J:T])929H-=BOFG[+G^ Z!FJXQ2PF.NA1URB+-.1
MP@B;4?.MO&S&I$XLH+E6=;0414)+6>2OW]ERMO 0V-L.E B4M-(IKK](8D*>
MF0XZCNX1D6VU[GN,;V#2PI)J12**P42HMH,E1U9R%D6X[I/88G<12ZS$5'<H
M\!J:V=R>0IS,46ZV;?9RCGJ?2JM5<81*U4:>S3&HR%)LEPE..F96VF7$ YQV
MI0:GBVK2*_#G3V(SG!X[#+2G&T$5R,S(N/9^(ELGKYL8HJ46!%GLT=Y!.M(D
M-J232RWD5^+:)!^F5K#U?G3J#&:G0)QDX]&4X2%I<Y2,^+?VB<P],K<R0^NK
MTYJ#'))$TDG<]9JOMO;9:P#5RC55^CX4ER(BC0^HR:2HMZ<X[7+VV%?2&J%]
MGC9BTFL)JQ-DI$W@Z\\W-][\EQ:6*:.W7J')I[BLS2%="^:HMI'VCFX,_&$"
M&W"?HK$M]HB0F0B024*(MQF6\!#8/E2:7B2G/3R6@J[&(G"<(TF3Z#,KF1\9
MVO\ _<)&.Z=4R@5:HJ\^'1HYMM\9&Y:Y_P"HD\746HUB@07FDM)KD-:'T$E7
MFDO9G$1GQ?(;>":&Y2\/:"H$DYLE2W9)D=[J49\?N 5SAR92)\-^;B.F5*IS
MI+BC-U+*UH0GB2DRY!B=?G.X07"<X8VABIMIB./I4A9(.^;OY+?B.MH\/$>$
M4/4^% ;JE-SU+84EXD*01_NG<;-;@UZNT.,4R$PS*1.;=)I#M\UHK;3/EW@-
M7%F#:7"PK*D1VU(J$9O3%*SS-Q2BVF9G?C&EC*#&J% PU49;1.3'WH[3CAJ/
MSDFE1F7Q,=UBJ&]/P]4(L5)*>=94A!&=KF9#G\0T&I2L&4J-"2WK""IEW1J5
ML4:4F1E?X@.EHU'@4=EQNFQTL(<5G*))F=S^(D!ST.?7)-'GN.4M$.<A!\';
M4Z2R6JW';VC>PT[47J)%<K3:&J@HCTJ4;BVG;\+ -RH?]QD?\M7Y#E<DO[%1
M?^-?]0ZR8A3D5Y""NI2#(A Y/J7*H^&&(<]!(?0I1FDE$>\_8 Y"@KKR<38I
MU"W!6GAIZ3A.=<MJK6L?O'?8?55UQ7->HB(?SO,*-?-S?;<]XX^'#Q-1J[7'
MZ?2X\EB;)-U*EODG9<[;/B)OA.)).'ZGIZ<S'J&;FQDMO$HE7V&9GQ6 <:6(
MZ5)Q?6Y58<6IA+9PHQ);-99NTE&7)]1-Y*JHV_0YE+2X:S@J439JV&II1F:3
ML?Q_ =)A"AHHV'HD-U"#>2G.=/?=9[3^7P$;*H<N+CENK4]M*HLI@V):241&
M1\2K? MW( Y3)VYB=.';45JFJB:9=C?SL^]]NXQV$K#SN(8=/7B,TM3(CIND
M415D'NV;;\@Y["T;%N'J7P%BCQ7D$XI>>J01'M,34J=BU46 MFFQ6WE2#3(1
MI"61-[+'>_O =@*QQ/7X)91893G5\"I;>?9"361O&6S=R7+L%EO*4AEQ3:<]
M9),TIO:Y\1#F,!4*13:=*>JR$'49CZGGMI*MR%?M[0'/Y-ZO$+$5;IT1PSB2
M'#E1B4DTVOZ22(_AV##@O#\2L5C$#M42J3'9FK2W'6H\PE&9W5;EW$.BQ=1)
M;U8HM6I#2%2(;N:ZG.S34T>\OS[1FP329=+D5M4QLD)DS%.M641W2?& YRET
M>.UC'$&'&#6BER(9.Z(S,R0H\W:7:-K"E>53L%51J:?^UT7/84E1[3MZ':>S
MX"7ATB8UE$GU5;:2A.PTM(7G%<U73LM\#'+XPI*W,>1H$-PB8K!(<F-EOLVJ
M]SY+D7X .HR:4Y<+##+\FYRYIG)=-6\\X[E^%NT;N,G:2BBK17GC:BK46Q*C
M)2S([D16VF)M""0@DH(B2DK$1<1#DL>46?.D4JHTQMN0]3W36<9Q5B<([<?+
ML <36GZ3&G4:3AZF3J<\B4@C=4RIM#B3/<9GO'04VFLXIQO7G:P1R(E/64=F
M.I1YA'M(SM\/Q'YB"!B;$O ENT]F#'BR$.:$WB4MS;M.^XB(ANR*;6J#BBH5
M.C1$3X50L;K&D)"D++CV_'M 12*)%I>52G18J3X$]$<4EDU&:47)1&17XCW_
M !&_@*5J7[04>:LR337%/M&KC9.YW]VS\1]4^DU^7CF#7*K'8982RMLFD.9Q
MM%8[$?*9F?$/S'V&:G4*FW)H9(3PIDXDRZB*Z+W(_;]" 0+<Z5!P;6L3)-3<
MZKOYC2N-MO.,BL?;V$-.2U0_LZ;,2DU@JL2"4F:<=>>;F^]^0615\-,3L)ZD
M;/1H0TE#2N:I.X^T0\.H8PA0T0WJ*Q+?;(D%)3()*%%Q&9;P'-/MRZ]7<)QY
M[K\=R3!4F3O2M:4FJY'Q^=F_B)W&F%BAX?2UAN"HFN$(<E1V5F2GFR([E>]Q
MONTFJ2<9T"JR6FB1'BK1)-"]B5F2MA<9EM(3F(9%5C1VG:-$:EN$O](TM>89
MIMQ'RW <IA;[(3*I&5!AZNJK)W3'=SFUWMR7LH1%>J46HXYF,UJ-.F4^GI)#
M<:.VI:34>]2B(3+E.K.(<14J;.I3-,:@N:13ANDMQ?\ "5N(;-7I%7I6)7:W
MAYIJ2W)02945:\TU&6XTF A\'O(9QSF42%/B4B2P>D9?:4A"%EM(ROL+ZF.U
MQ?47*5AJH36/UK31FCV&>PC_ !&M0Y]>FSSUC2FH,)*3VF\2UJ5Q6MQ"5K-/
M:JM+DP9%]&^@T&9<7M 5' *AO4 RG4NKR:J^WI%3= M2L\]I&E7(-G#,F72J
MA0*O4B>2<TE4Z2;I&DS-)D2%*O[+=T='2G<64*"BFKI3-10P68S(0^2"-!;"
MSB/:)+$5(GX@P?H)C;+-639Y"6U72EPC.Q$?NV?$!&SR.N93(D8KJATEG3.;
M?--U6XOQ+\1RU+J--JE0JD_$=/J%16M]3;"$,J<;907$5CM?;_=QWF3^C3:9
M!EOU@DZRFOFZ]FF1V+B+9LY3^(BXE.KV%*A.*DPVZE2Y;IO(:TN8ME1[RV\7
MR(!CR9//(FUF$VS,;I3:DN1"DH4DTD=[I*XC,FV'(-7BU&354'*0B6XVTRXH
M\Q&VYG;E.X[S#\FK2VGW*Q":AW,M"VAS/5;CSCW"-R=4B91J9-9J#:6W'):W
M4D2B.Z3M8]GN 5EB*F1H<G$<-M"E,PWF3CDI9F31+,LXB*_M+L%P4&@TVCI4
MY38J6%.I22S29G>WO,<;7<(U.H5'$[K2&TIEDRN,:EE99HL9D?)N,=9AF;5Y
M2%HK%,3"T:$D2B=)>D5QV(MQ /G'5..J84J,9!7<-O/1_P 2=I?D.+K-1<KN
M$L,4IAPR?J1I0Z:3VD3?I&?Q(6E:Y&1[C%?8+PC.I>)Y4F>2>!Q](F%99'L4
MK?;BV (>157BR7IIIFKAY2=6&G.\Z^<?%[M@F,!0FF<18FA6NRC1-6W7(D6'
MX]A&<YC_ (7FHU,;Y3#\XOUI%R;]_P"8F<,4B9!Q+B"9);)+$M:#:42B.Y$6
MW9Q .:P=AFD2L1XD:D0D+;B24)92:E>86WV^SC#"N'X=8Q5BAVIH.0PS-62&
M%&>9G&I7G&1;SL7XB29AUV@8EJ\F!3VZA$J+B7",G20;9E???WB4P;29E.JF
M(7YC:4(F2S=:LHCNDS4?^H"'PW'11,H]0I,#.13W(A/Z'.,TI5<MW]\8[J:\
M<>&^\17T:%*M[BN.;9H\Q.4=^K&VG@*H9,DO.*^=<MEO@.H>;2\TMMPKH61I
M,N4C 5Y@>@PL24IRMUYOATN8XO\ 6*.S:2,R(DEQ;ARV)--3(U6H+,EY3$68
MP]&6I1W;)1'L+M_ =C2XF(L)ID0*?3VZG33<4N,HGB0ILCVV5<1M1P?6IE+E
MRI26':O-F-.+0A=DMM)(R(KGOX@$ABK!U*@83ER8[*DSXK6F*7GGI%+3M,S.
M_&-/$K<^HX=PQ.=C2*E";0ER;':4><Y=*;*,BW[C[1VV*H;U0PU4HD5)*?>8
M4A!&=KF9<HB4'7:-0Z.S IS4PVF";DMZ4DJ2HB*UCW'Q@-7!R<)RJD4FAM)B
MU!M!I4P=T*(N.Z3W^\<LFI0*GB>LR,0P9]1:8>./&9::4XVTDC,CW<9V'2TR
ME56I8RC5RH0&:8W':4@T)<);CIF5MMN+:/PZ76\-UVH3*)%:J%/GKTKC!N$A
M;:]NTC/BV@.02PU(9Q)';AS449N*J7#1)0M!,ND5C)-_>?8.^P%0:;$I-/J$
M:*E$QR.G/<(SN=RV\89E=KU*JL6IP6*>T\PIMDM)GJSC(R\ZW$/G!3E=C-1:
M95*4AEB.V:#DD\2B5;=8@'7&=BN>X5O4G,(/U2<HZ?*J\IQ9Z5;#:W20?(1E
ML+X"PY;6GBO-$K--Q!IOR7(5_AR-B?#M,51HM)COYKBC1,TY$@\X_2,MX#F6
M(K,W)C5I$E+CKL%]:(RG5'G-)-2=EK^TQ)8SPY28.$:;*BPT-ONK8):R4>VY
M%?C$C&PK5F,!5VENI;=G27U.(,ED1.7-)W]FXQ.8KH,NJ8/CPHV84V.EI:4J
M/8I2;7*_: V=74_"]$J4VEQ$LK3'-Q5C,\XTI,RWF*[H2Z')HQN5RF56?49.
M<MR63"U&5SV9JN0A8U(74JQ3I<2O4PH2%-:+8Z2\^Y&1F5MP@**G%.&86K$T
MQJJ1FC/0/MO$@\TSO8R,!R4A^I2\.X?8E.2H\ANIG&:=<(TN$C-*RMNW]ZWP
M%IT##%,H:S=@,&4A2,Q;RE&I2RO>YW]HYZO4NN5IJ@O2HK#<B/-)YU#;ER0V
M7M/>8[L!R^4B&Q*P?452&\]3#1N-[3\U1%L,<NJATZ)DN>J$>*E$QZGEGND9
MW.YE<6!B&GG5:)-@I62%2&C;)1[B,QQ3$/$+^#I6'Y-*0A3<4VFWR?29.&1E
M;8 RX:P52)F$8CLY@WY<B.2S?6HS4BY;"3MV$0@V*_.CY(B>0^YPDY!Q4O9Q
MYR4YQG>_+;8+)P]$=AX=@1)"22^U'2VLB.]C(K'M''TC!DM_)Z[1:AFQYFG4
M\VHE9Q).^P]GQ <Y46J(BB:.ETFL-59I)*;E\'62U.%QF?M%IX9DR)F'Z?(F
M(4B2XRDW"45CSK;;D.=C5/&#$=$5VAL/R4D2.$\((D*_B,MX["*;IQFCDDDG
M\PM(23N1*MMM[+@*VKE ICF4ZFQG(J5,2F''7DFI7GJV[=XD)L9J'E-PY&C(
MT;+<)Q*$$>PB\\2E2H\Q_*#2ZHVVDX;$9;:UYQ7)1WML^(_:E2)C^/Z35&VT
MG#CQUMN+SBN1GG6V?$@'/8HIIU?*;#A*D.LL.0KO:-5C6@E*,T^X]PVL9X8*
M'0FFJ!!4J(F2EZ5$849*>21&6_?\!+/TB8O*)&JJ6T\"1#-I2\XKDJY[+?$2
M6(9%7BML.T:&S,LK]*TM>8HTV_=/WV <938F#*RAQN-!*'/;;5>*X:FUGLXR
MOYUADR4T"F/T&-478B536WUYKMSN5E;..PS/4FL8CQ#39T^FM4MJ$:C4O2DM
MQVY;BMQ>_E,9L&Q:[A]14=RFMO02?4HIB7B(B09WOF[[@.DQ94'*7ARH36/U
MK31FCV'Q&.7PO@VF3,,,2J@VJ149;6G5*4L\]*E%<K'?9;8.SK%/;JE+DPGS
MLV^@T&9<7M'&4C[6TBFIHY4R/)T1:-B83Q$@D\1J+?L 1&'YLBA8!Q"ZVXI<
MIF4XV3AGMSKYN=[[[1.T; E(?P^SPYM3\V0V3BY:E'I"4HK[#OQ7##>%)2<+
MU:E5HTZ24\XHG4'>]]R^W;88X3^,J=3$TQ-,CR7VDZ-J;IR)&;Q&:3V[" 0\
M)RKUO)[/@L../RX,G0*S5><^VDR/-ORVOV#;PVG"$R7$953E4JK,J2I++YJ;
M6:B/=>_G;1,TFCU3#&&$M4MMB;45.Z:02UYI+,[9V:?N(A&5>G5S%<FGMS*0
MS3&XSZ7ER5/$M=B_=3;^]P#2QK469..FJ?5&YDBF1&"=5&C(-6E6>XU$7%M_
MNXPTB2S&QO35X<IU1B0)%VI;+C"T-\=E;?[V#I<24:J,8D9Q#0$M//I:T#\9
MQ6;I4^P^7=V$-ZD5'$,RHM)FT=J#"(CTJUODM9G8[9I%[; )BKR3A4F;*25S
M886Z1?\ "DS_ -!P^"<+4^L8>;J5<;.?.FFI:G75F9I+.,B(MNS<._E,(E17
MF'2NVZ@T*+E(RL8X2C,XGPO"52X]-9J<9M1G'?2\2+),[V41^TP&IAJ.F3"Q
M-0*DIR7%IKEV#<6=R38[%LY,T;62.CP"H,:J%'3P[.<1I;G>U[;MVX2F%L.R
MZ=3JL]4'&W:I4E*<=S/129D=DEVF-G)[2Y5'PRQ#GH)#Z5K,R)5]AJN6T!EQ
MY$GSL+38])-92U$6:2#L:BN5R(_:5QQE#9P?-X/!J%,72ZFG-2:'\YM2U<=E
M7VW%AUQRH,TY:Z0RT_+29&3;JLTE%?;MY1Q-<A5_%7!(TJBL4]#3J7%27'B6
MI)$>W-MM :F"\,TB97\2MR(2%HB3"2P6<?F%=6S?["$M6-F5>AD6[@CG_N'Q
M%AUZ@8DJ[T*G-SX=1>)TED\2#;VG>]_>8V\6TFJ%B&FUZCM-RG8J#:<CJ5FF
MI)WVD9^\!BRD':7AJQ__ -2;&I.BIQ+E'D4ZI&I=.IT=+A1\XR2M2K;3[?P'
MQ5J?B7$%4I$N3 9AQ8<E*S8-XE+/;M49[MA%N$C7*35:?BG7]!9:E:9HF9,9
M2\TU$5K&1G[B[ $16Z#%HV.,-KIJ#8BO/^<PE1YA+(O2(N+8-_#7_P"3^-JM
M273S8T[_ &R-Q$1[<XB[/P&-VG8BK&)J-5)T-F)%B._J"=)2TE8[K,]WLL09
M6XZVHE/J<-PFIS#IM-GQJ)96,B_OE 9<$H.KXIKN(%W-DU\%C&>[-3L,R["[
M1W8B,(THJ-AV#!L1+;;(W+<:SVJ_$2X              #C\H?[*U'W)_J(=
M@./RA_LK4?<G^H@'$84])/P_,6I2/U2?[XQ5>%/23\/S%J4C]4G^^,%28  (
MQ2?0/W#'#WJ]Q#))] _<,</>KW$ V0             :;-2ANU-ZGMOI5,90
M3CC5CNE)[C_$AS3^,)<FJ2X>'J,NIHB*S'GM,3:"5R$9D=^,16"ZBJIY1:U)
M7&=BNG$0AQEWTD*(TD9?@ L:P6' P\?RZDE:*/0'YDEM:B<2EVR$$1V*ZK;S
MY!/0\1+>Q(FCO0S:=X(F2M6DOFF=KIM;BOO =!8+"#K]?*DU*DQ#CF[P]XVL
M[.MF;MMK;=XT*EBJ45=>I5#I2JD^PDE/+TQ-H1?BN9'M =78+#C\-8MGUFL/
MP'**<8XRLV2I4@C-L]MO-M<R.W$);%T^93Z%)?I\54ETDJ([+)&C*Q^?MWVY
M" 24Z6Q ANRI;A-,-)SEK/B(?4.0U,BM2(RR6PZDEH47[Q'M(Q61U2K2\G$A
MJ;37$Q> FHIRY!+-P]EKIW[1N8=Q15FL,03IV')$N)%C(0MY3I(SS2DB,TIL
M9F6PP%C@.6<QC'/!IX@C1U.(*Q*94K-,E9V:9&8QT?%4ZL3V. T-\Z4X=CFN
M.9I;MIDFVTK[ '6V"PXQW&4R7/E,8=HCM2:BJ-#C^F)M!J+B29D=Q)X;Q,U6
M8\HEQW(D^)<GXCA^<@_D Z !"X/KI8BHC=0*.<<EK4G,SLZUCMOL0UJ9BEJ6
M]B GV= U2'#0M9KOGD6=<[6V>CN =&-294HD*1&8E/I;=DKS&4F1^>KD'''C
M>K+I2JM'PTXNEE=1.G)(EFDOWLVVX0^(L0NROLS6)L!4=M$HW&VVW"=4XBQ'
M<K6VWV6 6H XB1C2I4]<=VLX=>AT]Y9)T^G)9HN>PU)(M@[9*B4DC29&1[2,
MN,!^C2?J<-BI1Z>Z^E,R0DU--F1W417N?X&.*Q97*O'QO1XD."ZMM.>I#12"
M04KS3O?B(B]HC\15:5'QGAR?,ICK<PF'4E#;63BE*/.2DB,MFVY>X!:0#C&L
M83HM2B1J_0W*<U+43;3Q/DXG./<1V(K#?Q'B<Z9/CTV!"<J-4?3GI80HDDE/
M.4?%N =( YBAXI=E5=5*K--73)YHSVDJ<):74\>:HB+^[CIG%I;;4M:B2A)7
M-1G8B+E ?H#AT8VJ,QIZ71\.2)E-:,RTYO$@UVWFE-C,Q.P\1QIN&':S$2:T
M-LJ<-HSLHE)(S-)\A[ $V X6'C6J5.$4NC8:?DQR3=2U/DBZN,DE:ZK;AD/*
M#%<HT63#AO/U"2X;+<$C\_.+?<^3=V@.JJE3ATMA+U0?2RTI9-DHR,[J/<6P
M;A"I\?UNH2J;$B5>C.TYU<EMQI1.DZA9$9W(S+<>TM@M@MP!8+#G<38F*D2H
M\&'#=J%3D$:FXS9V\TK^<9\1;#[!IT_%TA-78IU?I+E+>D[&%FZ3B'#Y+D1;
M0$[6JS3Z)'2]5)2([:SS4YUS-1^PBVF/NCU6%6812J:^3S!J-.>1&6TMY6,5
MWB67/>RBP$JH?"= TO01W'DV=+;Y_(7N,6/3$V@M&J(B&M99RV4VLE1[]I;P
M&V-*-5(<BHR8#+Z5RXY$;K9$=TD>[\R'!LXAKRL=5!MJD./:*,2$Q.%)224Y
MQ&3E]USO[]HTX=8EP,HE>.-2WI<^0VR11T+(B1YB3,U*W$1<H"U0(ARU#Q4_
M*K9TBL4M=-GJ0;C23<)Q+B2Y#(B]O8/BI8LD:W?IM!I2ZH_'_P"\*)TFT-GS
M;F1[0'66"PY_"V)$UI4F._%7"J,4R)^,X=S3?<9'QD-K%%<9P_25S7VUN^<3
M:&T;UJ/<7Y@)8!R4+$5?7+BHEX7>98?623=1)2O1D?&HK;"(0];KU::R@Q8L
M:G.N-M-.&W'*022D$9>F?$5K;"/: L4+#FH&)7GL2,T:73SC2%Q>$J/2DK,.
MYEF["V[MXV*_7]4U2C0CCF[K%XV<_/MH[6VVMMW@)VPTI-4A1:A%@OOI1+DW
M-ILR.Z[;Q!US%;D2L%2:13G*G423GNH2O,2TGBNJWM+M'*R:M)J64;#B)].<
MI\MC2$MI:B41D9'8TJ+>6P^P!:8""PGB!->C2E''.-(BO&RZRI6<:3+X>_L'
MY2<0ZRQ%5*:S&,F8)$2I&=<E+/\ =(K>_CX@$S*CMRHSK#Z<YIU)H47*1[QQ
M\3"57IC7!:3B)UF"1GF-N,)6I!&>XC':B!Q3B1FA-QT$PY+G2E9C$9KTEG_H
M0#]PSAMBAJE/:=Z7-DJ)3\E[TE\A>PA.V'&-8QF0YL=G$=$<IC$A1(;D:8G$
M$H]Q*,B*PV<38P10JS'@+A.R%OLFXC1'=2E7,B02;<=MX#JK (;#=2J51;?5
M5*2JFF@R)M*G26:R/>>XK6V#XQ#5ZC3W6&J91GZBMPC,U)62$(MRF=P$Y8!S
M&'L4.SJP]2:K37*=44(TJ4&X3B5HY2,B&O5<9KAX@D4>-2WYDQ*4FTEM9%GF
M97.^SS2(N/: Z\!R5*Q9*<KB*56J0NFR74&IE1NDXARW%<B$AA+$)5^+*4N.
M<61&>4RZR:LXTF6X[V+?_H G0L(&DXA34\0U.FL1ST4 B)<C.V&L_P!VUO?Q
M\0_<4XB;H3+"4QW)DV2O,8C-'YRSY?86X!.@.1@XMEHK$:GU^CKIBY6QAW3$
MXA2N:9D16,2%+Q#PO$=2H[\8V'HI$MM1KOID'QD5MG$ GK .4Q-C2+0JLU">
M:SR-HWG5DNV87$5K;3/DV#17C:I18[<ZJ8;D1:6LRN_IB4I!'N,T6N0#N;!8
M0&)\2LT.DQZCHN$QWG$)(T*MYJBOG%R[!"3,:U2+$U@YAF05*N1Z93Q$O,YQ
MHML[0'= .!Q_7YZ(5+52H[BHLEUEPI*'B1GF9F9-VW[;%<]PZJA3:A-:=54Z
M8=/6E1$A)O$YGERW+< E#&G+J42')BQY+R6WI*LQE)D?GGR#C,I%9JD.?2(T
M&*Z3*I2%$ZAXDZ<R_P#IVXBV[S&ABRL2VZEAV=5Z6[#6Q+59A#A/*66:6TK6
MVW.U@%G6 <0]C.HT]V,NMX>>A07UD@GR?)>9?=G$1;!/XBJLVG,L'3J4]4G7
M5&G-;4221[5'Q$ F+ .3I&*Y3M>;I%:I*Z=+>0;C)Z4G$K(BN97(BY#$/B"N
MUIG'E.C1::ZMMM#IH8*222DD9'YY\16MN,!8@6&K2WY,F T]-BG$D*(\]C/)
M>9M/C+?LVB-P_7]:U&J0G8_!WX+I(,C7G9Z3W*W; $Y8!RV&\8,5RNU&FML&
MWP8ST;N?<G2)6:9D5M@^'\7/G/K$:GTA^<=/6AN[*]JUJW[+;"*QW/: ZP!Q
MK&+Y\>JPH=>H:Z>B8K,:>)\G$YW$1V(K#?Q-B55)G0Z?"@KGU&41J;92LD$2
M2XS,_<?8 Z,+#GZ!6*M-GN1JI0G:>E*,\GM,3B%;=UR(MHW<358J)1)51-K3
M$P1'H\[-O<R+?\0$F X8\:U1Z&=0@X9DO4TDYVF4\25*+C,DVN9"0GXRBLX2
M;K\5E4AA:DIT9JS329G8R/?M(!U(6'*T3$\^KU!K@]#?;I+E[377,VY$6\DV
MW&?M&H>,YTUZ6= H+M0A1E&A4C3$V2S+?F%8[@.U AQCN/8QT:'*B0WGYLIX
MXZ86<25I<+>2CXN+M&]2*Y6I%4;B5+#KD-I:3/A"7R<0FQ<=B =* Y:L8J>9
MJYTNB4Q=4F-ISGB2X2$-<A&HR/:,4'&>EC55$VGN1*G3F3><B+61YR2*]TJM
MNW<7&0#HZHQ(D0'V84G@TA2;(=S25F'RV,0N&\,'3:C)J50FKGU)])(-U:22
M2$\B2XA%L8TJ=1B%+HV&I$N(2;J<4\2+JXR25KJL>RX5G%CTW S]2H\-PU+;
M6VZ>D))Q3M8S/E,K[+ .Y <K@:IU693X+<^F+9CE%0:9:I!+-X[%MMO*^\=#
M4Y*X<!^0U'=DK;3G$RT5U+]A -FP#AY.,ZK3T-2:OAIZ+ 6LDJ>*02U((SWF
MFVP?F5&L3H6'TG36G":>--Y:'23F;2,B(MYW =R,4B0S&;SY#J&D7MG+41$(
MZA3ZE-TVLZ2=/S;9EWTN9_+N+8.>RN$D\,M$NV:<EN]^2X#K&*C"?7F,RV'%
M'Q)61F-LA6^(J/@UF@R78ZX3$I#1J:7'?NO/MYI$1'MVV$S1JE5:?@:FR'Z=
M+J%141(-DCLNQF>:I1GN*Q%V@.OL XZ+B^:S6(4"O41=.X8>:RZ3Q.)-7(=B
MV<7:/G[7U&;*EIH- <GQ8SAM&^I\FR4HM]B,@'9@(5FNZ+#JZK6(CE.)LC-;
M+AW45CL7;Q#GUXVJ;,1-1DX:D-TE5E:?3$:TH/<HT6W .N54HB*DBGJ>24Q:
M#<2U8[FDN,??#HI3BA'(;X6:-(3.=YV;RVY!QO"6IF4RDR8RR<9=IREH47&1
MW$@Y*@?>,B,=/(Z@4+/*7I-R;GYN;_J ZNP6'!TW'4^LQS71,//2E-W)[.?)
M"$'Q$1F6T[;1.87Q,U6HLM4AA4&5#4:9+#JMK=N._)L/L =  X9&-JC,9>F4
M?#K\RFM&9$^;Q(-=MYI38S,=10*O'K=+9G1#_1N%M2>]!\9'[0&2;4X<&1%C
MRWTMO2E9C*3(_/,K;/Q(;MA7V4^8F!6,+REH6X34A:LQ!74JV9L(N4QMN8TJ
M%/=8<KV'WH$!U1)X3IB<T=]V<1%L =L%A U/$286(J12TL:4J@E2B>)=B21%
M?=;:/W%V("P]!CR3CG(TTA#&:2\VV=?;N/D 3H"NL0UZLLX_IT6+3W5MMMN*
M1'*022DD:3\X^(K6V$?(.ZI<B3)@MNS8O!)"O29SR7F_$@&W8!!4/$!5*L5>
MG.,:!Z X2=J[Z1)WLK=LXNT:6',91ZW7YU,:8-O09QMNFNY.DD[&9%;9M =5
M8!S].Q*W,K%8B:'1QZ:1:22:]AGQE:VRUC[!#M8TJ<]#TFBX<?F4]"C)+YO$
M@W"(]II3;: [@!S<;%D:7A676HK2E<&0HW(ZCS5)4G>D^01U+QG.J[D95+H+
M[T-1I2])4[FI;,_2ML\XB =K8+#BRQ?4ITF65!H"Y\2.X;1OG()LEJ+?8C(9
MYN,'8D"%I*1(UO+,R:IV<6?8C.ZC.VPMG( ZT!R=,Q9).LLTRO4E=,D2"O'4
M;I.(</DN1%M#$6,=3UUNEHIS\M]UDG&B95M4HS,LVW$6R]P'6 ./B8NFM5F)
M3Z]15TWA1YK+VF)Q!JY#,B(;>(<3JI]29IE,@.5.I.)SS:0LDDVGE4KB =+8
M!RU$Q8<FH2:?68*J7.8;-[-6X2TK06\R5[!H1<:U*H(=E4C#<B734*-)/:8D
MJ7;>:4VV@.LI]2B5!4E,-]+JH[ALND1'YJRWD,DF9&BNL-R'VVG'U9C25JL:
MU<A<HXO)1(1,3B&2V2DH>J"W$DHK&1'MVB4Q;)@LUO#C4VGE*>=DF3#IKS=
MHLWSK<>\NP!U!;@L.9Q7BQO#LZ#'<ANR>%)7FZ(_.N5K$2>.YF-!>,JA!E1"
MKM =@0Y*R;2^3Y.9AGNSB(M@#M1KPIL::EQ4-]MY+:S;4:%7S5%O(_:-CBY2
M'*9/I4&7$J2Z=3R@I3,6AQ).9^>HOWO9[@'5V <) QU-JI.)HV'WI3S*U)=N
M\2$(L9V\XRVF=MPWZ1BUZIP*CHJ4ZBK03(G(*G"([G?:2CXM@#K L*YR<5ZL
M2(!'(@+D1')3AN37))6:*]S+-/;8AOEC2H2TR)-&P\_-IS*C+A!O$C2$6\TI
MMM =N%A!P,1QY^&':U%0I2&V5N*:4=E$I)&9I/V[! P\;5.J0RE47#;\IA)>
M>M3Y(+.XR3L\ZP#NK .%;RA(F-PF:53'I53D&HCB&X2-$:=^<JWO[!-4"L56
M=.=C52A.T\D(SR=TI.(5MW7(BV@)B+-C2S>**^VZ;2LQPD*OFJY#&<<CA&;$
M<^T*J3229?8E*2M"7?\ O"ROMN>Q-_\ 4<WAG$]=0O$$G5#LU"))J<1PHBX/
M8MJ"(R.^[B 6G8+"+P[6&:S0X]2:+1H=1G*2:KYAEO(S]@UL)5_[11),I$4V
M(Z'E--J-5](1?O;M@"=&E4ZI#I:&5SWTLI><)I!F1GG*/<6P<GE4JU1I],9;
M@,.$V\X@ER4.DDTGG7))%OVVWB&RB5*>]1Z<]5J6JGDS46U)3IB=-9$E1GN]
MP"TB"PX:7C6J08Y3IV&I+-+,RN\;Q&M*3W&:+;.T26)L7QZ$W2WE,G(C3C.S
MB%6S4VN1D5MM^0!TX6',4?$DV2F5)JU'<I=.::-Y+[SI&:BY#3;8=MHC&\:5
M:3$5/@X7DO4TMI.F\25J3RDBUS =U8+#G'\5Q?LB[7H:#?:;21FT:LTR.Y$:
M3/;8RN)>).X12&9Q(S=(P3V9?==-[7 ;@#D(^.&%8.*O/Q5H)3AM(CI7G*4J
M]B(CL7)<:51QI6:8U'=J&&5,MR%$A!\+([*/<2O-\WX@.O*J0CJJJ:3Z>');
MTIM6.^;R\@W154JKRX64?A*J6Z[/>IZ4%#:62C)1GN-6ZVS>.GIF+91UUBE5
MRD+IK\A)FRO3$XE9EQ7(B =<16 ?BC,DF9%<[;N45K!Q!7U8UJZ6Z.Z\:&4)
MX(<I)$T5]BN0S._$ [^+4X<J=)AQWTKDQK:5!$=TW*Y#<L*LI]8E4_'5?1"I
MCLV=(T9DRA9))%D)N:E;B(AU>'\4NSJP[2JM35TV>E&D0A3F>EQ/*1V+V@.H
ML%AR4_%LI57DTZ@T=RIN1=C[FE)M"#YMS([F-_"N(T5UN0AR,N'.C+S'HSAW
M4GV^T@$]8+#1K-3CTBF2)TQ5F64W,BWJ/<1%[3/8.37C>I1HK4^H8;D1Z4X9
M?I],2E)2>Y1HM<@'=#D6\)R)=9CSJY57)S<19KCL$V2$D=]AJMOML'Y6,:I@
MUENG1*>]/=?CI?CZ%7ZS.,]F[85BO<(&+I::W&IE>HSE-<E;&'-,3B%'R7(B
MV_,!UY#2?JD./48\!Y]*9;Y&IILR.ZB+>(.N8K<B5A-)H]-<J=0).>XA+A(2
MTGBN=CY1RZJI)J.4F@E/I[M/ELH<2MI:B41D9'925%O+?V +1
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MH4>2[$[R4F4=Z6I;)'S<Y&W^^06! F,,8$C27'4$RB DS5?9^KW"6*GQ2IW
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MD^3.A$FI0Y!15LI59!K/<=^(M_8)"GO8Q*7&5-CTER(XHM)H5J)3:>6Y[_@
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M="@RD2(M,CH>0><E=C/-/E*^X!!Y26UT]RDX@CI\^#()+QD6]I6P_P"_:/C
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M9;!U-7H%+K"VUU*$S(6V5DJ45C(N2Y<0ROTB!(;B(>BMK1$,E,$9?JS+=;L
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M4NF0J5'4Q3HS<=I2C6:4%8C/E_ AHS<*T.;,5+E4R.Y(4=U+,K9Q\ID6P_B
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M5;75"9?G4UXHZ%-E9+ZC,R2?X&?N&Y AXSDM,2WJM$86Y92HO!R-*2Y+[[V
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MG+(I,;.1)V6LI.T]A>P<;2,7UZNSUPX4EB-IUJ>)YULK,,D=BMRF?MY" 6P
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MCJ&V&FW'%MMH2MPR-:DE8U>_E&N=+@G).0<..<@SOI-&6=?W@.1J7^]^D_\
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M%OJ096-.<>R_P(NT="Y3H;DHI+D5A4@MI.FV1J+XC:L
M                  X_*'^RM1]R?ZB'8#C\H?[*U'W)_J(!Q&%/23\/S%J4
MC]4G^^,57A3TD_#\Q:E(_5)_OC!4F  ",4GT#]PQP]ZO<0RR/U9^X8(AV7;E
M(!M@
M              0
M
M           6  "P6
M             L
M                        ..RAF185J%SWYI%WB'8*/-29GQ"OLJ,LFJ B
M/?SY#R2M[".Y@.9PIZ2/A^8M6D?JD_WQBK<)I\]'P_,6I2B_1)_OC!4B  "/
MAXO-,:*5&2SMO28D%%<C$7/);:M*C>F^SE 2;:R6G.(?0BX<I+A&MH]I;%)/
MB,2#;R%<=CY# 9
M
M
M
M
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MYN:9IX^0^42=.H1(L9H+L,=-"A):+<7X@/VGQ2:27UY1))*Q#\0DB(?0(
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M)[!,6+D"Q<@"'U6WS$]@:K;YB>P3%BY L7( A]5M\Q/8&JV^8GL$Q8N0+%R
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MJV^8GL$Q8N0+%R (?5;?,3V!JMOF)[!,6+D"Q<@"'U6WS$]@:K;YB>P3%BY
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H":8V7[A=@V&X#:=R"[!OV+D !A;82G822(94D1%L'Z        /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g50309g11m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g11m02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1=@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %T,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)36"L_!#4Y3A&"<X5G7"TBA%8V5V@Z+#\?_$ !L! 0 # 0$! 0
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M95;HJN15$Q$15'S$SC]G.@0>1!^5"0.9 ^9KHG2G;HL.RZ<7!C,M.O-^L4)
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MK5B;K6UWV%%<V(: E33IP5<59Q^1K]U3?]-W&8BXP($E%R<>:==<6< !)!(
M[R!5&I31")\1O5:HJQ.J<]/7IF.VRUZUU0B]:EBW:VH=CKCH2$]9SVDJSV=E
M6->M]-SI\6]7.SO^F8R0$A"LH)'(Y\,G&>5<QI31'0H\2O4UU5[3JG,YC;,=
M)7ZT:_"+M?I]TCN%5P:2TTAGB&T@* !S\_ZU%]'NI(VF3=-[9==WMI+:.KQP
M(SS\ZJM;"H,M$)$Q<5],-:ME+Y0=A1[@::8Z=T4\=Q$U4UYS-&9Z=^N5IT%J
M>%9K7<;3=X[KL&;Q4MH^LG(P16VO5]H8TM=K#:[8]'COIV67"O:4LGFI?=R%
M4.E)HB9R6_$+UNW%NG&T3'3?$^F5MU9J>->M-V2W1V76W8  6I>,*PG'"JBL
M;2"!VBOW(QG(Q6Q,A2X*FTS8K\=3B=M =04[2>\5:(BG:&%Z[<XBJ;E?Q'^(
M6?6VJ8M_M=FBQF7FUP4;*RYC"O5 X>5;VE]7VB!I!5CO$"1*;6XI:PC@D@G(
M_I5"I5=$8PWCQ"]%V;VVJ8QTVQ^/V=)L^KM)V6>9MKLTME_JRWC(((/'M^55
M>!J^\,7EB:]<9CC:9'7+9+RBE2<Y*<9Y8JO4I%$05^(7Z],1.,;[1C^SH)UG
M:T:_3J)F+)#:F"VZV0,E6, C\JQ7O4&D+B)KPLDD3Y 4H.J5R6>WG5#I31"T
M^)7IB:9B)B9STCK(.0SSI2E7<!2E*!2E?H&2 ,DG@ *#\I6V[;9[+76OV^8T
MUC.VMA03YXK7:;<><2VRVMUQ7)"$[1/R J$S35$XF'Q2LLB._&7L2F'6%XSL
MNH*#COP>RLS=MN#K:5M6Z:XVH92I#"B".\'%"**IG$0U*5D?8>CN=7)9=9<Q
MG8=04JQWX-8ZE$QC:2E*4"E*VHUOG2F^LBP9;[?MM,J4/,43%,U;1&6K2OMU
MIQEPMOMN-.#FAQ)21^1KXHB8QM)2E*!2MJVV^9=)6[6Z.N1(V2KJT<\#F>-8
M'FG&'G&7D%#K:BA:3S2H<"*A.FK&K&SXI2E2@I2OT#)P.)/(=]!^4K<5:[BE
M)4NVSDI',F.H ?Z5IU"9IFGK&"E*WF[3<'+6Y<D1'%6]L[*WQC92<X_J10IH
MJJ_3&6C2E*E!2@(/*E$%*5N6NV3KJ^IBV17)+R4[90C&0.6>/S%%J:9JG33&
M9:=*^G$*:=6VXDI<0HI4D]A' BOFB"E*4"E*4%]TGJ:T*TK*T]J9#HB$[33C
M()(XYQX$'MI?M1V)W0;EALS4EKJWP6NM&=M.UDJ)["<GA5"I5-$9R[X\1N\O
MEXCIISC?';*^7?4=FN-ATW;Y"7W&X:D;T@(*<I"<'9/;4K9]3:7TO%G+LLJZ
MRU/(PW$?SU:3^?+YURZMNU6^3=;@S!@H"Y+N=A). <#)X_E431&&EOQ*]S-5
M-,35M$3C?IC;=<]-:HM$C3#NG]4,NIB[9<;=8!."5;6/#!)K68OUETWJ:!,T
MPR^]%;;4B27R0IW:/9GNP*JES@R+9/?AS$!$AE6RM(.0#C//\ZU:G1#.KC[U
M,135$:J=LX_BC$]'4F-2Z/L\^=>[2S,=NLE*B&5I(0E2CD^ X_.H70VJHUNG
M:@EWE;G77%'JEM&T-H[6?D.-4>E-$8PM/B=[7373$1IS.(C;,]97/HVU# T^
MQ=T7$N@R6TI;V$;7$9Y^=;&A=16B+IBY6+4 ?1'E**@XR"200,CAR/"J)7Z0
M4G!!!\1BIFB)RSL\?=LQ133$8IB8_,5=<K[I._V'3]PU$B.J5N$IE#<8J1M*
M)"3G:[N)K2AZA@M=%\BPK+OI!;I6!L>KC;!Y_(53J5&B$QXA=IIT1$1&*HZ>
ME4YG_A=(^HX".C258R7=_<<*DC8]7&T#S^0J67J73-^TO;8>I!,;E0  $L ^
MO@8Y]Q KG##3C[R&6$*<=<4$H0D9*B>0 K9N-LG6U:$W&&_%4L$I#J-G:QSQ
M4:(:4>(7XISIB:8B*9VVQ'3/RM72+JB!J2WVEN VXPN/M!;:AP0,8 ![>52;
MVIM/:EMD).I%SX4^(CJ^LB$X6.&3P[\<NRJ' M-QN#:UV^#)DH0=E2F6RH ]
MQI.M-QM[:5SX$F*A1V4J=;*03W4TT]$_[WB9JJO54YBJ(SMM..BUV;4MJTYK
M%,NT(EO6M3 8=+ZB7%9.2H9^0X5.6;4NC;#J!Z;;69JS*2KK'5).&LG.RE)X
M\3Y5RNE3-N)5M>*7;72FG:<QMT_#+)6')3[B<[*W%*&>XDD5BI2K/.F<SDI2
ME2%*4H%*^FVUNN);:0MQQ1PE"!E2CX"ON1'?C+")+#S"R,A+J"DD=^#0Q.,L
M5*4H%*^D)4M:4(!4M1"4I'$DGD!6S<[;-M4@,7**Y&>*=L(7VI[ZA,4U3&J(
MVAJ4I2I04I2@4I66+'>ER&X\9M3K[B@E"$\U'NH1$S.(8J5M7"!+MLE4:X1U
MQY"0"4*YX/*OF/!F24%<6'*?0#@J::4H9[LBHRMHJSIQNUZ5D?8>CK")+#S*
MSR2Z@I)\ZQU*LQ,;24I2@4I2@4I2@5>-(:KM5KTO,L]WA/RFI+JEK"#@%) X
M?Z51Z5$Q$QB6W#\17P]>NWUZ;[KE,O\ IV++MTS3MH=C2XLA+RNL5P6D<TU-
M2];Z>3?V;]&M4IVYJ"4.=:O"6T\B4CM.*YG2J\N'53XG>HSIB(Z3TC:8]8^5
MV7>],72[7.1>[?*4F2\'676SA: $@;)QXC-?.L-7L7.):X%JCNHB6]8<2N0K
M:6LIY ^%4NE-$*5>(7:J:J=HU=9B-YWSU_+H.J]5:=U% $F5;9 O(9+2"%>H
MA1' Y[0#5%@NB/-C/+!*6G$K(',@&L'YTJ8IB(PSO\77?KBY7C/Q'7\NH7?7
M6E[I.:G3;'(DRF4[+9<(Q@'.".7.JOJ'6MQN]ZB3TI3&1"6%QF$G*4X(XGO)
MP/RJKU](0I9PA*E'N2"?Z5$44PVN^)<1>VF<9WVC&9^733K?34FY,WV9:)'I
MME(2 E64$CMS_P!\566K_;[KJ"X3]5052&9:0E"63@L8/#!^55I3+B4DJ;<
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M_H<BK?JPZZ;GW%=L,06A*24;6QM; 3ZWCWUANDB)>+MHS4++K*%;82^CK!E
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M[HXC@^'IBB*XB/XXB9C;,8_,_>R7T=9M-VW6RFK)<7W)T5I3;S+O$*SC)2K
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M&XB<AH8'/ /+(J4Z5[:S?66[[!N<)45B(1L[8*EG:R /.IPWV7?K-;Y&E[O
MC/MMA,F/) R#@=_$8X_.HS,4QAU5V+=SBKDUTQG$:?7,>LXS&?Z*0[T=O?;!
MFTLRLPG6MY3((];JP0",>UDCCXU;]"VK3L#5\I%@N3SLAAE33[#PSGB,J2K
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M]L.CU-X:2%/P):\@</[O)'^W9/Y5BTG>8>D^C^5+8?B/W:6L+3&4L$@9"0%
M<< 9-2&D-=,WU5QME_;M\",['.RM/J!6>!!R<9P<_E43G.J/1T<+%FBQ3PE=
M>)KB9G\STW],88NB!$MS25_1;7$MS%.X96KDE6QP)JN=(#&J(T*&C4T^/*96
MX2TEH@X4!S/ =E3'1VN QIK45IFW6+$6\\6D.J< R-G&T./$55]4V"):(;#L
M74+-U6M>P6V\90,?B_$:FG]4L;\U?["B(SM&^*HB(W]:?56:4I6SY\I2E I2
ME I2F<#)H+[T10&U7:;=Y '46QDKR>Q9!_[ UN:_?&I-$6?4J4)2\A:F7P.P
M$D?Z$#SK?L-SBZ,Z.6Y 1'ES9[@<7'4L<=KL(X\ D5MZ=U+#UC9KQ9YD.);!
MU.6PA8"5$Y&>0X@XK"9G.I]/9MVXX>.#FK%55,SC'K.\;]-HC&%:TUI"UKTG
MZ?OSLU;"U%*6H8VBD!6,G@3V&L]BT;8+U-G2;=<)S]HAM)4M(3AU2R"=D<.P
M =G.MCH]8OD"VLOVF[VY3"UJ$B#*7@-J"L$\^&<9_.IFY)3(U/)FZ,N]OB3&
M4)1*:40&I"LD@\.!(Y$U$U3F=RQPMF;5NJJW'IF/6=NL3G?O,*%>H>G6Y=M.
MGID_KURDMN,R$[*V>(];B!@Y(QSJ5Z0[+)=UQ;K9O[\I^2TA"7I)!V<J(QP
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MU$J?Q_>.)XD8&.X$\NZMNYZ5L\[3TN[:5DS%"'Q?9EIP2D#.1P'9QJP:)O\
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M2JSIBWRPSIW6#HN=PC@8(4P27$I\%X3GA5@_M //IA:/L,*&\_ N,_8?A17
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M8!UXXGPJU=+:S:%Z5UO 4E;EHDMM35MJ"MN&\ E>3W X-!='M36]K6$?3/\
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M+JA^) 3M-GQR215LZ!+>_ Z+;*Y-+AF3D&<^5G)VG3M#Y<"GA0=!I2E I2E
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M4M$[I GZPO&@#J:,AVV-HF+OHB)+ZVG!ZK8:_ #DY*O"IC2VHM0LVK7EEO\
M.9N%QL*,LSTLI1UJ%M%2=I'+(QQH.B6745LN^FXM^B2DIM<AL.H>>_NP$YQQ
MSRXU+)4%)!200>(([:\\ZVFWB]?V<++=/2;<5+[+6^,-14 2 IU(2!C&P!SX
M#CRJVV:[:ETKT@66SZGOB+K9KS%6B*^8B(_5R$84$>KSRG.*#K5*YW;M0W:]
M=,=PMEODA.G;+#2):4MA76R7,D)VN8V4X./"NB4"E*4"E*4"E*4"E*4'*[_@
M_P!HO30/'-DD</\ ^Y7+^G6T2=#LWZ(PTM6E=2NH>8",!$*<%A1&!R0L _\
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MJY2+7T3]$]X9FBVS8O4I9GN#:982IL;?6(YJ! ' 5Z.;@Q&X.Y(C,IA[!1U
M0 C9/,;/+'A7,=>:6ND;6-IU!9['#OUMB0U0_1#BPT&23D.M@@HS@;/+E01/
M1;<-.7S7KU\FZW@W_5&YF,RRPUN[;+ .TK92>)/:3GOJ5Z%$+OUZU;K9_);N
MLO=H!(Q_X1G@DCP423^5:,#2EZU/KNQ7NXZ:MVE[?:%J>ZMM:7)$E121LDH
M 1QKK\2*Q#CHCQ&6V&$#"6VTA*4_(#@*#S YI>[W;6.N;]8E[[,L%_,MFTNI
M!9DG'K9[=K PGN/SJP]*6K;3>+/HK6UDN MLQJ:6$SGD[3<,E)#K;R/Q'EC
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M:\6G0UFT7H^\2RU>)$1MAEK8*LK2D;0)' <3BK<C3UF;N&_HM,!,[:*MX$=
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MK23L.-I5P/ @'\Z[+2@X5J&/(U)T=:NC67H]D6)]R*AIDK0TAV02XDE(2GL
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M)4>K_P#5QKLE*#G?1?:9]NZ$;5:YL5QFX-VUQI3"QA04=K _U%4]C05ZO/\
M9XLED;CHC7Z X);4>6/5+B'5D)5X$*_UKNE*#C&G[@W+N4"&[T1NPY:G$I?D
MK:82RR1^)85S(&,CAW5UN[VR%>+:_ ND9N5#?3L.-.#*5#N-;E*"A_<]T?\
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M<DDU^4Q2@#G6^Q_@I^5: YUOL?X*?E0?=*4H%<VZ4?XN'_-'^TUTFN;=*/\
M%P_YH_VF@LND/X5/Y59*K>D/X5/Y59*"/M?\3._F#^E2%1]K_B9W\P?TJ0H0
M5\N_X2OE7U7R[_A*^5!'UROI9O.J;#)E(TAH>+=F9D4JDSPR"H+XC"@/QX&.
M==4[:XI=+;TY1I4J+:KS994!Q:^JD.[(=;0HG XC.0#B@^_[*K-E8T/<DV>:
M]*FJEA<\/-=66U[(V0$Y/J\^/^@KM%<XZ$.CEWH\L<]NX2VI=TN+P>D+:SL)
M '!(SQ)YDGQKH] I2E K\4E*DE*TI4D\PH9!_*OVOQ2DH2I;BDI0D%2E*. D
M#F2>P4'[6-YEI]&P^TVZC.=EQ 4/(U!V'6FFK_<G;?9;Y!F36\DLM.>L0.93
M[7Y5L7;4]BL^]>E;O#B*BH2X\EUT!2$J)"3CF<X/*@E@E*<;*$)P,#"0,#N^
M5.K;((ZMO!.2-D8)[_G5?7KC2Z-/IOBK] %J6OJTR.LX%?LXYY\,4N%_B3]#
M76\Z=N+,EM$-YQF2PH*"5I02/D1PX&@L*DI4,*2E0Y^L,T*4JQM)2K!R,C.#
MWUSO0O2':/LKI=C5&HH:-03HC;CB7G E:E*Y%6."<\.>*O5UN4&T079MUF,0
MX;8]9YY82D?GVT&P\TV^V6WVFW6S_E<2%#R-?02E* @(2$ 8"0D 8[L5%:6U
M/8M4-J=L%TBSVVU;+@:7Q3\P>.*H_1SJ&]7CH\U5/EW5D7*+.FLQI<M(ZJ.E
M'X"L ?A30=-  3LA*0G&-D#ACY5^%""V6RA!;(P4%(V<=V.55>/JJ!9-'6FX
MZOO]K#K[2=J6T=EJ0O&26T\R/RJ1M>J+%=+._=;==HDFW, EY]M>4M <]KN_
M.@E6V6FFTH:9:0A'%*4H "?D.ROM*4A95L@$\U <35=7KG2J+O'M:M06[?WP
MDMM=:..T,CCR!/#@:R'6FF4ZA-B5?8 NX.R8W6C.UC\.>6?#.:"KL:<U1J+6
MUJO&L#;(EKLJUNQ($):G.O>.0EU9.,8'971^9XT^=*!2E*"OZ_TX-6Z-NMCZ
M_=URV@&WB,A"P0I)([1D<:I<+I!O.D#!M72+85Q(VTB,W>X2NLB.*Y)*D\T9
MQ5_U-Z;]#NJTON)NB2%-HFYZI8!XI)'$9';7.-06'I"UW;TV/4<2Q66S+>;=
MENQI"GW74H4#L('^7)[?"@F+G/F(_M 6BWHEO" NPN.JCA9ZM2PLX5CD3XU^
MZDG2V^F2RP6Y+R83MBDN.,)60A:@K 44\B?&OG7.F-1)UO9]6:-3;Y$B%"7;
MWH$QPMAQLDD%*^PC/^E:-ITMK2;TAQ=4:G<M2&TVYZ&F'%63NP5C9&2/7).2
M3V4%4Z'="2-2]'D:7)U+>H"2Z^B$S D%IN/AP^N0/QJ*N)S\JDK9J;5]_P"@
MNXOVUR1(U);YRK>](B)'7NMMK 6ML<NL*3_6MC1^G^DS1&F6[/9X^G[BVI;C
MJ%O2%(5$6M1)![%I',8':15ETWI2^:'Z/$6W3#T&X7\R3+DKF$H:?6LY<"2.
M*>S!\*"KZ'DZ:8$J\V+5NH),ZWQ'9$JS7*8K;<*4*.%MK[B,Y&>=4B%J!F_:
M:7?;CK+4\35<EM4AA$-MW=8QXE#00!LJ&, GQKHRM':DU=K"UWC6%NM%IC6]
MMU"DPGBZ_,#B-@H4KL0!_6FG+5TDZ(M:-/V*-8[S:(JE)A2I,A3#C;9.0EQ(
MYXSS%!$ZBU3<[]8.CP76=)T[;+TI2;M+:5U*DJ2,!!7PZL+4/#G7[H^U1OOA
M%OLFI[Q>++!AIF.!-Q4XU'?V\!M9R0L*''9[*W.D\WG4-UTMHYI$*7J$(%VF
M(?'_ +.6A!*<+2?65QY ?,UL6>[W_0VJ[%8K_8]-QH%^?++"K(E390ZD9RM*
MN8X\_&@C],V2XZXU3K6-=M27ABTV^[.-1HL.06B%* ))4.)2!R3R&36GT9:>
MN^O;)<E:AUA?2W;)[UKB[K(+)/5G_%<(XJ5QQSY"NB]'NFIVGKUJZ5<"P6KI
M=%3(_5+VCU9&/6X<#X5CZ(M,3])6B\1;L6"Y+N\B<WU*]H=6L@C/#GPY4'/4
M](5YA=!ZI3\M:[R+BJRMW C:6/7V>N(_S*"<_G4(_J!G3<VSW#26I=47FX[V
MTU<(MP;=4U+:4<+5A0P@CF,=]7BW]&$YSHSN6G[A(8C715R=N4&2THK2TYUF
MVVH\./<1XU-6>;TJ&7$BW2!IM#"%I$F>B0M76(!]8H;')1&>'*@J>BM/W+6M
MVU>B[ZFO;5J@7IZ-&C1)):RK@2HJ'$@9 ">0XUDTJ_<[MHCI#TW=KQ/D&P2G
MXC,]+FP^ZTE!4$J5S[,'O!J\=&>G)VFE:E-Q+)%PO#LYCJE[7]VH #:[CPY5
M'Z/T9/MLGI"%Q6REC4,]U^.II6TI+:T%.5#' \>5!!] &GV(6@;+J!=UN(Z^
MWJ"V'I1W5A.TK*DH/!.,9S\ZH>L;S:K+89-ZTQKS4]VO\4AU$E2G5Q7O6P4*
M&-C9QPJ[:?T3K#[OYF@KTBULVIN"[&C7..^HK<4591M(QP'$YK4ONE>DG4'1
MXYI!R)IVU0FXZ65.,OJ49.Q@I2D8]0*(!)/'SH)C1$E4SIKU))6D)4]8H3A
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M5P2MM@25#:S(=5Z[Q[5'GCY"J%*O\?3KMMN>EM4:HNUU;DM)G1YS3RF9J%*
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MR7IG1MI>1*SUSEN9*B>W"<9\@*HSNF>D>=IIO1<YRR)L@;3$=NZ'5%]<9)'
M-^V4C9[JNTR%J.W7?3$'3 @)TO%;ZB>E_B]L) "-GQP#R[>=!DUA>-56QQM.
ME],,WE"FRIQQ<T,;"\\!LXRKA51Z E1WHVJ9+[SWVBDW(O7:*ZSU6ZNE/!"1
MVIYX5VU+W65TEQ+E+1;;3IVYP%.$QW5RE,K2@\DK3VD=XK8Z-=(W"P/WV[Z@
ME1Y-^OCZ7Y.[ ]4RE(PEM&>)QWT$%TC(N]PZ3](V6UWR9:8TV-)WE49>"I"=
MDG'8%=@5V9JO2K'=K7TGPM$V[5E\:L5U@JGO]8^7'T=62"EMP\4[6!DCQKHM
MYTY.F=)>F;^R6=PMT>0T^%*PO+@&S@=O*L%QTO<)/2_9]3MECT;$M;T-P%?]
MYUBE$C"<<1QYYH*[I-%PTGTCWO3;%TN-WM[EI3<8K,UXNJ9="E#9"CQ(./\
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MQ,FZVWIU%HBA]JTV5ITC;<1D;<@ _B) P@\LUS"3+1<.B:;JJ1KJZ)UL=O\
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MBDI_\8.K!'6<.P>J,=E6JUV75=RZ3[1J>\6^';;5&B/QFX3;Z7'6-I(PI9'
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MU9IJ):[M)C65$-RV7(8;4DG:VFUG@E?_ &J<DZ@M][Z+==(C6(6"ZPXRV[C
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MDB#*MSB6UO!@*0XRE6/6&<A6,\14DJ_QH+UT7<)[*F&7D--MH;5MI44Y"/\
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M&>/RJ+FZG?5HZ/=(89;E..H86ET$I;7M;*LC.>!S06^E0]A7<EK>](S8$E(
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MH.?7"R3YQUFTVRL&2['6P5'9#H0 2 ?RQ\\5&W2$;G;+@J-#U$Y<$QBA._\
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MQCB<X_[UM7"SS9,QQYF]2H[:L8:0VV0GAXI)J;K#,D(B1'Y+V>K9;4XK R<
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M8FS5Q)5K=>6EQ]2CUB3^($G()[:L6@834/3$%UMQY1>CMN+#CA6$G9'+/(>
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(.!7U2E!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g50309g12m03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g12m03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1CN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &-$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"C_P  1" *$!V0# 2(  A$! Q$!_\0 '  !  $% 0$
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MBG6SYGXK%')$5E=;/F?BJ=;_ ,GXK&[%15&5UO\ R?BG6_\ )^*Q40976_\
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M35MKK(HW-J-^ V/#<$'U9^U9?1;U75&G**GNLS&RZ4K15-<_!VH,$X]&1S\
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MSC,54_=-(>T]@'9]B[OW";Y]*4/[COS3W";Y]*4/[COS3Q,?NGA9_:4<.O\
M<7:=@L1F;[&03=8CCV!D/X\=KGVG@NNT7K&*;7,E\U;5[%9U4PTU6V'+(9,
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M1B&*3=-P&@$ 8Y'@5WGN$WSZ4H?W'?FGN$WSZ4H?W'?FD7Q1[$XL\]XG^?\
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MV_U*K>E:PEP!BKVCO,3>'^Y!WZ+ LEXH+W2=9ME0V>+.#@$%I[B#Q"ST!$1
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MG+3XH,"LL=RHQ1&II'L%: ZGX@[P''+'I"MU]IKJ"Y"WU5.YE:2T"($.))Y
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M&CF25]34</5Z2"'.UNV-9GOP,(+J(B B(@(B("(B O,LC8HGR2.#6,:7.)[
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M"23DG)1$!"<XV@#L\LC.$118"23DG)50XCD<>A41 '-5)RJ!50!P7K:." <
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MF-PZHE=$)!"W'[+>&3V$CBK'17-8.C&TW>XT=+75U?-2NK:^..0.92P-)W3
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M#J.%@/[3IV8'J*GY$'!Z"T!%8)A77"1M1<0"&;&=B,'N[SX^*[Q$0$1$!$1
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MJPME9J]EUM%'<(6.CCJHQ(UCSDM&3P/J7&6(YL?2&3S-74?\'+H]!?J38O\
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MRSU%(^6-W'.T]D9R!P]\.16*Q&XU+=IGEG<(@DUG<-%V4U5M<*B:GE&;+'1
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MLN[0ULU,UMMJHZ:</!+I(MX'-XY&,CPXK$L-F-MI*L35!GJZR5TT\NR&@N(
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M'5JU2?XGI5U6J3_$]*"^B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MD=4M\BF/#_,[L/JXKJT12M>5VSY[9[<UA<C7V4F^,AB:13S_ *3(_9'[0_\
M/>NN1)K$K@XBV"9FOJI&QL;&L8,-:  .X*J(JX.;U9;G2%E7 TN?PC>!V]Q6
MYM5&VAH8X1[[&7GO=VK,5%(K$3MWOQ%K8XQ3V@5BNI65E)+!)[UXQGN/85?1
M5QK::SN'+Z8M;F5DT]2W!@<8V^+NT_\ GO74(BE8Y8TZY\]L]^>PB(JXB(B
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MP.!([#Q6RGK::GH363S,BI0P/,C^ #3R*B^OJQ5UEZ;BY#3LU2VHFW%('DN
M!?EY(+<$<>!QA2#J+J=?INH=4PU%90SL8_8I@3(YI(+2T=XX%4T]4VHK34TU
M140UC3# 6ME<YCF[!<<-R".TJ_<;M16[>BJG:V2.%TY9QR6-YG\0N+)O%TT[
M>J<-K:NCB,+Z1U7$(IW[+PYS<<-K@.9 R5EOGGO^H'U%);ZV& VV>!LE3'N\
MR.Q@8/+TJ&FXI-76B>V0ULE4(FR8;L;+G.#L9+< <<#M'!953J*T4U#3U<UP
MA%/49W+AEQDQSP!QX=O<N.@N]Q;1VJE,%YI*"GIQ#4.IZ4&9TP PT$Y\GAS
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MF6\U[!5[%@K9-S4"&/#P-\TY_2#AP Q^*CRS]*EWL%T@L72E8IZ"XRD-BN%
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M?J1_R18250?%6>A$H/BK/0B(Q;C\:=Z L99-Q^-.] 6,HHJCDJ*HY*PBJ(B
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ME-;;5<:)M+''+'52$$2-&#V$$<%<T99IK'9WTU2^(R23OGW<.3'"'8Q&W/'
MP@Y:&X6VAUMJL7*U3UY?41EABHA4;'D<<YY9_P"BZ*ZW".&QT=30W"ET]1R.
M.34TS0]K>YL?##LK(L=LJ:'4.HJZ4L$-?/')#LNR<-:0<CLXK"U/9:^JU#;+
MQ014=;U2)T3J2K<0TDDG;!P1GC^"#56C64\=#J5]15PW:*UQLEIZF.+=;[:X
M!KA];'XK=6:DU14P4U75WVGADJ(]IU*VA:6P[0RW!SQ(X+74NE*ZL?J0WF2E
MC]EZ>-C>K9V87-Y#'#(&&\>U;33_ +9J4T=)<8+8^G@ 9)5ME>7R- P"&XX$
M^*#D-+W&YV/H\?>Q7,J8&RR,9120#RI728#C)G.,G./L6]N=;J+3E+1W*Y7&
M"X4KY8XZRF%,(]SM</(<#DX*Q*/2EX]K=5IBK=1>QSGOEAKF/=O&NVMIN68[
M^:S:VTZBOT-';[U['T]##*R2IF@D<]]2&=@;CR<\_P#SA!ZM53J.]72ZQQW&
M"AMU!6R0,D;3![YL'WAR>  [?%;K65J-[TS<:"-IWLD>W"!S$C3M-Q]HQ]J:
M:M\]O%VZR& U5PEJHPPY\AV,9\>"W()!!',**CJ\7Q]]T58:"!V:Z]2,I)AV
MMV"-Z3ZA]A6ST1#'3ZPUE!"T,BBD@C8T<@!&X#^2\6#2$MNUG77*9['6YKI)
M:&('X-\A\OAV8 QZEM;!:JFAU+J6OGV-Q<)8WP[+LG#6D'([.:J,+HL_42W?
M6E_^HY=6M'HBUU%FTQ24%;L=8B+R[8=D<7DCCZ"MXH"(B B(@]#DB#DB*=BH
MJ]BHK""(B O;>2\+VWD@JB(H#?A!]BV*US?A!]BV*H(B("M2>_5U6I/?I"2\
M(B*H(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B A (((!!X$'M18EWN--:;=/75S]B"%NTX]I[@/$H
MEK16)F>T.<TKH>CT_?:^X1.VQ(=FF:1\$P\7#TYX#P77*':GI:N#JG:I;;2L
MIP>#)'%SB/$A2%HK5%-JB@?+#&8:F$ALT).=DGD0>T'CZENU;=Y?,X'C.#M/
M@<-.N\ZUIT.2.U%H-;ZHH](V-]QKV/DRX1Q0L(#I7G.!QY#AQ/8H:;TYWKKF
M\=:Z#JWR(+LX^MW_ &*TQ6O&X>^^>F.=6E]"+57FQTUTEAG?+4TU5$"UD]+*
M8WAIYC(YA6-&ZDH]5V.&Y6_::'>3+$XY=$\<VGUCCW%;6OJH:"BGJZN014\#
M#)(]W(- R5B8F)U+I$Q,;ACV:U4UHIGQ4@D)D>9)))7E[Y'=[G'B5GJ ;OTY
MW&2L=[#VRFAI ?)ZP2Y[QWG& /0I%Z,>D&GUI#40R4XI+E3 .?$';37M/#:;
MVXSP(/>%NV*U8W,.5.(I>W+$MM4Z0M\\TY,U?'33O,DM+'4N9"YQY^2.]=#&
MUL;&LC :QH#6@<  .05*B5E/!+/.X1PQ-+WO=R:T#)/J4#WWISK7UCVV*VT\
M=(TX:^IRY[QWX'  ]RE,<W_*UDRUQ_FE/>4RH^Z,>DB#63YJ.JIFT5SB;M[#
M7Y9,WM+<\1CM"D'![BI:LUG4M4O%XYJF3WE,GO6#>;G2V>V3U]>\LIX0"X@9
M)R< #QRM+#K2A?::RXS4=QIX*5K'.$T&R7!YPTMXX*FG.^?'2W+:VIUO]G49
M3*T%QU7;Z":**9E2Z26F-6P,CVLL SCGS6NT_K:.XV"2X5%NK6/BQML@A+P[
M+B!L']KLSW)J>[,\5BB_)-NO7Z.MEC;-$^*5H?&]I:YIX@@\PN?I='VV"2',
MM=-3P/#X:6:H<^&,CEAI[O%+;K"V5M)<)Y144;J!H=4Q5,>R]@/+@M/<];PU
MNG[C/;>OVY\+&O;534NTTM+@ 6@G!SE.66;<9AK7FBV^DS_'WZNTKJ2"NIGT
M]9$R:%Q!+7#(R#D%7\G&,E<I<-:V^URLHZEE94UHIF3D00YW@(Y@9X=Y[E:I
M^D.R5$])''UO=U#@P3&'$;'G]EQSS]&4Y9)XW!$\LWC;L 2.15BFI8*9TSH(
MFL=,_>2. XO=C&2N6;J-E%J/4?LC<B:"@CC.X,(&Z)[G<W$_]5EV;6%)=;JR
MW1T-R@JGLWFS/"&AK.QQ.> /#UII:\7BF>69U.]?Q.O[.D1:34.HX;'*QDU#
M<*G+-XYU-!MM8W/$N/8K%;K.ST=%;ZN265U/7,<Z!S(\YV>;2._/#'>FI:MQ
M.*LS%K1&N[HD7'3](5K@8=Y27+?"-LSH1!ES6'M/'ACQ5^@UW:*ZY4E'"*H=
M:.S#.^+9C>[S0<\^STIJ6(XW!,\O/&W5(B*/4(B(,@(@11H1$0<YKS]6KE_I
M-_YA8NB/BC/JA96O/U:N7^DW_F%BZ(^*,^J$'5JU2?XGI5U6J3_$]*"^B(@+
M'N-7'04-15S-D=% QTCQ&TN=@#)P!SY+(6'>+C26FVSUUPDW=+"W:>[!.!Z
MD)/2$+P34D,EQKK-TE6ZAH:NJ=4FGZNW::YW/R7.VL\.Y3+8KK37JUPU]"7N
MI9LF-[V%A> 2,X/'!QP4?2:NZ,YJK?R16Y]03\(Z@RXGT[*D]C6M8 P - X
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M&_"#[%L5KF_"#[%L501$0%:D]^KJM2>_2$EX1$501$0$1$!$1 1$0$1$!$1
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M4[-ES21D<B1V'M70+D= :*BT@;@]E;)5RUIC,A,38V@L!'!K1@<UURYVUO\
M#V=:<TU_%W>)_@)/JE<M=J^.UVBMN$X+HJ6%TK@.9P.7V\EU,_P$GU2N:K:6
M&NH:BDJF"2GGC,<C3VM(P5K&YY4)T73-=_91KZRAHC;G/ ="QI#V,SS#\Y)
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MV._/XK!G;)IFHL^IJ?:-MGI((+I&,\!LM#9L=X.!_P#=:T'/0H2PCC+D'_\
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MO=FW:71:WL U/INHMAF$,CG-EBD(R&O;RR.T<2/M4=Z.Z)JVBO<57?ZBF--
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MMS6';!(SL/=V8[<*;R<G*$Y))[45O>U_S)CQ5QQJL"(BPZ"(B B(@(B("(B
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M(TM=Q&>(P>!!02 BXJ#5MZK*.XU5OL5/)!022-EDDJ"-X&<]@=X'$Y5'ZTN
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M5!$1 1$0$1$!$1 5<JB(*JB(@(B("KD]ZHB"N3WE41$!$1 51PY*B(*Y5$1
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M?J1_R18250?%6>A$H/BK/0B(Q;C\:=Z L99-Q^-.] 6,HHJCDJ*HY*PBJ(B
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M"QE%%4<E15')6$51$0$1%%@1$0 M?J3]6[O_ /)R_P# K8!8MXIY*NS7"F@
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M?%&?5"RM>?JU<O\ 2;_S"Q=$?%&?5"#JU:I/\3TJZK5)_B>E!?1$0$1$!$1
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MQ4M&YC'D;)+W;;_): .T]N%A]%U!%66VAO-)?M4SP-$E.Z@NLS'!CV.,;FO
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M5SH[U7T1=^CFA$@'^9IQ_)Q4S("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MAZ>*CM$'U=%(R6-LD3FO8X!S7-.00>T+TN%Z';FZMTMU:5VT^C>8Q]0\6_\
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M(9K;M/< \8X!NSC9R.''@NGI[5%<M9:TM]2W]#/1TT0<1D [L '[#Q^Q=O\
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MJ@N];;97MA>ZV3[B.5S6X>'Y'E')[/\ J@[[2=RJKQ8J:XUD,$)J 7QLA<2
MS...>W(*VX6GTE<**X6.'V,@?304IZJ:=XPZ%S>;3W^E;@(*HB("(B"H50J!
M5"BJHB(@%54"JBB(B"B(B((B("(B#T.2(.2(IV*BKV*BL((B("]MY+PO;>2"
MJ(B@-^$'V+8K7-^$'V+8J@B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB M)J;2]LU%"UMQA)E8,1S,.R]GH/_0Y6[1!#U=T1U8E/4;E Z// 3,((]6<
MK&]R2[_/Z'_?^2FI$$*^Y)=_G]#_ +_R3W)+O\_H?]_Y*:D00K[DEW^?T/\
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M/.QT%=@ 5$9P3CEM#D5U"((9GZ([DV0BGN5(^/L+VN:?4,JW[DEW^?T/^_\
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MJ@^*L]")0?%6>A$1BW'XT[T!8RR;C\:=Z L9115')451R5A%41$!$118$1$
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MDOX%SCQ!)4UQ2,E8'Q/:]AY.:<@K3U>GK0()Y/8ZFV]ESL[ Y\5;T)^J=O\
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M"-;::N#JR#V/DI:AK:ESP(W'B/?'@K&C[G0VJ\:E9=:RGI:BHJQ5133/#1-
M1Y):3S'@.]=;-;**II8Z2:AII::/WD+HFN:WT#& O-5:Z"K9"VKH:6=L(V8Q
M)"UVP.X9' >"",ZE@ET'?*AD;HZ"LO.]IFD8!C+P,@=Q4M&-D)W,36LBC\EC
M&C :!P  5J:FCEB$4T#'Q-QACF M&.7#EP[%<.<^5G)X\4' =(554:<OE-J&
MC:XBHI)*&79'[>"8R?MQ^ZK%VM@L^G=#TCF@3BY0OF.,%TCO*=GQXX^Q2%/#
M%/&&3Q1RL#@X->T.&1R.#VI-#%.6&>*.4L=MLVVAVR[O&>1\4',N_P#C ?\
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MPOXG'&1>.74Q^_\ AM44<TU1=JS1>^=<*^:N@J*AI--)'$^4-<0"=H8V1@<
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MC$[*NFCDH6>0,8<_D<8/IRIO4*:^@U%3Z^JJNGM=YN-*]A93=5D.Y8UT!9C
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ML.HB(@(B("(B B(@(B("(B#G->?JU<O])O\ S"Q=$?%&?5"RM>?JU<O])O\
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M!9J(,*VVJBMK7MH8&Q!X:TX).0T8 XJ[0T<%!3[BDC$<0<7!H)(!)R?Q60B
MB(@(B("(B B(@+BNF9H?T;WAI87Y$6!G SO68SX=_@NU6AUS"RHTO6Q2VF2\
M,=L9HHW;+I/+';X<_L6J3JT2Q>-UF''=%-MJ:.\5,D]DTY0,=38$MLF#WN\I
MO ^4?)[?2 L#IBU$ZFN#+/<Z"KZ@YT$]+6T@=O(I X@N:>1<.QO;E9G1DZUT
MNK*NA@TG+8+AU/>;4LNT9&;;1@#TXY=RZK55HOU16QUVG;K##(U@8ZCJXMY
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M3+OBIX=(J@[W4.E6B?LW+HPEF:SWSZ5TG'T8R%0_VA9J:5L=WT#J*B/[6,N
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M;[^$2G 'Z0 _;Z?%;!GO&^A>E].:5F=S#XE,EZQJ)2Q_9O?LZNN;CQ_N!_\
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M?@Y=^K7_ )>?6OPI^LWPDOH"VJX_0^K+%J"LJ8++<HZN:.,/>UK'MPW.,^4
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M#N/$MPH$W;_DY?NW?DNW#VB*]9?6XRMK7C4>CRIQ_LV_$M0_ZD'\I%"&[?\
M)R_=N_)2QT&ZDM.GJ6],O56:1T[XC&'PR':#0_/)I[PM9K1-)U+GPU+1DB9A
M/2V2X#W1M)_3+/X>;^A=^#D CD5X'U1$1 1$0>9?@W>A15=?U_J?J1_R4JR_
M!N]"BJZ_K_4_4C_DBPDJ@^*L]")0?%6>A$1BW'XT[T!8RR;C\:=Z L9115')
M451R5A%41$!$118$1$ *JH%5 1$0%4<E15') 1$0%4*BJ$@51$500(@051$0
M$1$%0JA4"J%%51$1 *JH%5%$1$%$1$01$0$1$'H<D0<D13L5%7L5%801$0%[
M;R7A>V\D%41% ;\(/L6Q6N;\(/L6Q5!$1 1$0$1$!1WTA66]0ZPL.K=.6Z.Z
MU%OAFI9Z%TXA=)')@AS''@"".1Y@J1$01UI:@U-IS2%SKQ:Z6LU'=+D^X34+
M:C8CBWCF@L$A''98T=G$A:S5MHU;;-1ZIETU9Z:Z4>I*>)IEDJA$:.9D>ZVG
M CRF;(!X<>"EA$'&0:6FM?1$_2]$6SU45H?1L/O1)(8BW/AEQ_%;C0U!46O1
MEBH*Y@954M###*T'(:]K ",]O$+=H@YZMT5IVNJ9IZNTT\TLSBZ0NR=HGGD9
MPMXRFA8P,9$QK ,!H&!A7406Q3Q#E&T>@85!3PCE&T'P&%=1!:%/"#D1M![\
M)U>'.=VW/?A7406C3PDY,;2>\A5-/$><;3Z1E7$06S3Q'G&T^D)U>+&-VW'=
MA7$06^KQ8QNVX[L<$%/$!@1M [L*XB"V*>(<HVCT!4%/$.4;1Z!A7406Q3Q
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MG0EY<' /\1C@MA>9:G35;?*6SS5+HFVYE0ULTAE+'F38<\$\O)R4$@[):!M
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M!' A;]8M72-F\IN&O_F@U*J.2]R121G#VD>/8O Y(*HB("(BBP(B( 550*J
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D:$W$?FA$0-Q'YH3<1^:$1 $,8Y-"N,8T#D$1![1$0$1$'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g50309g13m04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g13m04.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1@&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %^D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*/_  !$( AT#O@,!(@ "$0$#$0'_Q  <  $  @(# 0
M    !@<#!0($" '_Q !.$  ! P, ! @*!P8% P0# 0$  0(#! 41!A(A,1,6
M05%2<9&2!Q05%R(T4U1583)S@9.QT=(C-D*4H>$D,U9RP0AB\$."HO$E-6-T
MPO_$ !L! 0 # 0$! 0             ! @0#!08'_\0 ,Q$!  $# P,"! 0&
M P$!      $" Q$2%%$$$R$Q02)28:$%,G&Q!H&1P='P(T+QX7+_V@ , P$
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MJ^I#.
M
M                                      ,-7$V6![7MUFJBHJ<Z<IF"
MIE%0"(:/5BTMQJK?([;"_5;GE;O3^BH2]%RA7=YE\5TV]%<<)$Q5^S83^E=K
MPHH'%OK3NHSF!GK3NHS@
M
M        .M<JZFMM#/65\S8*:%NO)([<U .R:&]Z8:/V15;<KO1PR(N%CX5%
M>G_M1<E >$/PK732*6:CM$DE!:,JU$;Z,LR<[G;VI\D^TK7&U5WJN]5WJ:J.
MFSYJEAN=;$3BB,O5OG9T-^,-^[=^0\[.AOQAOW;OR/*8.FVH<M[<XAZL\[.A
MOQAOW;OR'G9T-^,-^[=^1Y3 VU)O;G$/5GG9T-^,-^[=^0\[.AOQAOW;OR/*
M8&VI-[<XAZL\[.AOQAOW;OR'G9T-^,-^[=^1Y3 VU)O;G$/5GG9T-^,-^[=^
M0\[.AOQAOW;OR/*8&VI-[<XAZL\[.AOQAOW;OR'G9T-^,-^[=^1Y3 VU)O;G
M$/5GG9T-^,-^[=^0\[.AOQAOW;OR/*8&VI-[<XAZL\[.AOQAOW;OR'G9T-^,
M-^[=^1Y3 VU)O;G$/5GG9T-^,-^[=^0\[.AOQAOW;OR/*8&VI-[<XAZL\[.A
MOQAOW;OR'G9T-^,-^[=^1Y3 VU)O;G$/5GG9T-^,-^[=^0\[.AOQAOW;OR/*
M8&VI-[<XAZL\[.AOQAOW;OR'G9T-^,-^[=^1Y3 VU)O;G$/5B>%G0U5__<,^
M[=^1O[)I78KWA+7=:.=Z[HVRIK]W.3QH$V.1S55')N<BX5.I2)Z:GVE,=;7[
MP]S \U^#CPMU]DEAH=(9'UMJV,254S+ F=^=[DZ]OX'H^DJ8:RFBJ*65LL$K
M4>Q[5RCD7<J&:Y;FB?+;:O4W8S#* #FZ@  K'2Q<:<0?4M_$L2VKFE;U%=:6
M_OQ!]2W\2Q;;ZJWJ YL]:=U&<P,]:=U&<
M
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MCE39G81DM$Q/F%)IFF<2%W_].NE<G#S:,U;\Q:KIZ17+M3=K,3Y?Q=I2!O=
M[@^UZ9V:KC>K5;4M8Y4Z+O15.Q2MRG53,.EFN:*XE[) 3:@/,>T  "L-+?WX
M@^I;^)8MM]5;U%=:6_OQ!]2W\2Q;;ZJWJ YL]:=U&<P,]:=U&<
M
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M78[QR%T3?07@M1NIZ6W;OR13R_2<3K]:M6;QFNKVU42ZJ:J,3/TESL7;S$8
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M>M.ZC.8&>M.ZC.
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M;ZJWJ YL]:=U&<P,]:=U&<
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MBD" V]!N[GT3WC3;>G)W%'&FV].3N*0(#;T&[N?1/>--MZ<G<4<:;;TY.XI
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MEOXEBVWU5O4!S9ZT[J,Y@9ZT[J,X
M                                   "">&BH=#H3(QJXX:HCC7YIE5_
MX)V0'PVQ*_0Q'HF>#JHW+U;4_P"2U'YH8OQ+.TN8XE1(<F6J@!L?G"Q:R]Z(
MW6V6:.[NN;I*"!(UBAC1&O7"915YMGR,MOT_I*J\W2>Y,EH63TS::DF@8DCZ
M=K=;^JZV?L0K7<A,;5H'4U]+3N\J6V&KJ8^%@I72Y?(W&>0Y333$>7LV.MZJ
M]7FS3&8QGQZ^,1GS_1ETOT@I;W9K/;K5)7U-51S.5)*AN9)-FQVSESR<B&^\
M)=VD31*W4]3!XM=+DC)JQFYV&)LS]J)V$=T?T/NC5972W"FLTK)UAIGU#\.D
MD15:J-^U%0T.DT5S@O=3#?9)9+A&J->Z1VME,;%1>; BF,XCV6N=1U%%FNN[
M3,37B/IB/OG&?Y-6 #J\5:G@'JG>-W>D7Z*M9*G7M1?^"X"FO /"Y;I=I\+J
M-B8S/S554N5RHUJJY<(FU5,MS\TOO?P.9GHJ,_7]Y#X]S6,5SU1K43*JO(1B
MZZ6L2VI5:/TSKPJ5'B[VP*N6+S[LK_<R>2+C67NNFKJU)++54W!-HG-PYBJB
M97FSOV[=_P CF]9FN>E5OH:FUQ+PD[;@_4BEA1',WXRJY^:&N?:[U?H;W07]
MT=/0R/1*.6F=AVJB\J9Y4QO^9O[+9Z*S6^&CH8M6&'.KK+K+E=ZY^9L -=06
M:CHV4N(^&GIHDA9/*B.DU4^>#8@          #36K2:U7.IEIH*MC:N)[F/@
MD75>BHN-B+O^P#<@    !IM*;FZWV_$*HD\JZK/DG*IN2 :8SK->GLSED+$8
MG7O7\3K9IU5>7#J*]%'AHSZ ;GE@       /AMTL<KF4^*NF26=B/CB<Y4<Y
M%Y-QJ%W*2B>"*H=:*AU93Q14\+.$R]-9%3"X1.<I7,PZ6Z8JSE'FTE0ZHD@;
M#(Z:-51S&IE4.,4$TLJQ11/?*G\"-RI(6U:5L5R2@J&TU3)4(]KG.U%>Q$QO
M_J95K$6]U3J58)V.B9'*JR\&KUVY5KOD5USPOVJ>492GF6?@$BD6;=J:OI=A
MPF8^%[V2L<Q[=[7)A4)1234D-RN<3:E9WR1M2.22755<9RW7Y.3::O26=9GP
M(YD;7,BU?0EX5?EE><M37,SC"M5N(ISETZ^C?12QLD<UROC21-7F7_Z,2T\R
M4Z3K%(D*_P :M]'M-Y>Z3QM8:B*HIE8R!J.:LB:RXRJI@V-QKHGP324S89*:
M2GU%UJC&$QNX/G*]R<0MVHS/G"(K#*CVL6-^N[:UN-J]1R;2SNC?(V"18V+A
MSD:N$)!;ZV!;5'62R-2MHHGQ,:J[79^BO_GS.U05K$H*%]/P3W1,5LC9*G@]
M5>55;RY$W)CV*;5,^Z.)19M'CW"?^KP6IC^N3G06U:MC%\:IXG2.U(V/=Z3E
MZN0["RL71AS$<Q'K5J[41=J)U<QFL5'''!X\LM,ZIW0QR2(U&+TE_(F:IB)1
M31$S$?1I9X7P3R0RIB1BZKD^9P,M8DC:J5)I$EDUO2>BY1R\^3$=(]'&?4
M     !\ZR<:&W-:FE=23.59H4V*O\3>0A!L='*A:6]4STW.7@UZE_O@YW:=5
M,NMBO17"R0 8'K   K#2W]^(/J6_B6+;?56]176EO[\0?4M_$L6V^JMZ@.;/
M6G=1G,#/6G=1G
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M6L;Z2_Q<_4>A#XUJ-3#41$YD T^BEMN-KMW W:Z/N,VQ4>YN-1.;.]W6IN0
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MMM]5;U <V>M.ZC.8&>M.ZC.
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M2Q;;ZJWJ*ZTM_?B#ZEOXEBVWU5O4!S9ZT[J,Y@9ZT[J,X
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MBIF8U&+RYYM^Q?EMVDHI[C333MI^&C95\&V1U.YR<(U%3E0#M@
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MI;^_$'U+?Q+%MOJK>H#FSUIW49S SUIW49P
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M;ZJWJ*ZTM_?B#ZEOXEBVWU5O4!S9ZT[J,Y@9ZT[J,X
M                                                       T]]NZ
M4;5A@5'5#DW\C/FOS/E]O#:)JPP.:M2J?8Q.=?G\B(N<KG*YSE<YRY55WJH$
MBL-Z762GK7YS]"1R\O,I)2MR16"]:JMI:Q^4W,D5?Z*!)@
M         1K3;1>32>F@I_*+Z2"-RN<QL:.UUY%7:F[;VD9M7@PFM-Q@K:&^
MO;-"Y'-S3['<Z+Z6Y2RP 3=M   KVME6>KGE7>YZJ6$5U*U62O:N]'*G]0.
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MOQ!]2W\2Q;;ZJWJ*ZTM_?B#ZEOXEBVWU5O4!S9ZT[J,Y@9ZT[J,X
M
M    &)U- YRN=#$JKM558FT@-4B)53HB81)';$ZU+#*]J_6Y_K'?BH&%=RD[
MH*6!U% KH(E56)E58G,01=RE@V[U&G^K;^ &=$PF$W
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MO45UI;^_$'U+?Q+%MOJK>H#FSUIW49S SUIW49P
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M  XM(             Z-RME/7M_:)JRHF&R)O3\R-55AK(,JQK9F<[-_83,
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M+?Q+%MOJK>H#FSUIW49S SUIW49P
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M-OK(:NAG?!50NUHY&+A6K_YR&  >OO!QI9%IAHW%7M:V.I8O!5$2+G4D3?\
M8N]/DI*#S9_T[WJ2BTPEM:N7@+A$JZO)KL151>S6/29YUVC15B'L]/<[E&9]
M0 ')V
M 5AI;^_$'U+?Q+%MOJK>HKK2W]^(/J6_B6+;?56]0'-GK3NHSF!GK3NHS@
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M11\$S]0 &=L
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M&\L;,>@Q?FF55?FI8@!YU54U3F7LT4113%,  *K
M                                   *PTM_?B#ZEOXEBVWU5O45UI;^
M_$'U+?Q+%MOJK>H#FSUIW49S SUIW49P                   '4N5SHK7
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M79K9UF]O(2-CVO:CF.1S5W*BY13-735$_$UVZZ*H^!] !5T
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M-:B.=UJ9@            XR/;'&Y[U1K&HJJJ\B'(C&F]<Z*GBHXUPLV7/\
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M'(KFMSJIE=R'=TBIZ:G?1+1QK''+ CU15RJ_-?F3J\Q"-$XF>&I !*H
M&UL%YEM<J-=E](Y?29T?FGY&J!$Q%48E--4TSF%L12,EB9)&Y',<B*BIRH<B
M*Z#5VM%+12+E6>G'GF7>G_G.2H\^NG3.'KVZ^Y3%0 "JX
M                                        "L-+?WX@^I;^)8MM]5;U
M%=:6_OQ!]2W\2Q;;ZJWJ YL]:=U&<P,]:=U&<                 >;/"#,
MZ?32[O<N52;4^Q$1#TF><?"52NI--KHQR8UWI*GS1R(IUL^KY[^(XG;T_P#Z
M_M*,DFT)TCIM'_*;*VA?6PUT21.8U^ILVYSUY(R#1,9C#Y&S=JLUQ<H]8_\
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M?F>AT?Y)_4 !G:P
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M"7F*E@CIJ>.&!J-C8F$0RGGUU:ZLO6M4=NF*0 %'0
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MR Y55U5>KO1:IM_E@ !1T
M                   !6&EO[\0?4M_$L6V^JMZBNM+?WX@^I;^)8MM]5;U
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MOL\]4K7O;LX*-5V97[4W[-^W<!,P=*ENU#57"IH:>JCDJZ;'"Q(OI-_\R=T
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M[LIRHN].M"OS/154M'4)- N')L5%W.3F4"P08*&JCK*9DT2Y:Y-W,O*AG
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MJ?T4G(
M     5AI;^_$'U+?Q+%MOJK>HKK2W]^(/J6_B6+;?56]0'-GK3NHSF!GK3NH
MS@                    .G='U:0:M!$CI7;-97(B-^8'1OUX2D:L%.J+4*
MFU>1B?F1-KWME21KU21%UM;ESSF>MHZBDD1*IN'OR[.MG)U@)G8[LVN9P<JH
MVI:FU$W.3G0VI K?1U=2Y7T:>E&J>DCL*BDTM[ZE]/\ XR)(Y4V+A<H[Y@=D
M                          "&:31+'=GN5-DC4<GX?\$S-+I11+44C9XT
MR^'*JB)O;R@1$             ,%=4-I*&HJ7IE(F*['.O(G;@SG3O4#ZFT5
MD,2*LCH\M3G5%SC[< :]]VJ:.X4\-P;'P*P-?.]C<<&]RJB?^W.$.]'6JVHN
M:5&&PTKF(BM:JKA6Y7.-^TPPPMKZY]:]C74=31MB5CM^=955%3_S:<;3;JBG
M971U<[GI*YC8Y6.U7JQJ8157D7& ,[+E%5-D90R(M0C5<WA8GM:GS78ATXJ^
MLDEJX::HI:Q8H.&;-&S#4=G_ "UPN-J(N#O)2+3,?)3NJ*B75PD<]0JM=V[C
MH1L?2S5%QEHXJ*-E.L? 1.1RRN5=BKJIC?L3E W%+.RII89X_H2L1Z9Y,IN,
MAU;33NI+92P/^FR-$=\EY4.T              ;+1R-9+O#LV,17+V$V-%HK
M1+#3/J)&X?+]'*;F_P!S>@
M                    !6&EO[\0?4M_$L6V^JMZBNM+?WX@^I;^)8MM]5;U
M <V>M.ZC.8&>M.ZC.                      1?3#UFF_V+^)'R0:8>LTW
M^Q?Q(^!)M#OH57^Y/P)$1W0[Z%5_N3\"1
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MQ2+G'V&S (B(B(B81
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M*V2\)33)E,[%:O*U4Y%0R7+4V_T;[%^+L<2V0 .3N
M
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MZJ9A>W7-%450]M@XPNUXF.SG6:BG(\M[@
M
M                      K#2W]^(/J6_B6+;?56]176EO[\0?4M_$L6V^JM
MZ@.;/6G=1G,#/6G=1G   #I7VG=5V2X4[/I34\D:=:M5#Q(QJL:C7)AS=BI\
MT/="[4P>3/"[H\_1[3>NC;&K:.K=XS3NY,.VN;]CLIV&KI:O,TL'6T>(J0P
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MLW5L<=ET^2*M6OI/*--P=2_"K)+KO7.4V+Z.MM38-4Y-$:<H  #HY
M    &>@@?55U-3QHJOEE8QJ)RJKD0P%A^ O1V6\Z;4]:Z-5HK8O#R/Y.$PNH
MWMV_85JJTQ,K44ZZHIAZ@IVZD$;>BU$_H<P#RWN@
M
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M4^\6K[Y_Z1YC]*?>+5]\_P#2.[1R=BY\JK@6DSP&Z4.<B.JK4Q.DLKUQ_P#
MD>CW@'8R5K](;KPS$WPTC58B_P#N7;_0B;U$>ZT=/=GV5!HOH]<M)KHR@M%.
MZ65=KWJGH1-Z3EY$_JO(>L-!M%:+1&Q16ZB]-V=>:9R8=*]=[E_X3D0[NC]A
MMFCU"E'9J.*E@3:J,3:Y>=57:J]9LS)=O37XCT;['3Q:\SYD !Q:0
M
M                                         !6&EO[\0?4M_$L6V^JM
MZBNM+?WX@^I;^)8MM]5;U <V>M.ZC.=?.*OK0[
M
M
M             ^.75:J\R 5CI;^_$'U+?Q+%MOJK>HK*_3I4Z?RL8N4@9'&O
M7A%7\2S[>F*9O4!PK,L<U^<?/F.S$]'L14^T^31I)&K538IITK%M\VI4KJQ;
MFR+NZE_,#=@QQ3,D:BHJ;=J?,R
M
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(,:B(?0 /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g50309g15m06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g15m06.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1Q.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-C=B=)0(8\+B)$/P)B=$176"@V2C\82%*#A'9:*STO_$ !L! 0$  P$! 0
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M98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98
M8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GX
MU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2
M/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@
M^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?
M4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CV
MH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98
M 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8G
MXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]
M2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:
M@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-
M?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4C
MVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH9
M8 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8
MGXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU
M]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/
M:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^
M-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4
MCVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH
M98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98
M8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GX
MU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2
M/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@
M^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?
M4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CV
MH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98
M 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8G
MXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]
M2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:
M@^-?4CVH98 8GXU]2/:@^-?4CVH98 8GXU]2/:@6>YL3X5.QWL__ %F6 &'2
MZOC7*I@='VG;@N$,O$QZ9\R\1W'-:Y%1R(J<RH=&IM5/+FK$WIW.WP [C9&N
M3B4NBYF D;5V]?A*LD2?M(=RDN#9$RSX^8#)@JQZ.Y2P       *RR-BC<]Z
MY-:F:J!Q5=2REB621>+4B)K53&T]-+<7I/6+E$GR6)Q9BEB=<JEU3.BI WB8
MWG,R@16-C6,1K$1&IQ(B%@ H
M
M
M
M
M                      "HBHJ+QHIAKC:]'.6E3++C5B?R,R -=H;@YCD9
M*OYZC.P2M>Q%14,3>[?FUU1$F7*]$_5#I6JO<R18I5XT]O&@&T XX9$>G$<@
M   #$7-[JJJCHXEXL\WJAE)I$BB>]VIJ9F.L<:OWZI?\J1W%[ ,C%&V*-K(T
MR:U,D0N        0]S6-5SG(UJ:U5<D0Q\M[ML2Y.KJ;/FWUOB!D08GA#;.F
M0>]9XD\(;9TR#WS/$#*@Q28@MG3*?WS/$GS_ &SIE/[YGB!E 8OS_;.F4_OF
M>(\_VSIE/[YGB!E 8OS_ &SIE/[YGB3Y^MO3*;WS/$#)@QGGZV],IO?,\0E]
MMO3*;WS/$#)@QOGRV]-IO?L\1Y\MO3:;W[/$#) QOGVV]-IO?L\1Y\MO3:;W
M[/$#) QOGRV]-IO?L\1Y\MO3:;W[/$#) QOGRW=-I??L_P#^AY\MW3:7W[/$
M#) QOGRW=-IO?L\2?/5NZ;2^_9X@9$&/\]6[IM+[]GB//5NZ;2^_9XC(S9 &
M/\]6[IM+[]GB//5NZ;2^_9XC),V0!C_/5NZ;2^_9XCSU;NG4OOV>(R7-D 8_
MSU;NG4OOV>(\\V[IU+[]GB,C-D 8_P ]6[IU+[]GB//5NZ=2^_9XA,V0!C_/
M5NZ=2^_9XCSS;NG4OOV>(7-D 8_SS;NG4OOV>(\\V[IU+[]GB,DS9 &/\\V[
MIU+[]GB//-NZ=2^_9XC)<V0!C_/-NZ=2^_9XD^>;=TZE]^SQ+D9N^#H>>+=T
MZE]^SQ'GBW=.I??L\1DF;O@Z'GBW=.I??L\1YXMW3J7W[/$929N^#H>>+=TZ
ME]^SQ'GBW=.I??L\1DN;O@Z'GBW=.I??L\1YXMW3J7W[/$9&;O@Z/GBW=.I/
M?L\1YXMW3J3W[/$F1F[P.CYXMW3J7WS/$>>+=TZE]\SQ&1F[P.CYXMW3J7WS
M/$>=[=TZD]\SQ+D9N\#H^=[=TZD]\SQ'G>W=.I/?,\1E*9N\#H^=[=TZD]\S
MQ'G>W=.I??,\1E)F[P.CYWMW3J7WS/$>=[=TZD]\WQ&4F;O Z/G>W=.I/?-\
M1YWMW3Z3WS?$929N\#I>=[=T^D]\WQ'G>W=/I/?-\29&;N@Z7G>W=/I/?-\2
M/.]NZ?2>^;XC)<W>!TO.]NZ?2>^;XCSO;NGTGOF^)<C-W0=+SO;NGTGOF^)'
MG>W=/I/?-\1D9N\#I>=[=T^D]\WQ'G>W=/I/?-\1D9NZ#I>=[=T^D]\WQ'G>
MW=/I/?-\1D9NZ#I>=[=T^D]\WQ'G>W=/I/?-\1D9NZ#I>=[=T^D]\WQ'G>W=
M/I/?-\1E)F[H.EYWMW3Z3WS?$>=[=T^D]\WQ&4F;N@Z/G>W=/I/?-\2?.]NZ
M?2>^;XC(S=T'2\[V[I])[YOB/.]NZ?2>^;XC*3-W0=+SO;NGTGOF^(\[V[I]
M)[YOB,I,W=!TO.]NZ?2>^;XCSO;NGTGOF^(RDS=T'2\[V[I])[YOB/.]NZ?2
M>^;XC*3-W0=+SM;NGTGOF^(\[6[I])[YOB,C-W0=+SM;NGTGOF^(\[6[I])[
MYOB,C-W0=+SM;NGTGOF^(\[6[I])[YOB,C-W0=+SM;^GTGOF^(\[6[I])[YO
MB,C-W0=+SM;NGTGOF^(\[6[I])[YOB,C-W0=+SM;NGTGOF^(\[6[I])[YOB,
MC-W0=+SM;NGTGOF^(\[6[I])[YOB,C-W0=+SM;NGTGOF^)/G:W=/I/?-\1D9
MNX#I^=K=T^D]\WQ'G:W=/I/?-\1D9NX#I^=K=T^D]\WQ'G:W=/I/?-\1D9NX
M#I^=K=T^D]\WQ'G:W=/I/?-\1D9NX#I^=K=T^D]\WQ'G:W=/I/?-\1D9NX#I
M^=K=T^D]\WQ'G:W=/I/?-\1D9NX#I^=K=T^D]\WQ'G:W=/I/?-\1D9NX#I^=
MK=T^D]\WQ'G:W=/I/?-\1D9NX#I^=K=T^D]\WQ'G:W=/I/?-\1D9NX#I^=K=
MT^D]\WQ'G:W=/I/?-\1D9NX#I^=K=T^D]\WQ'G:W=/I/?-\1D9NX#5\08YLM
MCDA953/F65%5JTZ)(B9<^2\6LQ7I6P[S5WN/ZEY9V<N)QW#X=II>\1,>]OH-
M"]*V'>:N]Q_4>E;#O-7>X_J.2VS#[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<
M?U');8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L
M.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');
M8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[
MC^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');8^\N$
M_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[C^H]*
MV'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');8^\N$_,CXM
M]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[C^H]*V'>:N
M]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');8^\N$_,CXM]!H7I
M6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[C^H]*V'>:N]Q_4<
MEMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');8^\N$_,CXM]!H7I6P[S5
MWN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[C^H]*V'>:N]Q_4<EMC[R
MX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');8^\N$_,CXM]!H7I6P[S5WN/ZC
MTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/
MBWT&A>E;#O-7>X_J/2MAWFKO<?U');8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=Y
MJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A
M>E;#O-7>X_J/2MAWFKO<?U');8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']
M1R6V/O+A/S(^+?0:%Z5L.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O
M-7>X_J/2MAWFKO<?U');8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/
MO+A/S(^+?0:%Z5L.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_
MJ/2MAWFKO<?U');8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S
M(^+?0:%Z5L.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MA
MWFKO<?U');8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0
M:%Z5L.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<
M?U');8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L
M.\U=[C^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');
M8^\N$_,CXM]!H7I6P[S5WN/ZCTK8=YJ[W']1R6V/O+A/S(^+?0:%Z5L.\U=[
MC^H]*V'>:N]Q_4<EMC[RX3\R/BWT&A>E;#O-7>X_J/2MAWFKO<?U');8^\N$
M_,CXM]!H7I6P[S5WN/ZDLW5<..7)75C.UT']1R6V/O+A/S(^+? 8&T8OL=V<
MC**XPK(NICUT';%,\8Y9.K#Q*8D<U)SCW  #,  $.1%145,T4T[$%(ZCF66)
M.)JZ3<N5O*GY&Y&/O=/OU&JHF;F<?Y<H&/L=>V:%O&B_F9]BYIF><VJ=U%7R
MTSG+DU<V^Q4S-\H9M\C10.V  ,??)-"A<U-;U1#M44>]4D3.9J&/O7PIJ6/G
M<99-0     !265D43Y)7M9&Q%<YSER1$3E53Q/'F[6V"5]'A"..=4S:^MF:N
MBB_Y&_M>U>(P6[AC^2ZU\M@L\^5L@7*IDC=\_(FMN?JI^]3R1.(Z\' C+FL\
M[B.*G/EI\64O>(+O?)W376XU50Y5SR614:GL:G$AB5C8JYN:BKSJF9<'7'3L
MX)GFZRIO4?V;-@WJ/[-FPN F4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+
M@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4
M*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U
M']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']F
MS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-
MZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^
MS9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L
M+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&
M4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;
MU']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']
MFS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8
M-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC
M^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9
ML+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@
M&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*
M;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U'
M]FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS
M8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-Z
MC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS8-ZC^S
M9L+@&4*;U']FS8-ZC^S9L+@&4*;U']FS81O4?V;-AR$ RAFL--:V.HT6HG&F
MI/:9DQ&'/FY_:AES3;N^8X__ %%O\]@ #%R
M
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MX@
M
M                                               $$D 9S#GS<_M0
MRYB,.?-S^U#+FFW=\OQ_^HM_GL  8N0
M
M                               /<]Q:[/KL-RT<SLWT,F@W-?V%3-/W
MYGAAZ?N$2JEWND6?$Z!KLO8[^IKQ8SJ];[#Q9P^,K$=ISCY9_P#CV4 '*^]
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M:,X9WPYI.4NJ #)K
M
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MGDVS]C<1&#%^6>;/++W;YYO+ $7-$4&QY   H
M
M       !Z3N%?WAN/^E3^)#S8])W"O[PW'_2I_$AAB>K+T?LC_68?Z_^2]K
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M#PN1AC<1JP  W.<
M
M                               ()( SF'/FY_:AES$8<^;G]J&7--N[
MY?C_ /46_P ]@ #%R   (>_VRVRWC<LI[? ]C):BC1C7/U(O:> (>ZK/-2[C
MB3TTKXIF4**U['9.:O8IIQ?8]W["FL3C3;MRN7 6#TP>VMKKA6QO?)&C7*B:
M+&,3C5<U/(L<W2*\8KN%=3.S@<]&Q/3BS1J9(IT*V[7*N9H5MPJZAGJR3.<F
MS/(RFYZVF?C&UMK4C6%9=3]6EDNC^_(RBO+G:6G'XNG%5P^#P*\E,_;U[_\
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MO;WW_P _8 !L>4  *
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MWB]JGGJY9KHIDW/B3F3F $5B,Y@M>UHB)]@ #)@
M
M                                                          02
M0!G,.?-S^U#+F(PY\W/[4,N:;=WR_'_ZBW^>P !BY   #+NQ)>'6I;8ZOE6@
MT-[WG1;EH\VK,Q )E#*F)>F?),QGL$M545%:JHJ+FBIR*0"L6QICC$J0[TEX
MJ-#++/1;GMRS_>8^*_72.VU%O973>1SJY98UR5'JNO-53/C,8"<L;-T\3C6[
MWGXRRMGQ#=K-%)%:ZZ2FC>NDYK4:N:\_&AC)'NEE?)(JN>]RN<J\JKK4J!E#
M7.)>U8K,S,1V]SN6JYUMJJ?*+;4R4TV66DQ=:<RIJ4[]UQ7?+M2NIKC<I9H'
M:X]%K47VY(AA ,H[LJXV+6O)6TQ&V<Y? ,[0XNOU!1Q4M'=)H:>)-%C&M;DU
M-A@@)B)[IAXM\*<\.TQ^DY,_48RQ%41.CEO%5H.3)4:J-_1# :U55XU7C5><
M 1$1V,3%Q,7KB6F?UG, !6
M                                                           >
MD[A7]X;C_I4_B0\V/2=PK^\-Q_TJ?Q(88GJR]'[(_P!9A_K_ .2]K !R/T(
M 'G>ZG]$D_$C_13@P;J;[3GW4_HDGXD?Z*<&#=3?:"'H<'S3?8!!\TWV #HW
M7ZQH_O&60Q-U^L:/[QED    >+?\3GU18?\ 4R?P'M)XM_Q.?5%A_P!3)_ ;
M<#UX:.)_"EX$""3T7C ! $@          ""0 ( $@@D
M        " !(( $@        $ 2""0            $ 2" !(()
M    0!(( $@@ 2                           ! $@@ 2" !(( $@  "
M!(( $@@ 2         0!(     02 ,WASYN?VH9<Q&'/FY_:AES3;N^7X_\
MU%O\]@ #%R
M
M          !Z3N%?WAN/^E3^)#S8])W"O[PW'_2I_$AAB>K+T?LC_68?Z_\
MDO:P <C]"  !YWNI_1)/Q(_T4X,&ZF^TY]U/Z))^)'^BG!@W4WV@AZ'!\TWV
M 0?--]@ Z-U^L:/[QED,3=?K&C^\99    &A[K>#),86VB9'6-I?(Y'2JKF:
M6EFW+(WPZ]Q^@S?=+6TUG.&-JQ>.6>SYV]#L_7$?N5\1Z'9^N(O<KXGL!*&W
M7ONT>%PMGC_H<GZXB]ROB/0Y-UQ%[E?$]A(&O?<\+A;/'TW')U_^<1>Y7Q'H
M<GZXB]ROB>Q-'*->^YX7"V>/)N-3]<1>Y7Q)3<:GZYB]ROB>Q)J)0:]]UCA<
M+9XYZ&I^N8O<KXCT-3]<Q>Y7Q/9 37Q-U\+A;/&_0S/US%[E?$MZ&)^N8O<K
MXGL2%D'B,3<\)A;/&_0Q/UU%[E?$>AB?KJ+W*^)[(2@\1B;GA,+9XUZ%Y^NH
MO<KXCT+S]=1>Y7Q/9@/$8FZ>$PMGC/H7GZZB]ROB/0O-US%[E?$]E)'B,3=?
M"86SQGT+S=<Q>Y7Q'H7FZYB]ROB>S >(Q-SPF%L\:]"T_747N5\1Z%I^NHO<
MKXGLP+KWW3PN%L\:3<6GZZB]ROB3Z%9^NHO<KXGLK>4N@U[[GA<+9XOZ%9^N
MHO<KXCT*S]=1>Y7Q/: ->^YX7"V>+^A2?KN+W*^(]"D_7<7N5\3VE ->^YX7
M"V>+>A2?KN+W*^)/H4GZ[B]ROB>T$\BC7ON>%PMGBR;B<Z__ #N+W"^(]"<_
M7<7N%\3VEI(U[[GA<+9XMZ$I^NXO<+XCT)3]=Q>X7Q/:DU GB,3<\+A;/%?0
ME/UW%[A?$>A*?KN+W"^)[42FH>(Q-U\)A;/%?0C/UW#[A?$>A&?KN'W"^)[4
M!XC$W/"86SQ5-Q&?KN'W"^(]",_7D7N%\3VM-1)=>^Z>%PMGB?H1GZ[B]POB
M/0C/UW%[A?$]L"#7ON>%PMGBOH/J.O(?<+XCT'5'7D/N%\3VY 3Q%]SPN%L\
M2]!U1UY#[A?$>@ZHZ\A]POB>W NO?<\+A;/$/0=4=>0^X7Q)]!M1UY#[A?$]
MN)0FO?<\+A;/$/0;4=>0^X7Q";AL_7D/N%\3V\)K41CXFY/"X6SQ'T&5'7D/
MN%\1Z#*CKR'W"^)[@"Z]]T\+A;/#_094=>0^X7Q'H,J.O(?<+XGN'.!KWW7P
MN%L\/]!E1UY#[A?$E-PNH7_YY#[A?$]O+-U*->^YX7"V>'>@NHZ\A]POB/07
M4=>0^X7Q/<0->^Z>%PMGA_H*J.O(O<+XCT$U/7D/N%\3W1-0+KWW7PN%L\+]
M!-3UY#[A?$>@JHZ\A]POB>Z#G&O?<\+A;/"_054=>0^X7Q'H*J.O(?<+XGN8
M0:]]T\+A;/#/034]>0^X7Q'H)J>O(?<+XGN@)KWW7PN%L\+]!-3UY#[A?$E-
MPBIZ\A]POB>YEFZAKWW/"X6SPKT$5/7D/N%\1Z"*GKR'W"^)[L!KWW/"X6SP
MGT$5/7D/N%\1Z"*GKR'W"^)[L!KWW/"X6SPGT$5/7D7N5\1Z"*GKR+W*^)[N
MFH#7ONGA<+9X1Z"*GKR+W*^(]!%3UY%[E?$]W U[[GA<+9X1Z"*GKR+W*^(]
M!%3UY%[E?$]W U[[GA<+9X1Z"*GKR+W"^(]!%3UY%[A?$]W!/$8FZ^$PMGA'
MH(J>O(O<+XCT$5/7D7N%\3W<#Q&)NOA,+9X1Z"*GKR+W"^(] ]3UY%[A?$]W
M)0>(Q-T\)A;/"/0/5=>1>X7Q'H'JNO(O<+XGO +KWW/"X6SP?T#U77D7N%\1
MZ!ZGKR+W"^)[P!KWW/"X6SP?T#U/7D7N%\1Z!ZGKR+W"^)[P!KWW/"X6SP?T
M#U/7D7N%\1Z!ZGKR+W"^)[P!KWW/"X6SP=-P>JZ\B]POB/0-5==Q>X7Q/>6\
MI(U[[GA<+9X+Z!JKKN+W"^(] U5UW%[A?$]Z U[[GA<+9X+Z!JKKN+W"^(]
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M$^@B%)K6/1_A_-;Y?1\_<"L1]45.UOB.!6(^J*C:WQ/H @:UCT?X?S6^7T>
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MNI0  ".1-0":@50<X'.! 0! B0 10LW45+-U 2     E-0":@$       $9
M  $H02@@2 "H        EO*20WE)      +( @         ENLDANLD
M      @  L   JNL!=8   (  *  #2K_ /XE8:_"G_A-U0TJ_P#^)6&OPI_X
M3=4+/:')POXF+_-_;4 !'7"J:P$U@0   @ ! +J 74!  "   ( @(L!5=98J
MNL0J  5$H @(@NL@E=9!5  $   (7420NH"H "BD$J0)8R<B@<B@@$$D" (Y
M"2.0J+(02A $$$D   $""2"0  *B$)(0DD 1SDD<Y4$)(0D A5=99"JZR"
M!":@$U L(A0%!%  6  !$  !Q@    !4L5""E2RE0L 74 NH"H *@ "(*02I
M 0'*!R@5761R*2NLCD4J"!0@4"#OV?Y]_P!W^9T#OV?Y]_W?YD94]9E@ 5U
M  \[W4_HDGXD?Z*<&#=3?:<^ZG]$D_$C_13@P;J;[00]#@^:;[ (/FF^P =&
MZ_6-']XRR&)NOUC1_>,L@   #KW'Z#-]T[!U[C]!F^Z!JQ*$$H$2020!9HY0
MT <-?6TUMH9:NOGCIZ:),WR/7)$-"FW7K#'.K(Z6OEC1<M\1J-1>W)5S./=V
M;4+A6C6//R9M4F_9:L\ET<_SS,-N8T>"KO9XJ&X4L#[UQ[[Y0Y6K)FO%O:YY
M9=B<9OI2O)SVZN7$Q;ZFG68C]7H=IQ=:[Q9JVXVM\D[:2-TDL*L5KTR15R_/
M(Q&YYCU<75573OMWDKH6)(CFR:;515RR7BXE,Q26>BPCAZYMLL"Q(UDE3E*J
MOS<C>)%SY$RU&H;C^)JF]UER@GH[?31QQ)+_ .$@2/2<JY<>6LQBM9K:8AGS
MVBU:VGK+T]"R'B=#NLW=)*Z"HHH*JJ<N]T;88U;D_25/A(G&[BY$Y3A7=.Q9
M:+DUE^HH%C7)SJ=]/O+M'G:I?#W3Q>&]R)0U^_8HH[3A+S_HOFIGL8Z&-.)S
MW/\ DM[.WV'G-'C/']VM]7>+71T*6RF5RO3>47B1,URS7-V2<IA7"M:,VR^/
M6DY=Y]SV=$S5$/.<%[I,N(\4-L[[7'3M5LKM];*KE^!V9<IC-S_&^+,47R&%
MD-O?0Q/:ZK<V-&.9&JZTX]9JFX[_ (FL^Y4_HIMK@Y1;F[Q#1;B)M-)IVF7T
M&2:7ND8XCPE3PPP0I47*I:KHV.7)C&IQ:3N77J0T>7'N/;?1PW:XVV'S7,J:
M*OI=!JHNKC1<TSYU-=<&UHSAMOQ%*3RR]L!AL(XAI<3V2.XT;7QM5RQR1OUL
M>FM.W6G&9E$S5$-<Q,3E+?6T6C.&L8PQQ:\*5%/!<&3RS3M5Z-A1%5K47+-<
MSO81Q+18IMDE=;FRLCCE6)[)41'-7)%X\N1<SQVOB;CW=?EIFO5U'IK$BHNJ
M*-,E7;^IV]Q.XRVG%]?8*K-OE&DW17[6//\ 5,SIG!B*>_NXJ\1:<3*?5F<G
MN3>4NAHFZ?CA^$8J6"CIV3U]6USVK)\B-J+EFJ<JY\AI:XZW1*.DCN-9:V24
M$B(]J^0Y-<U=62M7-$4UUP;6C-NOQ%*6Y>O1[>#$UEY;:L,+>+W'O"10-FFB
MC72R5<LFIGK7-40\B=NG8OO57,F'+=$V"/X6]LIM_<UO)I.YR4PK7[+B8]</
M*)[R]T0'G6$L=W!V%[K=\7TK*>*B>D3-ZC6-\SU_9T5U<FTU>GW0,=WYU14X
M=M47D4*_";'3;[H]BN5>-<N1"Q@VG/W,9XFD1'?J]M)Y%//]S/=!X4RRV^Y0
M,IKI$W330XF2M3B7)%XT<G*AAL5[IEQP]CRKMTT$$UIIW-TFM9E*J*Q%^5[5
M)&%:;37VLIXBD5B^?27K+23P>X;IF-Z;>JZ6WP4EOE7^S;)2+HN3D337C/1;
M3N@4%5@2?$=1$Z-U-_9S4[5XUEY&M7F7-/8A;8-J]4IQ%+S,=FZ(><T>Z3+4
M;H2896UQM8M:ZD\HWY<\DS^%HY=FHTVBW4,:7.MFEM=OIYZ:+X3Z>*E61&M[
M7Z\S"X-KVW7=DMUP8QT:55Q6;0=K;FCLT-E<#+/FV:+\5S37DW^3TW%6Z:EA
MQ@VQI:73L1T;7S++DY=/+Y+<N/+,](5-%53F/&L?8RK;9NB14,-%;)6QO@1D
MTU,CY6:66>3N36;UNIX@K<+X8?<+8D2U"5+(O[9NDFB[2SXN?B0UVP\^6(CN
MW4Q<N>;3GDVD'B+=U+%-WHH8</VILE;''I54S*=9$TLU^2W4B99:^/,RNYKN
MGUMXO<=GQ%%#Y14+H03PLWOX:9_!<W\MHG M$3*UXK#F8C=ZTFHD\YW4-T27
M"]3%:[13QS7-[4D>^5,V1M7Y*(G*Y35;[C?=%PPVG??::@C94IG%G3M7\ER7
MB7L45P;6C,OQ-*S,;/<#!XOQ1;\)T5/571L[HIY%B9O+-)<\L^/C,9N:7;$-
M[M4EPQ%#2QP3(UU&Z!$17MX])51%XN0UO_B(_NS:?]8O\"DK3^/EE;XN6%-Z
MN^W=EPNJHBLN3>U8$XOWFX8<Q+9\1PNDLU?%4JQ$5\2<4C/:U>/^1Y_N9X'P
MW>L"4-7=+5'-52K(CYD>YKER<J)J4\_Q7;*C<XQ]!+:IY$B9HU%.Y5^$L2KD
MYCN?4J=IMTZ6F:U[M&MBTB+WRF)?3(-8Q?C.APYABGO,L3Y4JT;Y- U>-[G-
MTLE7D1$UJ>3)NG8[JJ>6Y4=% EMC7X2LHE?&WL5VO\S73"M:,V[$XBE)RGN^
M@"4-&W-L?T^+J.I;4PI27"C8DDS$7-CV>NSE]J&C5>ZEBB_7N:DP7;XTB;FK
M&NA265S4XM)<UR3^I(P;3,QL3Q%(K%N^;W()K4\SW-\6XLNV(9K5B6V1PMAA
M65\RPK"YO'DB(FI<U.?=/W1^"LT=MM=.RINLC--ROXV0HNK-$XU<O,32MS<L
M,M>O)SSTAZ.#PF;=%Q[8?)JO$5KA6@G7)K7TV]:78CD7B7+G/8\-WJDQ#9*:
MZ6]7>3SIGHN^4QR<2M7M12WPYKUE,/&KB3E'=D^<#G!K;@LW4I4LW4H  !'(
MFH!-0*H.<#G @( @1( (H6;J*EFZ@)     2FH!-0"       ",@  "4()00
M) !4        2WE)(;RD@     %D 0         2W620W62           0
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MNL@@  0FH!-0+"(4!010 %@  1   <8     5+%0@I4LI4+ %U +J J "H
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M" @"!$@ BA9NHJ6;J D    !*:@$U (       (R   )0@E! D %0
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M><*)Q/6RZ_J\<W%((:B]U[:B&*5J4J*B2,1R(NDG.;%NLX9H?,;[I1TT<%5
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MD  "HA"2$)) $<Y)'.5!"2$) (57660JNL@@  0FH!-0+"(4!010 %@  1
M <8     5+%0@I4LI4+ %U +J J "H  B"D$J0$!R@<H%5UD<BDKK(Y%*@@4
M(% @[]G^??\ =_F= []G^??]W^9&5/698 %=0  /.]U/Z))^)'^BG!@W4WVG
M/NI_1)/Q(_T4X,&ZF^T$/0X/FF^P"#YIOL '1NOUC1_>,LAB;K]8T?WC+(
M  Z]Q^@S?=.P=>X_09ON@:L2A!*!$D$D 6:.4-'*!9-1*$)J)0+"0 11"W(5
M0L@&G;I."TQ=;X$@G9!74ZKO;Y$56.:NMKLN/\S6:6P;J=+31T=/>*5M-&Q(
MV.\H8JM:G$F6;<]1ZN2ALKBS6,N[3; K:W-G,3[GGV ]SV6RW>2\WZM;7W1V
M:MT<U:QRZW*J\;G9'H0!C:\WG.6>'AUPXRJ@D@DQ9@  D %1+>4NA1O*70
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MDCD*BR$$H0!!!)   ! @D@D  "HA"2$)) $<Y)'.5!"2$) (57660JNL@@
M0FH!-0+"(4!010 %@  1   <8     5+%0@I4LI4+ %U +J J "H  B"D$J0
M$!R@<H%5UD<BDKK(Y%*@@4(% @[]G^??]W^9T#OV?Y]_W?YD94]9E@ 5U
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MY5>JN5>55S4@ W.<
M               ECG,=I,<K7<[5R4@ 9RUXEJZ3)M0JU,7^9?A)[%-RMMQI
M[A"DE-(B^LU?E-]J'F)ST=5-1U"34SU9(G+SIS*:;X,6ZQW=&%Q-J=+=8>HK
MK!C[+<X[G2[XQ-&1O$]B\B^!D#CF)B<I>E6T6C.  $  !0  :5?_ /$K#7X4
M_P#";JAI5_\ \2L-?A3_ ,)NJ%GM#DX7\3%_F_MJ  CKA5-8":P(   0  @%
MU +J @ !   $ 0$6 JNM2Q5=8A4  J)0! 1!=9!*ZR"J  (   0NHDA=0%0
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M()   "0 5$MY2Z%&\I=    E $  GD4@GD4 TDAI($IJ 34"+ 2FH@E-0
M2FHDA-1)4 @" <B (""0 4"4()0A $UJ FM1!*P *AS@<X"A9NI2I9NI0  "
M.1-0":@50<X'.! 0! B0 1599&11/DE=HL8FDY>9#SVYUKZ^L?.]>)>)C?5;
MR&S8PJ]ZH64S5^%,N:_=3^IIYU\/3*.9Y_%XF<\D  .AR
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M')'&UNWC,*9/$GUU4_E^AC#T<.,JP\C%G.\@ ,FL
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M;VFC3QP.9$SF;E^I<2TY3D8-(SB;>UKG.!S^T&QH
M  SN#)ECN^]Y\4K%1?RXS!&3PQGY]I,O67]%,;QG66>%.5X>B@ \YZX  H
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M=_>4:3O7?WE)H>\](_\ C^?[/IY/:FT?FFT^8<W>N_O*,W>N_O*71]YZ1?\
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MO+UY'L:[]V7\C#FUXSI5=##5-3Y"[V[V+J-4._"G.D/)QZ\N)( #8U
M               #,VF:"IH);;52)%F[3BD74CN8XUL-:CE1$B<WUTD3(Q0S
M7++-<N;/B,.68GI+9SQ,1%H[,Q9W1P35M!4R-:V=N][XB_!1R=I%/8YVU#5J
MG11T[5S=*KTR5$YC$?H%553)57).3,<L^R2+QE$3'9LL=8RLJ;Q,Q41BPZ+<
MUUHA@*#Z;3?B-_4X06M.7/(MB3;*99V2L91XKJ)G\<>GHN5.943C.&:Q5"SN
M\F?%) Y<VRZ:9(B\YB BJB*B*N2\A.28[2NI$Y\T>W-LK:B%;W;*:!Z/CI6Z
M"OSXE7+C,!6<=949?:._53A!:TY4OB<T9,]+3/N5GH5I%8]\**Q[-)$5.,P3
MVJQ[FNUM7)2$54SR54]@%:\J7M%NN75FW2NMUB@;!)H5-2_?'*U>-&IJ.K1W
MBLBJHI):F62-KD5S7+Q*AC@(I'M6<6V<9=,F>K:MUKJZF."."6GJ525-),^)
M>0Y[%<_**US'4]-"F]N728W17V&M QTHF,F48\Q;..SL5U2M5-OBQ119)HZ,
M:9)[3K@&R(RZ-,S,SG(                     &:P?$LEZ8[+-(VJY?T,*
M;A@:E5L%15.3Y:HQOL36:\6<J2V\/7FQ(;0 #@>J  *  #2K_P#XE8:_"G_A
M-U0TJ_\ ^)6&OPI_X3=4+/:')POXF+_-_;4 !'7"J:P$U@0   @ ! +J 74!
M  "   ( @(L!5=98JNL0J  5$H%5$15541$XU52$/-=US%3Z*)++;Y=&:9F=
M2]-;6+J:B\Z_H6M9M.4.7B^)IPN%.+?V?-CMT'="DD?-;+!*L<;5T9:MCN-_
M.C.9.W8>8*N:JJJJJO&JKRD(F6H'76L5C*'P'%\7B\7?GQ)_2/9  #)S
M                                                          93
M#]]KK%6)/02JC57X<3E^!(G,J?S,6"3&?265+VP[1:DY3#Z"PQB"DQ#;_**7
MX$C5T987+\*-?!>13+'SUAV\U%BND=;2KGH_!>SDD;RHI[[;JR&X4,%92N5T
M$S$>U5U^Q>TY<2G++[3[,^T/%TRMZT=_J["E2RE36]6 +J 74!4 %0 !$%()
M4@(#E Y0*KK(Y%)761R*5! H0*!!W[/\^_[O\SH'?L_S[_N_S(RIZS+  KJ
M !YWNI_1)/Q(_P!%.#!NIOM.?=3^B2?B1_HIP8-U-]H(>AP?--]@$'S3?8 .
MC=?K&C^\99#$W7ZQH_O&60   !U[C]!F^Z=@Z]Q^@S?= U8E""4")()( LT<
MH:.4"R:B4(342@6$@ BB%D*H60 2A!* 2  ()()   "0 5$MY2Z%&\I=
ME $  GD4@GD4 TDAI($IJ 34"+ 2FH@E-0   2FHDA-1)4 @" <B (""0 4"
M4()0A $UJ FM1!*P *AS@<X"A9NI2I9NI0  ".1-0":@50<X'.! 0! B0 17
M%5T[*JED@E^1(F2]G:>=U=.^EJ9()4R>Q<O;VGI)B<06E+A#OD625,:<7%\M
M.93=@XG+.4]G-Q&#SQG'>&C@E[',>YCVJU[5R5KDR5%(.UYH
M                                                     3&QTCVL
MC:KGN7)&HF:J!RT5-)654=/"F<CUR3LYU/3*.G924L4$7R(VHU#%X;LR6Z%9
M)D1:IZ<:^JG,AFCBQL3FG*.STN&PN2,Y[R  TN@  4  &E7_ /Q*PU^%/_";
MJAI5_P#\2L-?A3_PFZH6>T.3A?Q,7^;^VH ".N%4U@)K @  !  " 74 NH"
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M=3^B2?B1_HIP8-U-]H(>AP?--]@$'S3?8 .C=?K&C^\99#$W7ZQH_O&60
M!U[C]!F^Z=@Z]Q^@S?= U8E""4")()( LT<H:.4"R:B4(342@6$@ BB%D*H6
M0 2A!* 2  ()()   "0 5$MY2Z%&\I=    E $  GD4@GD4 TDAI($IJ 34"
M+ 2FH@E-0   2FHDA-1)4 @" <B (""0 4"4()0A $UJ FM1!*P *AS@<X"A
M9NI2I9NI0  ".1-0":@50<X'.! 0! B0 10LFHJ6;J QEWLT%Q17_-U&7%(G
M+V+SFG7"VU5 [*HC^#R/;QM7\ST4A4145%R5%UHIMIC6IT]C1B\/7$Z]I>7@
MWVKL5OJ55SH=[<O+&NB=%^%*95^!53-3F5$4Z(QZSW<D\)>.S4 ;8F$HNF/[
MB#@E%TQ_<0NO3=CX;$V:F#;."473']Q!P2BZ8_N(->FYX;$V:F#;."473']Q
M!P2BZ8_N(->FYX;$V:F#;>"473']Q!P2BZ8_N(->FYX;$V:D#;>"473']Q!P
M2BZ8_N(->FYX;$V:D#;>"473']Q!P2BZ8_N(->FYX;$V:D#;>",73']Q!P1B
MZ8_N(->FYX;$V:D#;>",73']Q!P1BZ8_N(->FYX;$V:D#;N",73']Q!P1BZ8
M_N(->FYX7$V:B#;N",73']Q!P1BZ8_N(->FYX7$V:B#;DPA$O_QDG<0G@A%T
MR3N(->FYX;$V:@#;^"$73).X@X(1=,D[B#7IN>&Q-FH V_@A%TR3N(."$73)
M.X@UZ;GAL39J -OX'Q=,D[B#@?%TR3N(->FYX;$V:@#;^!\73).X@X'Q=,D[
MB#7IN>&Q-FH V_@?%TR3N(.!\73).X@UZ;GAL39J -OX'Q=,D[B#@?%TR3N(
M->FYX;$V:@#<$P?$O_QDG<0<#HNF2=Q!K4W/#8FS3P;AP.BZ9)W$' Z+IDG<
M0:]-SPV)LT\&X<#HNF2=Q!P.BZ9)W$&O3<\-B;-/!N' Z+IDG<0<#HNF2=Q!
MKTW/#8FS3P;AP.BZ9)W$' Z+IDG<0:U-SPV)LT\&YQX/ID7X=5,Y.9$1#(T>
M'K=2N1S8=\<G+(NE_0DX]8[,J\+>>[2+9:ZNXNRIX_@<LCN)J>)NUDL<%L:C
M_G*E4R61>3L1.0RR-1J(B<2)J1"3GOC3?I['5A</7#Z]Y54!=8-3H  $  %
M !I5_P#\2L-?A3_PFZH:/B66.#=&PW)*]&,2*9%<NKC1$0W@L]H<G#>OB_S?
MVU  1UPJFL!-8$   (  0"Z@%U 0  @  " ("+ 5766*KK$*@ %1Y3NYO7.T
M1_L_#=^?$>5'K&[E"JQ6F=,]%'/8NS/Q/)SJPO5?!?;>?C;Y^[_H !L>4
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M4!-:B"5@ 5#G YP%"S=2E2S=2@  $<B:@$U J@YP.<" @"!$@ BA9NHJ6;J
MD    !*:@$U (       (R    )00) !4        2WE)(;RD@     %D 0
M        2W620W62           0  6   576 NL   $  %  !YKND_WJLWX
M$O\ TF4PIB30<RAN,GP=4<[W:O\ *OB8O=)_O59OP)?^DP$O*6>T.7A_7Q/Y
MO[8>T@T/!^*-!S*"YR*K55&PRK^S_E<O\S>R.J$)K 36!   "  $ NH!=0$
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MOJJJ>HF5%DF>KW*G.NLX@(K$=DQN*QL>(C%M,Y;@ *T
M  &P8"MZW#%=O9HZ4<3]^?Q:D;Q_KD:^>N;DMF=1VN:YSMRDJ\FQ9ZTC3E_-
M?T,,2W+67?\ 9G#SQ'$UCV1UG^C?'+GQJ5+*5.-]Y %U +J J "H  B"D$J0
M$!R@<H%5UD<BDKK(Y%*@@4(% @[]G^??]W^9T#OV?Y]_W?YD94]9E@ 5U
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MP5LK=:^R?\]KJ  S<
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MN_9YFN7FYE-#?K.M)J ^CP>8;G^-4AWNUWB5$B1$;!4.Y./B:Y>;F4]/]H$
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M?<'#^:WR^CP;@)B3JY?>-' 3$?5R^\:>\ FM8]'^'\UOE]'@_ 3$?5R^\:.
MF(^KE]XT]XS!=:Q]P</YI^7T>#\!,1]7+[QHX"XCZN7WC3W@$UK'W!P_FGY?
M1X/P%Q'U<OO&C@+B/JY?>-/>"!K6/N#A_-/R^CPR' &(I/\ X*-GWYFH96AW
M,+G(J+6UE)3MY49F]W\D/6P-:S.GV%PM>^<_U^F36+%@>RVES)=Y6JJ6\:2S
M\>2\Z-U(;/F :YF9[O4PL'#P:\N'6(@*EBI&P4J64J%@"Z@%U 5 !4  1!2"
M5(" Y0.4"JZR.125UD<BE00*$"@0=^S_ #[_ +O\SH'?L_S[_N_S(RIZS+
MKJ  !YWNI_1)/Q(_T4X,&ZF^TY]U/Z))^)'^BG!@W4WV@AZ'!\TWV 0?--]@
M Z-U^L:/[QED,3=?K&C^\99    '7N/T&;[IV#KW'Z#-]T#5B4()0(D@D@"S
M1RAHY0+)J)0A-1*!82 "*(60JA9 !*$$H!(  @D@D   ) !42WE+H4;RET
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M=0  /.]U/Z))^)'^BG!@W4WVG/NI_1)/Q(_T4X,&ZF^T$/0X/FF^P"#YIOL
M'1NOUC1_>,LAB;K]8T?WC+(    Z]Q^@S?=.P=>X_09ON@:L2A!*!$D$D 6:
M.4-'*!9-1*$)J)0+"0 11"R%4+( )0@E )  $$D$@  !( *B6\I="C>4N@
M 2@"  3R*03R* :20TD"4U )J!%@)3402FH   )3420FHDJ 0! .1 $!!( *
M!*$$H0@*N718]>9"Q2?YE_L"NDW+--+5RGRAB>YOO.(KE<)%S6>9RIV-1<D3
M8B'U+='K%:+C(W6REE>GY,<I\BQ+G&B\Z9G9PL=Y>=QUO5JL #K>>
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MAYJ[4<2\H'U0%U'DNYKCM8EBM%\F58U7*"KD?\CF8Y5Y.9>0]9Y @  @  "
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MO<?H,WW3L'7N/T&;[H&K$H02@1)!) %FCE#1R@6342A":B4"PD $40LA5"R
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M3L  K$  $*F:*B\:*=B.MJXHM[CJJAL?JI(Y$_4X #LC+C5=:KK5=:D@
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MRET   "4 0 ">12">10#22&D@2FH!-0(L!*:B"4U   !*:B2$U$E0" (!R(
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MXONN+:B"2[.@R@S2)D,>BC<]?:IKYGAUFM8B6G'O%[S:  &QJ
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M@Z]Q^@S?= U8E""4")()( LT<H:.4"R:B4(342@6$@ BB%D*H60 2A!* 2
M()()   "0 5$MY2Z%&\I=    E $  GD4@GD4 TDAI($IJ 34"+ 2FH@E-0
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M#P6+[GSX#Z#]$>%O5N/^Z_[1Z(\+>K<?]U_VCQ-#P6+[GSX#Z#]$>%O5N/\
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M=_S?W&0 '0\V?\W]P\V)]K^XR* #HLML:?*>Y?9Q'/'201\:,15YUXSG
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M0DCD*BR$$H0!!!)   ! @D@D  "HA"2$)) $<Y)'.5!"2$) (57660JNL@@
M 0FH!-0+"(4!010 %@  1   <8     5+%0@I4LI4+ %U +J J "H  B"D$J
M0$!R@<H%5UD<BDKK(Y%*@@4(% @[]G^??]W^9T#OV?Y]_P!W^9&5/698 %=0
M  /.]U/Z))^)'^BG!@W4WVG/NI_1)/Q(_P!%.#!NIOM!#T.#YIOL @^:;[ !
MT;K]8T?WC+(8FZ_6-']XRR    .O<?H,WW3L'7N/T&;[H&K$H02@1)!) %FC
ME#1R@6342A":B4"PD $40LA5"R "4()0"0 !!)!(   2 "HEO*70HWE+H
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M  !*$$H($@ J        );RDD-Y20     "R (         );K)(;K)
M      (  +   *KK 76   "  "@  \UW2?[U6;\"7_I,#+RF>W2?[U6;\"7_
M *3"Q4\M54,@IV*^5ZY-:A?8Y>']?$_F_MAU(:>6KJ&04S%DE>N36H>H85P[
M#9:?2?HR5LB?VDF6K_*G87PQ8(K/!I.R?6/3^TDYNQ.PS9'4CE 36!   "
M$ NH!=0$  (   @" BP%5UEBJZQ"H !42@" B"ZR"5.E=;G16FE6HN-3'!$G
M*Y>-?8FM2PDVBL9VG*'<!YC>-UBE9I,L]!+,O)+4+H-[J<?Z&K5.Z9B25SMZ
MGIH&KJ1D*+E^:FR,*TO)Q?MOA,.<HMS?I#W<'S]Z0<4=:+[EG@/2%BCK3_\
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M?=.P=>X_09ON@:L2A!*!$D$D 6:.4-'*!9-1*$)J)0+"0 11"R%4+( )0@E
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M:<:!5@ $        2WE)(;RD@     %D 0         2W620W62
M  0  6   576 NL   $  %  !YSN@P25&,+)# Q7R/AE1K4_^TVW#MDBM,*N
M=D^J>GPW\W8G88.__P")6&OPI_X3=4+/:'+PTYWQ?YO[:@ (ZH536 FL"
M$  (!=0"Z@(  0  ! $!%@*KK+%5UB%0 "HE 0AJ&Z3BI,.VQ(*;CN-4U4BR
M7YMO*]?Y=I8C.<H:<?'IP^'.+B3TAU\=X\@L&G1V_>ZBZ:G-=GHP]KN=>P\5
MN=PJ[I6/JKA.^>=VMSUU=B<R'7DD?+(^25[I)'JKG/<N:N5=:JI4ZJ4BL/@N
M.^T<7C+?Q3E7V1_GM  9N
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M,E0V#$-7+0)26ZCD?#'#$US]!<E<Y>52EQE6XX9@K)UTJJGEWES^5S5U9@8
M$<AFFV-&TE-5U%9'!2RLTU>Y.-%]5$36H&&!G'8>66)D]#60STBYZ<J_!WO+
M6JHI1UFAFI9I;;<(ZM\*:3XT:K5RYTS PP,K!:8V4455<JQM+'-QQ-T5>YR<
M^2'+76:FI;>VK2XLDCD1=YRC7^T7F[/S PH            "#=L$WETB);JE
MV:M3.%R\J>KX&E%HI'Q2LDC56O8J.:J<BH![$#JVNM9<*"&JCU2-XTYEY4VG
M:         EO*20WE)      +( @         ENLDANLD           @  L
M   JNL!=8   (  *  #2K_\ XE8:_"G_ (3=4-*O_P#B5AK\*?\ A-U0L]H<
MG"_B8O\ -_;4 !'7"J:P$U@0   @ ! +J 74!  "   ( @(L!5=98JNL0J
M5%)I8X(9)IG:,<;5<Y>9$UGS7B6[RWR]U5?,Y521RI&U?V6(OP4/9MUJO\BP
M941M=E)5/; GL7C7]R'@IT8-?:^2_P#HN)F;UP([1UG_ ,_SW@ -SYH
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MUC1_>,L@   #KW'Z#-]T[!U[C]!F^Z!JQ*$$H$2020!9HY0T<H%DU$H0FHE
ML) !%$+(50L@ E""4 D  0202   $@ J);RET*-Y2Z   !* ( !IV*YUDNBQ
MY_!B:C4]J\:FY(:!>7:=VK'+]HJ =,  4=&Q_P MC'?>:BEDXDR3B0D
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MK_>;:>?8!>K;U(SD?"O[E0]!         EO*20WE)      +( @
MENLDANLD           @  L   JNL!=8   (  *  #2K_P#XE8:_"G_A-U0T
MJ_\ ^)6&OPI_X3=4+/:')POXF+_-_;4 !'7"J:P$U@0   @ ! +J 74!  "
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M+),ER3(\9/8=TW_#NW??A_A4\>+A>JY_MZ<^*C^6/_0 &UXH
M      !S4<BQ5<$B:V2-=L5#A.2!BR3Q,36Y[6[5"USSC)])H[3:UZZW(CMJ
M9D"-NC#$WU6-38@.!^DP!=0"Z@JH *@ "(*02I 0'*!R@5761R*2NLCD4J"!
M0@4"#OV?Y]_W?YG0._9_GW_=_F1E3UF6 !74  #SO=3^B2?B1_HIP8-U-]IS
M[J?T23\2/]%.#!NIOM!#T.#YIOL @^:;[ !T;K]8T?WC+(8FZ_6-']XRR
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MI>R)/U7^1N0        $MY22&\I(     !9 $         $MUDD-UD@
M     $  %@  %5U@+K   !  !0  :5?_ /$K#7X4_P#";JAI5_\ \2L-?A3_
M ,)NJ%GM#DX7\3%_F_MJ  CKA5-8":P(   0  @%U +J @ !   $ 0$6 JNL
ML576(5  *C1-V2@\IPHVJ:BJZDG:]<N1JYM7]4/#SZANE!%<[;4T-0B;U.Q6
M.[,^4^9[C1RVZOJ:*I14F@D6-V?8NO\ /6=&#/3)\=_]%P\UQ:XT=IC+^L?L
MZP -SYX                    !&^X/W07VBW,MMSI?*J.-JM8YORD;ZJHO
M$J'?N6.K V@J8K59="::-S-/>VLT<TRUZSS,&$X=9G-Z=/M;B:8<8><3$=(S
MCK#=,$8W=8J)]NN%/Y7;W9JB)EI,SUIDO$J+S&8K=T2WT5NDIL,6M*9[\_AO
M:C6M5>7)-:GF8$TK,YL<+[5XG"PXPZVZ1TB<NL1[I;=N?XK@PS/6RU5/-4+4
M(WC8J9YHJJJKF8BVW6.DQ9'=G1N=$RJ=4;VB_"R557+]YB 7ECK[VCQ>+R4I
MGTI.<?KW;CB/&CZW$M'>+7&^GEIF:.C*J*CN/C1<N14-D;NBV*I?%65]F>MP
MB3)KD:U^7L<IY4":=713[6XFEK6B8GFZSG'3/=L>+,4U&(KK!43QI%34[O[*
M%JYY)GFJJO*JY&0Q[B^GQ+14,%/2S0+3O5RK(J+GFF7(:8"\L=/<TSQV/:+Q
M:<^?+/\ HV[ &+DPS+41U$#IJ2=4<[0^4UR:E08WO]FNU/%%9K;Y*])5EDE5
MB-5_%JXC40.6,\UCC\;0\/,_P_IU^+EI9$AJ8)5152.1KU1.7)<SU.IW3+/5
MY>5622?17-N^HQV7LS/)P+5BW<X7C\;A(FN%/2>_3-OV*]T.2YVQ]NM=&E)2
MR-T)'.5%<K?5:B<2(:"J<2H 6M8KTAJXGBL7BK\^+.<MXQ9C.FO6&*:UPTDT
M4D+HU5[W)DNBF2ZC1P"5K%8R@XGB<3B;\^)/7+( !DT
M  &7PC1K7XFMM.B*K5F:YV7(C>-?T,0>F;C]H72J[M,Q<D_L8%5-?K*G[D,+
MSRUF79]GX$\1Q%:>_.?TAZ:]<U55Y5*%E*G&^_@"Z@%U 5 !4  1!2"5(" Y
M0.4"JZR.125UD<BE00*$"@0=^S_/O^[_ #.@=^S_ #[_ +O\R,J>LRP *Z@
M >=[J?T23\2/]%.#!NIOM.?=3^B2?B1_HIP8-U-]H(>AP?--]@$'S3?8 .C=
M?K&C^\99#$W7ZQH_O&60   !U[C]!F^Z=@Z]Q^@S?= U8E""4")()( LT<H:
M.4"R:B4(342@6$@ BB%D*H60 2A!* 2  ()()   "0 5$MY2Z%&\I=    E
M$  P>+*3?J%M0Q,WPKQY>JIG J(YKFN1%:J9*B\J >:@[UYM[K=5JSC6)W'&
M[G3F]J'1                    $7)R*NI%100!NV.6N=:Z5[>.-'IG^;>(
MTDVFT8AI_(4HKM$KXT311R)I(K>94_F145F'XJ6=*.G<Z9['-:JL7X*JFOC
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M[;O! -ML%!YMM,-.OR\M)_WEUF0          EO*20WE)      +( @
M    ENLDANLD           @  L   JNL!=8   (  *  #2K_P#XE8:_"G_A
M-U0TJ_\ ^)6&OPI_X3=4+/:')POXF+_-_;4 !'7"J:P$U@0   @ ! +J 74!
M  "   ( @(L!5=98JNL0J  5!#S7=<PJZLA\]V^-%FA9E4L36]B:G(G.G+V'
MI:!4145%3-%XES+6TUG.'+Q?"TXK"G"O[?D^4_8#U'="W/I&2RW/#\2R,<JN
MFI6IQLYW,3E3L/+N54Y47)4YCKK:+1G#X#B^#Q.$Q.3$C])]D@ ,G,
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M#-.= )!&:<Z#-.= )!&:<Z#-.= )!&:<Z#-.= )!&:<Z#-.= )!&:<Z#-.=
M)!&:<Z#-.= )!&:<Z#-.= )!&:<Z#-.= )!&:<Z#-.= )!&:<Z#-.= )!&:<
MZ!%S7)O&O,G&!)!DZ"QW&N5-YIG-;Z\GP4_>;7:,)4U-E)7N2IE3C1J<3$\0
M-?PYAZ6Y/;-4(Z*C:N>:IQR=B>)Z'#%'#$R*%B,C8F36IJ1"R(B(B(B(B)DB
M)R$H!(          EO*20WE)      +( @         ENLDANLD
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M#!'3P-U,C;DG]3L UVM-N[U^&X+!X6,L*N7O]H5+%3%TBE2RE0L 74 NH"H
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MED*KK((  $)J 34"PB% 4$4 !8  $0  '&     %2Q4(*5+*5"P!=0"Z@*@
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MRDD-Y20     "R (         );K)(;K)           (  +   *KK 76
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M-0PN<Z.!F@USM:IGRF.?3)U<DZW/[,LOF[2:@$U 0VH4!010 %@  1   <8
M    5+%0@I4LI4+ %U +J J "H  B"D$J0$!R@<H%5UD<BDKK(Y%*@@4(% @
M[]G^??\ =_F= []G^??]W^9&5/698 %=0  /.]U/Z))^)'^BG!@W4WVG/NI_
M1)/Q(_T4X,&ZF^T$/0X/FF^P"#YIOL '1NOUC1_>,LAB;K]8T?WC+(    Z]
MQ^@S?=.P=>X_09ON@:L2A!*!$D$D 6:.4-'*!9-1INZ[;7W' ]8L:9OI7-J<
MDUJC<\_W+G^1N2:CIW>>.GMTZRM:])&K'H.U.S3++86MN68E+UYZS6?:P/\
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MK[3N7!;54TL-)3W:.GI(M4;8U57KSN7E,+6P4E%O4U!<&U4K7HNBC%3++CS
MXKWGYXKL]>^N._>,^#5DSR_;R]ARUS+7=:CRSS@VC?(B;[$]BJJ.Y50Z5^KH
M:I]/!1HODE*S>XU=Q*[G4#%\J>U#9<9UD[:Z&F9*]D+86/5K5RS5>5=AK7*G
MM,OBBJ@K+FV6ED22-(6-TDYTSS0#(7*XU+<+V]R2N22971O?G\)6IR9G6MD[
MY\/7.&H<Z2*)6/:CESRX^,Z]PJH9</VVGCD1TT3WJ]O*W/4+-(SS?<:5'?\
MB*A&,B9RO7/D R>)Z6NK:V":W-EEI%B:D2PKQ-Y]6I3JXOD59J*)\FG41P(D
M^2\6EXG=N*6_*G@J+E+12P1)&^&G17-1>7C3E,/=+7%3TD=9157E5*]RL5RI
MDYKNT#%@            !:&5T$T<L:Y/8Y'(O:BE0!ZQ2SI54L-0SY,K$>GY
MG*AA\(2[YA^G1=;%<S8O]3,(5$@ BA9NHJ6;J D    !*:@$U (       (R
M   )0@E! D %0       !+>4DAO*2      60!         !+=9)#=9(
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M2"5(" Y0.4"JZR.125UD<BE00*$"@0=^S_/O^[_,Z!W[/\^_[O\ ,C*GK,L
M"NH  'G>ZG]$D_$C_13@P;J;[3GW4_HDGXD?Z*<&#=3?:"'H<'S3?8!!\TWV
M #HW7ZQH_O&60Q-U^L:/[QED    =>X_09ONG8.O<?H,WW0-6)0@E B2"2 +
M-'*&CE LWD-&J_I<_P"([]3>4U(:9=H]ZN=2W_.JI^?&%=0
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MTXWYOVJ99"HD $4+-U%2S=0$@    )34 FH!       !&0  !*$$H($@ J
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M2<KOSU ;1'&V*)D4?R&-1K?8A9 $*B0 10LW45+-U 2     E-0":@$
M  $9   $H02@@2 "H        EO*20WE)      +( @      !A<58BH\.6U
MU35NTI'<44*+\*1W,G9SJ3BG$-)ARVK55:Z3W<44+5^%([F3LYUY#P"_W>MO
MMQ?6W"32D7B:U/DQM]5J <>(+Q67ZY25MP?I2.XFL3Y,;?5:G,<N%[]68<N2
M5E"Y%S31DB=\F1O,O;S*8W1&B!]+8;OM%B"VMK*"32;\E[%XG,=RHJ&5/FO#
M%]K,.W)M71N5S=4D*KDV1.9?$^@,.7RCOUM95T+T7/)'QY_"C=S*!E
M !  !8  !5=8"ZP   0  4  &E7_ /Q*PU^%/_";JAI5_P#\2L-?A3_PFZH6
M>T.3A?Q,7^;^VH ".N%4U@)K @  !  " 74 NH"  $   0! 18"JZRQ5=8A4
M  J)0! 1!=9!*ZR"J  (   0NHDA=0%0 %%()4@2QDY% Y%! ()($ 1R$D<A
M460@E" (()(  &*Q+?:2P6YU35.19%3**%%R=*[F3LYU C$M^I,/V]:JL=FY
MV;8HD^5([F3LYU/![]=JN^W)];7O19')HM:WB:QO(B(<M^NU5>[C)65SU5SE
M^"Q%^#&WU6F/T0SB,G%HGI.YUC9*=L5IO4J) B(RGJ':VKGQ-<O-S+R'G>B1
MHH#+-],99$GEVY[C3>=[M=YESCU0U,COD<S7+S<R\AZB1KF,@CG)(YRL1"2$
M) (57660JNL@@  0FH!-0+"(4!010 %@  1   <8     5+%0@I4LI4+ %U
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MJ(B(FI$)3B1$1$1$XD1.0<Y1 0! B0 10LW45+-U 2     E-0":@$
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M_P#$K#7X4_\ ";JA9[0Y.%_$Q?YO[:@ (ZX536 FL"   $  (!=0"Z@(  0
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ME8ZHJW:3EXFMY&)S(!U+O7U-VKGU58[-Z\36I\EB<R'2WL[N]=@WKL Z6@-
M[N]=@WKL Z6@- [N]=@WKL Z6@- [N]=@WKL Z6@- [N]=@WKL Z6@- [N]=
M@WKL Z6@9"Q72ILM:E32+GGQ/8[4].9?$IO78-Z[ /8[-=*:[43:BD=FW4YJ
MZVKS*=X\=LEQJ+16)/3*JIJ?&J_!>G:>JVBY4]SHVSTSD_S,SXV+S*$=T !8
M  !5=8"ZP   0  4  &E7_\ Q*PU^%/_  FZH:5?_P#$K#7X4_\ ";JA9[0Y
M.%_$Q?YO[:@ (ZX536 FL"   $  (!=0"Z@(  0  ! $!%@*KK+%5UB%0 "H
ME $!$%UD$KK(*H  @  !"ZB2%U 5  44@E2!+&3D4#D4$ @D@0!!)TKM<8+9
M2NFF7-W[$:+QO4HK>;I!::19JA<U7BCC36]>;^IY;=:VINE8ZIJW(KUXD:FI
MJ<R'<N=7/<JM]14NS5?DM1>)J<R'5WL,HC)T=Z&]'>WL;V%='>AO1WM[&]@=
M'>AO1WM[&]@='>AO1WM[&]@='>AO1WM[&]@='>AO1WM[&]@='>C<<(XBWE&4
M-Q>F](FC%*NM/\J]G::YO9&]!)C-ZZ576:AA:_+'HT=>_-FJ.5R_)[%[.TV]
M0U3&2  1$)J 34"PB% 4$4 !8  $0  '&     %2Q4(*5+*5"P!=0"Z@*@ J
M  (@I!*D! <H'*!5=9'(I*ZR.12H(%"!0(._9_GW_=_F= []F^?D^[_,C*GK
M,L "NH  'G>ZG]$D_$C_ $4X,&ZF^TY]U/Z))^)'^BG!@W4WV@AZ'!\TWV 0
M?--]@ Z-U^L:/[QED,3=?K&C^\99    '7N/T&;[IV#&WZOI*&B=Y;41P;XB
MM9IK\I<M18B9Z0DS$1G+ $H8[SU;.G0;5)2]6SIT&TRT[[2UZM/-'Q9$@Z'G
MJV=.@VDI>;8O_P ?3I[7*-.VTFK3S1\60:.4Z+;Q:N6Y4^U? GSQ:NLJ?:O@
M-.VTKJT\T?%WTU$H=!+S:NLJ?:I*7FU=94^U? FG?:5C%IYH^+O@Z'GFU=94
M^U? >>;5UE3[5\!IWVDU</S1\7?0LACDO-JZRI]J^!;SU:>LJ;:O@-.^TFKA
M^:/B[Y*'0\]6GK*FVKX!+U:>LJ;:O@-.^TFKA^:/BR .AY[M/65-M7P'GNT]
M94VU? :=]I-6GFCXN\2=#SU:>LZ;:O@3YZM'6=-M7P&G?:35IYH^+O Z/GJT
M=9TVU? CSU:.LZ;:O@-.^TFKA^:/BR .AYZM'6=-M7P'GJT=9TVU? <EMI35
MIYH^+(-Y2Z&-2]VA/_F=-M7P+)?+1UG3;5\!IWVDU:>:/BR ,?Y\M'6=-M7P
M'GRT=9TVU? NG;:35IYH^+(H#'>?;1UG3;5\"?/MHZSIMJ^ T[;2:M/-'Q9
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M^?
M
M             ,[@I,[TJ?\ *<8(V' :9WY4_P"2_P#D:L;\.S?POXU?U;MO
M?:-[[3M:*#10\9]$ZN]]HWOM.UHH-% .KO?:-[[3M:*#10#J[WVC>^T[6B@T
M4 ZN]]HWOM.UHH-% /-L7IE?94_R,_0PYG,:)EB&;+[-GZ&#/:P?PZ_H^<XC
M\6WZR  V-(
M                        .U:?K6C3_FM_4]1='\)3R^S?6]%^,W]3UIS5
MTEXN4\[C?6AZ_P!F^I;]74WL;V=K17F&BO,<3TG5WL;V=K17F&BO,!U=[&]G
M:T5YAHKS =7>QO9VM%>8:*\P'5WOL-?QLS1LS5_YS?T4VK17F-<QZF5C;^,W
M]%-N!^)#1Q/X-OT>?  ]E\Z
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MU%XD1>TR-_P]66-L*USX,Y55&MC=FO%RZC=-HB>7/JYHI::S:(Z0PX ,F(
M        !LFY\F>(%_!?_(ULV?<Z3/$2_@/_ )&K'_#LW\+^-7]7H6B-$Y]#
ML&AV'C/HG!HC1.?0[!H=@'!HC1.?0[!H=@'!HC1.?0[!H=@'!HC1.?0[!H=@
M'EN.4RQ)/^&S]# FP8]3+$T_X<?Z&OGLX/X=?T?.<1^+;]9  ;6D
M
M      '<LOUS0_C,_4]@<WX2\7*>06/ZZH/QV?J>SO9\-WM/.XWUH>O]F^I;
M]76T1HG/H#0.)Z3@T1HG/H#0 X-$:)SZ T .#1&B<^@- #@T36MT%N5A9^.W
M]%-LT#5]T9N5@9^.W]%-N!^)#1Q/X-OT>:@ ]E\Z
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MC5YC=BWGGY9Z1EMFY\##B<.;1UG/?+)R;JC6NPY ]<E<VH;DOM1Q-A_PS?\
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M2C)0/(]T!,L45'X<?Z&NFQ[H7]ZJG\./]#7#VL'U(_1\WC_BV_60 &QJ
M
M          !WK#]>6_\ '9^I[<]GPW>T\1L'U[;OQV?J>YN;\)WM/.XWUH>O
M]F^I;]7#H*-!3ET>T:/:<3TG%H*-!3ET>T:/:!Q:"C04Y='M&CV@<6@HT%.7
M1[1H]H'%H*:GNE)EAUG^H;^BFXZ/::ENG)EAQG^H;^BF[ _$JT<3^#;]'E@
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M C).8D ",D)  $9)S$@"$3+43[0 "<1"(B:B0!")EJ)X@ (R37RD^T ",D)
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M" 3D,@(!.0R \?W1/[UU/X;/T-<-DW1/[V5/X;/T-;/:P?4C]'S>/^+;]9
M;&H
M                 '>L'U[;OQV?J>ZN^4OM/"L/_7MN_P!0S]3W=VM3SN-]
M:'K_ &;ZMOU4!8'$]+)4%@#)4%@#)4%@#)4U+=/_ +ML_P!0W]'&WFH[J/\
M=N/_ %#/T<;<#\2K1Q/X-OT>4@ ]E\Z
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MI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI
M<F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F
M8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S
M./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./
M2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&
MD!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!
MR9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9
MC,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,
MX](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X]
M(:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:
M0')F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0'
M)F,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F
M,SCTAI <F8S./2&D!R9C,X](:0')F,SCTAI <F8S./2&D!R9C,X](:0')F,S
MCTAI <F8S./2&D!R9C,X](:0')F=ZT+G/)]W^9C=(R%E7^WD^[_,QMVEE3NR
MX .=T   \[W4_HDGXD?Z*<&#=3?:<^ZG]$D_$C_13@P;J;[00]#@^:;[ (/F
MF^P =&Z_6-']XRR&)NOUC1_>,L@   #@KOHDOW3G."N^AS?=+7ND]FN@J#J<
MJP*@"Q2:5D,$LTBY1QL5[EYD1,U_<A)U+Q]2W+_2R_P*!K7I.PEUF_W+C8+'
M?;7?872VBNAJFLRTT8OPF^U%XT-*W%Z"BJ,!PR5-'2S2>42II2PM<N6:<6:H
M8W$=NIL.[JN&9K'&E,^X/RJ(8^)JM5VBJY<B*F?%V&<UC.8:8O;EBT]I>L@T
M_$F.*3#N(XK=<HM&D?2NJ%J&JJNTDSR8C>555",,8BQ%=KO''6X8?;[7*QSF
MU$CU5R<6;45.WB,>6<LV?/&>3<0:+<\=U$MWJ+7A*SR7FJIE5*B32T(HUSRR
MSY>/E+63',KKU'9\46I]FKYD3>55VE'*JZD1>3,<LFI7/)O -8QABR/#\E)1
MP4<M?=JQ<J>ECXM+CRS53$QXJQ;3S1><L&/;3R/1NE3SZ:L15RX]?[Q%9DF\
M1.3?0:QC;%D6%9;5Y5"CZ:KE='+)I+G$UJ9JY$37[#!5.-L2I ZOI,'3.M*-
MTTDED5)7,];135Q<>H169)Q*QT>B UZS8NM5TPU+>V3+%24[56I:]/A0N1.-
MJIRKS<YK<..,17*%U=8<(R5-IS562RRZ+Y$36J-\,QRR3B5AZ*#!80Q-18HM
M:UE"CXW1NWN:&3Y43^9>SF4QV+,:PV6X0VJWT4MTO4R(K:6+B1J+JTE[>8<L
MYY+SURYL^C;B,TST=)-+7EGQFEV3$F)Y[G'37C";Z6&1'.2>*7-&Y(JY+GQ9
M\AIL&)+_ ";IE;61X>EDKF4:0>0+)DZ*/-%1RKS\?[RQ1C.+$9/3L4XDM^&:
M&.KNJRI%)(D3=Z9I+FOYZC+Q2-EB9(Q<V/:CFKV*F9HV)\32T&$*2XWS#\*S
MRU21.HJA=)(]>3L\M?%^\R-DQ6ZNQA<</5=&RFGIHDFB>U^:3,XEU<G$J*.7
MHO/&>6;:@8;%U\CPYAVLNLS$D2%$1L:KEIN5<D;GM7\CCI\01PX1BOUZC2AC
M= D[XT725J+\E$YU7BXNTQR7FC/)G0>=1XXQ+5TRW&VX/DFM"HKFR/FRD>Q/
MVD:;9A7$-%B6T-K[<KD9I:$D;TR=&]-:+XEFLPE;Q;I#,@J<55-Y/25$V6EO
M4;I,N?)%7+]Q&;G!YQ;=T:MO5#'Y@P]-77')5GC1ZI% F>3<W<JJG'D=_#N.
M9ZB_-LF)+2ZT7*1,X4TE<R1>;/DU<2ZB\DM<8E9;P#!XIO519:2G?16JINE1
M/)O3(H.1<L\W+R(:O5X\OEEWFHQ/A9U#;7N1KJB&;?%8JZLT_D(K,K.)%>[T
M-51$555$1-:J2BHJ9HJ*AYUNNWRLBPM)3V^BDEM]=$Q9*_/)C6N7-&HFO-4R
MVG=P1?+[4LME'68<DI;>E.U$K5DS141J:*Y=O\QR],SGCFY6\ UB;%#HMT&#
M#/DK5;+3>4>4:?&GP57+1_(S-ZKEMMGKJY&)(M-"Z705<M+),\LR9,HM$Y^Y
MW@:S9\3NN.!%Q$M*V-R122^3Z>:?!54RS[<C78-T>LNE%2MPY89+C<GQ;[4Q
MM<N]TW&N35=RKDF?YEY98SB5AZ0#7:V_5U!ABFN-39JB6X2Z+74-.N;F/55R
M157D\37*['.)+53>6WG![J>W(J:<C)\WL1>=.3\Q%9DG$B.[<L37B+#]AJ[K
M40OGBID171L5$<[-43B5?:<]FKV76T4=PBC=&RJB25K'+FK47D4U7=(K8+CN
M5W*MHY-\IYX8Y(W999HKT_>9G J_^Q=C_P!(P9=,R+?Q9>YRXLOT.&K'-=*B
M"2HBB<UJQQN1'+FO.ID;?4MK:"FJV-5C)XVRHU5S5$5,\E--W9^/<^KD37OL
M?ZJ="T8QN]1:**/"V&Y;I34\+(9*F1^]M=(C4TD;SY%BN<9I.)E;*7I"&%I,
M36VJQ55X>B?*MRIH]\>BL^!DF6:(N>M,T,?@K%[,1R5M'44<EONM$N4],]<\
MN/+-%[%Y%*VZ]03;H]UM#+;3QU$%,V1U<WYR1,D^"O%JX_W$Y>^:\\3E,2VP
M&F8AQG44U]?9,.VB2[W2-B/F33T(XD[5_-"UAQ)B&>[0T-\PM+1-ESRJ8I=*
M-N29KG_11RSEF:D9Y-P5414153-=29\:DGCEQQ'?)-T^GEBL$SJFEIGQPT#I
M/A.8Y%S>JIQ=IZ#08AFBP]577$] ZS-IW+I1N7356\62ISJJKED6:Y%<2)S;
M$#SJ''&)+C%Y99,'RU%L7-62RRZ+Y&\Z)_\ K-CP=BNCQ/22N@8^GK*==&HI
M9?EQ+GE^:$FLP1B5F<H;$#1;MNA06R^72V343Y9Z9(VTT<*JKZE[OV<N3+G.
MC5XZQ);*"6NO6%$I*5DC&JJS+GD[E_+(O))J5AZ0#AI:B*JIH:BG?IPS,;(Q
MW.BIFAKEGQ6Z[8NN5HI*-JT= W^TJ]/C5^K11/;GL,8C-E-HAM(*@*L"H L"
MH L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"
MH L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"
MH L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"
MH L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"
MH L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"H L"
MH L"H L"H L"H L"H L9&R?/R?=_F8PR5C^D2?=_F8W]665.[,@ YG2  #SO
M=3^B2?B1_HIP8-U-]IS[J?T23\2/]%.#!NIOM!#T.#YIOL @^:;[ !T;K]8T
M?WC+(8FZ_6-']XRR    .O</H4WW5.P=>X_09ONJ6O=)[2UG-1FI4'6Y%LU&
M:E0!;-3J7A?B:X_Z67^!3LG6N3'36RMBC172202,:B<JJU41 CR7<UMF*ZO"
M<<EBOU)04*RO1(I(E<]'<6:YY*;GA?!2VZ\.O-\N<MXNZIDR61,FQ=K<^79D
M6W*[76V;!\5'<Z=U/4I/(Y8W99Y*J9*;<9VGK+5ATCEB9>:8KIH:S=DPY%4Q
MMDBWA'*UR9HJHKE3/\ST:XS214%7+&JI(V)[FKVHBY&FWBSU\^ZC9;K#3/=0
M4\"LEF3+)J_"XOWH;OQ<J(J<J+RDGV,J1UM^KS_<0BC;A6JG;DL\]6]97<JJ
MB)EGM7:<6[LQJ88MM2F25,-<S>G)KXT7/]$..CM6(L$W2O6Q4#;O9*R7?6T[
M7Y2PK_ZXN;4)[/B#&MWH9,1T3;79*.3?6TJOSDD?VY?KJR,O]W,U]>3DRZLW
MC;#-;>JFU7FS5K:2]4,:+&LB?!?FF:HO,N:KM,=2X^N-IK8*+&MEDH%D<C&U
ML*YQ.75FO9[%_(S>*;CB.AKJ>6R6J*Y4*L5)HT=HR-?FN6CV99&KXAAQ1C2"
M"V2V)+10I,V6::ID1SLD]5$_,D>];=)F:YYK;M+8YI\)L>K71/K51>/B5%T?
MW'J#U5LRZ/%D[)$/*-V>D1T6%*.&58__ !"Q,D<F>BN3415_<92>^XZIX'4B
MX;9+<6IH)6QR(L*KJT\N?E&6<0L6Y;6>9WI[J.+%]!1YI0OND:*C5R;Q.DR3
M_P!<QZ;;KCCJFH:6*EP[9D@CB:V/*H<GP43B_:."S[GJ)@VY6Z[3-?=+D_RB
M69JYI%(F>C[<E5<_:5M-QQK8:..VUN'_ #LE.W0BJJ>5/A-35G[-IE,Q+"L3
M7K.<?Y+M;F]BO-LQ!?*Z\4L%)#7Y/;#!(CF(_2S7)/9F=+<Z1*G='QI5U"(Z
MI9)H,TN-6MTU3BYN)$0VS"M5?:N"JFQ#0PT*JYOD\,;M)4;DNDKN/7GD:S?;
M!>[-BR?$>$XHJI*MN5;1/7)7]J<^>OBU*8]\\V6641,>QZ)FIYS9E_\ ?=?%
M_P#R:?HPRUEO6)[A=J>*KP[YMMZ<<\TTF;LLM3>/G,5?[9?+1CY^([';O.=-
M4P)%- UR(]%RR_DBYB(RZ,K6SRF/9*V[BN>$Z7_6Q_PN.MNBM7#]\PYBNG1=
M%JLI:K+BS8J<6:^S-/R.7'-'?,3X-I42SR05WEC9%I=)%<UB(Y,U7\S:<569
MM]PK56UZ)OCX46//DD:G%^_B_,1TR8VB;3.7N:MND.6_XJP_A6%^E!,[RRH5
MO&FAQY*OY(J_FA3=P>]ECM%+ U$@?5HU69Y-^"WX+5[#DW,\/W6GN-9>,2PO
MBK]ZCI($>J*J1HU$5>+L1$VFS8UP_'B6PS4+GI%.B[Y!*NIDB:L^SD+G$3!E
M-JS.[#PW+'L#&1Q8;LC&1HC6M;4NR1$U)\HIN86*[62:]/NU/#3,K)6S,BBD
M1S47CS1.9.,ZMOO&-K32MH:_#:W*6%J,;54\J9/1-2KS\7L,U37:]4V&+O<\
M1TE/130L=)!#$[2T6HWBTNW2Y">Y:S$SG.;:\U.M=%7S57?Z>3^%37MS>MNM
MRPK!7WR??JBI<KXUT$;E'J3B3MS-@N#'2V^KCC17/?"]K4YU5JHACEE+9$\T
M9M(W#8VQX)<]C41\E4]7KRKDC40X]T9='="P&YN2.6?)5Y53?&\7[S)[E5JK
MK-A-*2Z4[J>H2=[]!V6>2Y9+^XX<<6>ON.,<(5E%3/EIJ*;2J)$RRC33:N:_
MDBF7^Z6K*=.(_1W<4XR6T76"SVNW372\3-TTIXW:*,:NI7+^_P!AJFZ/68LJ
M<$7%MXM-JI:!48KW1U"OD:NDF629Y:S)8FM%[MF.F8IL-&RXMD@2GFIL\GHF
M62JGM3+CY#I8NI\7XOL553>:6VRC8F^)32/1TU3(B_!:G,G+^18B(R2\VF+1
M.;L8]7_W/4'X%+^B&\X<7_V>M?\ I8OX$,!?,/5%WW.8;0U$BKF4L*-:]<D2
M1B)\%5_)4S.M@VY8E:E!:[MAZ2GB@9O<E8KTT51J9(J)S\2$[PSB<K?T=&L7
M_P!_M#_].7^!QMV,E_\ 9"]YK_\ "2?PJ:OC>QWEF*;?BC#D,=354T6\RTSE
MR61O&G%S\2Y<YP7J7&&*+34VYEE;9Z:2-=_DJ)$<^1$XT8Q.U41!EGDQB9KS
M1DMA)?\ W'N_TL_\2G>W&*>.GP!1OB:B/GD?)([+C<N>29^Q$&'K17TVY6ZU
M5%,^.X+3S,WE<L\W.7)#O[FUOJK3@R@HKA"Z"JCT]*-VM,W<0GM*TB<Z_HOC
M'%T>''T=+#22U]SK5RIZ6)<E7CRS5>;/B-=Q1<,8U6&+DE?8[52T;H';[G4*
MZ1K?9GEF=G'UDN[\16;$=@IV5=1;TT7T[ER5R9JN:<_$JH=>\+BS%=LJ;>EH
M2R4CV*LKYWHZ27),TC:B:LURXQ$1T2TVF9B<V/D7/_A]?QJN4*)Q_BF]X&7_
M -B['_I&&JNL5S7<<=9O(W^<UCR\GS3//?,_T-NPG3346%[52U4:QU$-.UDC
M%_95.03V6D3$_P!(8#=E5?1_6_B1_JIL.$H(Z;"UIB@:C6)3,7).=4S5=JF(
MW3K;67?!U51VV!T]2][%;&W6J(O&9VQQ/I[+;X)FJR6*G8Q[5Y%1.-"?[641
M_',^YI%C^#NV7S1R1%HT5<N5=%G&7L:_^_#$/^A9^C#MVNSU\.ZG=;K)3/;;
MYJ9(XYERR<[)J9?N4M:K17P[JMYNTM.]MOGI&QQS+EDYR(WB_<IE]&$1/3]?
MJX,08;O=!B>IQ)A*>!\]0U&U%#.F22Y<R_DB\G&=G#>//+KNVS7VV3VB[/XF
M,D559*O,F?&G9K]I>ZWC%5NO%2R##[;G;%=G3R02(UZ-RU._/,Q,5KO^*,7V
MF[WJW1VJAM:Z4<3GZ4LBYYY<7:3O'4SRG^',>O\ []HE_P#R'_0IR;N4C^"=
M+#I*V&6L8DF7,B+D6QA:+U28RH\3V"D;7N;%O$]-GDY4XTS3VHOY'?K[?68U
MPC6T5ZMSK14.D1:=LCM-6JU,T>N7)FJI["^V))B9BU6VT;&04=-%"U&Q1Q,:
MQ&ZD1&ID>>6U$I]W:Y1T_P &.>BTYD;J5VBB\?YHBEZ"[8VM-"RWU6&TN,\#
M4CCJX94T'HG$BN_=S&0P-ANX4=SN%^Q')&^\U_P59$N;86<WMXD3BU(A(C+-
M9GGF,H8JQ4T<V[5>YY&HY]/3HZ-5_954:F:=N6>TWN_VYEXL=?;ID31J871H
MJ_LN_97\ER-8LEHKZ?=*O=SFIG-H:B!K(I5RR<J9<7[C<\R2RI'2<_>\YP!B
M;S7N?W".XKE6V+3A<UW$J\:Z'[^(R.X]:Y+?A-:NJ15J[E,M2]SDX]'4W^:_
MF:9NA62:;=!\WV^1&Q7W>I)XV\BM=\)5[.)5/9XV1Q1,BA;HQ1M1C$YFHF2%
MMV_5AAYS/7V=')FHS4J#!O6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;
M-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU
M&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49
MJ5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI
M4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0
M!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %
MLU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S
M49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1
MFI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:
ME0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5 %LU&:E0!;-1FI4 6S49J5
M %LU&:E0!;-1FI4 6S4R=A7.HD^Y_,Q1D\/_ $F7[G\S&_JRRIZT,Z #E=0
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MA4 6V#85 %M@V%0!;8-A4 6V#85 %M@V%0!;8-A4 6V#85 %M@V%0!;8-A4
M6V#85 %M@V%0!;8-A4 6V#85 %M@V%0!;8-A4 6V#85 %M@V%0!;8-A4 6V#
M85 %M@V%0!;8-A4 6V#85 %M@V%0!;8-A4 6V#85 %M@V%0!;8-A4 6V#85
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M+(
M
M
M
M
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MJF.BHYZJ=52*%CI'JB9KDB9K^@',#J6BX076W4]=1JY:>=NFQ7)DN7L.V
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MSYYITG^6;UOV6CQ:.>6LR(
M
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MM*RM2.2"23B:]$1<^/\ ,KAVZ4]WW5ZVJHE5],M!H,D5%1),G(BJG.F?%GV
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MF,E_GAJI4FH74:W&9:E9--95=Q:6CR9:LCTD\YW,KO14#;C:*V=L%Q=<I5;
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M)62-^$]%1<TSY<N+C FCQ!?L1+55.'66^GM]/*L3'52N5U0K=>66I#.8.O\
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MNQI.?_O:1/\ ^V_]:F[
M
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MMUNN+J:\W&V16JFI(GMCC1[722JY,OA9:D0W*IHJ6J5%J::&94U+)&CLMIV
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MVMKDS1?R+@#@IJ.FI=+R:GAATM>]L1N>PIYNHM^W[R.FWW//3WINEGSYY':
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MF7
M
M                 !2>1(H7O=J:BJ7,-B>NCI*%VFY$:C5>_CU-0#RK&L_E
M.(8X47/>8\W?>=Q_ID;AA&'18W-#SRVK)<+C-52\;Y7*[V<R;#UK#-/H1)Q!
M6QPI_9H"[$R;D @Y,T4P=TC='*R>/-'-4SIUJR))(W(!:BJ6U5.V1NM>)4YE
M.<UFGG?;JM>+-B\2ISH;'#*R:-'QN1S5U*!<
M
M
M
M
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M,-TII-;E8O,Y,CMLEC?\F1J^Q0+@
M
M
M
M
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MYWB;EP=9ZJ;!P=9ZJ; =&F\*;IT6G[SO$<*;IT6G[SO$W+@ZSU4V#@ZSU4V
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MYWB;EP=9ZJ;!P=9ZJ; =&F\*;IT6G[SO$<*;IT6G[SO$W+@ZSU4V#@ZSU4V
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MMF&T3)5;^AMULLK(D3-N1G(:1C-2(=AC=% CAIZ=L:9(AV$3+4
M     !DG,@ $*U%4C>V\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S
M -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -
M!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O
M,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-
M!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O
M,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,
M T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T
M&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\
MPT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT
M&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\
MP #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P
M#0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0
M;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S
M#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0
M;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S
M  -!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S
M-!O,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #0;S#0;S  -!
MO,-!O,  T&\PT&\P #0;S#0;S  -!O,-!O,  T&\PT&\P #>V\PWMJ<@ $HU
0$Y"<D            #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g50309g16m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g16m01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1JP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &I,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"C_P  1" *S!4H# 2(  A$! Q$!_\0 '  !  (# 0$!
M          0' P4&" (!_\0 61   0,# 00%!PD' @0#!0,- 0 " P0%$08'
M$B%1$Q0Q5)$5(D%287&2%A<R-8&3HK+1"#1"<G-TL2,S)$6AP39ULS=#4V*"
M&"4X1/ F559C9':4X8/#TO_$ !L! 0 # 0$! 0             ! @,$!08'
M_\0 .!$!  $!! H! @0$!@,       $"!!$24P,3%B$Q46&1H>$507$%%#*Q
M(H'!\ 8C,S1"PE+1\?_:  P# 0 "$0,1 #\ ]4J+55K('=&T&68]D;.)_P#[
M)<*AT$($0S,\[K![5^T-(VG82?.F?Q>\]I*#"TW"49W881R.7%.BN'_QX?A*
MGH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'
M>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/P
ME.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W
M#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ
M(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB
M'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3
MH;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[
MQ#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"
M!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^
M$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&
MX=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0
M_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=
M#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*
MGH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'
M>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/P
ME.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W
M#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ
M(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB
M'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3
MH;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[
MQ#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"
M!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^
M$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0_"4Z&
MX=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=#<.\0
M_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*GH@@=
M#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'>(?A*
MGH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/PE.AN'
M>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W#O$/P
ME.AN'>(?A*GH@@=#<.\0_"4Z&X=XA^$J>B"!T-P[Q#\)3H;AWB'X2IZ(('0W
M#O$/PE!%<!QZ:$^PM*GH@UCJVIIS_P 7!AGKLXA3*>ICG;EC@0LSFAP(< 0>
MT'TKG;M$^UR"HI\] >UO+F@Z-%#MM8VKA#FD'/M4Q!KY!TEYC![(HB['M)PM
M@H#/KJ3^B/\ *GH"PU%73TQ:*B:.,N[-]V,K,J=V]M!K;-D9\R7_ "%:BG%-
MSCM]JFR:"K31%]UWF;EK>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0M=3U?/[2U9
M7GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0
M=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5"
M:GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y
M!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?
M5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/
M57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/
MC"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZF
MTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$
M\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FX
MWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4
MH.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*
MNXWU0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E
M>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!
MWR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)
MJ>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD
M'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]
M4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]
M5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^
M,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;
M2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y!\83
MRI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C
M?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2
M@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J
M[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65
MY]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'
M?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0F
MIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0
M?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU
M0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U
M5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#X
MPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM
M+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/
M*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/5?E*BW"_K<.Z#C.^,97YY4H.^0?&%
MYM8QOR.J> ^L(_\ TW+3[C?5"B-#?]5Z_P#$55%W^7QB_CZ>JO*E!WR#XPGE
M2@[Y!\87E7<;ZH3<;ZH4ZGJIM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J[C?5";C
M?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65Y]/57E2
M@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'?(/C"\J
M[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0FIZFTM65
MY]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0?&$\J4'
M?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU0FXWU0F
MIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U5Y4H.^0
M?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#XPO*NXWU
M0FXWU0FIZFTM65Y]/57E2@[Y!\83RI0=\@^,+RKN-]4)N-]4)J>IM+5E>?3U
M5Y4H.^0?&$\J4'?(/C"\J[C?5";C?5":GJ;2U97GT]5>5*#OD'QA/*E!WR#X
MPO*NXWU0FXWU0FIZFTM65Y]/57E2@[Y!\87Z;E1!K7&KA#7=AWQQ7E3<;ZH6
MWN30=.V'('T)O_5<HG0]5Z/\15515.KX1?QZQ'+J])^5*#OD'QA/*E!WR#XP
MO*NXWU0FXWU0IU/53:6K*\^GJKRI0=\@^,)Y4H.^0?&%Y5W&^J$W&^J$U/4V
MEJRO/IZJ\J4'?(/C">5*#OD'QA>5=QOJA-QOJA-3U-I:LKSZ>JO*E!WR#XPG
ME2@[Y!\87E7<;ZH3<;ZH34]3:6K*\^GJKRI0=\@^,)Y4H.^0?&%Y5W&^J$W&
M^J$U/4VEJRO/IZJ\J4'?(/C">5*#OD'QA>5=QOJA-QOJA-3U-I:LKSZ>JO*E
M!WR#XPGE2@[Y!\87E7<;ZH3<;ZH34]3:6K*\^GJKRI0=\@^,)Y4H.^0?&%Y5
MW&^J$W&^J$U/4VEJRO/IZJ\J4'?(/C">5*#OD'QA>5=QOJA-QOJA-3U-I:LK
MSZ>JO*E!WR#XPGE2@[Y!\87E7<;ZH3<;ZH34]3:6K*\^GJKRI0=\@^,)Y4H.
M^0?&%Y5W&^J$W&^J$U/4VEJRO/IZJ\J4'?(/C">5*#OD'QA>5=QOJA-QOJA-
M3U-I:LKSZ>JO*E!WR#XPGE2@[Y!\87E7<;ZH3<;ZH34]3:6K*\^GJKRI0=\@
M^,)Y4H.^0?&%Y5W&^J$W&^J$U/4VEJRO/IZJ\J4'?(/C">5*#OD'QA>5=QOJ
MA-QOJA-3U-I:LKSZ>JO*E!WR#XPGE2@[Y!\87E7<;ZH3<;ZH34]3:6K*\^GK
M2*1DL;7Q.#V.&0X'(*^ESFSGAHBS?V[5T:QF+GU&AKUFCIKYQ$BAW:)LMOF:
MX9X94Q8*_P#<YOY5#1P^B;@3-+3N=G<D+/ X7>!_!5/HMY%ZK!__ !#_ ,Q5
MJL=YHX>A!&9]=2?T1_E3U 9]=2?T1_E3T!4_MY_?+-_)+_V5P*G]O/[Y9OY)
M?^RTT7ZGD_CG^RK_ )?O"JT1%U/@A$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!%^.<&_2("_001D<0B!$7T&.<TN#7%H[2!P")XOE$1
M 1$0$1$!$) [2 @XC@B!$) &2<!$!$) [3A$!$1$B(2 ,DX"_ X$$@@@(A^H
M@XC([$1(B(@(B(-PS_P=4_\ F$7_ *;EIUN&?^#JG_S"+_TW+3JM+;3_ /'[
M1_41$5F(B(@(B_4'XB(@(F1G&1GDB($1$2(B("(B B+]0?B(B B(@(B("+]7
MX@(B("(B MO<?_#MA_IS?^JY:A;>X_\ AVP_TYO_ %7*L_1MH?TU_;_M2U"(
MBLQ$1$!$1 1$0$1?N$'XB(@(B("(@()(!&0B!$7ZB7XB(@(B_4'XB(@(B("(
MB B(@(B(/26SK_P19_[=JZ)<[LZ_\$6?^W:NB7%/&7Z79/\ 0H^T?L+!7_N<
MW\I6=8*_]SF_E*AT*IT9]=UG]P_\Q5K,^B/<JIT9]=UG]P_\Q5K,^B/<@CL^
MNI/Z(_RIZ@,^NI/Z(_RIZ J?V\_OEF_DE_[*X%3^WG]\LW\DO_9::+]3R?QS
M_95_R_>%5HB+J?!"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@+[AC=--'#'_N2/#&^\G 7PLM)-U:LIZC&]T,K9,<]TY1--U\7\%J7^MM.S
MZ.CME#:*:X5SXA)-/4 9QV<O20>'H7$72H&K=04L=FM,-%-,!'T,6 '.[7.)
M[,?]EW6O],U.KJBAO>G7P54,E.(WMZ0 CB2#_P!>(]&%H=(4;](;0*&"]O@8
M^:(M#FORUA=V9/V8^U8TS%U_U?0VO1Z6K31H:HNT-\1$Q$77=)ZON;9E48F@
MH[Q05-RA;O/I&G#A_P!>'VA;#9U035NS_4] P-CGDF=$>E.Z&'=:#O<L<5M[
M!I>XVS:1<;U6OB;;CTKQ.Z0>>'=@/+'MY+7VBLCJ]%:^JZ3+8IJF9[".&06C
MC]H_RJS5,Q<WT5ET6ATF/!A_7%U_&(CCO<U?-"36^PONU#<J6Y4T1_U3!_ .
MPD')S@K%I[1,USM NE?<*:UT#W;L4E1_'Z,CB,!;G1_#9+J@#LWWX'_TM4VO
MML^K=F5DAL@CEGHW!LM.7AI! +3V^_/N*MBF-U[EIL>@KNTE-%]]%^&^=\WW
M?=Q&L-,UFF:B)M2YD]/,W>AJ(OHOYCV'L71MV9U37QOJ+G204;X6R"HD&!O'
M^#!/;CCE2=J;F6[2=@LE1*R6X0,:Z0-.=T!N/#/9[DVS/>:;346\>CZNYV[G
MAO8:,XYJ8JJFY7266SZ&K3554WQ3%,W7\)GC%Z34;/[:S2=O?)=;?3ULDA<^
MM<_,<@XX8WC@^CP57O&Z]S0<@$C(].#VJU*VS5>H]ENG(;1''/)"\%[2\#&
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M=?6M_P#_ %L7_P#TI%2^-FA+&Z>+IH6W&4OBWMW?&.+<^C*C>5=/?_LHW_\
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MN/;]F%%,M[713-%<Q'##,3==QC??][K[OHY=$1:/*$1$!;>X_P#AVP_TYO\
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MQNX_W<T&HM(72Q4+:RJ;%+1N.[T\#PYH/HRNCU[24T&B-*2P4\,<LD+2][&
M%QZ-O:?2MS?V1LV.5?0VJ6U1.E:YM-+(7N ,C>)SQ&>2UNT3_P !Z0_H-_\
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M2F9/OPS-!X%KAGAQ;Z3VKFY]OVJ?D[2:EAT9 --](RGJ*F2I.7RYPX1\FYX
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MYT>0.8';X+9_LQ6C4MITM7LU$VL@H'SYMU-6$]+%'Z<@]@/#A[T%RHB("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M$><0>(' #Q4"XD1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!:S453=**W&>P6V"Y7 .#1#-.(!N'M.^1[N'I6S7+ZLH
M=73U]+4:4O=MHZ=L9;-25U(96O=GZ8>TY'#ACV(.&T9+)-K37-5KV$VJ\SVL
M=+31\8&6]H(=(R0$[YSVGACDN&$VHV;)Z6T5%#.W9UT@:;LR$&M-%O%S7.AW
MN )P-_'9QPK<L&A*V2IO=PUM=VW>XW6A=;'"FB,,-/3.SO,C!R>).<GTK3NT
M)K9^GODN_5UN^3^YU8SMH7"K=38QT9.=W..&4%GT!@-!2FB<UU(86="YIR#'
MNC=/AA<AM>OM3;M,,M=KD=Y:OTPME" [!:Y_!\GN:W)S[ELFV:[TNI+*ZV75
MD&EZ&A-++;7,RZ5X&&/WL>@!O@>:Q5&F):[:'3:BN51#+26ZD,-NI6M.8I7D
M=)*XGAD@8&/0@W.E[)2:>LENLMO %)11-A9P^D!VD^TG)^U<!L!=Y1TUJ"ZU
M;6RU5TO56^9SAG>:UVZUI'(#T>U6>T[K@>152Z3M5SL;-;:)M=4;=<)IY+E:
M+@^,O8(9CQP<<7,((^T<D$O:%*-=7J@T=9-V:.BK(JR[UC>+*)D9RV('LZ1W
M(=@'%=[JS4-/IK3MRO=>[=IZ2(R;I)\]W8UGO+L#[56&F]"[1=.6YM#:-4:<
MAAWC)(\VUSI)GDY+Y'$Y<X\RNTUOI2?5C+!25E7$VV4E6VLKX=PYJG,'F-')
MN]Q.4&IT' W0VSM]WU*:AU?<)?*-Q='$Z63I9B,,W6@N(:"!Z<8*YK:KJJFU
M1IK3T%BI:JM@J[_!2S4T\3Z;IR 7B-V^!YI(&3V<%=.\=[(.#[%H=;:=CU59
M.I254M)4Q2LJ:2KCXOIIV'+) /3CE[4'/RZGU-I_4ECMVJZ:SRVV[RNI8:BV
M=(TP3!I<UKFO/G-(!XC"E;1]0QVJTR6.U4[*S4-X8^"BM\> 7EP(=*_T!C<D
MDGMPH5ITAJ*X:AMERUY>Z"Y0VHF6DI:&F,+3,1NF5Y)XD#L X<5SE'H#:#0Z
MBN=ZIM56&6X5K\=9JK>Z62.($[L3#_"P9[!VE!-UOIEFGOV?9+;)()JNQ4D5
M3%..&[/&\.WF\ADD#V*R[36FXVNCK7L#'5$+)2T=@+F@_P#=5IKYFH)=%6S2
M%TGAN=^U#5=5FJJ2G='%%3AV\][A_" T >TE6G##%3PQP4S=R&-H8QO)H& @
M^T1$!$1 1$0$1$&'_F+/Z+O\A9EA_P"8L_HN_P A9D!$1 1$0$1$!$1!JM2W
MZWZ7M%1=KD_<C: T-8W,D[_X8V@<7.). /:N4V;Z6D^3E]GU11,;/JBKDKZR
MWDG=A8_@V(X].Z!GVE:_6NA]77G7,-^M=_M4-/1- M]+64KY13.(\Z0 '=+R
M?XCD@=BZS1='JFCCK/EA=[?<Y'N:8#1TQAW!QWM[/;G@@Y?0]#2VS;)KFBMU
M/%34D%#;V10Q-#6L&X>  5F#(7,6G3<]#M!U+J)]3$^"ZP4T,< :=Z,Q-P23
MV'/L4NUT%[AU3=ZRX7>.HLL[8Q14+8=UU.0#O$N].?\ K[$'*[5))]0WS3VB
M*9SG0U\O7KJ6D^91Q'Z)_G=@?8NKUQ<C9=%WZX4[2U]+0ROC#.&Z0T@8Y8R%
MKM*Z6J+9JS4VH+G5Q5=;=9&,@W&D"GIF#S(^/I])*Z&\4$5UL]?;I\=%5P/@
M<2,@;S2,_P#=!HMF5HIK1L[TW2PAKFBBBJ'.<!QD>T/<[WY).5SM%5'76T^B
MNE P^0=,-FCBKMWA6U,@#7-8?2Q@!R1PRM+;;?J76&R<:4AN'D:[VF46NY.G
MB=B>*,8 8YN#NO;CB.WB%N])Z:U]9I[;2S:AT]Y"I2UKJ.EMKHST0[6M/H/M
M01]JMFMM!7:7KZ*A@AKJ[4U*^JG:WSYB&/QD]N/9V+N-5ZFMVF88Y[J:H1S2
M%C.KTTDQR.88#C[5#UQIR;4;; *>IB@\FW6*X/Z1I/2-8' M&.PG>[5T^^0Y
MQ:2,G/!!IJ;4%KFTZS4+YQ36WHG2]8J8S$Z-@.#D. <.([/3P7'[.Z.>_:NO
M>O9Z>6CI+G3QT-#33-Q(^"/CTSQZ-XYP#Z%][6-%Z@UC6V@VJ\T5+;Z)W32T
M5; Z6*IE!\TO:/I- [&GAE2].VO:!3SU1OFI;-50NI9&0-IZ QF.8CS'G/:!
MR00-K-1\HZ4;/;,P35MRZ,5KV#,=NI0X$O?Z X[N&M[?9V+%M<@\E3[/+K32
M.;+;KU!1 CZ3XI6%CFD\CN@X6GTWH#:+IR&J9:]66 2U<IGJJB:@?)+42'^)
M[R<GV#L"W&J:6NU)K/1E@>XRNLCV7B[U#8RV%SVM#8VM]KG$G=] 06<\;KW
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M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!"=]<,_H._,%-4)WUPS^@[\P4U
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4.D^L:[WM_
M*%,4.D^L:[WM_*$$Q$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M(B L%?\ N<W\I6=8*_\ <YOY2@JG1GUW6?W#_P Q5K,^B/<JIT9]=UG]P_\
M,5:S/HCW(([/KJ3^B/\ *GJ SZZD_HC_ "IZ B(@(B("(B B(@$X"^=]OK-\
M5I]<$C1>H""0?)]1@C^FY4/LKL>R^OT3IR:^W"E-]FAC,S'W61KS*3P!;O\
M YQPP@])(JNN.O=3W.ZW-F@M-T]VMMJG=35=14570F69OTXXAZ2.S)X9*7K:
MN(-(:7OMHM4M<Z\U;:/JF\&RQRD.!9RW@]N[_P!4%HHJ>?M&UK;;['8KUHR$
MW>X1.DMC:.L#XGEI&^)7'&Z&M.2<'V=JZ'0.M+O<M1W/3>KK3!;;[1PLJFBF
MFZ6&6%Q(#@[M!!&,%!8"P15E-+4ST\51#)408Z6)KP71Y&1O#M&1V958WG7&
MM["^2Z7O2-'!IJ&9K)I(Z\25#(R\-$FX.!XD'&<X6?1\D-'M9VGU,Y;'%&VA
MDD?CL:*<DD_8@LY%3K]J.I&6TZK=I5C="M_U#4.J1UPP$X$PB[,<0<9SA6Y0
MU45;1P55,[?@GC;+&[FUPR#X%!F1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$ D#M**C=>VJ[TVU+1=SO%V?4B>]&&CI8,QQ04^ZXX</XWDXRX\AA7D@$@
M=I7QTK-_<WV[^,[N>*JVR-?JW;!J>JJ:B<6^P0MME'$QQ:&S2,S-*/\ YL$-
M!5>ZYM6SZU4-99=)UE;5;0XYA'1.%7,^J-5O<-YQ(;CMSG@@]+/>UC27N#0/
M23A&N#AEI!',*L->6;2YL]DO&U*ME8*:!E,^-U0]E.Z=S<N):S&3P=V\,+5;
M"(HG7_5%7I26=V@I7L;;Q-(YPZ<#$IC#B7!F<=J"Y'O:QI<]S6M':2<+\#VE
MN]O#=YYX*O=JMET8Y])?-?UD\=# .K1PR5,C*<N=DY+&=KN':>2Y#9'9J"^Q
MZZI;.^KDV?7 MAH!+,XG?W2)3%D[S6 XQE!>815]L-NE=7:)ZE>9'2W*SU<M
MLFD=])_1'#7'V[I:K!0$1$!$1 1$0$1$!$1!"=]<,_H._,%-4)WUPS^@[\P4
MU 1$0$1$!$1 1$0$1$!?(D87%H<TN': >*QUU.*NCGIS)+$)6.9TD3MU[<C&
M6GT%49M%T)I_15EME3ICKT>KY*^".WS.JY))JJ0R#?#P3AS=TNSPP$%\K\WA
MG&>/)?,1<(&F3Z0:"[WXXJB['?ZBET1K3:C(Q\MSJY)(*%CW>9%3L>(H@&]G
MTLDGTH+U,C \,+VAQ[ 3Q*_7.#1EQ ',KSYH*79M!<[-+<ZRNN.I9IF2-N]9
MUCHI:HX);&\X9C>[!V>]9M>:DL=]VEW.SZOJ:V2R61D8I[90ME+ZN=[0Y[WB
M/B6M:0.T#B@OR-[9&!S'!S3V$'(*_=]OI</%<GLN=I=^E6NT. RTF9^6#?RR
M3AO-(?Q:>S@M+K'9UH9K+MJ*_P!%, QKZNJE%9,T8 )<0 \ >X(+&WV^L/%?
MH7G_ $IH(R[&;S<X#445?<'NO5N8)GDT?1[Q@ R2?HXSG/TBK=V<:B^5>A[-
M?"T-?6T[9'M P _L<!]H*#HT1$!$1 1$0$1$!$1 4.D^L:[WM_*%,4.D^L:[
MWM_*$$Q$1 1$0$1$!$1 1$0$)P$6BUO8Z'4&G:BBNM764M",2S24DYA?NMXD
M%PX[O,(-VR1C\[CVNP<'!SA?2\ZV$:3J-I>F/F?F>]\,CG7AT$TAAZMC'GB0
M\7$]F..5>6L;RS3NE;O>) "*&EDG (R"6M) ^TX0;?>;QXCAV\4#FDX#@?M7
MG'5=LJ*']GVV2W.6=]?>;G35ETG8YY<>DDWG]G$ - &!R77;,&;,#JD?)-\T
M5]CB=NPU$M0UY8>TADAP1[4%OND8QP:Y[0YW8"<97TJ'T5HFW[2K=J+46IC4
MS7*MK:B&DD;4/8*-D;W1LZ, \,;N3VY7>;#;Y6Z@V9VFKNLQGN#.DIYY#VO?
M&\LR?:0 4'=.D8UP:Y[0YW8">)7[D9QD9Y*@]"Z,H=I^G]0:CU%)4R7BNK:F
M&CG94/9U%D;RV,1@' QC)[<K'7UU?4;(M*:Z-0]UZTW/BIDWB!/"V5T,K7#^
M+( =[P@] HOB"5DT+)8G!T;QO-</2%]H"(B B(@(B("(B B(@(B("P5_[G-_
M*5G6"O\ W.;^4H*IT9]=UG]P_P#,5:S/HCW*J=&?7=9_</\ S%6LSZ(]R".S
MZZD_HC_*GJ SZZD_HC_*GH"(B B(@(B("(B#3ZRBDGTA?(8&.DFDH9V,8P9<
MYQC<  .:XO8WHRUT^S?3+KOIR@CNT5*PRFHHF"9KP>TDMSGL5F(@\V0:<M&C
MKQ?*+6FF;W<&U%?+5T-RM[9Y&31R'>W'",^:]IR./;E=3>K#$+1LW^3.GJ^@
MH8]00U<M+)$[I*=F79?("26CT\>:NI$%>ZEH*R;;+HNMBI9WT=/25S99VL)9
M&7,;NAQ[!G'!:.\6Z_-VNZJN%FI)A+)IIL5%4N8>B=4!SBUN]V9SC@K>1!Y7
MK;?'<]#OHZ;2FJ+EK,")]SK*X3?\/('-,CAD[KN(=NM:#PX^A6Y;+)65FN]J
M$<L$U/37.FI8(*E["&/_ .&+"6GTX)XJS$0>8]/VO3MJL=+8M7:"U'-?H(^K
M/BIF3S158;YH>QS7;FZ[&?0 O2-HABI[51PT\#J:&*%C&0N[8VAH :?<."EH
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"N-J5NK:S5NSZ:CI)YX::[=
M).^-A<(F[A\YQ'8/:58Z(@J;0=6^R[0]I=MEB=+5F=MV@@9].>-\0^CSXMW?
M>5H]<ZIMNK=.W6S6_0=YJ-05D3HHXZBV&$Q2GLD=*1ANZ>.<^A6Y5::MU3J>
MBU Z-[+K20OIVS,>6[\3N)8X=CAGB.16Y05?4:D&C[%9K+JNQ7:Z""BA:^NA
MHS51/E#<.!P#APQVD<<K5: @J_EIJO65!8*RTZ?DM[(X*!\/025<T8WC((O0
M2/-!(X^*N5$%8UFTND-IME3?=(7T4U93MJ!_P!J&1/)<-QV <.& >(['!0=E
MM)/+KC5&J(+-/I_3M530QPT]1'T!J'MXNG,?\/#AD@9\5;B@WRV0WFT5EMJW
MS,IZJ,Q2&%Y8_=/: X<1D<$' [!I#<;%?;]N%D5YO-360#T&/(:'#V'=*LQ1
M+3;:.T6VFM]LIV4U%3,$<43!AK&CL 4M 1$0$1$!$1 1$0$1$$)WUPS^@[\P
M4U0G?7#/Z#OS!34!$1 1$0$1$!$1 1$0:_4%P?:;+6U\5'45TE/$7MIJ=N])
M*1V-:.95&Z3U),R^RZHUCIC5-;J!X+:>**U2NAMT1S_IQ9'%QSYS_2O02((U
M/**^VLDZ.6(3Q!VY(W=>W>'81Z",JD-&V"HU+L!O6BF;L%VMT\]$Z.0\>D9+
MTK-[D' M&?:KX6EH=,VV@U+<+Y1LDAK:^-K*EK7D1REO8\L[-['#/)!3^J+W
M6ZYTE0Z,H=*7:@O+I*5M0Z>D,<% (W-<YX?]''FD-QV@K;S%^S;:+J"]UMFK
M:^UWZ*!S:RAIS,^GEC8&.C>&C(#L;P/9E7&B"E=/7&ZZ6L^LM<3:;N<@NUQ9
M+36AD>[4"/#6=(YO'=)P21V]G-;S:HRX:J&G-*4MOK64%XE;472<,(;3TT>'
MF-[NP.<?-QGT=BLY$'/:PK*73VA;O4/,<-+1T,FZ,8 PPAK0/?@86FV&6RHL
M^R;3-%6L,=0RE#GL/:TN)=@^*Z+5.G+?J>AAHKNV26DCG9.Z%KRULA8<AK\?
M2;GCCV!;@<$!$1 1$0$1$!$1 1$0%#I/K&N][?RA3%"I/K&N][?RA!-1$0$1
M$!$1 1$0$1$!:36%\=I^T==%JK[I'T@CDAHHNED:T@Y=N^D#''WK=H@HJOJJ
M?7&J-*NTAI2X6]]ON#*FJNTM$:1L,+?I1<0-_?[,>C'M5E[4[7->=G&I+?2C
M>J)Z&5L8Q])P:2!]N,+JD05KIC6\-+LITU>Z>UW"Y4LL$<4K*&'I9(2&D$EH
MXD!S<'"T(K*C:'M,TG=K18;C06RR&:6HN=93F R;S<"%H=ASAZ3Z.*M#3>G+
M=IR.LBM$;X*>JJ'5+H=[+&/=C>W!_"#C.!PSE;A!1NG+[<=F<5]T[5Z>O%?*
MZMGGM$U)3.DCJVR.+V@D<&$.=@Y]ZW>BC<=FNA=(66MM%5<*^NJ71U;J4;S:
M=\CG/+GGD,X^PJUT043IB\W/9C:[UIB?3UWKZTUE3-:9:2E,D54V1Q<P%PX-
M()XY(POO5=LJ-,_LZ0:=KF@WFZ;E&(F<2:B>4O+1SQEW@KS6EN^F;;=[W:KI
M<8GSU%L+GTK7//1L>[AO[O87 #@?0@V-KI!0VZFI0XO$,;8PX^G PI*(@(B(
M"(B B(@(B("(B B(@+!7_N<W\I6=8*_]SF_E*"J=&?7=9_</_,5:S/HCW*J=
M&?7=9_</_,5:S/HCW(([/KJ3^B/\J>H#/KJ3^B/\J>@+'*R1Q'1R[G/S<Y61
M$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#
MHI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^
M\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@
M"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%
M/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC
M\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6
M=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&
M#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI
M^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?
M@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=
M%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/W
MC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\
M6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$
M&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#H
MI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&#HI^\?@"=%/WC\ 6=$&M<R7R
MHP=-YW0GSMP=F0I?13]X_ %A=]<,_H._,%-08.BG[Q^ )T4_>/P!9T08.BG[
MQ^ )T4_>/P!9T08.BG[Q^ )T4_>/P!9T08.BG[Q^ )T4_>/P!9T08.BG[Q^
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M'X G13]X_ %G1!@Z*?O'X G13]X_ %G1!@Z*?O'X G13]X_ %G1!@Z*?O'X
MG13]X_ %G1!@Z*?O'X G13]X_ %G1!@Z*?O'X G13]X_ %G1!@Z*?O'X G13
M]X_ %G1!^,!#0'.WCZ3C&5^HB L%?^YS?RE9U@K_ -SF_E*"J=&?7=9_</\
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M4E1$T^9(YI["6D9]J[Y 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZ2MNB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MZ7;NY.[_ -,+MT!$1 1$0$1$!$1 1$08?^8L_HN_R%F6'_F+/Z+O\A9D!$1
M1$0$1$!$1 1$0%Q5^AVAUUUG;I^?3ULMT3@(75;'U$E0.;L8#![.)7:KD]8:
M09K2)W0:EO%L9'&^F>VV5#6L)SQWQ@G([.T(/K9MJB75>G75=73,IZZFJ):.
MI;$[>C=)&[=+F'U3VA?&J=15D&J;#IJQ] +G7EU3/+.TN9!2QYWG8':YQ\T<
MEJ-A]>^?35QMG14O5[+<);=!4TL>XRJ8P_[F,GSCZ3Z2L%OW_P#[1UYZ;_\
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MO%S=WGG@OSIHO_B,^((/M$7P^6-AP][6GD3A!]HOP.!) (R.T97Z@(B("(B
MB(@(B("P5_[G-_*5G6"O_<YOY2@JG1GUW6?W#_S%6LSZ(]RJG1GUW6?W#_S%
M6LSZ(]R".SZZD_HC_*GJ SZZD_HC_*GH"(B B(@+\<,M(Y\%^H@\X;+;S+HK
M7FU*QUD\CZ:W0ON-.9WGZ#>( SZ"'M7._LX:KKK#J&[07^IFFBN5J-XC#G%P
M.X7$X)[.&]P]BE?M)Z4OC-H3[KIZW5=6R]6T4-08HRYH=O <<=G -4G;WHR[
M62#2E9IF@J*A]/:9+/.VEB+MUI9V\.>7J1KMEFOQHG1=WU3<V5=TN6I+J^"W
M4F^<N+23](\ W+_0K1TAM6NKM:TNEM=:=-EN-=%TM)*R<21R<,[IY'M^T85?
M;1]F%[=LCV?BU4,M;-8XC)6T<;MR4ME#7/W1V[P.0<<1VCL7SLFL.EKIKNSS
M6G2NK*>HI<SR55PJ'=#3.#20./TLGAZ% WUIO>G;+MUUK7/LDM/4T% ^IJ:Q
MM6Y^^T!N<1G@"?>L5QVZZGIM/4NIAI"%FGJ^<P4DLE7YY.2 7#=X X/'V*%+
M0RV[;)M"NUZH"RR.M4C7350,=/)D ;I?R)..'%51IJLL\5JMC=54^K*FR4E1
MUH4<#1U-@WL@M<>+FX]O'GQ0=K:]17VR;?\ 4M;#ISK^IJZA9&+?2SAS(WED
M;BXR8XM#0./,CDKAV5;6)=9VV^Q5-EEIM06@'I:%DF>E/' :2!@Y&[Q7([+1
M+=?VB-1ZEHJ:H?8KC;6/I:PQ%L<C<1< 3Z1@C'L*F;$[3<:+;%M$JZRAJ8*:
MHJ'&&62,M;(-\]A]*#2;*=I6N+YK:]M;:9KE;Y;FR*=CIP&VEF\X;@&/.X9R
M?_E7??M*:HK=-[.W1VB;H;C=*AE#$\'!:'YWB/L&/M5:;)+C>-G.T+4]CN&F
MKG52WJZM=#-#'_IM9TCQOEW9N[KLY]BZS]KBB>=&V.[C>,5LNL4LH SAIR,^
M('B@Y?\ :'TY!IO9QHJT0!TA@K6"1SG%[I)"!O.R>)R<KO6[5*JZ:]@TAHFT
MMN;J,-;<J^23=@IL8!P0#O8XCT9/#T+2_M/T=9J+2>FIK'2U-8R6I;*'4\9<
M6L<W@[AV<"M3I*SWK8QM";1TE)5W+1M]$9DG;"9):>0#&\_''@2<^PY[0@Z:
M][7+Y4:GU';-'::9<*?3S7.K:BHJ1'O;HX[@P<]A]/'"YZ\WVZ[4]BEVU/'1
M"UUML?UJV34M5O/)C/\ J!P&,< >!]A5<:RKZ9^U76T]MDO3+=5NZ"5^GSTK
M9SCSQ(YW $^D#L5IZ?U=I*E_9WU*-+T]524ELIY*6:GJQ_JB:08!)['9+NWV
M>A!:NRW4+]4[/K#>9_WBJI6F;L_W!YKCPYD$_:MEJ^[OL.F+G=(XA,^D@?,(
MR<!Q SC*IW8QJP:<M>A-$&WSU%PN- :Z5[7- IF.<YPW@>/T<'[0K3VF02U.
M@+_#31/EF?1R-:Q@RYQW3P 04O\ _:%O<MBI=04NC)'V&-[8*RJ=4X'2G&6L
M..SB!D^E2ZK]H"Y4E;:;C6:0J*;2ESE$=-5R3#I)!G&\&XQ[<9[/2N>\@7?_
M .R3+;/)=8+B:@'JW1'I,=*..[VJ7MAL=VK-D.S6EI+;635%.^ S11Q$NCQ&
M/I#T(+*VD[4)=/Z@MVF=,VA][U%7L$K(1*&,B9ZSCQ] )]'#CE?.SW:?6:AK
M;W8[O89+?JBU1F5U&)0YDX]&Z['#/ ?;E5EMVT-6QZ_H]55%HN-VT_-21P5L
M=!(630N:" 01QQV'D>Q1-,V".:R:NN&S73FIZ&Z>3NKTU9<)R72DO:7L8T_Q
M;H.#E!V%XVRZKTT^DN6JM#OM^GZFHZ$2"J#IH^/#>;CMQQXXS@K8:MVT5-GU
M])IJTZ?DO$DU'%-1=!+NNED>-X9!'!H ))5 5^FIKIL^B%FTIJ*>_P!,\.NU
M?5.>6@DD;D;"?.R<$\,C"MW3=DND7[2EGN$MNJF4++''$Z=T1#&O$&-TGLSG
M@@[/9'M6J=7:@NFG-069UIOM"TR.C$F^PM! (]!#AD<\@K[_ &D-3U>G] =5
MM4O17&\3MM\3P<%H?G>(/H..'VKG-(6BX0_M.:DN$M!4LH9*3=94.C(C<<-[
M'=BS?M8T,ATQIV\-#C#:;K'/, ,X8?3_ -!XH)^K]3MV(:'TK1QT9KH7S"GJ
MI'3'>' NDD!.2X]IPI>GMH^J+OIZ_P!Z;HFM9#3")UMI7N+9:MKS@NXMQP&#
M@<US7[4='5:ETII&HL5'45\+Z]L^88R_$9;D$@=@XK<_M/TVI*G0,#--BI-*
MV=KJ]E*2)3$.S&..,]N/8@P6;:]?J+6UGT[KG2ODN2\EK:22&I$N">'G#WX'
ML4*IVUWZIU)J#3VG=(27.[6V=[0(YO,$+3@N=P[2> "K.RZ<=-M!T!==-:5O
ME!98ZV)L]37N=(^:0'+GG).ZT<1G@"K-V)V>OHMLNT:LK*"I@IZB;_1FDC+6
MR#?/T3Z4'3[.=KM#JG0UYO\ 7T4M ^S9%;"';_8W>RT\.WB,'L*XBX[<]44V
MG*74S=(0MT]7SF"DEDK//)R0"X;O '!XJ#L.H9=/Z"VFRZGH>JTDE1(_=KP8
MHY6ECAQ/;@D@9'-51IBLM$%JM@U73:LJ;)25/6Q1P-'4VC>R"UQ\XMQ[>//B
M@ORHVO:EK+[)IO3FE(J_4%! )KD!6-$$1QG<8_'G'BT9YDCT*%J+4T&UG8W>
MKM:(:NUZAL,AD#!+A\$L>''!':TMS]H]BK&_62C=KFXZFNUFO5ST9?O^,H*R
MT/<QS"X [K@/2,$$'LP"%9.DX[/I/8AK:\4-ENMGI:EL@$=RE+Y9LL#&/ (X
M E^,>PH+6V4:AEU3L[L-XJ<=9J*9O38/;(WS7'[2"?M76*N/V>+9);-D.G63
MM>R6:$SEKO0'N)'_ $(*L= 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1!CJ865%/+!+DQR-+'8.#@C!XJC=I^SO2&E=*U-;2TMTENE0X
M4E!%Y3J#TE3)P9PWO0?.QR"O95C74,^K]L-*ZIIYX[+I6/I8WO86MGK9!PQG
MZ08STC@"4$6YZ+TU8-!V&GUU>*SR=;(VPRM?6OC@GF=DES\8+CDNQQ[%#V,F
ME?K*_NT5//)H1L4;6"21SX^M\=_HB\EV[N[N<<,X79Z[U=:M/20T]_M-QJJ&
M5H>*B*A-3"UV3YKL9(=PSV>E<1HEK[AM,N6K=/V6NM>EVVSH9&.I^A-PG#B0
MYD1QV 8S@90;G]HNJ=3[/1&'S,BJ*ZGAF=$7!PC+\N^CQ[ >Q:W9;3[-OE07
MZ0K:PWB*)V(*JJJ-XL/ D,E/'W@+J:?:%$[15%J6HL5Y;332.9+!'3=)+  7
M#?<T'.[YO:.87'UE=\Y&OM)U^F[77P45FGDGJKI54QIP6EF!"S>\YV2>([$'
M2[;+C4LTY0V*V5+J:X:@K8K:R5IPZ.-Y_P!1P/H(:",^U<=M(N=LMM]LVC:Z
MZ5-OTQ;[>)ZN"E<\U%:[.[' TM\\]CG'';Z5TFVV,4=;HK4,SMVCM5YBZP<?
M19)YF]]AQXK#K!ITIM.IM:36FHN%HJ;=U*HGIHNEDHG!^\U^Z/.W7 X)"#:[
M,':4GL%R?LZ#::1Q(DAJ#+O13;OF](QYWFCL]ZY79_0W2U;;[C1WR\3W6O=9
M8YZB9YQ&'ND.6QL[&L   'VK:[.8*F^[3M1ZU@HJFCL=;1P45-UF,Q25#F<7
M2;AX@#L!/:I5!0U3?V@KI6NIIA1NL<,;9RP[A<)'9 /9E!9;L[IQVXX+RU52
MZ?CM=WH]7OO$FU5M0]D1AGD$KIG._P! PX.YT>[N>CLS[%?L^HYJO4]VTU1T
M57#50T'6(JY[/]$O=P !]A(\"J5M#K+;MGM1I/5NEKM5ZQF$AG HGRR5%0XD
MLE9..&/HG.1C"#T#IME=%IZV,O+VON3::,5+FG@90T;Y\<J?.'F"00D"4M.X
M3V9QP584>S$ZATMIT:TN5W9>*.A93R]2KW1 GM.]N_2<.S/L5@5=%-!IN>AM
MDKA4,I'0T\DCLD.#"&DGTG..*#S&9;*S3E=1WZ2[R;7FU#HFEE3()C4$YB='
M@[G18W3V=F5>-TV;6G5$5NK=5MK);O'210SOIZR6%I<!YQPQP'TB>*J>U&R4
M>S-VD+_I*[SZQ=$\21BB=)++5');,V<<,9P<[W *RM3U&I;+L;I:&-LM;JVI
MI8;>UT;=[=G>T-<]Q'H;YQWN80:#8=I^A9K/5EZLPJH['!)Y+H6RU4DPE+#_
M *LN7$\"X #V KH=NFIZG3^GK=2V^X-ME3=:UE*ZM./^'A +I'C_ .;=&![2
MNETU:X=%:!I:&GCDF9;*,N<U@RZ5S6ESL>USL^*X#7;:S7.B=(ZLMUBJ:B:W
MUS*Y]IF8.D?'Q8\ '@7#@X<T'[LM=LUEU$(]."L;?F1/PZX.J&RU+,8<\"0X
M>#VY \%L]EM1/9]::PT=/.Z6DH965UN#G%QCIYLN,>3QPUV1]JT\UT^<7:/H
MZNT];+A%0V.6:>MKJNF,&YO,W1"W>XN)/:!P6TT6\73;GKBX4Y#J6AI::VN<
M!C,OTW#VX[$%IHB("(B B(@A.^N&?T'?F"FJ$[ZX9_0=^8*:@(B("(B B(@J
MK76SG15OH+WJ:\Q7+$;9*R?<N,[ X\3@ .P,G@ .:UFA-'TD.Q:G&K*^XT%+
M42NNM6V*M?'N,=]&)S\[Q:&AN1D<0MWM5HJ[5&I-,Z5IJ>8VE\_E"[3;I#.A
MC/F1[W-SNT<@NLUIJ*ETY;F3W&V5]=0R$LEZI3=.(QS>T<=T]G84%3Z+=8G;
M5;2S97/.ZR,IY3>Q'.^2E.1_HXWB?]3.]V>A6IM+JGT6SS4M1$'ND9;I]P,!
M+LEA QCVE5C ZFUEM,TG=M$V.KH:*UOE=<+C)2&D8^,MP(@" 7DD\N"L"V:Z
M%=2ZEG\A7<"RU3J=T8@R^I /%T8SYWI.$%5;+Z39E-5Z?9Y0KVZD#(Y *FJJ
M6,DF !( >0UW'T!6]M3U!/I?9]?+Q1@&LIZ<]7!&?]5Q#6</3YS@<*M-H=^@
MVJ6BCT_I2T7.2X"M@J'5571N@CHF,?O.>7N].!C SG*[+;Y12U>R6^= QTLM
M*R.K#&_Q"*1KS_T:4$6U;*[-<](V.#40KIZZ&$S3RLK)8W232X=(YVZX9\[L
MY#@N3T5IRUVS:U?:^P,K8[+IFC=#*9:N283U;FESQYY. UAQ[RK+NVJ#!LT.
MH+13R5DTM"V6DAB:7F21[1N# ]&2,^S*C[,-)/L&SR"TW,E]?5,?-7R9R7S2
MY+S_ -<?8@K/3FDFZHV65>MKE6UKM7U,,UPIK@VH>TTKFY=$QC0=W=  &,<5
M;NS2]RZCT%8KO4_O%52,?*>;P,./B"JBLU_N>E-G-9H*IT_=)M3QQ345!'#
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M$[ZX9_0=^8*:@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@*'2?6-=[V_E"F*'2?6-=[V_E""8B(@(B("(B B(@(B("(B B(@(B("(B
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M/KJ3^B/\J>H#/KJ3^B/\J>@(B("(JTV[;0KAL\L5MKK71TE7+550IW-J2X
MM)R-WTYP@LM%0D^V+6&F=4V>W:]TI145'<I&QLFI)RXC) R.)!P2,C@>*M#4
M6T72.FZT4=\U!0T=7NAQA>_+V@]F0,X^U!U:+6T=^M-996W>FN5)):W-W^MB
M5O18YEV<!:&Q[3=&7VYQVZTZCM]36RG$<+7X<\\FY[?L0=@BY2_[1M(:?N/4
M+SJ&WTE9Z87R9<W^;&=W[<+@_P!H3:!==+V;2];I.O@Z*XUO0NF:ULK9(R.!
M:>(^T(+G15P^^W<;;6687VSBSFBZ0VPG_BR_=)SC'9GCVXQ[5M*O:EHBCIFS
MU.IK:R-TCH@>DR=YO!PP./#F@[-%JX]0V>2QMO3+G1FTN9OBLZ5O18[,[V<=
MO!:K36T+2>IJTT=AO]#6U0&>A8_#R.8!QG[$'4HM1J^Z2V72UWNE/&R2:CI9
M)V,DSNN+6D@''''!<]L8UE5Z\T'27ZX4T%+/-)(PQ0$EH#78';Q0=PBYK5&O
M-+Z6J8Z?4-\HJ&HD;OMBD?YY;SW1DX]JY;:AK]D.R>Y:DT1=:2I=%N]'/%B1
MH.\,@CT''H*"SD5:;/MJ%BKK-8Z&^ZBMPU+4T['30%X83(X9QR!/#S<Y78ZG
MU58M+4K*C4-UI;?$\X89GX+C[!VG[$&Z1:;36J+'J>C?5:?NE+<(&<'N@>#N
M?S#M'8>U:J7:5HZ*CIZI^HJ 05$YIHB'Y+Y <%H X\$'7(N.O>T[1=CN,E!=
M=26^GK(SB2(R;Q8>3L9P?85K]I6U2S:+T]27*-\%TEK2WJM/!4-!F8>UX/'S
M1S[$%@HN;L^N--7>S5%TH;W024%-@3SB8!D1QG!)QS6'36T/26IJXT=BO]#6
MU>,B%C\.(]@.,_8@ZI%H+CK/3MMK*^DN%YHZ:HH8145,<LFZ8XSV..>>1[>*
MC:;V@:5U-7"BL-]HJVK,9E$,;COE@[3@^CB$'4(M)0ZLL5=J"HL='=*:>[4P
M)FI8W9?&!C.>7:%Q6TW:-<-$ZXTI;Y:*E?8KS,():N0N#H7[P!Q@X['-/$<T
M%H(JPVS[1Z[153IZW6&BI;A=[M4]"V"9SO-9P&]AO'M(\"NBU!M$TIIFK;0Z
MAU!04E>&!SXG.)<,^D@9(^U!UJ*H]NNT"JLFS*EU%HNY4\@GJHVLJ(PV5CV.
M#L_X'@NR;K&U6?3ECJ]3W2GHY;A%&&.E.[TLA:"0/%!U2+3735%DM5XH+5<;
ME3T]QKSBEIWNP^8YQYH]ZA:FU]I72]4RFO\ ?:&BJ7C(BD?E^.9 R0/>@Z9%
MHZK5VGZ33[+Y47FACM$GT*LS#HW]O 'TG@> X\%@TMKG3.JYI8=.WJCKYHAO
M/CB=YS1SP>./:@Z-$7.W;6^F;1<JBWW2^4%)6T\'6989I0US8_6X_P".U!T2
M+C(MJ6B);1+<V:GMIHHGB)\G2X(<>P;OTO\ HM]I_45HU%;!<;'<::NHLD&6
M%X(:1V@\C[T&U1<A3[3=%U-X\EP:FMCZXNW!&)A@NY!WT2?<5,U3KC3.E)8H
MM17JCH)I6[[(Y7^>YO9G='''M0=&BY^EUIIRKT[/?J6]44MH@&9:IDF6Q\<>
M=Z0?85K9=J&B(KA#12:GMC:F8-+&F88\[LR>P?:4'9(@((R.(5<:<U]7:DVH
MWS3]JHZ=MDL;0RLK9"XODF/\#,<!CCV^J4%CHN2J=I&CZ:A;5SZBH&T[J@TK
M7=)DF4=K0!Q)'N7S?MIFC+#<'T%WU';Z:L9].(OWG,_FQG'VH.O1:&NUCIVA
MM]OKZN]4,5%<)!%2SF4;DSCV!I[%#MFT32-TO;K1;M0VZHN326]"R4$N([0#
MV./N)0=4BY_5&L].Z5Z(:BO%)0.EXQLE?YSAS#1QQ[<*':-H^C[N:@6W45OG
MZO":B8MDP(XP0"YQ/8,D>*#K$7+:;VAZ2U-7&BL5_H:VK WNB8_#B.8!QG[%
MH=":^K[EKF_Z1U-1TU)=K>1+3O@)#*F ]CL..<]A^WV(+'1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$)WUPS^@
M[\P4U0G?7#/Z#OS!34!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!0Z3ZQKO>W\H4Q0Z3ZQKO>W\H03$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6"O_ '.;^4K.L%?^YS?RE!5.C/KN
ML_N'_F*M9GT1[E5.C/KNL_N'_F*M9GT1[D$=GUU)_1'^5/4!GUU)_1'^5/0$
M1$!4#^V+_P"#K#P_YDW[/-/%7\N>UKHRR:TH:>DU%1]:@@DZ6-N^YN'8QGA[
M"@\LZVM\.C==Z0N,&J&:TJ.F8!35;Q-T(W@ 1NN(!R>'M [5TNHK^[6.N=:0
MT%FTA01VF-U/67"]-+Y9F,#F^8!V'@>SB.'%71IC9-HO35SAN-HL<$=;"2Z.
M9[G/+#C&1DX!]J^+SLCT7>-2^7KA98I;@7]*\[[@R1_K.;G!/^?2@I/8U:Z;
M47[/&H[-679ELI)ZYS(JF=V&1N.X6YR1P)QXK%LUFET5M*TQIO5=DT_<9Y'.
M;;+M;BUTD8<"W+G#Z78?I><-[*O^GV;Z6@T_<;&RUL\EW"<U%1 7N(<_(.0<
MY'$#L4+1VR31ND;H+C9;2UE<W.Y-+(Z0LR,'=SV(/,FA+==;]<-<Q1-TO-6S
MU<D5<Z_NQ. 2\9C)[ .?:" I6T.Q5NF]D6@[97W"DKS#?9>AEI)^FC$9/!H=
M[#G@O1^K-D&BM571]QNUF8ZMD=O22Q/,9D/-V.T^U2;ALOTE7V&UV:>U-%MM
MDIFI862O:(W$DDYSD\2>U!5TW_XS8/\ RK__ %%<9L2TO9;WIG:C77>VT]95
M4KIXX))6Y,0W9'^;R.\ <]O!>ECHJR'6HU8:0^76Q=")^D=C<W=W&[G'85@T
MYH#3VG:"[T=IHC#3W4N-6TRN=TF\"#Q)X<''L0>1*J6K/[+VGX\O\GOO\K:G
M'8!@EH/(;V2N]M.C+U6:QT;>H:K0M!U&:(0>3*C<?/$?X=W^-V,^WB<J_P"S
MZ TW:=*2Z;I;9&ZS2N<]]-,3("7=IR>/H^Q:73>QK1.G+W%=K5:.CK87[\3W
M2O<(SS )0;W:;_[.M2Y[?)T_Y"JT_9>OMHM^Q^V05]UH*6?I9B8YJAC' %YP
M<$Y5SW6WT]UMM505K.DI:F)T,K,D;S7#!&1[%6_S![/, &Q]G_[]_P"J#@M9
MZD&J]L-;9[-9-+LJ;93=%+=-0-W@6#SB&MS@CSACT]IX!5CI' V-[5F1.C+&
MUM.6]%PCSO.XL'JG'#V87J+4VR;1VIKK3W&\VEL]5"QL>\)'-#VM&&AP!XX"
MS?-?I,6Z]T#+6(Z.\R,DJXF2.:USF_1W0#YH'((/+^NJ+24'[/6E:VRMI!J:
M2H:Y\D3AUASO/Z3?QQ[0WMY#"Z_4<=-<?VC-)P:^#9+;Y&B<QM;YL1E,;B<Y
MX?[F<Y]("N2+8UH6*^P79EAA%5#N[K=YQCRWL<6YP3P"WFMM"Z>UK2QP:CMT
M=4(_]N3):]GN<../8@HO9='247[1VK:71C6-T^:4]9;#QB#ACZ)[,;Y./M4'
M]F71.G]2C4%PO]N97ST5>64PE+BV+!WLM .,Y7H31FB-/Z,H):33MOCI(YL&
M5P)<^3'9EQXE?NC=%V31T-7%I^D-,RJDZ67,CG[SN?$H/,=TU -<6_6]YHK+
MH^T6Z%SVU,M>PNK)W 8!81V.X<,<,GTKG;Y%%)L TA63,#JJ&YR4D<SAY[(=
MYSC'GU<\<+U!\SFACJ*2]NL4#JQ[B\M+CT>\>UVYV9XK8,V:Z6;I!VF/)C76
M8O,HA<]Q+7DYW@[.0>*"C/VC**RV[9C9H-*Q4$-KFN43KDVWEI:7;AW=_=]Q
MQ[E#VMT.E[5JW9Q-LU921W5U0S=- =XNCRW=W@/3Q=V\>W*OZP;,M)V/3U99
M**T1&W5AS41S.,G2'T$D\O1A1M(;)=&Z2NGE&RVAD=:,[DLCW2&//JY[$%-Z
MCT_;]4?M4/M=\@-10/HXY98"XM;(6Q@@.QVC/H4W:K9*/97M&TAK&Q4S:2T!
MIMU3!""0&AIP./#BWLX]K5=PT38QK(ZJZH?+9CZ/I^D=C=QC&[G'8JKV_P >
MK]92OT58-+3/HG3PS.N\A B  WN!/8020>T\/:@^?V5+/+56_4.L[HTOK[U7
M/Z.1X.]T0.3Q](+B?A71?M-::-^V8U=73@==M#A7PN#<N&[](#EPX_8K#TI9
M*;3FG+=9Z( 04<#86G'TL#B[[3D_:MA5TT59234U0P/@F8Z.1A_B:1@CP*#S
M'LPKW[4=MUOO58XU%%8K1$[_ %!_^4$ $C'_ ,Y<[CR6/46I/EMK+6/D^S:2
MH(+;&8*NX7MI?-*U@<WS .SL/9Q'#BK_ -$:%T_HF&JBTW0]4;4N#I?]1S][
M' =I6JN^R71EWU.+_7V:*6X;PD=YQ$;W>LYG83_GTH/*K9"[]F2N8'ET3-0C
MHQR!9G@K&_:0(9H39C([@QE3&YSO0 (VDGP"N:791I"73]39#;"+;/6&N?"V
M9X'2GAD'.0/9V+<:@T;8]0:=BL=WH&5-NB#1%&YQRPM& 0[M! ]*"C]K=UM]
MR_:$V8MM]73U?12QE[H)&O#<RG )!].,KB:&GNESVQZ^C;'IJ>YFHDCD9?SY
M@BW\ 1?9N_9C"]$639!HNRR6V6W6AL4U!4=:AEZ1Q?TGH).>(X#@>"E:VV7:
M2UI6-J[_ &EDU6T!O3QN,;W =@)';]J"@V;*ZNHV9,LE9J;3T$\%WDK+<&U8
M?3N=N#?B+N8X$#CC[5U&PC4T=/KNZV+45@LU!J""EWI;E;0QD3XV')#@WS1V
M@Y&/:K-JMDFC*G3%/I^2SM\F4\KIXF"5X+9'  NSG.2 H;ME-HL>C+]:M#TE
M/;KA<Z<P&JG+I#@\#DG)Q@G@/8@L"AKJ2X0F6@JH*F('&_#('MSRR%YOU18K
M=J+]KNGM]YIF55%Y.9,Z%XRUSF1N+<CTC/'"O'9GI.+16BK78XBQ\E-$.FE8
MW DD/%SO$G[,+*[1=D=K5NJS2'RXV+H1/TCOH;N[C=SCL*#SSLQT;I^X_M :
MTMU=:J::WT#7FGIGMS'&7. R![B<<LK4;,W5-'LKVT,M1DC?#*61B(G+6>>T
MX_\ IRO3=FT38[/J:XW^WTACNMPR*B4R.._DY["<#B%^:5T/8=+"YBRT0B;<
MI.DJFO>YXD/'T'/K%!Y+LFC[AJ?99;J>W3Z)HJ .Z=E7-4"*M9('.STCO0?9
MV8 5AZGOU1>MI%NTQ3VG3,UVM=KC9/=[Z#(P^8'/W!Z02>![3DG@K*J-A>SZ
M>YNK7V",/<=XQMD<V//\H*VFK=E6D-67.GN%[M+9JF%K6!S9',#VM^B' 'B
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M!P>U4!:[YI75-36WW:!?ZL1SRR-H[5#+,(*& $M:YYB'![L%V78[1P5\6]L
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M7-KX8NFE?54;X6,R<;F7=KO8.16DOX-!MVTK7U&&4U?:ZFW1O<>'2@AX;[R
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MCZ.STJX YP& X@>PIDYSDYYH*MUK4-NU%HG7=/8ZNNH;=(^HJ*"2'-0R*1A
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MB9)NMD>WZ.^/XF@\<<T$39K;);/L^TY05'^]#;X0\8QAVX"1]BZ1"<E$!$1
M1$0$':B#M03X/]ION7VOB#_:;[E]H"P5_P"YS?RE9U@K_P!SF_E*"J=&?7=9
M_</_ #%6LSZ(]RJG1GUW6?W#_P Q5K,^B/<@CL^NI/Z(_P J>H#/KJ3^B/\
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MREJW-W'MGBD!.6_PD'>&,\$%](M?IRM=<;!;:UXW75%-'*1R+F@_]UL$!$1
M1$0%#I/K&N][?RA3%#I/K&N][?RA!,1$0$1$!$1 )P"3V!5U4[9]&4]8Z)]?
M4NIF2=$^N922&F8_.,&3&.WAGL5BGB%66V&LI8-*R:/LM##47B^L=2TU%!&
M(F.^G.X 8:QN<Y/I0=;JS6-ETK:H;A>*O<AG>(X&Q,,KYW$9#6-;DDKYT9K*
MSZOIZF2SS2])2O#*BGGB=%+"X]@<UW$9QP5>.MGD_;%H"QU,O6:>V629T1D'
M!TH&X7@'TX"V%>[J7[1]L;2M#17V&0U( ^D8Y?,)]O$C*"TII8X(9)9GMCBC
M:7O>XX#0.))/):32&K[+K"EJJG3M:VMIJ>8P/E:TAI< "<$]HXCBINH+)0:@
MM<MNN\'6*.0@OBWW-#L'.#@C(]BXC8_#%3777D%/&R*&._2M9'&T-:T"*+
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M#CL>[! 'H06XJ]N6V'2%OKYZ:2LJI8Z=_1U%73TDDM/"[."'2-&."[]H;%"
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M,HB!E,HB!E,HB!E,HB!E,HB!E,HB!E,HB!E,HB!E,HB!E,HB!E B#M03X/\
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MM0T0K+%<:6X4V=WI*>0/ /(\C[UK:S7>E*&\OM-=J.UT]Q8[=?!). YIY'T
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M,W&HKJ2MK''.732SA[L^T9 ^Q!:-WU354.U.Q:6CIX'4=PH9ZJ29V>D:Z/.
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M[;$;7-<II:BNI+]%2P53SE\YCJ2UKR?2[='$^DA!?Y&#A%]S?[K\<U\("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M :.))716"VV[2>G+;:H)HH:2F:V!CY9 WI'GB223Q<YV3CVK4[8/_9;JH?\
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M_</_ #%6LSZ(]RJG1GUW6?W#_P Q5K,^B/<@CL^NI/Z(_P J>H#/KJ3^B/\
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MR";HY!$0-T<@FZ.01$#='()NCD$1 W1R";HY!$0-T<@FZ.01$#='()NCD$1
DW1R";HY!$0-T<@FZ.01$#='()NCD$1!D:!N]@7ZB("(B#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g50309g16m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g16m02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2(*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (>T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0M'P\>$C_]H # ,!  (1 Q$ /P#U2
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M/15'4P5E-%44LK)H)6HYDC%S1R+N5%,N3'-)ZO0Q9JY8W5]@ 5K0
M
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MC$NC>OL&#Z7$%174TL4R1JL+&JBM1_Q<E7?TE'.1:+=82M2:3JT  .H@
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MPE.O"MRYOXD^SW'[ABX)44[=H%D 1<TS $:?OIF-7<22,_PII)
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M6L8F2-1-R(AS!DODF\[EOQ8:XHU4 !!:
M      "+<(TEB5CMST5B^E#.,"U:M5(U7XKM7[-AI=3N9](Q_!<B\=D3_P"*
M[W@AL,3\XVKGR ^5,N<#.H ?KO"F]9)(SO"F]9)                  (J+
MN7,9Y;P "*BIL
M
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M^ZI-(5\_8MP\WD^ZH&-=B?\ (Y2^>U'O0V Q_L3_ )'*7SVH]Z&P
M
M                                       !*HOB.ZR01Z+XCNLD
M     ?&JW,^D8U@SPZ3ZUWO-EJMS/I&-8,\.D^M=[P0U^D\'9U 4G@[.H <W
M>%-ZR21G>%-ZR2                      "%?/V+</-Y/NJ32%?/V+</-Y
M/NJ!C78G_(Y2^>U'O0V Q_L3_D<I?/:CWH;
M
M                       $JB^([K)!'HOB.ZR0        !\:K<SZ1C6#/
M#I/K7>\V6JW,^D8U@SPZ3ZUWO!#7Z3P=G4!2>#LZ@!S=X4WK))&=X4WK)(
M                    (5\_8MP\WD^ZI-(5\_8MP\WD^ZH&-=B?\CE+Y[4>
M]#8#'^Q/^1RE\]J/>AL
M
M       2J+XCNLD$>B^([K)         'QJMS/I&-8,\.D^M=[S9:K<SZ1C6
M#/#I/K7>\$-?I/!V=0%)X.SJ '-WA3>LDD9WA3>LD@
M    A7S]BW#S>3[JDTA7S]BW#S>3[J@8UV)_R.4OGM1[T-@,?[$_Y'*7SVH]
MZ&P
M                                                  !*HOB.ZR01
MZ+XCNLD         ?&JW,^D8U@SPZ3ZUWO-EJMS/I&-8,\.D^M=[P0U^D\'9
MU 4G@[.H <W>%-ZR21G>%-ZR2                      "%?/V+</-Y/NJ
M32%?/V+</-Y/NJ!C78G_ ".4OGM1[T-@,?[$_P"1RE\]J/>AL
M
M                                     2J+XCNLD$>B^([K)
M  'QJMS/I&-8,\.D^M=[S9:K<SZ1C6#/#I/K7>\$-?I/!V=0%)X.SJ '-WA3
M>LDD9WA3>LD@                      A7S]BW#S>3[JDTA7S]BW#S>3[J
M@8UV)_R.4OGM1[T-@,?[$_Y'*7SVH]Z&P
M
M                    !*HOB.ZR01Z+XCNLD         ?&JW,^D8U@SPZ3
MZUWO-EJMS/I&-8,\.D^M=[P0U^D\'9U 4G@[.H <W>%-ZR21G>%-ZR2
M                 "%?/V+</-Y/NJ32%?/V+</-Y/NJ!C78G_(Y2^>U'O0V
M Q_L3_D<I?/:CWH;              ( !U=?6W:&J<RBLK*N!$35F6M9%K<_
M>JBJF1U=3B*[TURH:&7#C>'K.$X+*X,5.\;K+FNKLV 6@'1_"-__ /=N/_\
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MZUG"RNU6Z]'*QN?2Y6Y)Z0.]
M                      $JB^([K)!'HOB.ZR0        !\:K<SZ1C6#/#
MI/K7>\V6JW,^D8U@SPZ3ZUWO!#7Z3P=G4!2>#LZ@!S=X4WK))&=X4WK)(
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MLH
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ME;'8K>RZKK5[8&).N:+F_)-;:G3F<O:T1J;;2Q5I:VZUFNOZ.P !G:P
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M=:RKHJ>1D[$5$<Z>1R;4R78JJ@'=@
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MR.!J54<R?HY,VY)JJFU%RR^PNPUBUNL;9^)O-:;B==4M<9:6,ERPW)GYDO\
M<;5AZ:KJ;'037*+@JV2!CIH]75U7JB9IER;3&5T^R(BKVMNV?_R%_M-GP_</
MA:R4%P6+@EJ863<'GGJZR9Y9^D[EB8CK73F"U9F>6TRG@ H:0  5W#.$;?AV
M[WZXT+ZAT]YJ>-5"2O16M?EEDU$1,DZ\R!C[1W9\:3T5762UU!=*+/BUPM\W
M U$2+O1'Y+L_^_.I<0!3='VCJSX(DKZBWR5M;<:]46IK[A-PT\F6Y%=DFS_\
MY"Y  "%?/V+</-Y/NJ32%?/V+</-Y/NJ!DG8B?(Y3^>U'WD-H,7[$3Y'*?SV
MH^\AM     ?CD56JB+DJ\I6%L%]VKVVUB)YK!L_E M!GNFJV25>&HZR)%<M'
M*CWHB;F+L5?1L.EO>(JBTWIE+)C6IGITB?PJP4D#W-D16ZJ?%RW*[[#\CQ11
M5-'4OK<<U<$$;%=(RIH(>^:F],D8N?4FTE6)B=Z>?Q67AN(I;AIR1N>G?[LH
M!<&8-N%WMEUQ#347P/:FZT])25BKP[X4:KE>K43O,^1JYKSY$JQZ,KQ<X(*A
M]12TU--&V1KU57.R5,TV9?ZFF,E?+XZ_I'&4OR<F_P X[.MT:6Z6XXSMR1M5
M8Z=_#R.RV-1N[/K7)#T8=#A'"]#AFA=!1HKY7KG+.].^>O\ HG0=\9[VYI?7
M>D\#/!8.6_XIG<A5,0_O[A/_ .:_I%K*IB']_<)__-?TB#TUK     52+Y4Y
M_P#<[?ZREK*I%\J<_P#N=O\ 64M8         KF&?WAQ3YY'_0C+&5S#/[PX
MI\\C_H1@6,        X311S1NCFC9(QVQ6N3-%]!S %'P]:Z#M\Q.SB-+J0M
MI5C;P+<F*L:JN6S9FI>$3+<5/#WR@8M^C2?TU+8$:TK7\,:  $G77>QVJ\P\
M#=[915T7(VI@;(B=6LBE,[DMHHIUGPU=+YA^3//4M]:Y(57DSB=FQ43FR0T0
M 9[4TNDBS-3X.N%DQ'$FU65T#J.7+F1\:N:J];4.<.D&OH&_^UN#[W:LMKIJ
M5B5\#6\ZOB[Y/2TOX5$5,E3- *QA['V%,0R<%9[_ &^HJ,]7@.%1DJ+S<&[)
MWL+.=#?,'8<OJ+\+V2WU;E3+A)(&ZZ=3LLT7I12M3Z-'T3D=A'%%]L+6_$IV
MS\:ITY_T<VLGV*@&A@S]'Z1K'"JR,L>)X6>(KZ&I?Z,G1^U#C#I0IZ-W!XJP
M]?L/N38^:HI5FIT7HEBUDRZ51 -",PQ?I1@I)I*2Q01UCDS:^=[E1B+S(B?&
MZS[XXQY::S!D\F&+U0UDL[FPJM-.USV-=GFJHBYIL3+;SF)EV.D3UE\YZUZI
MDX:T8<,ZG6YE>+!I+N]GHJ6B2FHYZ6GC2-K51S7:J=.>_P!!K6#L6T&)Z5SJ
M5>"JHTSEIW+WS.GI3I/-IW.#[K+9L1T-7"JY<(V.1$7+68Y<E3_\YB=L<3'1
MY? >M9\>6(S6YJSY^WYO38 ,S[<
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M!)4=ZOV(AH5ELUOLE$VDM-'!2P)MU8F(W->=>=>D[/MQ'3JC7W9GZM1'ZIX
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M9'<K>KYE^ZM5_P Y!_<6, <('O?!&^6-8GN:BN8JHJM7+:F:;%R.8
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MOG[%N'F\GW5)I"OG[%N'F\GW5 R3L1/D<I_/:C[R&T&+]B)\CE/Y[4?>0V@
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M8'H5F7-8U?$B]#7*B%P,DQJ=/T/A\L9L5<L?>(G]0 '%P
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M%NS=L8AW)\+?!Q:A@@S1>#C:S-$RW)D?<
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MHD^BIS.$_P"HD^BH'1X _<JR>:1^X[\Z# '[E63S2/W'?@
M     5$5%14S13S5C;#TV'+[-2O:JT\BK)!)EL<U5W=:;E/2I!O-IH;S1.I;
MG3LG@7;D[D7G14VHI.E^67F>I^GQQV.(B=6CL\LGVHZ6>MJHZ:CB=-42KJL8
MU,U5?P-0OFCRT4N)['0T\E8VGKW3<(G"(JMU&HY-5<NDT'#>$[1AU'.MM-JS
M.35=,]VL]R<V?X%LYH^SY[#_  ]Q%KZRS$5_7]$C"MH;8K#1V]BHY86=\Y$R
MUG+M5?MS.U ,[[*E(QUBE>T  "0                     ^-5N9](QK!GA
MTGUKO>;+5;F?2,:P9X=)]:[W@AK])X.SJ I/!V=0 YN\*;UDDC.\*;UDD
M   &9Z5\?1VK#?#87O-!)<4J&L<R.1DKD;MS[W-33#$-+FC>TVW#;JO#5FF?
M<GU+=985DE=JKFKMF:EN**S:.93GF\4GD_[_ "6C&6.HJ;1[55MCO%!+>8X(
MY-6.1DCD57-1RZF?2O47'"59/<,,6JLJW(^HGIHY)'(F6;E:BKL,LQCHZM-L
MT=5M98;-,EXDIHV*V-9'O7-S-9-557FYC3L$1208/LL4\;XY64D37,>F2M5&
MIFBH+17E^GRYCF_/JWAW8 *EX        0KY^Q;AYO)]U2:0KY^Q;AYO)]U0
M,D[$3Y'*?SVH^\AM!B_8B?(Y3^>U'WD-H  '"HX7@).+ZG#:JZFOGJZW)GEM
MR YE'TW+_P#I??6^,V)GVRL3_4[).W++;VO?_6*!I;N&)9,.7.U5K+-J_P"P
MR*Z%9=9VO5M:B)GTLV] &R@KL7;9QAG"_ 7 :R:VKPVMJY[<N3/(L0
M     #HL28NL6&D9\-W&&F>]%5D:YN>Y.AJ9J1=)&)>U3"-9<V-:^H3**!CM
MSI'+DF?5M7T'D>X5E5<:V:LN$[ZBJF<KGR/7-57_ $3H+\.'GZSV9>(XGVOI
MCN]0T6EW!U5-P:W-U/MR1T\+F-7TY;/27JGGBJ8634\C)8GIFU['(YKDYT5#
MPX:;H.QE56;$E-9:F9S[37OX-&.7-(953O7-YD54R5"S)P\1&ZJ</&3:W+>.
M[TT 0;G>+9:H4ENEQHZ*)=FO4SMC3[7*AD>@G H=5I6PQFL=GEK;]4(N7 VF
MDDJ57G[Y$U?:?"'%^,+L_5LN!IJ.%VQE3>JQL")TK'&CW>C8!H85<DS7<9[-
M8-(-U<KJ_%]!9HUV+#:*!)%R^LF55S_RG.#19:)FJF(J^]8A=R?"-?(YJ=3&
MJUOL [2]Z1L'V63@[EB.W1S9Y<"R5)9,_H,S=[#K7Z19*YN6&,*XANZN_5RN
MI>*0/3GX296^XLEGPK8+*U$M-EMU'DF6<-.QBKUJB9J=RB(B9(B(G,@&=0UF
MDVZR;+7A[#],[9G/.^NF;TY-U&^C,^M1@"[79BIB+'-]G3=P=MU*!F7*BZB*
MY?\ B-  %)LNBS!UJDX5EE@JYU3;-7YU3UZ=:3-2Y00101MC@B9&QJ9(UC41
M$ZD0^@    5S&F#+1B^C9#=X7<)'GP4\2ZLD>?,O-T+L+&#L3,3N'+5BT:EA
MTF@*+AOT6(9DA_Q4S5<GIUD3V%YP)HTLN$)EJJ?A*RXJFKQFHR56IRZB(F3?
M?TEX!.V6]HU,JJ\/CI.X@ !6N?*HIH*F)\51#'+$],G,D:CD7K12H7C1;@VZ
MOX26PTE/+_XM$G%G]>M'JJ70 9[3Z-JFU]]A_&>):-R?$CJ:A*R%J<VI*BKE
MZ3]J(-)5L:C:*MP[?F)M5:NGDHY%Z,V.<WV&@@#/J?&F**-/_:+ -RC9EEPE
MKJ8ZU%7Z.;79>@^O=9PC!*V&[5U19JE5R6&Z4DM,J=:N;J^TOA\:FDIZECF5
M-/%,QVQ6R,1R+]H$2T7RU7EBOM%SHJYB<M-.V1/Y54[$J%QT:8-N$B23X=H(
MY4_[2F8M._\ XH]53K)-&]32/5^'L98DM>K^KA=4\:A9T:DR.S3T@:$<)_U$
MGT5*'!;M)%LS2&]V"^1[_P#;J1]+)U9Q*Y/Y3X5&-<4V]KVWK %P="B*BSVN
MJCJDW;T8NH[("SX _<JR>:1^X[\RS ^D[#%'A:TTMWJZFTSQT[&*VX4LD*+L
MWHY4U53IS- M.(+->&YVB[4%<B)FO%JADF7V*H'9@9IEL
M     5/$W[\80^E5?TT+85/$W[\80^E5?TT+8
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M5D:-7V$D
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M-PK<H+7:[>MRNLK-=S$<J)&G(BHB*JJN_(LQ;W,5^ZG-RZB;3K4L4J\1P6S
M5TP9=+:J7&GK7/BF<J(L2Z^:KSHNS9EOS/2^!GULF$+0^Z(Y*Q::/A-;>NSE
MZ<C-*?&-%78$J,:W;"5NK*VGK.+R-C:W61J9(CU<YJKL540UJQW"*[6>CN%.
MF453$V5J>+FF>7HW%F:=QV^ZKAZZG\6^D:_DF@ SM8  !FFF"ZXRAB?;L(T3
M*6D=1R5-7?)'(J4R-SS8QF]7JB)DO)GZ4TLZ3'/[F7WS&;[B@=#H.N%9=-%.
M&ZVY5,M5634ZK)-*Y7.>NNY,U5=^XO)GO8]_(UA;S9?ON-" $*^?L6X>;R?=
M4R^^V#3%->JZ6SXML-/;7S/=312T^;V1Y]ZU5X-=J)ERJ=1<L.Z:VVZJ=48Q
MPZ^%(GJ]J4VU6Y+FGZH"9V(GR.4_GM1]Y#:#$.Q+D='H<I<LLUK:C[R&Q\9?
MT 3 0^,OZ"!<9KPY[/@N:W1LR[_C4;W*J]&JY .[*]!\H%;_ +L@_JRGRU\4
M_P#FK#_R\W]Y!90XE;>I;GQZR++)3LIU9Q>751&N<Y%^-GGWR_8!= 5G7Q3_
M .:L/_+S?WG94$]<VF1+B^E?4YKFZG8YK,N38Y54#M 0^,OZ!QE_0!,.JQ/?
MZ##5FJ+G=IN"IXDV(B9ND<NQK&IRN5=B)TGY=;U2VBVU-PNM5#24-,S7EGDV
M-8G^J\B)O5=A1\.T%9C&\08LQ13+%10KKV2U3(N<"9[*F9NY9G)EDFU&(O/F
MH$[!EBN-XO3,8XPA?!<5C=';[6YV;+="[>O3,Y$36=R)WJ;#L;OHVPG=:IU1
M56>!)G?&=#G'GUHW(L?&7]'V#C+^@[%IKV1M6+=)AUV',(V+#B.^![;!3O=O
MD1N;U_S+M.](?&7] XR_H$S,]9=B(K&H3 0^,OZ!QE_0<=3 0^,OZ!QE_0!,
M!#XR_H'&7] $P$/C+^@<9?T 3 0^,OZ!QE_0!,!#XR_H'&7] $P$/C+^@<9?
MT 3 0^,OZ!QE_0!,!#XR_H'&7] $P$/C+^@<9?T 3 0^,OZ!QE_0!,!#XR_H
M'&7] $P$/C+^@<9?T 3 0^,OZ!QE_0!,!#XR_H'&7] $P$/C+^@<9?T 3 0^
M,OZ!QE_0!,!#XR_H'&7] $P$/C+^@<9?T 3 0^,OZ!QE_0!,!#XR_H'&7] $
MP$/C+^@<9?T 3 0^,OZ!QE_0!,!#XR_H'&7] $P$/C+^@<9?T 3%1%3)4S0\
MA:2,(U.$,13T\D;EH*A[I*2;+O7-5<]7/QDW9=2GJ>XSW)T+4MDE''-K=\M4
MQSFZO0C51<SH;Q;+S>:)]'=4PW5TS]\<M+,J=:=_L7I0MQ9/;E1GP>[7\WDT
ME6JVUMXN,-OM=.ZHK9ER9&WWKS(G*ILU9H5X:5[X*V@ID5<T8QLSFIMW)F[/
MHWERPQA2LPQ&K;+#AV![DR=,M/,Z1Z=+E?GZ#1/$UUT8Z\%>9^J>BU8-L46&
ML-4%JA<KTIXT1SU_B>NUR_;F=T=/;9KHUDGPI)0R/S346EC>U$3ESUE7:3.,
MOZ#',[G<O2B(B-0F A\9?T#C+^@XZF A\9?T#C+^@"8"'QE_0.,OZ )@(?&7
M] XR_H F A\9?T#C+^C[ )@.,3E=&BKO4Y         ?&JW,^D8U@SPZ3ZUW
MO-EJMS/I&-8,\.D^M=[P0U^D\'9U 4G@[.H <W>%-ZR21G>%-ZR2      #!
M](5;4X&TL+B6IHEJK=7TW!-<W8K%1J-5$<NQ';$7;O136L<XA[5L+UMX6F6I
M2FU?T2/U=;-R-WY+SF43:<HZNG>R?"CIX';'-=,CVKU]YD7X:V[Q&X9N(M3\
M,VU/=GM!BV1VCZHP?;:.2>LN%:LJO;D[-KE14:UJ;<\T3;N/3^#;6^RX7MEN
ME5%EIX&,?DN??9;?:8O1Z9+=0/=+0X)AIY,MKH7-8OVHPW&P7#X5LM#7\$L/
M&863<&JYZNLF>6?I)9]Z[:0X6*[GZMSK]D\ &9L   (EWH67.U5E!*YS(ZF%
MT+G-WHCD5%5/M)8 Z3!.':?">%;=8J.66:"BC6-DDN6LY,U7;DB)RG=@ "%?
M/V+</-Y/NJ32%?/V+</-Y/NJ!C78G_(Y2^>U'O0V Q_L3_D<I?/:CWH;
M    U%<N2)FH,CT^8LGMU+!AZ@>L<E;%PU3(U51R1YY(Q%Y-947/H0G2DWG4
M*\F2,=9M*SW_ $H86LE6ZEGK):J=BJCVTD?"(U4Y%=FB"Q:4,*7F98HZ]]'(
MC5=E6Q\$BHB9KWV>7M/+Z(B)DFX*B*BHJ(J+R*:_C5T\_P";DWVC3TA9Z:HT
MAW*EOUUBFI\*4STDM=MG;JNJY$7952M\7Q&KUJ:*93H&Q9/=;?46.Y3.FJ:)
MJ/IY'KFYT.Y6JO+JKNZ%Z#5C'>DTG4O1QY(R5BT  (I@
M
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MG4B2I/6SN22JG3<YR)DC6_X4Y/2I:CS\UXO;</8X?'./'$3W  5+P
M
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ME5*WI.<^X7G!>'6(JQW"YI55+>1:>F3A7(Y.97:B%^<N:JJ[U _
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MWHK4V9*G)EO+#I=POHXT<Z.[JCK#12W"XJ^.C1_?3\([-4<Q5VM:S8NSH3E
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MI2E>U[J55<C55%1$5,M;-.141=B >HP?KFZKE3F7(_
M  GT_P"I;U',X4_ZEO4<P        /C5;F?2,:P9X=)]:[WFRU6YGTC&L&>'
M2?6N]X(:_2>#LZ@*3P=G4 .;O"F]9)(SO"F]9)
M!"OG[%N'F\GW5)I"OG[%N'F\GW5 QKL3_D<I?/:CWH; 8_V)_P CE+Y[4>]#
M8    'ZB*NY,S\.KO%CIKM+%)4S5L:QM5J)3U3X45,\]J-5,P.UU7<R_8-5W
M,OV%0NN$Z&GM%PGBJ[NDL5-+(Q?A&;8Y&*J+\;G.%KPQ;76.BK:VNNS46DCG
MF>MQF1/B(YRKWW6H$>R3-O.EO$-5L6*PT,-LCY4X695FD5.E&I&A>2@Z%+6V
MDP<Z[+P_&+_4RW23A9'/75>Y4CVJN:_HT9MWKRE^
M                             P/LL<.7G$-#AEMBME7<'02S+(E/&K]1
M%U,L\MV>2FB:8J&MN>AN_6^@IYJFMEHHV1P1MUGN<CF9HB<^Q2\(JIN4)LW
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MZ8S/U7*N]54 Y<U55WGX                    $^G_ %+>HYG"G_4MZCF
M       !\:K<SZ1C6#/#I/K7>\V6JW,^D8U@SPZ3ZUWO!#7Z3P=G4!2>#LZ@
M!S=X4WK))&=X4WK)(                      (5\_8MP\WD^ZI-(5\_8MP
M\WD^ZH&-=B?\CE+Y[4>]#8#'^Q/^1RE\]J/>AL      !!OW[OW7S.;[CBEZ
M09YV:'(Z.A<K:^Z4E):Z9$3:KYT8Q<NIJN7T%TOW[OW7S.;[CBARRON>--'=
ME1-:EH+:M[J6KNUFQI%#Z=9SE] &@VVCBMUMI*&G3*"EA9!&G,UC4:GL0D@
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M=:3#S,G25*UL+IHV*OQE@W\O.:3;JR"XVZDKJ-_"4M5"R>)^66LQS4<U?L5
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M&--C*RNJ8XT@K8%2.J@1<T8Y=SF_X5Y/L+29IB:SJ6RMHO'-7L  XD
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M0LD5$Y%<U%_U)!PBC;#$R*-$1D;48U$Y$1,D]QS GT_ZEO4<SA3_ *EO4<P
M       /C5;F?2,:P9X=)]:[WFRU6YGTC&L&>'2?6N]X(:_2>#LZ@*3P=G4
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MK:KV<>]\L";$R1$1$V9( ""T
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MD*^?L6X>;R?=4#&NQ/\ D<I?/:CWH; 8_P!B?\CE+Y[4>]#8
M
M !2\2:+L&XDNDEQN]C@EK9?UDK'OB61>=VHJ9KTJ70 =;AZQ6K#EM;06*@IZ
M&D1=;@X6:NL[QG+O5>E3LN=-Z+L5%Y0 ";$R3<     #-<LN0
M       $V9[$S7>N6T    )]/^I;U',X4_ZEO4<P        /C5;F?2,:P9X
M=)]:[WFRU6YGTC&L&>'2?6N]X(:_2>#LZ@*3P=G4 .;O"F]9)(SO"F]9)
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MW&\5_.SB+U:_F#N-XK^=G$7JU_, UD&3=QO%?SLXB]6OY@[C>*_G9Q%ZM?S
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M,;[$3Y'*?SVH^\AM!7\"80M6"+ VSV%DS*)LCI42617NUG+MVJ6
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M /ZYNY7+W@NS7K%-FQ#7PRON=IUN*O;*K6MUM^;4V*6,
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MIGM39TDXK.CU<*/P_P +@1MM;:)97/7B#4:SA,D1<T3<[)&[]NXLP
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M0A7>U4%YHG4=VHZ>MI'*CG0U$:/8JHN:+DNP"L:1JRZT&B>\5>'E>EUAMVO
MZ-,W-5&IFK4YT3-4Z3*\-6C1+5Z'X:BZU%JDJ9J3C5;535#>.I5:N;W9JNNC
M];/)O+LV+GM]#M:C6HUJ(C43)$3<B%8GT>X1GN?PA-AJT/K-;761:1F:NYUV
M;5Z0*]V.M;=KCHELM3?9)I9G<(D,L_ZQ\*/5&*[T)Z4R4TD_&-:QJ-8B-:B9
M(B)DB'Z      ?&JW,^D8U@SPZ3ZUWO-EJMS/I&-8,\.D^M=[P0U^D\'9U 4
MG@[.H <W>%-ZR21G>%-ZR2
M
M                                              !\:K<SZ1C6#/#I
M/K7>\V6JW,^D8U@SPZ3ZUWO!#7Z3P=G4!2>#LZ@!S=X4WK))&=X4WK)(
M
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M(]/8I+..]P
M  !\:K<SZ1C6#/#I/K7>\V6JW,^D8U@SPZ3ZUWO!#7Z3P=G4!2>#LZ@!S=X4
MWK))&=X4WK)(
M               "[E Q#'6CW$=KQ35XHP-4Y2S.662!CD21KE^-DB['-54^
M*IV& <9Q:1*&OPKBVD5E8^->$X+.-)6-5,T5,\VN1=Z$6LI-+-INE>RT/IZV
M@DG<^%99(WJUJJJHG?*BID=AHFT?76T7VMQ'BF2/X4GUD;%&Y'Y:RYN<Y4V9
MKNR0U3,<GU3&_MY8:Q/N?1$Q$]]]F?:','67%-YOU+>:9\T-&J<"C97,U>_<
MG(NW8B;RP=DQ314]OPS!$W]%$LK&HNW)$:U$/A;L&Z0L'XCNTF%:>DGIZR1R
M)/+(S)6:RN:JM545%3/I+AI;P1=\7X8M*TRPOO%%MEB5R,;)K-1'Y+N145$R
M)3>/<BV^B$8Y]FU(KU_OU?/3PB+HIA1<OUU,4[%-TGH.Q]PS2T[W,;6Y12Y?
MQ,17.5OIR0^UXPII,Q186T=Z92,@HFM6"G21B.G>G>IK*BJFQ%5<U+=4Z/ZR
MZZ'[;8*Q&T]WHHTDC371S4D179-54Y%1<MA&)K2(B9^Z5HODM:T1,=-*7-HU
MM,&AYM];PB7E*5*M9FRKJJB[59J[LM79SY\IW&BVPLQ-H0NEJ>B*Z>IFX-5_
MA>BM5J_:B'74&$M)57A:3#%8VDI+/%$Y&*Y['ODR[YL:.1=RKRKEDAHFA?#U
MRPU@U:"]0-@JUJ9)=1LB/357++:FSD.WOJL]=SLQ8XF\?3J-:EDV L6R6/1A
MC"V3O2.LI5U*=B[T=*JL<B=3D52^]CKAZ.VX-==',1*BY/5R+R\$U=5OM1R^
MDS+2?AZ.32W+:[7*CGW6>-SV-7]6^1>^S]KO2>F[710VVW4U%2MU8*>-L3$Z
M$3)#F:T17I_NZG#4F;_5_MZ?]_HRKLE_W.HO.T^ZXO."$C71W9N'U>"^#H]?
M6W:O!IGF=!IMPQ=<48=I*2R4[)YV5*2.:^1&=[JN3>O6A1DPSI6K[-#8:B6D
MH[6V-L&;9F(O!HF62JW-RIE]I&L1:D1O2RUIIEFW+,[B$3L;_P!]K\D&?%>*
MKEEN_6][[,SL=(EUP'68ZE6ILEROUYC8E/+%2JJ1JK<^9457)N7DV&D:-<#T
MF"K0^"*19ZV=4=43JF6LJ;D:G(U/Q,S[2,:X3QW<+KA.BHZ^&I=(K'SR-1$:
M]VLJ.15145%Y4)1>MKS;?^%?MWIBK68WUZ]-Z=#HKD2DTR+36^DJ;;1522L?
M13_'8S4UD8_GR5,TS.UPRR/1_ISJ[<N45NKFJQG-J/[]FU>9R*AW&$L 8HM^
MD^CQ#>.+U#9FOFJYHWHB,D>Q45B-WJB+DF:'YV2]OIF6^T75)&QUS)5I\L^^
M>Q45V:?15/:2YHM?E\PA%)ICYYC7+._Z.IT24TF,-*EUQ15,5T%*]SX];;DY
MV;8T]#<U*Q?[>W#&/;K48YL4MVHJN:1[)4D<Q'HKLT>UR*B*J(N6JJFV:$+
MZQ8$IEG8K:JN<M7)GO361-5/^%$^TJMVCTK.9<;:ZW6NY6^H=)'')*Z/-(U5
M<E7ODVHF6]#D7^N==NWAV<7_ .<3,3OOVW^L+7H=9A9,/U$N#DF9!+.KIXZA
M?TL;_%=T9;M_67TSC0I@>LP=:*MUU>SCU8]JOB8[6;&UJ*B=]RKM7,T<SY-<
MTZG;9AW[<;C0 ""T
M      'QJMS/I&-8,\.D^M=[S9:K<SZ1C6#/#I/K7>\$-?I/!V=0%)X.SJ '
M-WA3>LDD6394MZR4
M                             .GQA9YK]ANNME+724$U0U$;4QHJNC5'
M(N:9*G-EOY3N =B=3MR8W&I9QH_T5TF%[M)=J^OENUS5.\EE9JI&J[U3:JJY
M>=5-' .VM-IW*-*5QQJL  (I@  _')FU4SRS0R&FT*LGOC:S$%_JKG2LD5[:
M9[%1%3//555<N3>=$WFO@E6]J]D+XZWUS0_&-:QJ-8B-:B9(B)DB(?H!%,
M                                                     !\:K<SZ
M1C6#/#I/K7>\V2K5&M:J[D7-3&\$KKUCG)N=(J^T.PU^D\'9U _:5/T#.H!P
MJMDB+RDJ-VLQ%3E0^%8Q71KJ_&Y%/E13HJ99[%]B@30
M
M
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M , +6"J=O=B\J0>K?^ [>[%Y4@]6_P# "U@JG;W8O*D'JW_@.WNQ>5(/5O\
MP M8*IV]V+RI!ZM_X#M[L7E2#U;_ , +6"J=O=B\J0>K?^ [>[%Y4@]6_P#
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M , +6"J=O=B\J0>K?^ [>[%Y4@]6_P# "U@JG;W8O*D'JW_@.WNQ>5(/5O\
MP M8*IV]V+RI!ZM_X#M[L7E2#U;_ , +6"J=O=B\J0>K?^ [>[%Y4@]6_P#
M"U@J;L>6)$S^$XEZ&Q/5?<=7<-(UN8Q4HXJJK?R)J<&W[5_ "^22HW8WOG<R
M&;8XQLD?"VZRR<)6+FR6=NUL2<J-7E=T\A7+OB*]X@8M.N5)2.WQ09HKNMV]
M21A_##G.:KF+R!U'PG9%D>USFY]9KMGHTIX6HB$2RVEE+&W9DJ'>M:C4#C]
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g50309g17m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g17m01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1<@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %P,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M25]'(3%)&S=P0]HSCR$A86ITMS;W]E62G)K4]IC8B(IJQ./42#U$=2(@^O\
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MGF[D<\.'OJL(I3$3&I0K::SN$S=-27*OOU3=>ZIXI9:@U 8V5VZPYR ./(<
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MF\^49DDESR7.)R2>L]91$5J@1$0%L?\ AKM$DM]N=W>P]#! *=CCUO<03CR
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MU3:+M8[+36R&U[O0T[#D28.27D <3G"J")R5WLZEM17?AHVLMHE!?)8[A;K
MR@OHEBE[O,H>X;G(#P1GJ'D4MZ;M!+5Q7>JTG2OU!#'T;*D2X'7Q]3GK[??6
M1HN=*NM)=>^][:#I/:946?4M[O5QHC7U-S:&N:V7HQ'@\ ,@\ , #Q+/WG>>
MYW:25^(I16([PKF]IC4O933R4U1%/ XLFB>'L<.H@Y"T':+M/FUA8Z:VMMW<
M3&2"69W3;_2$# &,# R<]?4LZ1)K$S$S]B+VK$UB>TKGL_UNW25OO5*ZWFK]
M$8PS>$VYT>&N&<8.?5>)>.E=:ML6B[W8#0&<W'>_#B7=Z/+ WU.#GEGF%3D7
M)I$NQDM&M3X7*TZV;;]G5RTMW 9#6.<[NGI<!F2#ZG''U/:J9@=B_44HB(\(
MS:;:B?LO^AMI$E@LLECNMLAN]G>21%*[!9DY(X@@C/'&.:XM;:KM%ZMM/0V3
M3=+:(XY>E=+&6E[^!&.#1PX^/J5-11Y*[VGU;<O+OLM&SG5$&D+^ZZ36\USQ
M"Z*-@EZ/<)(R[.#U#'OJ/K]27.KOL]T[KJ(YI)S.&-E=NM\+(&,\AR4.B[RQ
MO://;7+OLU2NVOS/U-0WJAM+89HZ<TE5')/OMJ(]X.&#NC=(.3GCS45J_6UC
MO%LKX;7I6GH*ZN<UTU7OM+FX<''=PT<\<50$48QUCPG.:\Q,3+2K%M)H(-(4
MEBU!IR&Z14;@87&0-!P>&06GCQ(SUJ%T]K1EGTMJ2S"W=(+N7%LC9=T0 C &
M,<<>4*GHN\E7.K?MW\-"V:;3)M%VVJH9* UU/))TL;>FZ/HW8P>HYS@*KV6_
MRT.L*:_U3#4S1U1JI&;V[ODDDC/''-0J+O)$3,^W.I;41OQX6R[:SEJ]HC=5
MTM(()62QRMIWOWAX+0T@N ', ]76IK6.I:3:!(ZGLNE',OM2YKWSQO$DCFL:
M<M W03P^@+.5U6NXUEJK8ZRV5,E+5QYW)8SAPR,'Z%SDCM,?9V,D]XGQ/EN6
MT*\U]BV.V^SWF1C+Y6Q,IWQM=EPB:>)X=>Z #XR5@:[+K=*^[U7=-UK)ZRHQ
MN]),\N('8.P+C2E.2-&7)U)V+RBAEJ)60T["^:1P8QH&27$X 7BMCV"Z%DK*
M^/4MSC+:2G<>Y(WM(Z1^/QGD&>'C\B[>\4C<N8\<Y+<L-PTQ;A:=.VRWC'_3
M4T<1QUD- )^'*DT1>7,[>W$:C0B(CHB(@(B("(B B(@(B(."YV]M0TR1>#.!
MP(X9\14?:KD1*ZGJ.$C>WK4^J;K)G<-7!6Q\ 7#>QX^'W(+BTAPR$4?9*L5-
M*QV>.$0>=/\ E6J\UJ[EPTWY4J_-:NY 1$0$1$!$1 1$0$1$!$1 1$0$1$!?
MCV->QS'@.:X8(/(A?J(,<UQL4I:^=]7I>:.@F><OII<F$^;@9;](66W/9EJZ
MW/W9+.^8=3H)&/!^G*^M45]>(O7MY9;\)CM.X[/CCO,U+^P;A\DG>9J7]@W#
MY)?8Z*?RI](?!K[E\<=YFI?V#</DD[S-2_L&X?)+['1/E3Z/@U]R^..\S4O[
M!N'R2=YFI?V#</DE]CHGRI]'P:^Y?''>9J7]@W#Y).\S4O[!N'R2^QT3Y4^C
MX-?<OCCO,U+^P;A\DG>9J7]@W#Y)?8Z)\J?1\&ON7QQWF:E_8-P^23O,U+^P
M;A\DOL=$^5/H^#7W+XX[S-2_L&X?))WF:E_8-P^27V.B?*GT?!K[E\<=YFI?
MV#</DD[S-2_L&X?)+['1/E3Z/@U]R^..\S4O[!N'R2=YFI?V#</DE]CHGRI]
M'P:^Y?''>9J7]@W#Y).\S4O[!N'R2^QT3Y4^CX-?<OCCO,U+^P;A\DG>9J7]
M@W#Y)?8Z)\J?1\&ON7QQWF:E_8-P^23O,U+^P;A\DOL=$^5/H^#7W+XX[S-2
M_L&X?))WF:E_8-P^27V.B?*GT?!K[E\<=YFI?V#</DD[S-2_L&X?)+['1/E3
MZ/@U]R^..\S4O[!N'R2=YFI?V#</DE]CHGRI]'P:^Y?''>9J7]@W#Y).\S4O
M[!N'R2^QT3Y4^CX-?<OCCO,U+^P;A\DNRW[.M65\@9!9*AF>N9S8Q])7UVBY
M\FWH^#3W+!]';#I3,V?5E4SHAQ[EI7G)\3GXY>3X5N%OHJ:W44-)0PL@IHF[
MK(V# :%T(J;Y+7\M./#3''\,"(B@L$1$!$1 1$0$1$!$1 1$0$1$!$1!!ZS
M.GZK/4QWV2JWL[J724L8)ZE9=9^QZL_EN^R53]FI_P"GC\U!I8Y+ENA(M\^/
M:E=3>07)=?R?/YJ#WTH IH@.0:%[%X4_XB/S0O- 1$0$1$!$1 1$0$1$!$1
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MK/)$.&73R,C ^$Y^A?6J+D\3;T1P5/<L9T1L3IJ.5M5JJ9E=(WBVEB)$0/\
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M>';KAS:<<CXE[$!$7%<[I16MM,ZXU+*=M3.RFA+\^'*[@U@\90=J(00<'FB
MB+PFEB@+!/+'%OO$;.D>&[SCR:,\R>Q!YHB("(B B(@(B("(B B(@(B("(B
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MX;KJ%\[&3:3,49< Y_HG$[<'6< <?(K @(B("(B B(@(B("(B B(@(B("(B
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MT^,,DD '$MYCQJR("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MD[H[PR&6[5&Z#GN>$<(S_,>0WWE;&U1U9H^&KT_='6[T1IV2Q5<3!*Z(.P7
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MB@)=2"XU/2-@>>!>UH &]CADY5P1! :5LE3:;AJ"NKJONBHN=<ZHC <XMAA
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MU,;!WN/BJ;@&OSNLCA<';OMCE9IILU&GK;;-67:P4M=9I*XUE /19P= )I/
M=%3<8P]N\,@$D<>M?29 (((!!X$'K56H=GFD:&[LNE)I^ACKHY#-'(&D]&\G
M)<UI.&G/8$$9MM@J(M.VN[4M.ZJ=8KM3W*6-@)<8FDMD( [&NS[R[+M9JFY;
M3-)ZCHNBEM5)05;))-[B>E#2P@=8.%<@X@Y!XKQ: T -  '  =2#)[;LYK[;
MM+Z:-[)M&FGJS%3&0M=2NJ,=)$W&"&DMR,'AE7&FT+IZAF954%N>VK@/20&2
MMJ'-#QZG(+R",XZBK0B#*-16G4^M:>GM=PTM:[))W1%/-=VU;9G1[CP\]$ T
M.R[=W>)Y%76T7ZKN&M[]:.Y&,MMKA@S5'>WI)I 7%HZB T=7658D)) &> Y(
M,[@V?4M]U?J*_:PHFSNGE936^)E1(WHJ6-N <L<.+W$N(ZERVBRZMT?HF_67
M3-/2U$\-8\V62>8;L=/)QP01SC.< \#E:<B#.MF5%?K,\45?IF"E949FKKJZ
MX">>IGQZMXW1G)SPS@#@%W:GMEZMVLZ;56GZ.&ZDT+K;4V]\P@?N;_2-D8\@
MC((P0>U7=$&:.H]76W57?;262CJYKC0QTM?:VUNXZ%\;G%CF2%N'#!P1P7%+
MH:^&QVQ\QII;I4:HBO\ 71QNQ'3M+]YS&D^JW0 /&5K"(*=>M-U-TVA5-<_=
M9:JG3]1:WR@^$)))6G@WS03E58Z?U?>-/671MYMU!3VZWS4W=%VBJMX3PP.!
M:&1;N6N=NMSDX'%:TB"G;*;!7:<TQ44-T:QD[ZZIG:&/WAN/D+F\?(53655\
MT-LJN=BNMF8]T$$M!05-/4=)W=-.]X8&Q[N6\'Y.>Q;&@X$'AD<0>Q!P:?H7
MVS3UJM\K@Z2DI(J=Q'(EK #](7>B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@ZJ+U+_*NA<]%ZE_E70@(B("(B#*]<^S"D\QWUK0=/^LF
M>:%GVN?9A2>8[ZUH.G_63/-""37!'^6I?Y0^M=ZX(_RU+_*'UH.]$1!C>T6I
MU+>=IE+IJRW=]G@[D$[7AY8)3Q)/#B3PQCQ%=FG- ZOH+]0U=SU:ZMHHI Z:
MG=)(1(WK&#P/OKAVTV&U5>H*.OO>JA:OP(9!!T#I7#!.7#=XC.?H5>T-;K!%
MK"T24FNY:Z=LX+*8TLK1*?:Y/ >^M4?Z.WKTPS_^R>;W[_P^AF,;&T-8T-:.
M  & %^HBRMPB(@(B("(B#)MJGYW-EO\ 557]MJT=9QM4_.YLM_JJK^VU:.@(
MB("(B B(@(B("(B B(@++MI>EC7Z@II+.WI;C5L<Z:G:/T6C\:3U \&\>9Y=
M:T6[W&"TVV>NJ]\PP@9;&W><XDX#6CK)) "Y-,VZ>F,U=<L&ZUSFOJ #EL;1
MG<B;XF@X\9R5*MIK.X9N*X7'Q>/IY8[,IT5H:>[U+YJ_=CHZ>=\,K,G><]AP
MYOB&??6F1VB[6X_^R;P9X .%+<F](WWI1X8 '(<5ZM >L+S_ )S6?W%9DM:;
M>4."X'%P59KB^_F4 W4;J5SF7VVU5N#<_P#4#\-3GCC.^WB,]C@%-4E3!60"
M:CGBJ(3P$D3P]OPA>T$CD<*%J-,VV2J=5T[):"M<,&HH9.A>>.3G' ^^"HMB
M:15Z-NI+>\[SJ2]4XR<$"FJ.? 9]0<<^."O=2:GMTU0*:J,UNJSG$-='T1.#
MC@X^"[WB@FU$:Q]B-\_H9_L.4P01S"IVT+4ELM]HN-KFF<ZOJ:62-D4;=[=+
MFD N/(<UV(F?"O+EIAKSY)B(_5-Z3]BMD_H*?^VU2JJ6@-2VRY6FWVVGG+:Z
MEI8HGQ2-W2XM8 2WM' JVI,3'DQ9:9J\^.=Q^@B(N+!$1 50VE>L;!_GE%]H
MJWJH;2O6-@_SRB^T4@7%_JW>5>*\G^K=Y5XH"(B B(@(B("(B JY??9KHW^9
M6?V%8U7+[[-=&_S*S^P@L9YHAYH@(B("(B B(@(B("(B B(@-]4/*I)1K?5#
MRJ20$1$!5/:9[&I_-/UA6Q5/:9[&I_-/UA!Q;/O6K?(B;/O6K?(B"UTWY4J_
M-:NY<--^5*OS6KN0@1$0?/\ K#4U-<]<UALNAX+S4VZ7HY*G<<\O<TD9<UHQ
MC((&<YPN_3]F9M N,U'J?19L,,+34MJ:>-\!D>7 %I): <C)[>"]'1ZXTWK;
M4=7IK3Q=05M4Y^X\!S),$XD!R",Y)QXU>]GU\UA<[K4PZILD5OI&P[\<C!@N
M?O 8]4>K*U6GEKNO^[#2.:VK[_;79=J"C@M]%!24<38J>%@CC8T<&@# 7O1%
ME;A$1 1$0%G^WO\ -)JG^B/VFK0%G^WO\TFJ?Z(_::@F=*>Q:S?T4/V I516
ME/8M9OZ*'[ 4J@(B("(B B(@(B("(B B(@(B("(B B(@(B("*NU5WOT=7+%3
MZ7-1$UY:R47!C=\=1P6\,]BX+9JF^7*@@K*72;W03-WF$W&,''Q4%Q1>,9<Z
M-I>W<<0"6YS@]F>M>2 B(@(B]5340TL#IJJ:*"%GJI)7AC1Y2> 0>U%#56J;
M!20.FJ+W;6QMQDMJ6//$XY DKIAO=IGF9%!=;=+*\[K6,JF.<X]@ .24$@B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@ZJ+U#O*NA<]%ZAWE70@
M(B((36?L>K/Y;OLE4[9MZWC\U7'6?L>K/Y;OLE4[9MZWC\U!IC>07)=?R=/Y
MJZV\@N2Z_DZ?S4'13_B(_-"\UX4_XB/S0O-!\JW^":^5MZO-YNU3 8;TVADA
M!+A3Q.+O" SPP&D =>%?MB5)06K76H[;1W W/HX&.BJXY Z-\9()&!D;P) Y
M]JY=8Z\T?!57ZR1:9FK&5,SN[9X2UG23 GP@>).#G!X<<J3V#5^GY:ZY4MCL
ME715#8FR25%3+TCGMWL!OB&>*V7F9QSN'G8XK&6-3$S_ #_5L:(BQO1$1$!$
M1 64[0?SV;-_,K?L-6K+*=H/Y[-F_F5OV&H-$1$0$1$!$1 1$0$1$!$1 1$"
M B@+AIM];72U#;]?*82'/14]461L\T8X*!TO8:FYV9E54:EU%TCI9F>#6D##
M97-'5V (+ZBXK10FW47<[JRLK#O%W2U<G2/X]6>Q=J B(@(B("(B B(@(B("
M(OP@$$$9!&"#UH/2*RD) %73$GLF;]Z_.[:3W92_+-^]5?6FGK+!I*\2P6>W
MQ2LIGN:]D#06GM!QP4PS3-@,;,V.VG+1_P##M[/(@EP00"""#R(ZU^KQC8R.
M-L<;6L8P!K6M&  .0"\D!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M'51>I?Y5T+GHO4O\JZ$!$1 1$097KGV84GF.^M:#I_UDSS0L^US[,*3S'?6M
M!T_ZR9YH02:X(_RU+_*'UKO7!'^6I?Y0^M!WHB(,5V@:8J+SM-K^GME164\M
MF?W+*UI+(I@';N3RSD' [7!4_0%?02:ST;%8;6^.YPM,%UWF M..!D'81@DG
MAV+1-H.K]3,UM#IK1U+$ZJ$ GDDD:"2#GMX  8X]I7/I.FVAPZFI9KI;K;#1
MRRCNN6**)KW-Z\D<2M<3,4[^O;!-8G)_#OSW[->1$61O$1$!$1 1$09-M4_.
MYLM_JJK^VU:.LXVJ?G<V6_U55_;:M'0$1$!$1 1$0$1$!<E7<Z"CE$597TE/
M*1O;DT[6.QVX)Y+K4?7V2TW*H$]QM5!5S[H;TD\#7NP.0R1R0?AOMH !-VMW
M'E_U4?WKMIIXJJ)LM++'/$_U+XG!S3U<"."H&C]-V.74>LHYK+;9(X;@QD37
MTS"&#HAP QP"GKJQGX'3-@$=#TC3)4FGC#6TU.3QW0. <\Y _P#4>I!^T#AJ
M*\MN37DVFWO<RD;S;4S<0Z;L(;Q:WQY*F);O;:6I,55<J*&5A&\R2H8UP\H)
MRNBG@BIJ>*"FC;%#$T,8QHX-:.07!6:?LM;4OJ*VS6ZIJ'^KEEIF.<[RDC)0
M5W0MYM<5#=Q+=*!A==ZQ[=ZI8,M,G CCR5RBD9+&V2)[9(W#+7L((<.T$<U$
M]ZFG/W>M'S./[E*P0Q4\+(:>)D4,8W61L;NM:.P <@@]B(B O7400U,+H:J&
M*>%W-DK ]I]XKV(@KATWZ'-EFT_7U=N<UI<*<'IH">9_!NX GM!"P.:>2JFD
MJ)WE\LKB][B<DDE?3X."LAUUH"6CDK+G:71FWM:Z>6)QPZ+ )=CM"MQ6B/+Y
M_P"O<)FXBE+8HWK>X_?7=0:.:6GK()J=Q;-'(US'#F"#P7TQ3R.FIXI7C#GM
M!(\?6LATGL]K*Z""XU-4RF8]C)Z<M9TF<@.:YP/ CQ+0X;\^AF%)J.&.A?P;
M'6,)[DF.. #CQ8[GX+NPX)3+:)GL[]!X3-P]+VRQK>M1_E/HA!'-%4]\1$0%
M4-I7K&P?YY1?:*MZJ&TKUC8/\\HOM%(%Q?ZMWE7BO)_JW>5>* B(@(B("(B
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MIJI&Q01-+WO<<!H',E9E;[%JG5.N[%?-7VVCM-%88WOIJ:&I%0Z>HD:&N>2
M &@#@/&M1<T.:6N (/ @H*QZ8.E/V]0_**D;:M8Z=N6R_4M+0WBCGJ)*-S61
ML?DN.\#P^!:QW'3_ *B/XH5$V[TT+-D.JG,B8UPHS@AO\003>E/8M9OZ*'[
M4JN?18'>C9>'_P '#]@*9W1V!!'(I'='8$W1V!!'(I'='8$W1V!!'(I'='8$
MW1V!!'(I'='8$W1V!!'(I'='8$W1V!!'(I'='8$W1V!!'(N&^C4W=C?0%MF[
MEW!GNSI-_>R?:\,<E V^X:WKJBOAB9IH.HYN@>3T_$[C79'QL>\@MB+V687#
MT/C]&A2=VY._W+O='C/#&]QY+MW1V!!'(I'='8$W1V!!'(I'='8$W1V!!PP?
MC6^55S9_[";-_)/VW*Y8 ZE6=FH'>-:.'_NC]HH)1%([H[ FZ.P((Y%([H[
MFZ.P((Y%([H[ FZ.P(*'M2]@ET__ $7]UJMLGXQ_E*KVUP : N6!UQ?W&JX8
M'8$$<BD=T=@3='8$$<BD=T=@3='8$$<BD=T=@3='8$$<BD=T=@3='8$$<OT-
M)' $J0W1V!0E_P!*6>_3Q376D,TD3=QA$KV8&<_HD(.O<=V%"TCF,+/+'HBP
M5.M-34,U$]U+2"FZ%G=$G@;T>7?I=95[L&F;38#,;32F$S8W\R/?G'+U1/:@
M]Z*1W1V!-T=@01R*1W1V!-T=@01R*1W1V!-T=@01R*1W1V!-T=@01R*1W1V!
M-T=@01R*1W1V!-T=@01R*1W1V!-T=@0>BB]0[RKH0 #DB B(@A-9^QZL_EN^
MR53MFWK>/S5<=9^QZL_EN^R53MFWK>/S4&F-Y!<EU_)T_FKK;R"Y+K^3I_-0
M=%/^(C\T*)U?IZDU18*FU5V6QS %KV^JC<#D.'C"EJ?\1'YH5?UEK.T:0CIG
MWE\S6U!<(^BC+^6,\O*I5WO^'RC?EY9YO#,XMFNOK=%W#:M8-;;AX+ 99&%K
M?)@X\@*O.S/0<6CJ>IEGJC6W2K(,]201P''=&>.,YX]:BO3MT?C/3UV/Z9RL
M&C=?635U744UF?4.E@C$C^EB+!@G'#*MO.37>.W[,^*,'-_!.Y_?:UHB*AJ$
M1$!$1 64[0?SV;-_,K?L-6K+*=H/Y[-F_F5OV&H-$1$0$1$!$1 1$0$1$ <U
M6-$>N=4?YU/]EBLXYJL:(]<ZH_SJ?[+$%G1$:,G"#U5%3!1PF>KFB@A;S?(X
M- ]\JM;.KA1U%ACIH*N"2I9-4.=$UXW@#,\@X[""#[ZS':5>*BZ:GJZ>5Y[E
MHI###'U#',^4E5B"62GG9-!(Z.9ARQ[3@M/:%=&+<;?,Y_\ Y#T\TTK3=8G7
MGN^GT43I.Y2W?3M%75#0)I6>'@8!<.!/OJ65+Z/'>,E8O7Q(B(B8B(@\X?QK
M?*JSLZ]A=M\LW]YZLL9#'![W!K&G)<XX 59V<D.T5;BTYP9@?$>F>@LB(B B
M(@(B((+77L,O?]*]3<?XJ/S1]2A-=>PR]_TKU-Q_BH_-'U(/)$1 1$0$1$!$
M1 1%Z:SNCN2;N+H>ZMP]%TV=S>ZM['''D0>Y%2+Q<]8VN"GEFBTX\35$5,T-
M,_!SW;H/D4S:^^CNZ/T5%C[BX])W+TW2<CC&]PYXYH)Y$1 1$0$1$!$1 1$0
M$1$!$1!U47J7^5="YZ+U+_*NA 1$0$1$&5ZY]F%)YCOK6@Z?]9,\T+/M<^S"
MD\QWUK0=/^LF>:$$FN"/\M2_RA]:[UP1_EJ7^4/K0=Z(H;6-TJK+IRMN%OI'
M5E3"T%D#027\0.0XKL1N=.3.HW*IZCV/Z:O-;)5QLFH)I#EXIG8:XYXG=.0/
M>PIG1>S^Q:2>^6VT[GU;QNFHF=O/QV#J'O+.';8-3,JH*5^E=VJG!,4)$@>\
M#F0W&<<"IC36TK45RU;0V6X:<%$Z<[S]\N:YL?6X \U?-<NM3/;]V6M\'-NL
M=_V:VB(L[6X;U<J"SVRHN5UGBIZ2E89))9#@-'W]6!SY+/=F5OKKWK*];0*^
MGDH8+G3LHK?1S-W913L.1)(.HN/$#J"E-I^@)M<2VAS+Y5VUENE,[8X6->U\
MG#=>0X$$MP<>5<]LT'J"!E>ROUY>*Z.II)*=K7M8WHGN'"0$ '(0<%(#)_B2
MKS4M!Z+3T?<Q<.0,QWMWW^:_=GX$>VG:4RE %*6T+Y T -Z8QNR>'61C*[KK
MLT-9#8JNGO\ <J74EHI^YH[JTM<^6,^J;(T@AP//Q*:V?Z+I='TE=T=54UUQ
MN$_=-=6U+@9)Y.W@  !U#J02NH)[S!'";%1T=4\N(D%3,Z,-&.&,-.>*A>[]
M;?L:R_/9/^"MZ(,1UE->I]K.S,WZBHJ7%55=%W-.Z3>_!C.<M&.I;1W/'V'X
M5E^U+\[.RS^JK/[35JR#T]SQ]A^%.YX^P_"O<B#T]SQ]A^%.YX^P_"O<B#T]
MSQ]A^%.YX^P_"O<B#T]SQ]A^%.YX^P_"O<B#T]SQ^/X51=<6:FU1>J6S4\8;
M44[.GJ*X>%W.PYW8\=;G'C@\@">M6O4MX;9K<)A&Z:IF>(*:%HXR2N]2/$.L
MGJ )5;AOUAT2#07NX2>BM1_U=5(*>1_2/=P)!:W '@X Z@ NQ.O"O+BIFI-,
MD;B52T)H:DJ-17B*NE=.+35-A#2,-D):'9(]_DM?92Q,:&M& !@#*RC2.O=.
MT.H-65%56S,AK*UDL#C23>&T1M!/J.W(6HV6ZT=ZML-?;93+2RYW'ECF$X)!
MX. /,%)M,^5?#<)AX6O+AKI[^YX^P_"G<\?8?A7N1<:'I[GC[#\*=SQ]A^%>
MY$'I[GC[#\*=SQ]A^%>Y$'I[GC[#\*=SQ]A^%>Y$'I[GC[#\*A=;PL9HV^D9
MSW#-U_P%6!5;6]WMK]'WV-EPHW/-%,T-$S22=P\.:#LT= QVD;$3G)H(.O\
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M'3U-JC3U7::USF1S@8D:,EC@<AP]\*943J'45IT[!%->JV.DCE=NL<\$Y/O
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MWU;_ +]_#7%Z:VKIZ"DEJZV>."FB&7R2'#6J*K]01BJ-%9H?12X @/9$_$4
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MN*SW2EN]"RJHI-Z,G=<TC#F.'-KAU.'6"NU$A$1 1$0$1$!$1 1$0$1$!$1
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M=&UQP23Q!&<K3-G^A;=HNDG91R2U%54$&:HEQO.QR  Y!:+VKR_[,>*EN?\
M:>\[\_R6Q$19FT1$0$1$!93M!_/9LW\RM^PU:LLIV@_GLV;^96_8:@T1$1 1
M$0$1$!$1 0(B##MK+96ZUJ>E/!T,9C\W'WY5-=ZDK;M>6BGU'=+=:HFEMP8.
MFEJ0.$%/D\^TN=P \I5?T/HBDFN5?-6S/F]#:Y],UF &O+-T[Q'O\EHKDB*O
MC^-^B\1EXJUJ=ZVG>_6U[T72-HM*VZ!L38L1ASFM&,D\R?&>U32_    . '
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M+Q8\ C.#@\_&N] 1$0$1$&5ZY]F%)YCOK6@Z?]9,\T+/M<^S"D\QWUK0=/\
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MOJ81$!97K[\]NSCS*W[ 6J+*]??GNV<>96_8"#5,)A$0,)@(B!@=B8'8B(&
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M(/?0UM+7PF6AJ8*F('=+X9 ]N>S(ZU[UZJ:F@I8^CI88H8\YW8V!HSVX"]J
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MV]O7A!Y(O'?;V]>$WV]OB0>2+QWV\>/)"]HSD\N:#R5>O5@E?7>BMBF91W8
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MR7JF8#+'%"&%T9/;N@CCC@?$5":/V>:BJ]4T%VUO5Q31VMC6TL37;V\6^IY
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MJ%/"V,.\N ,KN04OTK](_LEORC_O5/VN:"TO:=G=^K8+9T;H:;>WF2.+@-X
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MGL7E!4WYQH>FM]&T/B>:G=GST;QG<#>/$'AD^,]BF$015)47IS+?W50TL;I
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M-<M+SLHJV3C)3/&:6H/\3!ZEW >$WCVY7G'1:GH@1#=*&Y NY5D!A<T>)T?
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MI-0]!1LIW1XJP'$R!Y.3N_PA!?$7%:+?Z&TA@-;6UN7EW2UD@D>/%G X+M0
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M([4]FHKS?ZJ:M$[-YM$? IV$'KC'!YY\79Y\E<HV,BC;'$QK(V@-:UHP !R
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M"/\ +4O\H?6N]<$?Y:E_E#ZT'>B(@R[:?J#3&G-1T]77VV2XWY](8FQQG ;
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MO]UM_P!JKC_J,?W)W^ZV_P"U5Q_U&/[D&EHLT[_=;?\ :JX_ZC']R=_NMO\
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MBE8[1X?C0&M :  .  7ZB+BP1$0%2]5_G$T1_P#KO]MJNBKE]L]56ZOTU<8
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M=FJZC7EDNT8C[CI*:HBE)=X6\_=W<#KY%65 1$0$1$&5ZY]F%)YCOK6@Z?\
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MW'W-7:DJFUC:3]*FA:W=B8_^/=Y_?E!H:(B B(@(B("(B#PFEC@A?+,]L<3
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M(P]U=<*LL8\G]!K& NR,<2>'$+SV::NJ]44=SBN]O9;[O:ZMU'5PQR])'O
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M&V49)SO%I()S@D=0"G],6&WZ9L5'9[/#T-%2LW(VYR3VDGK).23VE2B("(B
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MI(&[L<;>31G/7XRNM$5:V(T(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MT_M1\5.]*G]J/BJWH@JT&E:=I]0/@4O1VF"G]2P</$I)$'XQH:, +]1$!$1
M7/4TL<[2'M!70B"J7'2U/4$D,&?(H671$1<<,'P+15X'F4&<]X\?M!\"=X\?
MM!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=
MX\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!
M\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\
M?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&=
M=X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5
M$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\
M"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?
MM!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=
MX\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!
M\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\
M?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&=
M=X\?M!\"=X\?M!\"T5$&==X\?M!\"=X\?M!\"T5$&==X\?M!\"\F:(C!]0/@
M6AH@IU#I"&)P+FCX%9:"V14K0&M'#Q*0'((@  <D1$!$1 (SS7)4T,4[2'M!
M]Y=:(*U4Z9IY"3N#X%RG25/[4?%5O1!4.]&G]J/BIWHT_M1\56]$%0[T:?VH
M^*G>C3^U'Q5;T05#O1I_:CXJ=Z-/[4?%5O1!4.]&G]J/BIWHT_M1\56]$%0[
MT:?VH^*G>C3^U'Q5;T05#O1I_:CXJ=Z-/[4?%5O1!4.]&G]J/BIWHT_M1\56
M]$%0[T:?VH^*G>C3^U'Q5;T05#O1I_:CXJ=Z-/[4?%5O1!4.]&G]J/BIWHT_
MM1\56]$%0[T:?VH^*G>C3^U'Q5;T05#O1I_:CXJ=Z-/[4?%5O1!4.]&G]J/B
MIWHT_M1\56]$%0[T:?VH^*G>C3^U'Q5;T05#O1I_:CXJ=Z-/[4?%5O1!4.]&
MG]J/BIWHT_M1\56]$%0[T:?VH^*G>C3^U'Q5;T05#O1I_:CXJ=Z-/[4?%5O1
M!4.]&G]J/BIWHT_M1\56]$%0[T:?VH^*G>C3^U'Q5;T05#O1I_:CXJ=Z-/[4
M?%5O1!4.]&G]J/BIWHT_M1\56]$%0[T:?VH^*G>C3^U'Q5;T05#O1I_:CXJ=
MZ-/[4?%5O1!4.]&G]J/BIWHT_M1\56]$%0[T:?VH^*G>C3^U'Q5;T05#O1I_
M:CXJ=Z-/[4?%5O1!4.]&G]J/BIWHT_M1\56]$%0[T:?VH^*G>C3^U'Q5;T05
M#O1I_:CXJ=Z-/[4?%5O1!4.]&G]J/BIWHT_M1\56]$%0[T:?VH^*G>C3^U'Q
M5;T05#O1I_:CXJ=Z-/[4?%5O1!4.]&G]J/BIWHT_M1\56]$%0[TJ?VH^*O?3
?Z7IV'.X/@5H1!P4=LAIQX+ />7<UH:,!?J("(B#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g50309g17m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g17m02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1B*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &&T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MP='A,S1C<J+P!15B0O$C_]H # ,!  (1 Q$ /P#ZI
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M5F[XIPYQ(8K+",K01]J\GOT_B7(+#&2U9K.)>C2\7C>J  "JP
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M1"O\7,?+T[[G&.])I.)>AIZE=2N]4  %70
M               !Y<6EM"EN*)*$EE2C/!$7.8#T(;<NDNV+?=4S+J!/RD[#
M8BIX51'S'C87E,A46E+2K*K$AZF6V^Y&IB#U5R6U:JY'/@RW)]9BJ.?G,:M/
M9\QFS!J[9B<47[*T]0DK442BR7$YV&XZE&2Z-HP=GQOZ/K_F2_**) =N!3LS
M^*U>Z]NSXW]'U_S)?E#L^-_1]?\ ,E^442 <"G8\5J]U[=GQOZ/K_F2_*'9\
M;^CZ_P"9+\HHD X%.QXK5[KV[/C?T?7_ #)?E#L^-_1]?\R7Y11(!P*=CQ6K
MW7MV?&_H^O\ F2_*'9\;^CZ_YDORBB0#@4['BM7NO;L^-_1]?\R7Y0[/C?T?
M7_,E^442 <"G8\5J]U[=GQOZ/K_F2_*'9\;^CZ_YDORBB0#@4['BM7NO;L^-
M_1]?\R7Y0[/C?T?7_,E^442 <"G8\5J]U[=GQOZ/K_F2_*'9\;^CZ_YDORBB
M0#@4['BM7NO;L^-_1]?\R7Y0[/C?T?7_ #)?E%$@' IV/%:O=>W9\;^CZ_YD
MORAV?&_H^O\ F2_**) .!3L>*U>Z]NSXW]'U_P R7Y0[/C?T?7_,E^442 <"
MG8\5J]U[=GQOZ/K_ )DORAV?&_H^O^9+\HHD X%.QXK5[KV[/C?T?7_,E^4.
MSXW]'U_S)?E%$@' IV/%:O=>W9\;^CZ_YDORAV?&_H^O^9+\HHD X%.QXK5[
MKV[/C?T?7_,E^4.SXW]'U_S)?E%$@' IV/%:O=>W9\;^CZ_YDORAV?&_H^O^
M9+\HHD X%.QXK5[KV[/C?T?7_,E^4.SXW]'U_P R7Y11(!P*=CQ6KW7MV?&_
MH^O^9+\H=GQOZ/K_ )DORBB0#@4['BM7NOAO3XP:OUE!=)/.F01G]PD=$TT6
MO/-*)KDBG.'ROMF:,_63GUX'S( B=GI*8VO5A]P0I<>=&1(AOMOL++*7&U$I
M*N@R&8?'EE7G5K1G)>IKZEQC/];$<4?!.>3D/QD/JBSKE@W516JC3EEA7:NM
M&>5-+QM2KQC-J:,TY^3=H;175Y=)=L  <6@              'AUU#*#6ZLD
MIYS&D=2)S)16'7O&18(!T '.XS//=#+'C60<8J'@:?XR =$!SN,5#P1/\9!Q
MBH>")_C(!T0'.XQ4/!$_QD'&*AX(G^,@'1 <[C%0\$3_ !D'&*AX(G^,@'1
M<[C%0\$3_&0<8J'@B?XR =$!SN,5#P1/\9!QBH>")_C(!T0'.XQ4/!$_QD'&
M*AX(G^,@'1 <[C%0\$3_ !D'&*AX(G^,@'1 <[C%0\$3_&0<8J'@B?XR =$!
MSN,5#P1/\9!QBH>")_C(!S[_ +A3:]J3ZH>UUM.JRGOG%'A)>?;T$/C^5(>E
MRGY4IQ3LA]9N.+5O4HSR9F+O_2-J4OJ91X+[?!(==6\9$K)*U2P7]0HL;MGK
MBN>[R]LOO7W>P  -#(#]2E2CPE*E'S$61^"06/=<RSZNY4:>Q'?>6R;)I?SJ
MX,R/.PRV]J0B<XY)C&>;@\&Y\DY_ 8V*=3IE2G-PX,9UZ4YG4:2GME8+)XSX
MB'TG#OZHO:(Y-UJBQ"G-:V&2UN#/#A(Y\[O&*^LN[YMY:8*!.J,>.PZRRZR2
M6-;!EJ+/)Y,]NT<HU+3$SCHT3HTB:QO=<>2JZC!DTV:[#GL+8DM&1+;7O3LS
M]PUQ?UUZ,H=P7O4I$^XF(4N8LEQXB$I4XI)((LF1F1\A[B%7NV/+B:0(UKU!
M]+3C[B4ID(3K$:%$9DHBV<VX6KJUM"E]"U)Z<LX1$!;;FAER$=3=J]9:BQ&"
M/BCA)3K2,)R>2,^UYL;3'!T?:-Y%STURK5":W2Z.C)%(61*-9EOP1F6"+G,.
M)7&<HX%\Q7'- @%BWMHQ<H=#ZMT6IM5>E)QPKB"(E)+.-8L&9*+._&X;5'T2
MN5*VZ36BK+$>))1PLI3R-4H[>W:1Y[8]G+@.)7&<G OG=QS5@ M^HZ%5\!$E
MT2NQYD!P]9Y]Q))2VWO-9&1F2BV>(:%W:*VJ5:KM=HE;;JL5DM9S501$:<X,
MTFDS(\<P1JTGS3.SZD1,S'1 H=OU:;2WZE$@/NP&-8W'TD6JG5+)YZ"',%^:
M(X3M1T-UR$P:$N27'VB4L\)3K(263/F+.1&*UHAX*VG:K;E;9K!L$:G4()))
M,DEE6JHC/:7,8B-6,S%EIV>V[%J\^2N*=1ZE4F)#]/@R9+,<LNK:;-1(Z<#1
M%M:%859F6Y<)TBKMP&",B<0N*3IJ/4/:1F98/&SE$9T=6([>K-7./-3'>A(2
M:$*1K$ZI6M@C//:EVN_;O$[\1G/DIPIF*[O64+ 7#%T+LRX;S4:Y8SM:83^N
MBH22D-K[U1D>2Z<>05%)8<C27H[Z=1YE9MK3S*(\']PFMZVZ(OIVI]:&+.-X
MRICOJ1K)COJ1OUB:49>? M703;%.FE4[BK;:7(U-/]4E991DDFI2S+EP6,#:
MF:;ZVN>M='HT4Z8E6JTEQM9K4GQFD\$?BQL$3><S%8SA:-*-V+7G&?139;1^
MB22DU2^KW63$5+=0J#F4LXU4MI(MY[-Q$63/E$[/0_3CD*IC=V1E5]+>OQ,V
MR+;C..ZSCR>03-XKU5KI6OG=Z*@ 36S[ DUN\9]NSY/$)4)M2W%$CA"R2DE@
MMI;#ULY$KI>AEEU1PJE<D:/6<&HH;24K,D\AF6L1[MNX1.I6.LIKHWMSB%/@
M) NT*J5Y*ME#25U$G>#(R/M-7&=?/>ZNT3\]#T!4I=+9NN.JX$-<(<,VR(BV
M9Y\X\GCP)G4K'645TKVSB%0 )E9UAR:Y>,NWJ@^=.DQ6U+<5J<)M29%LVEDC
MSG.1UZ]HN5;UIS:G6:LTU4&B-34))$?")UB26W._;G86P)U*Q.,D:5YC>B.2
MM@%B6S8=#J%OQ*G6;NB4XY6=1DTIUB,C,C(\J+;LYAK7IHYDVW7*=#.H1EP:
M@K59FO'P:$&6_7WXV;<\H<2N<$Z5\;V$#R-^F4>HU5+ZJ;!D2DL)UG390:M0
MO'YA>EVZ.*"=KV_$.L0*6<=)ZTQ:$:TLS3DSSDL\Y;3V&(MH7AU<X]T=1*NU
M#;8(DK-48G>$P2]52>V+5W>/?XA3BQ-9M#IX>8O%;>:I@$[T>:.9-UT]VJRY
MK=.I#9F2I"RUE*,MIF1&9%@L[S,;UY:+ETF@G6J#5&JQ36R-3RT$1&@N^+!F
M2BY^4A?B5SNY<XT;S7?QR5L G%A:/9%Y4:I2X4Q+4F*M*&V5H[5PS+.U6=GF
M,2A6AEF72I#M!N2/49[&Q;*$IU-?E2:B49D?2(G4K$XF4UT;VC,0I\!^K2:%
MJ2LL*29I,N8RWC\'1R   &[1:I+HM5C5&GN&W)CK):3+EYR/Q&6P?95!JC%:
MH\.HQ#RS);)Q/BSO+R'L'Q0/HS]'^H3';#4PVT3J8TMQM)FO&",B5CSJ,9MI
MKFN\V[%>8M->ZV@'.XQ4/!$_QD'&*AX(G^,AB>DZ(#G<8J'@B?XR#C%0\$3_
M !D Z(#G<8J'@B?XR#C%0\$3_&0#H@.=QBH>")_C(.,5#P1/\9 .B YW&*AX
M(G^,@XQ4/!$_QD Z(#G<8J'@B?XR#C%0\$3_ !D Z(#G<8J'@B?XR#C%0\$3
M_&0#H@.=QBH>")_C(.,5#P1/\9 .B YW&9Y;50R,O$LA^=4^#/$EEQGQF62
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MC(?,>FR:[,TBU$GB-/%T-LDG.<=KD_68[:%=Z_/R9MJO-=/EYH*/T 'H/)
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MVV,^L1&G.<SWRO.O7$UCIC"T8CSK?Z-+QH<41Y4C?N2;^#+HP9C'89F?Z/\
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MQ#[%T?4 K:M*GTPR+A6T:SQD6]Q6U7K/'D&?:+8KAKV.N;Y[)"  ,+U
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M8IM3K+R-7C*TL,GSH3M4?G/U#EK3BDN^S5WM2%T  #SGL
M      Q/QVGT&EU"5%X^090 <&2V_3%:S:E.,'S\GB'0@342$$9'MYAN.MI=
M;4A992HL&0AK[JJ35B09GP:U8\O_ -@$T :T)\GFB,CWD-D   ,\$9GR -"<
M^XMXHD4\.J+*E]X0SQ(C45&$%E1]TL]YC6HR36V[)7M6ZH]OB(=$    !\GZ
M:6E-:3*R2OVS;670;:?8/K 4+^DA;QMR(%P,I+47_P"%?QR'O0?]1>8=]GG%
MV7;*S.GF/)28  WO*!^#] !<&C%1HT-WJI)X4DUJ(RY#)LC(3^A0XER,6K>L
ME:"5"@N'(-S:9J))%G/^%25GY1\\4RYJM2Z+.I,&4ENGS<\8:-I*C7DL'M,L
MELYAL4^\J_3[?>H<.H&W2W26E;7!I,\+[HB5C)9Z1PMI3,S,-6GKUK$1,>7W
MY6O0:DY6-#]ZU%W.O)E2'-IYP6JC!>0L!:<9ZK?H]5*'3FU2)1DXDFD%VQF2
MDJ,BYSP*BI]TUBGV_*H<.6ENER34;K/!),U&9$1]L99+<7*,UJWE7;52ZBB3
MN!:=/66TMM*T&>[.#+8?0$Z4\\=\D:\9C>[8E<FBBCSZ3HON$ZG%=BKD-O*0
MV\DTKU2;,LF1[LCA:&/^EEW]"O\ 9$&?TDW:^J8;U74M,MO@G4&TC4U,&6$I
MQA.\]I;1RZ)=-8HE*F4VF2TLPIGNS9M)5K;-7>99+9S!P[3$Y\R-:D37&<1$
MK,_1L2:XUS-H(C6IEHB+E/8H5Q#HM3I-QTHZG3I4-+DY"4&\T:"69.%G&=^\
MO.-6V;BJMLS3ET26<9Y2=17:DI*T\QD>PQNW%>U?N*5"D5:8AUR$OA(Y)92@
MD*V;<$6W<6\7W9BTSY2Y[]9TZUGK"\KK_P"NMI?NCOW*$)NEQ9_I%4[*U'JR
MHZ4[=Q8W=&T_.(-+ONXY==B5F1/2JI1$&VR[P"")*3SDM7&#WGO&C*N2JRKC
M;KTB2E56;6EQ+W!I(B4G<>KC'J%*Z4Q\,.E]>MNG>)3[3))>/3!!+A%%P!Q>
M#P?<Y7G9Y1)])\EB)IHM!^8I"(Z$)-:EG@D]NHLGY<"EZS<%3K5935:E()Z>
MG4PX3:4]SM3L(L#U<UQU6YY;<JN24R7VT<&A1-I1A.<XPDBY1,:<\O<K.M'T
MO68GX+\TGS8E-N"*_+L5ZNK4VG@IK2E'JF2C[3!)/!EO\HB<^X9-P:6K47/H
MC]'DLK3EI]>LM25'L/<6-Q[Q#:5I0N^F0T18]5X1E!$E'#LH<4DBY-8RSYQQ
MI-U5J5<35=D33<JK1D:'E-IPG&["<8QY!6NE,=?S7OM$6G,9ZQY0F/Z0KSJ]
M(!M+<6IIN*UJ(,]B<ZQG@A61[AT[AKM1N*I'/K#Y2)9H)!K)"4=J6XL)(BY1
MS1VI&[6(9]2T7M-H\U[W!39U5T"6Y&I<-^9(U6%<&R@U*P6=N"Y!MZ(J"]8E
MOU>O71_X'726&7%$1I0GG\9GL(O:*LI.DJ[*338\"GU-#42.@FVD'&;5JI+D
MR:<F.5<%U5RXB)-:J;\IM*M8FSPE!'SDDL%D<>':8FL]&CC4B8O$3F(QZ)OH
M!=X?2*^]C5X5IU>.;)YQZQV:?<U=MJ[KN<8H4BL4)ZI/)>2TDS-M63SC!'O(
M]QE@^<51;M?J5N3SFT:04>3JFC7-M*]A[]BB,AV:/I$N>D2)ST&H(2N:\<A\
ME,(42G#WJ(L;/(+6TYF9E2FK%:Q7,Q,2GNE>UJ$[93-U4B Y27UK02HRF^"U
MB4HR/*.17+DN0;LVG2ZI^CO3&:;'<E/(2A1MM)UE8)W;@BVF*INB\J]="6T5
MN>I]EL]9#2$)0@CY\$6T]I[3&>V;]N.V82XE'GDW&4K6X-QI+A)/G+);!'#M
MNQSYQ*W%IO3..4QA-?T>X<B!?]2BSH[L:2W!,EM.I-*D]N@]I'N$?FR'Y.FD
MUR7G'5)JJ4)-:C/"261$1>(B'$@WI7X-P2ZY&G$FJ2TZCSQLH5K%LV:IE@MQ
M;B',.K33K1U8WBZH&]QCA=0N[SG.-V_D%MR=Z;3YPY\2NY%8\IRMK3U_U(MG
M[)K_ 'S'3_2&M^L5>71'*7"DS6D\(V:6$FO@U'JX,R+=G&_Q"GJ_=-8N"I1:
MA5Y:7Y<8B2TLFDHU2)6L6PB(CVCM-:4KQ;GKF=5]9U2";-"F4<'@CSW.,$?C
MWBL:=HW<>3I.K2V_$YQ.$[_2)/B]I6]"D+)4U.-8MYGJMF2C\XV--=$J-9M:
MU'J3#?FI9;PLF$&LRUD)P>SDV;Q3=PUZIW%4#FUJ6J5(U=0C,B224\Q$6PB'
M<HNDFZJ-3$4^!4\16TZK9.,H6;9<Q&99P$:=JQ&.L(G6K:UM[.)Q]RPM*%.?
MI&@^W($LM60PXPEQ/>JU5&9>3<,]3AR:I^CQ36J9&=END:%<&R@U*PET\["V
M[!4E7N^O5FDIIE5J*Y4-+O#D3B$FK7R>W6QGE/8-NV;^N2VH!PJ1/2W$UC43
M;C27"29[\9+8'#MB.^<IXU)M/7$QA,_T>XS\.^JE&ELN,2&HBDK:<3JJ0>LG
M89<@FUDN)G472'3()EU3X[-(DD>%&:]8D'GI(Q1M-O&NTVNS*S#FI14I>>'=
M-E"M;.,]J98+<6XA@IMSUFF5R16($Y;%1D*4MUQ"2PX:CUCRG&#+/)@+:4VF
M9]QIZ]:1$8[K?_1\HM4HBJS+K$=^G0]1*#3*2;9*41Y-6WD(LEGQCG?H^.(<
MNVYG6"U6E,FM!%R$;AF0@MP:1;HKT!<*HU/,1986VRTEO7+F,R+)EXAR[:N6
MK6R^^]1)*8[CZ.#<,VDKRG.<=L1X"=.TQ;/645UJUFL1G%<IYH>?=>TRS'77
M%+<=.6:U&>U7;'O$/TE?'ZO?O)_TD.?1;@J=$K"JK3)!,SU:^7#;2KNNZV&6
M-HU*G.DU.H2)TYPG)3ZM=Q9)).3Z"V$.D5Q;/HY3>)IN^><M8  7<P?F,["Y
M1^B0:/Z&Y<5WTRGH29MJ=);Q\B6T]LH_,6/*(F<1E,1-IQ#ZLLB+Q.SJ'',C
M)3<)DE$?(>H6?6.T/Q*22DDI(B218(BY!^CRYG/-[L1B, U)T%J4@\D27.19
M%M&V A*.,S784G@).=^,F.\PZ3B",CR.)>$;6@*?1L6DL9]9#6M2I\:CHR>\
MB 2D +:0 .?5_P!83$8O_-66>@AOI(DI(BW$6!H2=M8B$>XDJ/U#H
M                               #YNTR:.'J)-?K5&96[2GU*=?0DO>R
MC/)[.\//D\P^D1Y<0AQ"D.)2M"BP:5%DC+F,=-/4FDYARU=*-6N)?#6_</T?
M1]Y:%J35GURJ&_U*D*VFTEO694?U=FKY-GB%:U'0W=D5XT1V(TQ'?M/$DC\B
ML&-M=:EO-YE]FU*^65= )EV,+Q^8W?2(]H_.QA>/S&]Z1'M%M^O=3A7]F?@A
MP"8]C"\?F-[TB/:'8PO'YC>](CVAOU[HX5_9GX(< F/8PO'YC>](CVAV,+Q^
M8WO2(]H;]>YPK^S/P0X!,>QA>/S&]Z1'M#L87C\QO>D1[0WZ]SA7]F?@AP"8
M]C"\?F-[TB/:'8PO'YC>](CVAOU[G"O[,_!#@$Q[&%X_,;WI$>T.QA>/S&]Z
M1'M#?KW.%?V9^"' )CV,+Q^8WO2(]H=C"\?F-[TB/:&_7N<*_LS\$. 3'L87
MC\QO>D1[0[&%X_,;WI$>T-^O<X5_9GX(< F/8PO'YC>](CVAV,+Q^8WO2(]H
M;]>YPK^S/P0X!,>QA>/S&]Z1'M#L87C\QO>D1[0WZ]SA7]F?@AP"8]C"\?F-
M[TB/:'8PO'YC>](CVAOU[G"O[,_!#@$Q[&%X_,;WI$>T.QA>/S&]Z1'M#?KW
M.%?V9^"' )CV,+Q^8WO2(]H=C"\?F-[TB/:&_7N<*_LS\$. 3'L87C\QO>D1
M[0[&%X_,;WI$>T-^O<X5_9GX(< F/8PO'YC>](CVAV,+Q^8WO2(]H;]>YPK^
MS/P0X!,>QA>/S&]Z1'M#L87C\QO>D1[0WZ]SA7]F?@AP"8]C"\?F-[TB/:'8
MPO'YC>](CVAOU[G"O[,_!#@$Q[&%X_,;WI$>T.QA>/S&]Z1'M#?KW.%?V9^"
M' )CV,+Q^8WO2(]H_4Z+[Q4HBZB.ED\9-Q&/O#?KW3PK^S/P0T?A["VBRZ3H
M7NF8YJS$Q(".53KFOYB3D6G9&B*BV\\F7/5U5G),C0IYLB;;/G2C;M\9Y%+:
MU*^;I39M2_EA$M"&CEY,EJXZ\P;:4$2H4=9;3/Y11<GB+R\PO8"+&X!BO>;S
MF7IZ6E&E7=@  %'0                           ?BTDM"DJVDHL&/T %
M=+>.G7&IK."66MCQD>#^XA/8+I.LDHCWD*VO=S@KHC&G89DK[Q.;><-R(DSY
MB =@  !SIA<)58:.1&5CHC0=^&6?LS&^
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M$&D141V$[3U2[99\JE'O,QU!AU=7B3Z/4V?0C2CGU  !R:
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M?=TGI A;;6U! /QCW(@ :,CX9B_44.B.=(^&8OU%#H@
M
M
M          JC2#\9XG0K\!.;6]Z)Z"$&T@_&>)T*_ 3BUO>B>@@/)WP  '/=
M^&F?LS'0'/=^&F?LS'0
M
M                              !$-)WQ=>^J?WD)>(AI.^+KWU3^\@'+
ML'W%'0+#3N%>6#[BCH%AIW  Q2O>SOU3^X91BE>]G?JG]P##2/@YGH_$;8U*
M1\',]'XC;
M                                    !S+C^"G?(*UT?=TGI%E7'\%.
M^05KH^[I/2!"VH_N1 $?W(@ :,CX9B_44.B.=(^&8OU%#H@
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M2K>?I:BX'+>H>7CU^0L<F/6.+6*'4^.4^/"9=2S5XD9$C"#PDTZN=;FW$?G
M=G195:M4ZW.8JL^4ZGBVN2%K[DS,MI<VPQ(;"J4TJM6Z'4Y#DEV"[K-/.;5*
M;/G]7G&A9\1UC2-75<7<;C\$2&U&@R29$:2(B/R#+9ZN.:1[GF,[6&TI8-7.
MHC(O_I,!I7K*J3M^Q*7$K3]-CO1R4:DJ[5)]MMQDN8N49+(NR0S%KB*[,3,8
MIIY*6G;K%DRP7/DRV=(PWA0TUK25 8EQWUP5Q\+6@C(BQK'W1;MN!W+@L^.U
M950I=OQDM..ZKF#49FXI*B/:9^(@&*FZ0F)$R&U,I<R#'F*U8\ETBU%GG9^'
M..C<5T/TB?Q6/0ZA/PWPBG&4]H1=.W;L%=4*GPI#]+AS*-<!SD.H2LU+,F6S
M(RRK:6PO$.G=)U%=Z36:I&K$NGJ07$V8:C2C6,BP9F6PBWY/> [-QW(S7=&=
M3J-.-YA230@R,\*0HEIR62\1^L?M*NY$"EV]36([U2J<F.@U(0O:C);U&>[G
MZ-HC5)I\QG13<$9V(^F1QHL-ZAZQX4WN+EW&/RA0:A9TBD5=J._*ASV4IEMD
MT9N-&>W=O+_@R 6A<4&;4:4N/3IRH$E1I,GD%DRP>TN05C1XURU.XJC24W/*
M;7#+)NGDR7MQNSL%P-+2XVE:.Y462V8%?V=&?;TBW$ZXPZAI9=JM2#)*MI;C
MY0'&I5ROT.Z;E2N/.J:R=P3;63)!)SK*/?JD)4[?L)-KQJVB,ZIEV04=;>L1
M&VK;DSY]A9\HY=J1'D73>KKD=U).&9-J4@R)195NY^01)5/F=BE#'$Y'#=4]
M;@^"/6QJ;\8W +!CW[#729]2D0Y4>+'6E#1K+!R-;.-4O(/-$OQB=5(\&=39
M=-=DD1QU/EL<SNQNW\@\:1J+*JMFL-0&C6]'-MS@B+:HB29&1%S[=WB$=UY]
MWW/;[C=*E0F:::5/N/IU=I&1F1'_ .G9T@._4-(3<6I5""S29DJ1#6:5$SMR
MDNZ6>S81;/.-5>E"+Q5,EFD3W8R<$\Z1$26E'^SG<9C':T5]%^7<XY'=2TXA
M1(4I!D2MO(?*.)3($E&AVJ,G$?*0N3G@^#/6,M9&W&_D =/2)6M2J6G4(KKY
MQ7#X<T-*,C<3E!XQRGR8'?HEZ,UB3/I[\*73IK+*G.#=V+,B+;CF/:1B(7%&
MG(BV,[&@OONQFDK4V2#WIU#P?-N,;E'3-K][SJ[U.DPXC413:2>0:5+/4U<>
M,]IGY &_9%<;IU@3ZIKS9B([ZSU9"RUS[G81[<%M^\>TZ3HN8SCE*G-PWE$C
MC*B+5)7*1<^!Q+?ARD:(:TPN,^E]3RC2V;9DH^XW%OY![N"%)5HIH3#<5XWD
MN(-3:6SUB[K.2 6A4'#*F276EX,F5*2I)_X3P9"(Z(JC,J5M/O5"4[)=*2I)
M+=5DR+53L]9B3+2KK=6C5/6XJ9:N-N=7<*KL*Y)=LT9R&[0:C(4MXW=9"#26
MTB+&[Q )I6;Z9A5.3!@4Z74G(I&<A3!;&ND?D^_H<:BTZJLQ7GX<MPVE*)1$
M;*BY%>OS"$5*E*I]RU*55J?5G84]1OLKIZL&6L9GJJ\^,&)1&MN/4-&S\.'"
MDQ#<4N0TU*5EPED>S.PM^/6 [M6NMB!<4&DI8-Y<A'"J=2X1):1M[8_%@C,<
M7LE1N$-TJ5..F$[P7'<=IGGP.%8U#GUQ%6GU1"VI)Q.(,&Z@TX[3&<8YL%Y3
M'$I]+:BQETVM4:O.3$N:J4QE_J5[=^['E+("8W3+<5I$MSB\ASB[J"5A"SU5
M%D]N.4;4?2(B7(7Q&B5"3$0Z32I#9$9$9GO,N3RF-*X*>ZU?EL)88>..PTE!
MJ))J))$>XS$7<:?*L,N6G2ZS2ZDMTR=:67ZG&=^3Y/$>P!=4N0F+#>D.9U&F
MS<5T$616M&O"13Z8=?K*I,AFI2E-,QTJ[2.A.=J2/?S>06!6V')5 GQ][KL9
M:.UYS29"GI'"S]'5O,QF'77(LU;;J4(-1IVF>TBW;P%@4.^FJC7&J7*IDRGO
MO)-37&"QKEC);.3)$8BEH7-4DWV]%J$Q]Z$_(=CMI<5E*%$>2QZB\H[EQ1GU
MZ5K?>0PZIE#!DIPD&:4^Z;S$0.DU H5;J$:,^F7 JA26<MGE19,CP7+R& Z-
MPW'5%Z06V8<R0U3D3&HIH0K"%&1EK?B)/,J,VCZ1X<9V2Z[3:FV9);6>2:<+
MO?,7\0B9TF8U3;2>=CO*DR:BJ7(PV>4ZRDXUN;80DEXKXWI#M:$T67&5*D+P
M>Y/C_A,!/P                                %4:0?C/$Z%?@)Q:WO1
M/00@^D'XSQ.A7X"<6M[T3T$!Y.^   Y[OPTS]F8Z Y[OPTS]F8Z
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M'XB2%.O.(PV:2)/;$?-@L^49W6*PS<%ZO4EF0B2M)<$XE!EK%KEK:I\IXSN
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M9WZI_< PTCX.9Z/Q&V-2D?!S/1^(VP
M                                                         <RX
M_@IWR"M='W=)Z195Q_!3OD%:Z/NZ3T@0MJ/[D0!']R( &C(^&8OU%#HCG2/A
MF+]10Z(                                                YM3HD
M&I2X<F6T:I$1>NRXE1I-)^3>6S<.D        /Q:26A23,R(RQDCP8T*)1H-
M$C+8IS/!H6LUJR9J-2CY3,]HZ
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M*49X+F(CW>0=$
M     <BZZ$U<5'73WWG&4*4E6N@B,]AYY1UP 8($8H<&/&2HU)9;2V2CWF1%
MC/J&<                                !$-)WQ=>^J?WD)>(AI.^+KW
MU3^\@'+L'W%'0+#3N%>6#[BCH%AIW  Q2O>SOU3^X91BE>]G?JG]P##2/@YG
MH_$;8U*1\',]'XC;
M                                           !S+C^"G?(*UT?=TGI
M%E7'\%.^05KH^[I/2!"VH_N1 $?W(@ :,CX9B_44.B.=(^&8OU%#H@
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M.=3=W<3CKGRCT@  %'H       YEQ_!3OD%:Z/NZ3TBRKC^"G?(*UT?=TGI
MA;4?W(@"/[D0 -&1\,Q?J*'1'.D?#,7ZBAT0             !^*(E)-)[C+
M J6G61>EI%5:;9-5HW4.:\X]'1/:<X6"I>35J&G8HL[LBVP 4^>AUZFVO;C5
MMUA+%QT.0N6U-?;,VWUNG^M):2VD2O%S#KVY9EPS+\:NR]I\!R1#C''@0J>A
M7!,:W=K-2MIF?X^(62     IFR/[0.D;]TB"U!5=D?V@=(W[I$%J
M                  _20HRR25&70/W@U]XKS /(#UP:^\5Y@X-?>*\P#R _
M32:=Y&72/P
M                         3O $[P'0:]R3T#T/+7N2>@>@       51I!
M^,\3H5^ G%K>]$]!"#Z0?C/$Z%?@)Q:WO1/00'D[X  #GN_#3/V9CH#GN_#3
M/V9CH           /+K:'FEMNI);:RU5)462,N8<15H6ZNA(HJZ)3ETE!ZR8
MBHZ3;2><Y))E@CV[QW0 <"W;,MNVW5NT&AT^ \LL*<992E9ES:V_'B'?  %-
M_I*_!MH?Y]&_J%J.^ZKZ3%6?I*_!MH?Y]&_J%IN^ZKZ0'D
M
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MVW=[,YW )@ X74VO?2)G_34_G'6A-OM16T2Y!27R+MG2;X,E?^G)X\X#.
M   .%/M*BSYCTJ5$6M]U6LM12'$Y/H)6"&OUCV_X$Y_-._F$E ! Z!:5&DRZ
MVB1'=<3'G&RT1R7>U1P:#P7;<YGYQU^L>W_ G/YIW\PSVQ[]N/\ S)7^TV.\
M YU&HL"C(>3365-$Z9&O+JUYQN[HSP.B
M                                                "=X G> Z#7N2
M>@>AY:]R3T#T       "J-(/QGB="OP$XM;WHGH(0?2#\9XG0K\!.+6]Z)Z"
M \G?   <]WX:9^S,= <]WX:9^S,=                  %.?I*_!MH?Y]&_
MJ%IN^ZKZ15GZ2OP;:'^?1OZA:;ONJ^D!Y
M
M          " " =(@ @        $0TG?%U[ZI_>0EXB&D[XNO?5/[R <NP?<
M4= L-.X5Y8/N*.@6&G< #%*][._5/[AE&*5[V=^J?W ,-(^#F>C\1MC4I'P<
MST?B-L              !^*[D^@?H_%=R?0 ^4)/ON3]LO\ J,8QDD^^Y/VR
M_P"HQC&V.C\OU?XEO?(  )4          !Z3W"_)]X\CTGN%^3[Q$KZ?6?=/
MX2\@ "5              'M?[/U"'@>U_L_4(0O7ZMOL>  !*@
M   [%G_&JC_O3?WCZ<'S'9_QJH_[TW]X^G!FUNK[+Y-_R]_[OR@  ')]"
M   #F7'\%.^05KH^[I/2+*N/X*=\@K71]W2>D"%M1_<B (_N1  T9'PS%^HH
M=$<Z1\,Q?J*'1                        %,V1_:!TC?ND06H*KLC^T#I
M&_=(@M0           $;LDNVN+_.)/WI$,TK:3'Z#/51[?X$YJ$EQB2LM8F3
M/:24EN-6-YGNR*KI%_W+2I3K\6I*4;KRGW6W$)4AQ:MYF6.4=ZZ%K1EFOM=*
M6W>KZK 131Q>3%XT8WS0ABHL'JR8Z3,R29[E)S^R?JW"5CC:LUG$N];1>-Z
M  0L      #@VQ[]N/\ S)7^TV.\.#;'OVX_\R5_M-CO
M
M   G> )W@.@U[DGH'H>6O<D] ]        JC2#\9XG0K\!.+6]Z)Z"$'T@_&
M>)T*_ 3BUO>B>@@/)WP  '/=^&F?LS'0'/=^&F?LS'0
M!4'Z2R"ZW+=?V\(S6XJD\W="SW?=5])BL_TEOBG1/\ZB_P!8LQWW5?28#R
M
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M\.#;'OVX_P#,E?[38[P
M                                     )W@"=X#H->Y)Z!Z'EKW)/0/
M0       *HT@_&>)T*_ 3BUO>B>@A!](/QGB="OP$XM;WHGH(#R=\  !SW?A
MIG[,QT!SW?AIG[,QT                  5'^DM\4Z)_G47^L68[[JOI,5G
M^DM\4Z)_G47^L68[[JOI,!Y
M
M" " =(@ @        $0TG?%U[ZI_>0EXB&D[XNO?5/[R <NP?<4= L-.X5Y8
M/N*.@6&G< #%*][._5/[AE&*5[V=^J?W ,-(^#F>C\1MC4I'P<ST?B-L
M          !^*[D^@?H_%=R?0 ^4)/ON3]LO^HQC&23[[D_;+_J,8QMCH_+]
M7^);WR  "5           >D]POR?>/(])[A?D^\1*^GUGW3^$O(  E0
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MX):<^8RY#'S"+'T &Z6D B;SP9PWN%QS;,9\N!VUM.LUF6;9]6T7B,\I?1H
M P/6
M                  $[P!.\!T&O<D] ]#RU[DGH'H       %4:0?C/$Z%?
M@)Q:WO1/00@^D'XSQ.A7X"<6M[T3T$!Y.^   Y[OPTS]F8Z Y[OPTS]F8Z
M                *C_26^*=$_SJ+_6+,=]U7TF*R_28SUHT75QGJS%QGZXF
M3IW1PJ\(H&,GC*W\_< [("+RZC<L:H0(BF*$I<Q2TH4E;V$ZJ#4>=G,0W,W1
MWMO?Q/\ L =P!HTSJIAWJL5/+=P?%#6?3K:WDW#>
M
M            ( (!TB "         1#2=\77OJG]Y"7B(:3OBZ]]4_O(!R[!
M]Q1T"PT[A7E@^XHZ!8:=P ,4KWL[]4_N&48I7O9WZI_< PTCX.9Z/Q&V-2D?
M!S/1^(VP              'XKN3Z!^C\5W)] #Y0D^^Y/VR_ZC&,9)/ON3]L
MO^HQC&V.C\OU?XEO?(  )4          !Z3W"_)]X\CTGN%^3[Q$KZ?6?=/X
M2\@ "5              'M?[/U"'@>U_L_4(0O7ZMOL>  !*@
M  [%G_&JC_O3?WCZ<'S'9_QJH_[TW]X^G!FUNK[+Y-_R]_[OR@  ')]"
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M'%U^+SC< !I\77XO.'%U^+SC< !I\77XO.'%U^+SC< !I\77XO.'%U^+SC<
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M9CONJ^DP'!K'QEMS[21_L+'<'#K'QEMS[21_L+'<
M
M               " " =(@ @        $0TG?%U[ZI_>0EXB&D[XNO?5/[R
M<NP?<4= L-.X5Y8/N*.@6&G< #%*][._5/[AE&*5[V=^J?W ,-(^#F>C\1MC
M4I'P<ST?B-L              !^*[D^@?H_%=R?0 ^4)/ON3]LO^HQC&23[[
MD_;+_J,8QMCH_+]7^);WR  "5           >D]POR?>/(])[A?D^\1*^GUG
MW3^$O(  E0             ![7^S]0AX'M?[/U"$+U^K;['@  2H
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MVHZ3<,C+ERK4(3L0&FJ55-,]7=4G,>BTUJ*C6VX=>/A%&7_I2DO* GP
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M>5*P6\SYQ[
M            %4:0?C/$Z%?@)Q:WO1/00@^D'XSQ.A7X"<6M[T3T$!Y.^
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M\P#R ]<&OO%>8.#7WBO, \@/7!K[Q7F#@U]XKS /(#UP:^\5Y@X-?>*\P#R
M]<&OO%>8.#7WBO, \@/7!K[Q7F#@U]XKS /(#UP:^\5Y@X-?>*\P#R ]<&OO
M%>8.#7WBO, \@/7!K[Q7F#@U]XKS /(#UP:^\5Y@X-?>*\P#R ]<&OO%>8.#
M7WBO, \@/7!K[Q7F#@U]XKS /(#UP:^\5Y@X-?>*\P#R ]<&OO%>8.#7WBO,
M \@/7!K[Q7F#@U]XKS /(#UP:^\5Y@X-?>*\P#R!#UP:^\5Y@)M?>*\P#H$
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MR?0 ^4)/ON3]LO\ J,8QDD^^Y/VR_P"HQC&V.C\OU?XEO?(  )4
M !Z3W"_)]X\CTGN%^3[Q$KZ?6?=/X2\@ "5  &1]EV.O4D-.,KP2M5Q)I/![
MCP?(!CS8P&1UEUG4X9IQO73KIUTFG63SEG>7C&/?NVF!C  V)4*7$)!RXLB.
M2^Y-UI2"5T9(>78LAEEIUZ.^TTZ66UK;-*5]!GL,0F:S'6&$![<:<;2VIQM:
M$N%K(-23(EESESD/ E$Q@'M?[/U"'@>U_L_4(0O7ZMOL>  !*@
M   [%G_&JC_O3?WCZ<'S'9_QJH_[TW]X^G!FUNK[+Y-_R]_[OR@  ')]"
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M&?EW@.H                (Y:'O^YO\S5_M-"1B.6A[_N;_ #-7^TT)&
M  \/--O-+:>0EQM9&E2%EDE$>\C+E'L %<OVO6++==FV!B53W'"7(H,E?:$6
M=IQ5F9$TK_ ?:'XA*+5NREW*B0F XXW,C*U)4*0C@Y$97,M![2Z=I'R&8[PB
M]VV9#KSC<V,^]2:XR7ZBJ0L)>3_A5R+1SH5DN@!* $"IEXSJ)/;I%_QVH3ID
ME+%89UN)2SW$1J,OU3A]XH\'R&8GJ3)22,C(R/<9        "-Z1_B74^A'^
MXD201O2/\2ZGT(_W$@)(
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MNT6B22G.\-(0ZJ2^DL)0E*3[DMNTQ9=R6M3KB4PJI$\9LY)'!N&G?O\ N'<
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M$$6L1\QXSY1T1JTB"W3*5"@,*4IF*PAA"E;S2E))(S\>P;0R3U;XZ   A(
M IVP/[0ND7]UB?<+B%.V!_:%TB_NL3[A<0       (#I'4J==-DT-)IU)$]4
MYXCVY;CIU\&7C4:1/A!:(YU6TL7!)PG@Z/"9IZ.7*W#-U9^(\$@A.@
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M   1O2/\2ZGT(_W$B2"-Z1_B74^A'^XD!)
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M<JDF:3/RXSY176THISATV;7G4S6W5(@ !G:P
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MLFG/M3R;3G*B;5DRV>(S/R":4ZN(JUH,UJE-<;*1$*0RTA1?K#-.21D]F<[
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M_P# AM>BMPJO(C,ZW!-&24ZQY/ FMXM/)GVK_B];8]*;ZDQB9B.7_P"0YX
MN\L             =BS_ (U4?]Z;^\?3@^8[/^-5'_>F_O'TX,VMU?9?)O\
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M6HE/G$Y&C0("*70Z?3VCRW$CML)/&,DE)%^ W@
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M"O$?/XQ&II3I]5M'7KJ].K;  '-V
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MMNLKQK-++D/[R/E%;Z-J<Y7TMHIJSB.J0  #D[@
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M8L_XU4?]Z;^\?3@^8[/^-5'_ 'IO[Q].#-K=7V7R;_E[_P!WY0  #D^A
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MD<RO, S@,'&D<RO,'&D<RO, S@,'&D<RO,'&D<RO, S@,'&D<RO,'&D<RO,
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M:?4H-12M5/F1I24&1*-EU*]7IP>P!M
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MH\OWF,PLH              PO>^(WUE?TF,PPO>^(WUE?TF S
M     #]+>*QNSXQ3OK_@+.+>*QNSXQ3OK_@.FEU>%\H/Y6/[H_"7('I!:RTI
M(R(S,BR9X(>0&A\8LJW(ET4RIL2JS/4FBME^N<>EI<96WC:1%D\GCQ#F1ZS;
MC\2%3SBU1IEJ2IXB9<0E"UJ5L4HC+.PL$7,0A&W&,GCFSL <]S/5Z/\ V$TB
M*TCE_P"IS/EZ1B.27W;"CU>^I$.B$X4M]]9.JD.%J*619[4R+86"/>->@TJY
MW8CQT!]TFDNFAUN/+)LR4G9DR,RV>,1CRF!9+<9ER;#P+8G&'&=HI;4MJ6K,
M3,STG'Y3]O=/;DK$N-7J649R)/JQ0RBS2-).-/*4>Q"N16"QM'876'9LRIT:
M!(0=2;AFAIQ!DCA9)F7":A\F$EJET&*J+9N#=NV"O#C#17_D]2+6GRF>_EC'
MQ\\]_+JD5_+2NXU942WT1V42%$HE9=)!$K:6\\[Q'0 7B,1A@UM3BZEM3O.7
M8L_XU4?]Z;^\?3@^8[/^-5'_ 'IO[Q].#/K=7UWR;_E[_P!WY0  #D^A
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M#M/L:HIBF7&IVI3V"QDU+>42,$7/@S/R"3Q(K4&''AQ\\#&:0RC/>I(DEZB
M90                                           <&_?B=5/JH_W$CO
M#@W[\3:I]5'^XD!('?=%])CR/3ONJ^DQY !SJ]0Z7<$,HE<@1YT=)ZR4/(SJ
M'SI/>D_&6!T0 0DZ%<UOR$KMBK%4Z6DMM*K#AJ67B:DX-2=A8(EDHAMT>^J;
M+J9TJJLR:%62V<4J)$@G#W?JG,ZCA9SM(\^(2L:E6IT*L0'8-5B,3(CA&2FG
MD$I/-DL[CV[RV@-LR,CP98,!!T6M6K8C.=8]4X:.6332:PI3K"=YX;=+MT>(
MCUB&S!ON$TZS#NN*_;=4<5JH9G&1LNGM]S?3VBO*9'X@$O ,'L\>T@
M                                !.\ 3O =!KW)/0/0\M>Y)Z!Z
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M(5224Q\V$$MC!H,N56W87C'Z_>$-EJI+5"J)E >)EPDL9-9F9EE&W:6S>)(
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MB4AM9M+4RX2R2LMZ3QN,N8;*NY/H 55"]ZH\OWF,PPPO>J/+]YC,+*
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M@]4M7!'MW8&X,\M4=   $@  "F;(_M Z1OW2(+4%5V1_:!TC?ND06H   %M
M0^[4)JMY6E2"5E$=YVK2$IY":3JMY\1K7ZA,!#+<2JH:2+KJAD:F83;%(85N
M+)%PCO\ \RD^83,                                            !
MP;]^)M4^JC_<2.\.#?OQ-JGU4?[B0$@=]U7TF/(].^ZKZ3'D        :\^%
M$J,-R)48K$N*X6%LOMDXA721[!L  A/6=4:(Z3UDUI<1A.WJ14#5(AJ\2#,]
M=GE[DS+Q#W"OMN*\B+>=-?MJ4H]5+LA7"0W5;-B)!=KR[E:IB9C')89EQG(\
MMEM^.X6%M.))25%S&1[# >D*2XA*VU)6A192I)Y(RYR,>A"'K)DT<N%L"J*H
MRB/6.G2"-^ YS_JS[9LSP6U!ET#TN^NHLIB%>]-=HSKADA$]L^&@NJW9X4BR
MWDR,\+(ND!-0'EEQ#S*'F'$.LK+*'&U$I*BYR,MACT
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M2DBP1$7(0#0MN@TVVZ6W3Z-%1&C(,U&2=IK4>]2C/:I1\IGM'3
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MQD  /S)<Y#]  'YK%SD/W)<Y     ,+WOB-]97])C,,+WOB-]97])@,P
M&9%O,B#)8SDL   1D?*0  !DLXR60(R/<8    _2WC!%W2/MU_@,Y;Q@B[I'
MVZ_P$C,  (             !Z:]V8^V;_K2+.%8M>[,?;-_UI%G")6@  $)
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MJ(S,C;U2U3R?BP-T:U,AM4ZFQ(4;6X",TAEO6/)ZJ2(BR?00V1DEOCH   D
M  4S9']H'2-^Z1!:@JNR/[0.D;]TB"U  8I,AN)%?DOJ)#+#:G5J/D2DC,S\
MQ#*(II0DK;LR9"C*44NJ+;IK!)WFIY9)/_Y34 \:*&W3LB).E$HI=5==J3VM
MRJ=6:B_^75$N&*+%9@QF8D9.JPPA+39<R4E@ON&4
M                        !P;]^)M4^JC_ '$CO#@W[\3:I]5'^XD!('?=
M5])CR/3ONJ^DQY               ?BTI6VMMQ*5MK(TJ0HLDHCWD9'O(?H
M(8Y8C=.G/U"S*B]0)CIFIR.A!.PG3V]TP>Q)YY4&DQC:O*?0VW"T@4@Z8T@]
ME4@ZTB$HMN#49=NT>[8HL;=XFX'M2:5$1I/89&62,!@@2XU1A,S*?(:E1'DZ
MS;S*R6A9<Y&6PQG$/F6'$8E.3;3FOVU/</6<XD1'&>5SN,'VBN7:6#V[Q@3=
M=9H"^"O2C*XJG!=6*4E3T<]VU;6#<:W^,MF\!-P&K3*C!JT-$NE3(TV*ON78
M[A+2?E+E\0V@                        !.\ 3O =!KW)/0/0\M>Y)Z!Z
M       !5&D'XSQ.A7X"<6M[T3T$(/I!^,\3H5^ G%K>]$]! >3O@  .>[\-
M,_9F.@.>[\-,_9F.@ "BM(E4@V;I3;KR'5SZBXSM@I3J);2:301J7MVGMV8Y
M!>H^=[YJQV]IK?J[M+<J+;#:-5HBP631@C(\&18SD=M",S/N9]IG%8GU6=HV
MTCP;T-Z,3"X=293PBF%'K$I&<92KEP>,EXQ.A\NP;X7"TD2;J8M^0AI]LT*A
MH49;321&K6U>4RSN%YZ.+S5><*9(72W:=Q=PF]1QS7-62SGN2#5TIKSB.2-#
M7B_T9GFEX  XM( K>J]D^IU29U)ZWZ+3V'%(C\:UWW)*2W+/5P22/FWD(^C2
M]47]%<JO-4Z(U7(U1*E*94I2F%/<(E)J(\D9)PK("Z $$MYW2.JL1TU]BV4T
MS)\,J(I[A,8V:NMLW\XG8"I/TF?B'"_S2+_N$+;%2?I,_$.%_FD7_<(6V
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MN1)>7)B5#F[
M                         (AI.^+KWU3^\A+Q$-)WQ=>^J?WD Y=@^XHZ
M!8:=PKRP?<4= L-.X &*5[V=^J?W#*,4KWL[]4_N 8:1\',]'XC;&I2/@YGH
M_$;8        ""Z;+GDVGHZJ=0IV>J+FK&BXW\*L]4C\FT_(*_NB@'2BT76;
M-F3%4ZH27#JJE2%$J4XEK7PM>=;!JY,\P"^@'SJJXY% L&I6Q1JH?&)%=F4N
M#+??UCB0T&7"/&L_V&R5C.2QDMHEE;8HMRZ'9,6PJ]PS]&;)R-+CO*-U#S9:
MW;9/6[;;OV=MX@%O#\5W)] CFC>X#NFQ:)6EI)+LR,E;A$><++8KUD8D:NY/
MH 55"]ZH\OWF,PPPO>J/+]YC,+*/;*^"=0O52O5/.JHLD?2.L4EV93)KDQ+?
M!((B;4E!),EYV$6/$.7%0TY(;3(<X)HS[9>-Q#JU(HKR<,SV$,-%^K82A7_>
M3YP3#9-4PH\-NFG&4G@"UDGJ&HU;<[]HCRR,EJ)9&2B,\D?(8Z$5B&TXS(54
M$X1A9H2V9+SOQS>48EJ9FRIC[SO :VLXVG&=8^1(#;ID^:_(9C(6TE.[)M)/
M"2WGN&S'D+D.R'XC2%<)*2VKM"/#6/5G:.9$>:CTZ2I*_P#Q3OZI*2WI1O,_
MP&.G.$B2DEOK99/N]51EK$7)LY]P#INT]2&I*8:4&M]TTEK*(M5O)ZI%GE5^
M X9D:3,E$9&1X,CY!V&IK4LEE)=3'Q(2\G)&9:I;-4L<Q#ERG2>DO.D6"6LU
M$728#$,+WOB-]97])C,,+WOB-]97])@AF   ;<.<[$0I+"6B4HR[<T$I7061
MO5.0[$FLN(2TW+-DB>22",B,_%SXP,=&XHTA;[LEIN26QM+B3,D_XMF\^8:T
MEAKC"/\ QZ'^$5^L<P9:OC/();TN8^JB_P#BM0W)*NTP@DZJ"WGLYS&A28I3
M*@RRK.J9Y5CE(MX_:I(3(EGP7N#1$VT7^$N7RCW">:@2(DAMTW%&1\*@BQJ9
MV&7F ;-1.<N*\2DQD14&6LTR:3-LL[,XVC<EQW)*9$<VTI:0XVF.HDD6$XVG
MGE+&T:".*0692V992%O(-M*"098(^570,3,Q3-/4GA5./+/42DU&?!(+?CIW
M= #W6([B%$LD)3%;(FVR)1&9%R&HN<]XY@Z]0DQUL2W&74K7+4A7!X,C;QOR
M.0")?I;Q@B[I'VZ_P&<MXP1=TC[=?X"1F  $              ]->[,?;-_U
MI%G"L6O=F/MF_P"M(LX1*T   A(      .9<?P4[Y!6NC[ND](LJX_@IWR"M
M='W=)Z0(6U']R( C^Y$ #1D?#,7ZBAT1SI'PS%^HH=$        :=;^!I_[N
MY_28W!^.(2XA2%I)2%%@R/<9! ^6='%D5ZYZ3(DT2M(@,MN\&IM3CB<JP1Y[
M79RB6'HAO3!__BIGTSPNJE4^F4C7B4N-%BFK]:IIE))SR:V"\FT=!:TH0I:U
M$E*2R9F>"(AHMM%IGDR4V2D5^EU]\M*@Q'H%#IT.4Z3TB/&;:<<(S/74E)$9
M[=NTRY1O#PP\W(8;>86EQIQ)*0M)Y)1'N,C'L9VJ.0  "0  !3-D?V@=(W[I
M$%J"G[<G' T]Z0W"AS)>M&B)U(K9+46S>99+8+$ZXC^8;@_DR_, [@A=U-G4
M](5H4PB4IJ%PU7?+<1:A$VT9_P#K6?F'2?NIJ.;)/T6O-F\X33>M$(M91D9D
M1=MS$8C-M5Y4R]KIJJJ167VV^!IC'!QB4;1-D:G$F6ML/77Z@%D .*U7S<=0
MCJ'7D:RB3K+B$22\9GK;"':/88
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M[9)[#V&1#I@                  G> )W@.@U[DGH'H>6O<D] ]
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M$ &;C*_\/F#C*_\ #YAA !FXRO\ P^8.,K_P^880 9N,K_P^8.,K_P /F&$
M&;C*_P##Y@XRO_#YAA !FXRO_#Y@XRO_  ^880 9N,K_ ,/F#C*_\/F&$ &;
MC*_\/F#C*_\ #YAA !FXRO\ P^8.,K_P^880 9N,K_P^8.,K_P /F&$ &;C*
M_P##Y@XRO_#YAA !FXRO_#Y@XRO_  ^880 9N,K_ ,/F#C*_\/F&$ &;C*_\
M/F#C*_\ #YAA !FXRO\ P^8.,K_P^880 9N,K_P^8.,K_P /F&$ &;C*_P##
MY@XRO_#YAA !FXRO_#Y@XRO_  ^880 9N,K_ ,/F#C*_\/F&$ &\PLUI,U8W
MC(,,3N%=(S        "(:3OBZ]]4_O(2\1#2=\77OJG]Y .78/N*.@6&G<*\
ML'W%'0+#3N !BE>]G?JG]PRC%*][._5/[@&&D?!S/1^(VQJ4CX.9Z/Q&V
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MW=)Z195Q_!3OD%:Z/NZ3T@0MJ/[D0!']R( &C(^&8OU%#HCG2/AF+]10Z(
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MLJ:5K)U2+!$1^(A::S'6%:WK;ZLY;0  JL
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MJ7EM&LS6FH-$1ZRU*_\ J';A3ZN]*;;ET#BK"C[9[CS;FI_Z2+)@.L
M
M-R)W"ND9AAB=PKI&8        1#2=\77OJG]Y"7B(:3OBZ]]4_O(!R[!]Q1T
M"PT[A7E@^XHZ!8:=P ,4KWL[]4_N&48I7O9WZI_< PTCX.9Z/Q&V-2D?!S/1
M^(VP              'XKN3Z!^C\5W)] #XDJWPM.^W<_J,:HVJM\+3OMW/Z
MC&J/5CH\&>L@  E           /;?N3W07WCP/;?N3W07WB)3#P  )0
M        /P7EHU^)5/Z5_P!0HT7EHV^)5/Z5_P!0S[1]6&O8_KS[DE'ZG&2U
MLXSMQS#\ 8WHNM(F4]]#:#9EH:;+"4)6DB+Q](\1YD)N"<=34@C4HS6MM1$:
MBY"Z-PY@ 9;1+AIF(433JHQ=TA2BUC\I>0;$";%CQ7FU-ODXZ>#<;41'J]Z1
MGZQS0 RSR.*J<1P"'DM?M:YD9^0;?5%"WW^%:5Q5UO@20D]J$ENP.: #8G2"
MDR-=*32@DI0DC/)X(L;1K@ #TU[LQ]LW_6D6<*Q:]V8^V;_K2+.$2M   (2
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MP?>,7[%']) ,X
M                                                    -R)W"ND9
MAAB=PKI&8        1#2=\77OJG]Y"7B(:3OBZ]]4_O(!R[!]Q1T"PT[A7E@
M^XHZ!8:=P ,4KWL[]4_N&48I7O9WZI_< PTCX.9Z/Q&V-2D?!S/1^(VP
M          'XKN3Z!^C\5W)] #XDJWPM.^W<_J,:HVJM\+3OMW/ZC&J/5CH\
M&>L@  E           /;?N3W07WCP/;?N3W07WB)3#P  )0
M/P2*GW=6:5!8AP)26XZ$$I*3;(]I[3VF(Z,CN]O[-(K-8MRE:MIKSK*3=?\
M<?AR/0I#K_N/PY'H4B+ (X=.RW&U/:E*>O\ N/PY'H4AU_W'X<CT*1%@#AT[
M'&U/:E*>O^X_#D>A2'7_ ''X<CT*1%@#AT['&U/:E*>O^X_#D>A2'7_<?AR/
M0I$6 .'3L<;4]J4IZ_[C\.1Z%(=?]Q^'(]"D18 X=.QQM3VI6#9=Y5RI7?18
M4R6A<9^8VAQ)-)+):Q<H^I1\<Z.OC];O[\U]X^QADVBL5M&'H;':UJS-ISS
M !G:P      <RX_@IWR"M='W=)Z195Q_!3OD%:Z/NZ3T@0MJ/[D0!']R( &C
M(^&8OU%#HCG2/AF+]10Z(         /$AU+##CSAX0VDUJ/F(BR J?313*K$
MK5#NNCQ3FG3SU7620:]4LY)6"VXWEDMVP512ZI6JQ2JM;-(I;BW*W.XRXHTG
MVI9(]7)E@BR1&:C$MZ_M(-Q+J-5MMA"*1#49FA#2%:J?'K;5'C:>-PMG1?=2
M[PM-JI/M(:DI<4P\E&=773C:6>0R,C&O,Z=><9>?NUUKSNS,9].OER=.A41J
M%:4.B2B2ZTW#3%>(C/"^UU5>/![1!^P59NIP))JQ0<^\^J+O X[W5SN\HM$!
MDF<\V^(Q&(1BNV%;E:MJ/09E-;338VKQ=#)FV;!IW&A1;2,8+)T>4"SI4N72
M69"YTHB0[*E/J>=-);DZRCV$)< )   %.V!_:%TB_NL3[A(M*&CB->+2),5Q
M$2L-%JI?41FEQ/>K(O4?(([8']H72+^ZQ/N%Q"U;36<PK>D7C=L^5INB:Z(<
MN*S(:A)3)?*.VZ3^4FHR,RR6,D6$GR"Z-%NCB/9S3DJ6ZB75WDZJGDD9(;3W
MJ,^L^42&[??%O_YHW_MN"0"]]:UHQ+CI[-33G>@  ')H
M
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MJ'V['^ZD3F#[QB_8H_I(!G
M
M !N1.X5TC,,,3N%=(S        "(:3OBZ]]4_O(2\1#2=\77OJG]Y .78/N*
M.@6&G<*\L'W%'0+#3N !BE>]G?JG]PRC%*][._5/[@&&D?!S/1^(VQJ4CX.9
MZ/Q&V               _%=R?0/T?BNY/H ?$E6^%IWV[G]1C5&U5OA:=]NY
M_48U1ZL='@SUD  $H          ![;]R>Z"^\>![;]R>Z"^\1*8>  !*
M         !^#([O;^S2,8R.[V_LTB!X  $@             D&CKX_6[^_-?
M>/L8?'.CKX_6[^_-?>/L88MI^M'N>EL/U)]_Y   S-H      .9<?P4[Y!6N
MC[ND](LJX_@IWR"M='W=)Z0(6U']R( C^Y$ #1D?#,7ZBAT1SI'PS%^HH=$
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M%KZC;N<<N.VWB0
M                                                     /G/](NA
MR(USL5K54J'+:2R:\;$K3G8?21Y\ABI1]LUBE0:S3W(-4C-R8KG=-K+9T^(_
M&0I6^=#E,I5*G5.F5"4VTPG7)APB7RXQK;_O&O2UZQ7%GGZ^RVFTVIYJ9I<!
M^J5*+ B(4Y(DN);0E)9/:>_H+>/M*D0DTVE0X2%:R8S*&B/&,ZI$6?4(W8^C
MZAVE^OI[*W9JTX5)?5K+QS%R)+H(2\<];5B_*.CMLVA.E$S;K(  .#4
M "J-(/QGB="OP$XM;WHGH(0?2#\9XG0K\!.+6]Z)Z" \G?   <]WX:9^S,=
M<]WX:9^S,=                  %6_I*_\ 2FH?;L?[J1.8/O&+]BC^DA!O
MTE?^E-0^W8_W4B<P?>,7[%']) ,X
M
M       -R)W"ND9AAB=PKI&8        1#2=\77OJG]Y"7B(:3OBZ]]4_O(!
MR[!]Q1T"PT[A7E@^XHZ!8:=P ,4KWL[]4_N&48I7O9WZI_< PTCX.9Z/Q&V-
M2D?!S/1^(VP   !Y):#<-!*3KD6=7.W'/@?CKK;1$;KB$$9X(U'@5E2<_P#[
MQ5:+)XZWV=F?_CF./^E#35UFWK:IC+BFWIE8:8;4D\84I*B+UX 70,?#LZRR
MX5O*"RHM8NUZ>85YHWOQF;HC1<-8/@W*8TXS.Y,.,]JK>>\\$?E%6:#*?(JE
M[W<JL\(<FO44ICZ3V8)]Q1D6.3M#2 ^F$+0M!+0I*D&6241Y(P;<0ZG6;6E:
M>=)Y(?/]I70Y:WZ/UPP9"O\ VC079-)0@^U42C4:6^D^V]0V]!LIVP*'=EM5
MMTG'Z(2*DDLX-33K25GM\2LETF O1MUMPU$VM*C2>%:IYP?C'I7<GT"L/T<:
M8Y#T;,5"09*DUE]RI.'R]N>PC/H+UBSU=R?0 ^)*M\+3OMW/ZC&J-JK?"T[[
M=S^HQJCU8Z/!GK(  )0          #VW[D]T%]X\#VW[D]T%]XB4P\  "4
M           #\&1W>W]FD8QD=WM_9I$#P  )             !(-'7Q^MW]^
M:^\?8P^.='7Q^MW]^:^\?8PQ;3]:/<]+8?J3[_R  !F;0      <RX_@IWR"
MM='W=)Z195Q_!3OD%:Z/NZ3T@0MJ/[D0!']R( &C(^&8OU%#HCG2/AF+]10Z
M(                        IVP/[0ND7]UB?<+B%.V!_:%TB_NL3[A<0
M
M                                          "-:2OB/5_LB_J(241K
M25\1ZO\ 9%_40"2([A/0/T?B.X3T#]           51I!^,\3H5^ G%K>]$]
M!"#Z0?C/$Z%?@)Q:WO1/00'D[X  #GN_#3/V9CH#GN_#3/V9CH
M        JW])7_I34/MV/]U(G,'WC%^Q1_20@WZ2O_2FH?;L?[J1.8/O&+]B
MC^D@&<
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MG?(*UT?=TGI A;4?W(@"/[D0 -&1\,Q?J*'1'.D?#,7ZBAT0
M           !3M@?VA=(O[K$^X7$*=L#^T+I%_=8GW"X@
M
M                          8)\;CD-V.3[\?A"QPK"M5:?&1\@S@ C76H
MKZ0W!_-E^48)]D-3X;L657:\XRZ6JI*I1&1E_")8 "-=:A_2"O\ DE%^4#M-
M6/C#<'\V7Y1)0 >&6^"9;;UUKU$DG66>5*QRGXQ[         51I!^,\3H5^
M G%K>]$]!"#Z0?C/$Z%?@)Q:WO1/00'D[X  #GN_#3/V9CH#GN_#3/V9CH
M          #6F5"'"4V4R4PP;AX03BR3K'S%G>-DC(RR1EC?D  :\.=$FFX4
M.2R^;:M5?!K)6J?,>-PV %6_I*_]*:A]NQ_NI$Y@^\8OV*/Z2$&_25_Z4U#[
M=C_=2)S!]XQ?L4?TD S@
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M!.@  %.V!_:%TB_NL3[A<0IZP/[0ND7]UB?<+A
M
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MPB"3GMBU<'O(!"_TE?\ I34/MV/]U(G,'WC%^Q1_20J&Z='FE:Z*.[2ZU>%
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MY@@_P"4@&]/<W*]D;AV+;$.6S*BT2&U(962VW$HP:5%N,A)  )F9ZIB(CH
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MTZ?8+D !3?81E_WB7;Z=/L#L(R_[Q+M].GV"Y  4WV$9?]XEV^G3[ [",O\
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M!$=)UAS;)H42HMWO=4TWYS,/@URR022<,RULD7)C</I(5-^DO\1Z5_G43[U
M--.A*4:2/LB7;M_^.GV#][",O^\2[?3I]@N-ON$]!#] 4WV$9?\ >)=OIT^P
M.PC+_O$NWTZ?8+D !3?81E_WB7;Z=/L#L(R_[Q+M].GV"Y  4WV$9?\ >)=O
MIT^P.PC+_O$NWTZ?8+D !3?81E_WB7;Z=/L#L(R_[Q+M].GV"Y  4WV$9?\
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MC)\YCV         @^E?9 HG^9L__ %"<#PZRV\22=;0X23UB)22/!\X]@
M                        "+Z3_B)5OLT_U$)0-6J4^-5(#T*<WPD=TL+3
MDRSMSR ,5O? %-_=FOZ2&^,<=E$>.TRRG5;;22$ES$18(9
M              !";$^--X?O:?\ ZA-AHP*5$@2IDF*UJ/2UDX\K)GK*Y_68
M#>                             !"M&_OVY_\R6)J-*FTJ)35REPVN#5
M)<-YW:9ZRCY=HW0       !$-)WQ=>^J?WD)>(AI.^+KWU3^\@'+L'W%'0+#
M3N%>6#[BCH%AIW  Q2O>SOU3^X91BE>]G?JG]P##2/@YGH_$;8U*1\',]'XC
M;                     !7^G[_ */75^YJ^\A8 XEZV\Q==K5*ARWG&&)S
M1M+<;QK)(^4L@/E*C4"[](-GV?0(5K-QJ/#62BKBU$DUMZQY41[^?<1Y,B$E
MN&D5:X?T@ZQ:$"XJA3(#M.8X9UM9J6:$-IV$62(C,\9,O&/HBR;=8M.U:=0H
MCSC[$)O@T..8UE%DSVXZ1PXVCJ"QI3E7RF;).<_&XL<<R3P9%JD6=V<[ %"Z
M0WJBYI,B6,3MR3:-1J>T28U&>U)4A?!DHW5&9GG:KS><2G1C>=QV'951.^*1
M<+\=J>ABG(>CF<@VE),]N=Y%J[^<Q8.D/11 NVN1J[#JD^A5YA)(*= 425J2
M6<$KG/;C.=VP=K1U9:;-I4F*[5ZA67Y+QONR9R]=1JP1;.8MFX!T+)N-JZ[=
MCU>/%DQ&WC41-24:BRU5&6TO(.Z!$1%@B(B\0           /GO1['8D_I*W
MZW)9;>:.*64N))1'VR>0Q#HA6[3M+&EAA2EHM7J8YQQ,5.-56S)-D18(R69D
M7)Y,BU+HT$TVNW34JZ5P5B#)GJRXF*LD$18QC);3(2&W=$EJT.U*C0F(2GF:
MBV;<N0\K6>>WXRKQ9,R ?+M.:JT6BV,_?4:0UH_9E*7">C);X;)J49<(9;=N
MT^CR#[A0I*T)4@R4DRR1EN,A2=+_ $>Z:Q,@)JMQUFK46"X;D>ER5_J4GG.-
MA[N@B%VI(DD1$1$1;"(@           ?.VA**Q,TR:2V9;#3[*GE$I#J"4D^
MW3O(Q]$BEJQ^C_3*E7JI5$W%6HJZB\IYYN.X2$GG]G9O+I 0O0/$H[EYZ4Z;
MJM.6<2LFAP\L$DEJVF9\Q$?D(;E/@)TJ:5Z3.H%.3#LBV5%P$]#/!E+4DR/5
M1N/5RGDW%MY19+NA^WVM'TNTJ2J338DM252)#*LO/F1D?;J/>6PBQN$:I?Z/
ML&FOQ%Q;KN!#4=U+B64O:J-AD>-4MF#P B-<H5U65I1NZL1;33<5-K$<R;DN
MK23;)&2<ZYF?:D6J9'NR7*)/^A^B0G1W4E.+2<552<X DEL+M$:V/%G&!([^
MT1G>=R/5"7=5:B4Y]"&W:;&<U6E$DNGEW[A/;9H-.MFB1:31HR(T*.DDH0DM
M_.9GRF?*8#J                #F7'\%.^05KH^[I/2+*N/X*=\@K71]W2>
MD"%M1_<B (_N1  T9'PS%^HH=$<Z1\,Q?J*'1
M>'G4,M+=>6E#:"-2E*/!$1;S,P$8HEF1J3?->N9N2\N35FVFW&E$6J@D;L<H
ME0K*-IOLV14&XZ)$XHKKW%T5!41915+SC8YS9V9W"S0
M    :%P4>'7Z+-I54;-V#,;-IY!*-)J2>\LEM(;%0EMP(,B6_K<"PVIQ>J63
MP19/!<NX5B>G>T2(S-FN8+:9]37/8 LFC4R+1J5$IM/0;<2*TEEI!J-1DDBP
M19/:8W!P[+NBFWC;\>M413JX+YJ)"G6S0H]4S(]A^,AW
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M\9XG0K\!.+6]Z)Z" \G?   <]WX:9^S,= <]WX:9^S,=
M         0:]-)$"VZTQ1(M.J-;KCK9O<2IS9+6VV7[:S,R))<PZMB7E3;TI
MC\NEID,+C/*CR(TI'!O,.%O2I.3P(7H^;:=TY:2I+BM:4VF$PC;N;X/.[I(A
M^V?B+I_OF+&PAAV%$D.-I+8;FKC6Z<& M<
M>77$--K<=6E#:"-2E*/!$1;S,Q";/TG4&[KKJ-#H1OR%0F>&5+U2)ESMM4R0
M><G@^7&-A[1+JI3XM5ITF!4&$2(DEM33K2RR2DF6#(57:T"+3/T@JM!I[#<>
M)'MV.VTTV6$I23FX@$BO/27!MVN-T2'2JI7*P;7#KBTYLEFTWG>LS,L;MA#L
MV)>-,O2C*J%*)]K@W%,OQI*.#>8<+>E:<G@Q ]#I'(TH:5)4E.9**@PPE1GD
MR;)!X(O%N,9-')ICZ<=)D2*O,5:8<A9$6YU2#UO^_& ML
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MQONHI&1%AK&MKFDL"Z:)3F:11X5.C9X"(RAE&=^$E@ON ;H
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MZ)Z"$'T@_&>)T*_ 3BUO>B>@@/)WP  '/=^&F?LS'0'/=^&F?LS'0
M                 %87/9]QTR_I-Y6/(@/2IL9,6=3I^LEMTD]PM*T[247C
M'5T96=/M]VLU:XIK$ZOUAXG9#C*#)#2$EA#:#/;@B$Z
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M)&6Q..0C%F"%6Q=LN5?UQ6K5V&T2H*4RXCS6=5Z,L\%G/[:3P1XV":@
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M10Z(
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M;N,:ZB+:K!<Y[1F'!J
M        51I!^,\3H5^ G%K>]$]!"#Z0?C/$Z%?@)Q:WO1/00'D[X  #GN_#
M3/V9CH#GN_#3/V9CH
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ML&MWI.JY,W!38'4Q;7"IF1G"4GQ$1D9D>WD"=*T1F2NO6T[L+%  '-V
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M)AA/<M)(CW%RGRF)2
M           .9<?P4[Y!6NC[ND](LJX_@IWR"M='W=)Z0(6U']R( C^Y$ #1
MD?#,7ZBAT1SI'PS%^HH=$
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MOQXS;3BB/)&I*2(SSTD-X '%HCD
M                 JC2#\9XG0K\!.+6]Z)Z"$'T@_&>)T*_ 3BUO>B>@@/)
MWP  '/=^&F?LS'0'/=^&F?LS'0
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MQ7=P[VT)F\7ST]/S9  !Q:
M      $0TG?%U[ZI_>0EXB&D[XNO?5/[R <NP?<4= L-.X5Y8/N*.@6&G< #
M%*][._5/[AE&*5[V=^J?W ,-(^#F>C\1MC4I'P<ST?B-L
M
M            ',N/X*=\@K71]W2>D65<?P4[Y!6NC[ND]($+:C^Y$ 1_<B !
MHR/AF+]10Z(YTCX9B_44.B
M
M                                                 "J-(/QGB="O
MP$XM;WHGH(0?2#\9XG0K\!.+6]Z)Z" \G?   <]WX:9^S,= <]WX:9^S,=
M
M
M          $0TG?%U[ZI_>0EXB&D[XNO?5/[R <NP?<4= L-.X5Y8/N*.@6&
MG< #%*][._5/[AE&*5[V=^J?W ,-(^#F>C\1MC4I'P<ST?B-L
M
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MR2%*RHRY]4MN/( ZX"/TF\[>J\LHM/JK#LA6Q+9Y0I702B+(D
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M"TK22D*)23W&1Y(?JC))&9F1$6\S  'XDR4DE),C2>TC+E'Z
M       #E7/78MNTE=0G)=4RA24F3995DSP0#J@/+2R=:0XGN5I)19\8]
M     JC2#\9XG0K\!.+6]Z)Z"$'T@_&>)T*_ 3BUO>B>@@/)WP  '/=^&F?L
MS'0'/=^&F?LS'0
M
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ML&][;FD\<>KQOU*==?"&;>$\_;$0]T>\:!6)A1:=4V7I)EE+9DI!JZ-8BSY
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M4[Y!6NC[ND]($+:C^Y$ 1_<B !HR/AF+]10Z(YTCX9B_44.B
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M,F9!D1EF9(>;4V9ER$9&7XBL-'ERQK5ANVU=*^I\J*ZK@E.)/4<09YV'Y_.
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M^,\3H5^ G%K>]$]! >3O@  .>[\-,_9F.@.>[\-,_9F.@
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MG?(*UT?=TGI A;4?W(@"/[D0 -&1\,Q?J*'1'.D?#,7ZBAT0
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M/L1Z7";9?QPJ"83JN8/)9+&W W'X,20EE,B*PZEE1+:);9*)M1;C3G<?0-@
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MA!](/QGB="OP$XM;WHGH(#R=\  !SW?AIG[,QT!SW?AIG[,QT
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M/'?ALDVY&4HDN&:2P6$[SSL/)<_2(6F&_&T0S9$EM3139Y26TJV=H:BP>/(
MM>LO5IB@Q3MR+&DS5&A)ID+U4)09'E6\LXV;!'&;AN:B7+2J=<S=/?BU)9MM
MOQ"41H7R$9'R;N3E\0TK^J,E-1MVEO5)ZD4>2G+TQI6J:C(NXUN0MVWQY/<(
M_4(]%BWU:S-"G/3]66CAG3D&\A)F98(E;LGM/8 F]U7)5T73%M^WD042763>
M6_,,\$63P22+>>SQ_B-NDRKJB1:HNX6Z8I$>.;C#T8U?K%$1GA1&>PBP7,,%
MZQK3JLU,2O3(\.I--ZS3RG>!<0DSWDH]A[2/9M$:M.IS"E7314U5=:I$6$M;
M,U?;84:>XUMN=Y\O[.P!GHURWM<%"35:7$I33#23)27=8U2%)SG5+.PN3:>\
MCVCW1KIO"ZJ>J50H--AM,%JNJD*4KAG2WD@N0MV_GWCK:+/^F,#[-W^M0U-"
M)D=FO_O3OX .W8]Q2KBMIV8[%;:J#+CC"VB,R0;B>8]ID1Y(1VK5B_:/2G:S
M/C44HS!$IV(V:C42<X,];.,^4<BBU.;2=&=RS*7GC**D\25$6301FDC5Y"',
MN&-;Z;*<D]<4JJUB0RDTH.6;BC7L,\H(]A%MW\P"Z:1-34J5#G(2:4R64/$D
M]Y:Q$>/6(-I6-53GV];J%F3<V43D@DG@^#3_ /<_,0E=E_%"AX\"9_H(12]C
MXCI'M.>[J\"Z:XQ9+.%'L_\ J(!UJ57Y2;[GV[+:81';CI>B*;2:3-.S);\;
M/)N'*MZ_7JC?DRCOM,E3S6XS$=0D\K6C?D\XW9Y.8:.E9]RWKCHUS,(4HT-.
MQ%F6PB,TJU/69GY!R9]&<M^QK7KK:%G*@R4S9.KLUDNF1JSY"20"9P;FF5"Z
M[E@-LQU4NF1\:QI/64[C:D]N,;%<G((M4ZQ4YVALYT*+38<=U#B92&$FV2$:
M^K^K26S)\N3YQV=&L=2[*JE7D$1R:HM^0I?*:=I%]Q^<<.G-./\ Z/DA#"%.
M+-I9X263P3QF9^8L@.DQUP=CF=U6*G%2^HW_ (;B^OPON9:NMG9NWXY1K6E,
MO61:,!^B1J6W!CLDAI#YJ4[(U=AGLV%DR/!;/Q'4ZLTZH:*'H\.;'=DM4?\
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MD6S629'JY\Y^H=G1)3%PK09E2B4<RH+5*=4HNV/6/M=O+LV^4!R]#WOZ[?\
M,3_$?FC7XV7_ /OA?>X/W0\9<>NW_,3_ !'YHU/_ /%E_P#[X7WN -+1[33J
MFCF>P50?IVK4'7#D,GA2229'OYA#XLR<[4RJCM:EL4>6LZ:56)I).F2=J<\I
M$9\N_!>(6/H3P=I2MQEQ][\!-"ID HR(Y08I1VU\(AHFDZJ59SK$6,$>T]H"
M/UVVTNZ/I-(6\[,=:CJ-M]W!N*6G*DGGGSLZ![T8U-RK633)$@\OI0;+A\YH
M,TY\Q$.[6'T1:3-D.;&VF5K5T$DS$0T*L*9L.*M6</NN.ISS:V/P 3H
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M->E.=J^E:D0VI;\1#M./A76%:J]3669D1\F=WE 6D JFK4]>C^X:))I4Z6Y
MGR.+R(K[AK3MQVQ>/>.E?4F=5KSI-JQ9C\&+(95)DO,*PM22UNU(^3N?6 L0
M!4]Q4ES1](IE5HL^<N&N2EF5%>=-:7"/E\1[_.0SWA&GU32?$I<*I2(+,B!^
MN4THR/4)1FHBYC/!%D!:("%2K<IEO6C+@G7)M.B..DZJ4N1A:3V921^,BW"
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M !R(ELT2(V\W&I,)M#R=5PB9+MRWX/G(;\R#%FQ3C3([3\<\9;<22D[-VP;
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MNIUNCE3:6ZRPU(6293KAGDFN4DD1;3,=JEP6*93HT*(G5CQT$V@CYB_$;(
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M(4DI4B9L0A!&1GJGR[O^!NW10)+=9L9JG1W7HE.<U''"+N$EP9$9_P )BPP
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MBE>]G?JG]PRC%*][._5/[@&&D?!S/1^(VQJ4CX.9Z/Q&V
M
M            #F7'\%.^05KH^[I/2+*N/X*=\@K71]W2>D"%M1_<B (_N1
MTJPVI<;607;H,E$8VH;Z9$=#B<;2VES&/;R-=!D.(P^=-F*0O/ +/S>,!W@'
MXA:7$$I!D:3VD9#]
M
M                                     !KU"0F+%6XHR(\8+I&9QQ+2
M%+6HDI3O,Q5VD2YU2'%4R M1.*V+,OV$GO+I/U$ X#+YUBXWI2=K>MJ(^J6S
M/EWBW:$T;45!'S$*_LBCFG44:1:$5O@VR(!E   <RJF;4F-(Y&U85T&.F1D9
M$9'DC&M.9)YA23Y2&E2)FJ?%'SPM&Q)GRES .L
M
M                                                *UTJU$E)8A(/
M)N+(CP?(D\GZ\$)S7*HS3(;CKKB4&E.<G^R7.*9X=ZX*ZJ4LE<'G5:2?(G/W
MGO 3NQ&32P@SYA/"W"/VU#X"*G9R"0$ #P^G69<27*DR'L?BBRDP&G15$JG-
MX_9RD_.-T<F"Z42<Y'7L;</60?,?,.L
M                                                          #D
MW2ZAFCO*6>"+:?K%<:/2VH/G,C'6TH5M/%N(1UY=>[7!=[^T?X#%8<,T)2>-
MFP"%DL>Y$ _6BP@B !Z&A4H:9#2BQMY!O@99(!#DSY5'=4E:34SSXSYR]@ZT
M&Y(,I/NA$K=@MO\ R-Z;!;D),E$0B=5M5MTS4A)$?.1 )<51B'N>+S&/WJA%
M^63ZQ5\BUY2%'P;[Z2\2U%^(UCMR<7_O,KTBO:!A;/5&+\LGUAU1B_+)]8J7
MK<G>$R?2*]H=;D_PF3Z17M PMKJC%^63ZPZHQ?ED^L5+UN3_  F3Z17M#K<G
M^$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y
M9/K#JC%^63ZQ4O6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<
MG^$R?2*]H=;D_P )D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$
MR?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/
MK#JC%^63ZQ4O6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^
M$R?2*]H=;D_PF3Z17M PMKJC%^63ZPZHQ?ED^L5+UN3_  F3Z17M#K<G^$R?
M2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#
MJC%^63ZQ4O6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^$R
M?2*]H=;D_P )D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*
M]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC
M%^63ZQ4O6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^$R?2
M*]H=;D_PF3Z17M PMKJC%^63ZPZHQ?ED^L5+UN3_  F3Z17M#K<G^$R?2*]H
M&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^
M63ZQ4O6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^$R?2*]
MH=;D_P )D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%
MM=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63
MZQ4O6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^$R?2*]H=
M;D_PF3Z17M PMKJC%^63ZPZHQ?ED^L5+UN3_  F3Z17M#K<G^$R?2*]H&%M=
M48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ
M4O6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^$R?2*]H=;D
M_P )D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=48
MORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ4O
M6Y/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^$R?2*]H=;D_P
MF3Z17M PMKJC%^63ZPZHQ?ED^L5+UN3_  F3Z17M#K<G^$R?2*]H&%M=48OR
MR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ4O6Y
M/\)D^D5[0ZW)_A,GTBO:!A;75&+\LGUAU1B_+)]8J7K<G^$R?2*]H=;D_P )
MD^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=48ORR?
M6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ4O6Y/\
M)D^D5[0ZW)WA,GTBO:!A;)U&(7_G%Y",<FJW;3:>@S<?;(R[X_P+:*[.VIB^
M[?D*Z5J/\1[C6:HU94DS/G,@,%PWI-JRC8IB5(:/)<*HL'_Z2Y.D]HPVS;JW
M'"6X2C,SR9GM,Q*J3::&C2:DEYA+H%.;CH(DI+9X@&*CT],5HBQ@QU2V#\(L
M#]    'XHLD9#B5B"I1<*UL60[@\K22B/) (O$N(XJB9GEJGNRKV[AVV*O#=
M1K)=P7C(:=4HS4I)Y27F$/J%J*)1FR:T?5,R^X!8/5"+\LGUAU1B_+)]8JAR
MVYI&>),GTBO:/'6[.\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<
MG^$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7
MY9/K#JC%^63ZQ4O6Y/\ "9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*E
MZW)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^
M$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_  F3Z17M PMKJC%^
M63ZPZHQ?ED^L5+UN3_"9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW
M)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R
M?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K
M#JC%^63ZQ4O6Y/\ "9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW)_
MA,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2
M*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_  F3Z17M PMKJC%^63ZP
MZHQ?ED^L5+UN3_"9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW)_A,
MGTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]
MH&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%
M^63ZQ4O6Y/\ "9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW)_A,GT
MBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&
M%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_  F3Z17M PMKJC%^63ZPZHQ?
MED^L5+UN3_"9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW)_A,GTBO
M:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M
M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63Z
MQ4O6Y/\ "9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW)_A,GTBO:'
M6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=4
M8ORR?6'5&+\LGUBI>MR?X3)](KVAUN3_  F3Z17M PMKJC%^63ZPZHQ?ED^L
M5+UN3_"9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW)_A,GTBO:'6Y
M/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=48O
MRR?6'5&+\LGUBI>MR?X3)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ4O6
MY/\ "9/I%>T.MR?X3)](KV@86UU1B_+)]8=48ORR?6*EZW)_A,GTBO:'6Y/\
M)D^D5[0,+7<JD1"3,W=A<Q&(W7+[IT$E(:=)QWD2CME>8MA>4Q"CM:2YGA''
MEYWZRC//K&U!LTR41FGU 8<2HSJC<THN'2;<<E9)HCSD^=1\IB;6I0.!)*E)
MV[!U*/;;4?!FDO,)/'CI:3@B(@'[';)M!)(MPR@     Y57B&ZV:D=T6X<^'
M7^+J)B;L,MA&>P_/RB2*22BP8XE6HS4I"LI+/0 WVZI$6DC)W&><C'OJA%^6
M3ZQ7<^UG4K,V7'4?449?<.4JW)Q&?_B)/I%>T#"V>J,7Y9/K#JC%^63ZQ4O6
M[.\)D^D5[0ZW)_A,GTBO: MKJC%^63ZPZHQ?ED^L5+UN3_"9/I%>T.MR?X3)
M](KV@86UU1B_+)]8=48ORR?6*EZW)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L
M.J,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3
M)](KVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ4O6Y/\ "9/I%>T.MR?X3)](
MKV@86UU1B_+)]8=48ORR?6*EZW)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J
M,7Y9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)]
M(KVAUN3_  F3Z17M PMKJC%^63ZPZHQ?ED^L5+UN3_"9/I%>T.MR?X3)](KV
M@86UU1B_+)]8=48ORR?6*EZW)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7
MY9/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](K
MVAUN3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ4O6Y/\ "9/I%>T.MR?X3)](KV@8
M6UU1B_+)]8=48ORR?6*EZW)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9
M/K%2];D_PF3Z17M#K<G^$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVA
MUN3_  F3Z17M PMKJC%^63ZPZHQ?ED^L5+UN3_"9/I%>T.MR?X3)](KV@86U
MU1B_+)]8=48ORR?6*EZW)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K
M%2];D_PF3Z17M#K<G^$R?2*]H&%M=48ORR?6'5&+\LGUBI>MR?X3)](KVAUN
M3_"9/I%>T#"VNJ,7Y9/K#JC%^63ZQ4O6Y/\ "9/I%>T.MR?X3)](KV@86UU1
MB_+)]8=48ORR?6*EZW)_A,GTBO:'6Y/\)D^D5[0,+:ZHQ?ED^L.J,7Y9/K%2
M];D_PF3Z17M#K<G^$R?2*]H&%K/5:&T@U*>+!;]@A=S7]';;6Q3C*0]NU4'L
M+ZRMWD(1H[5D.G^M6ZOGUE&?WCI4VS]51&I.SH PCU+@RJM452YAFMU9[3QL
M(N0B\0MFWJ<45A.2VCQ1Z(W%27:EL\0[R$$DL$ ]%L       ?AI(P !C6R@
MR/)#'Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'
M%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@
M  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?
M>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;
M[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #
MB[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0
M<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2
M  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M
M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=
MOO2  #B[?>D'%V^](  .+M]Z0R(801;@ !D)!%N(?H            #R;:3W
MD  ,)L-Y[DA^<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@
M XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>
MD'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[
MT@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B
M[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<
M7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2
M #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]
MZ0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=O
MO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI#*AE!%L(  9"(BW
M   99  'A323(\D,7 -]Z0  _.+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%
MV^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@
M XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>
MD'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[
MT@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B
M[?>D'%V^](  .+M]Z0<7;[T@  XNWWI!Q=OO2  #B[?>D'%V^](  .+M]Z0R
1H:01;"  &0BQN      '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g50309g62g77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g62g77.jpg
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M$Q0B(T)R<Y&2H<'1%3)28H+")"6B\#,U0__$ !L!  (# 0$!
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MIA1M(:;I'E1[7R-S3?8M(:"MX,72)?:%8*K[05O!BZ1+[0K!6&;B.3FDX#,
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M_P#V"[N@7?T>BR>UJWOX/HDD7S?\ORM%HB)2NG1$7(O&)K/9W%EQN$,4@_\
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M/DT;?\B_4?TS/H5D5\\65%2&F)V=NLLNK3.A>M=6:/Z$2$EU.Y\.?F#LQ^A
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MB.Z>(K1$ZVQ<?E^C?-&V9@OF[\/]*KD1%<N-17/H(HGQ6FYUC@0R>5D;?/L
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4(YV\JR."./N- 1$105J(B(0O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g50309g99a30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50309g99a30.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1=H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %TL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 2(  A$! Q$!_\0 '  !  $% 0$               $"! 4&!P,(_\0 51
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MX L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X
ML.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.
M3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y
M/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6
MYMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YM
MXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY
M/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D
M];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];
MFWE^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FW
ME^ +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^
M +#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +
M#D^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D
M^3UN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3
MUN;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN
M;>.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>
M.3Y/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3
MY/6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/
M6YMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6Y
MMY?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY
M?@"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@
M"PY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"P
MY/D];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/
MD];FWCD^3UN;>7X L.3Y/6YMXY/D];FWE^ +#D^3UN;>.3Y/6YMY?@"PY/D]
M;FWE*T-0W'@ZR3_]729$ 8MTM=2IG3L;,Q-+F:4+FDKXJA,6KT[%+LQMQMR2
MXS4_S)TZ>C0X#)(J+H!@[9<EX189_FR(N'29MJHY,4 D  6=TG=%3HV/Z61<
MUI[4=.VF@;&W5I7:I:R?Q;Q&Q=$;,[\S(    !JOE+N]99<F9*NW2-CG1[4Q
M5,>A5.3?*/E+ZY%W:&Z:)JB\/F;9[6P=CQ-/$B;\=W_;Z#!\^?*1E+ZY%W:#
MY2,I?7(N[0UI5/)WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\
MH^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1
ME+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?0
M8/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(
MN[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?
M*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2
MJ.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?
M7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV
M7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:
M#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H
M^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E
M+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08
M/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N
M[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*
M1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J
M.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7
M(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7
ME/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#
MY2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^
MKZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+
MZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/
MGSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[
M0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1
ME+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.
M\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(
MN[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E
M/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y
M2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^K
MZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+Z
MY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/G
MSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0
M:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E
M+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\
M.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N
M[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/
ME'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2
M,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ
M#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY
M%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GS
MY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:
M51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+
MZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.
MR\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[
M0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E
M'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,
MI?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#
M!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%
MW:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:51WAV7E/E'U?08/GSY
M2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+ZY%W:#Y2,I?7(N[0:5
M1WAV7E/E'U?08/GSY2,I?7(N[0?*1E+ZY%W:#2J.\.R\I\H^KZ#!\^?*1E+Z
MY%W:%Q:_*'E%/=:&&2KC6.6=C'(D:=**O22<*8;P_;VS8E<41$WF;>'C^[O8
M(:N+47[BE[E1<$.;[:L'EG+M&<NT#U!Y9ZC.4#UQ08H>6<HSE ]<4&*'EG*,
MY0/7%!BAXYRC.4#VQ08H>.<HSE ]L4&*'CG*,Y0/;%!BAXYRD9[MH'OB@Q0\
M,]Q3PCMH%SB@Q0MN$=AI'"NV@7.*#%"VX5VT)(_:!<XH,4+;A'[2%E?M0"ZQ
M08H6G#/VH.&?M0"[Q08H6G#/VH.&?M0"[Q08H6:S/36FXCAW[?T O<4&*%EP
M[]OZ#AW[4W 7N* \&O<K4Q)SU ]@>/".)X1P'J#QSW;2.$=AI+9+O<'@DCMH
MX1VT6+O<%OPKMI'"OVH+%UR"UX9^U!PS]HL9ET"T29^T+,_:@LF:%V"S6>3:
MA3QB3:@RF:%\"QXQ)M0CC,NU-Q<IGA?@QRU4NU-Q3QJ;#SDW#+*9X9,&+XW-
MUDW$<;FQ\Y-PR29X94&(XY/T_.3<0M;/UDW%R2:D,P##\=GZR;B./3]9-PR2
MFI#,@PBUU1UTW%*U]1UTW#)*:L,Z# K<*GKIN*>4:GKIN&G)JPV &O+<JK#S
MTW%<=WG;Y[6O3<-.35I9X%G1W&&I^;CF/ZJEX9F)CBZ1,3O@ !%:WE32+$U*
MR!,'MZ5P+O)^X-K*9BXXK@9"Y1)-0S,7JJ:)DE5K#<*BF5>ADKD0#H@*8USF
M(H L(/MNH_#0R)CH/MNH_#0R(   :-Y9?Y+F_$9_<X*ND[UY9?Y+F_$9_<X*
MND].#[K\3_J'_P!J/E'\H !U?"
M
M                      &A  -NMV2%-R32U]^O$=M96*O%X^#5[E1-:[$T
M;RFHR6I8K10UL=9+4-J*Y*7.C9T.;CYS4VF,\/9&P8^7-;POQB]OEQ:F#.5N
M3M6ZZUE/9J6JJX*>3@\YS41R+]Z'E!8ZJ&^TMNNU-44SI7=*-1'.PVIJ4N:'
M*=FQ8JM-,\;7\+\.+$ RZ6&MK+K64MGI*BJ9 _-Q5$:J)]^K$BER;O-543P4
M]NE?- N;*W.:F8NS%5+>$[/BWM%,SX<)8D&PU63RTF2?*E0LL=8VH6!\#DP1
MN"X%62>3M)?Y4IWW=E)6O>K8X'0J[.1$QQQQZ"9HM=J-DQ9KC#MOF+QOB./S
M\>C7 9^\Y.MI+@M%::Q;K4L1RS,CB5BQYN&U>G25)DW-36:NJ[K!5TT\36O@
M8C45KD76Y<>@9H.R8V::<O#CRW=8W->!E9<G+U%0+6R6V9*5&YROQ1>C;ACB
M7E]L$5MR=L=RCF>]]P8YSV.PP;AL&:$[-BY9JFFUHOOW;KV:\ #3@
M
M  !>63[=MG_N6?W+,O+)]NVS_P!RS^Y)X2]&R?\ GP__ *C^[ZG9YC?84/\
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M !U?"
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MPM $7%,4T ZOD  "@
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M\(
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M_P!_-8 J=&]J-5\;VM=YJN:J([V;2,#H^:@$D
M                                             +RR?;ML_P#<L_N6
M9>63[=MG_N6?W)/"7HV3_P ^'_\ 4?W?4[/,;["A_G%;/,;["A_G'B?TM2
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M0       0  4  0  4                  0  4
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M/1U- W@8E:O0J)CBJ&HOFM=YJM&=EG%FB(JF;1R^?[;X_=JP .CY0
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MO!MN/LU=$4[/3:;[]WA&Z//C*D '1\P          0  4       $     4
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M:]&.1V:NQ=BGLF@Y.\ 76#PGJZ:":&&>>*.:9<(F/<B.>OW)K"JP3HTD$0
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M45'T$GNJ<BM?\UUWXW^$.NU'T$GNJ<BM?\UUWXW^$,M0ZO2?5V>P"D^KL]@
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MU"U,EE'7+<KU4U*U#ZEKL&MF>W-<]$32J:C&G6.&]\?%BF*ZHHX7W  *P
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M=1^&AD0
M
M  'B_P Y3V/%_G*!2  @                            !#WC\Q"2(_,0
MD*                             "Z%+<N%T*6X0
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MSXD\"Y$_&,/],^GU=\!P%<I;YVO6?$G@4KE-?<?M>L^)/ 9&?QK#_1/I]7T
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M#OA>(8/+/[%_WX_[F<,'EG]B_P"_'_<KK#8HOHF>ZA2_SBJ+Z)GNH4O\X*I
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M]@ MX/MNH_#0R)CH/MNH_#0R(
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MBJOY'H0QJ,:C6I@U$P1"3#[4                   %K64;:CYR+FO30I=
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M@]7'ER#OG4I_C4IYA7WJ4_QJ=C S2GX7@]7&ER OO4IOC4I7R?W[J4WQJ=G
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M8!2?5V>P 6\'VW4?AH9$QT'VW4?AH9$
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M6O\ FNN_&_PAEJ'5Z3ZNSV 4GU=GL %O!]MU'X:&1,=!]MU'X:&1
M
M                                                >+_.4]CQ?YR@
M0" $2" !(( $@@ 2" !(( $@@ 2" !(( $@@ 2" !)  'O'YB$D1^8A(4
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M4.KTGU=GL I/J[/8 +>#[;J/PT,B8Z#[;J/PT,B
M
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MZO2?5V>P"D^KL]@ MX/MNH_#0R)CH/MNH_#0R(
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ML;L%5J=."_<I:7&KJ6Y5Y7QMJ)D9%;E5B9RX-7-7I3[RY7.K;Z8F;1>+VO\
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M!J8*N\ZLNE36+QN^/[)O&'71QBFJ8CY  .;Z@
M                      K@D6*5KVK]R_>AFC!88JB)I5<#.M3!J)L3 0[X
M7"0P>6?V+_OQ_P!S.&#RS^Q?]^/^Y76&Q1?1,]U"E_G%47T3/=0I?YP52
M       *2)'I'&Y[O-:F*DGC6_4Y_<4Y8M4T4551X1+4/.EKX:F1&1(_%4QQ
M5N"$PUL,T,LK55&Q*J/Q31@>-GCF931N?-G1JWYK,W# Q5W9)%6RTT+5S:]$
M1%3^E<>G]#YU.UX]&ST8U<<?"W.-W"9\?[DQ%YB&8?<J=EO;6N5R4[L,%PZ3
MTJZR&E;"Z951)7I&S!-:Z#&Y3Q-AL"QL3YK'-:@RD^BM?_NH_P"QZIQJZ<T3
MQB(\YO=B5[=+G3VQ(UJL_P#B+FM1B8JJE-LNM+<N$XJ]5='YS')@Y/R,;E;-
M'3UUHFF7-C949SG88X)@IXT$C;EE2^MH8WMI8X58^96JU)'+HPVG74G/-+$U
MS%5FQ<-'PJQ<(WA$_IQZ3$W;*.WVJ=T5;PZ*UJ.5S68MP]I@^2[DMSPP>C<_
M3A\U%Q55DSM/2FHJR^J:&9C:6HK:BGJ:9.&C:D.<R=VA$^_V?>=Z/S<7+$Q:
MHHF8W6YMI;74[K:E<Y_!TJLX3.>F&#?O,?8LH:*]RRQT3*A.#3.SI&9K7)M0
MQ.4O'[AY/'.GIG-JG,8Z6%B=.:CDQP3V:BTR(K'.R@EI;?6U-=9^+HYTD\>;
MP4G1\U%1$W'>G#B:)JY,58\QB4T>$_RS-URMM5KN7$JJ25945J2/8W%D6.C.
M749]CD<QKF*CFN1%14UH<MN=1%;H\L[=70R<=N$K74C,Q56=%:B)F^Q3HF3\
M$M-8K?!48I-' U'(NE%PT'3'P::*(JC_ +W7O_";-CU8E=5-7AZ;YBWI=?A=
M8"ZSRO:\P 1   0X@EQ 4#=(#=(& F^MS>^I=0:$+6;ZW-[ZEU!H0J,C!H0N
MF:5+6#0A=,TJ$5A= "Z"J)H"Z%": NA0* H"A%.L)I&L)I#,B$*2A"E%*E.L
MJ4IUEAE&LC63K(UB!0N@C42N@C4:A%*D:R5(UA%&M2"=:D%1"D(2I"!E2I0I
M6I0I825*Z"E=94N@I766$4NT%)4[04E120NA22%T*5&PV#[/3WE,B8ZP?9Z>
M\ID3S5<9>VCW845'T$GNJ<BM?\UUWXW^$.NU'T$GNJ<BM?\ -==^-_A#+4.K
MTGU=GL I/J[/8 +>#[;J/PT,B8Z#[;J/PT,B
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MLUNM7"+;J*"G61<7+&Q&JNXL56>?%]FTUQ31$_EO>T_VCYWWL@B(B(B=")T
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MB!.S=6AJQ_4?\*E*M?Z-_P *F_8)L0C-38@3LO5S[-?T_P -_P *E"M?BO\
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MY9_8O^_'_<SA@\L_L7_?C_N%AL47T3/=0I?YQ5%]$SW4*7^<%4@
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M=1^&AD0
M
M  'B_P Y3V/%_G*!2  @                            !#WC\Q"2(_,0
MD*                             "Z%+<N%T*6X0
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M(K7_ #77?C?X0RU#J])]79[ *3ZNSV "W@^VZC\-#(F.@^VZC\-#(@
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M\;_"&6H=7I/J[/8!2?5V>P 6\'VW4?AH9$QT'VW4?AH9$
M
M                                        !XO\Y3V/)Z+G+T 4 G!=
MBC!=BA$ G!=BC!=B@0"<%V*,%V*! )P78HP78H$ G!=BC!=B@0"<%V*,%V*!
M )P78HP78H$ G!=BC!=B@0"<%V*,%V*! )P78HP78H$ G!=BC!=B@0"<%V*,
M%V*![1^8A)$?F(2%                             !="EN7"Z%/#!=BA
M$ G!=BC!=B@0"<%V*,%V*! )P78HP78H$ G!=BC!=B@0"<%V*,%V*! )P78H
MP78H$ G!=BC!=B@0"<%V*,%V*! )P78HP78H$ G!=BC "   ,'EG]B_[\?\
M<SA@\L_L7_?C_N"&Q1?1,]U"E_G%47T3/=0I?YP52          *0 10 %9
M  ()(! 4%90%2OFE)4OFE)80)3002F@$ 76 NL*\P 1   0X@EQ 4#=(#=(&
M F^MS>^I=0:$+6;ZW-[ZEU!H0J,C!H0NF:5+6#0A=,TJ$5A= "Z"J)H"Z%":
M NA0* H"A%.L)I&L)I#,B$*2A"E%*E.LJ4IUEAE&LC63K(UB!0N@C42N@C4:
MA%*D:R5(UA%&M2"=:D%1"D(2I"!E2I0I6I0I825*Z"E=94N@I766$4NT%)4[
M04E120NA22%T*5&PV#[/3WE,B8ZP?9Z>\ID3S5<9>VCW845'T$GNJ<BM?\UU
MWXW^$.NU'T$GNJ<BM?\ -==^-_A#+4.KTGU=GL I/J[/8 +>#[;J/PT,B8Z#
M[;J/PT,B                                         !B+_E%;;$R-
M;C.C'R>9&G2YWL0\\G\J+7?9'Q4,_P#'8F+HGIFO1-N!;2Y:^'GT\T9N3-@M
M8;C23RU$4%1')+3KA*QKL5:NQ2QR;O\ 3WV"JEIV.C2GJ'4[L_6YN&.&\C6I
M1>*;[Y_AF 0JHB8JJ(GWC.3#'%,-H;2",45<$5,4U!7-3'%4Z-/2!(,/E3?Z
M?)ZVLK:ECY(W2MB1&:<5_P#Y&59*UT;7*J(CD14Q4,173-4T1.^%8/"MK::A
M@X:LGCABQ1N<]<$Q70A[(]JMSD<BMTXXAJ\7LD&*REOD%AL\UQJ&NDBC5$5&
M:5Q5$_R7]'4LJ:2*H;\UDC4<F.K$,QB4S5-%]\;WL#PJZNGHZ9U153,B@;I>
MY<$0]8I&2QM?&Y',<F**BZ4#5XO94#QJZAE-32S/Z4C8KU1-*HB8FNMRSI76
MFW5[*6H='6R\$Q&MQ5JXX8J+,5XM%&ZJ;-H!"N:F&<J)[0KFHF*JB)[0Z) 5
M41,55,",Y.GI3HT@2#!NRCIDRH;8^#>M0Z'AD>GFX8X&;5S45$5415^\,48E
M-=\L\-R01G)CABF(5[4PQ<G3HZ0VD          #'UU<L;ECA\Y-*["^E=FQ
M/<FE$Q-<3IZ5TJ'+$JF-T*GU$SG8K([$H6>5$^D=O*5\XI=H(\]Y5K/+Z1V\
MH6>;-^E?O(4I=YH9O(L\WI7[RA:B?TS]Y"GF[05+R+4S]/\ &?O/)]548?3R
M;PNL\7Z YS,J7U=3Z>3>>#ZRIZ?^HDWDO+=^L.=4SS0^MJT_U,N\\'U]8F/_
M %4OQ"0MY-97*:IYH?<*U/\ 5S?$6[[C7>N3?$1)I+:305PJJJYIDN5?T_\
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MV\H +RKX63TCMXX63TCMY0 7E7PLGI';QPLGI';R@ O*OA9/2.WCA9/2.WE
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M/[%_WX_[F<,'EG]B_P"_'_<.D-BB^B9[J%+_ #BJ+Z)GNH4O\X*I
M  %( (H "L@  $$D @*"LH"I7S2DJ7S2DL($IH()30" +K 76%>8 (@  (<0
M2X@*!ND!ND# 3?6YO?4NH-"%K-];F]]2Z@T(5&1@T(73-*EK!H0NF:5"*PN@
M!=!5$T!="A- 70H% 4!0BG6$TC6$TAF1"%)0A2BE2G65*4ZRPRC61K)UD:Q
MH701J)701J-0BE2-9*D:PBC6I!.M2"HA2$)4A RI4H4K4H4L)*E=!2NLJ704
MKK+"*7:"DJ=H*2HI(70I)"Z%*C8;!]GI[RF1,=8/L]/>4R)YJN,O;1[L**CZ
M"3W5.16O^:Z[\;_"'7:CZ"3W5.16O^:Z[\;_  AEJ'5Z3ZNSV 4GU=GL %O!
M]MU'X:&1,=!]MU'X:&1
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M!2?5V>P 6\'VW4?AH9$QT'VW4?AH9$
M
M                         !XO\Y3V/%_G*!2  @
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M3IO01_"@XG3>@C^% ,;SHLWK\?PN\!SHLWK\?PN\#)<3IO01_"@XG3>@C^%
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M.F]!'\*#B=-Z"/X4 QO.BS>OQ_"[P'.BS>OQ_"[P,EQ.F]!'\*#B=-Z"/X4
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MH=7I/J[/8!2?5V>P 6\'VW4?AH9$QT'VW4?AH9$
M
M                                  !XO\Y3V/%_G*!2  @
M                   !#WC\Q"2(_,0D*
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MU\0 &'0
M      A51$555$1-:DZ$-<N-8ZID5&JJ1(N"(FLU33F8KKRPR[[E2,7!9D_)
M%4IY6H_3?_%36\$Z>@H5#KIPXZU39N5Z+TW_ ,5(Y8H?3?\ Q4UAR% TX-:I
MM7+-#Z?_ .*D<MT'I_\ XJ:FJ(>:ITC2A-:IM_+EO]/_ /%? CEZW>L?_%?
MT[!,%//!!I0:U3=.7[=ZQ_\ !? CG!;?6/\ X+X&DN0H5"Z5)KU-XYPVSUG_
M .#O <XK9ZS_ /!W@:(J)T]!0J(-*E->IOO.2U^L_P#P=X$<Y;5ZS_\ !W@:
M"J(4*B#2I->IT#G-:O6O_@[P(YSVGUK_ .#O Y[@4X)L&E2:]3HG.BT>M?\
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MIR*U_P UUWXW^$,M0ZO2?5V>P"D^KL]@ MX/MNH_#0R)CH/MNH_#0R(
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M*2V-5KI8TSIWIH=(OG*GW:C,'2J;S,L8=.6F(D !EH
M                #'#!4THILK5Q:B[4-?I85GG:QNA.E5V(; <L1WPHXR&#
MRS^Q?]^/^YG#!Y9_8O\ OQ_W.3K#8HOHF>ZA2_SBJ+Z)GNH4O\X*I
M   %)XU55!21H^ID2-BN1J*NU=1[%C?*)+A:JBG5$SE;G-78Y-!SKFJ*9FGB
M3>VY<5-5!2L:^HD:QKE1K576JZ$#JN!M4RF=*U*AZ9S6:U0U.@J77ROM,;TQ
M;2M669%ZR="%_E5A1UULNBX(D$F8]=>:N*?Y.%.T353-=/#=]W&<3=-4</\
M+LY%64\KYV1RM<Z!<)$3^GVD15U-+1K5QS-=3(BJLFK!-)S]E3+;XZJKD<N-
MSA<]OO9RHGZ&U55*E%D1-3HB)F4JX^U4Q4Z8>+-?^>3%.--43NX1_P!+ZFO5
MMJIDB@K(GR+H:BZ2_-$N-+0,R$@J.#BCK&L:Z*1B(C\_'HZ4Z3)WV:J2UT'2
MY%?#BY,Y6H^3#H:Y4T)B=:9F>+-.T3$3FCPB=W5LTCVQQN>]41K4Q5=B&,@O
MUKGE9'#71/D>N:UJ8]*EGDM---3U"5?3&B-5S57.:QRI\YJ*NE-&\P<\;;5E
M32UM734,U'4/X"D2G:B+#I7.5-:KM.M%,5,8VU54TTUTQNF=]_#>W:JJ(:6G
M?-4R-BB9TN<Y>A"WMMRH[G$Z6@G;,QJX*J:E-9R];-4W.RT+'1<'+(JJDV*Q
MN<B*J9R)I3[B_P CZR1U5<+=4T])'4TCTSWTK,UDB+H7#:=-*-/-XLQM=4[3
M.#:U,;OG-K_MN9*JO=MI*UE'4UD<=2[#!B_?H,BF@YK!!23V+*RHKF1OK&SN
MP>]/G-P\W!=*&\Y-/DDR?M[IU59%B3%5.F-@4X=-XGIZ7W)L>UUX]<Q5$6F+
MQ;E>8W]61"ZP%UGE?1>8 (@  (<02X@*!ND!ND# 3?6YO?4NH-"%K-];F]]2
MZ@T(5&1@T(73-*EK!H0NF:5"*PN@!=!5$T!="A- 70H% 4!0BG6$TC6$TAF1
M"%)0A2BE2G65*4ZRPRC61K)UD:Q H701J)701J-0BE2-9*D:PBC6I!.M2"HA
M2$)4A RI4H4K4H4L)*E=!2NLJ704KK+"*7:"DJ=H*2HI(70I)"Z%*C8;!]GI
M[RF1,=8/L]/>4R)YJN,O;1[L**CZ"3W5.16O^:Z[\;_"'7:CZ"3W5.16O^:Z
M[\;_  AEJ'5Z3ZNSV 4GU=GL %O!]MU'X:&1,=!]MU'X:&1
M                            Q64F3]MRCH$HKO3I/3H]'HU=2ICXJ5R6
M.VRV5+3+21OMZ,S$A<G1@9(%O*98O=K.360M@R;EFEM=$C)94S7/<N<J)L38
M>D.1=CAMEPM\=&B4M?(LE0S'SW8XXFQ N:>:113$6B%K:Z"GMEOIZ*B9P=-
MQ&1MV(AC*#).ST%^J+S2T;67"?'/EQTXZ3.@EY7+#!V;)2SV:Z5EQMU(V&JJ
ME597IKZ<2*;)2T4T%VAAI4;'=%SJI,?I%PP_R9T#-*98Y-<I<B;%2\E<#1(W
MDQ5=2]/F*JXJ>64V0=@RCJVU5SHLZH;T<(QV:JIL4V@%S3>]S)3:UFIU7D\R
M:JF0,FMK'-@@XO&F*_-9BJ]'WXJIZT>0>3])D]/9(:%$H)U1TK57I>J+BF*F
MS@9ZN9DIY,16Y-VNML#;+4TK9+>UB1MC74B:,#&6;(#)VSU5+4T%"C*BFQX.
M57*KNE,%QWFU 9IC=<R4SOLP-'DC9J2"Y0P4B-CN+E?4ICYZKI+&N\GN3E;:
M*.VST"+34:XPX+@YF.E,3; ,T\S)3.ZS"6#)6SV"JJ*BTT;:>2=J-DS5THAZ
M92Y-VS*2FCI[Q3I/%&[/:BKA@IEP3--[F6+6MN8#)W(ZQ9.R.DM-OBAF=IDT
MNWEG5^3[)VKCN#)J%%X]*V:94<J*KTQP5-ZFU@N:>-S)3:UF R<R0LN3U+/3
MVRC:UD_TJO7.5_W*IC:'R;9,4-V2XTUO1L[79S6YRYC5VHAN(&:KF9*>32V^
M3')5)JJ5;8U75"XN17+@U<<<4347.4'D_P G[]44\]QI'/D@B2%JM>J8L30U
M=J&U@9ZN-TTZ+6LPE=DI9:VQLM%101.M\:8,BPPS?O0\LE,C[-DLD_(],L;Y
M\.$>YV<JX:$-@!,TVM=<E-[V  1H        /*IIXZAF;*W'8NM#U +78EUD
MC5?FRN1/84\AL]*NXS -9ZF-.GDPW(3/2NW$<@Q^E=N,T!GJ-.GDPO-^+TKM
MQ3S>A]*XS@+GJ-.GDP?-V'TKB.;<'I'&= SU)I4\F!YM4_I'D<V*;TCS/@:E
M7,TJ>37^:]-Z1XYK4OI'FP :E7,TJ>37N:M)UWD<U*3KO-B U*N9I4<FN<TJ
M/KO(YHT?7>;(!J5<S2HY-:YH477>.9]#UY#90-2KF:5')K*Y&T/7DWD<S*#K
M2;S9P-2KF:5')J_,NW]:3>4+D;;D54SI-YM9XO\ .4:E7,TJ.36.9EMZTF\C
MF5;>M)O-F U*N::5')K/,FV;9-_[$<R+7MDW_L;.!J5<S2HY-7YCVO;)O_8C
MF-:MLN_]C:0-2KF:5')JO,2T[9=_[$<P[3MEW_L;6!J5<S2HY-47(&T?_5^+
M]B.8%G_^K\7[&V :E7,TJ.34?D_L_P#];?\ L/D^LW_U?B_8VX#4JYFE1R:A
M\GME73PWQ?L/D[LG_P!;XOV-O U*N9HT<FG_ "=6/_ZWQ?L1\G-C_P#K?%^Q
MN(&I7S-&CDTWY.+%LF^+]B%\FUBV3?%^QN8&I7S-&CDTOY-;#LG^+]B/DSL&
MR?XOV-U U:^::.'R:5\F5@V3_%^Q'R8Y/[)_C_8W8#5KYFCA\FD?)?D]LG^/
M]B/DNR>V3_'^QO +JU\S1P^32$\E63RICFU'QIX#Y*,GNK4?&G@;]'YB$C5K
MYKH8?)S_ .2?)WJU'QIX$?)-D[U:CXT\#H(&K7S30P^3GOR1Y-]6H^-/ ?)'
MDWU:GXT\#H0&K7S-##Y.>?)#DUU*GXT\"/D@R9ZE3\:>!T0#5KYFAA\G.OD?
MR9ZE3WB>!'R.Y,=2I[Q/ Z,!JU\S0P^3G'R.9,=2I[Q/ CY&\E^I4]XG@=(
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MZ3ZNSV 4GU=GL %O!]MU'X:&1,=!]MU'X:&1
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MT$GNJ<BM?\UUWXW^$,M0ZO2?5V>P"D^KL]@ MX/MNH_#0R)CH/MNH_#0R(
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M4=ZHYL6_;4=ZIFP!A.;%OVU'>J.;%OVU'>J9L 83FQ;]M1WJCFQ;]M1WJF;
M&$YL6_;4=ZHYL6_;4=ZIFP!A.;%OVU'>J.;%OVU'>J9L 83FQ;]M1WJCFQ;]
MM1WJF; &$YL6_;4=ZHYL6_;4=ZIFP!A.;%OVU'>J.;%OVU'>J9L 83FQ;]M1
MWJCFQ;]M1WJF; &$YL6_;4=ZHYL6_;4=ZIFP!A.;%OVU'>J>;LF[>BJG_4=Z
MIGSQ?YR@87FY0;*COE'-R@V5'?*9@!+L/S<H-E1WRCFY0;*COE,P 78?FY0;
M*COE'-R@V5'?*9@ NP_-R@V5'?*.;E!LJ.^4S !=A^;E!LJ.^4<W*#94=\IF
M "[#\W*#94=\HYN4&RH[Y3, %V'YN4&RH[Y1S<H-E1WRF8 +L/S<H-E1WRCF
MY0;*COE,P 78?FY0;*COE'-R@V5'?*9@ NP_-R@V5'?*.;E!LJ.^4S !=A^;
ME!LJ.^4<W*#94=\IF "[#\W*#94=\HYN4&RH[Y3, #%MR9MZM1?^H[U2>;%O
MVU'>J9J/S$)"L)S8M^VH[U1S8M^VH[U3-@#"<V+?MJ.]4<V+?MJ.]4S8 PG-
MBW[:CO5'-BW[:CO5,V ,)S8M^VH[U1S8M^VH[U3-@#"<V+?MJ.]4<V+?MJ.]
M4S8 PG-BW[:CO5'-BW[:CO5,V ,)S8M^VH[U1S8M^VH[U3-@#"<V+?MJ.]4<
MV+?MJ.]4S8 PG-BW[:CO5'-BW[:CO5,V ,)S8M^VH[U1S8M^VH[U3-@#"<V+
M?MJ.]4<V+?MJ.]4S8 P?-BWX::CO5//FY0;*COE-@70I;@8?FY0;*COE'-R@
MV5'?*9@!+L/S<H-E1WRCFY0;*COE,P 78?FY0;*COE'-R@V5'?*9@ NP_-R@
MV5'?*.;E!LJ.^4S !=A^;E!LJ.^4<W*#94=\IF "[#\W*#94=\HYN4&RH[Y3
M, %V'YN4&RH[Y1S<H-E1WRF8 +L/S<H-E1WRCFY0;*COE,P 78?FY0;*COE'
M-R@V5'?*9@ NP_-R@V5'?*.;E!LJ.^4S !=A^;E!LJ.^4<W*#94=\IF "[#\
MW*#94=\IB<J++1TML;+#PV>D\?G2*J:3;C!Y9_8O^_'_ '"PV*'Z)GNH4O\
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MN_&_PAEJ'5Z3ZNSV 4GU=GL %O!]MU'X:&1,=!]MU'X:&1
M
M                                          >+_.4]CQ?YR@4@ (
M                           0]X_,0DB/S$)"@
M          NA2W+A="EN$                              P>6?V+_OQ
M_P!S.&#RS^Q?]^/^X(;%%]$SW4*7^<51?1,]U"E_G!5(          I !%
M5D   @D@$!05E 5*^:4E2^:4EA E-!!*: 0!=8"ZPKS !$  !#B"7$!0-T@-
MT@8";ZW-[ZEU!H0M9OK<WOJ74&A"HR,&A"Z9I4M8-"%TS2H16%T +H*HF@+H
M4)H"Z% H"@*$4ZPFD:PFD,R(0I*$*44J4ZRI2G66&4:R-9.LC6(%"Z"-1*Z"
M-1J$4J1K)4C6$4:U()UJ05$*0A*D(&5*E"E:E"EA)4KH*5UE2Z"E=9812[04
ME3M!25%)"Z%)(70I4;#8/L]/>4R)CK!]GI[RF1/-5QE[:/=A14?02>ZIR*U_
MS77?C?X0Z[4?02>ZIR*U_P UUWXW^$,M0ZO2?5V>P"D^KL]@ MX/MNH_#0R)
MCH/MNH_#0R(                                         'B^J@94L
MIWS,2=Z9S8U7I5-N![     /"*LIY9Y((YF.FC\YB+TM]H'N"SFNE#!.L$U7
M"R9%PS'.1%/62KIXJB."29C9I$Q8Q5Z7>P6+O<%L^OI63/A?41ME8W/<U7=*
M-VJ>4-VM\\K8X:R!\CEP:UKT55+8NO@ 0  JHB*JZ$  L+/>*"\0RRVVICJ(
MXWK&]S%QP<FE"NINE#32K%45<,<B)BK7.1%+:4O'%> QERO]KMM)#55M;#%3
MRO2-CU=T.<NA$W&3145$5-"DLMP   6%YO%!9H(YKG4QT\;W(QKGK@BJNHI@
MO=NGO,]JBJXG7"%J/D@1?G-1=:I^:%M*7AD0 10             /.>>.!BO
ME>C6_>>CE1&JJZ$Z35:ZH=52J]R_-3S4V&J*<S%=>5E)+Y U?FL>Y-N!YKE!
M$G_9D,&[0IY.T';3I<-6IGERCA3_ +,A0N4\*?\ 8EW&NO/%^@1ATIJU-E7*
MJ!/]/*4KE9 G^GFW&K.T*>+BZ=*:U3;5RO@3_33;D*%RRIT_TLVY#4'Z#R<-
M.E-:MN2Y:TZ?Z6?<A0N7%,G^EGW(:6X\':5+I4IKUMY7+NF3_23[D\2A<OJ5
M/]'4;D\31''D_6-*DUZV^KY0J5/]'4;D\2E?*)2)_HJC<GB<]<>3M9=*E->M
MT1?*/2)_HJG<GB4KY2Z-/]#4[D\3F[CQ?I4:5*:]?-TM?*;1I_H:G<GB4KY4
M*-/]!5;D\3F*GD\NC2G:,3FZ@OE3HD_T%5N3Q*5\JU$G_CZK<GB<K<>3BZ-!
MVC$YNK+Y6J)/_'5>Y/$\G>5J@Q55MU7N3Q.3N/)^L:-#/:<3FZTOE<MZ?^-K
M-R>)0OE?MZ?^-K-R>)R%VL\G%T:#M.)S=A7RQ6Y/_&5FY/$H7RRVY/\ Q=;N
M3Q.-N/)XT*.3/:<3F[,OEHMR?^+K=R>)2OEKMJ?^*K=R>)Q5QXN+H4<CM6)S
M=M7RW6U/_%5VY/$\W>7.UM\ZU5NY/$X;4.<F:R-JNED<C6-32JJN"'=,@_(S
M;&VZ*KRI9QVJF:C^!SE1D>/3AT88J9KP\*B+RWAXN/B3:F5S;/+?D]42-;70
M5E&U5PX1\>+4]N&)O]'?J.MI(JJB<E132IG1RQKBUR&D95>1>P5M#*MBAY.K
M43%BL<JL5=BHN)R[R:7FLR2RQEL-T5S::29T$L7],<R:')[<#$8>'7%Z&YQ<
M7"F(Q+6GQ?1W*D?HWCE2/T;S%.16N5%TH08TZ7;4J9;E2/T;QRI'Z-YB0-.#
M4J9;E2/T;QRI'Z-YB0-.#4J9;E2/T;QRI'Z-YB0-.#4J9;E2/T;QRI'Z-YB0
M-.#4J9;E2/T;QRI'Z-YB0-.#4J9;E2/T;QRI'Z-YB0-.DU*F8;=XT3#@WD\L
M1^B>88#3I-2IF>6(_1/'+$?HGF& TZ34J9GEB/T3QRQ'Z)YA@-.DU*F9Y8C]
M$\<L1^B>88#3I-2IF>6(_1/'+$?HGF& TZ34J9GEB/T3QRQ'Z)YA@-.DU*F9
MY8C]$\<L1^B>88#3I-2IF>6(_1/'+$?HGF& TZ34J9GEB/T3QRQ'Z)YA@-.D
MU*F9Y8C]$\<L1^B>88#3I-2IF>6(_1/'+$?HGF& TZ34J9GEB/T3QRQ'Z)YA
M@-.DU*F9Y8C]$\HY4C]&\Q(&G2:E3+<J1^C>.5(_1O,2!IP:E3+<J1^C>.5(
M_1O,2!IP:E3+<J1^C>.5(_1O,2!IP:E3+<J1^C>.5(_1O,2!IP:E3+<J1^C>
M.5(_1O,2!IP:E3+<J1^C>.5(_1O,2!IP:E3+<J1^C>.5(_1O,2!IP:E3+<J1
M^C>.5(_1O,2!IP:E3+<J1^C>.5(_1O,2!IP:E3+<J1>C>5,N<"K\]'M^]4,.
M!IP:E39(WMD8CF.1S5UH28*@J%@F3I_ANZ')_DSIRJIRR[459H#!Y9_8O^_'
M_<SA@\L_L7_?C_N9:AL47T3/=0I?YQ5%]$SW4*7^<%4@         "D $4 !
M60  ""2 0%!64!4KYI25+YI26$"4T$$IH! %U@+K"O, $0  $.()<0% W2 W
M2!@)OK<WOJ74&A"UF^MS>^I=0:$*C(P:$+IFE2U@T(73-*A%870 N@JB: NA
M0F@+H4"@* H13K":1K":0S(A"DH0I12I3K*E*=9891K(UDZR-8@4+H(U$KH(
MU&H12I&LE2-811K4@G6I!40I"$J0@94J4*5J4*6$E2N@I765+H*5UEA%+M!2
M5.T%)44D+H4DA="E1L-@^ST]Y3(F.L'V>GO*9$\U7&7MH]V%%1]!)[JG(K7_
M #77?C?X0Z[4?02>ZIR*U_S77?C?X0RU#J])]79[ *3ZNSV "W@^VZC\-#(F
M.@^VZC\-#(@                                        <ERG1/_Z@
M\F%PZ>3W_P!WF2\IN5%XH[Y9LG<G)(J:NN3\%J9&(](V_<U>A=)[Y<Y UM_R
MJHKY;+TMMJ:6GX!JMB1Z^<JJO3[2TKO)K7W&VT;J_*&62^T4W"4]P2%$5J=5
M6Z%U;CO$T[IF7FFFO\T1'&?HUZGRSRK@@RKLM7602WJSQ\/#5,A:B2L3%516
MZ$7!"TD\JEYJ+A9*BC?$EJ93TZW->#142217(O3AT:#?,CO)W%94NU1<JY]S
MN5S:K9ZA[,WH7'H1/S,';/(]%19*WVS\IJ]UQD8]DO!_1(Q<6IAC]ZFLV'X_
MYS8R8UMW7[,OY+LH[KE-=,HZFLG8^U05/ 4;6QHG0BKBN.O4:YE0B9)^6FU7
MA%2*@ND2PU#E7!,[!W2OZ'0?)_DO'DCDY#;(Y>'>U5?)+AAGN766OE*R-CRS
ML;:):CBL\<B213(W.S5__D8BJF*YY.DT53AQ^J-[A-SLTF4.3.4V6KHEXR^X
M\) O3BV-JX=&XO,IKK/?<KZ'*BE?G45C2CCD<B]"9ZJYV*[SN-KR0I:#(5F3
M37Y\*0+$Z16]+E55578>U35\F_)3#:<B;U89:[AY;DN*U&9AF8)@WHQU=.\Z
M1BT^/^0XSL]7"/'?/S_[:?09E]NWE(RC:B.A2W/I878XI@L>*X+_ /I+?R-4
MMH=46-RY)UJU[5SN54>_@\=N&@Z3DOY/6V/(*XY/)6\)-6QR,?4YF'2Y%1%P
M^[$V#(:P+DSDS1VEU1QA:=N;PF;FX_D9JQ(M,0W1@SFBJK_-[&^4R\R6BR,=
M27FGM55)(C622Q)*KDUHUNM32L@LMK[4WJ_6FX5J5[:6B6J@JI*5*=^.&/2Q
M-1N/E'R(3*Z.@DAK5HJVB?GQ2YF>GYHIC<GO)S4VV]W&Z5MZ?755=1+32N=$
MC?G88(J(G0B(F'09IFC)OXMU1B3B1,<'/5RYR[ER0FRF;<*1E)1U'!.@XNW&
M=,[!55=6K0;'<LK<J,HLM667)RII[=%%1MJ)EDB23.545<%QU:N@S#/)@]/)
MW5Y,+<TSIYN%X?@]'SD7##'[A<_)A/)>**Z6B^2VZMCIVTT[V1([A41,,<%7
MHZ#>:AST\6/&?#Q^=_X6O_X=FO;DW=TE:ULO*4N>C=&=T8X&C^4*DBJO*]=6
MRV"2^X4**E/'*L:M7KXILV?>=B\G.1_,VVUE&E8ZK;/4NG1[FX*B+AT+]_08
M#*;R<W*XY7U5^M.4#[;-/"D*HV%'+FZTQ4E-<17,K5A53A4TVX?)QUC6M\EE
M.SAG*YM]BQI78KQ;S_F].TZ=Y0\MKK3954F3]GK6VR-D"2SU?%^'<N*(J(C2
M[G\D,/-B*UTUS>DZUK*VHJ9&8K*YN/1ACT:3,Y89 +>+Q2WBTW-]LNT+.#69
M(TD:]OWM7H+.)1,[^K-.%B4TVCHYU)Y5,HN0J.@ES:>ZS53X>/NIE^=$F&#T
MC7H55Q7<9_)3+V]4T&4K+N];G#;:7C%/6K3+3\*N.&:J:-*H9BO\FDUSLE-'
M<KW)+>Z6=T\%>V!K<S'#YN8G0J='ZF3L61E='1W2FRDO3KK%70I#F) V)&)T
MXJF&E? DU8=FJ:,6)WRXSE9794WG(JTW>_UU-44%75M=' V%&NB7'HZ4TH=)
MLUTD=Y;<HJ)(*5K8J-KDE;$B2+\UNEVE3'KY&ZQ]KBM\V4TTE'2R))2PK"F:
MSIU].*FX4.13J;RA77*;CJ.;6P)#P&9YN"(F./Y%JKHM:.J8>'B1,3/3^7+(
MLM\N:_)R]7N"Z4L--:*E8W1\6:JSICH5=6"8:-IF,I,OKY-5V2""Z4UD@J;8
MZM?4N@21))$5R<&F=HQP3>;#;_)<ZCR-R@L7*:.6Z3K,DO!_1XX=&&/2<[RQ
MM\=!E9;[;=J^>V4EKH$A@K%HG5"5*JY57!J(J(O@:C)5.Z&)C$HI_-/+QZ_1
MU;R/W6^7W)QURR@J.$=,]4B9P"1YK47#'HTXF]G.?(I77RMLE4MXSGTC)<VC
MF?#P+I&;<S#H0Z,>?$BU4O7A3>B  &'0       !YU"8T\B)U5-27S3<5T&M
M7*B?2R.5$58G=*+L]IUPY\''%CQ8YVA3R=H/5VA3R=H.SSO!YXOT'LX\7KI$
M,O%VA3Q<>SE3I/%Q4>3]!Y./5ZIAI/)RIM+"/)QX.TJ>SE3#2>+E3IZ2H\G'
MD_6>KE3:AXO5.GI0(\7'D[6>CU3:AY.5.GI0J/)QXOTJ>KE3:AXO5,5Z4*CS
M4\GGHJIM0\GN3:@1Y./)QZ.5.GI0\7.3:A4>3CR?K/1SDZ>E-YY.<G3TIO*R
M\7:SR<>CG)T]*;SR<YNU-Y8)>3SR>>CW-VIO/%[F[4WE9>;CQ<>KG-ZR;SQ<
MYO63>$7N2;XHLN+#)4JU(4J6XJ[0BZOUP/L-JHK45%147I14/B:I:V1O0]$<
MU<6JBZ%.N9">6R*VV^.@RK@F>L+48RJIVH[.1.LW%,%^\X8^'-=II>K9<:G#
MO35-KN_'RYY3V-K/+2Z*W],G#PM<K.GYZ)T_F;OE/Y=*&:C=3Y)4=74UTB9K
M9)8LUK%]G2JK^1C?);D;<(KI+E-E,W_K9\7P12>?G.7%9')J74B&<*B<.]53
M>/B4XUJ*-_5U27Z1VLH (V
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M$,M0ZO2?5V>P"D^KL]@ MX/MNH_#0R)CH/MNH_#0R(
M                                                    /*:F@G5%
MGACD5-&>U%P/4 0QK6-1K&HUJ:$1,$)             0YJ.14<B*BZE) %D
M^V4KG8\'A["GDFE]&7X-9I9R4\EAR12>C(Y'H_1(9 #-/,R4\F/Y&HO0H1R+
M0^A:9$#-/,R4\F.Y%H?0-W$<B4'J[-QD@,T\S)3R8WD.W^KLW$<A6_U9FXR8
M&:>9DIY,9R#;O58]Q'(-M]5C^%#* 9IYF2GDQ?-^V>J1?"A'-^V>IQ?"AE0,
MT\S)3R8KF]:_4X?A0CF[:O4H?@0RP&>KF9*>3$\W+3ZC!\"$<V[3ZC!\"&7
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M          I !%  5D   @D@$!05E 5*^:4E2^:4EA E-!!*: 0!=8"ZPKS
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MKL]@ MX/MNH_#0R)CH/MNH_#0R(
M
M                      #Q?YRGL>+_ #E I  0
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MY%:_YKKOQO\ "&6H=7I/J[/8!2?5V>P 6\'VW4?AH9$QT'VW4?AH9$
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MJE:J(Y4V&Z
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MU'-5%:NM"0!@\L_L7_?C_N9PP>6?V+_OQ_W!#8HOHF>ZA2_SBJ+Z)GNH4O\
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M1A@94(B(F"="
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M]SI8$585>N*IAYS?R-^.2Y$O6L\HTM13?1.DFDZ$Z,W!3K0
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MQ>9YN.<[1]QU;R5_R-;/< VP
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ML:C&(UJ8-1,$0L[==J"Y1N?05D%0UOG+&]%P]I9NRIL;9W0NNU&DC=+>%3H
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MQK(*9'>;PCT3$FVW.AN<:R6^JAJ6)I6-R+@!>
M                                                         'B_
MSE/8\7^<H%( "                             $/>/S$)(C\Q"0H
M                         +H4MRX70I;A
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M[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL
MU_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>
MNPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]
M=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]
MIL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[
M1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U
M_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>N
MPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=
MAKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]I
ML  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[1RK>NPU[]IL  U_E6]=AKW[2
ME;E>57%;$[_D--B/%_G*!@N4;QV$[_D-'*-X["=_R&F<Q&(+L'RC>.PG?\AH
MY1O'83O^0TSF(Q!=@^4;QV$[_D-'*-X["=_R&F<Q&(+L'RC>.PG?\AHY1O'8
M3O\ D-,YB,078/E&\=A._P"0T<HWCL)W_(:9S$8@NP?*-X["=_R&CE&\=A._
MY#3.8C$%V#Y1O'83O^0T<HWCL)W_ "&F<Q&(+L'RC>.PG?\ (:.4;QV$[_D-
M,YB,078/E&\=A._Y#1RC>.PG?\AIG,1B"[!\HWCL)W_(:.4;QV$[_D-,YB,0
M78/E&\=A._Y#1RC>.PG?\AIG,1B"[!\HWCL)W_(:.4;QV$[_ )#3.8@%V&2Z
M7I$Z+$O?M'*MZ[#7OVF?C\Q"0-?Y5O78:]^T<JWKL->_:;  -?Y5O78:]^T<
MJWKL->_:;  -?Y5O78:]^T<JWKL->_:;  -?Y5O78:]^T<JWKL->_:;  -?Y
M5O78:]^T<JWKL->_:;  -?Y5O78:]^T<JWKL->_:;  -?Y5O78:]^T<JWKL-
M>_:;  -?Y5O78:]^T<JWKL->_:;  -?Y5O78:]^T<JWKL->_:;  -?Y5O78:
M]^T<JWKL->_:;  -?Y5O78:]^T<JWKL->_:;  -?Y4O78:]^THY1O'83O^0T
MV-="GAB!@^4;QV$[_D-'*-X["=_R&F<Q&(+L'RC>.PG?\AHY1O'83O\ D-,Y
MB,078/E&\=A._P"0T<HWCL)W_(:9S$8@NP?*-X["=_R&CE&\=A._Y#3.8C$%
MV#Y1O'83O^0T<HWCL)W_ "&F<Q&(+L'RC>.PG?\ (:.4;QV$[_D-,YB,078/
ME&\=A._Y#1RC>.PG?\AIG,1B"[!\HWCL)W_(:.4;QV$[_D-,YB,078/E&\=A
M._Y#1RC>.PG?\AIG,1B"[!\HWCL)W_(:.4;QV$[_ )#3.8C$%V#Y1O'83O\
MD-'*-X["=_R&F<Q&(+L'RC>.PG?\AIB<IZVY2VQK:FTK3Q+/'B]9FNPZ=AN6
M)@LL_L7_ 'X_[@NV*'Z)GNH4O\XJB^B9[J%+_. I          %( (H "L@
M $$D @*"LH"I7S2DJ7S2DL($IH()30" +K 76%>8 (@  (<02X@*!ND!ND#
M3?6YO?4NH-"%K-];F]]2Z@T(5&1@T(73-*EK!H0NF:5"*PN@!=!5$T!="A-
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MCL-YZ@#S@@AIV9D$4<3.JQJ-3]#T
M                                                          'B
M_P Y3V/%_G*!2  @                            !#WC\Q"2(_,0D*
M                           "Z%+<N%T*6X0
M        #!Y9_8O^_'_<SA@\L_L7_?C_ +@AL47T3/=0I?YQ5%]$SW4*7^<%
M4@         "D $4 !60  ""2 0%!64!4KYI25+YI26$"4T$$IH! %U@+K"O
M, $0  $.()<0% W2 W2!@)OK<WOJ74&A"UF^MS>^I=0:$*C(P:$+IFE2U@T(
M73-*A%870 N@JB: NA0F@+H4"@* H13K":1K":0S(A"DH0I12I3K*E*=9891
MK(UDZR-8@4+H(U$KH(U&H12I&LE2-811K4@G6I!40I"$J0@94J4*5J4*6$E2
MN@I765+H*5UEA%+M!25.T%)44D+H4DA="E1L-@^ST]Y3(F.L'V>GO*9$\U7&
M7MH]V%%1]!)[JG(K7_-==^-_A#KM1]!)[JG(K7_-==^-_A#+4.KTGU=GL I/
MJ[/8 +>#[;J/PT,B8Z#[;J/PT,B
M                                                     #RJ:B.G
M9G2.PV)K4]'+FM55T(F)K=3*Z:1SW+TKH^X"\DO2HJYD.*?>IX.OTJ?]AN\L
M'EL_6$9-V4<J?Z=OQ'D[*>9/],WXC$/T%N_0%9MV5DZ?Z5GQ'D[+"=/]&SXC
M OTEL_6!L;LM*A/]$SXCR=ES4I_HF?&:T\MY-8&T.R]J4_T,?QGD[RA52?\
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M1^&AD0
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M+N @$X+L7<,%V+N @$X+L7<,%V+N @$X+L7<,%V+N @$X+L7<$:Y5P1JJOL
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M^:Z[\;_"&6H=7I/J[/8!2?5V>P 6\'VW4?AH9$QT'VW4?AH9$
M
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M$
M                                                        !XO\
MY3V/)Z+G+T 4 G!=BC!=BA+(!."[%&"[%!9 )P78HP78H+(!."[%&"[%!9 )
MP78HP78H+(!."[%&"[%!9 )P78HP78H+(!."[%&"[%!9 )P78HP78H+(!."[
M%&"[%!9 )P78HP78H+(!."[%&"[%"V>T?F(20SS$)
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M$.KTGU=GL I/J[/8 +>#[;J/PT,B8Z#[;J/PT,B
M
M
M
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MK4KILL+;47'BD:3X.SN"F5G\.96Z48NLM<F;'64>0O)\BI#<)HW.>NQ[NE3
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MA8LCL,,78=/ZEV$3!,$T
M
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M22)2R*]D#<<%>KE7SE1=('7U5$155<$0MZ"MIZ^%TM)(DD:.5F<FC%.A3E7
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MHJ:T)
M
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M,:-Z%]NTFKM5!6/SZJDAE=FHS%[<>C87H AK48U&M1$:B8(B:B0
M
M
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M#B=^[0G_ $\!Q._=H3_IX =?X:/KMWCAH^NW><@XG?NT)_T\!Q._=H3_ *>
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MWG(.)W[M"?\ 3P'$[]VA/^G@!U_AH^NW>.&CZ[=YR#B=^[0G_3P'$[]VA/\
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MJ'GQ:+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@
M#BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+
MJH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750
M<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK
M%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ
M .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8
MNJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5
M!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #B
ML750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH
M  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5
MBZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U
M4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .
M*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ
M@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q
M6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL7
M50<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH
MXK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZ
MJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'
M%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q
M=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@
M#BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+
MJH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750
M<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK
M%U4'%8NJ@ #BL750<5BZJ  .*Q=5!Q6+JH  XK%U4'%8NJ@ #BL750)31)_2
3@ 'LV%B)T(>B(B:       #_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
